PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Dixon, M; Kay, S				Dixon, Michael; Kay, Stewart			Will polyclinics deliver real benefits for patients?	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Dixon, Michael] NHS Alliance, Retford, Notts, England; [Kay, Stewart] Aylesbury Med Ctr, London SE17 2XE, England		Dixon, M (corresponding author), NHS Alliance, Retford, Notts, England.	michaeldixon@nhs.net; stewart.kay@gp-G85012.nhs.uk							0	6	6	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2008	336	7654					1164	1165		10.1136/bmj.39577.488507.AD	http://dx.doi.org/10.1136/bmj.39577.488507.AD			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308WJ	18497414	Green Published			2022-12-28	WOS:000256420900037
J	Hamada, FN; Rosenzweig, M; Kang, K; Pulver, SR; Ghezzi, A; Jegla, TJ; Garrity, PA				Hamada, Fumika N.; Rosenzweig, Mark; Kang, Kyeongjin; Pulver, Stefan R.; Ghezzi, Alfredo; Jegla, Timothy J.; Garrity, Paul A.			An internal thermal sensor controlling temperature preference in Drosophila	NATURE			English	Article							ION CHANNELS; ANTENNAL LOBE; NEURONS; THERMOSENSATION; MELANOGASTER; THERMOTAXIS; SENSATION; GENETICS; FLY	Animals from flies to humans are able to distinguish subtle gradations in temperature and show strong temperature preferences(1-4). Animals move to environments of optimal temperature and some manipulate the temperature of their surroundings, as humans do using clothing and shelter. Despite the ubiquitous influence of environmental temperature on animal behaviour, the neural circuits and strategies through which animals select a preferred temperature remain largely unknown. Here we identify a small set of warmth- activated anterior cell ( AC) neurons located in the Drosophila brain, the function of which is critical for preferred temperature selection. AC neuron activation occurs just above the fly's preferred temperature and depends on dTrpA1, an ion channel that functions as amolecular sensor of warmth. Flies that selectively express dTrpA1 in the AC neurons select normal temperatures, whereas flies in which dTrpA1 function is reduced or eliminated choose warmer temperatures. This internal warmth- sensing pathway promotes avoidance of slightly elevated temperatures and acts together with a distinct pathway for cold avoidance to set the fly's preferred temperature. Thus, flies select a preferred temperature by using a thermal sensing pathway tuned to trigger avoidance of temperatures that deviate even slightly from the preferred temperature. This provides a potentially general strategy for robustly selecting a narrow temperature range optimal for survival.	[Hamada, Fumika N.; Rosenzweig, Mark; Kang, Kyeongjin; Pulver, Stefan R.; Ghezzi, Alfredo; Garrity, Paul A.] Brandeis Univ, Dept Biol, Volen Ctr Complex Syst, Natl Ctr Behav Genom, Waltham, MA 02454 USA; [Jegla, Timothy J.] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; [Jegla, Timothy J.] Scripps Res Inst, Inst Childhood & Neglected Dis, La Jolla, CA 92037 USA	Brandeis University; Scripps Research Institute; Scripps Research Institute	Garrity, PA (corresponding author), Brandeis Univ, Dept Biol, Volen Ctr Complex Syst, Natl Ctr Behav Genom, MS-008,415 South St, Waltham, MA 02454 USA.	pgarrity@brandeis.edu	Ghezzi, Alfredo/I-4620-2012	Ghezzi, Alfredo/0000-0001-9176-1320; Pulver, Stefan/0000-0001-5170-7522; Jegla, Timothy/0000-0001-8616-2390; Kang, KyeongJin/0000-0003-0446-469X; Garrity, Paul/0000-0002-8274-6564	NCRR NIH HHS [RR16780] Funding Source: Medline; NEI NIH HHS [R01 EY013874-06, R01 EY013874, R01 EY13874] Funding Source: Medline; NIMH NIH HHS [R01 MH067284, R01 MH067284-05] Funding Source: Medline; NINDS NIH HHS [P01 NS044232, P01 NS044232-070002, P30 NS045713S10, P30 NS045713-069006, P30 NS045713, P01 NS044232-060002] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR016780] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY013874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH067284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS045713, P01NS044232] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barolo S, 2004, BIOTECHNIQUES, V36, P436, DOI 10.2144/04363ST03; BROWN AWA, 1951, NATURE, V167, P202, DOI 10.1038/167202a0; Caterina MJ, 2007, AM J PHYSIOL-REG I, V292, pR64, DOI 10.1152/ajpregu.00446.2006; Dhaka A, 2006, ANNU REV NEUROSCI, V29, P135, DOI 10.1146/annurev.neuro.29.051605.112958; FANGER PO, 1974, EUR J APPL PHYSIOL O, V33, P255, DOI 10.1007/BF00430233; Fischer H, 2002, J COMP PHYSIOL A, V188, P643, DOI 10.1007/s00359-002-0339-1; FRAENKEL GS, 1940, ORIENTATION ANIMALS; FRIEND WG, 1977, ANNU REV ENTOMOL, V22, P309, DOI 10.1146/annurev.en.22.010177.001521; Heinrich B., 1993, HOT BLOODED INSECTS; Ito K, 1998, LEARN MEMORY, V5, P52; Kalidas S, 2002, NEURON, V33, P177, DOI 10.1016/S0896-6273(02)00560-3; KITAMOTO T, 1995, J NEUROBIOL, V28, P70, DOI 10.1002/neu.480280107; Liu L, 2003, NAT NEUROSCI, V6, P267, DOI 10.1038/nn1009; Mori I, 1999, ANNU REV GENET, V33, P399, DOI 10.1146/annurev.genet.33.1.399; Nakai J, 2001, NAT BIOTECHNOL, V19, P137, DOI 10.1038/84397; Ng M, 2002, NEURON, V36, P463, DOI 10.1016/S0896-6273(02)00975-3; Parmesan C, 2003, NATURE, V421, P37, DOI 10.1038/nature01286; Patapoutian A, 2003, NAT REV NEUROSCI, V4, P529, DOI 10.1038/nrn1141; Rong YS, 2000, SCIENCE, V288, P2013, DOI 10.1126/science.288.5473.2013; Rosenzweig M, 2005, GENE DEV, V19, P419, DOI 10.1101/gad.1278205; Sayeed O, 1996, P NATL ACAD SCI USA, V93, P6079, DOI 10.1073/pnas.93.12.6079; SIDDIQUI WH, 1972, ANN ENTOMOL SOC AM, V65, P993, DOI 10.1093/aesa/65.5.993; STEVENSON RD, 1985, AM NAT, V125, P102, DOI 10.1086/284330; Tayler TD, 2004, DEVELOPMENT, V131, P5935, DOI 10.1242/dev.01465; Tichy H., 2001, ECOLOGY SENSING, P271, DOI [10.1007/978-3-662-22644-5_14, DOI 10.1007/978-3-662-22644-5_14]; Tominaga M, 2004, J NEUROBIOL, V61, P3, DOI 10.1002/neu.20079; Viswanath V, 2003, NATURE, V423, P822, DOI 10.1038/423822a; Vosshall LB, 2007, ANNU REV NEUROSCI, V30, P505, DOI 10.1146/annurev.neuro.30.051606.094306	28	647	655	5	145	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 10	2008	454	7201					217	U55		10.1038/nature07001	http://dx.doi.org/10.1038/nature07001			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	323RU	18548007	Green Accepted			2022-12-28	WOS:000257466900044
J	Kuhn, L; Aldrovandi, GM; Sinkala, M; Kankasa, C; Semrau, K; Mwiya, M; Kasonde, P; Scott, N; Vwalika, C; Walter, J; Bulterys, M; Tsai, WY; Thea, DM				Kuhn, Louise; Aldrovandi, Grace M.; Sinkala, Moses; Kankasa, Chipepo; Semrau, Katherine; Mwiya, Mwiya; Kasonde, Prisca; Scott, Nancy; Vwalika, Cheswa; Walter, Jan; Bulterys, Marc; Tsai, Wei-Yann; Thea, Donald M.		Zambia Exclusive Breastfeeding	Effects of early, abrupt weaning on HIV-free survival of children in Zambia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; PROSPECTIVE COHORT; BREAST-MILK; TRANSMISSION; MOTHER; INFANT; MORTALITY; WOMEN; INTERVENTION	Background: In low-resource settings, many programs recommend that women who are infected with the human immunodeficiency virus (HIV) stop breast-feeding early. We conducted a randomized trial to evaluate whether abrupt weaning at 4 months as compared with the standard practice has a net benefit for HIV-free survival of children. Methods: We enrolled 958 HIV-infected women and their infants in Lusaka, Zambia. All the women planned to breast-feed exclusively to 4 months; 481 were randomly assigned to a counseling program that encouraged abrupt weaning at 4 months, and 477 to a program that encouraged continued breast-feeding for as long as the women chose. The primary outcome was either HIV infection or death of the child by 24 months. Results: In the intervention group, 69.0% of the mothers stopped breast-feeding at 5 months or earlier; 68.8% of these women reported the completion of weaning in less than 2 days. In the control group, the median duration of breast-feeding was 16 months. In the overall cohort, there was no significant difference between the groups in the rate of HIV-free survival among the children; 68.4% and 64.0% survived to 24 months without HIV infection in the intervention and control groups, respectively (P=0.13). Among infants who were still being breast-fed and were not infected with HIV at 4 months, there was no significant difference between the groups in HIV-free survival at 24 months (83.9% and 80.7% in the intervention and control groups, respectively; P=0.27). Children who were infected with HIV by 4 months had a higher mortality by 24 months if they had been assigned to the intervention group than if they had been assigned to the control group (73.6% vs. 54.8%, P=0.007). Conclusions: Early, abrupt cessation of breast-feeding by HIV-infected women in a low-resource setting, such as Lusaka, Zambia, does not improve the rate of HIV-free survival among children born to HIV-infected mothers and is harmful to HIV-infected infants.(ClinicalTrials.gov number, NCT00310726.).	[Kuhn, Louise; Walter, Jan] Columbia Univ, Mailman Sch Publ Hlth, Gertrude H Sergievsky Ctr, New York, NY 10032 USA; [Kuhn, Louise; Walter, Jan] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA; [Tsai, Wei-Yann] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY 10032 USA; [Aldrovandi, Grace M.] Univ So Calif, Childrens Hosp Los Angeles, Dept Pediat, Los Angeles, CA USA; [Sinkala, Moses; Vwalika, Cheswa] Lusaka Dist Hlth Management Team, Lusaka, Zambia; [Kankasa, Chipepo; Mwiya, Mwiya; Kasonde, Prisca] Univ Zambia, Univ Teaching Hosp, Lusaka, Zambia; [Bulterys, Marc] US Ctr Dis Control & Prevent, Global AIDS Program, Lusaka, Zambia; [Semrau, Katherine; Scott, Nancy; Thea, Donald M.] Boston Univ, Sch Publ Hlth, Ctr Int Hlth & Dev, Boston, MA USA	Columbia University; Columbia University; Columbia University; Children's Hospital Los Angeles; University of Southern California; University of Zambia; Boston University	Kuhn, L (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Gertrude H Sergievsky Ctr, 630 W 168th St, New York, NY 10032 USA.	lk24@columbia.edu		Kapiga, Saidi/0000-0003-1753-4060; Walter, Jan/0000-0003-2247-5560; Semrau, Katherine/0000-0002-8360-1391; Scott, Nancy/0000-0002-4713-4642; Thea, Donald/0000-0002-6933-1030	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039611, R01HD040777] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [D43TW001035] Funding Source: NIH RePORTER; FIC NIH HHS [D43 TW001035, D43 TW001035-09] Funding Source: Medline; NICHD NIH HHS [R01 HD 39611, R01 HD040777, R01 HD039611, R01 HD 40777] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bertolli J, 1996, J INFECT DIS, V174, P722, DOI 10.1093/infdis/174.4.722; Bolton-Moore C, 2007, JAMA-J AM MED ASSOC, V298, P1888, DOI 10.1001/jama.298.16.1888; Bulterys M, 2004, J INFECT DIS, V189, P2149, DOI 10.1086/420835; Coovadia HM, 2007, LANCET, V369, P1107, DOI 10.1016/S0140-6736(07)60283-9; Coutsoudis A, 2004, J INFECT DIS, V189, P2154, DOI 10.1086/420834; Coutsoudis A, 2001, AIDS, V15, P379, DOI 10.1097/00002030-200102160-00011; CUNNINGHAM AS, 1991, J PEDIATR-US, V118, P659, DOI 10.1016/S0022-3476(05)80023-X; Dunn DT, 1998, AIDS, V12, P2211, DOI 10.1097/00002030-199816000-00017; Ekpini ER, 1997, LANCET, V349, P1054, DOI 10.1016/S0140-6736(96)06444-6; Embree JE, 2000, AIDS, V14, P2535, DOI 10.1097/00002030-200011100-00016; Fawzi W, 2002, JAIDS-J ACQ IMM DEF, V31, P331, DOI 10.1097/00126334-200211010-00010; Fewtrell MS, 2007, AM J CLIN NUTR, V85, p635S, DOI 10.1093/ajcn/85.2.635S; Gartner LM, 2005, PEDIATRICS, V115, P496, DOI 10.1542/peds.2004-2491; Ghosh MK, 2003, J CLIN MICROBIOL, V41, P2465, DOI 10.1128/JCM.41.6.2465-2470.2003; Humphrey J, 2001, NUTR REV, V59, P119, DOI 10.1111/j.1753-4887.2001.tb06999.x; Iliff PJ, 2005, AIDS, V19, P699, DOI 10.1097/01.aids.0000166093.16446.c9; Jelliffe D. B., 1978, HUMAN MILK MODERN WO; Kourtis AP, 2003, LANCET INFECT DIS, V3, P786, DOI 10.1016/S1473-3099(03)00832-6; Kuhn L, 1997, AM J PUBLIC HEALTH, V87, P926, DOI 10.2105/AJPH.87.6.926; Mbori-Ngacha D, 2001, JAMA-J AM MED ASSOC, V286, P2413, DOI 10.1001/jama.286.19.2413; Miotti PG, 1999, JAMA-J AM MED ASSOC, V282, P744, DOI 10.1001/jama.282.8.744; NAGELKERKE NJD, 1995, J ACQ IMMUN DEF SYND, V8, P176; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; Piwoz EG, 2005, J NUTR, V135, P1113, DOI 10.1093/jn/135.5.1113; Stringer EM, 2003, AIDS, V17, P1377, DOI 10.1097/00002030-200306130-00012; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; Stringer JSA, 2005, AIDS, V19, P1309, DOI 10.1097/01.aids.0000180102.88511.7d; Thea DM, 2004, CONTROL CLIN TRIALS, V25, P353, DOI 10.1016/j.cct.2004.06.005; Thea DM, 2006, AIDS, V20, P1539, DOI 10.1097/01.aids.0000237370.49241.dc; Thior I, 2006, JAMA-J AM MED ASSOC, V296, P794, DOI 10.1001/jama.296.7.794; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5; Walter J, 2006, J INFECT DIS, V194, P1510, DOI 10.1086/508996; *WHO, 2007, HIV INF FEED NEW EV; *WHO COLL STUD TEA, 2000, LANCET, V355, P1104; Wilfert CM, 2007, J INFECT DIS, V195, P165, DOI 10.1086/510255	36	205	209	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 10	2008	359	2					130	141		10.1056/NEJMoa073788	http://dx.doi.org/10.1056/NEJMoa073788			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	323PJ	18525036	Green Accepted			2022-12-28	WOS:000257459000004
J	Theilen, U; Wilson, L; Wilson, G; Beattie, JO; Qureshi, S; Simpson, D				Theilen, U.; Wilson, L.; Wilson, G.; Beattie, J. O.; Qureshi, S.; Simpson, D.		Guideline Dev Grp	Guidelines - Management of invasive meningococcal disease in children and young people: summary of SIGN guidelines	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HEALTH-CARE-DELIVERY		[Theilen, U.; Simpson, D.] Royal Hosp Sick Children, Dept Anaesthesia & Paediat Crit Care, Edinburgh EH9 1LF, Midlothian, Scotland; [Wilson, L.] Univ Glasgow, Dept Publ Hlth & Hlth Policy, Glasgow, Lanark, Scotland; [Wilson, G.] Royal Aberdeen Childrens Hosp, High Dependency Unit, Aberdeen, Scotland; [Beattie, J. O.] Royal Hosp Sick Children, Dept Emergency Med, Glasgow G3 8SJ, Lanark, Scotland; [Qureshi, S.] Scottish Intercollegiate Guideline Network, Edinburgh, Midlothian, Scotland	University of Glasgow; University of Aberdeen; University of Glasgow	Simpson, D (corresponding author), Royal Hosp Sick Children, Dept Anaesthesia & Paediat Crit Care, Edinburgh EH9 1LF, Midlothian, Scotland.	dave.simpson@luht.scot.nhs.uk						Booy R, 2001, ARCH DIS CHILD, V85, P386, DOI 10.1136/adc.85.5.386; Carcillo JA, 2002, CRIT CARE MED, V30, P1365, DOI 10.1097/00003246-200206000-00040; Health Protection Agency, 2003, ENH SURV MEN DIS NAT; Health Protection Agency Meningococcus Forum, 2006, GUID PUBL HLTH MAN M; *HLTH PROT SCOTL, 2008, SURV SYST MEN INV DI; *NAT I HLTH CLIN E, 2007, FEV ILLN ASS IN MAN; Ninis N, 2005, BRIT MED J, V330, P1475, DOI 10.1136/bmj.330.7506.1475; RIORDAN FAI, 1995, EUR J PEDIATR, V154, P472; Scottish Intercollegiate Guidelines Network, 2008, MAN INV MEN DIS CHIL; Thompson MJ, 2006, LANCET, V367, P397, DOI 10.1016/S0140-6736(06)67932-4; Tibby SM, 2002, ARCH DIS CHILD, V87, P559, DOI 10.1136/adc.87.6.559	11	10	11	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 14	2008	336	7657					1367	1370		10.1136/bmj.a129	http://dx.doi.org/10.1136/bmj.a129			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316YB	18556318	Green Published			2022-12-28	WOS:000256984700044
J	Canadell, JG; Raupach, MR				Canadell, Josep G.; Raupach, Michael R.			Managing forests for climate change mitigation	SCIENCE			English	Editorial Material							CARBON-CYCLE; GLOBAL FORESTS	Forests currently absorb billions of tons of CO2 globally every year, an economic subsidy worth hundreds of billions of dollars if an equivalent sink had to be created in other ways. Concerns about the permanency of forest carbon stocks, difficulties in quantifying stock changes, and the threat of environmental and socioeconomic impacts of large-scale reforestation programs have limited the uptake of forestry activities in climate policies. With political will and the involvement of tropical regions, forests can contribute to climate change protection through carbon sequestration as well as offering economic, environmental, and sociocultural benefits. A key opportunity in tropical regions is the reduction of carbon emissions from deforestation and degradation.	[Canadell, Josep G.; Raupach, Michael R.] CSIRO Marine & Atmospher Res, Global Carbon Project, Canberra, ACT 2601, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Canadell, JG (corresponding author), CSIRO Marine & Atmospher Res, Global Carbon Project, GPO Box 3023, Canberra, ACT 2601, Australia.	pep.canadell@csiro.au	Canadell, Pep/E-9419-2010	Canadell, Pep/0000-0002-8788-3218				Bala G, 2007, P NATL ACAD SCI USA, V104, P6550, DOI 10.1073/pnas.0608998104; Betts RA, 2000, NATURE, V408, P187, DOI 10.1038/35041545; Canadell JG, 2007, P NATL ACAD SCI USA, V104, P18866, DOI 10.1073/pnas.0702737104; Canadell Josep G., 2007, P1; Chowdhury J. A., 2006, BETTER FOREST MANAGE; Friedlingstein P, 2006, J CLIMATE, V19, P3337, DOI 10.1175/JCLI3800.1; Gruber N, 2004, SCOPE SER, V62, P45; Gullison RE, 2007, SCIENCE, V316, P985, DOI 10.1126/science.1136163; Houghton RA, 2000, GLOBAL ECOL BIOGEOGR, V9, P145, DOI 10.1046/j.1365-2699.2000.00164.x; House JI, 2002, GLOBAL CHANGE BIOL, V8, P1047, DOI 10.1046/j.1365-2486.2002.00536.x; *INT TROP TIMB ORG, 2006, TECHN SER ITTO, V24; Jackson RB, 2005, SCIENCE, V310, P1944, DOI 10.1126/science.1119282; Kurz WA, 2008, P NATL ACAD SCI USA, V105, P1551, DOI 10.1073/pnas.0708133105; Li WH, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2006GL028364; Nabuurs GJ, 2007, AR4 CLIMATE CHANGE 2007: MITIGATION OF CLIMATE CHANGE, P541; Raupach MR, 2007, P NATL ACAD SCI USA, V104, P10288, DOI 10.1073/pnas.0700609104; Raupach MR, 2004, SCOPE SER, V62, P131; Sabine CL, 2004, SCOPE SER, V62, P17; Sathaye J, 2006, ENERG J, P127; Sohngen B, 2006, ENERG J, P109; Strengers BJ, 2008, CLIMATIC CHANGE, V88, P343, DOI 10.1007/s10584-007-9334-4; Wang S, 2007, J ENVIRON MANAGE, V85, P524, DOI 10.1016/j.jenvman.2006.09.019; Westerling AL, 2006, SCIENCE, V313, P940, DOI 10.1126/science.1128834	23	776	823	22	472	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2008	320	5882					1456	1457		10.1126/science.1155458	http://dx.doi.org/10.1126/science.1155458			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556550	Green Submitted			2022-12-28	WOS:000256676400033
J	Destler, B				Destler, Bill			A new relationship	NATURE			English	Editorial Material									Rochester Inst Technol, Rochester, NY 14623 USA	Rochester Institute of Technology	Destler, B (corresponding author), Rochester Inst Technol, 1 Lomb Mem Dr, Rochester, NY 14623 USA.							OKIMOTO D, 1994, JAPANESE FIRM SOURCE, P178	1	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2008	453	7197					853	854		10.1038/453853a	http://dx.doi.org/10.1038/453853a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311WV	18548050				2022-12-28	WOS:000256632000021
J	Wang, NC; Maggioni, AP; Konstam, MA; Zannad, F; Krasa, HB; Burnett, JC; Grinfeld, L; Swedberg, K; Udelson, JE; Cook, T; Traver, B; Zimmer, C; Orlandi, C; Gheorghiade, M				Wang, Norman C.; Maggioni, Aldo P.; Konstam, Marvin A.; Zannad, Faiez; Krasa, Holly B.; Burnett, John C., Jr.; Grinfeld, Liliana; Swedberg, Karl; Udelson, James E.; Cook, Thomas; Traver, Brian; Zimmer, Christopher; Orlandi, Cesare; Gheorghiade, Mihai		Efficacy Vasopressin Antagonism He	Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BUNDLE-BRANCH BLOCK; CARDIAC-RESYNCHRONIZATION THERAPY; LONG-TERM MORTALITY; DILATED CARDIOMYOPATHY; ELDERLY PATIENTS; CONDUCTION; PROGNOSIS; OUTCOMES; TRIAL; DEFIBRILLATOR	Context Hospitalization for heart failure is associated with high postdischarge mortality and morbidity. The predictive value of the QRS duration during admission for heart failure has not been well studied. Objective To investigate the predictive value of the QRS duration in patients hospitalized for heart failure with reduced left ventricular ejection fraction ( LVEF). Design, Setting, and Participants Retrospective, post hoc analysis from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan ( EVEREST), an event- driven, randomized, double- blind, placebo- controlled study in patients hospitalized for heart failure and having an LVEF of 40% or less. A total of 4133 patients were enrolled at 359 North American, South American, and European sites between October 7, 2003, and February 3, 2006. After excluding 1029 patients with a pacemaker, implantable cardioverter- defibrillator, or both at enrollment and 142 patients without a reported baseline QRS duration, 2962 patients were included in the analysis: 1641 had a normal QRS duration ( < 120 ms) and 1321 had a prolonged QRS duration ( < 120 ms). Main Outcome Measures Dual primary end points were all- cause mortality and the composite of cardiovascular death or hospitalization for heart failure. Results During a median follow- up of 9.9 months, all- cause mortality was 18.7% for patients with a normal baseline QRS duration and 28.1% for patients with a prolonged baseline QRS duration ( hazard ratio [ HR], 1.61; 95% confidence interval [ CI], 1.38- 1.87). The composite of cardiovascular death or hospitalization for heart failure was 32.4% for patients with a baseline QRS duration less than 120 ms and 41.6% for patients with a baseline QRS duration of 120 ms or greater ( HR, 1.40; 95% CI, 1.24-1.58). The increased risk associated with prolonged QRS duration was confirmed after adjusting for multiple variables for all- cause mortality ( HR, 1.24; 95% CI, 1.02-1.50) and the composite of cardiovascular death or hospitalization for heart failure ( HR, 1.28; 95% CI, 1.10- 1.49). Only 105 patients ( 3.6%) who presented with a prolonged baseline QRS duration had a normal QRS duration on their last inpatient electrocardiogram. Conclusion A prolonged QRS duration appears common in patients with reduced LVEF who are hospitalized for heart failure and is an independent predictor of high postdischarge morbidity and mortality.	[Wang, Norman C.; Gheorghiade, Mihai] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Maggioni, Aldo P.] ANMCO Res Ctr, Florence, Italy; [Konstam, Marvin A.; Udelson, James E.] Tufts Univ, New England Med Ctr, Boston, MA 02111 USA; [Zannad, Faiez] CHU Nancy, CIC, INSERM, Nancy, France; [Krasa, Holly B.; Zimmer, Christopher; Orlandi, Cesare] Otsuka Pharmaceut Co Ltd, Rockville, MD USA; [Burnett, John C., Jr.] Mayo Clin, Rochester, MN USA; [Grinfeld, Liliana] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina; [Swedberg, Karl] Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden; [Cook, Thomas; Traver, Brian] Univ Wisconsin, Madison, WI USA	Northwestern University; Feinberg School of Medicine; Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO); Tufts Medical Center; Tufts University; CHU de Nancy; Institut National de la Sante et de la Recherche Medicale (Inserm); Otsuka Pharmaceutical; Mayo Clinic; Hospital Italiano de Buenos Aires; University of Buenos Aires; Sahlgrenska University Hospital; University of Wisconsin System; University of Wisconsin Madison	Gheorghiade, M (corresponding author), Northwestern Univ, Feinberg Sch Med, 201 E Huron St,Galter Pavil 10-240, Chicago, IL 60611 USA.	m-gheorghiade@northwestern.edu	Swedberg, Karl/B-2475-2008; Zannad, Faiez/K-4649-2019; Maggioni, Aldo Pietro/AAL-5334-2020	Maggioni, Aldo Pietro/0000-0003-2764-6779				Abraham WT, 2006, J AM COLL CARDIOL, V47, p19A; Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Aranda JM, 2002, AM J CARDIOL, V90, P335, DOI 10.1016/S0002-9149(02)02479-7; Baldasseroni S, 2002, AM HEART J, V143, P398, DOI 10.1067/mhj.2002.121264; Barsheshet A, 2008, AM J CARDIOL, V101, P1303, DOI 10.1016/j.amjcard.2007.12.035; Beshai JF, 2007, NEW ENGL J MED, V357, P2461, DOI 10.1056/NEJMoa0706695; Bleeker GB, 2004, J CARDIOVASC ELECTR, V15, P544, DOI 10.1046/j.1540-8167.2004.03604.x; Breidthardt T, 2007, HEART, V93, P1093, DOI 10.1136/hrt.2006.102319; Breithardt OA, 2003, J AM COLL CARDIOL, V41, P765, DOI 10.1016/S0735-1097(02)02937-6; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; BROPHY JM, 1994, CAN J CARDIOL, V10, P543; Buxton AE, 2005, J AM COLL CARDIOL, V46, P310, DOI 10.1016/j.jacc.2005.03.060; Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496; Cleland JGF, 2001, EUR J HEART FAIL, V3, P481, DOI 10.1016/S1388-9842(01)00176-3; Danciu SC, 2006, AM J CARDIOL, V97, P256, DOI 10.1016/j.amjcard.2005.08.031; Fonarow GC, 2007, ARCH INTERN MED, V167, P1493, DOI 10.1001/archinte.167.14.1493; FRANZ MR, 1992, CIRCULATION, V86, P968, DOI 10.1161/01.CIR.86.3.968; Gheorghiade M, 2005, J CARD FAIL, V11, P260, DOI 10.1016/j.cardfail.2005.03.009; Gheorghiade M, 2005, CIRCULATION, V112, P3958, DOI 10.1161/CIRCULATIONAHA.105.590091; Grigioni F, 2002, J HEART LUNG TRANSPL, V21, P899, DOI 10.1016/S1053-2498(02)00431-X; Higgins SL, 2000, J AM COLL CARDIOL, V36, P824, DOI 10.1016/S0735-1097(00)00795-6; Iuliano S, 2002, AM HEART J, V143, P1085, DOI 10.1067/mhj.2002.122516; Koelling TM, 2005, CIRCULATION, V111, P179, DOI 10.1161/01.CIR.0000151811.53450.B8; Konstam MA, 2007, JAMA-J AM MED ASSOC, V297, P1319, DOI 10.1001/jama.297.12.1319; Krumholz HM, 2002, J AM COLL CARDIOL, V39, P83, DOI 10.1016/S0735-1097(01)01699-0; Leclercq C, 1998, J AM COLL CARDIOL, V32, P1825, DOI 10.1016/S0735-1097(98)00492-6; McCullough PA, 2005, INT J CARDIOL, V102, P303, DOI 10.1016/j.ijcard.2004.10.008; Mueller C, 2006, J INTERN MED, V260, P421, DOI 10.1111/j.1365-2796.2006.01703.x; Nelson GS, 2000, CIRCULATION, V102, P3053; Nelson GS, 2000, CIRCULATION, V101, P2703, DOI 10.1161/01.CIR.101.23.2703; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Rosamond W, 2007, CIRCULATION, V115, pE69, DOI 10.1161/CIRCULATIONAHA.106.179918; Shamim W, 2002, HEART, V88, P47, DOI 10.1136/heart.88.1.47; Shenkman HJ, 2002, CHEST, V122, P528, DOI 10.1378/chest.122.2.528; SILVERMAN ME, 1995, AM J CARDIOL, V75, P460, DOI 10.1016/S0002-9149(99)80581-5; Solomon SD, 2007, CIRCULATION, V116, P1482, DOI 10.1161/CIRCULATIONAHA.107.696906; Tabrizi F, 2007, EUR HEART J, V28, P2449, DOI 10.1093/eurheartj/ehm262; Taneja T, 2001, PACE, V24, P16, DOI 10.1046/j.1460-9592.2001.00016.x; Ukkonen H, 2003, CIRCULATION, V107, P28, DOI 10.1161/01.CIR.0000047068.02226.95; WILLEMS JL, 1985, J AM COLL CARDIOL, V5, P1261, DOI 10.1016/S0735-1097(85)80335-1; Xiao HB, 1996, INT J CARDIOL, V53, P163, DOI 10.1016/0167-5273(95)02502-2; Zimetbaum PJ, 2004, CIRCULATION, V110, P766, DOI 10.1161/01.CIR.0000139311.32278.32	42	142	156	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2008	299	22					2656	2666		10.1001/jama.299.22.2656	http://dx.doi.org/10.1001/jama.299.22.2656			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311FN	18544725	Bronze			2022-12-28	WOS:000256586200022
J	Charlesworth, G; Shepstone, L; Wilson, E; Reynolds, S; Mugford, M; Price, D; Harvey, I; Poland, F				Charlesworth, Georgina; Shepstone, Lee; Wilson, Edward; Reynolds, Shirley; Mugford, Miranda; Price, David; Harvey, Ian; Poland, Fiona			Befriending carers of people with dementia: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							SOCIAL SUPPORT; CAREGIVERS; INTERVENTION; DEPRESSION; SCALE	Objective To evaluate the effectiveness of a voluntary sector based befriending scheme in improving psychological wellbeing and quality of life for family carers of people with dementia. Design Single blind randomised controlled trial. Setting Community settings in East Anglia and London. Participants 236 family carers of people with primary progressive dementia. Intervention Contact with a befriender facilitator and offer of match with a trained lay volunteer befriender compared with no befriender facilitator contact; all participants continued to receive "usual care." Main outcome measures Carers' mood (hospital anxiety and depression scale-depression) and health related quality of life (EuroQoL) at 15 months post-randomisation. Results The intention to treat analysis showed no benefit for the intervention "access to a befriender facilitator" on the primary outcome measure or on any of the secondary outcome measures. Conclusions In common with many carers' services, befriending schemes are not taken up by all carers, and providing access to a befriending scheme is not effective in improving wellbeing.	[Charlesworth, Georgina] UCL, Ctr Behav & Social Sci Med, London W1W 7EJ, England; [Charlesworth, Georgina] NE London Mental Hlth Trust, London, England; [Shepstone, Lee; Wilson, Edward; Reynolds, Shirley; Mugford, Miranda; Harvey, Ian] Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England; [Price, David] Univ Aberdeen, Dept Gen Practice & Primary Care, Aberdeen AB25 2AY, Scotland; [Poland, Fiona] Univ E Anglia, Sch Allied Hlth Profess, Norwich NR4 7TJ, Norfolk, England	University of London; University College London; University of East Anglia; University of Aberdeen; University of East Anglia	Charlesworth, G (corresponding author), UCL, Ctr Behav & Social Sci Med, London W1W 7EJ, England.	g.charlesworth@ucl.ac.uk	Charlesworth, Georgina/C-2571-2008; Wilson, Ed/P-4310-2019; Reynolds, Shirley/E-2800-2010; Price, David/H-2837-2019	Charlesworth, Georgina/0000-0002-5278-1756; Wilson, Ed/0000-0002-8369-1577; Price, David/0000-0002-9728-9992; Poland, Fiona/0000-0003-0003-6911; Reynolds, Shirley/0000-0001-9975-2023	Department of Health [99/34/07] Funding Source: Medline; National Institute for Health Research [99/34/07] Funding Source: researchfish	Department of Health; National Institute for Health Research(National Institute for Health Research (NIHR))		Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; CHARLESWORTH G, 2008, HEALTH TECHNOL ASSES, V12, P1; Charlesworth G, 2007, QUAL AGEING OLDER AD, V8, P37, DOI 10.1108/14717794200700011; Cuijpers P, 2005, AGING MENT HEALTH, V9, P325, DOI 10.1080/13607860500090078; Drentea P, 2006, SOC SCI MED, V63, P957, DOI 10.1016/j.socscimed.2006.02.020; ELASHOFF JD, 2002, NQUERY ADVISOR VERSI; Harris T, 1999, BRIT J PSYCHIAT, V174, P219, DOI 10.1192/bjp.174.3.219; Hawkins S., 2006, VOLUNTEERS NHS IMPRO; HM Treasury, 2002, ROL VOL COMM SECT SE; LIPSEY MW, 1993, AM PSYCHOL, V48, P1181, DOI 10.1037/0003-066X.48.12.1181; National Centre for Volunteering, 2000, SAF AL GOOD PRACT AD; Ory MG, 1999, GERONTOLOGIST, V39, P177, DOI 10.1093/geront/39.2.177; Pillemer K, 2002, RES AGING, V24, P171, DOI 10.1177/0164027502242001; Richards K, 2003, AGING MENT HEALTH, V7, P7, DOI 10.1080/1360786021000058157; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; *SCOTT BEFR DEV FO, 1997, COD PRACT WORK TOG P; Stanley MA, 1998, AGING MENT HEALTH, V2, P186, DOI 10.1080/13607869856669; Stroebe W, 1996, J PERS SOC PSYCHOL, V70, P1241, DOI 10.1037/0022-3514.70.6.1241; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; ZIMET GD, 1988, J PERS ASSESS, V52, P30, DOI 10.1207/s15327752jpa5201_2	21	47	47	0	19	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2008	336	7656					1295	+		10.1136/bmj.39549.548831.AE	http://dx.doi.org/10.1136/bmj.39549.548831.AE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	312XO	18505757	Green Published, Green Submitted, Green Accepted, Bronze			2022-12-28	WOS:000256705900034
J	Douma, S; Petidis, K; Doumas, M; Papaefthimiou, P; Triantafyllou, A; Kartali, N; Papadopoulos, N; Vogiatzis, K; Zamboulis, C				Douma, Stella; Petidis, Konstantinos; Doumas, Michael; Papaefthimiou, Panagiota; Triantafyllou, Areti; Kartali, Niki; Papadopoulos, Nikolaos; Vogiatzis, Konstantinos; Zamboulis, Chrysanthos			Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study	LANCET			English	Article							PRIMARY ALDOSTERONISM; SECONDARY HYPERTENSION; UNRECOGNIZED EPIDEMIC; DIAGNOSIS; OUTCOMES; PATIENT; FORMS; RATIO	Background Results of several studies published since 1999 suggest that primary hyperaldosteronism (also known as Conn's syndrome) affects more than 10% of people with hypertension; however, such a high prevalence has also been disputed. Experts generally agree that resistant hypertension has the highest prevalence of primary hyperaldosteronism, on the basis of small studies. We aimed to assess the prevalence of primary hyperaldosteronism in a large group of patients with resistant hypertension. Methods Patients with resistant hypertension (blood pressure >140/90 mm Hg despite a three drug regimen, including a diuretic) who attended our outpatient clinic were assessed for primary hyperaldosteronism. Serum aldosterone and plasma renin activity were determined and their ratio was calculated. Patients with a positive test (ratio >65.16 and aldosterone concentrations >416 pmol/L) underwent salt suppression tests with intravenous saline and fludrocortisone. Diagnosis of primary hyperaldosteronism was further confirmed by the response to treatment with spironolactone. Findings Over 20 years, we studied 1616 patients with resistant hypertension. 338 patients (20.9%) had a ratio of more than 65.16 and aldosterone concentrations of more than 416 pmol/L. On the basis of salt suppression tests, 182 (11.3%) patients had primary hyperaldosteronism, and response to spironolactone treatment further confirmed this diagnosis. Hypokalaemia was seen only in 83 patients with primary hyperaldosteronism (45.6%). Interpretation Although the prevalence of Primary hyperaldosteronism in patients with resistant hypertension was high, it was substantially lower than previously reported. On the basis of this finding, we could assume that the prevalence of primary hyperaldosteronism in the general unselected hypertensive population is much lower than currently reported. Thus, the notion of an epidemic of primary hyperaldosteronism is not supported. Funding None.	[Douma, Stella; Petidis, Konstantinos; Doumas, Michael; Papaefthimiou, Panagiota; Triantafyllou, Areti; Kartali, Niki; Papadopoulos, Nikolaos; Vogiatzis, Konstantinos; Zamboulis, Chrysanthos] Aristotle Univ Thessaloniki, Hippokratio Gen Hosp, Propedeut Dept Internal Med 2, Thessaloniki 54643, Greece	Aristotle University of Thessaloniki	Doumas, M (corresponding author), Aristotle Univ Thessaloniki, Hippokratio Gen Hosp, Propedeut Dept Internal Med 2, Thessaloniki 54643, Greece.	michalisdoumas@yahoo.co.uk	N.G., Papadopoulos/L-8670-2013; Douma, Stella/O-2904-2013	N.G., Papadopoulos/0000-0002-4448-3468; Kartali, Nikoleta/0000-0003-3750-4782; Doumas, Michael/0000-0002-7269-8044; Triantafyllou, Areti/0000-0001-7644-0684				ANDERSEN GS, 1988, J HUM HYPERTENS, V2, P187; Calhoun DA, 2002, HYPERTENSION, V40, P892, DOI 10.1161/01.HYP.0000040261.30455.B6; Calhoun DA, 2002, CURR HYPERTENS REP, V4, P221, DOI 10.1007/s11906-002-0011-8; Calhoun DA, 2007, HYPERTENSION, V50, P447, DOI 10.1161/HYPERTENSIONAHA.106.086116; Catena C, 2008, ARCH INTERN MED, V168, P80, DOI 10.1001/archinternmed.2007.33; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; CONN JW, 1955, J LAB CLIN MED, V45, P3; Eide IK, 2004, J HYPERTENS, V22, P2217, DOI 10.1097/00004872-200411000-00026; Gallay BJ, 2001, AM J KIDNEY DIS, V37, P699, DOI 10.1016/S0272-6386(01)80117-7; GIFFORD RW, 1969, MILBANK FUND Q, V47, P170, DOI 10.2307/3349261; KAPLAN NM, 1967, ANN INTERN MED, V66, P1079, DOI 10.7326/0003-4819-66-6-1079; Kaplan NM, 2007, HYPERTENSION, V50, P454, DOI 10.1161/HYPERTENSIONAHA.106.086124; Lim PO, 1999, LANCET, V353, P40, DOI 10.1016/S0140-6736(05)74868-6; Mancia G, 2007, EUR HEART J, V28, P1462, DOI [10.1093/eurheartj/ehm236, 10.1093/eurheartj/eht151]; Martell N, 2003, BLOOD PRESSURE, V12, P149, DOI 10.1080/08037050310009950; Milliez P, 2005, J AM COLL CARDIOL, V45, P1243, DOI 10.1016/j.jacc.2005.01.015; Mosso L, 2003, HYPERTENSION, V42, P161, DOI 10.1161/01.HYP.0000079505.25750.11; Mulatero P, 2004, J CLIN ENDOCR METAB, V89, P1045, DOI 10.1210/jc.2003-031337; Mulatero P, 2002, HYPERTENSION, V40, P897, DOI 10.1161/01.HYP.0000038478.59760.41; Mulatero P, 2005, TRENDS ENDOCRIN MET, V16, P114, DOI 10.1016/j.tem.2005.02.007; Rossi GP, 2006, HYPERTENSION, V48, P232, DOI 10.1161/01.HYP.0000230444.01215.6a; Rossi GP, 2006, J AM COLL CARDIOL, V48, P2293, DOI 10.1016/j.jacc.2006.07.059; Schwartz GL, 2005, CLIN CHEM, V51, P386, DOI 10.1373/clinchem.2004.041780; Sechi LA, 2006, JAMA-J AM MED ASSOC, V295, P2638, DOI 10.1001/jama.295.22.2638; SETARO JF, 1992, NEW ENGL J MED, V327, P543; SINCLAIR AM, 1987, ARCH INTERN MED, V147, P1289, DOI 10.1001/archinte.147.7.1289; Stowasser M, 2001, J RENIN-ANGIO-ALDO S, V2, P156, DOI 10.3317/jraas.2001.022; Stowasser M, 2003, J HYPERTENS, V21, P2149, DOI 10.1097/00004872-200311000-00025; Stowasser M, 2005, J CLIN ENDOCR METAB, V90, P5070, DOI 10.1210/jc.2005-0681; Stowasser M, 2004, MOL CELL ENDOCRINOL, V217, P33, DOI 10.1016/j.mce.2003.10.006; Strauch B, 2003, J HUM HYPERTENS, V17, P349, DOI 10.1038/sj.jhh.1001554; Strauch B, 2006, AM J HYPERTENS, V19, P909, DOI 10.1016/j.amjhyper.2006.02.002; SWALES JD, 1982, LANCET, V1, P894; Tanabe A, 1997, Hypertens Res, V20, P85, DOI 10.1291/hypres.20.85; Umpierrez GE, 2007, DIABETES CARE, V30, P1699, DOI 10.2337/dc07-0031; Weinberger MH, 2006, AM J HYPERTENS, V19, P628, DOI 10.1016/j.amjhyper.2006.01.002; Young WF, 2003, ENDOCRINOLOGY, V144, P2208, DOI 10.1210/en.2003-0279	37	368	387	1	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	2008	371	9628					1921	1926		10.1016/S0140-6736(08)60834-X	http://dx.doi.org/10.1016/S0140-6736(08)60834-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310OI	18539224				2022-12-28	WOS:000256538500028
J	Greenhalgh, T; Wood, GW; Bratan, T; Stramer, K; Hinder, S				Greenhalgh, Trisha; Wood, Gary W.; Bratan, Tanja; Stramer, Katja; Hinder, Susan			Patients' attitudes to the summary care record and HealthSpace: qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFORMATION; PROGRAM	Objective To document the views of patients and the public towards the summary care record (SCR, a centrally stored medical record drawn from the general practice record) and HealthSpace (a personal health organiser accessible through the internet from which people can view their SCR), with a particular focus on those with low health literacy, potentially stigmatising conditions, or difficulties accessing health care. Design 103 semistructured individual interviews and seven focus groups. Setting Three early adopter primary care trusts in England where the SCR and HealthSpace are being piloted. All were in areas of relative socioeconomic deprivation. Participants Individual participants were recruited from general practice surgeries, walk-in centres, out of hours centres, and accident and emergency departments. Participants in focus groups were recruited through Voluntary sector organisations; they comprised advocates of vulnerable groups and advocates of people who speak limited English; people with HIV; users of mental health services; young adults; elderly people; and participants in a drug rehabilitation programme. Methods Participants were asked if they had received information about the SCR and HealthSpace and about their views on shared electronic records in different circumstances. Results Most people were not aware of the SCR or HealthSpace and did not recall receiving information about it. They saw both benefits and drawbacks to having an SCR and described a process of weighing the former against the latter when making their personal choice. Key factors influencing this choice included the nature of any illness (especially whether it was likely to lead to emergency care needs); past and present experience of healthcare and government surveillance; the person's level of engagement and health literacy; and their trust and confidence in the primary healthcare team and the wider NHS. Overall, people with stigmatising illness were more positive about the SCR than people who claimed to speak for "vulnerable groups." Misconceptions about the SCR were common, especially confusion about what data it contained and who would have access to it. Most people were not interested in recording their medical data or accessing their SCR via HealthSpace, but some saw the potential for this new technology to support self management and lay care for those with chronic illness. Conclusion Despite an extensive information programme in early adopter sites, the public remains unclear about current policy on shared electronic records, though most people view these as a positive development. The "implied consent" model for creating and accessing a person's SCR should be revisited, perhaps in favour of "consent to view" at the point of access.	[Greenhalgh, Trisha; Wood, Gary W.; Bratan, Tanja; Stramer, Katja] UCL, Dept Primary Care & Populat Sci, London N19 5LW, England; [Hinder, Susan] RaFT Consulting, Clitheroe BB7 4BN, Lancs, England	University of London; University College London	Greenhalgh, T (corresponding author), UCL, Dept Primary Care & Populat Sci, Highgate Hill, London N19 5LW, England.	p.greenhalgh@pcps.ucl.ac.uk	Greiver, Michelle/N-8764-2015; Greenhalgh, Trisha/B-1825-2015	Greiver, Michelle/0000-0001-8957-0285; Greenhalgh, Trisha/0000-0003-2369-8088	Medical Research Council [G0600654] Funding Source: Medline; Department of Health Funding Source: Medline; MRC [G0600654] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adams T, 2004, BRIT MED J, V328, P871, DOI 10.1136/bmj.328.7444.871; Anderson R, 2008, BRIT J GEN PRACT, V58, P75, DOI 10.3399/bjgp08X263992; BRENNAN S, 2005, NHS IT PROJECT; British Computer Society, 2006, WAY FORW NHS HLTH IN; CAYTON H, 2006, REPORT MINISTERIAL T; Davies M, 2008, BRIT J GEN PRACT, V58, P148, DOI 10.3399/bjgp08X277230; *DEP HLTH, 2005, CONN HLTH GUID NAT P; Gadd CS, 2001, J AM MED INFORM ASSN, P194; Greenhalgh T., 2008, SUMMARY CARE RECORD; Hanseth O, 2007, RISK, COMPLEXITY AND ICT, P1; Hibbard JH, 2007, MED CARE RES REV, V64, P379, DOI 10.1177/1077558707301630; Hillestad R, 2005, HEALTH AFFAIR, V24, P1103, DOI 10.1377/hlthaff.24.5.1103; Keen J, 2006, BRIT MED J, V333, P3, DOI 10.1136/bmj.38889.569201.DE; Krippendorff K., 1980, CONTENT ANAL INTRO I; MONTGOMERY I, 2005, GLASS CONSUMER LIFE, P187; Montgomery J., 2005, GLASS CONSUMER LIFE, P187; *NAT AUD OFF, 2006, DEP HLTH NAT PROGR I; *NAT AUD OFF, 2006, DEP HLTH NATL PROGRA; *NHS CONN HLTH, 2004, CONN HLTH BUS PLAN; Pyper C, 2004, BRIT J GEN PRACT, V54, P38; Ritchie J, 2002, ANAL QUALITATIVE DAT, P187; Ross SE, 2003, J AM MED INFORM ASSN, V10, P129, DOI 10.1197/jamia.M1147; *TNS UK, 2007, NHS CONN HLTH NAT EA; *TNS UK, 2007, 133643160085 TNS UK; WANLESS D, 2004, SECURING PUBLIC HLTH; Williams J, 2005, BRIT J GEN PRACT, V55, P340	26	90	92	0	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 7	2008	336	7656					1290	+		10.1136/bmj.a114	http://dx.doi.org/10.1136/bmj.a114			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	312XO	18511764	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000256705900033
J	Chen, XH; Wu, T; Wu, G; Liu, RH; Chen, H; Fang, DF				Chen, X. H.; Wu, T.; Wu, G.; Liu, R. H.; Chen, H.; Fang, D. F.			Superconductivity at 43 K in SmFeAsO(1-x)F(x)	NATURE			English	Article							ZRCUSIAS TYPE-STRUCTURE	Since the discovery of high- transition- temperature ( high-T(c)) superconductivity in layered copper oxides, extensive effort has been devoted to exploring the origins of this phenomenon. A T(c) higher than 40 K ( about the theoretical maximum predicted from Bardeen - Cooper - Schrieffer theory(1)), however, has been obtained only in the copper oxide superconductors. The highest reported value for non- copper- oxide bulk superconductivity is T(c) = 39 K in MgB(2) ( ref. 2). The layered rare- earth metal oxypnictides LnOFeAs ( where Ln is La - Nd, Sm and Gd) are now attracting attention following the discovery of superconductivity at 26 K in the iron-based LaO(1-x)F(x)FeAs ( ref. 3). Here we report the discovery of bulk superconductivity in the related compound SmFeAsO(1-x)F(x), which has a ZrCuSiAs-type structure. Resistivity and magnetization measurements reveal a transition temperature as high as 43 K. This provides a new material base for studying the origin of high- temperature superconductivity.	[Chen, X. H.; Wu, T.; Wu, G.; Liu, R. H.; Chen, H.; Fang, D. F.] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Peoples R China; [Chen, X. H.; Wu, T.; Wu, G.; Liu, R. H.; Chen, H.; Fang, D. F.] Univ Sci & Technol China, Dept Phys, Hefei 230026, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Chen, XH (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Peoples R China.	chenxh@ustc.edu.cn	Liu, Ronghua/AAA-3672-2019; Liu, Ronghua/A-9790-2013	Liu, Ronghua/0000-0002-4053-3923; Liu, Ronghua/0000-0002-4053-3923				Kamihara Y, 2008, J AM CHEM SOC, V130, P3296, DOI 10.1021/ja800073m; MCMILLAN WL, 1968, PHYS REV, V167, P331, DOI 10.1103/PhysRev.167.331; Nagamatsu J, 2001, NATURE, V410, P63, DOI 10.1038/35065039; Quebe P, 2000, J ALLOY COMPD, V302, P70, DOI 10.1016/S0925-8388(99)00802-6; ZIMMER BI, 1995, J ALLOY COMPD, V229, P238, DOI 10.1016/0925-8388(95)01672-4	5	1555	1607	10	614	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 5	2008	453	7196					761	762		10.1038/nature07045	http://dx.doi.org/10.1038/nature07045			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308UK	18500328	Green Submitted			2022-12-28	WOS:000256415300038
J	Calonge, N; Petitti, DB; DeWitt, TG; Dietrich, AJ; Gordis, L; Gregory, KD; Harris, R; Isham, G; Leipzig, R; LeFevre, ML; Loveland-Cherry, C; Marion, LN; Moyer, VA; Ockene, JK; Sawaya, GF; Yawn, BP				Calonge, Ned; Petitti, Diana B.; DeWitt, Thomas G.; Dietrich, Allen J.; Gordis, Leon; Gregory, Kimberly D.; Harris, Russell; Isham, George; Leipzig, Rosanne; LeFevre, Michael L.; Loveland-Cherry, Carol; Marion, Lucy N.; Moyer, Virginia A.; Ockene, Judith K.; Sawaya, George F.; Yawn, Barbara P.		US Preventive Serv Task Force	Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; IMPAIRED FASTING GLUCOSE; NUTRITION EXAMINATION SURVEY; CONVERTING-ENZYME-INHIBITOR; CARDIOVASCULAR RISK-FACTORS; LOW-DOSE ASPIRIN; GLYCATED HEMOGLOBIN; RANDOMIZED-TRIAL; NATIONAL-HEALTH; DIAGNOSIS	Description: Updated U. S. Preventive Services Task Force (USPSTF) recommendation about screening for type 2 diabetes mellitus in adults. Methods: To estimate the balance of benefits and harms of screening, the USPSTF updated its 2003 evidence review, adding evidence from new trials as well as updates on earlier studies. The review for this current recommendation focused on evidence that early treatment prevented long-term adverse outcomes of diabetes, including cardiovascular events, visual impairment, renal failure, and amputation. Recommendations: Screen for type 2 diabetes in asymptomatic adults with sustained blood pressure (either treated or untreated) greater than 135/80 mm Hg. (B recommendation) Current evidence is insufficient to assess the balance of benefits and harms of routine screening in asymptomatic adults with blood pressure of 135/80 mm Hg or lower. (I statement).	[Calonge, Ned] Colorado Dept Publ Hlth & Environm, Denver, CO USA; [Petitti, Diana B.] Univ So Calif, Keck Sch Med, Sierra Madre, CA USA; [DeWitt, Thomas G.] Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; [Dietrich, Allen J.] Dartmouth Med Sch, Hanover, NH USA; [Gordis, Leon] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Gregory, Kimberly D.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; [Harris, Russell] Univ N Carolina, Sch Med, Chapel Hill, NC USA; [Isham, George] HealthPartners, Minneapolis, MN USA; [Leipzig, Rosanne] Mt Sinai Sch Med, New York, NY USA; [LeFevre, Michael L.] Univ Missouri, Sch Med, Columbia, MO USA; [Loveland-Cherry, Carol] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA; [Marion, Lucy N.] Med Coll Georgia, Augusta, GA 30912 USA; [Moyer, Virginia A.] Univ Texas Houston, Hlth Sci Ctr, Houston, TX USA; [Ockene, Judith K.] Univ Massachusetts, Sch Med, Worcester, MA USA; [Sawaya, George F.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Yawn, Barbara P.] Olmsted Med Ctr, Rochester, MN USA	Colorado Department of Public Health & Environment; University of Southern California; Cincinnati Children's Hospital Medical Center; Dartmouth College; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Cedars Sinai Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Icahn School of Medicine at Mount Sinai; University of Missouri System; University of Missouri Columbia; University of Michigan System; University of Michigan; University System of Georgia; Augusta University; University of Texas System; University of Texas Health Science Center Houston; University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California San Francisco; Olmsted Medical Center	Calonge, N (corresponding author), US Prevent Serv Task Force, Agcy Healthcare Res & Qual, Rockville, MD USA.							*AM AC FAM PHYS, 2007, AAFP POL ACT SUMM RE; [Anonymous], 2007, DIABETES CARE, V30, pS4, DOI [10.2337/dc07-S004, DOI 10.2337/DC07-S004]; Berg AO, 2003, ANN INTERN MED, V138, P212, DOI 10.7326/0003-4819-138-3-200302040-00014; BRADFORD RH, 1994, AM J CARDIOL, V74, P667, DOI 10.1016/0002-9149(94)90307-7; *CDCP, 2005, NAT DIAB FACT SHEET; Chowdhury TA, 2002, QJM-INT J MED, V95, P241, DOI 10.1093/qjmed/95.4.241; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Collins R, 2003, LANCET, V361, P2005; Colwell JA, 1997, DIABETES CARE, V20, P1767, DOI 10.2337/diacare.20.11.1767; Colwell JA, 2000, DIABETES CARE, V23, pS61; Coutinho M, 1999, DIABETES CARE, V22, P233, DOI 10.2337/diacare.22.2.233; Cowie CC, 2006, DIABETES CARE, V29, P1263, DOI 10.2337/dc06-0062; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; Davis TME, 1997, DIABETES CARE, V20, P1435, DOI 10.2337/diacare.20.9.1435; Edelman D, 2004, J GEN INTERN MED, V19, P1175, DOI 10.1111/j.1525-1497.2004.40178.x; Engelgau MM, 1997, DIABETES CARE, V20, P785, DOI 10.2337/diacare.20.5.785; Feig DS, 2005, CAN MED ASSOC J, V172, P177, DOI 10.1503/cmaj.1041197; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gregg EW, 2004, DIABETES CARE, V27, P2806, DOI 10.2337/diacare.27.12.2806; HAFFNER SM, 1990, JAMA-J AM MED ASSOC, V263, P2893, DOI 10.1001/jama.263.21.2893; Haffner SM, 1999, ARCH INTERN MED, V159, P2661, DOI 10.1001/archinte.159.22.2661; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; HARRIS MI, 1992, DIABETES CARE, V15, P815, DOI 10.2337/diacare.15.7.815; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Harris R, 2003, ANN INTERN MED, V138, P215, DOI 10.7326/0003-4819-138-3-200302040-00015; Hayden M, 2002, ANN INTERN MED, V136, P161, DOI 10.7326/0003-4819-136-2-200201150-00016; Henricsson M, 1996, ACTA OPHTHALMOL SCAN, V74, P533; Hu FB, 2002, DIABETES CARE, V25, P1129, DOI 10.2337/diacare.25.7.1129; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234; Khaw KT, 2001, BMJ-BRIT MED J, V322, P15, DOI 10.1136/bmj.322.7277.15; KLEIN R, 1988, JAMA-J AM MED ASSOC, V260, P2864, DOI 10.1001/jama.260.19.2864; Lauritzen T, 2000, INT J OBESITY, V24, pS6, DOI 10.1038/sj.ijo.0801420; Little RR, 2001, CLIN CHEM, V47, P1985; *LIV DIAB EY STUD, 2003, LANCET, V361, P195; MCCANCE DR, 1994, BRIT MED J, V308, P1323, DOI 10.1136/bmj.308.6940.1323; MCPHILLIPS JB, 1990, AM J EPIDEMIOL, V131, P443, DOI 10.1093/oxfordjournals.aje.a115519; Meigs JB, 1998, ANN INTERN MED, V128, P524, DOI 10.7326/0003-4819-128-7-199804010-00002; Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761; Norberg M, 2006, J INTERN MED, V260, P263, DOI 10.1111/j.1365-2796.2006.01689.x; Norris SL, 2008, ANN INTERN MED, V148, P855, DOI 10.7326/0003-4819-148-11-200806030-00008; PAN WH, 1986, AM J EPIDEMIOL, V123, P504, DOI 10.1093/oxfordjournals.aje.a114266; Peters AL, 1996, JAMA-J AM MED ASSOC, V276, P1246, DOI 10.1001/jama.276.15.1246; PIERCE LR, 1990, JAMA-J AM MED ASSOC, V264, P71, DOI 10.1001/jama.264.1.71; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Stratton IM, 2001, DIABETOLOGIA, V44, P156, DOI 10.1007/s001250051594; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Tuomilehto J, 1999, NEW ENGL J MED, V340, P677, DOI 10.1056/NEJM199903043400902; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Yusuf S, 2000, NEW ENGL J MED, V342, P145	52	122	122	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2008	148	11					846	U63		10.7326/0003-4819-148-11-200806030-00007	http://dx.doi.org/10.7326/0003-4819-148-11-200806030-00007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308CG	18519930				2022-12-28	WOS:000256365300006
J	Dehaene, S; Izard, V; Spelke, E; Pica, P				Dehaene, Stanislas; Izard, Veronique; Spelke, Elizabeth; Pica, Pierre			Log or linear? Distinct intuitions of the number scale in western and amazonian indigene cultures	SCIENCE			English	Article							NUMERICAL ESTIMATION; REPRESENTATIONS	The mapping of numbers onto space is fundamental to measurement and to mathematics. Is this mapping a cultural invention or a universal intuition shared by all humans regardless of culture and education? We probed number- space mappings in the Mundurucu, an Amazonian indigene group with a reduced numerical lexicon and little or no formal education. At all ages, the Mundurucu mapped symbolic and nonsymbolic numbers onto a logarithmic scale, whereas Western adults used linear mapping with small or symbolic numbers and logarithmic mapping when numbers were presented nonsymbolically under conditions that discouraged counting. This indicates that the mapping of numbers onto space is a universal intuition and that this initial intuition of number is logarithmic. The concept of a linear number line appears to be a cultural invention that fails to develop in the absence of formal education.	[Dehaene, Stanislas; Izard, Veronique] INSERM, Cognit Neuroimaging Unit, IFR 49, Gif Sur Yvette, France; [Dehaene, Stanislas; Izard, Veronique] Comis Energia Atom, Neurospin Ctr, IFR 49, Gif Sur Yvette, France; [Dehaene, Stanislas] Coll France, F-75231 Paris, France; [Dehaene, Stanislas; Izard, Veronique] Univ Paris Sud, IFR 49, F-91191 Gif Sur Yvette, France; [Izard, Veronique; Spelke, Elizabeth] Harvard Univ, Dept Psychol, Cambridge, MA 02139 USA; [Pica, Pierre] CNRS, UMR 7023, Paris, France; [Pica, Pierre] Univ Paris 08, Paris, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; College de France; UDICE-French Research Universities; Universite Paris Saclay; Harvard University; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Humanities & Social Sciences (INSHS); Universite Paris-VIII	Dehaene, S (corresponding author), INSERM, Cognit Neuroimaging Unit, IFR 49, Gif Sur Yvette, France.	stanislas.dehaene@cea.fr	Pica, Pierre/H-9523-2012; Pica, Pierre/N-1342-2019	Pica, Pierre/0000-0001-9452-5446; Pica, Pierre/0000-0001-9452-5446				BANKS WP, 1981, PERCEPT PSYCHOPHYS, V29, P95, DOI 10.3758/BF03207272; Booth JL, 2006, DEV PSYCHOL, V42, P189, DOI 10.1037/0012-1649.41.6.189; Butterworth B., 1999, MATH BRAIN; Dehaene S, 2002, Q J EXP PSYCHOL-A, V55, P705, DOI 10.1080/02724980244000044; Dehaene S, 2006, SCIENCE, V311, P381, DOI 10.1126/science.1121739; Dehaene S, 2004, CURR OPIN NEUROBIOL, V14, P218, DOI 10.1016/j.conb.2004.03.008; DEHAENE S, 1993, J EXP PSYCHOL GEN, V122, P371, DOI 10.1037/0278-7393.21.2.314; Dehaene S., 1997, NUMBER SENSE; DEHAENE S, 2007, ATTENTION PERFORM, V22, P527, DOI DOI 10.1093/ACPR0F:0S0/9780199231447.003.0024; Feigenson L, 2004, TRENDS COGN SCI, V8, P307, DOI 10.1016/j.tics.2004.05.002; Fischer MH, 2003, NAT NEUROSCI, V6, P555, DOI 10.1038/nn1066; Galton F., 1880, NATURE, V21, P252, DOI [10.1038/021252a0, DOI 10.1038/021252A0]; Gordon P, 2004, SCIENCE, V306, P496, DOI 10.1126/science.1094492; Hubbard EM, 2005, NAT REV NEUROSCI, V6, P435, DOI 10.1038/nrn1684; Izard V, 2008, COGNITION, V106, P1221, DOI 10.1016/j.cognition.2007.06.004; Kline M., 1980, MATH LOSS CERTAINTY; Nieder A, 2005, NAT REV NEUROSCI, V6, P177, DOI 10.1038/nrn1626; Nieder A, 2004, P NATL ACAD SCI USA, V101, P7457, DOI 10.1073/pnas.0402239101; Piazza M, 2006, COGN NEUROPSYCHOL, V23, P1162, DOI 10.1080/02643290600780080; Pica P, 2004, SCIENCE, V306, P499, DOI 10.1126/science.1102085; Pinel P, 2004, NEURON, V41, P983, DOI 10.1016/S0896-6273(04)00107-2; Shepard RN, 2001, BEHAV BRAIN SCI, V24, P581, DOI 10.1017/S0140525X01000012; SHEPARD RN, 1975, COGNITIVE PSYCHOL, V7, P82, DOI 10.1016/0010-0285(75)90006-7; Siegler RS, 2004, CHILD DEV, V75, P428, DOI 10.1111/j.1467-8624.2004.00684.x; Siegler RS, 2003, PSYCHOL SCI, V14, P237, DOI 10.1111/1467-9280.02438; Simon O, 2002, NEURON, V33, P475, DOI 10.1016/S0896-6273(02)00575-5; VANOEFFELEN MP, 1982, PERCEPT PSYCHOPHYS, V32, P163, DOI 10.3758/BF03204275	28	362	374	2	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2008	320	5880					1217	1220		10.1126/science.1156540	http://dx.doi.org/10.1126/science.1156540			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	306FF	18511690	Green Submitted, Green Published, Green Accepted			2022-12-28	WOS:000256233000039
J	Kind, J; Vaquerizas, JM; Gebhardt, P; Gentzel, M; Luscombe, NM; Bertone, P; Akhtar, A				Kind, Jop; Vaquerizas, Juan M.; Gebhardt, Philipp; Gentzel, Marc; Luscombe, Nicholas M.; Bertone, Paul; Akhtar, Asifa			Genome-wide analysis reveals MOF as a key regulator of dosage compensation and gene expression in Drosophila	CELL			English	Article							GLOBAL HISTONE ACETYLATION; MSL COMPLEX; HIGH-RESOLUTION; H4 ACETYLATION; X-CHROMOSOME; ACETYLTRANSFERASE; PROTEIN; TRANSCRIPTION; RECRUITMENT; METHYLATION	Dosage compensation, mediated by the MSL complex, regulates X-chromosomal gene expression in Drosophila. Here we report that the histone H4 lysine 16 (H4K16) specific histone acetyltransferase MOF displays differential binding behavior depending on whether the target gene is located on the X chromosome versus the autosomes. More specifically, on the male X chromosome, where MSL1 and MSL3 are preferentially associated with the 30 end of dosage compensated genes, MOF displays a bimodal distribution binding to promoters and the 30 ends of genes. In contrast, on MSL1/MSL3 independent X-linked genes and autosomal genes in males and females, MOF binds primarily to promoters. Binding of MOF to autosomes is functional, as H4K16 acetylation and the transcription levels of a number of genes are affected upon MOF depletion. Therefore, MOF is not only involved in the onset of dosage compensation, but also acts as a regulator of gene expression in the Drosophila genome.	[Kind, Jop; Gebhardt, Philipp; Gentzel, Marc; Luscombe, Nicholas M.; Bertone, Paul; Akhtar, Asifa] European Mol Biol Lab, Gene Express Unit, D-69117 Heidelberg, Germany; [Vaquerizas, Juan M.; Luscombe, Nicholas M.; Bertone, Paul] EMBL European Bioinformat Inst, Cambridge CB10 1SD, England	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL)	Akhtar, A (corresponding author), European Mol Biol Lab, Gene Express Unit, Meyerhofstr 1, D-69117 Heidelberg, Germany.	akhtar@embl.de	Vaquerizas, Juan M/F-2676-2011; Vaquerizas, Juan M/AAY-2339-2020; Bertone, Paul/A-6600-2013; Bertone, Paul/Z-3734-2019	Vaquerizas, Juan M/0000-0002-6583-6541; Vaquerizas, Juan M/0000-0002-6583-6541; Bertone, Paul/0000-0001-5059-4829; Bertone, Paul/0000-0001-5059-4829; Gentzel, Marc/0000-0002-4482-6010; Gebhardt, Philipp/0000-0001-5879-2512				Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Alekseyenko AA, 2006, GENE DEV, V20, P848, DOI 10.1101/gad.1400206; Anguita E, 2001, P NATL ACAD SCI USA, V98, P12114, DOI 10.1073/pnas.201413098; BASHAW GJ, 1995, DEVELOPMENT, V121, P3245; Bell O, 2008, MOL CELL BIOL, V28, P3401, DOI 10.1128/MCB.00006-08; Bhadra U, 1999, GENETICS, V152, P249; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; Calestagne-Morelli A, 2006, BIOCHEM CELL BIOL, V84, P518, DOI 10.1139/O06-067; Carrozza MJ, 2005, CELL, V123, P581, DOI 10.1016/j.cell.2005.10.023; Corona DFV, 2002, EMBO REP, V3, P242, DOI 10.1093/embo-reports/kvf056; Dahlsveen IK, 2006, PLOS GENET, V2, P104, DOI 10.1371/journal.pgen.0020005; Dion MF, 2005, P NATL ACAD SCI USA, V102, P5501, DOI 10.1073/pnas.0500136102; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Duncan K, 2006, GENE DEV, V20, P368, DOI 10.1101/gad.371406; Gilfillan GD, 2006, GENE DEV, V20, P858, DOI 10.1101/gad.1399406; Han ZF, 2006, MOL CELL, V22, P137, DOI 10.1016/j.molcel.2006.03.018; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Horak CE, 2002, METHOD ENZYMOL, V350, P469, DOI 10.1016/S0076-6879(02)50979-4; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; Kelley RL, 1999, CELL, V98, P513, DOI 10.1016/S0092-8674(00)81979-0; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; Kind J, 2007, GENE DEV, V21, P2030, DOI 10.1101/gad.430807; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Larschan E, 2007, MOL CELL, V28, P121, DOI 10.1016/j.molcel.2007.08.011; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Legube G, 2006, GENE DEV, V20, P871, DOI 10.1101/gad.377506; Lucchesi JC, 2005, ANNU REV GENET, V39, P615, DOI 10.1146/annurev.genet.39.073003.094210; Marin I, 2003, J MOL EVOL, V56, P527, DOI 10.1007/s00239-002-2422-1; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; Mendjan S, 2006, MOL CELL, V21, P811, DOI 10.1016/j.molcel.2006.02.007; Mendjan S, 2007, CHROMOSOMA, V116, P95, DOI 10.1007/s00412-006-0089-x; Morales V, 2004, EMBO J, V23, P2258, DOI 10.1038/sj.emboj.7600235; Park Y, 2002, SCIENCE, V298, P1620, DOI 10.1126/science.1076686; Parkinson H, 2007, NUCLEIC ACIDS RES, V35, pD747, DOI 10.1093/nar/gkl995; Schubeler D, 2006, GENE DEV, V20, P749, DOI 10.1101/gad.1423006; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Smith ER, 2005, MOL CELL BIOL, V25, P9175, DOI 10.1128/MCB.25.21.9175-9188.2005; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; Smith ER, 2001, J BIOL CHEM, V276, P31483, DOI 10.1074/jbc.C100351200; Straub T, 2007, NAT REV GENET, V8, P47, DOI 10.1038/nrg2013; Taipale M, 2005, MOL CELL BIOL, V25, P6798, DOI 10.1128/MCB.25.15.6798-6810.2005; WORBY C, 2001, SCI STKE, V1, P95; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Yang XJ, 2007, ONCOGENE, V26, P5310, DOI 10.1038/sj.onc.1210599; ZHOU SB, 1995, EMBO J, V14, P2884, DOI 10.1002/j.1460-2075.1995.tb07288.x	46	121	122	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	2008	133	5					813	828		10.1016/j.cell.2008.04.036	http://dx.doi.org/10.1016/j.cell.2008.04.036			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510926	Bronze			2022-12-28	WOS:000256274500014
J	Simon, DJ; Madison, JM; Conery, AL; Thompson-Peer, KL; Soskis, M; Ruvkun, GB; Kaplan, JM; Kim, JK				Simon, David J.; Madison, Jon M.; Conery, Annie L.; Thompson-Peer, Katherine L.; Soskis, Michael; Ruvkun, Gary B.; Kaplan, Joshua M.; Kim, John K.			The MicroRNA miR-1 regulates a MEF-2-dependent retrograde signal at neuromuscular junctions	CELL			English	Article							SYNAPTIC-TRANSMISSION; ACETYLCHOLINE-RECEPTORS; NICOTINIC RECEPTOR; DIFFERENTIATION; ABUNDANCE; TARGETS; IDENTIFICATION; EXPRESSION; MATURATION; PROTEINS	We show that miR-1, a conserved muscle-specific microRNA, regulates aspects of both pre- and post-synaptic function at C. elegans neuromuscular junctions. miR-1 regulates the expression level of two nicotinic acetylcholine receptor (nAChR) subunits (UNC-29 and UNC-63), thereby altering muscle sensitivity to acetylcholine (ACh). miR-1 also regulates the muscle transcription factor MEF-2, which results in altered presynaptic ACh secretion, suggesting that MEF-2 activity in muscles controls a retrograde signal. The effect of the MEF-2-dependent retrograde signal on secretion is mediated by the synaptic vesicle protein RAB-3. Finally, acute activation of levamisole-sensitive nAChRs stimulates MEF-2-dependent transcriptional responses and induces the MEF-2-dependent retrograde signal. We propose that miR-1 refines synaptic function by coupling changes in muscle activity to changes in presynaptic function.	[Simon, David J.; Madison, Jon M.; Conery, Annie L.; Thompson-Peer, Katherine L.; Ruvkun, Gary B.; Kaplan, Joshua M.; Kim, John K.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; [Simon, David J.; Soskis, Michael] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Kaplan, JM (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.	kaplan@molbio.mgh.harvard.edu	Thompson-Peer, Katherine/AAC-1051-2020	Thompson-Peer, Katherine/0000-0002-4200-3870; Simon, David/0000-0002-2683-5757	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032196, F32NS010310] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS032196-15, R01 NS032196-13, R01 NS032196, F32 NS010310, R01 NS032196-14, R01 NS032196-11, R01 NS032196-12, 1F32NS10310] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Black BL, 1997, MOL CELL BIOL, V17, P2756, DOI 10.1128/MCB.17.5.2756; Brown LA, 2006, INT J PARASITOL, V36, P617, DOI 10.1016/j.ijpara.2006.01.016; Cao XW, 2006, ANNU REV NEUROSCI, V29, P77, DOI 10.1146/annurev.neuro.29.051605.112839; CHEN L, 1992, SCIENCE, V256, P240, DOI 10.1126/science.1314423; Davis GW, 2001, ANNU REV PHYSIOL, V63, P847, DOI 10.1146/annurev.physiol.63.1.847; Dichoso D, 2000, DEV BIOL, V223, P431, DOI 10.1006/dbio.2000.9758; Dittman JS, 2006, P NATL ACAD SCI USA, V103, P11399, DOI 10.1073/pnas.0600784103; Doi M, 2002, NEURON, V33, P249, DOI 10.1016/S0896-6273(01)00587-6; Dreier L, 2005, NEURON, V46, P51, DOI 10.1016/j.neuron.2004.12.058; Enright Anton J, 2003, Genome Biol, V5, pR1, DOI 10.1186/gb-2003-5-1-r1; Flavell SW, 2006, SCIENCE, V311, P1008, DOI 10.1126/science.1122511; Francis MM, 2005, NEURON, V46, P581, DOI 10.1016/j.neuron.2005.04.010; Giraldez AJ, 2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020; Gottschalk A, 2005, EMBO J, V24, P2566, DOI 10.1038/sj.emboj.7600741; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; GU Y, 1988, NEURON, V1, P117, DOI 10.1016/0896-6273(88)90195-X; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Kalinovsky A, 2004, CURR OPIN NEUROBIOL, V14, P272, DOI 10.1016/j.conb.2004.05.011; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kosik KS, 2006, NAT REV NEUROSCI, V7, P911, DOI 10.1038/nrn2037; Koushika SP, 2001, NAT NEUROSCI, V4, P997, DOI 10.1038/nn732; Lall S, 2006, CURR BIOL, V16, P460, DOI 10.1016/j.cub.2006.01.050; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; McEwen JM, 2006, NEURON, V51, P303, DOI 10.1016/j.neuron.2006.06.025; Millar NS, 2003, BIOCHEM SOC T, V31, P869, DOI 10.1042/BST0310869; Miller KG, 1996, P NATL ACAD SCI USA, V93, P12593, DOI 10.1073/pnas.93.22.12593; Missias AC, 1996, DEV BIOL, V179, P223, DOI 10.1006/dbio.1996.0253; Nguyen HT, 2006, CURR OPIN GENET DEV, V16, P533, DOI 10.1016/j.gde.2006.08.010; Nurrish S, 1999, NEURON, V24, P231, DOI 10.1016/S0896-6273(00)80835-1; Rao PK, 2006, P NATL ACAD SCI USA, V103, P8721, DOI 10.1073/pnas.0602831103; Richmond JE, 1999, NAT NEUROSCI, V2, P791, DOI 10.1038/12160; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Roy PJ, 2002, NATURE, V418, P975, DOI 10.1038/nature01012; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; Scheiffele P, 2003, ANNU REV NEUROSCI, V26, P485, DOI 10.1146/annurev.neuro.26.043002.094940; Schluter OM, 2004, J NEUROSCI, V24, P6629, DOI 10.1523/JNEUROSCI.1610-04.2004; Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367; Shalizi A, 2006, SCIENCE, V311, P1012, DOI 10.1126/science.1122513; Shalizi AK, 2005, CURR TOP DEV BIOL, V69, P239, DOI 10.1016/S0070-2153(05)69009-6; Sokol NS, 2005, GENE DEV, V19, P2343, DOI 10.1101/gad.1356105; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Thiagarajan R, 2004, J PHYSIOL-LONDON, V555, P439, DOI 10.1113/jphysiol.2003.056333; Touroutine D, 2005, J BIOL CHEM, V280, P27013, DOI 10.1074/jbc.M502818200; Turrigiano GG, 2004, NAT REV NEUROSCI, V5, P97, DOI 10.1038/nrn1327; van der Linden AM, 2007, EMBO J, V26, P358, DOI 10.1038/sj.emboj.7601479; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817; Zhao Y, 2007, CELL, V129, P303, DOI 10.1016/j.cell.2007.03.030; Zhen M, 1999, NATURE, V401, P371, DOI 10.1038/43886	48	145	160	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	2008	133	5					903	915		10.1016/j.cell.2008.04.035	http://dx.doi.org/10.1016/j.cell.2008.04.035			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510933	Green Accepted, Bronze			2022-12-28	WOS:000256274500021
J	Tosca, NJ; Knoll, AH; McLennan, SM				Tosca, Nicholas J.; Knoll, Andrew H.; McLennan, Scott M.			Water activity and the challenge for life on early Mars	SCIENCE			English	Article							MERIDIANI-PLANUM; BURNS FORMATION; ASSEMBLAGES; RECORD	In situ and orbital exploration of the martian surface has shown that acidic, saline liquid water was intermittently available on ancient Mars. The habitability of these waters depends critically on water activity (aH(2)O), a thermodynamic measure of salinity, which, for terrestrial organisms, has sharply defined limits. Using constraints on fluid chemistry and saline mineralogy based on martian data, we calculated the maximum aH(2)O for Meridiani Planum and other environments where salts precipitated from martian brines. Our calculations indicate that the salinity of well-documented surface waters often exceeded levels tolerated by known terrestrial organisms.	[Tosca, Nicholas J.; Knoll, Andrew H.] Harvard Univ, Dept Organism & Evolut Biol, Cambridge, MA 02138 USA; [McLennan, Scott M.] SUNY Stony Brook, Dept Geosci, Stony Brook, NY 11794 USA	Harvard University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Tosca, NJ (corresponding author), Harvard Univ, Dept Organism & Evolut Biol, Cambridge, MA 02138 USA.	ntosca@fas.harvard.edu		McLennan, Scott/0000-0003-4259-7178; Tosca, Nicholas/0000-0003-4415-4231				Andrews-Hanna JC, 2007, NATURE, V446, P163, DOI 10.1038/nature05594; Bridges JC, 2000, EARTH PLANET SC LETT, V176, P267, DOI 10.1016/S0012-821X(00)00019-4; Carr M. H, 2007, SURFACE MARS; Clark BC, 2005, EARTH PLANET SC LETT, V240, P73, DOI 10.1016/j.epsl.2005.09.040; Gendrin A, 2005, SCIENCE, V307, P1587, DOI 10.1126/science.1109087; Grant WD, 2004, PHILOS T R SOC B, V359, P1249, DOI 10.1098/rstb.2004.1502; Grotzinger JP, 2005, EARTH PLANET SC LETT, V240, P11, DOI 10.1016/j.epsl.2005.09.039; Hardie L. A, 1970, MINERALOG SOC AM SPE, P273; Hurowitz JA, 2007, EARTH PLANET SC LETT, V260, P432, DOI 10.1016/j.epsl.2007.05.043; Johnson JR, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL029894; Keller JM, 2006, J GEOPHYS RES-PLANET, V111, DOI 10.1029/2006JE002679; Klingelhofer G, 2004, SCIENCE, V306, P1740, DOI 10.1126/science.1104653; Knoll AH, 2005, EARTH PLANET SC LETT, V240, P179, DOI 10.1016/j.epsl.2005.09.045; Knoll AH, 2008, J GEOPHYS RES-PLANET, V113, DOI 10.1029/2007JE002949; Madden MEE, 2004, NATURE, V431, P821, DOI 10.1038/nature02971; MARION GM, 2008, COLD AQUEOUS GEOCHEM; McLennan SM, 2005, EARTH PLANET SC LETT, V240, P95, DOI 10.1016/j.epsl.2005.09.041; Ming DW, 2006, J GEOPHYS RES-PLANET, V111, DOI 10.1029/2005JE002560; Oren A, 2002, J IND MICROBIOL BIOT, V28, P56, DOI 10.1038/sj.jim.7000176; Osterloo MM, 2008, SCIENCE, V319, P1651, DOI 10.1126/science.1150690; Peterson RC, 2006, GEOLOGY, V34, P957, DOI 10.1130/G22678A.1; Squyres SW, 2004, SCIENCE, V306, P1709, DOI 10.1126/science.1104559; Tosca NJ, 2006, EARTH PLANET SC LETT, V241, P21, DOI 10.1016/j.epsl.2005.10.021; Tosca NJ, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2003JE002218; Tosca NJ, 2005, EARTH PLANET SC LETT, V240, P122, DOI 10.1016/j.epsl.2005.09.042	25	190	190	1	90	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	2008	320	5880					1204	1207		10.1126/science.1155432	http://dx.doi.org/10.1126/science.1155432			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306FF	18511686				2022-12-28	WOS:000256233000035
J	Robinson, RG; Jorge, RE; Moser, DJ; Acion, L; Solodkin, A; Small, SL; Fonzetti, P; Hegel, M; Arndt, S				Robinson, Robert G.; Jorge, Ricardo E.; Moser, David J.; Acion, Laura; Solodkin, Ana; Small, Steven L.; Fonzetti, Pasquale; Hegel, Mark; Arndt, Stephan			Escitalopram and problem-solving therapy for prevention of poststroke depression - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOUBLE-BLIND; MOOD DISORDERS; ANXIETY DISORDER; MAJOR DEPRESSION; STROKE PATIENTS; HEART-DISEASE; PLACEBO; MORTALITY; SYMPTOMS; NORTRIPTYLINE	Context Depression occurs in more than half of patients who have experienced a stroke. Poststroke depression has been shown in numerous studies to be associated with both impaired recovery in activities of daily living and increased mortality. Prevention of depression thus represents a potentially important goal. Objective To determine whether treatment with escitalopram or problem- solving therapy over the first year following acute stroke will decrease the number of depression cases that develop compared with placebo medication. Design, Setting, and Participants A multisite randomized controlled trial for prevention of depression among 176 nondepressed patients was conducted within 3 months following acute stroke from July 9, 2003, to October 1, 2007. The 12- month trial included 3 groups: a double- blind placebo- controlled comparison of escitalopram ( n= 59) with placebo ( n= 58), and a nonblinded problem- solving therapy group ( n= 59). Main Outcome Measures The main outcome measure was the development of major or minor poststroke depression based on symptoms elicited by the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders ( Fourth Edition) ( DSM- IV) and the diagnostic criteria from DSM- IV for depression due to stroke with major depressivelike episode or minor depression ( ie, research criteria). Results Patients who received placebo were significantly more likely to develop depression than individuals who received escitalopram ( 11 major and 2 minor cases of depression [ 22.4%] vs 3 major and 2 minor cases of depression [ 8.5%], adjusted hazard ratio [ HR], 4.5; 95% confidence interval [ CI], 2.4- 8.2; P <. 001) and also more likely than individuals who received problem- solving therapy ( 5 major and 2 minor cases of depression [ 11.9%], adjusted HR, 2.2; 95% CI, 1.4- 3.5; P <. 001). These results were adjusted for history of mood disorders and remained significant after considering possible confounders such as age, sex, treatment site, and severity of impairment in the model. Using an intention- to-treat conservative method of analyzing the data, which assumed that all 27 patients who did not start randomized treatment would have developed depression, and controlling for prior history of mood disorders, escitalopram was superior to placebo ( 23.1% vs 34.5%; adjusted HR, 2.2; 95% CI, 1.2- 3.9; P=. 007), while problem- solving therapy was not significantly better than placebo( 30.5% vs 34.5%; adjusted HR, 1.1; 95% CI, 0.8- 1.5; P=. 51). Adverse events, including all- cause hospitalizations, nausea, and adverse effects associated with escitalopram were not significantly different between the 3 groups. Conclusions In this study of nondepressed patients with recent stroke, the use of escitalopram or problem- solving therapy resulted in a significantly lower incidence of depression over 12 months of treatment compared with placebo, but problem- solving therapy did not achieve significant results over placebo using the intention- to- treat conservative method of analysis. Trial Registration clinicaltrials. gov Identifier: NCT00071643.	[Robinson, Robert G.; Jorge, Ricardo E.; Moser, David J.; Acion, Laura; Arndt, Stephan] Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA; [Acion, Laura; Arndt, Stephan] Univ Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA 52242 USA; [Solodkin, Ana; Small, Steven L.] Univ Chicago, Dept Neurol, Chicago, IL 60637 USA; [Fonzetti, Pasquale] Cornell Univ, Burke Rehabil Ctr, Weill Med Coll, White Plains, NY USA; [Hegel, Mark] Dartmouth Med Sch, Dept Psychiat, Hanover, NH USA; [Hegel, Mark] Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH USA	University of Iowa; University of Iowa; University of Chicago; Cornell University; Dartmouth College; Dartmouth College	Robinson, RG (corresponding author), Univ Iowa, Dept Psychiat, Carver Coll Med, 200 Hawkins Dr, Iowa City, IA 52242 USA.	robert-robinson@uiowa.edu	Arndt, Stephan/A-6976-2013; Robinson, Robert/AAF-6191-2021	Arndt, Stephan/0000-0003-0783-8204; Small, Steven/0000-0002-5293-6172; Acion, Laura/0000-0001-5213-6012; Moser, David/0000-0003-4102-5266	NIMH NIH HHS [R01 MH-65134, R01 MH065134] Funding Source: Medline; NINDS NIH HHS [R01 NS054942, R01 NS054942-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH065134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS054942] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Almeida OP, 2006, J CLIN PSYCHIAT, V67, P1104, DOI 10.4088/JCP.v67n0713; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDERSEN G, 1994, ACTA PSYCHIAT SCAND, V90, P190, DOI 10.1111/j.1600-0447.1994.tb01576.x; ASTROM M, 1993, STROKE, V24, P976, DOI 10.1161/01.STR.24.7.976; Bender R, 2001, CONTROL CLIN TRIALS, V22, P102, DOI 10.1016/S0197-2456(00)00134-3; Berg A, 2003, STROKE, V34, P138, DOI 10.1161/01.STR.0000048149.84268.07; BURVILL PW, 1995, BRIT J PSYCHIAT, V166, P320, DOI 10.1192/bjp.166.3.320; CAPLAN GA, 1964, CONCEPTUAL MODEL PRI; Chen Y, 2007, INT CLIN PSYCHOPHARM, V22, P159, DOI 10.1097/YIC.0b013e32807fb028; *COMM PREV MENT DI, 1997, RED RISKS MENT DIS F; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; FEDOROFF JP, 1991, AM J PSYCHIAT, V148, P1172; FEIBEL JH, 1982, ARCH PHYS MED REHAB, V63, P276; Forer S, 1987, FUNCTIONAL INDEPENDE; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; Hegel MT, 2002, BEHAV THER, V33, P511, DOI 10.1016/S0005-7894(02)80014-4; Hollingshead August B., 1958, SOCIAL CLASS MENTAL; House A, 2001, STROKE, V32, P696, DOI 10.1161/01.STR.32.3.696; HOUSE A, 1991, BRIT J PSYCHIAT, V158, P83, DOI 10.1192/bjp.158.1.83; Jorge RE, 2003, AM J PSYCHIAT, V160, P1823, DOI 10.1176/appi.ajp.160.10.1823; Kimura M, 2003, AM J GERIAT PSYCHIAT, V11, P320, DOI 10.1176/appi.ajgp.11.3.320; Kraemer HC, 2006, BIOL PSYCHIAT, V59, P990, DOI 10.1016/j.biopsych.2005.09.014; KUNITZ SC, 1984, STROKE, V15, P740, DOI 10.1161/01.STR.15.4.740; Lincoln NB, 2003, STROKE, V34, P111, DOI 10.1161/01.STR.0000044167.44670.55; Moore N, 2005, INT CLIN PSYCHOPHARM, V20, P131, DOI 10.1097/00004850-200505000-00002; MORRIS PLP, 1993, AM J PSYCHIAT, V150, P124; MORRIS PLP, 1990, INT J PSYCHIAT MED, V20, P349, DOI 10.2190/N8VU-6LWU-FLJN-XQKV; MORRIS PLP, 1993, AUST NZ J PSYCHIAT, V27, P443, DOI 10.3109/00048679309075801; MYNORSWALLIS LM, 1995, BMJ-BRIT MED J, V310, P441, DOI 10.1136/bmj.310.6977.441; Narushima K, 2003, J NERV MENT DIS, V191, P645, DOI 10.1097/01.nmd.0000092197.97693.d2; Narushima K, 2007, BRIT J PSYCHIAT, V190, P260, DOI 10.1192/bjp.bp.106.025064; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Palomaki H, 1999, J NEUROL NEUROSUR PS, V66, P490, DOI 10.1136/jnnp.66.4.490; Paradiso S, 1997, INT J PSYCHIAT MED, V27, P137, DOI 10.2190/BWJA-KQP3-7VUY-D06T; Randolph C., 1998, REPEATABLE BATTERY A; Rasmussen A, 2003, PSYCHOSOMATICS, V44, P216, DOI 10.1176/appi.psy.44.3.216; Robinson R.G., 2006, CLIN NEUROPSYCHIATRY; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; Robinson RG, 2000, AM J PSYCHIAT, V157, P351, DOI 10.1176/appi.ajp.157.3.351; Rovner BW, 2007, ARCH GEN PSYCHIAT, V64, P886, DOI 10.1001/archpsyc.64.8.886; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; SCHUBERT DSP, 1992, PSYCHOSOMATICS, V33, P290, DOI 10.1016/S0033-3182(92)71967-7; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Shimoda K, 1998, J NEUROPSYCH CLIN N, V10, P34, DOI 10.1176/jnp.10.1.34; Spitzer RL, 1995, STRUCTURED CLIN INTE; Starr L B, 1982, Soc Work Res Abstr, V18, P28; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; Tamminga CA, 2002, BIOL PSYCHIAT, V52, P589, DOI 10.1016/S0006-3223(02)01470-1; Thom T, 2006, CIRCULATION, V113, pE85, DOI 10.1161/CIRCULATIONAHA.105.171600; Williams LS, 2004, AM J PSYCHIAT, V161, P1090, DOI 10.1176/appi.ajp.161.6.1090; Wong ML, 2001, NAT REV NEUROSCI, V2, P343, DOI 10.1038/35072566	53	247	269	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2008	299	20					2391	2400		10.1001/jama.299.20.2391	http://dx.doi.org/10.1001/jama.299.20.2391			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305BD	18505948	Green Accepted			2022-12-28	WOS:000256151900023
J	Piazza, N; Gregoire, J				Piazza, Nicolo; Gregoire, Jean			Starr-Edwards heart valves	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Piazza, Nicolo; Gregoire, Jean] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada	Universite de Montreal	Piazza, N (corresponding author), Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada.	nicolopiazza@mac.com							0	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2008	358	21					E24	E24		10.1056/NEJMicm071210	http://dx.doi.org/10.1056/NEJMicm071210			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	303EK	18499563				2022-12-28	WOS:000256023600010
J	Soderberg, AM; Berger, E; Page, KL; Schady, P; Parrent, J; Pooley, D; Wang, XY; Ofek, EO; Cucchiara, A; Rau, A; Waxman, E; Simon, JD; Bock, DCJ; Milne, PA; Page, MJ; Barentine, JC; Barthelmy, SD; Beardmore, AP; Bietenholz, MF; Brown, P; Burrows, A; Burrows, DN; Byrngelson, G; Cenko, SB; Chandra, P; Cummings, JR; Fox, DB; Gal-Yam, A; Gehrels, N; Immler, S; Kasliwal, M; Kong, AKH; Krimm, HA; Kulkarni, SR; Maccarone, TJ; Meszaros, P; Nakar, E; O'Brien, PT; Overzier, RA; de Pasquale, M; Racusin, J; Rea, N; York, DG				Soderberg, A. M.; Berger, E.; Page, K. L.; Schady, P.; Parrent, J.; Pooley, D.; Wang, X. -Y.; Ofek, E. O.; Cucchiara, A.; Rau, A.; Waxman, E.; Simon, J. D.; Bock, D. C. -J.; Milne, P. A.; Page, M. J.; Barentine, J. C.; Barthelmy, S. D.; Beardmore, A. P.; Bietenholz, M. F.; Brown, P.; Burrows, A.; Burrows, D. N.; Byrngelson, G.; Cenko, S. B.; Chandra, P.; Cummings, J. R.; Fox, D. B.; Gal-Yam, A.; Gehrels, N.; Immler, S.; Kasliwal, M.; Kong, A. K. H.; Krimm, H. A.; Kulkarni, S. R.; Maccarone, T. J.; Meszaros, P.; Nakar, E.; O'Brien, P. T.; Overzier, R. A.; de Pasquale, M.; Racusin, J.; Rea, N.; York, D. G.			An extremely luminous X-ray outburst at the birth of a supernova	NATURE			English	Article							SHOCK BREAKOUT; RADIO; BURST; AFTERGLOWS; GRB-980425; GRB-060218; EVOLUTION; EMISSION; NOVAE; STARS	Massive stars end their short lives in spectacular explosions-supernovae-that synthesize new elements and drive galaxy evolution. Historically, supernovae were discovered mainly through their 'delayed' optical light (some days after the burst of neutrinos that marks the actual event), preventing observations in the first moments following the explosion. As a result, the progenitors of some supernovae and the events leading up to their violent demise remain intensely debated. Here we report the serendipitous discovery of a supernova at the time of the explosion, marked by an extremely luminous X-ray outburst. We attribute the outburst to the 'break-out' of the supernova shock wave from the progenitor star, and show that the inferred rate of such events agrees with that of all core-collapse supernovae. We predict that future wide-field X-ray surveys will catch each year hundreds of supernovae in the act of exploding.	[Soderberg, A. M.; Berger, E.; Burrows, A.] Princeton Univ, Dept Astrophys Sci, Princeton, NJ 08544 USA; [Soderberg, A. M.; Berger, E.] Carnegie Inst Washington Observ, Pasadena, CA 91101 USA; [Page, K. L.; Beardmore, A. P.; O'Brien, P. T.] Univ Leicester, Dept Phys & Astron, Leicester LE1 7RH, Leics, England; [Schady, P.; Page, M. J.; de Pasquale, M.] UCL, Mullard Space Sci Lab, Dorking RH5 6NT, Surrey, England; [Parrent, J.] Dartmouth Coll, Dept Phys & Astron, Hanover, NH 03755 USA; [Pooley, D.] Univ Wisconsin, Dept Astron, Madison, WI 53706 USA; [Wang, X. -Y.] Nanjing Univ, Dept Astron, Nanjing 210093, Peoples R China; [Ofek, E. O.; Rau, A.; Simon, J. D.; Kasliwal, M.; Kulkarni, S. R.] CALTECH, Dept Astron, Pasadena, CA 91125 USA; [Cucchiara, A.; Brown, P.; Burrows, D. N.; Fox, D. B.; Meszaros, P.; Racusin, J.] Penn State Univ, Dept Astron & Astrophys, University Pk, PA 16802 USA; [Waxman, E.; Gal-Yam, A.] Weizmann Inst Sci, Fac Phys, IL-76100 Rehovot, Israel; [Bock, D. C. -J.] Univ Calif Berkeley, Radio Astron Lab, Berkeley, CA 94720 USA; [Milne, P. A.] Univ Arizona, Steward Observ, Tucson, AZ 85721 USA; [Barentine, J. C.] Univ Texas Austin, Dept Astron, Austin, TX 78712 USA; [Barthelmy, S. D.] NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; [Bietenholz, M. F.] York Univ, Dept Phys & Astron, N York, ON M3J 1P3, Canada; [Bietenholz, M. F.] Hartebeestehoek Radio Observ, ZA-1740 Krugersdorp, South Africa; [Byrngelson, G.] Clemson Univ, Dept Phys & Astron, Clemson, SC 29634 USA; [Cenko, S. B.; Nakar, E.] CALTECH, Space Radiat Lab, Pasadena, CA 91125 USA; [Chandra, P.] Univ Virginia, Dept Astron, Charlottesville, VA 22904 USA; [Cummings, J. R.; Gehrels, N.; Immler, S.; Krimm, H. A.] CRESST, Greenbelt, MD 20771 USA; [Cummings, J. R.; Gehrels, N.; Immler, S.; Krimm, H. A.] NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; [Kong, A. K. H.] Natl Tsing Hua Univ, Inst Astron, Hsinchu, Taiwan; [Kong, A. K. H.] Natl Tsing Hua Univ, Dept Phys, Hsinchu, Taiwan; [Krimm, H. A.] Univ Space Res Assoc, Columbia, MD 21044 USA; [Maccarone, T. J.] Univ Southampton, Sch Phys & Astron, Southampton SO17 1BJ, Hants, England; [Overzier, R. A.] Max Planck Inst Astrophys, D-85748 Garching, Germany; [Rea, N.] Univ Amsterdam, Astron Inst Anton Pannekoek, NL-1098 SJ Amsterdam, Netherlands; [York, D. G.] Univ Chicago, Dept Astron & Astrophys, Chicago, IL 60637 USA	Princeton University; Carnegie Institution for Science; University of Leicester; University of London; University College London; Dartmouth College; University of Wisconsin System; University of Wisconsin Madison; Nanjing University; California Institute of Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Weizmann Institute of Science; University of California System; University of California Berkeley; University of Arizona; University of Texas System; University of Texas Austin; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; York University - Canada; National Research Foundation - South Africa; Hartebeesthoek Radio Astronomy Observatory; Clemson University; California Institute of Technology; University of Virginia; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; National Tsing Hua University; National Tsing Hua University; Universities Space Research Association (USRA); University of Southampton; Max Planck Society; University of Amsterdam; University of Chicago	Soderberg, AM (corresponding author), Princeton Univ, Dept Astrophys Sci, Ivy Lane, Princeton, NJ 08544 USA.	alicia@astro.princeton.edu	Overzier, Roderik/U-1473-2019; De Pasquale, Massimiliano/AAC-5695-2020; Racusin, Judith L/D-2935-2012; Simon, Joshua D/AAX-7117-2021; Gehrels, Neil/D-2971-2012; Barthelmy, Scott D/D-2943-2012; Rea, Nanda/I-2853-2015; Barentine, John C./T-8832-2019; WAXMAN, ELI/K-1557-2012	Overzier, Roderik/0000-0002-8214-7617; Rea, Nanda/0000-0003-2177-6388; Barentine, John C./0000-0002-7042-068X; Kong, Albert/0000-0002-5105-344X; Page, Kim/0000-0001-5624-2613; Schady, Patricia/0000-0002-1214-770X; Chandra, Poonam/0000-0002-0844-6563; O'Brien, Paul/0000-0002-5128-1899; Fox, Derek/0000-0002-3714-672X; Meszaros, Peter/0000-0002-4132-1746; Beardmore, Andrew/0000-0001-5186-5950; Nakar, Ehud/0000-0002-4534-7089	STFC [PP/E001173/1, ST/F006489/1] Funding Source: UKRI; Science and Technology Facilities Council [ST/F006489/1, PP/E001173/1] Funding Source: researchfish	STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))		ARNETT WD, 1982, ASTROPHYS J, V253, P785, DOI 10.1086/159681; ARNETT WD, 1989, ANNU REV ASTRON ASTR, V27, P629, DOI 10.1146/annurev.aa.27.090189.003213; Band DL, 2006, ASTROPHYS J, V644, P378, DOI 10.1086/503326; Berger E, 2003, ASTROPHYS J, V590, P379, DOI 10.1086/374892; Berger E, 2003, ASTROPHYS J, V599, P408, DOI 10.1086/379214; Blanton MR, 2003, ASTROPHYS J, V592, P819, DOI 10.1086/375776; Campana S, 2006, NATURE, V442, P1008, DOI 10.1038/natureO4892; Cappa C, 2004, ASTRON J, V127, P2885, DOI 10.1086/383286; Cappellaro E, 1999, ASTRON ASTROPHYS, V351, P459; CHEVALIER RA, 1982, ASTROPHYS J, V258, P790, DOI 10.1086/160126; COLGATE SA, 1974, ASTROPHYS J, V187, P333, DOI 10.1086/152632; Dahlen T, 2004, ASTROPHYS J, V613, P189, DOI 10.1086/422899; DENG J, 2008, 7160 GCN; Filippenko AV, 1997, ANNU REV ASTRON ASTR, V35, P309, DOI 10.1146/annurev.astro.35.1.309; Frail DA, 2003, ASTRON J, V125, P2299, DOI 10.1086/374364; FYNBO JPU, 2008, 7186 GCN; KLEIN RI, 1978, ASTROPHYS J, V223, pL109, DOI 10.1086/182740; Kouveliotou C, 2004, ASTROPHYS J, V608, P872, DOI 10.1086/420878; Kulkarni SR, 1998, NATURE, V395, P663, DOI 10.1038/27139; LI W, 2008, 1202 CTR BUR EL TEL; Lonsdale CJ, 2006, ASTROPHYS J, V647, P185, DOI 10.1086/505193; MacFadyen AI, 2001, ASTROPHYS J, V550, P410, DOI 10.1086/319698; MALESANI D, 2008, 7169 GCN; Matzner CD, 1999, ASTROPHYS J, V510, P379, DOI 10.1086/306571; MODJAZ M, 2008, 1222 CTR BUR EL TEL; MOFFAT AFJ, 1989, IAU C, V113, P229; PAGE KL, 2008, 110 GCN; Pian E, 2006, NATURE, V442, P1011, DOI 10.1038/nature05082; READHEAD ACS, 1994, ASTROPHYS J, V426, P51, DOI 10.1086/174038; Sari R, 1998, ASTROPHYS J, V497, pL17, DOI 10.1086/311269; Schmidt M, 2001, ASTROPHYS J, V552, P36, DOI 10.1086/320450; Soderberg AM, 2006, NATURE, V442, P1014, DOI 10.1038/nature05087; Soderberg AM, 2006, ASTROPHYS J, V638, P930, DOI 10.1086/499121; Soderberg AM, 2006, ASTROPHYS J, V636, P391, DOI 10.1086/498009; Soderberg AM, 2005, ASTROPHYS J, V621, P908, DOI 10.1086/427649; Soderberg AM, 2004, NATURE, V430, P648, DOI 10.1038/nature02757; Valenti S, 2008, MON NOT R ASTRON SOC, V383, P1485, DOI 10.1111/j.1365-2966.2007.12647.x; VALENTI S, 2008, 7163 GCN; Wang XY, 2007, ASTROPHYS J, V664, P1026, DOI 10.1086/519228; Waxman E, 2007, ASTROPHYS J, V667, P351, DOI 10.1086/520715; Waxman E, 2004, ASTROPHYS J, V602, P886, DOI 10.1086/381230; Waxman E, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.071101; Woosley SE, 2002, REV MOD PHYS, V74, P1015, DOI 10.1103/RevModPhys.74.1015; WOOSLEY SE, 1986, ANNU REV ASTRON ASTR, V24, P205, DOI 10.1146/annurev.aa.24.090186.001225	44	368	374	0	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 22	2008	453	7194					469	474		10.1038/nature06997	http://dx.doi.org/10.1038/nature06997			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303EL	18497815	Green Accepted, Green Submitted			2022-12-28	WOS:000256023700032
J	Zhou, LB; Bar, I; Achouri, Y; Campbell, K; De Backer, O; Hebert, JM; Jones, K; Kessaris, N; de Rouvroit, CL; O'Leary, D; Richardson, WD; Goffinet, AM; Tissir, F				Zhou, Libing; Bar, Isabelle; Achouri, Younes; Campbell, Kenneth; De Backer, Olivier; Hebert, Jean M.; Jones, Kevin; Kessaris, Nicoletta; de Rouvroit, Catherine Lambert; O'Leary, Dennis; Richardson, William D.; Goffinet, Andre M.; Tissir, Fadel			Early forebrain wiring: Genetic dissection using conditional Celsr3 mutant mice	SCIENCE			English	Article							PLANAR CELL POLARITY; EXPRESSION; AXONS; CONNECTIONS; FLAMINGO; DEFECTS; NEURONS; LINEAGE; CORTEX; MOUSE	Development of axonal tracts requires interactions between growth cones and the environment. Tracts such as the anterior commissure and internal capsule are defective in mice with null mutation of Celsr3. We generated a conditional Celsr3 allele, allowing regional inactivation. Inactivation in telencephalon, ventral forebrain, or cortex demonstrated essential roles for Celsr3 in neurons that project axons to the anterior commissure and subcerebral targets, as well as in cells that guide axons through the internal capsule. When Celsr3 was inactivated in cortex, subcerebral projections failed to grow, yet corticothalamic axons developed normally, indicating that besides guidepost cells, additional Celsr3-independent cues can assist their progression. These observations provide in vivo evidence that Celsr3-mediated interactions between axons and guidepost cells govern axonal tract formation in mammals.	[Zhou, Libing; Achouri, Younes; Goffinet, Andre M.; Tissir, Fadel] Univ Catholique Louvain, B-1200 Brussels, Belgium; [Bar, Isabelle; De Backer, Olivier; de Rouvroit, Catherine Lambert] Fac Univ Notre Dame Paix, B-5000 Namur, Belgium; [Campbell, Kenneth] Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45229 USA; [Hebert, Jean M.] Albert Einstein Coll Med, Bronx, NY 10461 USA; [Jones, Kevin] Univ Colorado, Boulder, CO 80309 USA; [Kessaris, Nicoletta; Richardson, William D.] UCL, London WC1E 6AE, England; [O'Leary, Dennis] Salk Inst Biol Studies, La Jolla, CA 92037 USA	Universite Catholique Louvain; University of Namur; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Yeshiva University; Albert Einstein College of Medicine; University of Colorado System; University of Colorado Boulder; University of London; University College London; Salk Institute	Tissir, F (corresponding author), Univ Catholique Louvain, B-1200 Brussels, Belgium.	fadel.tissir@uclouvain.be	Campbell, Kenneth/ABC-3570-2021; Kessaris, Nicoletta/C-7249-2008; Kessaris, Nicoletta/AAD-6774-2019; bar, isabelle/AAQ-7795-2020; Richardson, William/C-1762-2008	Kessaris, Nicoletta/0000-0003-1191-6009; Kessaris, Nicoletta/0000-0003-1191-6009; Richardson, William/0000-0001-7261-2485; JONES, KEVIN/0000-0002-3802-7562; ACHOURI, Younes/0000-0001-7409-1441; Tissir, Fadel/0000-0002-9292-6622; Zhou, Libing/0000-0002-8975-5228	MRC [G9708005, G0501173] Funding Source: UKRI; Medical Research Council [G0501173, G0800575, G9708005] Funding Source: Medline; NIMH NIH HHS [R01 MH086147, R01 MH086147-05] Funding Source: Medline; NINDS NIH HHS [R37 NS031558-15, R37 NS031558] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH086147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS031558] Funding Source: NIH RePORTER	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENTLEY D, 1983, NATURE, V304, P62, DOI 10.1038/304062a0; Braisted JE, 1999, DEV BIOL, V208, P430, DOI 10.1006/dbio.1999.9216; Chae J, 1999, DEVELOPMENT, V126, P5421; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; GHOSH A, 1990, NATURE, V347, P179, DOI 10.1038/347179a0; Gorski JA, 2002, J NEUROSCI, V22, P6309; Hebert JM, 2000, DEV BIOL, V222, P296, DOI 10.1006/dbio.2000.9732; Hevner RF, 2002, J COMP NEUROL, V447, P8, DOI 10.1002/cne.10219; Kessaris N, 2006, NAT NEUROSCI, V9, P173, DOI 10.1038/nn1620; Lopez-Bendito G, 2006, CELL, V125, P127, DOI 10.1016/j.cell.2006.01.042; MITROFANIS J, 1993, TRENDS NEUROSCI, V16, P240, DOI 10.1016/0166-2236(93)90163-G; MOLNAR Z, 1991, NATURE, V351, P475, DOI 10.1038/351475a0; Molyneaux BJ, 2007, NAT REV NEUROSCI, V8, P427, DOI 10.1038/nrn2151; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stenman J, 2003, J NEUROSCI, V23, P167; Tessier-Lavigne Marc, 2002, Harvey Lect, V98, P103; Tissir F, 2006, EUR J NEUROSCI, V23, P597, DOI 10.1111/j.1460-9568.2006.04596.x; Tissir F, 2005, NAT NEUROSCI, V8, P451, DOI 10.1038/nn1428; Tissir F, 2002, MECH DEVELOP, V112, P157, DOI 10.1016/S0925-4773(01)00623-2; Tuttle R, 1999, DEVELOPMENT, V126, P1903; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; Wang YS, 2002, J NEUROSCI, V22, P8563	23	138	140	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 16	2008	320	5878					946	949		10.1126/science.1155244	http://dx.doi.org/10.1126/science.1155244			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301AH	18487195	Green Submitted, Green Accepted			2022-12-28	WOS:000255868300046
J	Gerber, S; Comellas-Bigler, M; Goetz, BA; Locher, KP				Gerber, Sabina; Comellas-Bigler, Mireia; Goetz, Birke A.; Locher, Kaspar P.			Structural basis of trans-inhibition in a molybdate/tungstate ABC transporter	SCIENCE			English	Article							AMINO-ACID TRANSPORT; BINDING-PROTEIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MECHANISM; COMPLEX; CELLS; MODE; DEREPRESSION; SPECIFICITY	Transport across cellular membranes is an essential process that is catalyzed by diverse membrane transport proteins. The turnover rates of certain transporters are inhibited by their substrates in a process termed trans- inhibition, whose structural basis is poorly understood. We present the crystal structure of a molybdate/ tungstate ABC transporter ( ModBC) from Methanosarcina acetivorans in a trans- inhibited state. The regulatory domains of the nucleotide- binding subunits are in close contact and provide two oxyanion binding pockets at the shared interface. By specifically binding to these pockets, molybdate or tungstate prevent adenosine triphosphatase activity and lock the transporter in an inward- facing conformation, with the catalytic motifs of the nucleotide- binding domains separated. This allosteric effect prevents the transporter from switching between the inward- facing and the outward- facing states, thus interfering with the alternating access and release mechanism.	[Gerber, Sabina; Comellas-Bigler, Mireia; Goetz, Birke A.; Locher, Kaspar P.] ETH, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Locher, KP (corresponding author), ETH, Inst Mol Biol & Biophys, HPK D14-3, CH-8093 Zurich, Switzerland.	kaspar.locher@mol.biol.ethz.ch						Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; Dawson RJP, 2007, MOL MICROBIOL, V65, P250, DOI 10.1111/j.1365-2958.2007.05792.x; Dawson RJP, 2006, NATURE, V443, P180, DOI 10.1038/nature05155; Debernardi R, 1999, BRAIN RES, V850, P39, DOI 10.1016/S0006-8993(99)02022-3; Delarbre L, 2001, J MOL BIOL, V308, P1063, DOI 10.1006/jmbi.2001.4636; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; Glaasker E, 1998, J BACTERIOL, V180, P5540, DOI 10.1128/JB.180.21.5540-5546.1998; Hall DR, 1999, EMBO J, V18, P1435, DOI 10.1093/emboj/18.6.1435; HEATON JH, 1977, J BIOL CHEM, V252, P2900; Hollenstein K, 2007, NATURE, V446, P213, DOI 10.1038/nature05626; HUNTER DR, 1973, ARCH BIOCHEM BIOPHYS, V154, P387, DOI 10.1016/0003-9861(73)90071-4; Hvorup RN, 2007, SCIENCE, V317, P1387, DOI 10.1126/science.1145950; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; KASHIWAGI K, 1995, J BIOL CHEM, V270, P25377, DOI 10.1074/jbc.270.43.25377; KELLEY DS, 1979, J BIOL CHEM, V254, P6691; Lee SJ, 2007, TRENDS MICROBIOL, V15, P389, DOI 10.1016/j.tim.2007.08.002; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; MARZLUF GA, 1973, ARCH BIOCHEM BIOPHYS, V156, P244, DOI 10.1016/0003-9861(73)90362-7; Mouncey NJ, 1996, MICROBIOL-SGM, V142, P1997, DOI 10.1099/13500872-142-8-1997; NELSON SO, 1984, EUR J BIOCHEM, V139, P29, DOI 10.1111/j.1432-1033.1984.tb07971.x; Oldham ML, 2007, NATURE, V450, P515, DOI 10.1038/nature06264; PALL ML, 1971, BIOCHEM BIOPH RES CO, V42, P940, DOI 10.1016/0006-291X(71)90521-3; Pinkett HW, 2007, SCIENCE, V315, P373, DOI 10.1126/science.1133488; REYES M, 1988, J BACTERIOL, V170, P4598, DOI 10.1128/jb.170.10.4598-4602.1988; Schuttelkopf AW, 2003, J MOL BIOL, V326, P761, DOI 10.1016/S0022-2836(02)01358-X; STEVENS BR, 1984, ANNU REV PHYSIOL, V46, P417; Strong M, 2006, P NATL ACAD SCI USA, V103, P8060, DOI 10.1073/pnas.0602606103; Verheul A, 1997, J BACTERIOL, V179, P6979, DOI 10.1128/jb.179.22.6979-6985.1997; Wagner UG, 2000, STRUCTURE, V8, P1127, DOI 10.1016/S0969-2126(00)00525-6; WOODWARD JR, 1977, J BACTERIOL, V130, P714, DOI 10.1128/JB.130.2.714-723.1977	32	150	155	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 11	2008	321	5886					246	250		10.1126/science.1156213	http://dx.doi.org/10.1126/science.1156213			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324IS	18511655				2022-12-28	WOS:000257512900039
J	Fischer, A; Cavazzana-Calvo, M				Fischer, Alain; Cavazzana-Calvo, Marina			Gene therapy of inherited diseases	LANCET			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; WISKOTT-ALDRICH-SYNDROME; INSERTIONAL MUTAGENESIS; TRANSGENE EXPRESSION; VECTOR INTEGRATION; CANINE MODEL; HUMAN GENOME; MOUSE MODEL; FACTOR-IX; TRANSPLANTATION		[Fischer, Alain] Hop Necker Enfants Malad, INSERM, U768, F-75015 Paris, France; [Fischer, Alain; Cavazzana-Calvo, Marina] Univ Paris 05, Paris, France; [Fischer, Alain] Hop Necker Enfants Malad, Paediat Haematol & Immunol Dept, F-75015 Paris, France; [Cavazzana-Calvo, Marina] Hop Necker Enfants Malad, Dept Biotherapy, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Fischer, A (corresponding author), Hop Necker Enfants Malad, INSERM, U768, 149 Rue Sevres, F-75015 Paris, France.	alain.fischer@nck.ap-hop-paris.fr		Cavazzana, Marina/0000-0002-0264-0891				Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008; Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/88327; Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Aiuti A, 2007, J CLIN INVEST, V117, P2233, DOI 10.1172/JCI31666; Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268; Brown BD, 2006, NAT MED, V12, P585, DOI 10.1038/nm1398; Bushman FD, 2007, J CLIN INVEST, V117, P2083, DOI 10.1172/JCI32949; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Cavazzana-Calvo Marina, 2005, Annu Rev Med, V56, P585, DOI 10.1146/annurev.med.56.090203.104142; Couzin J, 2006, SCIENCE, V312, P1121; Czechowicz A, 2007, SCIENCE, V318, P1296, DOI 10.1126/science.1149726; Dave UP, 2004, SCIENCE, V303, P333, DOI 10.1126/science.1091667; Deichmann A, 2007, J CLIN INVEST, V117, P2225, DOI 10.1172/JCI31659; Dupre L, 2004, MOL THER, V10, P903, DOI 10.1016/j.ymthe.2004.08.008; Gaspar HB, 2004, LANCET, V364, P2181, DOI 10.1016/S0140-6736(04)17590-9; Gorman L, 1998, P NATL ACAD SCI USA, V95, P4929, DOI 10.1073/pnas.95.9.4929; Grosveld F, 1999, CURR OPIN GENET DEV, V9, P152, DOI 10.1016/S0959-437X(99)80023-9; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Held PK, 2005, MOL THER, V11, P399, DOI 10.1016/j.ymthe.2004.11.001; Hematti P, 2004, PLOS BIOL, V2, P2183, DOI 10.1371/journal.pbio.0020423; Jacobson SG, 2005, P NATL ACAD SCI USA, V102, P6177, DOI 10.1073/pnas.0500646102; Kay MA, 2001, NAT MED, V7, P33, DOI 10.1038/83324; Klein C, 2003, BLOOD, V101, P2159, DOI 10.1182/blood-2002-05-1423; Li ZX, 2002, SCIENCE, V296, P497, DOI 10.1126/science.1068893; Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315; Manno CS, 2006, NAT MED, V12, P342, DOI 10.1038/nm1358; Mavilio F, 2006, NAT MED, V12, P1397, DOI 10.1038/nm1504; May C, 2000, NATURE, V406, P82, DOI 10.1038/35017565; Mingozzi F, 2007, NAT MED, V13, P419, DOI 10.1038/nm1549; Mitchell RS, 2004, PLOS BIOL, V2, P1127, DOI 10.1371/journal.pbio.0020234; Modlich U, 2006, BLOOD, V108, P2545, DOI 10.1182/blood-2005-08-024976; Montini E, 2006, NAT BIOTECHNOL, V24, P687, DOI 10.1038/nbt1216; Niculescu-Duvaz Ion, 2004, Methods Mol Med, V90, P1; Nienhuis AW, 2008, BLOOD, V111, P4431, DOI 10.1182/blood-2007-11-078121; O'Connor TP, 2006, NAT REV GENET, V7, P261, DOI 10.1038/nrg1829; Olivares EC, 2002, NAT BIOTECHNOL, V20, P1124, DOI 10.1038/nbt753; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Pawliuk R, 2001, SCIENCE, V294, P2368, DOI 10.1126/science.1065806; Pelletier R, 2006, CURR GENE THER, V6, P131, DOI 10.2174/156652306775515592; Persons DA, 2003, BLOOD, V102, P506, DOI 10.1182/blood-2003-03-0677; Porteus MH, 2005, NAT BIOTECHNOL, V23, P967, DOI 10.1038/nbt1125; Recillas-Targa F, 2004, BIOESSAYS, V26, P796, DOI 10.1002/bies.20059; Schambach A, 2006, MOL THER, V13, P391, DOI 10.1016/j.ymthe.2005.08.012; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Schwarzwaelder K, 2007, J CLIN INVEST, V117, P2241, DOI 10.1172/JCI31661; Seggewiss R, 2006, BLOOD, V107, P3865, DOI 10.1182/blood-2005-10-4108; Shou Y, 2006, P NATL ACAD SCI USA, V103, P11730, DOI 10.1073/pnas.0603635103; Thrasher AJ, 2006, NATURE, V443, pE5, DOI 10.1038/nature05219; Varmus H, 2002, NEW ENGL J MED, V347, P1526, DOI 10.1056/NEJMe020119; Verma IM, 2005, ANNU REV BIOCHEM, V74, P711, DOI 10.1146/annurev.biochem.74.050304.091637; Woods NB, 2006, NATURE, V440, P1123, DOI 10.1038/4401123a; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Yanez-Munoz RJ, 2006, NAT MED, V12, P348, DOI 10.1038/nm1365; Zhang F, 2007, BLOOD, V110, P1448, DOI 10.1182/blood-2006-12-060814; Zhang XB, 2008, J CLIN INVEST, V118, P1502, DOI 10.1172/JCI34371; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998; Zychlinski D, 2008, MOL THER, V16, P718, DOI 10.1038/mt.2008.5	57	64	69	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2008	371	9629					2044	2047		10.1016/S0140-6736(08)60874-0	http://dx.doi.org/10.1016/S0140-6736(08)60874-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312YY	18555917				2022-12-28	WOS:000256709500033
J	Petit, RJ; Hu, FS; Dick, CW				Petit, Remy J.; Hu, Feng Sheng; Dick, Christopher W.			Forests of the past: A window to future changes	SCIENCE			English	Editorial Material							RAPID CLIMATE-CHANGE; EVOLUTIONARY RESPONSES; WHITE SPRUCE; TREE FLORA; DIVERSITY; PHYLOGEOGRAPHY; CONSEQUENCES; RICHNESS; PATTERNS; ICE	The study of past forest change provides a necessary historical context for evaluating the outcome of human-induced climate change and biological invasions. Retrospective analyses based on fossil and genetic data greatly advance our understanding of tree colonization, adaptation, and extinction in response to past climatic change. For instance, these analyses reveal cryptic refugia near or north of continental ice sheets, leading to reevaluation of postglacial tree migration rates. Species extinctions appear to have occurred primarily during periods of high climatic variability. Transoceanic dispersal and colonization in the tropics were widespread at geological time scales, inconsistent with the idea that tropical forests are particularly resistant to biological invasions.	[Petit, Remy J.] INRA Biodivers Genes & Communities, UMR1202, F-33612 Cestas, France; [Petit, Remy J.] Univ Bordeaux 1, UMR1202, F-33612 Cestas, France; [Hu, Feng Sheng] Univ Illinois, Dept Plant Biol, Urbana, IL 61801 USA; [Hu, Feng Sheng] Univ Illinois, Dept Geol, Urbana, IL 61801 USA; [Hu, Feng Sheng] Univ Illinois, Program Ecol Evolut & Conservat Biol, Urbana, IL 61801 USA; [Dick, Christopher W.] Univ Michigan, Dept Ecol & Evolut Biol, Ann Arbor, MI 48103 USA; [Dick, Christopher W.] Univ Michigan, Herbarium, Ann Arbor, MI 48103 USA; [Dick, Christopher W.] Smithsonian Trop Res Inst, Balboa, Panama	INRAE; UDICE-French Research Universities; Universite de Bordeaux; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Smithsonian Institution; Smithsonian Tropical Research Institute	Petit, RJ (corresponding author), INRA Biodivers Genes & Communities, UMR1202, 69 Route Arcachon, F-33612 Cestas, France.	petit@pierroton.inra.fr	Petit, Remy/AAD-9078-2019; Petit, Rémy/A-8842-2008	Petit, Rémy/0000-0002-4809-1453				Alley RB, 2003, SCIENCE, V299, P2005, DOI 10.1126/science.1081056; Anderson LL, 2006, P NATL ACAD SCI USA, V103, P12447, DOI 10.1073/pnas.0605310103; Carstens BC, 2007, EVOLUTION, V61, P1439, DOI 10.1111/j.1558-5646.2007.00117.x; Cheddadi R, 2006, GLOBAL ECOL BIOGEOGR, V15, P271, DOI [10.1111/j.1466-822x.2006.00226.x, 10.1111/j.1466-822X.2006.00226.x]; Colinvaux PA, 1996, SCIENCE, V274, P85, DOI 10.1126/science.274.5284.85; Davis MB, 2005, ECOLOGY, V86, P1704, DOI 10.1890/03-0788; Dick CW, 2007, MOL ECOL, V16, P3039, DOI 10.1111/j.1365-294X.2007.03341.x; Huntley B., 1983, ATLAS PRESENT POLLEN; Jackson ST, 1999, P NATL ACAD SCI USA, V96, P13847, DOI 10.1073/pnas.96.24.13847; Jump AS, 2006, GLOBAL CHANGE BIOL, V12, P2163, DOI 10.1111/j.1365-2486.2006.01250.x; LATHAM RE, 1993, OIKOS, V67, P325, DOI 10.2307/3545479; Lloyd AH, 2005, ECOLOGY, V86, P1687, DOI 10.1890/03-0786; Magri D, 2006, NEW PHYTOL, V171, P199, DOI 10.1111/j.1469-8137.2006.01740.x; McLachlan JS, 2005, ECOLOGY, V86, P2088, DOI 10.1890/04-1036; Parmesan C, 2006, ANNU REV ECOL EVOL S, V37, P637, DOI 10.1146/annurev.ecolsys.37.091305.110100; Pennington RT, 2004, PHILOS T R SOC B, V359, P1611, DOI 10.1098/rstb.2004.1532; Petit RJ, 2006, ANNU REV ECOL EVOL S, V37, P187, DOI 10.1146/annurev.ecolsys.37.091305.110215; Petit RJ, 2004, FOREST ECOL MANAG, V197, P117, DOI 10.1016/j.foreco.2004.05.009; RITCHIE JC, 1986, J BIOGEOGR, V13, P527, DOI 10.2307/2844816; Shepherd LD, 2007, MOL ECOL, V16, P4536, DOI 10.1111/j.1365-294X.2007.03451.x; Svenning JC, 2003, ECOL LETT, V6, P646, DOI 10.1046/j.1461-0248.2003.00477.x; Williams JW, 2007, FRONT ECOL ENVIRON, V5, P475, DOI 10.1890/070037; Willis KJ, 2007, ECOL LETT, V10, P673, DOI 10.1111/j.1461-0248.2007.01056.x	23	201	209	2	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	2008	320	5882					1450	1452		10.1126/science.1155457	http://dx.doi.org/10.1126/science.1155457			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556547	Green Submitted			2022-12-28	WOS:000256676400030
J	Blechacz, B; Gajic, O				Blechacz, Boris; Gajic, Ognjen			Severe kyphosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Blechacz, Boris; Gajic, Ognjen] Mayo Clin, Rochester, MN 55905 USA	Mayo Clinic	Blechacz, B (corresponding author), Mayo Clin, Rochester, MN 55905 USA.								0	8	8	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2008	358	24					E28	E28		10.1056/NEJMicm074057	http://dx.doi.org/10.1056/NEJMicm074057			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311IJ	18550872				2022-12-28	WOS:000256593600010
J	Papadakis, MA; Arnold, GK; Blank, LL; Holmboe, ES; Lipner, RS				Papadakis, Maxine A.; Arnold, Gerald K.; Blank, Linda L.; Holmboe, Eric S.; Lipner, Rebecca S.			Performance during internal medicine residency training and subsequent disciplinary action by state licensing boards	ANNALS OF INTERNAL MEDICINE			English	Article							UNPROFESSIONAL BEHAVIOR; CLINICAL COMPETENCE; PROFESSIONALISM; CERTIFICATION; SCHOOL; PHYSICIAN; RATINGS; SCORES; ASSOCIATION; KNOWLEDGE	Background: Physicians who are disciplined by state licensing boards are more likely to have demonstrated unprofessional behavior in medical school. Information is limited on whether similar performance measures taken during residency can predict performance as practicing physicians. Objective: To determine whether performance measures during residency predict the likelihood of future disciplinary actions against practicing internists. Design: Retrospective cohort study. Setting: State licensing board disciplinary actions against physicians from 1990 to 2006. Participants: 66 171 physicians who entered internal medicine residency training in the United States from 1990 to 2000 and became diplomates. Measurements: Predictor variables included components of the Residents' Annual Evaluation Summary ratings and American Board of Internal Medicine (ABIM) certification examination scores. Results: 2 performance measures independently predicted disciplinary action. A low professionalism rating on the Residents' Annual Evaluation Summary predicted increased risk for disciplinary action (hazard ratio, 1.7 [95% CI, 1.3 to 2.2]), and high performance on the ABIM certification examination predicted decreased risk for disciplinary action (hazard ratio, 0.7 [CI, 0.60 to 0.70] for American or Canadian medical school graduates and 0.9 [CI, 0.80 to 1.0] for international medical school graduates). Progressively better professionalism ratings and ABIM certification examination scores were associated with less risk for subsequent disciplinary actions; the risk ranged from 4.0% for the lowest professionalism rating to 0.5% for the highest and from 2.5% for the lowest examination scores to 0.0% for the highest. Limitations: The study was retrospective. Some diplomates may have practiced outside of the United States. Nondiplomates were excluded. . Conclusion: Poor performance on behavioral and cognitive measures during residency are associated with greater risk for state licensing board actions against practicing physicians at every point on a performance continuum. These findings support the Accreditation Council for Graduate Medical Education standards for professionalism and cognitive performance and the development of best practices to remediate these deficiencies.			Papadakis, MA (corresponding author), Univ Calif San Francisco, 533 Parnassus Ave,S-245, San Francisco, CA 94143 USA.	papadakm@medsch.ucsf.edu						*ACCR COUNC GRAD M, 2008, ACGME COMM PROGR REQ; Accreditation Council for Graduate Medical Education, 2007, ACGME I REQ; Accreditation Council for Graduate Medical Education, 2007, COMM PROGR REQ GEN C; Bercovitch L, 2007, J AM ACAD DERMATOL, V56, P679, DOI 10.1016/j.jaad.2006.12.016; Brinkman WB, 2007, ARCH PEDIAT ADOL MED, V161, P44, DOI 10.1001/archpedi.161.1.44; Colliver JA, 2007, TEACH LEARN MED, V19, P213, DOI 10.1080/10401330701484276; Dorotta I, 2006, J CLIN ANESTH, V18, P148, DOI 10.1016/j.jclinane.2005.07.004; *FED STAT MED BOAR, 2004, SUMM 2003 BOARD ACT; Fitzgibbons JP, 2006, ANN INTERN MED, V144, P920, DOI 10.7326/0003-4819-144-12-200606200-00010; Gauger PG, 2005, AM J SURG, V189, P479, DOI 10.1016/j.amjsurg.2004.09.020; Haurani Mounir J, 2007, J Surg Educ, V64, P351, DOI 10.1016/j.jsurg.2007.06.012; Hickson GB, 2007, ACAD MED, V82, P1040, DOI 10.1097/ACM.0b013e31815761ee; Hojat M, 2007, MED EDUC, V41, P982, DOI 10.1111/j.1365-2923.2007.02841.x; Holmboe ES, 2008, JAMA-J AM MED ASSOC, V299, P338, DOI 10.1001/jama.299.3.338; HOLMBOE ES, 2008, ARCH INTERN IN PRESS; Humphrey HJ, 2007, ACAD MED, V82, P1098, DOI 10.1097/01.ACM.0000285344.10311.a8; Inui T, 2003, FLAG WIND ED PROFESS; JOYNER BD, 2007, J UROLOGY, V177, P2291; Joyner BD, 2007, J UROLOGY, V177, P2287, DOI 10.1016/j.juro.2007.01.149; Kohatsu ND, 2004, ARCH INTERN MED, V164, P653, DOI 10.1001/archinte.164.6.653; KOLEN MJ, 2004, TEST EQUATING SCALIN, P105; Leape LL, 2006, ANN INTERN MED, V144, P107, DOI 10.7326/0003-4819-144-2-200601170-00008; Lee AG, 2007, SURV OPHTHALMOL, V52, P680, DOI 10.1016/j.survophthal.2007.08.021; LEE ET, 2003, STAT METHODS SURVIVA, P326; Lipner RS, 2006, ANN INTERN MED, V144, P29, DOI 10.7326/0003-4819-144-1-200601030-00007; Lipner RS, 2002, ACAD MED, V77, pS64, DOI 10.1097/00001888-200210001-00021; Lucey C, 2008, PRACTICAL GUIDE EVAL; NORCINI JJ, 1987, J MED EDUC, V62, P457; Papadakis MA, 2004, ACAD MED, V79, P244, DOI 10.1097/00001888-200403000-00011; Papadakis MA, 2005, NEW ENGL J MED, V353, P2673, DOI 10.1056/NEJMsa052596; RAMSEY PG, 1989, ANN INTERN MED, V110, P719, DOI 10.7326/0003-4819-110-9-719; Rhodes RS, 2007, AM SURGEON, V73, P143; Riesenberg LA, 2006, ACAD MED, V81, P426, DOI 10.1097/01.ACM.0000222279.28824.f5; SHEA JA, 1993, ACAD MED, V68, pS22, DOI 10.1097/00001888-199310000-00034; Stern DT, 2006, NEW ENGL J MED, V355, P1794, DOI 10.1056/NEJMra054783; Tamblyn R, 2002, JAMA-J AM MED ASSOC, V288, P3019, DOI 10.1001/jama.288.23.3019; Tamblyn R, 2007, JAMA-J AM MED ASSOC, V298, P993, DOI 10.1001/jama.298.9.993; Weinberger SE, 2006, ANN INTERN MED, V144, P927, DOI 10.7326/0003-4819-144-12-200606200-00124; West CP, 2007, ACAD MED, V82, P587, DOI 10.1097/ACM.0b013e3180555fc5	39	162	162	1	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2008	148	11					869	U91		10.7326/0003-4819-148-11-200806030-00009	http://dx.doi.org/10.7326/0003-4819-148-11-200806030-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308CG	18519932				2022-12-28	WOS:000256365300008
J	Elliott, C; Abadie, R				Elliott, Carl; Abadie, Roberto			Exploiting a research underclass in phase 1 clinical trials	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Elliott, Carl] Univ Minnesota, Ctr Bioeth, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Elliott, C (corresponding author), Univ Minnesota, Ctr Bioeth, Minneapolis, MN 55455 USA.			Abadie, Roberto/0000-0002-4276-1620				ABADIE R, IN PRESS GUINEA PIGS; Cohen Laurie P, 1996, Wall St J (East Ed), pA10; Cohen Laurie P., 1996, WALL STREET J, pA10; *DEP HHS, 2007, FOOD DRUG ADM OV CLI; Elliott Carl, 2008, New Yorker, P36; Steinbrook R, 2006, NEW ENGL J MED, V354, P1871, DOI 10.1056/NEJMp068080	6	72	72	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2008	358	22					2316	2317		10.1056/NEJMp0801872	http://dx.doi.org/10.1056/NEJMp0801872			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307GF	18509119	Green Published			2022-12-28	WOS:000256306700002
J	Trainor, L				Trainor, Laurel			Science & music: The neural roots of music	NATURE			English	Editorial Material									McMaster Univ, McMaster Inst Mus & Mind, Hamilton, ON L8S 4L8, Canada; McMaster Univ, Auditory Dev Lab, Hamilton, ON L8S 4L8, Canada	McMaster University; McMaster University	Trainor, L (corresponding author), McMaster Univ, McMaster Inst Mus & Mind, 1280 Main St W, Hamilton, ON L8S 4L8, Canada.			Trainor, Laurel/0000-0003-3397-2079				Chang EF, 2003, SCIENCE, V300, P498, DOI 10.1126/science.1082163; Phillips-Silver J, 2005, SCIENCE, V308, P1430, DOI 10.1126/science.1110922; Trainor LJ, 2005, DEV PSYCHOBIOL, V46, P262, DOI 10.1002/dev.20059; TRAINOR LJ, IN PRESS CORTEX	4	51	55	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 29	2008	453	7195					598	599		10.1038/453598a	http://dx.doi.org/10.1038/453598a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305NN	18509429	Bronze			2022-12-28	WOS:000256185200028
J	Kickbusch, I; Matlin, S				Kickbusch, Ilona; Matlin, Stephen			A European Council on Global Health	LANCET			English	Editorial Material									[Kickbusch, Ilona] Grad Inst Int & Dev Studies, CH-1211 Geneva 21, Switzerland; [Matlin, Stephen] Global Forum Hlth Res, Geneva, Switzerland		Kickbusch, I (corresponding author), Grad Inst Int & Dev Studies, CH-1211 Geneva 21, Switzerland.	kickbusch@bluewin.ch						Amorim C, 2007, LANCET, V369, P1373, DOI 10.1016/S0140-6736(07)60498-X; *COMM EUR COMM, 2005, COMM ACC PROGR ATT M; *COMM EUR COMM, 2008, EU GLOB PARTN DEV SP; Commission European., 2007, TOG HLTH STRAT APPR; Kickbusch I., 2006, EUROPEAN PERSPECTIVE	5	5	5	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 24	2008	371	9626					1733	1734		10.1016/S0140-6736(08)60741-2	http://dx.doi.org/10.1016/S0140-6736(08)60741-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	304IO	18502283				2022-12-28	WOS:000256103400009
J	Morris, JW				Morris, J. W., Jr.			Materials science - Stronger, tougher steels	SCIENCE			English	Editorial Material							COHERENT TRANSFORMATIONS		[Morris, J. W., Jr.] Univ Calif Berkeley, Dept Mat Sci & Engn, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Morris, JW (corresponding author), Univ Calif Berkeley, Dept Mat Sci & Engn, Berkeley, CA 94720 USA.	jwmorris@berkeley.edu						Guo Z, 2004, ACTA MATER, V52, P5511, DOI 10.1016/j.actamat.2004.08.011; Kimura Y, 2008, SCIENCE, V320, P1057, DOI 10.1126/science.1156084; Maki T, 2007, FUNDAMENTALS MARTENS, P1; MCEVILY AJ, 2001, METAL FAILURES, pCH1; MCMEEKING RM, 1979, ELASTIC PLASTIC FRAC, P175; Morris JW, 2003, ISIJ INT, V43, P410, DOI 10.2355/isijinternational.43.410; *POH IR STEEL CO L, 2002, DEV HIGH PERF STEELS; RAO KTV, 1989, METALL TRANS A, V20, P485, DOI 10.1007/BF02653929; TAKAKI S, 2001, ULTRAFINE GRAINED ST; THOMAS G, 1971, METALL TRANS, V2, P2373, DOI 10.1007/BF02814875	10	93	98	3	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2008	320	5879					1022	1023		10.1126/science.1158994	http://dx.doi.org/10.1126/science.1158994			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18497282				2022-12-28	WOS:000256059800027
J	Arnold, JR; Karamitsos, TD; Petersen, SE				Arnold, Jayanth R.; Karamitsos, Theodoros D.; Petersen, Steffen E.			Athletes with repolarization abnormalities	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							HYPERTROPHIC CARDIOMYOPATHY		[Arnold, Jayanth R.; Karamitsos, Theodoros D.; Petersen, Steffen E.] Univ Oxford, Oxford OX3 9DU, England	University of Oxford	Arnold, JR (corresponding author), Univ Oxford, Oxford OX3 9DU, England.	ranjitarnold@yahoo.co.uk	Petersen, Steffen E/A-8389-2011; Karamitsos, Theodoros/AAF-8290-2021	Petersen, Steffen E/0000-0003-4622-5160; Karamitsos, Theodoros/0000-0002-4658-5273; Arnold, Jayanth/0000-0003-4533-8374				Assomull RG, 2007, HEART, V93, P985, DOI 10.1136/hrt.2003.025304; Maron MS, 2007, AM J CARDIOL, V100, P1293, DOI 10.1016/j.amjcard.2007.05.061; Nagueh SF, 2003, CIRCULATION, V108, P395, DOI 10.1161/01.CIR.0000084500.72232.8D; Tandri H, 2008, AM HEART J, V155, P147, DOI 10.1016/j.ahj.2007.08.011	4	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2008	358	21					2297	2297						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303EK	18504831				2022-12-28	WOS:000256023600032
J	Csete, J; Wolfe, D				Csete, Joanne; Wolfe, Daniel			Progress or backsliding on HIV and illicit drugs in 20008?	LANCET			English	Editorial Material									[Csete, Joanne] Canadian HIV AIDS Legal Network, Toronto, ON M5R 2A7, Canada; [Wolfe, Daniel] Open Soc Inst, New York, NY USA		Csete, J (corresponding author), Canadian HIV AIDS Legal Network, Toronto, ON M5R 2A7, Canada.	Jcsete2@hotmail.com						*AMN INT, 2004, THAIL ANT DRUG POL S; [Anonymous], 1961, SINGL CONV NARC DRUG; BEZLOV T, 2005, HEROIN USERS BULGARI; Csete J, 2007, DEPENDENT RIGHTS ASS; *INT NARC CONTR BO, 2005, ANN REP 2004; *INT NARC CONTR BO, 2006, ANN REP 2005; Lines R, 2005, INT J PRISON HEALTH, V1, P49, DOI 10.1080/17449200500157085; Mazlan M, 2006, DRUG ALCOHOL REV, V25, P473, DOI 10.1080/09595230600883354; *UN GEN ASS, 1998, AS24 UN GEN ASS; *UN GEN ASS, 2001, ARESS262 UN GEN ASS; *WHO, SUMM CONTR PROF HIV; WHO Model List of Essential Medicines, 2007, WHO MOD LIST ESS MED; Wolfe D, 2007, INT J DRUG POLICY, V18, P246, DOI 10.1016/j.drugpo.2007.01.012	13	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY-JUN	2008	371	9627					1820	1821		10.1016/S0140-6736(08)60777-1	http://dx.doi.org/10.1016/S0140-6736(08)60777-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	307NL	18514715				2022-12-28	WOS:000256325500008
J	Helliker, BR; Richter, SL				Helliker, Brent R.; Richter, Suzanna L.			Subtropical to boreal convergence of tree-leaf temperatures	NATURE			English	Article							OXYGEN-ISOTOPE RATIOS; RELATIVE-HUMIDITY; CELLULOSE; CARBON; WATER; HYDROGEN; FOREST; PLANTS; MODEL; RINGS	The oxygen isotope ratio (delta(18)O) of cellulose is thought to provide a record of ambient temperature and relative humidity during periods of carbon assimilation(1,2). Here we introduce a method to resolve tree-canopy leaf temperature with the use of delta(18)O of cellulose in 39 tree species. We show a remarkably constant leaf temperature of 21.4 +/- 2.2 degrees C across 50 degrees of latitude, from subtropical to boreal biomes. This means that when carbon assimilation is maximal, the physiological and morphological properties of tree branches serve to raise leaf temperature above air temperature to a much greater extent in more northern latitudes. A main assumption underlying the use of delta(18)O to reconstruct climate history is that the temperature and relative humidity of an actively photosynthesizing leaf are the same as those of the surrounding air(3,4). Our data are contrary to that assumption and show that plant physiological ecology must be considered when reconstructing climate through isotope analysis. Furthermore, our results may explain why climate has only a modest effect on leaf economic traits(5) in general.	[Helliker, Brent R.] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; [Richter, Suzanna L.] Univ Penn, Dept Earth & Environm Sci, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Helliker, BR (corresponding author), Univ Penn, Dept Biol, Philadelphia, PA 19104 USA.	helliker@sas.upenn.edu						Andersson S, 1998, J PHYS B-AT MOL OPT, V31, P625, DOI 10.1088/0953-4075/31/3/025; Barbour MM, 2000, PLANT CELL ENVIRON, V23, P473, DOI 10.1046/j.1365-3040.2000.00575.x; BERRY J, 1980, ANNU REV PLANT PHYS, V31, P491, DOI 10.1146/annurev.pp.31.060180.002423; Bowen GJ, 2003, WATER RESOUR RES, V39, DOI 10.1029/2003WR002086; Brendel O, 2000, PHYTOCHEM ANALYSIS, V11, P7, DOI 10.1002/(SICI)1099-1565(200001/02)11:1&lt;7::AID-PCA488&gt;3.0.CO;2-U; BUCK AL, 1981, J APPL METEOROL, V20, P1527, DOI 10.1175/1520-0450(1981)020<1527:NEFCVP>2.0.CO;2; Buhay WM, 1996, GEOCHIM COSMOCHIM AC, V60, P2209, DOI 10.1016/0016-7037(96)00073-7; Cernusak LA, 2005, TREE PHYSIOL, V25, P129, DOI 10.1093/treephys/25.2.129; Craig H., 1965, DEUTERIUM OXYGEN 18, P9, DOI DOI 10.1109/ISSRE.1993.624301; EPSTEIN S, 1977, SCIENCE, V198, P1209, DOI 10.1126/science.198.4323.1209; Evans MN, 2004, GEOCHIM COSMOCHIM AC, V68, P3295, DOI 10.1016/j.gca.2004.01.006; Farquhar G. D., 1993, Stable isotopes and plant carbon-water relations., P47; Gessler A, 2007, NEW PHYTOL, V174, P600, DOI 10.1111/j.1469-8137.2007.02007.x; GRAY J, 1976, NATURE, V262, P481, DOI 10.1038/262481a0; Helliker BR, 2000, P NATL ACAD SCI USA, V97, P7894, DOI 10.1073/pnas.97.14.7894; Jahren AH, 2003, GEOLOGY, V31, P463, DOI 10.1130/0091-7613(2003)031<0463:HEFTME>2.0.CO;2; Leuzinger S, 2007, AGR FOREST METEOROL, V146, P29, DOI 10.1016/j.agrformet.2007.05.007; Long S. P., 1988, PLANTS TEMPERATURE; Michaletz ST, 2006, NEW PHYTOL, V170, P87, DOI 10.1111/j.1469-8137.2006.01661.x; Miller DL, 2006, P NATL ACAD SCI USA, V103, P14294, DOI 10.1073/pnas.0606549103; MILLER PC, 1972, ECOLOGY, V53, P22, DOI 10.2307/1935708; PRENTICE IC, 1992, J BIOGEOGR, V19, P117, DOI 10.2307/2845499; RICHTER SL, IN PRESS GEOCHIM COS; Robertson I, 2001, EARTH PLANET SC LETT, V191, P21, DOI 10.1016/S0012-821X(01)00399-5; Roden JS, 2000, GEOCHIM COSMOCHIM AC, V64, P21, DOI 10.1016/S0016-7037(99)00195-7; Saurer M, 2000, J GEOPHYS RES-ATMOS, V105, P12461, DOI 10.1029/2000JD900160; SCHULZE ED, 1994, ANNU REV ECOL SYST, V25, P629, DOI 10.1146/annurev.es.25.110194.003213; SMITH WK, 1978, SCIENCE, V201, P614, DOI 10.1126/science.201.4356.614; SMITH WK, 1988, AM J BOT, V75, P496, DOI 10.2307/2444214; Sternberg LDSL., 1989, STABLE ISOTOPES ECOL, P124; Sternberg LDL, 2007, GEOCHIM COSMOCHIM AC, V71, P2463, DOI 10.1016/j.gca.2007.03.004; Wang XF, 1995, PLANT CELL ENVIRON, V18, P1377, DOI 10.1111/j.1365-3040.1995.tb00198.x; Way DA, 2008, GLOBAL CHANGE BIOL, V14, P624, DOI 10.1111/j.1365-2486.2007.01513.x; Wright IJ, 2004, NATURE, V428, P821, DOI 10.1038/nature02403; Wright WE, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006806	35	191	196	3	121	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 24	2008	454	7203					511	U6		10.1038/nature07031	http://dx.doi.org/10.1038/nature07031			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	329IC	18548005				2022-12-28	WOS:000257860300050
J	Amrani, N; Ghosh, S; Mangus, DA; Jacobson, A				Amrani, Nadia; Ghosh, Shubhendu; Mangus, David A.; Jacobson, Allan			Translation factors promote the formation of two states of the closed-loop mRNP	NATURE			English	Article							YEAST POLY(A)-BINDING PROTEIN; MESSENGER-RNA; POLY(A) TAIL; INITIATION; BINDING; CAP; RECOGNITION; TERMINATION; EIF4G; DOMAIN	Efficient translation initiation and optimal stability of most eukaryotic messenger RNAs depends on the formation of a closed- loop structure and the resulting synergistic interplay between the 59 m (7)G cap and the 3 ' poly( A) tail(1,2). Evidence of eIF4G and Pab1 interaction supports the notion of a closed- loop mRNP(3), but the mechanistic events that lead to its formation and maintenance are still unknown. Here we use toeprinting and polysome profiling assays to delineate ribosome positioning at initiator AUG codons and ribosome - mRNA association, respectively, and find that two distinct stable ( resistant to cap analogue) closed- loop structures are formed during initiation in yeast cell- free extracts. The integrity of both forms requires the mRNA cap and poly( A) tail, as well as eIF4E, eIF4G, Pab1 and eIF3, and is dependent on the length of both the mRNA and the poly( A) tail. Formation of the first structure requires the 48S ribosomal complex, whereas the second requires an 80S ribosome and the termination factors eRF3/ Sup35 and eRF1/ Sup45. The involvement of the termination factors is independent of a termination event.	[Amrani, Nadia; Ghosh, Shubhendu; Mangus, David A.; Jacobson, Allan] Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Jacobson, A (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA.	allan.jacobson@umassmed.edu	Amrani, Nadia/AAG-7474-2021	Amrani, Nadia/0000-0001-6871-7962	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027757, R01GM027757] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM027757-29, R37 GM027757, R01 GM027757, R37 GM027757-28, R37 GM027757-27, R37 GM027757-26] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amrani N, 2004, NATURE, V432, P112, DOI 10.1038/nature03060; BAER BW, 1983, J CELL BIOL, V96, P717, DOI 10.1083/jcb.96.3.717; BARNES CA, 1993, EMBO J, V12, P3323, DOI 10.1002/j.1460-2075.1993.tb06002.x; CHRISTENSEN AK, 1987, AM J ANAT, V178, P1, DOI 10.1002/aja.1001780102; Cosson B, 2002, MOL CELL BIOL, V22, P3301, DOI 10.1128/MCB.22.10.3301-3315.2002; De Gregorio E, 1998, RNA, V4, P828, DOI 10.1017/S1355838298980372; Dmitriev SE, 2003, FEBS LETT, V533, P99, DOI 10.1016/S0014-5793(02)03776-6; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Gebauer F, 1999, EMBO J, V18, P6146, DOI 10.1093/emboj/18.21.6146; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; Iizuka N, 1997, METHODS, V11, P353, DOI 10.1006/meth.1996.0433; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; Karim MM, 2006, P NATL ACAD SCI USA, V103, P9494, DOI 10.1073/pnas.0603701103; Kessler SH, 1998, MOL CELL BIOL, V18, P51, DOI 10.1128/MCB.18.1.51; Mangus DA, 1999, METHODS, V17, P28, DOI 10.1006/meth.1998.0704; Mangus DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-223; Mangus DA, 1998, MOL CELL BIOL, V18, P7383, DOI 10.1128/MCB.18.12.7383; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; Nielsen KH, 2004, EMBO J, V23, P1166, DOI 10.1038/sj.emboj.7600116; Otero LJ, 1999, EMBO J, V18, P3153, DOI 10.1093/emboj/18.11.3153; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; Salas-Marco J, 2004, MOL CELL BIOL, V24, P7769, DOI 10.1128/MCB.24.17.7769-7778.2004; Stansfield I, 1997, EUR J BIOCHEM, V245, P557, DOI 10.1111/j.1432-1033.1997.00557.x; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Uchida N, 2002, J BIOL CHEM, V277, P50286, DOI 10.1074/jbc.M203029200; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Wu C, 2007, METHOD ENZYMOL, V429, P203, DOI 10.1016/S0076-6879(07)29010-X	30	141	143	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 26	2008	453	7199					1276	U85		10.1038/nature06974	http://dx.doi.org/10.1038/nature06974			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318FA	18496529	Green Accepted			2022-12-28	WOS:000257075800051
J	Spano, JP; Chodkiewicz, C; Maurel, J; Wong, R; Wasan, H; Barone, C; Letourneau, R; Bajetta, E; Pithavala, Y; Bycott, P; Trask, P; Liau, K; Ricart, AD; Kim, S; Rixe, O				Spano, Jean-Philippe; Chodkiewicz, Catherine; Maurel, Joan; Wong, Ralph; Wasan, Harpreet; Barone, Carlo; Letourneau, Richard; Bajetta, Emilio; Pithavala, Yazdi; Bycott, Paul; Trask, Peter; Liau, Katherine; Ricart, Alejandro D.; Kim, Sinil; Rixe, Olivier			Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study	LANCET			English	Article							ENDOTHELIAL GROWTH-FACTOR; CLINICAL-TRIALS; HIGH EXPRESSION; POOR-PROGNOSIS; BEVACIZUMAB; QUESTIONNAIRE; FLUOROURACIL; MULTICENTER; COMBINATION; SURVIVAL	Background Axitinib (AG-013736) is a potent and selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, which have an important role in pancreatic cancer. The aim of this study was to assess the safety and efficacy of gemcitabine plus axitinib versus gemcitabine alone. Methods Between January and August, 2006, 103 patients with unresectable, locally advanced, or metastatic pancreatic cancer were randomly assigned in a two to one ratio to receive gemcitabine (1000 mg/m(2))plus axitinib 5 mg twice daily (n=69) or gemcitabine (1000 mg/m(2)) alone (n=34) by a centralised registration system. The primary endpoint was overall survival. Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00219557. Findings All randomised patients were included in the efficacy analyses. Median overall survival was longer with gemcitabine plus axitinib than with gemcitabine alone (6.9 [95% CI 5.3-10 . 1] months vs 5.6 [3.9-8.8] months). The hazard ratio for survival with gemcitabine plus axitinib versus with gemcitabine alone, adjusted for stratification factors, was 0 . 71 (95% CI 0 . 44-1.13). The most common grade 3 or worse adverse events were fatigue (15 [22%] patients in the gemcitabine plus axitinib group vs one [3%] in the gemcitabine alone group), abdominal pain (eight [12%] vs five [16%]), and asthenia (eight [12%] vs one [3%]). Interpretation Gemcitabine plus axitinib showed a similar safety profile to gemcitabine alone; the small, non-statistically significant gain in overall survival needs to be assessed in a randomised phase III trial. Funding Pfizer Inc.	[Spano, Jean-Philippe; Rixe, Olivier] Hop La Pitie Salpetriere, Paris, France; [Chodkiewicz, Catherine] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA; [Maurel, Joan] Hosp Clin Barcelona, CIBEREHD, Barcelona, Spain; [Wong, Ralph] Canc Care Manitoba, Winnipeg, MB, Canada; [Wasan, Harpreet] Hammersmith Hosp, London, England; [Barone, Carlo] Univ Cattolica Sacro Cuore, Rome, Italy; [Letourneau, Richard] Ctr Hosp Univ Montreal, Montreal, PQ, Canada; [Bajetta, Emilio] Fdn IRCCS Ist Nazl Tumori, Milan, Italy; [Pithavala, Yazdi; Bycott, Paul; Liau, Katherine; Ricart, Alejandro D.; Kim, Sinil] Pfizer Inc, La Jolla, CA USA; [Trask, Peter] Pfizer Inc, New London, CT USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Barcelona; Hospital Clinic de Barcelona; Imperial College London; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Universite de Montreal; Fondazione IRCCS Istituto Nazionale Tumori Milan; Pfizer; Pfizer	Spano, JP (corresponding author), Grp Hosp Pitie Salpetriere, 47-83 Blvd Hop, F-75651 Paris 13, France.	jean-philippe.spano@psl.ap-hop-paris.fr		Wasan, Harpreet/0000-0002-6268-2030				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Abou-Alfa GK, 2006, J CLIN ONCOL, V24, P4441, DOI 10.1200/JCO.2006.07.0201; Badgwell BD, 2008, ANN ONCOL, V19, P577, DOI 10.1093/annonc/mdm508; Berlin JD, 2002, J CLIN ONCOL, V20, P3270, DOI 10.1200/JCO.2002.11.149; Boeck S, 2008, ANN ONCOL, V19, P340, DOI 10.1093/annonc/mdm467; Bramhall SR, 2002, BRIT J CANCER, V87, P161, DOI 10.1038/sj.bjc.6600446; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Cannistra SA, 2007, J CLIN ONCOL, V25, P5180, DOI 10.1200/JCO.2007.12.0782; COHEN E, IN PRESS J CLIN ONCO; Fitzsimmons D, 1999, EUR J CANCER, V35, P939, DOI 10.1016/S0959-8049(99)00047-7; FRIBERG G, 2005, ANN M AM SOC CLIN ON; HEINEMANN V, 2007, J CLIN ONCOL, V25, pS201; Heinemann V, 2006, J CLIN ONCOL, V24, P3946, DOI 10.1200/JCO.2005.05.1490; Herrmann R, 2007, J CLIN ONCOL, V25, P2212, DOI 10.1200/JCO.2006.09.0886; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Khorana AA, 2004, LANCET ONCOL, V5, P655, DOI 10.1016/S1470-2045(04)01606-7; Kindler HL, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2007.12.0949; Kindler HL, 2005, J CLIN ONCOL, V23, P8033, DOI 10.1200/JCO.2005.01.9661; King MT, 1996, QUAL LIFE RES, V5, P555, DOI 10.1007/BF00439229; Korc M, 2003, Mol Cancer, V2, P8, DOI 10.1186/1476-4598-2-8; Langer C, 2007, J CLIN ONCOL, V25, P418, DOI 10.1200/JCO.2005.04.9452; Lima CMR, 2004, J CLIN ONCOL, V22, P3776, DOI 10.1200/JCO.2004.12.082; Louvet C, 2005, J CLIN ONCOL, V23, P3509, DOI 10.1200/JCO.2005.06.023; Maitland ML, 2006, J CLIN ONCOL, V24, p87S; Miksad RA, 2007, J CLIN ONCOL, V25, P4506, DOI 10.1200/JCO.2007.13.0401; Miller Kathy D, 2003, Clin Breast Cancer, V3, P421, DOI 10.3816/CBC.2003.n.007; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Niedergethmann M, 2002, PANCREAS, V25, P122, DOI 10.1097/00006676-200208000-00002; Osoba D, 1998, J CLIN ONCOL, V16, P139, DOI 10.1200/JCO.1998.16.1.139; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; PHILLIP PA, 2007, J CLIN ONCOL, V25, pS965; Rixe O, 2007, LANCET ONCOL, V8, P975, DOI 10.1016/S1470-2045(07)70285-1; Rugo HS, 2005, J CLIN ONCOL, V23, P5474, DOI 10.1200/JCO.2005.04.192; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Seo Y, 2000, CANCER, V88, P2239, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2239::AID-CNCR6>3.0.CO;2-V; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Trotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S1053-4296(03)00031-6; Van Cutsem E, 2004, J CLIN ONCOL, V22, P1430, DOI 10.1200/JCO.2004.10.112; van Heeckeren WJ, 2007, J CLIN ONCOL, V25, P2993, DOI 10.1200/JCO.2007.11.5113	41	209	217	1	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 21	2008	371	9630					2101	2108		10.1016/S0140-6736(08)60661-3	http://dx.doi.org/10.1016/S0140-6736(08)60661-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316ER	18514303				2022-12-28	WOS:000256932200030
J	Agrawal, A; Chhatre, A; Hardin, R				Agrawal, Arun; Chhatre, Ashwini; Hardin, Rebecca			Changing governance of the world's forests	SCIENCE			English	Editorial Material							PROTECTED AREAS; COMMONS; PARKS	Major features of contemporary forest governance include decentralization of forest management, logging concessions in publicly owned commercially valuable forests, and timber certification, primarily in temperate forests. Although a majority of forests continue to be owned formally by governments, the effectiveness of forest governance is increasingly independent of formal ownership. Growing and competing demands for food, biofuels, timber, and environmental services will pose severe challenges to effective forest governance in the future, especially in conjunction with the direct and indirect impacts of climate change. A greater role for community and market actors in forest governance and deeper attention to the factors that lead to effective governance, beyond ownership patterns, is necessary to address future forest governance challenges.	[Agrawal, Arun] Univ Michigan, Sch Nat Resources & Environm, Ann Arbor, MI 48109 USA; [Chhatre, Ashwini] Univ Illinois, Dept Geog, Urbana, IL 61801 USA; [Hardin, Rebecca] Univ Michigan, Dept Anthropol, Ann Arbor, MI 48109 USA; [Hardin, Rebecca] Univ Michigan, Sch Nat Resources & Environm, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Illinois System; University of Illinois Urbana-Champaign; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Agrawal, A (corresponding author), Univ Michigan, Sch Nat Resources & Environm, Ann Arbor, MI 48109 USA.	arunagra@umich.edu	Chhatre, Ashwini/E-5573-2013; Agrawal, Arun/A-4257-2009	Agrawal, Arun/0000-0001-6796-2958; Chhatre, Ashwini/0000-0002-5374-7867				Agrawal A, 2006, WORLD DEV, V34, P149, DOI 10.1016/j.worlddev.2005.07.013; Andersson K, 2007, J POLICY ANAL MANAG, V26, P99, DOI 10.1002/pam.20229; Cashore B., 2006, CONFRONTING SUSTAINA; Cronkleton P., 2008, ENV GOVERNANCE EMERG; Dietz T, 2003, SCIENCE, V302, P1907, DOI 10.1126/science.1091015; *FOOD AGR ORG, 2005, GLOB FOR RES ASS 200; *FOOD AGR ORG, 2001, GLOB FOR RES ASS 200; Grainger A, 2008, P NATL ACAD SCI USA, V105, P818, DOI 10.1073/pnas.0703015105; HARDIN R, 2002, 6 WP WORLD RES I I G; Hayes TM, 2006, WORLD DEV, V34, P2064, DOI 10.1016/j.worlddev.2006.03.002; Karsenty A., 2007, OVERVIEW IND FOREST; Keller M, 2007, FRONT ECOL ENVIRON, V5, P213, DOI 10.1890/1540-9295(2007)5[213:TPISLT]2.0.CO;2; Liu JG, 2007, SCIENCE, V317, P1513, DOI 10.1126/science.1144004; Meidinger Errol E., 1997, HUMAN ECOLOGY REV, V4, P52; Molnar A, 2004, WHO CONSERVES WORLDS; Ostrom, 1990, GOVERNING COMMONS; Ostrom E, 2007, P NATL ACAD SCI USA, V104, P15181, DOI 10.1073/pnas.0702288104; Ribot JC, 2006, WORLD DEV, V34, P1864, DOI 10.1016/j.worlddev.2005.11.020; *RIGHTS RES IN, 2007, TRANS FOR TEN GOV DR; West P, 2006, ANNU REV ANTHROPOL, V35, P251, DOI 10.1146/annurev.anthro.35.081705.123308; White AM A, 2002, WHO OWNS WORLDS FORE; Zimmerer KS, 2004, AMBIO, V33, P520, DOI 10.1639/0044-7447(2004)033[0520:GAMTIT]2.0.CO;2	22	450	463	7	159	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	2008	320	5882					1460	1462		10.1126/science.1155369	http://dx.doi.org/10.1126/science.1155369			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556552	Green Submitted			2022-12-28	WOS:000256676400035
J	Feely, RA; Sabine, CL; Hernandez-Ayon, JM; Ianson, D; Hales, B				Feely, Richard A.; Sabine, Christopher L.; Hernandez-Ayon, J. Martin; Ianson, Debby; Hales, Burke			Evidence for upwelling of corrosive "acidified" water onto the continental shelf	SCIENCE			English	Article							INORGANIC CARBON; SYSTEM; CO2; CALCIFICATION; DISSOLUTION; IMPACT; OCEAN	The absorption of atmospheric carbon dioxide (CO2) into the ocean lowers the pH of the waters. This so-called ocean acidification could have important consequences for marine ecosystems. To better understand the extent of this ocean acidification in coastal waters, we conducted hydrographic surveys along the continental shelf of western North America from central Canada to northern Mexico. We observed seawater that is undersaturated with respect to aragonite upwelling onto large portions of the continental shelf, reaching depths of similar to 40 to 120 meters along most transect lines and all the way to the surface on one transect off northern California. Although seasonal upwelling of the undersaturated waters onto the shelf is a natural phenomenon in this region, the ocean uptake of anthropogenic CO2 has increased the areal extent of the affected area.	[Feely, Richard A.; Sabine, Christopher L.] NOAA, Pacific Marine Environm Lab, Seattle, WA 98115 USA; [Hernandez-Ayon, J. Martin] Univ Autonoma Baja California, Inst Invest Oceanol, Ensenada, Baja California, Mexico; [Ianson, Debby] Inst Ocean Sci, Fisheries & Oceans Canada, Sidney, BC V8L 4B2, Canada; [Hales, Burke] Oregon State Univ, Coll Ocean & Atmospher Sci, Corvallis, OR 97331 USA	National Oceanic Atmospheric Admin (NOAA) - USA; Universidad Autonoma de Baja California; Fisheries & Oceans Canada; Oregon State University	Feely, RA (corresponding author), NOAA, Pacific Marine Environm Lab, 7600 Sand Point Way NE, Seattle, WA 98115 USA.	richard.a.feely@noaa.gov	Feely, Richard A./ABI-5740-2020; Hernandez-Ayon, Jose Martin/AAV-9088-2021	Hernandez-Ayon, Jose Martin/0000-0001-6869-6225; Ianson, Debby/0000-0001-8317-5196				Caldeira K, 2005, J GEOPHYS RES-OCEANS, V110, DOI 10.1029/2004JC002671; Delille B, 2005, GLOBAL BIOGEOCHEM CY, V19, DOI 10.1029/2004GB002318; Engel A, 2005, LIMNOL OCEANOGR, V50, P493, DOI 10.4319/lo.2005.50.2.0493; FEELY RA, 1988, MAR CHEM, V25, P227, DOI 10.1016/0304-4203(88)90052-7; Feely RA, 2004, J OCEANOGR, V60, P45, DOI 10.1023/B:JOCE.0000038317.01279.aa; Feely RA, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2002GB001866; Feely RA, 2004, SCIENCE, V305, P362, DOI 10.1126/science.1097329; FEELY RA, 2008, PICES PRESS, V16, P22; Friederich GE, 2002, PROG OCEANOGR, V54, P185, DOI 10.1016/S0079-6611(02)00049-6; Gazeau F, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2006GL028554; Green MA, 2004, LIMNOL OCEANOGR, V49, P727, DOI 10.4319/lo.2004.49.3.0727; Guinotte JM, 2003, CORAL REEFS, V22, P551, DOI 10.1007/s00338-003-0331-4; Hales B, 2005, GLOBAL BIOGEOCHEM CY, V19, DOI 10.1029/2004GB002295; HICKEY B, 1998, SEA, V2; Ianson D, 2003, DEEP-SEA RES PT I, V50, P1023, DOI 10.1016/S0967-0637(03)00114-6; Ishimatsu A, 2004, J OCEANOGR, V60, P731, DOI 10.1007/s10872-004-5765-y; Kleypas J. A., 2006, WORKSH HELD 18 20 AP; Langdon C, 2005, J GEOPHYS RES-OCEANS, V110, DOI 10.1029/2004JC002576; Orr JC, 2005, NATURE, V437, P681, DOI 10.1038/nature04095; Pennington JT, 2000, DEEP-SEA RES PT II, V47, P947, DOI 10.1016/S0967-0645(99)00132-0; Raven J.A., 2005, 1205 ROYAL SOC, DOI DOI 10.1080/02688690801911598; Riebesell U, 2000, NATURE, V407, P364, DOI 10.1038/35030078; Sabine CL, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001639; Sabine CL, 2004, SCIENCE, V305, P367, DOI 10.1126/science.1097403; SABINE CL, 2007, GREENHOUSE GASE SINK; Seibel BA, 2003, ADV APPL BIODIVERSIT, V4, P59; Siegenthaler U, 2005, SCIENCE, V310, P1313, DOI 10.1126/science.1120130; Solomon S, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P1; Spero HJ, 1997, NATURE, V390, P497, DOI 10.1038/37333; van Geen A, 2000, DEEP-SEA RES PT II, V47, P975, DOI 10.1016/S0967-0645(99)00133-2; Zondervan I, 2001, GLOBAL BIOGEOCHEM CY, V15, P507, DOI 10.1029/2000GB001321	31	978	1010	4	394	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2008	320	5882					1490	1492		10.1126/science.1155676	http://dx.doi.org/10.1126/science.1155676			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18497259	Green Submitted			2022-12-28	WOS:000256676400043
J	Hawkes, N				Hawkes, Nigel			A very British coup - Blairite ideology continues to dominate health care in the UK - so where is Brown's vision?	BRITISH MEDICAL JOURNAL			English	Editorial Material												nigel.hawkes@thetimes.co.uk							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2008	336	7656					1273	1273		10.1136/bmj.39601.467581.34	http://dx.doi.org/10.1136/bmj.39601.467581.34			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312XO	18535066	Green Published			2022-12-28	WOS:000256705900026
J	Markel, H; Stern, AM				Markel, Howard; Stern, Alexandra M.			Presidential health and the public's need to know	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Markel, Howard; Stern, Alexandra M.] Univ Michigan, Ctr Hist Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Markel, H (corresponding author), Univ Michigan, Ctr Hist Med, 100 Simpson Mem Inst,102 Observ, Ann Arbor, MI 48109 USA.	howard@umich.edu						Abrams Herbert L., 1992, PRESIDENT HAS BEEN S; Addison TW, 1868, COLLECTION PUBLISHED, P209; ANNAS GJ, 1995, NEW ENGL J MED, V333, P945, DOI 10.1056/NEJM199510053331420; BRUENN HG, 1970, ANN INTERN MED, V72, P579, DOI 10.7326/0003-4819-72-4-579; Dallek Robert, 2003, JF KENNEDY UNFINISHE; Ferrell R, 1992, ILL ADVISED PRESIDEN; Gallup George H., 1972, GALLUP POLL PUBLIC O; GILBERT RE, 1992, MORTAL PRESIDENCY; Joynt Robert J., 2001, PRESIDENTIAL DISABIL; Kassop N, 2005, PRES STUD Q, V35, P147, DOI 10.1111/j.1741-5705.2004.00240.x; LASBY CG, 1997, EISENHOWERS HEART AT; LINK AS, 1994, JAMA-J AM MED ASSOC, V272, P1694, DOI 10.1001/jama.272.21.1694; MCMURRAY C, 2006, GALLUP POLL PUBLIC O, P403; SCHLESINGER AM, 1965, 1000 DAYS JF KENNEDY, P19; 2008, WALL STREET J   0324	15	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2008	299	21					2558	2560		10.1001/jama.299.21.2558	http://dx.doi.org/10.1001/jama.299.21.2558			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308AR	18523224				2022-12-28	WOS:000256361200028
J	Norris, SL; Kansagara, D; Bougatsos, C; Fu, R				Norris, Susan L.; Kansagara, Devan; Bougatsos, Christina; Fu, Rongwei			Screening adults for type 2 diabetes: A review of the evidence for the U.S. Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Review							IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE INTERVENTION; CORONARY-HEART-DISEASE; LOW-DOSE ASPIRIN; RANDOMIZED CONTROLLED-TRIAL; NUTRITION EXAMINATION SURVEY; CARDIOVASCULAR RISK-FACTORS; LIPID-LOWERING TREATMENT; NO PREVIOUS DIAGNOSIS; II RECEPTOR BLOCKERS	Background: More than 19 million Americans are affected by type 2 diabetes mellitus, which is undiagnosed in one third of these persons. In addition, it is estimated that more than 54 million adults have prediabetes. Debate continues over the benefits and harms of screening and then treating adults who have asymptomatic diabetes or prediabetes. Purpose: To update the 2003 U. S. Preventive Services Task Force review on the evidence for potential benefits and harms of screening adults for type 2 diabetes and prediabetes in primary care settings. Data Sources: MEDLINE and the Cochrane Library for relevant studies and systematic reviews published in English between March 2001 and July 2007. Study Selection: Trials and observational studies that directly addressed the effectiveness and adverse effects of screening interventions were included. Randomized, controlled trials were used to assess the effectiveness of diabetes and prediabetes treatments. For diabetes interventions, trials of patients with disease for 1 year or less were included, as well as trials comparing outcomes among diabetic and nondiabetic patients. Data Extraction: Relevant data were abstracted in duplicate into a standardized template. Data Synthesis: Data were synthesized in a qualitative manner, and a random-effects meta-analysis of the effects of interventions in prediabetes on the incidence of diabetes was performed. Limitations: Most of the data on diabetes treatment were not from primary trial data but from subgroup analyses. Participants in intensive lifestyle interventions for prediabetes may not be representative of general prediabetic populations. Conclusion: Direct evidence is lacking on the health benefits of detecting type 2 diabetes by either targeted or mass screening, and indirect evidence also fails to demonstrate health benefits for screening general populations. Persons with hypertension probably benefit from screening, because blood pressure targets for persons with diabetes are lower than those for persons without diabetes. Intensive lifestyle and pharmacotherapeutic interventions reduce the progression of prediabetes to diabetes, but few data examine the effect of these interventions on long-term health outcomes.	Vet Adm Med Ctr, Portland, OR USA; Oregon Hlth & Sci Univ, Oregon Evidence Based Practice Ctr, Portland, OR 97239 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University	Norris, SL (corresponding author), Oregon Hlth & Sci Univ, Oregon Evidence Based Practice Ctr, 3181 SW Sam Jackson Pk Rd,Mail Stop B1CC, Portland, OR 97239 USA.				PHS HHS [290-02-0024] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adriaanse MC, 2005, QUAL LIFE RES, V14, P1501, DOI 10.1007/s11136-004-0028-3; Adriaanse MC, 2004, DIABETIC MED, V21, P1075, DOI 10.1111/j.1464-5491.2004.01277.x; Adriaanse MC, 2004, DIABETIC MED, V21, P992, DOI 10.1111/j.1464-5491.2004.01276.x; Adriaanse MC, 2002, DIABETIC MED, V19, P406; Agarwal S, 2006, ANN ACAD MED SINGAP, V35, P531; *ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI DOI 10.1016/S1062-1458(03)00049-7; [Anonymous], 1991, OPHTHALMOLOGY, V98, P741; [Anonymous], 2000, Diabetes Care, V23, P1619; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Barzilay JI, 2001, DIABETES CARE, V24, P654, DOI 10.2337/diacare.24.4.654; Berg AO, 2003, ANN INTERN MED, V138, P212, DOI 10.7326/0003-4819-138-3-200302040-00014; Berger JS, 2006, JAMA-J AM MED ASSOC, V295, P306, DOI 10.1001/jama.295.3.306; Black HR, 2003, JAMA-J AM MED ASSOC, V289, P2073, DOI 10.1001/jama.289.16.2073; Bolen S, 2007, ANN INTERN MED, V147, P386, DOI 10.7326/0003-4819-147-6-200709180-00178; Bonovas S, 2007, CAN MED ASSOC J, V176, P649, DOI 10.1503/cmaj.060803; Bosch J, 2005, CIRCULATION, V112, P1339, DOI 10.1161/CIRCULATIONAHA.105.548461; Bosch J, 2006, NEW ENGL J MED, V355, P1551; Caro JJ, 2004, DIABETIC MED, V21, P1229, DOI 10.1111/j.1464-5491.2004.01330.x; Chen THH, 2001, DIABETES RES CLIN PR, V54, pS37; Chiasson JL, 1998, DIABETES CARE, V21, P1720, DOI 10.2337/diacare.21.10.1720; Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5; Chiasson JL, 2003, JAMA-J AM MED ASSOC, V290, P486, DOI 10.1001/jama.290.4.486; Chowdhury TA, 2002, QJM-INT J MED, V95, P241, DOI 10.1093/qjmed/95.4.241; Colhoun HM, 2004, LANCET, V364, P685, DOI 10.1016/S0140-6736(04)16895-5; Collins R, 2003, LANCET, V361, P2005; Costa J, 2006, BMJ-BRIT MED J, V332, P1115, DOI 10.1136/bmj.38793.468449.AE; Coutinho M, 1999, DIABETES CARE, V22, P233, DOI 10.2337/diacare.22.2.233; Cowie CC, 2006, DIABETES CARE, V29, P1263, DOI 10.2337/dc06-0062; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Dailey GE, 2005, DIABETES CARE, V28, P220, DOI 10.2337/diacare.28.1.220; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dyson PA, 1997, METABOLISM, V46, P50, DOI 10.1016/S0026-0495(97)90318-8; Eborall H, 2007, BMJ-BRIT MED J, V335, P490, DOI 10.1136/bmj.39308.392176.BE; Eborall HC, 2007, BMJ-BRIT MED J, V335, P486, DOI 10.1136/bmj.39303.723449.55; Eddy DM, 2003, DIABETES CARE, V26, P3102, DOI 10.2337/diacare.26.11.3102; Eddy DM, 2003, DIABETES CARE, V26, P3093, DOI 10.2337/diacare.26.11.3093; Eddy DM, 2005, ANN INTERN MED, V143, P251, DOI 10.7326/0003-4819-143-4-200508160-00006; Edelman D, 2002, DIABETES CARE, V25, P1022, DOI 10.2337/diacare.25.6.1022; Edelstein SL, 2005, DIABETES CARE, V28, P138, DOI 10.2337/diacare.28.1.138; Engelgau MM, 1998, JAMA-J AM MED ASSOC, V280, P1757; Engelgau MM, 2005, ANN INTERN MED, V143, P301, DOI 10.7326/0003-4819-143-4-200508160-00011; Eriksson J, 1999, DIABETOLOGIA, V42, P793, DOI 10.1007/s001250051229; Farmer AJ, 2005, J CLIN EPIDEMIOL, V58, P991, DOI 10.1016/j.jclinepi.2005.02.016; Farmer AJ, 2003, DIABETIC MED, V20, P996, DOI 10.1046/j.1464-5491.2003.01042.x; Fujimoto WY, 2000, DIABETES CARE, V23, pB11; Gangji AS, 2007, DIABETES CARE, V30, P389, DOI 10.2337/dc06-1789; Gerstein HC, 2006, LANCET, V368, P1096, DOI 10.1016/S0140-6736(06)69420-8; Gerstein HC, 2000, LANCET, V355, P253; Gerstein HC, 2004, DIABETOLOGIA, V47, P1519, DOI 10.1007/s00125-004-1485-5; Glumer C, 2006, DIABETOLOGIA, V49, P1536, DOI 10.1007/s00125-006-0248-x; Goyder EC, 2000, DIABETIC MED, V17, P469, DOI 10.1046/j.1464-5491.2000.00308.x; Greaves CJ, 2004, FAM PRACT, V21, P57, DOI 10.1093/fampra/cmh113; Gregg EW, 2004, DIABETES CARE, V27, P2806, DOI 10.2337/diacare.27.12.2806; Grimes DA, 2002, LANCET, V359, P881, DOI 10.1016/S0140-6736(02)07948-5; HAFFNER SM, 1990, JAMA-J AM MED ASSOC, V263, P2893, DOI 10.1001/jama.263.21.2893; Haffner SM, 1999, ARCH INTERN MED, V159, P2661, DOI 10.1001/archinte.159.22.2661; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; HARRIS MI, 1993, DIABETES CARE, V16, P642, DOI 10.2337/diacare.16.4.642; HARRIS MI, 1992, DIABETES CARE, V15, P815, DOI 10.2337/diacare.15.7.815; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Harris R, 2003, ANN INTERN MED, V138, P215, DOI 10.7326/0003-4819-138-3-200302040-00015; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; HARRIS RP, 2003, SYSTEMATIC EVIDENCE, V19; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Henricsson M, 1996, ACTA OPHTHALMOL SCAN, V74, P533; Herman WH, 2005, ANN INTERN MED, V142, P323, DOI 10.7326/0003-4819-142-5-200503010-00007; Heymsfield SB, 2000, ARCH INTERN MED, V160, P1321, DOI 10.1001/archinte.160.9.1321; Hoerger TJ, 2004, ANN INTERN MED, V140, P689, DOI 10.7326/0003-4819-140-9-200405040-00008; Hofer TP, 2000, INT J TECHNOL ASSESS, V16, P822, DOI 10.1017/S0266462300102090; Hu FB, 2002, DIABETES CARE, V25, P1129, DOI 10.2337/diacare.25.7.1129; Khaw KT, 2001, BMJ-BRIT MED J, V322, P15, DOI 10.1136/bmj.322.7277.15; KLEIN R, 1988, JAMA-J AM MED ASSOC, V260, P2864, DOI 10.1001/jama.260.19.2864; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kosaka K, 2005, DIABETES RES CLIN PR, V67, P152, DOI 10.1016/j.diabres.2004.06.010; Kriska AM, 2006, MED SCI SPORT EXER, V38, P826, DOI 10.1249/01.mss.0000218138.91812.f9; Laaksonen DE, 2005, DIABETES, V54, P158, DOI 10.2337/diabetes.54.1.158; Lauritzen T, 2000, INT J OBESITY, V24, pS6, DOI 10.1038/sj.ijo.0801420; Law M, 2006, AM J CARDIOL, V97, p52C, DOI 10.1016/j.amjcard.2005.12.010; Li ZP, 2005, ANN INTERN MED, V142, P532, DOI 10.7326/0003-4819-142-7-200504050-00012; Lindgren P, 2007, INT J TECHNOL ASSESS, V23, P177, DOI 10.1017/S0266462307070286; Lindholm LH, 2002, LANCET, V359, P1004, DOI 10.1016/S0140-6736(02)08090-X; Lindstrom J, 2003, J AM SOC NEPHROL, V14, pS108, DOI 10.1097/01.ASN.0000070157.96264.13; Lindstrom J, 2003, DIABETES CARE, V26, P3230, DOI 10.2337/diacare.26.12.3230; Lindstrom J, 2006, LANCET, V368, P1673, DOI 10.1016/S0140-6736(06)69701-8; Lorenzo C, 2003, DIABETES CARE, V26, P3153, DOI 10.2337/diacare.26.11.3153; McClure DL, 2007, PHARMACOEPIDEM DR S, V16, P132, DOI 10.1002/pds.1341; McDonald MA, 2005, BMJ-BRIT MED J, V331, P873, DOI 10.1136/bmj.38595.518542.3A; MCPHILLIPS JB, 1990, AM J EPIDEMIOL, V131, P443, DOI 10.1093/oxfordjournals.aje.a115519; McQuaid KR, 2006, AM J MED, V119, P624, DOI 10.1016/j.amjmed.2005.10.039; Meigs JB, 1998, ANN INTERN MED, V128, P524, DOI 10.7326/0003-4819-128-7-199804010-00002; MOSS SE, 1991, AM J PUBLIC HEALTH, V81, P1158, DOI 10.2105/AJPH.81.9.1158; Nathan DM, 2005, NEW ENGL J MED, V353, P2643, DOI 10.1056/nejmoa052187; Nichols GA, 2004, DIABETIC MED, V21, P793, DOI 10.1111/j.1464-5491.2004.01191.x; *NIH CLIN EX, 2006, GUID MAN; Niskanen L, 1998, DIABETES CARE, V21, P1861, DOI 10.2337/diacare.21.11.1861; Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761; Norhammar A, 2002, LANCET, V359, P2140, DOI 10.1016/S0140-6736(02)09089-X; Norris SL, 2005, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004096.pub2, 10.1002/14651858.CD004095.pub2, 10.1002/14651858.CD005270]; NORRIS SL, 2006, DRUG CLASS REV THIAZ; Olafsdottir E, 2007, ACTA OPHTHALMOL SCAN, V85, P40, DOI 10.1111/j.1600-0420.2006.00753.x; Olivarius ND, 2001, BMJ-BRIT MED J, V323, P970, DOI 10.1136/bmj.323.7319.970; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P1271, DOI 10.1016/0895-4356(91)90160-B; Palmer AJ, 2004, CLIN THER, V26, P304, DOI 10.1016/S0149-2918(04)90029-X; Palmer AJ, 2004, CURR MED RES OPIN, V20, pS53, DOI 10.1185/030079903125002611; Pan CY, 2003, DIABETES RES CLIN PR, V61, P183, DOI 10.1016/S0168-8227(03)00117-7; PAN WH, 1986, AM J EPIDEMIOL, V123, P504, DOI 10.1093/oxfordjournals.aje.a114266; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; Peel E, 2004, PATIENT EDUC COUNS, V53, P269, DOI 10.1016/j.pec.2003.07.010; Ramachandran A, 2006, DIABETOLOGIA, V49, P289, DOI 10.1007/s00125-005-0097-z; Rathmann W, 2002, Z KARDIOL, V91, P620, DOI 10.1007/s00392-002-0826-y; Ratner R, 2005, DIABETES CARE, V28, P888, DOI 10.2337/diacare.28.4.888; Richter B, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006060.pub2; Richter B, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006063; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; Saaristo T, 2007, INT J CIRCUMPOL HEAL, V66, P101, DOI 10.3402/ijch.v66i2.18239; Sacco M, 2003, DIABETES CARE, V26, P3264, DOI 10.2337/diacare.26.12.3264; Saenz A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002966.pub3; Salpeter S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002967.pub2; Salpeter SR, 2003, ARCH INTERN MED, V163, P2594, DOI 10.1001/archinte.163.21.2594; Schellhase KG, 2003, J CLIN EPIDEMIOL, V56, P75, DOI 10.1016/S0895-4356(02)00533-4; Schmidt MI, 2005, DIABETES CARE, V28, P2013, DOI 10.2337/diacare.28.8.2013; Segal L, 1998, HEALTH PROMOT INT, V13, P197, DOI 10.1093/heapro/13.3.197; Selvin E, 2005, ARCH INTERN MED, V165, P1910, DOI 10.1001/archinte.165.16.1910; Selvin E, 2004, ANN INTERN MED, V141, P421, DOI 10.7326/0003-4819-141-6-200409210-00007; Setter SM, 2003, CLIN THER, V25, P2991, DOI 10.1016/S0149-2918(03)90089-0; Sever PS, 2005, DIABETES CARE, V28, P1151, DOI 10.2337/diacare.28.5.1151; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; Silva MA, 2006, CLIN THER, V28, P26, DOI 10.1016/j.clinthera.2006.01.005; Singh S, 2007, JAMA-J AM MED ASSOC, V298, P1189, DOI 10.1001/jama.298.10.1189; Skinner TC, 2005, DIABETIC MED, V22, P1497, DOI 10.1111/j.1464-5491.2005.01680.x; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Stern MP, 2002, ANN INTERN MED, V136, P575, DOI 10.7326/0003-4819-136-8-200204160-00006; Stettler C, 2006, AM HEART J, V152, P27, DOI 10.1016/j.ahj.2005.09.015; Stratton IM, 2001, DIABETOLOGIA, V44, P156, DOI 10.1007/s001250051594; Strippoli GFM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006254; Strippoli GFM, 2004, BMJ-BRIT MED J, V329, P828, DOI 10.1136/bmj.38237.585000.7C; Swinburn BA, 2001, DIABETES CARE, V24, P619, DOI 10.2337/diacare.24.4.619; Taubert G, 2003, AM HEART J, V145, P285, DOI 10.1067/mhj.2003.134; Thoolen BJ, 2006, DIABETES CARE, V29, P2257, DOI 10.2337/dc06-0617; Torgerson JS, 2001, CONTROL CLIN TRIALS, V22, P515, DOI 10.1016/S0197-2456(01)00165-9; Torgerson JS, 2004, DIABETES CARE, V27, P155, DOI 10.2337/diacare.27.1.155; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Turnbull F, 2005, ARCH INTERN MED, V165, P1410; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Van de Laar FA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005061; van de Laar FA, 2005, DIABETES CARE, V28, P154, DOI 10.2337/diacare.28.1.154; Vancheri F, 2005, QJM-INT J MED, V98, P871, DOI 10.1093/qjmed/hci134; Velazquez-Armenta EY, 2007, HYPERTENS PREGNANCY, V26, P51, DOI 10.1080/10641950601147937; Verdecchia P, 2005, EUR HEART J, V26, P2381, DOI 10.1093/eurheartj/ehi445; Verdecchia P, 2004, HYPERTENSION, V43, P963, DOI 10.1161/01.HYP.0000125726.92964.ab; Watanabe M, 2003, DIABETES CARE, V26, P3209, DOI 10.2337/diacare.26.12.3209; Waugh N, 2007, HEALTH TECHNOL ASSES, V11, P1; WAUGH N, 2007, HEALTH TECHNOL ASSES, V11, pR9; Whelton PK, 2005, ARCH INTERN MED, V165, P1401, DOI 10.1001/archinte.165.12.1401; Wilson PWF, 2007, ARCH INTERN MED, V167, P1068, DOI 10.1001/archinte.167.10.1068; Wiysonge CS, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002003.pub2; Wright AD, 2006, J DIABETES COMPLICAT, V20, P395, DOI 10.1016/j.jdiacomp.2005.08.010; Younis N, 2003, LANCET, V361, P195, DOI 10.1016/S0140-6736(03)12267-2; Zhang P, 2003, DIABETES CARE, V26, P2536, DOI 10.2337/diacare.26.9.2536; Zinman B, 2007, ANN INTERN MED, V146, P477, DOI 10.7326/0003-4819-146-7-200704030-00003; ACTION CONTROL CARDI	164	103	106	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2008	148	11					855	U82		10.7326/0003-4819-148-11-200806030-00008	http://dx.doi.org/10.7326/0003-4819-148-11-200806030-00008			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308CG	18519931				2022-12-28	WOS:000256365300007
J	Fan, L; Fuss, JO; Cheng, QJ; Arvai, AS; Hammel, M; Roberts, VA; Cooper, PK; Tainer, JA				Fan, Li; Fuss, Jill O.; Cheng, Quen J.; Arvai, Andrew S.; Hammel, Michal; Roberts, Victoria A.; Cooper, Priscilla K.; Tainer, John A.			XPD helicase structures and activities: Insights into the cancer and aging phenotypes from XPD mutations	CELL			English	Article							NUCLEOTIDE EXCISION-REPAIR; DNA-REPAIR; XERODERMA-PIGMENTOSUM; COCKAYNE-SYNDROME; TRANSCRIPTION FACTOR; BASAL TRANSCRIPTION; FACTOR TFIIH; GENE; TRICHOTHIODYSTROPHY; PROTEIN	Mutations in XPD helicase, required for nucleotide excision repair (NER) as part of the transcription/repair complex TFIIH, cause three distinct phenotypes: cancer-prone xeroderma pigmentosum (XP), or aging disorders Cockayne syndrome (CS), and trichothiodystrophy (TTD). To clarify molecular differences underlying these diseases, we determined crystal structures of the XPD catalytic core from Sulfolobus acidocaldarius and measured mutant enzyme activities. Substrate-binding grooves separate adjacent Rad51/RecA-like helicase domains (HD1, HD2) and an arch formed by 4FeS and Arch domains. XP mutations map along the HD1 ATP-binding edge and HD2 DNA-binding channel and impair helicase activity essential for NER. XP/CS mutations both impair helicase activity and likely affect HD2 functional movement. TTD mutants lose or retain helicase activity but map to sites in all four domains expected to cause framework defects impacting TFIIH integrity. These results provide a foundation for understanding disease consequences of mutations in XPD and related 4Fe-4S helicases including FancJ.	[Fan, Li; Arvai, Andrew S.; Tainer, John A.] Scripps Res Inst, Dept Mol Biol, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; [Fuss, Jill O.; Cheng, Quen J.; Cooper, Priscilla K.; Tainer, John A.] Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Genom Stabil, Div Life Sci, Berkeley, CA 94720 USA; [Hammel, Michal] Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biophys Div, Berkeley, CA 94720 USA; [Roberts, Victoria A.] Univ Calif San Diego, San Diego Supercomp Ctr, La Jolla, CA 92037 USA	Scripps Research Institute; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California San Diego	Tainer, JA (corresponding author), Scripps Res Inst, Dept Mol Biol, Skaggs Inst Chem Biol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jat@scripps.edu	Classen, Scott/AAY-8176-2020; Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429; Hammel, Michal/0000-0002-5610-9289; Cheng, Quen/0000-0002-0161-1917	NCI NIH HHS [P01 CA092584, F32 CA108393, 1F32CA108393, F32 CA108393-03, P01 CA92584, R01 CA112093, R01 CA112093-02, P01 CA092584-07] Funding Source: Medline; NIGMS NIH HHS [R01 GM070996, R01 GM070996-01, GM070996] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112093, F32CA108393, P01CA092584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070996] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bienstock RJ, 2003, J BIOL CHEM, V278, P5309, DOI 10.1074/jbc.M210159200; Boal AK, 2005, BIOCHEMISTRY-US, V44, P8397, DOI 10.1021/bi047494n; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; Botta E, 2002, HUM MOL GENET, V11, P2919, DOI 10.1093/hmg/11.23.2919; Buttner K, 2007, NAT STRUCT MOL BIOL, V14, P647, DOI 10.1038/nsmb1246; Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Chapados BR, 2004, CELL, V116, P39, DOI 10.1016/S0092-8674(03)01036-5; Clarkson SG, 2005, DNA REPAIR, V4, P1068, DOI 10.1016/j.dnarep.2005.07.001; Coin F, 2007, MOL CELL, V26, P245, DOI 10.1016/j.molcel.2007.03.009; de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174; Dubaele S, 2003, MOL CELL, V11, P1635, DOI 10.1016/S1097-2765(03)00182-5; Fan L, 2006, MOL CELL, V22, P27, DOI 10.1016/j.molcel.2006.02.017; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Ito S, 2007, MOL CELL, V26, P231, DOI 10.1016/j.molcel.2007.03.013; Laine JP, 2006, METHOD ENZYMOL, V408, P246, DOI 10.1016/S0076-6879(06)08015-3; Lee JY, 2006, CELL, V127, P1349, DOI 10.1016/j.cell.2006.10.049; Lehmann AR, 2001, GENE DEV, V15, P15, DOI 10.1101/gad.859501; Levran O, 2005, NAT GENET, V37, P931, DOI 10.1038/ng1624; Ludovic C, 2006, CHEM REV, V106, P253; Outten FW, 2007, NAT CHEM BIOL, V3, P206, DOI 10.1038/nchembio0407-206; Pugh RA, 2008, J BIOL CHEM, V283, P1732, DOI 10.1074/jbc.M707064200; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; Rudolf J, 2006, MOL CELL, V23, P801, DOI 10.1016/j.molcel.2006.07.019; Sarker AH, 2005, MOL CELL, V20, P187, DOI 10.1016/j.molcel.2005.09.022; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; Schumacher B, 2008, TRENDS GENET, V24, P77, DOI 10.1016/j.tig.2007.11.004; Shin DS, 2003, EMBO J, V22, P4566, DOI 10.1093/emboj/cdg429; Singleton MR, 2007, ANNU REV BIOCHEM, V76, P23, DOI 10.1146/annurev.biochem.76.052305.115300; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; Taylor EM, 1997, P NATL ACAD SCI USA, V94, P8658, DOI 10.1073/pnas.94.16.8658; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Theron T, 2005, MOL CELL BIOL, V25, P8368, DOI 10.1128/MCB.25.18.8368-8378.2005; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Vermeulen W, 2001, NAT GENET, V27, P299, DOI 10.1038/85864; Winkler GS, 2000, J BIOL CHEM, V275, P4258, DOI 10.1074/jbc.275.6.4258; Yamagata A, 2007, EMBO J, V26, P878, DOI 10.1038/sj.emboj.7601544; Yavin E, 2006, P NATL ACAD SCI USA, V103, P3610, DOI 10.1073/pnas.0600239103	38	290	298	1	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	2008	133	5					789	800		10.1016/j.cell.2008.04.030	http://dx.doi.org/10.1016/j.cell.2008.04.030			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510924	Green Submitted, Green Accepted, Bronze			2022-12-28	WOS:000256274500012
J	Dong, LM; Potter, JD; White, E; Ulrich, CM; Cardon, LR; Peters, U				Dong, Linda M.; Potter, John D.; White, Emily; Ulrich, Cornelia M.; Cardon, Lon R.; Peters, Ulrike			Genetic susceptibility to cancer - The role of polymorphisms in candidate genes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							GLUTATHIONE-S-TRANSFERASE; GENOME-WIDE ASSOCIATION; BASE-EXCISION-REPAIR; SINGLE-NUCLEOTIDE POLYMORPHISMS; NON-HODGKIN-LYMPHOMA; BREAST-CANCER; LUNG-CANCER; PROSTATE-CANCER; COLORECTAL-CANCER; BLADDER-CANCER	Context Continuing advances in genotyping technologies and the inclusion of DNA collection in observational studies have resulted in an increasing number of genetic association studies. Objective To evaluate the overall progress and contribution of candidate gene association studies to current understanding of the genetic susceptibility to cancer. Data Sources We systematically examined the results of meta- analyses and pooled analyses for genetic polymorphisms and cancer risk published through March 2008. Study Selection We identified 161 meta- analyses and pooled analyses, encompassing 18 cancer sites and 99 genes. Analyses had to meet the following criteria: include at least 500 cases, have cancer risk as outcome, not be focused on HLA antigen genetic markers, and be published in English. Data Extraction Information on cancer site, gene name, variant, point estimate and 95% confidence interval ( CI), allelic frequency, number of studies and cases, tests of study heterogeneity, and publication bias were extracted by 1 investigator and reviewed by other investigators. Results These 161 analyses evaluated 344 gene- variant cancer associations and included on average 7.3 studies and 3551 cases ( range, 508- 19 729 cases) per investigated association. The summary odds ratio ( OR) for 98 ( 28%) statistically significant associations ( P value <. 05) were further evaluated by estimating the false- positive report probability ( FPRP) at a given prior probability and statistical power. At a prior probability level of 0.001 and statistical power to detect an OR of 1.5, 13 gene- variant cancer associations remained noteworthy ( FPRP < 0.2). Assuming a very low prior probability of 0.000001, similar to a probability assumed for a randomly selected single-nucleotide polymorphism in a genome- wide association study, and statistical power to detect an OR of 1.5, 4 associations were considered noteworthy as denoted by an FPRP value < 0.2: GSTM1 null and bladder cancer ( OR, 1.5; 95% CI, 1.3- 1.6; P= 1.9 x 10(-14)), NAT2 slow acetylator and bladder cancer ( OR, 1.46; 95% CI, 1.26-1.68; P= 2.5 x 10(-7)), MTHFR C677T and gastric cancer ( OR, 1.52; 95% CI, 1.31-1.77; P= 4.9 x 10(-8)), and GSTM1 null and acute leukemia ( OR, 1.20; 95% CI, 1.14-1.25; P = 8.6 x 10(-15)). When the OR used to determine statistical power was lowered to 1.2, 2 of the 4 noteworthy associations remained so: GSTM1 null with bladder cancer and acute leukemia. Conclusion In this review of candidate gene association studies, nearly one- third of gene- variant cancer associations were statistically significant, with variants in genes encoding for metabolizing enzymes among the most consistent and highly significant associations.	[Dong, Linda M.; Potter, John D.; White, Emily; Ulrich, Cornelia M.; Cardon, Lon R.; Peters, Ulrike] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98109 USA; [Dong, Linda M.; Potter, John D.; White, Emily; Ulrich, Cornelia M.; Peters, Ulrike] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Cardon, Lon R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Peters, U (corresponding author), Fred Hutchinson Canc Res Ctr, Canc Prevent Program, M4-B402,POB 19024, Seattle, WA 98109 USA.	upeters@fhcrc.org	Liao, Linda M/B-3960-2011	Liao, Linda M/0000-0002-1923-5294; Potter, John/0000-0001-5439-1500	NCI NIH HHS [R25 CA94880, R25 CA094880-01, CA118421, R25 CA094880, CA059045] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R25CA094880, K22CA118421, R01CA059045] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ates NA, 2005, BIOCHEM GENET, V43, P149, DOI 10.1007/s10528-005-1508-z; Aydin-Sayitoglu M, 2006, AM J HEMATOL, V81, P162, DOI 10.1002/ajh.20434; Bethke L, 2008, HUM MOL GENET, V17, P800, DOI 10.1093/hmg/ddm351; Bethke L, 2008, J NATL CANCER I, V100, P270, DOI 10.1093/jnci/djn004; Boccia S, 2006, MUTAGENESIS, V21, P115, DOI 10.1093/mutage/gel005; Boccia S, 2008, AM J EPIDEMIOL, V167, P505, DOI 10.1093/aje/kwm344; Bolufer P, 2007, HAEMATOLOGICA, V92, P308, DOI 10.3324/haematol.10752; Bolufer P, 2006, LEUKEMIA RES, V30, P1471, DOI 10.1016/j.leukres.2006.01.016; Brenner AV, 2007, CARCINOGENESIS, V28, P2543, DOI 10.1093/carcin/bgm210; Broderick P, 2007, NAT GENET, V39, P1315, DOI 10.1038/ng.2007.18; Cengiz M, 2007, INT UROL NEPHROL, V39, P1043, DOI 10.1007/s11255-007-9179-9; Chao C, 2006, CANCER EPIDEM BIOMAR, V15, P979, DOI 10.1158/1055-9965.EPI-05-0899; Chen CW, 2007, J HUM GENET, V52, P423, DOI 10.1007/s10038-007-0131-8; Chen K, 2005, WORLD J GASTROENTERO, V11, P331, DOI 10.3748/wjg.v11.i3.331; Choi SW, 2002, J NUTR, V132, p2413S, DOI 10.1093/jn/132.8.2413S; Clavel J, 2005, EUR J CANCER PREV, V14, P531, DOI 10.1097/00008469-200512000-00007; Cox A, 2007, NAT GENET, V39, P352, DOI 10.1038/ng1981; Cox DG, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-175; Cox DG, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1635; Cybulski C, 2007, UROL INT, V79, P44, DOI 10.1159/000102913; de Jong MM, 2002, J MED GENET, V39, P225, DOI 10.1136/jmg.39.4.225; de Jong MM, 2002, CANCER EPIDEM BIOMAR, V11, P1332; De Ruyck K, 2007, MUTAT RES-GEN TOX EN, V631, P101, DOI 10.1016/j.mrgentox.2007.03.010; DICKERSIN K, 1992, EPIDEMIOL REV, V14, P154, DOI 10.1093/oxfordjournals.epirev.a036084; Duggan D, 2007, JNCI-J NATL CANCER I, V99, P1836, DOI 10.1093/jnci/djm250; Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887; Eeles RA, 2008, NAT GENET, V40, P316, DOI 10.1038/ng.90; Figueroa JD, 2007, CARCINOGENESIS, V28, P1788, DOI 10.1093/carcin/bgm132; Francisco G, 2008, EUR J HUM GENET, V16, P724, DOI 10.1038/ejhg.2008.6; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; Garcia-Closas M, 2005, LANCET, V366, P649, DOI 10.1016/S0140-6736(05)67137-1; Garcia-Closas M, 2007, CANCER EPIDEM BIOMAR, V16, P2269, DOI 10.1158/1055-9965.EPI-07-0449; Garcia-Closas M, 2007, INT J CANCER, V121, P2532, DOI 10.1002/ijc.22985; Gayther SA, 2007, CANCER RES, V67, P3027, DOI 10.1158/0008-5472.CAN-06-3261; Glick AB, 2004, CANCER BIOL THER, V3, P276, DOI 10.4161/cbt.3.3.849; Gorouhi F, 2008, BRIT J CANCER, V98, P1443, DOI 10.1038/sj.bjc.6604277; Grenet J, 1999, GENE, V226, P225, DOI 10.1016/S0378-1119(98)00565-4; Gudmundsson J, 2008, NAT GENET, V40, P281, DOI 10.1038/ng.89; Gudmundsson J, 2007, NAT GENET, V39, P631, DOI 10.1038/ng1999; Haiman CA, 2007, NAT GENET, V39, P954, DOI 10.1038/ng2098; Haiman CA, 2007, CANCER RES, V67, P3565, DOI 10.1158/0008-5472.CAN-06-4801; Haiman CA, 2007, NAT GENET, V39, P638, DOI 10.1038/ng2015; Han SZ, 2006, EUR J HUM GENET, V14, P1136, DOI 10.1038/sj.ejhg.5201681; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HAYES JD, 1995, FREE RADICAL RES, V22, P193, DOI 10.3109/10715769509147539; Hein DW, 2002, MUTAT RES-FUND MOL M, V506, P65, DOI 10.1016/S0027-5107(02)00153-7; Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29; Huang K, 2006, CANCER CAUSE CONTROL, V17, P385, DOI 10.1007/s10552-005-0424-1; Huang WY, 2005, CANCER EPIDEM BIOMAR, V14, P1747, DOI 10.1158/1055-9965.EPI-05-0162; Huang Y, 2007, J HUM GENET, V52, P73, DOI 10.1007/s10038-006-0082-5; Hubner RA, 2007, INT J CANCER, V120, P1027, DOI 10.1002/ijc.22440; Hung RJ, 2005, AM J EPIDEMIOL, V162, P925, DOI 10.1093/aje/kwi318; Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Kellen E, 2007, AM J EPIDEMIOL, V165, P1221, DOI 10.1093/aje/kwm003; Kiyohara Chikako, 2007, Int J Med Sci, V4, P59; Kiyohara C, 2006, LUNG CANCER, V54, P267, DOI 10.1016/j.lungcan.2006.08.009; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee KM, 2007, HUM GENET, V122, P525, DOI 10.1007/s00439-007-0431-2; Lee WJ, 2002, BIOMARKERS, V7, P230, DOI 10.1080/13547500210121882; Lewis SJ, 2005, CANCER EPIDEM BIOMAR, V14, P1967, DOI 10.1158/1055-9965.EPI-05-0196; Li HH, 2006, CLIN CANCER RES, V12, P5713, DOI 10.1158/1078-0432.CCR-05-2799; Lin BK, 2006, AM J EPIDEMIOL, V164, P1, DOI 10.1093/aje/kwj175; Little J, 2006, INT J CANCER, V119, P2155, DOI 10.1002/ijc.22093; Liu G, 2008, INT J CANCER, V122, P915, DOI 10.1002/ijc.23178; Lopez-Cima MF, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-162; Majumdar S, 2008, EUR J CANCER PREV, V17, P125, DOI 10.1097/CEJ.0b013e3282b6fd68; Martinez C, 2006, PHARMACOGENOMICS, V7, P711, DOI 10.2217/14622416.7.5.711; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Morgan TM, 2007, JAMA-J AM MED ASSOC, V297, P1551, DOI 10.1001/jama.297.14.1551; MORRIS RD, 1994, ENVIRON HEALTH PERSP, V102, P61, DOI 10.1289/ehp.94102s861; Mosteller F, 1996, ANNU REV PUBL HEALTH, V17, P1, DOI 10.1146/annurev.pu.17.050196.000245; NELSON HH, 1995, CARCINOGENESIS, V16, P1243, DOI 10.1093/carcin/16.5.1243; Onay UV, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-6; Pachouri SS, 2007, DNA CELL BIOL, V26, P186, DOI 10.1089/dna.2006.9999; Pakakasama S, 2005, AM J HEMATOL, V79, P202, DOI 10.1002/ajh.20404; Paracchini V, 2007, AM J EPIDEMIOL, V165, P115, DOI 10.1093/aje/kwj365; Parl FF, 2005, CANCER LETT, V221, P123, DOI 10.1016/j.canlet.2004.06.016; Pasche B, 2004, J CLIN ONCOL, V22, P756, DOI 10.1200/JCO.2004.99.271; Pereira TV, 2006, CANCER EPIDEM BIOMAR, V15, P1956, DOI 10.1158/1055-9965.EPI-06-0334; Poole C, 2001, EPIDEMIOLOGY, V12, P291, DOI 10.1097/00001648-200105000-00005; Raimondi S, 2006, AM J EPIDEMIOL, V164, P1027, DOI 10.1093/aje/kwj321; Rajagopal R, 2005, CARCINOGENESIS, V26, P2157, DOI 10.1093/carcin/bgi195; Rebbeck TR, 1997, CANCER EPIDEM BIOMAR, V6, P733; Rosfjord EC, 1999, J MAMMARY GLAND BIOL, V4, P229, DOI 10.1023/A:1018789527533; Rostami-Hodjegan A, 1998, PHARMACOGENETICS, V8, P227, DOI 10.1097/00008571-199806000-00005; Rothman N, 2006, LANCET ONCOL, V7, P27, DOI 10.1016/S1470-2045(05)70434-4; Rozen R, 1997, THROMB HAEMOSTASIS, V78, P523; Sanderson S, 2007, AM J EPIDEMIOL, V166, P741, DOI 10.1093/aje/kwm167; Setiawan VW, 2007, CANCER EPIDEM BIOMAR, V16, P2237, DOI 10.1158/1055-9965.EPI-07-0589; Shao JF, 2008, INT J UROL, V15, P216, DOI 10.1111/j.1442-2042.2007.01915.x; Shea PR, 2008, PROSTATE, V68, P354, DOI 10.1002/pros.20687; Shi XQ, 2008, LUNG CANCER, V59, P155, DOI 10.1016/j.lungcan.2007.08.004; Shook SJ, 2007, CLIN CANCER RES, V13, P5959, DOI 10.1158/1078-0432.CCR-07-0702; Sigurdson AJ, 2007, CANCER EPIDEM BIOMAR, V16, P2000, DOI 10.1158/1055-9965.EPI-07-0282; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; Sreeja L, 2008, J CANCER RES CLIN, V134, P645, DOI 10.1007/s00432-007-0328-4; Stacey SN, 2007, NAT GENET, V39, P865, DOI 10.1038/ng2064; Steffen J, 2006, INT J CANCER, V119, P472, DOI 10.1002/ijc.21853; Sun JL, 2007, UROL ONCOL-SEMIN ORI, V25, P250, DOI 10.1016/j.urolonc.2006.10.001; Taioli E, 2007, GENET MED, V9, P67, DOI 10.1097/GIM.0b013e31803068b1; Tan XL, 2008, INT J CANCER, V122, P2573, DOI 10.1002/ijc.23363; Thomas DC, 2004, JNCI-J NATL CANCER I, V96, P421, DOI 10.1093/jnci/djh094; Thomas G, 2008, NAT GENET, V40, P310, DOI 10.1038/ng.91; Tomlinson I, 2007, NAT GENET, V39, P984, DOI 10.1038/ng2085; Tripathy CB, 2006, HEAD NECK-J SCI SPEC, V28, P217, DOI 10.1002/hed.20295; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vineis P, 2007, ANN ONCOL, V18, P1230, DOI 10.1093/annonc/mdm109; Vineis P, 2003, INT J CANCER, V104, P650, DOI 10.1002/ijc.10995; Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075; Wang F, 2008, CANCER EPIDEM BIOMAR, V17, P507, DOI 10.1158/1055-9965.EPI-07-2507; Wang GY, 2008, AM J EPIDEMIOL, V167, P7, DOI 10.1093/aje/kwm264; Wang P, 2007, INT J CANCER, V120, P552, DOI 10.1002/ijc.22353; Weischer M, 2008, J CLIN ONCOL, V26, P542, DOI 10.1200/JCO.2007.12.5922; Wilkening S, 2007, CARCINOGENESIS, V28, P2262, DOI 10.1093/carcin/bgm191; Yang CX, 2005, WORLD J GASTROENTERO, V11, P2531, DOI 10.3748/wjg.v11.i17.2531; Ye Z, 2005, EUR J CANCER, V41, P980, DOI 10.1016/j.ejca.2005.01.014; Ye Z, 2004, J MED GENET, V41, P360, DOI 10.1136/jmg.2003.016246; Yeager M, 2007, NAT GENET, V39, P645, DOI 10.1038/ng2022; Yeh CC, 2007, J BIOMED SCI, V14, P183, DOI 10.1007/s11373-006-9139-x; Yin JY, 2007, LUNG CANCER, V56, P153, DOI 10.1016/j.lungcan.2006.12.012; Zanke BW, 2007, NAT GENET, V39, P989, DOI 10.1038/ng2089; Zeegers MP, 2004, CANCER EPIDEM BIOMAR, V13, P1765; Zhang DQ, 2008, J HUM GENET, V53, P18, DOI 10.1007/s10038-007-0215-5; Zhang YW, 2006, CANCER EPIDEM BIOMAR, V15, P353, DOI 10.1158/1055-9965.EPI-05-0653; Zhou Y, 2007, INT J CANCER, V121, P1481, DOI 10.1002/ijc.22833	127	329	341	0	34	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2008	299	20					2423	2436		10.1001/jama.299.20.2423	http://dx.doi.org/10.1001/jama.299.20.2423			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305BD	18505952	Green Accepted			2022-12-28	WOS:000256151900027
J	Fuller, PM; Lu, J; Saper, CB				Fuller, Patrick M.; Lu, Jun; Saper, Clifford B.			Differential rescue of light- and food-entrainable circadian rhythms	SCIENCE			English	Article							DORSOMEDIAL HYPOTHALAMIC NUCLEUS; CLOCK PROTEIN; BMAL1; OSCILLATORS; ENTRAINMENT; PACEMAKER; COMPONENT; LESIONS; SLEEP; BRAIN	When food is plentiful, circadian rhythms of animals are powerfully entrained by the light- dark cycle. However, if animals have access to food only during their normal sleep cycle, they will shift most of their circadian rhythms to match the food availability. We studied the basis for entrainment of circadian rhythms by food and light in mice with targeted disruption of the clock gene Bmal1, which lack circadian rhythmicity. Injection of a viral vector containing the Bmal1 gene into the suprachiasmatic nuclei of the hypothalamus restored light- entrainable, but not food- entrainable, circadian rhythms. In contrast, restoration of the Bmal1 gene only in the dorsomedial hypothalamic nucleus restored the ability of animals to entrain to food but not to light. These results demonstrate that the dorsomedial hypothalamus contains a Bmal1- based oscillator that can drive food entrainment of circadian rhythms.	[Fuller, Patrick M.; Lu, Jun; Saper, Clifford B.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol,Div Sleep Med, Boston, MA 02215 USA; [Fuller, Patrick M.; Lu, Jun; Saper, Clifford B.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Program Neurosci, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Saper, CB (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol,Div Sleep Med, Boston, MA 02215 USA.	csaper@bidmc.harvard.edu	Saper, Clifford/L-3815-2019		NHLBI NIH HHS [T32 HL007901, HL07901-08, P50 HL060292-08, HL60292, P50 HL060292] Funding Source: Medline; NINDS NIH HHS [NS33987, R01 NS051609, F32 NS057119, NS057119, NS051609, R01 NS033987, R01 NS033987-11] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060292, T32HL007901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS057119, R01NS051609, R01NS033987] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Bunger MK, 2005, GENESIS, V41, P122, DOI 10.1002/gene.20102; Chou TC, 2003, J NEUROSCI, V23, P10691; COOLEY JJ, 2008, J BIOL RHYTHM, V22, P479; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; FULLER CA, 1981, AM J PHYSIOL, V241, P5; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Gooley JJ, 2006, NAT NEUROSCI, V9, P398, DOI 10.1038/nn1651; Hastings MH, 2003, NAT REV NEUROSCI, V4, P649, DOI 10.1038/nrn1177; HIROSHIGE T, 1991, BRAIN RES BULL, V27, P441, DOI 10.1016/0361-9230(91)90139-B; Kramer A, 2001, SCIENCE, V294, P2511, DOI 10.1126/science.1067716; KRIEGER DT, 1977, SCIENCE, V197, P398, DOI 10.1126/science.877566; LANDRY GJ, 2006, AM J PHYSIOL, V290, P6; Laposky A, 2005, SLEEP, V28, P395, DOI 10.1093/sleep/28.4.395; Lowrey PL, 2004, ANNU REV GENOM HUM G, V5, P407, DOI 10.1146/annurev.genom.5.061903.175925; McDearmon EL, 2006, SCIENCE, V314, P1304, DOI 10.1126/science.1132430; Mieda M, 2006, P NATL ACAD SCI USA, V103, P12150, DOI 10.1073/pnas.0604189103; Rudic RD, 2004, PLOS BIOL, V2, P1893, DOI 10.1371/journal.pbio.0020377; Saper CB, 2005, TRENDS NEUROSCI, V28, P152, DOI 10.1016/j.tins.2004.12.009; Shimba S, 2005, P NATL ACAD SCI USA, V102, P12071, DOI 10.1073/pnas.0502383102; STEPHAN FK, 1979, BEHAV NEURAL BIOL, V25, P346, DOI 10.1016/S0163-1047(79)90415-1; STEPHAN FK, 1989, PHYSIOL BEHAV, V46, P489, DOI 10.1016/0031-9384(89)90026-7; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; Thompson RH, 1998, BRAIN RES REV, V27, P89, DOI 10.1016/S0165-0173(98)00010-1; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4	25	187	191	3	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2008	320	5879					1074	1077		10.1126/science.1153277	http://dx.doi.org/10.1126/science.1153277			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18497298	Green Accepted			2022-12-28	WOS:000256059800045
J	Roussel, EG; Cambon-Bonavita, MA; Querellou, J; Cragg, BA; Webster, G; Prieur, D; Parkes, RJ				Roussel, Erwan G.; Cambon-Bonavita, Marie-Anne; Querellou, Joel; Cragg, Barry A.; Webster, Gordon; Prieur, Daniel; Parkes, R. John			Extending the sub-sea-floor biosphere	SCIENCE			English	Article							PACIFIC-OCEAN; SEDIMENTS; DEEP; TEMPERATURE; BASIN		[Cragg, Barry A.; Webster, Gordon; Parkes, R. John] Cardiff Univ, Sch Earth & Ocean Sci, Cardiff CF10 3YE, Wales; [Roussel, Erwan G.; Cambon-Bonavita, Marie-Anne; Querellou, Joel; Prieur, Daniel] Univ Bretagne Occidentale, IFREMER, Ctr Brest, Lab Microbiol Environn Extremes,UMR 6197, F-29280 Plouzane, France	Cardiff University; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Ifremer; Universite de Bretagne Occidentale	Parkes, RJ (corresponding author), Cardiff Univ, Sch Earth & Ocean Sci, Main Bldg,Park Pl, Cardiff CF10 3YE, Wales.	J.Parkes@earth.cf.ac.uk	QUERELLOU, JOEL/E-9747-2010; Parkes, Ronald/B-1731-2010; Roussel, Erwan G/B-9992-2009; Cragg, Barry/D-2690-2009; Webster, Gordon/A-1877-2008	Parkes, Ronald/0000-0001-9402-5943; Roussel, Erwan G/0000-0002-8735-5597; Webster, Gordon/0000-0002-9530-7835; Cambon-Bonavita, Marie-Anne/0000-0002-4076-0472				Kallmeyer J, 2004, APPL ENVIRON MICROB, V70, P1231, DOI 10.1128/AEM.70.2.1231-1233.2004; Parkes RJ, 2007, ORG GEOCHEM, V38, P845, DOI 10.1016/j.orggeochem.2006.12.011; PARKES RJ, 1994, NATURE, V371, P410, DOI 10.1038/371410a0; Tucholke B.E., 2004, PROC OCEAN DRILL SCI, V210, DOI [10.2973/odp.proc.ir.210.2004, DOI 10.2973/ODP.PROC.IR.210.2004]; Wellsbury P, 2002, FEMS MICROBIOL ECOL, V42, P59, DOI 10.1111/j.1574-6941.2002.tb00995.x; Whitman WB, 1998, P NATL ACAD SCI USA, V95, P6578, DOI 10.1073/pnas.95.12.6578	6	141	152	0	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2008	320	5879					1046	1046		10.1126/science.1154545	http://dx.doi.org/10.1126/science.1154545			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18497290	Green Published			2022-12-28	WOS:000256059800036
J	Hargreaves, S; Burnett, A				Hargreaves, Sally; Burnett, Angela			UK Court decision: health care and immigration	LANCET			English	Editorial Material									[Hargreaves, Sally] The Lancet Infect Dis, London NW1 7BY, England; [Burnett, Angela] Medact & Med Fdn Care Victims Torture, London, England		Hargreaves, S (corresponding author), The Lancet Infect Dis, London NW1 7BY, England.	sally.hargreaves@lancet.com		Hargreaves, Sally/0000-0003-2974-4348				Arnold F, 2008, LANCET, V371, P201, DOI 10.1016/S0140-6736(08)60110-5; *DEP HLTH, 2004, IMPL OV VIS HOSP CHA; *DEP HLTH, 2008, FAIL AS SEEK ORD RES; Donaldson L, 2007, LANCET, V369, P857, DOI 10.1016/S0140-6736(07)60327-4; Gazzard B, 2005, TREAT RESPECT HIV PU; Hargreaves S, 2005, LANCET, V365, P732; HARGREAVES S, 2006, ID CHARG OV VIS NHS; *MED MOND UK, 2008, IMPR ACC HEALTHC COM; Sheather J, 2004, BRIT MED J, V329, P303, DOI 10.1136/bmj.329.7461.303; 2008, LANCET, V371, P178	10	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY-JUN	2008	371	9627					1823	1824		10.1016/S0140-6736(08)60779-5	http://dx.doi.org/10.1016/S0140-6736(08)60779-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	307NL	18514717				2022-12-28	WOS:000256325500010
J	Peters, SE				Peters, Shanan E.			Environmental determinants of extinction selectivity in the fossil record	NATURE			English	Article							MARINE; DIVERSITY; DYNAMICS; HISTORY	The causes of mass extinctions and the nature of biological selectivity during extinction events remain central questions in palaeobiology. Although many different environmental perturbations have been invoked as extinction mechanisms(1-3), it has long been recognized that fluctuations in sea level coincide with many episodes of biotic turnover(4-6). Recent work supports the hypothesis that changes in the areas of epicontinental seas have influenced the macroevolution of marine animals(7,8), but the extent to which differential environmental turnover has contributed to extinction selectivity remains unknown. Here I use a new compilation of the temporal durations of sedimentary rock packages to show that carbonate and terrigenous clastic marine shelf environments have different spatio- temporal dynamics and that these dynamics predict patterns of genus- level extinction, extinction selectivity and diversity among Sepkoski's Palaeozoic and modern evolutionary faunae(9). These results do not preclude a role for biological interactions or unusual physical events as drivers of macroevolution, but they do suggest that the turnover of marine shelf habitats and correlated environmental changes have been consistent determinants of extinction, extinction selectivity and the shifting composition of the marine biota during the Phanerozoic eon.	[Peters, Shanan E.] Univ Wisconsin, Dept Geol & Geophys, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Peters, SE (corresponding author), Univ Wisconsin, Dept Geol & Geophys, 1215 W Dayton St, Madison, WI 53706 USA.	peters@geology.wisc.edu	Peters, Shanan E/A-5620-2013	Peters, Shanan E/0000-0002-3346-4317				ALLISON PA, 1993, GEOLOGY, V21, P65, DOI 10.1130/0091-7613(1993)021<0065:PSBPSD>2.3.CO;2; Alroy J, 2004, EVOL ECOL RES, V6, P1; Bambach R.K., 1985, P191; Bambach RK, 2006, ANNU REV EARTH PL SC, V34, P127, DOI 10.1146/annurev.earth.33.092203.122654; BAMBACH RK, 1993, PALEOBIOLOGY, V19, P372, DOI 10.1017/S0094837300000336; CHILDS OE, 1985, AAPG BULL, V69, P173; Erwin D. H., 2006, EXTINCTION LIFE EART; Foote M, 2003, J GEOL, V111, P125, DOI 10.1086/345841; Foote M, 2006, PALEOBIOLOGY, V32, P345, DOI 10.1666/05062.1; Fraiser ML, 2007, PALEOBIOLOGY, V33, P397, DOI 10.1666/05072.1; HALLAM A, 1989, PHILOS T ROY SOC B, V325, P437, DOI 10.1098/rstb.1989.0098; Hallam A., 1997, MASS EXTINCTIONS THE; JOHNSON J G, 1974, Geology (Boulder), V2, P479, DOI 10.1130/0091-7613(1974)2<479:EOPF>2.0.CO;2; Kiessling W, 2007, PALEOBIOLOGY, V33, P414, DOI 10.1666/06069.1; Knoll AH, 2007, EARTH PLANET SC LETT, V256, P295, DOI 10.1016/j.epsl.2007.02.018; Madin JS, 2006, SCIENCE, V312, P897, DOI 10.1126/science.1123591; McKinney FK, 2006, GEOLOGY, V34, P881, DOI 10.1130/G22707.1; NEWELL NORMAN D., 1952, JOUR PALEONTOL, V26, P371; Peters SE, 2005, P NATL ACAD SCI USA, V102, P12326, DOI 10.1073/pnas.0502616102; Peters SE, 2006, PALEOBIOLOGY, V32, P387, DOI 10.1666/05081.1; Peters SE, 2006, J GEOL, V114, P391, DOI 10.1086/504176; RAUP DM, 1992, PALEOBIOLOGY, V18, P80, DOI 10.1017/S0094837300012227; Sepkoski J., 2002, B AM PALEONTOL, V363; SEPKOSKI JJ, 1984, PALEOBIOLOGY, V10, P246, DOI 10.1017/S0094837300008186; SEPKOSKI JJ, 1981, PALEOBIOLOGY, V7, P36, DOI 10.1017/S0094837300003778; Stanley S.M., 1977, DEV PALAEONTOLOGY ST, V5, P209, DOI DOI 10.1016/S0920-5446(08)70327-3; Stanley SM, 2007, PALEOBIOLOGY, V33, P1, DOI 10.1666/06020.1; Vermeij G.J., 1987, EVOLUTION ESCALATION; Walker LJ, 2002, J GEOL, V110, P75, DOI 10.1086/324318; Wright V. P., 1996, SEDIMENTARY ENV PROC, P325	30	102	106	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 31	2008	454	7204					626	U38		10.1038/nature07032	http://dx.doi.org/10.1038/nature07032			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	331QC	18552839	Green Published			2022-12-28	WOS:000258026500044
J	Cuffey, KM				Cuffey, Kurt M.			Climate change - A matter of firn	SCIENCE			English	Editorial Material							ANTARCTIC ICE-SHEET		[Cuffey, Kurt M.] Univ Calif Berkeley, Dept Geog, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Cuffey, KM (corresponding author), Univ Calif Berkeley, Dept Geog, Berkeley, CA 94720 USA.	kcuffey@berkeley.edu						Davis CH, 2005, SCIENCE, V308, P1898, DOI 10.1126/science.1110662; Gregory JM, 2006, PHILOS T R SOC A, V364, P1709, DOI 10.1098/rsta.2006.1796; Helsen MM, 2008, SCIENCE, V320, P1626, DOI 10.1126/science.1153894; MEIER MF, 1987, J GEOPHYS RES-SOLID, V92, P9051, DOI 10.1029/JB092iB09p09051; MERCER JH, 1978, NATURE, V271, P321, DOI 10.1038/271321a0; Paterson W.S.B., 1994, PHYS GLACIERS, Vthird; Rignot E, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020697; Rignot E, 2008, NAT GEOSCI, V1, P106, DOI 10.1038/ngeo102; Shepherd A, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021106; Velicogna I, 2006, SCIENCE, V311, P1754, DOI 10.1126/science.1123785	10	4	4	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 20	2008	320	5883					1596	1597		10.1126/science.1158683	http://dx.doi.org/10.1126/science.1158683			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315NM	18511657				2022-12-28	WOS:000256886700032
J	Patterson, GH; Hirschberg, K; Polishchuk, RS; Gerlich, D; Phair, RD; Lippincott-Schwartz, J				Patterson, George H.; Hirschberg, Koret; Polishchuk, Roman S.; Gerlich, Daniel; Phair, Robert D.; Lippincott-Schwartz, Jennifer			Transport through the Golgi apparatus by rapid partitioning within a two-phase membrane system	CELL			English	Article							CISTERNAL MATURATION; FLUORESCENT PROTEIN; PLASMA-MEMBRANE; COMPLEX; CELLS; STACK; CHOLESTEROL; CONTINUITIES; MECHANISM; DYNAMICS	The prevailing view of intra-Golgi transport is cisternal progression, which has a key prediction-that newly arrived cargo exhibits a lag or transit time before exiting the Golgi. Instead, we find that cargo molecules exit at an exponential rate proportional to their total Golgi abundance with no lag. Incoming cargo molecules rapidly mix with those already in the system and exit from partitioned domains with no cargo privileged for export based on its time of entry into the system. Given these results, we constructed a new model of intra-Golgi transport that involves rapid partitioning of enzymes and transmembrane cargo between two lipid phases combined with relatively rapid exchange among cisternae. Simulation and experimental testing of this rapid partitioning model reproduced all the key characteristics of the Golgi apparatus, including polarized lipid and protein gradients, exponential cargo export kinetics, and cargo waves.	[Patterson, George H.; Lippincott-Schwartz, Jennifer] NIH, Cell Biol & Metab Program, Bethesda, MD 20892 USA; [Phair, Robert D.] Integrat Bioinformat, Los Altos, CA 94024 USA; [Hirschberg, Koret] Tel Aviv Univ, Sackler Sch Med, Dept Pathol, IL-69978 Tel Aviv, Israel; [Polishchuk, Roman S.] Consorzio Mario Negri Sud Santa Maria Imbaro, Dept Cell Biol & Oncol, I-66030 Chieti, Italy; [Gerlich, Daniel] ETH, Inst Biochem, CH-8093 Zurich, Switzerland	National Institutes of Health (NIH) - USA; Tel Aviv University; Sackler Faculty of Medicine; Consorzio Mario Negri Sud; Swiss Federal Institutes of Technology Domain; ETH Zurich	Lippincott-Schwartz, J (corresponding author), NIH, Cell Biol & Metab Program, Bldg 18T,Room 101,18 Lib Dr, Bethesda, MD 20892 USA.	lippincj@mail.nih.gov	Patterson, George/ABI-4751-2020; Gerlich, Daniel Wolfram W/A-6991-2016; Hirschberg, Koret/AAF-4566-2019	Gerlich, Daniel Wolfram W/0000-0003-1637-3365; Polishchuk, Roman/0000-0002-7698-1955	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001609] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R44GM066611, R01GM079305, R43GM066611] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 EB999999, Z01 HD001609-14] Funding Source: Medline; NIGMS NIH HHS [R01GM079305, R43GM066611, R01 GM079305, R43 GM066611, R44 GM066611, R44GM066611, R01 GM079305-01A1] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bard F, 2006, ANNU REV CELL DEV BI, V22, P439, DOI 10.1146/annurev.cellbio.21.012704.133126; BERGMANN JE, 1983, J CELL BIOL, V97, P1777, DOI 10.1083/jcb.97.6.1777; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; D'Angelo G, 2007, NATURE, V449, P62, DOI 10.1038/nature06097; DUNPHY WG, 1983, J CELL BIOL, V97, P270, DOI 10.1083/jcb.97.1.270; FRIES E, 1984, EMBO J, V3, P147, DOI 10.1002/j.1460-2075.1984.tb01775.x; Gkantiragas I, 2001, MOL BIOL CELL, V12, P1819, DOI 10.1091/mbc.12.6.1819; Glick BS, 1997, FEBS LETT, V414, P177, DOI 10.1016/S0014-5793(97)00984-8; Griffiths G, 2000, TRAFFIC, V1, P738, DOI 10.1034/j.1600-0854.2000.010906.x; Holthuis JCM, 2001, PHYSIOL REV, V81, P1689, DOI 10.1152/physrev.2001.81.4.1689; Kepes F, 2005, INT REV CYTOL, V242, P55; Killian JA, 1998, BBA-REV BIOMEMBRANES, V1376, P401, DOI 10.1016/S0304-4157(98)00017-3; Ladinsky MS, 1999, J CELL BIOL, V144, P1135, DOI 10.1083/jcb.144.6.1135; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Losev E, 2006, NATURE, V441, P1002, DOI 10.1038/nature04717; Lundbaek JA, 2003, BIOPHYS J, V84, P2080, DOI 10.1016/S0006-3495(03)75015-2; Marsh BJ, 2004, P NATL ACAD SCI USA, V101, P5565, DOI 10.1073/pnas.0401242101; Martinez-Alonso E, 2005, TRAFFIC, V6, P32, DOI 10.1111/j.1600-0854.2004.00242.x; Matsuura-Tokita K, 2006, NATURE, V441, P1007, DOI 10.1038/nature04737; MELKONIAN M, 1991, J ELECTRON MICR TECH, V17, P165, DOI 10.1002/jemt.1060170205; Mogelsvang S, 2004, TRAFFIC, V5, P338, DOI 10.1111/j.1398-9219.2004.00186.x; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Orci L, 2000, P NATL ACAD SCI USA, V97, P10400, DOI 10.1073/pnas.190292497; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; Polishchuk RS, 2000, J CELL BIOL, V148, P45, DOI 10.1083/jcb.148.1.45; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; RABOUILLE C, 1995, J CELL SCI, V108, P1617; Rizzo MA, 2004, NAT BIOTECHNOL, V22, P445, DOI 10.1038/nbt945; ROTH J, 1986, J BIOL CHEM, V261, P14307; SLOT JW, 1983, J HISTOCHEM CYTOCHEM, V31, P1049, DOI 10.1177/31.8.6863900; Sun AQ, 2001, AM J PHYSIOL-GASTR L, V280, pG1305, DOI 10.1152/ajpgi.2001.280.6.G1305; Trucco A, 2004, NAT CELL BIOL, V6, P1071, DOI 10.1038/ncb1180; van Meer G, 2004, CURR OPIN CELL BIOL, V16, P373, DOI 10.1016/j.ceb.2004.06.004; Volchuk A, 2000, CELL, V102, P335, DOI 10.1016/S0092-8674(00)00039-8; White J, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-19	37	207	208	2	53	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	2008	133	6					1055	1067		10.1016/j.cell.2008.04.044	http://dx.doi.org/10.1016/j.cell.2008.04.044			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	312TJ	18555781	Green Accepted, Bronze			2022-12-28	WOS:000256693400020
J	Wright, PF				Wright, Peter F.			Focus on research: Vaccine preparations - Are we ready for the next influenza pandemic?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Dartmouth Med Sch, Hanover, NH 03756 USA	Dartmouth College	Wright, PF (corresponding author), Dartmouth Med Sch, Hanover, NH 03756 USA.							Treanor JJ, 2006, NEW ENGL J MED, V354, P1343, DOI 10.1056/NEJMoa055778; WHO, 2021, CUM NUMB CONF HUM CA	2	50	51	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2008	358	24					2540	2543		10.1056/NEJMp0803650	http://dx.doi.org/10.1056/NEJMp0803650			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311IJ	18550873	Bronze			2022-12-28	WOS:000256593600002
J	Evangelou, E; Tsianos, G; Ioannidis, JPA				Evangelou, Evangelos; Tsianos, Georgios; Ioannidis, John P. A.			Doctors' versus patients' global assessments of treatment effectiveness: empirical survey of diverse treatments in clinical trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RHEUMATOID-ARTHRITIS; FUNCTIONAL DISABILITY; PHYSICIAN; QUALITY; HETEROGENEITY; METAANALYSIS; DISCORDANCE; LIFE	Objective To examine whether doctors' global assessments of treatment effects agree with patients' global assessments. Design Survey of trials included in systematic reviews of treatments for diverse conditions. Data sources Cochrane database of systematic reviews. Data extracted Data on patients' global assessments and on doctors' global assessment for the same treatment against the same comparator. Main outcome measures Relative odds ratio (ratio of odds ratios of global improvement with the experimental intervention versus control according to doctors compared with patients), and improvement rates according to doctors and patients. Results Doctors' global assessments were compared with patients' global assessments for 63 different treatment comparisons (240 trials) in 18 conditions. The summary relative odds ratio across the comparisons was not significant (0.98, 95% confidence interval 0.88 to 1.08; I-2=0%, 95% confidence interval 0% to 30%). In 62 of the 63 comparisons the effects of treatment rated by patients and by doctors did not differ beyond chance, but for single comparisons the confidence intervals were large. Rates of improvement on average did not differ between doctors' assessments and patients' assessments (summary relative odds ratio 0.98, 0.88 to 1.06; I-2=0%, 0% to 24%). Conclusion Doctors' global assessments of the effects of treatments are on average similar to those of patients.	[Evangelou, Evangelos; Tsianos, Georgios; Ioannidis, John P. A.] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece	University of Ioannina	Ioannidis, JPA (corresponding author), Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece.	jioannid@cc.uoi.gr	Evangelou, Evangelos/C-3033-2013; Ioannidis, John P. A./G-9836-2011	Evangelou, Evangelos/0000-0002-5488-2999; 				Adams N, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002310.pub3; [Anonymous], 2000, COCHRANE DB SYST REV; AROWOJOLU AO, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004425.PUB2; Balk EM, 2002, JAMA-J AM MED ASSOC, V287, P2973, DOI 10.1001/jama.287.22.2973; Bassler D, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007802.pub2; Bellack AS, 2005, ISR J PSYCHIATR REL, V42, P5; Berkanovic E, 1995, ARTHRIT CARE RES, V8, P94, DOI 10.1002/art.1790080207; Bisson J, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003388.pub2; BUCHBINDER R, 1995, ARTHRITIS RHEUM, V38, P1568, DOI 10.1002/art.1780381108; CALKINS DR, 1991, ANN INTERN MED, V114, P451, DOI 10.7326/0003-4819-114-6-451; Canonica GW, 2007, ALLERGY, V62, P668, DOI 10.1111/j.1398-9995.2007.01352.x; Carr AJ, 1998, BRIT J RHEUMATOL, V37, P1; Chen J, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004800.pub2; CHEN J, 2004, COCHRANE DB SYST REV; CLARK P, 2000, COCHRANE DB SYST REV; Cohen SB, 2004, RHEUMATOLOGY, V43, P704, DOI 10.1093/rheumatology/keh152; Costa J, 2005, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003633.pub2, 10.1002/14651858.CD0004296.pub2, 10.1002/14651858.CD004312.pub2, 10.1002/14651858.CD004315.pub2, 10.1002/14651858.CD004314.pub2, 10.1002/14651858.CD004900.pub2, 10.1002/14651858.CD004899.pub2]; COULTHARD P, 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004287.pub2, DOI 10.1002/14651858.CD004287.PUB2]; den Boer PCAM, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004688.pub2; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DeWalt DA, 2004, CLIN EXP RHEUMATOL, V22, P453; Felson D, 2007, ARTHRIT RHEUM-ARTHR, V57, P193, DOI 10.1002/art.22552; Fidelix TSA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005117.pub2; GARNER S, 2002, COCHRANE DB SYST REV; Green S, 2002, COCHRANE DB SYST REV; HASSELBLAD V, 1995, PSYCHOL BULL, V117, P167, DOI 10.1037/0033-2909.117.1.167; HIDDING A, 1994, J RHEUMATOL, V21, P818; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; HULME J, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003523; Ioannidis JPA, 2007, BRIT MED J, V335, P914, DOI 10.1136/bmj.39343.408449.80; JACOBS JWG, 1992, ANN RHEUM DIS, V51, P765, DOI 10.1136/ard.51.6.765; KWOH CK, 1992, J RHEUMATOL, V19, P1031; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; Liu J P, 2006, Cochrane Database Syst Rev, pCD004116; Navarro-Sarabia F, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005113.pub2; Neville C, 2000, J RHEUMATOL, V27, P675; Orwin R.G., 1994, HDB RES SYNTHESIS; Pincus T, 2003, ARTHRITIS RHEUM, V48, P625, DOI 10.1002/art.10824; Samuel M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001782.pub2; Shea, 2000, COCHRANE DB SYST REV; Shea B., 2000, COCHRANE DB SYST REV, V2000, pCD002048, DOI [10.1002/14651858.CD002048, DOI 10.1002/14651858.CD002048]; SLEVIN ML, 1988, BRIT J CANCER, V57, P109, DOI 10.1038/bjc.1988.20; SRIDHAR AV, 2006, COCHRANE DB SYST REV, V3; Sterne JAC, 2002, STAT MED, V21, P1513, DOI 10.1002/sim.1184; Suarez-Almazor ME, 2000, COCHRANE DB SYST REV, V4, DOI [10.1002/14651858.CD000959, DOI 10.1002/14651858.CD000959]; SUAREZALMAZOR ME, 2000, COCHRANE DB SYST REV; SUAREZALMAZOR ME, 2000, COCHRANE DB SYST REV; TAKKEN T, 2001, COCHRANE DB SYST REV; Tammenmaa IA, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000207; Towheed TE, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004257.pub2; Tuunainen A, 2004, Cochrane Database Syst Rev, pCD004050, DOI 10.1002/14651858.CD004050.pub2; van Zuuren EJ, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003262.pub3; WALTERS EH, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001385; Wells G, 2000, COCHRANE DB SYST REV; Wilt T, 2002, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001423; Yen JC, 2003, J RHEUMATOL, V30, P1967	56	13	13	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 7	2008	336	7656					1287	+		10.1136/bmj.39560.759572.BE	http://dx.doi.org/10.1136/bmj.39560.759572.BE			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312XO	18495634	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000256705900032
J	Ogawa, Y; Sun, BK; Lee, JT				Ogawa, Yuya; Sun, Bryan K.; Lee, Jeannie T.			Intersection of the RNA interference and X-inactivation pathways	SCIENCE			English	Article							EMBRYONIC STEM-CELLS; CHROMOSOME INACTIVATION; XIST RNA; CHOICE; TSIX; GENE; DIFFERENTIATION; TRANSCRIPTION; DICER; XITE	In mammals, dosage compensation is achieved by X- chromosome inactivation ( XCI) in the female. The noncoding Xist gene initiates silencing of the X chromosome, whereas its antisense partner Tsix blocks silencing. The complementarity of Xist and Tsix RNAs has long suggested a role for RNA interference ( RNAi). Here, we report that murine Xist and Tsix form duplexes in vivo. During XCI, the duplexes are processed to small RNAs ( sRNAs), most likely on the active X ( Xa) in a Dicer- dependent manner. Deleting Dicer compromises sRNA production and derepresses Xist. Furthermore, without Dicer, Xist RNA cannot accumulate and histone 3 lysine 27 trimethylation is blocked on the inactive X ( Xi). The defects are partially rescued by truncating Tsix. Thus, XCI and RNAi intersect, down- regulating Xist on Xa and spreading silencing on Xi.	[Ogawa, Yuya; Sun, Bryan K.; Lee, Jeannie T.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; [Ogawa, Yuya; Sun, Bryan K.; Lee, Jeannie T.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; [Ogawa, Yuya; Sun, Bryan K.; Lee, Jeannie T.] Howard Hughes Med Inst, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Lee, JT (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.	lee@molbio.mgh.harvard.edu		Sun, Bryan/0000-0002-0740-0125	Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [R01 GM058839-10, R01 GM058839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058839] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avner P, 1998, GENET RES, V72, P217, DOI 10.1017/S0016672398003516; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BUZIN CH, 1994, DEVELOPMENT, V120, P3529; Cobb BS, 2005, J EXP MED, V201, P1367, DOI 10.1084/jem.20050572; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grewal SIS, 2007, NATURE, V447, P399, DOI 10.1038/nature05914; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kim DH, 2006, NAT STRUCT MOL BIOL, V13, P793, DOI 10.1038/nsmb1142; Lee JT, 2005, SCIENCE, V309, P768, DOI 10.1126/science.1113673; Lee JT, 1999, CELL, V99, P47, DOI 10.1016/S0092-8674(00)80061-6; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372; Murchison EP, 2005, P NATL ACAD SCI USA, V102, P12135, DOI 10.1073/pnas.0505479102; Ogawa Y, 2003, MOL CELL, V11, P731, DOI 10.1016/S1097-2765(03)00063-7; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Shibata S, 2004, CURR BIOL, V14, P1747, DOI 10.1016/j.cub.2004.09.053; Shibata S, 2003, HUM MOL GENET, V12, P125, DOI 10.1093/hmg/ddg010; Sun BK, 2006, MOL CELL, V21, P617, DOI 10.1016/j.molcel.2006.01.028; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Wutz A, 2002, NAT GENET, V30, P167, DOI 10.1038/ng820	21	218	246	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2008	320	5881					1336	1341		10.1126/science.1157676	http://dx.doi.org/10.1126/science.1157676			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309DO	18535243	Green Accepted			2022-12-28	WOS:000256441100044
J	Mitchell, TM; Shinkareva, SV; Carlson, A; Chang, KM; Malave, VL; Mason, RA; Just, MA				Mitchell, Tom M.; Shinkareva, Svetlana V.; Carlson, Andrew; Chang, Kai-Min; Malave, Vicente L.; Mason, Robert A.; Just, Marcel Adam			Predicting human brain activity associated with the meanings of nouns	SCIENCE			English	Article							BIOLOGICAL MOTION PERCEPTION; TEMPORAL CORTEX; FACE AREA; FMRI DATA; KNOWLEDGE; OBJECTS; REPRESENTATIONS; RETRIEVAL; PATTERNS; IMAGES	The question of how the human brain represents conceptual knowledge has been debated in many scientific fields. Brain imaging studies have shown that different spatial patterns of neural activation are associated with thinking about different semantic categories of pictures and words ( for example, tools, buildings, and animals). We present a computational model that predicts the functional magnetic resonance imaging ( fMRI) neural activation associated with words for which fMRI data are not yet available. This model is trained with a combination of data from a trillion- word text corpus and observed fMRI data associated with viewing several dozen concrete nouns. Once trained, the model predicts fMRI activation for thousands of other concrete nouns in the text corpus, with highly significant accuracies over the 60 nouns for which we currently have fMRI data.	[Mitchell, Tom M.; Carlson, Andrew] Carnegie Mellon Univ, Machine Learning Dept, Sch Comp Sci, Pittsburgh, PA 15213 USA; [Shinkareva, Svetlana V.] Univ S Carolina, Dept Psychol, Columbia, SC 29208 USA; [Chang, Kai-Min; Mason, Robert A.; Just, Marcel Adam] Carnegie Mellon Univ, Ctr Cognit Brain Imaging, Pittsburgh, PA 15213 USA; [Chang, Kai-Min] Carnegie Mellon Univ, Language Technol Inst, Sch Comp Sci, Pittsburgh, PA 15213 USA; [Malave, Vicente L.] Univ Calif San Diego, Dept Cognit Sci, La Jolla, CA 92093 USA	Carnegie Mellon University; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Carnegie Mellon University; Carnegie Mellon University; University of California System; University of California San Diego	Mitchell, TM (corresponding author), Carnegie Mellon Univ, Machine Learning Dept, Sch Comp Sci, Pittsburgh, PA 15213 USA.	Tom.Mitchell@cs.cmu.edu		Shinkareva, Svetlana/0000-0001-5112-4829; Just, Marcel/0000-0003-1245-3050				Blei DM, 2003, J MACH LEARN RES, V3, P993, DOI 10.1162/jmlr.2003.3.4-5.993; Caramazza A, 1998, J COGNITIVE NEUROSCI, V10, P1, DOI 10.1162/089892998563752; Carlson TA, 2003, J COGNITIVE NEUROSCI, V15, P704, DOI 10.1162/089892903322307429; Cerf B, 1998, ANN NY ACAD SCI, V855, P575, DOI 10.1111/j.1749-6632.1998.tb10627.x; Church K. W., 1990, Computational Linguistics, V16, P22; Cox DD, 2003, NEUROIMAGE, V19, P261, DOI 10.1016/S1053-8119(03)00049-1; Cree GS, 2003, J EXP PSYCHOL GEN, V132, P163, DOI 10.1037/0096-3445.132.2.163; Crutch SJ, 2003, BRAIN, V126, P1821, DOI 10.1093/brain/awg187; Edelman S, 1998, PSYCHOBIOLOGY, V26, P309; Fellbaum Christiane, 1998, WORDNET ELECT DATABA; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Goldberg RF, 2006, J NEUROSCI, V26, P4917, DOI 10.1523/JNEUROSCI.5389-05.2006; Hanson SJ, 2004, NEUROIMAGE, V23, P156, DOI 10.1016/j.neuroimage.2004.05.020; Hardoon DR, 2007, NEUROIMAGE, V37, P1250, DOI 10.1016/j.neuroimage.2007.06.017; Haxby JV, 2001, SCIENCE, V293, P2425, DOI 10.1126/science.1063736; Ishai A, 1999, P NATL ACAD SCI USA, V96, P9379, DOI 10.1073/pnas.96.16.9379; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Kay KN, 2008, NATURE, V452, P352, DOI 10.1038/nature06713; Kipper K., 2006, P 5 INT C LANG RES E; Landauer TK, 1997, PSYCHOL REV, V104, P211, DOI 10.1037/0033-295X.104.2.211; Lin Dekang, 2003, P 18 INT JOINT C ART, P1492; MAHON BZ, 2005, ENCY LANGUAGE LINGUI; Martin A, 2001, CURR OPIN NEUROBIOL, V11, P194, DOI 10.1016/S0959-4388(00)00196-3; MARTIN A, 2000, NEW COGNITIVE NEUROS, P1023; Miller G., 1990, INT J LEXICOGR, V3, P235, DOI DOI 10.1093/IJL/3.4.235; Mitchell TM, 2004, MACH LEARN, V57, P145, DOI 10.1023/B:MACH.0000035475.85309.1b; Norman KA, 2006, TRENDS COGN SCI, V10, P424, DOI 10.1016/j.tics.2006.07.005; O'Toole AJ, 2005, J COGNITIVE NEUROSCI, V17, P580, DOI 10.1162/0898929053467550; Pelphrey KA, 2005, CEREB CORTEX, V15, P1866, DOI 10.1093/cercor/bhi064; Polyn SM, 2005, SCIENCE, V310, P1963, DOI 10.1126/science.1117645; SAKAI K, 1995, MAGNET RESON MED, V33, P736, DOI 10.1002/mrm.1910330521; Samson D, 2004, BRAIN LANG, V91, P252, DOI 10.1016/j.bandl.2004.03.001; Shinkareva SV, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001394; SNOW R, 2006, P 44 ANN M ASS COMP; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Vaina LM, 2001, P NATL ACAD SCI USA, V98, P11656, DOI 10.1073/pnas.191374198	36	673	694	5	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2008	320	5880					1191	1195		10.1126/science.1152876	http://dx.doi.org/10.1126/science.1152876			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306FF	18511683	Green Submitted, Green Published			2022-12-28	WOS:000256233000031
J	Kennedy, M; Mrofka, D; von der Borch, C				Kennedy, Martin; Mrofka, David; von der Borch, Chris			Snowball Earth termination by destabilization of equatorial permafrost methane clathrate	NATURE			English	Article							ISOTOPIC EVIDENCE; HYDRATE; CARBONATES; GLACIATION; STABILITY; BASIN; END	The start of the Ediacaran period is defined by one of the most severe climate change events recorded in Earth history - the recovery from the Marinoan 'snowball' ice age, similar to 635 Myr ago ( ref. 1). Marinoan glacial- marine deposits occur at equatorial palaeolatitudes(2), and are sharply overlain by a thin interval of carbonate that preserves marine carbon and sulphur isotopic excursions of about 25 and 115 parts per thousand, respectively(3-5); these deposits are thought to record widespread oceanic carbonate precipitation during postglacial sea level rise(1,3,4). This abrupt transition records a climate system in profound disequilibrium(3,6) and contrasts sharply with the cyclical stratigraphic signal imparted by the balanced feedbacks modulating Phanerozoic deglaciation. Hypotheses accounting for the abruptness of deglaciation include ice albedo feedback(3), deep- ocean out- gassing during post- glacial oceanic overturn(7) or methane hydrate destabilization(8-10). Here we report the broadest range of oxygen isotope values yet measured in marine sediments ( -25 parts per thousand to +12 parts per thousand) in methane seeps in Marinoan deglacial sediments underlying the cap carbonate. This range of values is likely to be the result of mixing between ice- sheet- derived meteoric waters and clathrate- derived fluids during the flushing and destabilization of a clathrate field by glacial meltwater. The equatorial palaeolatitude implies a highly volatile shelf permafrost pool that is an order of magnitude larger than that of the present day. A pool of this size could have provided a massive biogeochemical feedback capable of triggering deglaciation and accounting for the global postglacial marine carbon and sulphur isotopic excursions, abrupt unidirectional warming, cap carbonate deposition, and a marine oxygen crisis. Our findings suggest that methane released from low- latitude permafrost clathrates therefore acted as a trigger and/ or strong positive feedback for deglaciation and warming. Methane hydrate destabilization is increasingly suspected as an important positive feedback to climate change(11-13) that coincides with critical boundaries in the geological record(14,15) and may represent one particularly important mechanism active during conditions of strong climate forcing.	[Kennedy, Martin; Mrofka, David] Univ Calif Riverside, Dept Earth Sci, Riverside, CA 92521 USA; [von der Borch, Chris] Flinders Univ S Australia, Sch Chem Phys & Earth Sci, Adelaide, SA 5001, Australia	University of California System; University of California Riverside; Flinders University South Australia	Kennedy, M (corresponding author), Univ Calif Riverside, Dept Earth Sci, Riverside, CA 92521 USA.	martink@mail.ucr.edu		Kennedy, Martin/0000-0002-1330-6864				Aiello IW, 2001, GEOLOGY, V29, P1111, DOI 10.1130/0091-7613(2001)029<1111:AAOOCS>2.0.CO;2; Allen PA, 2005, NATURE, V433, P123, DOI 10.1038/nature03176; Archer D, 2007, BIOGEOSCIENCES, V4, P521, DOI 10.5194/bg-4-521-2007; Bowen GJ, 2002, GEOLOGY, V30, P315, DOI 10.1130/0091-7613(2002)030<0315:SDOOIM>2.0.CO;2; Canfield DE, 2007, SCIENCE, V315, P92, DOI 10.1126/science.1135013; DICKENS GR, 1995, PALEOCEANOGRAPHY, V10, P965, DOI 10.1029/95PA02087; Fairchild IJ, 2007, J GEOL SOC LONDON, V164, P895, DOI 10.1144/0016-76492006-191; Greinert J., 2002, GEOPHYS MONOGR SER, V124, P99, DOI DOI 10.1029/GM124P0099; Grotzinger JP, 1995, PALAIOS, V10, P578, DOI 10.2307/3515096; Halverson GP, 2007, EARTH PLANET SC LETT, V263, P32, DOI 10.1016/j.epsl.2007.08.022; Herbert CT, 2007, SEDIMENT GEOL, V194, P263, DOI 10.1016/j.sedgeo.2006.06.008; Himmler T, 2008, PALAEOGEOGR PALAEOCL, V257, P185, DOI 10.1016/j.palaeo.2007.09.018; HOEFS J, 2004, STABLE ISOTOPE GEOCH, P55; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; Jiang GQ, 2003, NATURE, V426, P822, DOI 10.1038/nature02201; Kemp DB, 2005, NATURE, V437, P396, DOI 10.1038/nature04037; Kennedy MJ, 2001, GEOLOGY, V29, P443, DOI 10.1130/0091-7613(2001)029<0443:APCCAI>2.0.CO;2; Knoll AH, 2006, LETHAIA, V39, P13, DOI 10.1080/00241160500409223; KVENVOLDEN KA, 1988, CHEM GEOL, V71, P41, DOI 10.1016/0009-2541(88)90104-0; MACAYEAL DR, 1993, PALEOCEANOGRAPHY, V8, P775, DOI 10.1029/93PA02200; MACDONALD GJ, 1990, CLIMATIC CHANGE, V16, P247, DOI 10.1007/BF00144504; NISBET EG, 1990, CAN J EARTH SCI, V27, P148, DOI 10.1139/e90-012; Preiss W. V., 1987, GEOLOGICAL SURVEY S, V53, P1; Ridgwell AJ, 2003, SCIENCE, V302, P859, DOI 10.1126/science.1088342; RITGER S, 1987, GEOL SOC AM BULL, V98, P147, DOI 10.1130/0016-7606(1987)98<147:MACFBS>2.0.CO;2; Shields G, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000266; Shields GA, 2007, PRECAMBRIAN RES, V153, P209, DOI 10.1016/j.precamres.2006.11.011; Sohl LE, 1999, GEOL SOC AM BULL, V111, P1120, DOI 10.1130/0016-7606(1999)111<1120:PPRIMC>2.3.CO;2; WILLIAMS GE, 1986, PRECAMBRIAN RES, V32, P233, DOI 10.1016/0301-9268(86)90008-2; WILLIAMS GE, 1991, CLASTIC TIDAL SEDIME, P161	30	112	126	3	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	2008	453	7195					642	645		10.1038/nature06961	http://dx.doi.org/10.1038/nature06961			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305NN	18509441				2022-12-28	WOS:000256185200041
J	Mazmanian, SK; Round, JL; Kasper, DL				Mazmanian, Sarkis K.; Round, June L.; Kasper, Dennis L.			A microbial symbiosis factor prevents intestinal inflammatory disease	NATURE			English	Article							REGULATORY T-CELLS; BOWEL-DISEASE; BACTERIA; SUPPRESS; COLITIS; GUT; FLORA; INTERLEUKIN-10; PATHOGENESIS; MICROFLORA	Humans are colonized by multitudes of commensal organisms representing members of five of the six kingdoms of life; however, our gastrointestinal tract provides residence to both beneficial and potentially pathogenic microorganisms. Imbalances in the composition of the bacterial microbiota, known as dysbiosis, are postulated to be a major factor in human disorders such as inflammatory bowel disease. We report here that the prominent human symbiont Bacteroides fragilis protects animals from experimental colitis induced by Helicobacter hepaticus, a commensal bacterium with pathogenic potential. This beneficial activity requires a single microbial molecule ( polysaccharide A, PSA). In animals harbouring B. fragilis not expressing PSA, H. hepaticus colonization leads to disease and pro- inflammatory cytokine production in colonic tissues. Purified PSA administered to animals is required to suppress pro- inflammatory interleukin- 17 production by intestinal immune cells and also inhibits in vitro reactions in cell cultures. Furthermore, PSA protects from inflammatory disease through a functional requirement for interleukin- 10- producing CD4(+) T cells. These results show that molecules of the bacterial microbiota can mediate the critical balance between health and disease. Harnessing the immunomodulatory capacity of symbiosis factors such as PSA might potentially provide therapeutics for human inflammatory disorders on the basis of entirely novel biological principles.	[Mazmanian, Sarkis K.; Round, June L.] CALTECH, Div Biol, Pasadena, CA 91125 USA; [Kasper, Dennis L.] Harvard Univ, Sch Med, Channing Lab, Brigham & Womens Hosp, Boston, MA 02115 USA; [Kasper, Dennis L.] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	California Institute of Technology; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Mazmanian, SK (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	sarkis@caltech.edu; dennis_kasper@hms.harvard.edu	Mazmanian, Sarkis/ABD-7729-2021	Mazmanian, Sarkis/0000-0003-2713-1513	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039576] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI039576] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bell E B, 1992, Semin Immunol, V4, P43; Bregenholt S, 2000, EXP CLIN IMMUNOGENET, V17, P115, DOI 10.1159/000019131; Cahill RJ, 1997, INFECT IMMUN, V65, P3126, DOI 10.1128/IAI.65.8.3126-3131.1997; Dethlefsen L, 2007, NATURE, V449, P811, DOI 10.1038/nature06245; Elson CO, 2007, GASTROENTEROLOGY, V132, P2359, DOI 10.1053/j.gastro.2007.03.104; Elson CO, 2000, GASTROENTEROLOGY, V119, P254, DOI 10.1053/gast.2000.9159; Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Hue S, 2006, J EXP MED, V203, P2473, DOI 10.1084/jem.20061099; Izcue A, 2006, IMMUNOL REV, V212, P256, DOI 10.1111/j.0105-2896.2006.00423.x; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kullberg MC, 2006, J EXP MED, V203, P2485, DOI 10.1084/jem.20061082; Kullberg MC, 2003, P NATL ACAD SCI USA, V100, P15830, DOI 10.1073/pnas.2534546100; Kullberg MC, 2002, J EXP MED, V196, P505, DOI 10.1084/jem.20020556; Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017; Liu CH, 2008, P NATL ACAD SCI USA, V105, P3951, DOI 10.1073/pnas.0709266105; Maloy KJ, 2003, J EXP MED, V197, P111, DOI 10.1084/jem.20021345; Mazmanian SK, 2006, NAT REV IMMUNOL, V6, P849, DOI 10.1038/nri1956; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; O'Hara AM, 2006, EMBO REP, V7, P688, DOI 10.1038/sj.embor.7400731; PARNER EG, 2007, NATURE IMMUNOL, V8, P1173; Powrie F, 2003, SCIENCE, V299, P1030, DOI 10.1126/science.1082031; Poxton IR, 1997, J MED MICROBIOL, V46, P85, DOI 10.1099/00222615-46-1-85; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rutgeerts P, 2005, NEW ENGL J MED, V353, P2462, DOI 10.1056/NEJMoa050516; Sartor RB, 2006, NAT CLIN PRACT GASTR, V3, P390, DOI 10.1038/ncpgasthep0528; Scheinin T, 2003, CLIN EXP IMMUNOL, V133, P38, DOI 10.1046/j.1365-2249.2003.02193.x; Sellon RK, 1998, INFECT IMMUN, V66, P5224, DOI 10.1128/IAI.66.11.5224-5231.1998; Smith K, 2007, SEMIN IMMUNOL, V19, P59, DOI 10.1016/j.smim.2006.10.002; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; TAUROG JD, 1994, J EXP MED, V180, P2359, DOI 10.1084/jem.180.6.2359; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; TZIANABOS AO, 1992, J BIOL CHEM, V267, P18230; VIDELA S, 1994, GUT, V35, P1090, DOI 10.1136/gut.35.8.1090; Xavier R, 2005, GASTROENTEROLOGY, V128, P1122, DOI 10.1053/j.gastro.2005.02.053	38	1587	1697	56	552	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	2008	453	7195					620	625		10.1038/nature07008	http://dx.doi.org/10.1038/nature07008			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305NN	18509436				2022-12-28	WOS:000256185200036
J	Johnson, RP				Johnson, R. Paul			How HIV guts the immune system	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							T-CELL DEPLETION; GASTROINTESTINAL-TRACT; SIV INFECTION; REPLICATION		Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Southborough, MA 01772 USA; Massachusetts Gen Hosp, Partners AIDS Res Ctr, Infect Dis Unit, Boston, MA 02114 USA	Harvard University; Harvard University; Massachusetts General Hospital	Johnson, RP (corresponding author), Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Southborough, MA 01772 USA.							Arthos J, 2008, NAT IMMUNOL, V9, P301, DOI 10.1038/ni1566; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427	5	7	7	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2008	358	21					2287	2289		10.1056/NEJMcibr0802134	http://dx.doi.org/10.1056/NEJMcibr0802134			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	303EK	18499575				2022-12-28	WOS:000256023600017
J	Cavanaugh, K; Huizinga, MM; Wallston, KA; Gebretsadik, T; Shintani, A; Davis, D; Gregory, RP; Fuchs, L; Malone, R; Cherrington, A; Pignone, M; DeWalt, DA; Elasy, TA; Rothman, RL				Cavanaugh, Kerri; Huizinga, Mary Margaret; Wallston, Kenneth A.; Gebretsadik, Tebeb; Shintani, Ayumi; Davis, Dianne; Gregory, Rebecca Pratt; Fuchs, Lynn; Malone, Robb; Cherrington, Andrea; Pignone, Michael; DeWalt, Darren A.; Elasy, Tom A.; Rothman, Russell L.			Association of numeracy and diabetes control	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH LITERACY; KNOWLEDGE; SCALE	Background: The influence of a patient's quantitative skills (numeracy) on the management of diabetes is only partially understood. Objective: To examine the association between diabetes-related numeracy and glycemic control and other diabetes measurements. Design: Cross-sectional survey. Setting: 2 primary care and 2 diabetes clinics at 3 medical centers. Participants: 398 adult patients with type 1 or type 2 diabetes mellitus enrolled between March 2004 and November 2005. Measurements: Health literacy, general numeracy, and diabetes-related numeracy assessed by using the Rapid Estimate of Adult Literacy in Medicine; the Wide Range Achievement Test, 3rd edition; and the Diabetes Numeracy Test (DNT), respectively. The primary outcome was most recent level of hemoglobin A(1c). Additional measurements were diabetes knowledge, perceived self-efficacy of diabetes self-management, and self-management behaviors. Results: The median DNT score was 65% (interquartile range, 42% to 81%). Common errors included misinterpreting glucose meter readings and miscalculating carbohydrate intake and medication dosages. Lower DNT scores were associated with older age, nonwhite race, fewer years of education, lower reported income, lower literacy and general numeracy skills, lower perceived self-efficacy, and selected self-management behaviors. Patients scoring in the lowest DNT quartile (score < 42%) had a median hemoglobin A(1c) level of 7.6% (interquartile range, 6.5% to 9.0%) compared with 7.1% (interquartile range, 6.3% to 8.1%) in those scoring in the highest quartile (P = 0.119 for trend). A regression analysis adjusted for age, sex, race, income, and other factors found a modest association between DNT score and hemoglobin A1c level. Limitation: Causality cannot be determined in this cross-sectional study, especially with its risk for unmeasured confounding variables. Conclusion: Poor numeracy skills were common in patients with diabetes. Low diabetes-related numeracy skills were associated with worse perceived self-efficacy, fewer self-management behaviors, and possibly poorer glycemic control.	[Rothman, Russell L.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Hlth Serv Res, Sch Med, Nashville, TN 37232 USA; Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN USA; Univ N Carolina, Chapel Hill, NC USA; Univ Alabama Birmingham, Birmingham, AL USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; University of North Carolina; University of North Carolina Chapel Hill; University of Alabama System; University of Alabama Birmingham	Rothman, RL (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Hlth Serv Res, Sch Med, 6100 Med Ctr E,N Tower, Nashville, TN 37232 USA.	russell.rothman@vanderbilt.edu	Albertin, Paloma C/X-1093-2018; Fuchs, Lynn/AAV-3828-2021	Fuchs, Lynn/0000-0003-2099-5247; DeWalt, Darren/0000-0003-2270-751X; Rothman, Russsell/0000-0002-1506-3990; Pignone, Michael/0000-0002-6657-7342	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, K23DK065294] Funding Source: NIH RePORTER; NIDDK NIH HHS [5K23DK065294, 5P60DK020593] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apter AJ, 2006, J ASTHMA, V43, P705, DOI 10.1080/02770900600925585; Ashcraft MH, 2001, J EXP PSYCHOL GEN, V130, P224, DOI 10.1037/0096-3445.130.2.224; Baker DW, 1999, PATIENT EDUC COUNS, V38, P33, DOI 10.1016/S0738-3991(98)00116-5; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; Davis T C, 1993, Fam Med, V25, P391; Davis T C, 1991, Fam Med, V23, P433; DeVellis R. F., 2016, SCALE DEV THEORY APP, V4th; DeWalt DA, 2005, ARCH INTERN MED, V165, P1943, DOI 10.1001/archinte.165.17.1943; DeWalt DA, 2007, AM J HEALTH BEHAV, V31, pS27; Estrada CA, 2004, AM J MED SCI, V328, P88, DOI 10.1097/00000441-200408000-00004; Fitzgerald JT, 1998, DIABETES CARE, V21, P706, DOI 10.2337/diacare.21.5.706; Gazmararian JA, 2003, PATIENT EDUC COUNS, V51, P267, DOI 10.1016/S0738-3991(02)00239-2; Gazmararian JA, 1999, JAMA-J AM MED ASSOC, V281, P545, DOI 10.1001/jama.281.6.545; Harrell F.E., 2015, REGRESSION MODELING, DOI [10.1007/978-3-319-19425-7, DOI 10.1007/978-3-319-19425-7, 10.1007/978-1-4757-3462-1]; Hodge M B, 1999, Nurse Educ, V24, P41, DOI 10.1097/00006223-199907000-00010; HUIZINGA MM, 2008, BMC HLTH SE IN PRESS; *I MED, 2004, HLTH LIT PRESCR END; KIRSCH IS, NCES PUBLICATION; Kutner M., 2005, NCES PUBLICATION; Lipkus IM, 2001, MED DECIS MAKING, V21, P37, DOI 10.1177/0272989X0102100105; Montori VM, 2005, J GEN INTERN MED, V20, P1071, DOI 10.1111/j.1525-1497.2005.051498.x; Morris Nancy S, 2006, BMC Fam Pract, V7, P49, DOI 10.1186/1471-2296-7-49; Parker RM, 1999, JAMA-J AM MED ASSOC, V281, P552; Rothman RL, 2005, DIABETES EDUCATOR, V31, P215, DOI 10.1177/0145721705275002; Rothman RL, 2006, AM J PREV MED, V31, P391, DOI 10.1016/j.amepre.2006.07.025; Schapira MM, 2006, J HEALTH COMMUN, V11, P569, DOI 10.1080/10810730600829916; Schapira MM, 2004, RISK ANAL, V24, P665, DOI 10.1111/j.0272-4332.2004.00466.x; Schillinger D, 2002, JAMA-J AM MED ASSOC, V288, P475, DOI 10.1001/jama.288.4.475; Schwartz LM, 1997, ANN INTERN MED, V127, P966, DOI 10.7326/0003-4819-127-11-199712010-00003; Sheridan SL, 2003, J GEN INTERN MED, V18, P884, DOI 10.1046/j.1525-1497.2003.21102.x; Toobert DJ, 2000, DIABETES CARE, V23, P943, DOI 10.2337/diacare.23.7.943; Wallston KA, 2007, J BEHAV MED, V30, P395, DOI 10.1007/s10865-007-9110-y; Wilkinson G, 1993, WRAT 3 WIDE RANGE AC; Williams MV, 1998, ARCH INTERN MED, V158, P166, DOI 10.1001/archinte.158.2.166	34	236	238	0	32	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 20	2008	148	10					737	U40		10.7326/0003-4819-148-10-200805200-00006	http://dx.doi.org/10.7326/0003-4819-148-10-200805200-00006			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308EX	18490687				2022-12-28	WOS:000256372200003
J	Arndt, M; Nairz, O; Vos-Andreae, J; Keller, C; van der Zouw, G; Zeilinger, A				Arndt, M; Nairz, O; Vos-Andreae, J; Keller, C; van der Zouw, G; Zeilinger, A			Wave-particle duality of C-60 molecules	NATURE			English	Article							COHERENCE; EMISSION	Quantum superposition lies at the heart of quantum mechanics and gives rise to many of its paradoxes. Superposition of de Broglie matter waves(1) has been observed for massive particles such as electrons(2), atoms and dimers(3), small van der Waals clusters(4), and neutrons(5). But matter wave interferometry with larger objects has remained experimentally challenging, despite the development of powerful atom interferometric techniques for experiments in fundamental quantum mechanics, metrology and lithography(6). Here we report the observation of de Broglie wave interference of C-60 molecules by diffraction at a material absorption grating. This molecule is the most massive and complex object in which wave behaviour has been observed. Of particular interest is the fact that C-60 is almost a classical body, because of its many excited internal degrees of freedom and their possible couplings to the environment. Such couplings are essential for the appearance of decoherence(7,8), suggesting that interference experiments with large molecules should facilitate detailed studies of this process.	Univ Vienna, Inst Expt Phys, A-1090 Vienna, Austria	University of Vienna	Zeilinger, A (corresponding author), Univ Vienna, Inst Expt Phys, Boltzmanngasse 5, A-1090 Vienna, Austria.	zeilinger-office@exp.univie.ac.at	Arndt, Markus/P-3852-2019; Zeilinger, Anton/A-1170-2011; Arndt, Markus/A-4571-2012	Arndt, Markus/0000-0002-9487-4985; Arndt, Markus/0000-0002-9487-4985				ARNDT M, 1999, VIEN CIR INST YEARBK, V7, P221; Berman P., 1997, ATOM INTERFEROMETRY; Born M., 1984, PRINCIPLES OPTICS; CHAPMAN MS, 1995, PHYS REV LETT, V75, P3783, DOI 10.1103/PhysRevLett.75.3783; Clauser J., 1997, EXPT METAPHYSICS, P1; CLAUSER JF, 1994, PHYS REV A, V50, P2430, DOI 10.1103/PhysRevA.50.2430; Davisson C, 1927, NATURE, V119, P558, DOI 10.1038/119558a0; De Broglie L, 1923, NATURE, V112, P540, DOI 10.1038/112540a0; DING D, 1994, PHYS REV LETT, V73, P1084, DOI 10.1103/PhysRevLett.73.1084; Estermann I, 1930, Z PHYS, V61, P95, DOI 10.1007/BF01340293; Giulini D., 1996, DECOHERENCE APPEARAN; Grisenti RE, 1999, PHYS REV LETT, V83, P1755, DOI 10.1103/PhysRevLett.83.1755; GRISENTI RE, UNPUB PHYS REV A; JOOS E, 1985, Z PHYS B CON MAT, V59, P223, DOI 10.1007/BF01725541; KOLODNEY E, 1995, PHYS REV LETT, V74, P510, DOI 10.1103/PhysRevLett.74.510; KRATSCHMER W, 1990, NATURE, V347, P354, DOI 10.1038/347354a0; KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0; MITZNER R, 1995, J CHEM PHYS, V103, P2445, DOI 10.1063/1.469667; PFAU T, 1994, PHYS REV LETT, V73, P1223, DOI 10.1103/PhysRevLett.73.1223; RAUCH H, 1975, PHYS LETT A, V54, P425, DOI 10.1016/0375-9601(75)90798-7; Savas TA, 1995, J VAC SCI TECHNOL B, V13, P2732, DOI 10.1116/1.588255; SCHOLLKOPF W, 1994, SCIENCE, V266, P1345, DOI 10.1126/science.266.5189.1345; Scoles G., 1988, ATOMIC MOL BEAM METH, V1; von Halban H, 1936, CR HEBD ACAD SCI, V203, P73; WERNER SA, 1975, PHYS REV LETT, V35, P1053, DOI 10.1103/PhysRevLett.35.1053	26	762	778	12	219	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	1999	401	6754					680	682		10.1038/44348	http://dx.doi.org/10.1038/44348			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	18494170				2022-12-28	WOS:000083207400050
J	Barrera, NP; Di Bartolo, N; Booth, PJ; Robinson, CV				Barrera, Nelson P.; Di Bartolo, Natalie; Booth, Paula J.; Robinson, Carol V.			Micelles protect membrane complexes from solution to vacuum	SCIENCE			English	Article							IONIZATION MASS-SPECTROMETRY; MACROMOLECULAR ASSEMBLIES; GAS-PHASE; ESCHERICHIA-COLI; DISSOCIATION; STOICHIOMETRY; ARCHITECTURE; MECHANISM; ORIGIN	The ability to maintain interactions between soluble protein subunits in the gas phase of a mass spectrometer gives critical insight into the stoichiometry and interaction networks of protein complexes. Conversely, for membrane protein complexes in micelles, the transition into the gas phase usually leads to the disruption of interactions, particularly between cytoplasmic and membrane subunits, and a mass spectrum dominated by large aggregates of detergent molecules. We show that by applying nanoelectrospray to a micellar solution of a membrane protein complex, the heteromeric adenosine 5'- triphosphate ( ATP)- binding cassette transporter BtuC(2)D(2), we can maintain the complex intact in the gas phase of a mass spectrometer. Dissociation of either transmembrane ( BtuC) or cytoplasmic ( BtuD) subunits uncovers modifications to the transmembrane subunits and cooperative binding of ATP. By protecting a membrane protein complex within a n-dodecyl-beta-D-maltoside micelle, we demonstrated a powerful strategy that will enable the subunit stoichiometry and ligand- binding properties of membrane complexes to be determined directly, by precise determination of the masses of intact complexes and dissociated subunits.	[Barrera, Nelson P.; Robinson, Carol V.] Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; [Di Bartolo, Natalie; Booth, Paula J.] Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Cambridge; University of Bristol	Robinson, CV (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	cvr24@cam.ac.uk	Booth, Paula/A-9644-2011	Barrera, Nelson/0000-0001-7825-1406; Booth, Paula Jane/0000-0003-3893-360X; robinson, carol/0000-0001-7829-5505	Biotechnology and Biological Sciences Research Council Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Benesch JL, 2006, CURR OPIN STRUC BIOL, V16, P245, DOI 10.1016/j.sbi.2006.03.009; Benesch JLP, 2006, CHEM BIOL, V13, P597, DOI 10.1016/j.chembiol.2006.04.006; Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521-4095(199905)11:7<579::AID-ADMA579>3.0.CO;2-R; Cadene M, 2000, ANAL CHEM, V72, P5655, DOI 10.1021/ac000811l; Chapman HN, 2007, NATURE, V448, P676, DOI 10.1038/nature06049; Demmers JAA, 2003, FEBS LETT, V541, P28, DOI 10.1016/S0014-5793(03)00282-5; DRUMMOND CJ, 1985, J PHYS CHEM-US, V89, P2103, DOI 10.1021/j100256a060; Esteban O, 2008, J BIOL CHEM, V283, P2595, DOI 10.1074/jbc.M704941200; Felitsyn N, 2001, ANAL CHEM, V73, P4647, DOI 10.1021/ac0103975; Galka JJ, 2008, BIOCHEMISTRY-US, V47, P3513, DOI 10.1021/bi7021409; Geoghegan KF, 1999, ANAL BIOCHEM, V267, P169, DOI 10.1006/abio.1998.2990; Hanson CL, 2003, BIOPHYS J, V85, P3802, DOI 10.1016/S0006-3495(03)74795-X; Hernandez H, 2007, NAT PROTOC, V2, P715, DOI 10.1038/nprot.2007.73; Hernandez H, 2006, EMBO REP, V7, P605, DOI 10.1038/sj.embor.7400702; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Ilag LL, 2004, J AM CHEM SOC, V126, P14362, DOI 10.1021/ja0450307; Jarrold MF, 2007, PHYS CHEM CHEM PHYS, V9, P1659, DOI 10.1039/b612615d; Jurchen JC, 2003, J AM CHEM SOC, V125, P2817, DOI 10.1021/ja0211508; Kaltashov IA, 2005, ANAL CHEM, V77, P5370, DOI 10.1021/ac050511+; Kobayashi N, 2003, FEBS LETT, V546, P241, DOI 10.1016/S0014-5793(03)00579-9; le Maire M, 2000, BBA-BIOMEMBRANES, V1508, P86, DOI 10.1016/S0304-4157(00)00010-1; Lengqvist J, 2004, J BIOL CHEM, V279, P13311, DOI 10.1074/jbc.M310958200; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo JA, 1997, MASS SPECTROM REV, V16, P1; LOO RRO, 1994, PROTEIN SCI, V3, P1975, DOI 10.1002/pro.5560031109; Meier T, 2007, MOL MICROBIOL, V65, P1181, DOI 10.1111/j.1365-2958.2007.05857.x; Rundlett KL, 1996, ANAL CHEM, V68, P3493, DOI 10.1021/ac960472p; Ruotolo BT, 2005, SCIENCE, V310, P1658, DOI 10.1126/science.1120177; Sharon M, 2007, ANNU REV BIOCHEM, V76, P167, DOI 10.1146/annurev.biochem.76.061005.090816; Sharon M, 2007, J AM CHEM SOC, V129, P8740, DOI 10.1021/ja067820h; SIUZDAK G, 1995, ANGEW CHEM INT EDIT, V34, P2053, DOI 10.1002/anie.199520531; Sobott F, 2002, ANAL CHEM, V74, P1402, DOI 10.1021/ac0110552; van den Heuvel RH, 2004, CURR OPIN CHEM BIOL, V8, P519, DOI 10.1016/j.cbpa.2004.08.006; Versluis C, 2001, J AM SOC MASS SPECTR, V12, P329, DOI 10.1016/S1044-0305(00)00227-0	35	277	279	0	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	2008	321	5886					243	246		10.1126/science.1159292	http://dx.doi.org/10.1126/science.1159292			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324IS	18556516				2022-12-28	WOS:000257512900038
J	Harvey, CD; Yasuda, R; Zhong, HN; Svoboda, K				Harvey, Christopher D.; Yasuda, Ryohei; Zhong, Haining; Svoboda, Karel			The spread of Ras activity triggered by activation of a single dendritic spine	SCIENCE			English	Article							LONG-TERM POTENTIATION; CELLS; TRAFFICKING; INTEGRATION; PLASTICITY; RECEPTORS; CYCLE	In neurons, individual dendritic spines isolate N- methyl- D- aspartate ( NMDA) receptor- mediated calcium ion ( Ca(2+)) accumulations from the dendrite and other spines. However, the extent to which spines compartmentalize signaling events downstream of Ca(2+) influx is not known. We combined two- photon fluorescence lifetime imaging with two- photon glutamate uncaging to image the activity of the small guanosine triphosphatase Ras after NMDA receptor activation at individual spines. Induction of long- term potentiation ( LTP) triggered robust Ca(2+)- dependent Ras activation in single spines that decayed in similar to 5 minutes. Ras activity spread over similar to 10 micrometers of dendrite and invaded neighboring spines by diffusion. The spread of Ras- dependent signaling was necessary for the local regulation of the threshold for LTP induction. Thus, Ca(2+)- dependent synaptic signals can spread to couple multiple synapses on short stretches of dendrite.	[Harvey, Christopher D.; Yasuda, Ryohei; Zhong, Haining; Svoboda, Karel] Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA; [Harvey, Christopher D.; Zhong, Haining; Svoboda, Karel] Howard Hughes Med Inst, Ashburn, VA 20147 USA; [Yasuda, Ryohei] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Duke University	Yasuda, R (corresponding author), Cold Spring Harbor Lab, Watson Sch Biol Sci, POB 100, Cold Spring Harbor, NY 11724 USA.	yasuda@neuro.duke.edu; svobodak@janelia.hhmi.org	Yasuda, Ryohei/E-7726-2011	Zhong, Haining/0000-0002-7109-4724; Yasuda, Ryohei/0000-0001-6263-9297	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH080047] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIMH NIH HHS [R01 MH080047, R01 MH080047-01] Funding Source: Medline; Autism Speaks [AS1398] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Autism Speaks		Bloodgood BL, 2005, SCIENCE, V310, P866, DOI 10.1126/science.1114816; Fivaz M, 2008, CURR BIOL, V18, P44, DOI 10.1016/j.cub.2007.11.051; Gratton E, 2003, J BIOMED OPT, V8, P381, DOI 10.1117/1.1586704; Gray NW, 2006, PLOS BIOL, V4, P2065, DOI 10.1371/journal.pbio.0040370; Harvey CD, 2007, NATURE, V450, P1195, DOI 10.1038/nature06416; Kennedy MB, 2005, NAT REV NEUROSCI, V6, P423, DOI 10.1038/nrn1685; Kim MJ, 2005, NEURON, V46, P745, DOI 10.1016/j.neuron.2005.04.031; Kopec CD, 2006, J NEUROSCI, V26, P2000, DOI 10.1523/JNEUROSCI.3918-05.2006; Lommerse PHM, 2004, BIOPHYS J, V86, P609, DOI 10.1016/S0006-3495(04)74139-9; Losonczy A, 2008, NATURE, V452, P436, DOI 10.1038/nature06725; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Matsuzaki M, 2004, NATURE, V429, P761, DOI 10.1038/nature02617; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; Nimchinsky EA, 2002, ANNU REV PHYSIOL, V64, P313, DOI 10.1146/annurev.physiol.64.081501.160008; Nimchinsky EA, 2004, J NEUROSCI, V24, P2054, DOI 10.1523/JNEUROSCI.5066-03.2004; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; PISTON DW, 1992, TIME RESOLVED LASER, V3, P379; Reits EAJ, 2001, NAT CELL BIOL, V3, pE145, DOI 10.1038/35078615; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Sabatini BL, 2002, NEURON, V33, P439, DOI 10.1016/S0896-6273(02)00573-1; Svoboda K, 1996, SCIENCE, V272, P716, DOI 10.1126/science.272.5262.716; Tsuriel S, 2006, PLOS BIOL, V4, P1572, DOI 10.1371/journal.pbio.0040271; Yasuda R, 2006, NAT NEUROSCI, V9, P283, DOI 10.1038/nn1635; Yun HY, 1998, P NATL ACAD SCI USA, V95, P5773, DOI 10.1073/pnas.95.10.5773; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	28	293	302	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 4	2008	321	5885					136	140		10.1126/science.1159675	http://dx.doi.org/10.1126/science.1159675			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	321QE	18556515	Green Accepted			2022-12-28	WOS:000257320800056
J	Coombes, R				Coombes, Rebecca			BMJ in "smug docs" storm	BRITISH MEDICAL JOURNAL			English	Editorial Material												rcoombes@bmjgroup.com						Garlick PB, 2008, BMJ-BRIT MED J, V336, P1111, DOI 10.1136/bmj.39508.606157.BE; Ip H, 2008, BRIT MED J, V336, P1082, DOI 10.1136/bmj.39569.609641.80	2	1	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 14	2008	336	7657					1340	1341		10.1136/bmj.39609.446701.59	http://dx.doi.org/10.1136/bmj.39609.446701.59			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316YB	18556312	Green Published			2022-12-28	WOS:000256984700035
J	Acosta, JC; O'Loghlen, A; Banito, A; Guijarro, MV; Augert, A; Raguz, S; Fumagalli, M; Da Costa, M; Brown, C; Popov, N; Takatsu, Y; Melamed, J; di Fagagna, FD; Bernard, D; Hernando, E; Gil, J				Acosta, Juan C.; O'Loghlen, Ana; Banito, Ana; Guijarro, Maria V.; Augert, Arnaud; Raguz, Selina; Fumagalli, Marzia; Da Costa, Marco; Brown, Celia; Popov, Nikolay; Takatsu, Yoshihiro; Melamed, Jonathan; di Fagagna, Fabrizio d'Adda; Bernard, David; Hernando, Eva; Gil, Jesus			Chemokine signaling via the CXCR2 receptor reinforces senescence	CELL			English	Article							SQUAMOUS-CELL CARCINOMA; GENE-EXPRESSION; REPLICATIVE SENESCENCE; CANCER-CELLS; P53; FIBROBLASTS; GROWTH; TUMORIGENESIS; INTERLEUKIN-8; TRANSFORMATION	Cells enter senescence, a state of stable proliferative arrest, in response to a variety of cellular stresses, including telomere erosion, DNA damage, and oncogenic signaling, which acts as a barrier against malignant transformation in vivo. To identify genes controlling senescence, we conducted an unbiased screen for small hairpin RNAs that extend the life span of primary human fibroblasts. Here, we report that knocking down the chemokine receptor CXCR2 (IL8RB) alleviates both replicative and oncogene-induced senescence (OIS) and diminishes the DNA-damage response. Conversely, ectopic expression of CXCR2 results in premature senescence via a p53-dependent mechanism. Cells undergoing OIS secrete multiple CXCR2-binding chemokines in a program that is regulated by the NF-kappa B and C/EBP beta transcription factors and coordinately induce CXCR2 expression. CXCR2 upregulation is also observed in preneoplastic lesions in vivo. These results suggest that senescent cells activate a self-amplifying secretory network in which CXCR2-binding chemokines reinforce growth arrest.	[Acosta, Juan C.; O'Loghlen, Ana; Banito, Ana; Raguz, Selina; Da Costa, Marco; Brown, Celia; Popov, Nikolay; Takatsu, Yoshihiro; Gil, Jesus] Univ London Imperial Coll Sci Technol & Med, Fac Med, MRC, Clin Sci Ctr,Cell Proliferat Grp, London W12 0NN, England; [Guijarro, Maria V.; Melamed, Jonathan; Hernando, Eva] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; [Augert, Arnaud; Bernard, David] Univ Lille 1, CNRS, Inst Biol, UMR 8161, Lille, France; [Augert, Arnaud; Bernard, David] Univ Lille 2, Inst Pasteur, IFR 142, Lille, France; [Fumagalli, Marzia; di Fagagna, Fabrizio d'Adda] Mol Oncol Fdn, IFOM Fdn, FIRC Inst, I-20139 Milan, Italy	Imperial College London; New York University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; IFOM - FIRC Institute of Molecular Oncology	Gil, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, MRC, Clin Sci Ctr,Cell Proliferat Grp, Hammersmith Campus, London W12 0NN, England.	jesus.gil@csc.mrc.ac.uk	Gil, Jesus/C-7739-2012; d'Adda di Fagagna, Fabrizio/AAC-4683-2022; Banito, Ana/P-6168-2017; Acosta, Juan/AAE-6320-2021; Melamed, Jonathan/AAV-3769-2020; O'Loghlen, Ana/K-9965-2014; Bernard, David/D-6265-2018	Gil, Jesus/0000-0002-4303-6260; d'Adda di Fagagna, Fabrizio/0000-0002-9603-5966; Acosta, Juan/0000-0002-7989-7329; Melamed, Jonathan/0000-0003-2844-7990; O'Loghlen, Ana/0000-0002-8141-1965; Fumagalli, Marzia/0000-0002-2036-4544; Hernando, Eva/0000-0003-1023-0312; Bernard, David/0000-0002-1557-2074; DADDADIFAGAGNA, FABRIZIO/0000-0002-1976-3185; Banito, Ana/0000-0003-2188-0003	MRC [MC_U120085810] Funding Source: UKRI; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom; Medical Research Council [MC_U120085810] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ancrile B, 2007, GENE DEV, V21, P1714, DOI 10.1101/gad.1549407; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; BORDONI R, 1990, J CELL BIOCHEM, V44, P207, DOI 10.1002/jcb.240440403; Burger M, 1999, J IMMUNOL, V163, P2017; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Coppe JP, 2006, J BIOL CHEM, V281, P29568, DOI 10.1074/jbc.M603307200; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Gil J, 2004, NAT CELL BIOL, V6, P67, DOI 10.1038/ncb1077; Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Mantovani A, 2006, NAT REV IMMUNOL, V6, P907, DOI 10.1038/nri1964; Mason DX, 2006, CARCINOGENESIS, V27, P350, DOI 10.1093/carcin/bgi264; Maxwell PJ, 2007, ONCOGENE, V26, P7333, DOI 10.1038/sj.onc.1210536; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Narita M, 2005, NAT MED, V11, P920, DOI 10.1038/nm0905-920; Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052; Parrinello S, 2005, J CELL SCI, V118, P485, DOI 10.1242/jcs.01635; Passos JF, 2007, PLOS BIOL, V5, P1138, DOI 10.1371/journal.pbio.0050110; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Sai JQ, 2006, J BIOL CHEM, V281, P35931, DOI 10.1074/jbc.M605883200; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Toruner GA, 2004, CANCER GENET CYTOGEN, V154, P27, DOI 10.1016/j.cancergencyto.2004.01.026; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yuan A, 2005, FRONT BIOSCI-LANDMRK, V10, P853, DOI 10.2741/1579	41	1139	1164	8	88	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 13	2008	133	6					1006	1018		10.1016/j.cell.2008.03.038	http://dx.doi.org/10.1016/j.cell.2008.03.038			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	312TJ	18555777	Bronze			2022-12-28	WOS:000256693400016
J	Wick, MC; Rieger, M				Wick, Marius C.; Rieger, Michael			Rupture of a calcified achilles' tendon	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Wick, Marius C.; Rieger, Michael] Innsbruck Med Univ, A-6020 Innsbruck, Austria	Medical University of Innsbruck	Wick, MC (corresponding author), Innsbruck Med Univ, A-6020 Innsbruck, Austria.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2008	358	24					2618	2618		10.1056/NEJMicm070277	http://dx.doi.org/10.1056/NEJMicm070277			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311IJ	18550877				2022-12-28	WOS:000256593600009
J	Crump, B; Landefeld, CS; Shojania, KG; Auerbach, AD				Crump, Bernard; Landefeld, C. Seth; Shojania, Kaveh G.; Auerbach, Andrew D.			Should we use large scale healthcare interventions without clear evidence that benefits outweigh costs and harms?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Crump, Bernard] NHS Inst Innovat & Improvement, Coventry CV4 7AL, W Midlands, England; [Landefeld, C. Seth; Auerbach, Andrew D.] Univ Calif San Francisco, San Francisco, CA 94118 USA; [Landefeld, C. Seth] San Francisco VA Med Ctr, San Francisco, CA USA; [Shojania, Kaveh G.] Ottawa Hlth Res Inst, Ottawa, ON, Canada	University of Warwick; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of Ottawa; Ottawa Hospital Research Institute	Crump, B (corresponding author), NHS Inst Innovat & Improvement, Coventry CV4 7AL, W Midlands, England.	bernard.crump@institute.nhs.uk; sethl@medicine.ucsf.edu							0	7	7	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 7	2008	336	7656					1276	1277		10.1136/bmj.a145	http://dx.doi.org/10.1136/bmj.a145			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312XO	18535068	Green Published			2022-12-28	WOS:000256705900028
J	Polderman, KH				Polderman, Kees H.			Induced hypothermia and fever control for prevention and treatment of neurological injuries	LANCET			English	Review							TRAUMATIC BRAIN-INJURY; HOSPITAL CARDIAC-ARREST; MILD SYSTEMIC HYPOTHERMIA; WHOLE-BODY HYPOTHERMIA; PROMISING TREATMENT MODALITY; FOCAL CEREBRAL-ISCHEMIA; INTENSIVE-CARE-UNIT; SPINAL-CORD-INJURY; SEVERE HEAD-INJURY; MODERATE HYPOTHERMIA	Increasing evidence suggests that induction of mild hypothermia (32-35 degrees C) in the first hours after an ischaemic event can prevent or mitigate permanent injuries. This effect has been shown most clearly for postanoxic brain injury; but could also apply to other organs such as the heart and kidneys. Hypothermia has also been used as a treatment for traumatic brain injury, stroke, hepatic encephalopathy, myocardial infarction, and other indications. Hypothermia is a highly promising treatment in neurocritical care; thus, physicians caring for patients with neurological injuries, both in and outside the intensive care unit, are likely to be confronted with questions about temperature management more frequently. This Review discusses the available evidence for use of controlled hypothermia, and also deals with fever control. Besides discussing the evidence, the aim is to provide information to help guide treatments more effectively with regard to timing, depth, duration, and effective management of side-effects. In particular, the rate of rewarming seems to be an important factor in establishing successful use of hypothermia in the treatment of neurological injuries.	[Polderman, Kees H.] Univ Med Ctr Utrecht, Dept Intens Care, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Polderman, KH (corresponding author), Univ Med Ctr Utrecht, Dept Intens Care, POB 85500, NL-3508 GA Utrecht, Netherlands.	k.polderman@tip.nl	Polderman, Kees H/K-3623-2012					Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; Al-Senani FM, 2004, RESUSCITATION, V62, P143, DOI 10.1016/j.resuscitation.2004.02.016; Alam HB, 2006, J TRAUMA, V60, P134, DOI 10.1097/01.ta.0000198469.95292.ec; Alderson P, 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001048.pub2, DOI 10.1002/14651858.CD001048.PUB2]; ALLEN BT, 1994, J VASC SURG, V19, P332, DOI 10.1016/S0741-5214(94)70108-3; *AM ASS NEUR SURG, 2007, J NEUROTRAUMA S1, V24, pS21; ANDERSON S, 2006, STROKE, V37, P163; Anderson SW, 2006, ANN NEUROL, V60, P518, DOI 10.1002/ana.21018; Auer RN, 2001, ANN NY ACAD SCI, V939, P271; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; Azzopardi D, 2000, PEDIATRICS, V106, P684, DOI 10.1542/peds.106.4.684; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; BAKER CJ, 1992, J NEUROSURG, V77, P438, DOI 10.3171/jns.1992.77.3.0438; BASH SE, 1987, J AM COLL CARDIOL, V10, P1095, DOI 10.1016/S0735-1097(87)80351-0; Battin MR, 2003, PEDIATRICS, V111, P244, DOI 10.1542/peds.111.2.244; Battin MR, 2001, PEDIATRICS, V107, P480, DOI 10.1542/peds.107.3.480; Belliard G, 2007, RESUSCITATION, V75, P252, DOI 10.1016/j.resuscitation.2007.04.014; BENSON D W, 1959, Anesth Analg, V38, P423; BERGER R, 1994, CHEST, V106, P872, DOI 10.1378/chest.106.3.872; Bernard S, 2003, RESUSCITATION, V56, P9, DOI 10.1016/S0300-9572(02)00276-9; Bernard S., 1998, EMERG MED AUSTRALAS, V10, P25; Bernard SA, 1997, ANN EMERG MED, V30, P146, DOI 10.1016/S0196-0644(97)70133-1; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Berrouschot J, 1998, INTENS CARE MED, V24, P620, DOI 10.1007/s001340050625; Bissonnette B, 2000, ANESTHESIOLOGY, V93, P611, DOI 10.1097/00000542-200009000-00008; Boodhwani M, 2007, J THORAC CARDIOV SUR, V134, P1443, DOI 10.1016/j.jtcvs.2007.08.016; Bottiger BW, 2001, LANCET, V357, P1583, DOI 10.1016/S0140-6736(00)04726-7; Busch M, 2006, ACTA ANAESTH SCAND, V50, P1277, DOI 10.1111/j.1399-6576.2006.01147.x; Cairns Chris J S, 2002, Curr Opin Crit Care, V8, P106, DOI 10.1097/00075198-200204000-00003; Cambria RP, 1997, J VASC SURG, V25, P234, DOI 10.1016/S0741-5214(97)70365-3; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Conrad MF, 2007, ANN THORAC SURG, V83, pS856, DOI 10.1016/j.athoracsur.2006.10.096; *COOL MI 2, COOL ADJ THER PERC I; *COOL RCN, COOL PREV RAD NEPHR; Dae MW, 2002, AM J PHYSIOL-HEART C, V282, pH1584, DOI 10.1152/ajpheart.00980.2001; Dalrymple-Hay MJR, 1999, EUR J CARDIO-THORAC, V15, P515, DOI 10.1016/S1010-7940(99)00074-3; Deakin CD, 1998, ANAESTHESIA, V53, P848, DOI 10.1046/j.1365-2044.1998.00563.x; Debillon T, 2003, DEV MED CHILD NEUROL, V45, P17, DOI 10.1017/S0012162203000045; Diringer MN, 2004, CRIT CARE MED, V32, P559, DOI 10.1097/01.CCM.0000108868.97433.3F; Diringer MN, 2004, CRIT CARE MED, V32, P1611; Dixon SR, 2002, J AM COLL CARDIOL, V40, P1928, DOI 10.1016/S0735-1097(02)02567-6; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; Edwards P, 2005, LANCET, V365, P1957; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; Enomoto S, 1996, ANESTHESIOLOGY, V84, P1392, DOI 10.1097/00000542-199606000-00016; FAY T, 1943, ASS RES NERV MENT DI, V24, P611; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Felberg RA, 2001, CIRCULATION, V104, P1799, DOI 10.1161/hc4001.097037; FLACHS J, 1977, LANCET, V1, P489; FRANK SM, 1994, J VASC SURG, V19, P687, DOI 10.1016/S0741-5214(94)70043-5; Gal R, 2002, CLIN NEUROL NEUROSUR, V104, P318, DOI 10.1016/S0303-8467(02)00023-9; Gasser S, 2003, J NEUROSURG ANESTH, V15, P240, DOI 10.1097/00008506-200307000-00012; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Grigore AM, 2001, ANESTHESIOLOGY, V95, P1110, DOI 10.1097/00000542-200111000-00014; Grocott HP, 2002, STROKE, V33, P537, DOI 10.1161/hs0202.102600; Guluma KZ, 2006, ACAD EMERG MED, V13, P820, DOI 10.1197/j.aem.2006.03.559; Gunn AJ, 1998, PEDIATRICS, V102, P885, DOI 10.1542/peds.102.4.885; Hachimi-Idrissi S, 2001, RESUSCITATION, V51, P275, DOI 10.1016/S0300-9572(01)00412-9; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Hale SL, 2003, J AM COLL CARDIOL, V41, p381A; Hale SL, 1997, AM J PHYSIOL-HEART C, V273, pH220, DOI 10.1152/ajpheart.1997.273.1.H220; Hale SL, 1997, BASIC RES CARDIOL, V92, P351, DOI 10.1007/BF00788947; Harris OA, 2002, ARCH NEUROL-CHICAGO, V59, P1077, DOI 10.1001/archneur.59.7.1077; Hartemink KJ, 2004, CRIT CARE, V8, pR343, DOI 10.1186/cc2928; Hayashi N., 2004, BRAIN HYPOTHERMIA TR; Hayashi S, 2002, ACT NEUR S, V81, P83; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Hickey RW, 2003, CRIT CARE MED, V31, P531, DOI 10.1097/01.CCM.0000050323.84293.11; Hildebrand F, 2005, CYTOKINE, V31, P382, DOI 10.1016/j.cyto.2005.06.008; Holzer M, 2005, CRIT CARE MED, V33, P414, DOI 10.1097/01.CCM.0000153410.87750.53; Holzer M, 2002, NEW ENGL J MED, V346, P549; HORVATH SM, 1953, SCIENCE, V118, P100, DOI 10.1126/science.118.3056.100; Isaka M, 2006, J VASC SURG, V43, P1257, DOI 10.1016/j.jvs.2006.02.017; Jalan R, 2004, GASTROENTEROLOGY, V127, P1338, DOI 10.1053/j.gastro.2004.08.005; Jalan R, 2003, TRANSPLANTATION, V75, P2034, DOI 10.1097/01.TP.0000066240.42113.FF; Jalan R, 1999, LANCET, V354, P1164, DOI 10.1016/S0140-6736(98)12440-6; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Kammersgaard LP, 2000, STROKE, V31, P2251, DOI 10.1161/01.STR.31.9.2251; Kammersgaard LP, 2002, STROKE, V33, P1759, DOI 10.1161/01.STR.0000019910.90280.F1; Karkar KM, 2002, EPILEPSIA, V43, P932, DOI 10.1046/j.1528-1157.2002.03902.x; Kawahara F, 2003, ACTA ANAESTH SCAND, V47, P419, DOI 10.1034/j.1399-6576.2003.00063.x; Kim F, 2007, CIRCULATION, V115, P3064, DOI 10.1161/CIRCULATIONAHA.106.655480; Kollmar R, 2002, STROKE, V33, P1899, DOI 10.1161/01.STR.0000019603.29818.9C; Krieger DW, 2001, STROKE, V32, P1847, DOI 10.1161/01.STR.32.8.1847; Lavinio A, 2007, BRIT J ANAESTH, V99, P237, DOI 10.1093/bja/aem118; Leira R, 2004, NEUROLOGY, V63, P461, DOI 10.1212/01.WNL.0000133204.81153.AC; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Liu YQ, 2004, STROKE, V35, P1460, DOI 10.1161/01.STR.0000128029.50221.fa; Maeda T, 1999, BRAIN RES, V818, P228, DOI 10.1016/S0006-8993(98)01269-4; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARTIN TD, 1994, ANN THORAC SURG, V57, P298, DOI 10.1016/0003-4975(94)90987-3; Matsumoto M, 1997, ANESTHESIOLOGY, V86, P1120, DOI 10.1097/00000542-199705000-00016; Maxwell WL, 2005, J NEUROTRAUM, V22, P873, DOI 10.1089/neu.2005.22.873; Mayer S., 2005, THERAPEUTIC HYPOTHER; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; MELLERGARD P, 1991, NEUROSURGERY, V28, P709, DOI 10.1227/00006123-199105000-00012; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MOAT NE, 1992, EUR J CARDIO-THORAC, V6, P579, DOI 10.1016/1010-7940(92)90130-P; Mora CT, 1996, J THORAC CARDIOV SUR, V112, P514, DOI 10.1016/S0022-5223(96)70280-5; Mori K, 2000, CRIT CARE MED, V28, pA168; Moriyama Y, 1996, ANGIOLOGY, V47, P595, DOI 10.1177/000331979604700608; Munakata M, 2000, BRAIN DEV-JPN, V22, P373, DOI 10.1016/S0387-7604(00)00169-8; Nagao K, 2000, J AM COLL CARDIOL, V36, P776, DOI 10.1016/S0735-1097(00)00779-8; Nagao S, 2003, J CLIN NEUROSCI, V10, P208, DOI 10.1016/S0967-5868(02)00322-3; Nagao S, 2000, ACT NEUR S, V76, P547; NASLUND TC, 1992, ANN SURG, V215, P409, DOI 10.1097/00000658-199205000-00002; Nathan HJ, 2001, CIRCULATION, V104, pI85; Nathan HJ, 2007, J THORAC CARDIOV SUR, V133, P1206, DOI 10.1016/j.jtcvs.2006.09.112; NAYLOR CD, 1994, LANCET, V343, P559; Nolan JP, 2005, RESUSCITATION, V67, pS39, DOI 10.1016/j.resuscitation.2005.10.009; Nybo L, 2002, J PHYSIOL-LONDON, V545, P697, DOI 10.1113/jphysiol.2002.030023; Oddo M, 2006, CRIT CARE MED, V34, P1865, DOI 10.1097/01.CCM.0000221922.08878.49; Ohta H, 2007, NEUROSCI RES, V57, P424, DOI 10.1016/j.neures.2006.12.002; OKU K, 1994, RESUSCITATION, V27, P141, DOI 10.1016/0300-9572(94)90007-8; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Otake H, 2007, J AM COLL CARDIOL, V49, P250, DOI 10.1016/j.jacc.2006.06.080; Park CK, 1998, ACT NEUR S, V71, P225; PFAMMATTER JP, 1995, ANN THORAC SURG, V60, P556, DOI 10.1016/0003-4975(95)00425-K; Piepgras A, 2001, NEUROSURGERY, V48, P1128, DOI 10.1097/00006123-200105000-00033; Plourde G, 1997, J THORAC CARDIOV SUR, V114, P123, DOI 10.1016/S0022-5223(97)70125-9; Polderman KH, 2005, CRIT CARE MED, V33, P2744, DOI 10.1097/01.CCM.0000190427.88735.19; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2003, CIRCULATION, V108, P581; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Polderman KH, 2001, J NEUROSURG, V94, P853; Polderman KH, 2001, J NEUROSURG, V94, P697, DOI 10.3171/jns.2001.94.5.0697; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; POLDERMAN KH, 2007, CARDIAC ARREST SCI P, P859; POLDERMAN KH, 2003, INTENS CARE MED, V29, P1637; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Samra SK, 2007, STROKE, V38, P1864, DOI 10.1161/STROKEAHA.106.477448; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwab S, 1997, NEUROLOGY, V48, P762, DOI 10.1212/WNL.48.3.762; Schwab S, 1998, ACT NEUR S, V71, P131; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; Schwarz S, 2000, NEUROLOGY, V54, P354, DOI 10.1212/WNL.54.2.354; Shankaran S, 2002, PEDIATRICS, V110, P377, DOI 10.1542/peds.110.2.377; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Simbruner G, 1999, INTENS CARE MED, V25, P1111, DOI 10.1007/s001340051020; Small DL, 1999, PROG CARDIOVASC DIS, V42, P185, DOI 10.1016/S0033-0620(99)70002-2; SMITH PLC, 1995, ANN THORAC SURG, V59, P1359, DOI 10.1016/0003-4975(95)00104-S; Steiner T, 2001, STROKE, V32, P2833, DOI 10.1161/hs1201.99511; Stone GW, 2006, CIRCULATION, V114, P811; Sunde K, 2007, RESUSCITATION, V73, P29, DOI 10.1016/j.resuscitation.2006.08.016; Svensson LG, 1998, ANN THORAC SURG, V66, P132, DOI 10.1016/S0003-4975(98)00359-2; Takata T, 1999, J NEUROL SCI, V165, P94, DOI 10.1016/S0022-510X(99)00089-1; TAKINO M, 1991, INTENS CARE MED, V17, P419, DOI 10.1007/BF01720680; Tateishi A, 1998, NEUROSURGERY, V42, P1065, DOI 10.1097/00006123-199805000-00066; Thoresen M, 2000, PEDIATRICS, V106, P92, DOI 10.1542/peds.106.1.92; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; VERLOOY J, 1995, ACTA NEUROCHIR, V134, P76, DOI 10.1007/BF01428508; VILLAR J, 1993, RESUSCITATION, V26, P183, DOI 10.1016/0300-9572(93)90178-S; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404; WILLIAMS GR, 1958, ANN SURG, V148, P462, DOI 10.1097/00000658-195809000-00014; Yahagi N, 1998, J CLIN ANESTH, V10, P120, DOI 10.1016/S0952-8180(97)00255-9; Yan Y, 2001, Chin J Traumatol, V4, P8; Yanagawa Y, 1998, RESUSCITATION, V39, P61, DOI 10.1016/S0300-9572(98)00118-X; Zausinger S, 2003, STROKE, V34, P2246, DOI 10.1161/01.STR.0000083622.65684.21; Zeiner A, 2000, STROKE, V31, P86, DOI 10.1161/01.STR.31.1.86; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007; Zhang K, 2000, INNER MONGOLIA MED J, V32, P4; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	180	421	464	1	37	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	2008	371	9628					1955	1969		10.1016/S0140-6736(08)60837-5	http://dx.doi.org/10.1016/S0140-6736(08)60837-5			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310OI	18539227				2022-12-28	WOS:000256538500032
J	Wright, HR; Turner, A; Taylor, HR				Wright, Heathcote R.; Turner, Angus; Taylor, Hugh R.			Trachoma	LANCET			English	Review							SINGLE-DOSE AZITHROMYCIN; RANDOMIZED CONTROLLED-TRIAL; OCULAR CHLAMYDIAL INFECTION; MASS ANTIBIOTIC-TREATMENT; HEAT-SHOCK-PROTEIN; RISK-FACTORS; ACTIVE TRACHOMA; INTERFERON-GAMMA; FOLLOW-UP; TRICHIASIS RECURRENCE	Trachoma is a keratoconjunctivitis caused by ocular infection with Chlamydia trachomatis. Repeated or persistent episodes lead to increasingly severe inflammation that can progress to scarring of the upper tarsal conjunctiva. Trichiasis develops when scarring distorts the upper eyelid sufficiently to cause one or more lashes to abrade the cornea, scarring it in turn and causing blindness. Active trachoma affects an estimated 84 million people; another 7.6 million have end-stage disease, of which about 1.3 million are blind. Trachoma should stand on the brink of extinction thanks to a 1998 initiative launched by WHO-the Global Elimination of Trachoma by 2020. This programme advocates control of trachoma at the community level with four inter-related population-health initiatives that form the SAFE strategy: surgery for trichiasis, antibiotics for active trachoma, facial cleanliness, and environmental improvement. Evidence supports the effectiveness of this approach, and if current world efforts continue, blinding trachoma will indeed be eliminated by 2020.	[Wright, Heathcote R.; Taylor, Hugh R.] Univ Melbourne, Ctr Eye Res, WHO Collaborating Ctr Prevent Blindness, Melbourne, Vic 8002, Australia; [Wright, Heathcote R.; Taylor, Hugh R.] Univ New S Wales, Vis Cooperat Res Ctr, Sydney, NSW, Australia; [Turner, Angus] Royal Victorian Eye & Ear Hosp, Melbourne, Vic 8002, Australia	University of Melbourne; University of New South Wales Sydney; Visa Inc; Royal Victorian Eye & Ear Hospital	Wright, HR (corresponding author), Univ Melbourne, Ctr Eye Res, WHO Collaborating Ctr Prevent Blindness, Locked Bag 8, Melbourne, Vic 8002, Australia.	heathcote27@hotmail.com		Taylor, Hugh/0000-0002-9437-784X				Abu el-Asrar A M, 2001, Bull Soc Belge Ophtalmol, P73; Abu El-Asrar AM, 2006, EYE, V20, P362, DOI 10.1038/sj.eye.6701884; Abu El-Asrar AM, 1998, EYE, V12, P453, DOI 10.1038/eye.1998.104; ABUELASRAR AM, 1989, BRIT J OPHTHALMOL, V73, P276, DOI 10.1136/bjo.73.4.276; al Arab GE, 2001, BRIT J OPHTHALMOL, V85, P1406, DOI 10.1136/bjo.85.12.1406; Alemayehu W, 2004, OPHTHALMOLOGY, V111, P578, DOI 10.1016/j.ophtha.2003.06.030; ALRAJHI AA, 1993, OPHTHALMOLOGY, V100, P1293; [Anonymous], 2001, WHOPBDGET008; Bailey R, 1999, EPIDEMIOL INFECT, V123, P479, DOI 10.1017/S0950268899003076; BAILEY RL, 1994, J INFECT DIS, V170, P709, DOI 10.1093/infdis/170.3.709; BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9; Baltussen RMRM, 2005, OPHTHAL EPIDEMIOL, V12, P91, DOI 10.1080/09286580590932761; Baral K, 1999, B WORLD HEALTH ORGAN, V77, P461; Beatty Wandy L., 1994, Trends in Microbiology, V2, P94, DOI 10.1016/0966-842X(94)90542-8; BEATTY WL, 1994, INFECT IMMUN, V62, P3705, DOI 10.1128/IAI.62.9.3705-3711.1994; BEATTY WL, 1993, P NATL ACAD SCI USA, V90, P3998, DOI 10.1073/pnas.90.9.3998; BOG H, 1993, BRIT J OPHTHALMOL, V77, P81, DOI 10.1136/bjo.77.2.81; Bowman RJC, 2000, TROP MED INT HEALTH, V5, P528, DOI 10.1046/j.1365-3156.2000.00605.x; Bowman RJC, 2002, INVEST OPHTH VIS SCI, V43, P936; Bowman RJC, 2002, BRIT J OPHTHALMOL, V86, P339, DOI 10.1136/bjo.86.3.339; Bowman RJC, 2001, OPHTHALMOLOGY, V108, P2219, DOI 10.1016/S0161-6420(01)00645-5; Bowman RJC, 2000, EYE, V14, P864, DOI 10.1038/eye.2000.238; Bowman RJC, 2000, INVEST OPHTH VIS SCI, V41, P4074; Burton MJ, 2005, BRIT J OPHTHALMOL, V89, P1282, DOI 10.1136/bjo.2004.062489; Burton MJ, 2005, BRIT J OPHTHALMOL, V89, P575, DOI 10.1136/bjo.2004.055996; Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X; Burton MJ, 2004, INFECT IMMUN, V72, P7352, DOI 10.1128/IAI.72.12.7352-7356.2004; Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107; CHEN KJ, 1999, BR J OPHTHALMOL, V83, P1332; Chidambaram JD, 2006, JAMA-J AM MED ASSOC, V295, P1142, DOI 10.1001/jama.295.10.1142; Cohen CR, 2005, J INFECT DIS, V192, P591, DOI 10.1086/432070; COURTRIGHT P, 1994, E AFR MED J, V71, P803; Dawson CR, 1997, CLIN INFECT DIS, V24, P363, DOI 10.1093/clinids/24.3.363; Dawson CR, 1981, GUIDE TRACHOMA CONTR; Dhaliwal U, 2006, OPHTHAL EPIDEMIOL, V13, P59, DOI 10.1080/09286580500473803; el Toukhy E, 2006, OPHTHAL PLAST RECONS, V22, P109, DOI 10.1097/01.iop.0000203494.49446.60; Emerson PM, 2004, LANCET, V363, P1093, DOI 10.1016/S0140-6736(04)15891-1; Emerson PM, 2000, TROP MED INT HEALTH, V5, P515, DOI 10.1046/j.1365-3156.2000.00603.x; Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2; Faal N, 2005, CLIN EXP IMMUNOL, V142, P347, DOI 10.1111/j.1365-2249.2005.02917.x; Faal N, 2006, PLOS MED, V3, P1292, DOI 10.1371/journal.pmed.0030266; Frick K D, 2001, Ophthalmic Epidemiol, V8, P191, DOI 10.1076/opep.8.2.191.4163; Frick KD, 2001, ARCH OPHTHALMOL-CHIC, V119, P1839, DOI 10.1001/archopht.119.12.1839; Fry AM, 2002, CLIN INFECT DIS, V35, P395, DOI 10.1086/341414; Gaynor BD, 2005, BRIT J OPHTHALMOL, V89, P1097, DOI 10.1136/bjo.2005.068981; Guzey M, 1999, EUR J OPHTHALMOL, V9, P89, DOI 10.1177/112067219900900203; Guzey M, 2000, OPHTHALMOLOGICA, V214, P277, DOI 10.1159/000027504; Hessel T, 2001, INFECT IMMUN, V69, P4996, DOI 10.1128/IAI.69.8.4996-5000.2001; Holland MJ, 1996, CLIN EXP IMMUNOL, V105, P429, DOI 10.1046/j.1365-2249.1996.d01-792.x; Hsieh YH, 2000, AM J EPIDEMIOL, V152, P204, DOI 10.1093/aje/152.3.204; Hyde TB, 2001, JAMA-J AM MED ASSOC, V286, P1857, DOI 10.1001/jama.286.15.1857; Khandekar R, 2006, OPHTHAL EPIDEMIOL, V13, P43, DOI 10.1080/09286580500477507; Khandekar R, 2001, Ophthalmic Epidemiol, V8, P155, DOI 10.1076/opep.8.2.155.4165; Khandekar R, 2006, AM J OPHTHALMOL, V141, P1087, DOI 10.1016/j.ajo.2006.01.024; KNIRSCH C, 2002, CHLAMYDIAL INFECT, P485; LEACH AJ, 1997, CLIN INFECT DIS, V24, P248; Lietman T, 1999, NAT MED, V5, P572, DOI 10.1038/8451; Lietman TM, 2000, MED J AUSTRALIA, V172, P93, DOI 10.5694/j.1326-5377.2000.tb139214.x; Mabey D, 2003, AM J TROP MED HYG, V69, P11, DOI 10.4269/ajtmh.2003.69.11; MABEY D, 2005, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/1451858.CD001860.PUB2; Merbs SL, 2005, OPHTHALMOLOGY, V112, P705, DOI 10.1016/j.ophtha.2004.10.037; Michel CEC, 2006, LANCET, V367, P1585, DOI 10.1016/S0140-6736(06)68695-9; Miller K, 2004, OPHTHAL EPIDEMIOL, V11, P255, DOI 10.1080/09286580490514577; Miller K, 2004, BRIT J OPHTHALMOL, V88, P750, DOI 10.1136/bjo.2003.038661; MONNICKENDAM MA, 1980, BRIT J OPHTHALMOL, V64, P284, DOI 10.1136/bjo.64.4.284; MORRISON RP, 1989, J EXP MED, V169, P663, DOI 10.1084/jem.169.3.663; Munoz B, 1999, INT J EPIDEMIOL, V28, P1167, DOI 10.1093/ije/28.6.1167; Myatt M, 2003, B WORLD HEALTH ORGAN, V81, P877; Nagpal G, 2006, OPHTHAL EPIDEMIOL, V13, P53, DOI 10.1080/09286580500428518; Natividad A, 2005, GENES IMMUN, V6, P332, DOI 10.1038/sj.gene.6364182; Natividad A, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-40; Ngondi J, 2006, LANCET, V368, P589, DOI 10.1016/S0140-6736(06)69202-7; Oliva MS, 1997, INT OPHTHALMOL, V21, P235, DOI 10.1023/A:1006045824191; Peeling RW, 1998, J INFECT DIS, V177, P256, DOI 10.1086/517367; Polack S, 2005, B WORLD HEALTH ORGAN, V83, P913; Pruss A, 2000, B WORLD HEALTH ORGAN, V78, P258; RABIU M, 2000, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD004003.PUB3; Rabiu M M, 2001, Ophthalmic Epidemiol, V8, P181, DOI 10.1076/opep.8.2.181.4167; RAPOZA PA, 1991, INVEST OPHTH VIS SCI, V32, P2919; REACHER MH, 1992, ARCH OPHTHALMOL-CHIC, V110, P667, DOI 10.1001/archopht.1992.01080170089030; REACHER MH, 1993, WHOPBL9329; Resnikoff S, 1995, Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique, V72, P89; Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844; Reveneau N, 2005, ANTIMICROB AGENTS CH, V49, P1787, DOI 10.1128/AAC.49.5.1787-1793.2005; Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5; Schemann JF, 2002, INT J EPIDEMIOL, V31, P194, DOI 10.1093/ije/31.1.194; Solomon AW, 2004, NEW ENGL J MED, V351, P1962, DOI 10.1056/NEJMoa040979; Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8; Steele LN, 2004, J IMMUNOL, V173, P6327, DOI 10.4049/jimmunol.173.10.6327; STEPHENS RS, 1982, J IMMUNOL, V128, P1083; Tabbara KF, 1996, OPHTHALMOLOGY, V103, P842; TANG F F, 1957, J Hyg Epidemiol Microbiol Immunol, V1, P109; TAYLOR HR, 1982, INVEST OPHTH VIS SCI, V23, P507; TAYLOR HR, 1987, J IMMUNOL, V138, P3023; TAYLOR HR, 1984, J CLIN MICROBIOL, V20, P391, DOI 10.1128/JCM.20.3.391-395.1984; TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1821, DOI 10.1001/archopht.1989.01070020903037; TAYLOR HR, 1992, AM J TROP MED HYG, V46, P552, DOI 10.4269/ajtmh.1992.46.552; Thanh TTK, 2004, BRIT J OPHTHALMOL, V88, P1114, DOI 10.1136/bjo.2003.039834; THYGESON P, 1962, AM J OPHTHALMOL, V53, P786, DOI 10.1016/0002-9394(62)93399-8; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115; TURNER VM, 1993, INT J EPIDEMIOL, V22, P341, DOI 10.1093/ije/22.2.341; West ES, 2006, BRIT J OPHTHALMOL, V90, P171, DOI 10.1136/bjo.2005.075390; West ES, 2005, INVEST OPHTH VIS SCI, V46, P447, DOI 10.1167/iovs.04-0600; WEST S, 1989, B WORLD HEALTH ORGAN, V67, P71; WEST S, 1994, INT OPHTHALMOL, V18, P105, DOI 10.1007/BF00919249; WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1; West S K, 2001, Ophthalmic Epidemiol, V8, P137, DOI 10.1076/opep.8.2.137.4158; West SK, 2006, LANCET, V368, P596, DOI 10.1016/S0140-6736(06)69203-9; West SK, 2006, ARCH OPHTHALMOL-CHIC, V124, P309, DOI 10.1001/archopht.124.3.309; West SK, 2005, LANCET, V366, P1296, DOI 10.1016/S0140-6736(05)67529-0; WEST SK, 1991, ARCH OPHTHALMOL-CHIC, V109, P855, DOI 10.1001/archopht.1991.01080060119038; West SK, 1996, AM J EPIDEMIOL, V143, P73, DOI 10.1093/oxfordjournals.aje.a008659; World Health Organization, 2003, 2 GLOB SCI M TRACH G; Wright HR, 2005, LANCET INFECT DIS, V5, P313, DOI 10.1016/S1473-3099(05)70116-X; Wright HR, 2005, BRIT J OPHTHALMOL, V89, P526, DOI 10.1136/bjo.2005.066183; YORSTON D, 2006, COCHRANE DATABASE SY, V3; Zhang H, 2006, BRIT J OPHTHALMOL, V90, P943, DOI 10.1136/bjo.2006.093104; Zhang H, 2004, ARCH OPHTHALMOL-CHIC, V122, P511, DOI 10.1001/archopht.122.4.511; [No title captured]	119	131	133	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 7	2008	371	9628					1945	1954		10.1016/S0140-6736(08)60836-3	http://dx.doi.org/10.1016/S0140-6736(08)60836-3			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310OI	18539226				2022-12-28	WOS:000256538500031
J	Raebiger, H; Lany, S; Zunger, A				Raebiger, Hannes; Lany, Stephan; Zunger, Alex			Charge self-regulation upon changing the oxidation state of transition metals in insulators	NATURE			English	Article							IMPURITIES; SYSTEM	Transition- metal atoms embedded in an ionic or semiconducting crystal can exist in various oxidation states that have distinct signatures in X- ray photoemission spectroscopy and 'ionic radii' which vary with the oxidation state of the atom. These oxidation states are often tacitly associated with a physical ionization of the transition- metal atoms(1,2) - that is, a literal transfer of charge to or from the atoms. Physical models have been founded on this charge- transfer paradigm(3-6), but first- principles quantum mechanical calculations show only negligible changes in the local transition-metal charge(7-12) as the oxidation state is altered. Here we explain this peculiar tendency of transition- metal atoms to maintain a constant local charge under external perturbations in terms of an inherent, homeostasis- like negative feedback. We show that signatures of oxidation states and multivalence - such as X- ray photoemission core- level shifts, ionic radii and variations in local magnetization - that have often been interpreted as literal charge transfer(3,4,13-16) are instead a consequence of the negative- feedback charge regulation.	[Raebiger, Hannes; Lany, Stephan; Zunger, Alex] Natl Renewable Energy Lab, Golden, CO 80401 USA	United States Department of Energy (DOE); National Renewable Energy Laboratory - USA	Raebiger, H (corresponding author), Natl Renewable Energy Lab, Golden, CO 80401 USA.	hannes_raebiger@nrel.gov; alex_zunger@nrel.gov	Zunger, Alex/A-6733-2013; Raebiger, Hannes/D-1881-2013	Raebiger, Hannes/0000-0003-3969-9165; Lany, Stephan/0000-0002-8127-8885; ZUNGER, ALEXANDER/0000-0001-5525-3003				Angst M, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.086403; CLERJAUD B, 1985, J PHYS C SOLID STATE, V18, P3615, DOI 10.1088/0022-3719/18/19/005; Cotton F. A., 1988, ADV INORGANIC CHEM; Goodenough JB, 2005, MOD PHYS LETT B, V19, P1057, DOI 10.1142/S0217984905009079; HALDANE FDM, 1976, PHYS REV B, V13, P2553, DOI 10.1103/PhysRevB.13.2553; Ikeda N, 2005, NATURE, V436, P1136, DOI 10.1038/nature04039; Jeng HT, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.156403; Karppinen M, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.092105; Koster G, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.085109; Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169; Kresse G, 1999, PHYS REV B, V59, P1758, DOI 10.1103/PhysRevB.59.1758; Leonov I, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.146404; Luo W, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.036402; Mahadevan P, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.177201; Mazin II, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.176406; Persson C, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.035211; SHANNON RD, 1969, ACTA CRYSTALL B-STRU, VB 25, P925, DOI 10.1107/S0567740869003220; Shim JH, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.057209; Solomon EI, 2005, COORDIN CHEM REV, V249, P97, DOI 10.1016/j.ccr.2004.03.020; Wells A.F., 1975, STRUCTURAL INORGANIC, V4th; Wolverton C, 1998, PHYS REV LETT, V81, P606, DOI 10.1103/PhysRevLett.81.606; ZUNGER A, 1983, SOLID STATE COMMUN, V45, P343, DOI 10.1016/0038-1098(83)90892-X; ZUNGER A, 1986, SOLID STATE PHYS, V39, P275, DOI [10.1016/S0081-1947(08)60371-9, DOI 10.1016/S0081-1947(08)60371-9]	23	206	208	10	127	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 5	2008	453	7196					763	766		10.1038/nature07009	http://dx.doi.org/10.1038/nature07009			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308UK	18528391				2022-12-28	WOS:000256415300039
J	Jost, TS; Emanuel, EJ				Jost, Timothy Stoltzfus; Emanuel, Ezekiel J.			Legal reforms necessary to promote delivery system innovation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MEDICAL-CARE; QUALITY		[Emanuel, Ezekiel J.] NIH, Dept Bioeth, Ctr Clin, Bethesda, MD 20892 USA; [Jost, Timothy Stoltzfus] Washington & Lee Univ, Sch Law, Lexington, VA 24450 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Washington & Lee University	Emanuel, EJ (corresponding author), NIH, Dept Bioeth, Ctr Clin, Bldg 10,Room 1C118, Bethesda, MD 20892 USA.	eemanuel@nih.gov						Bodenheimer T, 2008, NEW ENGL J MED, V358, P1064, DOI 10.1056/NEJMhpr0706165; CHASELUBITZ JF, 1987, VANDERBILT LAW REV, V40, P445; CHERRY DK, 2007, ADV DATA, V387, P1; Cimasi R.J, 2005, US HEALTHCARE CERTIF; EMANUEL EJ, 2008, HEALTHCARE GUARANTEE, pCH2; *FED TRAD COMM DEP, COMP HLTH CAR MARK S; Fisher ES, 1999, JAMA-J AM MED ASSOC, V281, P446, DOI 10.1001/jama.281.5.446; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Mehrotra A, 2006, ANN INTERN MED, V145, P826, DOI 10.7326/0003-4819-145-11-200612050-00007; Pham HH, 2007, NEW ENGL J MED, V356, P1130, DOI 10.1056/NEJMsa063979; Shorten SM, 2007, ACCOUNTABLE CARE SYS	11	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2008	299	21					2561	2563		10.1001/jama.299.21.2561	http://dx.doi.org/10.1001/jama.299.21.2561			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308AR	18523225				2022-12-28	WOS:000256361200029
J	Ochs, N; Auer, R; Bauer, DC; Nanchen, D; Gussekloo, J; Cornuz, J; Rodondi, N				Ochs, Nicolas; Auer, Reto; Bauer, Douglas C.; Nanchen, David; Gussekloo, Jacobijn; Cornuz, Jacques; Rodondi, Nicolas			Meta-analysis: Subclinical thyroid dysfunction and the risk for coronary heart disease and mortality	ANNALS OF INTERNAL MEDICINE			English	Review							ALL-CAUSE MORTALITY; CARDIOVASCULAR RISK; MYOCARDIAL-INFARCTION; FOLLOW-UP; TASK-FORCE; HYPOTHYROIDISM; ASSOCIATION; HEALTH; WOMEN; THYROTROPIN	Background: Data on the association between subclinical thyroid dysfunction and coronary heart disease (CHD) and mortality are conflicting. Purpose: To summarize prospective evidence about the relationship between subclinical thyroid dysfunction and CHD and mortality. Data Sources: MEDLINE (1950 to January 2008) without language restrictions and reference lists of retrieved articles were searched. Study Selection: Two reviewers screened and selected cohort studies that measured thyroid function and then followed persons prospectively to assess CHD or mortality. Data Extraction: By using a standardized protocol and forms, 2 reviewers independently abstracted and assessed studies. Data Synthesis: Ten of 12 identified studies involved population-based cohorts that included 14 449 participants. All 10 population-based cohort studies examined risks associated with subclinical hypothyroidism (2134 CHD events and 2822 deaths), whereas only 5 examined risks associated with subclinical hyperthyroidism (1392 CHD events and 1993 deaths). In a random-effects model, the relative risk (RR) for subclinical hypothyroidism for CHD was 1.20 (95% CI, 0.97 to 1.49; P for heterogeneity = 0.14; l(2) = 33.4%). Risk estimates were lower when higher-quality studies were pooled (RR, 1.02 to 1.08) and were higher among participants younger than 65 years (RR, 1.51 [CI, 1.09 to 2.09] for studies with mean participant age <65 years and 1.05 [CI, 0.90 to 1.22] for studies with mean participant age >= 65 years). The RR was 1.18 (CI, 0.98 to 1.42) for cardiovascular mortality and 1.12 (CI, 0.99 to 1.26) for total mortality. For subclinical hyperthyroidism, the RR was 1.21 (CI, 0.88 to 1.68) for CHD, 1.19 (CI, 0.81 to 1.76) for cardiovascular mortality, and 1.12 (CI, 0.89 to 1.42) for total mortality (P for heterogeneity >0.50; l(2) = 0% for all studies). Limitations: Individual studies adjusted for different potential con-founders, and 1 study provided only unadjusted data. Publication bias or selective reporting of outcomes could not be excluded. Conclusion: Subclinical hypothyroidism and hyperthyroidism may be associated with a modest increased risk for CHD and mortality, with lower risk estimates when pooling higher-quality studies and larger CIs for subclinical hyperthyroidism.	Univ Lausanne, Dept Ambulatory Care & Commun Med, CH-1011 Lausanne, Switzerland; Univ Calif San Francisco, San Francisco, CA 94143 USA; Leiden Univ, Med Ctr, Leiden, Netherlands	University of Lausanne; University of California System; University of California San Francisco; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Rodondi, N (corresponding author), Univ Lausanne, Dept Ambulatory Care & Commun Med, Bugnon 44, CH-1011 Lausanne, Switzerland.	nicolas.rodondi@hospvd.ch	Nanchen, David/D-2432-2009; Gussekloo, Jacobijn/ABE-3879-2021; Nanchen, David/AAQ-1118-2021	Gussekloo, Jacobijn/0000-0001-7186-8278; Nanchen, David/0000-0002-2493-3505; Auer, Reto/0000-0003-4222-4849; Rodondi, Nicolas/0000-0001-9083-6896				AHO K, 1984, EUR HEART J, V5, P43, DOI 10.1093/oxfordjournals.eurheartj.a061550; Alevizaki M, 2007, EUR J CLIN INVEST, V37, P651, DOI 10.1111/j.1365-2362.2007.01839.x; ALTHAUS BU, 1988, CLIN ENDOCRINOL, V28, P157, DOI 10.1111/j.1365-2265.1988.tb03651.x; Altman DG, 2001, BMJ-BRIT MED J, V323, P224, DOI 10.1136/bmj.323.7306.224; BASTENIE PA, 1982, ACTA CARDIOL, V37, P365; Bauer DC, 2007, AM J MED, V120, P343, DOI 10.1016/j.amjmed.2006.04.034; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bell RJ, 2007, CLIN ENDOCRINOL, V66, P548, DOI 10.1111/j.1365-2265.2007.02771.x; BERLIN JA, 1995, AM J EPIDEMIOL, V142, P383, DOI 10.1093/oxfordjournals.aje.a117645; Bossoni S, 2002, J Endocrinol Invest, V25, P64; Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526; Cappola AR, 2006, JAMA-J AM MED ASSOC, V295, P1033, DOI 10.1001/jama.295.9.1033; Carrero JJ, 2007, J INTERN MED, V262, P690, DOI 10.1111/j.1365-2796.2007.01865.x; Cooper DS, 2004, JAMA-J AM MED ASSOC, V292, P2651, DOI 10.1001/jama.292.21.2651; Cooper DS, 2001, NEW ENGL J MED, V345, P260, DOI 10.1056/NEJM200107263450406; DAVIS PJ, 1974, MEDICINE, V53, P161, DOI 10.1097/00005792-197405000-00001; DEMERS LM, 2002, LAB SUPPORT DIAGNOSI; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Egger M, 2001, SYSTEMATIC REV HLTH; Enia G, 2007, NEPHROL DIAL TRANSPL, V22, P538, DOI 10.1093/ndt/gfl605; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; Flynn RWV, 2006, J CLIN ENDOCR METAB, V91, P2159, DOI 10.1210/jc.2005-1833; Friberg L, 2001, AM J MED, V111, P699, DOI 10.1016/S0002-9343(01)00980-9; GOLDMAN MB, 1990, CANCER RES, V50, P2283; Gorham ED, 2007, AM J PREV MED, V32, P210, DOI 10.1016/j.amepre.2006.11.004; Gussekloo J, 2004, JAMA-J AM MED ASSOC, V292, P2591, DOI 10.1001/jama.292.21.2591; Hak AE, 2000, ANN INTERN MED, V132, P270, DOI 10.7326/0003-4819-132-4-200002150-00004; HAUGEN B, 12 ANN M AM ASS CLIN; Helfand M, 2004, ANN INTERN MED, V140, P128, DOI 10.7326/0003-4819-140-2-200401200-00015; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hollowell JG, 2002, J CLIN ENDOCR METAB, V87, P489, DOI 10.1210/jc.87.2.489; Hulley SB., 2001, DESIGNING CLIN RES; Hunt JR, 1998, EPIDEMIOL REV, V20, P57, DOI 10.1093/oxfordjournals.epirev.a017972; Iervasi G, 2007, ARCH INTERN MED, V167, P1526, DOI 10.1001/archinte.167.14.1526; Imaizumi M, 2004, J CLIN ENDOCR METAB, V89, P3365, DOI 10.1210/jc.2003-031089; Kaji H, 2007, ENDOCR J, V54, P239, DOI 10.1507/endocrj.K06-129; Kanaya AM, 2002, ARCH INTERN MED, V162, P773, DOI 10.1001/archinte.162.7.773; KAPTEIN EM, 1982, CLIN ENDOCRINOL, V16, P565, DOI 10.1111/j.1365-2265.1982.tb03173.x; KENT S, 1979, GERIATRICS, V34, P97; Kvetny J, 2004, CLIN ENDOCRINOL, V61, P232, DOI 10.1111/j.1365-2265.2004.02088.x; Ladenson PW, 2000, ARCH INTERN MED, V160, P1573, DOI 10.1001/archinte.160.11.1573; LEE S, 12 ANN M AM ASS CLIN; Monzani F, 2004, J CLIN ENDOCR METAB, V89, P2099, DOI 10.1210/jc.2003-031669; Nyirenda MJ, 2005, THYROID, V15, P718, DOI 10.1089/thy.2005.15.718; Osman F, 2007, J AM COLL CARDIOL, V49, P71, DOI 10.1016/j.jacc.2006.08.042; Parle JV, 2001, LANCET, V358, P861, DOI 10.1016/S0140-6736(01)06067-6; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; Peters A, 2000, ARCH INTERN MED, V160, P1993, DOI 10.1001/archinte.160.13.1993; Petitti DB, 2001, STAT MED, V20, P3625, DOI 10.1002/sim.1091; Popovici D, 1980, Endocrinologie, V18, P293; Psaty BM, 2004, J AM GERIATR SOC, V52, P1639, DOI 10.1111/j.1532-5415.2004.52455.x; Radacsi A, 2003, ENDOCRINE, V21, P133, DOI 10.1385/ENDO:21:2:133; Rodondi N, 2005, ARCH INTERN MED, V165, P2460, DOI 10.1001/archinte.165.21.2460; RODONDI N, 2007, INT J CARDIOL; Rodondi N, 2006, AM J MED, V119, P541, DOI 10.1016/j.amjmed.2005.09.028; Ross DS, 2001, ENDOCRIN METAB CLIN, V30, P245, DOI 10.1016/S0889-8529(05)70186-9; SAWIN CT, 1985, ARCH INTERN MED, V145, P1386, DOI 10.1001/archinte.145.8.1386; Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0; Singer Richard B, 2006, J Insur Med, V38, P14; Singh S, 2008, INT J CARDIOL, V125, P41, DOI 10.1016/j.ijcard.2007.02.027; Smith SC, 2001, J AM COLL CARDIOL, V37, P2215, DOI 10.1016/S0735-1097(01)01344-4; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Surks MI, 2004, JAMA-J AM MED ASSOC, V291, P228, DOI 10.1001/jama.291.2.228; Tobias A., 1999, STATA TECHNICAL B, V8, P15; van den Beld AW, 2005, J CLIN ENDOCR METAB, V90, P6403, DOI 10.1210/jc.2005-0872; Vanderpump MPJ, 1996, THYROID, V6, P155; Villar HCCE, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003419.pub2; Volzke H, 2007, J CLIN ENDOCR METAB, V92, P2421, DOI 10.1210/jc.2007-0179; Walsh JP, 2005, ARCH INTERN MED, V165, P2467, DOI 10.1001/archinte.165.21.2467; Waterhouse DF, 2007, THYROID, V17, P243, DOI 10.1089/thy.2006.0208; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; 2007, BRIT MED J	73	343	361	0	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2008	148	11					832	U53		10.7326/0003-4819-148-11-200806030-00225	http://dx.doi.org/10.7326/0003-4819-148-11-200806030-00225			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308CG	18490668	Green Published			2022-12-28	WOS:000256365300005
J	McCartney, M				McCartney, Margaret			Leaping to conclusions	BRITISH MEDICAL JOURNAL			English	Editorial Material												Margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Angus DC, 2003, JAMA-J AM MED ASSOC, V290, P256, DOI 10.1001/jama.290.2.256; Montori VM, 2005, JAMA-J AM MED ASSOC, V294, P2203, DOI 10.1001/jama.294.17.2203; TROTTA F, 2008, ANN ONCOL       0409	3	7	7	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 31	2008	336	7655					1213	1214		10.1136/bmj.39589.396840.94	http://dx.doi.org/10.1136/bmj.39589.396840.94			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311PS	18511794	Green Published			2022-12-28	WOS:000256612700024
J	Shi, HF; Bencze, KZ; Stemmler, TL; Philpott, CC				Shi, Haifeng; Bencze, Krisztina Z.; Stemmler, Timothy L.; Philpott, Caroline C.			A cytosolic iron chaperone that delivers iron to ferritin	SCIENCE			English	Article							COPPER CHAPERONE; PROTEIN; BINDING; MECHANISMS; FRATAXIN; DISEASE	Ferritins are the main iron storage proteins found in animals, plants, and bacteria. The capacity to store iron in ferritin is essential for life in mammals, but the mechanism by which cytosolic iron is delivered to ferritin is unknown. Human ferritins expressed in yeast contain little iron. Human poly (rC)- binding protein 1 ( PCBP1) increased the amount of iron loaded into ferritin when expressed in yeast. PCBP1 bound to ferritin in vivo and bound iron and facilitated iron loading into ferritin in vitro. Depletion of PCBP1 in human cells inhibited ferritin iron loading and increased cytosolic iron pools. Thus, PCBP1 can function as a cytosolic iron chaperone in the delivery of iron to ferritin.	[Shi, Haifeng; Philpott, Caroline C.] NIDDKD, Liver Dis Branch, NIH, Bethesda, MD 20892 USA; [Bencze, Krisztina Z.; Stemmler, Timothy L.] Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Wayne State University	Philpott, CC (corresponding author), NIDDKD, Liver Dis Branch, NIH, Bethesda, MD 20892 USA.	carolinep@intra.niddk.nih.gov	Shi, Haifeng/AAT-4640-2020	Shi, Haifeng/0000-0001-9050-2140; Stemmler, Timothy/0000-0002-6298-088X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK054510, R01DK068139] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 DK054510-03] Funding Source: Medline; NIDDK NIH HHS [R01 DK068139, R01 DK068139-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banci L, 2006, NAT CHEM BIOL, V2, P367, DOI 10.1038/nchembio797; Bou-Abdallah F, 2002, BIOCHEMISTRY-US, V41, P11184, DOI 10.1021/bi020215g; Bourdon E, 2003, BLOOD CELL MOL DIS, V31, P247, DOI 10.1016/S1079-9796(03)00161-X; Bulteau AL, 2004, SCIENCE, V305, P242, DOI 10.1126/science.1098991; Cook JD, 2006, BIOCHEMISTRY-US, V45, P7767, DOI 10.1021/bi060424r; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; Epsztejn S, 1997, ANAL BIOCHEM, V248, P31, DOI 10.1006/abio.1997.2126; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Kuchar J, 2004, CHEM REV, V104, P509, DOI 10.1021/cr020613p; Makeyev AV, 2002, RNA, V8, P265, DOI 10.1017/S1355838202024627; Missirlis F, 2007, GENETICS, V177, P89, DOI 10.1534/genetics.107.075150; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Pandolfo M, 2006, J NEURAL TRANSM-SUPP, P143; Philpott CC, 2008, EUKARYOT CELL, V7, P20, DOI 10.1128/EC.00354-07; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rouault TA, 2006, NAT CHEM BIOL, V2, P406, DOI 10.1038/nchembio807; Theil EC, 2006, J BIOL INORG CHEM, V11, P803, DOI 10.1007/s00775-006-0125-6; Wernimont AK, 2004, J BIOL CHEM, V279, P12269, DOI 10.1074/jbc.M311213200	19	343	358	3	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2008	320	5880					1207	1210		10.1126/science.1157643	http://dx.doi.org/10.1126/science.1157643			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306FF	18511687	Green Accepted, Green Submitted			2022-12-28	WOS:000256233000036
J	Song, C; Wang, P; Makse, HA				Song, Chaoming; Wang, Ping; Makse, Hernan A.			A phase diagram for jammed matter	NATURE			English	Article							RANDOM CLOSE PACKING; SPHERES; DENSITY	The problem of finding the most efficient way to pack spheres has a long history, dating back to the crystalline arrays conjectured(1) by Kepler and the random geometries explored(2) by Bernal. Apart from its mathematical interest, the problem has practical relevance(3) in a wide range of fields, from granular processing to fruit packing. There are currently numerous experiments showing that the loosest way to pack spheres ( random loose packing) gives a density of similar to 55 per cent(4-6). On the other hand, the most compact way to pack spheres ( random close packing) results in a maximum density of similar to 64 per cent(2,4,6). Although these values seem to be robust, there is as yet no physical interpretation for them. Here we present a statistical description of jammed states(7) in which random close packing can be interpreted as the ground state of the ensemble of jammed matter. Our approach demonstrates that random packings of hard spheres in three dimensions cannot exceed a density limit of similar to 63.4 per cent. We construct a phase diagram that provides a unified view of the hard- sphere packing problem and illuminates various data, including the random-loose-packed state.	[Song, Chaoming; Wang, Ping; Makse, Hernan A.] CUNY City Coll, Levich Inst, New York, NY 10031 USA; [Song, Chaoming; Wang, Ping; Makse, Hernan A.] CUNY City Coll, Dept Phys, New York, NY 10031 USA; [Makse, Hernan A.] Univ Fed Ceara, Dept Fis, BR-60451970 Fortaleza, Ceara, Brazil	City University of New York (CUNY) System; City College of New York (CUNY); City University of New York (CUNY) System; City College of New York (CUNY); Universidade Federal do Ceara	Makse, HA (corresponding author), CUNY City Coll, Levich Inst, New York, NY 10031 USA.	hmakse@lev.ccny.cuny.edu	Wang, Ping/A-2692-2011					Alexander S, 1998, PHYS REP, V296, P65, DOI 10.1016/S0370-1573(97)00069-0; Aste T, 2006, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2006/07/P07010; Ball RC, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.115505; BEHRINGER RP, 1997, POWDERS GRAINS 97; BERNAL JD, 1960, NATURE, V188, P910, DOI 10.1038/188910a0; BERRYMAN JG, 1983, PHYS REV A, V27, P1053, DOI 10.1103/PhysRevA.27.1053; Bertin E, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.120601; Brujic J, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.128001; Brujic J, 2003, PHYSICA A, V327, P201, DOI 10.1016/S0378-4371(03)00477-1; Ciamarra MP, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.158001; DACRUZ F, 2005, POWDERS GRAINS 2005; EDWARDS SF, 1989, PHYSICA A, V157, P1080, DOI 10.1016/0378-4371(89)90034-4; Edwards SF, 1999, PHYS REV LETT, V82, P5397, DOI 10.1103/PhysRevLett.82.5397; Fierro A, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.061305; HALES TC, 2002, KEPLER CONJECTURE; Makse HA, 2000, PHYS REV LETT, V84, P4160, DOI 10.1103/PhysRevLett.84.4160; Nowak ER, 1998, PHYS REV E, V57, P1971, DOI 10.1103/PhysRevE.57.1971; O'Hern CS, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.075507; ONODA GY, 1990, PHYS REV LETT, V64, P2727, DOI 10.1103/PhysRevLett.64.2727; Parisi G, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2041507; Schroter M, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.030301; SCOTT GD, 1969, J PHYS D APPL PHYS, V2, P863, DOI 10.1088/0022-3727/2/6/311; Silbert LE, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.031304; STILLINGER FH, 1995, SCIENCE, V267, P1935, DOI 10.1126/science.267.5206.1935; Torquato S, 2000, PHYS REV LETT, V84, P2064, DOI 10.1103/PhysRevLett.84.2064; Torquato S, 2001, J PHYS CHEM B, V105, P11849, DOI 10.1021/jp011960q; Zhang HP, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.011301	28	666	678	9	205	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	2008	453	7195					629	632		10.1038/nature06981	http://dx.doi.org/10.1038/nature06981			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305NN	18509438				2022-12-28	WOS:000256185200038
J	Retnakaran, R; Drucker, DJ				Retnakaran, Ravi; Drucker, Daniel J.			Intensive insulin therapy in newly diagnosed type 2 diabetes	LANCET			English	Editorial Material							TERM GLYCEMIC CONTROL; INDUCTION; SULFONYLUREA		[Drucker, Daniel J.] Univ Toronto, Banting & Best Diabet Ctr, Toronto, ON M5G 1X5, Canada; [Retnakaran, Ravi; Drucker, Daniel J.] Univ Toronto, Div Endocrinol, Toronto, ON M5G 1X5, Canada; [Retnakaran, Ravi] Mt Sinai Hosp, Leadership Sinai Ctr Diabet, Toronto, ON M5G 1X5, Canada; [Drucker, Daniel J.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Drucker, DJ (corresponding author), Univ Toronto, Banting & Best Diabet Ctr, Toronto, ON M5G 1X5, Canada.	d.drucker@utoronto.ca	Retnakaran, Ravi/P-2002-2015; Drucker, Daniel J/A-4092-2010	Retnakaran, Ravi/0000-0003-1989-027X; 				BRUNZELL JD, 1976, J CLIN ENDOCR METAB, V42, P222, DOI 10.1210/jcem-42-2-222; Ilkova H, 1997, DIABETES CARE, V20, P1353, DOI 10.2337/diacare.20.9.1353; Kahn SE, 2003, DIABETOLOGIA, V46, P3, DOI 10.1007/s00125-002-1009-0; Li YB, 2004, DIABETES CARE, V27, P2597, DOI 10.2337/diacare.27.11.2597; Matthews DR, 1998, DIABETIC MED, V15, P297, DOI 10.1002/(SICI)1096-9136(199804)15:4<297::AID-DIA572>3.3.CO;2-N; Park S, 2003, DIABETES-METAB RES, V19, P124, DOI 10.1002/dmrr.343; Ryan EA, 2004, DIABETES CARE, V27, P1028, DOI 10.2337/diacare.27.5.1028; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; TURNER RC, 1995, DIABETES, V44, P1249; Weng JP, 2008, LANCET, V371, P1753, DOI 10.1016/S0140-6736(08)60762-X	10	37	41	1	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 24	2008	371	9626					1725	1726		10.1016/S0140-6736(08)60736-9	http://dx.doi.org/10.1016/S0140-6736(08)60736-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304IO	18502278				2022-12-28	WOS:000256103400004
J	Eisenbarth, SC; Colegio, OR; O'Connor, W; Sutterwala, FS; Flavell, RA				Eisenbarth, Stephanie C.; Colegio, Oscar R.; O'Connor, William, Jr.; Sutterwala, Fayyaz S.; Flavell, Richard A.			Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants	NATURE			English	Article							IMMUNE-RESPONSE; DYING CELLS; T-CELLS; INDUCTION; ANTIGEN; ACTIVATION; RECOGNITION; CASPASE-1; HYDROXIDE; RECEPTOR	Aluminium adjuvants, typically referred to as 'alum', are the most commonly used adjuvants in human and animal vaccines worldwide, yet the mechanism underlying the stimulation of the immune system by alum remains unknown. Toll-like receptors are critical in sensing infections and are therefore common targets of various adjuvants used in immunological studies. Although alum is known to induce the production of proinflammatory cytokines in vitro, it has been repeatedly demonstrated that alum does not require intact Toll-like receptor signalling to activate the immune system(1,2). Here we show that aluminium adjuvants activate an intracellular innate immune response system called the Nalp3 (also known as cryopyrin, CIAS1 or NLRP3) inflammasome. Production of the pro-inflammatory cytokines interleukin-1 beta and interleukin-18 by macrophages in response to alum in vitro required intact inflammasome signalling. Furthermore, in vivo, mice deficient in Nalp3, ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain) or caspase-1 failed to mount a significant antibody response to an antigen administered with aluminium adjuvants, whereas the response to complete Freund's adjuvant remained intact. We identify the Nalp3 inflammasome as a crucial element in the adjuvant effect of aluminium adjuvants; in addition, we show that the innate inflammasome pathway can direct a humoral adaptive immune response. This is likely to affect how we design effective, but safe, adjuvants in the future.	[Eisenbarth, Stephanie C.; Colegio, Oscar R.; O'Connor, William, Jr.; Sutterwala, Fayyaz S.; Flavell, Richard A.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; [Eisenbarth, Stephanie C.] Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06520 USA; [Colegio, Oscar R.] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA; [Flavell, Richard A.] Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; [Sutterwala, Fayyaz S.] Univ Iowa, Dept Med, Inflammat Program, Iowa City, IA 52241 USA	Yale University; Yale University; Yale University; Howard Hughes Medical Institute; Yale University; University of Iowa	Flavell, RA (corresponding author), Yale Univ, Sch Med, Dept Immunobiol, 333 Cedar St, New Haven, CT 06520 USA.	richard.flavell@yale.edu	Cassel, Suzanne/AAI-3947-2021; Sutterwala, Fayyaz/AAH-5859-2021; Ibrahim, Essam Hassan/G-1960-2018; Eckhardt, Erik/G-1567-2010	Cassel, Suzanne/0000-0003-2492-1923; Ibrahim, Essam Hassan/0000-0003-0130-2257; Colegio, Oscar/0000-0002-6519-3718; Colegio, Oscar/0000-0002-9524-6235; Eisenbarth, Stephanie/0000-0002-1244-208X	Howard Hughes Medical Institute Funding Source: Medline; NHLBI NIH HHS [T32 HL007974] Funding Source: Medline; NIAID NIH HHS [K08 AI065517] Funding Source: Medline; NIAMS NIH HHS [T32 AR007016] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI065517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007016] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Chang MF, 2001, VACCINE, V19, P2884, DOI 10.1016/S0264-410X(00)00559-4; Chen CJ, 2007, NAT MED, V13, P851, DOI 10.1038/nm1603; Davis CN, 2006, P NATL ACAD SCI USA, V103, P2953, DOI 10.1073/pnas.0510802103; DUNNE A, 2003, SCI STKE, pRE3, DOI DOI 10.1126/STKE.2003.171.RE3; Gavin AL, 2006, SCIENCE, V314, P1936, DOI 10.1126/science.1135299; Jordan MB, 2004, SCIENCE, V304, P1808, DOI 10.1126/science.1089926; KAYE J, 1984, J IMMUNOL, V133, P1339; Li HF, 2007, J IMMUNOL, V178, P5271, DOI 10.4049/jimmunol.178.8.5271; Lindblad EB, 2004, IMMUNOL CELL BIOL, V82, P497, DOI 10.1111/j.0818-9641.2004.01286.x; MANNHALTER JW, 1985, CLIN EXP IMMUNOL, V61, P143; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Mariathasan S, 2007, NAT REV IMMUNOL, V7, P31, DOI 10.1038/nri1997; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Nakae S, 2001, J IMMUNOL, V167, P90, DOI 10.4049/jimmunol.167.1.90; Pelegrin P, 2007, J BIOL CHEM, V282, P2386, DOI 10.1074/jbc.M610351200; Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Rimaniol AC, 2004, VACCINE, V22, P3127, DOI 10.1016/j.vaccine.2004.01.061; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Sokolovska A, 2007, VACCINE, V25, P4575, DOI 10.1016/j.vaccine.2007.03.045; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Sutterwala FS, 2007, J EXP MED, V204, P3235, DOI 10.1084/jem.20071239; Sutterwala FS, 2007, J LEUKOCYTE BIOL, V82, P259, DOI 10.1189/jlb.1206755; Sutterwala FS, 2006, IMMUNITY, V24, P317, DOI 10.1016/j.immuni.2006.02.004; Toda Y, 2002, J IMMUNOL, V168, P1984, DOI 10.4049/jimmunol.168.4.1984; Yoshimoto T, 2000, NAT IMMUNOL, V1, P132, DOI 10.1038/77811	30	1102	1157	4	157	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 19	2008	453	7198					1122	U13		10.1038/nature06939	http://dx.doi.org/10.1038/nature06939			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WM	18496530	Green Accepted			2022-12-28	WOS:000256839900061
J	Coggon, J; Brazier, M; Murphy, P; Price, D; Quigley, M				Coggon, John; Brazier, Margaret; Murphy, Paul; Price, David; Quigley, Muireann			Best interests and potential organ donors	BRITISH MEDICAL JOURNAL			English	Editorial Material							DONATION		[Coggon, John; Brazier, Margaret; Quigley, Muireann] Univ Manchester, Sch Law, Ctr Social Eth & Policy, Manchester M13 9PL, Lancs, England; [Coggon, John; Brazier, Margaret; Quigley, Muireann] Univ Manchester, Sch Law, Inst Sci Eth & Innovat, Manchester M13 9PL, Lancs, England; [Murphy, Paul] Gen Infirm, Leeds LS1 3EX, W Yorkshire, England; [Price, David] De Montfort Univ, Sch Law, Leicester LE1 9BH, Leics, England	University of Manchester; University of Manchester; Leeds General Infirmary; De Montfort University	Coggon, J (corresponding author), Univ Manchester, Sch Law, Ctr Social Eth & Policy, Manchester M13 9PL, Lancs, England.	John.Coggon@manchester.ac.uk		Coggon, John/0000-0002-6420-8420	ESRC [RES-451-25-4341] Funding Source: UKRI; Economic and Social Research Council [RES-451-25-4341] Funding Source: researchfish	ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))		Bell MDD, 2006, EMERG MED J, V23, P824, DOI 10.1136/emj.2006.036749; Bell MDD, 2005, BRIT J ANAESTH, V94, P474, DOI 10.1093/bja/aei048; *DEP CONST AFF, 2007, MENT CAP ACT COD PRA; Department of Health The Hong Kong SAR Government, ORG DON; Gardiner D, 2007, ANAESTHESIA, V62, P431, DOI 10.1111/j.1365-2044.2007.05093.x; General Medical Council, 2006, WITHH WITHDR LIF PRO; *I MED, 2000, NONH BEAT ORG TRANSP, P140; Intensive Care Society, 2004, GUID AD ORG TISS DON, P44; Organ Donation Taskforce, 2008, ORG TRANSPL	9	17	17	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 14	2008	336	7657					1346	1347		10.1136/bmj.39575.561898.94	http://dx.doi.org/10.1136/bmj.39575.561898.94			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316YB	18556316	Green Published, Green Submitted			2022-12-28	WOS:000256984700038
J	Miles, L; Kapos, V				Miles, Lera; Kapos, Valerie			Reducing greenhouse gas emissions from deforestation and forest degradation: Global land-use implications	SCIENCE			English	Editorial Material							TROPICAL FORESTS; PROTECTED AREAS; CONSERVATION	Recent climate talks in Bali have made progress toward action on deforestation and forest degradation in developing countries, within the anticipated post-Kyoto emissions reduction agreements. As a result of such action, many forests will be better protected, but some land-use change will be displaced to other locations. The demonstration phase launched at Bali offers an opportunity to examine potential outcomes for biodiversity and ecosystem services. Research will be needed into selection of priority areas for reducing emissions from deforestation and forest degradation to deliver multiple benefits, on-the-ground methods to best ensure these benefits, and minimization of displaced land-use change into nontarget countries and ecosystems, including through revised conservation investments.	[Miles, Lera; Kapos, Valerie] WCMC, UNEP, Cambridge CB3 0DL, England; [Kapos, Valerie] Univ Cambridge, Dept Zool, Conservat Sci Grp, Cambridge CB2 3EJ, England	University of Cambridge	Miles, L (corresponding author), WCMC, UNEP, 219 Huntingdon Rd, Cambridge CB3 0DL, England.	lera.miles@unep-wcmc.org; val.kapos@unep-wcmc.org	Kapos, Valerie/G-3136-2010; Miles, Lera/C-7334-2009	Kapos, Valerie/0000-0002-5739-8262; Miles, Lera/0000-0003-0377-5904				Aukland L, 2003, CLIM POLICY, V3, P123; DeFries R, 2005, ECOL APPL, V15, P19, DOI 10.1890/03-5258; Dutschke M., 2007, REDUCING EMISSIONS D; Ebeling J, 2008, PHILOS T R SOC B, V363, P1917, DOI 10.1098/rstb.2007.0029; *FAO, FAOSTAT PROD FORESTA; Gullison RE, 2007, SCIENCE, V316, P985, DOI 10.1126/science.1136163; James A, 2001, BIOSCIENCE, V51, P43, DOI 10.1641/0006-3568(2001)051[0043:CWATCB]2.0.CO;2; Laurance WF, 2007, BIOTROPICA, V39, P20, DOI 10.1111/j.1744-7429.2006.00229.x; Mollicone D, 2007, CLIMATIC CHANGE, V83, P477, DOI 10.1007/s10584-006-9231-2; Naughton-Treves L, 2005, ANNU REV ENV RESOUR, V30, P219, DOI 10.1146/annurev.energy.30.050504.164507; Niles JO, 2002, PHILOS T ROY SOC A, V360, P1621, DOI 10.1098/rsta.2002.1023; Page SE, 2002, NATURE, V420, P61, DOI 10.1038/nature01131; Ramankutty N, 2007, GLOBAL CHANGE BIOL, V13, P51, DOI 10.1111/j.1365-2486.2006.01272.x; Santilli M, 2005, CLIMATIC CHANGE, V71, P267, DOI 10.1007/s10584-005-8074-6; Wagner F., 2003, IPCC GOOD PRACTICE G; Wilson KA, 2006, NATURE, V440, P337, DOI 10.1038/nature04366; *WORLD BANK, 2002, BIOD CONS FOR EC WOR	17	305	324	8	152	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2008	320	5882					1454	1455		10.1126/science.1155358	http://dx.doi.org/10.1126/science.1155358			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556549				2022-12-28	WOS:000256676400032
J	Tsuda, H; Han, SM; Yang, YF; Tong, C; Lin, YQ; Mohan, K; Haueter, C; Zoghbi, A; Harati, Y; Kwan, J; Miller, MA; Bellen, HJ				Tsuda, Hiroshi; Han, Sung Min; Yang, Youfeng; Tong, Chao; Lin, Yong Qi; Mohan, Kriti; Haueter, Claire; Zoghbi, Anthony; Harati, Yadollah; Kwan, Justin; Miller, Michael A.; Bellen, Hugo J.			The Amyotrophic lateral sclerosis 8 protein VAPB is cleaved, secreted, and acts as a ligand for Eph receptors	CELL			English	Article							OOCYTE MEIOTIC MATURATION; AMYOTROPHIC-LATERAL-SCLEROSIS; ENDOPLASMIC-RETICULUM STRESS; MOTOR-NEURON DEGENERATION; C-ELEGANS; CAENORHABDITIS-ELEGANS; MEMBRANE-PROTEIN; TYROSINE KINASE; NEUROMUSCULAR-JUNCTION; BINDING-PROTEIN	VAP proteins (human VAPB/ALS8, Drosophila VAP33, and C. elegans VPR-1) are homologous proteins with an amino-terminal major sperm protein (MSP) domain and a transmembrane domain. The MSP domain is named for its similarity to the C. elegans MSP protein, a sperm-derived hormone that binds to the Eph receptor and induces oocyte maturation. A point mutation (P56S) in the MSP domain of human VAPB is associated with Amyotrophic lateral sclerosis (ALS), but the mechanisms underlying the pathogenesis are poorly understood. Here we show that the MSP domains of VAP proteins are cleaved and secreted ligands for Eph receptors. The P58S mutation in VAP33 leads to a failure to secrete the MSP domain as well as ubiquitination, accumulation of inclusions in the endoplasmic reticulum, and an unfolded protein response. We propose that VAP MSP domains are secreted and act as diffusible hormones for Eph receptors. This work provides insight into mechanisms that may impact the pathogenesis of ALS.	[Tsuda, Hiroshi; Tong, Chao; Mohan, Kriti; Zoghbi, Anthony; Bellen, Hugo J.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Han, Sung Min; Yang, Youfeng; Miller, Michael A.] Univ Alabama, Sch Med, Dept Cell Biol, Birmingham, AL 35294 USA; [Lin, Yong Qi; Haueter, Claire; Bellen, Hugo J.] Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; [Bellen, Hugo J.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Bellen, Hugo J.] Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA	Baylor College of Medicine; University of Alabama System; University of Alabama Birmingham; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine	Bellen, HJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.	hbellen@bcm.tmc.edu	Yang, Youfeng/E-2252-2011	Yang, Youfeng/0000-0003-0736-2680; Zoghbi, Anthony William/0000-0002-3441-440X; Tong, Chao/0000-0001-6521-5465; Miller, Michael/0000-0003-4872-7121; Bellen, Hugo/0000-0001-5992-5989	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NICHD NIH HHS [P30 HD024064] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Amarilio R, 2005, J BIOL CHEM, V280, P5934, DOI 10.1074/jbc.M409566200; Atkin JD, 2006, J BIOL CHEM, V281, P30152, DOI 10.1074/jbc.M603393200; Baker AME, 2002, J MOL BIOL, V319, P491, DOI 10.1016/S0022-2836(02)00294-2; Basso M, 2006, J BIOL CHEM, V281, P33325, DOI 10.1074/jbc.M603489200; Blelloch R, 1999, DEV BIOL, V216, P382, DOI 10.1006/dbio.1999.9491; Boillee S, 2006, NEURON, V52, P39, DOI 10.1016/j.neuron.2006.09.018; Bottino D, 2002, J CELL SCI, V115, P367; Boyle M, 2006, DEVELOPMENT, V133, P1845, DOI 10.1242/dev.02353; BRENNER S, 1974, GENETICS, V77, P71; Brickner JH, 2004, PLOS BIOL, V2, P1843, DOI 10.1371/journal.pbio.0020342; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Chai A, 2008, HUM MOL GENET, V17, P266, DOI 10.1093/hmg/ddm303; Chin-Sang ID, 2002, DEVELOPMENT, V129, P5499, DOI 10.1242/dev.00122; Chin-Sang ID, 1999, CELL, V99, P781, DOI 10.1016/S0092-8674(00)81675-X; Corrigan C, 2005, DEVELOPMENT, V132, P5225, DOI 10.1242/dev.02083; Culi J, 2003, CELL, V112, P343, DOI 10.1016/S0092-8674(02)01279-5; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; de Vrij FMS, 2004, PROG NEUROBIOL, V74, P249, DOI 10.1016/j.pneurobio.2004.10.001; Dearborn R, 2002, J NEUROSCI, V22, P1338, DOI 10.1523/JNEUROSCI.22-04-01338.2002; Elefant F, 1999, MOL BIOL CELL, V10, P2101, DOI 10.1091/mbc.10.7.2101; George SE, 1998, CELL, V92, P633, DOI 10.1016/S0092-8674(00)81131-9; Govindan JA, 2006, CURR BIOL, V16, P1257, DOI 10.1016/j.cub.2006.05.020; Harris JE, 2006, DEV BIOL, V299, P105, DOI 10.1016/j.ydbio.2006.07.013; Herpers B, 2004, MOL BIOL CELL, V15, P5306, DOI 10.1091/mbc.E04-05-0398; Himanen JP, 2007, CURR OPIN CELL BIOL, V19, P534, DOI 10.1016/j.ceb.2007.08.004; Iwamasa H, 1999, DEV GROWTH DIFFER, V41, P685; Kagiwada S, 2003, J BIOCHEM, V133, P515, DOI 10.1093/jb/mvg068; Kagiwada S, 1998, J BACTERIOL, V180, P1700, DOI 10.1128/JB.180.7.1700-1708.1998; Kaiser SE, 2005, STRUCTURE, V13, P1035, DOI 10.1016/j.str.2005.04.010; Kikuchi H, 2006, P NATL ACAD SCI USA, V103, P6025, DOI 10.1073/pnas.0509227103; Klein R, 2004, CURR OPIN CELL BIOL, V16, P580, DOI 10.1016/j.ceb.2004.07.002; Kosinski M, 2005, DEVELOPMENT, V132, P3357, DOI 10.1242/dev.01916; Kuijper S, 2007, TRENDS CARDIOVAS MED, V17, P145, DOI 10.1016/j.tcm.2007.03.003; Lai KO, 2001, MOL CELL NEUROSCI, V17, P1034, DOI 10.1006/mcne.2001.0997; Loewen CJR, 2005, J BIOL CHEM, V280, P14097, DOI 10.1074/jbc.M500147200; Magal E, 1996, J NEUROSCI RES, V43, P735, DOI 10.1002/(SICI)1097-4547(19960315)43:6<735::AID-JNR10>3.0.CO;2-X; McCarter J, 1999, DEV BIOL, V205, P111, DOI 10.1006/dbio.1998.9109; Miller MA, 2001, SCIENCE, V291, P2144, DOI 10.1126/science.1057586; Miller MA, 2003, GENE DEV, V17, P187, DOI 10.1101/gad.1028303; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Nishimura AL, 2004, AM J HUM GENET, V75, P822, DOI 10.1086/425287; Nishimura Y, 1999, BIOCHEM BIOPH RES CO, V254, P21, DOI 10.1006/bbrc.1998.9876; Omenn GS, 2005, PROTEOMICS, V5, P3226, DOI 10.1002/pmic.200500358; Palmer A, 2003, GENE DEV, V17, P1429, DOI 10.1101/gad.1093703; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Pennetta G, 2002, NEURON, V35, P291, DOI 10.1016/S0896-6273(02)00769-9; Perry RJ, 2006, MOL BIOL CELL, V17, P2604, DOI 10.1091/mbc.E06-01-0060; PESACRETA TC, 1989, J CELL BIOL, V108, P1697, DOI 10.1083/jcb.108.5.1697; Ricard J, 2006, MOL CELL NEUROSCI, V31, P713, DOI 10.1016/j.mcn.2006.01.002; Ryoo HD, 2007, EMBO J, V26, P242, DOI 10.1038/sj.emboj.7601477; Seto ES, 2006, J CELL BIOL, V173, P95, DOI 10.1083/jcb.200510123; Skehel PA, 2000, P NATL ACAD SCI USA, V97, P1101, DOI 10.1073/pnas.97.3.1101; Soussan L, 1999, J CELL BIOL, V146, P301, DOI 10.1083/jcb.146.2.301; Strigini M, 2000, CURR BIOL, V10, P293, DOI 10.1016/S0960-9822(00)00378-X; Talbot K, 2006, HUM MOL GENET, V15, pR182, DOI 10.1093/hmg/ddl202; Teuling E, 2007, J NEUROSCI, V27, P9801, DOI 10.1523/JNEUROSCI.2661-07.2007; WANG XD, 2005, J ORGAN DYSFUNCT, V1, P2; Wang XM, 1999, MOL CELL, V4, P903, DOI 10.1016/S1097-2765(00)80220-8; WARD S, 1988, J MOL BIOL, V199, P1, DOI 10.1016/0022-2836(88)90374-9; Weir ML, 1998, BIOCHEM J, V333, P247, DOI 10.1042/bj3330247; Whitten SJ, 2007, DEV BIOL, V301, P432, DOI 10.1016/j.ydbio.2006.08.038; Yamamoto I, 2006, DEV DYNAM, V235, P571, DOI 10.1002/dvdy.20662; Zallen JA, 1999, DEVELOPMENT, V126, P3679; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2; Zhong ZH, 2008, NAT NEUROSCI, V11, P420, DOI 10.1038/nn2073	66	168	177	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 13	2008	133	6					963	977		10.1016/j.cell.2008.04.039	http://dx.doi.org/10.1016/j.cell.2008.04.039			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	312TJ	18555774	Green Accepted, Bronze			2022-12-28	WOS:000256693400013
J	[Anonymous]				[Anonymous]			To thwart disease, apply now	NATURE			English	Editorial Material																			0	7	7	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2008	453	7197					823	823		10.1038/453823a	http://dx.doi.org/10.1038/453823a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311WV	18548013	Bronze			2022-12-28	WOS:000256632000001
J	Hutchison, JS; Ward, RE; Lacroix, J; Hebert, PC; Barnes, MA; Bohn, DJ; Dirks, PB; Doucette, S; Fergusson, D; Gottesman, R; Joffe, AR; Kirpalani, HM; Meyer, PG; Morris, KP; Moher, D; Singh, RN; Skippen, PW				Hutchison, James S.; Ward, Roxanne E.; Lacroix, Jacques; Hebert, Paul C.; Barnes, Marcia A.; Bohn, Desmond J.; Dirks, Peter B.; Doucette, Steve; Fergusson, Dean; Gottesman, Ronald; Joffe, Ari R.; Kirpalani, Haresh M.; Meyer, Philippe G.; Morris, Kevin P.; Moher, David; Singh, Ram N.; Skippen, Peter W.		Hypothermia Pediat Head Injury Tri; Canadian Crit Care Trials Grp	Hypothermia therapy after traumatic brain injury in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MODERATE HYPOTHERMIA; HEAD-INJURY; MANAGEMENT; SEVERITY; TRIAL	Background: Hypothermia therapy improves survival and the neurologic outcome in animal models of traumatic brain injury. However, the effect of hypothermia therapy on the neurologic outcome and mortality among children who have severe traumatic brain injury is unknown. Methods: In a multicenter, international trial, we randomly assigned children with severe traumatic brain injury to either hypothermia therapy (32.5 degreesC for 24 hours) initiated within 8 hours after injury or to normothermia (37.0 degreesC). The primary outcome was the proportion of children who had an unfavorable outcome (i.e., severe disability, persistent vegetative state, or death), as assessed on the basis of the Pediatric Cerebral Performance Category score at 6 months. Results: A total of 225 children were randomly assigned to the hypothermia group or the normothermia group; the mean temperatures achieved in the two groups were 33.1+/-1.2 degreesC and 36.9+/-0.5 degreesC, respectively. At 6 months, 31% of the patients in the hypothermia group, as compared with 22% of the patients in the normothermia group, had an unfavorable outcome (relative risk, 1.41; 95% confidence interval [CI], 0.89 to 2.22; P=0.14). There were 23 deaths (21%) in the hypothermia group and 14 deaths (12%) in the normothermia group (relative risk, 1.40; 95% CI, 0.90 to 2.27; P=0.06). There was more hypotension (P=0.047) and more vasoactive agents were administered (P<0.001) in the hypothermia group during the rewarming period than in the normothermia group. Lengths of stay in the intensive care unit and in the hospital and other adverse events were similar in the two groups. Conclusions: In children with severe traumatic brain injury, hypothermia therapy that is initiated within 8 hours after injury and continued for 24 hours does not improve the neurologic outcome and may increase mortality. (Current Controlled Trials number, ISRCTN77393684.).	[Hutchison, James S.; Bohn, Desmond J.] Hosp Sick Children, Dept Crit Care Med, Toronto, ON M5G 1X8, Canada; [Hutchison, James S.; Bohn, Desmond J.] Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; [Dirks, Peter B.] Hosp Sick Children, Dept Surg Neurosurg, Toronto, ON M5G 1X8, Canada; [Hutchison, James S.; Bohn, Desmond J.] Univ Toronto, Interdept Div Crit Care, Fac Med, Toronto, ON, Canada; [Hutchison, James S.; Barnes, Marcia A.] Hosp Sick Children, Res Inst, Neurosci & Mental Hlth Res Program, Toronto, ON M5G 1X8, Canada; [Ward, Roxanne E.; Moher, David] Childrens Hosp Eastern Ontario, Res Inst, Chalmers Res Grp, Ottawa, ON K1H 8L1, Canada; [Hebert, Paul C.; Doucette, Steve; Fergusson, Dean] Ottawa Gen Hosp, Dept Crit Care Med, Clin Epidemiol Program, Ottawa Hlth Res Inst, Ottawa, ON K1H 8L6, Canada; [Moher, David] Univ Ottawa, Dept Pediat, Fac Med, Ottawa, ON K1N 6N5, Canada; [Moher, David] Univ Ottawa, Dept Epidemiol & Community Med, Fac Med, Ottawa, ON K1N 6N5, Canada; [Lacroix, Jacques] Hop St Justine, Div Intens Care, Dept Pediat, Montreal, PQ H3T 1C5, Canada; [Gottesman, Ronald] Montreal Childrens Hosp, Dept Pediat Intens Care, Montreal, PQ H3H 1P3, Canada; [Barnes, Marcia A.] Univ Guelph, Dept Psychol, Guelph, ON N1G 2W1, Canada; [Joffe, Ari R.] Stollery Childrens Hosp, Dept Pediat Intens Care, Edmonton, AB, Canada; [Kirpalani, Haresh M.] McMaster Childrens Hosp, Intens Care Unit, Hamilton, ON, Canada; [Meyer, Philippe G.] Grp Hosp Necker Enfants Malad, Neurointens Care Unit, Paris, France; [Morris, Kevin P.] Birmingham Childrens Hosp, Intens Care Unit, Birmingham, W Midlands, England; [Singh, Ram N.] Childrens Hosp Western Ontario, Dept Pediat Intens Care, London, ON N6A 5A5, Canada; [Skippen, Peter W.] British Columbia Childrens Hosp, Dept Pediat Intens Care, Vancouver, BC V6H 3V4, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; Universite de Montreal; McGill University; University of Guelph; Stollery Children's Hospital; McMaster University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Birmingham; Western University (University of Western Ontario); BC Childrens Hospital; University of British Columbia	Hutchison, JS (corresponding author), Hosp Sick Children, Dept Crit Care Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	jamie.hutchison@sickkids.ca	kasyan, george/ABB-4616-2021; Kirkham, Fenella/C-2442-2009; Adelson, David/W-2083-2019; Meyer, Philippe/ABE-4242-2020	kasyan, george/0000-0001-7919-2217; Kirkham, Fenella/0000-0002-2443-7958; Meyer, Philippe/0000-0002-3829-6631; Moher, David/0000-0003-2434-4206; Fergusson, Dean/0000-0002-3389-2485; skippen, peter/0000-0001-6716-0381				ABRAMSON NS, 1986, JAMA-J AM MED ASSOC, V255, P2466, DOI 10.1001/jama.255.18.2466; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Alderson P, 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001048.pub2, DOI 10.1002/14651858.CD001048.PUB2]; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Atkins DL, 2006, PEDIATRICS, V117, pE955, DOI 10.1542/peds.2006-0206; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COHEN MJ, 1995, CHILDRENS MEMORY SCA; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Fiser DH, 2000, CRIT CARE MED, V28, P1173, DOI 10.1097/00003246-200004000-00043; GELLER NL, 1987, BIOMETRICS, V43, P213, DOI 10.2307/2531962; Gioia GA, 2000, BEHAV RATING INVENTO; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Harris OA, 2002, ARCH NEUROL-CHICAGO, V59, P1077, DOI 10.1001/archneur.59.7.1077; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; HENDRICK EB, 1959, ARCH SURG-CHICAGO, V79, P362; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hutchison J, 2006, DEV NEUROSCI-BASEL, V28, P291, DOI 10.1159/000094155; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; Wechsler D., 2014, WECHSLER PRESCHOOL P; Wechsler D., 1997, WECHSLER MEMORY SCAL, Vthird; Wechsler D, 1997, WECHSLER ADULT INTEL, VIII; Wechsler D.A., 1997, WECHSLER INTELLIGENC	34	407	433	0	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2008	358	23					2447	2456		10.1056/NEJMoa0706930	http://dx.doi.org/10.1056/NEJMoa0706930			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308HY	18525042	Bronze			2022-12-28	WOS:000256380700004
J	Patel, AD				Patel, Aniruddh D.			Science & music: Talk of the tone	NATURE			English	Editorial Material																			0	27	29	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 5	2008	453	7196					726	727		10.1038/453726a	http://dx.doi.org/10.1038/453726a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308UK	18528382	Bronze			2022-12-28	WOS:000256415300028
J	Fabian, AC				Fabian, Andrew C.			Astronomy - A blast from the past	SCIENCE			English	Editorial Material							CASSIOPEIA-A; LIGHT ECHOES; BLACK-HOLE; SUPERNOVA; PROGENITOR; 1993J; STAR		[Fabian, Andrew C.] Univ Cambridge, Inst Astron, Cambridge CB3 0HA, England	University of Cambridge	Fabian, AC (corresponding author), Univ Cambridge, Inst Astron, Madingley Rd, Cambridge CB3 0HA, England.	acf@ast.cam.ac.uk						Koyama K, 2008, PUBL ASTRON SOC JPN, V60, pS201, DOI 10.1093/pasj/60.sp1.S201; Krause O, 2005, SCIENCE, V308, P1604, DOI 10.1126/science.1112035; Krause O, 2008, SCIENCE, V320, P1195, DOI 10.1126/science.1155788; Liu JF, 2003, ASTROPHYS J, V582, P919, DOI 10.1086/344719; Maund JR, 2004, NATURE, V427, P129, DOI 10.1038/nature02161; Pavlov GG, 2000, ASTROPHYS J, V531, pL53, DOI 10.1086/312521; SUNTZEFF NB, 1988, NATURE, V334, P135, DOI 10.1038/334135a0; VANDENBERGH S, 1966, PUBL ASTRON SOC PAC, V78, P74, DOI 10.1086/128299; Vaughan S, 2006, ASTROPHYS J, V639, P323, DOI 10.1086/499353; Young PA, 2006, ASTROPHYS J, V640, P891, DOI 10.1086/500108	10	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	2008	320	5880					1167	1168		10.1126/science.1158538	http://dx.doi.org/10.1126/science.1158538			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306FF	18511676				2022-12-28	WOS:000256233000022
J	Kruse, JP; Gu, W				Kruse, Jan-Philipp; Gu, Wei			SnapShot: p53 posttranslational modifications	CELL			English	Editorial Material							UBIQUITINATION; ACETYLATION; ACTIVATION; PATHWAY		[Kruse, Jan-Philipp] Columbia Univ, Inst Canc Genet, New York, NY 10027 USA; Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA	Columbia University; Columbia University	Kruse, JP (corresponding author), Columbia Univ, Inst Canc Genet, New York, NY 10027 USA.				NATIONAL CANCER INSTITUTE [R01CA131439, R01CA104843, P01CA097403, R01CA129627, R01CA098821, R01CA085533, R01CA118561, P01CA080058] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA104843, R01 CA085533, R01 CA098821, P01 CA097403, P01 CA080058, R01 CA129627, R01 CA131439, R01 CA118561] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Prives C, 1999, J PATHOL, V187, P112; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675	10	119	123	0	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 30	2008	133	5							930.e1	10.1016/j.cell.2008.05.020	http://dx.doi.org/10.1016/j.cell.2008.05.020			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510935	Green Accepted, Bronze			2022-12-28	WOS:000256274500025
J	Tucker, TJ; Makgoba, MW				Tucker, T. J.; Makgoba, M. W.			Public health - Public-private partnerships and scientific imperialism	SCIENCE			English	Editorial Material									[Tucker, T. J.] Sci Med Res Proprietary Ltd, Cape Town, South Africa; [Tucker, T. J.] Univ Cape Town, Div Med Virol, Dept Clin Lab Sci, ZA-7925 Cape Town, South Africa; [Makgoba, M. W.] Univ Kwazulu Natal, Durban, South Africa	University of Cape Town; University of Kwazulu Natal	Tucker, TJ (corresponding author), Sci Med Res Proprietary Ltd, Mandela Rhodes Bldg,St Georges Mall, Cape Town, South Africa.	tim@smr.co.za; makgoba@ukzn.ac.za						Chataway J., 2007, EUR J DEV RES, V19, P100, DOI DOI 10.1080/09578810601144350; Eaton L, 2005, BRIT MED J, V331, P718, DOI 10.1136/bmj.331.7519.718; Trouiller P, 2001, TROP MED INT HEALTH, V6, P945, DOI 10.1046/j.1365-3156.2001.00803.x	3	24	24	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2008	320	5879					1016	1017		10.1126/science.1156720	http://dx.doi.org/10.1126/science.1156720			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18497279				2022-12-28	WOS:000256059800023
J	Ferrer, R; Artigas, A; Levy, MM; Blanco, J; Gonzalez-Diaz, G; Garnacho-Montero, J; Ibanez, J; Palencia, E; Quintana, M; de la Torre-Prados, MV				Ferrer, Ricard; Artigas, Antonio; Levy, Mitchell M.; Blanco, Jesus; Gonzalez-Diaz, Gumersindo; Garnacho-Montero, Jose; Ibanez, Jordi; Palencia, Eduardo; Quintana, Manuel; de la Torre-Prados, Maria Victoria		Edusepsis Study Grp	Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; GOAL-DIRECTED THERAPY; SEPTIC SHOCK; GUIDELINES; MANAGEMENT; IMPACT; IMPLEMENTATION; QUALITY; UNIT; INTERVENTION	Context Concern exists that current guidelines for care of patients with severe sepsis and septic shock are followed variably, possibly due to a lack of adequate education. Objective To determine whether a national educational program based on the Surviving Sepsis Campaign guidelines affected processes of care and hospital mortality for severe sepsis. Design, Setting, and Patients Before and after design in 59 medical-surgical intensive care units (ICUs) located throughout Spain. All ICU patients were screened daily and enrolled if they fulfilled severe sepsis or septic shock criteria. A total of 854 patients were enrolled in the preintervention period (November-December 2005), 1465 patients during the postintervention period (March-June 2006), and 247 patients during the long-term follow-up period 1 year later (November-December 2006) in a subset of 23 ICUs. Intervention The educational program consisted of training physicians and nursing staff from the emergency department, wards, and ICU in the definition, recognition, and treatment of severe sepsis and septic shock as outlined in the guidelines. Treatment was organized in 2 bundles: a resuscitation bundle (6 tasks to begin immediately and be accomplished within 6 hours) and a management bundle (4 tasks to be completed within 24 hours). Main Outcome Measures Hospital mortality, differences in adherence to the bundles' process-of-care variables, ICU mortality, 28-day mortality, hospital length of stay, and ICU length of stay. Results Patients included before and after the intervention were similar in terms of age, sex, and Acute Physiology and Chronic Health Evaluation II score. At baseline, only 3 process-of-care measurements (blood cultures before antibiotics, early administration of broad-spectrum antibiotics, and mechanical ventilation with adequate inspiratory plateau pressure) we had compliance rates higher than 50%. Patients in the postintervention cohort had a lower risk of hospital mortality (44.0% vs 39.7%; P =.04). The compliance with process-of-care variables also improved after the intervention in the sepsis resuscitation bundle (5.3% [95% confidence interval [CI], 4%-7%] vs 10.0% [95% CI, 8%-12%]; P < .001) and in the sepsis management bundle (10.9% [95% CI, 9%-13%] vs 15.7% [95% CI, 14%-18%]; P = .001). Hospital length of stay and ICU length of stay did not change after the intervention. During long-term follow-up, compliance with the sepsis resuscitation bundle returned to baseline but compliance with the sepsis management bundle and mortality remained stable with respect to the postintervention period. Conclusions A national educational effort to promote bundles of care for severe sepsis and septic shock was associated with improved guideline compliance and lower hospital mortality. However, compliance rates were still low, and the improvement in the resuscitation bundle lapsed by 1 year.	[Ferrer, Ricard; Artigas, Antonio] Univ Autonoma Barcelona, Ctr Criticos, Hosp Sabadell, CIBER Enfermedades Resp,Inst Univ Parc Tauli, Barcelona 08208, Spain; [Levy, Mitchell M.] Brown Univ, Med Intens Care Unit, Rhode Isl Hosp, Providence, RI 02912 USA; [Blanco, Jesus] Hosp Univ Rio Hortega, Serv Med Intensiva, Valladolid, Spain; [Gonzalez-Diaz, Gumersindo] Hosp Gen Univ Morales Meseguer, Serv Med Intensiva, Murcia, Spain; [Garnacho-Montero, Jose] Hosp Univ Virgen Rocio, Serv Med Intensiva, Seville, Spain; [Ibanez, Jordi] Hosp Univ Son Dureta, Serv Med Intensiva, Palma de Mallorca, Spain; [Palencia, Eduardo] Hosp Gen Univ Gregorio Maranon, Serv Med Intensiva, Madrid, Spain; [Quintana, Manuel] Hosp Nuestra Senora Prado, Serv Med Intensiva, Talavera De La Reina, Toledo, Spain; [de la Torre-Prados, Maria Victoria] Hosp Clin Univ Virgen Victoria, Serv Med Intensiva, Malaga, Spain	Autonomous University of Barcelona; Parc Tauli Hospital Universitari; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Hospital del Rio Hortega; Meseguer General University Hospital Morales; Virgen del Rocio University Hospital; Hospital Universitari Son Espases; Hospital Universitari Son Dureta; General University Gregorio Maranon Hospital; Hospital Virgen de la Victoria	Ferrer, R (corresponding author), Univ Autonoma Barcelona, Ctr Criticos, Hosp Sabadell, CIBER Enfermedades Resp,Inst Univ Parc Tauli, Barcelona 08208, Spain.	rferrer@tauli.cat	Quintana-Diaz, Manuel/AAE-2265-2022; Sierra, Rafael/I-3441-2015; Ruiz-Rodriguez, Juan Carlos/H-7703-2012; Garnacho-Montero, Jose/R-9496-2019; Ferrer, Ricard/K-9022-2017	Quintana-Diaz, Manuel/0000-0003-4852-4148; Sierra, Rafael/0000-0002-6021-396X; Ruiz-Rodriguez, Juan Carlos/0000-0001-7392-8617; Garnacho-Montero, Jose/0000-0003-2542-7601; Ferrer, Ricard/0000-0002-4859-4747; antonio, artigas/0000-0002-8029-1017; CABALLERO, JESUS/0000-0001-9005-9687; Carriedo Ule, Demetrio/0000-0001-8823-268X				*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Alberti C, 2002, INTENS CARE MED, V28, P108, DOI 10.1007/s00134-001-1143-z; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Barlow G, 2007, THORAX, V62, P67, DOI 10.1136/thx.2005.056689; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; BRUNBUISSON C, 1995, JAMA-J AM MED ASSOC, V274, P968, DOI 10.1001/jama.274.12.968; Capelastegui A, 2004, CLIN INFECT DIS, V39, P955, DOI 10.1086/423960; Carlbom DJ, 2007, CRIT CARE MED, V35, P2525, DOI 10.1097/01.ccm.0000298122.49245.d7; Curtis JR, 2006, CRIT CARE MED, V34, P211, DOI 10.1097/01.CCM.0000190617.76104.AC; De Miguel-Yanes JM, 2006, AM J EMERG MED, V24, P553, DOI 10.1016/j.ajem.2006.01.012; Dellinger RP, 2004, INTENS CARE MED, V30, P536, DOI 10.1007/s00134-004-2210-z; Esteban A, 2007, CRIT CARE MED, V35, P1284, DOI 10.1097/01.CCM.0000260960.94300.DE; Gao F, 2005, CRIT CARE, V9, pR764, DOI 10.1186/cc3909; Garnacho-Montero J, 2003, CRIT CARE MED, V31, P2742, DOI 10.1097/01.CCM.0000098031.24329.10; Guidet B, 2005, CHEST, V127, P942, DOI 10.1378/chest.127.3.942; Halm EA, 2004, CHEST, V126, P100, DOI 10.1378/chest.126.1.100; Kortgen A, 2006, CRIT CARE MED, V34, P943, DOI 10.1097/01.CCM.0000206112.32673.D4; Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9; MacArthur RD, 2004, CLIN INFECT DIS, V38, P284, DOI 10.1086/379825; Micek ST, 2006, CRIT CARE MED, V34, P2707, DOI 10.1097/01.CCM.0000241151.25426.D7; Mol PGM, 2005, J ANTIMICROB CHEMOTH, V55, P550, DOI 10.1093/jac/dki037; Nguyen HB, 2007, CRIT CARE MED, V35, P1105, DOI 10.1097/01.CCM.0000259463.33848.3D; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Rubenfeld Gordon D, 2004, Respir Care, V49, P837; Shapiro NI, 2006, CRIT CARE MED, V34, P1025, DOI 10.1097/01.CCM.0000206104.18647.A8; Trzeciak S, 2006, CHEST, V129, P225, DOI 10.1378/chest.129.2.225; Yealy DM, 2005, ANN INTERN MED, V143, P881, DOI 10.7326/0003-4819-143-12-200512200-00006	28	521	539	0	53	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2008	299	19					2294	2303		10.1001/jama.299.19.2294	http://dx.doi.org/10.1001/jama.299.19.2294			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302QN	18492971	Bronze			2022-12-28	WOS:000255984500024
J	Patel, P; Hanson, DL; Sullivan, PS; Novak, RM; Moorman, AC; Tong, TC; Holmberg, SD; Brooks, JT				Patel, Pragna; Hanson, Debra L.; Sullivan, Patrick S.; Novak, Richard M.; Moorman, Anne C.; Tong, Tony C.; Holmberg, Scott D.; Brooks, John T.		Adolescent Spectrum Dis Project &	Incidence of types of cancer among HIV-Infected persons compared with the general population in the United States, 1992-2003	ANNALS OF INTERNAL MEDICINE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; AIDS-DEFINING CANCERS; IMMUNODEFICIENCY-VIRUS-INFECTION; NON-HODGKINS-LYMPHOMA; EPSTEIN-BARR-VIRUS; HUMAN-PAPILLOMAVIRUS; LUNG-CANCER; IMMUNE-DEFICIENCY; MEDICAL PROGRESS; NATURAL-HISTORY	Background: Persons who are HIV-infected may be at higher risk for certain types of cancer than the general population. Objective: To compare cancer incidence among HIV-infected persons with incidence in the general population from 1992 to 2003. Design: Prospective observational cohort studies. Setting: United States. Patients: 54 780 HIV-infected persons in the Adult and Adolescent Spectrum of HIV Disease Project (47 832 patients) and the HIV Outpatient Study (6948 patients), who contributed 157 819 person-years of follow-up from 1992 to 2003, and 334 802 121 records from the Surveillance, Epidemiology, and End Results program of 13 geographically defined, population-based, central cancer registries. Measurements: Standardized rate ratios (SRRs) to compare cancer incidence in the HIV-infected population with standardized cancer incidence in the general population. Results: The incidence of the following types of non-AIDS-defining cancer was significantly higher in the HIV-infected population than in the general population: anal (SRR, 42.9 [95% CI, 34.1 to 53.3]), vaginal (21.0 [CI, 11.2 to 35.9]), Hodgkin lymphoma (14.7 [CI, 11.6 to 18.2]), liver (7.7 [CI, 5.7 to 10.1]), lung (3.3 [CI, 2.8 to 3.9]), melanoma (2.6 [CI, 1.9 to 3.6]), oropharyngeal (2.6 [CI, 1.9 to 3.4]), leukemia (2.5 [CI, 1.6 to 3.8]), colorectal (2.3 [CI, 1.8 to 2.9]), and renal (1.8 [CI, 1.1 to 2.7]). The incidence of prostate cancer was significantly lower among HIV-infected persons than the general population (SRR, 0.6 [CI, 0.4 to 0.8]). Only the relative incidence of anal cancer increased over time. Limitations: Lower ascertainment of cancer in the HIV cohorts may result in a potential bias to underestimate rate disparities. Tobacco use as a risk factor and the effect of changes in cancer screening practices could not be evaluated. Conclusion: The incidence of many types of non-AIDS-defining cancer was higher among HIV-infected persons than among the general population from 1992 to 2003.	[Patel, Pragna] Emory Univ, Div HIV AIDS, Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Univ Chicago, Chicago, IL 60637 USA; Northrop Grumman Informat Technol, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Emory University; University of Chicago	Patel, P (corresponding author), Emory Univ, Div HIV AIDS, Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop E-46, Atlanta, GA 30333 USA.	plp3@cdc.gov		Moorman, Anne/0000-0003-2411-2798; Sullivan, Patrick Sean/0000-0002-7728-0587	PHS HHS [200-2006-18797] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adami J, 2003, BRIT J CANCER, V89, P1221, DOI 10.1038/sj.bjc.6601219; Adani GL, 2006, TUMORI J, V92, P219, DOI 10.1177/030089160609200306; Allardice GM, 2003, BRIT J CANCER, V89, P505, DOI 10.1038/sj.bjc.6601139; Smith Nicole M., 2006, Morbidity and Mortality Weekly Report, V55, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Appleby P, 2000, JNCI-J NATL CANCER I, V92, P1823, DOI 10.1093/jnci/92.22.1823; Bedimo R, 2004, CLIN INFECT DIS, V39, P1380, DOI 10.1086/424883; Biggar RJ, 2004, JAIDS-J ACQ IMM DEF, V36, P861, DOI 10.1097/00126334-200407010-00014; Biggar RJ, 2007, J NATL CANCER I, V99, P962, DOI 10.1093/jnci/djm010; Bini EJ, 2006, ARCH INTERN MED, V166, P1626, DOI 10.1001/archinte.166.15.1626; Bower M, 2004, JAIDS-J ACQ IMM DEF, V37, P1563, DOI 10.1097/00126334-200412150-00004; Bower M, 2003, AIDS, V17, P371, DOI 10.1097/00002030-200302140-00011; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010; Burgi A, 2005, CANCER-AM CANCER SOC, V104, P1505, DOI 10.1002/cncr.21334; Chaturvedi AK, 2007, AIDS, V21, P207, DOI 10.1097/QAD.0b013e3280118fca; Chin-Hong PV, 2002, CLIN INFECT DIS, V35, P1127, DOI 10.1086/344057; Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072; Cooley TP, 2003, HEMATOL ONCOL CLIN N, V17, P889, DOI 10.1016/S0889-8588(03)00038-8; Crum NF, 2004, CANCER-AM CANCER SOC, V101, P294, DOI 10.1002/cncr.20389; Dal Maso L, 2003, AIDS, V17, P2117, DOI 10.1097/00002030-200309260-00013; Daling JR, 2004, CANCER-AM CANCER SOC, V101, P270, DOI 10.1002/cncr.20365; Del Maso L, 2003, BRIT J CANCER, V89, P94, DOI 10.1038/sj.bjc.6601017; DOBSON AJ, 1991, STAT MED, V10, P457, DOI 10.1002/sim.4780100317; Dunne Eileen F, 2003, Adolesc Med, V14, P613; Eltom MA, 2002, J NATL CANCER I, V94, P1204, DOI 10.1093/jnci/94.16.1204; Engels EA, 2006, AIDS, V20, P1645, DOI 10.1097/01.aids.0000238411.75324.59; Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Franceschi S, 2007, CLIN INFECT DIS, V45, P510, DOI 10.1086/520022; Frisch M, 2000, JNCI-J NATL CANCER I, V92, P1500, DOI 10.1093/jnci/92.18.1500; Frisch M, 2001, JAMA-J AM MED ASSOC, V285, P1736, DOI 10.1001/jama.285.13.1736; Galceran J, 2007, EUR J CANCER, V43, P1085, DOI 10.1016/j.ejca.2007.01.028; Gallagher B, 2001, AM J EPIDEMIOL, V154, P544, DOI 10.1093/aje/154.6.544; Gates AE, 2002, ONCOLOGY-NY, V16, P657; Gates AE, 2002, ONCOLOGY-NY, V16, P441; Gerard L, 2003, AIDS, V17, P81, DOI 10.1097/00002030-200301030-00011; Goedert JJ, 2006, BRIT J CANCER, V95, P642, DOI 10.1038/sj.bjc.6603282; Grinspoon S, 2003, CLIN INFECT DIS, V37, pS85, DOI 10.1086/375885; Grulich AE, 1999, AIDS, V13, P839, DOI 10.1097/00002030-199905070-00014; Grulich AE, 2002, AIDS, V16, P1155, DOI 10.1097/00002030-200205240-00009; Grulich AE, 2001, AIDS, V15, P629, DOI 10.1097/00002030-200103300-00013; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; Hankey BF, 1999, CANCER EPIDEM BIOMAR, V8, P1117; Hessol NA, 2004, JAIDS-J ACQ IMM DEF, V36, P978, DOI 10.1097/00126334-200408010-00013; HESSOL NA, 1992, ANN INTERN MED, V117, P309, DOI 10.7326/0003-4819-117-4-309; Hessol NA, 2007, AM J EPIDEMIOL, V165, P1143, DOI 10.1093/aje/kwm017; Hollenbeak CS, 2005, CANCER, V104, P1962, DOI 10.1002/cncr.21404; Holmberg SD, 2002, LANCET, V360, P1747, DOI 10.1016/S0140-6736(02)11672-2; Lichtenstein KA, 2001, AIDS, V15, P1389, DOI 10.1097/00002030-200107270-00008; Lohse N, 2007, ANN INTERN MED, V146, P87, DOI 10.7326/0003-4819-146-2-200701160-00003; Mbulaiteye SM, 2006, INT J CANCER, V118, P985, DOI 10.1002/ijc.21443; Mbulaiteye SM, 2003, JAIDS-J ACQ IMM DEF, V32, P527, DOI 10.1097/00126334-200304150-00010; Mitsuyasu R, 1999, CLIN INFECT DIS, V29, P35, DOI 10.1086/520177; Mondy K, 2003, CLIN INFECT DIS, V36, P482, DOI 10.1086/367569; Moore RD, 1999, AIDS, V13, P1933, DOI 10.1097/00002030-199910010-00017; Moorman AC, 1999, ANN EPIDEMIOL, V9, P349, DOI 10.1016/S1047-2797(99)00005-8; Moradpour D, 2005, EUR J GASTROEN HEPAT, V17, P477, DOI 10.1097/00042737-200505000-00002; National Cancer Institute, SURV EP END RES; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Newnham A, 2005, BRIT J CANCER, V92, P194, DOI 10.1038/sj.bjc.6602273; Palefsky JM, 2001, J ACQ IMMUN DEF SYND, V28, P422, DOI 10.1097/00042560-200112150-00003; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Phelps RM, 2001, INT J CANCER, V94, P753, DOI 10.1002/ijc.1528; RABKIN CS, 1993, INT J CANCER, V55, P208, DOI 10.1002/ijc.2910550207; Righetti E, 2002, AIDS, V16, P63, DOI 10.1097/00002030-200201040-00009; Sackoff JE, 2006, ANN INTERN MED, V145, P397, DOI 10.7326/0003-4819-145-6-200609190-00003; Sahai H, 1996, STAT EPIDEMIOLOGY ME; Smith C, 1998, ANN MED, V30, P323, DOI 10.3109/07853899809029932; Smith RA, 2003, CA-CANCER J CLIN, V53, P141, DOI 10.3322/canjclin.53.3.141; Vajdic CM, 2006, JAMA-J AM MED ASSOC, V296, P2823, DOI 10.1001/jama.296.23.2823; Villeneuve PJ, 2007, AM J TRANSPLANT, V7, P941, DOI 10.1111/j.1600-6143.2007.01736.x; Wingo PA, 2003, CANCER CAUSE CONTROL, V14, P175, DOI 10.1023/A:1023002322935; Wistuba II, 1999, AIDS PATIENT CARE ST, V13, P415, DOI 10.1089/apc.1999.13.415	75	678	687	2	29	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 20	2008	148	10					728	U29		10.7326/0003-4819-148-10-200805200-00005	http://dx.doi.org/10.7326/0003-4819-148-10-200805200-00005			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308EX	18490686				2022-12-28	WOS:000256372200002
J	Chen, TY; Tesanovic, Z; Liu, RH; Chen, XH; Chien, CL				Chen, T. Y.; Tesanovic, Z.; Liu, R. H.; Chen, X. H.; Chien, C. L.			A BCS-like gap in the superconductor SmFeAsO0.85F0.15	NATURE			English	Article							TUNNELING SPECTROSCOPY	Since the discovery of superconductivity in the high- transition-temperature ( high-T-c) copper oxides two decades ago, it has been firmly established that the CuO2 plane is essential for superconductivity and gives rise to a host of other very unusual properties. A new family of superconductors with the general composition of LaFeAsO1-xFx has recently been discovered(1-8) and the conspicuous lack of the CuO2 planes raises the tantalizing question of a different pairing mechanism in these oxypnictides. The superconducting gap ( its magnitude, structure, and temperature dependence) is intimately related to pairing. Here we report the observation of a single gap in the superconductor SmFeAsO0.85F0.15 with T-c= 42 K as measured by Andreev spectroscopy. The gap value of 2 Delta = 13.34 +/- 0.3meV gives 2 Delta/k(B)T(c) = 3.68 ( where k(B) is the Boltzmann constant), close to the Bardeen Cooper - Schrieffer ( BCS) prediction of 3.53. The gap decreases with temperature and vanishes at T-c in a manner consistent with the BCS prediction, but dramatically different from that of the pseudogap behaviour in the copper oxide superconductors. Our results clearly indicate a nodeless gap order parameter, which is nearly isotropic in size across different sections of the Fermi surface, and are not compatible with models involving antiferromagnetic fluctuations, strong correlations, the t- J model, and the like, originally designed for the high- T-c copper oxides.	[Chen, T. Y.; Tesanovic, Z.; Chien, C. L.] Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA; [Liu, R. H.; Chen, X. H.] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Anhua 230026, Peoples R China; [Liu, R. H.; Chen, X. H.] Univ Sci & Technol China, Dept Phys, Anhua 230026, Peoples R China	Johns Hopkins University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Chien, CL (corresponding author), Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA.	clc@pha.jhu.edu	Liu, Ronghua/A-9790-2013; Liu, Ronghua/AAA-3672-2019; Chen, Tingyong/L-9684-2018	Liu, Ronghua/0000-0002-4053-3923; Liu, Ronghua/0000-0002-4053-3923; Chen, Tingyong/0000-0001-8548-0848				Achsaf N., 1996, COHERENCE HIGH TEMPE, P428; BLONDER GE, 1982, PHYS REV B, V25, P4515, DOI 10.1103/PhysRevB.25.4515; CHEN GF, 2008, SUPERCONDUCTIVITY 41; CHEN XH, 2008, SUPERCONDUCTIVITY 43; DELACRUZ C, 2008, MAGNETIC ORDER VERSU; Deutscher G, 2005, REV MOD PHYS, V77, P109, DOI 10.1103/RevModPhys.77.109; Fischer O, 2007, REV MOD PHYS, V79, P353, DOI 10.1103/RevModPhys.79.353; Kamihara Y, 2008, J AM CHEM SOC, V130, P3296, DOI 10.1021/ja800073m; Li GH, 1999, PHYS REV LETT, V82, P1229, DOI 10.1103/PhysRevLett.82.1229; LIU RH, 2008, PHASE DIAGRAM QUANTU; MAZIN II, 2008, UNCONVENTIONAL SIGN; PLECENIK A, 1994, PHYS REV B, V49, P10016, DOI 10.1103/PhysRevB.49.10016; REN ZA, 2008, SUPERCONDUCTIVITY 52; REN ZA, 2008, NOVEL SUPERCONDUCTIV; REN ZA, 2008, SUPERCONDUCTIVITY 55; SHAN L, 2008, UNCONVENTIONAL PAIRI; Strijkers GJ, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.104510; WEN HH, 2008, SUPERCONDUCTIVITY 25; WEXLER G, 1966, P PHYS SOC LOND, V89, P927, DOI 10.1088/0370-1328/89/4/316; XIONG P, 1993, PHYS REV LETT, V71, P1907, DOI 10.1103/PhysRevLett.71.1907	21	276	281	3	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 26	2008	453	7199					1224	1227		10.1038/nature07081	http://dx.doi.org/10.1038/nature07081			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318FA	18528330	Green Submitted			2022-12-28	WOS:000257075800039
J	Phillips, K				Phillips, Katrina			Does blood discriminate?	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Phillips, K (corresponding author), The Lancet, London NW1 7BY, England.			Brown, Katrina/0000-0002-0637-1545				[Anonymous], 2008, BBC NEWS        0307; *AUSTR RED CROSS B, 2006, FREQ ASK QUEST; Hickson F, 2003, MAKING IT COUNT COLL; *HLTH PROT AG, 2007, TEST TIM HIV OTH SEX; *NZ BLOOD, 2007, FREQ ASK QUEST; Scott JD, 2007, JAMA-J AM MED ASSOC, V297, P724, DOI 10.1001/jama.297.7.724; Soldan K, 2003, VOX SANG, V84, P265, DOI 10.1046/j.1423-0410.2003.00295.x; Stramer SL, 2004, NEW ENGL J MED, V351, P760, DOI 10.1056/NEJMoa040085; *WHO, 2008, BLOOD SAF	9	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 14	2008	371	9629					1983	1984		10.1016/S0140-6736(08)60850-8	http://dx.doi.org/10.1016/S0140-6736(08)60850-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312YY	18555902				2022-12-28	WOS:000256709500010
J	Lawrence, P				Lawrence, Peter			Retiring retirement	NATURE			English	Editorial Material									[Lawrence, Peter] Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; [Lawrence, Peter] MRC, Mol Biol Lab, Cambridge CB2 0QH, England	University of Cambridge; MRC Laboratory Molecular Biology	Lawrence, P (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.	pal@mrc-lmb.cam.ac.uk		Lawrence, Peter/0000-0002-9554-8268	Medical Research Council [MC_U105184283] Funding Source: Medline; MRC [MC_U105184283] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anderson D, 2008, NATURE, V451, P139, DOI 10.1038/451139a; Ashenfelter O, 2002, AM ECON REV, V92, P957, DOI 10.1257/00028280260344542; Kovas Y, 2007, MONOGR SOC RES CHILD, V72, P1; Lawrence PA, 2007, CURR BIOL, V17, pR583, DOI 10.1016/j.cub.2007.06.014	4	6	6	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	2008	453	7195					588	590		10.1038/453588a	http://dx.doi.org/10.1038/453588a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305NN	18509422				2022-12-28	WOS:000256185200021
J	Pocock, SJ; Travison, TG; Wruck, LM				Pocock, Stuart J.; Travison, Thomas G.; Wruck, Lisa M.			How to interpret figures in reports of clinical trials	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CONSORT STATEMENT; MEDICINE; OUTCOMES; QUALITY; TABLES; PLOTS		[Pocock, Stuart J.] Univ London London Sch Hyg & Trop Med, Med Stat Unit, London WC1E 7HT, England; [Travison, Thomas G.] New England Res Inst, Watertown, MA USA; [Wruck, Lisa M.] Rho Inc, Chapel Hill, NC USA	University of London; London School of Hygiene & Tropical Medicine; HealthCore, Inc; Rho	Pocock, SJ (corresponding author), Univ London London Sch Hyg & Trop Med, Med Stat Unit, Keppel St, London WC1E 7HT, England.	stuart.pocock@lshtm.ac.uk						Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; Cleveland WS, 1994, ELEMENTS GRAPHING DA; Cuzick J, 2005, LANCET, V365, P1308, DOI 10.1016/S0140-6736(05)61026-4; Edwards RD, 2007, NEW ENGL J MED, V356, P360; Finfer S, 2006, BRIT MED J, V333, P1044, DOI 10.1136/bmj.38985.398704.7C; FITZMAURICE G, 2004, APPL LONGITUDINAL AN, P122; Gelman A, 2002, AM STAT, V56, P121, DOI 10.1198/000313002317572790; Hay EM, 2006, BRIT MED J, V333, P995, DOI 10.1136/BMJ.38977.590752.0B; Hochman JS, 2006, NEW ENGL J MED, V355, P2395, DOI 10.1056/NEJMoa066139; LANG T, 2006, REPORT STAT MED, P349; Mazzone T, 2006, JAMA-J AM MED ASSOC, V296, P2572, DOI 10.1001/jama.296.21.joc60158; Moher D, 2001, ANN INTERN MED, V134, P657, DOI 10.7326/0003-4819-134-8-200104170-00011; Pocock SJ, 2002, LANCET, V359, P1686, DOI 10.1016/S0140-6736(02)08594-X; Pocock SJ, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-36; Puhan MA, 2006, J CLIN EPIDEMIOL, V59, P1017, DOI 10.1016/j.jclinepi.2005.12.016; Schriger DL, 2006, ANN EMERG MED, V48, P750, DOI 10.1016/j.annemergmed.2006.06.017; Schriger DL, 2001, ANN EMERG MED, V37, P75, DOI 10.1067/mem.2001.111570; Smith I, 2007, LANCET, V369, P29, DOI 10.1016/S0140-6736(07)60028-2; Thiam S, 2007, JAMA-J AM MED ASSOC, V297, P380, DOI 10.1001/jama.297.4.380; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; Weinstein JN, 2006, JAMA-J AM MED ASSOC, V296, P2441, DOI 10.1001/jama.296.20.2441; Windish DM, 2007, JAMA-J AM MED ASSOC, V298, P1010, DOI 10.1001/jama.298.9.1010	24	16	17	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 24	2008	336	7654					1166	1169		10.1136/bmj.39561.548924.94	http://dx.doi.org/10.1136/bmj.39561.548924.94			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308WJ	18497415	Green Published, Green Accepted			2022-12-28	WOS:000256420900038
J	Hunt, DE; David, LA; Gevers, D; Preheim, SP; Alm, EJ; Polz, MF				Hunt, Dana E.; David, Lawrence A.; Gevers, Dirk; Preheim, Sarah P.; Alm, Eric J.; Polz, Martin F.			Resource partitioning and sympatric differentiation among closely related bacterioplankton	SCIENCE			English	Article							BACTERIAL DIVERSITY; FUNDAMENTAL UNITS; SEXUAL ISOLATION; COMMUNITY; SPECIATION; SYSTEMATICS; MECHANISMS; CHARACTER; MICROBES; GENOMICS	Identifying ecologically differentiated populations within complex microbial communities remains challenging, yet is critical for interpreting the evolution and ecology of microbes in the wild. Here we describe spatial and temporal resource partitioning among Vibrionaceae strains coexisting in coastal bacterioplankton. A quantitative model ( AdaptML) establishes the evolutionary history of ecological differentiation, thus revealing populations specific for seasons and life- styles ( combinations of free- living, particle, or zooplankton associations). These ecological population boundaries frequently occur at deep phylogenetic levels ( consistent with named species); however, recent and perhaps ongoing adaptive radiation is evident in Vibrio splendidus, which comprises numerous ecologically distinct populations at different levels of phylogenetic differentiation. Thus, environmental specialization may be an important correlate or even trigger of speciation among sympatric microbes.	[Hunt, Dana E.; Gevers, Dirk; Preheim, Sarah P.; Alm, Eric J.; Polz, Martin F.] MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA; [David, Lawrence A.] MIT, Computat & Syst Biol Initiat, Cambridge, MA 02139 USA; [Gevers, Dirk] Univ Ghent, Microbiol Lab, B-9000 Ghent, Belgium; [Gevers, Dirk] Univ Ghent, Bioinformat & Evolutionary Genom Grp, B-9000 Ghent, Belgium; [Alm, Eric J.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA; [Alm, Eric J.] MIT, Broad Inst, Cambridge, MA 02139 USA; [Alm, Eric J.] Harvard Univ, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Ghent University; Ghent University; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University	Alm, EJ (corresponding author), MIT, Dept Civil & Environm Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	ejalm@mit.edu; mpolz@mit.edu	David, Lawrence/B-1044-2010; Hunt, Dana/A-2051-2012; Gevers, Dirk/C-1451-2009; Polz, Martin/ABE-7199-2020; Preheim, Sarah P/B-3432-2010	David, Lawrence/0000-0002-3570-4767; Hunt, Dana/0000-0002-8801-9624; Preheim, Sarah P/0000-0001-7365-2382; Polz, Martin/0000-0002-4975-2946; /0000-0001-9296-3733				Acinas SG, 2004, NATURE, V430, P551, DOI 10.1038/nature02649; Cohan FM, 2002, GENETICA, V116, P359, DOI 10.1023/A:1021232409545; Cohan FM, 2007, CURR BIOL, V17, pR373, DOI 10.1016/j.cub.2007.03.032; Daubin V, 2004, SCIENCE, V306; DeLong EF, 2006, SCIENCE, V311, P496, DOI 10.1126/science.1120250; Doolittle WF, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-116; Ferris MJ, 2003, APPL ENVIRON MICROB, V69, P2893, DOI 10.1128/AEM.69.5.2893-2898.2003; Fraser C, 2007, SCIENCE, V315, P476, DOI 10.1126/science.1127573; Gevers D, 2005, NAT REV MICROBIOL, V3, P733, DOI 10.1038/nrmicro1236; Giovannoni SJ, 2005, NATURE, V437, P343, DOI 10.1038/nature04158; Heidelberg JF, 2002, APPL ENVIRON MICROB, V68, P5498, DOI 10.1128/AEM.68.11.5498-5507.2002; Hunt DE, 2008, APPL ENVIRON MICROB, V74, P44, DOI 10.1128/AEM.01412-07; Johnson ZI, 2006, SCIENCE, V311, P1737, DOI 10.1126/science.1118052; Kiorboe T, 2002, APPL ENVIRON MICROB, V68, P3996, DOI 10.1128/AEM.68.8.3996-4006.2002; Koeppel A, 2008, P NATL ACAD SCI USA, V105, P2504, DOI 10.1073/pnas.0712205105; MADDISON WP, 1991, EVOLUTION, V45, P1184, DOI [10.1111/j.1558-5646.1991.tb04385.x, 10.2307/2409726]; Majewski J, 2001, FEMS MICROBIOL LETT, V199, P161, DOI 10.1016/S0378-1097(01)00183-5; Martiny JBH, 2006, NAT REV MICROBIOL, V4, P102, DOI 10.1038/nrmicro1341; Panagiotopoulos C, 2002, ORG GEOCHEM, V33, P985, DOI 10.1016/S0146-6380(02)00057-8; Pernthaler J, 2005, MICROBIOL MOL BIOL R, V69, P440, DOI 10.1128/MMBR.69.3.440-461.2005; Polz MF, 2006, PHILOS T R SOC B, V361, P2009, DOI 10.1098/rstb.2006.1928; POMEROY LR, 1984, B MAR SCI, V35, P426; Ramette A, 2007, P NATL ACAD SCI USA, V104, P2761, DOI 10.1073/pnas.0610671104; Retchless AC, 2007, SCIENCE, V317, P1093, DOI 10.1126/science.1144876; Ronquist F, 2004, TRENDS ECOL EVOL, V19, P475, DOI 10.1016/j.tree.2004.07.002; Thompson JR, 2006, BIOLOGY OF VIBRIOS, P190; Thompson JR, 2005, SCIENCE, V307, P1311, DOI 10.1126/science.1106028; Thompson JR, 2004, APPL ENVIRON MICROB, V70, P4103, DOI 10.1128/AEM.70.7.4103-4110.2004; von Mering C, 2007, SCIENCE, V315, P1126, DOI 10.1126/science.1133420	29	362	367	4	120	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2008	320	5879					1081	1085		10.1126/science.1157890	http://dx.doi.org/10.1126/science.1157890			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18497299				2022-12-28	WOS:000256059800047
J	Huron, D				Huron, David			Lost in music	NATURE			English	Editorial Material									Ohio State Univ, Sch Mus, Columbus, OH 43210 USA; Ohio State Univ, Ctr Cognit Sci, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Huron, D (corresponding author), Ohio State Univ, Sch Mus, Columbus, OH 43210 USA.			Huron, David/0000-0001-5295-9457				Ekman P., 1980, FACE MAN EXPRESSIONS; Juslin PN, 2003, PSYCHOL BULL, V129, P770, DOI 10.1037/0033-2909.129.5.770; NETTL B, 1983, STUDY ETHNUOMUSICOLO; Patel A. D., 2007, MUSIC LANGUAGE BRAIN; Temperley D., 2007, MUSIC PROBABILITY; von Hippel P, 2000, MUSIC PERCEPT, V18, P59; WALLIN NL, 1999, ORIGINS MUSIC	7	25	26	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 22	2008	453	7194					456	457		10.1038/453456a	http://dx.doi.org/10.1038/453456a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	303EL	18497806	Bronze			2022-12-28	WOS:000256023700024
J	Husnjak, K; Elsasser, S; Zhang, NX; Chen, X; Randles, L; Shi, Y; Hofmann, K; Walters, KJ; Finley, D; Dikic, I				Husnjak, Koraljka; Elsasser, Suzanne; Zhang, Naixia; Chen, Xiang; Randles, Leah; Shi, Yuan; Hofmann, Kay; Walters, Kylie J.; Finley, Daniel; Dikic, Ivan			Proteasome subunit Rpn13 is a novel ubiquitin receptor	NATURE			English	Article							DEUBIQUITINATING ENZYME; 26S PROTEASOME; POLYUBIQUITIN CHAINS; PROTEIN INTERACTOME; UBA DOMAINS; DEGRADATION; PROTEOLYSIS; RAD23; BINDS; UCH37	Proteasomal receptors that recognize ubiquitin chains attached to substrates are key mediators of selective protein degradation in eukaryotes. Here we report the identification of a new ubiquitin receptor, Rpn13/ARM1, a known component of the proteasome. Rpn13 binds ubiquitin through a conserved amino-terminal region termed the pleckstrin-like receptor for ubiquitin (Pru) domain, which binds K48-linked diubiquitin with an affinity of approximately 90 nM. Like proteasomal ubiquitin receptor Rpn10/S5a, Rpn13 also binds ubiquitin-like (UBL) domains of UBL- ubiquitin- associated (UBA) proteins. In yeast, a synthetic phenotype results when specific mutations of the ubiquitin binding sites of Rpn10 and Rpn13 are combined, indicating functional linkage between these ubiquitin receptors. Because Rpn13 is also the proteasomal receptor for Uch37, a deubiquitinating enzyme, our findings suggest a coupling of chain recognition and disassembly at the proteasome.	[Husnjak, Koraljka; Dikic, Ivan] Univ Frankfurt, Inst Biochem 2, D-60590 Frankfurt, Germany; [Husnjak, Koraljka; Dikic, Ivan] Mediterranean Inst Life Sci, Tumor Biol Program, Split 21000, Croatia; [Elsasser, Suzanne; Shi, Yuan; Finley, Daniel] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Zhang, Naixia; Chen, Xiang; Randles, Leah; Walters, Kylie J.] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; [Hofmann, Kay] Miltenyi Biotec GmbH, D-50829 Cologne, Germany; [Dikic, Ivan] Univ Split, Sch Med, Dept Immunol, Split 21000, Croatia	Goethe University Frankfurt; Harvard University; Harvard Medical School; University of Minnesota System; University of Minnesota Twin Cities; Miltenyi Biotec; University of Split	Dikic, I (corresponding author), Univ Frankfurt, Inst Biochem 2, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	walte048@umn.edu; daniel_finley@hms.harvard.edu; Ivan.Dikic@biochem2.de	Husnjak, Koraljka/C-3717-2015; Hofmann, Kay/D-6714-2011; Dikic, Ivan/O-4650-2015; Chen, Xiang/E-2840-2010	Husnjak, Koraljka/0000-0003-0573-6239; Hofmann, Kay/0000-0002-2289-9083; Dikic, Ivan/0000-0001-8156-9511; 	NATIONAL CANCER INSTITUTE [R01CA097004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043601, T32GM008700, R01GM043601] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA097004, R01 CA097004-05, R01 CA097004-06A1, CA097004] Funding Source: Medline; NIGMS NIH HHS [R37 GM043601, GM043601, T32 GM008700-09, R01 GM043601, GM008700, T32 GM008700, R37 GM043601-17] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Bienko M, 2005, SCIENCE, V310, P1821, DOI 10.1126/science.1120615; Boutet SC, 2007, CELL, V130, P349, DOI 10.1016/j.cell.2007.05.044; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Elsasser S, 2005, NAT CELL BIOL, V7, P742, DOI 10.1038/ncb0805-742; Elsasser S, 2004, J BIOL CHEM, V279, P26817, DOI 10.1074/jbc.M404020200; Gandhi TKB, 2006, NAT GENET, V38, P285, DOI 10.1038/ng1747; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Guterman A, 2004, J BIOL CHEM, V279, P1729, DOI 10.1074/jbc.M307050200; Hamazaki J, 2006, EMBO J, V25, P4524, DOI 10.1038/sj.emboj.7601338; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; Jorgensen JP, 2006, J MOL BIOL, V360, P1043, DOI 10.1016/j.jmb.2006.06.011; Kaplun L, 2005, MOL CELL BIOL, V25, P5355, DOI 10.1128/MCB.25.13.5355-5362.2005; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Madura K, 2004, TRENDS BIOCHEM SCI, V29, P637, DOI 10.1016/j.tibs.2004.10.008; Qiu XB, 2006, EMBO J, V25, P5742, DOI 10.1038/sj.emboj.7601450; Raasi S, 2004, J MOL BIOL, V341, P1367, DOI 10.1016/j.jmb.2004.06.057; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V293, P986, DOI 10.1016/S0006-291X(02)00340-6; Schmidt M, 2005, BIOL CHEM, V386, P725, DOI 10.1515/BC.2005.085; Seong KM, 2007, FEBS LETT, V581, P2567, DOI 10.1016/j.febslet.2007.04.064; Sone T, 2004, J BIOL CHEM, V279, P28807, DOI 10.1074/jbc.M403165200; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; Wang QH, 2003, BIOCHEMISTRY-US, V42, P13529, DOI 10.1021/bi035391j; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Yao TT, 2006, NAT CELL BIOL, V8, P994, DOI 10.1038/ncb1460	36	468	479	1	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 22	2008	453	7194					481	488		10.1038/nature06926	http://dx.doi.org/10.1038/nature06926			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303EL	18497817	Green Accepted			2022-12-28	WOS:000256023700034
J	Wilson, JF				Wilson, Jennifer Fisher			Vermont health care reform aims for more coverage, less expense, and better care	ANNALS OF INTERNAL MEDICINE			English	News Item												jenwilson@acponline.org	Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136				Douglas Jim, 2007, Health Aff (Millwood), V26, pw697; Fisher ES, 2007, HEALTH AFFAIR, V26, pW44, DOI 10.1377/hlthaff.26.1.w44; Institute of Medicine, 2006, PATHW QUAL HLTH CAR; Wagner E H, 1998, Eff Clin Pract, V1, P2	4	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 20	2008	148	10					797	U150		10.7326/0003-4819-148-10-200805200-00022	http://dx.doi.org/10.7326/0003-4819-148-10-200805200-00022			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308EX	18490698				2022-12-28	WOS:000256372200017
J	Vetsch, G; Pato, U; Fischli, S; Lepper, S; Lonnfors-Weitzel, T; Offinger, A; Burgi, U; Schiemann, U				Vetsch, Gabi; Pato, Urs; Fischli, Stefan; Lepper, Sabine; Loennfors-Weitzel, Tarja; Offinger, Alexander; Buergi, Ulrich; Schiemann, Uwe			A combined presentation of Graves' disease and Miller-Fisher syndrome	LANCET			English	Editorial Material							IGG ANTIBODY; OPHTHALMOPLEGIA; ATAXIA		[Vetsch, Gabi; Offinger, Alexander; Buergi, Ulrich; Schiemann, Uwe] Univ Hosp Bern, Inselspital, Klin & Poliklin Allgemeine Innere Med, Dept Internal Med, CH-3010 Bern, Switzerland; [Pato, Urs] Univ Hosp Bern, Inselspital, Dept Neurol, CH-3010 Bern, Switzerland; [Fischli, Stefan] Univ Hosp Bern, Inselspital, Dept Endocrinol, CH-3010 Bern, Switzerland; [Lepper, Sabine] Univ Hosp Bern, Inselspital, Dept Ophthalmol, CH-3010 Bern, Switzerland; [Loennfors-Weitzel, Tarja] Univ Hosp Bern, Inselspital, Dept Radiol, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Schiemann, U (corresponding author), Univ Hosp Bern, Inselspital, Klin & Poliklin Allgemeine Innere Med, Dept Internal Med, Freiburg Str, CH-3010 Bern, Switzerland.	uwe.schiemann@insel.ch						CHIBA A, 1993, NEUROLOGY, V43, P1911, DOI 10.1212/WNL.43.10.1911; FISHER M, 1956, NEW ENGL J MED, V255, P57, DOI 10.1056/NEJM195607122550201; Mori M, 2007, NEUROLOGY, V68, P1144, DOI 10.1212/01.wnl.0000258673.31824.61; Schiemann U, 1999, EUR J ENDOCRINOL, V141, P332, DOI 10.1530/eje.0.1410332; Yuki N, 2001, OPHTHALMOLOGY, V108, P196, DOI 10.1016/S0161-6420(00)00420-6	5	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY-JUN	2008	371	9627					1886	1886		10.1016/S0140-6736(08)60803-X	http://dx.doi.org/10.1016/S0140-6736(08)60803-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307NL	18514733				2022-12-28	WOS:000256325500033
J	Feldkamp, ML; Reefhuis, J; Kucik, J; Krikov, S; Wilson, A; Moore, CA; Carey, JC; Botto, LD				Feldkamp, Marcia L.; Reefhuis, Jennita; Kucik, James; Krikov, Sergey; Wilson, Andy; Moore, Cynthia A.; Carey, John C.; Botto, Lorenzo D.			Case-control study of self reported genitourinary infections and risk of gastroschisis: findings from the national birth defects prevention study, 1997-2003	BMJ-BRITISH MEDICAL JOURNAL			English	Article							URINARY-TRACT-INFECTION; MATERNAL MEDICATION USE; PREGNANCY; PREVALENCE; EXPOSURES; AGE	Objective To assess the association between genitourinary infections in the month before conception to the end of the first trimesterand gastroschisis. Design Case-control study with self reported infections from a computer assisted telephone interview. Setting National birth defects,prevention study, a multisite, population based study including 10 state surveillance systems for birth defects in the United States. Participants Mothers of 505 offspring with gastroschisis and 4924 healthy liveborn infants as controls. Main outcome measure Adjusted odds ratios for gastroschisis with 95% confidence intervals. Results About 16% (n=81) of case mothers and 9% (n=425) of control mothers reported a genitourinary infection in the relevant time period; 4% (n='21) and 2% (n=98) reported a sexually transmitted infection and 13% (n=67) and 7% (n=338) reported a urinary tract infection, respectively. Case mothers aged <25 years reported higher rates of urinary tract infection alone and in combination with a sexually transmitted infection compared with control mothers. In women who reported both types of infection, there was a greater risk of gastroschisis in offspring (adjusted odds ratio 4.0, 95% confidence interval 1.4 to 11.6). Conclusion There is a significant association between self reported urinary tract infection plus sexually transmitted infection just before conception and in early pregnancy and gastroschisis.	[Feldkamp, Marcia L.; Krikov, Sergey; Wilson, Andy; Carey, John C.; Botto, Lorenzo D.] Univ Utah, Hlth Sci Ctr, Div Med Genet, Dept Pediat, Salt Lake City, UT 84132 USA; [Feldkamp, Marcia L.; Krikov, Sergey; Wilson, Andy; Carey, John C.; Botto, Lorenzo D.] Utah Dept Hlth, Utah Birth Defect Network, Salt Lake City, UT 84116 USA; [Reefhuis, Jennita; Kucik, James; Moore, Cynthia A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA	Utah System of Higher Education; University of Utah; Centers for Disease Control & Prevention - USA	Feldkamp, ML (corresponding author), Univ Utah, Hlth Sci Ctr, Div Med Genet, Dept Pediat, Salt Lake City, UT 84132 USA.	marcia.feldkamp@hsc.utah.edu	Reefhuis, Jennita/E-1793-2011	Reefhuis, Jennita/0000-0002-4747-4831; Wilson, Andrew/0000-0003-3679-9232	PHS HHS [U50/CCU822097] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Smith Nicole M., 2006, Morbidity and Mortality Weekly Report, V55, P1; Bermejo E, 2006, BRIT MED J, V332, P424, DOI 10.1136/bmj.332.7538.424; Bonny Andrea E, 2005, Adolesc Med Clin, V16, P149, DOI 10.1016/j.admecli.2004.09.010; CALZOLARI E, 1995, AM J MED GENET, V58, P187, DOI 10.1002/ajmg.1320580218; Canfield MA, 2006, BIRTH DEFECTS RES A, V76, P747, DOI 10.1002/bdra.20294; *CDCP, 2006, SEX TRANSM DIS SURV; Chambers CD, 2007, AM J MED GENET A, V143A, P653, DOI 10.1002/ajmg.a.31577; Currie MJ, 2007, AUST NZ J OBSTET GYN, V47, P2, DOI 10.1111/j.1479-828X.2006.00670.x; Draper ES, 2008, AM J EPIDEMIOL, V167, P485, DOI 10.1093/aje/kwm335; Banhidy F, 2006, BJOG-INT J OBSTET GY, V113, P1465, DOI 10.1111/j.1471-0528.2006.01110.x; Feldkamp ML, 2007, AM J MED GENET A, V143A, P639, DOI 10.1002/ajmg.a.31578; Gilson RJC, 2001, BMJ-BRIT MED J, V322, P1160, DOI 10.1136/bmj.322.7295.1160; GOLDBAUM G, 1990, TERATOLOGY, V42, P397, DOI 10.1002/tera.1420420408; HADDOW JE, 1993, TERATOLOGY, V47, P225, DOI 10.1002/tera.1420470306; Hooton TM, 1996, NEW ENGL J MED, V335, P468, DOI 10.1056/NEJM199608153350703; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Hougland KT, 2005, J PEDIATR SURG, V40, P535, DOI 10.1016/j.jpedsurg.2004.11.026; Kadzhaia D, 2005, Georgian Med News, P33; Kazaura MR, 2004, AM J EPIDEMIOL, V159, P358, DOI 10.1093/aje/kwh051; Kilby MD, 2006, BMJ-BRIT MED J, V332, P250, DOI 10.1136/bmj.332.7536.250; Kleinbaum D. G., 1998, APPL REGRESSION ANAL; Krcmery S, 2001, INT J ANTIMICROB AG, V17, P279, DOI 10.1016/S0924-8579(00)00351-4; Le J, 2004, ANN PHARMACOTHER, V38, P1692, DOI 10.1345/aph.1D630; LEDGER WL, 2007, VULVOVAGINAL INFECT; Macejko AM, 2007, UROL CLIN N AM, V34, P35, DOI 10.1016/j.ucl.2006.10.010; MartinezFrias ML, 1997, TERATOLOGY, V56, P241, DOI 10.1002/(SICI)1096-9926(199710)56:4<241::AID-TERA2>3.0.CO;2-1; Mastroiacovo P, 2006, BMJ-BRIT MED J, V332, P423, DOI 10.1136/bmj.332.7538.423-a; Millar LK, 1997, INFECT DIS CLIN N AM, V11, P13, DOI 10.1016/S0891-5520(05)70339-1; Nguyen H, 2002, SOUTHERN MED J, V95, P867, DOI 10.1097/00007611-200208000-00016; Nichols C R, 1997, J Matern Fetal Med, V6, P225; Norgard B, 2006, DEV MED CHILD NEUROL, V48, P674, DOI 10.1017/S0012162206001411; Pastore L M, 1999, J Perinatol, V19, P488, DOI 10.1038/sj.jp.7200264; Penman DG, 1998, BRIT J OBSTET GYNAEC, V105, P328, DOI 10.1111/j.1471-0528.1998.tb10095.x; Pimenta J, 2000, BRIT MED J, V321, P629, DOI 10.1136/bmj.321.7261.629; Rasmussen SA, 2003, BIRTH DEFECTS RES A, V67, P193, DOI 10.1002/bdra.10012; Rasmussen SJ, 1997, J CLIN INVEST, V99, P77, DOI 10.1172/JCI119136; Sadler TW., 2006, LANGMANS MED EMBRYOL; Scholes D, 2000, J INFECT DIS, V182, P1177, DOI 10.1086/315827; Scholes D, 2005, ANN INTERN MED, V142, P20, DOI 10.7326/0003-4819-142-1-200501040-00008; SHEPHARD TH, 2004, CATALOG TERATOGENIC; Stephens RS, 2003, TRENDS MICROBIOL, V11, P44, DOI 10.1016/S0966-842X(02)00011-2; TORFS CP, 1994, TERATOLOGY, V50, P44, DOI 10.1002/tera.1420500107; Torfs CP, 1996, TERATOLOGY, V54, P84, DOI 10.1002/(SICI)1096-9926(199606)54:2<84::AID-TERA4>3.0.CO;2-4; Weinstock H, 2004, PERSPECT SEX REPRO H, V36, P6, DOI 10.1111/j.1931-2393.2004.tb00002.x; WERLER MM, 1992, TERATOLOGY, V45, P361, DOI 10.1002/tera.1420450407; Werler MM, 2003, EPIDEMIOLOGY, V14, P349, DOI 10.1097/00001648-200305000-00016; Werler MM, 2002, AM J EPIDEMIOL, V155, P26, DOI 10.1093/aje/155.1.26; WERLER MM, 1992, TERATOLOGY, V45, P353, DOI 10.1002/tera.1420450406; Williams LJ, 2005, BIRTH DEFECTS RES A, V73, P177, DOI 10.1002/bdra.20114; Wilson PD, 1998, AM J EPIDEMIOL, V148, P414; Yoon PW, 2001, PUBLIC HEALTH REP, V116, P32, DOI 10.1093/phr/116.S1.32	51	62	66	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 21	2008	336	7658					1420	1423		10.1136/bmj.39567.509074.25	http://dx.doi.org/10.1136/bmj.39567.509074.25			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318WJ	18558640	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000257123200033
J	McAllister, SS; Gifford, AM; Greiner, AL; Kelleher, SP; Saelzler, MP; Ince, TA; Reinhardt, F; Harris, LN; Hylander, BL; Repasky, EA; Weinberg, RA				McAllister, Sandra S.; Gifford, Ann M.; Greiner, Ashley L.; Kelleher, Stephen P.; Saelzler, Matthew P.; Ince, Tan A.; Reinhardt, Ferenc; Harris, Lyndsay N.; Hylander, Bonnie L.; Repasky, Elizabeth A.; Weinberg, Robert A.			Systemic endocrine instigation of indolent tumor growth requires osteopontin	CELL			English	Article							HEMATOPOIETIC STEM-CELLS; BONE-MARROW; BREAST-CANCER; GENE-EXPRESSION; STROMAL FIBROBLASTS; TRANSGENIC MICE; MYELOID CELLS; IN-VITRO; ANGIOGENESIS; PROGENITORS	The effects of primary tumors on the host systemic environment and resulting contributions of the host to tumor growth are poorly understood. Here, we find that human breast carcinomas instigate the growth of otherwise-indolent tumor cells, micrometastases, and human tumor surgical specimens located at distant anatomical sites. This systemic instigation is accompanied by incorporation of bone-marrow cells (BMCs) into the stroma of the distant, once-indolent tumors. We find that BMCs of hosts bearing instigating tumors are functionally activated prior to their mobilization; hence, when coinjected with indolent cells, these activated BMCs mimic the systemic effects imparted by instigating tumors. Secretion of osteopontin by instigating tumors is necessary for BMC activation and the subsequent outgrowth of the distant otherwise-indolent tumors. These results reveal that outgrowth of indolent tumors can be governed on a systemic level by endocrine factors released by certain instigating tumors, and hold important experimental and therapeutic implications.	[McAllister, Sandra S.; Gifford, Ann M.; Greiner, Ashley L.; Kelleher, Stephen P.; Saelzler, Matthew P.; Ince, Tan A.; Reinhardt, Ferenc; Weinberg, Robert A.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Greiner, Ashley L.] Boston Univ, Dept Biol, Boston, MA 02215 USA; [Kelleher, Stephen P.] Williams Coll, Dept Biol, Williamstown, MA 01267 USA; [Saelzler, Matthew P.; Weinberg, Robert A.] MIT, Dept Biol, Cambridge, MA 02139 USA; [Ince, Tan A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol,Div Womens & Perinatal Pathol, Boston, MA 02115 USA; [Harris, Lyndsay N.] Yale Univ, Med Ctr, Dept Med Oncol, New Haven, CT 06510 USA; [Hylander, Bonnie L.; Repasky, Elizabeth A.] Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA; [Weinberg, Robert A.] MIT Ludwig Ctr Mol Oncol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Boston University; Williams College; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard Medical School; Yale University; Roswell Park Cancer Institute; Massachusetts Institute of Technology (MIT)	Weinberg, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	weinberg@wi.mit.edu	McAllister, Sandra/J-7373-2012	Ince, Tan/0000-0003-0315-6425	NATIONAL CANCER INSTITUTE [K08CA092013, P01CA080111] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA080111, K08 CA092013, P0-CA080111] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Cook AC, 2005, MOL CARCINOGEN, V43, P225, DOI 10.1002/mc.20105; Direkze NC, 2006, HEMATOL ONCOL, V24, P189, DOI 10.1002/hon.788; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Feng F, 2000, BREAST CANCER RES TR, V63, P71, DOI 10.1023/A:1006466516192; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Gohongi T, 1999, NAT MED, V5, P1203, DOI 10.1038/13524; Graudens E, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-3-r19; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hylander BL, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-22; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Iwata M, 2004, BLOOD, V103, P4496, DOI 10.1182/blood-2004-01-0256; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Klarmann K, 2003, BLOOD, V102, P3120, DOI 10.1182/blood-2003-04-1249; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; Kopp HG, 2006, CURR OPIN HEMATOL, V13, P175, DOI 10.1097/01.moh.0000219664.26528.da; Lamagna C, 2006, J LEUKOCYTE BIOL, V80, P677, DOI 10.1189/jlb.0506309; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Mor G, 2005, P NATL ACAD SCI USA, V102, P7677, DOI 10.1073/pnas.0502178102; Naka T, 2002, CANCER RES, V62, P5800; Nilsson SK, 2005, BLOOD, V106, P1232, DOI 10.1182/blood-2004-11-4422; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Olumi AF, 1999, CANCER RES, V59, P5002; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Ramankulov A, 2007, J CANCER RES CLIN, V133, P643, DOI 10.1007/s00432-007-0215-z; Randall TD, 1998, STEM CELLS, V16, P38, DOI 10.1002/stem.160038; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Rittling SR, 2004, BRIT J CANCER, V90, P1877, DOI 10.1038/sj.bjc.6601839; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; Scott LM, 2003, MOL CELL BIOL, V23, P9349, DOI 10.1128/MCB.23.24.9349-9360.2003; Sendobry SM, 1997, BRIT J PHARMACOL, V120, P1199, DOI 10.1038/sj.bjp.0701007; Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323; Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Stier S, 2005, J EXP MED, V201, P1781, DOI 10.1084/jem.20041992; Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224; Tuck AB, 2007, J CELL BIOCHEM, V102, P859, DOI 10.1002/jcb.21520; Udagawa T, 2006, FASEB J, V20, P95, DOI 10.1096/fj.04-3669com; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wai PY, 2005, CARCINOGENESIS, V26, P741, DOI 10.1093/carcin/bgi027; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004	45	327	336	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	2008	133	6					994	1005		10.1016/j.cell.2008.04.045	http://dx.doi.org/10.1016/j.cell.2008.04.045			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	312TJ	18555776	Green Accepted, Bronze			2022-12-28	WOS:000256693400015
J	Kahn, R				Kahn, Richard			Metabolic syndrome - what is the clinical usefulness?	LANCET			English	Editorial Material							AMERICAN-DIABETES-ASSOCIATION; CARDIOVASCULAR-DISEASE; RISK; DIAGNOSIS		Amer Diabet Assoc, Alexandria, VA 22307 USA	American Diabetes Association	Kahn, R (corresponding author), Amer Diabet Assoc, Alexandria, VA 22307 USA.	rkahn@diabetes.org						Brunzell JD, 2008, DIABETES CARE, V31, P811, DOI 10.2337/dc08-9018; Cull CA, 2007, CIRCULATION, V116, P2119, DOI 10.1161/CIRCULATIONAHA.107.733428; Eckel RH, 2006, DIABETES CARE, V29, P1697, DOI 10.2337/dc06-9911; Gami AS, 2007, J AM COLL CARDIOL, V49, P403, DOI 10.1016/j.jacc.2006.09.032; Greenland P, 2005, CIRCULATION, V112, P3675, DOI 10.1161/CIRCULATIONAHA.105.583310; Grundy SM, 2007, J CLIN ENDOCR METAB, V92, P399, DOI 10.1210/jc.2006-0513; Grundy SM, 2006, AM J CLIN NUTR, V83, P1248, DOI 10.1093/ajcn/83.6.1248; Iribarren C, 2006, J AM COLL CARDIOL, V48, P1800, DOI 10.1016/j.jacc.2006.03.070; Kahn R, 2005, DIABETES CARE, V28, P2289, DOI 10.2337/diacare.28.9.2289; Pepe MS, 2004, AM J EPIDEMIOL, V159, P882, DOI 10.1093/aje/kwh101; Reaven GM, 2006, AM J CLIN NUTR, V83, P1237, DOI 10.1093/ajcn/83.6.1237; SATTAR N, 2008, LANCET; Wilson PWF, 2005, CIRCULATION, V112, P3066, DOI 10.1161/CIRCULATIONAHA.105.539528	13	85	91	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 7	2008	371	9628					1892	1893		10.1016/S0140-6736(08)60731-X	http://dx.doi.org/10.1016/S0140-6736(08)60731-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310OI	18501420				2022-12-28	WOS:000256538500006
J	Peacock, T; Bradley, E				Peacock, Thomas; Bradley, Elizabeth			Applied physics - Going with (or against) the flow	SCIENCE			English	Editorial Material									[Peacock, Thomas] MIT, Dept Mech Engn, Cambridge, MA 02139 USA; [Bradley, Elizabeth] Univ Colorado, Dept Comp Sci, Boulder, CO 80309 USA	Massachusetts Institute of Technology (MIT); University of Colorado System; University of Colorado Boulder	Peacock, T (corresponding author), MIT, Dept Mech Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	tomp@mit.edu						Carrilho G., 2004, BUILD SERV ENG RES T, V25, P223; Choi H, 2008, ANNU REV FLUID MECH, V40, P113, DOI 10.1146/annurev.fluid.39.050905.110149; Coulliette C, 2007, ENVIRON SCI TECHNOL, V41, P6562, DOI 10.1021/es0630691; Fish FE, 2006, ANNU REV FLUID MECH, V38, P193, DOI 10.1146/annurev.fluid.38.050304.092201; Glezer A, 2002, ANNU REV FLUID MECH, V34, P503, DOI 10.1146/annurev.fluid.34.090501.094913; HAMILTON T, 2008, MIT TECH REV    0306; Hunt GR, 2005, J FLUID MECH, V527, P27, DOI 10.1017/S0022112004002575; Kim J, 2007, ANNU REV FLUID MECH, V39, P383, DOI 10.1146/annurev.fluid.39.050905.110153; Lee SM, 2007, ENVIRON MODEL ASSESS, V12, P63, DOI 10.1007/s10666-006-9053-7; Lou HD, 2006, AIAA J, V44, P58, DOI 10.2514/1.13347; Rathnasingham R, 2003, J FLUID MECH, V495, P209, DOI 10.1017/S0022112003006177; Rowley CW, 2005, INT J BIFURCAT CHAOS, V15, P997, DOI 10.1142/S0218127405012429; Sharfman B, 2006, SCIENTIST, V20, P17; Stone HA, 2004, ANNU REV FLUID MECH, V36, P381, DOI 10.1146/annurev.fluid.36.050802.122124; Triantafyllou MS, 2004, IEEE J OCEANIC ENG, V29, P585, DOI 10.1109/JOE.2004.833216; van Nierop EA, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.054502; WELDON M, IN PRESS J FLUID MEC; Wong PK, 2003, J FLUID MECH, V497, P55, DOI 10.1017/S002211200300658X	18	4	5	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	2008	320	5881					1302	1303		10.1126/science.1153479	http://dx.doi.org/10.1126/science.1153479			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309DO	18535235				2022-12-28	WOS:000256441100033
J	Levy, MM; Rapoport, J; Lemeshow, S; Chalfin, DB; Phillips, G; Danis, M				Levy, Mitchell M.; Rapoport, John; Lemeshow, Stanley; Chalfin, Donald B.; Phillips, Gary; Danis, Marion			Association between critical care physician management and patient mortality in the intensive care unit	ANNALS OF INTERNAL MEDICINE			English	Article							DESCRIPTIVE ANALYSIS; RESOURCE UTILIZATION; FULL-TIME; IMPACT; OUTCOMES; STATES; ICU; EFFICIENCY; LENGTH; STAY	Background: Critically ill patients admitted to intensive care units (ICUs) are thought to gain an added survival benefit from management by critical care physicians, but evidence of this benefit is scant. Objective: To examine the association between hospital mortality in critically ill patients and management by critical care physicians. Design: Retrospective analysis of a large, prospectively collected database of critically ill patients. Setting: 123 ICUs in 100 U. S. hospitals. Patients: 101 832 critically ill adults. Measurements: Through use of a random-effects logistic regression, investigators compared hospital mortality between patients cared for entirely by critical care physicians and patients cared for entirely by non-critical care physicians. An expanded Simplified Acute Physiology Score was used to adjust for severity of illness, and a propensity score was used to adjust for differences in the probability of selective referral of patients to critical care physicians. Results: Patients who received critical care management (CCM) were generally sicker, received more procedures, and had higher hospital mortality rates than those who did not receive CCM. After adjustment for severity of illness and propensity score, hospital mortality rates were higher for patients who received CCM than for those who did not. The difference in adjusted hospital mortality rates was less for patients who were sicker and who were predicted by propensity score to receive CCM. Limitation: Residual confounders for illness severity and selection biases for CCM might exist that were inadequately assessed or recognized. Conclusion: In a large sample of ICU patients in the United States, the odds of hospital mortality were higher for patients managed by critical care physicians than those who were not. Additional studies are needed to further evaluate these results and clarify the mechanisms by which they might occur.	Brown Univ, Providence, RI 02912 USA; Mt Holyoke Coll, S Hadley, MA 01075 USA; Ohio State Univ, Coll Hlth, Columbus, OH 43210 USA; Albert Einstein Coll Med, New York, NY USA; NIH, Bethesda, MD 20892 USA	Brown University; Mount Holyoke College; University System of Ohio; Ohio State University; Yeshiva University; National Institutes of Health (NIH) - USA	Levy, MM (corresponding author), Rhode Isl Hosp, 593 Eddy St, Providence, RI 02903 USA.	Mitchell_Levy@brown.edu			Intramural NIH HHS [ZIA MH002240-23] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Angus DC, 2000, JAMA-J AM MED ASSOC, V284, P2762, DOI 10.1001/jama.284.21.2762; Barie PS, 2000, SURG CLIN N AM, V80, P791, DOI 10.1016/S0039-6109(05)70096-7; BROWN JJ, 1989, CHEST, V96, P127, DOI 10.1378/chest.96.1.127; Carlson RW, 1996, CRIT CARE CLIN, V12, P525, DOI 10.1016/S0749-0704(05)70260-8; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; DANIS M, 2004, CRIT CARE MED, V32, pA94; Dara SI, 2005, CHEST, V128, P567, DOI 10.1378/chest.128.2.567; Dimick JB, 2001, CRIT CARE MED, V29, P753, DOI 10.1097/00003246-200104000-00012; Fuchs RJ, 2005, BEST PRACT RES-CLIN, V19, P125, DOI 10.1016/j.bpa.2004.07.003; Ghorra S, 1999, ANN SURG, V229, P163, DOI 10.1097/00000658-199902000-00001; GROEGER JS, 1993, CRIT CARE MED, V21, P279, DOI 10.1097/00003246-199302000-00022; GROEGER JS, 1992, CRIT CARE MED, V20, P846, DOI 10.1097/00003246-199206000-00024; Hanson CW, 1999, CRIT CARE MED, V27, P270, DOI 10.1097/00003246-199902000-00030; Higgins TL, 2003, CRIT CARE MED, V31, P45, DOI 10.1097/00003246-200301000-00007; Kelley MA, 2004, CRIT CARE MED, V32, P1219, DOI 10.1097/01.CCM.0000126403.89958.80; *LEAPFR GROUP, LEAPFR HOSP QUAL SAF; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; Manthous CA, 1997, MAYO CLIN PROC, V72, P391, DOI 10.4065/72.5.391; Milstein A, 2000, Eff Clin Pract, V3, P313; Multz AS, 1998, AM J RESP CRIT CARE, V157, P1468, DOI 10.1164/ajrccm.157.5.9708039; POLLACK MM, 1988, CRIT CARE MED, V16, P11, DOI 10.1097/00003246-198801000-00003; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; REYNOLDS HN, 1988, JAMA-J AM MED ASSOC, V260, P3446, DOI 10.1001/jama.260.23.3446; Varelas PN, 2004, CRIT CARE MED, V32, P2191, DOI 10.1097/01.CCM.0000146131.03578.21; Young M P, 2000, Eff Clin Pract, V3, P284	26	179	185	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2008	148	11					801	U10		10.7326/0003-4819-148-11-200806030-00002	http://dx.doi.org/10.7326/0003-4819-148-11-200806030-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308CG	18519926	Green Accepted			2022-12-28	WOS:000256365300001
J	Cooper, A; O'Flynn, N				Cooper, Angela; O'Flynn, Norma		Guideline Dev Grp	Guidelines - Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Cooper, Angela; O'Flynn, Norma] Royal Coll Gen Practitioners, Natl Collaborating Ctr Primary Care, London SW7 1PU, England		O'Flynn, N (corresponding author), Royal Coll Gen Practitioners, Natl Collaborating Ctr Primary Care, London SW7 1PU, England.	noflynn@rcgp.org.uk	Cappuccio, Francesco Paolo/ABF-1094-2020; Robson, John/H-3904-2014; Nherera, Leo/P-1567-2018	Cappuccio, Francesco Paolo/0000-0002-7842-5493; Robson, John/0000-0001-6889-0415; Nherera, Leo/0000-0003-1758-9504				ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; *NAT I HLTH CLIN E, 2007, EZ TREATM PRIM HET F; National Institute for Health and Clinical Excellence, 2008, LIP MOD CARD RISK AS; National Institute for Health and Clinical Excellence, 2006, STAT PREV CARD EV PA; National Institute for Health and Clinical Excellence, 2006, HYP MAN HYP AD PRIM; National Institute for HealthandClinical Excellence, 2006, OB PREV ID ASS MAN O	6	70	71	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 31	2008	336	7655					1246	1248		10.1136/bmj.39554.624086.AD	http://dx.doi.org/10.1136/bmj.39554.624086.AD			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311PS	18511800	Green Published			2022-12-28	WOS:000256612700034
J	Liu, H; Rudolf, J; Johnson, KA; McMahon, SA; Oke, M; Carter, L; McRobbie, AM; Brown, SE; Naismith, JH; White, MF				Liu, Huanting; Rudolf, Jana; Johnson, Kenneth A.; McMahon, Stephen A.; Oke, Muse; Carter, Lester; McRobbie, Anne-Marie; Brown, Sara E.; Naismith, James H.; White, Malcolm F.			Structure of the DNA repair helicase XPD	CELL			English	Article							XERODERMA-PIGMENTOSUM; CRYSTAL-STRUCTURE; COCKAYNE-SYNDROME; BASAL TRANSCRIPTION; DIFFRACTION DATA; TRICHOTHIODYSTROPHY; DEFICIENT; MUTATIONS; SEQUENCE; FEATURES	The XPD helicase (Rad3 in Saccharomyces cerevisiae) is a component of transcription factor IIH (TFIIH), which functions in transcription initiation and Nucleotide Excision Repair in eukaryotes, catalyzing DNA duplex opening localized to the transcription start site or site of DNA damage, respectively. XPD has a 50 to 30 polarity and the helicase activity is dependent on an iron-sulfur cluster binding domain, a feature that is conserved in related helicases such as FancJ. The xpd gene is the target of mutation in patients with xeroderma pigmentosum, trichothiodystrophy, and Cockayne's syndrome, characterized by a wide spectrum of symptoms ranging from cancer susceptibility to neurological and developmental defects. The 2.25 angstrom crystal structure of XPD from the crenarchaeon Sulfolobus tokodaii, presented here together with detailed biochemical analyses, allows a molecular understanding of the structural basis for helicase activity and explains the phenotypes of xpd mutations in humans.	[Liu, Huanting; Rudolf, Jana; Johnson, Kenneth A.; McMahon, Stephen A.; Oke, Muse; Carter, Lester; McRobbie, Anne-Marie; Brown, Sara E.; Naismith, James H.; White, Malcolm F.] Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland	University of St Andrews	Naismith, JH (corresponding author), Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland.	jhn@st-and.ac.uk; mfw2@st-and.ac.uk	White, Malcolm F/A-6055-2010; Naismith, James Henderson/AAB-8614-2020; Carter, Lester/G-6561-2014; Naismith, James Henderson/H-3408-2012	White, Malcolm F/0000-0003-1543-9342; Naismith, James Henderson/0000-0001-6744-5061; Naismith, James Henderson/0000-0001-6744-5061; Rudolf, Jana/0000-0003-1134-2340; Liu, Huanting/0000-0001-5953-9367; Oke, Muse/0000-0002-0169-752X	MRC [G0500367] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/B/14426] Funding Source: Medline; Medical Research Council [G0500367] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Andressoo JO, 2006, CANCER CELL, V10, P121, DOI 10.1016/j.ccr.2006.05.027; Berneburg M, 2000, CANCER RES, V60, P431; Boal AK, 2005, BIOCHEMISTRY-US, V44, P8397, DOI 10.1021/bi047494n; Botta E, 2002, HUM MOL GENET, V11, P2919, DOI 10.1093/hmg/11.23.2919; Botta E, 1998, AM J HUM GENET, V63, P1036, DOI 10.1086/302063; Broughton BC, 2001, HUM MOL GENET, V10, P2539, DOI 10.1093/hmg/10.22.2539; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruns CM, 1999, J MOL BIOL, V288, P427, DOI 10.1006/jmbi.1999.2697; Buttner K, 2007, NAT STRUCT MOL BIOL, V14, P647, DOI 10.1038/nsmb1246; Chen J, 2003, NATURE, V424, P228, DOI 10.1038/nature01746; Chen J, 2003, CELL CYCLE, V2, P503, DOI 10.4161/cc.2.6.558; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174; Dubaele S, 2003, MOL CELL, V11, P1635, DOI 10.1016/S1097-2765(03)00182-5; DUPUY JM, 1978, PEDIATRICS, V61, P675; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fujimoto M, 2005, J INVEST DERMATOL, V125, P86, DOI 10.1111/j.0022-202X.2005.23745.x; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Guerrero SA, 2001, APPL MICROBIOL BIOT, V56, P718, DOI 10.1007/s002530100690; Hinks JA, 2002, J BIOL CHEM, V277, P16936, DOI 10.1074/jbc.M200668200; Hirata A, 2008, NATURE, V451, P851, DOI 10.1038/nature06530; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kawarabayasi Y, 2001, DNA RES, V8, P123, DOI 10.1093/dnares/8.4.123; Kelman Z, 2005, CURR OPIN MICROBIOL, V8, P669, DOI 10.1016/j.mib.2005.10.001; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Klinge S, 2007, NAT STRUCT MOL BIOL, V14, P875, DOI 10.1038/nsmb1288; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; Lee BS, 2000, MOL CELL BIOL, V20, P2436, DOI 10.1128/MCB.20.7.2436-2445.2000; Lehmann AR, 2001, GENE DEV, V15, P15, DOI 10.1101/gad.859501; Lehmann AR, 2003, BIOCHIMIE, V85, P1101, DOI 10.1016/j.biochi.2003.09.010; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Nishiwaki Y, 2004, J INVEST DERMATOL, V122, P526, DOI 10.1046/j.0022-202X.2004.22226.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pugh RA, 2008, J BIOL CHEM, V283, P1732, DOI 10.1074/jbc.M707064200; Rudolf J, 2006, MOL CELL, V23, P801, DOI 10.1016/j.molcel.2006.07.019; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Seetharamappa J, 2007, ACTA CRYSTALLOGR F, V63, P488, DOI 10.1107/S1744309107020362; Singleton MR, 2007, ANNU REV BIOCHEM, V76, P23, DOI 10.1146/annurev.biochem.76.052305.115300; Singleton MR, 2004, NATURE, V432, P187, DOI 10.1038/nature02988; Singleton MR, 2002, J BACTERIOL, V184, P1819, DOI 10.1128/JB.184.7.1819-1826.2002; Soultanas P, 2000, EMBO J, V19, P3799, DOI 10.1093/emboj/19.14.3799; Taylor EM, 1997, P NATL ACAD SCI USA, V94, P8658, DOI 10.1073/pnas.94.16.8658; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; Theron T, 2005, MOL CELL BIOL, V25, P8368, DOI 10.1128/MCB.25.18.8368-8378.2005; van Hoffen A, 1999, NUCLEIC ACIDS RES, V27, P2898, DOI 10.1093/nar/27.14.2898; Vermeulen W, 2001, NAT GENET, V27, P299, DOI 10.1038/85864; Voloshin ON, 2007, J BIOL CHEM, V282, P18437, DOI 10.1074/jbc.M700376200; Winkler GS, 2000, J BIOL CHEM, V275, P4258, DOI 10.1074/jbc.275.6.4258	50	199	222	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	2008	133	5					801	812		10.1016/j.cell.2008.04.029	http://dx.doi.org/10.1016/j.cell.2008.04.029			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510925	Green Accepted, Bronze			2022-12-28	WOS:000256274500013
J	Long, JA; Trinajstic, K; Young, GC; Senden, T				Long, John A.; Trinajstic, Kate; Young, Gavin C.; Senden, Tim			Live birth in the Devonian period	NATURE			English	Article							X-RAY TOMOGRAPHY; VIVIPARITY; FISH	The extinct placoderm fishes were the dominant group of vertebrates throughout the Middle Palaeozoic era(1), yet controversy about their relationships within the gnathostomes ( jawed vertebrates) is partly due to different interpretations of their reproductive biology(2-5). Here we document the oldest record of a live- bearing vertebrate in a new ptyctodontid placoderm, Materpiscis attenboroughi gen. et sp. nov., from the Late Devonian Gogo Formation of Australia ( approximately 380 million years ago)(6). The new specimen, remarkably preserved in three dimensions, contains a single, intra- uterine embryo connected by a permineralized umbilical cord. An amorphous crystalline mass near the umbilical cord possibly represents the recrystallized yolk sac. Another ptyctodont from the Gogo Formation, Austroptyctodus gardineri(7), also shows three small embryos inside it in the same position. Ptyctodontids have already provided the oldest definite evidence for vertebrate copulation(8), and the new specimens confirm that some placoderms had a remarkably advanced reproductive biology, comparable to that of some modern sharks and rays. The new discovery points to internal fertilization and viviparity in vertebrates as originating earliest within placoderms.	[Long, John A.] Museum Victoria, Melbourne, Vic 3001, Australia; [Long, John A.; Young, Gavin C.] Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; [Long, John A.] Monash Univ, Sch Geosci, Clayton, Vic 3800, Australia; [Trinajstic, Kate] Univ Western Australia, Sch Earth & Geog Sci, Perth, WA 6009, Australia; [Senden, Tim] Australian Natl Univ, Dept Appl Math, Res Sch Phys Sci & Engn, Canberra, ACT 0200, Australia	Museum Victoria; Australian National University; Monash University; University of Western Australia; Australian National University	Long, JA (corresponding author), Museum Victoria, POB 666, Melbourne, Vic 3001, Australia.	jlong@museum.vic.gov.au	Trinajstic, Kate/B-2537-2009; Senden, Tim J/A-7319-2008	Senden, Tim J/0000-0001-6808-7219; Trinajstic, Kate/0000-0002-6519-6396; Long, John/0000-0001-8012-0114				Bottcher R., 1990, STUTTGARTER BEITRA B, V164, P1; Caldwell MW, 2001, P ROY SOC B-BIOL SCI, V268, P2397, DOI 10.1098/rspb.2001.1796; DENISON R, 1978, HDB PALEOICHTHYOLOGY, P128; Gardiner B.G., 1984, Journal of Vertebrate Paleontology, V4, P379; Goujet D, 2004, RECENT ADV ORIGIN EA, P109; LONG JA, 2006, SWIMMING STONE AMAZI, P320; Long John A., 1997, Geodiversitas, V19, P515; LUND R, 1980, SCIENCE, V209, P697, DOI 10.1126/science.209.4457.697; Maxwell EE, 2003, P ROY SOC B-BIOL SCI, V270, pS104, DOI 10.1098/rsbl.2003.0029; Miles R. S, 1977, Linnean Soc Symp Ser, VNo. 4, P123; MILES ROGER S., 1967, J LINN SOC ZOOL, V47, P99; Sakellariou A, 2004, PROC SPIE, V5535, P473, DOI 10.1117/12.559200; Sakellariou A, 2004, PHYSICA A, V339, P152, DOI 10.1016/j.physa.2004.03.055; Trinajstic K, 2007, BIOL LETTERS, V3, P197, DOI 10.1098/rsbl.2006.0604; Upeniece Ieva, 2001, Mitteilungen aus dem Museum fuer Naturkunde in Berlin Geowissenschaftliche Reihe, V4, P101; WOURMS JP, 1993, ENVIRON BIOL FISH, V38, P269, DOI 10.1007/BF00842922; YOUNG GC, 1986, ZOOL J LINN SOC-LOND, V88, P1, DOI 10.1111/j.1096-3642.1986.tb00876.x	17	83	86	2	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 29	2008	453	7195					650	U6		10.1038/nature06966	http://dx.doi.org/10.1038/nature06966			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305NN	18509443				2022-12-28	WOS:000256185200043
J	Chen, ZC; Yang, HJ; Pavletich, NP				Chen, Zhucheng; Yang, Haijuan; Pavletich, Nikola P.			Mechanism of homologous recombination from the RecA-ssDNA/dsDNA structures	NATURE			English	Article							DOUBLE-STRAND BREAKS; AMINO-ACID-RESIDUES; DNA-BINDING SITE; SUBUNIT INTERFACE; CRYSTAL-STRUCTURE; PROTEIN; FILAMENTS; REPAIR; RAD51; COMPLEXES	The RecA family of ATPases mediates homologous recombination, a reaction essential for maintaining genomic integrity and for generating genetic diversity. RecA, ATP and single-stranded DNA (ssDNA) form a helical filament that binds to double-stranded DNA (dsDNA), searches for homology, and then catalyses the exchange of the complementary strand, producing a new heteroduplex. Here we have solved the crystal structures of the Escherichia coli RecA-ssDNA and RecA-heteroduplex filaments. They show that ssDNA and ATP bind to RecA-RecA interfaces cooperatively, explaining the ATP dependency of DNA binding. The ATP c-phosphate is sensed across the RecA-RecA interface by two lysine residues that also stimulate ATP hydrolysis, providing a mechanism for DNA release. The DNA is underwound and stretched globally, but locally it adopts a B-DNA-like conformation that restricts the homology search to Watson - Crick- type base pairing. The complementary strand interacts primarily through base pairing, making heteroduplex formation strictly dependent on complementarity. The underwound, stretched filament conformation probably evolved to destabilize the donor duplex, freeing the complementary strand for homology sampling.	[Chen, Zhucheng; Yang, Haijuan; Pavletich, Nikola P.] Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10021 USA; [Pavletich, Nikola P.] Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; [Chen, Zhucheng] Cornell Univ, Weill Med Coll, Dept Biochem & Struct Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Cornell University	Pavletich, NP (corresponding author), Mem Sloan Kettering Canc Ctr, Struct Biol Program, 1275 York Ave, New York, NY 10021 USA.	pavletin@mskcc.org	Zhang, Qiuyu/E-3326-2010; Chen, Zhucheng/E-3327-2010		Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bell CE, 2005, MOL MICROBIOL, V58, P358, DOI 10.1111/j.1365-2958.2005.04876.x; BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; Bianco P R, 1998, Front Biosci, V3, pD570; Campbell MJ, 1999, J MOL BIOL, V286, P417, DOI 10.1006/jmbi.1998.2456; Conway AB, 2004, NAT STRUCT MOL BIOL, V11, P791, DOI 10.1038/nsmb795; Cox JM, 2006, J BIOL CHEM, V281, P12968, DOI 10.1074/jbc.M513736200; COX MM, 2007, TOP CURR GEN, V17, P53; Cromie GA, 2001, MOL CELL, V8, P1163, DOI 10.1016/S1097-2765(01)00419-1; Daumke O, 2004, NATURE, V429, P197, DOI 10.1038/nature02505; De Zutter JK, 2001, STRUCTURE, V9, P47, DOI 10.1016/S0969-2126(00)00552-9; DICAPUA E, 1990, J MOL BIOL, V214, P557, DOI 10.1016/0022-2836(90)90198-U; DUTREIX M, 1992, MOL GEN GENET, V232, P489, DOI 10.1007/BF00266254; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; Galletto R, 2006, NATURE, V443, P875, DOI 10.1038/nature05197; Hortnagel K, 1999, J MOL BIOL, V286, P1097, DOI 10.1006/jmbi.1998.2515; Ishimori K, 1996, J MOL BIOL, V264, P696, DOI 10.1006/jmbi.1996.0670; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joo C, 2006, CELL, V126, P515, DOI 10.1016/j.cell.2006.06.042; Kelley JA, 1997, J BIOL CHEM, V272, P25778, DOI 10.1074/jbc.272.41.25778; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Kurumizaka H, 1999, ARCH BIOCHEM BIOPHYS, V365, P83, DOI 10.1006/abbi.1999.1166; LARMINAT F, 1992, J BACTERIOL, V174, P6264, DOI 10.1128/JB.174.19.6264-6269.1992; Leger JF, 1998, P NATL ACAD SCI USA, V95, P12295, DOI 10.1073/pnas.95.21.12295; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; MALKOV VV, 1995, J BIOL CHEM, V270, P30230; Mazin AV, 1998, EMBO J, V17, P1161, DOI 10.1093/emboj/17.4.1161; McGrew DA, 2003, CRIT REV BIOCHEM MOL, V38, P385, DOI 10.1080/10409230390242489; MIKAWA T, 1995, J MOL BIOL, V250, P471, DOI 10.1006/jmbi.1995.0391; MORIMATSU K, 1995, ADV BIOPHYS, V31, P23, DOI 10.1016/0065-227X(95)99381-X; Morimatsu K, 2002, P NATL ACAD SCI USA, V99, P11688, DOI 10.1073/pnas.142404499; Neale MJ, 2006, NATURE, V442, P153, DOI 10.1038/nature04885; NGUYEN TT, 1993, J BIOL CHEM, V268, P3107; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RADDING CM, 1981, CELL, V25, P3, DOI 10.1016/0092-8674(81)90224-5; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Seitz EM, 1998, GENE DEV, V12, P1248, DOI 10.1101/gad.12.9.1248; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Skiba MC, 1999, BIOCHEMISTRY-US, V38, P11933, DOI 10.1021/bi991118z; SKIBA MC, 1994, J BIOL CHEM, V269, P3823; STASIAK A, 1988, J MOL BIOL, V202, P659, DOI 10.1016/0022-2836(88)90293-8; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; VanLoock MS, 2003, STRUCTURE, V11, P187, DOI 10.1016/S0969-2126(03)00003-0; Wang Y, 1996, BIOCHEMISTRY-US, V35, P3563, DOI 10.1021/bi952438v; Wu Y, 2004, MOL CELL, V15, P423, DOI 10.1016/j.molcel.2004.07.014; Yu X, 2004, CURR PROTEIN PEPT SC, V5, P73, DOI 10.2174/1389203043486883; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398	50	494	505	1	102	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 22	2008	453	7194					489	U3		10.1038/nature06971	http://dx.doi.org/10.1038/nature06971			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303EL	18497818				2022-12-28	WOS:000256023700035
J	Sjoqvist, F; Garle, M; Rane, A				Sjoqvist, Folke; Garle, Mats; Rane, Anders			Use of doping agents, particularly anabolic steroids, in sports and society	LANCET			English	Review							DENSITY LIPOPROTEIN-CHOLESTEROL; MASS-SPECTROMETRIC ANALYSIS; ANDROGENIC STEROIDS; EXOGENOUS TESTOSTERONE; CEREBROSPINAL-FLUID; MALE-ADOLESCENTS; MEN; ABUSE; POLYMORPHISM; PERFORMANCE	The use of doping agents, particularly anabolic androgenic steroids (AAS), has changed from being a problem restricted to sports to one of public-health concern. We review the prevalence of misuse, the evidence that some drugs improve performance in sport, their side-effects, and the long-term consequences of AAS misuse for society at large. There is substantial under-reporting of the side-effects of AAS to health authorities. We describe neuropsychiatric side-effects of AAS and their possible neurobiological correlates, with particular emphasis on violent behaviour. Analytical methods and laboratories accredited by the World Anti-Doping Agency can detect the misuse of all doping agents; although the analysis of testosterone requires special techniques, and recently discovered interethnic differences in testosterone excretion should be taken into account. The prevention of misuse of doping agents should include random doping analyses, medical follow-ups, pedagogic interventions, tougher legislation against possession of AAS, and longer disqualifications of athletes who use AAS.	[Sjoqvist, Folke; Garle, Mats; Rane, Anders] Karolinska Univ Hosp, Karolinska Inst, Dept Lab Med, Div Clin Pharmacol, SE-14186 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Sjoqvist, F (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Dept Lab Med, Div Clin Pharmacol, SE-14186 Stockholm, Sweden.	folke.sjoqvist@ki.se	Rane, Anders/L-2675-2013					Aguilera R, 1999, J CHROMATOGR B, V727, P95, DOI 10.1016/S0378-4347(99)00066-3; ALEN M, 1984, INT J SPORTS MED, V5, P341, DOI 10.1055/s-2008-1025929; [Anonymous], 1987, Med Sci Sports Exerc, V19, P534; Arvary D, 2000, NEW ENGL J MED, V342, P1532, DOI 10.1056/NEJM200005183422018; ASBERG M, 1976, ARCH GEN PSYCHIAT, V33, P1193; Bagatell CJ, 1996, NEW ENGL J MED, V334, P707, DOI 10.1056/NEJM199603143341107; Bahrke MS, 1996, SPORTS MED, V22, P367, DOI 10.2165/00007256-199622060-00005; BARKER S, 1987, BRIT J PSYCHIAT, V151, P564, DOI 10.1192/S0007125000217698; Basaria S, 2001, J CLIN ENDOCR METAB, V86, P5108, DOI 10.1210/jc.86.11.5108; Beckett A H, 1978, Br J Sports Med, V12, P185; Belanger A, 2003, TRENDS ENDOCRIN MET, V14, P473, DOI 10.1016/j.tem.2003.10.005; Bent S, 2003, ANN INTERN MED, V138, P468, DOI 10.7326/0003-4819-138-6-200303180-00010; Bents RT, 2006, INT J SPORT NUTR EXE, V16, P636, DOI 10.1123/ijsnem.16.6.636; Bhasin S, 1996, NEW ENGL J MED, V335, P1, DOI 10.1056/NEJM199607043350101; BIEGON A, 1990, ANN NY ACAD SCI, V600, P427, DOI 10.1111/j.1749-6632.1990.tb16899.x; BJORKHEM I, 1982, LAKARTIDNINGEN, P1238; BOHM AM, 2003, CURR SPORT MED REP, V2, P220; BOJE O, 1939, B HLTH ORG LEAGUE NA, P439; BONSON KR, 1994, PHARMACOL BIOCHEM BE, V49, P313, DOI 10.1016/0091-3057(94)90427-8; Bowers LD, 1998, CLIN SPORT MED, V17, P299, DOI 10.1016/S0278-5919(05)70082-X; Brower Kirk J, 2002, Curr Psychiatry Rep, V4, P377, DOI 10.1007/s11920-002-0086-6; BULOWKLED D, 2006, UGESTER LAEGER, V168, P3121; CABASSO A, 1994, MED SCI SPORT EXER, V26, P2; Calfee R, 2006, PEDIATRICS, V117, pE577, DOI 10.1542/peds.2005-1429; Catlin DH, 1996, JAMA-J AM MED ASSOC, V276, P231, DOI 10.1001/jama.276.3.231; Choi P Y, 1994, Ann Clin Psychiatry, V6, P21, DOI 10.3109/10401239409148835; Clarkson PM, 1997, SPORTS MED, V24, P366, DOI 10.2165/00007256-199724060-00003; Coen B, 2003, INT J SPORTS MED, V24, P428; Dai D, 2001, J PHARMACOL EXP THER, V299, P825; Daly RC, 2001, ARCH GEN PSYCHIAT, V58, P172, DOI 10.1001/archpsyc.58.2.172; Daly RC, 2003, PSYCHONEUROENDOCRINO, V28, P317, DOI 10.1016/S0306-4530(02)00025-2; DELATORRE X, 1997, RECENT ADV DOPING AN, P71; Donike M, 1982, SPORT LEISTUNG GESUN, P293; Dvorak J, 2006, BRIT J SPORT MED, V40, P40, DOI 10.1136/bjsm.2006.027490; EKBLOM B, 1991, Scandinavian Journal of Medicine and Science in Sports, V1, P88; Eklof AC, 2003, EUR J CLIN PHARMACOL, V59, P571, DOI 10.1007/s00228-003-0633-z; Eriksson A, 2005, HISTOCHEM CELL BIOL, V124, P167, DOI 10.1007/s00418-005-0029-5; Eriksson A, 2006, THESIS UMEA U; Faigenbaum AD, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.5.e6; Feigelson HS, 1998, CANCER RES, V58, P585; Franke WW, 1997, CLIN CHEM, V43, P1262; Garle M, 1996, J CHROMATOGR B, V687, P55, DOI 10.1016/S0378-4347(96)00210-1; Giorgi A, 1999, J Sci Med Sport, V2, P341, DOI 10.1016/S1440-2440(99)80007-3; GORDON B, 1935, ANN MED HIST, P513; Grivetti LE, 1997, J NUTR, V127, pS860, DOI 10.1093/jn/127.5.860S; Hall RCW, 2005, SOUTH MED J, V98, P550, DOI 10.1097/01.SMJ.0000157531.04472.B2; HALLBERG M, 2004, METHODS FIND EXP S2, V26, P33; Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502; HANNAN CJ, 1991, PSYCHONEUROENDOCRINO, V16, P335, DOI 10.1016/0306-4530(91)90019-P; HAUPT HA, 1984, AM J SPORT MED, V12, P469, DOI 10.1177/036354658401200613; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Herbst KL, 2004, CURR OPIN CLIN NUTR, V7, P271, DOI 10.1097/00075197-200405000-00006; Hikim IS, 2002, AM J PHYSIOL-ENDOC M, V283, pE154, DOI 10.1152/ajpendo.00502.2001; Hodges K, 2006, MED SCI SPORT EXER, V38, P329, DOI 10.1249/01.mss.0000183201.79330.9c; Isacsson G, 1998, COMPR PSYCHIAT, V39, P203, DOI 10.1016/S0010-440X(98)90061-X; Jakobsson J, 2007, PHARMACOGENOMICS J, V7, P282, DOI 10.1038/sj.tpj.6500419; Jakobsson J, 2006, J CLIN ENDOCR METAB, V91, P687, DOI 10.1210/jc.2005-1643; Jakobsson J, 2004, PHARMACOGENOMICS J, V4, P245, DOI 10.1038/sj.tpj.6500236; JIN CJ, 1993, BIOCHEM BIOPH RES CO, V194, P496, DOI 10.1006/bbrc.1993.1847; Johansson P, 2000, PHARMACOL BIOCHEM BE, V67, P271, DOI 10.1016/S0091-3057(00)00365-8; JOHNSON MD, 1990, PEDIATR CLIN N AM, V37, P1111; Johnston AM, 2006, CHEST, V130, P1283, DOI 10.1378/chest.130.4.1283-a; Kadi F, 1999, MED SCI SPORT EXER, V31, P1528, DOI 10.1097/00005768-199911000-00006; Kanayama G, 2003, DRUG ALCOHOL DEPEN, V71, P77, DOI 10.1016/S0376-8716(03)00069-3; Kanayama G, 2003, J CLIN PSYCHIAT, V64, P156, DOI 10.4088/JCP.v64n0208; Kanayama G, 2001, PSYCHOTHER PSYCHOSOM, V70, P137, DOI 10.1159/000056238; Karila TAM, 2003, INT J SPORTS MED, V24, P337; KASHKIN KB, 1989, JAMA-J AM MED ASSOC, V262, P3166, DOI 10.1001/jama.262.22.3166; Keller Evan T., 1996, Frontiers in Bioscience (online), V1, pD59; KENNEDY MC, 1993, MED J AUSTRALIA, V158, P346, DOI 10.5694/j.1326-5377.1993.tb121797.x; Kindermann W, 2004, INT J SPORTS MED, V25, P241, DOI 10.1055/s-2004-817850; Kindlundh AMS, 2003, NEUROSCIENCE, V119, P113, DOI 10.1016/S0306-4522(03)00120-9; Kindlundh AMS, 2001, EUR J PUBLIC HEALTH, V11, P322, DOI 10.1093/eurpub/11.3.322; Klotz F, 2006, ARCH GEN PSYCHIAT, V63, P1274, DOI 10.1001/archpsyc.63.11.1274; Kmietowicz Z, 2007, BRIT MED J, V334, P387, DOI 10.1136/bmj.39133.511563.DB; KOURI EM, 1995, DRUG ALCOHOL DEPEN, V40, P73, DOI 10.1016/0376-8716(95)01192-7; Labrie F, 2005, J ENDOCRINOL, V187, P169, DOI 10.1677/joe.1.06264; Lage JMM, 2002, NEUROLOGY, V58, P665, DOI 10.1212/WNL.58.4.665; Landry Gregory L, 2003, Curr Sports Med Rep, V2, P1; LENDERS JWM, 1988, INT J SPORTS MED, V9, P19, DOI 10.1055/s-2007-1024972; Lippi G, 2006, CRIT REV CL LAB SCI, V43, P349, DOI 10.1080/10408360600755313; LUKAS SE, 1993, TRENDS PHARMACOL SCI, V14, P61, DOI 10.1016/0165-6147(93)90032-F; Madea B, 1998, LANCET, V352, P33, DOI 10.1016/S0140-6736(05)79512-X; Magkos Faidon, 2004, Sports Med, V34, P871, DOI 10.2165/00007256-200434130-00002; Mark P B, 2005, Heart, V91, P888, DOI 10.1136/hrt.2004.053843; NILSSON S, 1995, EUR J CLIN PHARMACOL, V48, P9; Nilsson S, 2001, EUR J PUBLIC HEALTH, V11, P195, DOI 10.1093/eurpub/11.2.195; Nilsson S, 2005, SUBST USE MISUSE, V40, P1, DOI 10.1081/JA-200030485; NILSSON S, 2003, THESIS U GOTHENBURG; Pagonis TA, 2006, EUR PSYCHIAT, V21, P551, DOI 10.1016/j.eurpsy.2005.09.001; Parssinen M, 2000, INT J SPORTS MED, V21, P225, DOI 10.1055/s-2000-304; Pascual JA, 2004, THER DRUG MONIT, V26, P175, DOI 10.1097/00007691-200404000-00016; Perry P., 1990, ANN CLIN PSYCHIATRY, V2, P11, DOI [10.3109/10401239009150000, DOI 10.3109/10401239009150000]; Petersson A, 2006, DRUG ALCOHOL DEPEN, V81, P241, DOI 10.1016/j.drugalcdep.2005.07.003; Petersson A, 2006, DRUG ALCOHOL DEPEN, V81, P215, DOI 10.1016/j.drugalcdep.2005.07.001; Placidi GPA, 2001, BIOL PSYCHIAT, V50, P783, DOI 10.1016/S0006-3223(01)01170-2; Pope HG, 2004, ADDICTION, V99, P1189, DOI 10.1111/j.1360-0443.2004.00781.x; POPE HG, 1994, ARCH GEN PSYCHIAT, V51, P375, DOI 10.1001/archpsyc.1994.03950050035004; POPE HG, 1988, AM J PSYCHIAT, V145, P487; Prendergast HM, 2003, VET HUM TOXICOL, V45, P97; RYAN AJ, 1981, FED PROC, V40, P2682; Saugy M, 2006, BRIT J SPORT MED, V40, P35, DOI 10.1136/bjsm.2006.027573; SEMMENS J, 1983, METABOLISM, V32, P428, DOI 10.1016/0026-0495(83)90002-1; Shackleton CHL, 1997, STEROIDS, V62, P379, DOI 10.1016/S0039-128X(96)00253-X; SJOQVIST F, 1997, AVERYS DRUG TREATMEN, P1; SMITH GM, 1960, JAMA-J AM MED ASSOC, V172, P1623, DOI 10.1001/jama.1960.03020150047009; SMITH GM, 1959, JAMA-J AM MED ASSOC, V170, P542, DOI 10.1001/jama.1959.63010050001008; STRAUSS RH, 1985, JAMA-J AM MED ASSOC, V253, P2871; Striegel H, 2006, DRUG ALCOHOL DEPEN, V81, P11, DOI 10.1016/j.drugalcdep.2005.05.013; SU TP, 1993, JAMA-J AM MED ASSOC, V269, P2760, DOI 10.1001/jama.269.21.2760; Thiblin I, 2000, J FORENSIC SCI, V45, P16; Thiblin I, 2005, FUND CLIN PHARMACOL, V19, P27, DOI 10.1111/j.1472-8206.2004.00298.x; Thiblin I, 1997, J FORENSIC PSYCHIATR, V8, P299, DOI 10.1080/09585189708412012; Tirassa P, 1997, J NEUROSCI RES, V47, P198, DOI 10.1002/(SICI)1097-4547(19970115)47:2<198::AID-JNR8>3.0.CO;2-A; Tokish JM, 2004, AM J SPORT MED, V32, P1543, DOI 10.1177/0363546504268041; TRASKMAN L, 1981, ARCH GEN PSYCHIAT, V38, P631; Turgeon D, 2001, ENDOCRINOLOGY, V142, P778, DOI 10.1210/en.142.2.778; URHAUSEN A, 1989, EUR J APPL PHYSIOL O, V58, P633, DOI 10.1007/BF00418510; VENERI RJ, 1988, J CLIN GASTROENTEROL, V10, P467, DOI 10.1097/00004836-198808000-00025; WADE N, 1972, SCIENCE, V176, P1399, DOI 10.1126/science.176.4042.1399; Wadelius M, 1999, PHARMACOGENETICS, V9, P635, DOI 10.1097/01213011-199910000-00010; WEBB OL, 1984, METABOLISM, V33, P971, DOI 10.1016/0026-0495(84)90222-1; WEISS B, 1968, AB CENTR STIM S ORG; Wilber RL, 2002, SPORTS MED, V32, P125, DOI 10.2165/00007256-200232020-00004; WILSON IC, 1974, AM J PSYCHIAT, V131, P21, DOI 10.1176/ajp.131.1.21; Wilson W, 2004, GENOMICS, V84, P707, DOI 10.1016/j.ygeno.2004.06.011; Yamazaki H, 1997, ARCH BIOCHEM BIOPHYS, V346, P161, DOI 10.1006/abbi.1997.0302; YOSHIDA EM, 1994, J CLIN GASTROENTEROL, V18, P268, DOI 10.1097/00004836-199404000-00036	128	221	229	0	105	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY-JUN	2008	371	9627					1872	1882		10.1016/S0140-6736(08)60801-6	http://dx.doi.org/10.1016/S0140-6736(08)60801-6			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307NL	18514731				2022-12-28	WOS:000256325500031
J	Kumwenda, NI; Hoover, DR; Mofenson, LM; Thigpen, MC; Kafulafula, G; Li, Q; Mipando, L; Nkanaunena, K; Mebrahtu, T; Bulterys, M; Fowler, MG; Taha, TE				Kumwenda, Newton I.; Hoover, Donald R.; Mofenson, Lynne M.; Thigpen, Michael C.; Kafulafula, George; Li, Qing; Mipando, Linda; Nkanaunena, Kondwani; Mebrahtu, Tsedal; Bulterys, Marc; Fowler, Mary Glenn; Taha, Taha E.			Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TO-CHILD TRANSMISSION; POSTEXPOSURE PROPHYLAXIS; ZIDOVUDINE; INFANTS; TRIAL	Background: Effective strategies are urgently needed to reduce mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) through breast-feeding in resource-limited settings. Methods: Women with HIV-1 infection who were breast-feeding infants were enrolled in a randomized, phase 3 trial in Blantyre, Malawi. At birth, the infants were randomly assigned to one of three regimens: single-dose nevirapine plus 1 week of zidovudine (control regimen) or the control regimen plus daily extended prophylaxis either with nevirapine (extended nevirapine) or with nevirapine plus zidovudine (extended dual prophylaxis) until the age of 14 weeks. Using Kaplan-Meier analyses, we assessed the risk of HIV-1 infection among infants who were HIV-1-negative on DNA polymerase-chain-reaction assay at birth. Results: Among 3016 infants in the study, the control group had consistently higher rates of HIV-1 infection from the age of 6 weeks through 18 months. At 9 months, the estimated rate of HIV-1 infection (the primary end point) was 10.6% in the control group, as compared with 5.2% in the extended-nevirapine group (P<0.001) and 6.4% in the extended-dual-prophylaxis group (P=0.002). There were no significant differences between the two extended-prophylaxis groups. The frequency of breast-feeding did not differ significantly among the study groups. Infants receiving extended dual prophylaxis had a significant increase in the number of adverse events (primarily neutropenia) that were deemed to be possibly related to a study drug. Conclusions: Extended prophylaxis with nevirapine or with nevirapine and zidovudine for the first 14 weeks of life significantly reduced postnatal HIV-1 infection in 9-month-old infants. (ClinicalTrials.gov number, NCT00115648.).	[Kumwenda, Newton I.; Li, Qing; Mebrahtu, Tsedal; Taha, Taha E.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; [Fowler, Mary Glenn] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA; [Hoover, Donald R.] Rutgers State Univ, Piscataway, NJ USA; [Mofenson, Lynne M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA; [Thigpen, Michael C.; Bulterys, Marc] Ctr Dis Control & Prevent, Atlanta, GA USA; [Kafulafula, George] Univ Malawi, Coll Med, Blantyre, Malawi; [Mipando, Linda; Nkanaunena, Kondwani] Johns Hopkins Univ Coll Med Res Project, Blantyre, Malawi	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Rutgers State University New Brunswick; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Centers for Disease Control & Prevention - USA; University of Malawi; University of Malawi	Taha, TE (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Rm E7138,615 N Wolfe St, Baltimore, MD 21205 USA.	ttaha@jhsph.edu	Mofenson, Lynne/P-9631-2019; Kumwenda, Newton/ADL-6890-2022	Mofenson, Lynne/0000-0002-2818-9808; Taha, Taha/0000-0001-9814-4894; Kumwenda, Newton/0000-0003-2622-4339	NCHHSTP CDC HHS [5-U50-PS022061-05] Funding Source: Medline; CDC HHS [U50-CC0222061] Funding Source: Medline; NATIONAL CENTER FOR HIV, VIRAL HEPATITIS, STDS AND TB PREVENTION [U50PS022061] Funding Source: NIH RePORTER	NCHHSTP CDC HHS; CDC HHS; NATIONAL CENTER FOR HIV, VIRAL HEPATITIS, STDS AND TB PREVENTION(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)		ARENDT V, 2007, P INT AIDS SOC C HIV, P96; Bulterys M, 2005, J INFECT DIS, V192, P709, DOI 10.1086/432490; Danel C, 2006, LANCET, V367, P1981, DOI 10.1016/S0140-6736(06)68887-9; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Emery S, 2008, J INFECT DIS, V197, P1133, DOI 10.1086/586713; Gray GE, 2005, AIDS, V19, P1289, DOI 10.1097/01.aids.0000180100.42770.a7; HOLLANDER M, 1973, NONPARAMETRIC STAT M, P120; John-Stewart G, 2004, JAIDS-J ACQ IMM DEF, V35, P196, DOI 10.1097/00126334-200402010-00015; JOHNSTEWART G, 2004, J ACQ IMMUN DEF SYND, V35, P539; KILEWO C, 2007, P INT AIDS SOC C HIV, P96; KILEWO C, 2007, P 4 DOM DORM INT C H, P56; Leroy V, 2002, AIDS, V16, P631, DOI 10.1097/00002030-200203080-00016; MIROCHNICK M, 2007, 14 C RETR OPP INF LO, P91; Saba J, 2002, LANCET, V359, P1178; Shapiro RL, 2005, J INFECT DIS, V192, P720, DOI 10.1086/432483; Taha TE, 2004, JAMA-J AM MED ASSOC, V292, P202, DOI 10.1001/jama.292.2.202; Taha TE, 2003, LANCET, V362, P1171, DOI 10.1016/S0140-6736(03)14538-2; THOMAS T, 2008, 15 C RETR OPP INF BO, P87; Volmink J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003510.pub2; WHO, 2006, ANT DRUGS TREAT PREG; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9; Wilfert CM, 2007, J INFECT DIS, V195, P165, DOI 10.1086/510255; ZEH C, 2008, 15 C RETR OPP INF BO, P102	23	280	284	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 10	2008	359	2					119	129		10.1056/NEJMoa0801941	http://dx.doi.org/10.1056/NEJMoa0801941			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	323PJ	18525035				2022-12-28	WOS:000257459000003
J	Neumuller, RA; Betschinger, J; Fischer, A; Bushati, N; Poernbacher, I; Mechtler, K; Cohen, SM; Knoblich, JA				Neumueller, Ralph A.; Betschinger, Joerg; Fischer, Anja; Bushati, Natascha; Poernbacher, Ingrid; Mechtler, Karl; Cohen, Stephen M.; Knoblich, Juergen A.			Mei-P26 regulates microRNAs and cell growth in the Drosophila ovarian stem cell lineage	NATURE			English	Article							NEUROBLAST SELF-RENEWAL; RIBOSOMAL-RNA SYNTHESIS; ASYMMETRIC DIVISION; TUMOR-SUPPRESSOR; PROLIFERATION; MELANOGASTER; PROTEIN; CANCER; POLARITY; BRAIN	Drosophila neuroblasts(1) and ovarian stem cells(2,3) are well characterized models for stem cell biology. In both cell types, one daughter cell self- renews continuously while the other undergoes a limited number of divisions, stops to proliferate mitotically and differentiates. Whereas neuroblasts segregate the Trim - NHL( tripartite motif and Ncl- 1, HT2A and Lin- 41 domain)- containing protein Brain tumour ( Brat) into one of the two daughter cells(4-6), ovarian stem cells are regulated by an extracellular signal from the surrounding stem cell niche. After division, one daughter cell looses niche contact. It undergoes 4 transit- amplifying divisions to form a cyst of 16 interconnected cells that reduce their rate of growth and stop to proliferate mitotically. Here we show that the Trim - NHL protein Mei- P26 ( refs 7, 8) restricts growth and proliferation in the ovarian stem cell lineage. Mei- P26 expression is low in stem cells but is strongly induced in 16- cell cysts. In mei- P26 mutants, transit-amplifying cells are larger and proliferate indefinitely leading to the formation of an ovarian tumour. Like brat, mei- P26 regulates nucleolar size and can induce differentiation in Drosophila neuroblasts, suggesting that these genes act through the same pathway. We identify Argonaute- 1, a component of the RISC complex, as a common binding partner of Brat and Mei- P26, and show that Mei- P26 acts by inhibiting the microRNA pathway. Mei- P26 and Brat have a similar domain composition that is also found in other tumour suppressors and might be a defining property of a new family of microRNA regulators that act specifically in stem cell lineages.	[Neumueller, Ralph A.; Betschinger, Joerg; Fischer, Anja; Poernbacher, Ingrid; Mechtler, Karl; Knoblich, Juergen A.] Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria; [Bushati, Natascha; Cohen, Stephen M.] European Mol Biol Lab, D-69117 Heidelberg, Germany; [Mechtler, Karl] Res Inst Mol Pathol, A-1030 Vienna, Austria	Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); European Molecular Biology Laboratory (EMBL); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Knoblich, JA (corresponding author), Austrian Acad Sci, Inst Mol Biotechnol, Dr Bohr Gasse 3, A-1030 Vienna, Austria.	juergen.knoblich@imba.oeaw.ac.at	Knoblich, Juergen A/C-2974-2015; Cohen, Stephen M/G-9930-2011; Mechtler, Karl/AAF-2717-2019	Knoblich, Juergen A/0000-0002-6751-3404; Cohen, Stephen M/0000-0003-2858-9163; Mechtler, Karl/0000-0002-3392-9946; Poernbacher, Ingrid/0000-0003-2766-9700; Betschinger, Joerg/0000-0002-2627-8479	Austrian Science Fund FWF [P 16629] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Bello B, 2006, DEVELOPMENT, V133, P2639, DOI 10.1242/dev.02429; Betschinger J, 2006, CELL, V124, P1241, DOI 10.1016/j.cell.2006.01.038; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Caussinus E, 2005, NAT GENET, V37, P1125, DOI 10.1038/ng1632; Chen DH, 2003, DEVELOPMENT, V130, P1159, DOI 10.1242/dev.00325; Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011; Frank DJ, 2002, DEVELOPMENT, V129, P399; Fuller MT, 2007, SCIENCE, V316, P402, DOI 10.1126/science.1140861; Gilboa L, 2004, DEVELOPMENT, V131, P4895, DOI 10.1242/dev.01373; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; Jin ZG, 2007, CURR BIOL, V17, P539, DOI 10.1016/j.cub.2007.01.050; Kai T, 2004, NATURE, V428, P564, DOI 10.1038/nature02436; Knoblich JA, 2008, CELL, V132, P583, DOI 10.1016/j.cell.2008.02.007; LANTZ V, 1994, GENE DEV, V8, P598, DOI 10.1101/gad.8.5.598; Lee CY, 2006, GENE DEV, V20, P3464, DOI 10.1101/gad.1489406; Lee CY, 2006, DEV CELL, V10, P441, DOI 10.1016/j.devcel.2006.01.017; LIN HF, 1994, DEVELOPMENT, V120, P947; Ohlmeyer JT, 2003, DEVELOPMENT, V130, P6339, DOI 10.1242/dev.00855; Page SL, 2000, GENETICS, V155, P1757; Park JK, 2007, CURR BIOL, V17, P533, DOI 10.1016/j.cub.2007.01.060; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Rudra D, 2004, GENE DEV, V18, P2431, DOI 10.1101/gad.1256704; Sekelsky JJ, 1999, GENETICS, V152, P529; Tolia NH, 2007, NAT CHEM BIOL, V3, P36, DOI 10.1038/nchembio848; Wang H, 2006, GENE DEV, V20, P3453, DOI 10.1101/gad.1487506; Zaccai M, 1996, ZYGOTE, V4, P159, DOI 10.1017/S096719940000304X	28	169	173	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 10	2008	454	7201					241	U72		10.1038/nature07014	http://dx.doi.org/10.1038/nature07014			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	323RU	18528333	Green Accepted			2022-12-28	WOS:000257466900049
J	Buckley, BM				Buckley, Brendan M.			Clinical trials of orphan medicines	LANCET			English	Article							RANDOMIZED-TRIALS; CYSTIC-FIBROSIS; RARE DISEASES; N-OF-1 TRIALS		Natl Univ Ireland Univ Coll Cork, European Ctr Clin Trials Rare Dis, Cork, Ireland	University College Cork	Buckley, BM (corresponding author), Natl Univ Ireland Univ Coll Cork, European Ctr Clin Trials Rare Dis, Lancaster Hall,7 Little Hanover St, Cork, Ireland.	b.buckley@ucc.ie						Backman CL, 1999, AM J PHYS MED REHAB, V78, P170, DOI 10.1097/00002060-199903000-00022; Berry DA, 2006, NAT REV DRUG DISCOV, V5, P27, DOI 10.1038/nrd1927; Bollert FGE, 1999, EUR RESPIR J, V13, P107; Chiron C, 2000, LANCET, V356, P1638, DOI 10.1016/S0140-6736(00)03157-3; Committee for Medicinal Products for Human Use, 2006, GUID CLIN TRIALS SMA; Cook DJ, 1996, PSYCHOPHARMACOL BULL, V32, P363; FREEDMAN LS, 1994, STAT MED, V13, P1371, DOI 10.1002/sim.4780131312; Friedman L. M., 1998, FUNDAMENTALS CLIN TR; GUNN TR, 1979, J PEDIATR-US, V94, P106, DOI 10.1016/S0022-3476(79)80370-4; Jones B., 2003, DESIGN ANAL CROSS OV, V2nd; Lagakos SW, 2003, NEW ENGL J MED, V348, P2455, DOI 10.1056/NEJMe030024; Lilford RJ, 1995, BMJ-BRIT MED J, V311, P1621, DOI 10.1136/bmj.311.7020.1621; LUBITZ JA, 1973, JAMA-J AM MED ASSOC, V223, P1109, DOI 10.1001/jama.223.10.1109; SCHEIN PS, 1972, CANCER, V30, P1616, DOI 10.1002/1097-0142(197212)30:6<1616::AID-CNCR2820300630>3.0.CO;2-O; Stallard N, 2003, STAT MED, V22, P689, DOI 10.1002/sim.1362; Sung L, 2006, J PEDIAT HEMATOL ONC, V28, P263, DOI 10.1097/01.mph.0000212904.68899.1d; Suri R, 2004, PEDIATR PULM, V37, P305, DOI 10.1002/ppul.10442; Walshe J M, 1979, Prog Clin Biol Res, V34, P271; Whitehead J, 1997, DESIGN ANAL SEQUENTI; 1998, NOTE GUIDANCE STAT P	20	58	59	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2008	371	9629					2051	2055		10.1016/S0140-6736(08)60876-4	http://dx.doi.org/10.1016/S0140-6736(08)60876-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312YY	18555919				2022-12-28	WOS:000256709500035
J	Li, S; Wei, HC; Zheng, QS				Li, Sumei; Wei, Haichun; Zheng, Qingsi			Elimination of iodine-deficiency disorders in Tibet	LANCET			English	Editorial Material									[Li, Sumei; Zheng, Qingsi] Chinese Ctr Dis Control & Prevent, Inst Communicable Dis Control & Prevent, Beijing 102206, Peoples R China; [Wei, Haichun] Chinese Ctr Dis Control & Prevent, Natl Ctr Rural Water Supply Tech Guidance, Beijing 102206, Peoples R China	Chinese Center for Disease Control & Prevention; National Institute for Communicable Disease Control & Prevention, Chinese Center for Disease Control & Prevention; Chinese Center for Disease Control & Prevention; National Center for Rural Water Supply Technical Guidance, Chinese Center for Disease Control & Prevention	Li, S (corresponding author), Chinese Ctr Dis Control & Prevent, Inst Communicable Dis Control & Prevent, Beijing 102206, Peoples R China.	lisumeinttst@163.com						Chen ZP., 2000, J PREV MED INF, V16, P93; HETZEL BS, 2005, CHANCE COMMITMENT; LI SM, 2008, ZHONGGUO DI FANG BIN, V23, P43; XU J, 2007, ZHONGHUA LIU XING BI, V29, P253	4	4	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 14	2008	371	9629					1980	1981		10.1016/S0140-6736(08)60848-X	http://dx.doi.org/10.1016/S0140-6736(08)60848-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312YY	18555900				2022-12-28	WOS:000256709500008
J	Sievenpiper, JL; McIntyre, EA; Verrill, M; Quinton, R; Pearce, SHS				Sievenpiper, John L.; McIntyre, Elizabeth A.; Verrill, Mark; Quinton, Richard; Pearce, Simon H. S.			Unrecognised severe vitamin D deficiency	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MUSCULOSKELETAL PAIN; HYPOVITAMINOSIS-D; CANCER-RISK; SUPPLEMENTATION; POPULATION; PREVALENCE; IMMIGRANTS; CALCIUM; ADULTS; HEALTH		[Sievenpiper, John L.; McIntyre, Elizabeth A.; Verrill, Mark; Quinton, Richard; Pearce, Simon H. S.] Royal Victoria Infirm, Endocrine Unit, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK	Pearce, SHS (corresponding author), Royal Victoria Infirm, Endocrine Unit, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	S.H.S.Pearce@ncLac.uk	Pearce, Simon/AAB-3692-2019	Pearce, Simon/0000-0001-8384-8063; Verrill, Mark/0000-0002-8676-1120				Allison TR, 2002, ANN RHEUM DIS, V61, P151, DOI 10.1136/ard.61.2.151; Autier P, 2007, ARCH INTERN MED, V167, P1730, DOI 10.1001/archinte.167.16.1730; Bischoff-Ferrari HA, 2006, AM J CLIN NUTR, V84, P18, DOI 10.1093/ajcn/84.1.18; Diamond TH, 2005, MED J AUSTRALIA, V182, P281, DOI 10.5694/j.1326-5377.2005.tb06701.x; DUNNIGAN M G, 1962, Scott Med J, V7, P159; Erkal MZ, 2006, OSTEOPOROSIS INT, V17, P1133, DOI 10.1007/s00198-006-0069-2; GLOTH FM, 1995, JAMA-J AM MED ASSOC, V274, P1683, DOI 10.1001/jama.274.21.1683; *HLTH PROT AUTH, SUNS PROT YOURS ULTR; Holick MF, 2004, AM J CLIN NUTR, V80, p1678S, DOI 10.1093/ajcn/80.6.1678S; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Hypponen E, 2007, AM J CLIN NUTR, V85, P860, DOI 10.1093/ajcn/85.3.860; Institute of Medicine of the National Academies, 1997, DIET REF INT CALC PH; Lappe JM, 2007, AM J CLIN NUTR, V85, P1586, DOI 10.1093/ajcn/85.6.1586; Lin J, 2007, ARCH INTERN MED, V167, P1050, DOI 10.1001/archinte.167.10.1050; Macfarlane GJ, 2005, ANN RHEUM DIS, V64, P1217, DOI 10.1136/ard.2004.032656; Pal BR, 2003, J ENDOCRINOL, V179, P119, DOI 10.1677/joe.0.1790119; Plotnikoff GA, 2003, MAYO CLIN PROC, V78, P1463, DOI 10.4065/78.12.1463; PREECE MA, 1973, LANCET, V1, P907; Rajakumar K, 2003, PEDIATRICS, V112, pE132, DOI 10.1542/peds.112.2.e132; Reginato AJ, 1999, SEMIN ARTHRITIS RHEU, V28, P287, DOI 10.1016/S0049-0172(99)80013-4; Swan C H, 1971, Lancet, V2, P356; van Dam RM, 2007, AM J CLIN NUTR, V85, P755, DOI 10.1093/ajcn/85.3.755; Vieth R, 2001, EUR J CLIN NUTR, V55, P1091, DOI 10.1038/sj.ejcn.1601275; Vieth R, 2007, AM J CLIN NUTR, V85, P649, DOI 10.1093/ajcn/85.3.649	25	18	19	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 14	2008	336	7657					1371	1374		10.1136/bmj.39555.820394.BE	http://dx.doi.org/10.1136/bmj.39555.820394.BE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316YB	18556320	Green Published			2022-12-28	WOS:000256984700046
J	van Brakel, TJ; Buijs, J				van Brakel, Thomas J.; Buijs, Jacqueline			Striking cysts: recurrent haematuria in a kickboxer	LANCET			English	Editorial Material									[van Brakel, Thomas J.; Buijs, Jacqueline] Atrium Med Centrum Heerlen, Dept Internal Med, NL-6401 CX Heerlen, Netherlands	Atrium Medical Center	van Brakel, TJ (corresponding author), Atrium Med Centrum Heerlen, Dept Internal Med, Postbus 4446, NL-6401 CX Heerlen, Netherlands.	thomasvanbrakel@gmail.com							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2008	371	9629					2026	2026		10.1016/S0140-6736(08)60870-3	http://dx.doi.org/10.1016/S0140-6736(08)60870-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312YY	18555913				2022-12-28	WOS:000256709500029
J	van den Hout, WB; Peul, WC; Koes, BW; Brand, R; Kievit, J; Thomeer, RTWM				van den Hout, Wilbert B.; Peul, Wilco C.; Koes, Bart W.; Brand, Ronald; Kievit, Job; Thomeer, Ralph T. W. M.		Leiden The Hague Spine Intervent	Prolonged conservative care versus early surgery in patients with sciatica from lumbar disc herniation: cost utility analysis alongside a randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; NONOPERATIVE TREATMENT; ECONOMIC-EVALUATION; HEALTH; DISKECTOMY; MICRODISCECTOMY; VALUATION; DIAGNOSIS; SPORT	Objective To determine whether the faster recovery after early surgery for sciatica compared with prolonged conservative care is attained at reasonable costs. Design Cost utility analysis alongside a randomised controlled trial. Setting Nine Dutch hospitals. Participants 283 patients with sciatica for 6-12 weeks, caused by lumbar disc herniation. Interventions Six months of prolonged conservative care compared with early surgery. Main outcome measures Quality adjusted life years (QALYs) at one year and societal costs, estimated from patient reported utilities (UK and US EuroQol, SF-6D, and visual analogue scale) and diaries on costs (healthcare, patient's costs, and productivity). Results Compared with prolonged conservative care, early surgery provided faster recovery, with a gain in QALYs according to the UK EuroQol of 0.044 (95% confidence interval 0.005 to 0.083), the US EuroQol of 0.032 (0.005 to 0.059), the SF-6D of 0.024 (0.003 to 0.046), and the visual analogue scale of 0.032 (-0.003 to 0.066). From the healthcare perspective, early surgery resulted in higher costs (difference (euro)1819 (1449; pound $2832), 95% confidence interval (euro)842 to (euro)2790), with a cost utility ratio per QALY of (euro)41 000 ((euro)14 000 to (euro)430 000). From the societal perspective, savings on productivity costs led to a negligible total difference in cost ((euro)-12, (euro)-4029 to (euro)4006). Conclusions Faster recovery from sciatica makes early surgery likely to be cost effective compared with prolonged conservative care. The estimated difference in healthcare costs was acceptable and was compensated for by the difference in absenteeism from work. For a willingness to pay of (euro)40 000 or more per QALY, early surgery need not be withheld for economic reasons. Trial registration Current Controlled Trials ISRCTN 26872154.	[van den Hout, Wilbert B.; Kievit, Job] Leiden Univ, Med Ctr, Dept Med Decis Making, NL-2300 RC Leiden, Netherlands; [Peul, Wilco C.; Thomeer, Ralph T. W. M.] Leiden Univ, Med Ctr, Dept Neurosurg, NL-2300 RC Leiden, Netherlands; [Peul, Wilco C.] Med Ctr Haaglanden, Dept Neurosurg, The Hague, Netherlands; [Koes, Bart W.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Gen Practice, Rotterdam, Netherlands; [Brand, Ronald] Leiden Univ, Med Ctr, Dept Med Stat, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Haaglanden Medical Center; Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van den Hout, WB (corresponding author), Leiden Univ, Med Ctr, Dept Med Decis Making, POB 9600, NL-2300 RC Leiden, Netherlands.	hout@lumc.nl	Koes, Bart w/K-4614-2016	Koes, Bart w/0000-0002-0450-9969; van den Hout, Wilbert B./0000-0002-6425-0135				Andersson GBJ, 1996, SPINE, V21, pS75, DOI 10.1097/00007632-199612151-00009; Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8; Briggs A, 2003, HEALTH ECON, V12, P377, DOI 10.1002/hec.766; Carragee E, 2006, JAMA-J AM MED ASSOC, V296, P2485, DOI 10.1001/jama.296.20.2485; CHERKIN DC, 1994, SPINE, V19, P1201, DOI 10.1097/00007632-199405310-00001; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; *DUTCH HLTH INS EX, 2006, PHARM COMP; Hansson E, 2007, EUR SPINE J, V16, P329, DOI 10.1007/s00586-006-0131-y; Karppinen J, 2001, SPINE, V26, P2587, DOI 10.1097/00007632-200112010-00013; Koes BW, 2007, BMJ-BRIT MED J, V334, P1313, DOI 10.1136/bmj.39223.428495.BE; Lafuma A, 1997, REV RHUM, V64, P549; LAUNOIS R, 1994, PHARMACOECONOMICS, V6, P453, DOI 10.2165/00019053-199406050-00007; Luijsterburg PAJ, 2004, CLIN NEUROL NEUROSUR, V106, P313, DOI 10.1016/j.clineuro.2004.02.003; Malter AD, 1996, SPINE, V21, P1048, DOI 10.1097/00007632-199605010-00011; McKinley DS, 1999, NEUROL RES, V21, pS67, DOI 10.1080/01616412.1999.11741030; Oostenbrink JB, 2002, PHARMACOECONOMICS, V20, P443, DOI 10.2165/00019053-200220070-00002; OOSTENBRINK JB, 2004, MANUAL COST ANAL MET; Ostelo RWJG, 2004, SPINE, V29, P615, DOI 10.1097/01.BRS.0000115130.42394.0B; Osterman H, 2006, SPINE, V31, P2409; Ozkose Z, 2001, J NEUROSURG ANESTH, V13, P296, DOI 10.1097/00008506-200110000-00003; PATRICK DL, 1995, SPINE, V20, P1899, DOI 10.1097/00007632-199509000-00011; Peul WC, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-8; Peul WC, 2008, BRIT MED J, V336, P1355, DOI 10.1136/bmj.a143; Peul WC, 2007, NEW ENGL J MED, V356, P2245, DOI 10.1056/NEJMoa064039; Price C, 2005, HEALTH TECHNOL ASSES, V9, P1; Shaw JW, 2005, MED CARE, V43, P203, DOI 10.1097/00005650-200503000-00003; Smulders Y M, 2006, Ned Tijdschr Geneeskd, V150, P2467; Statistic Netherlands, 2008, CONS PRIC IND; STEVENSON RC, 1995, SPINE, V20, P739, DOI 10.1097/00007632-199503150-00017; Stiggelbout AM, 1996, INT J TECHNOL ASSESS, V12, P291, DOI 10.1017/S0266462300009648; STIGGELBOUT AM, 1996, HLTH CARE, V12, P291; Ubel PA, 2003, ARCH INTERN MED, V163, P1637, DOI 10.1001/archinte.163.14.1637; Vader JP, 2000, SPINE, V25, P1831, DOI 10.1097/00007632-200007150-00015; van den Berg B, 2005, HEALTH ECON, V14, P169, DOI 10.1002/hec.893; WEBER H, 1975, ACTA ORTHOP SCAND, V46, P631, DOI 10.3109/17453677508989245; Weinstein JN, 2006, JAMA-J AM MED ASSOC, V296, P2451, DOI 10.1001/jama.296.20.2451; Weinstein JN, 2006, JAMA-J AM MED ASSOC, V296, P2441, DOI 10.1001/jama.296.20.2441; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Zethraeus N, 2003, PHARMACOECONOMICS, V21, P39, DOI 10.2165/00019053-200321010-00003	39	95	97	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 14	2008	336	7657					1351	1354		10.1136/bmj.39583.709074.BE	http://dx.doi.org/10.1136/bmj.39583.709074.BE			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316YB	18502912	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000256984700040
J	Boehr, DD; Wright, PE				Boehr, David D.; Wright, Peter E.			How do proteins interact?	SCIENCE			English	Editorial Material							CONFORMATIONAL DIVERSITY; BINDING; NMR; DYNAMICS; VIEW		[Boehr, David D.; Wright, Peter E.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; [Boehr, David D.; Wright, Peter E.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Boehr, DD (corresponding author), Scripps Res Inst, Dept Mol Biol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	boehr@scripps.edu; wright@scripps.edu	Boehr, David/A-2068-2010	Wright, Peter/0000-0002-1368-0223				Bax A, 2005, CURR OPIN STRUC BIOL, V15, P563, DOI 10.1016/j.sbi.2005.08.006; Berger C, 1999, FEBS LETT, V450, P149, DOI 10.1016/S0014-5793(99)00458-5; BUCK E, 2003, SCI STKE, pRE14; FABER HR, 1990, NATURE, V348, P263, DOI 10.1038/348263a0; FOOTE J, 1994, P NATL ACAD SCI USA, V91, P10370, DOI 10.1073/pnas.91.22.10370; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Grunberg R, 2004, STRUCTURE, V12, P2125, DOI 10.1016/j.str.2004.09.014; Gsponer J, 2008, STRUCTURE, V16, P736, DOI 10.1016/j.str.2008.02.017; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; James LC, 2003, TRENDS BIOCHEM SCI, V28, P361, DOI 10.1016/S0968-0004(03)00135-X; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; Lange OF, 2008, SCIENCE, V320, P1471, DOI 10.1126/science.1157092; Lazaridis T, 1997, SCIENCE, V278, P1928, DOI 10.1126/science.278.5345.1928; Lindorff-Larsen K, 2005, NATURE, V433, P128, DOI 10.1038/nature03199; Ma BY, 1999, PROTEIN ENG, V12, P713, DOI 10.1093/protein/12.9.713; Mittermaier A, 2006, SCIENCE, V312, P224, DOI 10.1126/science.1124964; Tang C, 2007, NATURE, V449, P1078, DOI 10.1038/nature06232	17	153	154	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	2008	320	5882					1429	1430		10.1126/science.1158818	http://dx.doi.org/10.1126/science.1158818			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556537				2022-12-28	WOS:000256676400021
J	Sugden, A; Smith, J; Pennisi, E				Sugden, Andrew; Smith, Jesse; Pennisi, Elizabeth			The future of forests	SCIENCE			English	Editorial Material																			0	5	6	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	2008	320	5882					1435	1435		10.1126/science.320.5882.1435	http://dx.doi.org/10.1126/science.320.5882.1435			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556541				2022-12-28	WOS:000256676400025
J	Richardson, SH; Shirey, SB				Richardson, Stephen H.; Shirey, Steven B.			Continental mantle signature of Bushveld magmas and coeval diamonds	NATURE			English	Article							RE-OS ISOTOPE; KAAPVAAL CRATON; SOUTH-AFRICA; CRUSTAL CONTAMINATION; LITHOSPHERIC MANTLE; OSMIUM ISOTOPES; MERENSKY REEF; SR ISOTOPE; COMPLEX; SYSTEMATICS	The emplacement of the 2.05- billion- year- old Bushveld complex, the world's largest layered intrusion and platinum- group element ( PGE) repository(1), is a singular event in the history of the Kaapvaal craton of southern Africa(2-4), one of Earth's earliest surviving continental nuclei. In the prevailing model for the complex's mineralization, the radiogenic strontium and osmium isotope signatures of Bushveld PGE ores are attributed to continental crustal contamination of the host magmas(5-11). The scale of the intrusion and lateral homogeneity of the PGE- enriched layers(1), however, have long been problematical for the crustal contamination model, given the typically heterogeneous nature of continental crust. Furthermore, the distribution of Bushveld magmatism matches that of seismically anomalous underlying mantle(3,12), implying significant interaction before emplacement in the crust. Mineral samples of the ancient 200- km- deep craton keel, encapsulated in macrodiamonds and entrained by proximal kimberlites, reveal the nature of continental mantle potentially incorporated by Bushveld magmas(13,14). Here we show that sulphide inclusions in 2- billion- year- old diamonds from the 0.5- billion- year- old Venetia and 1.2- billion- year- old Premier kimberlites ( on opposite sides of the complex) have initial osmium isotope ratios even more radiogenic than those of Bushveld sulphide ore minerals(6,15). Sulphide Re - Os and silicate Sm - Nd and Rb - Sr isotope compositions indicate that continental mantle harzburgite and eclogite components, in addition to the original convecting mantle magma, most probably contributed to the genesis of both the diamonds and the Bushveld complex. Coeval diamonds provide key evidence that the main source of Bushveld PGEs is the mantle rather than the crust.	[Richardson, Stephen H.] Univ Cape Town, Dept Geol Sci, ZA-7701 Rondebosch, South Africa; [Shirey, Steven B.] Carnegie Inst Sci, Dept Terr Magnetism, Washington, DC 20015 USA	University of Cape Town; Carnegie Institution for Science	Richardson, SH (corresponding author), Univ Cape Town, Dept Geol Sci, ZA-7701 Rondebosch, South Africa.	steve.richardson@uct.ac.za						ALLEGRE CJ, 1980, EARTH PLANET SC LETT, V48, P148, DOI 10.1016/0012-821X(80)90177-6; Boshoff R, 2006, J GEOL, V114, P699, DOI 10.1086/507615; Carlson R.W., 1999, P 7 INT KIMBERLITE C, P99; Cawthorn RG, 1998, J PETROL, V39, P1669, DOI 10.1093/petrology/39.9.1669; DAVIES G, 1980, NATURE, V287, P33, DOI 10.1038/287033a0; DEWIT MJ, 1992, NATURE, V357, P553, DOI 10.1038/357553a0; Eales H.V., 1996, LAYERED INTRUSIONS, P181; Eglington BM, 2004, S AFR J GEOL, V107, P13, DOI 10.2113/107.1-2.13; HAMILTON PJ, 1977, J PETROL, V18, P24; HARMER RE, 1985, ECON GEOL, V80, P813, DOI 10.2113/gsecongeo.80.4.813; Harris C, 2005, J PETROL, V46, P579, DOI 10.1093/petrology/egh089; HART SR, 1989, ECON GEOL, V84, P1651, DOI 10.2113/gsecongeo.84.6.1651; James DE, 2001, GEOPHYS RES LETT, V28, P2485, DOI 10.1029/2000GL012578; KRUGER FJ, 1982, NATURE, V298, P53, DOI 10.1038/298053a0; LAMBERT DD, 1994, J PETROL, V35, P1717, DOI 10.1093/petrology/35.6.1717; LEE CA, 1990, ECON GEOL BULL SOC, V85, P877, DOI 10.2113/gsecongeo.85.4.877; Maier WD, 2000, CONTRIB MINERAL PETR, V140, P316, DOI 10.1007/s004100000186; Mathez EA, 2007, GEOCHIM COSMOCHIM AC, V71, P5514, DOI 10.1016/j.gca.2007.09.014; MCCANDLESS TE, 1991, GEOLOGY, V19, P1225, DOI 10.1130/0091-7613(1991)019<1225:OIACSF>2.3.CO;2; McCandless TE, 1999, GEOCHIM COSMOCHIM AC, V63, P911, DOI 10.1016/S0016-7037(99)00092-7; McCourt S, 2004, S AFR J GEOL, V107, P147, DOI 10.2113/107.1-2.147; MITCHELL RH, 1981, GEOCHIM COSMOCHIM AC, V45, P2425, DOI 10.1016/0016-7037(81)90096-X; Nagler TF, 1997, GEOLOGY, V25, P983, DOI 10.1130/0091-7613(1997)025<0983:GOSLMB>2.3.CO;2; Prevec SA, 2005, CONTRIB MINERAL PETR, V149, P306, DOI 10.1007/s00410-005-0650-2; Richardson SH, 2001, EARTH PLANET SC LETT, V191, P257, DOI 10.1016/S0012-821X(01)00419-8; RICHARDSON SH, 1984, NATURE, V310, P198, DOI 10.1038/310198a0; RICHARDSON SH, 1993, NATURE, V366, P256, DOI 10.1038/366256a0; Schmitz MD, 2004, EARTH PLANET SC LETT, V222, P363, DOI 10.1016/j.epsl.2004.03.036; Schoenberg R, 1999, EARTH PLANET SC LETT, V172, P49, DOI 10.1016/S0012-821X(99)00198-3; SHARP ZD, 2006, PRINCIPLES STABLE IS, pCH11; Shirey SB, 2002, SCIENCE, V297, P1683, DOI 10.1126/science.1072384; Shirey SB, 2001, GEOPHYS RES LETT, V28, P2509, DOI 10.1029/2000GL012589; Westerlund KJ, 2006, CONTRIB MINERAL PETR, V152, P275, DOI 10.1007/s00410-006-0101-8	33	110	112	1	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 12	2008	453	7197					910	913		10.1038/nature07073	http://dx.doi.org/10.1038/nature07073			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311WV	18548068				2022-12-28	WOS:000256632000041
J	Sargent, M				Sargent, Murray			Willis E. Lamb Jr (1913-2008) - Obituary	NATURE			English	Biographical-Item									Microsoft Corp, Redmond, WA 98052 USA	Microsoft	Sargent, M (corresponding author), Microsoft Corp, 1 Microsoft Way, Redmond, WA 98052 USA.	murrays@microsoft.com						LAMB W, PUBLICATION LIST	1	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2008	453	7197					867	867		10.1038/453867a	http://dx.doi.org/10.1038/453867a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311WV	18548063	Bronze			2022-12-28	WOS:000256632000032
J	Schreiner, PR; Reisenauer, HP; Pickard, FC; Simmonett, AC; Allen, WD; Matyus, E; Csaszar, AG				Schreiner, Peter R.; Reisenauer, Hans Peter; Pickard, Frank C.; Simmonett, Andrew C.; Allen, Wesley D.; Matyus, Edit; Csaszar, Attila G.			Capture of hydroxymethylene and its fast disappearance through tunnelling	NATURE			English	Article							MOLECULAR VIBRATIONAL ANHARMONICITY; HIGHER-DERIVATIVE METHODS; POTENTIAL-ENERGY SURFACE; METAL-CARBENE COMPLEXES; GAUSSIAN-BASIS SETS; SOLID RARE-GASES; AB-INITIO LIMIT; HYDROXYCARBENE INTERMEDIATE; POLYATOMIC-MOLECULES; ROTATION INTERACTION	Singlet carbenes exhibit a divalent carbon atom whose valence shell contains only six electrons, four involved in bonding to two other atoms and the remaining two forming a non- bonding electron pair. These features render singlet carbenes so reactive that they were long considered too short- lived for isolation and direct characterization. This view changed when it was found that attaching the divalent carbon atom to substituents that are bulky and/ or able to donate electrons produces carbenes that can be isolated and stored(1). N- heterocyclic carbenes are such compounds now in wide use, for example as ligands in metathesis catalysis(2). In contrast, oxygen- donor- substituted carbenes are inherently less stable and have been less studied. The pre- eminent case is hydroxymethylene, H-C-OH; although it is the key intermediate in the high- energy chemistry of its tautomer formaldehyde(3-7), has been implicated since 1921 in the photocatalytic formation of carbohydrates(8), and is the parent of alkoxycarbenes that lie at the heart of transition- metal carbene chemistry, all attempts to observe this species or other alkoxycarbenes have failed(9). However, theoretical considerations indicate that hydroxymethylene should be isolatable(10). Here we report the synthesis of hydroxymethylene and its capture by matrix isolation. We unexpectedly find that H -C-OH rearranges to formaldehyde with a half- life of only 2 h at 11 K by pure hydrogen tunnelling through a large energy barrier in excess of 30 kcal mol(-1).	[Schreiner, Peter R.; Reisenauer, Hans Peter] Univ Giessen, Inst Organ Chem, D-35392 Giessen, Germany; [Pickard, Frank C.; Simmonett, Andrew C.; Allen, Wesley D.] Univ Georgia, Ctr Computat Chem, Athens, GA 30602 USA; [Pickard, Frank C.; Simmonett, Andrew C.; Allen, Wesley D.] Univ Georgia, Dept Chem, Athens, GA 30602 USA; [Matyus, Edit; Csaszar, Attila G.] Eotvos Lorand Univ, Lab Mol Spect, Inst Chem, H-1518 Budapest, Hungary	Justus Liebig University Giessen; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Eotvos Lorand University; Hungarian Academy of Sciences	Schreiner, PR (corresponding author), Univ Giessen, Inst Organ Chem, Heinrich Buff Ring 58, D-35392 Giessen, Germany.	prs@org.chemie.uni-giessen.de; wdallen@uga.edu	Csaszar, Attila G/A-5241-2009; Schreiner, Peter Richard R/A-4084-2008; Mátyus, Edit/B-3668-2012; Allen, Wesley D./C-9867-2010	Csaszar, Attila G/0000-0001-5640-191X; Schreiner, Peter Richard R/0000-0002-3608-5515; Mátyus, Edit/0000-0001-7298-1707; Allen, Wesley D./0000-0002-4288-2297; Pickard, Frank/0000-0002-9608-3466				ALLEN WD, 1990, CHEM PHYS, V145, P427, DOI 10.1016/0301-0104(90)87051-C; ALLEN WD, 1993, NATO ADV SCI INST SE, V410, P343; Allen WD, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2207614; BALASUBRAMANIAN K, 1997, RELATIVISTIC EFFEC A; Baly ECC, 1921, J CHEM SOC, V119, P1025, DOI 10.1039/ct9211901025; Bomble YJ, 2005, J CHEM PHYS, V123, DOI 10.1063/1.1950567; Bourissou D, 2000, CHEM REV, V100, P39, DOI 10.1021/cr940472u; CARRINGTON T, 1984, J CHEM PHYS, V80, P4347, DOI 10.1063/1.447266; CLABO DA, 1988, CHEM PHYS, V123, P187, DOI 10.1016/0301-0104(88)87271-9; Csaszar AG, 1998, J CHEM PHYS, V108, P9751, DOI 10.1063/1.476449; Csaszar AG, 2001, NATO SCI SER II-MATH, V20, P317; Czako G, 2004, MOL PHYS, V102, P2411, DOI 10.1080/0026897042000274991; DeKock RL, 2004, J PHYS CHEM A, V108, P2893, DOI 10.1021/jp036809q; DUNNING TH, 1989, J CHEM PHYS, V90, P1007, DOI 10.1063/1.456153; Evangelista FA, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2743014; Evangelista FA, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2357923; FISCHER EO, 1964, ANGEW CHEM INT EDIT, V3, P580, DOI 10.1002/anie.196405801; FUKUI K, 1970, J PHYS CHEM-US, V74, P4161, DOI 10.1021/j100717a029; GODDARD JD, 1979, J CHEM PHYS, V70, P5117, DOI 10.1063/1.437353; Gonzales JM, 2003, CHEM-EUR J, V9, P2173, DOI 10.1002/chem.200204408; GONZALEZ C, 1990, J PHYS CHEM-US, V94, P5523, DOI 10.1021/j100377a021; GRAY SK, 1980, J CHEM PHYS, V73, P2733, DOI 10.1063/1.440494; HOFFMANN MR, 1981, ASTROPHYS J, V249, P563, DOI 10.1086/159315; Jacox ME, 2002, CHEM SOC REV, V31, P108, DOI 10.1039/b102907j; Johnston H.S., 1966, GAS PHASE REACTION R; Kallay M, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2121589; KEMPER MJH, 1978, J AM CHEM SOC, V100, P7841, DOI 10.1021/ja00493a010; Liboff R.L., 2003, INTRO QUANTUM MECH, V4th ed.; LUCCHESE RR, 1978, J AM CHEM SOC, V100, P298, DOI 10.1021/ja00469a059; Macoas EMS, 2004, J CHEM PHYS, V121, P1331, DOI 10.1063/1.1760733; Matyus E, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2756518; MCMAHON RJ, 1987, J AM CHEM SOC, V109, P683, DOI 10.1021/ja00237a008; MILLER WH, 1979, J AM CHEM SOC, V101, P6810, DOI 10.1021/ja00517a004; MILLER WH, 1980, J CHEM PHYS, V72, P99, DOI 10.1063/1.438959; Mills I, 1972, MOL SPECTROSCOPY MOD, V1, P115; NIELSEN HH, 1951, REV MOD PHYS, V23, P90, DOI 10.1103/RevModPhys.23.90; Nolan, 2006, N HETEROCYCLIC CARBE; Papousek D., 1982, MOL VIBRATIONAL ROTA; PAU CF, 1982, J PHYS CHEM-US, V86, P1252, DOI 10.1021/j100397a008; PERERA SA, 1993, CHEM PHYS LETT, V216, P606, DOI 10.1016/0009-2614(93)90150-Y; Pettersson M, 2002, J CHEM PHYS, V117, P9095, DOI 10.1063/1.1521429; Razavy Mohsen, 2003, QUANTUM THEORY TUNNE; Reid DL, 2000, J PHYS CHEM A, V104, P3398, DOI 10.1021/jp9941965; Reisenauer HP, 2006, EUR J ORG CHEM, V2006, P4813, DOI 10.1002/ejoc.200600485; ROSENFELD RN, 1983, J AM CHEM SOC, V105, P3485, DOI 10.1021/ja00349a019; Schreiner PR, 2006, CHEMPHYSCHEM, V7, P880, DOI 10.1002/cphc.200500555; Schuurman MS, 2005, J COMPUT CHEM, V26, P1106, DOI 10.1002/jcc.20238; Schuurman MS, 2004, J CHEM PHYS, V120, P11586, DOI 10.1063/1.1707013; Sierra MA, 2000, CHEM REV, V100, P3591, DOI 10.1021/cr9804137; SODEAU JR, 1978, CHEM PHYS LETT, V57, P71, DOI 10.1016/0009-2614(78)80353-4; Tarczay G, 2001, MOL PHYS, V99, P1769, DOI 10.1080/00268970110073907; VENKATESWARLU P, 1955, J CHEM PHYS, V23, P1200, DOI 10.1063/1.1742240; Watson J. K. G., 1977, VIBRATIONAL SPECTRA, P1; WEINER BR, 1983, J ORG CHEM, V48, P5362, DOI 10.1021/jo00174a042; WOON DE, 1995, J CHEM PHYS, V103, P4572, DOI 10.1063/1.470645; Zou SL, 2003, J CHEM PHYS, V118, P10012, DOI 10.1063/1.1571520; ZUEV PS, 1994, J AM CHEM SOC, V116, P4123, DOI 10.1021/ja00088a076	57	212	213	4	119	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 12	2008	453	7197					906	U42		10.1038/nature07010	http://dx.doi.org/10.1038/nature07010			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311WV	18548067				2022-12-28	WOS:000256632000040
J	Tewksbury, JJ; Huey, RB; Deutsch, CA				Tewksbury, Joshua J.; Huey, Raymond B.; Deutsch, Curtis A.			Ecology - Putting the heat on tropical animals	SCIENCE			English	Editorial Material							CLIMATE-CHANGE; THERMAL TOLERANCE; MOUNTAIN PASSES; SENSITIVITY; ADAPTATION; CAPACITY		[Tewksbury, Joshua J.; Huey, Raymond B.] Univ Washington, Dept Biol, Seattle, WA 98195 USA; [Deutsch, Curtis A.] Univ Calif Los Angeles, Dept Atmospher & Ocean Sci, Los Angeles, CA 90095 USA	University of Washington; University of Washington Seattle; University of California System; University of California Los Angeles	Tewksbury, JJ (corresponding author), Univ Washington, Dept Biol, Seattle, WA 98195 USA.	tewksjj@u.washington.edu	Huey, Raymond/F-1597-2010; Deutsch, Curtis A/D-1703-2011	Huey, Raymond/0000-0002-4962-8670				Addo-Bediako A, 2000, P ROY SOC B-BIOL SCI, V267, P739, DOI 10.1098/rspb.2000.1065; Bradshaw WE, 2008, MOL ECOL, V17, P157, DOI 10.1111/j.1365-294X.2007.03509.x; Brett J. R., 1970, MARINE ECOLOGY, P515; Calosi P, 2008, BIOL LETTERS, V4, P99, DOI 10.1098/rsbl.2007.0408; Crozier L, 2006, AM NAT, V167, P853, DOI 10.1086/504848; Currano ED, 2008, P NATL ACAD SCI USA, V105, P1960, DOI 10.1073/pnas.0708646105; Deutsch CA, 2008, P NATL ACAD SCI USA, V105, P6668, DOI 10.1073/pnas.0709472105; Ghalambor CK, 2006, INTEGR COMP BIOL, V46, P5, DOI 10.1093/icb/icj003; Gilman SE, 2006, P NATL ACAD SCI USA, V103, P9560, DOI 10.1073/pnas.0510992103; Helmuth B, 2005, ANNU REV PHYSIOL, V67, P177, DOI 10.1146/annurev.physiol.67.040403.105027; Hoffmann AA, 2003, SCIENCE, V301, P100, DOI 10.1126/science.1084296; IPCC (Intergovernmental Panel on Climate Change), 2007, CLIM CHANG 2007 PHYS; JANZEN DH, 1967, AM NAT, V101, P233, DOI 10.1086/282487; Kearney M, 2004, ECOLOGY, V85, P3119, DOI 10.1890/03-0820; Kurz WA, 2008, NATURE, V452, P987, DOI 10.1038/nature06777; Parmesan C, 2007, GLOBAL CHANGE BIOL, V13, P1860, DOI 10.1111/j.1365-2486.2007.01404.x; PARSONS PA, 1989, AMBIO, V18, P322; Portner HO, 2007, SCIENCE, V315, P95, DOI 10.1126/science.1135471; Root TL, 2003, NATURE, V421, P57, DOI 10.1038/nature01333; RUIBAL R, 1961, EVOLUTION, V15, P98, DOI 10.2307/2405846; Stillman JH, 2003, SCIENCE, V301, P65, DOI 10.1126/science.1083073; VANBERKUM FH, 1988, AM NAT, V132, P327, DOI 10.1086/284856; Whitfield SM, 2007, P NATL ACAD SCI USA, V104, P8352, DOI 10.1073/pnas.0611256104; Williams JW, 2007, P NATL ACAD SCI USA, V104, P5738, DOI 10.1073/pnas.0606292104	24	629	643	3	275	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	2008	320	5881					1296	1297		10.1126/science.1159328	http://dx.doi.org/10.1126/science.1159328			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309DO	18535231				2022-12-28	WOS:000256441100028
J	Okie, S				Okie, Susan			A new attack on malaria	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		DELACOLLETTE C, 2006, WHO PUBLICATION; Greenwood BM, 2008, J CLIN INVEST, V118, P1266, DOI 10.1172/JCI33996; Kiszewski A, 2007, B WORLD HEALTH ORGAN, V85, P623, DOI 10.2471/BLT.06.039529; MCNEIL DG, 2008, GATES FDN INFLUENCE	4	13	14	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2008	358	23					2425	2428		10.1056/NEJMp0803483	http://dx.doi.org/10.1056/NEJMp0803483			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308HY	18525039				2022-12-28	WOS:000256380700001
J	Dressaire, E; Bee, R; Bell, DC; Lips, A; Stone, HA				Dressaire, Emilie; Bee, Rodney; Bell, David C.; Lips, Alex; Stone, Howard A.			Interfacial polygonal nanopatterning of stable microbubbles	SCIENCE			English	Article							SURFACE-TENSION; MONOLAYERS; STABILITY; DISSOLUTION; MEDIA; FOAMS	Micrometer- sized bubbles are unstable and therefore difficult to make and store for substantial lengths of time. Short- term stabilization is achieved by the addition of amphiphilic molecules, which reduce the driving force for dissolution. When these molecules crystallize on the air/ liquid interface, the lifetime of individual bubbles may extend over a few months. We demonstrated low gas- fraction dispersions with mean bubble radii of less than 1 micrometer and stability lasting more than a year. An insoluble, self- assembled surfactant layer covers the surface of the microbubbles, which can result in nanometer- scale hexagonal patterning that we explain with thermodynamic and molecular models. The elastic response of the interface arrests the shrinkage of the bubbles. Our study identifies a route to fabricate highly stable dispersions of microbubbles.	[Dressaire, Emilie; Bell, David C.; Stone, Howard A.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA; [Bee, Rodney; Lips, Alex] Unilever Res Labs, Trumbull, CT 06611 USA	Harvard University; Unilever	Stone, HA (corresponding author), Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA.	has@seas.harvard.edu	Lips, Alex/AAF-3408-2020	Bell, David/0000-0002-8215-127X				Abkarian M, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.188301; Baumgart T, 2003, NATURE, V425, P821, DOI 10.1038/nature02013; Bloch SH, 2005, ULTRASOUND MED BIOL, V31, P439, DOI 10.1016/j.ultrasmedbio.2004.12.016; Borden MA, 2006, LANGMUIR, V22, P4291, DOI 10.1021/la052841v; Borden MA, 2004, J PHYS CHEM B, V108, P6009, DOI 10.1021/jp037815p; Cohen-Addad S, 1998, PHYS REV E, V57, P6897, DOI 10.1103/PhysRevE.57.6897; Cox AR, 2007, LANGMUIR, V23, P7995, DOI 10.1021/la700451g; DAILLANT J, 1990, J PHYS CONDENS MA SA, V2, P405; Diamant H, 2000, EUROPHYS LETT, V52, P171, DOI 10.1209/epl/i2000-00419-1; Dickinson E, 2004, LANGMUIR, V20, P8517, DOI 10.1021/la048913k; Duncan PB, 2004, LANGMUIR, V20, P2567, DOI 10.1021/la034930i; EDWARDS SF, 1980, J PHYS D, V13, P209; EPSTEIN PS, 1950, J CHEM PHYS, V18, P1505, DOI 10.1063/1.1747520; Faruk O, 2007, MACROMOL MATER ENG, V292, P113, DOI 10.1002/mame.200600406; Garofalakis G, 2002, LANGMUIR, V18, P4765, DOI 10.1021/la011784c; Hilgenfeldt S, 2001, PHYS REV LETT, V86, P4704, DOI 10.1103/PhysRevLett.86.4704; ISRAELACHVILI JN, 1992, INTERMOELCULAR SURFA; Kim DH, 2003, LANGMUIR, V19, P8455, DOI 10.1021/la034779c; Kloek W, 2001, J COLLOID INTERF SCI, V237, P158, DOI 10.1006/jcis.2001.7454; Larson R. G., 1999, STRUCTURE RHEOLOGY C, P443; MacPherson RD, 2007, NATURE, V446, P1053, DOI 10.1038/nature05745; Myers D, 1999, SURFACES INTERFACES; Stratford K, 2005, SCIENCE, V309, P2198, DOI 10.1126/science.1116589; Subramonian S, 2004, CELL POLYM, V23, P349, DOI 10.1177/026248930402300601; Talu E, 2006, LANGMUIR, V22, P9487, DOI 10.1021/la062095+; Wang M, 2007, J PHYS D APPL PHYS, V40, P260, DOI 10.1088/0022-3727/40/1/024; Wang YC, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2185629; Yu LMY, 2004, J APPL PHYSIOL, V97, P704, DOI 10.1152/japplphysiol.00089.2003	28	109	117	10	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	2008	320	5880					1198	1201		10.1126/science.1154601	http://dx.doi.org/10.1126/science.1154601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306FF	18511685				2022-12-28	WOS:000256233000033
J	Lee, JH; Lin, HW; Joo, S; Goodenough, U				Lee, Jae-Hyeok; Lin, Huawen; Joo, Sunjoo; Goodenough, Ursula			Early sexual origins of homeoprotein heterodimerization and evolution of the plant KNOX/BELL family	CELL			English	Article							MATING-TYPE LOCUS; KNOX GENE-FUNCTION; CHLAMYDOMONAS-REINHARDTII; HOMEODOMAIN PROTEIN; LAND PLANTS; NUCLEAR-LOCALIZATION; COMPARATIVE GENOMICS; MOLECULAR-GENETICS; DNA RECOGNITION; USTILAGO-MAYDIS	Developmental mechanisms that yield multicellular diversity are proving to be well conserved within lineages, generating interest in their origins in unicellular ancestors. We report that molecular regulation of the haploid-diploid transition in Chlamydomonas, a unicellular green soil alga, shares common ancestry with differentiation pathways in land plants. Two homeoproteins, Gsp1 and Gsm1, contributed by gametes of plus and minus mating types respectively, physically interact and translocate from the cytosol to the nucleus upon gametic fusion, initiating zygote development. Their ectopic expression activates zygote development in vegetative cells and, in a diploid background, the resulting zygotes undergo a normal meiosis. Gsm1/Gsp1 dyads share sequence homology with and are functionally related to KNOX/BELL dyads regulating stem-cell (meristem) specification in land plants. We propose that combinatorial homeoprotein-based transcriptional control, a core feature of the fungal/animal radiation, may have originated in a sexual context and enabled the evolution of land-plant body plans.	[Lee, Jae-Hyeok; Lin, Huawen; Joo, Sunjoo; Goodenough, Ursula] Washington Univ, Dept Biol, St Louis, MO 63130 USA	Washington University (WUSTL)	Goodenough, U (corresponding author), Washington Univ, Dept Biol, Campus Box 1137, St Louis, MO 63130 USA.	ursula@biology.wustl.edu	Lin, Huawen/B-7768-2012; Lee, Jae-Hyeok/AAE-6736-2022	Lee, Jae-Hyeok/0000-0001-8993-1853				ARMBRUST EV, 1993, CELL, V74, P801, DOI 10.1016/0092-8674(93)90460-8; BAILEY TL, 1994, P 2 INT C INT SYST M, P28; BALDAUF SL, 2003, PLANT CELL, V13, P2455; Bezanilla M, 2003, PLANT PHYSIOL, V133, P470, DOI 10.1104/pp.103.024901; Bhatt AA, 2004, GENE, V328, P103, DOI 10.1016/j.gene.2003.12.033; Bowman JL, 2007, CELL, V129, P229, DOI 10.1016/j.cell.2007.04.004; CAMPBELL AM, 1995, MOL BIOL CELL, V6, P87, DOI 10.1091/mbc.6.1.87; Chan RL, 1998, BBA-GENE STRUCT EXPR, V1442, P1, DOI 10.1016/S0167-4781(98)00119-5; Cole M, 2006, NUCLEIC ACIDS RES, V34, P1281, DOI 10.1093/nar/gkl016; Dacks J, 1999, J MOL EVOL, V48, P779, DOI 10.1007/PL00013156; Damante G, 1996, EMBO J, V15, P4992, DOI 10.1002/j.1460-2075.1996.tb00879.x; Davidson EH, 2006, SCIENCE, V311, P796, DOI 10.1126/science.1113832; DePristo MA, 2006, GENE, V378, P19, DOI 10.1016/j.gene.2006.03.023; Derelle R, 2007, EVOL DEV, V9, P212, DOI 10.1111/j.1525-142X.2007.00153.x; DUTCHER SK, 1988, P NATL ACAD SCI USA, V85, P3946, DOI 10.1073/pnas.85.11.3946; EBERSOLD WT, 1967, SCIENCE, V157, P447, DOI 10.1126/science.157.3787.447; FERNANDEZ E, 1984, CURR GENET, V8, P635, DOI 10.1007/BF00395710; Ferris PJ, 1997, GENETICS, V146, P859; FERRIS PJ, 1994, CELL, V76, P1135, DOI 10.1016/0092-8674(94)90389-1; Ferris PJ, 2002, GENETICS, V160, P181; FERRIS PJ, 1987, MOL CELL BIOL, V7, P2360, DOI 10.1128/MCB.7.7.2360; Floyd SK, 2007, INT J PLANT SCI, V168, P1, DOI 10.1086/509079; GALLOWAY RE, 1985, GENETICS, V111, P447; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GILLISSEN B, 1992, CELL, V68, P647, DOI 10.1016/0092-8674(92)90141-X; Goodenough U, 2007, SEMIN CELL DEV BIOL, V18, P350, DOI 10.1016/j.semcdb.2007.02.006; GOODENOUGH UW, 1995, ANNU REV PLANT PHYS, V46, P21; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; Graham LE, 2000, ALGAE; Hake S, 2004, ANNU REV CELL DEV BI, V20, P125, DOI 10.1146/annurev.cellbio.20.031803.093824; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; Hu CD, 2003, NAT BIOTECHNOL, V21, P539, DOI 10.1038/nbt816; Hull CM, 2005, EUKARYOT CELL, V4, P526, DOI 10.1128/EC.4.3.526-535.2005; Karol KG, 2001, SCIENCE, V294, P2351, DOI 10.1126/science.1065156; Kenrick P., 1997, ORIGIN EARLY DIVERSI; King N, 2008, NATURE, V451, P783, DOI 10.1038/nature06617; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; Krusell L, 1997, FEBS LETT, V408, P25, DOI 10.1016/S0014-5793(97)00382-7; KUES U, 1992, GENE DEV, V6, P568, DOI 10.1101/gad.6.4.568; Kurvari V, 1998, J CELL BIOL, V143, P1971, DOI 10.1083/jcb.143.7.1971; Lewis LA, 2004, AM J BOT, V91, P1535, DOI 10.3732/ajb.91.10.1535; Lin H, 2007, GENETICS, V176, P913, DOI 10.1534/genetics.106.066167; Mann RS, 2000, ANNU REV CELL DEV BI, V16, P243, DOI 10.1146/annurev.cellbio.16.1.243; Meisel L, 1996, PLANT MOL BIOL, V30, P1, DOI 10.1007/BF00017799; Merchant SS, 2007, SCIENCE, V318, P245, DOI 10.1126/science.1143609; Meyerowitz EM, 2002, SCIENCE, V295, P1482, DOI 10.1126/science.1066609; MINAMI SA, 1978, J CELL BIOL, V77, P165, DOI 10.1083/jcb.77.1.165; Muller J, 2001, PLANT J, V27, P13, DOI 10.1046/j.1365-313x.2001.01064.x; Nam J, 2005, MOL BIOL EVOL, V22, P2386, DOI 10.1093/molbev/msi229; PASQUALE SM, 1987, J CELL BIOL, V105, P2279, DOI 10.1083/jcb.105.5.2279; Pearson JC, 2005, NAT REV GENET, V6, P893, DOI 10.1038/nrg1726; Qiu YL, 2006, P NATL ACAD SCI USA, V103, P15511, DOI 10.1073/pnas.0603335103; Ramesh MA, 2005, CURR BIOL, V15, P185, DOI 10.1016/j.cub.2005.01.003; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; SAKAKIBARA K, 2008, EVOL DEV IN PRESS, V10; Sano R, 2005, EVOL DEV, V7, P69, DOI 10.1111/j.1525-142X.2005.05008.x; Saupe SJ, 2000, MICROBIOL MOL BIOL R, V64, P489, DOI 10.1128/MMBR.64.3.489-502.2000; Scofield S, 2006, PLANT MOL BIOL, V60, P929, DOI 10.1007/s11103-005-4478-y; Shiu SH, 2005, PLANT PHYSIOL, V139, P18, DOI 10.1104/pp.105.065110; SINGER SD, 2007, PLANT CELL REP, V28, P28; Smith HMS, 2002, P NATL ACAD SCI USA, V99, P9579, DOI 10.1073/pnas.092271599; Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446; Stevens KE, 2007, GENETICS, V175, P1625, DOI 10.1534/genetics.106.066449; Uchida H, 1999, CURR GENET, V36, P232, DOI 10.1007/s002940050495; UCHIDA H, 1993, CURR GENET, V24, P296, DOI 10.1007/BF00336779; Urban M, 1996, MOL GEN GENET, V251, P31; VANWINKLESWIFT KP, 1977, J PHYCOL, V13, P225; Viola IL, 2006, BIOL CHEM, V387, P31, DOI 10.1515/BC.2006.006; WEGENER D, 1991, PLANT MOL BIOL, V16, P937, DOI 10.1007/BF00016066; WILLER M, 1995, MOL CELL BIOL, V15, P4964; Zhao H, 2001, GENE DEV, V15, P2767, DOI 10.1101/gad.919501	73	133	137	0	46	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 30	2008	133	5					829	840		10.1016/j.cell.2008.04.028	http://dx.doi.org/10.1016/j.cell.2008.04.028			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510927	Bronze			2022-12-28	WOS:000256274500015
J	Blow, N				Blow, Nathan			Metagenomics: Exploring unseen communities	NATURE			English	Editorial Material													Martinez, Octavio/B-7375-2009					Korlach J, 2008, P NATL ACAD SCI USA, V105, P1176, DOI 10.1073/pnas.0710982105; Mavromatis K, 2007, NAT METHODS, V4, P495, DOI 10.1038/nmeth1043	2	31	37	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 29	2008	453	7195					687	692		10.1038/453687a	http://dx.doi.org/10.1038/453687a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305NN	18509446				2022-12-28	WOS:000256185200051
J	Cardinale, CJ; Washburn, RS; Tadigotla, VR; Brown, LM; Gottesman, ME; Nudler, E				Cardinale, Christopher J.; Washburn, Robert S.; Tadigotla, Vasisht R.; Brown, Lewis M.; Gottesman, Max E.; Nudler, Evgeny			Termination factor Rho and its cofactors NusA and NusG silence foreign DNA in E-coli	SCIENCE			English	Article							DEPENDENT TRANSCRIPTION TERMINATION; COMPLETE GENOME SEQUENCE; LAMBDA N PROTEIN; BACTERIOPHAGE-LAMBDA; RNA-POLYMERASE; REQUIREMENT; BINDING; BICYCLOMYCIN; SALMONELLA; EXPRESSION	Transcription of the bacterial genome by the RNA polymerase must terminate at specific points. Transcription can be terminated by Rho factor, an essential protein in enterobacteria. We used the antibiotic bicyclomycin, which inhibits Rho, to assess its role on a genome-wide scale. Rho is revealed as a global regulator of gene expression that matches Escherichia coli transcription to translational needs. We also found that genes in E. coli that are most repressed by Rho are prophages and other horizontally acquired portions of the genome. Elimination of these foreign DNA elements increases resistance to bicyclomycin. Although rho remains essential, such reduced-genome bacteria no longer require Rho cofactors NusA and NusG. Deletion of the cryptic rac prophage in wild-type E. coli increases bicyclomycin resistance and permits deletion of nusG. Thus, Rho termination, supported by NusA and NusG, is required to suppress the toxic activity of foreign genes.	[Washburn, Robert S.; Gottesman, Max E.] Columbia Univ, Med Ctr, Dept Microbiol, New York, NY 10032 USA; [Cardinale, Christopher J.; Nudler, Evgeny] NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; [Tadigotla, Vasisht R.] Rutgers State Univ, BioMaPS Inst Quantitat Biol, Piscataway, NJ 08854 USA; [Brown, Lewis M.] Columbia Univ, Comparat Proteom Ctr, Dept Biol Sci, New York, NY 10027 USA; [Gottesman, Max E.] Columbia Univ, Med Ctr, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University; New York University; Rutgers State University New Brunswick; Columbia University; Columbia University	Gottesman, ME (corresponding author), Columbia Univ, Med Ctr, Dept Microbiol, New York, NY 10032 USA.	meg8@columbia.edu; evgeny.nudler@med.nyu.edu	Cardinale, Christopher J./G-3351-2013	Cardinale, Christopher J./0000-0001-7513-8977; Nudler, Evgeny/0000-0002-8811-3071	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058750, R01GM037219, R01GM072814] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM72814, R01 GM037219, R01 GM058750, R01 GM37219, R01 GM072814, R01 GM58750] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1978, ANNU REV BIOCHEM, V47, P967, DOI 10.1146/annurev.bi.47.070178.004535; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Browne RJ, 2005, J BIOL CHEM, V280, P13292, DOI 10.1074/jbc.M500221200; Ciampi MS, 2006, MICROBIOL-SGM, V152, P2515, DOI 10.1099/mic.0.28982-0; COURT D, 1980, J MOL BIOL, V138, P231, DOI 10.1016/0022-2836(80)90285-5; DAS A, 1976, P NATL ACAD SCI USA, V73, P1959, DOI 10.1073/pnas.73.6.1959; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; Glasner JD, 2008, NUCLEIC ACIDS RES, V36, pD519, DOI 10.1093/nar/gkm973; HART CM, 1991, J BIOL CHEM, V266, P24140; Kolisnychenko V, 2002, GENOME RES, V12, P640, DOI 10.1101/gr.217202; Lesnik EA, 2001, NUCLEIC ACIDS RES, V29, P3583, DOI 10.1093/nar/29.17.3583; Mah TF, 1999, MOL MICROBIOL, V34, P523, DOI 10.1046/j.1365-2958.1999.01618.x; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; Navarre WW, 2006, SCIENCE, V313, P236, DOI 10.1126/science.1128794; Nudler E, 2002, GENES CELLS, V7, P755, DOI 10.1046/j.1365-2443.2002.00563.x; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; Perna NT, 2001, NATURE, V409, P529, DOI 10.1038/35054089; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; Posfai G, 2006, SCIENCE, V312, P1044, DOI 10.1126/science.1126439; Richardson JP, 2003, CELL, V114, P157, DOI 10.1016/S0092-8674(03)00554-3; Richardson LV, 1996, J BIOL CHEM, V271, P21597, DOI 10.1074/jbc.271.35.21597; Rivard CJ, 2007, J BIOL CHEM, V282, P6644, DOI 10.1074/jbc.M609432200; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; SCHMIDT MC, 1984, J BIOL CHEM, V259, P5000; Skordalakes E, 2006, CELL, V127, P553, DOI 10.1016/j.cell.2006.08.051; STEWART V, 1986, J BACTERIOL, V166, P217, DOI 10.1128/jb.166.1.217-223.1986; SULLIVAN SL, 1992, CELL, V68, P989, DOI 10.1016/0092-8674(92)90041-A; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vincent F, 2000, BIOCHEMISTRY-US, V39, P9077, DOI 10.1021/bi000504+; Washburn RS, 2003, J MOL BIOL, V329, P655, DOI 10.1016/S0022-2836(03)00465-0; Zhou Y, 2002, J BACTERIOL, V184, P3416, DOI 10.1128/JB.184.12.3416-3418.2002; ZWIEFKA A, 1993, BIOCHEMISTRY-US, V32, P3564, DOI 10.1021/bi00065a007	33	211	216	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 16	2008	320	5878					935	938		10.1126/science.1152763	http://dx.doi.org/10.1126/science.1152763			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301AH	18487194	Green Accepted			2022-12-28	WOS:000255868300043
J	Boseley, S				Boseley, Sarah			Profile - Miriam Were: bringing health care to African villages	LANCET			English	Biographical-Item												sarah.boseley@guardian.co.uk		Were, Miriam/0000-0001-5811-9424				WERE M, PUBLICATION LIST	1	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 14	2008	371	9629					1991	1991		10.1016/S0140-6736(08)60856-9	http://dx.doi.org/10.1016/S0140-6736(08)60856-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312YY	18555903				2022-12-28	WOS:000256709500014
J	Ferriman, A				Ferriman, Annabel			A patient's journey - Becoming a live kidney donor	BRITISH MEDICAL JOURNAL			English	Editorial Material									BMJ, London WC1H 9JR, England		Ferriman, A (corresponding author), BMJ, London WC1H 9JR, England.	aferriman@bmj.com							0	5	5	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 14	2008	336	7657					1374	1376		10.1136/bmj.a277	http://dx.doi.org/10.1136/bmj.a277			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316YB	18556321	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000256984700047
J	Haffner, ME; Torrent-Farnell, J; Maher, PD				Haffner, Marlene E.; Torrent-Farnell, Josep; Maher, Paul D.			Does orphan drug legislation really answer the needs of patients?	LANCET			English	Article							PHARMACOGENOMICS; DEFICIENCY; WORLD		[Haffner, Marlene E.] Amgen Corp, Washington, DC 20004 USA; [Torrent-Farnell, Josep; Maher, Paul D.] US FDA, Off Orphan Prod Dev, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Haffner, ME (corresponding author), Amgen Corp, 555 13th St NW,Suite 600 W, Washington, DC 20004 USA.	marlene.haffner@amgen.com						ANAND G, 2005, WALL STREET J   1116; Anand Geeta, 2005, Wall St J (East Ed), pA10; [Anonymous], REP INF DIS REM OBST; Arnon SS, 2007, PEDIATRICS, V119, P785, DOI 10.1542/peds.2006-0646; Broder S, 2002, EMBO REP, V3, P806, DOI 10.1093/embo-reports/kvf187; Cheung Richard Y, 2004, Health Law J, V12, P183; *DEP HHS, 2001, ORPH DRUG ACT IMPL I; *FDA, MEFL HCL DES TREATM; *FDA, RIF DES TREATM PUL T; *FDA, QUIN SULF DES TREATM; *FDA, HAL DES TREATM AD WH; *FDA, CUM LIST DES APPR OR; *FDA, 2004, CHALL POO CRIT PATH; *FDA, RIF COMB IS PYRAZ DE; *FDA, RIF DES ANT TREATM U; Futerman AH, 2004, TRENDS PHARMACOL SCI, V25, P147, DOI 10.1016/j.tips.2004.01.004; HERSHFIELD M, 1989, SCIENCE, V246, P1375; HERSHFIELD MS, 1987, NEW ENGL J MED, V316, P589, DOI 10.1056/NEJM198703053161005; *HOFFM LA ROCH, PEG PEG ALPH 2A PACK; *INT MYEL FDN, 2006, INT MYEL FDN APPL FD; Joppi R, 2006, BRIT J CLIN PHARMACO, V61, P355, DOI 10.1111/j.1365-2125.2006.02579.x; Loughnot D, 2005, AM J LAW MED, V31, P365, DOI 10.1177/009885880503100210; LOVE J, BRIEF NOTE ABUSE ORP; Maeder T, 2003, SCI AM, V288, P80, DOI 10.1038/scientificamerican0503-80; Maher PD, 2006, BIODRUGS, V20, P71, DOI 10.2165/00063030-200620020-00001; Milne CP, 2002, NAT BIOTECHNOL, V20, P780, DOI 10.1038/nbt0802-780; Office of Orphan Products Development, LIST ORPH DES APPR; Rados Carol, 2003, FDA Consum, V37, P10; Scott CR, 2006, AM J MED GENET C, V142C, P121, DOI 10.1002/ajmg.c.30092; SIMON HJ, 1981, ANN INTERN MED, V95, P231, DOI 10.7326/0003-4819-95-2-231; SMITH A, ORPHAN BLOCKBUSTER B; *TUFTS CTR STUD DR, 2001, PEGS COST NEW PRESCR	32	56	59	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 14	2008	371	9629					2041	2044		10.1016/S0140-6736(08)60873-9	http://dx.doi.org/10.1016/S0140-6736(08)60873-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312YY	18555916				2022-12-28	WOS:000256709500032
J	McColl, K				McColl, Karen			Can we feed the world?	BRITISH MEDICAL JOURNAL			English	Editorial Material												karen@karenmccoll.co.uk						Food and Agriculture Organization of the United Nations (FAO), 2008, CROP PROSP FOOD SIT; *OFF UN HIGH COMM, 2008, AN WORLD FOOD CRIS U; *ROYAL I INT AFF, 2008, WHAT UN SUMM WORLD F; Stamoulis KG, 2006, STATE FOOD INSECURIT; *UN DEV PROGR, 2005, HUM DEV REP 2005; United Nations, MILL DEV GOALS REP 2; United Nations Children's Fund, 2007, PROGR CHILDR WORLD F; *WORLD FOOD PROGR, 2008, WFP LETT APP GOV DON	8	4	4	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	2008	336	7657					1336	1338		10.1136/bmj.a270	http://dx.doi.org/10.1136/bmj.a270			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316YB	18523024	Green Published			2022-12-28	WOS:000256984700033
J	Ackerman, SL; Cox, GA				Ackerman, Susan L.; Cox, Gregory A.			From ER to Eph receptors: New roles for VAP fragments	CELL			English	Editorial Material							TRAFFICKING; MUTATION	Dominantly inherited mutations in an endoplasmic reticulum protein called VAPB have been found in a subset of patients with a rare familial form of amyotrophic lateral sclerosis (ALS). In this issue, Tsuda et al. (2008) identify a secreted form of VAPB that binds directly to Eph receptors inducing their activation and signaling, providing fresh insights into ALS pathogenesis, including non-neuronal aspects of this disorder.	[Ackerman, Susan L.; Cox, Gregory A.] Jackson Lab, Bar Harbor, ME 04609 USA; [Ackerman, Susan L.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Jackson Laboratory; Howard Hughes Medical Institute	Ackerman, SL (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.	susan.ackerman@jax.org			Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Calo L, 2006, J NEUROCHEM, V98, P1, DOI 10.1111/j.1471-4159.2006.03844.x; Hanada K, 2007, BBA-MOL CELL BIOL L, V1771, P644, DOI 10.1016/j.bbalip.2007.01.009; Marques VD, 2006, MUSCLE NERVE, V34, P731, DOI 10.1002/mus.20657; Nishimura AL, 2004, AM J HUM GENET, V75, P822, DOI 10.1086/425287; Pasinelli P, 2006, NAT REV NEUROSCI, V7, P710, DOI 10.1038/nrn1971; Pennetta G, 2002, NEURON, V35, P291, DOI 10.1016/S0896-6273(02)00769-9; Schymick JC, 2007, HUM MOL GENET, V16, pR233, DOI 10.1093/hmg/ddm215; Sreedharan J, 2008, SCIENCE, V319, P1668, DOI 10.1126/science.1154584; Teuling E, 2007, J NEUROSCI, V27, P9801, DOI 10.1523/JNEUROSCI.2661-07.2007	9	5	5	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	2008	133	6					949	951		10.1016/j.cell.2008.05.028	http://dx.doi.org/10.1016/j.cell.2008.05.028			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	312TJ	18555770	Bronze			2022-12-28	WOS:000256693400009
J	Chen, WS; Antic, D; Matis, M; Logan, CY; Povelones, M; Anderson, GA; Nusse, R; Axelrod, JD				Chen, Wei-Shen; Antic, Dragana; Matis, Maja; Logan, Catriona Y.; Povelones, Michael; Anderson, Graham A.; Nusse, Roel; Axelrod, Jeffrey D.			Asymmetric homotypic interactions of the atypical cadherin Flamingo mediate intercellular polarity signaling	CELL			English	Article							PLANAR-CELL-POLARITY; 7-PASS TRANSMEMBRANE CADHERIN; CYSTEINE-RICH DOMAIN; TISSUE POLARITY; DROSOPHILA; MORPHOGENESIS; MECHANISM; ADHESION; NIGHT; PROTOCADHERIN	Acquisition of planar cell polarity (PCP) in epithelia involves intercellular communication, during which cells align their polarity with that of their neighbors. The transmembrane proteins Frizzled (Fz) and Van Gogh (Vang) are essential components of the intercellular communication mechanism, as loss of either strongly perturbs the polarity of neighboring cells. How Fz and Vang communicate polarity information between neighboring cells is poorly understood. The atypical cadherin, Flamingo (Fmi), is implicated in this process, yet whether Fmi acts permissively as a scaffold or instructively as a signal is unclear. Here, we provide evidence that Fmi functions instructively to mediate Fz-Vang intercellular signal relay, recruiting Fz and Vang to opposite sides of cell boundaries. We propose that two functional forms of Fmi, one of which is induced by and physically interacts with Fz, bind each other to create cadherin homodimers that signal bidirectionally and asymmetrically, instructing unequal responses in adjacent cell membranes to establish molecular asymmetry.	[Chen, Wei-Shen; Antic, Dragana; Matis, Maja; Anderson, Graham A.; Axelrod, Jeffrey D.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Logan, Catriona Y.; Povelones, Michael; Nusse, Roel] Howard Hughes Med Inst, Stanford, CA 94305 USA; [Logan, Catriona Y.; Povelones, Michael; Nusse, Roel] Beckman Ctr, Dept Dev Biol, Stanford, CA 94305 USA	Stanford University; Howard Hughes Medical Institute	Axelrod, JD (corresponding author), Stanford Univ, Sch Med, Dept Pathol, 300 Pasteur Dr, Stanford, CA 94305 USA.	jaxelrod@stanford.edu	Matis, Maja/P-1437-2019; Matis, Maja/J-3562-2017	Matis, Maja/0000-0003-3972-1983; Matis, Maja/0000-0003-3972-1983	Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [R01 GM059823-07, R01 GM059823-08, R01 GM059823, R01 GM059823-06A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059823] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adler PN, 2000, MECH DEVELOP, V96, P197, DOI 10.1016/S0925-4773(00)00392-0; Adler PN, 1997, CURR BIOL, V7, P940, DOI 10.1016/S0960-9822(06)00413-1; Amonlirdviman K, 2005, SCIENCE, V307, P423, DOI 10.1126/science.1105471; Axelrod JD, 2001, GENE DEV, V15, P1182; Bastock R, 2003, DEVELOPMENT, V130, P3007, DOI 10.1242/dev.00526; Casal J, 2006, DEVELOPMENT, V133, P4561, DOI 10.1242/dev.02641; Chae J, 1999, DEVELOPMENT, V126, P5421; Chen CM, 2004, P NATL ACAD SCI USA, V101, P15961, DOI 10.1073/pnas.0407103101; Chen X, 2006, CURR OPIN CELL BIOL, V18, P572, DOI 10.1016/j.ceb.2006.07.002; Feiguin F, 2001, DEV CELL, V1, P93, DOI 10.1016/S1534-5807(01)00010-7; Halbleib JM, 2006, GENE DEV, V20, P3199, DOI 10.1101/gad.1486806; Kimura H, 2006, J CELL SCI, V119, P1118, DOI 10.1242/jcs.02832; Lawrence PA, 2004, DEVELOPMENT, V131, P4651, DOI 10.1242/dev.01351; Lawrence PA, 2002, DEVELOPMENT, V129, P2749; Lee TM, 2000, NEURON, V25, P307, DOI 10.1016/S0896-6273(00)80896-X; Ma D, 2003, NATURE, V421, P543, DOI 10.1038/nature01366; Medina A, 2004, EMBO J, V23, P3249, DOI 10.1038/sj.emboj.7600329; Pokutta S, 2007, ANNU REV CELL DEV BI, V23, P237, DOI 10.1146/annurev.cellbio.22.010305.104241; Povelones M, 2005, EMBO J, V24, P3493, DOI 10.1038/sj.emboj.7600817; Seifert JRK, 2007, NAT REV GENET, V8, P126, DOI 10.1038/nrg2042; Shimada Y, 2001, CURR BIOL, V11, P859, DOI 10.1016/S0960-9822(01)00233-0; Strutt D, 2007, DEV BIOL, V302, P181, DOI 10.1016/j.ydbio.2006.09.026; Strutt DI, 2001, MOL CELL, V7, P367, DOI 10.1016/S1097-2765(01)00184-8; Strutt H, 2005, BIOESSAYS, V27, P1218, DOI 10.1002/bies.20318; Tree DRP, 2002, CELL, V109, P371, DOI 10.1016/S0092-8674(02)00715-8; Tree DRP, 2002, SEMIN CELL DEV BIOL, V13, P217, DOI 10.1016/S1084-9521(02)00042-3; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; Wang YS, 2007, DEVELOPMENT, V134, P647, DOI 10.1242/dev.02772; Wasserscheid I, 2007, DEV DYNAM, V236, P1064, DOI 10.1002/dvdy.21089; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wolff T, 1998, DEVELOPMENT, V125, P1149; Wu CH, 2002, J BIOL CHEM, V277, P41762, DOI 10.1074/jbc.M207850200; Yamada S, 2007, ANNU REV BIOCHEM, V76, P267, DOI 10.1146/annurev.biochem.75.103004.142811; Yang CH, 2002, CELL, V108, P675, DOI 10.1016/S0092-8674(02)00658-X; Zallen JA, 2007, CELL, V129, P1051, DOI 10.1016/j.cell.2007.05.050	35	180	184	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 13	2008	133	6					1093	1105		10.1016/j.cell.2008.04.048	http://dx.doi.org/10.1016/j.cell.2008.04.048			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	312TJ	18555784	Green Accepted, Bronze			2022-12-28	WOS:000256693400023
J	Simon, SM				Simon, Sanford M.			Golgi governance: The third way	CELL			English	Editorial Material							CONTINUITIES; CISTERNAE; TRANSPORT; APPARATUS; COMPLEX	It is a subject of intense debate whether proteins are transported by vesicles through the membranous stacks of the Golgi or whether the stacks mature, carrying the cargo along. In this issue, Patterson et al. (2008) present evidence for a third model in which the Golgi stacks are a continuous structure and proteins rapidly equilibrate between the layers.	Rockefeller Univ, Lab Cellular Biophys, New York, NY 10021 USA	Rockefeller University	Simon, SM (corresponding author), Rockefeller Univ, Lab Cellular Biophys, 1230 York Ave, New York, NY 10021 USA.	simon@mail.rockefeller.edu		Simon, Sanford/0000-0002-8615-4224	NIGMS NIH HHS [P20 GM072015, P20 GM072015-04, P20 GM072015-04S1, P20 GM072015-03, P20 GM072015-02, P20 GM072015-02S1, R01 GM087977, P20 GM072015-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM087977, P20GM072015] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beznoussenko GV, 2002, ANAT RECORD, V268, P226, DOI 10.1002/ar.10157; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; FARQUHAR MG, 1981, J CELL BIOL, V91, P77; Marsh BJ, 2004, P NATL ACAD SCI USA, V101, P5565, DOI 10.1073/pnas.0401242101; Orci L, 2000, P NATL ACAD SCI USA, V97, P10400, DOI 10.1073/pnas.190292497; Pelham HRB, 2000, CELL, V102, P713, DOI 10.1016/S0092-8674(00)00060-X; Pelham HRB, 2001, J CELL BIOL, V155, P1099, DOI 10.1083/jcb.200110160; Pelham HRB, 2006, TRENDS BIOCHEM SCI, V31, P601, DOI 10.1016/j.tibs.2006.09.002; Trucco A, 2004, NAT CELL BIOL, V6, P1071, DOI 10.1038/ncb1180	9	2	2	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 13	2008	133	6					951	953		10.1016/j.cell.2008.05.037	http://dx.doi.org/10.1016/j.cell.2008.05.037			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	312TJ	18555771	Green Accepted, Bronze			2022-12-28	WOS:000256693400010
J	Skerker, JM; Perchuk, BS; Siryaporn, A; Lubin, EA; Ashenberg, O; Goulian, M; Laub, MT				Skerker, Jeffrey M.; Perchuk, Barrett S.; Siryaporn, Albert; Lubin, Emma A.; Ashenberg, Orr; Goulian, Mark; Laub, Michael T.			Rewiring the specificity of two-component signal transduction systems	CELL			English	Article							PROTEIN-PROTEIN INTERACTIONS; ESCHERICHIA-COLI K-12; HISTIDINE-KINASE; MOLECULAR RECOGNITION; RESPONSE REGULATOR; PHOSPHORELAY; DOMAINS; SENSOR; INFORMATION; SEQUENCE	Two-component signal transduction systems are the predominant means by which bacteria sense and respond to environmental stimuli. Bacteria often employ tens or hundreds of these paralogous signaling systems, comprised of histidine kinases (HKs) and their cognate response regulators (RRs). Faithful transmission of information through these signaling pathways and avoidance of detrimental crosstalk demand exquisite specificity of HK-RR interactions. To identify the determinants of two-component signaling specificity, we examined patterns of amino acid co-evolution in large, multiple sequence alignments of cognate kinase-regulator pairs. Guided by these results, we demonstrate that a subset of the coevolving residues is sufficient, when mutated, to completely switch the substrate specificity of the kinase EnvZ. Our results shed light on the basis of molecular discrimination in two-component signaling pathways, provide a general approach for the rational rewiring of these pathways, and suggest that analyses of coevolution may facilitate the reprogramming of other signaling systems and protein-protein interactions.	[Skerker, Jeffrey M.; Perchuk, Barrett S.; Lubin, Emma A.; Ashenberg, Orr; Laub, Michael T.] MIT, Dept Biol, Cambridge, MA 02139 USA; [Siryaporn, Albert; Goulian, Mark] Univ Penn, Dept Phys, Philadelphia, PA 19104 USA; [Goulian, Mark] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA	Massachusetts Institute of Technology (MIT); University of Pennsylvania; University of Pennsylvania	Laub, MT (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	laub@mit.edu		Laub, Michael/0000-0002-8288-7607	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM068763, R01GM080279, R01GM082899] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM082899-01, R01 GM082899, P50 GM068763-05, R01 GM080279, P50 GM068763, R01 GM080279-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atchley WR, 2000, MOL BIOL EVOL, V17, P164, DOI 10.1093/oxfordjournals.molbev.a026229; Batchelor E, 2005, J BACTERIOL, V187, P5723, DOI 10.1128/JB.187.16.5723-5731.2005; Batchelor E, 2003, P NATL ACAD SCI USA, V100, P691, DOI 10.1073/pnas.0234782100; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bloom JD, 2005, CURR OPIN STRUC BIOL, V15, P447, DOI 10.1016/j.sbi.2005.06.004; Buck MJ, 2005, MOL BIOL EVOL, V22, P1627, DOI 10.1093/molbev/msi157; Danese PN, 1998, J BACTERIOL, V180, P831, DOI 10.1128/JB.180.4.831-839.1998; DeLano W.L, PYMOL MOL GRAPHICS S; Dunn SD, 2008, BIOINFORMATICS, V24, P333, DOI 10.1093/bioinformatics/btm604; Fersht A., 1985, ENZYME STRUCTURE MEC; Fisher SL, 1996, BIOCHEMISTRY-US, V35, P4732, DOI 10.1021/bi9525435; Fodor AA, 2004, PROTEINS, V56, P211, DOI 10.1002/prot.20098; Grimshaw CE, 1998, BIOCHEMISTRY-US, V37, P1365, DOI 10.1021/bi971917m; Havranek JJ, 2003, NAT STRUCT BIOL, V10, P45, DOI 10.1038/nsb877; Hsing WH, 1997, J BACTERIOL, V179, P3729, DOI 10.1128/jb.179.11.3729-3735.1997; Janiak-Spens F, 2000, MOL MICROBIOL, V37, P136, DOI 10.1046/j.1365-2958.2000.01973.x; Jiang M, 1999, MOL MICROBIOL, V33, P389, DOI 10.1046/j.1365-2958.1999.01481.x; Kato A, 1999, J BACTERIOL, V181, P5516, DOI 10.1128/JB.181.17.5516-5520.1999; Kortemme T, 2004, CURR OPIN CHEM BIOL, V8, P91, DOI 10.1016/j.cbpa.2003.12.008; Kortemme T, 2004, NAT STRUCT MOL BIOL, V11, P371, DOI 10.1038/nsmb749; Laub MT, 2007, ANNU REV GENET, V41, P121, DOI 10.1146/annurev.genet.41.042007.170548; Levskaya A, 2005, NATURE, V438, P441, DOI 10.1038/nature04405; Lo LW, 2003, P NATL ACAD SCI USA, V100, P4463, DOI 10.1073/pnas.0737647100; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Marina A, 2005, EMBO J, V24, P4247, DOI 10.1038/sj.emboj.7600886; Miller J. H., 1992, LAB MANUAL HDB ESCHE; Miyashiro T, 2007, P NATL ACAD SCI USA, V104, P16305, DOI 10.1073/pnas.0700025104; Newman JRS, 2003, SCIENCE, V300, P2097, DOI 10.1126/science.1084648; Ohta N, 2003, J BACTERIOL, V185, P4424, DOI 10.1128/JB.185.15.4424-4431.2003; Pei JM, 2003, BIOINFORMATICS, V19, P427, DOI 10.1093/bioinformatics/btg008; Perraud AL, 1998, MOL MICROBIOL, V27, P875, DOI 10.1046/j.1365-2958.1998.00716.x; Qin L, 2003, J BACTERIOL, V185, P3429, DOI 10.1128/JB.185.11.3429-3435.2003; Schwartz MA, 2004, ANNU REV GENET, V38, P725, DOI 10.1146/annurev.genet.39.073003.112634; Skerker JM, 2005, PLOS BIOL, V3, P1770, DOI 10.1371/journal.pbio.0030334; Socolich M, 2005, NATURE, V437, P512, DOI 10.1038/nature03991; Stiffler MA, 2007, SCIENCE, V317, P364, DOI 10.1126/science.1144592; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Tomomori C, 1999, NAT STRUCT BIOL, V6, P729; Ubersax JA, 2007, NAT REV MOL CELL BIO, V8, P530, DOI 10.1038/nrm2203; UTSUMI R, 1989, SCIENCE, V245, P1246, DOI 10.1126/science.2476847; White RA, 2007, METHOD ENZYMOL, V422, P75, DOI 10.1016/S0076-6879(06)22004-4; Zapf J, 2000, STRUCTURE, V8, P851, DOI 10.1016/S0969-2126(00)00174-X; Zarrinpar A, 2003, NATURE, V426, P676, DOI 10.1038/nature02178; Zhu Y, 2004, J BIOL CHEM, V279, P48152, DOI 10.1074/jbc.M401024200	44	348	360	3	75	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	2008	133	6					1043	1054		10.1016/j.cell.2008.04.040	http://dx.doi.org/10.1016/j.cell.2008.04.040			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	312TJ	18555780	Green Accepted, Bronze			2022-12-28	WOS:000256693400019
J	Patel, A; MacMahon, S; Chalmers, J; Neal, B; Billot, L; Woodward, M; Marre, M; Cooper, M; Glasziou, P; Grobbee, D; Hamet, P; Harrap, S; Heller, S; Liu, LS; Mancia, G; Mogensen, CE; Pan, CY; Poulter, N; Rodgers, A; Williams, B; Bompoint, S; de Galan, BE; Joshi, R; Travert, F				Patel, Anushka; MacMahon, Stephen; Chalmers, John; Neal, Bruce; Billot, Laurent; Woodward, Mark; Marre, Michel; Cooper, Mark; Glasziou, Paul; Grobbee, Diederick; Hamet, Pavel; Harrap, Stephen; Heller, Simon; Liu, Lisheng; Mancia, Giuseppe; Mogensen, Carl Erik; Pan, Changyu; Poulter, Neil; Rodgers, Anthony; Williams, Bryan; Bompoint, Severine; de Galan, Bastiaan E.; Joshi, Rohina; Travert, Florence		ADVANCE Collaborat Grp	Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CAUSE-SPECIFIC MORTALITY; CARDIOVASCULAR EVENTS; RANDOMIZED-TRIALS; GLYCEMIC CONTROL; MELLITUS; COMPLICATIONS; DISEASE; METAANALYSIS; ASSOCIATION; HEMOGLOBIN	Background: In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain. Methods: We randomly assigned 11,140 patients with type 2 diabetes to undergo either standard glucose control or intensive glucose control, defined as the use of gliclazide (modified release) plus other drugs as required to achieve a glycated hemoglobin value of 6.5% or less. Primary end points were composites of major macrovascular events (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) and major microvascular events (new or worsening nephropathy or retinopathy), assessed both jointly and separately. Results: After a median of 5 years of follow-up, the mean glycated hemoglobin level was lower in the intensive-control group (6.5%) than in the standard-control group (7.3%). Intensive control reduced the incidence of combined major macrovascular and microvascular events (18.1%, vs. 20.0% with standard control; hazard ratio, 0.90; 95% confidence interval [CI], 0.82 to 0.98; P=0.01), as well as that of major microvascular events (9.4% vs. 10.9%; hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), primarily because of a reduction in the incidence of nephropathy (4.1% vs. 5.2%; hazard ratio, 0.79; 95% CI, 0.66 to 0.93; P=0.006), with no significant effect on retinopathy (P=0.50). There were no significant effects of the type of glucose control on major macrovascular events (hazard ratio with intensive control, 0.94; 95% CI, 0.84 to 1.06; P=0.32), death from cardiovascular causes (hazard ratio with intensive control, 0.88; 95% CI, 0.74 to 1.04; P=0.12), or death from any cause (hazard ratio with intensive control, 0.93; 95% CI, 0.83 to 1.06; P=0.28). Severe hypoglycemia, although uncommon, was more common in the intensive-control group (2.7%, vs. 1.5% in the standard-control group; hazard ratio, 1.86; 95% CI, 1.42 to 2.40; P<0.001). Conclusions: A strategy of intensive glucose control, involving gliclazide (modified release) and other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21% relative reduction in nephropathy. (ClinicalTrials.gov number, NCT00145925.).	[Patel, Anushka; MacMahon, Stephen; Chalmers, John; Neal, Bruce; Billot, Laurent; Woodward, Mark; Bompoint, Severine; de Galan, Bastiaan E.; Joshi, Rohina] Univ Sydney, Div Cardiovasc, George Inst Int Hlth, Sydney, NSW 2050, Australia; [Woodward, Mark] Mt Sinai Sch Med, New York, NY USA; [Marre, Michel; Travert, Florence] Hop Bichat Claude Bernard, F-75877 Paris 18, France; [Marre, Michel; Travert, Florence] Univ Paris 07, Paris, France; [Cooper, Mark] Baker Heart Res Inst, Melbourne, Vic, Australia; [Glasziou, Paul] Univ Oxford, Oxford, England; [Glasziou, Paul] Univ Queensland, Brisbane, Qld, Australia; [Grobbee, Diederick] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Hamet, Pavel] CHU Montreal, Montreal, PQ, Canada; [Hamet, Pavel] Univ Montreal, Montreal, PQ, Canada; [Harrap, Stephen] Univ Melbourne, Melbourne, Vic, Australia; [Harrap, Stephen] Royal Melbourne Hosp, Melbourne, Vic, Australia; [Heller, Simon] Univ Sheffield, Sheffield, S Yorkshire, England; [Heller, Simon] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England; [Liu, Lisheng] Chinese Hypertens League Inst, Beijing, Peoples R China; [Mancia, Giuseppe] Univ Milano Bicocca, Milan, Italy; [Mancia, Giuseppe] Osped San Gerardo, Milan, Italy; [Mogensen, Carl Erik] Aarhus Sygehus, Med Dept M, Aarhus, Denmark; [Pan, Changyu] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China; [Poulter, Neil] Univ London Imperial Coll Sci Technol & Med, London, England; [Poulter, Neil] St Marys Hosp, London, England; [Rodgers, Anthony] Clin Trials Res Unit, Auckland, New Zealand; [Rodgers, Anthony] Univ Auckland, Auckland 1, New Zealand; [Williams, Bryan] Univ Leicester, Sch Med, Leicester, Leics, England; [Williams, Bryan] Leicester Royal Infirm, Leicester, Leics, England; [de Galan, Bastiaan E.] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Joshi, Rohina] Univ Sydney, Sydney, NSW 2006, Australia	University of Sydney; Icahn School of Medicine at Mount Sinai; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Baker Heart and Diabetes Institute; University of Oxford; University of Queensland; Utrecht University; Utrecht University Medical Center; Universite de Montreal; Universite de Montreal; University of Melbourne; Royal Melbourne Hospital; University of Sheffield; University of Sheffield; Chinese Hypertension League; University of Milano-Bicocca; San Gerardo Hospital; Aarhus University; Chinese People's Liberation Army General Hospital; Imperial College London; Imperial College London; University of Auckland; University of Leicester; University of Leicester; Radboud University Nijmegen; University of Sydney	Patel, A (corresponding author), Univ Sydney, Div Cardiovasc, George Inst Int Hlth, POB M201,Missenden Rd, Sydney, NSW 2050, Australia.	apatel@george.org.au	Cossette, Suzanne/I-8008-2016; Stanton, Alice V/F-4697-2012; McManus, Ruth/G-3938-2011; Soedamah-Muthu, Sabita/A-8166-2014; Minárik, Peter/AAM-1803-2020; Stolk, Ronald P/B-2341-2013; morton, adam/I-1771-2013; Del Prato, Stefano/K-3405-2016; Aldington, Steve J/G-7828-2012; Prabhakaran, Dorairaj/B-4147-2011; Longo, Kenneth A/A-5631-2010; Liaw, Siaw-Teng/C-3673-2012; Woodward, Mark/D-8492-2015; Woodward, Mark/L-6817-2017; Whalley, Gillian/H-7376-2019; Fassett, Robert G/F-1752-2010; Cooper, Mark/AAC-5326-2020; Grobbee, Diederick/C-7651-2014; Nolan, Christopher J/B-2026-2008; Hopkins, David/AAP-4541-2020; Lim, Sern/AAX-4218-2021; Billot, Laurent/Y-1241-2019; Petrovsky, Nikolai/P-1912-2017; de Galan, Bastiaan E/H-3161-2015; Greiver, Michelle/N-8764-2015; Glasziou, Paul/A-7832-2008; Nawawi, Hapizah/F-3617-2018	Soedamah-Muthu, Sabita/0000-0002-8830-3502; Minárik, Peter/0000-0002-2387-0485; Stolk, Ronald P/0000-0002-0518-1205; morton, adam/0000-0001-9887-714X; Del Prato, Stefano/0000-0002-5388-0270; Aldington, Steve J/0000-0003-1808-3580; Prabhakaran, Dorairaj/0000-0002-3172-834X; Liaw, Siaw-Teng/0000-0001-5989-3614; Whalley, Gillian/0000-0002-5713-6967; Fassett, Robert G/0000-0002-5318-6940; Grobbee, Diederick/0000-0003-4472-4468; Nolan, Christopher J/0000-0002-6964-3819; Hopkins, David/0000-0002-0451-0900; Lim, Sern/0000-0002-6569-1805; Billot, Laurent/0000-0002-4975-9793; Petrovsky, Nikolai/0000-0002-1580-5245; de Galan, Bastiaan E/0000-0002-1255-7741; Greiver, Michelle/0000-0001-8957-0285; Glasziou, Paul/0000-0001-7564-073X; Mullan, Karen R/0000-0002-6355-1964; Al Aloul, Basel/0000-0002-9494-1295; Joshi, Rohina/0000-0002-3374-401X; Woodward, Mark/0000-0001-9800-5296; Neal, Bruce/0000-0002-0490-7465; Stanton, Alice/0000-0002-4961-165X; Marre, Michel/0000-0002-3071-1837; Chalmers, John/0000-0002-9931-0580; Williams, Bryan/0000-0002-8094-1841; Bohme, Philip/0000-0002-5280-2959; Bompoint, Severine/0000-0001-5226-4321; Czerwienska, Beata/0000-0001-8258-9223; Ficek, Rafal/0000-0002-8230-5101; Chaturvedi, Vivek/0000-0002-1792-4678; Kengne, Andre Pascal/0000-0002-5183-131X; Nawawi, Hapizah/0000-0003-4462-8484; Harrap, Stephen/0000-0003-2907-6714; MacMahon, Stephen/0000-0003-2064-7699; Heller, Simon/0000-0002-2425-9565; Patel, Anushka/0000-0003-3825-4092; Rodgers, Anthony/0000-0003-1282-1896				Abraira C, 1997, ARCH INTERN MED, V157, P181, DOI 10.1001/archinte.157.2.181; Abraira C, 2003, J DIABETES COMPLICAT, V17, P314, DOI 10.1016/S1056-8727(02)00277-5; [Anonymous], 2007, DIABETES CARE, V30, pS4, DOI [10.2337/dc07-S004, DOI 10.2337/DC07-S004]; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Belcher G, 2004, INT J CLIN PRACT, V58, P833, DOI 10.1111/j.1742-1241.2004.00291.x; Chalmers J, 2001, DIABETOLOGIA, V44, P1118; Fava D, 2002, DIABETIC MED, V19, P752, DOI 10.1046/j.1464-5491.2002.00762.x; Fox CS, 2007, CIRCULATION, V115, P1544, DOI 10.1161/CIRCULATIONAHA.106.658948; Gaede P, 2008, NEW ENGL J MED, V358, P580, DOI 10.1056/NEJMoa0706245; Gerstein HC, 2001, JAMA-J AM MED ASSOC, V286, P421, DOI 10.1001/jama.286.4.421; Gerstein HC, 2000, LANCET, V355, P253; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Heart Outcomes Prevention Evaluation Study Investigators, 2000, LANCET, V356, P860; Home P, 2008, BMJ-BRIT MED J, V336, P458, DOI 10.1136/bmj.39499.514410.80; IDF Clinical Guidelines Task Force, 2005, GLOB GUID TYP 2 DIAB; Keech AC, 2007, LANCET, V370, P1687, DOI 10.1016/S0140-6736(07)61607-9; MEINERT CL, 1970, DIABETES, V19, P789; MOSS SE, 1994, ARCH INTERN MED, V154, P2473; MOSS SE, 1991, AM J PUBLIC HEALTH, V81, P1158, DOI 10.2105/AJPH.81.9.1158; *NIH, 2008, SAF NHLBI CHANG INT; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Patel A, 2007, LANCET, V370, P829, DOI 10.1016/S0140-6736(07)61303-8; Ryden L, 2007, EUR HEART J, V28, P88, DOI [10.1093/eurheartj/ehl260, 10.1093/eurheartj/ehm124]; Schulz KF, 2005, LANCET, V365, P1591, DOI 10.1016/S0140-6736(05)66461-6; Selvin E, 2004, ANN INTERN MED, V141, P421, DOI 10.7326/0003-4819-141-6-200409210-00007; Shichiri M, 2000, DIABETES CARE, V23, pB21; Stettler C, 2006, AM HEART J, V152, P27, DOI 10.1016/j.ahj.2005.09.015; Stolk RP, 2007, CONTEMP CLIN TRIALS, V28, P6, DOI 10.1016/j.cct.2006.08.011; Turnbull F, 2005, ARCH INTERN MED, V165, P1410; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Wascher TC, 2005, CLIN PHYSIOL FUNCT I, V25, P40, DOI 10.1111/j.1475-097X.2004.00580.x; Woodward M., 2013, EPIDEMIOLOGY STUDY D	34	5162	5472	6	88	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2008	358	24					2560	2572		10.1056/NEJMoa0802987	http://dx.doi.org/10.1056/NEJMoa0802987			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311IJ	18539916	Green Published, Bronze			2022-12-28	WOS:000256593600004
J	Shafir, S; Reich, T; Tsur, E; Erev, I; Lotem, A				Shafir, Sharoni; Reich, Taly; Tsur, Erez; Erev, Ido; Lotem, Arnon			Perceptual accuracy and conflicting effects of certainty on risk-taking behaviour	NATURE			English	Article							APIS-MELLIFERA; DECISION; CHOICE	The 'certainty effect'(1,2) is a notable violation of expected utility theory by decision makers(3-6). It shows that people's tendency to select the safer of two prospects increases when this prospect provides a good outcome with certainty ( for example, people prefer a monetary gain of 3 with certainty over 4 with a probability of 0.8, but do not prefer 3 with a probability of 0.25 over 4 with a probability of 0.2). Subsequent work on experience- based decision making in rats(7) extended the certainty effect to other animals, suggesting its generality across different species and different decision- making mechanisms. However, an attempt to replicate this study with human subjects showed a surprising 'reversed certainty effect'(8,9), namely, the tendency to prefer the safer option decreases when this prospect is associated with certainty ( and people now prefer 4 with a probability of 0.8 over 3 with certainty). Here we show that these conflicting results can be explained by perceptual noise and that the certainty effect can be restored experimentally by reducing perceptual accuracy. Using complementary experiments in humans and honeybees ( Apis mellifera), we show that by manipulating perceptual accuracy in experience-based tasks, both the certainty and the reversed certainty effects can be exhibited by humans and other animals: the certainty effect emerges when it is difficult to discriminate between the different rewards, whereas the reversed certainty effect emerges when discrimination is easy. Our results fit a simple process- based model of matching behaviour(10,11), capable of explaining the certainty effect in humans and other animals that make repeated decisions based on experience. This mechanism should probably be distinguished from those involved in the original certainty effect that was exhibited by human subjects in single description- based problems(1,2).	[Lotem, Arnon] Tel Aviv Univ, Dept Zool, Fac Life Sci, IL-69978 Tel Aviv, Israel; [Shafir, Sharoni; Tsur, Erez] Hebrew Univ Jerusalem, B Triwaks Bee Res Ctr, Dept Entomol, Fac Agr Food & Environm Qual Sci, IL-76100 Rehovot, Israel; [Reich, Taly; Erev, Ido] Technion Israel Inst Technol, Max Wertheimer Minerva Ctr Cognit Studies, Fac Ind Engn & Management, IL-32000 Haifa, Israel	Tel Aviv University; Hebrew University of Jerusalem; Technion Israel Institute of Technology	Lotem, A (corresponding author), Tel Aviv Univ, Dept Zool, Fac Life Sci, IL-69978 Tel Aviv, Israel.	erev@techunix.technion.ac.il; lotem@post.tau.ac.il	Shafir, Sharoni/D-9821-2011	Shafir, Sharoni/0000-0002-9068-1078; Reich, Taly/0000-0002-2978-4406; Erev, Ido/0000-0001-9889-4070				Allais M, 1953, ECONOMETRICA, V21, P503, DOI 10.2307/1907921; Barron G, 2003, J BEHAV DECIS MAKING, V16, P215, DOI 10.1002/bdm.443; Dickhaut J, 2003, P NATL ACAD SCI USA, V100, P3536, DOI 10.1073/pnas.0530279100; Erev I, 2005, PSYCHOL REV, V112, P912, DOI 10.1037/0033-295X.112.4.912; ESTES WK, 1950, PSYCHOL REV, V57, P94, DOI 10.1037/h0058559; GIBBON J, 1988, PSYCHOL REV, V95, P102, DOI 10.1037/0033-295X.95.1.102; Gottlieb DA, 2007, PSYCHOL SCI, V18, P240, DOI 10.1111/j.1467-9280.2007.01883.x; Herrnstein RJ, 1970, J EXP ANAL BEHAV, V13, P243, DOI 10.1901/jeab.1970.13-243; Hertwig R, 2004, PSYCHOL SCI, V15, P534, DOI 10.1111/j.0956-7976.2004.00715.x; KAHNEMAN D, 1979, ECONOMETRICA, V47, P263, DOI 10.2307/1914185; MACDONALD DH, 1991, ECON J, V101, P1065; March JG, 1996, PSYCHOL REV, V103, P309, DOI 10.1037/0033-295X.103.2.309; Marsh B, 2002, P NATL ACAD SCI USA, V99, P3352, DOI 10.1073/pnas.042491999; Osborne MJ, 1998, AM ECON REV, V88, P834; Real LA, 1996, AM ZOOL, V36, P518; Savage L.J., 1954, FDN STAT; Scheiner R, 2004, APIDOLOGIE, V35, P133, DOI 10.1051/apido:2004001; Shafir S, 2005, ANIM BEHAV, V69, P859, DOI 10.1016/j.anbehav.2004.07.011; Stevens S. S., 1975, PSYCHOPHYSICS; Sugrue LP, 2004, SCIENCE, V304, P1782, DOI 10.1126/science.1094765; TVERSKY A, 1995, ECONOMETRICA, V63, P1255, DOI 10.2307/2171769; von Neumann J., 1947, THEORY GAMES EC BEHA, V2	22	59	59	4	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2008	453	7197					917	U51		10.1038/nature06841	http://dx.doi.org/10.1038/nature06841			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311WV	18548069				2022-12-28	WOS:000256632000043
J	Ercan, S; Lieb, JD				Ercan, Sevinc; Lieb, Jason D.			Chromatin proteins do double duty	CELL			English	Editorial Material							DOSAGE COMPENSATION; DROSOPHILA; TRANSCRIPTION; COMPLEX	The histone acetyltransferase MOF (males-absent-on-the-first) is required for the regulation of X chromosome gene dosage compensation in Drosophila males. In this issue, Kind et al. (2008) show that MOF is also found on autosomes and that it has two modes of binding: one in males for X chromosome dosage compensation and the other in both sexes for X chromosome and autosomal gene regulation independent of dosage compensation.	[Ercan, Sevinc; Lieb, Jason D.] Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; [Ercan, Sevinc; Lieb, Jason D.] Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Lieb, JD (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.	jlieb@bio.unc.edu		Lieb, Jason/0000-0001-7601-8061				Carrozza MJ, 2005, CELL, V123, P581, DOI 10.1016/j.cell.2005.10.023; Eisen A, 2001, J BIOL CHEM, V276, P3484, DOI 10.1074/jbc.M008159200; Gilfillan GD, 2007, NUCLEIC ACIDS RES, V35, P3561, DOI 10.1093/nar/gkm282; Larschan E, 2007, MOL CELL, V28, P121, DOI 10.1016/j.molcel.2007.08.011; Lieb JD, 1998, CELL, V92, P265, DOI 10.1016/S0092-8674(00)80920-4; Liu CL, 2005, PLOS BIOL, V3, P1753, DOI 10.1371/journal.pbio.0030328; Lyman LM, 1997, GENETICS, V147, P1743; Mendjan S, 2006, MOL CELL, V21, P811, DOI 10.1016/j.molcel.2006.02.007; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Straub T, 2007, NAT REV GENET, V8, P47, DOI 10.1038/nrg2013	10	0	0	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 30	2008	133	5					763	765		10.1016/j.cell.2008.05.011	http://dx.doi.org/10.1016/j.cell.2008.05.011			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510918	Bronze			2022-12-28	WOS:000256274500006
J	Gladyshev, EA; Meselson, M; Arkhipova, IR				Gladyshev, Eugene A.; Meselson, Matthew; Arkhipova, Irina R.			Massive horizontal gene transfer in bdelloid rotifers	SCIENCE			English	Article							EUKARYOTES; TELOMERES; EVOLUTION; GENOMES	Horizontal gene transfer in metazoans has been documented in only a few species and is usually associated with endosymbiosis or parasitism. By contrast, in bdelloid rotifers we found many genes that appear to have originated in bacteria, fungi, and plants, concentrated in telomeric regions along with diverse mobile genetic elements. Bdelloid proximal gene- rich regions, however, appeared to lack foreign genes, thereby resembling those of model metazoan organisms. Some of the foreign genes were defective, whereas others were intact and transcribed; some of the latter contained functional spliceosomal introns. One such gene, apparently of bacterial origin, was overexpressed in Escherichia coli and yielded an active enzyme. The capture and functional assimilation of exogenous genes may represent an important force in bdelloid evolution.	[Gladyshev, Eugene A.; Meselson, Matthew; Arkhipova, Irina R.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; [Meselson, Matthew; Arkhipova, Irina R.] Marine Biol Lab, Josephine Bay Paul Ctr Comparat Mol Biol & Evolut, Woods Hole, MA 02543 USA	Harvard University; Marine Biological Laboratory - Woods Hole	Meselson, M (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	msm@wjh.harvard.edu; iarkhipova@mbl.edu	Puigbò, Pere/A-2214-2008	Arkhipova, Irina/0000-0002-4805-1339; Gladyshev, Eugene/0000-0002-4074-4966	NIGMS NIH HHS [R01 GM072708, GM072708] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072708] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersson JO, 2005, CELL MOL LIFE SCI, V62, P1182, DOI 10.1007/s00018-005-4539-z; Arkhipova IR, 2005, P NATL ACAD SCI USA, V102, P11781, DOI 10.1073/pnas.0505333102; Baird DM, 2003, NAT GENET, V33, P203, DOI 10.1038/ng1084; Bergthorsson U, 2003, NATURE, V424, P197, DOI 10.1038/nature01743; Boucher Y, 2003, ANNU REV GENET, V37, P283, DOI 10.1146/annurev.genet.37.050503.084247; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Doolittle WE, 1998, TRENDS GENET, V14, P307; Dunn CW, 2008, NATURE, V452, P745, DOI 10.1038/nature06614; Finking R, 2004, ANNU REV MICROBIOL, V58, P453, DOI 10.1146/annurev.micro.58.030603.123615; Gladyshev E, 2008, P NATL ACAD SCI USA, V105, P5139, DOI 10.1073/pnas.0800966105; Gladyshev EA, 2007, GENE, V390, P136, DOI 10.1016/j.gene.2006.09.025; Gladyshev EA, 2007, P NATL ACAD SCI USA, V104, P9352, DOI 10.1073/pnas.0702741104; Haviv-Chesner A, 2007, NUCLEIC ACIDS RES, V35, P5192, DOI 10.1093/nar/gkm521; HUR JH, 2006, THESIS HARVARD U; Jain R, 1999, P NATL ACAD SCI USA, V96, P3801, DOI 10.1073/pnas.96.7.3801; Katz LA, 2002, INT J SYST EVOL MICR, V52, P1893, DOI 10.1099/00207713-52-5-1893; KIDWELL MG, 1993, ANNU REV GENET, V27, P235, DOI 10.1146/annurev.ge.27.120193.001315; Kondo N, 2002, P NATL ACAD SCI USA, V99, P14280, DOI 10.1073/pnas.222228199; Lapinski J, 2003, FEBS LETT, V553, P387, DOI 10.1016/S0014-5793(03)01062-7; Loftus B, 2005, NATURE, V433, P865, DOI 10.1038/nature03291; Morrison HG, 2007, SCIENCE, V317, P1921, DOI 10.1126/science.1143837; Normark BB, 2003, BIOL J LINN SOC, V79, P69, DOI 10.1046/j.1095-8312.2003.00182.x; Otto SP, 2002, NAT REV GENET, V3, P252, DOI 10.1038/nrg761; Pouchkina-Stantcheva NN, 2005, MOL BIOL EVOL, V22, P1482, DOI 10.1093/molbev/msi139; Suga K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000671; Syvanen M., 2002, HORIZONTAL GENE TRAN; Welch DBM, 2008, P NATL ACAD SCI USA, V105, P5145, DOI 10.1073/pnas.0800972105; Welch DM, 2000, SCIENCE, V288, P1211, DOI 10.1126/science.288.5469.1211	28	306	322	3	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	2008	320	5880					1210	1213		10.1126/science.1156407	http://dx.doi.org/10.1126/science.1156407			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306FF	18511688	Green Submitted			2022-12-28	WOS:000256233000037
J	Gostin, LO				Gostin, Lawrence O.			The deregulatory effects of preempting tort litigation - FDA regulation of medical devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Gostin, Lawrence O.] Georgetown Univ, Ctr Law, Oneill Inst Natl & Global Hlth Law, Washington, DC 20001 USA	Georgetown University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, Oneill Inst Natl & Global Hlth Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu						*FOOD DRUG ADM SCI, 2007, SCI MISS RISK REP SU; Institute of Medicine, 2006, FUT DRUG SAF PROM PR; Kesselheim AS, 2007, JAMA-J AM MED ASSOC, V297, P308, DOI 10.1001/jama.297.3.308; Kessler DA, 2008, GEORGETOWN LAW J, V96, P461; OREILLY JT, IN PRESS CORNELL LAW; Porter MJ, 1997, FOOD DRUG LAW J, V52, P7; ROSEN J, 2008, NY TIMES MAG    0316, P38; VLADECK DC, 2005, PEPP L REV, V33, P95; VLADECK DC, IN PRESS CORNELL LAW	9	16	16	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2008	299	19					2313	2316		10.1001/jama.299.19.2313	http://dx.doi.org/10.1001/jama.299.19.2313			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302QN	18492972				2022-12-28	WOS:000255984500026
J	Janssens, HJEM; Janssen, M; van de Lisdonk, EH; van Riel, PLCM; van Weel, C				Janssens, Hein J. E. M.; Janssen, Matthijs; van de Lisdonk, Eloy H.; van Riel, Piet L. C. M.; van Weel, Chris			Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial	LANCET			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRIAMCINOLONE ACETONIDE; RISK; THERAPY; METAANALYSIS; PREVENTION; INHIBITORS; DIAGNOSIS; PAIN; MEN	Background Non-steroidal anti-inflammatory drugs and colchicine used to treat gout arthritis have gastrointestinal, renal, and cardiovascular adverse effects. Systemic corticosteroids might be a beneficial alternative. We investigated equivalence of naproxen and prednisolone in primary care. Methods We did a randomised clinical trial to test equivalence of prednisolone and naproxen for the treatment of monoarticular gout. Primary-care patients with gout confirmed by presence of monosodium urate crystals were eligible. 120 patients were randomly assigned with computer-generated randomisation to receive either prednisolone (35 mg once a day; n=60) or naproxen (500 mg twice a day; n=60), for 5 days. Treatment was masked for both patients and physicians. The primary outcome was pain measured on a 100 mm visual analogue scale and the a priori margin for equivalence set at 10%. Analyses ware done per protocol and by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN14648181. Findings Data were incomplete for one patient in each treatment group, so per-protocol analyses included 59 patients in each group. After 90 h the reduction in the pain score was 44.7 mm and 46.0 mm for prednisolone and naproxen, respectively (difference 1.3 mm; 95% CI-9.8 to 7.1), suggesting equivalence. The difference in the size of change in pain was 1.57 mm (95% CI -8.65 to 11.78). Adverse effects were similar between groups, minor, and resolved by 3 week follow-up. Interpretation Oral prednisolone and naproxen are equally effective in the initial treatment of gout arthritis over 4 days. Funding Rheumatology Research Fund Arnhem, Netherlands.	[Janssens, Hein J. E. M.; van de Lisdonk, Eloy H.; van Weel, Chris] Radboud Univ Nijmegen, Med Ctr, Dept Gen Practice, NL-6500 HB Nijmegen, Netherlands; [van Riel, Piet L. C. M.] Radboud Univ Nijmegen, Med Ctr, Dept Rheumatol, NL-6500 HB Nijmegen, Netherlands; [Janssen, Matthijs] Rijnstate Hosp, Dept Rheumatol, Arnhem, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Rijnstate Hospital	Janssens, HJEM (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Gen Practice, POB 9101, NL-6500 HB Nijmegen, Netherlands.	h.janssens@hag.umcn.nl	Janssens, Hein J.E.M./E-3519-2016; van Riel, P.L.C.M./H-8082-2014; Janssen, Matthijs/AAZ-2784-2020; van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701; Janssen, Matthijs/0000-0003-3752-7837				AHERN MJ, 1987, AUST NZ J MED, V17, P301, DOI 10.1111/j.1445-5994.1987.tb01232.x; ALLOWAY JA, 1993, J RHEUMATOL, V20, P111; Antman EM, 2007, CIRCULATION, V115, P1634, DOI 10.1161/CIRCULATIONAHA.106.181424; Bieber JD, 2004, ARTHRITIS RHEUM-US, V50, P2400, DOI 10.1002/art.20438; Brook RA, 2006, CURR MED RES OPIN, V22, P1381, DOI 10.1185/030079906X112606; Choi HK, 2004, LANCET, V363, P1277, DOI 10.1016/S0140-6736(04)16000-5; Choi HK, 2008, BMJ-BRIT MED J, V336, P309, DOI 10.1136/bmj.39449.819271.BE; Fam AG, 1998, DRUG AGING, V13, P229, DOI 10.2165/00002512-199813030-00006; GOTZSCHE PC, 2005, COCHRANE DB SYST REV, V1; GROFF GD, 1990, SEMIN ARTHRITIS RHEU, V19, P329, DOI 10.1016/0049-0172(90)90070-V; Janssens HJEM, 2006, ANN RHEUM DIS, V65, P1080, DOI 10.1136/ard.2005.040360; Janssens HJ, 2008, COCHRANE DB SYST REV, V2; Janssens HJEM, 2003, FAM PRACT, V20, P413, DOI 10.1093/fampra/cmg413; Kearney PM, 2006, BMJ-BRIT MED J, V332, P1302, DOI 10.1136/bmj.332.7553.1302; Krishnan E, 2006, ARTHRITIS RHEUM-US, V54, P2688, DOI 10.1002/art.22014; Lanza FL, 1998, AM J GASTROENTEROL, V93, P2037; Laporte JR, 2004, DRUG SAFETY, V27, P411, DOI 10.2165/00002018-200427060-00005; Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176; Lewis SC, 2002, BRIT J CLIN PHARMACO, V54, P320, DOI 10.1046/j.1365-2125.2002.01636.x; Man CY, 2007, ANN EMERG MED, V49, P670, DOI 10.1016/j.annemergmed.2006.11.014; Ordi J, 2006, NEW ENGL J MED, V355, P516, DOI 10.1056/NEJMon060780; Petersel D, 2007, J RHEUMATOL, V34, P1566; Porter R., 2000, GOUT PATRICIAN MALAD; Rostom A, 2007, CLIN GASTROENTEROL H, V5, P818, DOI 10.1016/j.cgh.2007.03.011; Rowe BH, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002178; Schlesinger N, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006190; Schlesinger N, 2002, J RHEUMATOL, V29, P331; Schumacher HR, 2005, J RHEUMATOL, V32, P2452; SIEGEL LB, 1994, J RHEUMATOL, V21, P1325; Stahmer SA, 1998, ACAD EMERG MED, V5, P851, DOI 10.1111/j.1553-2712.1998.tb02811.x; Sutaria S, 2006, RHEUMATOLOGY, V45, P1422, DOI 10.1093/rheumatology/kel071; ten Klooster PM, 2006, PAIN, V121, P151, DOI 10.1016/j.pain.2005.12.021; Terkeltaub RA, 2003, NEW ENGL J MED, V349, P1647, DOI 10.1056/NEJMcp030733; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X; Underwood M, 2006, BMJ-BRIT MED J, V332, P1315, DOI 10.1136/bmj.332.7553.1315; Werlen D, 1996, REV RHUM, V63, P248; Zhang W, 2006, ANN RHEUM DIS, V65, P1301, DOI 10.1136/ard.2006.055251	37	193	206	0	46	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY-JUN	2008	371	9627					1854	1860		10.1016/S0140-6736(08)60799-0	http://dx.doi.org/10.1016/S0140-6736(08)60799-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307NL	18514729				2022-12-28	WOS:000256325500029
J	Morris, JA; Harrison, LM				Morris, James A.; Harrison, Linda M.			Sudden unexpected death in infancy: evidence of infection	LANCET			English	Editorial Material							PERSPECTIVES; TOXINS		[Morris, James A.; Harrison, Linda M.] Royal Infirm, Lancaster LA1 4RP, England		Morris, JA (corresponding author), Royal Infirm, Lancaster LA1 4RP, England.	Jim.A.Morris@rli.mbht.nhs.uk		Morris, James/0000-0001-7713-0004				Banks RE, 2000, LANCET, V356, P1749, DOI 10.1016/S0140-6736(00)03214-1; Blair SN, 2006, INT J EPIDEMIOL, V35, P69, DOI 10.1093/ije/dyi259; Fleming P., 2000, SUDDEN UNEXPECTED DE; GILBERT R, 1992, ARCH DIS CHILD, V67, P171, DOI 10.1136/adc.67.2.171; Harrison LM, 1999, FEMS IMMUNOL MED MIC, V25, P19, DOI 10.1111/j.1574-695X.1999.tb01323.x; Morris JA, 2006, J CLIN PATHOL, V59, P1, DOI 10.1136/jcp.2005.028183; Morris JA, 1999, FEMS IMMUNOL MED MIC, V25, P11, DOI 10.1111/j.1574-695X.1999.tb01322.x; Morris JA, 2007, CURR DIAGNOS PATHOL, V13, P65, DOI DOI 10.1016/J.CDIP.2006.07.005; Poets CF, 1999, PEDIATR RES, V45, P350, DOI 10.1203/00006450-199903000-00010; Weber MA, 2008, LANCET, V371, P1848, DOI 10.1016/S0140-6736(08)60798-9; Zorgani A, 1999, FEMS IMMUNOL MED MIC, V25, P103, DOI 10.1111/j.1574-695X.1999.tb01332.x	11	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY-JUN	2008	371	9627					1815	1816		10.1016/S0140-6736(08)60774-6	http://dx.doi.org/10.1016/S0140-6736(08)60774-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307NL	18514712				2022-12-28	WOS:000256325500005
J	Caplan, LR; Burns, RB				Caplan, Louis R.; Burns, Risa B.			A 70-year-old man with a transient ischemic attack - Review of internal carotid artery stenosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MAGNETIC-RESONANCE ANGIOGRAPHY; CEREBRAL PROTECTION; ENDARTERECTOMY; STROKE; RISK; CHOLESTEROL; COMPLICATIONS; ANGIOPLASTY; ATHEROSCLEROSIS; HYPOPERFUSION	Mr V, a man with severe coronary, aortic, and peripheral artery disease, had an episode of brain ischemia caused by severe preocclusive carotid artery disease in the neck. The major treatment options for his symptomatic carotid artery disease are optimizing medical treatment, carotid endarterectomy, and carotid artery stenting. Selection of treatment must take into consideration his severe symptomatic coronary artery disease as well as Mr V's concerns about surgery. Carotid endarterectomy presents a risk of myocardial infarction unless his coronary disease is treated effectively before surgery. Carotid stenting is problematic because the severity of the preocclusive arterial narrowing makes passing a protective device beyond the stenosis difficult without first performing potentially hazardous angioplasty. Optimizing medical treatment may be the best option for his severe systemic atherosclerosis. Treatment decisions in complex patients like Mr V require weighing the particular risks and benefits of available options, and the patient's own wishes and fears. These decisions, in this and other complex patients, often cannot be directly informed by results from randomized trials.	[Caplan, Louis R.] Beth Israel Deaconess Med Ctr, Div Cerebrovasc Stroke, Boston, MA 02215 USA; [Caplan, Louis R.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Caplan, LR (corresponding author), Beth Israel Deaconess Med Ctr, Div Cerebrovasc Stroke, 1 Deaconess Rd, Boston, MA 02215 USA.	lcaplan@bidmc.harvard.edu						Adami CA, 2002, J ENDOVASC THER, V9, P147, DOI 10.1583/1545-1550(2002)009<0147:UOTPAE>2.0.CO;2; Amarenco P, 2007, STROKE, V38, P3198, DOI 10.1161/STROKEAHA.107.493106; Amarenco P, 2006, NEW ENGL J MED, V355, P549; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; Biller J, 1998, STROKE, V29, P554, DOI 10.1161/01.STR.29.2.554; Blauw GJ, 1997, STROKE, V28, P946, DOI 10.1161/01.STR.28.5.946; Breen JC, 1996, NEUROLOGY, V46, P175, DOI 10.1212/WNL.46.1.175; Brown MM, 2001, LANCET, V357, P1729; Bucher HC, 1998, ANN INTERN MED, V128, P89, DOI 10.7326/0003-4819-128-2-199801150-00002; Cambria RP, 2004, NEW ENGL J MED, V351, P1565, DOI 10.1056/NEJMe048234; Caplan Louis R, 2002, Curr Neurol Neurosci Rep, V2, P1, DOI 10.1007/s11910-002-0044-z; Caplan Louis R, 2007, Rev Neurol Dis, V4, P113; CAPLAN LR, 1973, NEW ENGL J MED, V288, P1008, DOI 10.1056/NEJM197305102881907; Caplan LR, 1998, ARCH NEUROL-CHICAGO, V55, P1475, DOI 10.1001/archneur.55.11.1475; Caplan LR, 2006, CEREBROVASC DIS, V21, P145, DOI 10.1159/000090791; CAPLAN LR, 1986, STROKE, V17, P648, DOI 10.1161/01.STR.17.4.648; CAPLAN LR, 1995, JAMA-J AM MED ASSOC, V274, P1383, DOI 10.1001/jama.274.17.1383; Caplan LR, 2001, J NEUROL NEUROSUR PS, V71, P569, DOI 10.1136/jnnp.71.5.569; CAPLAN LR, 1978, STROKE, V9, P457, DOI 10.1161/01.STR.9.5.457; Caplan LR., 2000, CAPLANS STROKE CLIN, V3rd ed., P34; Carter JE, 1988, AMAUROSIS FUGAX, P118; DIENER HC, 2000, REV NEUROL DIS, V4, P177; Dzau V, 2005, J HYPERTENS, V23, pS9, DOI 10.1097/01.hjh.0000165623.72310.dd; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; FISHER CM, 1986, REV NEUROL, V142, P573; FISHER CM, 1970, NEUROLOGY, V20, P476, DOI 10.1212/WNL.20.5.476; FISHER CM, 1959, NEUROLOGY, V9, P333, DOI 10.1212/WNL.9.5.333; Fisher M, 2005, STROKE, V36, P2324, DOI 10.1161/01.STR.0000179039.76922.e8; Fisher M, 2005, STROKE, V36, P253, DOI 10.1161/01.STR.0000152336.71224.21; FORTEZA AM, 2003, IMAGING CEREBROVASCU, P3; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; Gillard Jonathan H, 2007, Cerebrovasc Dis, V24 Suppl 1, P40, DOI 10.1159/000107378; GORELICK PB, 1984, NEUROLOGY, V34, P54, DOI 10.1212/WNL.34.1.54; Gurm HS, 2008, NEW ENGL J MED, V358, P1572, DOI 10.1056/NEJMoa0708028; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; Hobson RW, 2004, J VASC SURG, V40, P1106, DOI 10.1016/j.jvs.2004.10.022; Hodis HN, 1996, ANN INTERN MED, V124, P548, DOI 10.7326/0003-4819-124-6-199603150-00002; Hofmann R, 2006, STROKE, V37, P2557, DOI 10.1161/01.STR.0000240688.81918.32; HOLLENHORST RW, 1959, AM J OPHTHALMOL, V47, P753, DOI 10.1016/S0002-9394(14)76496-7; Kachel R, 1996, J ENDOVASC SURG, V3, P22, DOI 10.1583/1074-6218(1996)003<0022:ROBAIT>2.0.CO;2; Kastrup A, 2003, STROKE, V34, P813, DOI 10.1161/01.STR.0000058160.53040.5F; KEARNS TP, 1963, MAYO CLIN PROC, V38, P304; KERBER CW, 1980, AM J NEURORADIOL, V1, P348; Kern R, 2004, STROKE, V35, P870, DOI 10.1161/01.STR.0000120728.72958.4A; Landry A, 2004, STROKE, V35, P864, DOI 10.1161/01.STR.0000121161.61324.ab; Lehv MS, 1970, STROKE, V1, P307, DOI 10.1161/01.STR.1.5.307; Levi CR, 1996, CEREBROVASC DIS, V6, P231, DOI 10.1159/000108026; Lonn EM, 2001, CIRCULATION, V103, P919; MARKUS H, 1993, STROKE, V24, P1246, DOI 10.1161/01.STR.24.8.1246; Mas J, 2006, NEW ENGL J MED, V355, P1660, DOI 10.1056/NEJMoa061752; McCabe DJH, 2005, STROKE, V36, P281, DOI 10.1161/01.STR.0000152333.75932.fe; McKinlay S, 2003, J ENDOVASC THER, V10, P1021, DOI 10.1177/152660280301000601; Meyers PM, 2006, ANNU REV MED, V57, P437, DOI 10.1146/annurev.med.57.121304.131320; MITTL RL, 1994, STROKE, V25, P4, DOI 10.1161/01.STR.25.1.4; Molloy J, 1999, STROKE, V30, P1440, DOI 10.1161/01.STR.30.7.1440; Morgenstern LB, 1997, NEUROLOGY, V48, P911, DOI 10.1212/WNL.48.4.911; Nissen SE, 2005, NEW ENGL J MED, V352, P29, DOI 10.1056/NEJMoa042000; Parodi JC, 2007, J CARDIOVASC SURG, V48, P117; Parodi JC, 2005, J VASC SURG, V41, P416, DOI 10.1016/j.jvs.2005.01.003; Perry JR, 1997, ARCH NEUROL-CHICAGO, V54, P25, DOI 10.1001/archneur.1997.00550130015009; Ringleb PA, 2006, LANCET, V368, P1239, DOI 10.1016/S0140-6736(06)69122-8; Rothwell PM, 2004, LANCET, V363, P915, DOI 10.1016/S0140-6736(04)15785-1; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; ROWED DW, 1986, STROKE, V17, P848; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SIEBLER M, 1995, STROKE, V26, P2184, DOI 10.1161/01.STR.26.11.2184; SUNDT TM, 1975, MAYO CLIN PROC, V50, P301; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; THIBAULT GE, 1993, NEW ENGL J MED, V328, P946, DOI 10.1056/NEJM199304013281309; WADE JG, 1970, NEW ENGL J MED, V282, P823, DOI 10.1056/NEJM197004092821501; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; Wholey MH, 2000, CATHETER CARDIO INTE, V50, P160, DOI 10.1002/(SICI)1522-726X(200006)50:2<160::AID-CCD2>3.0.CO;2-E; Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127	73	6	7	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2008	300	1					81	90		10.1001/jama.299.21.jrr80004	http://dx.doi.org/10.1001/jama.299.21.jrr80004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320NW	18523206				2022-12-28	WOS:000257242800027
J	Frank, PI; Morris, JA; Hazell, ML; Linehan, MF; Frank, TL				Frank, Peter I.; Morris, Julie A.; Hazell, Michelle L.; Linehan, Mary F.; Frank, Timothy L.			Long term prognosis in preschool children with wheeze: longitudinal postal questionnaire study 1993-2004	BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; FOLLOW-UP; PREVALENCE; LIFE; PHENOTYPES; INCREASE; DISEASE; BIRTH	Objectives To follow a population of preschool children with and without parent reported wheeze over a period of 6-11 years to determine prognosis and its important predictive factors. Design Longitudinal series of five postal surveys based on the international study of asthma and allergies in childhood questionnaire carried out between 1993 and 2004. Setting Two general practice populations, south Manchester. Participants 628 children aged less than 5 years at recruitment and those with at least six years' follow-up data. Main outcome measures Parent completed questionnaire data for respiratory symptoms and associated features. Results Of 628 children included in the study, 201 (32%) had parent reported wheeze at the first observation (baseline), of whom 27% also reported the symptom on the second occasion (persistent asthma). The only important baseline predictors of persistent asthma were exercise induced wheeze (odds ratio 3.94, 95% confidence interval 1.72 to 9.00) and a history of atopic disorders (4.44, 1.94 to 10.13). The presence of both predictors indicated a likelihood of 53.2% of developing asthma; if only one feature was present this decreased to 17.2%, whereas if neither was present the likelihood was 10.9%. Family history of asthma was not predictive of persistent asthma among children with preschool wheeze. Conclusion Using two simple predictive factors (baseline parent reported exercise induced wheeze and a history of atopic disorders), it is possible to estimate the likelihood of future asthma in children presenting with preschool wheeze. The absence of baseline exercise induced wheeze and a history of atopic disorders reduces the likelihood of subsequent asthma by a factor of five.	[Frank, Peter I.; Hazell, Michelle L.; Linehan, Mary F.; Frank, Timothy L.] Wythenshawe Hosp, Gen Practice Res Unit, NW Lung Res Ctr, Manchester M23 9LT, Lancs, England; [Morris, Julie A.] Univ S Manchester Hosp, NHS Fdn Trust, Dept Med Stat, Manchester M20 8LR, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Oxford University Hospitals NHS Foundation Trust; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Hazell, ML (corresponding author), Wythenshawe Hosp, Gen Practice Res Unit, NW Lung Res Ctr, Manchester M23 9LT, Lancs, England.	michelle.hazell@manchester.ac.uk	frank, timothy/AAF-9833-2020	Frank, Timothy/0000-0002-1580-8980				Barraclough R, 2002, EUR RESPIR J, V20, P826, DOI 10.1183/09031936.02.00822002; BUTLER D, 1993, HLTH INEQUALITIES MA; Chinn S, 2004, THORAX, V59, P646, DOI 10.1136/thx.2004.021642; Frank P, 1996, BRIT J GEN PRACT, V46, P295; Frank PI, 2005, BRIT J GEN PRACT, V55, P596; Garcia-Marcosa L, 2005, INT ARCH ALLERGY IMM, V137, P303, DOI 10.1159/000086461; KEIL U, 1992, LANCET, V340, P46; KELL U, 1992, LANCET, V340, P46; Kuehni CE, 2000, EUR RESPIR J, V16, P81, DOI 10.1034/j.1399-3003.2000.16a14.x; Kurukulaaratchy RJ, 2004, PEDIATRICS, V113, P345, DOI 10.1542/peds.113.2.345; Kurukulaaratchy RJ, 2003, EUR RESPIR J, V22, P767, DOI 10.1183/09031936.03.00005903; Kurukulaaratchy RJ, 2003, CLIN EXP ALLERGY, V33, P573, DOI 10.1046/j.1365-2222.2003.01657.x; Linehan MF, 2005, ARCH DIS CHILD, V90, P516, DOI 10.1136/adc.2004.061879; Lowe LA, 2005, AM J RESP CRIT CARE, V171, P231, DOI 10.1164/rccm.200406-695OC; Martinez Fernando D, 2002, Paediatr Respir Rev, V3, P193, DOI 10.1016/S1526-0542(02)00188-4; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Osman M, 2007, PEDIATR PULM, V42, P60, DOI 10.1002/ppul.20545; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176, DOI 10.1164/ajrccm.165.2.2104032; Strunk RC, 2002, PEDIATRICS, V109, P357; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Turner SW, 2004, AM J RESP CRIT CARE, V169, P921, DOI 10.1164/rccm.200307-891OC	22	29	31	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 21	2008	336	7658					1423	+		10.1136/bmj.39568.623750.BE	http://dx.doi.org/10.1136/bmj.39568.623750.BE			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318WJ	18558639	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000257123200034
J	Ayme, S; Kole, A; Groft, S				Ayme, Segolene; Kole, Anna; Groft, Stephen			Empowerment of patients: lessons from the rare diseases community	LANCET			English	Article							FACIO-CUTANEOUS SYNDROME; PATIENTS ASSOCIATIONS; EXPERT PATIENT; MUTATIONS; INTERNET; FRANCE		[Ayme, Segolene; Kole, Anna] INSERM, F-75014 Paris, France; [Groft, Stephen] NIH, Office Rare Dis, Dept Hlth & Human Serv, Bethesda, MD 20892 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); National Institutes of Health (NIH) - USA	Ayme, S (corresponding author), INSERM, SC11,102 Rue Didot, F-75014 Paris, France.	ayme@orpha.net	Ayme, Segolene/ABE-2545-2020					Angelmar R, 2007, PATIENT EMPOWERMENT; Broom A, 2005, QUAL HEALTH RES, V15, P325, DOI 10.1177/1049732304272916; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; *EUR COMM, STRONG EUR BAS PHARM; European Commission, 2005, INV COMM MEMB STAT I; Fox NJ, 2005, SOC SCI MED, V60, P1299, DOI 10.1016/j.socscimed.2004.07.005; *FRENCH MIN HLTH S, 2004, FRENCH NAT PLAN RAR; GEORGES J, 2006, PHARM POLICY LAW, V8, P133; Knight AW, 2006, MED J AUSTRALIA, V185, P82, DOI 10.5694/j.1326-5377.2006.tb00477.x; Lasker Judith N, 2005, J Med Internet Res, V7, pe10, DOI 10.2196/jmir.7.1.e10; MARC, 2006, WALL ST J NEW Y 0711, pD2; Marcus Amy Dockser, 2006, Wall St J (East Ed), pD2; Marshall E, 2004, SCIENCE, V305, P1226; Neuhauser Duncan, 2003, Qual Manag Health Care, V12, P171; Niihori T, 2006, NAT GENET, V38, P294, DOI 10.1038/ng1749; Rabeharisoa V, 2000, M S-MED SCI, V16, P945, DOI 10.4267/10608/1762; Rabeharisoa V, 2006, SOC SCI MED, V62, P564, DOI 10.1016/j.socscimed.2005.06.036; Rabeharisoa V, 2003, SOC SCI MED, V57, P2127, DOI 10.1016/S0277-9536(03)00084-4; Rabeharisoa V, 2002, INT SOC SCI J, V54, P57, DOI 10.1111/1468-2451.00359; Rodriguez-Viciana P, 2006, SCIENCE, V311, P1287, DOI 10.1126/science.1124642; Tomes N, 2007, LANCET, V369, P698, DOI 10.1016/S0140-6736(07)60318-3; Wallerstein N, 2006, WHAT IS EVIDENCE EFF; Wilson PM, 2001, HEALTH SOC CARE COMM, V9, P134, DOI 10.1046/j.1365-2524.2001.00289.x; World Bank, WHAT IS EMP	24	150	151	0	28	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 14	2008	371	9629					2048	2051		10.1016/S0140-6736(08)60875-2	http://dx.doi.org/10.1016/S0140-6736(08)60875-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312YY	18555918				2022-12-28	WOS:000256709500034
J	Krojer, T; Sawa, J; Schafer, E; Saibil, HR; Ehrmann, M; Clausen, T				Krojer, Tobias; Sawa, Justyna; Schaefer, Eva; Saibil, Helen R.; Ehrmann, Michael; Clausen, Tim			Structural basis for the regulated protease and chaperone function of DegP	NATURE			English	Article							OUTER-MEMBRANE BIOGENESIS; ENVELOPE STRESS-RESPONSE; ESCHERICHIA-COLI; PDZ DOMAINS; PERIPLASMIC PROTEIN; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURE; RESOLUTION; SYSTEM; PORIN	All organisms have to monitor the folding state of cellular proteins precisely. The heat- shock protein DegP is a protein quality control factor in the bacterial envelope that is involved in eliminating misfolded proteins and in the biogenesis of outer- membrane proteins. Here we describe the molecular mechanisms underlying the regulated protease and chaperone function of DegP from Escherichia coli. We show that binding of misfolded proteins transforms hexameric DegP into large, catalytically active 12- meric and 24- meric multimers. A structural analysis of these particles revealed that DegP represents a protein packaging device whose central compartment is adaptable to the size and concentration of substrate. Moreover, the inner cavity serves antagonistic functions. Whereas the encapsulation of folded protomers of outer- membrane proteins is protective and might allow safe transit through the periplasm, misfolded proteins are eliminated in the molecular reaction chamber. Oligomer reassembly and concomitant activation on substrate binding may also be critical in regulating other HtrA proteases implicated in protein- folding diseases.	[Krojer, Tobias; Sawa, Justyna; Clausen, Tim] Inst Mol Pathol, Res Inst Mol Pathol, A-1030 Vienna, Austria; [Schaefer, Eva; Saibil, Helen R.] Univ London Birkbeck Coll, Dept Crystallog, London WC1E 7HX, England; [Schaefer, Eva; Saibil, Helen R.] Univ London Birkbeck Coll, Inst Struct Mol Biol, London WC1E 7HX, England; [Ehrmann, Michael] Univ Duisburg Essen, Ctr Med Biotechnol, FB Biol & Geog, D-45117 Essen, Germany	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of London; Birkbeck University London; University of London; Birkbeck University London; University of Duisburg Essen	Clausen, T (corresponding author), Inst Mol Pathol, Res Inst Mol Pathol, Dr Bohrgasse 7, A-1030 Vienna, Austria.	clausen@imp.univie.ac.at	Ehrmann, Michael/A-7307-2012; Krojer, Tobias/ABE-3829-2021	Ehrmann, Michael/0000-0002-1927-260X; Krojer, Tobias/0000-0003-0661-0814; Clausen, Tim/0000-0003-1582-6924	BBSRC [BB/F010281/1, BB/C516179/1, BB/C516144/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/C516144/1, BB/F010281/1, BBS/B/03955, BB/C516179/1] Funding Source: Medline; Wellcome Trust [070776, 079605] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Alba BM, 2004, MOL MICROBIOL, V52, P613, DOI 10.1111/j.1365-2958.2003.03982.x; BANYARD SH, 1978, NATURE, V271, P282, DOI 10.1038/271282a0; Basle A, 2006, J MOL BIOL, V362, P933, DOI 10.1016/j.jmb.2006.08.002; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CastilloKeller M, 2003, J BACTERIOL, V185, P148, DOI 10.1128/JB.185.1.148-154.2003; Chen R, 1996, MOL MICROBIOL, V19, P1287, DOI 10.1111/j.1365-2958.1996.tb02473.x; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; DECOCK H, 1990, J BIOL CHEM, V265, P4646; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeLano W.L, PYMOL MOL GRAPHICS S; DUBOCHET J, 1983, J BACTERIOL, V155, P381, DOI 10.1128/JB.155.1.381-390.1983; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Grau S, 2005, P NATL ACAD SCI USA, V102, P6021, DOI 10.1073/pnas.0501823102; Guisbert E, 2007, J BACTERIOL, V189, P1963, DOI 10.1128/JB.01243-06; Harris BZ, 2001, J CELL SCI, V114, P3219; Hasselblatt H, 2007, GENE DEV, V21, P2659, DOI 10.1101/gad.445307; Iwanczyk J, 2007, J BACTERIOL, V189, P3176, DOI 10.1128/JB.01788-06; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KLOSE M, 1993, J BIOL CHEM, V268, P25664; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; LEDUC M, 1985, J BACTERIOL, V161, P627, DOI 10.1128/JB.161.2.627-635.1985; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Macario AJL, 2005, NEW ENGL J MED, V353, P1489, DOI 10.1056/NEJMra050111; MATSUYAMA S, 1984, J BACTERIOL, V158, P1041, DOI 10.1128/JB.158.3.1041-1047.1984; Meltzer M, 2008, ANGEW CHEM INT EDIT, V47, P1332, DOI 10.1002/anie.200703273; Misra R, 2000, J BACTERIOL, V182, P4882, DOI 10.1128/JB.182.17.4882-4888.2000; MISRA R, 1991, J BIOL CHEM, V266, P13592; Mortier E, 2005, EMBO J, V24, P2556, DOI 10.1038/sj.emboj.7600722; NAKAE T, 1979, J BIOL CHEM, V254, P1457; Pan L, 2007, EMBO J, V26, P4576, DOI 10.1038/sj.emboj.7601860; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Plun-Favreau H, 2007, NAT CELL BIOL, V9, P1243, DOI 10.1038/ncb1644; Purdy GE, 2007, J BACTERIOL, V189, P5566, DOI 10.1128/JB.00483-07; Rhodius VA, 2006, PLOS BIOL, V4, P43, DOI 10.1371/journal.pbio.0040002; Rizzitello AE, 2001, J BACTERIOL, V183, P6794, DOI 10.1128/JB.183.23.6794-6800.2001; Rouviere PE, 1996, GENE DEV, V10, P3170, DOI 10.1101/gad.10.24.3170; Ruiz N, 2006, NAT REV MICROBIOL, V4, P57, DOI 10.1038/nrmicro1322; SCHWEIZER M, 1978, EUR J BIOCHEM, V82, P211, DOI 10.1111/j.1432-1033.1978.tb12013.x; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; SEN K, 1991, J BACTERIOL, V173, P926, DOI 10.1128/jb.173.2.926-928.1991; Sklar JG, 2007, GENE DEV, V21, P2473, DOI 10.1101/gad.1581007; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P111, DOI 10.1016/0304-3991(87)90078-7; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Wilken C, 2004, CELL, V117, P483, DOI 10.1016/S0092-8674(04)00454-4; WINKLER FK, 1977, NATURE, V265, P509, DOI 10.1038/265509a0; Wu H, 2007, MOL CELL, V28, P886, DOI 10.1016/j.molcel.2007.10.028; Wu T, 2005, CELL, V121, P235, DOI 10.1016/j.cell.2005.02.015; Yan J, 2005, EMBO J, V24, P3985, DOI 10.1038/sj.emboj.7600858; Zimmermann P, 2002, MOL CELL, V9, P1215, DOI 10.1016/S1097-2765(02)00549-X	55	285	294	1	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2008	453	7197					885	U31		10.1038/nature07004	http://dx.doi.org/10.1038/nature07004			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311WV	18496527				2022-12-28	WOS:000256632000035
J	Weber, W; Vander Stoep, A; McCarty, RL; Weiss, NS; Biederman, J; McClellan, J				Weber, Wendy; Vander Stoep, Ann; McCarty, Rachelle L.; Weiss, Noel S.; Biederman, Joseph; McClellan, Jon			Hypericum perforatum (St John's Wort) for attention-deficit/hyperactivity disorder in children and adolescents - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEFICIT-HYPERACTIVITY DISORDER; DAILY ATOMOXETINE TREATMENT; DOUBLE-BLIND; OPEN-LABEL; ALTERNATIVE THERAPIES; CHILDHOOD ATTENTION; METHYLPHENIDATE; COMPLEMENTARY; DEPRESSION; SYMPTOMS	Context Stimulant medication can effectively treat 60% to 70% of youth with attention-deficit/ hyperactivity disorder ( ADHD). Yet many parents seek alternative therapies, and Hypericum perforatum ( St John's wort) is 1 of the top 3 botanicals used. Objective To determine the efficacy and safety of H perforatum for the treatment of ADHD in children. Design, Setting, and Participants Randomized, double- blind, placebo-controlled trial conducted between March 2005 and August 2006 at Bastyr University, Kenmore, Washington, among a volunteer sample of 54 children aged 6 to 17 years who met Diagnostic and Statistical Manual of Mental Disorders ( Fourth Edition) criteria for ADHD by structured interview. Intervention After a placebo run- in phase of 1 week, participants were randomly assigned to receive 300 mg of H perforatum standardized to 0.3% hypericin ( n= 27) or a matched placebo ( n= 27) 3 times daily for 8 weeks. Other medications for ADHD were not allowed during the trial. Main Outcome Measures Performance on the ADHD Rating Scale - IV ( range, 0- 54) and Clinical Global Impression Improvement Scale ( range, 0- 7), and adverse events. Results One patient in the placebo group withdrew because of an adverse event. No significant difference was found in the change in ADHD Rating Scale - IV scores from baseline to week 8 between the treatment and placebo groups: inattentiveness improved 2.6 points ( 95% confidence interval [ CI], - 4.6 to - 0.6 points) with H perforatum vs 3.2 points ( 95% CI, - 5.7 to - 0.8 points) with placebo ( P=. 68) and hyperactivity improved 1.8 points ( 95% CI, - 3.7 to 0.1 points) with H perforatum vs 2.0 points ( 95% CI, - 4.1 to 0.1 points) with placebo ( P=. 89). There was also no significant difference between the 2 groups in the percentage of participants who met criteria for improvement ( score <= 2) on the Clinical Global Impression Improvement Scale ( H perforatum, 44.4%; 95% CI, 25.5%- 64.7% vs placebo, 51.9%; 95% CI, 31.9%- 71.3%; P=. 59). No difference between groups was found in the number of participants who experienced adverse effects during the study period ( H perforatum, 40.7%; 95% CI, 22.4%- 61.2% vs placebo, 44.4%; 95% CI, 25.5%- 64.7%; P=. 78). Conclusion In this study, use of H perforatum for treatment of ADHD over the course of 8 weeks did not improve symptoms. Trial Registration clinicaltrials. gov Identifier: NCT00100295.	[Weber, Wendy; McCarty, Rachelle L.] Bastyr Univ, Sch Naturopath Med, Kenmore, WA USA; [Vander Stoep, Ann] Univ Washington, Dept Psychiat & Behav Sci, Childrens Hosp & Reg Med Ctr, Seattle, WA 98195 USA; [Vander Stoep, Ann; Weiss, Noel S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [McClellan, Jon] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Biederman, Joseph] Massachusetts Gen Hosp, Dept Pediat Psychopharmacol, Boston, MA 02114 USA; [Biederman, Joseph] Harvard Univ, Dept Psychiat, Boston, MA 02115 USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harvard University; Massachusetts General Hospital; Harvard University	Weber, W (corresponding author), 14500 Juanita Dr NE, Kenmore, WA USA.	wendyw@bastyr.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [K23AT000929, T32AT000815] Funding Source: NIH RePORTER; NCCIH NIH HHS [K23AT000929, T32AT00815, T32 AT000815-05, K23 AT000929-05, K23 AT000929, T32 AT000815] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Achenbach T. M., 2001, MANUAL ASEBA SCH AGE; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Baumgaertel A, 1999, PEDIATR CLIN N AM, V46, P977, DOI 10.1016/S0031-3955(05)70167-X; Biederman J, 2004, INT J NEUROPSYCHOPH, V7, P77, DOI 10.1017/S1461145703003973; Bussing R, 2002, PSYCHIAT SERV, V53, P1096, DOI 10.1176/appi.ps.53.9.1096; Cala S, 2003, PHARMACOTHERAPY, V23, P222, DOI 10.1592/phco.23.2.222.32092; Chan E, 2002, J DEV BEHAV PEDIATR, V23, pS37, DOI 10.1097/00004703-200202001-00007; Chan E, 2003, J DEV BEHAV PEDIATR, V24, P4, DOI 10.1097/00004703-200302000-00003; Conners C.K., 1997, CONNERSRATING SCALES; Davidson JRT, 2002, JAMA-J AM MED ASSOC, V287, P1807, DOI 10.1001/jama.287.14.1807; DUPAUL GJ, 1998, ADHD RATING SCALE, V4; Faraone Stephen V, 2003, World Psychiatry, V2, P104; Findling RL, 2003, J AM ACAD CHILD PSY, V42, P908, DOI 10.1097/01.CHI.0000046900.27264.2A; Froehlich TE, 2007, ARCH PEDIAT ADOL MED, V161, P857, DOI 10.1001/archpedi.161.9.857; Greenhill LL, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.3.e39; Homer CJ, 2000, PEDIATRICS, V105, P1158; Hubner WD, 2001, PHYTOTHER RES, V15, P367, DOI 10.1002/ptr.829; Kalachnik J., 1986, DRUG THERAPY BEHAV D, P153; Kasper S, 2007, EUR ARCH PSY CLIN N, V258, P59, DOI 10.1007/s00406-007-0779-2; Kelsey DK, 2004, PEDIATRICS, V114, pE1, DOI 10.1542/peds.114.1.e1; Kratochvil CJ, 2002, J AM ACAD CHILD PSY, V41, DOI 10.1097/00004583-200207000-00008; Linde K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000448.pub3; Markowitz JS, 2003, JAMA-J AM MED ASSOC, V290, P1500, DOI 10.1001/jama.290.11.1500; Michelson D, 2002, AM J PSYCHIAT, V159, P1896, DOI 10.1176/appi.ajp.159.11.1896; Michelson D, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.5.e83; Muller WE, 1997, PHARMACOPSYCHIATRY, V30, P102, DOI 10.1055/s-2007-979528; National Institute of Mental Health, 1985, PSYCHOPHARMACOL BULL, V21, P839; Orth HCJ, 1999, J PHARM PHARMACOL, V51, P193, DOI 10.1211/0022357991772132; Orvaschel H, 1987, SCHEDULE AFFECTIVE D; Prasad S, 2007, CURR MED RES OPIN, V23, P379, DOI 10.1185/030079906X167309; Robison LM, 2004, INT CLIN PSYCHOPHARM, V19, P17, DOI 10.1097/00004850-200401000-00003; Schachter HA, 2001, CAN MED ASSOC J, V165, P1475; Shelton RC, 2001, JAMA-J AM MED ASSOC, V285, P1978, DOI 10.1001/jama.285.15.1978; Spencer T, 2002, J CLIN PSYCHIAT, V63, P1140, DOI 10.4088/JCP.v63n1209; *STATACORP, 2007, STAT SE COMP PROGR V; Stubberfield TG, 1999, J PAEDIATR CHILD H, V35, P450, DOI 10.1046/j.1440-1754.1999.355401.x; Szegedi A, 2005, BMJ-BRIT MED J, V330, P759; Szegedi A, 2005, BMJ-BRIT MED J, V330, P503, DOI 10.1136/bmj.38356.655266.82; U.S. Census Bureau; American Community Survey (ACS), AM FACT FIND; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Visser SN, 2007, PEDIATRICS, V119, pS99, DOI 10.1542/peds.2006-2089O	41	44	45	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2008	299	22					2633	2641		10.1001/jama.299.22.2633	http://dx.doi.org/10.1001/jama.299.22.2633			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311FN	18544723	Green Accepted			2022-12-28	WOS:000256586200020
J	Vlaar, PJ; Svilaas, T; van der Horst, IC; Diercks, GFH; Fokkema, ML; de Smet, BJGL; van den Heuvel, AFM; Anthonio, RL; Jessurun, GA; Tan, ES; Suurmeijer, AJH; Zijlstra, F				Vlaar, Pieter J.; Svilaas, Tone; van der Horst, Iwan C.; Diercks, Gilles F. H.; Fokkema, Marieke L.; de Smet, Bart J. G. L.; van den Heuvel, Ad F. M.; Anthonio, Rutger L.; Jessurun, Gillian A.; Tan, Eng-Shiong; Suurmeijer, Albert J. H.; Zijlstra, Felix			Cardiac death and reinfarction after 1 year in the thrombus aspiration during percutaneous coronary intervention in acute myocardial infarction study (TAPAS): a 1-year follow-up study	LANCET			English	Article							ST-SEGMENT ELEVATION; PRIMARY ANGIOPLASTY; ANGIOGRAPHIC ASSESSMENT; DISTAL EMBOLIZATION; RANDOMIZED-TRIALS; REMEDIA TRIAL; BLUSH GRADE; REPERFUSION; METAANALYSIS; PREDICTORS	Background Percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction can be complicated by spontaneous or angioplasty-induced embolisation of atherothrombotic material. Distal blockage induces microvascular obstruction and can result in less than optimum reperfusion of viable myocardium. The Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS) found that thrombus aspiration resulted in improved myocardial reperfusion compared with conventional PCI, but whether this benefit improves clinical outcome is unknown. We aimed to investigate whether the early efficacy of thrombus aspiration seen in TAPAS translated into clinical benefit after 1 year. Methods Patients with ST-elevation myocardial infarction enrolled at the University Medical Centre Groningen were randomly assigned in a 1:1 ratio to either thrombus aspiration or conventional treatment, before undergoing initial coronary angiography. Exclusion criteria were rescue PCI after thrombolysis and known existence of a concomitant disease with life expectancy less than 6 months. Of the 1071 patients enrolled between January, 2005, and December, 2006, vital status at or beyond 1 year after randomisation was available for 1060 (99%). The primary endpoint was cardiac death or non-fatal reinfarction after 1 year, and analysis was by intention to treat. The TAPAS trial is registered with Current Controlled Trials number ISRCTN16716833. Findings Cardiac death at 1 year was 3.6% (19 of 535 patients) in the thrombus aspiration group and 6.7% (36 of 536) in the conventional PCI group (hazard ratio [HR] 1. 93; 95% CI 1. 11-3.37; p=0 . 020). 1-year cardiac death or non-fatal reinfarction occurred in 5.6% (30 of 535) of patients in the thrombus aspiration group and 9.9% (53 of 536) of patients in the conventional PCI group (HR 1. 81; 95% Cl 1. 16-2.84; p=0.009). Interpretation Compared with conventional PCI, thrombus aspiration before stenting of the infarcted artery seems to improve the 1-year clinical outcome after PCI for ST-elevation myocardial infarction. Funding Medtronic and the Thorax Centre of the University Medical Centre Groningen.	[Vlaar, Pieter J.; Svilaas, Tone; van der Horst, Iwan C.; Fokkema, Marieke L.; de Smet, Bart J. G. L.; van den Heuvel, Ad F. M.; Anthonio, Rutger L.; Jessurun, Gillian A.; Tan, Eng-Shiong; Zijlstra, Felix] Univ Groningen, Univ Med Ctr Groningen, Ctr Thorax, Dept Cardiol, NL-9713 AV Groningen, Netherlands; [Diercks, Gilles F. H.; Suurmeijer, Albert J. H.] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol, NL-9713 AV Groningen, Netherlands	University of Groningen; University of Groningen	Vlaar, PJ (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Ctr Thorax, Dept Cardiol, NL-9713 AV Groningen, Netherlands.	p.j.j.vlaar@thorax.umcg.nl	Diercks, Gilles/P-7413-2019	Diercks, Gilles/0000-0001-8053-216X; Suurmeijer, Albert/0000-0003-1361-9454				Burzotta F, 2005, J AM COLL CARDIOL, V46, P371, DOI 10.1016/j.jacc.2005.04.057; Burzotta F, 2008, INT J CARDIOL, V123, P313, DOI 10.1016/j.ijcard.2006.12.018; De Luca G, 2007, AM HEART J, V153, P343, DOI 10.1016/j.ahj.2006.11.020; De Luca L, 2006, HEART, V92, P951, DOI 10.1136/hrt.2005.074716; Galiuto L, 2006, J AM COLL CARDIOL, V48, P1355, DOI 10.1016/j.jacc.2006.05.059; Henriques JPS, 2003, CIRCULATION, V107, P2115, DOI 10.1161/01.CIR.0000065221.06430.ED; Hong MK, 2004, CIRCULATION, V109, P881, DOI 10.1161/01.CIR.0000116751.88818.10; Javaid A, 2008, AM J CARDIOL, V101, P452, DOI 10.1016/j.amjcard.2007.09.091; Kernis SJ, 2003, J AM COLL CARDIOL, V42, P1173, DOI 10.1016/S0735-1097(03)00920-3; Morrow DA, 2000, CIRCULATION, V102, P2031, DOI 10.1161/01.CIR.102.17.2031; Sianos G, 2007, J AM COLL CARDIOL, V50, P573, DOI 10.1016/j.jacc.2007.04.059; Silva-Orrego P, 2006, J AM COLL CARDIOL, V48, P1552, DOI 10.1016/j.jacc.2006.03.068; Svilaas T, 2006, AM HEART J, V151, DOI 10.1016/j.ahj.2005.11.010; Svilaas T, 2008, NEW ENGL J MED, V358, P557, DOI 10.1056/NEJMoa0706416; Van de Werf F, 2003, EUR HEART J, V24, P28, DOI 10.1016/S0195-668X(02)00618-8; van't Hof AWJ, 1998, CIRCULATION, V97, P2302, DOI 10.1161/01.CIR.97.23.2302; vantHof AWJ, 1997, LANCET, V350, P615, DOI 10.1016/S0140-6736(96)07120-6	17	650	733	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	2008	371	9628					1915	1920		10.1016/S0140-6736(08)60833-8	http://dx.doi.org/10.1016/S0140-6736(08)60833-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310OI	18539223				2022-12-28	WOS:000256538500027
J	Fiechtl, JF; Stack, LB				Fiechtl, James F.; Stack, Lawrence B.			Bilateral peritonsillar abscesses	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Fiechtl, James F.; Stack, Lawrence B.] Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA	Vanderbilt University	Fiechtl, JF (corresponding author), Vanderbilt Univ, Med Ctr, 221 Kirkland Hall, Nashville, TN 37232 USA.								0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2008	358	23					E27	E27		10.1056/NEJMicm072980	http://dx.doi.org/10.1056/NEJMicm072980			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308HY	18525038				2022-12-28	WOS:000256380700009
J	Wiens, DA; Anandakrishnan, S; Winberry, JP; King, MA				Wiens, Douglas A.; Anandakrishnan, Sridhar; Winberry, J. Paul; King, Matt A.			Simultaneous teleseismic and geodetic observations of the stick-slip motion of an Antarctic ice stream	NATURE			English	Article							FREE OSCILLATIONS; GLACIAL EARTHQUAKES; WAVES; MOUTH; MODEL	Long- period seismic sources associated with glacier motion have been recently discovered(1,2), and an increase in ice flow over the past decade has been suggested on the basis of secular changes in such measurements(3). Their significance, however, remains uncertain, as a relationship to ice flow has not been confirmed by direct observation. Here we combine long- period surface- wave observations with simultaneous Global Positioning System measurements of ice displacement to study the tidally modulated stick - slip motion of the Whillans Ice Stream in West Antarctica(4,5). The seismic origin time corresponds to slip nucleation at a region of the bed of the Whillans Ice Stream that is likely stronger than in surrounding regions and, thus, acts like an 'asperity' in traditional fault models. In addition to the initial pulse, two seismic arrivals occurring 10 - 23 minutes later represent stopping phases as the slip terminates at the ice stream edge and the grounding line. Seismic amplitude and average rupture velocity are correlated with tidal amplitude for the different slip events during the spring- to- neap tidal cycle. Although the total seismic moment calculated from ice rigidity, slip displacement, and rupture area is equivalent to an earthquake of moment magnitude seven ( M-w 7), seismic amplitudes are modest ( M-s 3.6 - 4.2), owing to the source duration of 20 - 30 minutes. Seismic radiation from ice movement is proportional to the derivative of the moment rate function at periods of 25 - 100 seconds and very long- period radiation is not detected, owing to the source geometry. Long- period seismic waves are thus useful for detecting and studying sudden ice movements but are insensitive to the total amount of slip.	[Wiens, Douglas A.] Washington Univ, Dept Earth & Planetary Sci, St Louis, MO 63130 USA; [Anandakrishnan, Sridhar; Winberry, J. Paul] Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; [King, Matt A.] Univ Newcastle, Sch Civil Engn & Geosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Newcastle University - UK	Wiens, DA (corresponding author), Washington Univ, Dept Earth & Planetary Sci, St Louis, MO 63130 USA.	doug@wustl.edu	Wiens, Douglas A/J-9259-2016; Winberry, Paul/E-5557-2011; King, Matt/B-4622-2008	Wiens, Douglas A/0000-0002-5169-4386; King, Matt/0000-0001-5611-9498	Natural Environment Research Council [NE/C002121/1] Funding Source: researchfish; NERC [NE/C002121/1] Funding Source: UKRI	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Aki K., 1966, B EARTHQ RES I TOKYO, V44, P73; ALLEY RB, 1993, J GLACIOL, V39, P447, DOI 10.3189/S0022143000016336; Anandakrishnan S, 2004, GLOBAL PLANET CHANGE, V42, P167, DOI 10.1016/j.gloplacha.2003.10.005; Anandakrishnan S, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016329; BEROZA GC, 1990, J GEOPHYS RES-SOLID, V95, P2485, DOI 10.1029/JB095iB03p02485; Bindschadler RA, 2003, SCIENCE, V301, P1087, DOI 10.1126/science.1087231; Bindschadler RA, 2003, ANN GLACIOL, V36, P263, DOI 10.3189/172756403781816284; Bindschadler RA, 2002, SCI AM, V287, P98, DOI 10.1038/scientificamerican1202-98; BINDSCHADLER RA, 1987, J GEOPHYS RES-SOLID, V92, P8885, DOI 10.1029/JB092iB09p08885; Chen G., 1998, THESIS MIT; DAHLEN FA, 1993, B SEISMOL SOC AM, V83, P130; DAS S, 1977, J GEOPHYS RES, V82, P5658, DOI 10.1029/JB082i036p05658; De Angelis H, 2003, SCIENCE, V299, P1560, DOI 10.1126/science.1077987; Dow JM, 2005, ADV SPACE RES, V36, P320, DOI 10.1016/j.asr.2005.05.125; EISSLER HK, 1987, J GEOPHYS RES-SOLID, V92, P4827, DOI 10.1029/JB092iB06p04827; Ekstrom G, 2006, SCIENCE, V311, P1756, DOI 10.1126/science.1122112; Ekstrom G, 2003, SCIENCE, V302, P622, DOI 10.1126/science.1088057; Fischer UH, 1997, ANN GLACIOL, V24, P390, DOI 10.3189/S0260305500012490; Horgan HJ, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL027091; Joughin I, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL024319; KANAMORI H, 1981, PHYS EARTH PLANET IN, V27, P8, DOI 10.1016/0031-9201(81)90083-2; KAWAKATSU H, 1989, J GEOPHYS RES-SOLID, V94, P12363, DOI 10.1029/JB094iB09p12363; Kennett B., 1983, SEISMIC WAVE PROPAGA; LAWRENCE JF, 2006, J GEOPHYS RES, V111, DOI DOI 10.1029/2005GL024523; Lay T., 1981, Earthquake Prediction. An International Review. Symposium on Earthquake Prediction, P579, DOI 10.1029/ME004p0579; Padman L, 2002, ANN GLACIOL, V34, P247, DOI 10.3189/172756402781817752; Peters ME, 2005, J GEOPHYS RES-SOL EA, V110, DOI 10.1029/2004JB003222; Rhie J, 2004, NATURE, V431, P552, DOI 10.1038/nature02942; Russell DR, 2006, B SEISMOL SOC AM, V96, P665, DOI 10.1785/0120050055; Scambos TA, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020670; Suda N, 1998, SCIENCE, V279, P2089, DOI 10.1126/science.279.5359.2089; Tsai VC, 2007, J GEOPHYS RES-EARTH, V112, DOI 10.1029/2006JF000596; WIENS DA, 2006, EOS, V87; Zumberge JF, 1997, J GEOPHYS RES-SOL EA, V102, P5005, DOI 10.1029/96JB03860	34	108	113	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 5	2008	453	7196					770	U3		10.1038/nature06990	http://dx.doi.org/10.1038/nature06990			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308UK	18528392				2022-12-28	WOS:000256415300041
J	Ha, TS; Smith, DP				Ha, Tal Soo; Smith, Dean P.			Insect odorant receptors: Channeling scent	CELL			English	Editorial Material							OLFACTORY RECEPTORS; DROSOPHILA-ANTENNA; EXPRESSION	Odorant detection in insects involves heterodimers between an odorant receptor (OR) and a conserved seven-transmembrane protein called Or83b, but the exact mechanism of OR signal transduction is unclear. Two recent studies in Nature (Sato et al., 2008; Wicher et al., 2008) now reveal that these OR-Or83b heterodimers form odorant-gated ion channels, revealing a surprising new mode of olfactory transduction.	[Ha, Tal Soo; Smith, Dean P.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA; [Ha, Tal Soo; Smith, Dean P.] Univ Texas SW Med Ctr Dallas, Dept Neurosci, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Smith, DP (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	dean.smith@utsouthwestern.edu			NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002539] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC002539] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Benton R, 2006, PLOS BIOL, V4, P240, DOI 10.1371/journal.pbio.0040020; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; Elmore T, 2003, J NEUROSCI, V23, P9906; Gao Q, 1999, GENOMICS, V60, P31, DOI 10.1006/geno.1999.5894; Hallem EA, 2004, CELL, V117, P965, DOI 10.1016/j.cell.2004.05.012; Larsson MC, 2004, NEURON, V43, P703, DOI 10.1016/j.neuron.2004.08.019; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Sato K, 2008, NATURE, V452, P1002, DOI 10.1038/nature06850; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; Wetzel CH, 2001, P NATL ACAD SCI USA, V98, P9377, DOI 10.1073/pnas.151103998; Wicher D, 2008, NATURE, V452, P1007, DOI 10.1038/nature06861	11	13	16	1	16	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 30	2008	133	5					761	763		10.1016/j.cell.2008.05.007	http://dx.doi.org/10.1016/j.cell.2008.05.007			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510917	Bronze			2022-12-28	WOS:000256274500005
J	Maurange, C; Cheng, L; Gould, AP				Maurange, Cedric; Cheng, Louise; Gould, Alex P.			Temporal transcription factors and their targets schedule the end of neural proliferation in Drosophila	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; PROGENITOR-CELL PROLIFERATION; POSTEMBRYONIC NEUROBLASTS; ASYMMETRIC SEGREGATION; SELF-RENEWAL; STEM-CELLS; SOX-DOMAIN; PROSPERO; IDENTITY; PROTEIN	The timing mechanisms responsible for terminating cell proliferation toward the end of development remain unclear. In the Drosophila CNS, individual progenitors called neuroblasts are known to express a series of transcription factors endowing daughter neurons with different temporal identities. Here we show that Castor and Seven-Up, members of this temporal series, regulate key events in many different neuroblast lineages during late neurogenesis. First, they schedule a switch in the cell size and identity of neurons involving the targets Chinmo and Broad Complex. Second, they regulate the time at which neuroblasts undergo Prospero-dependent cell-cycle exit or Reaper/Hid/Grim-dependent apoptosis. Both types of progenitor termination require the combined action of a late phase of the temporal series and indirect feedforward via Castor targets such as Grainyhead and Dichaete. These studies identify the timing mechanism ending CNS proliferation and reveal how aging progenitors transduce bursts of transcription factors into long-lasting changes in cell proliferation and cell identity.	[Maurange, Cedric; Cheng, Louise; Gould, Alex P.] Natl Inst Med Res, MRC, London NW7 1AA, England	MRC National Institute for Medical Research	Gould, AP (corresponding author), Natl Inst Med Res, MRC, Ridgeway, London NW7 1AA, England.	agould@nimr.mrc.ac.uk	Cheng, Louise/B-5112-2012; Gould, Alex/M-5353-2019; Gould, Alex/A-7479-2010	Gould, Alex/0000-0002-6875-6985; Gould, Alex/0000-0002-6875-6985; Maurange, Cedric/0000-0001-8931-1419; Cheng, Louise/0000-0001-9712-4082	MRC [MC_U117584237] Funding Source: UKRI; Medical Research Council [MC_U117584237] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Almeida MS, 2005, MECH DEVELOP, V122, P1282, DOI 10.1016/j.mod.2005.08.004; Bello BC, 2003, NEURON, V37, P209, DOI 10.1016/S0896-6273(02)01181-9; Bello B, 2006, DEVELOPMENT, V133, P2639, DOI 10.1242/dev.02429; Betschinger J, 2006, CELL, V124, P1241, DOI 10.1016/j.cell.2006.01.038; Betschinger J, 2004, CURR BIOL, V14, pR674, DOI 10.1016/j.cub.2004.08.017; Bossing T, 1996, DEV BIOL, V179, P41, DOI 10.1006/dbio.1996.0240; BRAY SJ, 1989, GENE DEV, V3, P1130, DOI 10.1101/gad.3.8.1130; Brody T, 2000, DEV BIOL, V226, P34, DOI 10.1006/dbio.2000.9829; Brown HLD, 2006, DEVELOPMENT, V133, P275, DOI 10.1242/dev.02191; Caviness VS, 2003, CEREB CORTEX, V13, P592, DOI 10.1093/cercor/13.6.592; Cenci C, 2005, DEVELOPMENT, V132, P3835, DOI 10.1242/dev.01932; Choksi SP, 2006, DEV CELL, V11, P775, DOI 10.1016/j.devcel.2006.09.015; Cleary MD, 2006, GENE DEV, V20, P429, DOI 10.1101/gad.1382206; Donovan SL, 2005, SEMIN CELL DEV BIOL, V16, P407, DOI 10.1016/j.semcdb.2005.02.012; Dyer MA, 2003, NAT GENET, V34, P53, DOI 10.1038/ng1144; EMERY IF, 1994, DEVELOPMENT, V120, P3275; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Grosskortenhaus R, 2006, GENE DEV, V20, P2618, DOI 10.1101/gad.1445306; Hanashima C, 2004, SCIENCE, V303, P56, DOI 10.1126/science.1090674; Higashijima S, 1996, DEVELOPMENT, V122, P527; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; IkeshimaKataoka H, 1997, NATURE, V390, P625, DOI 10.1038/37641; Isshiki T, 2001, CELL, V106, P511, DOI 10.1016/S0092-8674(01)00465-2; ITO K, 1992, DEV BIOL, V149, P134, DOI 10.1016/0012-1606(92)90270-Q; Jefferis GSXE, 2001, NATURE, V414, P204, DOI 10.1038/35102574; Kambadur R, 1998, GENE DEV, V12, P246, DOI 10.1101/gad.12.2.246; Kanai MI, 2005, DEV CELL, V8, P203, DOI 10.1016/j.devcel.2004.12.014; Kessaris N, 2001, NEURON, V31, P677, DOI 10.1016/S0896-6273(01)00430-5; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Lee CY, 2006, DEV CELL, V10, P441, DOI 10.1016/j.devcel.2006.01.017; Lee T, 1999, DEVELOPMENT, V126, P4065; Li L, 2000, GENE DEV, V14, P147; Livesey FJ, 2001, NAT REV NEUROSCI, V2, P109, DOI 10.1038/35053522; Maurange C, 2005, TRENDS NEUROSCI, V28, P30, DOI 10.1016/j.tins.2004.10.009; MCCONNELL SK, 1988, BRAIN RES REV, V13, P1, DOI 10.1016/0165-0173(88)90002-1; McGuire SE, 2003, SCIENCE, V302, P1765, DOI 10.1126/science.1089035; Mettler U, 2006, DEVELOPMENT, V133, P429, DOI 10.1242/dev.02229; Nambu PA, 1996, DEVELOPMENT, V122, P3467; Novotny T, 2002, DEVELOPMENT, V129, P1027; Pearson BJ, 2004, ANNU REV CELL DEV BI, V20, P619, DOI 10.1146/annurev.cellbio.19.111301.115142; Pearson BJ, 2003, NATURE, V425, P624, DOI 10.1038/nature01910; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Peterson C, 2002, DEVELOPMENT, V129, P1467; PROKOP A, 1991, DEVELOPMENT, V111, P79; Prokop A, 1998, MECH DEVELOP, V74, P99, DOI 10.1016/S0925-4773(98)00068-9; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; Roy K, 2004, J NEUROSCI, V24, P8333, DOI 10.1523/JNEUROSCI.1148-04.2004; Schmid A, 1999, DEVELOPMENT, V126, P4653; Schmidt H, 1997, DEV BIOL, V189, P186, DOI 10.1006/dbio.1997.8660; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; Shen Q, 2006, NAT NEUROSCI, V9, P743, DOI 10.1038/nn1694; Soriano NS, 1998, DEVELOPMENT, V125, P3989; SPANA EP, 1995, DEVELOPMENT, V121, P3187; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; Wang HY, 2005, BIOL CELL, V97, P63; Yu FW, 2006, NEURON, V51, P13, DOI 10.1016/j.neuron.2006.06.016; Zhao GY, 2002, DEVELOPMENT, V129, P1165; Zhu SJ, 2006, CELL, V127, P409, DOI 10.1016/j.cell.2006.08.045	58	228	232	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	2008	133	5					891	902		10.1016/j.cell.2008.03.034	http://dx.doi.org/10.1016/j.cell.2008.03.034			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510932	Bronze			2022-12-28	WOS:000256274500020
J	Hutko, AR; Lay, T; Revenaugh, J; Garnero, EJ				Hutko, Alexander R.; Lay, Thorne; Revenaugh, Justin; Garnero, Edward J.			Anticorrelated seismic velocity anomalies from post-perovskite in the lowermost mantle	SCIENCE			English	Article							PHASE-TRANSITION; P-WAVE; MGSIO3; BENEATH; BOUNDARY; ELASTICITY	Earth's lowermost mantle has thermal, chemical, and mineralogical complexities that require precise seismological characterization. Stacking, migration, and modeling of over 10,000 P and S waves that traverse the deep mantle under the Cocos plate resolve structures above the core- mantle boundary. A small -0.07 +/- 0.15% decrease of P wave velocity ( V-p) is accompanied by a 1.5 +/- 0.5% increase in S wave velocity ( Vs) near a depth of 2570 km. Bulk- sound velocity [ V-b = ( V-p(2) - 4/3V(s)(2))(1/2)] decreases by - 1.0 +/- 0.5% at this depth. Transition of the primary lower- mantle mineral, ( Mg1-x-y FexAly)(Si,Al)O-3 perovskite, to denser post- perovskite is expected to have a negligible effect on the bulk modulus while increasing the shear modulus by similar to 6%, resulting in local anticorrelation of V-b and V-s anomalies; this behavior explains the data well.	[Hutko, Alexander R.; Lay, Thorne] Univ Calif Santa Cruz, Dept Earth & Planetary Sci, Santa Cruz, CA 95064 USA; [Revenaugh, Justin] Univ Minnesota, Dept Geol & Geophys, Minneapolis, MN 55455 USA; [Garnero, Edward J.] Arizona State Univ, Sch Earth & Space Explorat, Tempe, AZ 85287 USA	University of California System; University of California Santa Cruz; University of Minnesota System; University of Minnesota Twin Cities; Arizona State University; Arizona State University-Tempe	Lay, T (corresponding author), Univ Calif Santa Cruz, Dept Earth & Planetary Sci, Santa Cruz, CA 95064 USA.	thorne@pmc.ucsc.edu	Lay, Thorne/ABE-6272-2021; Revenaugh, Justin/GVR-8368-2022	Revenaugh, Justin/0000-0002-7855-5159				Akber-Knutson S, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023192; Boschi L, 2007, GEOCHEM GEOPHY GEOSY, V8, DOI 10.1029/2007GC001733; Cara R, 2007, PROSPETTIVA, P115, DOI 10.1029/174GM10; Caracas R, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023164; Ding XM, 1997, PHYS EARTH PLANET IN, V101, P245, DOI 10.1016/S0031-9201(97)00001-0; GARNERO EJ, 2007, ORIGIN MELTING ANOMA, P79; Grand SP, 2002, PHILOS T R SOC A, V360, P2475, DOI 10.1098/rsta.2002.1077; Hernlund JW, 2005, NATURE, V434, P882, DOI 10.1038/nature03472; Hirose K, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL024468; Hutko AR, 2006, NATURE, V441, P333, DOI 10.1038/nature04757; Iitaka T, 2004, NATURE, V430, P442, DOI 10.1038/nature02702; Kito T, 2007, GEOPHYS J INT, V169, P631, DOI 10.1111/j.1365-246X.2007.03350.x; Lay T, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2007GL032465; Lay T, 2004, GEOPHYS MONOGR SER, V150, P25, DOI 10.1029/150GM04; Lay T, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020300; Lay T, 2006, SCIENCE, V314, P1272, DOI 10.1126/science.1133280; Mao WL, 2005, P NATL ACAD SCI USA, V102, P9751, DOI 10.1073/pnas.0503737102; Masters G., 2000, EARTHS DEEP INTERIOR, V117, P63, DOI DOI 10.1029/GM117P0063; McNamara AK, 2005, NATURE, V437, P1136, DOI 10.1038/nature04066; Murakami M, 2004, SCIENCE, V304, P855, DOI 10.1126/science.1095932; Ni SD, 2005, GEOPHYS J INT, V161, P283, DOI 10.1111/j.1365-246X.2005.02508.x; Oganov AR, 2004, NATURE, V430, P445, DOI 10.1038/nature02701; Reasoner C, 1999, J GEOPHYS RES-SOL EA, V104, P955, DOI 10.1029/1998JB900053; Saltzer RL, 2001, GEOPHYS RES LETT, V28, P1335, DOI 10.1029/2000GL012339; Stackhouse S, 2007, GEOPHYS MONOGR SER, V174, P99, DOI 10.1029/174GM09; SUN D, 2006, GEOPHYS RES LETT, V33; Thomas C, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2004JB003013; Trampert J, 2004, SCIENCE, V306, P853, DOI 10.1126/science.1101996; Tsuchiya T, 2004, EARTH PLANET SC LETT, V224, P241, DOI 10.1016/j.epsl.2004.05.017; Tsuchiya T, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL025706; van der Hilst RD, 2007, SCIENCE, V315, P1813, DOI 10.1126/science.1137867; Wen LX, 2001, EARTH PLANET SC LETT, V189, P141, DOI 10.1016/S0012-821X(01)00365-X; Wentzcovitch RM, 2006, P NATL ACAD SCI USA, V103, P543, DOI 10.1073/pnas.0506879103; Wookey J, 2005, NATURE, V438, P1004, DOI 10.1038/nature04345	34	57	57	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2008	320	5879					1070	1074		10.1126/science.1155822	http://dx.doi.org/10.1126/science.1155822			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18497297				2022-12-28	WOS:000256059800044
J	Lindquist, L; Vapalahti, O				Lindquist, Lars; Vapalahti, Olli			Tick-borne encephalitis	LANCET			English	Review							LYME BORRELIOSIS; TICKBORNE ENCEPHALITIS; TBE VACCINATION; CLINICAL-COURSE; MOLECULAR EPIDEMIOLOGY; BOOSTER IMMUNIZATION; VIRUS TRANSMISSION; ANTIBODY-RESPONSE; IXODES-RICINUS; SEVERE FORMS	We review the epidemiological and clinical characteristics of tick-borne encephalitis, and summarise biological and virological aspects that are important for understanding the life-cycle and transmission of the virus. Tick-borne encephalitis virus is a flavivirus that is transmitted by Ixodes spp ticks in a vast area from western Europe to the eastern coast of Japan. Tick-borne encephalitis causes acute meningoencephalitis with or without myelitis. Morbidity is age dependent, and is highest in adults of whom half develop encephalitis. A third of patients have longlasting sequelae, frequently with cognitive dysfunction and substantial impairment in quality of life. The disease arises in patchy endemic foci in Europe, with climatic and ecological conditions suitable for circulation Of the virus. Climate change and leisure habits expose more people to tick-bites and have contributed to the increase in number of cases despite availability of effective vaccines. The serological diagnosis is usually straightforward. No specific treatment for the disease exists, and immunisation is the main preventive measure.	[Lindquist, Lars] Karolinska Univ Hosp, Karolinska Inst, Dept Med, SE-14186 Stockholm, Sweden; [Lindquist, Lars] Karolinska Univ Hosp, Karolinska Inst, Clin Infect Dis, SE-14186 Stockholm, Sweden; [Vapalahti, Olli] Univ Helsinki, Dept Vet Basic Sci, Fac Vet Med, Helsinki, Finland; [Vapalahti, Olli] Univ Helsinki, Dept Virol, Haartman Inst, Helsinki, Finland; [Vapalahti, Olli] Hosp Dist Helsinki & Uusimaa, Huslab, Helsinki, Finland	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Lindquist, L (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Dept Med, SE-14186 Stockholm, Sweden.	lars.lindquist@ki.se		Vapalahti, Olli/0000-0003-2270-6824				ACKERMANN R, 1986, DEUT MED WOCHENSCHR, V111, P927, DOI 10.1055/s-2008-1068558; ALEKSEEV AN, 1990, PARAZITOLOGIYA+, V24, P177; [Anonymous], FIELDS VIROLOGY; AVSICZUPANC T, 1995, CLIN DIAGN VIROL, V4, P51, DOI 10.1016/0928-0197(94)00062-Y; BANNOVA GG, 1982, VOP VIRUSOL+, P41; Bender A, 2004, J NEUROL, V251, P353, DOI 10.1007/s00415-004-0329-z; Best SM, 2005, J VIROL, V79, P12828, DOI 10.1128/JVI.79.20.12828-12839.2005; Chiba N, 1999, VACCINE, V17, P1532, DOI 10.1016/S0264-410X(98)00360-0; Cizman M, 1999, WIEN KLIN WOCHENSCHR, V111, P484; Craig SC, 1999, AM J TROP MED HYG, V61, P874, DOI 10.4269/ajtmh.1999.61.874; Daniel M, 2003, EUR J CLIN MICROBIOL, V22, P327, DOI 10.1007/s10096-003-0918-2; Danielova V., 1991, P7; DEKONENKO EP, 1984, ZH NEVROPATOL PSIKH, V84, P202; DEMICHELI V, 2000, COCHRANE DB SYST REV, V2; Dobson A, 2006, PLOS MED, V3, P714, DOI 10.1371/journal.pmed.0030231; Dumpis U, 1999, CLIN INFECT DIS, V28, P882, DOI 10.1086/515195; Duniewicz M, 1975, Infection, V3, P223, DOI 10.1007/BF01642770; Ecker M, 1999, J GEN VIROL, V80, P179, DOI 10.1099/0022-1317-80-1-179; FALISEVAC J, 1981, TICK BORNE ENCEPHALI, P13; Falk W, 1981, TICK BORNE ENCEPHALI, P20; Fritsch P, 2008, ACTA PAEDIATR, V97, P535, DOI 10.1111/j.1651-2227.2008.00763.x; Gaunt MW, 2001, J GEN VIROL, V82, P1867, DOI 10.1099/0022-1317-82-8-1867; Gelpi E, 2005, J NEUROPATH EXP NEUR, V64, P506, DOI 10.1093/jnen/64.6.506; Girgsdies OE, 1996, VACCINE, V14, P1421, DOI 10.1016/S0264-410X(96)00081-3; Golovljova I, 2004, J MED VIROL, V74, P580, DOI 10.1002/jmv.20224; Grard G, 2007, VIROLOGY, V361, P80, DOI 10.1016/j.virol.2006.09.015; Gritsun TS, 2003, J VIROL, V77, P25, DOI 10.1128/JVI.77.1.25-36.2003; GRUBBAUER HM, 1992, EUR J PEDIATR, V151, P743, DOI 10.1007/BF01959081; Grygorczuk S, 2002, SCAND J INFECT DIS, V34, P904, DOI 10.1080/0036554021000026979; GUIRAKHOO F, 1990, ZBL BAKT-INT J MED M, V272, P477; Gunther G, 1996, SCAND J INFECT DIS, V28, P131, DOI 10.3109/00365549609049063; Gunther G, 1997, J NEUROL, V244, P230, DOI 10.1007/s004150050077; Gunther G, 1997, CLIN DIAGN VIROL, V8, P17, DOI 10.1016/S0928-0197(97)00273-0; GUSTAFSON R, 1990, SCAND J INFECT DIS, V22, P297, DOI 10.3109/00365549009027051; GUSTAFSON R, 1992, EUR J CLIN MICROBIOL, V11, P894, DOI 10.1007/BF01962369; GUSTAFSON R, 1993, SCAND J INFECT DIS, V25, P595, DOI 10.3109/00365549309008548; Haglund M, 2003, J MED VIROL, V71, P610, DOI 10.1002/jmv.10497; Haglund M, 1996, SCAND J INFECT DIS, V28, P217, DOI 10.3109/00365549609027160; Hainz U, 2005, VACCINE, V23, P3232, DOI 10.1016/j.vaccine.2005.01.085; Han XQ, 2005, J MED VIROL, V77, P249, DOI 10.1002/jmv.20444; HARASEK G, 1974, DEUT MED WOCHENSCHR, V99, P1965, DOI 10.1055/s-0028-1108076; Hayasaka D, 2001, J GEN VIROL, V82, P1319, DOI 10.1099/0022-1317-82-6-1319; Hayasaka D, 2001, VACCINE, V19, P4774, DOI 10.1016/S0264-410X(01)00218-3; Heinz FX, 2003, ADV VIRUS RES, V59, P63, DOI 10.1016/S0065-3527(03)59003-0; Heinz FX, 1995, VACCINE, V13, P1636, DOI 10.1016/0264-410X(95)00133-L; HEINZ FX, 2003, VACCINE, V21, P3; HELWIG H, 1983, PADIATR PRAX, V28, P75; HOFMANN H, 1995, WIEN KLIN WOCHENSCHR, V107, P509; HOLMGREN EB, 1990, SCAND J INFECT DIS, V22, P287, DOI 10.3109/00365549009027050; Holzmann H, 1996, J MED VIROL, V48, P102, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;102::AID-JMV16&gt;3.0.CO;2-I; HOLZMANN H, 1992, VACCINE, V10, P345, DOI 10.1016/0264-410X(92)90376-U; Holzmann H, 2003, VACCINE, V21, pS36, DOI 10.1016/S0264-410X(02)00819-8; Iff T, 2005, EUR J PEDIATR, V164, P787, DOI 10.1007/s00431-005-1753-5; Jaaskelainen A, 2003, J CLIN MICROBIOL, V41, P4336, DOI 10.1128/JCM.41.9.4336-4342.2003; Jaaskelainen AE, 2006, EMERG INFECT DIS, V12, P1568, DOI 10.3201/eid1210.060320; JACOBS SC, 1992, J VIROL, V66, P2086, DOI 10.1128/JVI.66.4.2086-2095.1992; JAENSON TGT, 1994, J MED ENTOMOL, V31, P240, DOI 10.1093/jmedent/31.2.240; JEZYNA C, 1984, ZBL BAKT MIK HYG B, V178, P510; Jones N, 2007, PEDIATR INFECT DIS J, V26, P185, DOI 10.1097/01.inf.0000253056.34894.5f; Kaiser R, 1996, INFECTION, V24, P398, DOI 10.1007/BF01716094; Kaiser R, 2000, INFECTION, V28, P78, DOI 10.1007/s150100050051; Kaiser R, 1999, BRAIN, V122, P2067, DOI 10.1093/brain/122.11.2067; KLUGER G, 1995, LANCET, V346, P1502, DOI 10.1016/S0140-6736(95)92527-9; KOCK T, 1992, NERVENARZT, V63, P205; Kofler RM, 2004, P NATL ACAD SCI USA, V101, P1951, DOI 10.1073/pnas.0307145101; Kohl I, 1996, EUR J EPIDEMIOL, V12, P373, DOI 10.1007/BF00145300; Korenberg EI, 1999, ZBL BAKT-INT J MED M, V289, P525; KOZUCH O, 1990, ACTA VIROL, V34, P537; Krausler J, 1981, TICK BORNE ENCEPHALI, P6; KRECH T, 1980, THESIS U BERN BERN; Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998; KUNZ C, 1991, WIEN MED WOCHENSCHR, V141, P273; Kunz C, 2003, VACCINE, V21, pS50, DOI 10.1016/S0264-410X(02)00813-7; Kunz C, 2003, VACCINE, V21, pS1, DOI 10.1016/S0264-410X(02)00810-1; KUNZ C, 1980, J MED VIROL, V6, P103, DOI 10.1002/jmv.1890060202; Kunze U, 2005, WIEN MED WOCHENSCHR, V155, P289, DOI 10.1007/s10354-005-0178-0; LABUDA M, 1993, MED VET ENTOMOL, V7, P193, DOI 10.1111/j.1365-2915.1993.tb00674.x; Labuda M, 1997, VIROLOGY, V235, P138, DOI 10.1006/viro.1997.8622; Labuda M, 1996, VIROLOGY, V219, P357, DOI 10.1006/viro.1996.0261; LABUDA M, 1993, EXPERIENTIA, V49, P802, DOI 10.1007/BF01923553; LaSala PR, 2010, CLIN LAB MED, V30, P221, DOI 10.1016/j.cll.2010.01.002; Lesnicar G, 2003, PEDIATR INFECT DIS J, V22, P612, DOI 10.1097/00006454-200307000-00009; Lindenbach BD, 2003, ADV VIRUS RES, V59, P23, DOI 10.1016/S0065-3527(03)59002-9; Lindgren E, 2001, LANCET, V358, P16, DOI 10.1016/S0140-6736(00)05250-8; Lindgren E, 2000, ENVIRON HEALTH PERSP, V108, P119, DOI 10.2307/3454509; LOEWBASELLI, 2005, P 8 INT POTSD S TICK; Lorenzl S, 1996, LANCET, V347, P698, DOI 10.1016/S0140-6736(96)91256-8; LOTRICFURLAN S, 1995, INFECTION, V23, P203, DOI 10.1007/BF01781197; Lundkvist A, 2001, J MED VIROL, V65, P730, DOI 10.1002/jmv.2097; Marjelund S, 2004, ACTA RADIOL, V45, P88, DOI 10.1080/02841850410003356; McMichael A. J., 2003, CLIM CHANG HUM HLTH; McMinn PC, 1997, J GEN VIROL, V78, P2711, DOI 10.1099/0022-1317-78-11-2711; MESSNER H, 1981, TICK BORNE ENCEPHALI, P25; Mickiene A, 2002, CLIN INFECT DIS, V35, P650, DOI 10.1086/342059; Naslednikova IO, 2005, B EXP BIOL MED+, V139, P451, DOI 10.1007/s10517-005-0320-4; Parola P, 2001, CLIN INFECT DIS, V32, P897, DOI 10.1086/319347; Pavlova BG, 2003, VACCINE, V21, P742, DOI 10.1016/S0264-410X(02)00593-5; PIKELJ F, 1995, J INFECTION, V31, P83, DOI 10.1016/S0163-4453(95)91860-4; Poponnikova TV, 2006, INT J MED MICROBIOL, V296, P59, DOI 10.1016/j.ijmm.2006.01.023; PuchhammerStockl E, 1995, CLIN DIAGN VIROL, V4, P321, DOI 10.1016/0928-0197(95)00022-4; RADSELMEDVESCEK A, 1980, ARBOVIRUSES MEDITE S, V9, P277; RAKAR R, 1993, BEDJ S TICK BORN MEN, P37; Randolph S, 2002, INT J MED MICROBIOL, V291, P6, DOI 10.1016/S1438-4221(02)80002-9; Randolph SE, 2001, PHILOS T R SOC B, V356, P1045, DOI 10.1098/rstb.2001.0893; Randolph SE, 2000, PARASITOLOGY, V121, P15, DOI 10.1017/S0031182099006083; Randolph SE, 2000, P ROY SOC B-BIOL SCI, V267, P1741, DOI 10.1098/rspb.2000.1204; Randolph SE, 1999, PARASITOLOGY, V118, P177, DOI 10.1017/S0031182098003643; Randolph SE, 2000, ADV PARASIT, V47, P217, DOI 10.1016/S0065-308X(00)47010-7; Rendi-Wagner P, 2004, VACCINE, V23, P427, DOI 10.1016/j.vaccine.2004.07.002; Rendi-Wagner P, 2004, VACCINE, V22, P2743, DOI 10.1016/j.vaccine.2004.01.041; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Schmolck H, 2005, J CHILD NEUROL, V20, P500, DOI 10.1177/088307380502000606; Schneider H., 1931, WIEN KLIN WOCHENSCHR, V11, P350; Schondorf I, 2007, VACCINE, V25, P1470, DOI 10.1016/j.vaccine.2006.10.028; SCHOLZ E, 1987, DEUT MED WOCHENSCHR, V112, P544, DOI 10.1055/s-2008-1068092; Schwarz B, 1993, Wien Med Wochenschr, V143, P551; Sumilo D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000500; Sumilo D, 2006, INT J MED MICROBIOL, V296, P76, DOI 10.1016/j.ijmm.2005.12.006; Suss J, 2004, INT J MED MICROBIOL, V293, P69, DOI 10.1016/S1433-1128(04)80011-1; Suss J, 2003, VACCINE, V21, pS19, DOI 10.1016/S0264-410X(02)00812-5; TERNOVOI VA, 2003, EMERG INFECT DIS JUN; Tomazic J, 1996, ANTIBIOT MONIT, V12, P115; Vaisvieliene D., 1997, P 4 INT POTSDAM S TI, P100; WAHLBERG P, 1989, J INTERN MED, V225, P173, DOI 10.1111/j.1365-2796.1989.tb00059.x; Wahlberg P, 2006, SCAND J INFECT DIS, V38, P1057, DOI 10.1080/00365540600868297; Waldenstrom J, 2007, EMERG INFECT DIS, V13, P1215, DOI 10.3201/eid1308.061416; Walder G, 2006, INT J MED MICROBIOL, V296, P69, DOI 10.1016/j.ijmm.2006.01.031; Waldvogel K, 1996, EUR J PEDIATR, V155, P775, DOI 10.1007/BF02002905; *WHO, 2004, VECT BORN HUM INF EU, P37; Zeman P, 1997, INT J EPIDEMIOL, V26, P1121, DOI 10.1093/ije/26.5.1121; Zent O, 2004, VACCINE, V23, P312, DOI 10.1016/j.vaccine.2004.06.007; Zent O, 2003, VACCINE, V21, P4655, DOI 10.1016/j.vaccine.2003.08.005; Zent O, 2003, VACCINE, V21, P3584, DOI 10.1016/S0264-410X(03)00421-3; Zent O, 2003, VACCINE, V21, P738, DOI 10.1016/S0264-410X(02)00592-3	137	454	473	2	83	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY-JUN	2008	371	9627					1861	1871		10.1016/S0140-6736(08)60800-4	http://dx.doi.org/10.1016/S0140-6736(08)60800-4			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307NL	18514730				2022-12-28	WOS:000256325500030
J	Rainer, TH; Graham, CA				Rainer, Timothy H.; Graham, Colin A.			A significant step forward for gout	LANCET			English	Editorial Material							DOUBLE-BLIND; ARTHRITIS; THERAPY		[Rainer, Timothy H.; Graham, Colin A.] Chinese Univ Hong Kong, Prince Wales Hosp, Accident & Emergency Med Acad Unit, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital	Rainer, TH (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Accident & Emergency Med Acad Unit, Shatin, Hong Kong, Peoples R China.	thrainer@cuhk.edu.hk	Rainer, Timothy/I-2591-2013; Graham, Colin A/B-4535-2013	Rainer, Timothy/0000-0003-3355-3237; Graham, Colin A/0000-0002-4381-7470				Annemans L, 2008, ANN RHEUM DIS, V67, P960, DOI 10.1136/ard.2007.076232; James David S, 1999, J Am Osteopath Assoc, V99, pS1, DOI 10.7556/jaoa.1999.99.11.S1; Janssens HJEM, 2008, LANCET, V371, P1854, DOI 10.1016/S0140-6736(08)60799-0; Janssens HJ, 2008, COCHRANE DB SYST REV, V16; Man CY, 2007, ANN EMERG MED, V49, P670, DOI 10.1016/j.annemergmed.2006.11.014; Odio CM, 2003, PEDIATR INFECT DIS J, V22, P883, DOI 10.1097/01.inf.0000091293.32187.7b; Roddy E, 2007, RHEUMATOLOGY, V46, P1441, DOI 10.1093/rheumatology/kem150; Roddy E, 2007, NAT CLIN PRACT RHEUM, V3, P443, DOI 10.1038/ncprheum0556; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; Rodriguez LAG, 2001, ARTHRITIS RES, V3, P98, DOI 10.1186/ar146; Schumacher HR, 2005, J RHEUMATOL, V32, P2452; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X	12	5	5	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY-JUN	2008	371	9627					1816	1818		10.1016/S0140-6736(08)60775-8	http://dx.doi.org/10.1016/S0140-6736(08)60775-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307NL	18514713				2022-12-28	WOS:000256325500006
J	Weber, MA; Klein, NJ; Hartley, JC; Lock, PE; Malone, M; Sebire, NJ				Weber, M. A.; Klein, N. J.; Hartley, J. C.; Lock, P. E.; Malone, M.; Sebire, N. J.			Infection and sudden unexpected death in infancy: a systematic retrospective case review	LANCET			English	Review								Background The cause and mechanism of most cases of sudden unexpected death in infancy (SUDI) remain unknown, despite specialist autopsy examination. We reviewed autopsy results to determine whether infection was a cause of SUDI. Methods We did a systematic retrospective case review of autopsies, done at one specialist Centre between 1996 and 2005, of 546 infants (aged 7-365 days) who died suddenly and unexpectedly. Cases of SUDI were categorised as unexplained, explained with histological evidence of bacterial infection, or explained by non-infective causes. Microbial isolates gathered at autopsy were classified as non-pathogens, group 1 pathogens (organisms usually associated with an identifiable focus of infection), or group 2 pathogens (organisms known to cause septicaemia without an obvious focus of infection). Findings Of 546 SUDI cases, 39 autopsies were excluded because of viral or pneumocystis infection or secondary bacterial infection after initial collapse and resuscitation. Bacteriological sampling was done in 470 (93%) of the remaining 507 autopsies. 2079 bacteriological samples were taken, of which 571 (27%) were sterile. Positive cultures yielded 2871 separate isolates, 484 (32%) of which showed pure growth and 1024 (68%) mixed growth. Significantly more isolates from infants whose deaths were explained by bacterial infection (78/322, 24%) and from those whose death was unexplained (440/2306, 19%) contained group 2 pathogens than did those from infants whose death was explained by a non-infective cause (27/243, 11%; difference 13.1%, 95% CI 6.9-19.2, p<0 . 0001 vs bacterial infection; and 8.0%, 3.2-11.8, p=0.001 vs unexplained). Significantly more cultures from infants whose deaths were unexplained contained Staphylococcus aureus (262/1628, 16%) or Escherichia coli (93/1628;6%) than did those from infants whose deaths were of non-infective cause (S aureus: 19/211, 9%; difference 7.1%, 95% Cl 2.2-10.8, p=0 . 005; E coli: 3/211, 1%, difference 4.3%, 1.5-5 . 9, p=0 . 003). Interpretation Although many post-mortem bacteriological cultures in SUDI yield organisms, most seem to be unrelated to the cause of death. The high rate of detection of group 2 pathogens, particularly S aureus and E coli, in otherwise unexplained cases of SUDI suggests that these bacteria could be associated with this condition. Funding Foundation for the Study of Infant Deaths.	[Weber, M. A.; Malone, M.; Sebire, N. J.] Great Ormond St Hosp Sick Children, Dept Paediat Pathol, London WC1N 3JH, England; [Klein, N. J.; Hartley, J. C.; Lock, P. E.] Great Ormond St Hosp Sick Children, Dept Infect Dis & Microbiol, London WC1N 3JH, England; UCL, Inst Child Hlth, London, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Sebire, NJ (corresponding author), Great Ormond St Hosp Sick Children, Dept Paediat Pathol, Great Ormond St, London WC1N 3JH, England.	SebirN@gosh.nhs.uk	sebire, neil J/C-4960-2008; Weber, Martin/GPW-6095-2022	Sebire, Neil/0000-0001-5348-9063; Klein, Nigel/0000-0003-3925-9258				Arnestad M, 2002, FORENSIC SCI INT, V125, P262, DOI 10.1016/S0379-0738(02)00009-9; Byard R W, 2004, SUDDEN DEATH INFANCY; BYARD RW, 1994, PEDIATR PATHOL, V14, P817, DOI 10.3109/15513819409037679; Carmichael EM, 1996, J PAEDIATR CHILD H, V32, P412, DOI 10.1111/j.1440-1754.1996.tb00940.x; Chuang Yu-Yu, 2005, Paediatr Drugs, V7, P11, DOI 10.2165/00148581-200507010-00002; Dyer Clare, 2003, BMJ, V327, P10, DOI 10.1136/bmj.327.7405.10-a; Fleming P, 2000, SUDDEN UNEXPECTED DE, P97; Harrison LM, 1999, FEMS IMMUNOL MED MIC, V25, P19, DOI 10.1111/j.1574-695X.1999.tb01323.x; Highet AR, 2008, J APPL MICROBIOL, V105, P625, DOI 10.1111/j.1365-2672.2008.03747.x; Howatson A.G., 2006, CURRENT DIAGNOSTIC P, V12, P173, DOI [10.1016/j.cdip.2006.03.008, DOI 10.1016/J.CDIP.2006.03.008]; Krous HF, 2003, AM J FOREN MED PATH, V24, P1, DOI 10.1097/00000433-200303000-00001; Krous HF, 2004, PEDIATRICS, V114, P234, DOI 10.1542/peds.114.1.234; Mitchell E, 2000, AM J FOREN MED PATH, V21, P395, DOI 10.1097/00000433-200012000-00020; Moon RY, 2007, LANCET, V370, P1578, DOI 10.1016/S0140-6736(07)61662-6; Morris JA, 2006, J CLIN PATHOL, V59, P1, DOI 10.1136/jcp.2005.028183; Morris JA, 2007, CURR DIAGNOS PATHOL, V13, P65, DOI DOI 10.1016/J.CDIP.2006.07.005; *OFF NAT STAT, 2006, HLTH STAT Q, V31, P82; Royal College of Pathologists Royal College of Paediatrics and Child Health, 2004, SUDD UN DEATH INF MU; Sadler DW, 1998, J CLIN PATHOL, V51, P689, DOI 10.1136/jcp.51.9.689; Weinstein MP, 2003, J CLIN MICROBIOL, V41, P2275, DOI 10.1128/JCM.41.6.2275-2278.2003; 2006, ATTORNEY GEN ANNOUNC	21	110	112	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY-JUN	2008	371	9627					1848	1853		10.1016/S0140-6736(08)60798-9	http://dx.doi.org/10.1016/S0140-6736(08)60798-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307NL	18514728				2022-12-28	WOS:000256325500028
J	Saito, T; Owen, DM; Jiang, FG; Marcotrigiano, J; Gale, M				Saito, Takeshi; Owen, David M.; Jiang, Fuguo; Marcotrigiano, Joseph; Gale, Michael, Jr.			Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA	NATURE			English	Article							ANTIVIRAL RESPONSES; GENE-EXPRESSION; REPLICATION; TRANSLATION; ACTIVATION; INFECTION; RIBOSOME; HELICASE; ELEMENTS; PROTEIN	Innate immune defences are essential for the control of virus infection and are triggered through host recognition of viral macromolecular motifs known as pathogen-associated molecular patterns (PAMPs)(1). Hepatitis C virus (HCV) is an RNA virus that replicates in the liver, and infects 200 million people worldwide(2). Infection is regulated by hepatic immune defences triggered by the cellular RIG-I helicase. RIG-I binds PAMP RNA and signals interferon regulatory factor 3 activation to induce the expression of interferon-alpha/beta and antiviral/interferon-stimulated genes (ISGs) that limit infection(3-10). Here we identify the polyuridine motif of the HCV genome 3 ' non-translated region and its replication intermediate as the PAMP substrate of RIG-I, and show that this and similar homopolyuridine or homopolyriboadenine motifs present in the genomes of RNA viruses are the chief feature of RIG-I recognition and immune triggering in human and murine cells(8). 5 ' terminal triphosphate on the PAMP RNA was necessary but not sufficient for RIG-I binding, which was primarily dependent on homopolymeric ribonucleotide composition, linear structure and length. The HCV PAMP RNA stimulated RIG-I-dependent signalling to induce a hepatic innate immune response in vivo, and triggered interferon and ISG expression to suppress HCV infection in vitro. These results provide a conceptual advance by defining specific homopolymeric RNA motifs within the genome of HCV and other RNA viruses as the PAMP substrate of RIG-I, and demonstrate immunogenic features of the PAMP-RIG-I interaction that could be used as an immune adjuvant for vaccine and immunotherapy approaches.	[Saito, Takeshi; Owen, David M.; Gale, Michael, Jr.] Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA; [Owen, David M.] Univ Texas Dallas, SW Med Ctr, Dept Microbiol, Dallas, TX 75235 USA; [Jiang, Fuguo; Marcotrigiano, Joseph] Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA	University of Washington; University of Washington Seattle; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Rutgers State University New Brunswick	Gale, M (corresponding author), Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA.	mgale@u.washington.edu	Saito, Takeshi/N-2788-2014; Marcotrigiano, Joseph/K-6697-2016; JIANG, FUGUO/G-6581-2012	Saito, Takeshi/0000-0002-6165-664X; Marcotrigiano, Joseph/0000-0003-0346-3353; JIANG, FUGUO/0000-0003-4469-1803; Gale, Michael/0000-0002-6332-7436; Owen, David/0000-0002-5724-0342	NIAID NIH HHS [U19 AI040035-100004, R01 AI060389-03, U19 AI040035-120004, U19 AI040035-140004, U19 AI040035-110004, U19 AI040035-130004, R01 AI060389-08, U19 AI040035, R01 AI060389-04, U19AI40035, R56 AI060389, R01 AI060389-09, N01AI40035, R01 AI060389-02, R01 AI060389-06, R01 AI060389-07, R01 AI060389-01, R01 AI060389-05, R01 AI060389, R01AI060389] Funding Source: Medline; NIDA NIH HHS [R01DA021353, R01 DA024563, R01 DA024563-01, R01 DA024563-02, R01 DA024563-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI040035, R01AI060389, R56AI060389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA024563] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Afonina E, 1998, J BIOL CHEM, V273, P13015, DOI 10.1074/jbc.273.21.13015; Beard MR, 1999, HEPATOLOGY, V30, P316, DOI 10.1002/hep.510300137; Cui S, 2008, MOL CELL, V29, P169, DOI 10.1016/j.molcel.2007.10.032; Gale M, 2005, NATURE, V436, P939, DOI 10.1038/nature04078; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Honda M, 1996, VIROLOGY, V222, P31, DOI 10.1006/viro.1996.0395; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Ito T, 1999, VIROLOGY, V254, P288, DOI 10.1006/viro.1998.9541; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kim DH, 2004, NAT BIOTECHNOL, V22, P321, DOI 10.1038/nbt940; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Lau DTY, 2008, HEPATOLOGY, V47, P799, DOI 10.1002/hep.22076; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; Loo YM, 2006, P NATL ACAD SCI USA, V103, P6001, DOI 10.1073/pnas.0601523103; Loo YM, 2007, J INTERF CYTOK RES, V27, P697; Marques JT, 2006, NAT BIOTECHNOL, V24, P559, DOI 10.1038/nbt1205; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Saito T, 2007, P NATL ACAD SCI USA, V104, P582, DOI 10.1073/pnas.0606699104; Saito T, 2007, CURR OPIN IMMUNOL, V19, P17, DOI 10.1016/j.coi.2006.11.003; Simmonds P, 2004, J GEN VIROL, V85, P3173, DOI 10.1099/vir.0.80401-0; Smith MW, 2006, GASTROENTEROLOGY, V130, P179, DOI 10.1053/j.gastro.2005.08.015; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; Takahasi K, 2008, MOL CELL, V29, P428, DOI 10.1016/j.molcel.2007.11.028; Takaoka A, 2007, NATURE, V448, P501, DOI 10.1038/nature06013; Tse K, 2007, ANN RHEUM DIS, V66, P77, DOI 10.1136/ard.2007.078998; Yi MK, 2003, J VIROL, V77, P3557, DOI 10.1128/JVI.77.6.3557-3568.2003; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; You S, 2008, J VIROL, V82, P184, DOI 10.1128/JVI.01796-07; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	30	551	585	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 24	2008	454	7203					523	527		10.1038/nature07106	http://dx.doi.org/10.1038/nature07106			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	329IC	18548002	Green Accepted			2022-12-28	WOS:000257860300053
J	Holt, LJ; Krutchinsky, AN; Morgan, DO				Holt, Liam J.; Krutchinsky, Andrew N.; Morgan, David O.			Positive feedback sharpens the anaphase switch	NATURE			English	Article							MITOTIC EXIT; PHOSPHATASE CDC14; BUDDING YEAST; DNA-DAMAGE; PHOSPHORYLATION; SEPARASE; MITOSIS; APC; DESTRUCTION; DYNAMICS	At the onset of anaphase, sister- chromatid cohesion is dissolved abruptly and irreversibly, ensuring that all chromosome pairs disjoin almost simultaneously. The regulatory mechanisms that generate this switch- like behaviour are unclear. Anaphase is initiated when a ubiquitin ligase, the anaphase- promoting complex ( APC), triggers the destruction of securin, thereby allowing separase, a protease, to disrupt sister- chromatid cohesion(1-4). Here we demonstrate that the cyclin- dependent kinase 1 ( Cdk1)- dependent phosphorylation of securin near its destruction- box motif inhibits securin ubiquitination by the APC. The phosphatase Cdc14 reverses securin phosphorylation, thereby increasing the rate of securin ubiquitination. Because separase is known to activate Cdc14 ( refs 5 and 6), our results support the existence of a positive feedback loop that increases the abruptness of anaphase. Consistent with this model, we show that mutations that disrupt securin phosphoregulation decrease the synchrony of chromosome segregation. Our results also suggest that coupling securin degradation with changes in Cdk1 and Cdc14 activities helps coordinate the initiation of sister- chromatid separation with changes in spindle dynamics.	[Holt, Liam J.; Morgan, David O.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94158 USA; [Holt, Liam J.; Morgan, David O.] Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94158 USA; [Holt, Liam J.; Morgan, David O.] Univ Calif San Francisco, Dept Biophys, San Francisco, CA 94158 USA; [Krutchinsky, Andrew N.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Morgan, DO (corresponding author), Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94158 USA.	david.morgan@ucsf.edu		Holt, Liam/0000-0002-4002-0861; Morgan, David/0000-0001-8753-4416	NIGMS NIH HHS [R01 GM069901, R01 GM069901-05] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069901] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal R, 2003, J BIOL CHEM, V278, P45027, DOI 10.1074/jbc.M306783200; Agarwal R, 2002, GENE DEV, V16, P1371, DOI 10.1101/gad.971402; Blethrow JD, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000358; Carroll CW, 2005, METHOD ENZYMOL, V398, P219, DOI 10.1016/S0076-6879(05)98018-X; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Gerlich D, 2003, CELL, V112, P751, DOI 10.1016/S0092-8674(03)00189-2; Higuchi T, 2005, NATURE, V433, P171, DOI 10.1038/nature03240; Hornig NCD, 2002, CURR BIOL, V12, P973, DOI 10.1016/S0960-9822(02)00847-3; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Parry DH, 2003, CURR BIOL, V13, P647, DOI 10.1016/S0960-9822(03)00242-2; Pereira G, 2003, SCIENCE, V302, P2120, DOI 10.1126/science.1091936; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Queralt E, 2006, CELL, V125, P719, DOI 10.1016/j.cell.2006.03.038; Sage D, 2005, IEEE T IMAGE PROCESS, V14, P1372, DOI 10.1109/TIP.2005.852787; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Stegmeier F, 2004, ANNU REV GENET, V38, P203, DOI 10.1146/annurev.genet.38.072902.093051; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; Sullivan M, 2007, NAT REV MOL CELL BIO, V8, P894, DOI 10.1038/nrm2276; Thornton BR, 2006, GENE DEV, V20, P3069, DOI 10.1101/gad.1478306; Tyson JJ, 2003, CURR OPIN CELL BIOL, V15, P221, DOI 10.1016/S0955-0674(03)00017-6; VIG BK, 1983, CANCER GENET CYTOGEN, V8, P249, DOI 10.1016/0165-4608(83)90142-5; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; WAN J, 1992, J BIOL CHEM, V267, P11274; Wang H, 2001, GENE DEV, V15, P1361, DOI 10.1101/gad.893201; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Woodbury EL, 2007, NAT CELL BIOL, V9, P106, DOI 10.1038/ncb1523	30	148	150	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 17	2008	454	7202					353	357		10.1038/nature07050	http://dx.doi.org/10.1038/nature07050			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326ND	18552837	Green Accepted			2022-12-28	WOS:000257665300043
J	Crockett, MJ; Clark, L; Tabibnia, G; Lieberman, MD; Robbins, TW				Crockett, Molly J.; Clark, Luke; Tabibnia, Golnaz; Lieberman, Matthew D.; Robbins, Trevor W.			Serotonin modulates behavioral reactions to unfairness	SCIENCE			English	Article							ECONOMIC DECISION-MAKING; ULTIMATUM GAME; DEPLETION; FAIRNESS		[Crockett, Molly J.; Clark, Luke; Robbins, Trevor W.] Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England; [Crockett, Molly J.; Clark, Luke; Robbins, Trevor W.] Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge CB2 3EB, England; [Tabibnia, Golnaz; Lieberman, Matthew D.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA	University of Cambridge; University of Cambridge; University of California System; University of California Los Angeles	Crockett, MJ (corresponding author), Univ Cambridge, Dept Expt Psychol, Downing St, Cambridge CB2 3EB, England.	mc536@cam.ac.uk	Lieberman, Matthew/ABD-8197-2020; Crockett, Molly/F-8217-2014; Robbins, Trevor W/A-7551-2008	Lieberman, Matthew/0000-0002-4447-7359; Crockett, Molly/0000-0001-8800-410X; Robbins, Trevor/0000-0003-0642-5977; Clark, Luke/0000-0003-1103-2422; Tabibnia, Golnaz/0000-0003-3898-2313	Medical Research Council [G0001354] Funding Source: Medline; Wellcome Trust [076244, 076274] Funding Source: Medline; Medical Research Council [G0001354B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Clarke HF, 2005, J NEUROSCI, V25, P532, DOI 10.1523/JNEUROSCI.3690-04.2005; Evers EAT, 2006, PSYCHOPHARMACOLOGY, V187, P200, DOI 10.1007/s00213-006-0411-6; GUTH W, 1982, J ECON BEHAV ORGAN, V3, P367, DOI 10.1016/0167-2681(82)90011-7; Knoch D, 2006, SCIENCE, V314, P829, DOI 10.1126/science.1129156; Koenigs M, 2007, J NEUROSCI, V27, P951, DOI 10.1523/JNEUROSCI.4606-06.2007; Sanfey AG, 2003, SCIENCE, V300, P1755, DOI 10.1126/science.1082976; Tabibnia G, 2008, PSYCHOL SCI, V19, P339, DOI 10.1111/j.1467-9280.2008.02091.x	7	273	283	3	177	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 27	2008	320	5884					1739	1739		10.1126/science.1155577	http://dx.doi.org/10.1126/science.1155577			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318VP	18535210	Green Submitted, Green Accepted			2022-12-28	WOS:000257121200028
J	Klein, DE; Stayrook, SE; Shi, FM; Narayan, K; Lemmon, MA				Klein, Daryl E.; Stayrook, Steven E.; Shi, Fumin; Narayan, Kartik; Lemmon, Mark A.			Structural basis for EGFR ligand sequestration by Argos	NATURE			English	Article							EPIDERMAL-GROWTH-FACTOR; CRYSTAL-STRUCTURE; PLASMINOGEN-ACTIVATOR; ERBB RECEPTORS; COMPLEX; DOMAIN; SUPERFAMILY; INHIBITION; EXPRESSION; ALIGNMENT	Members of the epidermal growth factor receptor ( EGFR) or ErbB/ HER family and their activating ligands are essential regulators of diverse developmental processes(1,2). Inappropriate activation of these receptors is a key feature of many human cancers(3), and its reversal is an important clinical goal. A natural secreted antagonist of EGFR signalling, called Argos, was identified in Drosophila(4). We showed previously that Argos functions by directly binding ( and sequestering) growth factor ligands that activate EGFR(5). Here we describe the 1.6-angstrom resolution crystal structure of Argos bound to an EGFR ligand. Contrary to expectations(4,6), Argos contains no EGF- like domain. Instead, a trio of closely related domains ( resembling a three- finger toxin fold(7)) form a clamp- like structure around the bound EGF ligand. Although structurally unrelated to the receptor, Argos mimics EGFR by using a bipartite binding surface to entrap EGF. The individual Argos domains share unexpected structural similarities with the extracellular ligand- binding regions of transforming growth factor-beta family receptors(8). The three- domain clamp of Argos also resembles the urokinase- type plasminogen activator ( uPA) receptor, which uses a similar mechanism to engulf the EGF- like module of uPA(9). Our results indicate that undiscovered mammalian counterparts of Argos may exist among other poorly characterized structural homologues. In addition, the structures presented here define requirements for the design of artificial EGF- sequestering proteins that would be valuable anti- cancer therapeutics.	[Klein, Daryl E.; Stayrook, Steven E.; Shi, Fumin; Narayan, Kartik; Lemmon, Mark A.] Univ Penn, Sch Med, Dept Biochem & Biophys, Stellar Chance Labs 809C, Philadelphia, PA 19104 USA	University of Pennsylvania	Lemmon, MA (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, Stellar Chance Labs 809C, 422 Curie Blvd, Philadelphia, PA 19104 USA.	mlemmon@mail.med.upenn.edu	Shi, Fumin/H-3472-2013	Lemmon, Mark/0000-0002-3379-5319; Klein, Daryl/0000-0002-7188-0450; Stayrook, Steven/0000-0002-1677-8293	NCI NIH HHS [R01 CA079992-10, R01 CA125432-01A1, R01 CA125432, R01 CA079992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079992, R01CA125432] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allendorph GP, 2006, P NATL ACAD SCI USA, V103, P7643, DOI 10.1073/pnas.0602558103; Alvarado D, 2006, J BIOL CHEM, V281, P28993, DOI 10.1074/jbc.M603782200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barinka C, 2006, J MOL BIOL, V363, P482, DOI 10.1016/j.jmb.2006.08.063; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Dauter Z, 2000, ACTA CRYSTALLOGR D, V56, P232, DOI 10.1107/S0907444999016352; DeLano W.L, PYMOL MOL GRAPHICS S; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; Fujimoto N, 2005, CANCER RES, V65, P11478, DOI 10.1158/0008-5472.CAN-05-1977; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Greenwald J, 1999, NAT STRUCT BIOL, V6, P18; Hansen LV, 2008, INT J CANCER, V122, P734, DOI 10.1002/ijc.23082; Hayward S, 2002, J MOL GRAPH MODEL, V21, P181, DOI 10.1016/S1093-3263(02)00140-7; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huai Q, 2006, SCIENCE, V311, P656, DOI 10.1126/science.1121143; Hynes NE, 2006, CANCER CELL, V10, P7, DOI 10.1016/j.ccr.2006.06.012; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Iwaki T, 2003, BIOTECHNIQUES, V35, P482, DOI 10.2144/03353bm08; Kenny PA, 2007, J CLIN INVEST, V117, P337, DOI 10.1172/JCI29518; Klein DE, 2004, NATURE, V430, P1040, DOI 10.1038/nature02840; KRETZSCHMAR D, 1992, EMBO J, V11, P2531, DOI 10.1002/j.1460-2075.1992.tb05318.x; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lu HS, 2001, J BIOL CHEM, V276, P34913, DOI 10.1074/jbc.M102874200; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Miura GI, 2006, DEV CELL, V10, P167, DOI 10.1016/j.devcel.2005.11.017; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pape T, 2004, J APPL CRYSTALLOGR, V37, P843, DOI 10.1107/S0021889804018047; Rosel M, 1998, ONCOGENE, V17, P1989, DOI 10.1038/sj.onc.1202079; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Shilo BZ, 2005, DEVELOPMENT, V132, P4017, DOI 10.1242/dev.02006; Temerinac S, 2000, BLOOD, V95, P2569; Tsetlin V, 1999, EUR J BIOCHEM, V264, P281, DOI 10.1046/j.1432-1327.1999.00623.x; Zhang C, 2000, J MOL BIOL, V299, P1075, DOI 10.1006/jmbi.2000.3678; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	38	41	47	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 26	2008	453	7199					1271	U79		10.1038/nature06978	http://dx.doi.org/10.1038/nature06978			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318FA	18500331	Green Accepted			2022-12-28	WOS:000257075800050
J	Bonan, GB				Bonan, Gordon B.			Forests and climate change: Forcings, feedbacks, and the climate benefits of forests	SCIENCE			English	Review							LAND-COVER CHANGE; CARBON-CYCLE; BOREAL; CO2; IMPACT; ENERGY; WATER; HEAT; TEMPERATE; DYNAMICS	The world's forests influence climate through physical, chemical, and biological processes that affect planetary energetics, the hydrologic cycle, and atmospheric composition. These complex and nonlinear forest-atmosphere interactions can dampen or amplify anthropogenic climate change. Tropical, temperate, and boreal reforestation and afforestation attenuate global warming through carbon sequestration. Biogeophysical feedbacks can enhance or diminish this negative climate forcing. Tropical forests mitigate warming through evaporative cooling, but the low albedo of boreal forests is a positive climate forcing. The evaporative effect of temperate forests is unclear. The net climate forcing from these and other processes is not known. Forests are under tremendous pressure from global change. Interdisciplinary science that integrates knowledge of the many interacting climate services of forests with the impacts of global change is necessary to identify and understand as yet unexplored feedbacks in the Earth system and the potential of forests to mitigate climate change.	[Bonan, Gordon B.] Natl Ctr Atmospher Res, Boulder, CO 80307 USA	National Center Atmospheric Research (NCAR) - USA	Bonan, GB (corresponding author), Natl Ctr Atmospher Res, POB 3000, Boulder, CO 80307 USA.	bonan@ucar.edu	Nahas, Alberth/C-8379-2013	Bonan, Gordon/0000-0003-0830-6437				Albani M, 2006, GLOBAL CHANGE BIOL, V12, P2370, DOI 10.1111/j.1365-2486.2006.01254.x; Andreae MO, 2004, SCIENCE, V303, P1337, DOI 10.1126/science.1092779; Bala G, 2007, P NATL ACAD SCI USA, V104, P6550, DOI 10.1073/pnas.0608998104; Baldocchi D, 2000, GLOBAL CHANGE BIOL, V6, P69, DOI 10.1046/j.1365-2486.2000.06014.x; Baldocchi DD, 1997, J GEOPHYS RES-ATMOS, V102, P28939, DOI 10.1029/96JD03325; Baldocchi DD, 2007, ADV WATER RESOUR, V30, P2113, DOI 10.1016/j.advwatres.2006.06.013; Betts RA, 2004, THEOR APPL CLIMATOL, V78, P157, DOI 10.1007/s00704-004-0050-y; Bonan G.B., 2008, ECOLOGICAL CLIMATOLO, DOI [10.1017/CBO9781107339200, DOI 10.1017/CBO9781107339200]; Brovkin V, 2006, CLIM DYNAM, V26, P587, DOI 10.1007/s00382-005-0092-6; Brovkin V, 2004, GLOBAL CHANGE BIOL, V10, P1253, DOI 10.1111/j.1365-2486.2004.00812.x; Canadell JG, 2007, P NATL ACAD SCI USA, V104, P18866, DOI 10.1073/pnas.0702737104; Ciais P, 2005, NATURE, V437, P529, DOI 10.1038/nature03972; da Rocha HR, 2004, ECOL APPL, V14, pS22; Feddema JJ, 2005, SCIENCE, V310, P1674, DOI 10.1126/science.1118160; Fischlin A., 2007, CONTRIBUTION WORKING, P211; Foley JA, 2005, SCIENCE, V309, P570, DOI 10.1126/science.1111772; Friedlingstein P, 2006, J CLIMATE, V19, P3337, DOI 10.1175/JCLI3800.1; Fung IY, 2005, P NATL ACAD SCI USA, V102, P11201, DOI 10.1073/pnas.0504949102; Gu LH, 2003, SCIENCE, V299, P2035, DOI 10.1126/science.1078366; Hashimoto H, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2004JD004959; Hassan R., 2005, MILLENNIUM ECOSYSTEM, V1; Huete AR, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL025583; Jackson RB, 2005, SCIENCE, V310, P1944, DOI 10.1126/science.1119282; Jin YF, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014132; Juang JY, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL031296; Kurz WA, 2008, P NATL ACAD SCI USA, V105, P1551, DOI 10.1073/pnas.0708133105; Liu HP, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005158; Luyssaert S, 2007, GLOBAL CHANGE BIOL, V13, P2509, DOI 10.1111/j.1365-2486.2007.01439.x; Magnani F, 2007, NATURE, V447, P848, DOI 10.1038/nature05847; Malhi Y, 2008, SCIENCE, V319, P169, DOI 10.1126/science.1146961; Matthews HD, 2004, CLIM DYNAM, V22, P461, DOI 10.1007/s00382-004-0392-2; Meissner KJ, 2003, CLIM DYNAM, V21, P515, DOI 10.1007/s00382-003-0352-2; Nabuurs GJ, 2007, AR4 CLIMATE CHANGE 2007: MITIGATION OF CLIMATE CHANGE, P541; Norby RJ, 2005, P NATL ACAD SCI USA, V102, P18052, DOI 10.1073/pnas.0509478102; Oleson KW, 2004, CLIM DYNAM, V23, P117, DOI 10.1007/s00382-004-0426-9; Piao SL, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL028205; Randerson JT, 2006, SCIENCE, V314, P1130, DOI 10.1126/science.1132075; Randerson JT, 2005, GLOBAL BIOGEOCHEM CY, V19, DOI 10.1029/2004GB002366; Reichstein M, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2006GL027880; Roy SB, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003565; Sabine CL, 2004, SCOPE SER, V62, P17; Saleska SR, 2007, SCIENCE, V318, P612, DOI 10.1126/science.1146663; Sitch S, 2007, NATURE, V448, P791, DOI 10.1038/nature06059; Sitch S, 2005, GLOBAL BIOGEOCHEM CY, V19, DOI 10.1029/2004GB002311; Smith P, 2007, AR4 CLIMATE CHANGE 2007: MITIGATION OF CLIMATE CHANGE, P497; Snyder PK, 2004, CLIM DYNAM, V23, P279, DOI 10.1007/s00382-004-0430-0; Stephens BB, 2007, SCIENCE, V316, P1732, DOI 10.1126/science.1137004; THOMPSON K, 1980, CLIMATIC CHANGE, V3, P47, DOI 10.1007/BF02423168; von Randow C, 2004, THEOR APPL CLIMATOL, V78, P5, DOI 10.1007/s00704-004-0041-z; Zaitchik BF, 2006, INT J CLIMATOL, V26, P743, DOI 10.1002/joc.1280	50	3387	3581	191	3062	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2008	320	5882					1444	1449		10.1126/science.1155121	http://dx.doi.org/10.1126/science.1155121			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556546	Green Published			2022-12-28	WOS:000256676400029
J	Jones, AM; Chory, J; Dangl, JL; Estelle, M; Jacobsen, SE; Meyerowitz, EM; Nordborg, M; Weigel, D				Jones, Alan M.; Chory, Joanne; Dangl, Jeffery L.; Estelle, Mark; Jacobsen, Steven E.; Meyerowitz, Elliot M.; Nordborg, Magnus; Weigel, Detlef			The impact of Arabidopsis on human health: Diversifying our portfolio	CELL			English	Article							BLUE-LIGHT PHOTORECEPTOR; UBIQUITIN LIGASE; COP9 SIGNALOSOME; PROTEIN; PLANT; THALIANA; DISEASE; GENE; RNA; METHYLATION	Studies of the model plant Arabidopsis thaliana may seem to have little impact on advances in medical research, yet a survey of the scientific literature shows that this is a misconception. Many discoveries with direct relevance to human health and disease have been elaborated using Arabidopsis, and several processes important to human biology are more easily studied in this versatile model plant.	[Jones, Alan M.; Dangl, Jeffery L.] Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; [Jones, Alan M.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; [Chory, Joanne] Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; [Chory, Joanne] Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; [Estelle, Mark] Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; [Jacobsen, Steven E.] Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; [Jacobsen, Steven E.] Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; [Meyerowitz, Elliot M.] CALTECH, Div Biol, Pasadena, CA 91125 USA; [Nordborg, Magnus] Univ So Calif, Los Angeles, CA 90089 USA; [Weigel, Detlef] Max Planck Inst Dev Biol, D-72076 Tubingen, Germany	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Howard Hughes Medical Institute; Salk Institute; Salk Institute; Indiana University System; Indiana University Bloomington; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; California Institute of Technology; University of Southern California; Max Planck Society	Jones, AM (corresponding author), Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA.	alan_jones@unc.edu	Meyerowitz, Elliot M/A-7118-2009; Weigel, Detlef/C-1418-2008; Weigel, Detlef/AAR-3312-2021; Weigel, Detlef/GSJ-0799-2022; Estelle, Mark/ABD-6742-2021	Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; Nordborg, Magnus/0000-0001-7178-9748	NIGMS NIH HHS [R01 GM052413, R01 GM052413-16] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052413] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Chan SWL, 2005, NAT REV GENET, V6, P351, DOI 10.1038/nrg1601; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; Chapman EJ, 2007, NAT REV GENET, V8, P884, DOI 10.1038/nrg2179; CHORY J, 1989, CELL, V58, P991, DOI 10.1016/0092-8674(89)90950-1; Chow NW, 1996, J BIOL CHEM, V271, P11339, DOI 10.1074/jbc.271.19.11339; CORRELA JD, 2007, P NATL ACAD SCI USA, V107, P6764; Dornan D, 2004, CANCER RES, V64, P7226, DOI 10.1158/0008-5472.CAN-04-2601; Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Johanson U, 2000, SCIENCE, V290, P344, DOI 10.1126/science.290.5490.344; Johnston CA, 2007, P NATL ACAD SCI USA, V104, P17317, DOI 10.1073/pnas.0704751104; Jones JDG, 2006, NATURE, V444, P323, DOI 10.1038/nature05286; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kepinski S, 2007, BIOESSAYS, V29, P953, DOI 10.1002/bies.20657; Kim DH, 2007, NAT REV GENET, V8, P173, DOI 10.1038/nrg2006; Kim HJ, 2007, CELL DEATH DIFFER, V14, P103, DOI 10.1038/sj.cdd.4401935; Kim S, 2007, NAT GENET, V39, P1151, DOI 10.1038/ng2115; Li JB, 2004, CELL, V117, P541, DOI 10.1016/S0092-8674(04)00450-7; Li QH, 2007, PHOTOCHEM PHOTOBIOL, V83, P94, DOI 10.1562/2006-02-28-IR-826; Mata IF, 2006, TRENDS NEUROSCI, V29, P286, DOI 10.1016/j.tins.2006.03.006; Matzke M, 2001, SCIENCE, V293, P1080, DOI 10.1126/science.1063051; Mayor A, 2007, NAT IMMUNOL, V8, P497, DOI 10.1038/ni1459; Menon S, 2007, NAT IMMUNOL, V8, P1236, DOI 10.1038/ni1514; Ooi SKT, 2008, CURR BIOL, V18, pR174, DOI 10.1016/j.cub.2007.12.045; Parry G, 2006, CURR OPIN CELL BIOL, V18, P152, DOI 10.1016/j.ceb.2006.02.001; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Qi L, 2006, SCIENCE, V312, P1763, DOI 10.1126/science.1123374; Rodriguez-Navarro A, 2006, J EXP BOT, V57, P1149, DOI 10.1093/jxb/erj068; Schwartz Peter J., 2005, V266, P186; Temple BRS, 2007, ANNU REV PLANT BIOL, V58, P249, DOI 10.1146/annurev.arplant.58.032806.103827; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; Ting JPY, 2006, NAT REV IMMUNOL, V6, P183, DOI 10.1038/nri1788; TSAY YF, 1993, CELL, V72, P705, DOI 10.1016/0092-8674(93)90399-B; Virshup DM, 2007, CELL, V129, P857, DOI 10.1016/j.cell.2007.05.015; Wang WH, 2004, CURR OPIN NEPHROL HY, V13, P549, DOI 10.1097/00041552-200409000-00011; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Yi CL, 2005, TRENDS CELL BIOL, V15, P618, DOI 10.1016/j.tcb.2005.09.007; Zipfel C, 2006, CELL, V125, P749, DOI 10.1016/j.cell.2006.03.037	40	77	79	2	32	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 13	2008	133	6					939	943		10.1016/j.cell.2008.05.040	http://dx.doi.org/10.1016/j.cell.2008.05.040			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	312TJ	18555767	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000256693400006
J	Gerstein, HC; Miller, ME; Byington, RP; Goff, DC; Bigger, JT; Buse, JB; Cushman, WC; Genuth, S; Ismail-Beigi, F; Grimm, RH; Probstfield, JL; Simons-Morton, DG; Friedewald, WT				Gerstein, Hertzel C.; Miller, Michael E.; Byington, Robert P.; Goff, David C., Jr.; Bigger, J. Thomas; Buse, John B.; Cushman, William C.; Genuth, Saul; Ismail-Beigi, Faramarz; Grimm, Richard H., Jr.; Probstfield, Jeffrey L.; Simons-Morton, Denise G.; Friedewald, William T.		Act Control Cardiovasc Risk Diabet	Effects of intensive glucose lowering in type 2 diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROL CARDIOVASCULAR RISK; GLYCEMIC CONTROL; COMPLICATIONS; MELLITUS; DISEASE; DESIGN; TRIAL; RATIONALE; ASSOCIATION; PREVENTION	Background: Epidemiologic studies have shown a relationship between glycated hemoglobin levels and cardiovascular events in patients with type 2 diabetes. We investigated whether intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events in patients with type 2 diabetes who had either established cardiovascular disease or additional cardiovascular risk factors. Methods: In this randomized study, 10,251 patients (mean age, 62.2 years) with a median glycated hemoglobin level of 8.1% were assigned to receive intensive therapy (targeting a glycated hemoglobin level below 6.0%) or standard therapy (targeting a level from 7.0 to 7.9%). Of these patients, 38% were women, and 35% had had a previous cardiovascular event. The primary outcome was a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. The finding of higher mortality in the intensive-therapy group led to a discontinuation of intensive therapy after a mean of 3.5 years of follow-up. Results: At 1 year, stable median glycated hemoglobin levels of 6.4% and 7.5% were achieved in the intensive-therapy group and the standard-therapy group, respectively. During follow-up, the primary outcome occurred in 352 patients in the intensive-therapy group, as compared with 371 in the standard-therapy group (hazard ratio, 0.90; 95% confidence interval [CI], 0.78 to 1.04; P=0.16). At the same time, 257 patients in the intensive-therapy group died, as compared with 203 patients in the standard-therapy group (hazard ratio, 1.22; 95% CI, 1.01 to 1.46; P=0.04). Hypoglycemia requiring assistance and weight gain of more than 10 kg were more frequent in the intensive-therapy group (P<0.001). Conclusions: As compared with standard therapy, the use of intensive therapy to target normal glycated hemoglobin levels for 3.5 years increased mortality and did not significantly reduce major cardiovascular events. These findings identify a previously unrecognized harm of intensive glucose lowering in high-risk patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00000620.).	[Miller, Michael E.; Byington, Robert P.; Goff, David C., Jr.] Wake Forest Univ, Sch Med, Div Publ Hlth Sci, Winston Salem, NC 27157 USA; [Gerstein, Hertzel C.] McMaster Univ, Hamilton, ON, Canada; [Gerstein, Hertzel C.] Hamilton Hlth Sci Populat Hlth Res Inst, Hamilton, ON, Canada; [Bigger, J. Thomas] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Buse, John B.] Univ N Carolina, Sch Med, Chapel Hill, NC USA; [Cushman, William C.] Vet Affairs Med Ctr, Memphis, TN USA; [Genuth, Saul; Ismail-Beigi, Faramarz] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Grimm, Richard H., Jr.] Berman Ctr Outcomes & Clin Res, Minneapolis, MN USA; [Probstfield, Jeffrey L.] Univ Washington, Seattle, WA 98195 USA; [Simons-Morton, Denise G.] NHLBI, Bethesda, MD 20892 USA; [Friedewald, William T.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA	Wake Forest University; McMaster University; Population Health Research Institute; Columbia University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; Case Western Reserve University; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Columbia University	Byington, RP (corresponding author), Wake Forest Univ, Sch Med, Div Publ Hlth Sci, Med Ctr Blvd, Winston Salem, NC 27157 USA.	bbyingto@wfubmc.edu	Buse, John Bernard/J-9742-2019; Gerstein, Hertzel C/B-1235-2013; Vallis, Michael/R-8965-2019; Greiver, Michelle/N-8764-2015; Hramiak, Irene/G-3305-2011; Senior, Peter/O-4934-2019; Gerstein, Hertzel/ABB-8781-2020; Force, Rex W/K-4094-2012; Bryan, R. Nick/P-1661-2014; Friedewald, William T/C-8034-2011; Katula, Jeffrey/K-5905-2013	Buse, John Bernard/0000-0002-9723-3876; Gerstein, Hertzel C/0000-0001-8072-2836; Vallis, Michael/0000-0002-0165-5936; Greiver, Michelle/0000-0001-8957-0285; Senior, Peter/0000-0003-1033-8673; Gerstein, Hertzel/0000-0001-8072-2836; Redmon, J. Bruce/0000-0002-1883-9467; Lochnan, Heather/0000-0002-3820-7897; Wilderman, Igor/0000-0003-0499-2791; Rasouli, Neda/0000-0003-1269-3580; Stephens, Dianne/0000-0002-3785-6828; Yusuf, Salim/0000-0003-4776-5601; Arrey, Frida/0000-0003-4543-4219; Nyomba, B. L. Gregoire/0000-0001-9472-607X; Bryan, Robert Nick/0000-0002-2327-4579; Kaiser, Peter/0000-0001-5126-045X; Katula, Jeffrey/0000-0003-2009-2443; Sivitz, William/0000-0002-7829-0189	NHLBI NIH HHS [N01HC95181, IAA-Y1-HC-1010, Y01 HC009035, N01-HC-95180, Y01 HC001010, N01HC95184, N01-HC-95179, N01HC95180, N01-HC-95183, N01HC95179, N01-HC-95184, N01-HC-95182, N01HC95183, IAA-Y1-HC-9035, N01HC95178, N01-HC-95181, N01HC95182, N01-HC-95178] Funding Source: Medline; NINR NIH HHS [P30 NR005035] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC095182, N01HC095179, N01HC095180, N01HC095183, N01HC095184, N01HC095181, N01HC095178] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R44HL095181, N01HC95178, R43HL095181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [P30NR005035] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		*AACE DIAB MELL CL, 2007, ENDOCR PRACT S1, V13, P1; Abraira C, 1997, ARCH INTERN MED, V157, P181, DOI 10.1001/archinte.157.2.181; Abraira C, 2003, J DIABETES COMPLICAT, V17, P314, DOI 10.1016/S1056-8727(02)00277-5; Amer Diabet Assoc, 2008, DIABETES CARE, V31, pS12, DOI 10.2337/dc08-S012; Bonds DE, 2007, AM J CARDIOL, V99, p80I, DOI 10.1016/j.amjcard.2007.03.026; Booth GL, 2006, LANCET, V368, P29, DOI 10.1016/S0140-6736(06)68967-8; Buse JB, 2007, AM J CARDIOL, V99, p21I, DOI 10.1016/j.amjcard.2007.03.003; *CAN DIAB ASS CLIN, 2003, CAN J DIABETES S2, V27, pS1; Chalmers J, 2001, DIABETOLOGIA, V44, P1118; ERSTEIN HC, 2007, AM J CARDIOL, V99, pI34; Genuth S, 1996, ANN INTERN MED, V124, P104, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00005; Gerstein HC, 2005, DIABETOLOGIA, V48, P1749, DOI 10.1007/s00125-005-1858-4; Gerstein HC, 2008, AM HEART J, V155, P26, DOI 10.1016/j.ahj.2007.09.009; Ginsberg HN, 2007, AM J CARDIOL, V99, p56I, DOI 10.1016/j.amjcard.2007.03.024; Goff DC, 2007, AM J CARDIOL, V99, p4I, DOI 10.1016/j.amjcard.2007.03.002; Kingry C, 2007, AM J CARDIOL, V99, p68I, DOI 10.1016/j.amjcard.2007.03.025; Magee MF, 2006, AM J CARDIOL, V97, p20G, DOI 10.1016/j.amjcard.2006.02.024; MEINERT CL, 1970, DIABETES, V19, P789; Milicevic Z, 2005, J DIABETES COMPLICAT, V19, P80, DOI 10.1016/j.jdiacomp.2004.06.003; Ryden L, 2007, EUR HEART J, V28, P88, DOI [10.1093/eurheartj/ehl260, 10.1093/eurheartj/ehm124]; Selvin E, 2004, ANN INTERN MED, V141, P421, DOI 10.7326/0003-4819-141-6-200409210-00007; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Thomas RJ, 2003, ARCH INTERN MED, V163, P445, DOI 10.1001/archinte.163.4.445; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6	24	5565	5742	11	457	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2008	358	24					2545	2559		10.1056/nejmoa0802743	http://dx.doi.org/10.1056/nejmoa0802743			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311IJ	18539917	Green Accepted, Bronze, Green Submitted			2022-12-28	WOS:000256593600003
J	Kim, S; Jin, JH; Kim, YJ; Park, IY; Kim, Y; Kim, SW				Kim, Seungchul; Jin, Jonghan; Kim, Young-Jin; Park, In-Yong; Kim, Yunseok; Kim, Seung-Woo			High-harmonic generation by resonant plasmon field enhancement	NATURE			English	Article							NEAR-FIELD; PULSE LASER; X-RAYS; TIPS	High- harmonic generation by focusing a femtosecond laser onto a gas is a well- known method of producing coherent extreme-ultraviolet ( EUV) light(1-3). This nonlinear conversion process requires high pulse intensities, greater than 10(13) W cm(-2), which are not directly attainable using only the output power of a femtosecond oscillator. Chirped- pulse amplification enables the pulse intensity to exceed this threshold by incorporating several regenerative and/ or multi- pass amplifier cavities in tandem(4,5). Intracavity pulse amplification ( designed not to reduce the pulse repetition rate) also requires a long cavity(6,7). Here we demonstrate a method of high- harmonic generation that requires no extra cavities. This is achieved by exploiting the local field enhancement induced by resonant plasmons within a metallic nanostructure consisting of bow- tie- shaped gold elements on a sapphire substrate. In our experiment, the output beam emitted from a modest femtosecond oscillator ( 100- kW peak power, 1.3- nJ pulse energy and 10- fs pulse duration) is directly focused onto the nanostructure with a pulse intensity of only 10(11) W cm(-2). The enhancement factor exceeds 20 dB, which is sufficient to produce EUV wavelengths down to 47 nm by injection with an argon gas jet. The method could form the basis for constructing laptop- sized EUV light sources for advanced lithography and high- resolution imaging applications.	[Kim, Seungchul; Jin, Jonghan; Kim, Young-Jin; Park, In-Yong; Kim, Yunseok; Kim, Seung-Woo] Korea Adv Inst Sci & Technol, Billionth Uncertainty Precis Engn Grp, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Kim, SW (corresponding author), Korea Adv Inst Sci & Technol, Billionth Uncertainty Precis Engn Grp, Daedeok Sci Town, Taejon 305701, South Korea.	swk@kaist.ac.kr	Kim, Seung-Woo/C-1854-2011; Hädrich, Steffen/B-4331-2008; COLE, Murukeshan/ABD-6157-2020; KIM, YOUNG JIN/E-9374-2011	COLE, Murukeshan/0000-0001-6661-7597; KIM, YOUNG JIN/0000-0002-4271-5771; Kim, Seung-Woo/0000-0003-0235-1739; Kim, Seungchul/0000-0002-6765-2471; Jin, Jonghan/0000-0002-3511-4636				Bohn JL, 2001, J OPT SOC AM A, V18, P2998, DOI 10.1364/JOSAA.18.002998; Bragas AV, 2000, OPT LETT, V25, P631, DOI 10.1364/OL.25.000631; Chang ZH, 1997, PHYS REV LETT, V79, P2967, DOI 10.1103/PhysRevLett.79.2967; CORKUM PB, 1993, PHYS REV LETT, V71, P1994, DOI 10.1103/PhysRevLett.71.1994; Fromm DP, 2004, NANO LETT, V4, P957, DOI 10.1021/nl049951r; Gai HF, 2007, APPL OPTICS, V46, P2229, DOI 10.1364/AO.46.002229; Gohle C, 2005, NATURE, V436, P234, DOI 10.1038/nature03851; Gudde J, 1998, APPL SURF SCI, V127, P40, DOI 10.1016/S0169-4332(98)00002-6; Jin EX, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2194013; Jones RJ, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.193201; Krug JT, 2002, J CHEM PHYS, V116, P10895, DOI 10.1063/1.1479723; Lesuffleur A, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2218057; LEWENSTEIN M, 1994, PHYS REV A, V49, P2117, DOI 10.1103/PhysRevA.49.2117; Muhlschlegel P, 2005, SCIENCE, V308, P1607, DOI 10.1126/science.1111886; Nisoli M, 2007, NAT PHOTONICS, V1, P499, DOI 10.1038/nphoton.2007.154; Onuta TD, 2007, NANO LETT, V7, P557, DOI 10.1021/nl0621600; Roth RM, 2006, OPT EXPRESS, V14, P2921, DOI 10.1364/OE.14.002921; Schatz G.C., 2002, HDB VIBRATIONAL SPEC, P759, DOI DOI 10.1002/0470027320.S0601; Seres J, 2005, NATURE, V433, P596, DOI 10.1038/433596a; Stockman MI, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.137404; STRICKLAND D, 1985, OPT COMMUN, V56, P219, DOI 10.1016/0030-4018(85)90120-8; Sun WX, 2003, J OPT SOC AM A, V20, P2254, DOI 10.1364/JOSAA.20.002254; Tzeng YF, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/43/435703; WAHLSTROM CG, 1993, PHYS REV A, V48, P4709, DOI 10.1103/PhysRevA.48.4709; Wang XC, 2004, APPL SURF SCI, V228, P221, DOI 10.1016/j.apsusc.2004.01.009; Zhou J, 1996, PHYS REV LETT, V76, P752, DOI 10.1103/PhysRevLett.76.752	26	1150	1193	19	587	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 5	2008	453	7196					757	760		10.1038/nature07012	http://dx.doi.org/10.1038/nature07012			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308UK	18528390				2022-12-28	WOS:000256415300037
J	Chen, ST; Lin, YL; Huang, MT; Wu, MF; Cheng, SC; Lei, HY; Lee, CK; Chiou, TW; Wong, CH; Hsieh, SL				Chen, Szu-Ting; Lin, Yi-Ling; Huang, Ming-Ting; Wu, Ming-Fang; Cheng, Shih-Chin; Lei, Huan-Yao; Lee, Chien-Kuo; Chiou, Tzyy-Wen; Wong, Chi-Huey; Hsieh, Shie-Liang			CLEC5A is critical for dengue-virus-induced lethal disease	NATURE			English	Article							C-TYPE LECTINS; DC-SIGN; DENDRITIC CELLS; CARBOHYDRATE-RECOGNITION; DECOY RECEPTOR-3; INNATE IMMUNITY; INFECTION; ENHANCEMENT; ACTIVATION; ANTIBODY	Dengue haemorrhagic fever and dengue shock syndrome, the most severe responses to dengue virus ( DV) infection, are characterized by plasma leakage ( due to increased vascular permeability) and low platelet counts(1,2). CLEC5A ( C- type lectin domain family 5, member A; also known as myeloid DAP12- associating lectin ( MDL-1))(3) contains a C- type lectin- like fold similar to the natural- killer T- cell C- type lectin domains and associates with a 12- kDa DNAX- activating protein ( DAP12)(4) on myeloid cells. Here we show that CLEC5A interacts with the dengue virion directly and thereby brings about DAP12 phosphorylation. The CLEC5A DV interaction does not result in viral entry but stimulates the release of proinflammatory cytokines. Blockade of CLEC5A - DV interaction suppresses the secretion of proinflammatory cytokines without affecting the release of interferon-alpha, supporting the notion that CLEC5A acts as a signalling receptor for proinflammatory cytokine release. Moreover, anti- CLEC5A monoclonal antibodies inhibit DV- induced plasma leakage, as well as subcutaneous and vital- organ haemorrhaging, and reduce the mortality of DV infection by about 50% in STAT1- deficient mice. Our observation that blockade of CLEC5A- mediated signalling attenuates the production of proinflammatory cytokines by macrophages infected with DV ( either alone or complexed with an enhancing antibody) offers a promising strategy for alleviating tissue damage and increasing the survival of patients suffering from dengue haemorrhagic fever and dengue shock syndrome, and possibly even other virus- induced inflammatory diseases.	[Chen, Szu-Ting; Huang, Ming-Ting; Wu, Ming-Fang; Cheng, Shih-Chin; Hsieh, Shie-Liang] Natl Yang Ming Univ, Dept Microbiol & Immunol, Taipei 112, Taiwan; [Chen, Szu-Ting; Huang, Ming-Ting; Wu, Ming-Fang; Cheng, Shih-Chin; Hsieh, Shie-Liang] Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan; [Lin, Yi-Ling] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; [Lin, Yi-Ling; Wong, Chi-Huey; Hsieh, Shie-Liang] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Lei, Huan-Yao] Natl Cheng Kung Univ, Dept Microbiol & Immunol, Tainan 70101, Taiwan; [Lee, Chien-Kuo] Natl Taiwan Univ, Inst Immunol, Taipei 100, Taiwan; [Chiou, Tzyy-Wen] Natl Dong Hwa Univ, Dept Life Sci, Hualien 974, Taiwan; [Chiou, Tzyy-Wen] Natl Dong Hwa Univ, Inst Biotechnol, Hualien 974, Taiwan; [Hsieh, Shie-Liang] Natl Yang Ming Univ, Immunol Res Ctr, Taipei 112, Taiwan; [Hsieh, Shie-Liang] Taipei Vet Gen Hosp, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Cheng Kung University; National Taiwan University; National Dong Hwa University; National Dong Hwa University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital	Hsieh, SL (corresponding author), Natl Yang Ming Univ, Dept Microbiol & Immunol, Taipei 112, Taiwan.	slhsieh@ym.edu.tw	Lee, Chien-Kuo/AAZ-1039-2020; 陳, 斯婷/GVU-2169-2022; Lin, Yi-Ling/N-7128-2018; Hsieh, Shie-Liang Edmond/ABA-9184-2021; CHENG, SHIH-CHIN/M-3773-2019	Lee, Chien-Kuo/0000-0001-8189-6045; Lin, Yi-Ling/0000-0002-1838-6410; CHENG, SHIH-CHIN/0000-0003-1251-8774; Hsieh, Shie-Liang/0000-0001-9415-346X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62116] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arrighi JF, 2004, J VIROL, V78, P10848, DOI 10.1128/JVI.78.20.10848-10855.2004; Bakker ABH, 1999, P NATL ACAD SCI USA, V96, P9792, DOI 10.1073/pnas.96.17.9792; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Chang YC, 2004, J LEUKOCYTE BIOL, V75, P486, DOI 10.1189/jlb.0903448; Chen YC, 2002, J VIROL, V76, P9877, DOI 10.1128/JVI.76.19.9877-9887.2002; Cook DN, 2004, NAT IMMUNOL, V5, P975, DOI 10.1038/ni1116; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Goncalvez AP, 2007, P NATL ACAD SCI USA, V104, P9422, DOI 10.1073/pnas.0703498104; HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201; Hsu TL, 2002, J IMMUNOL, V168, P4846, DOI 10.4049/jimmunol.168.10.4846; Huang KJ, 2006, J IMMUNOL, V176, P2825, DOI 10.4049/jimmunol.176.5.2825; JOHNSON AJ, 1994, VIROLOGY, V203, P241, DOI 10.1006/viro.1994.1481; Klesney-Tait J, 2006, NAT IMMUNOL, V7, P1266, DOI 10.1038/ni1411; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; Lin YL, 1998, J VIROL, V72, P9729, DOI 10.1128/JVI.72.12.9729-9737.1998; Lozach PY, 2005, J BIOL CHEM, V280, P23698, DOI 10.1074/jbc.M504337200; Mackenzie JS, 2004, NAT MED, V10, pS98, DOI 10.1038/nm1144; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Modis Y, 2005, J VIROL, V79, P1223, DOI 10.1128/JVI.79.2.1223-1231.2005; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Palmer DR, 2005, J VIROL, V79, P2432, DOI 10.1128/JVI.79.4.2432-2439.2005; Palucka AK, 2000, NAT MED, V6, P748, DOI 10.1038/77470; Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008; Pokidysheva E, 2006, CELL, V124, P485, DOI 10.1016/j.cell.2005.11.042; Robinson MJ, 2006, NAT IMMUNOL, V7, P1258, DOI 10.1038/ni1417; Shresta S, 2005, J IMMUNOL, V175, P3946, DOI 10.4049/jimmunol.175.6.3946; Shresta S, 2006, J VIROL, V80, P10208, DOI 10.1128/JVI.00062-06; Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840; Wilder-Smith A, 2005, NEW ENGL J MED, V353, P924, DOI 10.1056/NEJMra041927; Wu SJL, 2000, NAT MED, V6, P816, DOI 10.1038/77553	30	285	293	2	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 29	2008	453	7195					672	U12		10.1038/nature07013	http://dx.doi.org/10.1038/nature07013			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305NN	18496526	Green Published			2022-12-28	WOS:000256185200048
J	Cumbo-Nacheli, G				Cumbo-Nacheli, Gustavo			Severe constipation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Cumbo-Nacheli, Gustavo] Wayne State Univ, Sch Med, Detroit, MI 48201 USA	Wayne State University	Cumbo-Nacheli, G (corresponding author), Wayne State Univ, Sch Med, Detroit, MI 48201 USA.	gcumbona@med.wayne.edu							0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2008	358	22					E26	E26		10.1056/NEJMicm0802320	http://dx.doi.org/10.1056/NEJMicm0802320			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307GF	18509117				2022-12-28	WOS:000256306700010
J	Rosenbaum, JT				Rosenbaum, James T.			In defense of phobias	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												rosenbaj@ohsu.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2008	299	20					2368	2368		10.1001/jama.299.20.2368	http://dx.doi.org/10.1001/jama.299.20.2368			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305BD	18505937				2022-12-28	WOS:000256151900001
J	Lyratzopoulos, G; Patrick, H; Campbell, B				Lyratzopoulos, Georgios; Patrick, Hannah; Campbell, Bruce			Registers needed for new interventional procedures	LANCET			English	Editorial Material							RANDOMIZED-TRIALS; PROGRAM		[Lyratzopoulos, Georgios; Patrick, Hannah; Campbell, Bruce] Natl Inst Hlth & Clin Excellence, Intervent Procedures Programme, London WC1V 6NA, England	National Institute for Health & Care Excellence	Lyratzopoulos, G (corresponding author), Natl Inst Hlth & Clin Excellence, Intervent Procedures Programme, London WC1V 6NA, England.	georgios.lyratzopoulos@nice.org.uk	Lyratzopoulos, Georgios/O-8260-2019; Lyratzopoulos, Georgios/B-6301-2012	Lyratzopoulos, Georgios/0000-0002-2873-7421; 				Black N, 2004, BMJ-BRIT MED J, V328, P1478, DOI 10.1136/bmj.328.7454.1478; Campbell WB, 2007, INT J TECHNOL ASSESS, V23, P101, DOI 10.1017/S026646230705163X; COOKSEY C, 2006, REV UK HLTH RES FUND; *DEP HLTH, 2008, NEW ARR CLIN AUD DEP; Fairbank J, 2005, BMJ-BRIT MED J, V330, P1233, DOI 10.1136/bmj.38441.620417.8F; Glasziou P, 2007, BMJ-BRIT MED J, V334, P349, DOI 10.1136/bmj.39070.527986.68; Ioannidis JPA, 2002, DRUG SAFETY, V25, P77, DOI 10.2165/00002018-200225020-00002; Lilford R, 2004, BRIT J SURG, V91, P6, DOI 10.1002/bjs.4418; *NAT I HLTH CLIN E, 2007, INT PROC ISS GUID; Newton J., 2002, DIS REGISTERS ENGLAN; Nordin P, 2008, BRIT MED J, V336, P934, DOI 10.1136/bmj.39525.514572.25; Potts M, 2006, BMJ-BRIT MED J, V333, P701, DOI 10.1136/bmj.333.7570.701	12	23	23	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 24	2008	371	9626					1734	1736		10.1016/S0140-6736(08)60742-4	http://dx.doi.org/10.1016/S0140-6736(08)60742-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304IO	18502284				2022-12-28	WOS:000256103400010
J	Mazzone, T; Chait, A; Plutzky, J				Mazzone, Theodore; Chait, Alan; Plutzky, Jorge			Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies	LANCET			English	Review							LOW-DENSITY-LIPOPROTEIN; PROTEIN-KINASE-C; FACTOR-KAPPA-B; TRIGLYCERIDE-RICH LIPOPROTEINS; ADVANCED ATHEROSCLEROTIC LESIONS; REVERSE CHOLESTEROL TRANSPORT; GLYCATION END-PRODUCTS; NECROSIS-FACTOR-ALPHA; ENDOTHELIAL-CELLS; INSULIN-RESISTANCE	Individuals with type 2 diabetes mellitus have increased cardiovascular disease risk compared with those without diabetes. Treatment of the residual risk, other than blood pressure and LDL-cholesterol control, remains important as the rate of diabetes increases worldwide. The accelerated atherosclerosis and cardiovascular disease in diabetes is likely to be multifactorial and therefore several therapeutic approaches can be considered. Results of mechanistic studies done in vitro and in vivo-animals and people-can provide important insights with the potential to improve clinical management decisions and outcomes. in this Review, we focus on three areas in which pathophysiological. considerations could be particularly informative ie, the roles of hyperglycaemia, diabetic dyslipidaemia (other than the control of LDL-cholesterol concentrations), and inflammation (including that in adipose tissue) in the acceleration of vascular injury.	[Mazzone, Theodore] Univ Illinois, Sect Endocrinol Diabet & Metab, Dept Med, Chicago, IL 60612 USA; [Chait, Alan] Univ Washington, Dept Med, Seattle, WA 98195 USA; [Plutzky, Jorge] Harvard Univ, Sch Med, Dept Med, Brigham & Womens Hosp, Boston, MA USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Washington; University of Washington Seattle; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Mazzone, T (corresponding author), Univ Illinois, Sect Endocrinol Diabet & Metab, Dept Med, MC 797,1819 W Polk St, Chicago, IL 60612 USA.	tmazzone@uic.edu	Plutzky, Jorge/V-3410-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030086, R01HL071745, P01HL048743, R01HL039653, P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK071711, R01DK071711] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL018645-340022, P01 HL048743-160013, R01 HL039653, HL19645, R01 HL071745-04, R01 HL039653-17, R01 HL071745, HL30086, HL39653, HL48743, HL071745, P01 HL030086-250013, P01 HL048743, P01 HL030086, P01 HL018645] Funding Source: Medline; NIDDK NIH HHS [R01 DK071711, R01 DK071711-03, DK71711, R56 DK071711] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asztalos BF, 2005, J LIPID RES, V46, P2246, DOI 10.1194/jlr.M500187-JLR200; Back M, 2007, CIRC RES, V100, P946, DOI 10.1161/01.RES.0000264498.60702.0d; Balkau B, 2004, DIABETOLOGIA, V47, P2118, DOI 10.1007/s00125-004-1574-5; Bansal S, 2007, JAMA-J AM MED ASSOC, V298, P309, DOI 10.1001/jama.298.3.309; Barter PJ, 2007, NEW ENGL J MED, V357, P2109, DOI 10.1056/NEJMoa0706628; Barter PJ, 2004, CIRC RES, V95, P764, DOI 10.1161/01.RES.0000146094.59640.13; Berg AH, 2005, CIRC RES, V96, P939, DOI 10.1161/01.RES.0000163635.62927.34; Biddinger SB, 2006, ANNU REV PHYSIOL, V68, P123, DOI 10.1146/annurev.physiol.68.040104.124723; Brown JD, 2007, CIRCULATION, V115, P518, DOI 10.1161/CIRCULATIONAHA.104.475673; BROWNLEE M, 1985, DIABETES, V34, P938, DOI 10.2337/diabetes.34.9.938; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; BUCALA R, 1991, J CLIN INVEST, V87, P432, DOI 10.1172/JCI115014; Burke AP, 2004, ARTERIOSCL THROM VAS, V24, P1266, DOI 10.1161/01.ATV.0000131783.74034.97; Buse JB, 2007, AM J CARDIOL, V99, p21I, DOI 10.1016/j.amjcard.2007.03.003; Camici GG, 2007, P NATL ACAD SCI USA, V104, P5217, DOI 10.1073/pnas.0609656104; Carmody BJ, 2002, J VASC SURG, V36, P833, DOI 10.1067/mva.2002.127525; Carmody RJ, 2007, CELL MOL IMMUNOL, V4, P31; Chahil TJ, 2006, ENDOCRIN METAB CLIN, V35, P491, DOI 10.1016/j.ecl.2006.06.002; Chalmers J, 2001, DIABETOLOGIA, V44, P1118; Cipolletta C, 2005, DIABETES, V54, P2779, DOI 10.2337/diabetes.54.9.2779; Cohen Richard A, 2005, Am J Ther, V12, P499, DOI 10.1097/01.mjt.0000178776.77267.19; Colhoun HM, 2004, LANCET, V364, P685, DOI 10.1016/S0140-6736(04)16895-5; Collins R, 2003, LANCET, V361, P2005; Costa J, 2006, BMJ-BRIT MED J, V332, P1115, DOI 10.1136/bmj.38793.468449.AE; Cuchel M, 2006, CIRCULATION, V113, P2548, DOI 10.1161/CIRCULATIONAHA.104.475715; Dasu MR, 2007, AM J PHYSIOL-ENDOC M, V293, pE337, DOI 10.1152/ajpendo.00718.2006; Davi G, 1999, CIRCULATION, V99, P224; DAVIDSON M, IN PRESS CIRCULATION; De Pascale C, 2006, FEBS J, V273, P5632, DOI 10.1111/j.1742-4658.2006.05552.x; de Winther MPJ, 2005, ARTERIOSCL THROM VAS, V25, P904, DOI 10.1161/01.ATV.0000160340.72641.87; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; Deeg MA, 2007, DIABETES CARE, V30, P2458, DOI 10.2337/dc06-1903; Devaraj S, 2006, DIABETES, V55, P774, DOI 10.2337/diabetes.55.03.06.db05-1417; Devaraj S, 2008, J CLIN ENDOCR METAB, V93, P578, DOI 10.1210/jc.2007-2185; Dogne JM, 2005, TRENDS PHARMACOL SCI, V26, P639, DOI 10.1016/j.tips.2005.10.001; El Harchaoui K, 2007, J AM COLL CARDIOL, V49, P547, DOI 10.1016/j.jacc.2006.09.043; Fantuzzi G, 2007, ARTERIOSCL THROM VAS, V27, P996, DOI 10.1161/ATVBAHA.106.131755; Friedman JM, 2002, NUTR REV, V60, pS1, DOI 10.1301/002966402320634878; Gargalovic PS, 2006, ARTERIOSCL THROM VAS, V26, P2490, DOI 10.1161/01.ATV.0000242903.41158.a1; Garvey WT, 2003, DIABETES, V52, P453, DOI 10.2337/diabetes.52.2.453; Gerrity RG, 2001, DIABETES, V50, P1654, DOI 10.2337/diabetes.50.7.1654; Gharavi NM, 2007, ARTERIOSCL THROM VAS, V27, P1346, DOI 10.1161/ATVBAHA.107.141283; Goldberg IJ, 2001, J CLIN ENDOCR METAB, V86, P965, DOI 10.1210/jc.86.3.965; Gowri MS, 1999, ARTERIOSCL THROM VAS, V19, P2226, DOI 10.1161/01.ATV.19.9.2226; Gregor MF, 2007, J LIPID RES, V48, P1905, DOI 10.1194/jlr.R700007-JLR200; Han S, 2006, CELL METAB, V3, P257, DOI 10.1016/j.cmet.2006.02.008; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; HEICKENDORFF L, 1994, DIABETOLOGIA, V37, P286, DOI 10.1007/BF00398056; Hevener AL, 2007, J CLIN INVEST, V117, P1658, DOI 10.1172/JCI31561; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hoang A, 2007, DIABETOLOGIA, V50, P1770, DOI 10.1007/s00125-007-0718-9; Hoffmann A, 2006, IMMUNOL REV, V210, P171, DOI 10.1111/j.0105-2896.2006.00375.x; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Huang ZH, 2006, DIABETES, V55, P3394, DOI 10.2337/db06-0354; Hussein OA, 2007, CLIN CHIM ACTA, V377, P114, DOI 10.1016/j.cca.2006.09.002; Isoda K, 2007, ATHEROSCLEROSIS, V192, P298, DOI 10.1016/j.atherosclerosis.2006.07.023; Jiang R, 2004, DIABETES CARE, V27, P1991, DOI 10.2337/diacare.27.8.1991; Johansson F, 2008, P NATL ACAD SCI USA, V105, P2082, DOI 10.1073/pnas.0709958105; Kadowaki T, 2006, J CLIN INVEST, V116, P1784, DOI 10.1172/JCI29126; Kawakami A, 2005, ARTERIOSCL THROM VAS, V25, pE53; Kawamura M, 2000, J LIPID RES, V41, P1054; KAWAMURA M, 1994, J CLIN INVEST, V94, P771, DOI 10.1172/JCI117396; Kuller L, 2002, ARTERIOSCL THROM VAS, V22, P1175, DOI 10.1161/01.ATV.0000022015.97341.3A; KWAN CY, 1988, BIOCHIM BIOPHYS ACTA, V967, P322, DOI 10.1016/0304-4165(88)90027-X; Liang CP, 2007, CIRC RES, V100, P1546, DOI 10.1161/CIRCRESAHA.107.152165; Lin Y, 2005, J BIOL CHEM, V280, P4617, DOI 10.1074/jbc.M411863200; LOVE DC, 2005, SCI STKE, P13; Mazzone T, 2007, LANCET, V370, P107, DOI 10.1016/S0140-6736(07)61063-0; Mazzone T, 2006, JAMA-J AM MED ASSOC, V296, P2572, DOI 10.1001/jama.296.21.joc60158; McDonald TO, 2007, J HISTOCHEM CYTOCHEM, V55, P1149, DOI 10.1369/jhc.7A7221.2007; McSorley PT, 2004, METABOLISM, V53, P755, DOI 10.1016/j.metabol.2003.11.026; Mita T, 2007, BIOCHEM BIOPH RES CO, V358, P679, DOI 10.1016/j.bbrc.2007.04.118; Miyazaki A, 2002, TRENDS CARDIOVAS MED, V12, P258, DOI 10.1016/S1050-1738(02)00171-8; Mooradian AD, 2004, DIABETES, V53, P513, DOI 10.2337/diabetes.53.3.513; Moore RE, 2005, CIRC RES, V97, P763, DOI 10.1161/01.RES.0000185320.82962.F7; Mora S, 2007, ATHEROSCLEROSIS, V192, P211, DOI 10.1016/j.atherosclerosis.2006.05.007; Neels JG, 2006, J CLIN INVEST, V116, P33, DOI 10.1172/JCI27280; Nestel PJ, 2001, J AM COLL CARDIOL, V37, P1929, DOI 10.1016/S0735-1097(01)01251-7; Ng CJ, 2007, ARTERIOSCL THROM VAS, V27, P1368, DOI 10.1161/ATVBAHA.106.134189; Norata GD, 2005, CIRCULATION, V111, P2805, DOI 10.1161/CIRCULATIONAHA.104.472886; Nordestgaard BG, 2007, JAMA-J AM MED ASSOC, V298, P299, DOI 10.1001/jama.298.3.299; Odegaard JI, 2007, NATURE, V447, P1116, DOI 10.1038/nature05894; Ohgami Nobutaka, 2003, J Atheroscler Thromb, V10, P1; Omi H, 2003, MICROVASC RES, V65, P118, DOI 10.1016/S0026-2862(02)00033-X; Otsuka A, 2005, DIABETOLOGIA, V48, P2667, DOI 10.1007/s00125-005-0005-6; Otvos JD, 2006, CIRCULATION, V113, P1556, DOI 10.1161/CIRCULATIONAHA.105.565135; Palmer AM, 2005, ATHEROSCLEROSIS, V180, P233, DOI 10.1016/j.atherosclerosis.2004.12.038; Pennathur S, 2001, J CLIN INVEST, V107, P853, DOI 10.1172/JCI11194; Pennathur S, 2007, ANTIOXID REDOX SIGN, V9, P955, DOI 10.1089/ars.2007.1595; PFEIFLE B, 1980, ARTERY, V8, P336; Piga R, 2007, ATHEROSCLEROSIS, V193, P328, DOI 10.1016/j.atherosclerosis.2006.09.016; Quagliaro L, 2005, ATHEROSCLEROSIS, V183, P259, DOI 10.1016/j.atherosclerosis.2005.03.015; Ramana KV, 2004, DIABETES, V53, P2910, DOI 10.2337/diabetes.53.11.2910; Rask-Madsen C, 2005, ARTERIOSCL THROM VAS, V25, P487, DOI 10.1161/01.ATV.0000155325.41507.e0; Rask-Madsen C, 2007, NAT CLIN PRACT ENDOC, V3, P46, DOI 10.1038/ncpendmet0366; Renard CB, 2004, J CLIN INVEST, V114, P659, DOI 10.1172/JCI200417867; Rodriguez-Lee M, 2007, CURR OPIN LIPIDOL, V18, P546, DOI 10.1097/MOL.0b013e3282ef534f; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rong JX, 2001, CIRCULATION, V104, P2447, DOI 10.1161/hc4501.098952; RUDEL LL, 1995, AM J CLIN NUTR, V62, p463S, DOI 10.1093/ajcn/62.2.463S; Saraswathi V, 2006, J LIPID RES, V47, P1406, DOI 10.1194/jlr.M600159-JLR200; Sarov-Blat L, 2007, ARTERIOSCL THROM VAS, V27, P1115, DOI 10.1161/ATVBAHA.106.138990; Seki N, 2003, METABOLISM, V52, P1558, DOI 10.1016/j.metabol.2003.07.010; Sell H, 2007, CURR OPIN LIPIDOL, V18, P258, DOI 10.1097/MOL.0b013e3281338546; Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898; Shin HK, 2004, CIRCULATION, V109, P1022, DOI 10.1161/01.CIR.0000117403.64398.53; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; Sniderman AD, 2001, ANN INTERN MED, V135, P447, DOI 10.7326/0003-4819-135-6-200109180-00014; Stark R, 2007, EUR J CLIN INVEST, V37, P236, DOI 10.1111/j.1365-2362.2007.01773.x; Steinberg HO, 1997, J CLIN INVEST, V100, P1230, DOI 10.1172/JCI119636; Tabas I, 2007, CIRCULATION, V116, P1832, DOI 10.1161/CIRCULATIONAHA.106.676890; Theilmeier G, 2006, CIRCULATION, V114, P1403, DOI 10.1161/CIRCULATIONAHA.105.607135; Ting HJ, 2007, CIRC RES, V100, P381, DOI 10.1161/01.RES.0000258023.76515.a3; Tso C, 2006, ARTERIOSCL THROM VAS, V26, P1144, DOI 10.1161/01.ATV.0000216600.37436.cf; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Unger RH, 2008, JAMA-J AM MED ASSOC, V299, P1185, DOI 10.1001/jama.299.10.1185; Van Eck M, 2005, ATHEROSCLEROSIS, V183, P230, DOI 10.1016/j.atherosclerosis.2005.03.045; Van Gaal LF, 2006, NATURE, V444, P875, DOI 10.1038/nature05487; Venugopal SK, 2002, DIABETES, V51, P3049, DOI 10.2337/diabetes.51.10.3049; Wang YT, 2007, J LIPID RES, V48, P1062, DOI 10.1194/jlr.M600437-JLR200; Weisberg SP, 2006, J CLIN INVEST, V116, P115, DOI 10.1172/JCI24335; WellsKnecht MC, 1997, J CLIN INVEST, V100, P839, DOI 10.1172/JCI119599; Wu HZ, 2007, CIRCULATION, V115, P1029, DOI 10.1161/CIRCULATIONAHA.106.638379; Wu KK, 2007, ATHEROSCLEROSIS, V191, P241, DOI 10.1016/j.atherosclerosis.2006.08.030; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yue LL, 2004, J BIOL CHEM, V279, P47626, DOI 10.1074/jbc.M408461200; Ziouzenkova O, 2004, CURR OPIN CLIN NUTR, V7, P369, DOI 10.1097/01.mco.0000134358.46159.61; Ziouzenkova O, 2003, P NATL ACAD SCI USA, V100, P2730, DOI 10.1073/pnas.0538015100; Ziouzenkova O, 2007, NAT MED, V13, P695, DOI 10.1038/nm1587	130	391	424	0	45	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	2008	371	9626					1800	1809		10.1016/S0140-6736(08)60768-0	http://dx.doi.org/10.1016/S0140-6736(08)60768-0			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304IO	18502305	Green Accepted			2022-12-28	WOS:000256103400035
J	Hato, N; Murakami, S; Gyo, K				Hato, Naohito; Murakami, Shingo; Gyo, Kiyofumi			Steroid and antiviral treatment for Bell's palsy	LANCET			English	Editorial Material							HERPES-SIMPLEX-VIRUS; RAMSAY-HUNT-SYNDROME; ACYCLOVIR; PREDNISOLONE; DNA		[Hato, Naohito; Gyo, Kiyofumi] Ehime Univ, Sch Med, Dept Otolaryngol, Matsuyama, Ehime 7910295, Japan; [Murakami, Shingo] Nagoya City Univ Hosp, Dept Otolaryngol, Nagoya, Aichi, Japan	Ehime University; Nagoya City University	Hato, N (corresponding author), Ehime Univ, Sch Med, Dept Otolaryngol, Matsuyama, Ehime 7910295, Japan.	nhato@m.ehime-u.ac.jp						Abiko Y, 2002, OTOL NEUROTOL, V23, P779, DOI 10.1097/00129492-200209000-00028; Adour KK, 1996, ANN OTO RHINOL LARYN, V105, P371, DOI 10.1177/000348949610500508; ADOUR KK, 1994, ANN NEUROL, V35, P62; Allen D, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001869.PUB2; Furuta Y, 2001, J CLIN MICROBIOL, V39, P2856, DOI 10.1128/JCM.39.8.2856-2859.2001; Furuta Y, 1998, J MED VIROL, V54, P162, DOI 10.1002/(SICI)1096-9071(199803)54:3&lt;162::AID-JMV3&gt;3.0.CO;2-3; Gilden DH, 2007, NEW ENGL J MED, V357, P1653, DOI 10.1056/NEJMe078188; Grogan PM, 2001, NEUROLOGY, V56, P830, DOI 10.1212/WNL.56.7.830; Hato N, 2003, OTOL NEUROTOL, V24, P948, DOI 10.1097/00129492-200311000-00022; Hato N, 2007, OTOL NEUROTOL, V28, P408, DOI 10.1097/01.mao.0000265190.29969.12; Murakami S, 1997, ANN NEUROL, V41, P353, DOI 10.1002/ana.410410310; Murakami S, 1996, ANN INTERN MED, V124, P27, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00005; Sullivan FM, 2007, NEW ENGL J MED, V357, P1598, DOI 10.1056/NEJMoa072006	13	56	57	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY-JUN	2008	371	9627					1818	1820		10.1016/S0140-6736(08)60776-X	http://dx.doi.org/10.1016/S0140-6736(08)60776-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307NL	18514714				2022-12-28	WOS:000256325500007
J	Mikkelsen, TS; Hanna, J; Zhang, XL; Ku, MC; Wernig, M; Schorderet, P; Bernstein, BE; Jaenisch, R; Lander, ES; Meissner, A				Mikkelsen, Tarjei S.; Hanna, Jacob; Zhang, Xiaolan; Ku, Manching; Wernig, Marius; Schorderet, Patrick; Bernstein, Bradley E.; Jaenisch, Rudolf; Lander, Eric S.; Meissner, Alexander			Dissecting direct reprogramming through integrative genomic analysis	NATURE			English	Article							PLURIPOTENT STEM-CELLS; GENERATION; FIBROBLASTS; MOUSE; MYC; EXPRESSION; MICE	Somatic cells can be reprogrammed to a pluripotent state through the ectopic expression of defined transcription factors. Understanding the mechanism and kinetics of this transformation may shed light on the nature of developmental potency and suggest strategies with improved efficiency or safety. Here we report an integrative genomic analysis of reprogramming of mouse fibroblasts and B lymphocytes. Lineage- committed cells show a complex response to the ectopic expression involving induction of genes downstream of individual reprogramming factors. Fully reprogrammed cells show gene expression and epigenetic states that are highly similar to embryonic stem cells. In contrast, stable partially reprogrammed cell lines show reactivation of a distinctive subset of stem- cell- related genes, incomplete repression of lineage- specifying transcription factors, and DNA hypermethylation at pluripotency- related loci. These observations suggest that some cells may become trapped in partially reprogrammed states owing to incomplete repression of transcription factors, and that DNA de- methylation is an inefficient step in the transition to pluripotency. We demonstrate that RNA inhibition of transcription factors can facilitate reprogramming, and that treatment with DNA methyltransferase inhibitors can improve the overall efficiency of the reprogramming process.	[Mikkelsen, Tarjei S.; Zhang, Xiaolan; Bernstein, Bradley E.; Lander, Eric S.; Meissner, Alexander] MIT, Broad Inst, Cambridge, MA 02142 USA; [Mikkelsen, Tarjei S.; Zhang, Xiaolan; Bernstein, Bradley E.; Lander, Eric S.; Meissner, Alexander] Harvard Univ, Broad Inst, Cambridge, MA 02142 USA; [Mikkelsen, Tarjei S.] MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Jaenisch, Rudolf; Lander, Eric S.] MIT, Dept Biol, Cambridge, MA 02139 USA; [Hanna, Jacob; Wernig, Marius; Schorderet, Patrick; Jaenisch, Rudolf; Lander, Eric S.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Ku, Manching; Bernstein, Bradley E.] Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA; [Ku, Manching; Bernstein, Bradley E.] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA; [Bernstein, Bradley E.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Lander, Eric S.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02114 USA; [Meissner, Alexander] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University	Meissner, A (corresponding author), MIT, Broad Inst, 7 Cambridge Ctr, Cambridge, MA 02142 USA.	alex@broad.mit.edu	Mikkelsen, Tarjei S/A-1306-2007; jia, xu/A-8386-2016; Hanna, Jacob/K-1339-2012	Mikkelsen, Tarjei S/0000-0002-8133-3135; Hanna, Jacob/0000-0003-2042-9974	NHGRI NIH HHS [U54 HG003067-04, U54 HG003067] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG003067] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Aoi T, 2008, SCIENCE, V321, P699, DOI 10.1126/science.1154884; Beard C, 2006, GENESIS, V44, P23, DOI 10.1002/gene.20180; Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033; Brambrink T, 2008, CELL STEM CELL, V2, P151, DOI 10.1016/j.stem.2008.01.004; Gregory MA, 2005, CELL CYCLE, V4, P249; Hajkova P, 2008, NATURE, V452, P877, DOI 10.1038/nature06714; Hanna J, 2008, CELL, V133, P250, DOI 10.1016/j.cell.2008.03.028; Imamura M, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-34; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jaenisch R, 2008, CELL, V132, P567, DOI 10.1016/j.cell.2008.01.015; Lei H, 1996, DEVELOPMENT, V122, P3195; Lim LS, 2007, MOL BIOL CELL, V18, P1348, DOI 10.1091/mbc.E06-07-0624; Lowry WE, 2008, P NATL ACAD SCI USA, V105, P2883, DOI 10.1073/pnas.0711983105; Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014; Meissner A, 2005, NUCLEIC ACIDS RES, V33, P5868, DOI 10.1093/nar/gki901; MEISSNER A, IN PRESS NATURE; Meissner A, 2007, NAT BIOTECHNOL, V25, P1177, DOI 10.1038/nbt1335; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Orford KW, 2008, NAT REV GENET, V9, P115, DOI 10.1038/nrg2269; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Rideout WM, 2000, NAT GENET, V24, P109, DOI 10.1038/72753; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; Silva J, 2008, CELL, V132, P532, DOI 10.1016/j.cell.2008.02.006; Singh AM, 2007, STEM CELLS, V25, P2534, DOI 10.1634/stemcells.2007-0126; Stadtfeld M, 2008, CELL STEM CELL, V2, P230, DOI 10.1016/j.stem.2008.02.001; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Yamanaka S, 2007, CELL STEM CELL, V1, P39, DOI 10.1016/j.stem.2007.05.012; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526	33	1089	1184	0	100	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	2008	454	7200					49	U1		10.1038/nature07056	http://dx.doi.org/10.1038/nature07056			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	321MC	18509334	Green Accepted			2022-12-28	WOS:000257308300033
J	Palevsky, PM; Zhang, JHY; O'Connor, TZ; Chertow, GM; Crowley, ST; Choudhury, D; Finkel, K; Kellum, JA; Paganini, E; Schein, RMH; Smith, MW; Swanson, KM; Thompson, BT; Vijayan, A; Watnick, S; Star, RA; Peduzzi, P				Palevsky, Paul M.; Zhang, Jane Hongyuan; O'Connor, Theresa Z.; Chertow, Glenn M.; Crowley, Susan T.; Choudhury, Devasmita; Finkel, Kevin; Kellum, John A.; Paganini, Emil; Schein, Roland M. H.; Smith, Mark W.; Swanson, Kathleen M.; Thompson, B. Taylor; Vijayan, Anitha; Watnick, Suzanne; Star, Robert A.; Peduzzi, Peter		VA NIH Acute Renal Failure Trial	Intensity of renal support in critically ill patients with acute kidney injury	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTINUOUS VENOVENOUS HEMOFILTRATION; REPLACEMENT THERAPY; CARE-UNIT; FAILURE; MANAGEMENT; MORTALITY; SURVIVAL; OUTCOMES	Background: The optimal intensity of renal-replacement therapy in critically ill patients with acute kidney injury is controversial. Methods: We randomly assigned critically ill patients with acute kidney injury and failure of at least one nonrenal organ or sepsis to receive intensive or less intensive renal-replacement therapy. The primary end point was death from any cause by day 60. In both study groups, hemodynamically stable patients underwent intermittent hemodialysis, and hemodynamically unstable patients underwent continuous venovenous hemodiafiltration or sustained low-efficiency dialysis. Patients receiving the intensive treatment strategy underwent intermittent hemodialysis and sustained low-efficiency dialysis six times per week and continuous venovenous hemodiafiltration at 35 ml per kilogram of body weight per hour; for patients receiving the less-intensive treatment strategy, the corresponding treatments were provided thrice weekly and at 20 ml per kilogram per hour. Results: Baseline characteristics of the 1124 patients in the two groups were similar. The rate of death from any cause by day 60 was 53.6% with intensive therapy and 51.5% with less-intensive therapy (odds ratio, 1.09; 95% confidence interval, 0.86 to 1.40; P=0.47). There was no significant difference between the two groups in the duration of renal-replacement therapy or the rate of recovery of kidney function or nonrenal organ failure. Hypotension during intermittent dialysis occurred in more patients randomly assigned to receive intensive therapy, although the frequency of hemodialysis sessions complicated by hypotension was similar in the two groups. Conclusions: Intensive renal support in critically ill patients with acute kidney injury did not decrease mortality, improve recovery of kidney function, or reduce the rate of nonrenal organ failure as compared with less-intensive therapy involving a defined dose of intermittent hemodialysis three times per week and continuous renal-replacement therapy at 20 ml per kilogram per hour. (ClinicalTrials.gov number, NCT00076219.).	[Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA; [Chertow, Glenn M.] Stanford Univ, Palo Alto, CA 94304 USA; [Zhang, Jane Hongyuan; O'Connor, Theresa Z.; Crowley, Susan T.; Peduzzi, Peter] VA Connecticut Healthcare Syst, CSP Coordinating Ctr, West Haven, CT USA; [Choudhury, Devasmita] VA N Texas Healthcare Syst, Dallas, TX USA; [Kellum, John A.] Univ Pittsburgh, Pittsburgh, PA USA; [Paganini, Emil] Cleveland Clin Fdn, Cleveland, OH 44195 USA; [Schein, Roland M. H.] Miami VA Healthcare Syst, Miami, FL USA; [Smith, Mark W.] VA Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, Menlo Pk, CA USA; [Swanson, Kathleen M.] Clin Res Pharm Coordinating Ctr, CSP, Albuquerque, NM USA; [Thompson, B. Taylor] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Star, Robert A.] NIDDK, Bethesda, MD 20892 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA North Texas Health Care System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Cleveland Clinic Foundation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Palevsky, PM (corresponding author), VA Pittsburgh Healthcare Syst, Rm 7E123 111F-U,Univ Dr, Pittsburgh, PA 15240 USA.	palevsky@pitt.edu	Kellum, John/AAP-3072-2020; Palevsky, Paul M./Q-1491-2019; Smith, Mark W/G-1522-2012; Kellum, John A/HCH-2944-2022; Macedo, Etienne/D-4659-2012	Kellum, John/0000-0003-1995-2653; Palevsky, Paul M./0000-0002-7334-5400; Smith, Mark W/0000-0002-4582-9088; Kellum, John A/0000-0003-1995-2653; Chertow, Glenn/0000-0002-7599-0534; Macedo, Etienne/0000-0002-3669-6519; Hurtado, Abdias/0000-0001-8850-7903; Sajgure, Atul/0000-0003-1746-9801; O'LEARY, TIMOTHY/0000-0002-2435-9136; Connors, Alfred F./0000-0001-7123-3360	NIDDK NIH HHS [Y01 DK003508-01, Y1-DK-3508-01, Y01 DK003508-03, Y01 DK003508, Y01 DK003508-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK043403] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bagshaw SM, 2008, NEPHROL DIAL TRANSPL, V23, P1203, DOI 10.1093/ndt/gfm744; Bouman CSC, 2002, CRIT CARE MED, V30, P2205, DOI 10.1097/00003246-200210000-00005; CROWLEY S, IN PRESS CLIN J AM S; de Mendonca A, 2000, INTENS CARE MED, V26, P915, DOI 10.1007/s001340051281; Gibney N, 2008, CLIN J AM SOC NEPHRO, V3, P876, DOI 10.2215/CJN.04871107; KOLFF WJ, 1965, ANN INTERN MED, V62, P608, DOI 10.7326/0003-4819-62-3-608; LAKATOS E, 1988, BIOMETRICS, V44, P923; Liangos O, 2006, CLIN J AM SOC NEPHRO, V1, P43, DOI 10.2215/CJN.00220605; Liano F, 1998, KIDNEY INT, V53, pS16; McCarthy JT, 1996, MAYO CLIN PROC, V71, P117, DOI 10.4065/71.2.117; Mehta RL, 2004, KIDNEY INT, V66, P1613, DOI 10.1111/j.1523-1755.2004.00927.x; Metnitz PGH, 2002, CRIT CARE MED, V30, P2051, DOI 10.1097/00003246-200209000-00016; Nash K, 2002, AM J KIDNEY DIS, V39, P930, DOI 10.1053/ajkd.2002.32766; Ostermann M, 2007, CRIT CARE MED, V35, P1837, DOI 10.1097/01.CCM.0000277041.13090.0A; Overberger P, 2007, CLIN J AM SOC NEPHRO, V2, P623, DOI 10.2215/CJN.00780207; Palevsky PM, 2005, CLIN TRIALS, V2, P423, DOI 10.1191/1740774505cn116oa; PALEVSKY PM, 2005, J AM SOC NEPHROL, V16, pA910; Pannu N, 2008, JAMA-J AM MED ASSOC, V299, P793, DOI 10.1001/jama.299.7.793; Ronco C, 2000, LANCET, V356, P26, DOI 10.1016/S0140-6736(00)02430-2; Rondon-Berrios H, 2007, CURR OPIN NEPHROL HY, V16, P64, DOI 10.1097/MNH.0b013e32802ef4a5; Saudan P, 2006, KIDNEY INT, V70, P1312, DOI 10.1038/sj.ki.5001705; Schiffl H, 2002, NEW ENGL J MED, V346, P305, DOI 10.1056/NEJMoa010877; Star RA, 1998, KIDNEY INT, V54, P1817, DOI 10.1046/j.1523-1755.1998.00210.x; TOLWANI AJ, IN PRESS J AM SOC NE; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; Uchino S, 2003, NEPHRON CLIN PRACT, V94, pC94, DOI 10.1159/000072492; Venkataraman R, 2002, J CRIT CARE, V17, P246, DOI 10.1053/jcrc.2002.36757; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156; Waikar SS, 2006, J AM SOC NEPHROL, V17, P1143, DOI 10.1681/ASN.2005091017; Xue JL, 2006, J AM SOC NEPHROL, V17, P1135, DOI 10.1681/ASN.2005060668	30	1111	1180	1	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 3	2008	359	1					7	20						14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320PB	18492867	Green Accepted, Bronze			2022-12-28	WOS:000257246000003
J	Kovacs, JJ; Whalen, EJ; Liu, RS; Xiao, KH; Kim, J; Chen, MY; Wang, JB; Chen, W; Lefkowitz, RJ				Kovacs, Jeffrey J.; Whalen, Erin J.; Liu, Renshui; Xiao, Kunhong; Kim, Jihee; Chen, Minyong; Wang, Jiangbo; Chen, Wei; Lefkowitz, Robert J.			beta-arrestin-mediated localization of smoothened to the primary cilium	SCIENCE			English	Article							HEDGEHOG SIGNALING PATHWAY; NEURONAL CILIA; RECEPTORS; TRANSPORT; PROTEIN; MOUSE; KINESIN-2; SMO	beta-arrestins have important roles in the regulation of seven- transmembrane receptors ( 7TMRs). Smoothened ( Smo) is a 7TMR that mediates effects of Hedgehog on developmental processes and whose dysregulation may cause tumorigenesis. beta-Arrestins are required for endocytosis of Smo and signaling to Gli transcription factors. In mammalian cells, Smo- dependent signaling requires translocation to primary cilia. We demonstrated that beta- arrestins mediate the activity- dependent interaction of Smo and the kinesin motor protein Kif3A. This multimeric complex localized to primary cilia and was disrupted in cells transfected with beta- arrestin small interfering RNA. beta- Arrestin 1 or beta- arrestin 2 depletion prevented the localization of Smo to primary cilia and the Smo- dependent activation of Gli. These results suggest roles for beta- arrestins in mediating the intracellular transport of a 7TMR to its obligate subcellular location for signaling.	[Kovacs, Jeffrey J.; Whalen, Erin J.; Liu, Renshui; Kim, Jihee; Chen, Minyong; Wang, Jiangbo; Chen, Wei; Lefkowitz, Robert J.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Kovacs, Jeffrey J.; Lefkowitz, Robert J.] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA; [Xiao, Kunhong; Lefkowitz, Robert J.] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; [Lefkowitz, Robert J.] Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Howard Hughes Medical Institute	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu	Xiao, Kunhong/AAG-4275-2020; Lefkowitz, Robert/AAW-2649-2021; Wang, Jiangbo/F-9246-2011	Xiao, Kunhong/0000-0002-1069-1226; Chen, Wei/0000-0002-9934-4000	NATIONAL CANCER INSTITUTE [R01CA113656] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R01HL070631, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007217] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [R01 CA113656-02, R01 CA113656-03, 5R01 CA113656-02, R01 CA113656] Funding Source: Medline; NHLBI NIH HHS [R01 HL016037, R01 HL070631, HL70631, R01 HL070631-04, R01 HL016037-35, HL16037] Funding Source: Medline; NIAID NIH HHS [T32 AI007217-26, T32 AI007217-25, T32 AI007217, 5T32 AI007217-25] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brailov I, 2000, BRAIN RES, V872, P271, DOI 10.1016/S0006-8993(00)02519-1; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Evangelista M, 2006, CLIN CANCER RES, V12, P5924, DOI 10.1158/1078-0432.CCR-06-1736; Handel M, 1999, NEUROSCIENCE, V89, P909, DOI 10.1016/S0306-4522(98)00354-6; Haycraft CJ, 2005, PLOS GENET, V1, P480, DOI 10.1371/journal.pgen.0010053; Hirokawa N, 2000, TRAFFIC, V1, P29, DOI 10.1034/j.1600-0854.2000.010105.x; Huangfu D, 2005, P NATL ACAD SCI USA, V102, P11325, DOI 10.1073/pnas.0505328102; Huangfu D, 2006, DEVELOPMENT, V133, P3, DOI 10.1242/dev.02169; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; Kolpakova-Hart E, 2007, DEV BIOL, V309, P273, DOI 10.1016/j.ydbio.2007.07.018; Koyama E, 2007, DEVELOPMENT, V134, P2159, DOI 10.1242/dev.001586; Lefkowitz RJ, 2004, CURR OPIN CELL BIOL, V16, P162, DOI 10.1016/j.ceb.2004.01.001; Lefkowitz RJ, 2006, MOL CELL, V24, P643, DOI 10.1016/j.molcel.2006.11.007; Mans DA, 2008, EXP CELL RES, V314, P1229, DOI 10.1016/j.yexcr.2007.12.020; Marszalek JR, 2000, CELL, V102, P175, DOI 10.1016/S0092-8674(00)00023-4; May SR, 2005, DEV BIOL, V287, P378, DOI 10.1016/j.ydbio.2005.08.050; Meloni AR, 2006, MOL CELL BIOL, V26, P7550, DOI 10.1128/MCB.00546-06; Rohatgi R, 2007, SCIENCE, V317, P372, DOI 10.1126/science.1139740; Satir P, 2007, ANNU REV PHYSIOL, V69, P377, DOI 10.1146/annurev.physiol.69.040705.141236; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Wang Y, 2007, CURR OPIN CELL BIOL, V19, P159, DOI 10.1016/j.ceb.2007.02.005; Wilbanks AM, 2004, SCIENCE, V306, P2264, DOI 10.1126/science.1104193; Woost PG, 2006, IN VITRO CELL DEV-AN, V42, P189; Xiao K, 2007, P NATL ACAD SCI USA, V104, P12011, DOI 10.1073/pnas.0704849104	24	203	209	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 27	2008	320	5884					1777	1781		10.1126/science.1157983	http://dx.doi.org/10.1126/science.1157983			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318VP	18497258	Green Accepted			2022-12-28	WOS:000257121200039
J	Wendt, S; Sprunger, PT; Lira, E; Madsen, GKH; Li, ZS; Hansen, JO; Matthiesen, J; Blekinge-Rasmussen, A; Laegsgaard, E; Hammer, B; Besenbacher, F				Wendt, Stefan; Sprunger, Phillip T.; Lira, Estephania; Madsen, Georg K. H.; Li, Zheshen; Hansen, Jonas O.; Matthiesen, Jesper; Blekinge-Rasmussen, Asger; Laegsgaard, Erik; Hammer, Bjork; Besenbacher, Flemming			The role of interstitial sites in the Ti3d defect state in the band gap of Titania	SCIENCE			English	Article							SCANNING-TUNNELING-MICROSCOPY; DENSITY-FUNCTIONAL THEORY; DEFICIENT RUTILE TIO2-X; OXIDIZED TIO2(110); MOLECULAR-OXYGEN; SURFACE SCIENCE; OH GROUPS; O-2; DISSOCIATION; METAL	Titanium dioxide ( TiO2) has a number of uses in catalysis, photochemistry, and sensing that are linked to the reducibility of the oxide. Usually, bridging oxygen ( O-br) vacancies are assumed to cause the Ti3d defect state in the band gap of rutile TiO2( 110). From high- resolution scanning tunneling microscopy and photoelectron spectroscopy measurements, we propose that Ti interstitials in the near- surface region may be largely responsible for the defect state in the band gap. We argue that these donor- specific sites play a key role in and may dictate the ensuing surface chemistry, such as providing the electronic charge required for O-2 adsorption and dissociation. Specifically, we identified a second O-2 dissociation channel that occurs within the Ti troughs in addition to the O-2 dissociation channel in O-br vacancies. Comprehensive density functional theory calculations support these experimental observations.	[Wendt, Stefan; Sprunger, Phillip T.; Lira, Estephania; Madsen, Georg K. H.; Li, Zheshen; Hansen, Jonas O.; Matthiesen, Jesper; Blekinge-Rasmussen, Asger; Laegsgaard, Erik; Hammer, Bjork; Besenbacher, Flemming] Aarhus Univ, Interdisciplinary Nanosci Ctr iNANO, Dept Phys & Astron, DK-8000 Aarhus C, Denmark; [Sprunger, Phillip T.] Louisiana State Univ, Dept Phys & Astron, Baton Rouge, LA 70808 USA	Aarhus University; Louisiana State University System; Louisiana State University	Hammer, B (corresponding author), Aarhus Univ, Interdisciplinary Nanosci Ctr iNANO, Dept Phys & Astron, DK-8000 Aarhus C, Denmark.	hammer@phys.au.dk; fbe@inano.dk	Matthiesen, Jesper/N-2477-2014; Hammer, Bjørk/C-3701-2013; Besenbacher, Flemming/A-9623-2010; Li, Zheshen/P-6639-2017	Matthiesen, Jesper/0000-0003-1040-1919; Hammer, Bjørk/0000-0002-7849-6347; Li, Zheshen/0000-0002-8381-1620				AONO M, 1993, PHYS REV B, V48, P12406, DOI 10.1103/PhysRevB.48.12406; Attwood AL, 2003, RES CHEM INTERMEDIAT, V29, P449, DOI 10.1163/156856703322148991; Bennett RA, 1999, PHYS REV LETT, V82, P3831, DOI 10.1103/PhysRevLett.82.3831; Bikondoa O, 2006, NAT MATER, V5, P189, DOI 10.1038/nmat1592; Chambers SA, 2007, CHEM PHYS, V339, P27, DOI 10.1016/j.chemphys.2007.04.024; Chen M, 2006, J AM CHEM SOC, V128, P6341, DOI 10.1021/ja0557536; Cho E, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.193202; Di Valentin C, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.166803; Diebold U, 2003, SURF SCI REP, V48, P53, DOI 10.1016/S0167-5729(02)00100-0; Dohnalek Z, 2006, J PHYS CHEM B, V110, P6229, DOI 10.1021/jp0564905; Epling WS, 1998, SURF SCI, V412-13, P333, DOI 10.1016/S0039-6028(98)00446-4; Finetti P, 2007, J PHYS CHEM C, V111, P869, DOI 10.1021/jp064883d; Ganduglia-Pirovano MV, 2007, SURF SCI REP, V62, P219, DOI 10.1016/j.surfrep.2007.03.002; GHOSH AK, 1969, PHYS REV, V184, P979, DOI 10.1103/PhysRev.184.979; HARUTA M, 1987, CHEM LETT, P405, DOI 10.1246/cl.1987.405; Henderson MA, 2003, J AM CHEM SOC, V125, P14974, DOI 10.1021/ja037764+; Henderson MA, 1999, J PHYS CHEM B, V103, P5328, DOI 10.1021/jp990655q; Henderson MA, 1999, SURF SCI, V419, P174, DOI 10.1016/S0039-6028(98)00778-X; Henderson MA, 2003, J PHYS CHEM B, V107, P534, DOI 10.1021/jp0262113; Henrich V.E., 1996, SURFACE SCI METAL OX; HENRICH VE, 1976, PHYS REV LETT, V36, P1335, DOI 10.1103/PhysRevLett.36.1335; Iddir H, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.073203; Krischok S, 2005, SURF INTERFACE ANAL, V37, P77, DOI 10.1002/sia.2013; Kruger P, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.055501; KURTZ RL, 1989, SURF SCI, V218, P178, DOI 10.1016/0039-6028(89)90626-2; Lauritsen JV, 2006, NANOTECHNOLOGY, V17, P3436, DOI 10.1088/0957-4484/17/14/015; Li M, 1999, SURF SCI, V437, P173, DOI 10.1016/S0039-6028(99)00720-7; Li M, 2000, J PHYS CHEM B, V104, P4944, DOI 10.1021/jp9943272; Liu LM, 2006, J AM CHEM SOC, V128, P4017, DOI 10.1021/ja056801p; Matthey D, 2007, SCIENCE, V315, P1692, DOI 10.1126/science.1135752; Onishi H, 1996, PHYS REV LETT, V76, P791, DOI 10.1103/PhysRevLett.76.791; Park KT, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.245415; Rasmussen MD, 2004, J CHEM PHYS, V120, P988, DOI 10.1063/1.1631922; Reyren N, 2007, SCIENCE, V317, P1196, DOI 10.1126/science.1146006; Thomas AG, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.035105; Thompson TL, 2006, CHEM REV, V106, P4428, DOI 10.1021/cr050172k; Valden M, 1998, SCIENCE, V281, P1647, DOI 10.1126/science.281.5383.1647; Wendt S, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.066107; Wendt S, 2005, SURF SCI, V598, P226, DOI 10.1016/j.susc.2005.08.041; Woicik JC, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.077401; Yagi E, 1996, PHYS REV B, V54, P7945, DOI 10.1103/PhysRevB.54.7945; Zhang Z, 2006, J PHYS CHEM B, V110, P21840, DOI 10.1021/jp063619h	42	729	732	10	519	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 27	2008	320	5884					1755	1759		10.1126/science.1159846	http://dx.doi.org/10.1126/science.1159846			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318VP	18535207				2022-12-28	WOS:000257121200033
J	Joh, NH; Min, A; Faham, S; Whitelegge, JP; Yang, D; Woods, VL; Bowie, JU				Joh, Nathan HyunJoong; Min, Andrew; Faham, Salem; Whitelegge, Julian P.; Yang, Duan; Woods, Virgil L., Jr.; Bowie, James U.			Modest stabilization by most hydrogen-bonded side-chain interactions in membrane proteins	NATURE			English	Article							EXCHANGE MASS-SPECTROMETRY; TRANSMEMBRANE HELICES; CRYSTAL-STRUCTURE; POLAR RESIDUES; STABILITY; MUTATIONS; NMR; BACTERIORHODOPSIN; ASSOCIATION; RESOLUTION	Understanding the energetics of molecular interactions is fundamental to all of the central quests of structural biology including structure prediction and design, mapping evolutionary pathways, learning how mutations cause disease, drug design, and relating structure to function. Hydrogen- bonding is widely regarded as an important force in a membrane environment because of the low dielectric constant of membranes and a lack of competition from water(1-6). Indeed, polar residue substitutions are the most common disease- causing mutations in membrane proteins(6,7). Because of limited structural information and technical challenges, however, there have been few quantitative tests of hydrogen- bond strength in the context of large membrane proteins. Here we show, by using a double- mutant cycle analysis, that the average contribution of eight interhelical side- chain hydrogen- bonding interactions throughout bacteriorhodopsin is only 0.6 kcal mol(-1). In agreement with these experiments, we find that 4% of polar atoms in the non- polar core regions of membrane proteins have no hydrogen- bond partner and the lengths of buried hydrogen bonds in soluble proteins and membrane protein transmembrane regions are statistically identical. Our results indicate that most hydrogen- bond interactions in membrane proteins are only modestly stabilizing. Weak hydrogen-bonding should be reflected in considerations of membrane protein folding, dynamics, design, evolution and function.	[Joh, Nathan HyunJoong; Min, Andrew; Yang, Duan; Bowie, James U.] Univ Calif Los Angeles, Inst Mol Biol, Dept Chem & Biochem, UCLA DOE Ctr Genom & Proteom, Los Angeles, CA 90095 USA; [Faham, Salem] Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90095 USA; [Whitelegge, Julian P.] Univ Calif Los Angeles, NPI Semel Inst, Pasarow Mass Spec Lab, Los Angeles, CA 90095 USA; [Woods, Virgil L., Jr.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Woods, Virgil L., Jr.] Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA	United States Department of Energy (DOE); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California San Diego; University of California System; University of California San Diego	Bowie, JU (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Dept Chem & Biochem, UCLA DOE Ctr Genom & Proteom, Los Angeles, CA 90095 USA.	bowie@mbi.ucla.edu		Joh, Nathan/0000-0003-3221-9325	NATIONAL CANCER INSTITUTE [R01CA081000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063919] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA081000, R01 CA081000-08, R01 CA081000-09, R01 CA081000-07] Funding Source: Medline; NIGMS NIH HHS [R01 GM063919, R01 GM063919-06, R01 GM063919-07, R01 GM063919-08] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamian L, 2005, PROTEINS, V59, P496, DOI 10.1002/prot.20456; Adamian L, 2002, PROTEINS, V47, P209, DOI 10.1002/prot.10071; Andrade SLA, 2005, P NATL ACAD SCI USA, V102, P14994, DOI 10.1073/pnas.0506254102; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Busenlehner LS, 2005, ARCH BIOCHEM BIOPHYS, V433, P34, DOI 10.1016/j.abb.2004.09.002; Busenlehner LS, 2004, BIOCHEMISTRY-US, V43, P11145, DOI 10.1021/bi048716k; Call ME, 2006, CELL, V127, P355, DOI 10.1016/j.cell.2006.08.044; Chamberlain AK, 2004, J MOL BIOL, V339, P471, DOI 10.1016/j.jmb.2004.03.072; Duong MT, 2007, J MOL BIOL, V371, P422, DOI 10.1016/j.jmb.2007.05.026; Faham S, 2004, J MOL BIOL, V335, P297, DOI 10.1016/j.jmb.2003.10.041; Faham S, 2002, J MOL BIOL, V316, P1, DOI 10.1006/jmbi.2001.5295; FERSHT AR, 1992, J MOL BIOL, V224, P771, DOI 10.1016/0022-2836(92)90561-W; Fleming KG, 2001, P NATL ACAD SCI USA, V98, P14340, DOI 10.1073/pnas.251367498; Fleming PJ, 2005, PROTEIN SCI, V14, P1911, DOI 10.1110/ps.051454805; Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880; Hamuro Y, 2003, J MOL BIOL, V327, P1065, DOI 10.1016/S0022-2836(03)00234-1; Hong H, 2006, NAT CHEM BIOL, V2, P627, DOI 10.1038/nchembio827; Jormakka M, 2002, SCIENCE, V295, P1863, DOI 10.1126/science.1068186; Khademi S, 2004, SCIENCE, V305, P1587, DOI 10.1126/science.1101952; Lear JD, 2003, BIOCHEMISTRY-US, V42, P6400, DOI 10.1021/bi020573j; Lees AM, 2005, ATHEROSCLEROSIS, V182, P219, DOI 10.1016/j.atherosclerosis.2005.01.041; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MOLDAY RS, 1972, BIOCHEMISTRY-US, V11, P150, DOI 10.1021/bi00752a003; Myers JK, 1996, BIOPHYS J, V71, P2033, DOI 10.1016/S0006-3495(96)79401-8; ONEIL JDJ, 1989, BIOCHEMISTRY-US, V28, P699, DOI 10.1021/bi00428a043; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Partridge AW, 2004, PROTEINS, V54, P648, DOI 10.1002/prot.10611; Partridge AW, 2002, BIOPOLYMERS, V66, P350, DOI 10.1002/bip.10313; Popot JL, 2000, ANNU REV BIOCHEM, V69, P881, DOI 10.1146/annurev.biochem.69.1.881; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; Rosenbaum DM, 2007, SCIENCE, V318, P1266, DOI 10.1126/science.1150609; Senes A, 2004, CURR OPIN STRUC BIOL, V14, P465, DOI 10.1016/j.sbi.2004.07.007; Shan SO, 1999, METHOD ENZYMOL, V308, P246; Stanley AM, 2007, J MOL BIOL, V370, P912, DOI 10.1016/j.jmb.2007.05.009; White SH, 2005, ADV PROTEIN CHEM, V72, P157, DOI 10.1016/S0065-3233(05)72006-4; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Zhang ZQ, 1998, J AM SOC MASS SPECTR, V9, P225, DOI 10.1016/S1044-0305(97)00284-5; Zhang ZQ, 1997, PROTEIN SCI, V6, P2203; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698	40	200	203	3	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 26	2008	453	7199					1266	U73		10.1038/nature06977	http://dx.doi.org/10.1038/nature06977			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318FA	18500332	Green Accepted			2022-12-28	WOS:000257075800049
J	Velliste, M; Perel, S; Spalding, MC; Whitford, AS; Schwartz, AB				Velliste, Meel; Perel, Sagi; Spalding, M. Chance; Whitford, Andrew S.; Schwartz, Andrew B.			Cortical control of a prosthetic arm for self-feeding	NATURE			English	Article							POPULATION REPRESENTATION; DRAWING MOVEMENTS; COMPUTER; NEURONS; RESTORATION; INTERFACES; DIRECTION; SIGNALS	Arm movement is well represented in populations of neurons recorded from the motor cortex(1-7). Cortical activity patterns have been used in the new field of brain-machine interfaces(8-11) to show how cursors on computer displays can be moved in two- and three-dimensional space(12-22). Although the ability to move a cursor can be useful in its own right, this technology could be applied to restore arm and hand function for amputees and paralysed persons. However, the use of cortical signals to control a multi-jointed prosthetic device for direct real-time interaction with the physical environment ('embodiment') has not been demonstrated. Here we describe a system that permits embodied prosthetic control; we show how monkeys (Macaca mulatta) use their motor cortical activity to control a mechanized arm replica in a self-feeding task. In addition to the three dimensions of movement, the subjects' cortical signals also proportionally controlled a gripper on the end of the arm. Owing to the physical interaction between the monkey, the robotic arm and objects in the workspace, this new task presented a higher level of difficulty than previous virtual (cursor-control) experiments. Apart from an example of simple one-dimensional control(23), previous experiments have lacked physical interaction even in cases where a robotic arm(16,19,24) or hand(20) was included in the control loop, because the subjects did not use it to interact with physical objects - an interaction that cannot be fully simulated. This demonstration of multi-degree-of-freedom embodied prosthetic control paves the way towards the development of dexterous prosthetic devices that could ultimately achieve arm and hand function at a near-natural level.	[Velliste, Meel; Schwartz, Andrew B.] Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15213 USA; [Perel, Sagi; Spalding, M. Chance; Whitford, Andrew S.; Schwartz, Andrew B.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15261 USA; [Perel, Sagi; Spalding, M. Chance; Whitford, Andrew S.; Schwartz, Andrew B.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA; [Perel, Sagi; Spalding, M. Chance; Whitford, Andrew S.; Schwartz, Andrew B.] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA; [Schwartz, Andrew B.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Schwartz, Andrew B.] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15219 USA; [Schwartz, Andrew B.] Carnegie Mellon Univ, Inst Robot, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University	Schwartz, AB (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurobiol, E1440 BST,Lothrop St, Pittsburgh, PA 15213 USA.	abs21@pitt.edu			NINDS NIH HHS [NS050256] Funding Source: Medline; PHS HHS [N01-2-2346] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050256] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brockwell AE, 2004, J NEUROPHYSIOL, V91, P1899, DOI 10.1152/jn.00438.2003; Carmena JM, 2003, PLOS BIOL, V1, P193, DOI 10.1371/journal.pbio.0000042; Chapin JK, 1999, NAT NEUROSCI, V2, P664, DOI 10.1038/10223; Georgopoulos A. P., 1984, DYNAMIC ASPECTS NEOC, P501; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; Hochberg LR, 2006, NATURE, V442, P164, DOI 10.1038/nature04970; Kennedy PR, 2000, IEEE T REHABIL ENG, V8, P198, DOI 10.1109/86.847815; Kennedy PR, 1998, NEUROREPORT, V9, P1707, DOI 10.1097/00001756-199806010-00007; Lebedev MA, 2005, J NEUROSCI, V25, P4681, DOI 10.1523/JNEUROSCI.4088-04.2005; Leuthardt EC, 2006, NEUROSURGERY, V59, P1, DOI 10.1227/01.NEU.0000221506.06947.AC; Moran DW, 1999, J NEUROPHYSIOL, V82, P2693, DOI 10.1152/jn.1999.82.5.2693; Moran DW, 1999, J NEUROPHYSIOL, V82, P2676, DOI 10.1152/jn.1999.82.5.2676; MORASSO P, 1981, EXP BRAIN RES, V42, P223; Musallam S, 2004, SCIENCE, V305, P258, DOI 10.1126/science.1097938; Sanchez JC, 2005, IEEE T NEUR SYS REH, V13, P213, DOI 10.1109/TNSRE.2005.847382; Santhanam G, 2006, NATURE, V442, P195, DOI 10.1038/nature04968; Schwartz AB, 1999, J NEUROPHYSIOL, V82, P2705, DOI 10.1152/jn.1999.82.5.2705; Schwartz AB, 2004, ANNU REV NEUROSCI, V27, P487, DOI 10.1146/annurev.neuro.27.070203.144233; Schwartz AB, 2001, CURR OPIN NEUROBIOL, V11, P701, DOI 10.1016/S0959-4388(01)00272-0; SCHWARTZ AB, 1994, SCIENCE, V265, P540, DOI 10.1126/science.8036499; Schwartz AB, 2006, NEURON, V52, P205, DOI 10.1016/j.neuron.2006.09.019; Serruya MD, 2002, NATURE, V416, P141, DOI 10.1038/416141a; SOECHTING JF, 1984, EXP BRAIN RES, V54, P121; Taylor DM, 2002, SCIENCE, V296, P1829, DOI 10.1126/science.1070291; Tillery SIH, 2003, P ANN INT IEEE EMBS, V25, P2043, DOI 10.1109/IEMBS.2003.1280137; Wahnoun R, 2006, J NEURAL ENG, V3, P162, DOI 10.1088/1741-2560/3/2/010; Wessberg J, 2000, NATURE, V408, P361, DOI 10.1038/35042582; Wolpaw JR, 2004, P NATL ACAD SCI USA, V101, P17849, DOI 10.1073/pnas.0403504101; Wolpaw JR, 2002, CLIN NEUROPHYSIOL, V113, P767, DOI 10.1016/S1388-2457(02)00057-3; Yu BM, 2007, J NEUROPHYSIOL, V97, P3763, DOI 10.1152/jn.00482.2006	30	1053	1105	11	417	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 19	2008	453	7198					1098	1101		10.1038/nature06996	http://dx.doi.org/10.1038/nature06996			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WM	18509337	Green Published			2022-12-28	WOS:000256839900056
J	Remuzzi, G; Garattini, S				Remuzzi, Giuseppe; Garattini, Silvio			Rare diseases: what's next?	LANCET			English	Editorial Material							DRUG		[Remuzzi, Giuseppe; Garattini, Silvio] Mario Negri Inst Pharmacol Res, Lab Negri Bergamo, Clin Res Ctr Rare Dis Aldo & Cele Dacco, I-24125 Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Remuzzi, G (corresponding author), Mario Negri Inst Pharmacol Res, Lab Negri Bergamo, Clin Res Ctr Rare Dis Aldo & Cele Dacco, I-24125 Bergamo, Italy.	gremuzzi@marionegri.it	Garattini, Silvio/AAA-6390-2020; Remuzzi, Giuseppe/V-9766-2017	Garattini, Silvio/0000-0003-0647-9297; Remuzzi, Giuseppe/0000-0002-6194-3446				Ayme S, 2008, LANCET, V371, P2048, DOI 10.1016/S0140-6736(08)60875-2; Buckley BM, 2008, LANCET, V371, P2051, DOI 10.1016/S0140-6736(08)60876-4; Cyranoski D, 2007, NAT MED, V13, P1005, DOI 10.1038/nm0907-1005; *EUR COMM, 2007, PUBL CONS REG EUR AC; Fischer A, 2008, LANCET, V371, P2044, DOI 10.1016/S0140-6736(08)60874-0; *FRENCH NAT PLAN R, 2004, ENS EQ ACC DIAGN TRE; Haffner ME, 2008, LANCET, V371, P2041, DOI 10.1016/S0140-6736(08)60873-9; Joppi R, 2006, BRIT J CLIN PHARMACO, V61, P355, DOI 10.1111/j.1365-2125.2006.02579.x; *OSS NAZ IMP FARM, 2006, US FARM IT; Schieppati A, 2008, LANCET, V371, P2039, DOI 10.1016/S0140-6736(08)60872-7; Taruscio Domenica, 2003, Community Genet, V6, P123, DOI 10.1159/000073009	11	30	30	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 14	2008	371	9629					1978	1979		10.1016/S0140-6736(08)60847-8	http://dx.doi.org/10.1016/S0140-6736(08)60847-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312YY	18555899				2022-12-28	WOS:000256709500007
J	Harrington, SE; Smith, TJ				Harrington, Sarah Elizabeth; Smith, Thomas J.			The role of chemotherapy at the end of life: "When is enough, enough?"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CELL LUNG-CANCER; PALLIATIVE CARE; BREAST-CANCER; SUPPORTIVE CARE; DECISION AID; PATIENTS PERCEPTIONS; COST-EFFECTIVENESS; TREATMENT OPTIONS; RANDOMIZED-TRIAL; IMMINENT DEATH	Patients face difficult decisions about chemotherapy near the end of life. Such treatment might prolong survival or reduce symptoms but cause adverse effects, prevent the patient from engaging in meaningful life review and preparing for death, and preclude entry into hospice. Palliative care and oncology clinicians should be logical partners in caring for patients with serious cancers for which symptom control, medically appropriate goal setting, and communication are paramount, but some studies have shown limited cooperation. We illustrate how clinicians involved in palliative care and oncology can more effectively work together with the story of Mr L, a previously healthy 56- year- old man, who wanted to survive his lung cancer at all costs. He lived 14 months with 3 types of chemotherapy, received chemotherapy just 6 days before his death, and resisted entering hospice until his prognosis and options were explicitly communicated. Approaches to communication about prognosis and treatment options and questions that patients may want to ask are discussed.	Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Thomas Palliat Care Program, Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Smith, TJ (corresponding author), Virginia Commonwealth Univ, Div Hematol Oncol & Palliat Care, MCV Box 980230, Richmond, VA 23298 USA.	tsmith@hsc.vcu.edu	Harrington, Sarah Beth/AAR-4802-2020	Smith, Thomas/0000-0003-3040-6434	NATIONAL CANCER INSTITUTE [R01CA116227] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [G08LM009525] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA116227-01, R01 CA116227] Funding Source: Medline; NLM NIH HHS [G08 LM009525-01, G08 LM009525, 1G08LM009525-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Agrawal M, 2006, J CLIN ONCOL, V24, P4479, DOI 10.1200/JCO.2006.06.0269; [Anonymous], 1996, J Clin Oncol, V14, P671; Back A, 2006, ONCOLOGY-NY, V20, P67; Bakitas Marie, 2004, J Palliat Med, V7, P363, DOI 10.1089/109662104773709530; Balmer CE, 2001, PSYCHO-ONCOL, V10, P410, DOI 10.1002/pon.538; BENNER SE, 1994, CANCER INVEST, V12, P451, DOI 10.3109/07357909409021402; Bodenheimer T, 2007, ANN INTERN MED, V146, P301, DOI 10.7326/0003-4819-146-4-200702200-00011; Bremnes RM, 1995, EUR J CANCER, V31A, P1955, DOI 10.1016/0959-8049(95)00513-7; Brickner Leslea, 2004, J Palliat Med, V7, P411, DOI 10.1089/1096621041349518; Brown RF, 2001, BRIT J CANCER, V85, P1273, DOI 10.1054/bjoc.2001.2073; Bruera E, 2003, J PAIN SYMPTOM MANAG, V25, P412, DOI 10.1016/S0885-3924(02)00686-3; Brundage MD, 2001, PATIENT EDUC COUNS, V45, P149, DOI 10.1016/S0738-3991(01)00155-0; Campbell DE, 2004, ANN INTERN MED, V140, P269, DOI 10.7326/0003-4819-140-4-200402170-00009; Casarett D, 2005, J AM GERIATR SOC, V53, P249, DOI 10.1111/j.1532-5415.2005.53110.x; Casarett D, 2005, JAMA-J AM MED ASSOC, V294, P211, DOI 10.1001/jama.294.2.211; Casarett DJ, 2007, ANN INTERN MED, V146, P443, DOI 10.7326/0003-4819-146-6-200703200-00011; Casarett DJ, 2004, J AM GERIATR SOC, V52, P1923, DOI 10.1111/j.1532-5415.2004.52520.x; Chow E, 2001, CLIN ONCOL-UK, V13, P204, DOI 10.1053/clon.2001.9255; Christakis NA, 2003, SOC SCI MED, V57, P465, DOI 10.1016/S0277-9536(02)00370-2; Collins R, 2007, HEALTH TECHNOL ASSES, V11, P1; Connor SR, 2007, J PAIN SYMPTOM MANAG, V33, P238, DOI 10.1016/j.jpainsymman.2006.10.010; Creagan Edward T, 2004, Cancer Control, V11, P266; Dancey J, 2004, LUNG CANCER-J IASLC, V43, P183, DOI 10.1016/j.lungcan.2003.09.001; Earle CC, 2004, J CLIN ONCOL, V22, P315, DOI 10.1200/JCO.2004.08.136; EISENBERG PD, 2002, ANN INTERN MED, V136; El Demery M, 2006, PROG UROL, V16, P320; Elsayem A, 2004, J CLIN ONCOL, V22, P2008, DOI 10.1200/JCO.2004.11.003; EMANUEL LL, 2007, NIH PUBLICATION; Fallowfield L, 2001, BRIT MED J, V323, P1144, DOI 10.1136/bmj.323.7322.1144; Finn JW, 2002, P AN M AM SOC CLIN, V21, P1452; Foley KM, 2001, IMPROVING PALLIATIVE; Gade G, 2008, J PALLIAT MED, V11, P180, DOI 10.1089/jpm.2007.0055; Glare P, 2003, BRIT MED J, V327, P195, DOI 10.1136/bmj.327.7408.195; Glynne-Jones R, 2006, CLIN ONCOL-UK, V18, P395, DOI 10.1016/j.clon.2006.01.005; Goldberg RM, 2007, ONCOLOGIST, V12, P38, DOI 10.1634/theoncologist.12-1-38; Grunfeld EA, 2006, J CLIN ONCOL, V24, P1090, DOI 10.1200/JCO.2005.01.9208; Hagerty RG, 2005, J CLIN ONCOL, V23, P1278, DOI 10.1200/JCO.2005.11.138; HAYES DF, 2008, UPTODATE; Helft PR, 2005, J CLIN ONCOL, V23, P3146, DOI 10.1200/JCO.2005.07.003; Hillner BE, 2005, CANCER-AM CANCER SOC, V104, P1871, DOI 10.1002/cncr.21411; Hirose T, 2005, INTERNAL MED, V44, P107, DOI 10.2169/internalmedicine.44.107; Jacobson M, 2006, HEALTH AFFAIR, V25, P437, DOI 10.1377/hlthaff.25.2.437; Kirk P, 2004, BMJ-BRIT MED J, V328, P1343, DOI 10.1136/bmj.38103.423576.55; Koedoot CG, 2004, EUR J CANCER, V40, P225, DOI 10.1016/j.ejca.2003.10.008; Koedoot CG, 2003, BRIT J CANCER, V89, P2219, DOI 10.1038/sj.bjc.6601445; Lamont E B, 2000, J Palliat Med, V3, P27, DOI 10.1089/jpm.2000.3.27; Lamont EB, 2001, ANN INTERN MED, V134, P1096, DOI 10.7326/0003-4819-134-12-200106190-00009; Lee SJ, 2003, BIOL BLOOD MARROW TR, V9, P389, DOI 10.1016/S1083-8791(03)00103-4; Lee SJ, 2001, JAMA-J AM MED ASSOC, V285, P1034, DOI 10.1001/jama.285.8.1034; Leighl NB, 2007, J CLIN ONCOL, V25; Mack JW, 2007, J CLIN ONCOL, V25, P5636, DOI 10.1200/JCO.2007.12.6110; MACKILLOP WJ, 1988, BRIT J CANCER, V58, P355, DOI 10.1038/bjc.1988.218; Mallinger JB, 2006, PSYCHO-ONCOLOGY, V15, P297, DOI 10.1002/pon.954; Martoni AA, 2007, TUMORI J, V93, P417; Massarelli E, 2003, LUNG CANCER-J IASLC, V39, P55, DOI 10.1016/S0169-5002(02)00308-2; Matsuyama R, 2006, J CLIN ONCOL, V24, P3490, DOI 10.1200/JCO.2005.03.6236; Meier DE, 2001, JAMA-J AM MED ASSOC, V286, P3007, DOI 10.1001/jama.286.23.3007; Meropol NJ, 2007, J CLIN ONCOL, V25, P180, DOI 10.1200/JCO.2006.09.6081; Meropol NJ, 2003, J CLIN ONCOL, V21, P2589, DOI 10.1200/JCO.2003.10.072; Meyers FJ, 2004, J PAIN SYMPTOM MANAG, V28, P548, DOI 10.1016/j.jpainsymman.2004.03.002; Murillo JR, 2006, ONCOLOGIST, V11, P1095, DOI 10.1634/theoncologist.11-10-1095; Neff P, 2002, J CLIN ONCOL, V20, P3035, DOI 10.1200/JCO.2002.20.13.3035; Passik Steven D, 2004, Palliat Support Care, V2, P419; Peele PB, 2005, MED DECIS MAKING, V25, P301, DOI 10.1177/0272989X05276851; Pfister DG, 2004, J CLIN ONCOL, V22, P330, DOI 10.1200/JCO.2004.09.053; PITORAK EF, 2002, PROJECT SAFE CONDUCT; QUILL TE, 1990, ARCH INTERN MED, V150, P1857, DOI 10.1001/archinte.150.9.1857; Rabinowitz T, 2006, CANCER INVEST, V24, P68, DOI 10.1080/07357900500449678; Rabow MW, 2003, J PAIN SYMPTOM MANAG, V26, P1010, DOI 10.1016/j.jpainsymman.2003.03.002; Santoso JT, 2006, CANCER J, V12, P73, DOI 10.1097/00130404-200601000-00013; Schockett ER, 2005, J PAIN SYMPTOM MANAG, V30, P400, DOI 10.1016/j.jpainsymman.2005.04.013; Schrag D, 2004, NEW ENGL J MED, V351, P317, DOI 10.1056/NEJMp048143; Shanafelt TD, 2004, J CLIN ONCOL, V22, P1966, DOI 10.1200/JCO.2004.08.176; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095; Silvestri G, 1998, BRIT MED J, V317, P771, DOI 10.1136/bmj.317.7161.771; Siminoff LA, 2006, PSYCHO-ONCOLOGY, V15, P1001, DOI 10.1002/pon.1040; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; SMITH RC, 1988, PSYCHOSOMATICS, V29, P392, DOI 10.1016/S0033-3182(88)72339-7; Smith T J, 1998, J Palliat Med, V1, P221, DOI 10.1089/jpm.1998.1.221; Smith TJ, 2006, J CLIN ONCOL, V24, P3187, DOI 10.1200/JCO.2006.06.4451; Smith Thomas J, 2003, J Palliat Med, V6, P699, DOI 10.1089/109662103322515202; SMITH TJ, 1995, J CLIN ONCOL, V13, P2464, DOI 10.1200/JCO.1995.13.9.2464; Smith TJ, 2000, J CLIN ONCOL, V18, P3441, DOI 10.1200/JCO.2000.18.19.3441; Smith TJ, 2001, J CLIN ONCOL, V19, P260, DOI 10.1200/JCO.2001.19.1.260; Smith TJ, 2002, J CLIN ONCOL, V20, P4040, DOI 10.1200/JCO.2002.02.118; Sullivan AM, 2007, J PALLIAT MED, V10, P882, DOI 10.1089/jpm.2007.0189; Tamburini M, 2000, SUPPORT CARE CANCER, V8, P223, DOI 10.1007/s005200050289; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Temel JS, 2007, J CLIN ONCOL, V25, P2377, DOI 10.1200/JCO.2006.09.2627; Teno JM, 2004, ANN INTERN MED, V141, P159, DOI 10.7326/0003-4819-141-2-200407200-00017; Teno JM, 2007, J PAIN SYMPTOM MANAG, V34, P120, DOI 10.1016/j.jpainsymman.2007.04.014; The AM, 2001, WESTERN J MED, V174, P247, DOI 10.1136/ewjm.174.4.247; TOBIAS JS, 1993, BRIT MED J, V307, P1199, DOI 10.1136/bmj.307.6913.1199; WHELAN TJ, 2002, AHRQ PUBLICATION; Wright AA, 2007, NEW ENGL J MED, V357, P324, DOI 10.1056/NEJMp078074	96	198	199	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2008	299	22					2667	E1		10.1001/jama.299.22.2667	http://dx.doi.org/10.1001/jama.299.22.2667			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311FN	18544726	Green Accepted			2022-12-28	WOS:000256586200023
J	Markowitz, AJ; Rabow, MW				Markowitz, Amy J.; Rabow, Michael W.			Palliative care for patients with head and neck cancer: "I would like a quick return to a normal lifestyle"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Goldstein NE, 2008, JAMA-J AM MED ASSOC, V299, P1818, DOI 10.1001/jama.299.15.1818	1	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2008	299	22					2679	2679		10.1001/jama.299.22.2679	http://dx.doi.org/10.1001/jama.299.22.2679			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311FN	18544727				2022-12-28	WOS:000256586200024
J	Cooper, MS; Gittoes, NJL				Cooper, Mark S.; Gittoes, Neil J. L.			Diagnosis and management of hypocalcaemia	BRITISH MEDICAL JOURNAL			English	Review							MAGNESIUM-DEFICIENCY; CRITICALLY-ILL; CALCIUM; POPULATION; PREVALENCE; THERAPY; DISEASE; LESSON		[Cooper, Mark S.; Gittoes, Neil J. L.] Univ Birmingham, Div Med Sci, Birmingham B15 2TH, W Midlands, England	University of Birmingham	Gittoes, NJL (corresponding author), Queen Elizabeth Hosp, Dept Endocrinol, Birmingham B15 2TH, W Midlands, England.	n.j.gittoes@bham.ac.uk	Cooper, Mark S/C-9529-2012	Cooper, Mark/0000-0003-3112-7728				Aishah A B, 1995, Med J Malaysia, V50, P246; ANAST CS, 1976, J CLIN ENDOCR METAB, V42, P707, DOI 10.1210/jcem-42-4-707; Ayuk J, 2001, LANCET, V357, P1262, DOI 10.1016/S0140-6736(00)04408-1; Bastepe M, 2003, J CLIN ENDOCR METAB, V88, P4055, DOI 10.1210/jc.2003-031271; Bushinsky DA, 1998, LANCET, V352, P306, DOI 10.1016/S0140-6736(97)12331-5; HAHN TJ, 1972, NEW ENGL J MED, V287, P900, DOI 10.1056/NEJM197211022871803; Hastbacka J, 2003, ACTA ANAESTH SCAND, V47, P1264, DOI 10.1046/j.1399-6576.2003.00236.x; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Hopper AD, 2007, BRIT MED J, V335, P558, DOI 10.1136/bmj.39316.442338.AD; Lienhardt A, 2001, J CLIN ENDOCR METAB, V86, P5313, DOI 10.1210/jc.86.11.5313; Malabanan A, 1998, LANCET, V351, P805, DOI 10.1016/S0140-6736(05)78933-9; Marx SJ, 2000, NEW ENGL J MED, V343, P1863, DOI 10.1056/NEJM200012213432508; Mughal MZ, 1999, BRIT MED J, V318, P39, DOI 10.1136/bmj.318.7175.39; Netter FH., 1965, CIBA COLLECTION MED, V4, P185; Peter R, 2004, BMJ-BRIT MED J, V328, P335, DOI 10.1136/bmj.328.7435.335; RYZEN E, 1985, CRIT CARE MED, V13, P19, DOI 10.1097/00003246-198501000-00006; Schimatschek HF, 2001, MAGNESIUM RES, V14, P283; Slomp J, 2003, CRIT CARE MED, V31, P1389, DOI 10.1097/01.CCM.0000063044.55669.3C; SPRINGHOUSE, 2006, PROFESSIONAL GUIDE S; Thakker R., 2003, OXFORD TXB MED; TOLMAN KG, 1975, PEDIATRICS, V56, P45; Urbano FL, 2000, HOSP PHYS, P43; Velasco PJ, 1999, PSYCHOSOMATICS, V40, P486	23	179	190	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2008	336	7656					1298	1302		10.1136/bmj.39582.589433.BE	http://dx.doi.org/10.1136/bmj.39582.589433.BE			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312XO	18535072	Green Published			2022-12-28	WOS:000256705900035
J	Schermelleh, L; Carlton, PM; Haase, S; Shao, L; Winoto, L; Kner, P; Burke, B; Cardoso, MC; Agard, DA; Gustafsson, MGL; Leonhardt, H; Sedat, JW				Schermelleh, Lothar; Carlton, Peter M.; Haase, Sebastian; Shao, Lin; Winoto, Lukman; Kner, Peter; Burke, Brian; Cardoso, M. Cristina; Agard, David A.; Gustafsson, Mats G. L.; Leonhardt, Heinrich; Sedat, John W.			Subdiffraction multicolor imaging of the nuclear periphery with 3D structured illumination microscopy	SCIENCE			English	Article							OPTICAL RECONSTRUCTION MICROSCOPY; PORE COMPLEX; CRYOELECTRON TOMOGRAPHY; INTERPHASE; ENVELOPE; RESOLUTION; NANOSCOPY; CHROMATIN; FRACTION; CHANNEL	Fluorescence light microscopy allows multicolor visualization of cellular components with high specificity, but its utility has until recently been constrained by the intrinsic limit of spatial resolution. We applied three- dimensional structured illumination microscopy ( 3D- SIM) to circumvent this limit and to study the mammalian nucleus. By simultaneously imaging chromatin, nuclear lamina, and the nuclear pore complex ( NPC), we observed several features that escape detection by conventional microscopy. We could resolve single NPCs that colocalized with channels in the lamin network and peripheral heterochromatin. We could differentially localize distinct NPC components and detect double- layered invaginations of the nuclear envelope in prophase as previously seen only by electron microscopy. Multicolor 3D- SIM opens new and facile possibilities to analyze subcellular structures beyond the diffraction limit of the emitted light.	[Schermelleh, Lothar; Leonhardt, Heinrich] Univ Munich, Dept Biol, Ctr Integrated Prot Sci, D-82152 Planegg Martinsried, Germany; [Carlton, Peter M.; Haase, Sebastian; Shao, Lin; Winoto, Lukman; Kner, Peter; Agard, David A.; Sedat, John W.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; [Burke, Brian] Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; [Haase, Sebastian; Cardoso, M. Cristina] Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; [Gustafsson, Mats G. L.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; [Gustafsson, Mats G. L.] Univ Calif San Francisco, Bioengn Program, San Francisco, CA 94143 USA	University of Munich; University of California System; University of California San Francisco; State University System of Florida; University of Florida; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Leonhardt, H (corresponding author), Univ Munich, Dept Biol, Ctr Integrated Prot Sci, D-82152 Planegg Martinsried, Germany.	h.leonhardt@lmu.de; sedat@msg.ucsf.edu	Carlton, Peter/AAD-2403-2021; Schermelleh, Lothar/H-4588-2019; Cardoso, M. Cristina/F-5215-2011; Leonhardt, Heinrich/B-2791-2014	Carlton, Peter/0000-0002-5320-6024; Schermelleh, Lothar/0000-0002-1612-9699; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025101] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-2501-25, R01 GM025101, R01 GM025101-25] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbe E., 1873, ARCH F MIKROSK ANAT, V9, P413, DOI [10.1007/bf02956173, DOI 10.1007/BF02956173, 10.1007/ BF02956173]; AGARD DA, 1989, METHOD CELL BIOL, V30, P353; Albiez H, 2006, CHROMOSOME RES, V14, P707, DOI 10.1007/s10577-006-1086-x; Bates M, 2007, SCIENCE, V317, P1749, DOI 10.1126/science.1146598; Beck M, 2004, SCIENCE, V306, P1387, DOI 10.1126/science.1104808; Beck M, 2007, NATURE, V449, P611, DOI 10.1038/nature06170; Betzig E, 2006, SCIENCE, V313, P1642, DOI 10.1126/science.1127344; Born M., 1998, PRINCIPLE OPTICS; Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Donnert G, 2006, P NATL ACAD SCI USA, V103, P11440, DOI 10.1073/pnas.0604965103; Fahrenkrog B, 2002, J STRUCT BIOL, V140, P254, DOI 10.1016/S1047-8477(02)00524-5; Fricker M, 1997, J CELL BIOL, V136, P531, DOI 10.1083/jcb.136.3.531; GERACE L, 1978, J CELL BIOL, V79, P546, DOI 10.1083/jcb.79.2.546; Gustafsson MGL, 2008, BIOPHYS J, V94, P4957, DOI 10.1529/biophysj.107.120345; Gustafsson MGL, 2000, J MICROSC-OXFORD, V198, P82, DOI 10.1046/j.1365-2818.2000.00710.x; Heintzmann Rainer, 2006, Briefings in Functional Genomics & Proteomics, V5, P289, DOI 10.1093/bfgp/ell036; Hell SW, 2007, SCIENCE, V316, P1153, DOI 10.1126/science.1137395; Hell SW, 2003, NAT BIOTECHNOL, V21, P1347, DOI 10.1038/nbt895; Huang B, 2008, SCIENCE, V319, P810, DOI 10.1126/science.1153529; Kittel RJ, 2006, SCIENCE, V312, P1051, DOI 10.1126/science.1126308; PADDY MR, 1990, CELL, V62, P89, DOI 10.1016/0092-8674(90)90243-8; Pawley J.B., 2006, HDB BIOL CONFOCAL MI, DOI [10.1007/978-0-387-45524-2_23, 10.1007/978-0-387-45524-2, DOI 10.1007/978-0-387-45524-2]; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; Rust MJ, 2006, NAT METHODS, V3, P793, DOI 10.1038/nmeth929; Stoffler D, 2003, J MOL BIOL, V328, P119, DOI 10.1016/S0022-2836(03)00266-3; Tonini R, 1999, FASEB J, V13, P1395, DOI 10.1096/fasebj.13.11.1395; Willig KI, 2006, NATURE, V440, P935, DOI 10.1038/nature04592; Winey M, 1997, MOL BIOL CELL, V8, P2119, DOI 10.1091/mbc.8.11.2119	28	817	851	14	326	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	2008	320	5881					1332	1336		10.1126/science.1156947	http://dx.doi.org/10.1126/science.1156947			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309DO	18535242	Green Accepted, Green Submitted			2022-12-28	WOS:000256441100043
J	Hesketh, PJ				Hesketh, Paul J.			Drug therapy: Chemotherapy-induced nausea and vomiting	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CISPLATIN-INDUCED EMESIS; HIGH-DOSE CISPLATIN; MODERATELY EMETOGENIC CHEMOTHERAPY; RECEPTOR ANTAGONIST APREPITANT; CLINICAL ONCOLOGY PROGRAM; PLACEBO-CONTROLLED TRIAL; TACHYKININ NK1 RECEPTOR; PHASE-II TRIAL; AREA POSTREMA; DOUBLE-BLIND		Caritas St Elizabeths Med Ctr, Boston, MA 02135 USA	St. Elizabeth's Medical Center	Hesketh, PJ (corresponding author), Caritas St Elizabeths Med Ctr, HOQ Rm 224,736 Cambridge St, Boston, MA 02135 USA.	phesketh@massmed.org						Aapro MS, 2006, ANN ONCOL, V17, P1441, DOI 10.1093/annonc/mdl137; AAPRO MS, 1981, CANCER CHEMOTH PHARM, V7, P11; ANDREWS PL, 2005, MANAGEMENT NAUSEA VO, P15; Andrews PLR, 2004, HANDB EXP PHARM, V164, P359; Andrews PLR, 2002, CURR OPIN PHARMACOL, V2, P650, DOI 10.1016/S1471-4892(02)00227-8; ANDREWS PLR, 1990, CAN J PHYSIOL PHARM, V68, P325, DOI 10.1139/y90-047; Bloechl-Daum B, 2006, J CLIN ONCOL, V24, P4472, DOI 10.1200/JCO.2006.05.6382; BLOWER PR, 1990, EUR J CANCER, V26, pS8; BORISON HL, 1989, PROG NEUROBIOL, V32, P351, DOI 10.1016/0301-0082(89)90028-2; BOUNTRA C, 1993, EUR J PHARMACOL, V249, pR3, DOI 10.1016/0014-2999(93)90673-6; BOWCOCK SJ, 1984, BRIT MED J, V288, P1879, DOI 10.1136/bmj.288.6434.1879; *CANC CAR ONT, 2003, 123 CANC CAR ONT; CARPENTER DO, 1984, BEHAV BRAIN RES, V11, P277, DOI 10.1016/0166-4328(84)90220-1; CARPENTER DO, 1983, CELL MOL NEUROBIOL, V3, P113, DOI 10.1007/BF00735276; de Wit R, 2004, EUR J CANCER, V40, P403, DOI 10.1016/j.ejca.2003.08.028; deBoerDennert M, 1997, BRIT J CANCER, V76, P1055, DOI 10.1038/bjc.1997.507; del Giglio A, 2000, CANCER, V89, P2301, DOI 10.1002/1097-0142(20001201)89:11<2301::AID-CNCR19>3.0.CO;2-6; Depre M, 2005, EUR J CLIN PHARMACOL, V61, P341, DOI 10.1007/s00228-005-0907-8; DUBOIS A, 1992, EUR J CANCER, V28A, P450, DOI 10.1016/S0959-8049(05)80075-9; Einhorn LH, 2005, SUPPORT CARE CANCER, V13, P112, DOI 10.1007/s00520-004-0704-4; Eisenberg P, 2003, CANCER-AM CANCER SOC, V98, P2473, DOI 10.1002/cncr.11817; Endo T, 2000, TOXICOLOGY, V153, P189, DOI 10.1016/S0300-483X(00)00314-0; Ettinger David S, 2007, J Natl Compr Canc Netw, V5, P12; FOZARD JR, 1984, NEUROPHARMACOLOGY, V23, P1473, DOI 10.1016/0028-3908(84)90091-1; FUKUDA H, 1992, NEUROSCI RES, V14, P180, DOI 10.1016/0168-0102(92)90079-R; FUKUI H, 1992, JPN J PHARMACOL, V59, P221, DOI 10.1254/jjp.59.221; Geling O, 2005, J CLIN ONCOL, V23, P1289, DOI 10.1200/JCO.2005.04.022; Gralla R, 2003, ANN ONCOL, V14, P1570, DOI 10.1093/annonc/mdg417; GRALLA RJ, 1983, DRUGS, V25, P63, DOI 10.2165/00003495-198300251-00007; Grunberg SM, 2005, SUPPORT CARE CANCER, V13, P80, DOI 10.1007/s00520-004-0718-y; HERRSTEDT J, 1993, NEW ENGL J MED, V328, P1076, DOI 10.1056/NEJM199304153281502; Herrstedt J, 2007, ANN ONCOL, V18, P83, DOI 10.1093/annonc/mdm050; Herrstedt J, 2006, CANCER, V106, P1641, DOI 10.1002/cncr.21855; Herrstedt J, 2005, CANCER-AM CANCER SOC, V104, P1548, DOI 10.1002/cncr.21343; Hesketh P, 1996, J CLIN ONCOL, V14, P2242, DOI 10.1200/JCO.1996.14.8.2242; Hesketh P J, 1999, Oncologist, V4, P191; Hesketh PJ, 2003, J CLIN ONCOL, V21, P4112, DOI 10.1200/JCO.2003.01.095; HESKETH PJ, 1994, J CLIN ONCOL, V12, P596, DOI 10.1200/JCO.1994.12.3.596; Hesketh PJ, 1997, J CLIN ONCOL, V15, P103, DOI 10.1200/JCO.1997.15.1.103; Hesketh PJ, 1998, SUPPORT CARE CANCER, V6, P221, DOI 10.1007/s005200050157; Hickok JT, 2003, CANCER, V97, P2880, DOI 10.1002/cncr.11408; HIGGINS GA, 1989, BRIT J PHARMACOL, V97, P247, DOI 10.1111/j.1476-5381.1989.tb11948.x; Horn CC, 2007, AUTON NEUROSCI-BASIC, V132, P44, DOI 10.1016/j.autneu.2006.09.005; Hornby PJ, 2001, AM J MED, V111, P106, DOI 10.1016/S0002-9343(01)00849-X; Ihbe-Heffinger A, 2004, ANN ONCOL, V15, P526, DOI 10.1093/annonc/mdh110; Ioannidis JPA, 2000, J CLIN ONCOL, V18, P3409, DOI 10.1200/JCO.2000.18.19.3409; Jordan K, 2005, SUPPORT CARE CANCER, V13, P26, DOI 10.1007/s00520-004-0672-8; KILPATRICK GJ, 1989, EUR J PHARMACOL, V159, P157, DOI 10.1016/0014-2999(89)90700-0; KOGA T, 1992, NEUROSCI RES, V14, P166, DOI 10.1016/0168-0102(92)90078-Q; Kris, 2006, J CLIN ONCOL, V24, P5341, DOI 10.1200/JCO.2006.06.006; Kris MG, 2006, J CLIN ONCOL, V24, P2932, DOI 10.1200/JCO.2006.06.9591; Kris MG, 1996, CANCER, V78, P2193, DOI 10.1002/(SICI)1097-0142(19961115)78:10<2193::AID-CNCR22>3.0.CO;2-T; KRIS MG, 1985, J CLIN ONCOL, V3, P1379, DOI 10.1200/JCO.1985.3.10.1379; LASZLO J, 1985, J CLIN ONCOL, V3, P864, DOI 10.1200/JCO.1985.3.6.864; LATREILLE J, 1995, SUPPORT CARE CANCER, V3, P307, DOI 10.1007/BF00335307; Lebeau B, 1997, ANN ONCOL, V8, P887, DOI 10.1023/A:1008276412559; LESLIE RA, 1990, CAN J PHYSIOL PHARM, V68, P279, DOI 10.1139/y90-042; Lindley C M, 1992, Qual Life Res, V1, P331, DOI 10.1007/BF00434947; Loos WJ, 2007, CANCER CHEMOTH PHARM, V59, P407, DOI 10.1007/s00280-006-0359-6; McCrea JB, 2003, CLIN PHARMACOL THER, V74, P17, DOI 10.1016/S0009-9236(03)00066-3; MILLER AD, 1994, FRONT NEUROENDOCRIN, V15, P301, DOI 10.1006/frne.1994.1012; MILLER AD, 1983, BRAIN RES, V270, P154, DOI 10.1016/0006-8993(83)90805-3; Miller AD, 1999, DIGEST DIS SCI, V44, p39S; Miller AD, 1997, NEURAL CONTROL RESP, P239; MINER WD, 1987, BRIT J CANCER, V56, P159, DOI 10.1038/bjc.1987.177; MOERTEL CG, 1963, JAMA-J AM MED ASSOC, V186, P116, DOI 10.1001/jama.1963.03710020036011; Morrow GR, 1998, SUPPORT CARE CANCER, V6, P244, DOI 10.1007/s005200050161; Navari RM, 2005, SUPPORT CARE CANCER, V13, P529, DOI 10.1007/s00520-004-0755-6; Navari RM, 2007, SUPPORT CARE CANCER, V15, P1285, DOI 10.1007/s00520-007-0248-5; Nygren P, 2005, CANCER CHEMOTH PHARM, V55, P609, DOI 10.1007/s00280-004-0946-3; Osoba D, 1997, J CLIN ONCOL, V15, P116, DOI 10.1200/JCO.1997.15.1.116; Perugi G, 2006, BIPOLAR DISORD, V8, P17; Poli-Bigelli S, 2003, CANCER-AM CANCER SOC, V97, P3090, DOI 10.1002/cncr.11433; POLLERA CF, 1989, CANCER, V64, P1117, DOI 10.1002/1097-0142(19890901)64:5<1117::AID-CNCR2820640525>3.0.CO;2-R; Quartara L, 1998, NEUROPEPTIDES, V32, P1, DOI 10.1016/S0143-4179(98)90015-4; RAZAVI D, 1993, J CLIN ONCOL, V11, P1384, DOI 10.1200/JCO.1993.11.7.1384; Roila F, 1998, J CLIN ONCOL, V16, P2937, DOI 10.1200/JCO.1998.16.9.2937; Roila F, 2006, ANN ONCOL, V17, P20, DOI 10.1093/annonc/mdj078; Roila F, 2004, J CLIN ONCOL, V22, P725, DOI 10.1200/JCO.2004.09.040; Roila F, 2004, J CLIN ONCOL, V22, P2038, DOI 10.1200/JCO.2004.03.955; Roila F, 2002, SUPPORT CARE CANCER, V10, P88, DOI 10.1007/s005200100295; ROILA F, 1995, NEW ENGL J MED, V332, P1; Roscoe JA, 2004, CANCER-AM CANCER SOC, V101, P2701, DOI 10.1002/cncr.20718; SACKETT DL, 1989, CHEST, V95, pS2, DOI 10.1378/chest.95.2.2S; Saito R, 2003, J PHARMACOL SCI, V91, P87; SALLER R, 1986, EUR J CANCER CLIN ON, V22, P1199, DOI 10.1016/0277-5379(86)90321-4; Sanchez RI, 2004, DRUG METAB DISPOS, V32, P1287, DOI 10.1124/dmd.104.000216; Sanger GJ, 2006, AUTON NEUROSCI-BASIC, V129, P3, DOI 10.1016/j.autneu.2006.07.009; Schmoll HJ, 2006, ANN ONCOL, V17, P1000, DOI 10.1093/annonc/mdl019; Severini C, 2002, PHARMACOL REV, V54, P285, DOI 10.1124/pr.54.2.285; STROMINGER NL, 1994, BRAIN RES BULL, V33, P33, DOI 10.1016/0361-9230(94)90047-7; TATTERSALL FD, 1993, EUR J PHARMACOL, V250, pR5, DOI 10.1016/0014-2999(93)90649-3; Tattersall FD, 1996, NEUROPHARMACOLOGY, V35, P1121, DOI 10.1016/S0028-3908(96)00020-2; Tavorath R, 1996, DRUGS, V52, P639, DOI 10.2165/00003495-199652050-00002; Tonini Giuseppe, 2005, Expert Opin Drug Metab Toxicol, V1, P143, DOI 10.1517/17425255.1.1.143; Tramer MR, 2001, BMJ-BRIT MED J, V323, P16, DOI 10.1136/bmj.323.7303.16; WAMPLER G, 1983, DRUGS, V25, P35, DOI 10.2165/00003495-198300251-00005; WANG SC, 1950, ARCH NEURO PSYCHIATR, V63, P928, DOI 10.1001/archneurpsyc.1950.02310240087005; Warr DG, 2005, J CLIN ONCOL, V23, P2822, DOI 10.1200/JCO.2005.09.050; ZAGON A, 1994, J COMP NEUROL, V340, P445, DOI 10.1002/cne.903400402	100	495	522	2	58	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2008	358	23					2482	2494		10.1056/NEJMra0706547	http://dx.doi.org/10.1056/NEJMra0706547			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308HY	18525044				2022-12-28	WOS:000256380700007
J	Chan, JA; Meyerhardt, JA; Niedzwiecki, D; Hollis, D; Saltz, LB; Mayer, RJ; Thomas, J; Schaefer, P; Whittom, R; Hantel, A; Goldberg, RM; Warren, RS; Bertagnolli, M; Fuchs, CS				Chan, Jennifer A.; Meyerhardt, Jeffrey A.; Niedzwiecki, Donna; Hollis, Donna; Saltz, Leonard B.; Mayer, Robert J.; Thomas, James; Schaefer, Paul; Whittom, Renaud; Hantel, Alexander; Goldberg, Richard M.; Warren, Robert S.; Bertagnolli, Monica; Fuchs, Charles S.			Association of family history with cancer recurrence and survival among patients with stage III colon cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MICROSATELLITE INSTABILITY; ADENOMATOUS POLYPS; IMPACT; PROGNOSIS; RISK	Context A family history of colorectal cancer in a first- degree relative increases the risk of developing colorectal cancer. However, the influence of family history on cancer recurrence and survival among patients with established disease remains uncertain. Objective To examine the association of family history of colorectal cancer with cancer recurrence and survival of patients with colon cancer. Design, Setting, and Participants Prospective observational study of 1087 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial ( CALGB 89803) between April 1999 and May 2001. Patients provided data on family history at baseline and were followed up until March 2007 for disease recurrence and death ( median follow- up, 5.6 years). In a subset of patients, we assessed microsatellite instability ( MSI) and expression of the mismatch repair ( MMR) proteins MLH1 and MSH2 in tumor specimens. Main Outcome Measures Disease- free survival, recurrence- free survival, and overall survival according to the presence or absence of a family history of colorectal cancer. Results Among 1087 eligible patients, 195 ( 17.9%) reported a family history of colorectal cancer in a first- degree relative. Cancer recurrence or death occurred in 57 of 195 patients ( 29%; 95% confidence interval [ CI], 23%- 36%) with a family history of colorectal cancer and 343 of 892 patients ( 38%; 95% CI, 35%- 42%) without a family history. Compared with patients without a family history, the adjusted hazard ratios ( HRs) among those with 1 or more affected first- degree relatives were 0.72 ( 95% CI, 0.54- 0.96) for disease- free survival, 0.74 ( 95% CI, 0.55- 0.99) for recurrence- free survival, and 0.75 ( 95% CI, 0.54- 1.05) for overall survival. This reduction in risk of cancer recurrence or death associated with a family history became stronger with an increasing number of affected first- degree relatives. Compared with participants without a family history of colorectal cancer, those with 1 affected relative had a multivariate HR of 0.77 ( 95% CI, 0.57- 1.04) for disease- free survival. For participants with 2 or more affected relatives, we observed a greater reduction in risk ( multivariate HR for disease- free survival, 0.49; 95% CI, 0.23- 1.04; P for trend with increasing number of affected relatives=. 01). The improved disease- free survival associated with a family history was independent of tumoral MSI or MMR status. Conclusion Among patients with stage III colon cancer receiving adjuvant chemotherapy, a family history of colorectal cancer is associated with a significant reduction in cancer recurrence and death.	[Chan, Jennifer A.; Meyerhardt, Jeffrey A.; Mayer, Robert J.; Fuchs, Charles S.] Dana Farber Canc Inst, Div Med Oncol, Boston, MA 02115 USA; [Niedzwiecki, Donna; Hollis, Donna] Duke Univ, Med Ctr, CALGB Stat Ctr, Durham, NC USA; [Saltz, Leonard B.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Thomas, James] Ohio State Univ, Columbus, OH 43210 USA; [Schaefer, Paul] Toledo Community Hosp Oncol Program, Community Clin Oncol Program, Toledo, OH USA; [Whittom, Renaud] Hop Sacre Coeur, Montreal, PQ H4J 1C5, Canada; [Hantel, Alexander] Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA; [Goldberg, Richard M.] Univ N Carolina, Dept Hematol Oncol, Chapel Hill, NC USA; [Warren, Robert S.] Univ Calif San Francisco, Div Surg Oncol, San Francisco, CA 94143 USA; [Bertagnolli, Monica] Brigham & Womens Hosp, Div Surg Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Duke University; Memorial Sloan Kettering Cancer Center; University System of Ohio; Ohio State University; Universite de Montreal; Loyola University Chicago; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Francisco; Harvard University; Brigham & Women's Hospital	Chan, JA (corresponding author), Dana Farber Canc Inst, Div Med Oncol, 44 Binney St, Boston, MA 02115 USA.	jang@partners.org	Goldberg, Richard M/M-1311-2013; Goldberg, Richard/O-1871-2017	Goldberg, Richard/0000-0003-3713-6895; Niedzwiecki, Donna/0000-0002-3566-0450; Saltz, Leonard/0000-0001-8353-4670	NATIONAL CANCER INSTITUTE [U10CA045564, U10CA077406, U10CA077440, U10CA046282, U10CA047559, U10CA007968, U10CA045418, U10CA021076, U10CA021115, U10CA045389, U10CA011789, U10CA023318, T32CA009172, U10CA016450, U10CA047555, U10CA037135, U10CA004326, U10CA002599, U10CA032102, U10CA077651, R01CA118553, U10CA060138, U10CA031983, U10CA071323, U10CA077597, U10CA066636, U10CA035415, U10CA035279, U10CA012046, U10CA047577, U10CA035421, U10CA041287, T32CA009001, U10CA003927, U10CA077298, U10CA077658, U10CA045808, U10CA011028, U10CA008025, U10CA031946, U10CA047642, U10CA033601, U10CA004457, U10CA012449, U10CA026806, U10CA074811, U10CA038926, U10CA032291] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benatti P, 2005, CLIN CANCER RES, V11, P8332, DOI 10.1158/1078-0432.CCR-05-1030; BERTAGNOLLI MM, 2006, J CLIN ONCOL, P24; CANNONALBRIGHT LA, 1989, CANCER, V64, P1971, DOI 10.1002/1097-0142(19891101)64:9<1971::AID-CNCR2820640935>3.0.CO;2-L; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; Clark TG, 2002, LANCET, V359, P1309, DOI 10.1016/S0140-6736(02)08272-7; FUCHS CS, 1994, NEW ENGL J MED, V331, P1669, DOI 10.1056/NEJM199412223312501; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; Johns LE, 2001, AM J GASTROENTEROL, V96, P2992, DOI 10.1111/j.1572-0241.2001.04677.x; JONES MP, 1989, BIOMETRICS, V45, P157, DOI 10.2307/2532042; Kerber RA, 1997, AM J EPIDEMIOL, V146, P244; KOYAMA Y, 1993, JPN J CLIN ONCOL, V23, P342; Lindor NM, 2002, J CLIN ONCOL, V20, P1043, DOI 10.1200/JCO.20.4.1043; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; Meyerhardt JA, 2007, JAMA-J AM MED ASSOC, V298, P754, DOI 10.1001/jama.298.7.754; Meyerhardt JA, 2006, J CLIN ONCOL, V24, P3535, DOI 10.1200/JCO.2006.06.0863; OGINO S, 2005, MOD PATHOL, V18, pA114; Parc Y, 2004, GUT, V53, P371, DOI 10.1136/gut.2003.019190; POTTER JD, 1993, EPIDEMIOL REV, V15, P499, DOI 10.1093/oxfordjournals.epirev.a036132; Ricciardiello L, 2003, CANCER RES, V63, P787; Rustgi AK, 2007, GENE DEV, V21, P2525, DOI 10.1101/gad.1593107; Saltz LB, 2007, J CLIN ONCOL, V25, P3456, DOI 10.1200/JCO.2007.11.2144; Samowitz WS, 2001, CANCER EPIDEM BIOMAR, V10, P917; Sinicrope FA, 2006, AM J GASTROENTEROL, V101, P2818, DOI 10.1111/j.1572-0241.2006.00845.x; Sinicrope FA, 2006, GASTROENTEROLOGY, V131, P729, DOI 10.1053/j.gastro.2006.06.005; SLATTERY ML, 1995, INT J EPIDEMIOL, V24, P888, DOI 10.1093/ije/24.5.888; SLATTERY ML, 1994, J NATL CANCER I, V86, P1618, DOI 10.1093/jnci/86.21.1618; Therneau TM., 2000, MODELING SURVIVAL DA; Wu YX, 2008, ANN THORAC SURG, V85, P1155, DOI 10.1016/j.athoracsur.2007.12.012	28	61	64	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2008	299	21					2515	2523		10.1001/jama.299.21.2515	http://dx.doi.org/10.1001/jama.299.21.2515			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308AR	18523220	Bronze, Green Accepted, Green Submitted			2022-12-28	WOS:000256361200023
J	Edes, TE				Edes, Thomas E.			Waging peace in the war on cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												thomas.edes@va.gov							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2008	299	21					2483	2483		10.1001/jama.299.21.2483	http://dx.doi.org/10.1001/jama.299.21.2483			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308AR	18523208				2022-12-28	WOS:000256361200001
J	Thomas, J; Karver, S; Cooney, GA; Chamberlain, BH; Watt, CK; Slatkin, NE; Stambler, N; Kremer, AB; Israel, RJ				Thomas, Jay; Karver, Sloan; Cooney, Gail Austin; Chamberlain, Bruce H.; Watt, Charles Kevin; Slatkin, Neal E.; Stambler, Nancy; Kremer, Alton B.; Israel, Robert J.			Methylnaltrexone for opioid-induced constipation in advanced illness	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MORPHINE-INDUCED DELAY; ORAL NALOXONE; DOUBLE-BLIND; SUBCUTANEOUS METHYLNALTREXONE; TRANSIT; GUT; FENTANYL; RATS	Background: Constipation is a distressing side effect of opioid treatment. As a quaternary amine, methylnaltrexone, a (mu)-opioid-receptor antagonist, has restricted ability to cross the blood-brain barrier. We investigated the safety and efficacy of subcutaneous methylnaltrexone for treating opioid-induced constipation in patients with advanced illness. Methods: A total of 133 patients who had received opioids for 2 or more weeks and who had received stable doses of opioids and laxatives for 3 or more days without relief of opioid-induced constipation were randomly assigned to receive subcutaneous methylnaltrexone (at a dose of 0.15 mg per kilogram of body weight) or placebo every other day for 2 weeks. Coprimary outcomes were laxation (defecation) within 4 hours after the first dose of the study drug and laxation within 4 hours after two or more of the first four doses. Patients who completed this phase were eligible to enter a 3-month, open-label extension trial. Results: In the methylnaltrexone group, 48% of patients had laxation within 4 hours after the first study dose, as compared with 15% in the placebo group, and 52% had laxation without the use of a rescue laxative within 4 hours after two or more of the first four doses, as compared with 8% in the placebo group (P<0.001 for both comparisons). The response rate remained consistent throughout the extension trial. The median time to laxation was significantly shorter in the methylnaltrexone group than in the placebo group. Evidence of withdrawal mediated by central nervous system opioid receptors or changes in pain scores was not observed. Abdominal pain and flatulence were the most common adverse events. Conclusions: Subcutaneous methylnaltrexone rapidly induced laxation in patients with advanced illness and opioid-induced constipation. Treatment did not appear to affect central analgesia or precipitate opioid withdrawal. (Clinical Trials.gov number, NCT00402038.).	[Thomas, Jay] San Diego Hospice & Palliat Care, San Diego, CA 92103 USA; [Thomas, Jay] Inst Palliat Med, San Diego, CA USA; [Karver, Sloan] Gulfside Reg Hospice, New Port Richey, FL USA; [Cooney, Gail Austin] Hospice Palm Beach Cty, W Palm Beach, FL USA; [Chamberlain, Bruce H.] Palliat Consulting, Orem, UT USA; [Watt, Charles Kevin] Res Ctr Ozarks, Everton, MO USA; [Slatkin, Neal E.] City Hope Natl Med Ctr, Duarte, CA 91010 USA; [Slatkin, Neal E.; Kremer, Alton B.; Israel, Robert J.] Progen Pharmaceut, Tarrytown, NY USA	City of Hope	Thomas, J (corresponding author), San Diego Hospice & Palliat Care, 4311 3rd Ave, San Diego, CA 92103 USA.	jthomas@sdhospice.org						American Pain Society, 2003, PRINC AN US TREATM A; [Anonymous], 2003, DUR FENT TRANSD SYST; BROWN DR, 1985, NEUROPHARMACOLOGY, V24, P181, DOI 10.1016/0028-3908(85)90072-3; CHESKIN LJ, 1995, DRUG ALCOHOL DEPEN, V39, P151, DOI 10.1016/0376-8716(95)01153-P; CULPEPPERMORGAN JA, 1992, CLIN PHARMACOL THER, V52, P90, DOI 10.1038/clpt.1992.106; De Schepper HU, 2004, NEUROGASTROENT MOTIL, V16, P383, DOI 10.1111/j.1365-2982.2004.00513.x; Department of Veterans Affairs; Department of Defense, 2003, VA DOD CLIN PRACT GU; DUNLOP GM, 1989, PALLIATIVE MED, V4, P37, DOI DOI 10.1177/026921639000400108; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; Goodman SR, 2002, REGION ANESTH PAIN M, V27, P374, DOI 10.1053/rapm.2002.33283; HOLMES S, 1989, INT J NURS STUD, V26, P69, DOI 10.1016/0020-7489(89)90047-3; Kolb L, 1938, AM J PSYCHIAT, V94, P759, DOI 10.1176/ajp.94.4.759; Latasch L, 1997, ANAESTHESIST, V46, P191, DOI 10.1007/s001010050390; LEHMANN KA, 1999, OPIOIDS PAIN CONTROL, P270; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Liu MW, 2002, J PAIN SYMPTOM MANAG, V23, P48, DOI 10.1016/S0885-3924(01)00369-4; MANARA L, 1986, J PHARMACOL EXP THER, V237, P945; Murphy DB, 1997, ANESTHESIOLOGY, V87, P765, DOI 10.1097/00000542-199710000-00008; Portenoy RK, 2008, J PAIN SYMPTOM MANAG, V35, P458, DOI 10.1016/j.jpainsymman.2007.12.005; *PURD PHARM, 2003, OXYCONTIN OX HCL CON; Sykes Nigel P, 2006, J Support Oncol, V4, P213; Sykes NP, 1996, PALLIATIVE MED, V10, P135, DOI 10.1177/026921639601000208; TAVANI A, 1980, LIFE SCI, V27, P2211, DOI 10.1016/0024-3205(80)90386-0; THOMAS J, 2005, J CLIN ONCOL, V23, pS16; Yuan Chun-Su, 2004, J Support Oncol, V2, P111; Yuan CS, 2000, JAMA-J AM MED ASSOC, V284, P1383, DOI 10.1001/jama.284.11.1383; Yuan CS, 1997, CLIN PHARMACOL THER, V61, P467, DOI 10.1016/S0009-9236(97)90197-1; Yuan CS, 2000, JAMA-J AM MED ASSOC, V283, P367, DOI 10.1001/jama.283.3.367; Yuan CS, 2002, J PHARMACOL EXP THER, V300, P118, DOI 10.1124/jpet.300.1.118; Yuan CS, 1996, CLIN PHARMACOL THER, V59, P469, DOI 10.1016/S0009-9236(96)90117-4; Yuan CS, 2000, DRUG DEVELOP RES, V50, P133, DOI 10.1002/1098-2299(200006)50:2<133::AID-DDR1>3.0.CO;2-8	31	366	380	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2008	358	22					2332	2343		10.1056/NEJMoa0707377	http://dx.doi.org/10.1056/NEJMoa0707377			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307GF	18509120				2022-12-28	WOS:000256306700004
J	Lu, PJ; Zaccarelli, E; Ciulla, F; Schofield, AB; Sciortino, F; Weitz, DA				Lu, Peter J.; Zaccarelli, Emanuela; Ciulla, Fabio; Schofield, Andrew B.; Sciortino, Francesco; Weitz, David A.			Gelation of particles with short-range attraction	NATURE			English	Article							COLLOID-POLYMER MIXTURES; PHASE-SEPARATION; AGGREGATION; SUSPENSIONS; BEHAVIOR; DEPENDENCE; DYNAMICS; DIAGRAM	Nanoscale or colloidal particles are important in many realms of science and technology. They can dramatically change the properties of materials, imparting solid-like behaviour to a wide variety of complex fluids(1,2). This behaviour arises when particles aggregate to form mesoscopic clusters and networks. The essential component leading to aggregation is an interparticle attraction, which can be generated by many physical and chemical mechanisms. In the limit of irreversible aggregation, infinitely strong interparticle bonds lead to diffusion-limited cluster aggregation(3) (DLCA). This is understood as a purely kinetic phenomenon that can form solid-like gels at arbitrarily low particle volume fraction(4,5). Far more important technologically are systems with weaker attractions, where gel formation requires higher volume fractions. Numerous scenarios for gelation have been proposed, including DLCA(6), kinetic or dynamic arrest(4,7-10), phase separation(5,6,11-16), percolation(4,12,17,18) and jamming(8). No consensus has emerged and, despite its ubiquity and significance, gelation is far from understood-even the location of the gelation phase boundary is not agreed on(5). Here we report experiments showing that gelation of spherical particles with isotropic, short-range attractions is initiated by spinodal decomposition; this thermodynamic instability triggers the formation of density fluctuations, leading to spanning clusters that dynamically arrest to create a gel. This simple picture of gelation does not depend on microscopic system-specific details, and should thus apply broadly to any particle system with short- range attractions. Our results suggest that gelation-often considered a purely kinetic phenomenon(4,8-10)-is in fact a direct consequence of equilibrium liquid gas phase separation(5,13-15). Without exception, we observe gelation in all of our samples predicted by theory and simulation to phaseseparate; this suggests that it is phase separation, not percolation(12), that corresponds to gelation in models for attractive spheres.	[Lu, Peter J.; Weitz, David A.] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; [Lu, Peter J.; Weitz, David A.] Harvard Univ, SEAS, Cambridge, MA 02138 USA; [Zaccarelli, Emanuela; Ciulla, Fabio; Sciortino, Francesco] Univ Roma La Sapienza, Dipartimento Fis, I-00185 Rome, Italy; [Zaccarelli, Emanuela; Sciortino, Francesco] Univ Roma La Sapienza, CNR INFM SOFT, I-00185 Rome, Italy; [Schofield, Andrew B.] Univ Edinburgh, Sch Phys, Edinburgh EH9 3JZ, Midlothian, Scotland	Harvard University; Harvard University; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Sapienza University Rome; University of Edinburgh	Lu, PJ (corresponding author), Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.	plu@fas.harvard.edu	Zaccarelli, Emanuela/K-4695-2013; Schofield, Andrew Bruce/AAV-4862-2020; Ciulla, Fabio/AFS-2169-2022; Lu, Peter J/G-1971-2011; Sciortino, Francesco/B-4768-2012	Zaccarelli, Emanuela/0000-0003-0032-8906; Schofield, Andrew Bruce/0000-0002-8741-856X; Ciulla, Fabio/0000-0002-2637-1737; Lu, Peter J/0000-0003-1489-5725; SCIORTINO, Francesco/0000-0002-2418-2713	EPSRC [EP/E030173/1] Funding Source: UKRI; Engineering and Physical Sciences Research Council [EP/E030173/1] Funding Source: researchfish	EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		ALLAIN C, 1995, PHYS REV LETT, V74, P1478, DOI 10.1103/PhysRevLett.74.1478; Allen M. P., 1989, COMPUTER SIMULATION, DOI DOI 10.1093/OSO/9780198803195.001.0001; ASAKURA S, 1954, J CHEM PHYS, V22, P1255, DOI 10.1063/1.1740347; Bergenholtz J, 2003, LANGMUIR, V19, P4493, DOI 10.1021/la0340089; Bolhuis PG, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.128302; Buzzaccaro S, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.098301; Cardinaux F, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.118301; CARPINETI M, 1992, PHYS REV LETT, V68, P3327, DOI 10.1103/PhysRevLett.68.3327; Charbonneau P, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.011507; de Hoog EHA, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.021407; Foffi G, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.078301; Frisken BJ, 2001, APPL OPTICS, V40, P4087, DOI 10.1364/AO.40.004087; FURUKAWA H, 1985, ADV PHYS, V34, P703, DOI 10.1080/00018738500101841; Gauckler LJ, 1999, MATER CHEM PHYS, V61, P78, DOI 10.1016/S0254-0584(99)00117-0; GRANT MC, 1993, PHYS REV E, V47, P2606, DOI 10.1103/PhysRevE.47.2606; Kroy K, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.148302; LEKKERKERKER HNW, 1992, EUROPHYS LETT, V20, P559, DOI 10.1209/0295-5075/20/6/015; LIN MY, 1989, NATURE, V339, P360, DOI 10.1038/339360a0; LIU J, 1990, PHYS REV A, V41, P3206, DOI 10.1103/PhysRevA.41.3206; Lu PJ, 2007, OPT EXPRESS, V15, P8702, DOI 10.1364/OE.15.008702; Lu PJ, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.028306; Mezzenga R, 2005, NAT MATER, V4, P729, DOI 10.1038/nmat1496; Miller MA, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.135702; Noro MG, 2000, J CHEM PHYS, V113, P2941, DOI 10.1063/1.1288684; Poon WCK, 1997, ADV COLLOID INTERFAC, V73, P71, DOI 10.1016/S0001-8686(97)90003-8; Puertas AM, 2007, J PHYS-CONDENS MAT, V19, DOI 10.1088/0953-8984/19/20/205140; PUSEY PN, 1993, PHYSICA A, V201, P322, DOI 10.1016/0378-4371(93)90430-C; Rapaport DC, 1995, ART MOL DYNAMIC SIMU; Royall CP, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2755962; SCIORTINO F, 1995, PHYS REV LETT, V74, P282, DOI 10.1103/PhysRevLett.74.282; Shah SA, 2003, J CHEM PHYS, V118, P3350, DOI 10.1063/1.1538602; Tanaka H, 2005, J PHYS-CONDENS MAT, V17, pL143, DOI 10.1088/0953-8984/17/15/L02; Trappe V, 2001, NATURE, V411, P772, DOI 10.1038/35081021; VERDUIN H, 1995, J COLLOID INTERF SCI, V172, P425, DOI 10.1006/jcis.1995.1273; Vliegenthart GA, 1999, PHYSICA A, V263, P378, DOI 10.1016/S0378-4371(98)00515-9; Zaccarelli E, 2007, J PHYS-CONDENS MAT, V19, DOI 10.1088/0953-8984/19/32/323101	36	739	743	8	494	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 22	2008	453	7194					499	U4		10.1038/nature06931	http://dx.doi.org/10.1038/nature06931			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303EL	18497820				2022-12-28	WOS:000256023700037
J	Tuffen, H; Smith, R; Sammonds, PR				Tuffen, Hugh; Smith, Rosanna; Sammonds, Peter R.			Evidence for seismogenic fracture of silicic magma	NATURE			English	Article							SOUFRIERE HILLS VOLCANO; MOUNT-ST-HELENS; ACOUSTIC-EMISSION; UNZEN VOLCANO; LAVA DOME; EARTHQUAKES; MONTSERRAT; SEISMICITY; ERUPTIONS; ANDESITE	It has long been assumed that seismogenic faulting is confined to cool, brittle rocks, with a temperature upper limit of similar to 600 degrees C (ref. 1). This thinking underpins our understanding of volcanic earthquakes, which are assumed to occur in cold rocks surrounding moving magma. However, the recent discovery of abundant brittle-ductile fault textures in silicic lavas(2-4) has led to the counter-intuitive hypothesis that seismic events may be triggered by fracture and faulting within the erupting magma itself. This hypothesis is supported by recent observations of growing lava domes, where microearthquake swarms have coincided with the emplacement of gouge-covered lava spines(5,6), leading to models of seismogenic stick-slip along shallow shear zones in the magma(7). But can fracturing or faulting in high-temperature, eruptible magma really generate measurable seismic events? Here we deform high-temperature silica-rich magmas under simulated volcanic conditions in order to test the hypothesis that hightemperature magma fracture is seismogenic. The acoustic emissions recorded during experiments show that seismogenic rupture may occur in both crystal- rich and crystal-free silicic magmas at eruptive temperatures, extending the range of known conditions for seismogenic faulting.	[Tuffen, Hugh] Univ Lancaster, Dept Environm Sci, Lancaster LA1 4YQ, England; [Tuffen, Hugh; Smith, Rosanna; Sammonds, Peter R.] UCL, Dept Earth Sci, London WC1E 6BT, England	Lancaster University; University of London; University College London	Tuffen, H (corresponding author), Univ Lancaster, Dept Environm Sci, Lancaster LA1 4YQ, England.	h.tuffen@lancaster.ac.uk	Tuffen, Hugh/A-5388-2009; Jiao, Liqing/A-8821-2011	Tuffen, Hugh/0000-0001-8829-1751	NERC [NE/D012910/1, NE/E013740/1] Funding Source: UKRI; Natural Environment Research Council [NE/D012910/1, NE/E013740/1] Funding Source: researchfish	NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Aki K., 1965, B EARTHQ RES I TOKYO, V43, P237; Aki K., 1980, QUANTITATIVE SEISMOL; Burlini L, 2007, GEOLOGY, V35, P183, DOI 10.1130/G23195A.1; CASHMAN KV, IN PRESS VOLCANO REK, pCH19; Chouet BA, 1996, NATURE, V380, P309, DOI 10.1038/380309a0; Gonnermann HM, 2003, NATURE, V426, P432, DOI 10.1038/nature02138; Goto A, 1999, GEOPHYS RES LETT, V26, P2541, DOI 10.1029/1999GL900569; Harrington RM, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2006GL028714; Hull D., 1999, FRACTOGRAPHY; Iverson RM, 2006, NATURE, V444, P439, DOI 10.1038/nature05322; Main IG, 2000, GEOPHYS J INT, V142, P151, DOI 10.1046/j.1365-246x.2000.00136.x; MAIN IG, 1993, GEOPHYS J INT, V115, P367, DOI 10.1111/j.1365-246X.1993.tb01192.x; MCGARR A, 1976, J GEOPHYS RES, V81, P1487, DOI 10.1029/JB081i008p01487; McKenzie D, 2005, EARTH PLANET SC LETT, V233, P337, DOI 10.1016/j.epsl.2005.02.005; McNutt SR, 2005, ANNU REV EARTH PL SC, V33, P461, DOI 10.1146/annurev.earth.33.092203.122459; MEREDITH PG, 1983, GEOPHYS J ROY ASTR S, V75, P1, DOI 10.1111/j.1365-246X.1983.tb01876.x; Nakada S, 1999, J VOLCANOL GEOTH RES, V89, P1, DOI 10.1016/S0377-0273(98)00118-8; Neuberg J, 2000, PHILOS T ROY SOC A, V358, P1533, DOI 10.1098/rsta.2000.0602; Neuberg JW, 2006, J VOLCANOL GEOTH RES, V153, P37, DOI 10.1016/j.jvolgeores.2005.08.008; READ MD, 1995, TECTONOPHYSICS, V245, P223, DOI 10.1016/0040-1951(94)00236-3; Rocchi V, 2004, J VOLCANOL GEOTH RES, V132, P137, DOI 10.1016/S0377-0273(03)00342-1; SAMMONDS PR, 1992, NATURE, V359, P228, DOI 10.1038/359228a0; Smith R, 2007, B VOLCANOL, V69, P681, DOI 10.1007/s00445-006-0102-5; Sparks RSJ, 2000, TERRA NOVA, V12, P14; Tuffen H, 2005, B VOLCANOL, V67, P370, DOI 10.1007/s00445-004-0383-5; Tuffen H, 2003, GEOLOGY, V31, P1089, DOI 10.1130/G19777.1; Uchida N, 2002, EARTH PLANETS SPACE, V54, P197, DOI 10.1186/BF03353019; UMAKOSHI K, 2002, B VOLCANOL SOC JPN, V47, P43; Voight B, 1999, SCIENCE, V283, P1138, DOI 10.1126/science.283.5405.1138; WEBB SL, 1990, J GEOPHYS RES-SOLID, V95, P15695, DOI 10.1029/JB095iB10p15695	30	104	105	1	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 22	2008	453	7194					511	514		10.1038/nature06989	http://dx.doi.org/10.1038/nature06989			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303EL	18497823				2022-12-28	WOS:000256023700040
J	Kerr, EA; Zikmund-Fisher, BJ; Klamerus, ML; Subramanian, U; Hogan, MM; Hofer, TP				Kerr, Eve A.; Zikmund-Fisher, Brian J.; Klamerus, Mandi L.; Subramanian, Usha; Hogan, Mary M.; Hofer, Timothy P.			The role of clinical uncertainty in treatment decisions for diabetic patients with uncontrolled blood pressure	ANNALS OF INTERNAL MEDICINE			English	Article							COMPETING DEMANDS; CHRONIC ILLNESS; PRIMARY-CARE; HYPERTENSION MANAGEMENT; INERTIA; PHYSICIAN; MODEL; GUIDELINES; PRIORITIES; BARRIERS	Background: Factors underlying failure to intensify therapy in response to elevated blood pressure have not been systematically studied. Objective: To examine the process of care for diabetic patients with elevated triage blood pressure (>= 140/90 mm Hg) during routine primary care visits to assess whether a treatment change occurred and to what degree specific patient and provider factors correlated with the likelihood of treatment change. Design: Prospective cohort study. Setting: 9 Veterans Affairs facilities in 3 midwestern states. Participants: 1169 diabetic patients with scheduled visits to 92 primary care providers from February 2005 to March 2006. Measurements: Proportion of patients who had a change in a blood pressure treatment (medication intensification or planned follow-up within 4 weeks). Predicted probability of treatment change was calculated from a multilevel logistic model that included variables assessing clinical uncertainty, competing demands and prioritization, and medication-related factors (controlling for blood pressure). Results: Overall, 573 (49%) patients had a blood pressure treatment change at the visit. The following factors made treatment change less likely: repeated blood pressure by provider recorded as less than 140/90 mm Hg versus 140/90 mm Hg or greater or no recorded repeated blood pressure (13% vs. 61%; P < 0.001); home blood pressure reported by patients as less than 140/90 mm Hg versus 140/90 mm Hg or greater or no recorded home blood pressure (18% vs. 52%; P < 0.001); provider systolic blood pressure goal greater than 130 mm Hg versus 130 mm Hg or less (33% vs. 52%; P = 0.002); discussion of conditions unrelated to hypertension and diabetes versus no discussion (44% vs. 55%; P = 0.008); and discussion of medication issues versus no discussion (23% vs. 52%; P < 0.001). Limitation: Providers knew that the study pertained to diabetes and hypertension, and treatment change was assessed for 1 visit per patient. Conclusion: Approximately 50% of diabetic patients presenting with a substantially elevated triage blood pressure received treatment change at the visit. Clinical uncertainty about the true blood pressure value was a prominent reason that providers did not intensify therapy.	[Kerr, Eve A.] Ann Arbor Vet Affairs Hlth Serv, Res & Dev Serv, Ctr Excellence, Ann Arbor, MI 48113 USA; Vet Affairs Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Indiana Univ, Indianapolis, IN 46204 USA; Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	Kerr, EA (corresponding author), Ann Arbor Vet Affairs Hlth Serv, Res & Dev Serv, Ctr Excellence, POB 130170, Ann Arbor, MI 48113 USA.	ekerr@umich.edu; thofer@umich.edu	Hofer, Timothy Philip/AAC-9238-2022; Kerr, Eve/I-3330-2013; Zikmund-Fisher, Brian J./A-7677-2009	Hofer, Timothy/0000-0003-0434-8787; Zikmund-Fisher, Brian/0000-0002-1637-4176	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andrade SE, 2004, AM J MANAG CARE, V10, P481; Asai Y, 2002, J HUM HYPERTENS, V16, P313, DOI 10.1038/sj.jhh.1001385; Asch Steven M, 2005, BMC Cardiovasc Disord, V5, P1, DOI 10.1186/1471-2261-5-1; Berlowitz DR, 2003, DIABETES CARE, V26, P355, DOI 10.2337/diacare.26.2.355; Berlowitz DR, 1998, NEW ENGL J MED, V339, P1957, DOI 10.1056/NEJM199812313392701; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; BOLEN SD, 2008, J GEN INTERN MED; BRUCE NG, 1988, J HYPERTENS, V6, P375; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Casalino L, 2003, JAMA-J AM MED ASSOC, V289, P434, DOI 10.1001/jama.289.4.434; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Cook CB, 1999, DIABETES CARE, V22, P1494, DOI 10.2337/diacare.22.9.1494; Cummings K M, 1980, J Behav Med, V3, P123; Ferrari P, 2004, J HYPERTENS, V22, P1221, DOI 10.1097/00004872-200406000-00024; Fine LJ, 2006, HYPERTENSION, V47, P319, DOI 10.1161/01.HYP.0000200692.23410.c9; Godley PJ, 2005, AM J MANAG CARE, V11, P206; Grant RW, 2004, DIABETIC MED, V21, P150, DOI 10.1111/j.1464-5491.2004.01095.x; GREEN L W, 1988, American Journal of Preventive Medicine, V4, P101; GREEN LW, 1988, AM J PREV MED, V4, P108; Haynes B, 1998, BMJ-BRIT MED J, V317, P273, DOI 10.1136/bmj.317.7153.273; Hicks PC, 2006, DIABETES CARE, V29, P2580, DOI 10.2337/dc06-1124; Hofer TP, 2006, J GEN INTERN MED, V21, P112; Horne R, 1999, PSYCHOL HEALTH, V14, P1, DOI 10.1080/08870449908407311; JAEN CR, 1994, J FAM PRACTICE, V38, P166; JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101; Kerr EA, 2007, J GEN INTERN MED, V22, P1635, DOI 10.1007/s11606-007-0313-2; La Batide-Alanore A, 2000, J HYPERTENS, V18, P391; Lin N D, 2006, AMIA Annu Symp Proc, P494; McManus RJ, 2003, BRIT J GEN PRACT, V53, P953; Messerli FH, 2002, J AM COLL CARDIOL, V40, P2201, DOI 10.1016/S0735-1097(02)02607-4; Nutting PA, 2000, ARCH FAM MED, V9, P1059, DOI 10.1001/archfami.9.10.1059; O'Connor PJ, 2003, ARCH INTERN MED, V163, P2677, DOI 10.1001/archinte.163.22.2677; Okonofua EC, 2006, HYPERTENSION, V47, P345, DOI 10.1161/01.HYP.0000200702.76436.4b; Oliveria SA, 2002, ARCH INTERN MED, V162, P413, DOI 10.1001/archinte.162.4.413; Parati G, 2004, J HYPERTENS, V22, P1075, DOI 10.1097/00004872-200406000-00003; Parchman ML, 2007, ANN FAM MED, V5, P196, DOI 10.1370/afm.679; Phillips LS, 2001, ANN INTERN MED, V135, P825, DOI 10.7326/0003-4819-135-9-200111060-00012; Pickering TG, 2005, CIRCULATION, V111, P697, DOI 10.1161/01.CIR.0000154900.76284.F6; Piette JD, 2006, DIABETES CARE, V29, P725, DOI 10.2337/diacare.29.03.06.dc05-2078; Rodondi N, 2006, ANN INTERN MED, V144, P475, DOI 10.7326/0003-4819-144-7-200604040-00006; Roumie CL, 2007, JT COMM J QUAL PATIE, V33, P277, DOI 10.1016/S1553-7250(07)33032-8; Rubenstein LV, 2000, MED CARE, V38, pS129; Saaddine JB, 2006, ANN INTERN MED, V144, P465, DOI 10.7326/0003-4819-144-7-200604040-00005; Safford MM, 2007, J GEN INTERN MED, V22, P1648, DOI 10.1007/s11606-007-0433-8; SASSANO P, 1987, AM J MED, V83, P227, DOI 10.1016/0002-9343(87)90690-5; Schaars CF, 2004, DIABETES CARE, V27, P123, DOI 10.2337/diacare.27.1.123; Sechrest L, 2005, HEALTH SERV RES, V40, P1584, DOI 10.1111/j.1475-6773.2005.00443.x; Snijders T.A., 1999, INTRO BASIC ADV MULT; STANGE KC, 1994, J FAM PRACTICE, V38, P231; Turchin A, 2006, DIABETES, V55, pA3; Vaur, 1998, Blood Press Monit, V3, P107; Vijan S, 2003, ANN INTERN MED, V138, P593, DOI 10.7326/0003-4819-138-7-200304010-00018; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; Weingarten SR, 2002, BRIT MED J, V325, P925, DOI 10.1136/bmj.325.7370.925; Yu W, 2003, MED CARE RES REV, V60, p146S, DOI 10.1177/1077558703257000	56	140	140	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 20	2008	148	10					717	U12		10.7326/0003-4819-148-10-200805200-00004	http://dx.doi.org/10.7326/0003-4819-148-10-200805200-00004			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308EX	18490685				2022-12-28	WOS:000256372200001
J	Wilhelm, BT; Marguerat, S; Watt, S; Schubert, F; Wood, V; Goodhead, I; Penkett, CJ; Rogers, J; Bahler, J				Wilhelm, Brian T.; Marguerat, Samuel; Watt, Stephen; Schubert, Falk; Wood, Valerie; Goodhead, Ian; Penkett, Christopher J.; Rogers, Jane; Bahler, Jurg			Dynamic repertoire of a eukaryotic transcriptome surveyed at single-nucleotide resolution	NATURE			English	Article							GENOME-WIDE TRANSCRIPTION; GENE-EXPRESSION; FISSION YEAST; MEIOSIS; IDENTIFICATION; PROGRAM; NETWORK; TER1; MAP	Recent data from several organisms indicate that the transcribed portions of genomes are larger and more complex than expected, and that many functional properties of transcripts are based not on coding sequences but on regulatory sequences in untranslated regions or non- coding RNAs1-9. Alternative start and polyadenylation sites and regulation of intron splicing add additional dimensions to the rich transcriptional output(10,11). This transcriptional complexity has been sampled mainly using hybridization- based methods under one or few experimental conditions. Here we applied direct high- throughput sequencing of complementary DNAs ( RNA- Seq), supplemented with data from high- density tiling arrays, to globally sample transcripts of the fission yeast Schizosaccharomyces pombe, independently from available gene annotations. We interrogated transcriptomes under multiple conditions, including rapid proliferation, meiotic differentiation and environmental stress, as well as in RNA processing mutants to reveal the dynamic plasticity of the transcriptional landscape as a function of environmental, developmental and genetic factors. High- throughput sequencing proved to be a powerful and quantitative method to sample transcriptomes deeply at maximal resolution. In contrast to hybridization, sequencing showed little, if any, background noise and was sensitive enough to detect widespread transcription in >90% of the genome, including traces of RNAs that were not robustly transcribed or rapidly degraded. The combined sequencing and strand- specific array data provide rich condition- specific information on novel, mostly non- coding transcripts, untranslated regions and gene structures, thus improving the existing genome annotation. Sequence reads spanning exon-exon or exon - intron junctions give unique insight into a surprising variability in splicing efficiency across introns, genes and conditions. Splicing efficiency was largely coordinated with transcript levels, and increased transcription led to increased splicing in test genes. Hundreds of introns showed such regulated splicing during cellular proliferation or differentiation.	[Wilhelm, Brian T.; Marguerat, Samuel; Watt, Stephen; Schubert, Falk; Wood, Valerie; Goodhead, Ian; Penkett, Christopher J.; Rogers, Jane; Bahler, Jurg] Wellcome Trust Sanger Inst, Canc Res UK Fiss Yeast Funct Genom Grp, Cambridge CB10 1HH, England	Wellcome Trust Sanger Institute	Bahler, J (corresponding author), UCL, Dept Genet Evolut & Environm, Mortimer St, London WC1E 6BT, England.	jurg@sanger.ac.uk	Goodhead, Ian/ABC-9200-2020; Wood, Valerie/Y-7759-2018; Marguerat, Samuel/AAY-3792-2020; Bahler, Jurg/B-4572-2009	Wood, Valerie/0000-0001-6330-7526; Marguerat, Samuel/0000-0002-2402-3165; Bahler, Jurg/0000-0003-4036-1532; Goodhead, Ian/0000-0002-3110-9442	Cancer Research UK [A6517, C9546/A6517] Funding Source: Medline; Wellcome Trust [077118] Funding Source: Medline	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission)		Averbeck N, 2005, MOL CELL, V18, P491, DOI 10.1016/j.molcel.2005.04.007; Bernstein BE, 2004, METHOD ENZYMOL, V376, P349; Bertone P, 2004, SCIENCE, V306, P2242, DOI 10.1126/science.1103388; Bickel KS, 2006, MOL CELL, V22, P309, DOI 10.1016/j.molcel.2006.04.010; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Blencowe BJ, 2006, CELL, V126, P37, DOI 10.1016/j.cell.2006.06.023; Borgne A, 2002, MOL BIOL CELL, V13, P2080, DOI 10.1091/mbc.01-10-0507; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; David L, 2006, P NATL ACAD SCI USA, V103, P5320, DOI 10.1073/pnas.0601091103; Harigaya Y, 2006, NATURE, V442, P45, DOI 10.1038/nature04881; Huber W, 2006, BIOINFORMATICS, V22, P1963, DOI 10.1093/bioinformatics/btl289; Hughes TA, 2006, TRENDS GENET, V22, P119, DOI 10.1016/j.tig.2006.01.001; Kapranov P, 2007, NAT REV GENET, V8, P413, DOI 10.1038/nrg2083; Kapranov P, 2007, SCIENCE, V316, P1484, DOI 10.1126/science.1138341; Lackner DH, 2007, MOL CELL, V26, P145, DOI 10.1016/j.molcel.2007.03.002; Leonardi J, 2008, NAT STRUCT MOL BIOL, V15, P26, DOI 10.1038/nsmb1343; Li L, 2006, NAT GENET, V38, P124, DOI 10.1038/ng1704; Lyne R, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-27; Malapeira J, 2005, MOL CELL BIOL, V25, P6330, DOI 10.1128/MCB.25.15.6330-6337.2005; Mata J, 2003, GENOME RES, V13, P2686, DOI 10.1101/gr.1420903; Mata J, 2002, NAT GENET, V32, P143, DOI 10.1038/ng951; Mata J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r217; Munoz MJ, 2002, MOL GENET GENOMICS, V267, P792, DOI 10.1007/s00438-002-0710-5; POTASHKIN J, 1989, EMBO J, V8, P551, DOI 10.1002/j.1460-2075.1989.tb03409.x; Stolc V, 2004, SCIENCE, V306, P655, DOI 10.1126/science.1101312; Struhl K, 2007, NAT STRUCT MOL BIOL, V14, P103, DOI 10.1038/nsmb0207-103; Watt S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001428; Webb CJ, 2008, NAT STRUCT MOL BIOL, V15, P34, DOI 10.1038/nsmb1354; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Yamada K, 2003, SCIENCE, V302, P842, DOI 10.1126/science.1088305	31	741	792	3	192	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 26	2008	453	7199					1239	U39		10.1038/nature07002	http://dx.doi.org/10.1038/nature07002			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318FA	18488015				2022-12-28	WOS:000257075800043
J	Matas, AJ				Matas, Arthur J.			Should we pay donors to increase the supply of organs for transplantation?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Minnesota, Dept Surg, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Matas, AJ (corresponding author), Univ Minnesota, Dept Surg, 420 Delaware St SE, Minneapolis, MN 55455 USA.	matas001@umn.edu	matas, arthur/ABE-1018-2021						0	23	23	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 14	2008	336	7657					1342	1343		10.1136/bmj.a157	http://dx.doi.org/10.1136/bmj.a157			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316YB	18556313	Green Published			2022-12-28	WOS:000256984700036
J	Meckel, M; Comtois, D; Zeidler, D; Staudte, A; Pavicic, D; Bandulet, HC; Pepin, H; Kieffer, JC; Dorner, R; Villeneuve, DM; Corkum, PB				Meckel, M.; Comtois, D.; Zeidler, D.; Staudte, A.; Pavicic, D.; Bandulet, H. C.; Pepin, H.; Kieffer, J. C.; Doerner, R.; Villeneuve, D. M.; Corkum, P. B.			Laser-induced electron tunneling and diffraction	SCIENCE			English	Article							STRONG-FIELD IONIZATION; MOLECULAR IONIZATION; DYNAMICS; PHOTOELECTRON; INTERFERENCE; PULSES; ION	Molecular structure is usually determined by measuring the diffraction pattern the molecule impresses on x-rays or electrons. We used a laser field to extract electrons from the molecule itself, accelerate them, and in some cases force them to recollide with and diffract from the parent ion, all within a fraction of a laser period. Here, we show that the momentum distribution of the extracted electron carries the fingerprint of the highest occupied molecular orbital, whereas the elastically scattered electrons reveal the position of the nuclear components of the molecule. Thus, in one comprehensive technology, the photoelectrons give detailed information about the electronic orbital and the position of the nuclei.	[Meckel, M.; Zeidler, D.; Staudte, A.; Pavicic, D.; Villeneuve, D. M.; Corkum, P. B.] Natl Res Council Canada, Ottawa, ON K1A 0R6, Canada; [Meckel, M.; Staudte, A.; Doerner, R.] Univ Frankfurt, Inst Kernphys, D-60438 Frankfurt, Germany; [Comtois, D.; Bandulet, H. C.; Pepin, H.; Kieffer, J. C.] Inst Natl Rech Sci Energie Mat & Telecommun, Varennes, PQ J3X 1S2, Canada; [Zeidler, D.] Carl Zeiss, D-73447 Oberkochen, Germany	National Research Council Canada; Goethe University Frankfurt; University of Quebec; Institut national de la recherche scientifique (INRS); Carl Zeiss AG	Corkum, PB (corresponding author), Natl Res Council Canada, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	paul.corkum@nrc.ca	Villeneuve, David M/I-4140-2012; Doerner, Reinhard/A-5340-2008	Villeneuve, David M/0000-0002-2810-3648; Doerner, Reinhard/0000-0002-3728-4268; Bandulet, Heidi/0000-0001-5991-1296; Staudte, Andre/0000-0002-8284-3831; Corkum, Paul/0000-0003-3394-5572				Akoury D, 2007, SCIENCE, V318, P949, DOI 10.1126/science.1144959; Alnaser AS, 2005, PHYS REV A, V72, DOI 10.1103/PhysRevA.72.030702; Alnaser AS, 2005, PHYS REV A, V71, DOI 10.1103/PhysRevA.71.031403; Baker S, 2006, SCIENCE, V312, P424, DOI 10.1126/science.1123904; BINNING G, 1982, PHYS REV LETT, V49, P57, DOI 10.1103/PhysRevLett.49.57; Bordas C, 1996, REV SCI INSTRUM, V67, P2257, DOI 10.1063/1.1147044; Brabec T, 1996, PHYS REV A, V54, pR2551, DOI 10.1103/PhysRevA.54.R2551; CORKUM PB, 1993, PHYS REV LETT, V71, P1994, DOI 10.1103/PhysRevLett.71.1994; CORNTOIS D, 2005, J PHYS B ATOM MOL PH, V38, P1923; DELONE NB, 1991, J OPT SOC AM B, V8, P1207, DOI 10.1364/JOSAB.8.001207; Eppink ATJB, 1997, REV SCI INSTRUM, V68, P3477, DOI 10.1063/1.1148310; Ergler T, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.193001; Hartl I, 2007, OPT LETT, V32, P2870, DOI 10.1364/OL.32.002870; Ihee H, 2001, SCIENCE, V291, P458, DOI 10.1126/science.291.5503.458; Itatani J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.173903; Itatani J, 2004, NATURE, V432, P867, DOI 10.1038/nature03183; Ivanov MY, 2005, J MOD OPTIC, V52, P165, DOI 10.1080/0950034042000275360; Kanai T, 2005, NATURE, V435, P470, DOI 10.1038/nature03577; Legare F, 2005, PHYS REV A, V72, DOI 10.1103/PhysRevA.72.052717; Lein M, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.051404; Lezius M, 2001, PHYS REV LETT, V86, P51, DOI 10.1103/PhysRevLett.86.51; Muth-Bohm J, 2000, PHYS REV LETT, V85, P2280, DOI 10.1103/PhysRevLett.85.2280; Niikura H, 2002, NATURE, V417, P917, DOI 10.1038/nature00787; Okunishi M, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.143001; Pavicic D, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.243001; Rudenko A, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.263003; Siwick BJ, 2003, SCIENCE, V302, P1382, DOI 10.1126/science.1090052; Spanner M, 2004, J PHYS B-AT MOL OPT, V37, pL243, DOI 10.1088/0953-4075/37/12/L02; Stapelfeldt H, 2003, REV MOD PHYS, V75, P543, DOI 10.1103/RevModPhys.75.543; Staudte A, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.263002; Tong XM, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.033402; Ullrich J, 2003, REP PROG PHYS, V66, P1463, DOI 10.1088/0034-4885/66/9/203; Yurchenko SN, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.223003; Zuo T, 1996, CHEM PHYS LETT, V259, P313, DOI 10.1016/0009-2614(96)00786-5	34	621	628	1	157	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	2008	320	5882					1478	1482		10.1126/science.1157980	http://dx.doi.org/10.1126/science.1157980			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556555	Green Submitted			2022-12-28	WOS:000256676400040
J	Brent, GA				Brent, Gregory A.			Graves' disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTITHYROID DRUGS; RADIOIODINE TREATMENT; THYROID-HORMONE; PAINLESS THYROIDITIS; CONSENSUS STATEMENT; I-131 THERAPY; BLOOD-FLOW; HYPERTHYROIDISM; MANAGEMENT; OPHTHALMOPATHY	A 23- year- old woman presents with palpitations. Over the past 6 months, she has reported loose stools, a 10- lb ( 4.5- kg) weight loss despite a good appetite and food intake, and increased irritability. She appears to be anxious and has a pulse of 119 beats per minute and a blood pressure of 137/ 80 mm Hg. Her thyroid gland is diffusely and symmetrically enlarged to twice the normal size, and it is firm and non-tender; a thyroid bruit is audible. She has an eyelid lag, but no proptosis or periorbital edema. The serum thyrotropin level is 0.02 mu U per milliliter ( normal range, 0.35 to 4.50) and the level of free thyroxine is 4.10 ng per deciliter ( normal range, 0.89 to 1.76). How should she be further evaluated and treated?	Vet Affairs Greater Los Angeles Healthcare Syst, Endocrinol & Diabet Div, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Brent, GA (corresponding author), Vet Affairs Greater Los Angeles Healthcare Syst, Endocrinol & Diabet Div, 111D,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	gbrent@ucla.edu			NIDDK NIH HHS [R01 DK 67233] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067233] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abalovich M, 2007, J CLIN ENDOCR METAB, V92, pS1, DOI 10.1210/jc.2007-0141; Abraham P, 2005, EUR J ENDOCRINOL, V153, P489, DOI 10.1530/eje.1.01993; Abraham-Nordling M, 2005, THYROID, V15, P1279, DOI 10.1089/thy.2005.15.1279; Alexander EK, 2002, J CLIN ENDOCR METAB, V87, P1073, DOI 10.1210/jc.87.3.1073; Allahabadia A, 2000, J CLIN ENDOCR METAB, V85, P1038, DOI 10.1210/jc.85.3.1038; Bartalena L, 1998, NEW ENGL J MED, V338, P73, DOI 10.1056/NEJM199801083380201; Bartalena L, 2008, THYROID, V18, P333, DOI 10.1089/thy.2007.0315; Baskin HJ, 2002, ENDOCR PRACT, V8, P457; Brenta G, 2007, NAT CLIN PRACT ENDOC, V3, P632, DOI 10.1038/ncpendmet0590; Brix TH, 2001, J CLIN ENDOCR METAB, V86, P930, DOI 10.1210/jc.86.2.930; Cappelli C, 2008, EUR J RADIOL, V65, P99, DOI 10.1016/j.ejrad.2007.03.015; Carani C, 2005, J CLIN ENDOCR METAB, V90, P6472, DOI 10.1210/jc.2005-1135; Ceccarelli C, 2006, CLIN ENDOCRINOL, V65, P446, DOI 10.1111/j.1365-2265.2006.02613.x; Chan GW, 2007, NAT CLIN PRACT ENDOC, V3, P470, DOI 10.1038/ncpendmet0508; Cooper DS, 2005, NEW ENGL J MED, V352, P905, DOI 10.1056/NEJMra042972; Cooper DS, 2003, LANCET, V362, P459, DOI 10.1016/S0140-6736(03)14073-1; Davies TF, 1998, J CLIN ENDOCR METAB, V83, P3777, DOI 10.1210/jc.83.11.3777; Erbil Y, 2007, J CLIN ENDOCR METAB, V92, P2182, DOI 10.1210/jc.2007-0229; Estcourt S, 2008, CLIN ENDOCRINOL, V68, P635, DOI 10.1111/j.1365-2265.2007.03087.x; Franklyn JA, 2005, JAMA-J AM MED ASSOC, V294, P71, DOI 10.1001/jama.294.1.71; Grodski S, 2007, THYROID, V17, P157, DOI 10.1089/thy.2006.0141; Jacobsen R, 2006, DIABETES OBES METAB, V8, P220, DOI 10.1111/j.1463-1326.2005.00486.x; Jacobson EM, 2007, THYROID, V17, P949, DOI 10.1089/thy.2007.0153; Kahaly GJ, 2001, EUR J ENDOCRINOL, V145, P107, DOI 10.1530/eje.0.1450107; Kempers MJE, 2007, J CLIN ENDOCR METAB, V92, P2984, DOI 10.1210/jc.2006-2042; Khoo TK, 2007, THYROID, V17, P1013, DOI 10.1089/thy.2007.0185; Klein I, 2001, NEW ENGL J MED, V344, P501, DOI 10.1056/NEJM200102153440707; Kubota S, 2008, THYROID, V18, P283, DOI 10.1089/thy.2007.0189; Laurberg P, 2006, EUR J ENDOCRINOL, V155, P783, DOI 10.1530/eje.1.02295; Leslie WD, 2003, J CLIN ENDOCR METAB, V88, P978, DOI 10.1210/jc.2002-020805; Luton D, 2005, J CLIN ENDOCR METAB, V90, P6093, DOI 10.1210/jc.2004-2555; Manji N, 2006, J CLIN ENDOCR METAB, V91, P4873, DOI 10.1210/jc.2006-1402; Maugendre D, 1999, CLIN ENDOCRINOL, V50, P127, DOI 10.1046/j.1365-2265.1999.00629.x; Metso S, 2007, J CLIN ENDOCR METAB, V92, P4008; Metso S, 2007, J CLIN ENDOCR METAB, V92, P2190, DOI 10.1210/jc.2006-2321; Motomura K, 1998, ENDOCRIN METAB CLIN, V27, P1, DOI 10.1016/S0889-8529(05)70294-2; Nakamura H, 2007, J CLIN ENDOCR METAB, V92, P2157, DOI 10.1210/jc.2006-2135; NORDYKE RA, 1988, ARCH INTERN MED, V148, P626, DOI 10.1001/archinte.148.3.626; Osman F, 2007, J AM COLL CARDIOL, V49, P71, DOI 10.1016/j.jacc.2006.08.042; Ota H, 2007, CLIN ENDOCRINOL, V67, P41, DOI 10.1111/j.1365-2265.2007.02832.x; Panzer C, 2004, J CLIN ENDOCR METAB, V89, P2142, DOI 10.1210/jc.2003-031981; Pellegriti G, 1998, J CLIN ENDOCR METAB, V83, P2805, DOI 10.1210/jc.83.8.2805; Perros P, 2005, J CLIN ENDOCR METAB, V90, P5321, DOI 10.1210/jc.2005-0507; Royal College of Physicians, 2007, REP WORK PART; Schwartz KM, 2002, J CLIN ENDOCR METAB, V87, P438, DOI 10.1210/jc.87.2.438; SINGER PA, 1995, JAMA-J AM MED ASSOC, V273, P808, DOI 10.1001/jama.273.10.808; Toft AD, 2001, NEW ENGL J MED, V345, P512, DOI 10.1056/NEJMcp010145; Torring O, 1996, J CLIN ENDOCR METAB, V81, P2986, DOI 10.1210/jc.81.8.2986; Vaidya B, 2008, CLIN ENDOCRINOL, V68, P814, DOI 10.1111/j.1365-2265.2007.03097.x; Vanderpump MPJ, 1996, BMJ-BRIT MED J, V313, P539; Walter MA, 2006, EUR J NUCL MED MOL I, V33, P730, DOI 10.1007/s00259-006-0092-8; Walter MA, 2007, BRIT MED J, V334, P514, DOI 10.1136/bmj.39114.670150.BE; Wartofsky L, 1991, Thyroid, V1, P129, DOI 10.1089/thy.1991.1.129; Weetman AP, 2007, CLIN ENDOCRINOL, V66, P757, DOI 10.1111/j.1365-2265.2007.02841.x; Weetman AP, 2000, NEW ENGL J MED, V343, P1236, DOI 10.1056/NEJM200010263431707; Woeber KA, 2006, THYROID, V16, P687, DOI 10.1089/thy.2006.16.687	56	328	366	1	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2008	358	24					2594	2605		10.1056/NEJMcp0801880	http://dx.doi.org/10.1056/NEJMcp0801880			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311IJ	18550875				2022-12-28	WOS:000256593600007
J	Logothetis, NK				Logothetis, Nikos K.			What we can do and what we cannot do with fMRI	NATURE			English	Review							INTERNEURON DIVERSITY SERIES; CEREBRAL-BLOOD-FLOW; CORTICAL AREA MT; SYNAPTIC ACTIVITY; VISUAL-CORTEX; NEURONAL-ACTIVITY; FUNCTIONAL MRI; INHIBITION; NEOCORTEX; CELLS	Functional magnetic resonance imaging ( fMRI) is currently the mainstay of neuroimaging in cognitive neuroscience. Advances in scanner technology, image acquisition protocols, experimental design, and analysis methods promise to push forward fMRI from mere cartography to the true study of brain organization. However, fundamental questions concerning the interpretation of fMRI data abound, as the conclusions drawn often ignore the actual limitations of the methodology. Here I give an overview of the current state of fMRI, and draw on neuroimaging and physiological data to present the current understanding of the haemodynamic signals and the constraints they impose on neuroimaging data interpretation.	Max Planck Inst Biol Cybernet, D-72076 Tubingen, Germany; Univ Manchester, Manchester M13 9PL, Lancs, England	Max Planck Society; University of Manchester	Logothetis, NK (corresponding author), Max Planck Inst Biol Cybernet, Spemannstr 38, D-72076 Tubingen, Germany.	nikos.logothetis@tuebingen.mpg.de	Jovicich, Jorge/D-2293-2010; Logothetis, Nikos/U-9282-2019; Li, Chong/F-4265-2015					ACKERMANN RF, 1984, J NEUROSCI, V4, P251; Attwell D, 2005, NAT REV NEUROSCI, V6, P841, DOI 10.1038/nrn1784; BARTELS A, IN PRESS TRENDS NEUR; Blake R, 2002, NAT REV NEUROSCI, V3, P13, DOI 10.1038/nrn701; Born RT, 2005, ANNU REV NEUROSCI, V28, P157, DOI 10.1146/annurev.neuro.26.041002.131052; Braitenberg V, 1998, CORTEX STAT GEOMETRY; Brunel N, 2001, J COMPUT NEUROSCI, V11, P63, DOI 10.1023/A:1011204814320; Buckner RL, 1996, P NATL ACAD SCI USA, V93, P14878, DOI 10.1073/pnas.93.25.14878; Buxton R., 2002, INTRO FUNCTIONAL MAG; Buzsaki G, 2004, TRENDS NEUROSCI, V27, P186, DOI 10.1016/j.tins.2004.02.007; Buzsaki G, 2007, NEURON, V56, P771, DOI 10.1016/j.neuron.2007.11.008; Chance FS, 2002, NEURON, V35, P773, DOI 10.1016/S0896-6273(02)00820-6; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; CRAGG BG, 1967, J ANAT, V101, P639; Crick F, 1998, NATURE, V391, P245, DOI 10.1038/34584; DeFelipe J, 1997, J CHEM NEUROANAT, V14, P1, DOI 10.1016/S0891-0618(97)10013-8; Devor A, 2007, J NEUROSCI, V27, P4452, DOI 10.1523/JNEUROSCI.0134-07.2007; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; Douglas RJ, 2004, ANNU REV NEUROSCI, V27, P419, DOI 10.1146/annurev.neuro.27.070203.144152; Douglas RJ, 2007, NEURON, V56, P226, DOI 10.1016/j.neuron.2007.10.017; Douglas RJ, 1989, NEURAL COMPUT, V1, P480, DOI 10.1162/neco.1989.1.4.480; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Freund TF, 2003, TRENDS NEUROSCI, V26, P489, DOI 10.1016/S0166-2236(03)00227-3; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Friston KJ, 1996, NEUROIMAGE, V4, P97, DOI 10.1006/nimg.1996.0033; Friston KJ, 2005, PHILOS T R SOC B, V360, P815, DOI 10.1098/rstb.2005.1622; Goense JBM, 2008, CURR BIOL, V18, P631, DOI 10.1016/j.cub.2008.03.054; Haacke E. M., 1999, MAGNETIC RESONANCE I; Haider B, 2006, J NEUROSCI, V26, P4535, DOI 10.1523/JNEUROSCI.5297-05.2006; Hamel E, 2006, J APPL PHYSIOL, V100, P1059, DOI 10.1152/japplphysiol.00954.2005; Haynes JD, 2006, NAT REV NEUROSCI, V7, P523, DOI 10.1038/nrn1931; Huk AC, 2001, NEURON, V32, P161, DOI 10.1016/S0896-6273(01)00452-4; JUEPTNER M, 1995, NEUROIMAGE, V2, P148, DOI 10.1006/nimg.1995.1017; Kayser C, 2004, EUR J NEUROSCI, V19, P485, DOI 10.1111/j.0953-816X.2003.03122.x; Krekelberg B, 2006, TRENDS NEUROSCI, V29, P250, DOI 10.1016/j.tins.2006.02.008; Liu J, 2006, J NEUROSCI, V26, P7779, DOI 10.1523/JNEUROSCI.5052-05.2006; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Logothetis NK, 2004, ANNU REV PHYSIOL, V66, P735, DOI 10.1146/annurev.physiol.66.082602.092845; Luck SJ, 1997, J NEUROPHYSIOL, V77, P24, DOI 10.1152/jn.1997.77.1.24; Markram H, 2004, NAT REV NEUROSCI, V5, P793, DOI 10.1038/nrn1519; Mather G., 1998, MOTION AFTEREFFECT M; Mathiesen C, 1998, J PHYSIOL-LONDON, V512, P555, DOI 10.1111/j.1469-7793.1998.555be.x; McCormick D, 2003, EXCITATORY INHIBITOR; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; NUDO RJ, 1986, J COMP NEUROL, V245, P553, DOI 10.1002/cne.902450410; OGAWA S, 1990, MAGNET RESON MED, V16, P9, DOI 10.1002/mrm.1910160103; OGAWA S, 1990, MAGNET RESON MED, V14, P68, DOI 10.1002/mrm.1910140108; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Peppiatt CM, 2006, NATURE, V443, P700, DOI 10.1038/nature05193; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; Poeppel D, 1996, BRAIN LANG, V55, P317, DOI 10.1006/brln.1996.0108; Rauch A, 2008, P NATL ACAD SCI USA, V105, P6759, DOI 10.1073/pnas.0800312105; ROCKEL AJ, 1980, BRAIN, V103, P221, DOI 10.1093/brain/103.2.221; SCHUZ A, 1995, J BRAIN RES, V36, P113; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; Sherman, 2006, EXPLORING THALAMUS I, P357; Shmuel A, 2006, NAT NEUROSCI, V9, P569, DOI 10.1038/nn1675; Shmuel A, 2002, NEURON, V36, P1195, DOI 10.1016/S0896-6273(02)01061-9; Shoham S, 2006, J COMP PHYSIOL A, V192, P777, DOI 10.1007/s00359-006-0117-6; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Stefanovic B, 2004, NEUROIMAGE, V22, P771, DOI 10.1016/j.neuroimage.2004.01.036; Steriade M, 2001, J NEUROPHYSIOL, V85, P1969, DOI 10.1152/jn.2001.85.5.1969; Szabadics J, 2006, SCIENCE, V311, P233, DOI 10.1126/science.1121325; TOOTELL RBH, 1995, NATURE, V375, P139, DOI 10.1038/375139a0; ULLMAN S, 1995, CEREB CORTEX, V5, P1, DOI 10.1093/cercor/5.1.1; Viswanathan A, 2007, NAT NEUROSCI, V10, P1308, DOI 10.1038/nn1977; Wandell BA, 2005, PHILOS T R SOC B, V360, P693, DOI 10.1098/rstb.2005.1628; Wang Y, 2002, CEREB CORTEX, V12, P395, DOI 10.1093/cercor/12.4.395; Wilke M, 2006, P NATL ACAD SCI USA, V103, P17507, DOI 10.1073/pnas.0604673103; Zeki S, 2004, J PHYSIOL-LONDON, V557, P1, DOI 10.1113/jphysiol.2004.063040; [No title captured]	72	2010	2039	10	561	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2008	453	7197					869	878		10.1038/nature06976	http://dx.doi.org/10.1038/nature06976			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311WV	18548064				2022-12-28	WOS:000256632000033
J	Bianchi, A; Shore, D				Bianchi, Alessandro; Shore, David			Molecular biology - Refined view of the ends	SCIENCE			English	Editorial Material							TELOMERIC PROTEINS; COMPLEX; TRF1; DOMAIN; LENGTH; POT1		[Bianchi, Alessandro; Shore, David] Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland; [Bianchi, Alessandro; Shore, David] Univ Geneva, Natl Ctr Competence Res Frontiers Genet Program, CH-1211 Geneva 4, Switzerland	University of Geneva; University of Geneva	Bianchi, A (corresponding author), Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland.	david.shore@molbio.unige.ch	Shore, David/F-6240-2015	Shore, David/0000-0002-9859-143X; Bianchi, Alessandro/0000-0001-6583-1671				Chen Y, 2008, SCIENCE, V319, P1092, DOI 10.1126/science.1151804; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Fairall L, 2001, MOL CELL, V8, P351, DOI 10.1016/S1097-2765(01)00321-5; Flory MR, 2004, MOL CELL, V16, P619, DOI 10.1016/j.molcel.2004.10.027; Gao H, 2007, NAT STRUCT MOL BIOL, V14, P208, DOI 10.1038/nsmb1205; Hug N, 2006, CHROMOSOMA, V115, P413, DOI 10.1007/s00412-006-0067-3; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Longhese MP, 2008, GENE DEV, V22, P125, DOI 10.1101/gad.1626908; Martin V, 2007, P NATL ACAD SCI USA, V104, P14038, DOI 10.1073/pnas.0705497104; Miyoshi T, 2008, SCIENCE, V320, P1341, DOI 10.1126/science.1154819; Sugiyama T, 2007, CELL, V128, P491, DOI 10.1016/j.cell.2006.12.035; Wang F, 2007, NATURE, V445, P506, DOI 10.1038/nature05454; Xin HW, 2007, NATURE, V445, P559, DOI 10.1038/nature05469	13	3	3	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2008	320	5881					1301	1302		10.1126/science.1159104	http://dx.doi.org/10.1126/science.1159104			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309DO	18535234				2022-12-28	WOS:000256441100032
J	Moeller, S; Freiwald, WA; Tsao, DY				Moeller, Sebastian; Freiwald, Winrich A.; Tsao, Doris Y.			Patches with links: A unified system for processing faces in the macaque temporal lobe	SCIENCE			English	Article							INFEROTEMPORAL AREA TE; CORTICAL CONNECTIONS; OBJECT RECOGNITION; FRONTAL-CORTEX; MONKEYS; PROJECTIONS; FMRI; REPRESENTATIONS; ORGANIZATION; PERCEPTION	The brain processes objects through a series of regions along the ventral visual pathway, but the circuitry subserving the analysis of specific complex forms remains unknown. One complex form category, faces, selectively activates six patches of cortex in the macaque ventral pathway. To identify the connectivity of these face patches, we used electrical microstimulation combined with simultaneous functional magnetic resonance imaging. Stimulation of each of four targeted face patches produced strong activation, specifically within a subset of the other face patches. Stimulation outside the face patches produced an activation pattern that spared the face patches. These results suggest that the face patches form a strongly and specifically interconnected hierarchical network.	[Moeller, Sebastian; Freiwald, Winrich A.; Tsao, Doris Y.] Univ Bremen, Inst Brain Res, D-28334 Bremen, Germany; [Moeller, Sebastian; Freiwald, Winrich A.; Tsao, Doris Y.] Univ Bremen, Ctr Adv Imaging, D-28334 Bremen, Germany	University of Bremen; University of Bremen	Tsao, DY (corresponding author), Univ Bremen, Inst Brain Res, POB 330440, D-28334 Bremen, Germany.	doris@nmr.mgh.harvard.edu			Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		BAYLIS GC, 1987, EXP BRAIN RES, V65, P614; Bosking WH, 1997, J NEUROSCI, V17, P2112; BRUCE V, 1986, BRIT J PSYCHOL, V77, P305, DOI 10.1111/j.2044-8295.1986.tb02199.x; Chein JM, 2005, COGNITIVE BRAIN RES, V25, P607, DOI 10.1016/j.cogbrainres.2005.08.013; Cheng K, 1997, J NEUROSCI, V17, P7902; Cohen JD, 2001, SCIENCE, V293, P2405, DOI 10.1126/science.1066018; EKSTROM LB, 2005, SOC NEUR ANN M WASH; EPSHTEIN B, 2006, IEEE COMP SOC C COMP; Fairhall SL, 2007, CEREB CORTEX, V17, P2400, DOI 10.1093/cercor/bhl148; Felleman DJ, 1997, J NEUROSCI, V17, P3185; Haxby JV, 2001, SCIENCE, V293, P2425, DOI 10.1126/science.1063736; LIVINGSTONE MS, 1984, J NEUROSCI, V4, P309; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Mathiesen C, 1998, J PHYSIOL-LONDON, V512, P555, DOI 10.1111/j.1469-7793.1998.555be.x; Pinsk MA, 2005, P NATL ACAD SCI USA, V102, P6996, DOI 10.1073/pnas.0502605102; Riesenhuber M, 1999, NAT NEUROSCI, V2, P1019, DOI 10.1038/14819; Saleem KS, 1996, J NEUROSCI, V16, P4757; SALEEM KS, 1993, CEREB CORTEX, V3, P454, DOI 10.1093/cercor/3.5.454; Saleem KS, 2000, J NEUROSCI, V20, P5083; Saleem KS, 2007, COMBINED MRI HISTOLO; SELTZER B, 1989, J COMP NEUROL, V290, P451, DOI 10.1002/cne.902900402; Summerfield C, 2006, SCIENCE, V314, P1311, DOI 10.1126/science.1132028; Suzuki W, 2000, J COMP NEUROL, V422, P206, DOI 10.1002/(SICI)1096-9861(20000626)422:2<206::AID-CNE5>3.0.CO;2-0; Tanaka K, 1996, ANNU REV NEUROSCI, V19, P109, DOI 10.1146/annurev.ne.19.030196.000545; Tolias AS, 2005, NEURON, V48, P901, DOI 10.1016/j.neuron.2005.11.034; Tsao DY, 2006, SCIENCE, V311, P670, DOI 10.1126/science.1119983; Tsao DY, 2003, NAT NEUROSCI, V6, P989, DOI 10.1038/nn1111; Ullman S, 2007, TRENDS COGN SCI, V11, P58, DOI 10.1016/j.tics.2006.11.009; Ungerleider LG, 2008, CEREB CORTEX, V18, P477, DOI 10.1093/cercor/bhm061; WEBSTER MJ, 1994, CEREB CORTEX, V4, P470, DOI 10.1093/cercor/4.5.470; WEBSTER MJ, 1991, J NEUROSCI, V11, P1095; WEBSTER MJ, 1993, J COMP NEUROL, V335, P73, DOI 10.1002/cne.903350106	32	290	292	2	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2008	320	5881					1355	1359		10.1126/science.1157436	http://dx.doi.org/10.1126/science.1157436			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309DO	18535247	Green Accepted			2022-12-28	WOS:000256441100049
J	Richardson, AJ; Poloczanska, ES				Richardson, Anthony J.; Poloczanska, Elvira S.			Ocean science - Under-resourced, under threat	SCIENCE			English	Editorial Material							CLIMATE-CHANGE; MARINE; IMPACT; BIODIVERSITY; PHENOLOGY; COMMUNITY; ECOLOGY		[Richardson, Anthony J.] CSIRO Marine & Atmospher Res, Climate Adaptat Flagship, Cleveland, Qld 4163, Australia; [Richardson, Anthony J.] Univ Queensland, Dept Math, St Lucia, Qld 4072, Australia; [Poloczanska, Elvira S.] CSIRO Marine & Atmospher Res, Climate Adaptat Flagship, Hobart, Tas 7001, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Queensland; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Richardson, AJ (corresponding author), CSIRO Marine & Atmospher Res, Climate Adaptat Flagship, POB 120, Cleveland, Qld 4163, Australia.	anthony.richardson@csiro.au; elvira.poloczanska@csiro.au	Poloczanska, Elvira/F-4366-2014; poloczanska, elvira/P-5356-2014; Richardson, Anthony J/B-3649-2010	Richardson, Anthony J/0000-0002-9289-7366; poloczanska, elvira/0000-0001-8470-0925				BARRY JP, 1995, SCIENCE, V267, P672, DOI 10.1126/science.267.5198.672; Beaugrand G, 2002, SCIENCE, V296, P1692, DOI 10.1126/science.1071329; Chambers LE, 2004, 100 BUR MET RES CTR; Duarte CM, 2007, TRENDS ECOL EVOL, V22, P331, DOI 10.1016/j.tree.2007.04.001; DUARTE CM, 1992, NATURE, V356, P190, DOI 10.1038/356190a0; Edwards K, 2004, PLANT BIOTECHNOL J, V2, P1, DOI 10.1111/j.1467-7652.2004.00058.x; Edwards M, 2004, NATURE, V430, P881, DOI 10.1038/nature02808; Field DB, 2006, SCIENCE, V311, P63, DOI 10.1126/science.1116220; Finkel ZV, 2007, P NATL ACAD SCI USA, V104, P20416, DOI 10.1073/pnas.0709381104; Halpern BS, 2008, SCIENCE, V319, P948, DOI 10.1126/science.1149345; Hendriks IE, 2006, SCIENCE, V312, P1715, DOI 10.1126/science.1128548; Kinlan BP, 2003, ECOLOGY, V84, P2007, DOI 10.1890/01-0622; Levin P, 2004, CONSERV BIOL, V18, P1160, DOI 10.1111/j.1523-1739.2004.00452.x; Mackas DL, 1998, CAN J FISH AQUAT SCI, V55, P1878, DOI 10.1139/cjfas-55-8-1878; Orr JC, 2005, NATURE, V437, P681, DOI 10.1038/nature04095; Parmesan C, 2003, NATURE, V421, P37, DOI 10.1038/nature01286; Raven J, 2005, OCEAN ACIDIFICATION; Root TL, 2003, NATURE, V421, P57, DOI 10.1038/nature01333; Rosenzweig C, 2007, AR4 CLIMATE CHANGE 2007: IMPACTS, ADAPTATION, AND VULNERABILITY, P79; Sabates A, 2006, GLOBAL CHANGE BIOL, V12, P2209, DOI 10.1111/j.1365-2486.2006.01246.x; STEELE JH, 1991, J THEOR BIOL, V153, P425, DOI 10.1016/S0022-5193(05)80579-X; Stergiou KI, 2005, MAR ECOL PROG SER, V304, P292; Visser ME, 2005, P ROY SOC B-BIOL SCI, V272, P2561, DOI 10.1098/rspb.2005.3356; Weishampel JF, 2004, GLOBAL CHANGE BIOL, V10, P1424, DOI 10.1111/j.1529-8817.2003.00817.x	24	163	166	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2008	320	5881					1294	1295		10.1126/science.1156129	http://dx.doi.org/10.1126/science.1156129			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309DO	18535230				2022-12-28	WOS:000256441100027
J	Schwarzberg, AB; Alexander, CB; DeAngelo, DJ; Helfgott, SM				Schwarzberg, Abraham B.; Alexander, Cristina B.; DeAngelo, Daniel J.; Helfgott, Simon M.			A joint venture	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; ADULT ACUTE-LEUKEMIA; MYELODYSPLASTIC SYNDROMES; MULTIVARIATE-ANALYSIS; GROUP-B; CANCER; MANIFESTATIONS		[Schwarzberg, Abraham B.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Schwarzberg, Abraham B.; Alexander, Cristina B.; DeAngelo, Daniel J.; Helfgott, Simon M.] Harvard Univ, Sch Med, Boston, MA USA; [Schwarzberg, Abraham B.; DeAngelo, Daniel J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Alexander, Cristina B.; Helfgott, Simon M.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital	Schwarzberg, AB (corresponding author), Massachusetts Gen Hosp, Dept Med, 10 N Grove St,POB 221, Boston, MA 02114 USA.	aschwarzberg@partners.org			NATIONAL CANCER INSTITUTE [P01CA066996, P01CA068484] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA68484, 2P01CA 066996-11A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARACTINGI S, 1995, J AM ACAD DERMATOL, V33, P187, DOI 10.1016/0190-9622(95)90232-5; BURNS CP, 1981, CANCER, V47, P2460, DOI 10.1002/1097-0142(19810515)47:10<2460::AID-CNCR2820471025>3.0.CO;2-4; BYRD JC, 1995, J CLIN ONCOL, V13, P1800, DOI 10.1200/JCO.1995.13.7.1800; Byrd JC, 1997, J CLIN ONCOL, V15, P466, DOI 10.1200/JCO.1997.15.2.466; CALDWELL DS, 1986, MED CLIN N AM, V70, P385, DOI 10.1016/S0025-7125(16)30960-9; DELMER A, 1989, J CLIN ONCOL, V7, P738, DOI 10.1200/JCO.1989.7.6.738; EVANS TI, 1994, SEMIN ARTHRITIS RHEU, V24, P48, DOI 10.1016/0049-0172(94)90099-X; Gur H, 1999, ACTA HAEMATOL-BASEL, V101, P1, DOI 10.1159/000040913; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; KARESH JW, 1989, J CLIN ONCOL, V7, P1528, DOI 10.1200/JCO.1989.7.10.1528; KINCAID MC, 1983, SURV OPHTHALMOL, V27, P211, DOI 10.1016/0039-6257(83)90123-6; LONGACRE TA, 1993, AM J CLIN PATHOL, V100, P276, DOI 10.1093/ajcp/100.3.276; PREISLER H, 1987, BLOOD, V69, P1441; SCHWARTZ RS, 1984, CANCER, V54, P1672, DOI 10.1002/1097-0142(19841015)54:8<1672::AID-CNCR2820540831>3.0.CO;2-F	14	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2008	358	23					2496	2501		10.1056/NEJMcps070565	http://dx.doi.org/10.1056/NEJMcps070565			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308HY	18525046				2022-12-28	WOS:000256380700010
J	Frikke-Schmidt, R; Nordestgaard, BG; Stene, MCA; Sethi, AA; Remaley, AT; Schnohr, P; Grande, P; Tybjaerg-Hansen, A				Frikke-Schmidt, Ruth; Nordestgaard, Borge G.; Stene, Maria C. A.; Sethi, Amar A.; Remaley, Alan T.; Schnohr, Peter; Grande, Peer; Tybjaerg-Hansen, Anne			Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTER TRANSFER PROTEIN; CORONARY-ARTERY-DISEASE; HDL CHOLESTEROL; MENDELIAN RANDOMIZATION; MYOCARDIAL-INFARCTION; TAQIB POLYMORPHISM; TANGIER-DISEASE; CARDIOVASCULAR-DISEASE; SELECTIVE RETENTION; LIPASE MUTATIONS	Context Low levels of high- density lipoprotein ( HDL) cholesterol are inversely related to cardiovascular risk. Whether this is a causal effect is unclear. Objective To determine whether genetically reduced HDL cholesterol due to heterozygosity for 4 loss- of- function mutations in ABCA1 cause increased risk of ischemic heart disease ( IHD). Design, Setting, and Participants Three studies of white individuals from Copenhagen, Denmark, were used: the Copenhagen City Heart Study ( CCHS), a 31-year prospective general population study ( n= 9022; 28 heterozygotes); the Copenhagen General Population Study ( CGPS), a cross- sectional general population study ( n= 31 241; 76 heterozygotes); and the Copenhagen Ischemic Heart Disease Study ( CIHDS), a case- control study ( n= 16 623; 44 heterozygotes). End points in all 3 studies were recorded during the period of January 1, 1976, through July 9, 2007. Main Outcome Measures Levels of HDL cholesterol in the general population, cellular cholesterol efflux, and the association between IHD and HDL cholesterol and genotype. Results Heterozygotes vs noncarriers for 4 ABCA1 mutations ( P1065S, G1216V, N1800H, R2144X) had HDL cholesterol levels of 41 mg/ dL ( interquartile range, 31- 50 mg/ dL) vs 58 mg/ dL ( interquartile range, 46- 73 mg/ dL), corresponding to a reduction in HDL cholesterol of 17 mg/ dL ( P <. 001). A 17- mg/ dL lower HDL cholesterol level in the CCHS was associated with a multifactorially adjusted hazard ratio for IHD of 1.70 ( 95% confidence interval [ CI], 1.57- 1.85). However, for IHD in heterozygotes vs noncarriers, the multifactorially adjusted hazard ratio was 0.67 ( 95% CI, 0.28-1.61; 1741 IHD events) in the CCHS, the multifactorially adjusted odds ratio was 0.82 ( 95% CI, 0.34- 1.96; 2427 IHD events) in the CGPS, and the multifactorially adjusted odds ratio was 0.86 ( 95% CI, 0.32- 2.32; 2498 IHD cases) in the CIHDS. The corresponding odds ratio for IHD in heterozygotes vs noncarriers for the combined studies ( n= 41 961; 6666 cases; 109 heterozygotes) was 0.93 ( 95% CI, 0.53- 1.62). Conclusion Lower plasma levels of HDL cholesterol due to heterozygosity for loss-of-function mutations in ABCA1 were not associated with an increased risk of IHD.	[Frikke-Schmidt, Ruth; Stene, Maria C. A.; Tybjaerg-Hansen, Anne] Univ Copenhagen Hosp, Dept Clin Biochem, Mol Genet Sect, Rigshosp, DK-2100 Copenhagen O, Denmark; [Grande, Peer] Rigshosp, Dept Cardiol, DK-2100 Copenhagen, Denmark; [Frikke-Schmidt, Ruth; Nordestgaard, Borge G.; Tybjaerg-Hansen, Anne] Herlev Hosp, Dept Clin Biochem, Copenhagen Gen Populat Study, DK-2730 Herlev, Denmark; [Nordestgaard, Borge G.; Schnohr, Peter; Tybjaerg-Hansen, Anne] Bispebjerg Hosp, Copenhagen City Heart Study, DK-2400 Copenhagen, Denmark; [Sethi, Amar A.; Remaley, Alan T.] Univ Copenhagen Hosp, Fac Hlth Sci, DK-2100 Copenhagen, Denmark; [Sethi, Amar A.; Remaley, Alan T.] NHLBI, Lipoprot Metab Sect, Vasc Med Branch, NIH, Bethesda, MD 20892 USA	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Tybjaerg-Hansen, A (corresponding author), Univ Copenhagen Hosp, Dept Clin Biochem, Mol Genet Sect, Rigshosp, KB3011,Blegdamsvej 9, DK-2100 Copenhagen O, Denmark.	at-h@rh.regionh.dk	Nordestgaard, Borge Gronne/ABF-1310-2020	Frikke-Schmidt, Ruth/0000-0003-4084-5027				Agerholm-Larsen B, 2000, CIRCULATION, V101, P1907, DOI 10.1161/01.CIR.101.16.1907; Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P630, DOI 10.1161/01.ATV.0000014804.35824.DA; Andersen RV, 2003, J AM COLL CARDIOL, V41, P1972, DOI 10.1016/S0735-1097(03)00407-8; ARMITAGE P, 1987, STAT METHODS MED RES, P67; Assmann G, 2001, METABOLIC MOL BASES, P2937; Barter PJ, 2007, NEW ENGL J MED, V357, P2109, DOI 10.1056/NEJMoa0706628; Borggreve SE, 2006, J CLIN ENDOCR METAB, V91, P3382, DOI 10.1210/jc.2005-2322; Brousseau ME, 2002, ARTERIOSCL THROM VAS, V22, P1148, DOI 10.1161/01.ATV.0000024566.57589.2E; Clarke R, 1999, AM J EPIDEMIOL, V150, P341; Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727; Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870; Cuchel M, 2006, CIRCULATION, V113, P2548, DOI 10.1161/CIRCULATIONAHA.104.475715; Eiriksdottir G, 2001, ATHEROSCLEROSIS, V159, P187, DOI 10.1016/S0021-9150(01)00489-0; Freeman DJ, 2003, EUR HEART J, V24, P1833, DOI 10.1016/j.ehj.2003.07.001; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Frikke-Schmidt R, 2004, J CLIN INVEST, V114, P1343, DOI 10.1172/JCI200420361; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014; Hokanson JE, 2002, DIABETES, V51, P1208, DOI 10.2337/diabetes.51.4.1208; Humphries SE, 1998, ARTERIOSCL THROM VAS, V18, P526, DOI 10.1161/01.ATV.18.4.526; Julian DG, 1997, EUR HEART J, V18, P394; Kastelein JJP, 1998, CLIN GENET, V53, P27, DOI 10.1034/j.1399-0004.1998.531530106.x; Kastelein JJP, 2007, NEW ENGL J MED, V356, P1620, DOI 10.1056/NEJMoa071359; Klein, 2003, SURVIVAL ANAL TECHNI, P295, DOI [10.1007/b97377, DOI 10.1007/B97377]; Kolovou GD, 2005, CURR MED CHEM, V12, P1931, DOI 10.2174/0929867054546609; Kuivenhoven JA, 1997, J LIPID RES, V38, P191; Liu S, 2002, ATHEROSCLEROSIS, V161, P469, DOI 10.1016/S0021-9150(01)00673-6; Liu SM, 2003, ATHEROSCLEROSIS, V166, P415, DOI 10.1016/S0021-9150(02)00108-9; Mahley RW., 2001, METABOLIC MOL BASES, V8th ed, P2835; Navab M, 2006, NAT CLIN PRACT ENDOC, V2, P504, DOI 10.1038/ncpendmet0245; Nissen SE, 2007, NEW ENGL J MED, V357, P835; Nissen SE, 2007, NEW ENGL J MED, V356, P1304, DOI 10.1056/NEJMoa070635; Nitsch D, 2006, AM J EPIDEMIOL, V163, P397, DOI 10.1093/aje/kwj062; Nordestgaard BG, 1996, CURR OPIN LIPIDOL, V7, P269, DOI 10.1097/00041433-199610000-00002; Nordestgaard BG, 1997, CIRCULATION, V96, P1737, DOI 10.1161/01.CIR.96.6.1737; NORDESTGAARD BG, 1995, ARTERIOSCL THROM VAS, V15, P534, DOI 10.1161/01.ATV.15.4.534; Nordestgaard BG, 2007, JAMA-J AM MED ASSOC, V298, P299, DOI 10.1001/jama.298.3.299; Ordovas JM, 2000, ARTERIOSCL THROM VAS, V20, P1323, DOI 10.1161/01.ATV.20.5.1323; Out R, 2008, CIRC RES, V102, P113, DOI 10.1161/CIRCRESAHA.107.161711; Qasim Atif, 2006, Curr Atheroscler Rep, V8, P198, DOI 10.1007/s11883-006-0074-0; Reilly MP, 2007, J CLIN INVEST, V117, P595, DOI 10.1172/JCI31608; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; SCHAEFER EJ, 1980, ANN INTERN MED, V93, P261, DOI 10.7326/0003-4819-93-2-261; Schnohr P, 2001, EUR HEART J SUPPL, V3, pH1; SERFATYLACROSNIERE C, 1994, ATHEROSCLEROSIS, V107, P85, DOI 10.1016/0021-9150(94)90144-9; SHAIKH M, 1991, ARTERIOSCLER THROMB, V11, P569, DOI 10.1161/01.ATV.11.3.569; Smith GD, 2004, INT J EPIDEMIOL, V33, P30, DOI 10.1093/ije/dyh132; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; TALL AR, 2001, METABOLIC MOL BASES, P2915; Tybjaerg-Hansen A, 1998, NEW ENGL J MED, V338, P1577, DOI 10.1056/NEJM199805283382203; Vaisar T, 2007, J CLIN INVEST, V117, P746, DOI 10.1172/JCI26206; Van Eck M, 2002, P NATL ACAD SCI USA, V99, P6298, DOI 10.1073/pnas.092327399; Wittrup HH, 1999, ARTERIOSCL THROM VAS, V19, P1535, DOI 10.1161/01.ATV.19.6.1535; Wittrup HH, 2006, J CLIN ENDOCR METAB, V91, P1438, DOI 10.1210/jc.2005-1725; Wittrup HH, 1997, J CLIN INVEST, V99, P1606, DOI 10.1172/JCI119323; Wittrup HH, 1999, CIRCULATION, V99, P2901, DOI 10.1161/01.CIR.99.22.2901; Zhong SB, 1996, J CLIN INVEST, V97, P2917, DOI 10.1172/JCI118751; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473; 1989, SCAND J SOC MED S, V41, P1	59	373	378	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2008	299	21					2524	2532		10.1001/jama.299.21.2524	http://dx.doi.org/10.1001/jama.299.21.2524			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308AR	18523221	Bronze			2022-12-28	WOS:000256361200024
J	Cappuccio, FP				Cappuccio, Francesco P.			Commentary: Controversies in NICE guidance on lipid modification for the prevention of cardiovascular disease	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							TRIAL		[Cappuccio, Francesco P.] Univ Warwick, Sch Med, Clin Sci Res Inst, Coventry CV2 2DX, W Midlands, England	University of Warwick	Cappuccio, FP (corresponding author), Univ Warwick, Sch Med, Clin Sci Res Inst, Coventry CV2 2DX, W Midlands, England.	f.p.cappuccio@warwick.ac.uk	Cappuccio, Francesco/D-3028-2009	Cappuccio, Francesco Paolo/0000-0002-7842-5493				Brindle P, 2006, HEART, V92, P1595, DOI 10.1136/hrt.2006.092346; *BRIT CARD SOC, 2005, HEART S5, V91, P52; Cappuccio FP, 2002, BRIT MED J, V325, P1271, DOI 10.1136/bmj.325.7375.1271; Cappuccio FP, 2007, BMJ-BRIT MED J, V334, P859, DOI 10.1136/bmj.39175.364954.BE; Little P, 2004, BMJ-BRIT MED J, V328, P1054, DOI 10.1136/bmj.38037.435972.EE; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; WHO Expert Committee on Problems Related to Alcohol Consumption, 2007, World Health Organ Tech Rep Ser, P1; Williams B, 2004, J HUM HYPERTENS, V18, P139, DOI 10.1038/sj.jhh.1001683	8	1	1	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	2008	336	7655					1248	1249		10.1136/bmj.39580.424352.AD	http://dx.doi.org/10.1136/bmj.39580.424352.AD			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311PS	18511801	Green Published, Green Submitted			2022-12-28	WOS:000256612700035
J	Hughes, WOH; Oldroyd, BP; Beekman, M; Ratnieks, FLW				Hughes, William O. H.; Oldroyd, Benjamin P.; Beekman, Madeleine; Ratnieks, Francis L. W.			Ancestral monogamy shows kin selection is key to the evolution of eusociality	SCIENCE			English	Article							SPHECID WASP; MOLE-RAT; RELATEDNESS; ORIGIN; BEES; MICROSTIGMUS; SOCIALITY; ALTRUISM; INSECTS	Close relatedness has long been considered crucial to the evolution of eusociality. However, it has recently been suggested that close relatedness may be a consequence, rather than a cause, of eusociality. We tested this idea with a comparative analysis of female mating frequencies in 267 species of eusocial bees, wasps, and ants. We found that mating with a single male, which maximizes relatedness, is ancestral for all eight independent eusocial lineages that we investigated. Mating with multiple males is always derived. Furthermore, we found that high polyandry (> 2 effective mates) occurs only in lineages whose workers have lost reproductive totipotency. These results provide the first evidence that monogamy was critical in the evolution of eusociality, strongly supporting the prediction of inclusive fitness theory.	[Hughes, William O. H.] Univ Leeds, Inst Integrat & Comparat Biol, Leeds LS2 9JT, W Yorkshire, England; [Oldroyd, Benjamin P.; Beekman, Madeleine] Univ Sydney, Sch Biol Sci, Sydney, NSW 2006, Australia; [Ratnieks, Francis L. W.] Univ Sussex, Dept Biol & Environm Sci, Brighton BN1 9QG, E Sussex, England	University of Leeds; University of Sydney; University of Sussex	Hughes, WOH (corresponding author), Univ Leeds, Inst Integrat & Comparat Biol, Leeds LS2 9JT, W Yorkshire, England.	w.o.h.hughes@leeds.ac.uk	Hughes, William OH/A-6957-2014; Oldroyd, Benjamin/A-4800-2008; Beekman, Madeleine/AAF-8574-2019; Beekman, Madeleine/A-3983-2011	Hughes, William OH/0000-0003-0951-9768; Oldroyd, Benjamin/0000-0001-6831-3677; Beekman, Madeleine/0000-0002-9040-3756; Beekman, Madeleine/0000-0002-9040-3756				Beekman M, 2006, BEHAV ECOL, V17, P622, DOI 10.1093/beheco/ark006; Boomsma JJ, 2007, CURR BIOL, V17, pR673, DOI 10.1016/j.cub.2007.06.033; Brady SG, 2006, P ROY SOC B-BIOL SCI, V273, P1643, DOI 10.1098/rspb.2006.3496; Burland TM, 2002, P ROY SOC B-BIOL SCI, V269, P1025, DOI 10.1098/rspb.2002.1978; Chapman TW, 2000, P NATL ACAD SCI USA, V97, P1648, DOI 10.1073/pnas.020510097; CRESPI BJ, 1995, BEHAV ECOL, V6, P109, DOI 10.1093/beheco/6.1.109; Crozier RH, 2008, AUST J ENTOMOL, V47, P2, DOI 10.1111/j.1440-6055.2007.00621.x; Duffy JE, 2002, GENES BEHAV EVOLUTIO, V217, P254; Field J, 2000, NATURE, V404, P869, DOI 10.1038/35009097; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Helantera H, 2007, OIKOS, V116, P217, DOI 10.1111/j.0030-1299.2007.15411.x; Hines HM, 2007, P NATL ACAD SCI USA, V104, P3295, DOI 10.1073/pnas.0610140104; HUGHES WOH, 2008, J EVOLUTION BIOL, DOI DOI 10.1111/J.14202008.01532.X; KIRKENDALL LR, 1997, EVOLUTION SOCIAL BEH; MATTHEWS RW, 1968, SCIENCE, V160, P787, DOI 10.1126/science.160.3829.787; Queller DC, 1998, BIOSCIENCE, V48, P165, DOI 10.2307/1313262; REEVE HK, 1990, P NATL ACAD SCI USA, V87, P2496, DOI 10.1073/pnas.87.7.2496; ROSS KG, 1989, ANIM BEHAV, V38, P613, DOI 10.1016/S0003-3472(89)80006-5; Schwarz MP, 2003, SYST BIOL, V52, P1, DOI 10.1080/10635150390132632; Strassmann J, 2001, INSECT SOC, V48, P1, DOI 10.1007/PL00001737; Sumner S, 2004, NATURE, V428, P35, DOI 10.1038/428035a; Sumner S, 2007, CURR BIOL, V17, P140, DOI 10.1016/j.cub.2006.11.064; Tarpy DR, 2004, INSECT SOC, V51, P203, DOI 10.1007/s00040-004-0734-4; Thompson GJ, 2004, MOL PHYLOGENET EVOL, V33, P452, DOI 10.1016/j.ympev.2004.06.016; Wilson E.O., 1975, P1; Wilson EO, 2008, BIOSCIENCE, V58, P17, DOI 10.1641/B580106; Wilson EO, 2005, SOC RES, V72, P159; Wilson EO, 2005, P NATL ACAD SCI USA, V102, P13367, DOI 10.1073/pnas.0505858102	28	447	456	2	567	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	2008	320	5880					1213	1216		10.1126/science.1156108	http://dx.doi.org/10.1126/science.1156108			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306FF	18511689				2022-12-28	WOS:000256233000038
J	Michaelson, MD; Iliopoulos, O; McDermott, DF; McGovern, FJ; Harisinghani, MG; Oliva, E				Michaelson, M. Dror; Iliopoulos, Othon; McDermott, David F.; McGovern, Francis J.; Harisinghani, Mukesh G.; Oliva, Esther			A man with metastatic renal-cell carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH-FACTOR ANTIBODY; CARBONIC-ANHYDRASE-IX; PHASE-III TRIAL; INTERFERON-ALPHA; SUBCUTANEOUS INTERLEUKIN-2; RADIOFREQUENCY ABLATION; DOSE INTERLEUKIN-2; PROGNOSTIC-FACTORS; SURVIVAL; CANCER		[Michaelson, M. Dror] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA; [Iliopoulos, Othon] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; [McGovern, Francis J.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; [Harisinghani, Mukesh G.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Oliva, Esther] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [McDermott, David F.] Harvard Univ, Sch Med, Dept Hematol Oncol, Beth Israel Deaconess Med Ctr, Boston, MA USA; [Michaelson, M. Dror; Iliopoulos, Othon; McDermott, David F.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [McGovern, Francis J.] Harvard Univ, Sch Med, Dept Surg, Boston, MA USA; [Harisinghani, Mukesh G.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA USA; [Oliva, Esther] Harvard Univ, Sch Med, Dept Pathol, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Michaelson, MD (corresponding author), Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA.		Harisinghani, Mukesh/D-7590-2011; Harisinghani, Mukesh/G-1347-2010	Michaelson, Dror/0000-0001-9249-6338				Amin MB, 2002, AM J SURG PATHOL, V26, P281, DOI 10.1097/00000478-200203000-00001; Atkins M, 2005, CLIN CANCER RES, V11, P3714, DOI 10.1158/1078-0432.CCR-04-2019; BELLDEGRUN A, 1989, J UROLOGY, V141, P499, DOI 10.1016/S0022-5347(17)40872-X; BRETHEAU D, 1995, CANCER, V76, P2543, DOI 10.1002/1097-0142(19951215)76:12<2543::AID-CNCR2820761221>3.0.CO;2-S; Bui MHT, 2003, CLIN CANCER RES, V9, P802; Chang AE, 2003, J CLIN ONCOL, V21, P884, DOI 10.1200/JCO.2003.08.023; Cheville JC, 2003, AM J SURG PATHOL, V27, P612, DOI 10.1097/00000478-200305000-00005; Childs R, 2000, NEW ENGL J MED, V343, P750, DOI 10.1056/NEJM200009143431101; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Coppin C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001425.pub2; de Peralta-Venturina M, 2001, AM J SURG PATHOL, V25, P275, DOI 10.1097/00000478-200103000-00001; Escudier B, 2007, NEW ENGL J MED, V357, P203; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Flanigan RC, 2001, NEW ENGL J MED, V345, P1655, DOI 10.1056/NEJMoa003013; FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688; Gervais DA, 2005, AM J ROENTGENOL, V185, P64, DOI 10.2214/ajr.185.1.01850064; Gervais DA, 2005, AM J ROENTGENOL, V185, P72, DOI 10.2214/ajr.185.1.01850072; Gleave ME, 1998, NEW ENGL J MED, V338, P1265, DOI 10.1056/NEJM199804303381804; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Iliopoulos O, 2006, J CLIN ONCOL, V24, P5593, DOI 10.1200/JCO.2006.08.8948; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jiang Z, 2006, LANCET ONCOL, V7, P556, DOI 10.1016/S1470-2045(06)70732-X; Kaelin WG, 2004, CLIN CANCER RES, V10, p6290S, DOI 10.1158/1078-0432.CCR-sup-040025; Lam John S, 2005, Curr Urol Rep, V6, P7, DOI 10.1007/s11934-005-0062-x; Lam JS, 2005, J UROLOGY, V173, P1853, DOI 10.1097/01.ju.0000165693.68449.c3; Leibovich BC, 2003, CANCER-AM CANCER SOC, V98, P2566, DOI 10.1002/cncr.11851; Lesimple T, 2000, J IMMUNOTHER, V23, P675, DOI 10.1097/00002371-200011000-00009; MARGOLIN KA, 1989, J CLIN ONCOL, V7, P486, DOI 10.1200/JCO.1989.7.4.486; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McDermott DF, 2005, J CLIN ONCOL, V23, P133, DOI 10.1200/JCO.2005.03.206; McDermott DF, 2005, J CLIN ONCOL, V23, P2877; Mickisch GHJ, 2001, LANCET, V358, P966, DOI 10.1016/S0140-6736(01)06103-7; Moch H, 2000, CANCER, V89, P604, DOI 10.1002/1097-0142(20000801)89:3<604::AID-CNCR16>3.3.CO;2-H; Motzer RJ, 1999, J CLIN ONCOL, V17, P2530, DOI 10.1200/JCO.1999.17.8.2530; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Motzer RJ, 2006, JAMA-J AM MED ASSOC, V295, P2516, DOI 10.1001/jama.295.21.2516; Negrier S, 2005, J CLIN ONCOL, V23, p380S; Negrier S, 2000, J CLIN ONCOL, V18, P4009, DOI 10.1200/JCO.2000.18.24.4009; Negrier S, 2002, ANN ONCOL, V13, P1460, DOI 10.1093/annonc/mdf257; Pantuck AJ, 2005, J CLIN ONCOL, V23, p386S; Rini BI, 2004, CLIN CANCER RES, V10, P2584, DOI 10.1158/1078-0432.CCR-03-0605; Ritchie A, 1999, LANCET, V353, P14; Schwartz BF, 2006, UROLOGY, V68, P14, DOI 10.1016/j.urology.2006.03.067; Shuch BM, 2006, SEMIN ONCOL, V33, P563, DOI 10.1053/j.seminoncol.2006.06.006; Stein RJ, 2007, BJU INT, V99, P1265, DOI 10.1111/j.1464-410X.2007.06816.x; Upton MP, 2005, J IMMUNOTHER, V28, P488, DOI 10.1097/01.cji.0000170357.14962.9b; VOGELZANG NJ, 1992, J UROLOGY, V148, P1247, DOI 10.1016/S0022-5347(17)36874-X; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491; Yang JC, 2003, J CLIN ONCOL, V21, P3127, DOI 10.1200/JCO.2003.02.122	53	6	6	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2008	358	22					2389	2396		10.1056/NEJMcpc0802449	http://dx.doi.org/10.1056/NEJMcpc0802449			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307GF	18509125				2022-12-28	WOS:000256306700011
J	Anderson, JS; Reisz, RR; Scott, D; Frobisch, NB; Sumida, SS				Anderson, Jason S.; Reisz, Robert R.; Scott, Diane; Frobisch, Nadia B.; Sumida, Stuart S.			A stem batrachian from the Early Permian of Texas and the origin of frogs and salamanders	NATURE			English	Article							PHYLOGENY; ANCESTRY	The origin of extant amphibians (Lissamphibia: frogs, salamanders and caecilians) is one of the most controversial questions in vertebrate evolution, owing to large morphological and temporal gaps in the fossil record(1-3). Current discussions focus on three competing hypotheses: a monophyletic origin within either Temnospondyli(4-7) or Lepospondyli(8-10), or a polyphyletic origin with frogs and salamanders arising among temnospondyls and caecilians among the lepospondyls(11-16). Recent molecular analyses are also controversial, with estimations for the batrachian (frog salamander) divergence significantly older than the palaeontological evidence supports(17,18). Here we report the discovery of an amphibamid temnospondyl from the Early Permian of Texas that bridges the gap between other Palaeozoic amphibians and the earliest known salientians(19,20) and caudatans(21) from the Mesozoic. The presence of a mosaic of salientian and caudatan characters in this small fossil makes it a key taxon close to the batrachian (frog and salamander) divergence. Phylogenetic analysis suggests that the batrachian divergence occurred in the Middle Permian, rather than the late Carboniferous as recently estimated using molecular clocks(18,22), but the divergence with caecilians corresponds to the deep split between temnospondyls and lepospondyls, which is congruent with themolecular estimates.	[Anderson, Jason S.] Univ Calgary, Dept Comparat Biol & Expt Med, Fac Vet Med, Calgary, AB T2N 4N1, Canada; [Reisz, Robert R.; Scott, Diane] Univ Toronto, Dept Biol, Mississauga, ON L5L 1C6, Canada; [Frobisch, Nadia B.] McGill Univ, Redpath Museum, Montreal, PQ H3A 2K6, Canada; [Sumida, Stuart S.] Calif State Univ San Bernardino, Dept Biol, San Bernardino, CA 92407 USA	University of Calgary; University of Toronto; University Toronto Mississauga; McGill University; California State University System; California State University San Bernardino	Anderson, JS (corresponding author), Univ Calgary, Dept Comparat Biol & Expt Med, Fac Vet Med, 3330 Hosp Dr, Calgary, AB T2N 4N1, Canada.	janders@ucalgary.ca						Anderson Jason S., 2007, P182; Anderson JS, 2008, J VERTEBR PALEONTOL, V28, P61, DOI 10.1671/0272-4634(2008)28[61:GCANGA]2.0.CO;2; Anderson JS, 2001, SYST BIOL, V50, P170; [Anonymous], 2020, BIOL AMPHIBIANS, V28, P32; [Anonymous], 2004, RECENT ADV ORIGIN EA; Bolt J.R., 1991, P194; Carroll R, 2004, NEUES JAHRB GEOL P-A, V232, P157; CARROLL RL, 1975, ZOOL J LINN SOC-LOND, V57, P229, DOI 10.1111/j.1096-3642.1975.tb00817.x; Carroll RL, 2007, ZOOL J LINN SOC-LOND, V150, P1, DOI 10.1111/j.1096-3642.2007.00246.x; Carroll Robert L., 2000, Amphibian Biology, V4, P1402; Frobisch NB, 2007, EVOL DEV, V9, P69; Gao KQ, 2003, NATURE, V422, P424, DOI 10.1038/nature01491; Ivachnenko M, 1978, PALEONTOL J, V1978, P362; Laurin M, 1998, ANN SCI NAT ZOOL, V19, P1, DOI 10.1016/S0003-4339(98)80132-9; Laurin Michel, 1997, P9, DOI 10.1016/B978-012676460-4/50003-2; Lee MSY, 2006, MOL PHYLOGENET EVOL, V40, P635, DOI 10.1016/j.ympev.2006.03.013; Milner Andrew R., 1993, Herpetological Monographs, V7, P8, DOI 10.2307/1466948; MILNER AR, 1988, PHYLOGENY CLASSIFICA, V1, P59; Piveteau J., 1937, ANN PALEONTOL, V26, P135; RAGE JC, 1989, Z PALAEONTOGRAPHIC A, V206, P1; Ruta M, 2003, BIOL REV, V78, P251, DOI 10.1017/S1464793102006103; Ruta M, 2007, J SYST PALAEONTOL, V5, P69, DOI 10.1017/S1477201906002008; San Mauro D, 2005, AM NAT, V165, P590, DOI 10.1086/429523; San Mauro D, 2004, MOL PHYLOGENET EVOL, V33, P413, DOI 10.1016/j.ympev.2004.05.014; Shubin Neil H., 2003, Amphibian Biology, V5, P1782; Trueb L, 1991, ORIGINS HIGHER GROUP, P174; Trueb Linda, 1993, P255; Vallin G, 2004, J VERTEBR PALEONTOL, V24, P56, DOI 10.1671/5.1; Wang Y, 2004, CHINESE SCI BULL, V49, P858, DOI 10.1360/03wd0115; Zhang P, 2005, SYST BIOL, V54, P391, DOI 10.1080/10635150590945278	30	155	161	2	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 22	2008	453	7194					515	518		10.1038/nature06865	http://dx.doi.org/10.1038/nature06865			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303EL	18497824				2022-12-28	WOS:000256023700041
J	Holvoet, P; Lee, DH; Steffes, M; Gross, M; Jacobs, DR				Holvoet, Paul; Lee, Duk-Hee; Steffes, Michael; Gross, Myron; Jacobs, David R., Jr.			Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-DISEASE; RISK-FACTORS; LDL; PLASMA; HEALTH; MEN; ATHEROSCLEROSIS; COMPLICATIONS; ADIPOGENESIS; MORTALITY	Context Experimental data support the hypothesis that oxidized low-density lipoprotein (LDL) is associated with the metabolic syndrome. However, this hypothesis has not been tested in humans. Objective To establish the relation of oxidized LDL with metabolic syndrome in the general community. Design, Setting, and Participants The Coronary Artery Risk Development in Young Adults (CARDIA) study is a population-based, prospective, observational study. We studied 1889 participants who were between the ages of 18 and 30 years at the time of recruitment in 1985 and 1986 and living in 1 of 4 US metropolitan areas (41% African American; 56% women) and were seen both at year 15 (2000-2001, ages 33-45 years) and year 20 examinations (2005-2006). Main Outcome Measure The longitudinal association of oxidized LDL and incident metabolic syndrome. Oxidized LDL was measured with a monoclonal antibody-based enzyme-linked immunosorbent assay. The metabolic syndrome was defined according to the Adult Treatment Panel III of the National Cholesterol Education Program. Results Incident metabolic syndrome was diagnosed at the year 20 follow-up in 12.9% (243 of 1889) of participants who did not have metabolic syndrome at the 15-year follow-up. The odds ratios (ORs) for incident metabolic syndrome after 5 years' follow-up and adjusted for age, sex, race, study center, cigarette smoking, body mass index, physical activity, and LDL cholesterol levels by quintiles of oxidized LDL were 2.1 (95% confidence interval [CI], 1.1-3.8) for the second quintile (55.4-69.1 U/L); 2.4 (95% CI, 1.3-4.3) for the third quintile (69.2-81.2 U/L); 2.8 (95% CI, 1.5-5.1) for the fourth quintile (81.3-97.3 U/L); and 3.5 (95% CI, 1.9-6.6) for the fifth quintile (>= 97.4U/L). The adjusted ORs for incidence of dichotomous components of metabolic syndrome in the highest vs the lowest quintile of oxidized LDL were 2.1 (95% CI, 1.2-3.6) for abdominal obesity, 2.4 (95% CI, 1.5-3.8) for high fasting glucose, and 2.1 (95% CI, 1.1-4.0) for high triglycerides. Low-density lipoprotein cholesterol was not associated with incident metabolic syndrome or with any of its components in the fully adjusted model containing oxidized LDL. Conclusion Higher concentration of oxidized LDL was associated with increased incidence of metabolic syndrome overall, as well as its components of abdominal obesity, hyperglycemia, and hypertriglyceridemia.	[Lee, Duk-Hee; Jacobs, David R., Jr.] Univ Minnesota, Div Epidemiol & Community Hlth, Sch Publ Hlth, Minneapolis, MN 55454 USA; [Steffes, Michael; Gross, Myron] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55454 USA; [Holvoet, Paul] Katholieke Univ Leuven, Atherosclerosis & Metab Unit, Louvain, Belgium; [Lee, Duk-Hee] Kyungpook Natl Univ, Dept Prevent Med, Sch Med, Taegu, South Korea; [Jacobs, David R., Jr.] Univ Oslo, Dept Nutr, Oslo, Norway	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; KU Leuven; Kyungpook National University; University of Oslo	Jacobs, DR (corresponding author), Univ Minnesota, Div Epidemiol & Community Hlth, Sch Publ Hlth, 1300 S 2nd St,Ste 300, Minneapolis, MN 55454 USA.	jacob004@umn.edu	HOLVOET, PAUL/T-8434-2017	HOLVOET, PAUL/0000-0001-9201-0772; Jacobs, David/0000-0002-7232-0543	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC048048, N01HC048050, N01HC048047, N01HC048049] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053560, R01HL048049, R01HL048050, R29HL048048, R01HL048048] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-48049, 1R01-HL53560, N01HC48049, N01HC95095, N01-HC-48050, R01 HL053560, N01HC48050, N01-HC-48048, N01HC48048, N01-HC-48047, R01 HL053560-05, N01HC48047] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVOGARO P, 1988, ARTERIOSCLEROSIS, V8, P79, DOI 10.1161/01.ATV.8.1.79; Chen NG, 2000, ATHEROSCLEROSIS, V152, P203, DOI 10.1016/S0021-9150(99)00460-8; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cnop M, 2003, DIABETOLOGIA, V46, P459, DOI 10.1007/s00125-003-1074-z; Cutter G R, 1991, Control Clin Trials, V12, p1S, DOI 10.1016/0197-2456(91)90002-4; Ehara S, 2001, CIRCULATION, V103, P1955, DOI 10.1161/01.cir.103.15.1955; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FRIEDMAN GD, 1988, J CLIN EPIDEMIOL, V41, P1105, DOI 10.1016/0895-4356(88)90080-7; Holvoet P, 2006, CLIN CHEM, V52, P760, DOI 10.1373/clinchem.2005.064337; Holvoet P, 1998, CIRCULATION, V98, P1487, DOI 10.1161/01.CIR.98.15.1487; Holvoet P, 2004, DIABETES, V53, P1068, DOI 10.2337/diabetes.53.4.1068; Holvoet P, 2003, ARTERIOSCL THROM VAS, V23, P1444, DOI 10.1161/01.ATV.0000080379.05071.22; Holvoet P, 2001, ARTERIOSCL THROM VAS, V21, P844, DOI 10.1161/01.ATV.21.5.844; Holvoet P, 1998, ARTERIOSCL THROM VAS, V18, P100, DOI 10.1161/01.ATV.18.1.100; Holvoet P, 2007, ATHEROSCLEROSIS, V194, P245, DOI 10.1016/j.atherosclerosis.2006.08.002; Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683; Isomaa B, 2001, DIABETOLOGIA, V44, P1148, DOI 10.1007/s001250100615; Jacobs David R Jr, 1989, J Cardiopulm Rehabil, V9, P448, DOI 10.1097/00008483-198911000-00003; Koonen DPY, 2007, DIABETES, V56, P2863, DOI 10.2337/db07-0907; Lamarche B, 1998, CORONARY ARTERY DIS, V9, P473, DOI 10.1097/00019501-199809080-00002; Lapointe A, 2007, ATHEROSCLEROSIS, V191, P362, DOI 10.1016/j.atherosclerosis.2006.03.036; Lindblad U, 2001, AM J EPIDEMIOL, V153, P481, DOI 10.1093/aje/153.5.481; Macy EM, 1997, CLIN CHEM, V43, P52; Maddux BA, 2001, DIABETES, V50, P404, DOI 10.2337/diabetes.50.2.404; Masella R, 2006, FEBS LETT, V580, P2421, DOI 10.1016/j.febslet.2006.03.068; Maziere C, 2004, ATHEROSCLEROSIS, V175, P23, DOI 10.1016/j.atherosclerosis.2004.02.006; National cholesterol education program National heart lung and blood institute National institutes of health, 2002, 3 REP NAT CHOL ED PR; Nishimura S, 2007, DIABETES, V56, P1517, DOI 10.2337/db06-1749; Shepherd J, 2001, CURR OPIN LIPIDOL, V12, P601, DOI 10.1097/00041433-200112000-00002; Shoji T, 2000, ATHEROSCLEROSIS, V148, P171, DOI 10.1016/S0021-9150(99)00218-X; Sigurdardottir V, 2002, J INTERN MED, V252, P440, DOI 10.1046/j.1365-2796.2002.01054.x; Trevisan M, 1998, AM J EPIDEMIOL, V148, P958; Tsimikas S, 2003, J AM COLL CARDIOL, V41, P360, DOI 10.1016/S0735-1097(02)02769-9; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; Verreth W, 2004, CIRCULATION, V110, P3259, DOI 10.1161/01.CIR.0000147614.85888.7A; Weinbrenner T, 2006, AM J CLIN NUTR, V83, P30; Yamagishi S, 2007, INT J CARDIOL, V118, P270, DOI 10.1016/j.ijcard.2006.06.058	38	240	266	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2008	299	19					2287	2293		10.1001/jama.299.19.2287	http://dx.doi.org/10.1001/jama.299.19.2287			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302QN	18492970	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000255984500023
J	Hillier, TA; Vesco, KK; Pedula, KL; Beil, TL; Whitlock, EP; Pettitt, DJ				Hillier, Teresa A.; Vesco, Kimberly K.; Pedula, Kathryn L.; Beil, Tracy L.; Whitlock, Evelyn P.; Pettitt, David J.			Screening for gestational diabetes mellitus: A systematic review for the US preventive services task force	ANNALS OF INTERNAL MEDICINE			English	Article							INTERNATIONAL WORKSHOP-CONFERENCE; DIAGNOSIS; INSULIN; PREGNANCY; GLYBURIDE; HEALTH; TRIAL; WOMEN; RECOMMENDATIONS; MANAGEMENT	Background: In 2003, the U. S. Preventive Services Task Force concluded that evidence was insufficient to advise for or against routinely screening all pregnant women for gestational diabetes mellitus. Purpose: To review evidence about the benefits and harms of screening for gestational diabetes. Data Sources: Databases (MEDLINE, Database of Abstracts of Reviews of Effects, Health Technology Assessment Database, National Institute for Health and Clinical Effectiveness, and Cochrane Library) were searched for reports published from January 2000 to 15 November 2007 (and from 1966 to 1999 for additional studies on screening at less than 24 weeks' gestation), citations in the 2003 evidence report, and studies identified through consultation of experts and searches of bibliographies. Study Selection: English-language studies that used standard 1- or 2- step testing for gestational diabetes and that evaluated at least 1 of the following outcomes: neonatal mortality; brachial plexus injury; clavicular fracture; admission to a neonatal intensive care unit for hypoglycemia, hyperbilirubinemia, or the respiratory distress syndrome; maternal mortality; and preeclampsia or pregnancy- induced hypertension. Data Extraction: 2 reviewers evaluated 1607 abstracts, critically appraised 288 articles, and qualitatively synthesized 13 studies. Data Synthesis: No randomized, controlled trials that directly evaluated the risks and benefits of gestational diabetes screening were found. One good- quality randomized, controlled trial of treatment of mild gestational diabetes in a screening- detected population supported a reduction in serious neonatal complications and showed that gestational diabetes treatment also reduced the risk for gestational hypertension. Very limited evidence was found to evaluate early screening for gestational diabetes (before 24 weeks' gestation). Limited evidence suggests that serious maternal hypoglycemia is rare with treatment and that overall quality of life is not worse among women receiving gestational diabetes treatment compared with women not receiving treatment. Limitation: The literature is limited by lack of a consistent standard for screening or diagnosis of gestational diabetes.	[Hillier, Teresa A.] Kaiser Permanente NW, Portland, OR USA; Sansun Diabet Res Inst, Santa Barbara, CA USA	Kaiser Permanente; William Sansum Diabetes Center	Hillier, TA (corresponding author), Kaiser Permanente NW, Portland, OR USA.				PHS HHS [290-02-0024] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ahluwalia IB, 2005, J WOMENS HEALTH, V14, P382, DOI 10.1089/jwh.2005.14.382; Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Am Diabetes Assoc, 2006, DIABETES CARE, V29, pS4; American College of Obstetricians and Gynecologists, 2005, OBSTET GYNECOL, V106, P671; American College of Obstetricians and Gynecologists Committee on Practice Bulletins--Obstetrics, 2001, Obstet Gynecol, V98, P525; Bancroft K, 2000, BRIT J OBSTET GYNAEC, V107, P959, DOI 10.1111/j.1471-0528.2000.tb10396.x; Bartha JL, 2000, AM J OBSTET GYNECOL, V182, P346, DOI 10.1016/S0002-9378(00)70222-5; Brody SC, 2003, OBSTET GYNECOL, V101, P380, DOI 10.1016/S0029-7844(02)03057-0; Cheng YW, 2006, J MATERN-FETAL NEO M, V19, P729, DOI 10.1080/14767050600926546; Contreras M, 2002, INT J GYNECOL OBSTET, V78, P69; Crowther CA, 2005, NEW ENGL J MED, V352, P2477, DOI 10.1056/NEJMoa042973; Dabelea D, 2005, DIABETES CARE, V28, P579, DOI 10.2337/diacare.28.3.579; Daniells S, 2003, DIABETES CARE, V26, P385, DOI 10.2337/diacare.26.2.385; DEVECIANA M, 1995, NEW ENGL J MED, V333, P1237, DOI 10.1056/NEJM199511093331901; Dodd JM, 2007, AUST NZ J OBSTET GYN, V47, P307, DOI 10.1111/j.1479-828X.2007.00743.x; Dornhorst A, 1998, DIABETES CARE, V21, pB43; Ferrara A, 2004, OBSTET GYNECOL, V103, P526, DOI 10.1097/01.AOG.0000113623.18286.20; HADDEN DR, 2007, P 43 ANN M EUR ASS S, pOP20; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Jovanovic L, 1999, DIABETES CARE, V22, P1422, DOI 10.2337/diacare.22.9.1422; Jovanovic L, 2001, JAMA-J AM MED ASSOC, V286, P2516, DOI 10.1001/jama.286.20.2516; Landon M B, 2002, J Matern Fetal Neonatal Med, V12, P413, DOI 10.1080/713605713; Landon MB, 2007, DIABETES CARE, V30, pS194, DOI 10.2337/dc07-s215; LANGER N, 1994, OBSTET GYNECOL, V84, P329; Langer O, 2005, AM J OBSTET GYNECOL, V192, P134, DOI 10.1016/j.ajog.2004.07.011; Langer O, 2000, NEW ENGL J MED, V343, P1134, DOI 10.1056/NEJM200010193431601; MCHORNEY CA, 1992, MED CARE, V30, pMS253, DOI 10.1097/00005650-199205001-00025; Metzger BE, 1998, DIABETES CARE, V21, pB161; Metzger BE, 2007, DIABETES CARE, V30, pS251, DOI 10.2337/dc07-s225; Montori Victor M, 2005, ACP J Club, V143, pA8; Moore L, 2005, AM J OBSTET GYNECOL, V193, pS92, DOI 10.1016/j.ajog.2005.10.310; Nachum Z, 1999, BRIT MED J, V319, P1223, DOI 10.1136/bmj.319.7219.1223; OSULLIVAN JB, 1966, OBSTET GYNECOL, V27, P683; Rowan JA, 2007, DIABETES CARE, V30, pS214, DOI 10.2337/dc07-s219; Rumbold AR, 2002, AUST NZ J OBSTET GYN, V42, P131, DOI 10.1111/j.0004-8666.2002.00131.x; SPIRITO A, 1989, OBSTET GYNECOL, V73, P562; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; Turok DK, 2003, AM FAM PHYSICIAN, V68, P1767; *US DEP HHS, 2006, NAT I CHILD HLTH HUM	39	82	85	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 20	2008	148	10					766	U93		10.7326/0003-4819-148-10-200805200-00009	http://dx.doi.org/10.7326/0003-4819-148-10-200805200-00009			26	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308EX	18490689				2022-12-28	WOS:000256372200006
J	Bateman, E; Nelson, H; Bousquet, J; Kral, K; Sutton, L; Ortega, H; Yancey, S				Bateman, Eric; Nelson, Harold; Bousquet, Jean; Kral, Kenneth; Sutton, Laura; Ortega, Hector; Yancey, Steven			Meta-analysis: Effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events	ANNALS OF INTERNAL MEDICINE			English	Review							METERED-DOSE INHALER; TO-MODERATE ASTHMA; MILD PERSISTENT ASTHMA; ACTING BETA-AGONISTS; 250 MU-G; FLUTICASONE PROPIONATE; SALMETEROL/FLUTICASONE PROPIONATE; COMBINATION THERAPY; SYMPTOMATIC ASTHMA; ADULT PATIENTS	Background: Recent analyses have suggested an increased risk for serious asthma-related adverse events in patients receiving longacting beta-agonists. Purpose: To examine whether the incidences of severe asthma-related events (hospitalizations, intubations, deaths, and severe exacerbations) differ in persons receiving salmeterol plus inhaled corticosteroids compared with inhaled corticosteroids alone. Data Sources: The GlaxoSmithKline (Research Triangle Park, North Carolina) database, MEDLINE, EMBASE, CINAHL, and the Cochrane Database of Systemic Reviews (1982 to September 2007) were searched without language restriction. Study Selection: Randomized, controlled trials reported in any language that compared inhaled corticosteroids plus salmeterol (administered as fluticasone propionate/salmeterol by means of a single device or concomitant administration of inhaled corticosteroids and salmeterol) versus inhaled corticosteroids alone in participants with asthma. Data Extraction: Three physicians independently reviewed and adjudicated blinded case narratives on serious adverse events that were reported in the GlaxoSmithKline trials. Data Synthesis: Data from 66 GlaxoSmithKline trials involving a total of 20 966 participants with persistent asthma were summarized quantitatively. The summary risk difference for asthma-related hospitalizations from these trials was 0.0002 (95% CI, -0.0019 to 0.00231; P = 0.84) for participants receiving inhaled corticosteroids plus salmeterol (n = 35 events) versus those receiving inhaled corticosteroids alone (n =34 events). One asthma- related intubation and 1 asthma- related death occurred among participants receiving inhaled corticosteroids with salmeterol; no such events occurred among participants receiving inhaled corticosteroids alone. A subset of 24 trials showed a decreased risk for severe asthma- related exacerbations for inhaled corticosteroids plus salmeterol versus inhaled corticosteroids alone (risk difference, -0.025 [CI, -0.036 to -0.014]; P < 0.001). Limitations: The included trials involved selected patients who received careful follow-up. Only 26 trials were longer than 12 weeks. Few deaths and intubations limited the ability to measure risk for these outcomes. Conclusion: Salmeterol combined with inhaled corticosteroids decreases the risk for severe exacerbations, does not seem to alter the risk for asthma- related hospitalizations, and may not alter the risk for asthma- related deaths or intubations compared with inhaled corticosteroids alone.	[Bateman, Eric] Univ Cape Town, Lung Inst, Dept Med, Div Pulmonol, ZA-7937 Cape Town, South Africa; Natl Jewish Med & Res Ctr, Denver, CO USA; Hop Arnaud Villeneuve, Montpellier, France; GlaxoSmithKline, Res Triangle Pk, NC USA	University of Cape Town; National Jewish Health; Universite de Montpellier; CHU de Montpellier; GlaxoSmithKline	Bateman, E (corresponding author), Univ Cape Town, Lung Inst, Dept Med, Div Pulmonol, POB 34560, ZA-7937 Cape Town, South Africa.	eric.bateman@uct.ac.za						Anderson HR, 2005, BRIT MED J, V330, P117, DOI 10.1136/bmj.38316.729907.8F; Aubier M, 1999, RESP MED, V93, P876, DOI 10.1016/S0954-6111(99)90053-7; Baraniuk J, 1999, CHEST, V116, P625, DOI 10.1378/chest.116.3.625; Bateman ED, 2006, J ALLERGY CLIN IMMUN, V117, P563, DOI 10.1016/j.jaci.2005.11.036; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bateman ED, 2001, RESP MED, V95, P136, DOI 10.1053/rmed.2000.1008; Bergmann KC, 2004, SWISS MED WKLY, V134, P50; Bradburn MJ, 2007, STAT MED, V26, P53, DOI 10.1002/sim.2528; Busse W, 2003, J ALLERGY CLIN IMMUN, V111, P57, DOI 10.1067/mai.2003.38; Chan J, 2007, J MANAG CARE PHARM, V13, P21, DOI 10.18553/jmcp.2007.13.1.21; Condemi JJ, 1999, ANN ALLERG ASTHMA IM, V82, P383, DOI 10.1016/S1081-1206(10)63288-7; CRANE J, 1992, INT J EPIDEMIOL, V21, P737, DOI 10.1093/ije/21.4.737; Creticos PS, 1999, INT ARCH ALLERGY IMM, V118, P345, DOI 10.1159/000024129; Fowler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P929, DOI 10.1067/mai.2002.123869; Giannini D, 1999, CHEST, V115, P629, DOI 10.1378/chest.115.3.629; Giroux M, 2003, J ASTHMA, V40, P41, DOI 10.1081/JAS-120017205; GlaxoSmithKline, GLAXOSMITHKLINE CLIN; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; Greenstone IR, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005533; Grutters JC, 1999, EUR RESPIR J, V14, P915, DOI 10.1034/j.1399-3003.1999.14d31.x; Houghton CM, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-52; Ind PW, 2003, RESP MED, V97, P555, DOI 10.1053/rmed.2003.1483; Jarjour NN, 2006, J ALLERGY CLIN IMMUN, V118, P44, DOI 10.1016/j.jaci.2006.03.043; Jenkins C, 2000, RESP MED, V94, P715, DOI 10.1053/rmed.2000.0875; JOHANSSON I, 1980, ACTA RADIOL DIAGN, V21, P633, DOI 10.1177/028418518002100510; Kavuru M, 2000, J ALLERGY CLIN IMMUN, V105, P1108, DOI 10.1067/mai.2000.105711; Kelsen SG, 1999, J ASTHMA, V36, P703, DOI 10.3109/02770909909055422; Koenig SM, 2008, RESP MED, V102, P665, DOI 10.1016/j.rmed.2007.12.023; Koopmans JG, 2006, THORAX, V61, P306, DOI 10.1136/thx.2005.051292; Lanes SF, 2002, THORAX, V57, P683, DOI 10.1136/thorax.57.8.683; Lanes SF, 1998, AM J RESP CRIT CARE, V158, P857, DOI 10.1164/ajrccm.158.3.9803047; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; LIANG G, 2005, CHIN J CLIN REHAB, V9, P24; Lundback B, 2006, RESP MED, V100, P2, DOI 10.1016/j.rmed.2005.09.006; Malone R, 2005, ANN ALLERG ASTHMA IM, V95, P66, DOI 10.1016/S1081-1206(10)61190-8; Mann RD, 1996, J CLIN EPIDEMIOL, V49, P247, DOI 10.1016/0895-4356(95)00555-2; Marceau C, 2006, J ALLERGY CLIN IMMUN, V118, P574, DOI 10.1016/j.jaci.2006.06.034; Martin RM, 1998, THORAX, V53, P558, DOI 10.1136/thx.53.7.558; Masoli M, 2005, THORAX, V60, P730, DOI 10.1136/thx.2004.039180; Medvedeva IV, 2002, TERAPEVT ARKH, V74, P21; Meier CR, 1997, THORAX, V52, P612, DOI 10.1136/thx.52.7.612; MIETTINEN O, 1985, STAT MED, V4, P213, DOI 10.1002/sim.4780040211; Minino Arialdi M, 2006, Natl Vital Stat Rep, V54, P1; Murray J, 2004, ANN ALLERG ASTHMA IM, V93, P351, DOI 10.1016/S1081-1206(10)61394-4; Murray JJ, 1999, ALLERGY ASTHMA PROC, V20, P173, DOI 10.2500/108854199778553028; Nathan RA, 2006, CLIN THER, V28, P73, DOI 10.1016/j.clinthera.2006.01.008; Nelson HS, 2006, ANN INTERN MED, V145, P706, DOI 10.7326/0003-4819-145-9-200611070-00017; Nelson HS, 2003, ANN ALLERG ASTHMA IM, V91, P263, DOI 10.1016/S1081-1206(10)63528-4; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Ni CM, 2005, COCHRANE DB SYST REV; O'Byrne P, 2006, GLOBAL STRATEGY ASTH; O'Connor RD, 2005, ANN ALLERG ASTHMA IM, V95, P535, DOI 10.1016/S1081-1206(10)61015-0; Pearlman DS, 2004, J ASTHMA, V41, P797, DOI 10.1081/JAS-200038368; Pearlman DS, 1999, ANN ALLERG ASTHMA IM, V82, P257, DOI 10.1016/S1081-1206(10)62606-3; Prieto L, 2005, ANN ALLERG ASTHMA IM, V95, P452, DOI 10.1016/S1081-1206(10)61171-4; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; Rojas RA, 2007, J ASTHMA, V44, P437, DOI 10.1080/02770900701421930; RYAN G, 1991, AUST NZ J MED, V21, P681, DOI 10.1111/j.1445-5994.1991.tb01370.x; Salpeter SR, 2006, ANN INTERN MED, V144, P904, DOI 10.7326/0003-4819-144-12-200606200-00126; Shapiro G, 2000, AM J RESP CRIT CARE, V161, P527, DOI 10.1164/ajrccm.161.2.9905091; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Stempel DA, 2005, RESP MED, V99, P1263, DOI 10.1016/j.rmed.2005.03.002; Stoloff SW, 2004, J ALLERGY CLIN IMMUN, V113, P245, DOI 10.1016/j.jaci.2003.10.011; Strand AM, 2004, RESP MED, V98, P1008, DOI 10.1016/j.rmed.2004.03.004; Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761; *UK STAT DIR, 2005, STATSDIRECT COMP PRO; *US DEP HHS, 2007, NIH PUBL US DEP HHS; van Noord JA, 1999, THORAX, V54, P207, DOI 10.1136/thx.54.3.207; van Noord JA, 2001, CLIN DRUG INVEST, V21, P243, DOI 10.2165/00044011-200121040-00002; Vermetten FAAM, 1999, J ASTHMA, V36, P97, DOI 10.3109/02770909909065153; Wallin A, 2003, J ALLERGY CLIN IMMUN, V112, P72, DOI 10.1067/mai.2003.1518; Walters EH, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001385.pub2; Wechsler ME, 2006, AM J RESP CRIT CARE, V173, P519, DOI 10.1164/rccm.200509-1519OC; Weersink EJM, 1997, AM J RESP CRIT CARE, V155, P1241, DOI 10.1164/ajrccm.155.4.9105061; Weiler JM, 2005, ANN ALLERG ASTHMA IM, V94, P65, DOI 10.1016/S1081-1206(10)61288-4; Williams C, 1998, THORAX, V53, P7, DOI 10.1136/thx.53.1.7; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	79	81	84	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	2008	149	1					33	+		10.7326/0003-4819-149-1-200807010-00229	http://dx.doi.org/10.7326/0003-4819-149-1-200807010-00229			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	323EZ	18523132				2022-12-28	WOS:000257428200005
J	Helsen, MM; van den Broeke, MR; van de Wal, RSW; van de Berg, WJ; van Meijgaard, E; Davis, CH; Li, YH; Goodwin, I				Helsen, Michiel M.; van den Broeke, Michiel R.; van de Wal, Roderik S. W.; van de Berg, Willem Jan; van Meijgaard, Erik; Davis, Curt H.; Li, Yonghong; Goodwin, Ian			Elevation changes in Antarctica mainly determined by accumulation variability	SCIENCE			English	Article							SEA-LEVEL RISE; FIRN DENSIFICATION; MASS-BALANCE; ICE; PRECIPITATION; FLUCTUATIONS; GREENLAND; SNOWFALL	Antarctic Ice Sheet elevation changes, which are used to estimate changes in the mass of the interior regions, are caused by variations in the depth of the firn layer. We quantified the effects of temperature and accumulation variability on firn layer thickness by simulating the 1980- 2004 Antarctic firn depth variability. For most of Antarctica, the magnitudes of firn depth changes were comparable to those of observed ice sheet elevation changes. The current satellite observational period (similar to 15 years) is too short to neglect these fluctuations in firn depth when computing recent ice sheet mass changes. The amount of surface lowering in the Amundsen Sea Embayment revealed by satellite radar altimetry ( 1995- 2003) was increased by including firn depth fluctuations, while a large area of the East Antarctic Ice Sheet slowly grew as a result of increased accumulation.	[Helsen, Michiel M.; van den Broeke, Michiel R.; van de Wal, Roderik S. W.; van de Berg, Willem Jan] Univ Utrecht, Inst Marine & Atmospher Res, NL-3584 CC Utrecht, Netherlands; [van Meijgaard, Erik] Royal Netherlands Meteorol Inst, NL-3732 GK De Bilt, Netherlands; [Davis, Curt H.; Li, Yonghong] Univ Missouri, Dept Elect & Comp Engn, Columbia, MO 65211 USA; [Goodwin, Ian] Univ Newcastle, Sch Environm & Life Sci, Callaghan, NSW 2308, Australia	Utrecht University; Royal Netherlands Meteorological Institute; University of Missouri System; University of Missouri Columbia; University of Newcastle	Helsen, MM (corresponding author), Univ Utrecht, Inst Marine & Atmospher Res, NL-3584 CC Utrecht, Netherlands.	m.m.helsen@uu.nl	Van den Broeke, Michiel R./F-7867-2011; van de Berg, Willem Jan/H-4385-2011; van de wal, roderik/D-1705-2011	Van den Broeke, Michiel R./0000-0003-4662-7565; van de Berg, Willem Jan/0000-0002-8232-2040; van de wal, roderik/0000-0003-2543-3892; Goodwin, Ian/0000-0001-8682-6409				Arthern RJ, 1998, CLIMATIC CHANGE, V40, P605, DOI 10.1023/A:1005320713306; Bamber JL, 2000, SCIENCE, V287, P1248, DOI 10.1126/science.287.5456.1248; Davis CH, 2005, SCIENCE, V308, P1898, DOI 10.1126/science.1110662; Goodwin I, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002995; Kaczmarska M, 2004, ANN GLACIOL-SER, V39, P339, DOI 10.3189/172756404781814186; Kaspari S, 2004, ANN GLACIOL-SER, V39, P585, DOI 10.3189/172756404781814447; Lemke P, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P337; Li J, 2007, ANN GLACIOL-SER, V46, P8, DOI 10.3189/172756407782871486; Meehl GA, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P747; Monaghan AJ, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2007GL032630; Monaghan AJ, 2006, SCIENCE, V313, P827, DOI 10.1126/science.1128243; NYE JF, 1963, GEOPHYS J ROY ASTR S, V7, P431, DOI 10.1111/j.1365-246X.1963.tb07087.x; OERLEMANS J, 1981, NATURE, V290, P770, DOI 10.1038/290770a0; Rignot E, 2002, SCIENCE, V297, P1502, DOI 10.1126/science.1073888; Rignot E, 2008, NAT GEOSCI, V1, P106, DOI 10.1038/ngeo102; Shepherd A, 2001, SCIENCE, V291, P862, DOI 10.1126/science.291.5505.862; Thomas ER, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2007GL032529; Thomas R, 2004, SCIENCE, V306, P255, DOI 10.1126/science.1099650; Turner J, 2005, ANN GLACIOL-SER, V41, P85, DOI 10.3189/172756405781813177; van de Berg WJ, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006495; van den Broeke M, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL025239; Wingham DJ, 2006, PHILOS T R SOC A, V364, P1627, DOI 10.1098/rsta.2006.1792; Zwally HJ, 2005, J GLACIOL, V51, P509, DOI 10.3189/172756505781829007; Zwally HJ, 2002, J GLACIOL, V48, P199, DOI 10.3189/172756502781831403	24	109	112	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 20	2008	320	5883					1626	1629		10.1126/science.1153894	http://dx.doi.org/10.1126/science.1153894			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315NM	18511656				2022-12-28	WOS:000256886700045
J	Wood, DA; Kotseva, K; Connolly, S; Jennings, C; Mead, A; Jones, J; Holden, A; De Bacquer, D; Collier, T; De Backer, G; Faergeman, O				Wood, D. A.; Kotseva, K.; Connolly, S.; Jennings, C.; Mead, A.; Jones, J.; Holden, A.; De Bacquer, D.; Collier, T.; De Backer, G.; Faergeman, O.		EUROACTION Study Grp	Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial	LANCET			English	Article							SECONDARY PREVENTION; NICOTINE DEPENDENCE; PHYSICAL-ACTIVITY; LIFE-STYLE; MANAGEMENT; PROJECT; REHABILITATION; INTERVENTION; METAANALYSIS; CLINICS	Background Our aim was to investigate whether a nurse-coordinated multidisciplinary, family-based preventive cardiology programme could improve standards of preventive care in routine clinical practice. Methods In a matched, cluster-randomised, controlled trial in eight European countries, six pairs of hospitals and six pairs of general practices were assigned to an intervention programme (INT) or usual care (UC) for patients with coronary heart disease or those at high risk of developing cardiovascular disease. The primary endpoints-measured at 1 year-were family-based lifestyle change; management of blood pressure, lipids, and blood glucose to target concentrations; and prescription of cardioprotective drugs. Analysis was by intention to treat. The trial is registered as ISRCTN 71715857. Findings 1589 and 1499 patients with coronary heart disease in hospitals and 1189 and 1128 at high risk were assigned to INT and UC, respectively. In patients with coronary heart disease who smoked in the month before the event, 136 (58%) in the INT and 154 (47%) in the UC groups did not smoke 1 year afterwards (difference in change 10.4%, 95% CI -0.3 to 21.2, p=0.06). Reduced consumption of saturated fat (196 [55%] vs 168 [40%]; 17.3%, 6.4 to 28.2, p=0.009), and increased consumption of fruit and vegetables (680 [72%] vs 349 [35%]; 37.3%,18.1 to 56.5, p=0.004), and oily fish (156 [17%] vs 81 [8%]; 8.9%, 0.3 to 17.5, p=0.04) at 1 year were greatest in the INT group. High-risk individuals and partners showed changes only for fruit and vegetables (p=0.005). Blood-pressure target of less than 140/90 mm Hg was attained by both coronary (615 [65%] vs 547 [55%]; 10.4%, 0.6 to 20.2, p=0.04) and high-risk (586 [58%] vs 407 [41%]; 16.9%, 2.0 to 31.8, p=0.03) patients in the INT groups. Achievement of total cholesterol of less than 5 mmol/L did not differ between groups, but in high-risk patients the difference in change from baseline to 1 year was 12.7% (2.4 to 23.0, p=0.02) in favour of INT. In the hospital group, prescriptions for statins were higher in the INT group (810 [86%] vs 794 [80%]; 6.0%, -0.5 to 11 . 5, p=0.04). In general practices in the intervention groups, angiotensin-converting enzyme inhibitors (297 [29%] INT vs 196 [20%] UC; 8.5%, 1.8 to 15.2, p=0.02) and statins (381 [37%] INT vs 232 [22%] UC; 14.6%, 2.5 to 26.7, p=0.03) were more frequently prescribed. Interpretation To achieve the potential for cardiovascular prevention, we need local preventive cardiology programmes adapted to individual countries, which are accessible by all hospitals and general practices caring for coronary and high-risk patients.	[Wood, D. A.; Kotseva, K.; Connolly, S.; Jennings, C.; Mead, A.; Jones, J.; Holden, A.] Univ London Imperial Coll Sci Technol & Med, Dept Cardiovasc Med, Natl Heart & Lung Inst, London W6 8RF, England; [De Bacquer, D.; De Backer, G.] Univ Ghent, Dept Publ Hlth, B-9000 Ghent, Belgium; [Faergeman, O.] Aarhus Sygehus Univ Hosp, Dept Internal Med & Cardiol, Aarhus, Denmark; [Collier, T.] Univ London, London Sch Hyg & Trop Med, Med Stat Unit, Dept Epidemiol & Populat Hlth, London, England	Imperial College London; Ghent University; Aarhus University; University of London; London School of Hygiene & Tropical Medicine	Wood, DA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Cardiovasc Med, Natl Heart & Lung Inst, Charing Cross Campus,Fulham Palace Rd, London W6 8RF, England.	d.wood@imperial.ac.uk	Zabojszcz, Michał/V-6422-2018; Grodzicki, Tomasz/K-4451-2012; Martini, Bortolo/A-1127-2009; De Bacquer, Dirk/HGU-3191-2022; De Backer, Guy/AAI-4607-2021; Thompson, David R/E-2431-2018; Thompson, David R/C-6320-2009; Stepaniak, Urszula/U-2387-2018; McGee, Hannah/D-6480-2012; BUIGUES, CRISTINA/S-1182-2018	Zabojszcz, Michał/0000-0002-5913-3815; Grodzicki, Tomasz/0000-0003-0159-4915; Martini, Bortolo/0000-0003-1935-0484; Thompson, David R/0000-0001-8518-6307; Stepaniak, Urszula/0000-0002-1904-4674; De Bacquer, Dirk/0000-0002-3202-7238; McGee, Hannah/0000-0003-1417-993X; Jones, Jennifer/0000-0001-8388-9025; BUIGUES, CRISTINA/0000-0002-8031-4215; BRUSAFERRO, Silvio/0000-0003-1018-7094; Fornal, Maria/0000-0003-3793-8986; Jankowski, Piotr/0000-0001-6223-8821				[Anonymous], 1997, Eur Heart J, V18, P1569; BLAIR SN, 1985, AM J EPIDEMIOL, V122, P794, DOI 10.1093/oxfordjournals.aje.a114163; Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702; Campbell NC, 1998, HEART, V80, P447, DOI 10.1136/hrt.80.5.447; Campbell NC, 2004, HEART, V90, P29, DOI 10.1136/hrt.2004.037606; Clark AM, 2005, ANN INTERN MED, V143, P659, DOI 10.7326/0003-4819-143-9-200511010-00010; Conroy RM, 2003, EUR HEART J, V24, P987, DOI 10.1016/S0195-668X(03)00114-3; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; DENOLLET J, 1993, PSYCHOL MED, V23, P111, DOI 10.1017/S0033291700038903; DiClemente C.C., 2002, MOTIVATIONAL INTERVI, V2nd ed., P201; Ebrahim S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001561.pub3; FAGERSTROM KO, 1989, J BEHAV MED, V12, P159, DOI 10.1007/BF00846549; Graham I, 2007, EUR HEART J, V28, P2375, DOI 10.1093/eurheartj/ehm316; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Jolly K, 1999, BMJ-BRIT MED J, V318, P706; Khunti K, 2007, HEART, V93, P1398, DOI 10.1136/hrt.2006.106955; Kim M T, 2000, Prog Cardiovasc Nurs, V15, P90, DOI 10.1111/j.1751-7117.2000.tb00211.x; Kotseva K, 2004, EUR HEART J SUPPL, V6, pJ17, DOI 10.1093/eurheartj/6.suppl_j.j17; Kotseva K, 2001, EUR HEART J, V22, P554, DOI 10.1053/euhj.2001.2610; Kotseva K, 2001, LANCET, V357, P995, DOI 10.1016/S0140-6736(00)04235-5; McAlister FA, 2001, BRIT MED J, V323, P957, DOI 10.1136/bmj.323.7319.957; MEAD A, THESIS; Moher M, 2001, BMJ-BRIT MED J, V322, P1338, DOI 10.1136/bmj.322.7298.1338; Moss-Morris R, 2002, PSYCHOL HEALTH, V17, P1, DOI 10.1080/08870440290001494; ORLEANS CT, 1993, NICOTINE ADDICTION P, P413; PETRIE K, 1996, BMJ-BRIT MED J, V312, P991; Prochaska J O, 1984, Prog Clin Biol Res, V156, P131; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Pyke SDM, 1997, ARCH FAM MED, V6, P354, DOI 10.1001/archfami.6.4.354; Slimani N, 1999, COMPUT METH PROG BIO, V58, P251, DOI 10.1016/S0169-2607(98)00088-1; Taylor RS, 2004, AM J MED, V116, P682, DOI 10.1016/j.amjmed.2004.01.009; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Welk GJ, 2000, MED SCI SPORT EXER, V32, pS481, DOI 10.1097/00005768-200009001-00007; *WHO, 1989, MEAS OB CLASS DISTR; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wood D, 1998, EUR HEART J, V19, P1434; Wood D A, 1997, J Cardiovasc Risk, V4, P7; Wood DA, 2004, EUR HEART J SUPPL, V6, pJ3, DOI 10.1093/eurheartj/6.suppl_j.j3	41	424	439	2	63	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2008	371	9629					1999	2012		10.1016/S0140-6736(08)60868-5	http://dx.doi.org/10.1016/S0140-6736(08)60868-5			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312YY	18555911				2022-12-28	WOS:000256709500026
J	Fischer, R				Fischer, Reinhard			Sex and poison in the dark	SCIENCE			English	Editorial Material							ASPERGILLUS-NIDULANS; SECONDARY METABOLISM; GENE-CLUSTER; VEA; STERIGMATOCYSTIN; REGULATOR; LIGHT		[Fischer, Reinhard] Univ Karlsruhe, D-76228 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology	Fischer, R (corresponding author), Univ Karlsruhe, D-76228 Karlsruhe, Germany.	reinhard.fischer@kit.edu	Fischer, Reinhard/I-1220-2016	Fischer, Reinhard/0000-0002-6704-2569				Bayram O, 2008, MOL BIOL CELL, V19, P3254, DOI 10.1091/mbc.E08-01-0061; Bayram O, 2008, SCIENCE, V320, P1504, DOI 10.1126/science.1155888; Bayram O, 2008, FUNGAL GENET BIOL, V45, P127, DOI 10.1016/j.fgb.2007.06.001; Blumenstein A, 2005, CURR BIOL, V15, P1833, DOI 10.1016/j.cub.2005.08.061; Bok JW, 2006, MOL MICROBIOL, V61, P1636, DOI 10.1111/j.1365-2958.2006.05330.x; Bok JW, 2004, EUKARYOT CELL, V3, P527, DOI 10.1128/EC.3.2.527-535.2004; Brown DW, 1996, P NATL ACAD SCI USA, V93, P1418, DOI 10.1073/pnas.93.4.1418; Busch S, 2003, MOL MICROBIOL, V49, P717, DOI 10.1046/j.1365-2958.2003.03612.x; Busch S, 2007, MOL MICROBIOL, V64, P873, DOI 10.1111/j.1365-2958.2007.05711.x; Calvo AM, 2008, FUNGAL GENET BIOL, V45, P1053, DOI 10.1016/j.fgb.2008.03.014; Dreyer J, 2007, APPL ENVIRON MICROB, V73, P3412, DOI 10.1128/AEM.00129-07; KAFER E, 1965, GENETICS, V52, P217; Kato N, 2003, EUKARYOT CELL, V2, P1178, DOI 10.1128/EC.2.6.1178-1186.2003; Kim HS, 2002, FUNGAL GENET BIOL, V37, P72, DOI 10.1016/S1087-1845(02)00029-4; Li SJ, 2006, MOL MICROBIOL, V62, P1418, DOI 10.1111/j.1365-2958.2006.05447.x; Purschwitz J, 2008, CURR BIOL, V18, P255, DOI 10.1016/j.cub.2008.01.061; Stinnett SM, 2007, MOL MICROBIOL, V63, P242, DOI 10.1111/j.1365-2958.2006.05506.x; Yu JH, 2005, ANNU REV PHYTOPATHOL, V43, P437, DOI 10.1146/annurev.phyto.43.040204.140214	18	24	33	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2008	320	5882					1430	1431		10.1126/science.1160123	http://dx.doi.org/10.1126/science.1160123			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556538				2022-12-28	WOS:000256676400022
J	Horton, JD				Horton, Jay D.			Unfolding lipid metabolism	SCIENCE			English	Editorial Material							ENDOPLASMIC-RETICULUM STRESS; MESSENGER-RNA; FATTY-ACID; CHOLESTEROL; CLEAVAGE; KINASE; LIVER; XBP-1; BIOSYNTHESIS; PATHWAY		Univ Texas SW Med Ctr Dallas, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Horton, JD (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	jay.horton@utsouthwestern.edu	Longo, Kenneth A/A-5631-2010		NHLBI NIH HHS [P01 HL020948-280017, P01 HL020948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; Goldstein JL, 2002, ARCH BIOCHEM BIOPHYS, V397, P139, DOI 10.1006/abbi.2001.2615; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Lee AH, 2008, SCIENCE, V320, P1492, DOI 10.1126/science.1158042; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Matsuda M, 2001, GENE DEV, V15, P1206, DOI 10.1101/gad.891301; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Reimold AM, 2000, GENE DEV, V14, P152; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; Sriburi R, 2007, J BIOL CHEM, V282, P7024, DOI 10.1074/jbc.M609490200; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Zhao LH, 2006, CURR OPIN CELL BIOL, V18, P444, DOI 10.1016/j.ceb.2006.06.005	14	7	7	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	2008	320	5882					1433	1434		10.1126/science.1159651	http://dx.doi.org/10.1126/science.1159651			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556540	Green Accepted			2022-12-28	WOS:000256676400024
J	Sallon, S; Solowey, E; Cohen, Y; Korchinsky, R; Egli, M; Woodhatch, I; Simchoni, O; Kislev, M				Sallon, Sarah; Solowey, Elaine; Cohen, Yuval; Korchinsky, Raia; Egli, Markus; Woodhatch, Ivan; Simchoni, Orit; Kislev, Mordechai			Germination, genetics, and growth of an ancient date seed	SCIENCE			English	Article									[Sallon, Sarah] Hadassah Med Org, Louis L Borick Nat Med Res Ctr, IL-91120 Jerusalem, Israel; [Solowey, Elaine] Arava Inst Environm, IL-88840 Kibbutz Ketura, Israel; [Cohen, Yuval; Korchinsky, Raia] Agr Res Org, Volcani Ctr, Dept Fruit Tree Sci, IL-50250 Bet Dagan, Israel; [Egli, Markus; Woodhatch, Ivan] Univ Zurich, Dept Geog, Radio Carbon Lab, CH-8057 Zurich, Switzerland; [Simchoni, Orit; Kislev, Mordechai] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; University of Zurich; Bar Ilan University	Sallon, S (corresponding author), Hadassah Med Org, Louis L Borick Nat Med Res Ctr, IL-91120 Jerusalem, Israel.			Egli, Markus/0000-0002-1528-3440				Bailly C, 2004, SEED SCI RES, V14, P93, DOI 10.1079/SSR2004159; GRASOVSKY A, 1932, GOVT PALESTINE DEP A, V29; PLINY, 1952, NATURAL HIST, V13, P44; SHENMILLER J, 1995, AM J BOT, V82, P1367, DOI 10.2307/2445863; STUIVER M, 1977, RADIOCARBON, V19, P355, DOI 10.1017/S0033822200003672; Yadin Y., 1965, ISRAEL EXPLOR J, V15, P1; ZOHARY D, 1975, SCIENCE, V187, P319, DOI 10.1126/science.187.4174.319	7	134	137	2	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	2008	320	5882					1464	1464		10.1126/science.1153600	http://dx.doi.org/10.1126/science.1153600			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556553				2022-12-28	WOS:000256676400036
J	Sancak, Y; Peterson, TR; Shaul, YD; Lindquist, RA; Thoreen, CC; Bar-Peled, L; Sabatini, DM				Sancak, Yasemin; Peterson, Timothy R.; Shaul, Yoav D.; Lindquist, Robert A.; Thoreen, Carson C.; Bar-Peled, Liron; Sabatini, David M.			The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; MAMMALIAN TARGET; PROTEIN COMPLEXES; S6 KINASE; RAPAMYCIN; PATHWAY; TOR; ACTIVATION; RHEB; MICROAUTOPHAGY	The multiprotein mTORC1 protein kinase complex is the central component of a pathway that promotes growth in response to insulin, energy levels, and amino acids and is deregulated in common cancers. We find that the Rag proteins - a family of four related small guanosine triphosphatases (GTPases)-interact with mTORC1 in an amino acid-sensitive manner and are necessary for the activation of the mTORC1 pathway by amino acids. A Rag mutant that is constitutively bound to guanosine triphosphate interacted strongly with mTORC1, and its expression within cells made the mTORC1 pathway resistant to amino acid deprivation. Conversely, expression of a guanosine diphosphate-bound Rag mutant prevented stimulation of mTORC1 by amino acids. The Rag proteins do not directly stimulate the kinase activity of mTORC1, but, like amino acids, promote the intracellular localization of mTOR to a compartment that also contains its activator Rheb.	[Sancak, Yasemin; Peterson, Timothy R.; Shaul, Yoav D.; Lindquist, Robert A.; Thoreen, Carson C.; Bar-Peled, Liron; Sabatini, David M.] MIT, Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA; [Sancak, Yasemin; Peterson, Timothy R.; Shaul, Yoav D.; Lindquist, Robert A.; Thoreen, Carson C.; Bar-Peled, Liron; Sabatini, David M.] MIT, Dept Biol, Cambridge, MA 02142 USA; [Sancak, Yasemin; Peterson, Timothy R.; Shaul, Yoav D.; Lindquist, Robert A.; Thoreen, Carson C.; Sabatini, David M.] MIT, Canc Res Ctr, Cambridge, MA 02139 USA; [Sabatini, David M.] Broad Inst, Cambridge Ctr 7, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Sabatini, DM (corresponding author), MIT, Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA.	sabatini@wi.mit.edu	Shaul, Yoav/AAY-7011-2020	Lindquist, Robert/0000-0003-4746-0605; /0000-0002-1446-7256	NCI NIH HHS [R01 CA103866, R01 CA103866-05] Funding Source: Medline; NIAID NIH HHS [R01 AI047389, R01 AI047389-09, AI47389] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA103866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI047389, R01AI047389] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beugnet A, 2003, BIOCHEM J, V372, P555, DOI 10.1042/BJ20021266; Buerger C, 2006, BIOCHEM BIOPH RES CO, V344, P869, DOI 10.1016/j.bbrc.2006.03.220; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; Chen EJ, 2003, J CELL BIOL, V161, P333, DOI 10.1083/jcb.200210141; Christie GR, 2002, J BIOL CHEM, V277, P9952, DOI 10.1074/jbc.M107694200; Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200; Dubouloz F, 2005, MOL CELL, V19, P15, DOI 10.1016/j.molcel.2005.05.020; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hirose E, 1998, J CELL SCI, V111, P11; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kunz JB, 2004, J BIOL CHEM, V279, P9987, DOI 10.1074/jbc.M307905200; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; MASANORI BY, 1992, MOL CELL BIOL, V12, P2958, DOI 10.1128/MCB.12.7.2958; Mavrakis M, 2007, AUTOPHAGY, V3, P151, DOI 10.4161/auto.3632; Nakashima N, 1999, GENETICS, V152, P853; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; Roberg KJ, 1997, J CELL BIOL, V137, P1469, DOI 10.1083/jcb.137.7.1469; Saito K, 2005, J BIOCHEM, V137, P423, DOI 10.1093/jb/mvi046; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; SCHURMANN A, 1995, J BIOL CHEM, V270, P28982, DOI 10.1074/jbc.270.48.28982; Sekiguchi T, 2001, J BIOL CHEM, V276, P7246, DOI 10.1074/jbc.M004389200; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609	27	1839	1896	7	164	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2008	320	5882					1496	1501		10.1126/science.1157535	http://dx.doi.org/10.1126/science.1157535			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18497260	Green Accepted			2022-12-28	WOS:000256676400045
J	Burzotta, F; Crea, F				Burzotta, Francesco; Crea, Filippo			Thrombus-aspiration: a victory in the war against no reflow	LANCET			English	Editorial Material							PERCUTANEOUS CORONARY INTERVENTION; ELEVATION MYOCARDIAL-INFARCTION; REMEDIA TRIAL; THROMBECTOMY; ANGIOPLASTY; REDUCTION		[Burzotta, Francesco; Crea, Filippo] Univ Cattolica Sacro Cuore, Inst Cardiol, I-00168 Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Burzotta, F (corresponding author), Univ Cattolica Sacro Cuore, Inst Cardiol, I-00168 Rome, Italy.	f.burzotta@rm.unicatt.it	Burzotta, Francesco/K-1004-2018; Trani, Carlo/K-3265-2018	Burzotta, Francesco/0000-0002-6569-9401; Trani, Carlo/0000-0002-6569-9401				Ali A, 2006, J AM COLL CARDIOL, V48, P244, DOI 10.1016/j.jacc.2006.03.044; Burzotta F, 2005, J AM COLL CARDIOL, V46, P371, DOI 10.1016/j.jacc.2005.04.057; Burzotta F, 2008, INT J CARDIOL, V123, P313, DOI 10.1016/j.ijcard.2006.12.018; Burzotta F, 2006, CATHETER CARDIO INTE, V67, P887, DOI 10.1002/ccd.20713; De Luca L, 2006, HEART, V92, P951, DOI 10.1136/hrt.2005.074716; Galiuto L, 2006, J AM COLL CARDIOL, V48, P1355, DOI 10.1016/j.jacc.2006.05.059; Ito H, 2006, NAT CLIN PRACT CARD, V3, P499, DOI 10.1038/ncpcardio0632; Stone GW, 2005, JAMA-J AM MED ASSOC, V293, P1063, DOI 10.1001/jama.293.9.1063; Svilaas T, 2008, NEW ENGL J MED, V358, P557, DOI 10.1056/NEJMoa0706416; Vlaar PJ, 2008, LANCET, V371, P1915, DOI 10.1016/S0140-6736(08)60833-8	10	15	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 7	2008	371	9628					1889	1890		10.1016/S0140-6736(08)60808-9	http://dx.doi.org/10.1016/S0140-6736(08)60808-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310OI	18539205				2022-12-28	WOS:000256538500004
J	Myers, M; Zimmet, P				Myers, Mark; Zimmet, Paul			Halting the accelerating epidemic of type 1 diabetes	LANCET			English	Editorial Material							AUTOIMMUNITY		[Myers, Mark; Zimmet, Paul] Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3004, Australia; [Zimmet, Paul] Int Diabet Inst, Melbourne, Vic 3162, Australia	Monash University	Zimmet, P (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3004, Australia.	pzimmet@idi.org.au	Myers, Mark/H-8599-2016; Myers, Mark/A-9334-2008; Zimmet, Paul/O-8486-2019	Myers, Mark/0000-0003-1156-4795; Zimmet, Paul/0000-0003-0627-0776				Gale EAM, 2002, DIABETES, V51, P3353, DOI 10.2337/diabetes.51.12.3353; Harjutsalo V, 2008, LANCET, V371, P1777, DOI 10.1016/S0140-6736(08)60765-5; Hettiarachchi KD, 2004, J AUTOIMMUN, V22, P287, DOI 10.1016/j.jaut.2004.02.004; Lamb MM, 2008, PEDIATR DIABETES, V9, P135, DOI 10.1111/j.1399-5448.2007.00311.x; Lindholm P, 1997, PLANT DIS, V81, P1317, DOI 10.1094/PDIS.1997.81.11.1317; MENSER MA, 1978, LANCET, V1, P57; Myers MA, 2003, ANN NY ACAD SCI, V1005, P418, DOI 10.1196/annals.1288.071; Myers MA, 2003, REV ENDOCR METAB DIS, V4, P225, DOI 10.1023/A:1025196127517; Natsume Masahiro, 1998, Annals of the Phytopathological Society of Japan, V64, P202, DOI 10.3186/jjphytopath.64.202; Rewers M, 2004, LANCET, V364, P1645, DOI 10.1016/S0140-6736(04)17368-6; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Virtanen SM, 2006, DIABETOLOGIA, V49, P1512, DOI 10.1007/s00125-006-0236-1	12	13	15	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 24	2008	371	9626					1730	1731		10.1016/S0140-6736(08)60739-4	http://dx.doi.org/10.1016/S0140-6736(08)60739-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304IO	18502281				2022-12-28	WOS:000256103400007
J	Roh, S; Patron, ME				Roh, Shiyoung; Patron, Mark E.			Ocular trauma due to a water-bottle cap	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Roh, Shiyoung; Patron, Mark E.] Lahey Clin Med Ctr, Peabody, MA 01960 USA	Lahey Hospital & Medical Center	Roh, S (corresponding author), Lahey Clin Med Ctr, Peabody, MA 01960 USA.	shiyoung.roh@lahey.org							0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2008	358	21					2265	2265		10.1056/NEJMicm075953	http://dx.doi.org/10.1056/NEJMicm075953			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	303EK	18499569				2022-12-28	WOS:000256023600009
J	Conrad, KL; Tseng, KY; Uejima, JL; Reimers, JM; Heng, LJ; Shaham, Y; Marinelli, M; Wolf, ME				Conrad, Kelly L.; Tseng, Kuei Y.; Uejima, Jamie L.; Reimers, Jeremy M.; Heng, Li-Jun; Shaham, Yavin; Marinelli, Michela; Wolf, Marina E.			Formation of accumbens GluR2-lacking AMPA receptors mediates incubation of cocaine craving	NATURE			English	Article							CULTURED HIPPOCAMPAL-NEURONS; NUCLEUS-ACCUMBENS; SURFACE EXPRESSION; SYNAPTIC PLASTICITY; BEHAVIORAL SENSITIZATION; DOPAMINE-RECEPTORS; SEEKING BEHAVIOR; NMDA RECEPTORS; RAT; ADDICTION	Relapse to cocaine use after prolonged abstinence is an important clinical problem. This relapse is often induced by exposure to cues associated with cocaine use. To account for the persistent propensity for relapse, it has been suggested(1) that cue- induced cocaine craving increases over the first several weeks of abstinence and remains high for extended periods. We and others identified an analogous phenomenon in rats that was termed 'incubation of cocaine craving': time- dependent increases in cue- induced cocaine- seeking over the first months after withdrawal from self- administered cocaine(2-4). Cocaine- seeking requires the activation of glutamate projections that excite receptors for alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid ( AMPA) in the nucleus accumbens(5-7). Here we show that the number of synaptic AMPA receptors in the accumbens is increased after prolonged withdrawal from cocaine self-administration by the addition of new AMPA receptors lacking glutamate receptor 2 ( GluR2). Furthermore, we show that these new receptors mediate the incubation of cocaine craving. Our results indicate that GluR2- lacking AMPA receptors could be a new target for drug development for the treatment of cocaine addiction. We propose that after prolonged withdrawal from cocaine, increased numbers of synaptic AMPA receptors combined with the higher conductance of GluR2- lacking AMPA receptors(8,9) causes increased reactivity of accumbens neurons to cocaine- related cues, leading to an intensification of drug craving and relapse.	[Conrad, Kelly L.; Reimers, Jeremy M.; Wolf, Marina E.] Rosalind Franklin Univ Med & Sci, Dept Neurosci, N Chicago, IL 60064 USA; [Tseng, Kuei Y.; Heng, Li-Jun; Marinelli, Michela] Rosalind Franklin Univ Med & Sci, Dept Mol & Cellular Pharmacol, N Chicago, IL 60064 USA; [Uejima, Jamie L.; Shaham, Yavin] NIDA, Behav Neurosci Branch, IRP, NIH, Baltimore, MD 21224 USA	Rosalind Franklin University Medical & Science; Rosalind Franklin University Medical & Science; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	Wolf, ME (corresponding author), Rosalind Franklin Univ Med & Sci, Dept Neurosci, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	marina.wolf@rosalindfranklin.edu	Marinelli, Michela/P-7645-2018; shaham, yavin/G-1306-2014	Marinelli, Michela/0000-0002-1903-1937; 	Intramural NIH HHS [Z01 DA000434-08] Funding Source: Medline; NIDA NIH HHS [R01 DA015835, K02 DA000453, R01 DA009621, DA00453, DA015835, R37 DA015835, DA020654, DA09621, R01 DA020654] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000434, R37DA015835, R01DA020654, R01DA015835, R01DA009621] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Archibald K, 1998, NEUROPHARMACOLOGY, V37, P1345, DOI 10.1016/S0028-3908(98)00135-X; Balland B, 2006, J PHYSIOL-LONDON, V574, P245, DOI 10.1113/jphysiol.2006.108738; Bellone C, 2006, NAT NEUROSCI, V9, P636, DOI 10.1038/nn1682; Bernard V, 1997, J NEUROSCI, V17, P819; Beveridge TJR, 2006, EUR J NEUROSCI, V23, P3109, DOI 10.1111/j.1460-9568.2006.04788.x; Bossert JM, 2007, J NEUROSCI, V27, P12655, DOI 10.1523/JNEUROSCI.3926-07.2007; Boudreau AC, 2005, J NEUROSCI, V25, P9144, DOI 10.1523/JNEUROSCI.2252-05.2005; Boudreau AC, 2007, J NEUROSCI, V27, P10621, DOI 10.1523/JNEUROSCI.2163-07.2007; Broutman G, 2001, J NEUROSCI, V21, P27, DOI 10.1523/JNEUROSCI.21-01-00027.2001; Clayton DA, 2002, J BIOL CHEM, V277, P14367, DOI 10.1074/jbc.C200074200; Cornish JL, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-15-j0006.2000; Cull-Candy S, 2006, CURR OPIN NEUROBIOL, V16, P288, DOI 10.1016/j.conb.2006.05.012; Di Ciano P, 2001, J NEUROSCI, V21, P9471, DOI 10.1523/JNEUROSCI.21-23-09471.2001; Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107; Gerges NZ, 2004, J NEUROSCI, V24, P4758, DOI 10.1523/JNEUROSCI.0594-04.2004; Goto Y, 2005, NEURON, V47, P255, DOI 10.1016/j.neuron.2005.06.017; Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; GROSSHANS DR, 2002, SCI STKE, V137, pPL8; Hall RA, 1997, J BIOL CHEM, V272, P4135, DOI 10.1074/jbc.272.7.4135; Hall RA, 1997, NEUROSCIENCE, V78, P361, DOI 10.1016/S0306-4522(96)00525-8; Hall RA, 1997, J NEUROCHEM, V68, P625; Hollander JA, 2007, J NEUROSCI, V27, P3535, DOI 10.1523/JNEUROSCI.3667-06.2007; Ju W, 2004, NAT NEUROSCI, V7, P244, DOI 10.1038/nn1189; Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403; Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234; Kourrich S, 2007, J NEUROSCI, V27, P7921, DOI 10.1523/JNEUROSCI.1859-07.2007; Liu SJ, 2007, TRENDS NEUROSCI, V30, P126, DOI 10.1016/j.tins.2007.01.006; Lu L, 2004, NEUROPHARMACOLOGY, V47, P214, DOI 10.1016/j.neuropharm.2004.06.027; Lu L, 2007, BIOL PSYCHIAT, V61, P591, DOI 10.1016/j.biopsych.2006.04.011; Mameli M, 2007, SCIENCE, V317, P530, DOI 10.1126/science.1142365; Mead AN, 2007, NEUROPSYCHOPHARMACOL, V32, P343, DOI 10.1038/sj.npp.1301045; Meredith GE, 1999, ANN NY ACAD SCI, V877, P140, DOI 10.1111/j.1749-6632.1999.tb09266.x; Neisewander JL, 2000, J NEUROSCI, V20, P798, DOI 10.1523/JNEUROSCI.20-02-00798.2000; Noh KM, 2005, P NATL ACAD SCI USA, V102, P12230, DOI 10.1073/pnas.0505408102; O'Brien RJ, 1998, NEURON, V21, P1067, DOI 10.1016/S0896-6273(00)80624-8; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V5th Edn, DOI 10.1016/c2009-0-63235-9; Pierce RC, 1996, J NEUROSCI, V16, P1550; Robinson R, 2004, HIGH EDUC, V47, P1, DOI 10.1023/B:HIGH.0000009803.70418.9c; Sans N, 2003, J NEUROSCI, V23, P9367; Stefani A, 1998, DEV NEUROSCI-BASEL, V20, P242, DOI 10.1159/000017318; Suto N, 2004, NEUROPSYCHOPHARMACOL, V29, P2149, DOI 10.1038/sj.npp.1300533; Sutton MA, 2003, NATURE, V421, P70, DOI 10.1038/nature01249; Takazawa A, 1996, BRAIN RES, V706, P173, DOI 10.1016/0006-8993(95)01334-2; Tseng KY, 2007, SYNAPSE, V61, P843, DOI 10.1002/syn.20432; Tseng KY, 2004, J NEUROSCI, V24, P5131, DOI 10.1523/JNEUROSCI.1021-04.2004; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Wolf ME, 1998, PROG NEUROBIOL, V54, P679, DOI 10.1016/S0301-0082(97)00090-7; Yao WD, 2004, NEURON, V41, P625, DOI 10.1016/S0896-6273(04)00048-0	50	638	648	3	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 3	2008	454	7200					118	U9		10.1038/nature06995	http://dx.doi.org/10.1038/nature06995			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	321MC	18500330	Green Accepted			2022-12-28	WOS:000257308300049
J	Mansy, SS; Schrum, JP; Krishnamurthy, M; Tobe, S; Treco, DA; Szostak, JW				Mansy, Sheref S.; Schrum, Jason P.; Krishnamurthy, Mathangi; Tobe, Sylvia; Treco, Douglas A.; Szostak, Jack W.			Template-directed synthesis of a genetic polymer in a model protocell	NATURE			English	Article							MONOCARBOXYLIC ACIDS; MEMBRANE; GROWTH; OLIGOMERIZATION; ENCAPSULATION; STABILITY; BILAYERS; WATER; RNA	Contemporary phospholipid- based cell membranes are formidable barriers to the uptake of polar and charged molecules ranging from metal ions to complex nutrients. Modern cells therefore require sophisticated protein channels and pumps to mediate the exchange of molecules with their environment. The strong barrier function of membranes has made it difficult to understand the origin of cellular life and has been thought to preclude a heterotrophic lifestyle for primitive cells. Although nucleotides can cross dimyristoyl phosphatidylcholine membranes through defects formed at the gel- to- liquid transition temperature(1,2), phospholipid membranes lack the dynamic properties required for membrane growth. Fatty acids and their corresponding alcohols and glycerol monoesters are attractive candidates for the components of protocell membranes because they are simple amphiphiles that form bilayer membrane vesicles(3-5) that retain encapsulated oligonucleotides(3,6) and are capable of growth and division(7-9). Here we show that such membranes allow the passage of charged molecules such as nucleotides, so that activated nucleotides added to the outside of a model protocell spontaneously cross the membrane and take part in efficient template copying in the protocell interior. The permeability properties of prebiotically plausible membranes suggest that primitive protocells could have acquired complex nutrients from their environment in the absence of any macromolecular transport machinery; that is, they could have been obligate heterotrophs.	[Mansy, Sheref S.; Schrum, Jason P.; Krishnamurthy, Mathangi; Tobe, Sylvia; Treco, Douglas A.; Szostak, Jack W.] Massachusetts Gen Hosp, Dept Mol Biol, Howard Hughes Med Inst, Boston, MA 02114 USA; [Mansy, Sheref S.; Schrum, Jason P.; Krishnamurthy, Mathangi; Tobe, Sylvia; Treco, Douglas A.; Szostak, Jack W.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital	Szostak, JW (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Howard Hughes Med Inst, Boston, MA 02114 USA.	szostak@molbio.mgh.harvard.edu	Mansy, Sheref/E-6266-2010	Mansy, Sheref/0000-0003-2382-198X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM074506] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [F32 GM074506-01, F32 GM07450601] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1992, INTERMOLECULAR SURFA; Apel CL, 2002, BBA-BIOMEMBRANES, V1559, P1, DOI 10.1016/S0005-2736(01)00400-X; Blochliger E, 1998, J PHYS CHEM B, V102, P10383, DOI 10.1021/jp981234w; CHAKRABARTI AC, 1994, J MOL EVOL, V39, P555, DOI 10.1007/BF00160400; Chen IA, 2005, J AM CHEM SOC, V127, P13213, DOI 10.1021/ja051784p; Chen IA, 2004, BIOPHYS J, V87, P988, DOI 10.1529/biophysj.104.039875; Chen IA, 2004, SCIENCE, V305, P1474, DOI 10.1126/science.1100757; Chen IA, 2004, P NATL ACAD SCI USA, V101, P7965, DOI 10.1073/pnas.0308045101; Chen IA, 2006, COLD SPRING HARB MON, V43, P57; CHEN PY, 1988, BIOCHEMISTRY-US, V27, P5713, DOI 10.1021/bi00415a048; DANILOV LL, 1981, FEBS LETT, V131, P310, DOI 10.1016/0014-5793(81)80392-4; DEAMER DW, 1985, NATURE, V317, P792, DOI 10.1038/317792a0; Eschenmoser A, 2007, TETRAHEDRON, V63, P12821, DOI 10.1016/j.tet.2007.10.012; Ferris JP, 1996, NATURE, V381, P59, DOI 10.1038/381059a0; Guernelli S, 2003, EUR J ORG CHEM, V2003, P4765, DOI 10.1002/ejoc.200300456; Hagenbuch P, 2005, ANGEW CHEM INT EDIT, V44, P6588, DOI 10.1002/anie.200501794; Hanczyc MM, 2003, SCIENCE, V302, P618, DOI 10.1126/science.1089904; HARGREAVES WR, 1978, BIOCHEMISTRY-US, V17, P3759, DOI 10.1021/bi00611a014; Huang YS, 2005, GEOCHIM COSMOCHIM AC, V69, P1073, DOI 10.1016/j.gca.2004.07.030; KAWANA M, 1992, J CHEM SOC P1, V4, P469; Khalil MM, 2000, J CHEM ENG DATA, V45, P70, DOI 10.1021/je9901886; Kozlov IA, 1998, P NATL ACAD SCI USA, V95, P13448, DOI 10.1073/pnas.95.23.13448; LANDE MB, 1995, J GEN PHYSIOL, V106, P67, DOI 10.1085/jgp.106.1.67; McCollom TM, 1999, ORIGINS LIFE EVOL B, V29, P153, DOI 10.1023/A:1006592502746; Monnard PA, 2007, PHILOS T R SOC B, V362, P1741, DOI 10.1098/rstb.2007.2066; Morowitz H. J., 2004, BEGINNINGS CELLULAR; NELSON AK, 1963, INORG CHEM, V2, P775, DOI 10.1021/ic50008a026; Paula S, 1996, BIOPHYS J, V70, P339, DOI 10.1016/S0006-3495(96)79575-9; Rowat AC, 2005, BBA-BIOMEMBRANES, V1713, P29, DOI 10.1016/j.bbamem.2005.04.014; Sacerdote MG, 2005, P NATL ACAD SCI USA, V102, P6004, DOI 10.1073/pnas.0408440102; TOHIDI M, 1987, J MOL EVOL, V25, P97, DOI 10.1007/BF02101750; WACHTERSHAUSER G, 1990, P NATL ACAD SCI USA, V87, P200, DOI 10.1073/pnas.87.1.200; WESTHEIMER FH, 1987, SCIENCE, V235, P1173, DOI 10.1126/science.2434996; Wilson MA, 1996, J AM CHEM SOC, V118, P6580, DOI 10.1021/ja9540381	34	465	479	7	254	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	2008	454	7200					122	U10		10.1038/nature07018	http://dx.doi.org/10.1038/nature07018			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	321MC	18528332	Green Accepted			2022-12-28	WOS:000257308300050
J	Emerson, JJ; Cardoso-Moreira, M; Borevitz, JO; Long, M				Emerson, J. J.; Cardoso-Moreira, Margarida; Borevitz, Justin O.; Long, Manyuan			Natural selection shapes genome-wide patterns of copy-number polymorphism in Drosophila melanogaster	SCIENCE			English	Article							EVOLUTION; DNA; DUPLICATIONS; POPULATIONS; SEQUENCES; INFERENCE; HISTORY; MODEL	The role that natural selection plays in governing the locations and early evolution of copy- number mutations remains largely unexplored. We used high- density full- genome tiling arrays to create a fine- scale genomic map of copy- number polymorphisms ( CNPs) in Drosophila melanogaster. We inferred a total of 2658 independent CNPs, 56% of which overlap genes. These include CNPs that are likely to be under positive selection, most notably high- frequency duplications encompassing toxin- response genes. The locations and frequencies of CNPs are strongly shaped by purifying selection, with deletions under stronger purifying selection than duplications. Among duplications, those overlapping exons or introns, as well as those falling on the X chromosome, seem to be subject to stronger purifying selection.	[Emerson, J. J.; Cardoso-Moreira, Margarida; Borevitz, Justin O.; Long, Manyuan] Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; [Emerson, J. J.] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Cardoso-Moreira, Margarida] Univ Porto, Grad Program Areas Basic & Appl Biol, P-4100 Oporto, Portugal; [Cardoso-Moreira, Margarida] Univ Porto, Fac Ciencias, P-4100 Oporto, Portugal	University of Chicago; Academia Sinica - Taiwan; Universidade do Porto; Universidade do Porto	Emerson, JJ (corresponding author), Univ Chicago, Dept Ecol & Evolut, 940 E 57Th St, Chicago, IL 60637 USA.	jje@uchicago.edu; mmoreira@uchicago.edu	Moreira, Margarida M Cardoso/A-7749-2012; Cardoso-Moreira, Margarida/L-8294-2019; Borevitz, Justin/B-5423-2012; Emerson, J.J./D-8955-2011	Cardoso-Moreira, Margarida/0000-0001-6639-3597; Borevitz, Justin/0000-0001-8408-3699; Emerson, James/0000-0001-9474-0891				Andolfatto P, 2005, NATURE, V437, P1149, DOI 10.1038/nature04107; ASHBURNER M, 1994, DEVELOPMENT, V120, P2077; Bergman CM, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-11-r112; Biemar F, 2005, P NATL ACAD SCI USA, V102, P15907, DOI 10.1073/pnas.0507817102; Borevitz JO, 2003, GENOME RES, V13, P513, DOI 10.1101/gr.541303; CHARLESWORTH B, 1989, ANNU REV GENET, V23, P251, DOI 10.1146/annurev.ge.23.120189.001343; Daborn PJ, 2002, SCIENCE, V297, P2253, DOI 10.1126/science.1074170; Deutsch M, 1999, NUCLEIC ACIDS RES, V27, P3219, DOI 10.1093/nar/27.15.3219; Dopman EB, 2007, P NATL ACAD SCI USA, V104, P19920, DOI 10.1073/pnas.0709888104; Feuk L, 2006, NAT REV GENET, V7, P85, DOI 10.1038/nrg1767; Fiston-Lavier AS, 2007, GENOME RES, V17, P1458, DOI 10.1101/gr.6208307; Gordo I, 2001, CURR BIOL, V11, pR684, DOI 10.1016/S0960-9822(01)00408-0; Graubert TA, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030003; Haddrill PR, 2005, GENOME RES, V15, P790, DOI 10.1101/gr.3541005; Halligan DL, 2006, GENOME RES, V16, P875, DOI 10.1101/gr.5022906; Kondrashov FA, 2006, J THEOR BIOL, V239, P141, DOI 10.1016/j.jtbi.2005.08.033; Lipatov M, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-24; Long M, 2003, NAT REV GENET, V4, P865, DOI 10.1038/nrg1204; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; Otto SP, 2002, ADV GENET, V46, P451; Petrov DA, 1996, NATURE, V384, P346, DOI 10.1038/384346a0; Pool JE, 2006, GENETICS, V174, P915, DOI 10.1534/genetics.106.058693; Pritchard JK, 2000, GENETICS, V155, P945; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Turner DJ, 2008, NAT GENET, V40, P90, DOI 10.1038/ng.2007.40; Williamson SH, 2005, P NATL ACAD SCI USA, V102, P7882, DOI 10.1073/pnas.0502300102	26	205	212	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 20	2008	320	5883					1629	1631		10.1126/science.1158078	http://dx.doi.org/10.1126/science.1158078			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315NM	18535209				2022-12-28	WOS:000256886700046
J	McMurray, HR; Sampson, ER; Compitello, G; Kinsey, C; Newman, L; Smith, B; Chen, SR; Klebanov, L; Salzman, P; Yakovlev, A; Land, H				McMurray, Helene R.; Sampson, Erik R.; Compitello, George; Kinsey, Conan; Newman, Laurel; Smith, Bradley; Chen, Shaw-Ree; Klebanov, Lev; Salzman, Peter; Yakovlev, Andrei; Land, Hartmut			Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype	NATURE			English	Article							CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; EPITHELIAL-CELLS; C-MYC; P53; TRANSFORMATION; METASTASIS; PATHWAY; MICE; REVEALS	Understanding the molecular underpinnings of cancer is of critical importance to the development of targeted intervention strategies. Identification of such targets, however, is notoriously difficult and unpredictable. Malignant cell transformation requires the cooperation of a few oncogenic mutations that cause substantial reorganization of many cell features(1) and induce complex changes in gene expression patterns(2-6). Genes critical to this multifaceted cellular phenotype have therefore only been identified after signalling pathway analysis(7-10) or on an ad hoc basis(4,11-14). Our observations that cell transformation by cooperating oncogenic lesions depends on synergistic modulation of downstream signalling circuitry(15-17) suggest that malignant transformation is a highly cooperative process, involving synergy at multiple levels of regulation, including gene expression. Here we show that a large proportion of genes controlled synergistically by loss-of-function p53 and Ras activation are critical to the malignant state of murine and human colon cells. Notably, 14 out of 24 'cooperation response genes' were found to contribute to tumour formation in gene perturbation experiments. In contrast, only 1 in 14 perturbations of the genes responding in a non-synergistic manner had a similar effect. Synergistic control of gene expression by oncogenic mutations thus emerges as an underlying key to malignancy, and provides an attractive rationale for identifying intervention targets in gene networks downstream of oncogenic gain- and loss-of-function mutations.	[McMurray, Helene R.; Sampson, Erik R.; Compitello, George; Kinsey, Conan; Newman, Laurel; Smith, Bradley; Chen, Shaw-Ree; Land, Hartmut] Univ Rochester, Med Ctr, Dept Biomed Genet, Rochester, NY 14642 USA; [Klebanov, Lev; Salzman, Peter; Yakovlev, Andrei] Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY 14642 USA; [Yakovlev, Andrei; Land, Hartmut] Univ Rochester, Med Ctr, James Wilmot Canc Ctr, Rochester, NY 14642 USA; [Klebanov, Lev] Charles Univ Prague, Dept Probabil & Stat, CZ-18675 Prague 8, Czech Republic	University of Rochester; University of Rochester; University of Rochester; Charles University Prague	Land, H (corresponding author), Univ Rochester, Med Ctr, Dept Biomed Genet, 601 Elmwood Ave, Rochester, NY 14642 USA.	land@urmc.rochester.edu	Klebanov, Lev/C-2408-2009; Klebanov, Lev/F-3373-2014	Klebanov, Lev/0000-0001-8496-6432; McMurray, Helene/0000-0003-1738-8622; salzman, peter/0000-0001-8114-4863	NCI NIH HHS [R01 CA090663-04, R01 CA120317-01A1, R01 CA120317-02, CA120317, T32 CA009363, R01 CA090663-05, T32 CA009363-25, R01 CA090663, R01 CA120317, CA90663, R01 CA090663-03, T32 CA09363] Funding Source: Medline; NIGMS NIH HHS [R01 GM075299, R01 GM075299-01, R01 GM075299-03, GM075299, R01 GM075299-03S1, R01 GM075299-02] Funding Source: Medline; NLM NIH HHS [K99 LM009477, K99 LM009477-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090663, R01CA120317, T32CA009363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075299] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [K99LM009477] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; Boiko AD, 2006, GENE DEV, V20, P236, DOI 10.1101/gad.1372606; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Fattman CL, 2003, FREE RADICAL BIO MED, V35, P236, DOI 10.1016/S0891-5849(03)00275-2; Godwin AR, 1998, GENE DEV, V12, P11, DOI 10.1101/gad.12.1.11; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Houde C, 2004, BLOOD, V104, P3697, DOI 10.1182/blood-2003-12-4114; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Klebanov L, 2006, COMPUT STAT DATA AN, V50, P3619, DOI 10.1016/j.csda.2005.08.005; Ledford JG, 2007, J IMMUNOL, V178, P5132, DOI 10.4049/jimmunol.178.8.5132; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; Panagopoulos L, 2003, GENE CHROMOSOME CANC, V36, P107, DOI 10.1002/gcc.10139; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; Rodriguez-Viciana P, 2005, COLD SH Q B, V70, P461, DOI 10.1101/sqb.2005.70.044; Rogulski K, 2005, ONCOGENE, V24, P7524, DOI 10.1038/sj.onc.1208897; Saaf AM, 2007, MOL BIOL CELL, V18, P4245, DOI 10.1091/mbc.E07-04-0309; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Westfall P.H., 1993, RESAMPLING BASED MUL; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; Xia MX, 2007, NAT STRUCT MOL BIOL, V14, P215, DOI 10.1038/nsmb1208; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhao RB, 2000, GENE DEV, V14, P981	37	113	123	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 19	2008	453	7198					1112	U10		10.1038/nature06973	http://dx.doi.org/10.1038/nature06973			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	314WM	18500333	Green Accepted			2022-12-28	WOS:000256839900059
J	Gallagher, FA; Kettunen, MI; Day, SE; Hu, DE; Ardenkjaer-Larsen, JH; in't Zandt, R; Jensen, PR; Karlsson, M; Golman, K; Lerche, MH; Brindle, KM				Gallagher, Ferdia A.; Kettunen, Mikko I.; Day, Sam E.; Hu, De-En; Ardenkjaer-Larsen, Jan Henrik; in't Zandt, Rene; Jensen, Pernille R.; Karlsson, Magnus; Golman, Klaes; Lerche, Mathilde H.; Brindle, Kevin M.			Magnetic resonance imaging of pH in vivo using hyperpolarized C-13-labelled bicarbonate	NATURE			English	Article							EXTRACELLULAR PH; CONTRAST AGENT; TUMOR PH; C-13; NMR; SPECTROSCOPY; INVIVO; BRAIN; MRS	As alterations in tissue pH underlie many pathological processes, the capability to image tissue pH in the clinic could offer new ways of detecting disease and response to treatment(1). Dynamic nuclear polarization is an emerging technique for substantially increasing the sensitivity of magnetic resonance imaging experiments(2,3). Here we show that tissue pH can be imaged in vivo from the ratio of the signal intensities of hyperpolarized bicarbonate ((HCO3-)-C-13) and (CO2)-C-13 following intravenous injection of hyperpolarized (HCO3-)-C-13. The technique was demonstrated in a mouse tumour model, which showed that the average tumour interstitial pH was significantly lower than the surrounding tissue. Given that bicarbonate is an endogenous molecule that can be infused in relatively high concentrations into patients(4), we propose that this technique could be used clinically to image pathological processes that are associated with alterations in tissue pH, such as cancer, ischaemia and inflammation.	[Gallagher, Ferdia A.; Kettunen, Mikko I.; Day, Sam E.; Hu, De-En; Brindle, Kevin M.] Canc Res UK, Cambridge Res Inst, Li Ka Shing Ctr, Cambridge CB2 0RE, England; [Gallagher, Ferdia A.; Kettunen, Mikko I.; Day, Sam E.; Hu, De-En; Brindle, Kevin M.] Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; [Gallagher, Ferdia A.] Univ Cambridge, Addenbrookes Hosp, Dept Radiol, Cambridge CB2 2QQ, England; [Ardenkjaer-Larsen, Jan Henrik] GE Healthcare, Grove Ctr GC 18, Amersham HP7 9LL, England; [in't Zandt, Rene; Jensen, Pernille R.; Karlsson, Magnus; Golman, Klaes; Lerche, Mathilde H.] Imagnia AB, SE-20041 Malmo, Sweden	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; General Electric	Brindle, KM (corresponding author), Canc Res UK, Cambridge Res Inst, Li Ka Shing Ctr, Robinson Way, Cambridge CB2 0RE, England.	kmb@mole.bio.cam.ac.uk	Kettunen, Mikko I/K-2299-2012; Jensen, Pernille Rose/GQQ-6261-2022; Karlsson, Magnus/AAZ-1768-2021; Ardenkjær-Larsen, Jan Henrik/B-5765-2017; Jensen, Pernille Rose/J-8648-2016; Jensen, Pernille Rose/AAX-5696-2020; Lerche, Mathilde Hauge/J-5487-2017	Kettunen, Mikko I/0000-0002-2004-660X; Jensen, Pernille Rose/0000-0003-4359-848X; Ardenkjær-Larsen, Jan Henrik/0000-0001-6167-6926; Jensen, Pernille Rose/0000-0003-4359-848X; Jensen, Pernille Rose/0000-0003-4359-848X; in 't Zandt, Rene/0000-0002-3610-9513; Karlsson, Magnus/0000-0001-7738-1700; Gallagher, Ferdia Aidan/0000-0003-4784-5230; Lerche, Mathilde Hauge/0000-0002-5899-2781	Cancer Research UK [C197/A3514] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Adrogue HJ, 1998, NEW ENGL J MED, V338, P26, DOI 10.1056/NEJM199801013380106; Ardenkjaer-Larsen JH, 2003, P NATL ACAD SCI USA, V100, P10158, DOI 10.1073/pnas.1733835100; BEAUREGARD DA, 1998, P 6 ANN M ISMRM SYDN, P653; BRINDLE KM, 1988, PROG NUCL MAG RES SP, V20, P257, DOI 10.1016/0079-6565(88)80003-7; Day SE, 2007, NAT MED, V13, P1382, DOI 10.1038/nm1650; Gillies RJ, 2004, IEEE ENG MED BIOL, V23, P57, DOI 10.1109/MEMB.2004.1360409; GILLIES RJ, 1994, AM J PHYSIOL, V267, pC195, DOI 10.1152/ajpcell.1994.267.1.C195; Golman K, 2006, CANCER RES, V66, P10855, DOI 10.1158/0008-5472.CAN-06-2564; Golman K, 2006, ACAD RADIOL, V13, P932, DOI 10.1016/j.acra.2006.06.001; GRINSTEIN S, 1991, CLIN BIOCHEM, V24, P241, DOI 10.1016/0009-9120(91)80014-T; HOFFMAN DW, 1987, BIOCHEM BIOPH RES CO, V143, P67, DOI 10.1016/0006-291X(87)90630-9; Hohn-Berlage M, 1989, NMR Biomed, V2, P240, DOI 10.1002/nbm.1940020512; MAREN TH, 1977, AM J PHYSIOL, V232, pF291, DOI 10.1152/ajprenal.1977.232.4.F291; Mason RP, 1999, CURR MED CHEM, V6, P481; MCCOY CL, 1995, BRIT J CANCER, V72, P905, DOI 10.1038/bjc.1995.431; MELDRUM N. IT., 1933, JOUR PHYSIOL, V80, P113; Merritt ME, 2007, P NATL ACAD SCI USA, V104, P19773, DOI 10.1073/pnas.0706235104; Raghunand N, 1999, BRIT J CANCER, V80, P1005, DOI 10.1038/sj.bjc.6690455; Raghunand N, 2002, ACAD RADIOL, V9, pS481, DOI 10.1016/S1076-6332(03)80270-2; Raghunand N, 2001, NEOPLASIA, V3, P227, DOI 10.1038/sj.neo.7900151; ROTTENBERG DA, 1985, ANN NEUROL, V17, P70, DOI 10.1002/ana.410170116; SIWETACH P, 2007, CANC METASTASIS REV, V26, P299; STABENAU EK, 1993, J EXP BIOL, V180, P311; STUBBS M, 1992, NMR BIOMED, V5, P351, DOI 10.1002/nbm.1940050606; van Sluis R, 1999, MAGN RESON MED, V41, P743, DOI 10.1002/(SICI)1522-2594(199904)41:4<743::AID-MRM13>3.0.CO;2-Z; Vermathen P, 2000, MAGN RESON MED, V43, P665, DOI 10.1002/(SICI)1522-2594(200005)43:5<665::AID-MRM8>3.0.CO;2-3; Ward KM, 2000, MAGN RESON MED, V44, P799, DOI 10.1002/1522-2594(200011)44:5<799::AID-MRM18>3.0.CO;2-S; WHITE A, 1968, PRINCIPLES BIOCH; Zhao M, 2001, NAT MED, V7, P1241, DOI 10.1038/nm1101-1241; Zhou JY, 2003, NAT MED, V9, P1085, DOI 10.1038/nm907	30	639	657	1	215	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 12	2008	453	7197					940	U73		10.1038/nature07017	http://dx.doi.org/10.1038/nature07017			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311WV	18509335				2022-12-28	WOS:000256632000048
J	Wolcott, RD; Ehrlich, GD				Wolcott, Randall D.; Ehrlich, Garth D.			Biofilms and chronic infections	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Wolcott, Randall D.] Med Biofilm Res Inst, Lubbock, TX 79410 USA; [Ehrlich, Garth D.] Drexel Coll Med, Ctr Genom Sci, Allegheny Singer Res Inst, Allegheny Gen Hosp, Pittsburgh, PA USA; [Ehrlich, Garth D.] Drexel Coll Med, Dept Microbiol & Immunol, Pittsburgh, PA USA; [Ehrlich, Garth D.] Drexel Coll Med, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA USA	Allegheny General Hospital; Drexel University; Drexel University; Drexel University	Wolcott, RD (corresponding author), Med Biofilm Res Inst, 2002 Oxford Ave, Lubbock, TX 79410 USA.	randy@randallwolcott.com		Ehrlich, Garth/0000-0003-1140-6594	NIDCD NIH HHS [R01 DC004173] Funding Source: Medline	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Blumenfeld TJ, 2006, J ARTHROPLASTY, V21, P689, DOI 10.1016/j.arth.2005.10.010; COSTERTON JW, 1978, SCI AM, V238, P86, DOI 10.1038/scientificamerican0178-86; Costerton W, 2003, J CLIN INVEST, V112, P1466, DOI 10.1172/JCI200320365; Dowd SE, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-43; Ehrlich GD, 2005, CLIN ORTHOP RELAT R, P20, DOI 10.1097/01.blo.0000175124.52590.c0; El-Azizi Mohamed, 2005, Ann Clin Microbiol Antimicrob, V4, P2, DOI 10.1186/1476-0711-4-2; Espy MJ, 2006, CLIN MICROBIOL REV, V19, P165, DOI 10.1128/CMR.19.1.165-256.2006; GEESEY GG, 1977, CAN J MICROBIOL, V23, P1733, DOI 10.1139/m77-249; Lewis K, 2007, NAT REV MICROBIOL, V5, P48, DOI 10.1038/nrmicro1557; Prince AS, 2002, NEW ENGL J MED, V347, P1110, DOI 10.1056/NEJMcibr021776; Walters MC, 2003, ANTIMICROB AGENTS CH, V47, P317, DOI 10.1128/AAC.47.1.317-323.2003	11	175	186	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2008	299	22					2682	2684		10.1001/jama.299.22.2682	http://dx.doi.org/10.1001/jama.299.22.2682			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311FN	18544729				2022-12-28	WOS:000256586200026
J	Bell, J; Harvey-Dodds, L				Bell, James; Harvey-Dodds, Lucy			Pregnancy plus - Pregnancy and injecting drug use	BMJ-BRITISH MEDICAL JOURNAL			English	Article							METHADONE-MAINTENANCE; NEONATAL WITHDRAWAL; ADDICTS; OUTCOMES; PROGRAM; HEROIN		[Bell, James] Inst Psychiat, Natl Addict Ctr, London SE5 8RS, England; [Bell, James; Harvey-Dodds, Lucy] Langton Ctr, Sydney, NSW 2011, Australia	University of London; King's College London	Bell, J (corresponding author), Inst Psychiat, Natl Addict Ctr, London SE5 8RS, England.	james.bell@sesiahs.health.nsw.gov.au						Advisory Council on the Misuse of Drugs, 2003, HIDD HARM RESP NEEDS; *AUSTR I HLTH WELF, 2005, STAT DRUG US AUSTR 2; BELL J, 2006, NATL CLIN GUIDELINES; Berghella V, 2003, AM J OBSTET GYNECOL, V189, P312, DOI 10.1067/S0002-9378(03)00520-9; BLINICK G, 1969, AM J OBSTET GYNECOL, V105, P997, DOI 10.1016/0002-9378(69)90117-3; Dashe JS, 2002, OBSTET GYNECOL, V100, P1244, DOI 10.1016/S0029-7844(02)02387-6; FINNEGAN L, 1997, SUBSTANCE ABUSE COMP; Fischer G, 2006, ADDICTION, V101, P275, DOI 10.1111/j.1360-0443.2006.01321.x; Fischer G, 1999, ADDICTION, V94, P231, DOI 10.1046/j.1360-0443.1999.9422317.x; Hulse GK, 1997, ADDICTION, V92, P1571; Jansson LM, 2005, AM J OBSTET GYNECOL, V193, P611, DOI 10.1016/j.ajog.2005.02.075; KALTENBACH K, 1987, NEUROTOXICOL TERATOL, V9, P311, DOI 10.1016/0892-0362(87)90021-3; Kennare R, 2005, AUST NZ J OBSTET GYN, V45, P220, DOI 10.1111/j.1479-828X.2005.00379.x; Klee H., 2002, DRUG MISUSE MOTHERHO; Klee H., 1998, INT J DRUG POLICY, V9, P437, DOI DOI 10.1016/S0955-3959(98)00060-7; Lejeune C, 2001, ANN MED INTERNE, V152, pS21; Lester BM, 2001, PEDIATRICS, V107, P309, DOI 10.1542/peds.107.2.309; Luty J, 2003, J SUBST ABUSE TREAT, V24, P363, DOI 10.1016/S0740-5472(03)00035-7; MADDUX JF, 1992, AM J DRUG ALCOHOL AB, V18, P63, DOI 10.3109/00952999209001612; McCarthy JJ, 2005, AM J OBSTET GYNECOL, V193, P606, DOI 10.1016/j.ajog.2005.03.072; Ornoy A, 1996, CHILD ABUSE NEGLECT, V20, P385, DOI 10.1016/0145-2134(96)00014-2; Sanaullah F, 2006, J Obstet Gynaecol, V26, P187, DOI 10.1080/01443610500508121; WITTMANN BK, 1991, INT J ADDICT, V26, P213, DOI 10.3109/10826089109053183; Wojnar-Horton RE, 1997, BRIT J CLIN PHARMACO, V44, P543, DOI 10.1046/j.1365-2125.1997.t01-1-00624.x	24	25	25	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 7	2008	336	7656					1303	1305		10.1136/bmj.39514.554375.AE	http://dx.doi.org/10.1136/bmj.39514.554375.AE			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312XO	18535073	Green Published			2022-12-28	WOS:000256705900036
J	McMichael, AJ; Neira, M; Heymann, DL				McMichael, Anthony J.; Neira, Maria; Heymann, David L.			World Health Assembly 2008: climate change and health	LANCET			English	Editorial Material									[McMichael, Anthony J.] Australian Natl Univ, Canberra, ACT 0200, Australia; [Neira, Maria; Heymann, David L.] WHO, CH-1211 Geneva, Switzerland	Australian National University; World Health Organization	McMichael, AJ (corresponding author), Australian Natl Univ, GPO Box 4, Canberra, ACT 0200, Australia.	tony.mcmichael@anu.edu.au						Confalonieri U, 2007, CLIMATE CHANGE 2007; McMichael AJ, 2006, LANCET, V367, P859, DOI 10.1016/S0140-6736(06)68079-3; McMichael AJ, 2008, SOCIAL ECOLOGY OF INFECTIOUS DISEASES, P378, DOI 10.1016/B978-012370466-5.50019-4; *UN, 1992, UN FRAM CONV CLIM CH; *WHO, 2008, IMP CLIM CHANG HUM H; Woods CW, 2002, EMERG INFECT DIS, V8, P138, DOI 10.3201/eid0802.010023	6	16	19	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 7	2008	371	9628					1895	1896		10.1016/S0140-6736(08)60811-9	http://dx.doi.org/10.1016/S0140-6736(08)60811-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310OI	18539208				2022-12-28	WOS:000256538500008
J	Sattar, N; McConnachie, A; Shaper, AG; Blauw, GJ; Buckley, BM; de Craen, AJ; Ford, I; Forouhi, NG; Freeman, DJ; Jukema, JW; Lennon, L; Macfarlane, PW; Murphy, MB; Packard, CJ; Stott, DJ; Westendorp, RG; Whincup, PH; Shepherd, J; Wannamethee, SG				Sattar, Naveed; McConnachie, Alex; Shaper, A. Gerald; Blauw, Gerard J.; Buckley, Brendan M.; de Craen, Anton J.; Ford, Ian; Forouhi, Nita G.; Freeman, Dilys J.; Jukema, J. Wouter; Lennon, Lucy; Macfarlane, Peter W.; Murphy, Michael B.; Packard, Chris J.; Stott, David J.; Westendorp, Rudi G.; Whincup, Peter H.; Shepherd, James; Wannamethee, S. Goya			Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies	LANCET			English	Article							CORONARY-HEART-DISEASE; RISK SCORE; FOLLOW-UP; OLDER; PRAVASTATIN; MORTALITY; STROKE; INDIVIDUALS; DEFINITION; PEOPLE	Background Clinical use of criteria for metabolic syndrome to simultaneously predict risk of cardiovascular disease and diabetes remains uncertain. We investigated to what extent metabolic syndrome and its individual components were related to risk for these two diseases in elderly populations. Methods We related metabolic syndrome (defined on the basis of criteria from the Third Report of the National Cholesterol Education Program) and its five individual components to the risk of events of incident cardiovascular disease and type 2 diabetes in 4812 non-diabetic individuals aged 70-82 years from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). We corroborated these data in a second prospective study (the British Regional Heart Study [BRHS]) of 2737 non-diabetic men aged 60-79 years. Findings In PROSPER, 772 cases of incident cardiovascular disease and 287 of diabetes occurred over 3.2 years. Metabolic syndrome was not associated with increased risk of cardiovascular disease in those without baseline disease (hazard ratio 1 . 07 [95% CI 0 . 86-1.32]) but was associated with increased risk of diabetes (4.41 [3.33-5.84]) as was each of its components, particularly fasting glucose (18.4 [13.9-24.5]). Results were similar in participants with existing cardiovascular disease. In BRHS, 440 cases of incident cardiovascular disease and 105 of diabetes occurred over 7 years. Metabolic syndrome was modestly associated with incident cardiovascular disease (relative risk 1.27 [1 . 04-1.56]) despite strong association with diabetes (7.47 [4.90-11.46]). In both studies, body-mass index or waist circumference, triglyceride, and glucose cutoff points were not associated with risk of cardiovascular disease, but all five components were associated with risk of new-onset diabetes. Interpretation Metabolic syndrome and its components are associated with type 2 diabetes but have weak or no association with vascular risk in elderly populations, suggesting that attempts to define criteria that simultaneously predict risk for both cardiovascular disease and diabetes are unhelpful. Clinical focus should remain on establishing optimum risk algorithms for each disease. Funding Diabetes UK and British Heart Foundation.	[Sattar, Naveed; Freeman, Dilys J.; Macfarlane, Peter W.; Packard, Chris J.; Stott, David J.; Shepherd, James] Univ Glasgow, Fac Med, BHF Glasgow Cardiovasc Res Ctr, Glasgow G12 8TA, Lanark, Scotland; [McConnachie, Alex; Ford, Ian] Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8TA, Lanark, Scotland; [Forouhi, Nita G.] Addenbrookes Hosp, MRC Epidemiol Unit, Inst Metab Sci, Cambridge, England; [Buckley, Brendan M.; Murphy, Michael B.] Cork Univ Hosp, Dept Pharmacol & Therapeut, Cork, Ireland; [Blauw, Gerard J.; de Craen, Anton J.; Westendorp, Rudi G.] Leiden Univ, Med Ctr, Sect Gerontol & Geriatr, Leiden, Netherlands; [Jukema, J. Wouter] Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands; [Shaper, A. Gerald; Lennon, Lucy; Wannamethee, S. Goya] UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London WC1E 6BT, England; [Whincup, Peter H.] Univ London St Georges Hosp, Div Community Hlth Sci, London, England	University of Glasgow; University of Glasgow; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University College Cork; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of London; University College London; UCL Medical School; St Georges University London	Sattar, N (corresponding author), Univ Glasgow, Fac Med, BHF Glasgow Cardiovasc Res Ctr, 126 Univ Pl, Glasgow G12 8TA, Lanark, Scotland.	nsattar@clinmed.gla.ac.uk	Murphy, Michael B/A-1310-2011; Ford, Ian/ABE-6145-2020; Lennon, Lucy/ABB-9433-2020; Blauw, Gerard/GWD-1079-2022; Blauw, Gerard/AAW-7904-2021; Jukema, J. Wouter/ABD-6503-2021; Lennon, Lucy/AFT-1973-2022	Lennon, Lucy/0000-0002-1738-1351; Jukema, J. Wouter/0000-0002-3246-8359; Forouhi, Nita/0000-0002-5041-248X; Wannamethee, Sasiwarang/0000-0001-9484-9977; Murphy, Michael/0000-0001-6722-7080; Whincup, Peter/0000-0002-5589-4107	British Heart Foundation Funding Source: Medline; Medical Research Council [MC_U106179471] Funding Source: Medline	British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Boshuizen HC, 1998, BMJ-BRIT MED J, V316, P1780, DOI 10.1136/bmj.316.7147.1780; Chien KL, 2007, ATHEROSCLEROSIS, V194, P214, DOI 10.1016/j.atherosclerosis.2006.07.033; Deedwania P, 2006, LANCET, V368, P919, DOI 10.1016/S0140-6736(06)69292-1; Emberson JR, 2002, ANN CLIN BIOCHEM, V39, P493, DOI 10.1258/000456302320314511; Espinola-Klein C, 2007, AM J CARDIOL, V99, P1623, DOI 10.1016/j.amjcard.2007.01.049; Ferrannini E, 2007, J CLIN ENDOCR METAB, V92, P396, DOI 10.1210/jc.2006-0944; Gale EAM, 2005, DIABETOLOGIA, V48, P1679, DOI 10.1007/s00125-005-1873-5; Gami AS, 2007, J AM COLL CARDIOL, V49, P403, DOI 10.1016/j.jacc.2006.09.032; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Jeppesen J, 2007, J AM COLL CARDIOL, V49, P2112, DOI 10.1016/j.jacc.2007.01.088; Kahn R, 2005, DIABETES CARE, V28, P2289, DOI 10.2337/diacare.28.9.2289; Lawlor DA, 2006, DIABETOLOGIA, V49, P41, DOI 10.1007/s00125-005-0040-3; Lindstrom J, 2003, DIABETES CARE, V26, P725, DOI 10.2337/diacare.26.3.725; McNeill AM, 2006, J AM GERIATR SOC, V54, P1317, DOI 10.1111/j.1532-5415.2006.00862.x; Packard CJ, 2005, CIRCULATION, V112, P3058, DOI 10.1161/CIRCULATIONAHA.104.526848; Pepe MS, 2004, AM J EPIDEMIOL, V159, P882, DOI 10.1093/aje/kwh101; Rose G, 1982, CARDIOVASCULAR SURVE; Sattar N, 2003, CIRCULATION, V108, P414, DOI 10.1161/01.CIR.0000080897.52664.94; Sattar N, 2006, CURR OPIN LIPIDOL, V17, P404, DOI 10.1097/01.mol.0000236366.48593.07; Schulze MB, 2007, DIABETES CARE, V30, P510, DOI 10.2337/dc06-2089; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; Shepherd J, 1999, AM J CARDIOL, V84, P1192, DOI 10.1016/S0002-9149(99)00533-0; Stern MP, 2004, DIABETES CARE, V27, P2676, DOI 10.2337/diacare.27.11.2676; Takahashi K, 2007, INTERNAL MED, V46, P643, DOI 10.2169/internalmedicine.46.6094; Walker M, 2000, J PUBLIC HEALTH MED, V22, P479, DOI 10.1093/pubmed/22.4.479; Wang JJ, 2007, EUR HEART J, V28, P857, DOI 10.1093/eurheartj/ehl524; Wannamethee SG, 2007, AM J CLIN NUTR, V86, P1339, DOI 10.1093/ajcn/86.5.1339; Wannamethee SG, 2005, ARCH INTERN MED, V165, P2644, DOI 10.1001/archinte.165.22.2644; Wannamethee SG, 2002, CIRCULATION, V105, P1785, DOI 10.1161/01.CIR.0000016346.14762.71; Wilson PWF, 2005, CIRCULATION, V112, P3066, DOI 10.1161/CIRCULATIONAHA.105.539528	32	351	361	1	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	2008	371	9628					1927	1935		10.1016/S0140-6736(08)60602-9	http://dx.doi.org/10.1016/S0140-6736(08)60602-9			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310OI	18501419				2022-12-28	WOS:000256538500029
J	Wiberg-Itzel, E; Lipponer, C; Norman, M; Herbst, A; Prebensen, D; Hansson, A; Bryngelsson, AL; Christoffersson, M; Sennstrom, M; Wennerholm, UB; Nordstrom, L				Wiberg-Itzel, E.; Lipponer, C.; Norman, M.; Herbst, A.; Prebensen, D.; Hansson, A.; Bryngelsson, A-L; Christoffersson, M.; Sennstrom, M.; Wennerholm, U-B; Nordstrom, L.			Determination of pH or lactate in fetal scalp blood in management of intrapartum fetal distress: randomised controlled multicentre trial	BRITISH MEDICAL JOURNAL			English	Article							ACIDEMIA; FETUS; LABOR	Objective To examine the effectiveness of pH analysis of fetal scalp blood compared with lactate analysis in identifying hypoxia in labour to prevent acidaemia at birth. Design Randomised controlled multicentre trial. Setting Labour wards. Participants Women with a singleton pregnancy, cephalic presentation, gestational age >= 34 weeks, and clinical indication for fetal scalp blood sampling. Interventions Standard pH analysis (n=1496) or lactate analysis (n=1496) with an electrochemical microvolume (5 mu l) test strip device. The cut-off levels for intervention were pH < 7.21 and lactate > 4.8 mmol/l, respectively. Main outcome measure Metabolic acidaemia (pH < 7.05 and base deficit > 12 mmol/l) or pH < 7.00 in cord artery blood. Results Metabolic acidaemia occurred in 3.2% in the lactate group and in 3.6% in the pH group (relative risk 0.91, 95% confidence interval 0.61 to 1.36). pH <7.00 occurred in 1.5% in the lactate group and in 1.8% in the pH group (0.84, 0.47 to 1.50). There was no significant difference in Apgar scores < 7 at 5 minutes (1.15, 0.76 to 1.75) or operative deliveries for fetal distress (1.02, 0.93 to 1.11). Conclusion There were no significant differences in rate of acidaemia at birth after use of lactate analysis or pH analysis of fetal scalp blood samples to determine hypoxia during labour.	[Sennstrom, M.; Nordstrom, L.] Karolinska Univ Hosp, Karolinska Inst, S-17176 Stockholm, Sweden; [Wiberg-Itzel, E.] Soder Hosp, Dept Obstet, Stockholm, Sweden; [Wiberg-Itzel, E.] Soder Hosp, Dept Gynaecol, Stockholm, Sweden; [Lipponer, C.; Wennerholm, U-B] Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden; [Norman, M.] Danderyd Hosp, Gothenburg, Sweden; [Herbst, A.] Univ Lund Hosp, S-22185 Lund, Sweden; [Prebensen, D.] Trollhattan Cent Hosp, Trollhattan, Sweden; [Hansson, A.] Karlstad Cent Hosp, Karlstad, Sweden; [Bryngelsson, A-L] Orebro Univ Hosp, Orebro, Sweden; [Christoffersson, M.] Kalmar Cty Hosp, Kalmar, Sweden	Karolinska Institutet; Karolinska University Hospital; Sahlgrenska University Hospital; Danderyds Hospital; Lund University; Skane University Hospital; Orebro University	Nordstrom, L (corresponding author), Karolinska Univ Hosp, Karolinska Inst, S-17176 Stockholm, Sweden.	lennart.nordstrom@karolinska.se	Wiberg-Itzel, Eva/AAO-4169-2021	Wiberg-Itzel, Eva/0000-0002-4835-9616; Nordstrom, Lennart/0000-0002-7547-2569; Herbst, Andreas/0000-0002-2540-7339; Sennstrom, Maria/0000-0002-6532-022X				BRETSCHER J, 1967, AM J OBSTET GYNECOL, V97, P906, DOI 10.1016/0002-9378(67)90515-7; CLARK SL, 1985, AM J OBSTET GYNECOL, V153, P717, DOI 10.1016/0002-9378(85)90330-8; EGUILUZ A, 1983, AM J OBSTET GYNECOL, V147, P949, DOI 10.1016/0002-9378(83)90252-1; GOLDABER KG, 1991, OBSTET GYNECOL, V78, P1103; Ingemarsson I, 1993, FETAL HEART RATE MON; Kruger K, 1999, AM J OBSTET GYNECOL, V181, P1072, DOI 10.1016/S0002-9378(99)70083-9; LOW JA, 1994, AM J OBSTET GYNECOL, V170, P1081, DOI 10.1016/S0002-9378(94)70101-6; MacLennan A, 1999, BMJ-BRIT MED J, V319, P1054, DOI 10.1136/bmj.319.7216.1054; NORDSTROM L, 1995, BRIT J OBSTET GYNAEC, V102, P894, DOI 10.1111/j.1471-0528.1995.tb10878.x; Nordstrom L, 1998, J PERINAT MED, V26, P83, DOI 10.1515/jpme.1998.26.2.83; Samat HB, 1976, ARCH NEUROL-CHICAGO, V33, P696; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; SCHIMOJO N, 1993, CLIN CHEM, V39, P2312; SMITH NC, 1983, BRIT J OBSTET GYNAEC, V90, P821, DOI 10.1111/j.1471-0528.1983.tb09322.x; Tuffnell D, 2006, BJOG-INT J OBSTET GY, V113, P332, DOI 10.1111/j.1471-0528.2006.00859.x; VINTZILEOS AM, 1995, AM J OBSTET GYNECOL, V173, P1021, DOI 10.1016/0002-9378(95)91320-3; Westgren M, 1998, BRIT J OBSTET GYNAEC, V105, P29, DOI 10.1111/j.1471-0528.1998.tb09346.x; Wiberg N, 2006, AM J OBSTET GYNECOL, V195, P1651, DOI 10.1016/j.ajog.2006.05.043; YOSHIOKA T, 1970, J REPROD MED, V5, P63	19	90	96	0	17	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2008	336	7656					1284	+		10.1136/bmj.39553.406991.25	http://dx.doi.org/10.1136/bmj.39553.406991.25			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312XO	18503103	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000256705900031
J	Studt, F; Abild-Pedersen, F; Bligaard, T; Sorensen, RZ; Christensen, CH; Norskov, JK				Studt, Felix; Abild-Pedersen, Frank; Bligaard, Thomas; Sorensen, Rasmus Z.; Christensen, Claus H.; Norskov, Jens K.			Identification of non-precious metal alloy catalysts for selective hydrogenation of acetylene	SCIENCE			English	Article							SURFACES; KINETICS; PROPYNE; COPPER	The removal of trace acetylene from ethylene is performed industrially by palladium hydrogenation catalysts ( often modified with silver) that avoid the hydrogenation of ethylene to ethane. In an effort to identify catalysts based on less expensive and more available metals, density functional calculations were performed that identified relations in heats of adsorption of hydrocarbon molecules and fragments on metal surfaces. This analysis not only verified the facility of known catalysts but identified nickel- zinc alloys as alternatives. Experimental studies demonstrated that these alloys dispersed on an oxide support were selective for acetylene hydrogenation at low pressures.	[Studt, Felix; Abild-Pedersen, Frank; Bligaard, Thomas; Norskov, Jens K.] Tech Univ Denmark, Dept Phys, Ctr Atom Scale Mat Design, DK-2800 Lyngby, Denmark; [Studt, Felix; Abild-Pedersen, Frank] Computat Mat Design ApS, DK-2800 Lyngby, Denmark; [Sorensen, Rasmus Z.; Christensen, Claus H.] Tech Univ Denmark, Dept Chem, Ctr Sustainable & Green Chem, DK-2800 Lyngby, Denmark	Technical University of Denmark; Technical University of Denmark	Studt, F (corresponding author), Tech Univ Denmark, Dept Phys, Ctr Atom Scale Mat Design, Bldg 311, DK-2800 Lyngby, Denmark.		Abild-Pedersen, Frank/C-3248-2014; Norskov, Jens K/D-2539-2017; Studt, Felix/C-7874-2017; Bligaard, Thomas/A-6161-2011; Bligaard, Thomas/A-6161-2011	Abild-Pedersen, Frank/0000-0002-1911-074X; Norskov, Jens K/0000-0002-4427-7728; Studt, Felix/0000-0001-6841-4232; Bligaard, Thomas/0000-0003-0386-0201; Bligaard, Thomas/0000-0001-9834-9179				Abild-Pedersen F, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.016105; BLANKENSHIP SA, 2003, Patent No. 6509292; Bond G. C., 1962, MAT SAF DAT SHEET GC; BOS ANR, 1993, CHEM ENG PROCESS, V32, P1, DOI 10.1016/0255-2701(93)87001-B; Choudhary TV, 2003, CATAL LETT, V86, P1, DOI 10.1023/A:1022694505504; Collins B. M., 1978, US Patent, Patent No. [4 126 645, 4126645]; COUVILLON MC, 1984, Patent No. 4440956; FREVEL LK, 1975, Patent No. 3912789; HAMMER B, 1995, NATURE, V376, P238, DOI 10.1038/376238a0; HAMMER B, 2000, NORSKOV ADV CATAL, V45, P71; Kovnir K, 2007, SCI TECHNOL ADV MAT, V8, P420, DOI 10.1016/j.stam.2007.05.004; Liu ZP, 2003, J AM CHEM SOC, V125, P1958, DOI 10.1021/ja0207551; Mei D, 2006, J CATAL, V242, P1, DOI 10.1016/j.jcat.2006.05.009; NOVER G, 1980, J LESS-COMMON MET, V75, P51, DOI 10.1016/0022-5088(80)90368-9; Pourovskii LV, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.026105; Rodriguez JC, 1997, J CATAL, V171, P268, DOI 10.1006/jcat.1997.1815; Ruban AV, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.174201; Schbib NS, 1996, IND ENG CHEM RES, V35, P1496, DOI 10.1021/ie950600k; Sheth PA, 2005, J PHYS CHEM B, V109, P12449, DOI 10.1021/jp050194a; Sheth PA, 2003, J PHYS CHEM B, V107, P2009, DOI 10.1021/jp021342p; SHUSTOROVICH E, 1988, SURF SCI, V205, P492, DOI 10.1016/0039-6028(88)90299-3; Thanh C. N., 2000, US Patent, Patent No. [6,054,409, 6054409]; Vang RT, 2005, NAT MATER, V4, P160, DOI 10.1038/nmat1311; Volpe MA, 1999, CATAL LETT, V61, P27, DOI 10.1023/A:1019087814472; WEHRLI JT, 1991, APPL CATAL, V70, P253, DOI 10.1016/S0166-9834(00)84168-8; WEHRLI JT, 1990, APPL CATAL, V66, P199, DOI 10.1016/S0166-9834(00)81638-3	26	824	836	32	781	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	2008	320	5881					1320	1322		10.1126/science.1156660	http://dx.doi.org/10.1126/science.1156660			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	309DO	18535238				2022-12-28	WOS:000256441100039
J	Carmeliet, P; Baes, M				Carmeliet, Peter; Baes, Myriam			Metabolism and therapeutic angiogenesis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HYPOXIA TOLERANCE; COACTIVATORS		[Carmeliet, Peter] Katholieke Univ Leuven VIB, Vesalius Res Ctr, Louvain, Belgium; [Baes, Myriam] Katholieke Univ Leuven, Lab Cell Metab, Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; KU Leuven	Carmeliet, P (corresponding author), Katholieke Univ Leuven VIB, Vesalius Res Ctr, Louvain, Belgium.		Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821; Baes, Myriam/0000-0002-2525-2269				Aragones J, 2008, NAT GENET, V40, P170, DOI 10.1038/ng.2007.62; Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613; Finck BN, 2006, J CLIN INVEST, V116, P615, DOI 10.1172/JCI27794; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Ramirez JM, 2007, ANNU REV PHYSIOL, V69, P113, DOI 10.1146/annurev.physiol.69.031905.163111	5	33	35	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2008	358	23					2511	2512		10.1056/NEJMcibr0802500	http://dx.doi.org/10.1056/NEJMcibr0802500			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308HY	18525050				2022-12-28	WOS:000256380700014
J	Wille, M; Nagler, TF; Lehmann, B; Schroder, S; Kramers, JD				Wille, Martin; Naegler, Thomas F.; Lehmann, Bernd; Schroeder, Stefan; Kramers, Jan D.			Hydrogen sulphide release to surface waters at the Precambrian/Cambrian boundary	NATURE			English	Article							CAMBRIAN BLACK SHALES; NORTHWESTERN HUNAN; SOUTH CHINA; RE-OS; RECORD; CARBON; GEOCHEMISTRY; TRANSITION; ANOXIA; MARGIN	Animal- like multicellular fossils appeared towards the end of the Precambrian, followed by a rapid increase in the abundance and diversity of fossils during the Early Cambrian period, an event also known as the 'Cambrian explosion'(1-3). Changes in the environmental conditions at the Precambrian/ Cambrian transition ( about 542 Myr ago) have been suggested as a possible explanation for this event, but are still a matter of debate(1-3). Here we report molybdenum isotope signatures of black shales from two stratigraphically correlated sample sets with a depositional age of around 542 Myr. We find a transient molybdenum isotope signal immediately after the Precambrian/ Cambrian transition. Using a box model of the oceanic molybdenum cycle, we find that intense upwelling of hydrogen sulphide- rich deep ocean water best explains the observed Early Cambrian molybdenum isotope signal. Our findings suggest that the Early Cambrian animal radiation may have been triggered by a major change in ocean circulation, terminating a long period during which the Proterozoic ocean was stratified, with sulphidic deep water.	[Wille, Martin; Naegler, Thomas F.; Kramers, Jan D.] Univ Bern, Inst Geol Sci, CH-3012 Bern, Switzerland; [Lehmann, Bernd] Tech Univ Clausthal, Inst Mineral & Mineral Resources, D-38678 Clausthal Zellerfeld, Germany; [Schroeder, Stefan] MIT, Cambridge, MA 02139 USA	University of Bern; TU Clausthal; Massachusetts Institute of Technology (MIT)	Wille, M (corresponding author), Univ Bern, Inst Geol Sci, Baltzerstr 3, CH-3012 Bern, Switzerland.	martin.wille@anu.edu.au	Wille, Martin/A-1973-2009; Schröder, Stefan/P-4613-2015; Nägler, Thomas F/I-8136-2015; Wille, Martin/AAU-7512-2020	Schröder, Stefan/0000-0001-5464-0108; Nägler, Thomas F/0000-0002-6919-0151; Wille, Martin/0000-0003-1083-4730; Lehmann, Bernd/0000-0003-0762-6543				ALGEO J, 2006, PALEOCEANOGRAPHY, V21, P1; Amthor JE, 2005, GEOARABIA, V10, P89; Amthor JE, 2003, GEOLOGY, V31, P431, DOI 10.1130/0091-7613(2003)031<0431:EOCANA>2.0.CO;2; Arnold GL, 2004, SCIENCE, V304, P87, DOI 10.1126/science.1091785; Banerjee DM, 1997, PALAEOGEOGR PALAEOCL, V132, P183, DOI 10.1016/S0031-0182(97)00060-6; BRASIER MD, 1992, J GEOL SOC LONDON, V149, P585, DOI 10.1144/gsjgs.149.4.0585; Cao SL, 2004, PROG NAT SCI-MATER, V14, P181, DOI 10.1080/10020070412331343331; Cowie J.W., 1989, PRECAMBRIAN CAMBRIAN; Erickson BE, 2000, GEOCHIM COSMOCHIM AC, V64, P1149, DOI 10.1016/S0016-7037(99)00423-8; Fike DA, 2006, NATURE, V444, P744, DOI 10.1038/nature05345; GROTZINGER JP, 1995, SCIENCE, V270, P598, DOI 10.1126/science.270.5236.598; Kirschvink JL, 2003, CR GEOSCI, V335, P65, DOI 10.1016/S1631-0713(03)00011-7; Knoll AH, 1999, SCIENCE, V284, P2129, DOI 10.1126/science.284.5423.2129; Knoll AH, 2007, EARTH PLANET SC LETT, V256, P295, DOI 10.1016/j.epsl.2007.02.018; Kump LR, 2005, GEOLOGY, V33, P397, DOI 10.1130/G21295.1; Lehmann B, 2007, GEOLOGY, V35, P403, DOI 10.1130/G23543A.1; Maloof AC, 2005, CAN J EARTH SCI, V42, P2195, DOI 10.1139/E05-062; Mao JW, 2002, ECON GEOL BULL SOC, V97, P1051, DOI 10.2113/97.5.1051; Mort HP, 2007, GEOLOGY, V35, P483, DOI 10.1130/G23475A.1; Nagler TF, 2005, CHEM GEOL, V219, P283, DOI 10.1016/j.chemgeo.2005.03.006; Pan JY, 2004, PROG NAT SCI-MATER, V14, P64, DOI 10.1080/10020070412331343161; Schroder S, 2007, J GEOL SOC LONDON, V164, P175, DOI 10.1144/0016-76492005-022; Shen Y, 2000, PALAEOGEOGR PALAEOCL, V158, P99, DOI 10.1016/S0031-0182(00)00033-X; Siebert C, 2006, EARTH PLANET SC LETT, V241, P723, DOI 10.1016/j.epsl.2005.11.010; Siebert C, 2005, GEOCHIM COSMOCHIM AC, V69, P1787, DOI 10.1016/j.gca.2004.10.006; Siebert C, 2003, EARTH PLANET SC LETT, V211, P159, DOI 10.1016/S0012-821X(03)00189-4; Steiner M, 2001, PALAEOGEOGR PALAEOCL, V169, P165, DOI 10.1016/S0031-0182(01)00208-5; Twitchett RJ, 2006, PALAEOGEOGR PALAEOCL, V232, P190, DOI 10.1016/j.palaeo.2005.05.019	28	196	225	0	79	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 5	2008	453	7196					767	769		10.1038/nature07072	http://dx.doi.org/10.1038/nature07072			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308UK	18509331				2022-12-28	WOS:000256415300040
J	Bear, JE				Bear, James E.			Follow the monomer	CELL			English	Editorial Material							ACTIN-BASED MOTILITY; CELL MOTILITY; PROTEINS	Capping proteins limit actin filament growth, but paradoxically increase actin-based cell motility. This has been attributed to funneling of actin monomers to the filament ends that remain uncapped. Using a reconstituted motility system, Akin and Mullins (2008) now demonstrate that filament capping increases Arp2/3-based nucleation and branching, rather than elevating the rate of filament elongation.	[Bear, James E.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Bear, James E.] Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Bear, JE (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	jbear@email.unc.edu						Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Samarin S, 2003, J CELL BIOL, V163, P131, DOI 10.1083/jcb.200303191; van der Gucht J, 2005, P NATL ACAD SCI USA, V102, P7847, DOI 10.1073/pnas.0502121102	7	3	3	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 30	2008	133	5					765	767		10.1016/j.cell.2008.05.012	http://dx.doi.org/10.1016/j.cell.2008.05.012			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510919	Bronze			2022-12-28	WOS:000256274500007
J	Chell, JM; Brand, AH				Chell, James M.; Brand, Andrea H.			Forever young: Death-defying neuroblasts	CELL			English	Editorial Material							NEURAL STEM-CELLS; DROSOPHILA NEUROBLASTS; TRANSCRIPTION FACTORS; TEMPORAL IDENTITY; SELF-RENEWAL; DIFFERENTIATION; PROLIFERATION; SPECIFY	During development, many neural stem cells "age" as they sequentially generate distinct neuronal or glial cell types. In this issue, Maurange et al. (2008) now identify the temporal control factors in Drosophila neural stem cells (neuroblasts) that regulate the fate of stem cell progeny and signal the end of stem cell proliferation.	[Chell, James M.; Brand, Andrea H.] Univ Cambridge, Gurdon Inst, Cambridge CB2 1QN, England; [Chell, James M.; Brand, Andrea H.] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 1QN, England	University of Cambridge; University of Cambridge	Brand, AH (corresponding author), Univ Cambridge, Gurdon Inst, Tennis Court Rd, Cambridge CB2 1QN, England.	ahb@mole.bio.cam.ac.uk	Brand, Andrea H/F-8220-2014	Brand, Andrea H/0000-0002-2089-6954	MRC [G0300072] Funding Source: UKRI; Medical Research Council [G0300072] Funding Source: Medline; Wellcome Trust [068055] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Almeida MS, 2005, MECH DEVELOP, V122, P1282, DOI 10.1016/j.mod.2005.08.004; Bello BC, 2003, NEURON, V37, P209, DOI 10.1016/S0896-6273(02)01181-9; Choksi SP, 2006, DEV CELL, V11, P775, DOI 10.1016/j.devcel.2006.09.015; Doe CQ, 2008, DEVELOPMENT, V135, P1575, DOI 10.1242/dev.014977; HARTENSTEIN V, 1987, ROUX ARCH DEV BIOL, V196, P473, DOI 10.1007/BF00399871; Isshiki T, 2001, CELL, V106, P511, DOI 10.1016/S0092-8674(01)00465-2; Kanai MI, 2005, DEV CELL, V8, P203, DOI 10.1016/j.devcel.2004.12.014; Pearson BJ, 2004, ANNU REV CELL DEV BI, V20, P619, DOI 10.1146/annurev.cellbio.19.111301.115142	8	6	6	1	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	2008	133	5					769	771		10.1016/j.cell.2008.05.010	http://dx.doi.org/10.1016/j.cell.2008.05.010			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510921	Bronze			2022-12-28	WOS:000256274500009
J	Piccolo, S				Piccolo, Stefano			p53 regulation orchestrates the TGF-beta response	CELL			English	Editorial Material							ORGANIZER; INDUCTION; EMBRYOS	Among its multiple functions, p53 is a critical regulator of TGF-beta responses. Sasai et al. (2008) now identify a new p53 inhibitory protein, XFDL156. During embryonic development, this factor is expressed in the ectoderm germ layer and maintains the pluripotency of ectodermal cells by inhibiting TGF-beta target genes that promote mesoderm specification.	Univ Padua, Dept Med Biotechnol, Sect Histol & Embroyol, I-35126 Padua, Italy	University of Padua	Piccolo, S (corresponding author), Univ Padua, Dept Med Biotechnol, Sect Histol & Embroyol, Viale Colombo 3, I-35126 Padua, Italy.	piccolo@bio.unipd.it		PICCOLO, STEFANO/0000-0002-2037-0004				Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Camus A, 2006, DEV BIOL, V295, P743, DOI 10.1016/j.ydbio.2006.03.047; Chang CB, 2007, DEVELOPMENT, V134, P3861, DOI 10.1242/dev.007179; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Cordenonsi M, 2007, SCIENCE, V315, P840, DOI 10.1126/science.1135961; De Robertis EM, 2006, NAT REV MOL CELL BIO, V7, P296, DOI 10.1038/nrm1855; Dupont S, 2005, CELL, V121, P87, DOI 10.1016/j.cell.2005.01.033; Niehrs C, 2004, NAT REV GENET, V5, P425, DOI 10.1038/nrg1347; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5	9	26	26	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 30	2008	133	5					767	769		10.1016/j.cell.2008.05.013	http://dx.doi.org/10.1016/j.cell.2008.05.013			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510920	Bronze			2022-12-28	WOS:000256274500008
J	Rodriguez-Roisin, R; Krowka, MJ				Rodriguez-Roisin, Roberto; Krowka, Michael J.			Current concepts: Hepatopulmonary syndrome - A liver-induced lung vascular disorder	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NITRIC-OXIDE SYNTHASE; GAS-EXCHANGE; PORTOPULMONARY HYPERTENSION; DIFFUSING-CAPACITY; CIRRHOTIC-PATIENTS; HEME OXYGENASE-1; PERFUSION SCAN; TRANSPLANTATION; DISEASE; HYPOXEMIA		IDIBAPS, Hosp Clin, Serv Pneumol, Inst Torax, E-08036 Barcelona, Spain; Univ Barcelona, Barcelona, Spain; Mayo Clin, Div Pulm & Crit Care, Rochester, MN USA	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Mayo Clinic	Rodriguez-Roisin, R (corresponding author), IDIBAPS, Hosp Clin, Serv Pneumol, Inst Torax, E-08036 Barcelona, Spain.	rororo@clinic.ub.es			PHS HHS [065958] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAMS GA, 1995, GASTROENTEROLOGY, V109, P1283, DOI 10.1016/0016-5085(95)90589-8; Abrams GA, 1998, GASTROENTEROLOGY, V114, P305, DOI 10.1016/S0016-5085(98)70481-0; Aller R, 2002, J ENDOCRINOL INVEST, V25, P4, DOI 10.1007/BF03343954; Arguedas MR, 2005, GASTROENTEROLOGY, V128, P328, DOI 10.1053/j.gastro.2004.11.061; Arguedas MR, 2003, HEPATOLOGY, V37, P192, DOI 10.1053/jhep.2003.50023; Battaglia SE, 1997, HEPATOLOGY, V25, P1228, DOI 10.1002/hep.510250527; BERTHELO.P, 1966, NEW ENGL J MED, V274, P291, DOI 10.1056/NEJM196602102740601; Carter EP, 2002, AM J PHYSIOL-LUNG C, V283, pL346, DOI 10.1152/ajplung.00385.2001; Carter EP, 2000, AM J PHYSIOL-LUNG C, V279, pL903, DOI 10.1152/ajplung.2000.279.5.L903; CREMONA G, 1995, EUR RESPIR J, V8, P1883, DOI 10.1183/09031936.95.08111883; De BK, 2002, GASTROENTEROLOGY, V122, P897, DOI 10.1053/gast.2002.32419; Duncan BW, 2003, ANN THORAC SURG, V76, P1759, DOI 10.1016/S0003-4975(03)00450-8; EDELL ES, 1989, AM REV RESPIR DIS, V140, P1631, DOI 10.1164/ajrccm/140.6.1631; ERIKSSON LS, 1990, HEPATOLOGY, V12, P1350, DOI 10.1002/hep.1840120616; Fallon MB, 1997, GASTROENTEROLOGY, V113, P606, DOI 10.1053/gast.1997.v113.pm9247483; Fallon MB, 2006, LIVER TRANSPLANT, V12, pS105, DOI 10.1002/lt.20971; Fluckiger M., 1884, WIEN MED WOCHENSCHR, V34, P1457; Fuhrmann V, 2006, GASTROENTEROLOGY, V131, P69, DOI 10.1053/j.gastro.2006.04.014; GENOVESI MG, 1976, AM REV RESPIR DIS, V114, P59; Gomez FP, 2006, HEPATOLOGY, V43, P1084, DOI 10.1002/hep.21141; Gomez FP, 2004, HEPATOLOGY, V40, P660, DOI 10.1002/hep.20358; HOURANI JM, 1991, AM J MED, V90, P693; KENNEDY TC, 1977, CHEST, V72, P305, DOI 10.1378/chest.72.3.305; Kinane TB, 2004, NEW ENGL J MED, V351, P1667, DOI 10.1056/NEJMcpc049023; Krowka MJ, 2000, CHEST, V118, P615, DOI 10.1378/chest.118.3.615; Krowka MJ, 2004, LIVER TRANSPLANT, V10, P174, DOI 10.1002/lt.20016; Krowka MJ, 1997, HEPATOLOGY, V25, P1282, DOI 10.1002/hep.510250540; KROWKA MJ, 1990, CHEST, V97, P1165, DOI 10.1378/chest.97.5.1165; Lasch HM, 2001, LIVER TRANSPLANT, V7, P147, DOI 10.1053/jlts.2001.21287; Lee J, 1998, ANN THORAC SURG, V65, P848, DOI 10.1016/S0003-4975(98)00011-3; Martinez G, 1999, J HEPATOL, V30, P882, DOI 10.1016/S0168-8278(99)80143-3; Martinez GP, 2001, J HEPATOL, V34, P651, DOI 10.1016/S0168-8278(00)00108-2; Martinez-Palli G, 2006, WORLD J GASTROENTERO, V12, P5878, DOI 10.3748/wjg.v12.i36.5878; POTERUCHA JJ, 1995, HEPATOLOGY, V21, P96, DOI 10.1016/0270-9139(95)90414-X; Rabiller A, 2002, AM J RESP CRIT CARE, V166, P514, DOI 10.1164/rccm.200201-027OC; Rodriguez-Roisin R, 2004, EUR RESPIR J, V24, P861, DOI 10.1183/09031936.04.00010904; RODRIGUEZROISIN R, 1994, EUR RESPIR J, V7, P839; RODRIGUEZROISIN R, 1987, AM REV RESPIR DIS, V135, P1085; RYDELL R, 1956, AM J MED, V21, P450, DOI 10.1016/0002-9343(56)90043-2; Schenk P, 2000, ANN INTERN MED, V133, P701, DOI 10.7326/0003-4819-133-9-200011070-00012; Schenk P, 2002, GUT, V51, P853, DOI 10.1136/gut.51.6.853; Schiffer E, 2006, AM J TRANSPLANT, V6, P1430, DOI 10.1111/j.1600-6143.2006.01334.x; STANLEY NN, 1977, THORAX, V32, P457, DOI 10.1136/thx.32.4.457; Swanson KL, 2005, HEPATOLOGY, V41, P1122, DOI 10.1002/hep.20658; Sztrymf B, 2004, EUR RESPIR J, V23, P752, DOI 10.1183/09031936.04.00080404; Taille C, 2003, TRANSPLANTATION, V75, P1482, DOI 10.1097/01.TP.0000061612.78954.6C; Tang LP, 2007, AM J PHYSIOL-LUNG C, V292, pL1467, DOI 10.1152/ajplung.00446.2006; Whyte MKB, 1998, J HEPATOL, V29, P85, DOI 10.1016/S0168-8278(98)80182-7; Zhang JL, 2003, GASTROENTEROLOGY, V125, P1441, DOI 10.1016/j.gastro.2003.07.005; Zhang JL, 2007, J APPL PHYSIOL, V102, P949, DOI 10.1152/japplphysiol.01048.2006	50	398	424	0	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2008	358	22					2378	2387		10.1056/NEJMra0707185	http://dx.doi.org/10.1056/NEJMra0707185			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307GF	18509123				2022-12-28	WOS:000256306700008
J	Yang, HG; Sun, CH; Qiao, SZ; Zou, J; Liu, G; Smith, SC; Cheng, HM; Lu, GQ				Yang, Hua Gui; Sun, Cheng Hua; Qiao, Shi Zhang; Zou, Jin; Liu, Gang; Smith, Sean Campbell; Cheng, Hui Ming; Lu, Gao Qing			Anatase TiO2 single crystals with a large percentage of reactive facets	NATURE			English	Article							TOTAL-ENERGY CALCULATIONS; WAVE BASIS-SET; HYDROTHERMAL CONDITIONS; TITANIUM-DIOXIDE; SURFACE; OXIDE; NANOSTRUCTURES; NANOPARTICLES; NANOCRYSTALS; EFFICIENCY	Owing to their scientific and technological importance, inorganic single crystals with highly reactive surfaces have long been studied(1-13). Unfortunately, surfaces with high reactivity usually diminish rapidly during the crystal growth process as a result of the minimization of surface energy. A typical example is titanium dioxide ( TiO2), which has promising energy and environmental applications(14-17). Most available anatase TiO2 crystals are dominated by the thermodynamically stable {101} facets ( more than 94 per cent, according to the Wulff construction(10)), rather than the much more reactive {001} facets(8-13,18-20). Here we demonstrate that for fluorine- terminated surfaces this relative stability is reversed: {001} is energetically preferable to {101}. We explored this effect systematically for a range of non- metallic adsorbate atoms by first- principle quantum chemical calculations. On the basis of theoretical predictions, we have synthesized uniform anatase TiO2 single crystals with a high percentage ( 47 per cent) of {001} facets using hydrofluoric acid as a morphology controlling agent. Moreover, the fluorated surface of anatase single crystals can easily be cleaned using heat treatment to render a fluorine-	[Yang, Hua Gui; Sun, Cheng Hua; Qiao, Shi Zhang; Liu, Gang; Smith, Sean Campbell; Lu, Gao Qing] Univ Queensland, ARC Ctr Excellence Funct Nanomat, Sch Engn, Brisbane, Qld 4072, Australia; [Yang, Hua Gui; Sun, Cheng Hua; Qiao, Shi Zhang; Liu, Gang; Smith, Sean Campbell; Lu, Gao Qing] Univ Queensland, Australian Inst Bioengn & Nanotechnol, Ctr Computat Mol Sci, Brisbane, Qld 4072, Australia; [Zou, Jin] Univ Queensland, Ctr Microscopy & Microanal, Brisbane, Qld 4072, Australia; [Zou, Jin] Univ Queensland, Sch Engn, Brisbane, Qld 4072, Australia; [Liu, Gang; Cheng, Hui Ming] Chinese Acad Sci, Met Res Inst, Shenyang Natl Lab Mat sci, Shenyang 110016, Peoples R China	University of Queensland; University of Queensland; University of Queensland; University of Queensland; Chinese Academy of Sciences; Institute of Metal Research, CAS	Lu, GQ (corresponding author), Univ Queensland, ARC Ctr Excellence Funct Nanomat, Sch Engn, Brisbane, Qld 4072, Australia.	s.qiao@uq.edu.au; maxlu@uq.edu.au	Qiao, Shizhang/A-6057-2010; Smith, Sean/GYJ-6782-2022; Cheng, Hui-Ming/B-8682-2012; Yang, Hug Gui/N-7612-2018; Sun, Chenghua/U-2054-2017; Liu, Gang/J-9729-2012; Lu, Gaoqing/A-2859-2008; Zou, Jin/B-3183-2009; Sun, Chenghua/C-5734-2009; Smith, Sean C/H-5003-2015	Qiao, Shizhang/0000-0002-4568-8422; Yang, Hug Gui/0000-0003-0436-8622; Sun, Chenghua/0000-0001-7654-669X; Liu, Gang/0000-0002-6946-7552; Lu, Gaoqing/0000-0002-5223-1674; Zou, Jin/0000-0001-9435-8043; Smith, Sean C/0000-0002-5679-8205; Lu, Gaoqing (Max)/0000-0002-1456-6983; Cheng, Hui-Ming/0000-0002-5387-4241				Barbe CJ, 1997, J AM CERAM SOC, V80, P3157, DOI 10.1111/j.1151-2916.1997.tb03245.x; Barnard AS, 2005, NANO LETT, V5, P1261, DOI 10.1021/nl050355m; Barnard AS, 2004, J CHEM PHYS, V121, P4276, DOI 10.1063/1.1775770; BERGER H, 1993, J CRYST GROWTH, V130, P108, DOI 10.1016/0022-0248(93)90842-K; Bikondoa O, 2006, NAT MATER, V5, P189, DOI 10.1038/nmat1592; Chen X, 2007, CHEM REV, V107, P2891, DOI 10.1021/cr0500535; Diebold U, 2003, SURF SCI REP, V48, P53, DOI 10.1016/S0167-5729(02)00100-0; Dulub O, 2007, SCIENCE, V317, P1052, DOI 10.1126/science.1144787; FUJISHIMA A, 1972, NATURE, V238, P38; Gong XQ, 2005, J PHYS CHEM B, V109, P19560, DOI 10.1021/jp055311g; Gong XQ, 2006, NAT MATER, V5, P665, DOI 10.1038/nmat1695; Gratzel M, 2001, NATURE, V414, P338, DOI 10.1038/35104607; Herman GS, 2000, PHYS REV LETT, V84, P3354, DOI 10.1103/PhysRevLett.84.3354; HUBER KP, 1979, MOL SPECTRA MOL STRU, V4, P642; IZUMI F, 1978, B CHEM SOC JPN, V51, P1771, DOI 10.1246/bcsj.51.1771; Jun YW, 2003, J AM CHEM SOC, V125, P15981, DOI 10.1021/ja0369515; Kavan L, 1996, J AM CHEM SOC, V118, P6716, DOI 10.1021/ja954172l; KOHN W, 1965, PHYS REV, V140, P1133, DOI 10.1103/PhysRev.140.A1133; Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169; Kresse G, 1999, PHYS REV B, V59, P1758, DOI 10.1103/PhysRevB.59.1758; Kresse G, 1996, COMP MATER SCI, V6, P15, DOI 10.1016/0927-0256(96)00008-0; Lazzeri M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.266105; Lazzeri M, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.155409; Lou XW, 2003, J AM CHEM SOC, V125, P2697, DOI 10.1021/ja029086h; OREGAN B, 1991, NATURE, V353, P737, DOI 10.1038/353737a0; Penn RL, 1999, GEOCHIM COSMOCHIM AC, V63, P1549, DOI 10.1016/S0016-7037(99)00037-X; Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865; Thomas AG, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.035110; Tian N, 2007, SCIENCE, V316, P732, DOI 10.1126/science.1140484; Vittadini A, 1998, PHYS REV LETT, V81, P2954, DOI 10.1103/PhysRevLett.81.2954; Vittadini A, 2007, THEOR CHEM ACC, V117, P663, DOI 10.1007/s00214-006-0191-4; Yang HG, 2005, J AM CHEM SOC, V127, P270, DOI 10.1021/ja045253x; Yang HG, 2004, ANGEW CHEM INT EDIT, V43, P5206, DOI 10.1002/anie.200460767; Yang HG, 2004, J PHYS CHEM B, V108, P3492, DOI 10.1021/jp0377782; Yu JC, 2002, CHEM MATER, V14, P3808, DOI 10.1021/cm020027c; Zaban A, 2000, J PHYS CHEM B, V104, P4130, DOI 10.1021/jp993198m; ZMBOV KF, 1967, J PHYS CHEM-US, V71, P2893, DOI 10.1021/j100868a021	37	3504	3604	124	3525	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	2008	453	7195					638	U4		10.1038/nature06964	http://dx.doi.org/10.1038/nature06964			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305NN	18509440	Green Published			2022-12-28	WOS:000256185200040
J	Harjutsalo, V; Sjoberg, L; Tuomilehto, J				Harjutsalo, Valma; Sjoberg, Lena; Tuomilehto, Jaakko			Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study	LANCET			English	Article							POPULATION-BASED COHORT; YOUNG-ADULTS; MELLITUS; AGE; ONSET; RISK; FINLAND; DISEASE; EPIDEMIOLOGY; NATIONWIDE	Background Finland has the highest incidence of type 1 diabetes worldwide, reaching 40 per 100000 people per year in the 1990s. Our aim was to assess the temporal trend in type 1 diabetes incidence since 2000 in Finnish children aged younger than 15 years and to predict the number of cases of type 1 diabetes in the future. Methods Children with newly diagnosed type 1 diabetes in Finland who were listed on the National Public Health Institute diabetes register, Central Drug Register, and Hospital Discharge Register in 1980-2005 were included in a cohort study. We excluded patients with type 2 diabetes and diabetes occurring secondary to other conditions, such as steroid use, Down's syndrome, and congenital malformations of pancreas. Findings 10737 children-5816 boys and 4921 girls-were diagnosed with type 1 diabetes before 15 years of age during 1980-2005. The average age-standardised incidence was 42.9 per 100000 per year (95% Cl 42.6-44.3) during this period, increasing from 31.4 per 100 000 per year in 1980 to 64.2 per 100 000 per year in 2005. The age-specific rates per 100 000 per year were 31.0, 50.5, and 50 . 6 at ages 0-4 years, 5-9 years, and 10-14-years, respectively. We noted a significant non-linear component to the time trend (p<0 - 0003). In children aged 0-4 years, the increase was largest, at 4.7% more affected every year. The overall boy-to-girl ratio of incidence was 1 . 1; at the age of 13 years, it was 1 . 7 (1-4-2-0). The predicted cumulative number of new cases with type 1 diabetes before 15 years of age between 2006 and 2020 was about 10 800. Interpretation The incidence of type 1 diabetes in Finnish children is increasing even faster than before. The number of new cases diagnosed at or before 14 years of age will double in the next 15 years and the age of onset will be younger (0-4 years). Funding Academy of Finland, Sigrid Juselius Foundation, Juvenile Diabetes Research Foundation.	[Harjutsalo, Valma; Tuomilehto, Jaakko] Natl Publ Hlth Inst, Diabet Unit, Dept Hlth Promot & Chron Dis Prevent, FIN-00300 Helsinki, Finland; [Sjoberg, Lena; Tuomilehto, Jaakko] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; [Tuomilehto, Jaakko] S Ostrobotnia Cent Hosp, Seinajoki, Finland	Finland National Institute for Health & Welfare; University of Helsinki	Harjutsalo, V (corresponding author), Natl Publ Hlth Inst, Diabet Unit, Dept Hlth Promot & Chron Dis Prevent, Mannerheimintie 166, FIN-00300 Helsinki, Finland.	valma.harjutsalo@ktl.fi	Harjutsalo, Valma/AAL-6588-2021	Harjutsalo, Valma/0000-0003-3568-9779; Sjoberg, Lena/0000-0002-5420-5189				Bessaoud K, 2006, DIABETIC MED, V23, P857, DOI 10.1111/j.1464-5491.2006.01925.x; BLOM L, 1992, DIABETOLOGIA, V35, P528, DOI 10.1007/BF00400480; Bruno G, 2001, DIABETOLOGIA, V44, P22, DOI 10.1007/s001250051575; Feltbower RG, 2003, DIABETIC MED, V20, P437, DOI 10.1046/j.1464-5491.2003.00960.x; Gale EAM, 2005, DIABETOLOGIA, V48, P2445, DOI 10.1007/s00125-005-0028-z; Gale EAM, 2001, DIABETOLOGIA, V44, P3, DOI 10.1007/s001250051573; Green A, 2000, LANCET, V355, P873; Harjutsalo V, 2006, DIABETES, V55, P1517, DOI 10.2337/db05-1296; Harjutsalo V, 2005, DIABETES, V54, P563, DOI 10.2337/diabetes.54.2.563; Hastie TJ., 1990, GEN ADDITIVE MODELS, Vvol. 43, DOI DOI 10.1201/9780203753781; Hyttinen V, 2003, DIABETES, V52, P1052, DOI 10.2337/diabetes.52.4.1052; IAMMI N, 2008, DIABETOLOGIA, V51, P897; KAPRIO J, 1992, DIABETOLOGIA, V35, P1060, DOI 10.1007/BF02221682; Kautiainen S, 2002, INT J OBESITY, V26, P544, DOI 10.1038/sj.ijo.0801928; Lammi N, 2007, DIABETOLOGIA, V50, P1393, DOI 10.1007/s00125-007-0690-4; LAPORTE RE, 1991, DIABETES CARE, V14, P49; Lindblad K, 1999, SEMIN NEUROL, V19, P289, DOI 10.1055/s-2008-1040845; Morel B., 1857, TRAITE DEGENERESCENC; *NAT RES DEV CTR W, 2003, NORD MED BIRTH REG; Onkamo P, 1999, DIABETOLOGIA, V42, P1395, DOI 10.1007/s001250051309; Podar T, 1999, DIABETES CARE, V22, P2092, DOI 10.2337/diacare.22.12.2092a; Pundziute-Lycka A, 2004, ACTA PAEDIATR, V93, P1519, DOI 10.1080/08035250410026680; Pundziute-Lycka A, 2002, DIABETOLOGIA, V45, P783, DOI 10.1007/s00125-002-0845-2; ROSS CA, 1993, TRENDS NEUROSCI, V16, P254, DOI 10.1016/0166-2236(93)90175-L; Salo Matti, 2006, Duodecim, V122, P1211; SCHOBER E, 2007, EUR J PEDIAT; Schoenle EJ, 2001, DIABETOLOGIA, V44, P286, DOI 10.1007/s001250051615; Speiser PW, 2005, J CLIN ENDOCR METAB, V90, P1871, DOI 10.1210/jc.2004-1389; STEINBERG AG, 1950, P STAFF M MAYO CLIN, V25, P625; Stene LC, 2001, BMJ-BRIT MED J, V322, P889, DOI 10.1136/bmj.322.7291.889; Svensson J, 2002, DIABETES CARE, V25, P2197, DOI 10.2337/diacare.25.12.2197; THOMSON G, 1988, AM J HUM GENET, V43, P799; Todd JA, 1999, BIOESSAYS, V21, P164, DOI 10.1002/(SICI)1521-1878(199902)21:2<164::AID-BIES10>3.3.CO;2-W; TUOMILEHTO J, 1992, DIABETOLOGIA, V35, P70, DOI 10.1007/BF00400854; Tuomilehto J, 1999, DIABETOLOGIA, V42, P655, DOI 10.1007/s001250051212; Weets I, 2007, DIABETES-METAB RES, V23, P637, DOI 10.1002/dmrr.758; Weets I, 2002, DIABETES CARE, V25, P840, DOI 10.2337/diacare.25.5.840; Wilkin TJ, 2001, DIABETOLOGIA, V44, P914, DOI 10.1007/s001250100548	38	435	447	2	40	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 24	2008	371	9626					1777	1782		10.1016/S0140-6736(08)60765-5	http://dx.doi.org/10.1016/S0140-6736(08)60765-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304IO	18502302				2022-12-28	WOS:000256103400032
J	Falkowski, PG; Fenchel, T; Delong, EF				Falkowski, Paul G.; Fenchel, Tom; Delong, Edward F.			The microbial engines that drive Earth's biogeochemical cycles	SCIENCE			English	Review							LATERAL GENE-TRANSFER; NITROGEN-FIXATION; PROTEIN FAMILIES; EVOLUTION; BACTERIA; CARBON; PHOTOSYNTHESIS; OXYGEN	Virtually all nonequilibrium electron transfers on Earth are driven by a set of nanobiological machines composed largely of multimeric protein complexes associated with a small number of prosthetic groups. These machines evolved exclusively in microbes early in our planet's history yet, despite their antiquity, are highly conserved. Hence, although there is enormous genetic diversity in nature, there remains a relatively stable set of core genes coding for the major redox reactions essential for life and biogeochemical cycles. These genes created and coevolved with biogeochemical cycles and were passed from microbe to microbe primarily by horizontal gene transfer. A major challenge in the coming decades is to understand how these machines evolved, how they work, and the processes that control their activity on both molecular and planetary scales.	[Falkowski, Paul G.] Rutgers State Univ, Environm Biophys & Mol Ecol Program, Inst Marine & Coastal Sci, New Brunswick, NJ 08901 USA; [Falkowski, Paul G.] Rutgers State Univ, Dept Earth & Planetary Sci, New Brunswick, NJ 08901 USA; [Fenchel, Tom] Univ Copenhagen, Marine Biol Lab, DK-3000 Helsingor, Denmark; [Delong, Edward F.] MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA; [Delong, Edward F.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; University of Copenhagen; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Falkowski, PG (corresponding author), Rutgers State Univ, Environm Biophys & Mol Ecol Program, Inst Marine & Coastal Sci, New Brunswick, NJ 08901 USA.	falko@marine.rutgers.edu; tfenchel@bio.ku.dk; delong@mit.edu	Fenchel, Tom/F-8979-2011	Fenchel, Tom/0000-0003-0023-2402				Baas-Becking L.G.M., 1934, GEOBIOLOGIE INLEIDIN, P263; Bekker A, 2004, NATURE, V427, P117, DOI 10.1038/nature02260; Berman-Frank I, 2001, SCIENCE, V294, P1534, DOI 10.1126/science.1064082; BIANCHI M, 1992, MAR ECOL PROG SER, V88, P55, DOI 10.3354/meps088055; BLANKENSHIP RE, 1995, ANOXYGENIC PHOTOSYNT; Blankenship Robert E., 2007, P21; BRODA E, 1977, Z ALLG MIKROBIOL, V17, P491, DOI 10.1002/jobm.3630170611; Burns R.C., 2012, MOL BIOL BIOCH BIOPH, DOI DOI 10.1007/978-3-642-80926-2; Canfield DE, 1999, AM J SCI, V299, P697, DOI 10.2475/ajs.299.7-9.697; Canfield DE, 2005, ANNU REV EARTH PL SC, V33, P1, DOI 10.1146/annurev.earth.33.092203.122711; Carpenter EJ, 2000, APPL ENVIRON MICROB, V66, P4514, DOI 10.1128/AEM.66.10.4514-4517.2000; Catling DC, 2005, EARTH PLANET SC LETT, V237, P1, DOI 10.1016/j.epsl.2005.06.013; Chistoserdova L, 1998, SCIENCE, V281, P99, DOI 10.1126/science.281.5373.99; DeLong EF, 2006, SCIENCE, V311, P496, DOI 10.1126/science.1120250; Enright AJ, 2003, NUCLEIC ACIDS RES, V31, P4632, DOI 10.1093/nar/gkg495; Falkowski PG, 1997, NATURE, V387, P272, DOI 10.1038/387272a0; FALKOWSKI PG, 2008, P ROY SOC LOND B BIO, DOI DOI 10.1098/RSTB.2008.0054; Farquhar J, 2000, SCIENCE, V289, P756, DOI 10.1126/science.289.5480.756; Fennel K, 2005, AM J SCI, V305, P526, DOI 10.2475/ajs.305.6-8.526; Frigaard NU, 2006, NATURE, V439, P847, DOI 10.1038/nature04435; Gerlt JA, 2001, ANNU REV BIOCHEM, V70, P209, DOI 10.1146/annurev.biochem.70.1.209; Gogarten JP, 2002, MOL BIOL EVOL, V19, P2226, DOI 10.1093/oxfordjournals.molbev.a004046; Hallam A., 1997, MASS EXTINCTIONS THE; Hallam SJ, 2004, SCIENCE, V305, P1457, DOI 10.1126/science.1100025; Hallam SJ, 2006, PLOS BIOL, V4, P520, DOI 10.1371/journal.pbio.0040095; ISAKSEN MF, 1994, FEMS MICROBIOL ECOL, V14, P1; Jetten MSM, 1998, FEMS MICROBIOL REV, V22, P421, DOI 10.1111/j.1574-6976.1998.tb00379.x; Kechris KJ, 2006, P NATL ACAD SCI USA, V103, P9584, DOI 10.1073/pnas.0603534103; Klein M, 2001, J BACTERIOL, V183, P6028, DOI 10.1128/JB.183.20.6028-6035.2001; Kluyver A. J., 1926, CHEMIE ZELLEN GEWEBE, V13; Knoll AH, 2003, LIFE YOUNG PLANET 1; Konneke M, 2005, NATURE, V437, P543, DOI 10.1038/nature03911; Kunin V, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-401; Lerat E, 2005, PLOS BIOL, V3, P807, DOI 10.1371/journal.pbio.0030130; LONG SP, 1994, ANNU REV PLANT PHYS, V45, P633, DOI 10.1146/annurev.pp.45.060194.003221; Ludden P. W., 1995, Anoxygenic photosynthetic bacteria., P929; Milner-White EJ, 2008, BIOL DIRECT, V3, DOI 10.1186/1745-6150-3-3; Nagashima KVP, 1997, J MOL EVOL, V45, P131, DOI 10.1007/PL00006212; OHAD I, 1984, J CELL BIOL, V99, P481, DOI 10.1083/jcb.99.2.481; OLIVER M, 2007, GENOME RES; Orphan VJ, 2001, SCIENCE, V293, P484, DOI 10.1126/science.1061338; Postgate J., 1998, NITROGEN FIXATION; Raymond J, 2005, REV MINERAL GEOCHEM, V59, P211, DOI 10.2138/rmg.2005.59.9; Schink B, 2002, ANTON LEEUW INT J G, V81, P257, DOI 10.1023/A:1020579004534; Schlesinger WH., 1997, BIOGEOCHEMISTRY; Shi T, 2005, MOL BIOL EVOL, V22, P2179, DOI 10.1093/molbev/msi216; Shi T, 2008, P NATL ACAD SCI USA, V105, P2510, DOI 10.1073/pnas.0711165105; Sogin ML, 2006, P NATL ACAD SCI USA, V103, P12115, DOI 10.1073/pnas.0605127103; Tyson GW, 2004, NATURE, V428, P37, DOI 10.1038/nature02340; Vernadsky V., 2007, GEOCHEMISTRY BIOSPHE, P480; WACHTERSHAUSER G, 1990, P NATL ACAD SCI USA, V87, P200, DOI 10.1073/pnas.87.1.200; Williams R.J.P., 1996, NATURAL SELECTION CH; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; Woese CR, 2002, P NATL ACAD SCI USA, V99, P8742, DOI 10.1073/pnas.132266999; Yooseph S, 2007, PLOS BIOL, V5, P432, DOI 10.1371/journal.pbio.0050016	55	1573	1696	85	1314	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2008	320	5879					1034	1039		10.1126/science.1153213	http://dx.doi.org/10.1126/science.1153213			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18497287	Green Submitted			2022-12-28	WOS:000256059800033
J	Whitlock, EP; Lin, JS; Chou, R; Shekelle, P; Robinson, KA				Whitlock, Evelyn P.; Lin, Jennifer S.; Chou, Roger; Shekelle, Paul; Robinson, Karen A.			Using existing systematic reviews in complex systematic reviews	ANNALS OF INTERNAL MEDICINE			English	Review							LOW-BACK-PAIN; CLINICAL-PRACTICE GUIDELINES; METHODOLOGICAL QUALITY; DATA EXTRACTION; METAANALYSES; CARE; CONCLUSIONS; RECOMMENDATIONS; ARTICLES; TRIALS	Systematic reviewers increasingly must decide whether and how to incorporate existing systematic reviews into complex systematic reviews that are commissioned to support clinical guideline development or for other health policy uses. To date, however, this issue has been largely unexamined. Reviewers seeking to incorporate existing reviews into new reviews face a set of important questions: Can this practice adhere to systematic review principles? Will it save time? When should it be avoided? Will it produce valid results and be acceptable to users? Drawing from their collective experience, the authors outline a series of steps that can help reviewers reach reasoned decisions about the incorporation of existing systematic reviews and enumerate potential hazards to consider in doing so. They highlight issues surrounding the main steps reviewers must undertake, including locating existing reviews; assessing their relevance to the new review; assessing the quality of relevant reviews; determining how to incorporate high-quality, relevant existing systematic reviews; and clearly reporting the methods used and the results from this process. Further specification of methods, including the development of reporting standards for this approach, is needed.	Kaiser Permanente Ctr Hlth Res, Oregon Evidence Based Practice Ctr, Portland, OR USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA; So Calif Evidence Based Practice Ctr, Santa Monica, CA USA; RAND Corp, Santa Monica, CA USA; Johns Hopkins Univ, Baltimore, MD USA; Johns Hopkins Evidence Based Practice Ctr, Baltimore, MD USA	Kaiser Permanente; Oregon Health & Science University; RAND Corporation; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Whitlock, EP (corresponding author), Kaiser Permanente NW, Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA.	evelyn.whitlock@kpchr.org		Chou, Roger/0000-0001-9889-8610				ASSENDELFT WJJ, 1995, JAMA-J AM MED ASSOC, V274, P1942, DOI 10.1001/jama.274.24.1942; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Bero LA, 1997, ANN INTERN MED, V127, P37, DOI 10.7326/0003-4819-127-1-199707010-00007; Burgers JS, 2002, DIABETES CARE, V25, P1933, DOI 10.2337/diacare.25.11.1933; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; *COCHR COLL, 2008, COCHR MAN ISS 2; EDEN KB, 2002, AHRQ PUBLICATION; French Simon D, 2005, BMC Med Res Methodol, V5, P33, DOI 10.1186/1471-2288-5-33; Furlan A D, 2001, Spine (Phila Pa 1976), V26, pE155, DOI 10.1097/00007632-200104010-00018; Gotzsche PC, 2007, JAMA-J AM MED ASSOC, V298, P430, DOI 10.1001/jama.298.4.430; GRAY JAM, 2001, SYSTEMATIC REV HLTH; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Hopayian K, 1999, BRIT J GEN PRACT, V49, P57; Humphrey LL, 2002, ANN INTERN MED, V137, P273, DOI 10.7326/0003-4819-137-4-200208200-00012; Jadad AR, 1997, CAN MED ASSOC J, V156, P1411; Jadad AR, 1998, JAMA-J AM MED ASSOC, V280, P278, DOI 10.1001/jama.280.3.278; Jadad AR, 1996, J CLIN EPIDEMIOL, V49, P235, DOI 10.1016/0895-4356(95)00062-3; Jones AP, 2005, J CLIN EPIDEMIOL, V58, P741, DOI 10.1016/j.jclinepi.2004.11.024; LAU J, 1995, J CLIN EPIDEMIOL, V48, P45, DOI 10.1016/0895-4356(94)00106-Z; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; Lorenz KA, 2008, ANN INTERN MED, V148, P147, DOI 10.7326/0003-4819-148-2-200801150-00010; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Moher D, 2007, J CLIN EPIDEMIOL, V60, P1095, DOI 10.1016/j.jclinepi.2007.03.008; Moher D, 2007, PLOS MED, V4, P447, DOI 10.1371/journal.pmed.0040078; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P1271, DOI 10.1016/0895-4356(91)90160-B; Oxman Andrew D, 2006, Health Res Policy Syst, V4, P28, DOI 10.1186/1478-4505-4-28; *PAN ANT GUID AD A, 2008, GUID US ANT AG HIV 1; *S PREV SERV TASK, 2003, COUNS PREV TOB US TO; Salerno SM, 2002, ARCH INTERN MED, V162, P19, DOI 10.1001/archinte.162.1.19; Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10; Shekelle PG, 2001, JAMA-J AM MED ASSOC, V286, P1461, DOI 10.1001/jama.286.12.1461; Shojania KG, 2007, ANN INTERN MED, V147, P224, DOI 10.7326/0003-4819-147-4-200708210-00179; Silagy CA, 2001, BRIT MED J, V323, P833, DOI 10.1136/bmj.323.7317.833; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; SWANN C, 2005, HDA EVIDENCE BASE PR; *US PREV SERV TASK, 2008, USPSTF PROC IN PRESS; van Tulder MW, 2004, SPINE, V29, pE357, DOI 10.1097/01.brs.0000137056.64166.51; WARD NG, 1986, SPINE, V11, P661, DOI 10.1097/00007632-198609000-00003; West S, 2002, AHRQ PUBLICATION, V02-E016; Whitlock Evelyn P, 2003, BMJ, V327, pE263, DOI 10.1136/bmj.327.7429.E263; YANK V, 2003, BMJ-BRIT MED J, V327, pE265; Yank V, 2007, BMJ-BRIT MED J, V335, P1202, DOI 10.1136/bmj.39376.447211.BE	42	100	102	1	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 20	2008	148	10					776	U103		10.7326/0003-4819-148-10-200805200-00010	http://dx.doi.org/10.7326/0003-4819-148-10-200805200-00010			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308EX	18490690				2022-12-28	WOS:000256372200007
J	Gilbert, MTP; Kivisild, T; Gronnow, B; Andersen, PK; Metspalu, E; Reidla, M; Tamm, E; Axelsson, E; Gotherstrom, A; Campos, PF; Rasmussen, M; Metspalu, M; Higham, TFG; Schwenninger, JL; Nathan, R; De Hoog, CJ; Koch, A; Moller, LN; Andreasen, C; Meldgaard, M; Villems, R; Bendixen, C; Willerslev, E				Gilbert, M. Thomas P.; Kivisild, Toomas; Gronnow, Bjarne; Andersen, Pernille K.; Metspalu, Ene; Reidla, Maere; Tamm, Erika; Axelsson, Erik; Gotherstrom, Anders; Campos, Paula F.; Rasmussen, Morten; Metspalu, Mait; Higham, Thomas F. G.; Schwenninger, Jean-Luc; Nathan, Roger; De Hoog, Cees-Jan; Koch, Anders; Moller, Lone Nukaaraq; Andreasen, Claus; Meldgaard, Morten; Villems, Richard; Bendixen, Christian; Willerslev, Eske			Paleo-Eskimo mtDNA genome reveals matrilineal discontinuity in Greenland	SCIENCE			English	Article							MITOCHONDRIAL-DNA DIVERSITY; CIRCUMPOLAR POPULATIONS; GENETIC-STRUCTURE; AMERICA; ALEUTS; HAIR; EVOLUTIONARY; HAPLOGROUPS; SEQUENCES; SELECTION	The Paleo- Eskimo Saqqaq and Independence I cultures, documented from archaeological remains in Northern Canada and Greenland, represent the earliest human expansion into the New World's northern extremes. However, their origin and genetic relationship to later cultures are unknown. We sequenced a mitochondrial genome from a Paleo- Eskimo human by using 3400- to 4500- year- old frozen hair excavated from an early Greenlandic Saqqaq settlement. The sample is distinct from modern Native Americans and Neo- Eskimos, falling within haplogroup D2a1, a group previously observed among modern Aleuts and Siberian Sireniki Yuit. This result suggests that the earliest migrants into the New World's northern extremes derived from populations in the Bering Sea area and were not directly related to Native Americans or the later Neo- Eskimos that replaced them.	[Gilbert, M. Thomas P.; Axelsson, Erik; Campos, Paula F.; Rasmussen, Morten; Willerslev, Eske] Univ Copenhagen, Dept Biol, Ctr Ancient Genet, DK-2100 Copenhagen, Denmark; [Kivisild, Toomas] Univ Cambridge, Leverhulme Ctr Human Evolutionary Studies, Cambridge CB2 1QH, England; [Gronnow, Bjarne] Natl Museum Denmark, SILA Greenland Res Ctr, DK-1220 Copenhagen, Denmark; [Andersen, Pernille K.; Bendixen, Christian] Univ Aarhus, Fac Agr Sci, Dept Genet & Biotechnol, DK-8830 Tjele, Denmark; [Metspalu, Ene; Reidla, Maere; Tamm, Erika; Metspalu, Mait; Villems, Richard] Univ Tartu, Dept Evolut Biol, EE-51010 Tartu, Estonia; [Metspalu, Ene; Reidla, Maere; Tamm, Erika; Metspalu, Mait; Villems, Richard] Estonian Bioctr, EE-51010 Tartu, Estonia; [Gotherstrom, Anders] Uppsala Univ, Dept Evolut Biol, S-74236 Uppsala, Sweden; [Higham, Thomas F. G.; Schwenninger, Jean-Luc; Nathan, Roger] Univ Oxford, Archaeol & Hist Art Res Lab, Oxford OX1 3QY, England; [De Hoog, Cees-Jan] Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England; [Koch, Anders] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark; [Moller, Lone Nukaaraq] Univ Copenhagen, Danish Ctr Expt Parasitol, Dept Vet Pathobiol, Fac Life Sci, DK-1870 Frederiksberg C, Denmark; [Andreasen, Claus] Greenland Natl Museum & Archives, Nuuk 3900, Greenland; [Meldgaard, Morten] Geologisk Museum, Natl Hist Museum Denmark, DK-1350 Copenhagen, Denmark	University of Copenhagen; University of Cambridge; Aarhus University; University of Tartu; Estonian Biocentre; Uppsala University; University of Oxford; University of Oxford; Statens Serum Institut; University of Copenhagen	Willerslev, E (corresponding author), Univ Copenhagen, Dept Biol, Ctr Ancient Genet, Universitetsparken 15, DK-2100 Copenhagen, Denmark.	ewillerslev@bi.ku.dk	Gilbert, Marcus TP/A-8936-2013; Willerslev, Eske/A-9619-2011; Kivisild, Toomas/P-5889-2017; Axelsson, Erik/A-6119-2009; Willerslev, Eske/AAA-5686-2019; Campos, Paula F/B-1634-2010; Metspalu, Mait/G-8671-2015; Campos, Paula/ABF-9898-2021; Tamm, Erika/G-2818-2017; Higham, Tom/Y-2707-2019; De Hoog, Jan CM/C-1354-2010	Gilbert, Marcus TP/0000-0002-5805-7195; Willerslev, Eske/0000-0002-7081-6748; Kivisild, Toomas/0000-0002-6297-7808; Campos, Paula F/0000-0003-1285-4671; Metspalu, Mait/0000-0003-3099-9161; Tamm, Erika/0000-0003-0694-3598; Higham, Tom/0000-0002-5949-598X; De Hoog, Jan CM/0000-0002-5930-3597; Koch, Anders/0000-0001-9205-1048; Gronnow, Bjarne/0000-0003-1979-1482; Gotherstrom, Anders/0000-0001-8579-1304				Achilli A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001764; Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; Crawford MH, 2007, AM J HUM BIOL, V19, P203, DOI 10.1002/ajhb.20631; DAMAS DE, 1984, HDB N AM INDIANS, V5, P72; Derbeneva OA, 2002, AM J HUM GENET, V71, P415, DOI 10.1086/341720; Derenko M, 2007, AM J HUM GENET, V81, P1025, DOI 10.1086/522933; Fagundes NJR, 2008, AM J HUM GENET, V82, P583, DOI 10.1016/j.ajhg.2007.11.013; Gilbert MTP, 2008, SCIENCE, V320, P786, DOI 10.1126/science.1154116; Gilbert MTP, 2007, SCIENCE, V317, P1927, DOI 10.1126/science.1146971; Gilbert MTR, 2007, AM J PHYS ANTHROPOL, V133, P847, DOI 10.1002/ajpa.20602; Gilbert MTP, 2004, CURR BIOL, V14, pR463, DOI 10.1016/j.cub.2004.06.008; Goebel T, 2008, SCIENCE, V319, P1497, DOI 10.1126/science.1153569; GRONNOW B, 1994, CANADIAN MUSEUM CIVI, P197; Gullov H.C., 1999, LATE DORSET HIGH ARC; Hayes M. G., 2003, MUMMIES NEW MILLENNI, P125; Hayes MG., 2005, CONTRIBUTIONS STUDY, P11, DOI [DOI 10.2307/J.CTV16P21.9, 10.2307/j.ctv16p21.9]; Helgason A, 2006, AM J PHYS ANTHROPOL, V130, P123, DOI 10.1002/ajpa.20313; Kivisild T, 2006, GENETICS, V172, P373, DOI 10.1534/genetics.105.043901; Koch B, 1996, PROGRESS IN ENVIRONMENTAL REMOTE SENSING RESEARCH AND APPLICATIONS, P3; McGhee R., 1996, ANCIENT PEOPLE ARCTI; McGhee R, 2000, IDENTITIES CULTURAL, P181; Meldgaard M., 2004, ANCIENT HARP SEAL HU, V30; Mishmar D, 2003, P NATL ACAD SCI USA, V100, P171, DOI 10.1073/pnas.0136972100; Rubicz R, 2003, HUM BIOL, V75, P809, DOI 10.1353/hub.2004.0009; Saillard J, 2000, AM J HUM GENET, V67, P718, DOI 10.1086/303038; SHIELDS GF, 1993, AM J HUM GENET, V53, P549; Starikovskaya EB, 2005, ANN HUM GENET, V69, P67, DOI 10.1046/j.1529-8817.2003.00127.x; Tamm E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000829; Zlojutro M, 2006, AM J PHYS ANTHROPOL, V129, P446, DOI 10.1002/ajpa.20287	29	144	149	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 27	2008	320	5884					1787	1789		10.1126/science.1159750	http://dx.doi.org/10.1126/science.1159750			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318VP	18511654				2022-12-28	WOS:000257121200042
J	Chen, X; Xu, H; Yuan, P; Fang, F; Huss, M; Vega, VB; Wong, E; Orlov, YL; Zhang, WW; Jiang, JM; Loh, YH; Yeo, HC; Yeo, ZX; Narang, V; Govindarajan, KR; Leong, B; Shahab, A; Ruan, YJ; Bourque, G; Sung, WK; Clarke, ND; Wei, CL; Ng, HH				Chen, Xi; Xu, Han; Yuan, Ping; Fang, Fang; Huss, Mikael; Vega, Vinsensius B.; Wong, Eleanor; Orlov, Yuriy L.; Zhang, Weiwei; Jiang, Jianming; Loh, Yuin-Han; Yeo, Hock Chuan; Yeo, Zhen Xuan; Narang, Vipin; Govindarajan, Kunde Ramamoorthy; Leong, Bernard; Shahab, Atif; Ruan, Yijun; Bourque, Guillaume; Sung, Wing-Kin; Clarke, Neil D.; Wei, Chia-Lin; Ng, Huck-Hui			Integration of external signaling pathways with the core transcriptional network in embryonic stem cells	CELL			English	Article							SELF-RENEWAL; BINDING-SITES; DEVELOPMENTAL REGULATORS; C-MYC; PLURIPOTENT; GENOME; NANOG; DIFFERENTIATION; FIBROBLASTS; ACTIVATION	Transcription factors (TFs) and their specific interactions with targets are crucial for specifying gene-expression programs. To gain insights into the transcriptional regulatory networks in embryonic stem (ES) cells, we use chromatin immunoprecipitation coupled with ultra-high-throughput DNA sequencing (ChIP-seq) to map the locations of 13 sequence-specific TFs (Nanog, Oct4, STAT3, Smad1, Sox2, Zfx, c-Myc, n-Myc, Klf4, Esrrb, Tcfcp2l1, E2f1, and CTCF) and 2 transcription regulators (p300 and Suz12). These factors are known to play different roles in ES-cell biology as components of the LIF and BMP signaling pathways, self-renewal regulators, and key reprogramming factors. Our study provides insights into the integration of the signaling pathways into the ES-cell-specific transcription circuitries. Intriguingly, we find specific genomic regions extensively targeted by different TFs. Collectively, the comprehensive mapping of TF-binding sites identifies important features of the transcriptional regulatory networks that define ES-cell identity.	[Wong, Eleanor; Ruan, Yijun; Wei, Chia-Lin] Genome Inst Singapore, Genome Technol & Biol Grp, Singapore 138672, Singapore; [Chen, Xi; Yuan, Ping; Fang, Fang; Zhang, Weiwei; Jiang, Jianming; Loh, Yuin-Han; Ng, Huck-Hui] Genome Inst Singapore, Gene Regulat Lab, Singapore 138672, Singapore; [Chen, Xi; Fang, Fang; Zhang, Weiwei; Jiang, Jianming; Loh, Yuin-Han; Ng, Huck-Hui] Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; [Orlov, Yuriy L.; Yeo, Hock Chuan; Yeo, Zhen Xuan; Clarke, Neil D.] Genome Inst Singapore, Computat & Syst Biol Grp, Singapore 138672, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Wei, CL (corresponding author), Genome Inst Singapore, Genome Technol & Biol Grp, Singapore 138672, Singapore.	weicl@gis.a-star.edu.sg; nghh@gis.a-star.edu.sg	Orlov, Yuriy L/F-1520-2013; Chen, Xi/C-6889-2012; Xu, Han/H-1963-2012; jiang, jianming/B-3421-2012; Huss, Mikael/B-1300-2009; Ramamoorthy, Govindarajan Kunde/AAK-6866-2020; Ng, Huck Hui/A-1135-2009; Loh, Yuin-Han/E-1096-2014; Clarke, Neil/D-9613-2014; Fang, Fang/G-7679-2016; Bourque, Guillaume/AFR-2927-2022	Orlov, Yuriy L/0000-0003-0587-1609; jiang, jianming/0000-0003-3251-2716; Loh, Yuin-Han/0000-0002-4715-6454; Bourque, Guillaume/0000-0002-3933-9656; Fang, Fang/0000-0002-5272-302X; Chen, Xi/0000-0002-7995-6202; Yuan, Ping/0000-0001-7243-3487; Yeo, Hock Chuan/0000-0001-5176-8800; Narang, Vipin/0000-0001-8669-9964; Huss, Mikael/0000-0003-0839-2451; Wong, Eleanor/0000-0001-7094-7679; Sung, Wing-Kin/0000-0001-7806-7086	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003521] Funding Source: NIH RePORTER; NHGRI NIH HHS [1R01HG003521-01] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Arnosti DN, 2005, J CELL BIOCHEM, V94, P890, DOI 10.1002/jcb.20352; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bieda M, 2006, GENOME RES, V16, P595, DOI 10.1101/gr.4887606; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chew JL, 2005, MOL CELL BIOL, V25, P6031, DOI 10.1128/MCB.25.14.6031-6046.2005; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Faiola F, 2005, MOL CELL BIOL, V25, P10220, DOI 10.1128/MCB.25.23.10220-10234.2005; Galan-Caridad JM, 2007, CELL, V129, P345, DOI 10.1016/j.cell.2007.03.014; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Ivanova N, 2006, NATURE, V442, P533, DOI 10.1038/nature04915; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jiang JM, 2008, NAT CELL BIOL, V10, P353, DOI 10.1038/ncb1698; Johnson DS, 2007, SCIENCE, V316, P1497, DOI 10.1126/science.1141319; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Panne D, 2007, CELL, V129, P1111, DOI 10.1016/j.cell.2007.05.019; Pavesi G, 2001, Bioinformatics, V17 Suppl 1, pS207; Pettersson K, 1996, MECH DEVELOP, V54, P211, DOI 10.1016/0925-4773(95)00479-3; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Robertson G, 2007, NAT METHODS, V4, P651, DOI 10.1038/NMETH1068; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Struhl K, 2001, SCIENCE, V293, P1054, DOI 10.1126/science.1064050; Struhl K, 2007, NAT STRUCT MOL BIOL, V14, P103, DOI 10.1038/nsmb0207-103; Suzuki A, 2006, P NATL ACAD SCI USA, V103, P10294, DOI 10.1073/pnas.0506945103; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THOMAS KR, 1986, NATURE, V324, P34, DOI 10.1038/324034a0; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103; Zhou Q, 2007, P NATL ACAD SCI USA, V104, P16438, DOI 10.1073/pnas.0701014104	50	1870	1929	6	272	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	2008	133	6					1106	1117		10.1016/j.cell.2008.04.043	http://dx.doi.org/10.1016/j.cell.2008.04.043			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	312TJ	18555785	Bronze			2022-12-28	WOS:000256693400024
J	Cyr, DM				Cyr, Douglas M.			Swapping nucleotides, tuning Hsp70	CELL			English	Editorial Material							MOLECULAR CHAPERONES; EXCHANGE; HSP110; FAMILY	Molecular chaperones such as heat shock protein 70 (Hsp70) are crucial for protein folding. Crystal structures of Hsp70 in a complex with the nucleotide exchange factor (NEF) Hsp110 reported in this issue of Cell (Polier et al., 2008) and in Molecular Cell (Schuermann et al., 2008) provide new insights into how NEF action specifies Hsp70 cellular function.	Univ N Carolina, Sch Med, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Cyr, DM (corresponding author), Univ N Carolina, Sch Med, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA.	dmcyr@med.unc.edu		Cyr, Douglas/0000-0002-4928-3414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056981, R01GM067785] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM056981, R01 GM067785] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Dragovic Z, 2006, EMBO J, V25, P2519, DOI 10.1038/sj.emboj.7601138; Liu QL, 2007, CELL, V131, P106, DOI 10.1016/j.cell.2007.08.039; Raviol H, 2006, EMBO J, V25, P2510, DOI 10.1038/sj.emboj.7601139; SCHUERMANN JP, 2008, MOL CELL        0612; Senderek J, 2005, NAT GENET, V37, P1312, DOI 10.1038/ng1678; Shaner L, 2007, CELL STRESS CHAPERON, V12, P1, DOI 10.1379/CSC-245R.1; Shomura Y, 2005, MOL CELL, V17, P367, DOI 10.1016/j.molcel.2004.12.023; Steel GJ, 2004, SCIENCE, V303, P98, DOI 10.1126/science.1092287	9	19	20	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	2008	133	6					945	947		10.1016/j.cell.2008.05.036	http://dx.doi.org/10.1016/j.cell.2008.05.036			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	312TJ	18555768	Bronze, Green Accepted			2022-12-28	WOS:000256693400007
J	Ringe, D; Petsko, GA				Ringe, Dagmar; Petsko, Gregory A.			How enzymes work	SCIENCE			English	Editorial Material							CATALYSIS; INTERMEDIATE; PROTEIN		[Ringe, Dagmar; Petsko, Gregory A.] Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA	Brandeis University	Ringe, D (corresponding author), Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA.	petsko@brandeis.edu	Petsko, Gregory/AAO-7962-2020		NIGMS NIH HHS [R37 GM032415] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032415] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1983, CIBA F SYMP, V93, P4; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; Bruice TC, 2000, BIOCHEMISTRY-US, V39, P6267, DOI 10.1021/bi0003689; Cleland WW, 1998, J BIOL CHEM, V273, P25529, DOI 10.1074/jbc.273.40.25529; Hammes-Schiffer S, 2006, ANNU REV BIOCHEM, V75, P519, DOI 10.1146/annurev.biochem.75.103004.142800; Henzler-Wildman KA, 2007, NATURE, V450, P838, DOI 10.1038/nature06410; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; Koshland DE, 2004, NATURE, V432, P447, DOI 10.1038/432447a; Kraut DA, 2006, PLOS BIOL, V4, P501, DOI 10.1371/journal.pbio.0040099; Kraut DA, 2003, ANNU REV BIOCHEM, V72, P517, DOI 10.1146/annurev.biochem.72.121801.161617; Lad C, 2003, P NATL ACAD SCI USA, V100, P5607, DOI 10.1073/pnas.0631607100; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; Lerner R A, 1996, Harvey Lect, V92, P1; Nagel ZD, 2006, CHEM REV, V106, P3095, DOI 10.1021/cr050301x; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; STEITZ TA, 1983, CIBA F SYMP, V93, P25; Sumner JB, 1926, J BIOL CHEM, V69, P435; Vocadlo DJ, 2001, NATURE, V412, P835, DOI 10.1038/35090602; Warshel A, 2006, CHEM REV, V106, P3210, DOI 10.1021/cr0503106	20	161	161	0	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2008	320	5882					1428	1429		10.1126/science.1159747	http://dx.doi.org/10.1126/science.1159747			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556536				2022-12-28	WOS:000256676400020
J	Son, SW; Polvani, LM; Waugh, DW; Akiyoshi, H; Garcia, R; Kinnison, D; Pawson, S; Rozanov, E; Shepherd, TG; Shibata, K				Son, S. -W.; Polvani, L. M.; Waugh, D. W.; Akiyoshi, H.; Garcia, R.; Kinnison, D.; Pawson, S.; Rozanov, E.; Shepherd, T. G.; Shibata, K.			The impact of stratospheric ozone recovery on the Southern Hemisphere westerly jet	SCIENCE			English	Article							ANNULAR MODE; CLIMATE; TRENDS	In the past several decades, the tropospheric westerly winds in the Southern Hemisphere have been observed to accelerate on the poleward side of the surface wind maximum. This has been attributed to the combined anthropogenic effects of increasing greenhouse gases and decreasing stratospheric ozone and is predicted to continue by the Intergovernmental Panel on Climate Change/Fourth Assessment Report (IPCC/AR4) models. In this paper, the predictions of the Chemistry-Climate Model Validation (CCMVal) models are examined: Unlike the AR4 models, the CCMVal models have a fully interactive stratospheric chemistry. Owing to the expected disappearance of the ozone hole in the first half of the 21st century, the CCMVal models predict that the tropospheric westerlies in Southern Hemisphere summer will be decelerated, on the poleward side, in contrast with the prediction of most IPCC/AR4 models.	[Son, S. -W.; Polvani, L. M.] Columbia Univ, Dept Appl Phys & Appl Math, New York, NY 10027 USA; [Polvani, L. M.] Columbia Univ, Dept Earth & Environm Sci, New York, NY 10027 USA; [Waugh, D. W.] Johns Hopkins Univ, Dept Earth & Planetary Sci, Baltimore, MD 21218 USA; [Akiyoshi, H.] Natl Inst Environm Studies, Tsukuba, Ibaraki, Japan; [Garcia, R.; Kinnison, D.] Natl Ctr Atmospher Res, Boulder, CO 80325 USA; [Pawson, S.] NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; [Rozanov, E.] ETH, Inst Atmospher & Climate Sci, Zurich, Switzerland; [Rozanov, E.] World Radiat Ctr, Phys Meteorol Observ, Davos, Switzerland; [Shepherd, T. G.] Univ Toronto, Dept Phys, Toronto, ON, Canada; [Shibata, K.] Meteorol Res Inst, Tsukuba, Ibaraki 305, Japan	Columbia University; Columbia University; Johns Hopkins University; National Institute for Environmental Studies - Japan; National Center Atmospheric Research (NCAR) - USA; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Toronto; Meteorological Research Institute - Japan	Son, SW (corresponding author), Columbia Univ, Dept Appl Phys & Appl Math, New York, NY 10027 USA.	sws2112@columbia.edu	Waugh, Darryn W/K-3688-2016; Pawson, Steven/I-1865-2014; Rozanov, Eugene/A-9857-2012; Son, Seok-Woo/A-8797-2013; Akiyoshi, Hideharu/H-8170-2018; Rozanov, Eugene/V-1881-2018; Polvani, Lorenzo M/E-5949-2011	Waugh, Darryn W/0000-0001-7692-2798; Pawson, Steven/0000-0003-0200-717X; Rozanov, Eugene/0000-0003-0479-4488; Rozanov, Eugene/0000-0003-0479-4488; 				[Anonymous], 2007, GEOPHYS RES LETT, DOI DOI 10.1029/2006GL028443; Arblaster JM, 2006, J CLIMATE, V19, P2896, DOI 10.1175/JCLI3774.1; Chen G, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL031200; Cordero EC, 2006, ATMOS CHEM PHYS, V6, P5369, DOI 10.5194/acp-6-5369-2006; Crook JA, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2007GL032698; Eyring V, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD008332; Gillett NP, 2003, SCIENCE, V302, P273, DOI 10.1126/science.1087440; Kushner PJ, 2004, J CLIMATE, V17, P629, DOI 10.1175/1520-0442(2004)017<0629:SCIARS>2.0.CO;2; Lorenz DJ, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD008087; Marshall GJ, 2003, J CLIMATE, V16, P4134, DOI 10.1175/1520-0442(2003)016<4134:TITSAM>2.0.CO;2; Meehl GA, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P747; Mignone BK, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL024464; Miller RL, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006323; Perlwitz J, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL033317; Randel WJ, 1999, GEOPHYS RES LETT, V26, P3089, DOI 10.1029/1999GL900615; Russell JL, 2006, J CLIMATE, V19, P6382, DOI 10.1175/JCLI3984.1; Shindell DT, 2001, J GEOPHYS RES-ATMOS, V106, P7193, DOI 10.1029/2000JD900547; Shindell DT, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020724; Thompson DWJ, 2006, J ATMOS SCI, V63, P2616, DOI 10.1175/JAS3771.1; Thompson DWJ, 2000, J CLIMATE, V13, P1018, DOI 10.1175/1520-0442(2000)013<1018:AMITEC>2.0.CO;2; Thompson DWJ, 2002, SCIENCE, V296, P895, DOI 10.1126/science.1069270; Yang ES, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL022296; Yin JH, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023684	23	258	264	3	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2008	320	5882					1486	1489		10.1126/science.1155939	http://dx.doi.org/10.1126/science.1155939			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556557				2022-12-28	WOS:000256676400042
J	Tsuji, K; Tsutani, K				Tsuji, Kaori; Tsutani, Kiichiro			Follow the leader	NATURE			English	Editorial Material									[Tsuji, Kaori] Hlth Care Sci Inst, Minato Ku, Tokyo 1070052, Japan; [Tsutani, Kiichiro] Univ Tokyo, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Tsuji, K (corresponding author), Hlth Care Sci Inst, Minato Ku, Akasaka NOA 5F,3-2-12 Akasaka, Tokyo 1070052, Japan.							FUKUHARA H, 2006, 31 OFF PHARM IND RES; McCurry J, 2007, LANCET, V369, P1333, DOI 10.1016/S0140-6736(07)60615-1; TSUJI K, 2007, JAP J CLIN PHARM T S, V38, pS198; Tsuji K, 2008, EUR J PHARM BIOPHARM, V68, P496, DOI 10.1016/j.ejpb.2007.07.013	4	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2008	453	7197					851	852		10.1038/453851a	http://dx.doi.org/10.1038/453851a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311WV	18548049				2022-12-28	WOS:000256632000020
J	Yang, SH; Cheng, PH; Banta, H; Piotrowska-Nitsche, K; Yang, JJ; Cheng, ECH; Snyder, B; Larkin, K; Liu, J; Orkin, J; Fang, ZH; Smith, Y; Bachevalier, J; Zola, SM; Li, SH; Li, XJ; Chan, AWS				Yang, Shang-Hsun; Cheng, Pei-Hsun; Banta, Heather; Piotrowska-Nitsche, Karolina; Yang, Jin-Jing; Cheng, Eric C. H.; Snyder, Brooke; Larkin, Katherine; Liu, Jun; Orkin, Jack; Fang, Zhi-Hui; Smith, Yoland; Bachevalier, Jocelyne; Zola, Stuart M.; Li, Shi-Hua; Li, Xiao-Jiang; Chan, Anthony W. S.			Towards a transgenic model of Huntington's disease in a non-human primate	NATURE			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; GENE; MICE	Non- human primates are valuable for modelling human disorders and for developing therapeutic strategies; however, little work has been reported in establishing transgenic non- human primate models of human diseases. Huntington's disease ( HD) is an autosomal dominant neurodegenerative disorder characterized by motor impairment, cognitive deterioration and psychiatric disturbances followed by death within 10 - 15 years of the onset of the symptoms(1-4). HD is caused by the expansion of cytosine-adenine-guanine ( CAG, translated into glutamine) trinucleotide repeats in the first exon of the human huntingtin ( HTT) gene(5). Mutant HTT with expanded polyglutamine ( polyQ) is widely expressed in the brain and peripheral tissues(2,6), but causes selective neurodegeneration that is most prominent in the striatum and cortex of the brain. Although rodent models of HD have been developed, these models do not satisfactorily parallel the brain changes and behavioural features observed in HD patients. Because of the close physiological(7), neurological and genetic similarities(8,9) between humans and higher primates, monkeys can serve as very useful models for understanding human physiology and diseases(10,11). Here we report our progress in developing a transgenic model of HD in a rhesus macaque that expresses polyglutamine- expanded HTT. Hallmark features of HD, including nuclear inclusions and neuropil aggregates, were observed in the brains of the HD transgenic monkeys. Additionally, the transgenic monkeys showed important clinical features of HD, including dystonia and chorea. A transgenic HD monkey model may open the way to understanding the underlying biology of HD better, and to the development of potential therapies. Moreover, our data suggest that it will be feasible to generate valuable non-human primate models of HD and possibly other human genetic diseases.	[Yang, Shang-Hsun; Cheng, Pei-Hsun; Banta, Heather; Piotrowska-Nitsche, Karolina; Yang, Jin-Jing; Cheng, Eric C. H.; Snyder, Brooke; Larkin, Katherine; Liu, Jun; Orkin, Jack; Smith, Yoland; Bachevalier, Jocelyne; Zola, Stuart M.; Chan, Anthony W. S.] Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA; [Yang, Shang-Hsun; Cheng, Pei-Hsun; Piotrowska-Nitsche, Karolina; Yang, Jin-Jing; Cheng, Eric C. H.; Snyder, Brooke; Liu, Jun; Fang, Zhi-Hui; Li, Shi-Hua; Li, Xiao-Jiang; Chan, Anthony W. S.] Emory Univ, Dept Human Genet, Atlanta, GA 30329 USA; [Yang, Shang-Hsun; Li, Xiao-Jiang; Chan, Anthony W. S.] Emory Univ, Genet & Mol Biol Program, Atlanta, GA 30329 USA; [Liu, Jun; Smith, Yoland; Zola, Stuart M.; Li, Xiao-Jiang; Chan, Anthony W. S.] Emory Univ, Neurosci Program, Atlanta, GA 30329 USA; [Smith, Yoland] Emory Univ, Dept Neurol, Atlanta, GA 30329 USA; [Bachevalier, Jocelyne] Emory Univ, Dept Psychol, Atlanta, GA 30329 USA; [Bachevalier, Jocelyne; Zola, Stuart M.] Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30329 USA; [Piotrowska-Nitsche, Karolina] Polish Acad Sci, Dept Expt Embryol, Inst Genet & Anim Breeding, PL-05552 Wolka Kosowska, Poland; [Zola, Stuart M.] Vet Affairs Med Ctr, Atlanta, GA 30033 USA	Emory University; Emory University; Emory University; Emory University; Emory University; Emory University; Emory University; Institute of Genetics & Animal Biotechnology, Polish Academy of Sciences; Polish Academy of Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System	Chan, AWS (corresponding author), Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA.	achan@genetics.emory.edu	Yang, Shang-Hsun/AAV-3763-2020	Yang, Shang-Hsun/0000-0002-1601-3653	NIA NIH HHS [R01 AG019206-07, R01 AG019206] Funding Source: Medline; NIH HHS [R24 OD010930] Funding Source: Medline; NINDS NIH HHS [R01 NS036232, R01 NS041669, R01 NS041669-07, R01 NS036232-09] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036232, R01NS041669] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019206] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [R24OD010930] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bates GP, 1998, BIOCHEM SOC T, V26, P471, DOI 10.1042/bst0260471; Chan AWS, 2001, SCIENCE, V291, P309, DOI 10.1126/science.291.5502.309; CHAN AWS, 2002, TRANSGENIC ANIMAL TE; Cummings CJ, 2000, ANNU REV GENOM HUM G, V1, P281, DOI 10.1146/annurev.genom.1.1.281; Davies S, 2001, J CLIN PATHOL-MOL PA, V54, P409, DOI 10.1136/mp.54.6.409; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; Lane MA, 2000, EXP GERONTOL, V35, P533, DOI 10.1016/S0531-5565(00)00102-9; Li H, 2001, J NEUROSCI, V21, P8473, DOI 10.1523/JNEUROSCI.21-21-08473.2001; Li H, 1999, HUM MOL GENET, V8, P1227, DOI 10.1093/hmg/8.7.1227; Lin CH, 2001, HUM MOL GENET, V10, P137, DOI 10.1093/hmg/10.2.137; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; McConkey EH, 2000, SCIENCE, V289, P1295; Myers R.H. M.K., 1998, HUNTINGTONS DIS GENE, P301; Rubinsztein DC, 2002, TRENDS GENET, V18, P202, DOI 10.1016/S0168-9525(01)02625-7; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; Yang SH, 2007, GENESIS, V45, P177, DOI 10.1002/dvg.20289; Yu ZX, 2003, J NEUROSCI, V23, P2193; Zhou H, 2003, J CELL BIOL, V163, P109, DOI 10.1083/jcb.200306038	21	341	367	3	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 12	2008	453	7197					921	U56		10.1038/nature06975	http://dx.doi.org/10.1038/nature06975			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311WV	18488016	Green Accepted			2022-12-28	WOS:000256632000044
J	Thea, D; Qazi, S				Thea, Donald; Qazi, Shamim			Neonatal mortality - 4 million reasons for progress	LANCET			English	Editorial Material									[Thea, Donald] Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA; [Qazi, Shamim] WHO, Dept Child & Adolescent Hlth, CH-1211 Geneva, Switzerland	Boston University; World Health Organization	Thea, D (corresponding author), Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA.	dthea@bu.edu		Thea, Donald/0000-0002-6933-1030				Ahmad OB, 2000, B WORLD HEALTH ORGAN, V78, P1175; Carlin JB, 2008, LANCET, V371, P135, DOI 10.1016/S0140-6736(08)60106-3; Knippenberg R, 2005, LANCET, V365, P1087, DOI 10.1016/S0140-6736(05)74233-1; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Lawn JE, 2005, ESTIMATING CAUSES 4; Mulholland K, 1999, PEDIATR INFECT DIS J, V18, pS4; Stoll BJ, 1997, CLIN PERINATOL, V24, P1; Zupan J., 2005, PERINATAL MORTALITY	8	6	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	2008	371	9628					1893	1895		10.1016/S0140-6736(08)60810-7	http://dx.doi.org/10.1016/S0140-6736(08)60810-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310OI	18539207				2022-12-28	WOS:000256538500007
J	Belin, D; Mar, AC; Dalley, JW; Robbins, TW; Everitt, BJ				Belin, David; Mar, Adam C.; Dalley, Jeffrey W.; Robbins, Trevor W.; Everitt, Barry J.			High impulsivity predicts the switch to compulsive cocaine-taking	SCIENCE			English	Article							SUBSTANCE USE DISORDERS; DRUG-ADDICTION; PERSONALITY; BEHAVIOR; REINFORCEMENT; VULNERABILITY; AMPHETAMINE; STRIATUM; STIMULI; SEEKING	Both impulsivity and novelty- seeking have been suggested to be behavioral markers of the propensity to take addictive drugs. However, their relevance for the vulnerability to compulsively seek and take drugs, which is a hallmark feature of addiction, is unknown. We report here that, whereas high reactivity to novelty predicts the propensity to initiate cocaine self- administration, high impulsivity predicts the development of addiction- like behavior in rats, including persistent or compulsive drug- taking in the face of aversive outcomes. This study shows experimental evidence that a shift from impulsivity to compulsivity occurs during the development of addictive behavior, which provides insights into the genesis and neural mechanisms of drug addiction.	[Belin, David; Mar, Adam C.; Dalley, Jeffrey W.; Robbins, Trevor W.; Everitt, Barry J.] Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge CB2 3EB, England; [Belin, David; Mar, Adam C.; Dalley, Jeffrey W.; Robbins, Trevor W.; Everitt, Barry J.] Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England; [Dalley, Jeffrey W.] Univ Cambridge, Addenbrookes Hosp, Dept Psychiat, Cambridge CB2 2QQ, England	University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Belin, D (corresponding author), Univ Cambridge, Behav & Clin Neurosci Inst, Downing St, Cambridge CB2 3EB, England.	bdb26@cam.ac.uk; bje10@cam.ac.uk	Belin, David/E-1231-2014; Mar, Adam/A-3455-2013; Robbins, Trevor W/A-7551-2008	Belin, David/0000-0002-7383-372X; Mar, Adam/0000-0002-2095-2936; Dalley, Jeffrey/0000-0002-2282-3660; Robbins, Trevor/0000-0003-0642-5977; Everitt, Barry/0000-0003-4431-6536	MRC [G0600196] Funding Source: UKRI; Medical Research Council [G0001354B] Funding Source: researchfish; Medical Research Council [G0600196, G0600196(77608), G0001354] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244; Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073; Dawe S, 2004, NEUROSCI BIOBEHAV R, V28, P343, DOI 10.1016/j.neubiorev.2004.03.007; Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020; Dom G, 2006, ADDICTION, V101, P50, DOI 10.1111/j.1360-0443.2005.01270.x; Evenden J, 1999, PSYCHOPHARMACOLOGY, V143, P111, DOI 10.1007/s002130050926; Evenden JL, 1999, PSYCHOPHARMACOLOGY, V146, P348, DOI 10.1007/PL00005481; Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; Haber SN, 2000, J NEUROSCI, V20, P2369; Jentsch JD, 1999, PSYCHOPHARMACOLOGY, V146, P373, DOI 10.1007/PL00005483; Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0; Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583; Nader MA, 2006, NAT NEUROSCI, V9, P1050, DOI 10.1038/nn1737; Nigg JT, 2006, J AM ACAD CHILD PSY, V45, P468, DOI 10.1097/01.chi.0000199028.76452.a9; Perry JL, 2005, PSYCHOPHARMACOLOGY, V178, P193, DOI 10.1007/s00213-004-1994-4; PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295; Poulos CX, 1995, BEHAV PHARMACOL, V6, P810; Rikoon SH, 2006, J SUBST ABUSE TREAT, V31, P17, DOI 10.1016/j.jsat.2006.03.003; Sher KJ, 2000, J CONSULT CLIN PSYCH, V68, P818, DOI 10.1037/0022-006X.68.5.818; Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05.2005; Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975; VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210; White TL, 2006, NEUROPSYCHOPHARMACOL, V31, P1064, DOI 10.1038/sj.npp.1300939; Wills T A, 1994, J Subst Abuse, V6, P1, DOI 10.1016/S0899-3289(94)90039-6; Zilberman ML, 2007, J ADDICT DIS, V26, P79, DOI 10.1300/J069v26n01_10	26	693	708	0	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	2008	320	5881					1352	1355		10.1126/science.1158136	http://dx.doi.org/10.1126/science.1158136			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309DO	18535246	Green Accepted			2022-12-28	WOS:000256441100048
J	Garzione, CN; Hoke, GD; Libarkin, JC; Withers, S; MacFadden, B; Eiler, J; Ghosh, P; Mulch, A				Garzione, Carmala N.; Hoke, Gregory D.; Libarkin, Julie C.; Withers, Saunia; MacFadden, Bruce; Eiler, John; Ghosh, Prosenjit; Mulch, Andreas			Rise of the Andes	SCIENCE			English	Review							FOLD-THRUST BELT; ISOTOPE PALEOALTIMETRY; EASTERN CORDILLERA; CANYON INCISION; ATACAMA DESERT; NORTHERN CHILE; CLIMATE-CHANGE; PUNA PLATEAU; UPLIFT; ALTIPLANO	The surface uplift of mountain belts is generally assumed to reflect progressive shortening and crustal thickening, leading to their gradual rise. Recent studies of the Andes indicate that their elevation remained relatively stable for long periods ( tens of millions of years), separated by rapid ( 1 to 4 million years) changes of 1.5 kilometers or more. Periodic punctuated surface uplift of mountain belts probably reflects the rapid removal of unstable, dense lower lithosphere after long- term thickening of the crust and lithospheric mantle.	[Garzione, Carmala N.; Hoke, Gregory D.] Univ Rochester, Dept Earth & Environm Sci, Rochester, NY 14627 USA; [Libarkin, Julie C.] Michigan State Univ, Dept Geol Sci, E Lansing, MI 48824 USA; [Withers, Saunia] Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA; [MacFadden, Bruce] Univ Florida, Florida Museum Nat Hist, Gainesville, FL 32611 USA; [Eiler, John] CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; [Ghosh, Prosenjit] Indian Inst Sci, Ctr Atmospher & Ocean Sci, Bangalore 560012, Karnataka, India; [Mulch, Andreas] Leibniz Univ Hannover, Inst Geol, D-30167 Hannover, Germany	University of Rochester; Michigan State University; Michigan State University; State University System of Florida; University of Florida; California Institute of Technology; Indian Institute of Science (IISC) - Bangalore; Leibniz University Hannover	Garzione, CN (corresponding author), Univ Rochester, Dept Earth & Environm Sci, 601 Elmwood Ave, Rochester, NY 14627 USA.	garzione@earth.rochester.edu	Mulch, Andreas/A-1324-2013; Libarkin, Julie/H-2316-2011	Hoke, Gregory/0000-0002-3720-3245; Ghosh, Prosenjit/0000-0001-7828-577X				Allmendinger RW, 1997, ANNU REV EARTH PL SC, V25, P139, DOI 10.1146/annurev.earth.25.1.139; ALPERS CN, 1988, GEOL SOC AM BULL, V100, P1640, DOI 10.1130/0016-7606(1988)100<1640:MMCCIT>2.3.CO;2; BAKER MCW, 1978, EARTH PLANET SC LETT, V41, P175, DOI 10.1016/0012-821X(78)90008-0; Barke R, 2006, EARTH PLANET SC LETT, V249, P350, DOI 10.1016/j.epsl.2006.07.012; Barnes JB, 2006, EARTH PLANET SC LETT, V248, P118, DOI 10.1016/j.epsl.2006.05.018; Beck SL, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2000JB000124; BIRD P, 1978, J GEOPHYS RES, V83, P4975, DOI 10.1029/JB083iB10p04975; Carlier G, 2005, GEOLOGY, V33, P601, DOI 10.1130/G21643.1; de Silva SL, 2007, J VOLCANOL GEOTH RES, V167, P320, DOI 10.1016/j.jvolgeores.2007.07.015; Dorbath C, 1996, TECTONOPHYSICS, V259, P117, DOI 10.1016/0040-1951(95)00052-6; Echavarria L, 2003, AAPG BULL, V87, P965, DOI 10.1306/01200300196; ENGLAND P, 1989, J GEOPHYS RES-SOLID, V94, P17561, DOI 10.1029/JB094iB12p17561; Farias M, 2005, TECTONICS, V24, DOI 10.1029/2004TC001667; Garcia M, 2005, GEOMORPHOLOGY, V65, P279, DOI 10.1016/j.geomorph.2004.09.007; Garzione CN, 2006, EARTH PLANET SC LETT, V241, P543, DOI 10.1016/j.epsl.2005.11.026; Garzione CN, 2004, PALAEOGEOGR PALAEOCL, V212, P119, DOI 10.1016/j.palaeo.2004.05.020; Gilbert H, 2006, GEOPHYS J INT, V165, P383, DOI 10.1111/j.1365-246X.2006.02867.x; Gillis RJ, 2006, TECTONICS, V25, DOI 10.1029/2005TC001887; Gregory-Wodzicki KM, 1998, J S AM EARTH SCI, V11, P533, DOI 10.1016/S0895-9811(98)00031-5; Gregory-Wodzicki KM, 2000, GEOL SOC AM BULL, V112, P1091, DOI 10.1130/0016-7606(2000)112<1091:UHOTCA>2.0.CO;2; GUBBELS TL, 1993, GEOLOGY, V21, P695, DOI 10.1130/0091-7613(1993)021<0695:HLSPUA>2.3.CO;2; Hoke GD, 2004, GEOLOGY, V32, P605, DOI 10.1130/G20601.1; Hoke GD, 2008, EARTH PLANET SC LETT, V271, P192, DOI 10.1016/j.epsl.2008.04.008; Hoke GD, 2007, TECTONICS, V26, DOI 10.1029/2006TC002082; HOKE L, 1994, EARTH PLANET SC LETT, V128, P341, DOI 10.1016/0012-821X(94)90155-4; Houseman GA, 2000, J GEOPHYS RES-SOL EA, V105, P16237, DOI 10.1029/2000JB900118; HOUSEMAN GA, 1981, J GEOPHYS RES, V86, P6115, DOI 10.1029/JB086iB07p06115; Houston J, 2003, INT J CLIMATOL, V23, P1453, DOI 10.1002/joc.938; Husson L, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016877; ISACKS BL, 1988, J GEOPHYS RES-SOLID, V93, P3211, DOI 10.1029/JB093iB04p03211; James D.E., 1999, GEOLOGIA DEPOSITOS M, V7, P1; KAY RW, 1993, TECTONOPHYSICS, V219, P177, DOI 10.1016/0040-1951(93)90295-U; KAY SM, 1994, J GEOPHYS RES-SOL EA, V99, P24323, DOI 10.1029/94JB00896; KENNAN L, 1997, GEOL SOC SPEC PUBL, V120, P307, DOI DOI 10.1144/GSL.SP.1997.120.01.20; Kim ST, 1997, GEOCHIM COSMOCHIM AC, V61, P3461, DOI 10.1016/S0016-7037(97)00169-5; Kober F, 2006, GEOL SOC AM SPEC PAP, V398, P75, DOI 10.1130/2006.2398(05); Lamb S, 1997, TECTONICS, V16, P623, DOI 10.1029/97TC00495; Mahlburg Kay S., 1999, GEOL ORE DEPOSIT+, V7, P27, DOI DOI 10.5382/SP.07.02; MARSHALL LG, 1992, J S AM EARTH SCI, V5, P1, DOI 10.1016/0895-9811(92)90056-5; McQuarrie N, 2005, TECTONOPHYSICS, V399, P15, DOI 10.1016/j.tecto.2004.12.013; Moretti I, 1996, PETROL GEOSCI, V2, P17, DOI 10.1144/petgeo.2.1.17; Mulch A, 2007, REV MINERAL GEOCHEM, V66, P89, DOI 10.2138/rmg.2007.66.4; Myers SC, 1998, J GEOPHYS RES-SOL EA, V103, P21233, DOI 10.1029/98JB00956; Pope DC, 1998, GEOLOGY, V26, P511, DOI 10.1130/0091-7613(1998)026<0511:TMMFCT>2.3.CO;2; Quade J, 2007, REV MINERAL GEOCHEM, V66, P53, DOI 10.2138/rmg.2007.66.3; Rech JA, 2006, GEOLOGY, V34, P761, DOI 10.1130/G22444.1; Roperch P, 1999, J GEOPHYS RES-SOL EA, V104, P20415, DOI 10.1029/1999JB900174; Rowley DB, 2007, ANNU REV EARTH PL SC, V35, P463, DOI 10.1146/annurev.earth.35.031306.140155; Schildgen TF, 2007, GEOLOGY, V35, P523, DOI 10.1130/G23532A.1; Sempere T, 1997, GEOL SOC AM BULL, V109, P709, DOI 10.1130/0016-7606(1997)109<0709:SACOUC>2.3.CO;2; Takahashi K, 2007, J CLIMATE, V20, P3434, DOI 10.1175/JCLI4198.1; TAO WC, 1992, J GEOPHYS RES-SOL EA, V97, P8877, DOI 10.1029/91JB02422; Thouret JC, 2007, EARTH PLANET SC LETT, V263, P151, DOI 10.1016/j.epsl.2007.07.023; Wigger P.J., 1994, TECTONICS SO CENTRAL, P23, DOI DOI 10.1007/978-3-642-77353-2_2	54	500	511	3	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	2008	320	5881					1304	1307		10.1126/science.1148615	http://dx.doi.org/10.1126/science.1148615			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309DO	18535236				2022-12-28	WOS:000256441100034
J	Lee, JY				Lee, Jae Yong			Ethmoid mucocele causing visual impairment	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Soonchunhyang Univ, Bucheon Hosp, Puchon 420767, South Korea	Soonchunhyang University	Lee, JY (corresponding author), Soonchunhyang Univ, Bucheon Hosp, Puchon 420767, South Korea.	jyent@schbc.ac.kr							0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2008	358	23					2495	2495		10.1056/NEJMicm070234	http://dx.doi.org/10.1056/NEJMicm070234			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308HY	18525045				2022-12-28	WOS:000256380700008
J	Klass, P				Klass, Perri			The moral of the story	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NYU, New York, NY USA	New York University	Klass, P (corresponding author), NYU, New York, NY USA.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2008	358	22					2313	2316		10.1056/NEJMp0802542	http://dx.doi.org/10.1056/NEJMp0802542			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307GF	18509118				2022-12-28	WOS:000256306700001
J	Osmond, R				Osmond, Ros			First catch your sloth	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Osmond, R (corresponding author), The Lancet, London NW1 7BY, England.							RATTENBORG NC, 2008, BIOL LETT       0515	1	0	0	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 24	2008	371	9626					1736	1736		10.1016/S0140-6736(08)60743-6	http://dx.doi.org/10.1016/S0140-6736(08)60743-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304IO	18502285				2022-12-28	WOS:000256103400011
J	Weng, JP; Li, YB; Xu, W; Shi, LX; Zhang, Q; Zhu, DL; Hu, Y; Zhou, ZG; Yan, X; Tian, HM; Ran, XW; Luo, ZJ; Xian, J; Yan, L; Li, FP; Zeng, LY; Chen, YM; Yang, LY; Yan, SJ; Liu, J; Li, M; Fu, ZZ; Cheng, H				Weng, Jianping; Li, Yanbing; Xu, Wen; Shi, Lixin; Zhang, Qiao; Zhu, Dalong; Hu, Yun; Zhou, Zhiguang; Yan, Xiang; Tian, Haoming; Ran, Xingwu; Luo, Zuojie; Xian, Jing; Yan, Li; Li, Fangping; Zeng, Longyi; Chen, Yanming; Yang, Liyong; Yan, Sunjie; Liu, Juan; Li, Ming; Fu, Zuzhi; Cheng, Hua			Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial	LANCET			English	Article							BLOOD-GLUCOSE CONTROL; SULFONYLUREA; INDUCTION; COMPLICATIONS; METFORMIN; FAILURE; OBESE	Background Early intensive insulin therapy in patients with newly diagnosed type 2 diabetes might improve beta-cell function and result in extended glycaemic remissions. We did a multicentre, randomised trial to compare the effects of transient intensive insulin therapy (continuous subcutaneous insulin infusion [CSII] or multiple daily insulin injections [MDI]) with oral hypoglycaemic agents on beta-cell function and diabetes remission rate. Methods 382 patients, aged 25-70 years, were enrolled from nine centres in China between September, 2004, and October, 2006. The patients, with fasting plasma glucose of 7.0-16.7 mmol/L, were randomly assigned to therapy with insulin (CSII or MDI) or oral hypoglycaemic agents for initial rapid correction of hyperglycaemia. Treatment was stopped after normoglycaemia was maintained for 2 weeks. Patients were then followed-up on diet and exercise alone. Intravenous glucose tolerance tests were done and blood glucose, insulin, and proinsulin were measured before and after therapy withdrawal and at 1-year follow-up. Primary endpoint was time of glycaemic remission and remission rate at 1 year after short-term intensive therapy. Analysis was per protocol. This study was registered with ClinicalTrials.gov, number NCT00147836. Findings More patients achieved target glycaemic control in the insulin groups (97.1% [133 of 137] in CSII and 95.2% [118 of 124] in MDI) in less time (4. 0 days [SD 2.51 in CSII and 5.6 days [SD 3.8] in MDI) than those treated with oral hypoglycaemic agents (83.5% [101 of 1211 and 9.3 days [SD 5.31). Remission rates after 1 year were significantly higher in the insulin groups (51. 1% in CSII and 44.9% in MDI) than in the oral hypoglycaemic agents group (26.7%; p=0.0012). beta-cell function represented by HOMA B and acute insulin response improved significantly after intensive interventions. The increase in acute insulin response was sustained in the insulin groups but significantly declined in the oral hypoglycaemic agents group at 1 year in all patients in the remission group. Interpretation Early intensive insulin therapy in patients with newly diagnosed type 2 diabetes has favourable outcomes on recovery and maintenance of beta-cell function and protracted glycaemic remission compared with treatment with oral hypoglycaernic agents. Funding 973 Programme from the Chinese Government, the Natural Science Foundation of Guangdong Province Government, Novo Nordisk (China), and Roche Diagnostics (Shanghai).	[Weng, Jianping; Zeng, Longyi; Chen, Yanming; Li, Ming] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou 510630, Peoples R China; [Li, Yanbing; Xu, Wen; Liu, Juan] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou 510630, Peoples R China; [Shi, Lixin; Zhang, Qiao] Guiyang Med Coll, Affiliated Hosp, Guizhou, Peoples R China; [Zhu, Dalong; Hu, Yun] Nanjing Univ, Gulou Hosp, Nanjing 210008, Peoples R China; [Zhou, Zhiguang; Yan, Xiang] Cent S Univ, Xiangya Affiliated Hosp 2, Changsha 410083, Peoples R China; [Tian, Haoming; Ran, Xingwu] Sichuan Univ, W China Hosp, Chengdu 610064, Peoples R China; [Luo, Zuojie; Xian, Jing] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Peoples R China; [Yan, Li; Li, Fangping; Fu, Zuzhi; Cheng, Hua] Sun Yat Sen Univ, Affiliated Hosp 2, Guangzhou, Peoples R China; [Yang, Liyong; Yan, Sunjie] Fujian Med Univ, Affiliated Hosp 1, Fuzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Guizhou Medical University; Nanjing University; Central South University; Sichuan University; Guangxi Medical University; Sun Yat Sen University; Fujian Medical University	Weng, JP (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou 510630, Peoples R China.	wjianp@mail.sysu.edu.cn	li, yan/GTI-4638-2022; Pillay, Nischalan/F-9536-2012	Weng, Jianping/0000-0002-7889-1697; Zhou, Zhiguang/0000-0002-0374-1838; Zeng, Longyi/0000-0003-4234-6459				Alvarsson M, 2003, DIABETES CARE, V26, P2231, DOI 10.2337/diacare.26.8.2231; Bloomgarden ZT, 2007, DIABETES CARE, V30, P2737, DOI 10.2337/dc07-zb10; Dandona P, 2001, J CLIN ENDOCR METAB, V86, P3257, DOI 10.1210/jc.86.7.3257; DEFRONZO RA, 1991, J CLIN ENDOCR METAB, V73, P1294, DOI 10.1210/jcem-73-6-1294; George D., 2016, SPSS WINDOWS STEP ST; Ilkova H, 1997, DIABETES CARE, V20, P1353, DOI 10.2337/diacare.20.9.1353; KARAM JH, 1986, DIABETES, V35, P1314, DOI 10.2337/diabetes.35.12.1314; LeRoith D, 2005, DIABETES-METAB RES, V21, P85, DOI 10.1002/dmrr.530; Li YB, 2004, DIABETES CARE, V27, P2597, DOI 10.2337/diacare.27.11.2597; Li YB, 2004, DIABETES, V53, pA112; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; McFarlane SI, 2001, DIABETIC MED, V18, P10, DOI 10.1046/j.1464-5491.2001.00395.x; Pacini G, 2003, BEST PRACT RES CL EN, V17, P305, DOI 10.1016/S1521-690X(03)00042-3; Prentki M, 2006, J CLIN INVEST, V116, P1802, DOI 10.1172/JCI29103; Rakatzi I, 2003, BIOCHEM BIOPH RES CO, V310, P852, DOI 10.1016/j.bbrc.2003.09.090; Rolla A, 2004, INT J OBESITY, V28, pS3, DOI 10.1038/sj.ijo.0802743; Ryan EA, 2004, DIABETES CARE, V27, P1028, DOI 10.2337/diacare.27.5.1028; Takahashi A, 2007, DIABETES RES CLIN PR, V77, P343, DOI 10.1016/j.diabres.2006.12.021; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; van Haeften TW, 2004, EUR J CLIN INVEST, V34, P249, DOI 10.1111/j.1365-2362.2004.01337.x; W.H. Organization, 1999, DEFINITION DIAGNOSIS; Wajchenberg BL, 2007, ENDOCR REV, V28, P187, DOI 10.1210/er.2006-0038; [翁建平 Weng Jianping], 2005, [中华医学杂志, National Medical Journal of China], V85, P2451; WENG JP, 2005, NATL MED J CHINA, V74, P1951	25	527	662	1	113	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	2008	371	9626					1753	1760		10.1016/S0140-6736(08)60762-X	http://dx.doi.org/10.1016/S0140-6736(08)60762-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304IO	18502299				2022-12-28	WOS:000256103400029
J	Lavallee, Y; Meredith, PG; Dingwell, DB; Hess, KU; Wassermann, J; Cordonnier, B; Gerik, A; Kruhl, JH				Lavallee, Y.; Meredith, P. G.; Dingwell, D. B.; Hess, K. -U.; Wassermann, J.; Cordonnier, B.; Gerik, A.; Kruhl, J. H.			Seismogenic lavas and explosive eruption forecasting	NATURE			English	Article							MOUNT-ST-HELENS; VOLCANIC-ERUPTIONS; MAGMA FRAGMENTATION; ACOUSTIC-EMISSION; MATERIAL-FAILURE; EARTHQUAKES; SEISMICITY; MONTSERRAT; RHEOLOGY; FRACTURE	Volcanic dome-building episodes commonly exhibit acceleration in both effusive discharge rate and seismicity before explosive eruptions(1). This should enable the application of material failure forecasting methods to eruption forecasting(2,3). To date, such methods have been based exclusively on the seismicity of the country rock(4). It is clear, however, that the rheology and deformation rate of the lava ultimately dictate eruption style(5). The highly crystalline lavas involved in these eruptions are pseudoplastic fluids that exhibit a strong component of shear thinning as their deformation accelerates across the ductile to brittle transition(6). Thus, understanding the nature of the ductile-brittle transition in dome lavas may well hold the key to an accurate description of dome growth and stability. Here we present the results of rheological experiments with continuous microseismic monitoring, which reveal that dome lavas are seismogenic and that the character of the seismicity changes markedly across the ductile-brittle transition until complete brittle failure occurs at high strain rates. We conclude that magma seismicity, combined with failure forecasting methods, could potentially be applied successfully to dome-building eruptions for volcanic forecasting.	[Lavallee, Y.; Dingwell, D. B.; Hess, K. -U.; Wassermann, J.; Cordonnier, B.; Gerik, A.] Univ Munich, Dept Earth & Environm Sci, D-80333 Munich, Germany; [Meredith, P. G.] UCL, Dept Earth Sci, London WC1E 6BT, England; [Gerik, A.; Kruhl, J. H.] Tech Univ Munich, Fac Civil & Geodet Engn, D-80333 Munich, Germany	University of Munich; University of London; University College London; Technical University of Munich	Lavallee, Y (corresponding author), Univ Munich, Dept Earth & Environm Sci, D-80333 Munich, Germany.	lavallee@min.uni-muenchen.de	Lavallée, Yan/A-3074-2010; Lavallee, Yan/AAC-5259-2020; Cordonnier, benoit/AAE-4571-2019; Hess, Kai-Uwe/C-8211-2009; Dingwell, Donald B/A-4724-2011; Auerbach, Leslie E Wallace/A-4606-2011	Cordonnier, benoit/0000-0001-8632-3844; Hess, Kai-Uwe/0000-0003-1860-8543; Dingwell, Donald B/0000-0002-3332-789X; Meredith, Philip/0000-0003-2193-5342	NERC [NE/D012910/1] Funding Source: UKRI; Natural Environment Research Council [NE/D012910/1] Funding Source: researchfish	NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Chmelik F, 2002, MAT SCI ENG A-STRUCT, V338, P1, DOI 10.1016/S0921-5093(02)00086-2; Chouet BA, 1996, NATURE, V380, P309, DOI 10.1038/380309a0; CORNELIUS RR, 1995, J VOLCANOL GEOTH RES, V64, P295, DOI 10.1016/0377-0273(94)00078-U; Costa A, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL024303; De la Cruz-Reyna S, 2001, B VOLCANOL, V63, P297, DOI 10.1007/s004450100152; Dingwell DB, 1996, SCIENCE, V273, P1054, DOI 10.1126/science.273.5278.1054; Dobson DP, 2004, PHYS EARTH PLANET IN, V143, P337, DOI 10.1016/j.pepi.2003.09.023; GERIK A, IN PRESS COMPUT GEOS; Gonnermann HM, 2003, NATURE, V426, P432, DOI 10.1038/nature02138; Harrington RM, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2006GL028714; HESS KU, IN PRESS EARTH PLANE; Iverson RM, 2006, NATURE, V444, P439, DOI 10.1038/nature05322; Kilburn CRJ, 2003, J VOLCANOL GEOTH RES, V125, P271, DOI 10.1016/S0377-0273(03)00117-3; Lavallee Y, 2007, GEOLOGY, V35, P843, DOI 10.1130/G23594A.1; McNutt SR, 2005, ANNU REV EARTH PL SC, V33, P461, DOI 10.1146/annurev.earth.33.092203.122459; Neuberg J, 2000, J VOLCANOL GEOTH RES, V101, P83, DOI 10.1016/S0377-0273(00)00169-4; Neuberg J, 2000, PHILOS T ROY SOC A, V358, P1533, DOI 10.1098/rsta.2000.0602; Neuberg JW, 2006, J VOLCANOL GEOTH RES, V153, P37, DOI 10.1016/j.jvolgeores.2005.08.008; Ojala IO, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020781; Papale P, 1999, NATURE, V397, P425, DOI 10.1038/17109; Petford N, 2003, ANNU REV EARTH PL SC, V31, P399, DOI 10.1146/annurev.earth.31.100901.141352; Prikryl R, 2003, ROCK MECH ROCK ENG, V36, P255, DOI 10.1007/s00603-003-0051-7; Smith R, 2007, B VOLCANOL, V69, P681, DOI 10.1007/s00445-006-0102-5; Sparks RSJ, 2003, EARTH PLANET SC LETT, V210, P1, DOI 10.1016/S0012-821X(03)00124-9; Tokarev P.I., 1963, B VOLCANOL, V26, P379, DOI DOI 10.1007/BF02597299; Tuffen H, 2005, B VOLCANOL, V67, P370, DOI 10.1007/s00445-004-0383-5; Tuffen H, 2003, GEOLOGY, V31, P1089, DOI 10.1130/G19777.1; VOIGHT B, 1989, SCIENCE, V243, P200, DOI 10.1126/science.243.4888.200; VOIGHT B, 1988, NATURE, V332, P125, DOI 10.1038/332125a0; WEBB SL, 1990, PHYS CHEM MINER, V17, P125, DOI 10.1007/BF00199663	30	139	139	2	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 22	2008	453	7194					507	510		10.1038/nature06980	http://dx.doi.org/10.1038/nature06980			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303EL	18497822				2022-12-28	WOS:000256023700039
J	Eder, AF; Hillyer, CD; Dy, BA; Notari, EP; Benjamin, RJ				Eder, Anne F.; Hillyer, Christopher D.; Dy, Beth A.; Notari, Edward P.; Benjamin, Richard J.			Adverse reactions to allogeneic whole blood donation by 16-and 17-year-olds	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; DONOR REACTIONS; REACTION-RATES; COLLECTION; SAFETY; AGE; PHLEBOTOMY; PRESSURE; 1ST-TIME; WEIGHT	Context Donations by minors (16- and 17-year-olds) now account for approximately 8% of the whole blood collected by the American Red Cross, but young age and first-time donation status are known to be independent risk factors for donation-related complications. Objective To evaluate adverse reactions to allogeneic whole blood donation by 16- and 17-year-olds compared with older donors in American Red Cross blood centers. Design, Setting, and Participants Prospective documentation of adverse events among 16- and 17-year-old donors using standardized collection protocols, definitions, and reporting methods in 2006. Data were from 9 American Red Cross blood centers that routinely collect from 16- and 17-year-olds, a population that provides 80% of its donations at high school blood drives. Main Outcome Measures Rate of systemic (syncopal-type) and phlebotomy-related donor complications per 10 000 collections. Results In 2006, 9 American Red Cross regions collected 145 678 whole blood donations from 16- and 17-year-olds, 113 307 from 18- and 19-year-olds, and 1 517 460 from donors aged 20 years or older. Complications were recorded in 15 632 (10.7%), 9359 (8.3%), and 42 987 (2.8%) donations in each corresponding age group. In a multivariate logistic regression model, young age had the strongest association with complications (odds ratio [OR], 3.05; 95% confidence interval [CI], 2.52-3.69; P <.001), followed by first-time donation status (OR, 2.63; 95% CI, 2.24-3.09; P <.001) and female sex (OR, 1.87; 95% CI, 1.62-2.16; P <.001). Infrequent but medically relevant complications, in particular physical injury from syncope-related falls, were significantly more likely in 16- and 17-year-old donors (86 events; 5.9/10 000 collections) compared with 18- and 19-year-old donors (27 events; 2.4/10 000 collections; OR, 2.48; 95% CI, 1.61-3.82) or adults aged 20 years or older (62 events; 0.4/10 000 collections; OR, 14.46; 95% CI, 10.43 -20.04). Sixteen-year-old donors who experienced even a minor complication were less likely to return to donate within 12 months than 16-year-olds who experienced uncomplicated donations (52% vs 73% return rate; OR, 0.40; 95% CI, 0.36-0.44). Conclusions A higher incidence of donation-related complications and injury occurs among 16- and 17-year-old blood donors compared with older donors. The increasing dependence on recruiting and retaining young blood donors requires a committed approach to donor safety, especially at high school blood drives.	[Eder, Anne F.; Dy, Beth A.; Benjamin, Richard J.] Amer Red Cross, Biomed Serv, Natl Headquarters, Med Off, Washington, DC 20006 USA; [Hillyer, Christopher D.] Emory Univ, Sch Med, Atlanta, GA 30322 USA; [Hillyer, Christopher D.] So Reg Amer Red Cross, Douglasville, GA USA; [Notari, Edward P.] Amer Red Cross, Jerome H Holland Lab, Rockville, MD USA	American Red Cross; Emory University; American Red Cross; American Red Cross	Eder, AF (corresponding author), Amer Red Cross, Biomed Serv, Natl Headquarters, Med Off, 2025 E St NW, Washington, DC 20006 USA.	edera@usa.redcross.org						BIANCO C, 1994, TRANSFUSION, V34, pS15; Bonk VA, 2001, PSYCHOSOM MED, V63, P447, DOI 10.1097/00006842-200105000-00014; BOYNTON MH, 1945, AM J MED SCI, V209, P421, DOI 10.1097/00000441-194504000-00001; Busch MP, 2006, EMERG INFECT DIS, V12, P395, DOI 10.3201/eid1203.051287; Custer B, 2007, TRANSFUSION, V47, P1514, DOI 10.1111/j.1537-2995.2007.01292.x; Davey RJ, 2004, TRANSFUSION, V44, P597, DOI 10.1111/j.0041-1132.2004.04402.x; Ditto B, 2003, TRANSFUSION, V43, P1269, DOI 10.1046/j.1537-2995.2003.00488.x; EDER AF, IN PRESS TRANSFUSION; Gammon RR, 2006, TRANSFUSION, V46, p82A; GRIBBIN B, 1971, CIRC RES, V29, P424, DOI 10.1161/01.RES.29.4.424; Harkin R, 2007, TRANSFUSION, V47, p105A; Kakaiya RM, 2005, TRANSFUSION, V45, p88A; Kamel HT, 2006, TRANSFUSION, V46, P1745, DOI 10.1111/j.1537-2995.2006.00967.x; Leiby DA, 2007, TRANSFUSION, V47, P1573, DOI 10.1111/j.1537-2995.2007.01418.x; Maisel WH, 2002, NEW ENGL J MED, V347, P931, DOI 10.1056/NEJMe020102; Newman BH, 2006, TRANSFUSION, V46, P284, DOI 10.1111/j.1537-2995.2006.00713.x; Newman BH, 2005, TRANSFUSION, V45, P1398, DOI 10.1111/j.1537-2995.2005.00212.x; Newman BH, 2004, CURR OPIN HEMATOL, V11, P339, DOI 10.1097/01.moh.0000142105.21058.96; Newman BH, 2001, TRANSFUSION, V41, P1390, DOI 10.1046/j.1537-2995.2001.41111390.x; Newman B, 2007, TRANSFUSION, V47, P1524, DOI 10.1111/j.1537-2995.2007.01293.x; Nguyen KT, 2007, TRANSFUSION, V47, p106A; O'Brien SF, 2006, TRANSFUSION, V46, P461, DOI 10.1111/j.1537-2995.2006.00744.x; Rader AW, 2005, TRANSFUSION, V45, p88A; Riley W, 2007, TRANSFUSION, V47, P1180, DOI 10.1111/j.1537-2995.2007.01252.x; Shehata N, 2004, TRANSFUSION MED, V14, P327, DOI 10.1111/j.0958-7578.2004.00524.x; Stramer S. L., 2007, Morbidity and Mortality Weekly Report, V56, P141; Sullivan MT, 2007, TRANSFUSION, V47, P385, DOI 10.1111/j.1537-2995.2007.01128.x; Szelei-Stevens K, 2006, TRANSFUSION, V46, P2030, DOI 10.1111/j.1537-2995.2006.01013.x; TOMASULO PA, 1980, TRANSFUSION, V20, P511, DOI 10.1046/j.1537-2995.1980.20581034503.x; Trouern-Trend JJ, 1999, TRANSFUSION, V39, P316, DOI 10.1046/j.1537-2995.1999.39399219291.x; *US DEP HHS, PUBL WELF PROT HUM S; Watanabe KK, 2000, TRANSFUSION, V40, P954, DOI 10.1046/j.1537-2995.2000.40080954.x; WHITAKER BI, 2005 NATIONWIDE BLOO; Wiltbank TB, 2007, TRANSFUSION, V47, P1002, DOI 10.1111/j.1537-2995.2007.01224.x; Zou SM, 2008, TRANSFUSION, V48, P251, DOI [10.1111/j.1537-2995.2007.01517.x, 10.1111/j.1537-2995.2008.01903.x]	35	109	111	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2008	299	19					2279	2286		10.1001/jama.299.19.2279	http://dx.doi.org/10.1001/jama.299.19.2279			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302QN	18492969	Bronze			2022-12-28	WOS:000255984500022
J	Wald, HS; Reis, S				Wald, Hedy S.; Reis, Shmuel			Brew	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												hedy_wald@brown.edu						Charon R., 2006, NARRATIVE MED HONORI; Suchman AL, 2004, J GEN INTERN MED, V19, P501, DOI 10.1111/j.1525-1497.2004.30157.x	2	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2008	299	19					2255	2256		10.1001/jama.299.19.2255	http://dx.doi.org/10.1001/jama.299.19.2255			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302QN	18492958				2022-12-28	WOS:000255984500001
J	Zhu, WD; Shiojima, I; Ito, Y; Li, Z; Ikeda, H; Yoshida, M; Naito, AT; Nishi, JI; Ueno, H; Umezawa, A; Minamino, T; Nagai, T; Kikuchi, A; Asashima, M; Komuro, I				Zhu, Weidong; Shiojima, Ichiro; Ito, Yuzuru; Li, Zhi; Ikeda, Hiroyuki; Yoshida, Masashi; Naito, Atsuhiko T.; Nishi, Jun-ichiro; Ueno, Hiroo; Umezawa, Akihiro; Minamino, Tohru; Nagai, Toshio; Kikuchi, Akira; Asashima, Makoto; Komuro, Issei			IGFBP-4 is an inhibitor of canonical Wnt signalling required for cardiogenesis	NATURE			English	Article							CATENIN; PROTEIN; GROWTH; DIFFERENTIATION; PATHWAY; IDENTIFICATION; SPECIFICATION; INDUCTION; MESODERM; RECEPTOR	Insulin- like growth- factor- binding proteins ( IGFBPs) bind to and modulate the actions of insulin- like growth factors ( IGFs)(1). Although some of the actions of IGFBPs have been reported to be independent of IGFs, the precise mechanisms of IGF- independent actions of IGFBPs are largely unknown(1,2). Here we report a previously unknown function for IGFBP- 4 as a cardiogenic growth factor. IGFBP- 4 enhanced cardiomyocyte differentiation in vitro, and knockdown of Igfbp4 attenuated cardiomyogenesis both in vitro and in vivo. The cardiogenic effect of IGFBP- 4 was independent of its IGF- binding activity but was mediated by the inhibitory effect on canonical Wnt signalling. IGFBP- 4 physically interacted with a Wnt receptor, Frizzled 8 ( Frz8), and a Wnt co- receptor, low-density lipoprotein receptor- related protein 6 ( LRP6), and inhibited the binding of Wnt3A to Frz8 and LRP6. Although IGF- independent, the cardiogenic effect of IGFBP- 4 was attenuated by IGFs through IGFBP- 4 sequestration. IGFBP- 4 is therefore an inhibitor of the canonical Wnt signalling required for cardiogenesis and provides a molecular link between IGF signalling and Wnt signalling.	[Zhu, Weidong; Shiojima, Ichiro; Li, Zhi; Ikeda, Hiroyuki; Yoshida, Masashi; Naito, Atsuhiko T.; Nishi, Jun-ichiro; Minamino, Tohru; Nagai, Toshio; Komuro, Issei] Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chiba 2608670, Japan; [Ito, Yuzuru; Asashima, Makoto] Japan Sci & Technol Agcy, ICORP Organ Regenerat Project, Tokyo 1538902, Japan; [Ueno, Hiroo] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA; [Umezawa, Akihiro] Natl Inst Child Hlth & Dev, Dept Reprod Biol, Tokyo 1578535, Japan; [Kikuchi, Akira] Hiroshima Univ, Dept Biochem, Grad Sch Biomed Sci, Hiroshima 7348551, Japan; [Asashima, Makoto] Univ Tokyo, Dept Life Sci Biol, Grad Sch Arts & Sci, Tokyo 1538902, Japan; [Asashima, Makoto] Natl Inst Adv Ind Sci & Technol, Tsukuba 3058562, Japan	Chiba University; Japan Science & Technology Agency (JST); Stanford University; National Center for Child Health & Development - Japan; Hiroshima University; University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST)	Komuro, I (corresponding author), Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chiba 2608670, Japan.	komuro-tky@umin.ac.jp	Minamino, Tohru/P-8145-2018; Asashima, Makoto/O-8389-2018	Minamino, Tohru/0000-0003-1627-6151; Asashima, Makoto/0000-0002-0012-026X				CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cohen ED, 2008, DEVELOPMENT, V135, P789, DOI 10.1242/dev.016865; Durai R, 2006, INT J ONCOL, V28, P1317; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Foley A, 2004, TRENDS CARDIOVAS MED, V14, P121, DOI 10.1016/j.tcm.2004.01.003; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Hosoda T, 2001, J BIOL CHEM, V276, P35978, DOI 10.1074/jbc.M100485200; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Kobayashi H, 2005, MECH DEVELOP, V122, P1138, DOI 10.1016/j.mod.2005.05.003; Kolossov E, 2005, FASEB J, V19, P577, DOI 10.1096/fj.03-1451fje; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Leri A, 2005, PHYSIOL REV, V85, P1373, DOI 10.1152/physrev.00013.2005; Liu Y, 2007, P NATL ACAD SCI USA, V104, P3859, DOI 10.1073/pnas.0609100104; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mohan S, 2002, J ENDOCRINOL, V175, P19, DOI 10.1677/joe.0.1750019; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Naito AT, 2006, P NATL ACAD SCI USA, V103, P19812, DOI 10.1073/pnas.0605768103; Ning Y, 2006, MOL ENDOCRINOL, V20, P2173, DOI 10.1210/me.2005-0196; Olson EN, 2003, GENE DEV, V17, P1937, DOI 10.1101/gad.1110103; Qin XZ, 1998, J BIOL CHEM, V273, P23509, DOI 10.1074/jbc.273.36.23509; Sasagawa S, 2002, GENESIS, V33, P81, DOI 10.1002/gene.10094; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Ueno H, 2003, NAT IMMUNOL, V4, P457, DOI 10.1038/ni916; Ueno S, 2007, P NATL ACAD SCI USA, V104, P9685, DOI 10.1073/pnas.0702859104; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	30	170	186	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 17	2008	454	7202					345	U51		10.1038/nature07027	http://dx.doi.org/10.1038/nature07027			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326ND	18528331	Bronze			2022-12-28	WOS:000257665300041
J	Hall-Spencer, JM; Rodolfo-Metalpa, R; Martin, S; Ransome, E; Fine, M; Turner, SM; Rowley, SJ; Tedesco, D; Buia, MC				Hall-Spencer, Jason M.; Rodolfo-Metalpa, Riccardo; Martin, Sophie; Ransome, Emma; Fine, Maoz; Turner, Suzanne M.; Rowley, Sonia J.; Tedesco, Dario; Buia, Maria-Cristina			Volcanic carbon dioxide vents show ecosystem effects of ocean acidification	NATURE			English	Article							CLIMATE-CHANGE; CO2; SEA; EMISSION; IMPACT	The atmospheric partial pressure of carbon dioxide (p(CO2)) will almost certainly be double that of pre- industrial levels by 2100 and will be considerably higher than at any time during the past few million years(1). The oceans are a principal sink for anthropogenic CO2 where it is estimated to have caused a 30% increase in the concentration of H+ in ocean surface waters since the early 1900s and may lead to a drop in seawater pH of up to 0.5 units by 2100 ( refs 2, 3). Our understanding of how increased ocean acidity may affect marine ecosystems is at present very limited as almost all studies have been in vitro, short- term, rapid perturbation experiments on isolated elements of the ecosystem(4,5). Here we show the effects of acidification on benthic ecosystems at shallow coastal sites where volcanic CO2 vents lower the pH of the water column. Along gradients of normal pH ( 8.1 - 8.2) to lowered pH ( mean 7.8 - 7.9, minimum 7.4 - 7.5), typical rocky shore communities with abundant calcareous organisms shifted to communities lacking scleractinian corals with significant reductions in sea urchin and coralline algal abundance. To our knowledge, this is the first ecosystem- scale validation of predictions that these important groups of organisms are susceptible to elevated amounts of p(CO2). Sea- grass production was highest in an area at mean pH 7.6 ( 1,827 mu atm p(CO2)) where coralline algal biomass was significantly reduced and gastropod shells were dissolving due to periods of carbonate sub- saturation. The species populating the vent sites comprise a suite of organisms that are resilient to naturally high concentrations of p(CO2) and indicate that ocean acidification may benefit highly invasive non- native algal species. Our results provide the first in situ insights into how shallow water marine communities might change when susceptible organisms are removed owing to ocean acidification.	[Hall-Spencer, Jason M.; Rodolfo-Metalpa, Riccardo; Ransome, Emma; Rowley, Sonia J.] Univ Plymouth, Marine Biol & Ecol Res Ctr, Inst Marine, Plymouth PL4 8AA, Devon, England; [Martin, Sophie] Univ Paris 06, CNRS, F-06234 Villefranche Sur Mer, France; [Fine, Maoz] Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel; [Fine, Maoz] Interuniv Inst Marine Sci, IL-88103 Elat, Israel; [Turner, Suzanne M.] Univ E Anglia, Sch Environm Sci, Norwich NR4 7TJ, Norfolk, England; [Tedesco, Dario] Univ Naples 2, Dept Environm Sci, I-81100 Caserta, Italy; [Tedesco, Dario] CNR, Ist Geol Ambientale & Geoingn, I-00138 Rome, Italy; [Buia, Maria-Cristina] Stn Zool Anton Dohrn, Lab Ecol Benthos, I-80077 Naples, Italy	University of Plymouth; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Bar Ilan University; University of East Anglia; Universita della Campania Vanvitelli; Consiglio Nazionale delle Ricerche (CNR); Istituto di Geologia Ambientale e Geoingegneria (IGAG-CNR); Stazione Zoologica Anton Dohrn di Napoli	Hall-Spencer, JM (corresponding author), Univ Plymouth, Marine Biol & Ecol Res Ctr, Inst Marine, Plymouth PL4 8AA, Devon, England.	jhall-spencer@plymouth.ac.uk	Fine, Maoz/S-5582-2019; Buia, Maria-Cristina/L-9948-2017; Hall-Spencer, Jason/F-9179-2013; Hall-Spencer, Jason/AFN-7866-2022; Buia, Maria Cristina/K-8771-2016	Fine, Maoz/0000-0003-4911-4562; Hall-Spencer, Jason/0000-0002-6915-2518; Ransome, Emma/0000-0002-5720-1570; MARTIN, Sophie/0000-0002-1256-3674; Buia, Maria Cristina/0000-0002-2370-898X				Bibby R, 2007, BIOLOGY LETT, V3, P699, DOI 10.1098/rsbl.2007.0457; Boudouresque CF, 2002, MAR POLLUT BULL, V44, P32, DOI 10.1016/S0025-326X(01)00150-3; Caldeira K, 2005, J GEOPHYS RES-OCEANS, V110, DOI 10.1029/2004JC002671; Dando PR, 1999, PROG OCEANOGR, V44, P333, DOI 10.1016/S0079-6611(99)00032-4; Davies AJ, 2007, BIOL CONSERV, V138, P299, DOI 10.1016/j.biocon.2007.05.011; Feely RA, 2004, SCIENCE, V305, P362, DOI 10.1126/science.1097329; Fine M, 2007, SCIENCE, V315, P1811, DOI 10.1126/science.1137094; GAMBI MC, 2003, MARINO COSTIERO TERR; Hoegh-Guldberg O, 2007, SCIENCE, V318, P1737, DOI 10.1126/science.1152509; *INT PAN CLIM CHAN, 2007, CLIM CHANG 2007 PHYS; KERRICK DM, 1995, CHEM GEOL, V121, P285, DOI 10.1016/0009-2541(94)00148-2; Kleypas JA, 2006, WORKSH HELD 18 20 AP; Kuffner IB, 2008, NAT GEOSCI, V1, P114, DOI 10.1038/ngeo100; Levitan O, 2007, GLOBAL CHANGE BIOL, V13, P531, DOI 10.1111/j.1365-2486.2006.01314.x; Miles H, 2007, MAR POLLUT BULL, V54, P89, DOI 10.1016/j.marpolbul.2006.09.021; Orr JC, 2005, NATURE, V437, P681, DOI 10.1038/nature04095; Palacios SL, 2007, MAR ECOL PROG SER, V344, P1, DOI 10.3354/meps07084; Pearson PN, 2000, NATURE, V406, P695, DOI 10.1038/35021000; Riebesell U, 2007, NATURE, V450, P545, DOI 10.1038/nature06267; Scheffer M, 2001, NATURE, V413, P591, DOI 10.1038/35098000; The Royal Society, 2005, 1205 ROYAL SOC; WILLIAMS SN, 1992, GEOCHIM COSMOCHIM AC, V56, P1765, DOI 10.1016/0016-7037(92)90243-C	22	1081	1103	18	642	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	2008	454	7200					96	99		10.1038/nature07051	http://dx.doi.org/10.1038/nature07051			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	321MC	18536730	Green Submitted			2022-12-28	WOS:000257308300044
J	Philip, PA				Philip, Philip A.			Targeting angiogenesis in pancreatic cancer	LANCET			English	Editorial Material							PHASE-II TRIAL; BEVACIZUMAB; GEMCITABINE		Karmanos Canc Ctr, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute	Philip, PA (corresponding author), Karmanos Canc Ctr, Detroit, MI 48201 USA.	philipp@karmanos.org						Abdollahi A, 2007, P NATL ACAD SCI USA, V104, P12890, DOI 10.1073/pnas.0705505104; Buchler P, 2002, ANN SURG, V236, P738, DOI 10.1097/01.SLA.0000036262.67458.E7; Cabebe E, 2007, EXPERT OPIN INV DRUG, V16, P467, DOI 10.1517/13543784.16.4.467; Duffy John P, 2003, Mol Cancer, V2, P12, DOI 10.1186/1476-4598-2-12; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Friess H, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-285; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Kindler HL, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2007.12.0949; Kindler HL, 2005, J CLIN ONCOL, V23, P8033, DOI 10.1200/JCO.2005.01.9661; Kleeff J, 2007, INT J CANCER, V121, P699, DOI 10.1002/ijc.22871; Korc M, 2003, Mol Cancer, V2, P8, DOI 10.1186/1476-4598-2-8; *PFIZ, 2008, RAND STUD GEM PLUS A; *SAN AV, 2008, AFL COMP PLAC TERMS; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288; Spano JP, 2008, LANCET, V371, P2101, DOI 10.1016/S0140-6736(08)60661-3	16	10	10	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 21	2008	371	9630					2062	2064		10.1016/S0140-6736(08)60770-9	http://dx.doi.org/10.1016/S0140-6736(08)60770-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316ER	18514302				2022-12-28	WOS:000256932200006
J	Kuilman, T; Michaloglou, C; Vredeveld, LCW; Douma, S; van Doom, R; Desmet, CJ; Aarden, LA; Mooi, WJ; Peeper, DS				Kuilman, Thomas; Michaloglou, Chrysiis; Vredeveld, Liesbeth C. W.; Douma, Sirith; van Doom, Remco; Desmet, Christophe J.; Aarden, Lucien A.; Mooi, Wolter J.; Peeper, Daniel S.			Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network	CELL			English	Article							RAS-INDUCED SENESCENCE; CELLULAR SENESCENCE; TUMOR SUPPRESSION; HUMAN-CELLS; REPLICATIVE SENESCENCE; C/EBP-BETA; CANCER; P53; TUMORIGENESIS; GROWTH	Oncogene-induced cellular senescence (OIS) is emerging as a potent cancer-protective response to oncogenic events, serving to eliminate early neoplastic cells from the proliferative pool. Using combined genetic and bioinformatic analysis, we find that OIS is linked specifically to the activation of an inflammatory transcriptome. Induced genes included the pleiotropic cytokine interleukin-6 (IL-6), which upon secretion by senescent cells acted mitogenically in a paracrine fashion. Unexpectedly, IL-6 was also required for the execution of OIS, but in a cell-autonomous mode. Its depletion caused the inflammatory network to collapse and abolished senescence entry and maintenance. Furthermore, we demonstrate that the transcription factor C/EBP beta cooperates with IL-6 to amplify the activation of the inflammatory network, including IL-8. In human colon adenomas, IL-8 specifically colocalized with arrested, p16(INK4A)-positive epithelium. We propose a model in which the context-dependent cytostatic and promitogenic functions of specific interleukins contribute to connect senescence with an inflammatory phenotype and cancer.	[Kuilman, Thomas; Michaloglou, Chrysiis; Vredeveld, Liesbeth C. W.; Douma, Sirith; van Doom, Remco; Desmet, Christophe J.; Peeper, Daniel S.] Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; [Aarden, Lucien A.] Sanquin AMC Landsteiner Lab, NL-1066 CX Amsterdam, Netherlands; [Mooi, Wolter J.] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1081 HV Amsterdam, Netherlands	Netherlands Cancer Institute; University of Amsterdam; Vrije Universiteit Amsterdam	Peeper, DS (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	d.peeper@nki.nl	Peeper, Daniel/AAA-2430-2020	Kuilman, Thomas/0000-0001-6724-6767; van Doorn, Remco/0000-0002-7019-6673				Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Adams PD, 2007, GENE, V397, P84, DOI 10.1016/j.gene.2007.04.020; Ancrile B, 2007, GENE DEV, V21, P1714, DOI 10.1101/gad.1549407; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Dai CY, 2000, GASTROENTEROLOGY, V119, P929, DOI 10.1053/gast.2000.17952; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dirac AMG, 2003, J BIOL CHEM, V278, P11731, DOI 10.1074/jbc.C300023200; Finkel T, 2007, NATURE, V448, P767, DOI 10.1038/nature05985; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Ha L, 2007, P NATL ACAD SCI USA, V104, P10968, DOI 10.1073/pnas.0611638104; HIRANO T, 1989, RES CLIN LAB, V19, P1; Hodge DR, 2001, J BIOL CHEM, V276, P39508, DOI 10.1074/jbc.C100343200; Hong DS, 2007, CANCER-AM CANCER SOC, V110, P1911, DOI 10.1002/cncr.22999; Kalai M, 1997, EUR J BIOCHEM, V249, P690, DOI 10.1111/j.1432-1033.1997.t01-2-00690.x; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; LU C, 1993, J CELL BIOL, V120, P1281, DOI 10.1083/jcb.120.5.1281; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Mason DX, 2004, ONCOGENE, V23, P9238, DOI 10.1038/sj.onc.1208172; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nicke B, 2005, MOL CELL, V20, P673, DOI 10.1016/j.molcel.2005.10.038; Peeper DS, 2002, NAT CELL BIOL, V4, P148, DOI 10.1038/ncb742; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Schnabl B, 2003, HEPATOLOGY, V37, P653, DOI 10.1053/jhep.2003.50097; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; Shay JW, 2005, CARCINOGENESIS, V26, P867, DOI 10.1093/carcin/bgh296; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Tremain R, 2000, ONCOGENE, V19, P1698, DOI 10.1038/sj.onc.1203471; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Ye XF, 2007, MOL CELL, V27, P183, DOI 10.1016/j.molcel.2007.05.034	52	1328	1361	6	104	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 13	2008	133	6					1019	1031		10.1016/j.cell.2008.03.039	http://dx.doi.org/10.1016/j.cell.2008.03.039			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	312TJ	18555778	Bronze			2022-12-28	WOS:000256693400017
J	Kukar, TL; Ladd, TB; Bann, MA; Fraering, PC; Narlawar, R; Maharvi, GM; Healy, B; Chapman, R; Welzel, AT; Price, RW; Moore, B; Rangachari, V; Cusack, B; Eriksen, J; Jansen-West, K; Verbeeck, C; Yager, D; Eckman, C; Ye, WJ; Sagi, S; Cottrell, BA; Torpey, J; Rosenberry, TL; Fauq, A; Wolfe, MS; Schmidt, B; Walsh, DM; Koo, EH; Golde, TE				Kukar, Thomas L.; Ladd, Thomas B.; Bann, Maralyssa A.; Fraering, Patrick C.; Narlawar, Rajeshwar; Maharvi, Ghulam M.; Healy, Brent; Chapman, Robert; Welzel, Alfred T.; Price, Robert W.; Moore, Brenda; Rangachari, Vijayaraghavan; Cusack, Bernadette; Eriksen, Jason; Jansen-West, Karen; Verbeeck, Christophe; Yager, Debra; Eckman, Christopher; Ye, Wenjuan; Sagi, Sarah; Cottrell, Barbara A.; Torpey, Justin; Rosenberry, Terrone L.; Fauq, Abdul; Wolfe, Michael S.; Schmidt, Boris; Walsh, Dominic M.; Koo, Edward H.; Golde, Todd E.			Substrate-targeting gamma-secretase modulators	NATURE			English	Article							AMYLOID-BETA-PROTEIN; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PRECURSOR PROTEIN; IN-VIVO; A-BETA-42; OLIGOMERIZATION; INHIBITORS; NSAIDS; SITE; ACETYLCHOLINESTERASE	Selective lowering of A beta 42 levels ( the 42- residue isoform of the amyloid-beta peptide) with small- molecule gamma-secretase modulators ( GSMs), such as some non- steroidal anti- inflammatory drugs, is a promising therapeutic approach for Alzheimer's disease(1). To identify the target of these agents we developed biotinylated photo-activatable GSMs. GSM photoprobes did not label the core proteins of the gamma- secretase complex, but instead labelled the beta- amyloid precursor protein ( APP), APP carboxy- terminal fragments and amyloid-beta peptide in human neuroglioma H4 cells. Substrate labelling was competed by other GSMs, and labelling of an APP gamma- secretase substrate was more efficient than a Notch substrate. GSM interaction was localized to residues 28 - 36 of amyloid-beta, a region critical for aggregation. We also demonstrate that compounds known to interact with this region of amyloid- beta act as GSMs, and some GSMs alter the production of cell- derived amyloid- beta oligomers. Furthermore, mutation of the GSM binding site in the APP alters the sensitivity of the substrate to GSMs. These findings indicate that substrate targeting by GSMs mechanistically links two therapeutic actions: alteration in A beta 42 production and inhibition of amyloid- beta aggregation, which may synergistically reduce amyloid- beta deposition in Alzheimer's disease. These data also demonstrate the existence and feasibility of 'substrate targeting' by small- molecule effectors of proteolytic enzymes, which if generally applicable may significantly broaden the current notion of 'druggable' targets(2).	[Kukar, Thomas L.; Ladd, Thomas B.; Bann, Maralyssa A.; Maharvi, Ghulam M.; Healy, Brent; Chapman, Robert; Price, Robert W.; Moore, Brenda; Rangachari, Vijayaraghavan; Cusack, Bernadette; Eriksen, Jason; Jansen-West, Karen; Verbeeck, Christophe; Yager, Debra; Eckman, Christopher; Rosenberry, Terrone L.; Fauq, Abdul; Golde, Todd E.] Mayo Clin, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA; [Fraering, Patrick C.] Ecole Polytech Fed Lausanne, Swiss Fed Inst Technol, Brain Mind Inst, CH-1025 Lausanne, Switzerland; [Fraering, Patrick C.] Ecole Polytech Fed Lausanne, Swiss Fed Inst Technol, Sch Life Sci, CH-1025 Lausanne, Switzerland; [Fraering, Patrick C.; Ye, Wenjuan; Wolfe, Michael S.] Harvard Univ, Sch Med, Ctr Neurol Dis, Brigham & Womens Hosp, Boston, MA 02115 USA; [Narlawar, Rajeshwar; Schmidt, Boris] Tech Univ Darmstadt, Clemens Schopf Inst Chem & Biochem, D-64287 Darmstadt, Germany; [Welzel, Alfred T.; Walsh, Dominic M.] Univ Coll Dublin, Lab Neurodegenerat Res, Conway Inst, Dublin 4, Ireland; [Sagi, Sarah; Cottrell, Barbara A.; Torpey, Justin; Koo, Edward H.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	Mayo Clinic; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Technical University of Darmstadt; University College Dublin; University of California System; University of California San Diego	Kukar, TL (corresponding author), Mayo Clin, Coll Med, Dept Neurosci, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	kukar.thomas@mayo.edu; golde.todd@mayo.edu	Eriksen, Jason/A-8054-2008; Kukar, Thomas/AAW-2612-2021; Narlawar, Rajeshwar/E-4981-2010; Cusack, Bernadette/D-4606-2013; Schmidt, Boris/M-7886-2019; Rangachari, vijay/K-1420-2015; Schmidt, Boris/D-3293-2009	Eriksen, Jason/0000-0003-1549-4165; Schmidt, Boris/0000-0003-1662-2392; Schmidt, Boris/0000-0003-1662-2392; Moore, Brenda/0000-0002-9685-6561; Bann, Maralyssa/0000-0002-5893-950X; Fraering, Patrick/0000-0002-5841-5327; Kukar, Thomas/0000-0002-3750-6262	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG020206, R01AG017574] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG020206, P01 AG020206-010002, R01 AG017574, R01 AG017574-09, R01 AG017574-08] Funding Source: Medline; NINDS NIH HHS [R01 NS041355, R01 NS041355-07, R01 NS041355-06A2] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Beher D, 2004, J BIOL CHEM, V279, P43419, DOI 10.1074/jbc.M404937200; Calabrese B, 2007, MOL CELL NEUROSCI, V35, P183, DOI 10.1016/j.mcn.2007.02.006; Chen YR, 2006, J BIOL CHEM, V281, P24414, DOI 10.1074/jbc.M602363200; Christensen Daniel D, 2007, Prim Care Companion J Clin Psychiatry, V9, P32; De Ferrari GV, 2001, J BIOL CHEM, V276, P23282, DOI 10.1074/jbc.M009596200; Dong DL, 1999, CHEM BIOL, V6, P133, DOI 10.1016/S1074-5521(99)89005-X; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; Ferrao-Gonzales AD, 2005, J BIOL CHEM, V280, P34747, DOI 10.1074/jbc.M501651200; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P9774, DOI 10.1021/bi0494976; Grziwa B, 2003, J BIOL CHEM, V278, P6803, DOI 10.1074/jbc.M210047200; Hirohata M, 2005, NEUROPHARMACOLOGY, V49, P1088, DOI 10.1016/j.neuropharm.2005.07.004; Johnson JL, 2003, BIOCHEMISTRY-US, V42, P5438, DOI 10.1021/bi027065u; Kodadek T, 2002, BIOPOLYMERS, V66, P134, DOI 10.1002/bip.10233; Kukar T, 2005, NAT MED, V11, P545, DOI 10.1038/nm1235; Kukar T, 2008, CURR TOP MED CHEM, V8, P47, DOI 10.2174/156802608783334042; Kukar T, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-54; Leuchtenberger S, 2006, J NEUROCHEM, V96, P355, DOI 10.1111/j.1471-4159.2005.03553.x; Lleo A, 2004, NAT MED, V10, P1065, DOI 10.1038/nm1112; Munter LM, 2007, EMBO J, V26, P1702, DOI 10.1038/sj.emboj.7601616; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Narlawar R, 2007, BIOORG MED CHEM LETT, V17, P5428, DOI 10.1016/j.bmcl.2007.07.044; Narlawar R, 2006, J MED CHEM, V49, P7588, DOI 10.1021/jm0610200; Okochi M, 2006, J BIOL CHEM, V281, P7890, DOI 10.1074/jbc.M513250200; Podlisny MB, 1998, BIOCHEMISTRY-US, V37, P3602, DOI 10.1021/bi972029u; SAGI SA, 2004, 26410 SOC NEUR; Sato T, 2006, BIOCHEMISTRY-US, V45, P5503, DOI 10.1021/bi052485f; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Weggen S, 2003, J BIOL CHEM, V278, P31831, DOI 10.1074/jbc.M303592200; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977	32	254	266	0	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2008	453	7197					925	U62		10.1038/nature07055	http://dx.doi.org/10.1038/nature07055			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	311WV	18548070	Green Submitted, Green Accepted			2022-12-28	WOS:000256632000045
J	Hickman, L				Hickman, Leo			Product placement in the waiting room	BRITISH MEDICAL JOURNAL			English	Editorial Material												leo.hickman@guardian.co.uk							0	1	1	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2008	336	7656					1274	1275		10.1136/bmj.39589.491030.BD	http://dx.doi.org/10.1136/bmj.39589.491030.BD			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312XO	18535067	Green Published			2022-12-28	WOS:000256705900027
J	Home, P; Mant, J; Diaz, J; Turner, C				Home, Philip; Mant, Jonathan; Diaz, Jose; Turner, Claire		Guideline Dev Grp	Guidelines - Management of type 2 diabetes: updated NICE guidance	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Home, Philip] Univ Newcastle, Sch Med, Newcastle Upon Tyne, Tyne & Wear, England; [Mant, Jonathan] Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham, W Midlands, England; [Diaz, Jose; Turner, Claire] Royal Coll Physicians, Natl Collaborating Ctr Chron Condit, London NW1 4LE, England	Newcastle University - UK; University of Birmingham; Royal College of Physicians	Home, P (corresponding author), Med Sch Newcastle Upon Tyne, SCMS Diabet, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	philip.home@ncl.ac.uk		Mant, Jonathan/0000-0002-9531-0268				*INT DIAB FED, 2006, DIAB ATL; Marshall SM, 2006, BMJ-BRIT MED J, V333, P475, DOI 10.1136/bmj.38922.650521.80; *NAT I HLTH CLIN E, 2007, EZ TREATM PRIM HET F; *NAT I HLTH CLIN E, 2008, MAN TYP 2 DIAB UPD; National Institute of Clinical Excellence, 2004, TYP 2 DIAB PREV MAN; *UK NAT SCREEN COM, 2007, ESS EL DEV DIAB RET, V4, P1; [WHO] World Health Organization, 2006, DIAB FACT SHEET	7	68	80	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2008	336	7656					1306	1308		10.1136/bmj.39560.442095.AD	http://dx.doi.org/10.1136/bmj.39560.442095.AD			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312XO	18535074	Green Published			2022-12-28	WOS:000256705900037
J	Satyanand, T				Satyanand, Tara			Aftermath of the Bhopal accident	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Satyanand, T (corresponding author), The Lancet, London NW1 7BY, England.							MOORIS C, 2008, BBC NEWS        0529; 2008, TIMES INDIA     0529	2	3	4	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 7	2008	371	9628					1900	1900		10.1016/S0140-6736(08)60814-4	http://dx.doi.org/10.1016/S0140-6736(08)60814-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310OI	18539211				2022-12-28	WOS:000256538500011
J	Bouchon, M; Karabulut, H				Bouchon, Michel; Karabulut, Hayrullah			The aftershock signature of supershear earthquakes	SCIENCE			English	Article							DENALI FAULT EARTHQUAKE; 1999 IZMIT EARTHQUAKE; SLIP DISTRIBUTION; RUPTURE VELOCITY; SURFACE RUPTURE; SHEAR CRACKS; ALASKA; MODELS; TURKEY; KUNLUNSHAN	Recent studies show that earthquake faults may rupture at speeds exceeding the shear wave velocity of rocks. This supershear rupture produces in the ground a seismic shock wave similar to the sonic boom produced by a supersonic airplane. This shock wave may increase the destruction caused by the earthquake. We report that supershear earthquakes are characterized by a specific pattern of aftershocks: The fault plane itself is remarkably quiet whereas aftershocks cluster off the fault, on secondary structures that are activated by the supershear rupture. The post- earthquake quiescence of the fault shows that friction is relatively uniform over supershear segments, whereas the activation of off- fault structures is explained by the shock wave radiation, which produces high stresses over a wide zone surrounding the fault.	[Bouchon, Michel] CNRS, F-38041 Grenoble, France; [Bouchon, Michel] Univ Grenoble 1, Lab Geophys Interne & Tectonophys, F-38041 Grenoble, France; [Karabulut, Hayrullah] Kandilli Observ, TR-81220 Istanbul, Turkey; [Karabulut, Hayrullah] Bogazici Univ, Istanbul Kandilli Observ, Earthquake Res Inst, TR-81220 Istanbul, Turkey	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Bogazici University; Bogazici University	Bouchon, M (corresponding author), CNRS, Boite Postale 53, F-38041 Grenoble, France.	Michel.Bouchon@ujf-grenoble.fr						Aagaard BT, 2004, B SEISMOL SOC AM, V94, P2064, DOI 10.1785/0120030249; ANDREWS DJ, 1976, J GEOPHYS RES, V81, P5679, DOI 10.1029/JB081i032p05679; Antolik M, 2004, B SEISMOL SOC AM, V94, P1173, DOI 10.1785/012003180; ARCHULETA RJ, 1984, J GEOPHYS RES, V89, P4559, DOI 10.1029/JB089iB06p04559; Barka A, 2002, B SEISMOL SOC AM, V92, P43, DOI 10.1785/0120000841; Bernard P, 2005, GEOPHYS J INT, V162, P431, DOI 10.1111/j.1365-246X.2005.02611.x; Bhat HS, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2006JB004425; Bouchon M, 2003, SCIENCE, V301, P824, DOI 10.1126/science.1086832; Bouchon M, 2001, GEOPHYS RES LETT, V28, P2723, DOI 10.1029/2001GL013112; Bouin MP, 2004, GEOPHYS J INT, V159, P207, DOI 10.1111/j.1365-246X.2004.02367,x; Brocher TM, 2004, B SEISMOL SOC AM, V94, pS85, DOI 10.1785/0120040615; BURRIDGE R, 1973, GEOPHYS J ROY ASTR S, V35, P439, DOI 10.1111/j.1365-246X.1973.tb00608.x; DAS S, 1977, GEOPHYS J ROY ASTR S, V50, P643, DOI 10.1111/j.1365-246X.1977.tb01339.x; Das S, 2007, SCIENCE, V317, P905, DOI 10.1126/science.1142143; Dunham EM, 2004, B SEISMOL SOC AM, V94, pS256, DOI 10.1785/0120040616; Eberhart-Phillips D, 2003, SCIENCE, V300, P1113, DOI 10.1126/science.1082703; Ellsworth WL, 2004, EARTHQ SPECTRA, V20, P597, DOI 10.1193/1.1778172; EMRE O, 2003, SURFACE RUPTURE ASS, P31; EMRE O, 1998, MINERAL RES EXPLORAT, V120, P119; Fisher MA, 2004, B SEISMOL SOC AM, V94, pS107, DOI 10.1785/0120040613; HAO P, 2004, ACTA SEISMOL SINICA, V17, P31; Karabulut H, 2002, B SEISMOL SOC AM, V92, P387, DOI 10.1785/0120000820; Klinger Y, 2005, B SEISMOL SOC AM, V95, P1970, DOI 10.1785/0120040233; Lu X, 2007, P NATL ACAD SCI USA, V104, P18931, DOI 10.1073/pnas.0704268104; MADARIAGA R, 1983, ANN GEOPHYS, V1, P17; Madariaga R, 2007, SCIENCE, V316, P842, DOI 10.1126/science.1142332; Oglesby DD, 2004, B SEISMOL SOC AM, V94, pS214, DOI 10.1785/0120040620; Orgulu G, 2001, GEOPHYS RES LETT, V28, P371, DOI 10.1029/2000GL011991; Ozalaybey S, 2002, B SEISMOL SOC AM, V92, P376, DOI 10.1785/0120000838; OZALAYBEY S, 2000, 27 GEN ASS EUR SEISM; Pucci S., 2006, THESIS U PERUGIA ITA, VXIII; Ratchkovski NA, 2004, B SEISMOL SOC AM, V94, pS156, DOI 10.1785/0120040621; REASENBERG PA, 1989, SCIENCE, V243, P1173, DOI 10.1126/science.243.4895.1173; Robinson DP, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2005JB004137; Rosakis AJ, 1999, SCIENCE, V284, P1337, DOI 10.1126/science.284.5418.1337; Xia KW, 2005, SCIENCE, V308, P681, DOI 10.1126/science.1108193	36	68	70	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2008	320	5881					1323	1325		10.1126/science.1155030	http://dx.doi.org/10.1126/science.1155030			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309DO	18535239				2022-12-28	WOS:000256441100040
J	Neumann, P; Mizuochi, N; Rempp, F; Hemmer, P; Watanabe, H; Yamasaki, S; Jacques, V; Gaebel, T; Jelezko, F; Wrachtrup, J				Neumann, P.; Mizuochi, N.; Rempp, F.; Hemmer, P.; Watanabe, H.; Yamasaki, S.; Jacques, V.; Gaebel, T.; Jelezko, F.; Wrachtrup, J.			Multipartite entanglement among single spins in diamond	SCIENCE			English	Article							N-V CENTERS; ELECTRON-SPIN; QUANTUM-DOT; QUBITS; STATES; SPECTROSCOPY; POLARIZATION; SEPARABILITY; DYNAMICS	Robust entanglement at room temperature is a necessary requirement for practical applications in quantum technology. We demonstrate the creation of bipartite- and tripartite- entangled quantum states in a small quantum register consisting of individual (13)C nuclei in a diamond lattice. Individual nuclear spins are controlled via their hyperfine coupling to a single electron at a nitrogen- vacancy defect center. Quantum correlations are of high quality and persist on a millisecond time scale even at room temperature, which is adequate for sophisticated quantum operations.	[Neumann, P.; Rempp, F.; Jacques, V.; Gaebel, T.; Jelezko, F.; Wrachtrup, J.] Univ Stuttgart, Inst Phys 3, D-70550 Stuttgart, Germany; [Mizuochi, N.] Univ Tsukuba, Grad Sch Lib Informat & Media Studies, Tsukuba, Ibaraki 3058550, Japan; [Hemmer, P.] Texas A&M Univ, Dept Elect & Comp Engn, College Stn, TX 77843 USA; [Watanabe, H.] Natl Inst Adv Ind Sci & Technol, Diamond Res Ctr, Tsukuba, Ibaraki 3058568, Japan; [Yamasaki, S.] Natl Inst Adv Ind Sci & Technol, Nanotechnol Res Inst, Tsukuba, Ibaraki 3058568, Japan	University of Stuttgart; University of Tsukuba; Texas A&M University System; Texas A&M University College Station; National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST)	Wrachtrup, J (corresponding author), Univ Stuttgart, Inst Phys 3, Pfaffenwaldring 57, D-70550 Stuttgart, Germany.	wrachtrup@physik.uni-stuttgart.de	MIZUOCHI, Norikazu/I-4199-2014; Watanabe, Hideyuki/L-7052-2018; Yamasaki, Satoshi/M-2589-2018; Gaebel, Torsten/E-2932-2010; Jacques, Vincent/D-3881-2014	MIZUOCHI, Norikazu/0000-0003-3099-3210; Watanabe, Hideyuki/0000-0003-3994-5610; Yamasaki, Satoshi/0000-0002-0268-0412; Gaebel, Torsten/0000-0002-2292-6045; Neumann, Philipp/0000-0003-2146-0412				Berezovsky J, 2006, SCIENCE, V314, P1916, DOI 10.1126/science.1133862; Beveratos A, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.061802; Chernobrod BM, 2005, J APPL PHYS, V97, DOI 10.1063/1.1829373; Childress L, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.070504; Childress L, 2006, SCIENCE, V314, P281, DOI 10.1126/science.1131871; Duan LM, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.080503; Elzerman JM, 2004, NATURE, V430, P431, DOI 10.1039/nature02693; Epstein RJ, 2005, NAT PHYS, V1, P94, DOI 10.1038/nphys141; Gaebel T, 2006, NAT PHYS, V2, P408, DOI 10.1038/nphys318; Giovannetti V, 2004, SCIENCE, V306, P1330, DOI 10.1126/science.1104149; Gruber A, 1997, SCIENCE, V276, P2012, DOI 10.1126/science.276.5321.2012; Dutt MVG, 2007, SCIENCE, V316, P1312, DOI 10.1126/science.1139831; Harrison J, 2006, DIAM RELAT MATER, V15, P586, DOI 10.1016/j.diamond.2005.12.027; Harrison J, 2004, J LUMIN, V107, P245, DOI 10.1016/j.jlumin.2003.12.020; Horodecki M, 1996, PHYS LETT A, V223, P1, DOI 10.1016/S0375-9601(96)00706-2; Jelezko F, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.130501; Krojanski HG, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.090501; Kurtsiefer C, 2000, PHYS REV LETT, V85, P290, DOI 10.1103/PhysRevLett.85.290; Loubser J.H.N., 1977, DIAM RES, V11, P4; Mahesh TS, 2007, PHYS REV A, V75, DOI 10.1103/PhysRevA.75.062303; Mehring M, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.153001; O'Brien JL, 2007, SCIENCE, V318, P1567, DOI 10.1126/science.1142892; Peres A, 1996, PHYS REV LETT, V77, P1413, DOI 10.1103/PhysRevLett.77.1413; REDMAN DA, 1991, PHYS REV LETT, V67, P3420, DOI 10.1103/PhysRevLett.67.3420; Roos CF, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.220402; Roos CF, 2004, SCIENCE, V304, P1478, DOI 10.1126/science.1097522; Steffen M, 2006, SCIENCE, V313, P1423, DOI 10.1126/science.1130886; Vandersypen LMK, 2001, NATURE, V414, P883, DOI 10.1038/414883a; Volz J, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.030404; Wrachtrup J, 2001, OPT SPECTROSC+, V91, P429, DOI 10.1134/1.1405224	30	576	587	2	173	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2008	320	5881					1326	1329		10.1126/science.1157233	http://dx.doi.org/10.1126/science.1157233			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309DO	18535240				2022-12-28	WOS:000256441100041
J	Avorn, J				Avorn, Jerry			Coagulation and adulteration - Building on science and policy lessons from 1905	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Avorn, Jerry] Harvard Univ, Sch Med, Boston, MA USA; [Avorn, Jerry] Brigham & Womens Hosp, Harvard Interfac Initiat Med & Soc, Boston, MA 02115 USA; [Avorn, Jerry] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Avorn, J (corresponding author), Harvard Univ, Sch Med, Boston, MA USA.							CROSSE M, 2008, GOVT ACCOUTNABILITY; HARRIS G, 2008, NY TIMES        0422; Hilts P, 2003, PROTECTING AM HLTH F; Morawitz P., 1905, ERG PHYSIOL BIOL CH, V4, P307, DOI DOI 10.1007/BF02321003; Owen CA., 2001, HIST BLOOD COAGULATI	5	9	9	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2008	358	23					2429	2431		10.1056/NEJMp0803685	http://dx.doi.org/10.1056/NEJMp0803685			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308HY	18525040				2022-12-28	WOS:000256380700002
J	Murray, CD; Beurle, K; Cooper, NJ; Evans, MW; Williams, GA; Charnoz, S				Murray, Carl D.; Beurle, Kevin; Cooper, Nicholas J.; Evans, Michael W.; Williams, Gareth A.; Charnoz, Sebastien			The determination of the structure of Saturn's F ring by nearby moonlets	NATURE			English	Article							CASSINI IMAGING SCIENCE; RADIO OCCULTATION; SMALL SATELLITES; ECCENTRICITY; PROMETHEUS; VOYAGER-2; ORBITS	Saturn's narrow F ring exhibits several unusual features that vary on timescales of hours to years. These include transient clumps, a central core surrounded by a multistranded structure and a regular series of longitudinal channels associated with Prometheus, one of the ring's two 'shepherding' satellites. Several smaller moonlets and clumps have been detected in the ring's immediate vicinity, and a population of embedded objects has been inferred. Here we report direct evidence of moonlets embedded in the ring's bright core, and show that most of the F ring's morphology results from the continual gravitational and collisional effects of small satellites, often combined with the perturbing effect of Prometheus. The F- ring region is perhaps the only location in the Solar System where large- scale collisional processes are occurring on an almost daily basis.	[Murray, Carl D.; Beurle, Kevin; Cooper, Nicholas J.; Evans, Michael W.; Williams, Gareth A.] Univ London Queen Mary Coll, Astron Unit, London E1 4NS, England; [Charnoz, Sebastien] Univ Paris 07, CE Saclay, F-91191 Gif Sur Yvette, France	University of London; Queen Mary University London; UDICE-French Research Universities; Universite Paris Cite	Murray, CD (corresponding author), Univ London Queen Mary Coll, Astron Unit, Mile End Rd, London E1 4NS, England.	c.d.murray@qmul.ac.uk	Evans, Michael W/AAG-4117-2020		Science and Technology Facilities Council [ST/F002696/1, PP/C50209X/1] Funding Source: researchfish; STFC [ST/F002696/1, PP/C50209X/1] Funding Source: UKRI	Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))		Barbara JM, 2002, ICARUS, V160, P161, DOI 10.1006/icar.2002.6962; BORDERIES N, 1983, ICARUS, V53, P84, DOI 10.1016/0019-1035(83)90022-2; Bosh AS, 2002, ICARUS, V157, P57, DOI 10.1006/icar.2002.6791; Charnoz S, 2005, SCIENCE, V310, P1300, DOI 10.1126/science.1119387; CUZZI JN, 1988, ICARUS, V74, P284, DOI 10.1016/0019-1035(88)90043-7; DERMOTT SF, 1980, ICARUS, V43, P338, DOI 10.1016/0019-1035(80)90179-7; Esposito LW, 2008, ICARUS, V194, P278, DOI 10.1016/j.icarus.2007.10.001; GEHRELS T, 1980, SCIENCE, V207, P434, DOI 10.1126/science.207.4429.434; LANE AL, 1982, SCIENCE, V215, P537, DOI 10.1126/science.215.4532.537; MAROUF EA, 1986, ICARUS, V68, P120, DOI 10.1016/0019-1035(86)90078-3; Murray C. D., 1999, SOLAR SYSTEM DYNAMIC; Murray CD, 2005, NATURE, V437, P1326, DOI 10.1038/nature04212; MURRAY CD, 2005, B AM ASTRON SOC, V37, P3; Porco CC, 2004, SPACE SCI REV, V115, P363, DOI 10.1007/s11214-004-1456-7; Porco CC, 2005, SCIENCE, V307, P1226, DOI 10.1126/science.1108056; PORCO CC, 2004, 8432 IAU; Poulet F, 2000, ICARUS, V144, P135, DOI 10.1006/icar.1999.6267; SHOWALTER MR, 1992, ICARUS, V100, P394, DOI 10.1016/0019-1035(92)90107-I; Showalter MR, 2004, ICARUS, V171, P356, DOI 10.1016/j.icarus.2004.05.006; Showalter MR, 1998, SCIENCE, V282, P1099, DOI 10.1126/science.282.5391.1099; SMITH BA, 1981, SCIENCE, V212, P163, DOI 10.1126/science.212.4491.163; SMITH BA, 1982, SCIENCE, V215, P504, DOI 10.1126/science.215.4532.504; Spitale JN, 2006, ASTRON J, V132, P692, DOI 10.1086/505206; Tiscareno MS, 2006, NATURE, V440, P648, DOI 10.1038/nature04581; TYLER GL, 1983, ICARUS, V54, P160, DOI 10.1016/0019-1035(83)90191-4; Winter SMG, 2000, PLANET SPACE SCI, V48, P817, DOI 10.1016/S0032-0633(00)00009-X	26	60	60	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 5	2008	453	7196					739	744		10.1038/nature06999	http://dx.doi.org/10.1038/nature06999			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308UK	18528389	Green Published			2022-12-28	WOS:000256415300034
J	Allen, LA; Yager, JE; Funk, MJ; Levy, WC; Tulsky, JA; Bowers, MT; Dodson, GC; O'Connor, CM; Felker, GM				Allen, Larry A.; Yager, Jonathan E.; Funk, Michele Jonsson; Levy, Wayne C.; Tulsky, James A.; Bowers, Margaret T.; Dodson, Gwen C.; O'Connor, Christopher M.; Felker, G. Michael			Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-LIFE; CANCER; END; DEPRESSION; SURVIVAL; PREFERENCES; VALIDATION; PROGNOSIS; MORTALITY; DEATH	Context Patients with chronic heart failure have impaired long- term survival, but their own expectations regarding prognosis have not been well studied. Objectives To quantify expectations for survival in patients with heart failure, to compare patient expectations to model predictions, and to identify factors associated with discrepancies between patient- predicted and model- predicted prognosis. Design, Setting, and Participants Prospective face- to- face survey of patients from the single- center Duke Heart Failure Disease Management Program between July and December 2004, with follow- up through February 2008. Patient- predicted life expectancy was obtained using a visual analog scale. Model- predicted life expectancy was calculated using the Seattle Heart Failure Model. Actuarial- predicted life expectancy, based on age and sex alone, was calculated using life tables. Observed survival was determined from review of medical records and search of the Social Security Death Index. Main Outcome Measure Life expectancy ratio ( LER), defined as the ratio of patient-predicted to model- predicted life expectancy. Results The cohort consisted of 122 patients ( mean age, 62 years; 47% African American, 42% New York Heart Association [ NYHA] class III or IV). On average, patients overestimated their life expectancy relative to model- predicted life expectancy ( median patient-predicted life expectancy, 13.0 years; model- predicted expectancy, 10.0 years). Median LER was 1.4 ( interquartile range, 0.8- 2.5). Younger age, increased NYHA class, lower ejection fraction, and less depression were the most significant predictors of higher LER. During a median follow- up of 3.1 years, 29% of the original cohort died. There was no association between higher LER and improved survival ( adjusted hazard ratio for overestimated compared with concordant LER, 1.05; 95% confidence interval, 0.46- 2.42). Conclusions Ambulatory patients with heart failure tended to substantially overestimate their life expectancy compared with model- based predictions for survival. Because differences in perceived survival could affect decision making regarding advanced therapies and end- of- life planning, the causes of these discordant predictions warrant further study.	[Allen, Larry A.; Bowers, Margaret T.; Dodson, Gwen C.; O'Connor, Christopher M.; Felker, G. Michael] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27705 USA; [Tulsky, James A.] Duke Univ, Med Ctr, Ctr Palliat Care, Durham, NC 27705 USA; [Tulsky, James A.] Duke Univ, Med Ctr, Div Gen Internal Med, Durham, NC 27705 USA; [Yager, Jonathan E.] Cardiac Care Assoc, Fairfax, VA USA; [Funk, Michele Jonsson] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Levy, Wayne C.] Univ Washington, Div Cardiol, Seattle, WA 98195 USA	Duke University; Duke University; Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of Washington; University of Washington Seattle	Allen, LA (corresponding author), Duke Univ, Med Ctr, Duke Clin Res Inst, 2400 Pratt St,Room 0311,Terrace Level, Durham, NC 27705 USA.	larry_allen@post.harvard.edu	Felker, Michael/AAX-2288-2021; Levy, Wayne/AAI-8177-2021; Funk, Michele Jonsson/F-6885-2011; Allen, Larry/AAI-1323-2020	Levy, Wayne/0000-0003-1530-2194; Funk, Michele Jonsson/0000-0002-3756-7540; Felker, Gary/0000-0002-5931-1239	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL069749, K23HL072357] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL069749, K23 HL72357-01A, 2 T32HL069749-04] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aaronson KD, 1997, CIRCULATION, V95, P2660, DOI 10.1161/01.CIR.95.12.2660; *AM HEART ASS AFF, 1994, NOM CRIT DIAGN DIS H; CHAPPELL NL, 1975, OMEGA-J DEATH DYING, V6, P325, DOI 10.2190/5WKA-QB1M-VTGA-RRGF; DARDAS T, 2007, AM HEART ASS SCI SES; Davidson PM, 2007, J CARDIOVASC NURS, V22, P159, DOI 10.1097/01.JCN.0000267821.74084.72; EIDINGER RN, 1984, CANCER, V53, P2736, DOI 10.1002/1097-0142(19840615)53:12<2736::AID-CNCR2820531233>3.0.CO;2-W; Fonarow GC, 2005, JAMA-J AM MED ASSOC, V293, P572, DOI 10.1001/jama.293.5.572; Formiga F, 2004, QJM-INT J MED, V97, P803, DOI 10.1093/qjmed/hch135; Gigerenzer G, 2003, BMJ-BRIT MED J, V327, P741, DOI 10.1136/bmj.327.7417.741; Hauptman PJ, 2008, AM J MED, V121, P127, DOI 10.1016/j.amjmed.2007.08.035; Hauptman PJ, 2007, ARCH INTERN MED, V167, P1990, DOI 10.1001/archinte.167.18.1990; Hauptman PJ, 2005, ARCH INTERN MED, V165, P374, DOI 10.1001/archinte.165.4.374; Heart Failure Society Of America, 2006, J Card Fail, V12, pe1; Hershberger RE, 2003, J CARD FAIL, V9, P180, DOI 10.1054/jcaf.2003.24; Hunt SA, 2005, CIRCULATION, V112, pE154, DOI 10.1161/CIRCULATIONAHA.105.167586; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; Jiang W, 2007, AM HEART J, V154, P102, DOI 10.1016/j.ahj.2007.03.043; Joynt KE, 2004, J CARD FAIL, V10, P258, DOI 10.1016/j.cardfail.2003.09.008; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Koenig H, 1997, AM J PSYCHIAT, V154, P885; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Krumholz HM, 1998, CIRCULATION, V98, P648, DOI 10.1161/01.CIR.98.7.648; Lamont EB, 2001, ANN INTERN MED, V134, P1096, DOI 10.7326/0003-4819-134-12-200106190-00009; Lee DS, 2003, JAMA-J AM MED ASSOC, V290, P2581, DOI 10.1001/jama.290.19.2581; Lee SJ, 2001, JAMA-J AM MED ASSOC, V285, P1034, DOI 10.1001/jama.285.8.1034; Levy WC, 2006, CIRCULATION, V113, P1424, DOI 10.1161/CIRCULATIONAHA.105.584102; LEVY WC, 2006, SEATTLE HEART FAILUR; Lewis EF, 2001, J HEART LUNG TRANSPL, V20, P1016, DOI 10.1016/S1053-2498(01)00298-4; Li CY, 2007, J AM GERIATR SOC, V55, P596, DOI 10.1111/j.1532-5415.2007.01103.x; Lowe B, 2005, J PSYCHOSOM RES, V58, P163, DOI 10.1016/j.jpsychores.2004.09.006; Mack JW, 2007, J CLIN ONCOL, V25, P1357, DOI 10.1200/JCO.2006.08.3170; Maggioni AP, 2005, J CARD FAIL, V11, P91, DOI 10.1016/j.cardfail.2004.05.004; May HT, 2007, AM J CARDIOL, V100, P697, DOI 10.1016/j.amjcard.2007.03.083; McDowell I., 1996, MEASURING HLTH GUIDE; Mozaffarian D, 2007, CIRCULATION, V116, P392, DOI 10.1161/CIRCULATIONAHA.106.687103; Murray SA, 2002, BRIT MED J, V325, P929, DOI 10.1136/bmj.325.7370.929; Nieminen MS, 2005, EUR HEART J, V26, P384; Robinson TM, 2008, SUPPORT CARE CANCER, V16, P1049, DOI 10.1007/s00520-007-0372-2; ROSAMOND W, 2007, CIRCULATION, V155, pE172; Rosamond W, 2007, CIRCULATION, V115, pE69, DOI 10.1161/CIRCULATIONAHA.106.179918; Rose EA, 2001, NEW ENGL J MED, V345, P1435, DOI 10.1056/NEJMoa012175; Steinhauser KE, 2006, PALLIATIVE MED, V20, P745, DOI 10.1177/0269216306073112; Stewart S, 2001, EUR J HEART FAIL, V3, P315, DOI 10.1016/S1388-9842(00)00141-0; Sulmasy DP, 1998, ANN INTERN MED, V128, P621, DOI 10.7326/0003-4819-128-8-199804150-00002; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Weinfurt KP, 2003, CANCER-AM CANCER SOC, V98, P166, DOI 10.1002/cncr.11483; Whelan T, 2004, JAMA-J AM MED ASSOC, V292, P435, DOI 10.1001/jama.292.4.435; Yamokoski LM, 2007, J CARD FAIL, V13, P8, DOI 10.1016/j.cardfail.2006.10.002	50	182	185	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2008	299	21					2533	2542		10.1001/jama.299.21.2533	http://dx.doi.org/10.1001/jama.299.21.2533			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308AR	18523222	Green Accepted, Green Submitted			2022-12-28	WOS:000256361200025
J	Canonico, M; Plu-Bureau, G; Lowe, GDO; Scarabin, PY				Canonico, Marianne; Plu-Bureau, Genevieve; Lowe, Gordon D. O.; Scarabin, Pierre-Yves			Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ESTROGEN PLUS PROGESTIN; ACTIVATED PROTEIN-C; TRANSDERMAL ESTROGEN/PROGESTERONE REGIMENS; CONJUGATED EQUINE ESTROGEN; FACTOR-V-LEIDEN; ORAL-CONTRACEPTIVES; CARDIOVASCULAR-DISEASE; ACQUIRED-RESISTANCE; PULMONARY-EMBOLISM; RANDOMIZED-TRIALS	Objective To assess the risk of venous thromboembolism in women using hormone replacement therapy by study design, characteristics of the therapy and venous thromboembolism, and clinical background. Design Systematic review and meta-analysis. Data sources Medline. Studies reviewed Eight observational studies and nine randomised controlled trials. Inclusion criteria Studies on hormone replacement therapy that reported venous thromboembolism. Review measures Homogeneity between studies was analysed using X-2 and I-2 statistics. Overall risk of venous thromboembolism was assessed from a fixed effects or random effects model. Results Meta-analysis of observational studies showed that oral oestrogen but not transdermal oestrogen increased the risk of venous thromboembolism. Compared with non-users of oestrogen, the odds ratio of first time venous thromboembolism in current users of oral oestrogen was 2.5 (95% confidence interval 1.9 to 3.4) and in current users of transdermal oestrogen was 1.2 (0.9 to 1.7). Past users of oral oestrogen had a similar risk of venous thromboembolism to never users. The risk of venous thromboembolism in women using oral oestrogen was higher in the first year of treatment (4.0, 2.9 to5.7) compared with treatment for more than one year(2.1, 1.3 to 3.8; P<0.05). No noticeable difference in the risk of venous thromboembolism was observed between unopposed oral oestrogen (2.2, 1.6 to 3.0) and opposed oral oestrogen (2.6, 2.0 to 3.2). Results from nine randomised controlled trials confirmed the increased risk of venous thromboembolism among women using oral oestrogen (2.1, 1.4 to 3.1). The combination of oral oestrogen and thrombogenic mutations or obesity further enhanced the risk of venous thromboembolism, whereas transdermal oestrogen did not seem to confer additional risk in women at high risk of venous thromboembolism. Conclusion Oral oestrogen increases the risk of venous thromboembolism, especially during the first year of treatment. Transdermal oestrogen may be safer with respect to thrombotic risk. More data are required to investigate differences in risk across the wide variety of hormone regimens, especially the different types of progestogens.	[Canonico, Marianne; Plu-Bureau, Genevieve; Scarabin, Pierre-Yves] Univ Paris Sud, INSERM, Cardiovasc Epidemiol Sect, Unit 780, Villejuif, France; [Canonico, Marianne] Univ Paris Sud, IFR69, Villejuif, France; [Plu-Bureau, Genevieve; Scarabin, Pierre-Yves] Univ Paris 05, Paris, France; [Lowe, Gordon D. O.] Univ Glasgow, Glasgow Royal Infirm, Div Cardiovasc & Med Sci, Glasgow G31 2ER, Lanark, Scotland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite; University of Glasgow	Canonico, M (corresponding author), Univ Paris Sud, INSERM, Cardiovasc Epidemiol Sect, Unit 780, Villejuif, France.	canonico@vjf.inserm.fr	Canonico, Marianne/F-9138-2013; Beau Yon de Jonage - Canonico, Marianne/ABE-4279-2021	Canonico, Marianne/0000-0002-2843-8640; Beau Yon de Jonage - Canonico, Marianne/0000-0002-2843-8640				Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; [Anonymous], 1974, NEW ENGL J MED, V290, P15; Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; Bertina RM, 2001, EUR J OBSTET GYN R B, V95, P189, DOI 10.1016/S0301-2115(00)00488-7; CAINE YG, 1992, THROMB HAEMOSTASIS, V68, P392; Canonico M, 2006, J THROMB HAEMOST, V4, P1259, DOI 10.1111/j.1538-7836.2006.01933.x; Canonico M, 2007, CIRCULATION, V115, P840, DOI 10.1161/CIRCULATIONAHA.106.642280; Canonico M, 2006, MATURITAS, V54, P372, DOI 10.1016/j.maturitas.2006.04.019; Cherry N, 2002, LANCET, V360, P2001; CONARD J, 1983, THROMB HAEMOSTASIS, V49, P252; Curb JD, 2006, ARCH INTERN MED, V166, P772, DOI 10.1001/archinte.166.7.772; Cushman M, 2004, JAMA-J AM MED ASSOC, V292, P1573, DOI 10.1001/jama.292.13.1573; Daly E, 1996, LANCET, V348, P1027, DOI 10.1016/S0140-6736(96)24041-3; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; Douketis JD, 2005, J THROMB HAEMOST, V3, P943, DOI 10.1111/j.1538-7836.2005.01268.x; Emmerich J, 2001, THROMB HAEMOSTASIS, V86, P809; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; Gomes MPV, 2004, ARCH INTERN MED, V164, P1965, DOI 10.1001/archinte.164.18.1965; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Gutthann SP, 1997, BMJ-BRIT MED J, V314, P796, DOI 10.1136/bmj.314.7083.796; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P525, DOI 10.1016/0002-9378(79)90288-6; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Herrington DM, 2002, ARTERIOSCL THROM VAS, V22, P1012, DOI 10.1161/01.ATV.0000018301.91721.94; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hoibraaten E, 2000, THROMB HAEMOSTASIS, V84, P961; Hoibraaten E, 2001, BRIT J HAEMATOL, V115, P415, DOI 10.1046/j.1365-2141.2001.03111.x; Holbraaten E, 1999, THROMB HAEMOSTASIS, V82, P1218; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; Lowe GDO, 2004, J INTERN MED, V256, P361, DOI 10.1111/j.1365-2796.2004.01400.x; Lowe GDO, 2001, THROMB HAEMOSTASIS, V86, P550; Lowe GDO, 2007, WOMENS HEALTH, V3, P87, DOI 10.2217/17455057.3.1.87; Miller J, 2002, ANN INTERN MED, V136, P680, DOI 10.7326/0003-4819-136-9-200205070-00011; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Oger E, 2003, ARTERIOSCL THROM VAS, V23, P1671, DOI 10.1161/01.ATV.0000087141.05044.1F; Oger E, 1999, DRUG AGING, V14, P55, DOI 10.2165/00002512-199914010-00004; Oger E, 2000, THROMB HAEMOSTASIS, V83, P657; Oger E, 2007, WOMENS VASCULAR HLTH, P436; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; Post MS, 2003, ARTERIOSCL THROM VAS, V23, P1116, DOI 10.1161/01.ATV.0000074146.36646.C8; QUINN DA, 1992, JAMA-J AM MED ASSOC, V268, P1689, DOI 10.1001/jama.268.13.1689; Rexrode KM, 2007, CIRCULATION, V115, P820, DOI 10.1161/CIRCULATIONAHA.106.675405; Rosendaal FR, 2003, J THROMB HAEMOST, V1, P1371, DOI 10.1046/j.1538-7836.2003.00264.x; Rosendaal FR, 2002, BRIT J HAEMATOL, V116, P851, DOI 10.1046/j.0007-1048.2002.03356.x; Rosing J, 1999, LANCET, V354, P2036, DOI 10.1016/S0140-6736(99)06092-4; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rymer J, 2003, BRIT MED J, V326, P322, DOI 10.1136/bmj.326.7384.322; Scarabin PY, 2003, LANCET, V362, P428, DOI 10.1016/S0140-6736(03)14066-4; Scarabin PY, 1997, ARTERIOSCL THROM VAS, V17, P3071, DOI 10.1161/01.ATV.17.11.3071; Smith NL, 2006, ARTERIOSCL THROM VAS, V26, P2807, DOI 10.1161/01.ATV.0000245792.62517.3b; Smith NL, 2004, JAMA-J AM MED ASSOC, V292, P1581, DOI 10.1001/jama.292.13.1581; Straczek C, 2005, CIRCULATION, V112, P3495, DOI 10.1161/CIRCULATIONAHA.105.565556; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Utian WH, 2007, MENOPAUSE, V14, P168, DOI 10.1097/gme.0b013e31803167ab; Varas-Lorenzo C, 1998, AM J EPIDEMIOL, V147, P387; Vickers MR, 2007, BMJ-BRIT MED J, V335, P239, DOI 10.1136/bmj.39266.425069.AD; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; White H, 2004, J THROMB HAEMOST, V2, P2262, DOI 10.1111/j.1538-7836.2004.01075.x; Wu O, 2005, THROMB HAEMOSTASIS, V94, P17, DOI 10.1160/TH04-11-0759; Wu Olivia, 2005, Gend Med, V2 Suppl A, pS18, DOI 10.1016/S1550-8579(05)80061-0	66	352	366	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	2008	336	7655					1227	+		10.1136/bmj.39555.441944.BE	http://dx.doi.org/10.1136/bmj.39555.441944.BE			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311PS	18495631	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000256612700030
J	Sidi, S; Sanda, T; Kennedy, RD; Hagen, AT; Jette, CA; Hoffmans, R; Pascual, J; Imamura, S; Kishi, S; Amatruda, JF; Kanki, JP; Green, DR; D'Andrea, AA; Look, AT				Sidi, Samuel; Sanda, Takaomi; Kennedy, Richard D.; Hagen, Andreas T.; Jette, Cicely A.; Hoffmans, Raymond; Pascual, Jennifer; Imamura, Shintaro; Kishi, Shuji; Amatruda, James F.; Kanki, John P.; Green, Douglas R.; D'Andrea, Alan A.; Look, A. Thomas			Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3	CELL			English	Article							CYTOCHROME-C RELEASE; CELL-DEATH; TRANSGENIC ZEBRAFISH; MITOTIC CATASTROPHE; CHECKPOINT KINASES; GENOTOXIC STRESS; GLIOMA-CELLS; S-PHASE; RADIATION; ACTIVATION	Evasion of DNA damage-induced cell death, via mutation of the p53 tumor suppressor or overexpression of prosurvival Bcl-2 family proteins, is a key step toward malignant transformation and therapeutic resistance. We report that depletion or acute inhibition of checkpoint kinase 1 (Chk1) is sufficient to restore gamma-radiation-induced apoptosis in p53 mutant zebrafish embryos. Surprisingly, caspase-3 is not activated prior to DNA fragmentation, in contrast to classical intrinsic or extrinsic apoptosis. Rather, an alternative apoptotic program is engaged that cell autonomously requires atm (ataxia telangiectasia mutated), atr (ATM and Rad3-related) and caspase-2, and is not affected by p53 loss or overexpression of bcl-2/xl. Similarly, Chk1 inhibitor-treated human tumor cells hyperactivate ATM, ATR, and caspase-2 after gamma-radiation and trigger a caspase-2-dependent apoptotic program that bypasses p53 deficiency and excess Bcl-2. The evolutionarily conserved "Chk1-suppressed'' pathway defines a novel apoptotic process, whose responsiveness to Chk1 inhibitors and insensitivity to p53 and BCL2 alterations have important implications for cancer therapy.	[Sidi, Samuel; Sanda, Takaomi; Hagen, Andreas T.; Jette, Cicely A.; Hoffmans, Raymond; Pascual, Jennifer; Kanki, John P.; Look, A. Thomas] Harvard Univ, Sch Med, Dept Pediat Oncol, Boston, MA 02115 USA; [Kennedy, Richard D.; D'Andrea, Alan A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol,Div Genom Stabil & DNA Repair, Boston, MA 02115 USA; [Look, A. Thomas] Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat,Div Hematol Oncol, Boston, MA 02115 USA; [Imamura, Shintaro; Kishi, Shuji] Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst, Boston, MA 02114 USA; [Amatruda, James F.] Univ Texas SW Med Ctr Dallas, Dept Pediat Mol Biol & Internal Med, Dallas, TX 75390 USA; [Green, Douglas R.] St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Schepens Eye Research Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; St Jude Children's Research Hospital	Look, AT (corresponding author), Harvard Univ, Sch Med, Dept Pediat Oncol, Boston, MA 02115 USA.	thomas_look@dfci.harvard.edu	Green, Douglas R/N-8083-2018; Kennedy, Richard/J-3489-2012	Green, Douglas R/0000-0002-7332-1417; Kennedy, Richard/0000-0003-4737-6163	NHLBI NIH HHS [HL-88664, R01 HL088664, R01 HL088664-02] Funding Source: Medline; NIAID NIH HHS [R01 AI047891, AI47891] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047891] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Afshar G, 2006, CANCER RES, V66, P4223, DOI 10.1158/0008-5472.CAN-05-1283; Arienti KL, 2005, J MED CHEM, V48, P1873, DOI 10.1021/jm0495935; BAPTISTEOKOH N, 2008, CELL CYCLE      0219, V7; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Bernassola F, 2005, ONCOGENE, V24, P6982, DOI 10.1038/sj.onc.1208843; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045; Cuadrado M, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-7; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Eimon PM, 2006, CELL DEATH DIFFER, V13, P1619, DOI 10.1038/sj.cdd.4402015; Fogarty P, 1997, CURR BIOL, V7, P418, DOI 10.1016/S0960-9822(06)00189-8; Frenkel J, 1999, ONCOGENE, V18, P2901, DOI 10.1038/sj.onc.1202518; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gong JG, 1999, NATURE, V399, P806; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hong WY, 2004, CANCER RES, V64, P7256, DOI 10.1158/0008-5472.CAN-04-0931; Hsu K, 2004, BLOOD, V104, P1291, DOI 10.1182/blood-2003-09-3105; Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kawabe T, 2004, MOL CANCER THER, V3, P513; Kohn EA, 2003, CANCER RES, V63, P31; Kolesnick R, 2003, ONCOGENE, V22, P5897, DOI 10.1038/sj.onc.1206702; Kratz E, 2006, CELL DEATH DIFFER, V13, P1631, DOI 10.1038/sj.cdd.4402016; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Langenau DM, 2005, BLOOD, V105, P3278, DOI 10.1182/blood-2004-08-3073; Langenau DM, 2003, SCIENCE, V299, P887, DOI 10.1126/science.1080280; Langheinrich U, 2002, CURR BIOL, V12, P2023, DOI 10.1016/S0960-9822(02)01319-2; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Liu QH, 2000, GENE DEV, V14, P1448; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Nutt LK, 2005, CELL, V123, P89, DOI 10.1016/j.cell.2005.07.032; Pyati UJ, 2007, SEMIN CANCER BIOL, V17, P154, DOI 10.1016/j.semcancer.2006.11.007; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Rentzsch F, 2003, GENE, V323, P19, DOI 10.1016/j.gene.2003.10.002; Rodriguez R, 2006, MOL BIOL CELL, V17, P402, DOI 10.1091/mbc.E05-07-0594; Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007; Shin S, 2005, EMBO J, V24, P3532, DOI 10.1038/sj.emboj.7600827; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tse AN, 2007, CLIN CANCER RES, V13, P1955, DOI 10.1158/1078-0432.CCR-06-2793; Tu S, 2006, NAT CELL BIOL, V8, P72, DOI 10.1038/ncb1340; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wichmann A, 2006, P NATL ACAD SCI USA, V103, P9952, DOI 10.1073/pnas.0510528103; Xiao Z, 2005, ONCOGENE, V24, P1403, DOI 10.1038/sj.onc.1208309; Yount GL, 2001, ONCOGENE, V20, P2826, DOI 10.1038/sj.onc.1204393; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhivotovsky B, 2005, BIOCHEM BIOPH RES CO, V331, P859, DOI 10.1016/j.bbrc.2005.03.191; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296	60	258	265	2	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	2008	133	5					864	877		10.1016/j.cell.2008.03.037	http://dx.doi.org/10.1016/j.cell.2008.03.037			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510930	Bronze, Green Accepted			2022-12-28	WOS:000256274500018
J	Milstein, JM				Milstein, Jay M.			Introducing spirituality in medical care - Transition from hopelessness to wholeness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DEATH; HEALTH		Univ Calif Davis, Div Neonatol, Dept Pediat, Sacramento, CA 95817 USA	University of California System; University of California Davis	Milstein, JM (corresponding author), Univ Calif Davis, Div Neonatol, Dept Pediat, 2516 Stockton Blvd, Sacramento, CA 95817 USA.	jmmilstein@ucdavis.edu						Croog SH, 2001, ALZ DIS ASSOC DIS, V15, P201, DOI 10.1097/00002093-200110000-00006; Enyert G, 1999, Am J Hosp Palliat Care, V16, P455, DOI 10.1177/104990919901600207; Frank Arthur W, 1995, WOUNDED STORYTELLER, P53; Handzo G, 2004, SOUTH MED J, V97, P1242, DOI 10.1097/01.SMJ.0000146490.49723.AE; Lang A, 2004, INT J NURS STUD, V41, P869, DOI 10.1016/j.ijnurstu.2004.03.013; Lang A, 2003, DEATH STUD, V27, P851, DOI 10.1080/716100345; Milstein Jay, 2005, J Perinatol, V25, P563, DOI 10.1038/sj.jp.7211358; Milstein Jay M, 2007, Am J Hosp Palliat Care, V24, P343, DOI 10.1177/1049909107305645; Milstein Jay M, 2003, J Perinatol, V23, P333, DOI 10.1038/sj.jp.7210903; Park CL, 2007, J BEHAV MED, V30, P319, DOI 10.1007/s10865-007-9111-x; Puchalski CM, 2004, CLIN GERIATR MED, V20, P689, DOI 10.1016/j.cger.2004.07.004; Raingruber B, 2007, J HOLIST NURS, V25, P39, DOI 10.1177/0898010106289859; Rajajee S, 2007, INDIAN J PEDIATR, V74, P837, DOI 10.1007/s12098-007-0149-0; RAO N, 1986, ARCH PHYS MED REHAB, V67, P759, DOI 10.1016/0003-9993(86)90011-0; Schaap AHP, 1997, EUR J OBSTET GYN R B, V75, P161, DOI 10.1016/S0301-2115(97)00127-9	15	26	26	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2008	299	20					2440	2441		10.1001/jama.299.20.2440	http://dx.doi.org/10.1001/jama.299.20.2440			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305BD	18505954				2022-12-28	WOS:000256151900029
J	Chowdhury, TA; Hitman, GA				Chowdhury, Tahseen A.; Hitman, Graham A.			Diabetes care for South Asian patients: a special case	LANCET			English	Editorial Material							ETHNIC-GROUPS; EUROPEANS		[Chowdhury, Tahseen A.; Hitman, Graham A.] Barts & London NHS Trust, Dept Diabet & Metab, London E1 1BB, England; [Chowdhury, Tahseen A.; Hitman, Graham A.] Barts & London Queen Marys Sch Med & Dent, London E1 1BB, England	Barts Health NHS Trust; University of London; Queen Mary University London	Chowdhury, TA (corresponding author), Barts & London NHS Trust, Dept Diabet & Metab, London E1 1BB, England.	Tahseen.Chowdhury@bartsandthelondon.nhs.uk						Bellary S, 2008, LANCET, V371, P1769, DOI 10.1016/S0140-6736(08)60764-3; BURDEN AC, 1992, DIABETIC MED, V9, P641, DOI 10.1111/j.1464-5491.1992.tb01860.x; Campbell S, 2007, NEW ENGL J MED, V357, P181, DOI 10.1056/NEJMsr065990; Davies MJ, 2008, BMJ-BRIT MED J, V336, P491, DOI 10.1136/bmj.39474.922025.BE; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; Greenhalgh T, 1998, BRIT MED J, V316, P978, DOI 10.1136/bmj.316.7136.978; *INF CTR, 2006, HLTH SURV ENGL 2004; Khan H, 2008, DIABETIC MED, V25, P1108, DOI 10.1111/j.1464-5491.2008.02538.x; Mather HM, 1998, DIABETIC MED, V15, P53, DOI 10.1002/(SICI)1096-9136(199801)15:1<53::AID-DIA521>3.0.CO;2-V; Riste L, 2001, DIABETES CARE, V24, P1377, DOI 10.2337/diacare.24.8.1377; Tuomilehto J, 2003, DIABETES CARE, V26, P1770	11	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	2008	371	9626					1728	1730		10.1016/S0140-6736(08)60738-2	http://dx.doi.org/10.1016/S0140-6736(08)60738-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304IO	18502280				2022-12-28	WOS:000256103400006
J	Hawkes, N				Hawkes, Nigel			Primary concern	BRITISH MEDICAL JOURNAL			English	Editorial Material												nigel.hawkes@thetimes.co.uk						*DEP HLTH, 2008, LORD DARZ SETS TOUGH; *DEP HLTH, OUR NHS OUR FUT NHS; *DEP HLTH, PAT PUBL INV DEV PRI; Department of Health, 2008, CHANG BETT GUID UND; *DEV PAT PARTN, 2006, NHS US SIL MAJ; HICKLING JA, 2008, BMJ; *LOND LMCS, 2008, PAT SURV; NHS Confederation, 2008, ID DARZ POL; OLSEY R, 2008, CAMDEN NEW J    0410, P2; THORLBY R, 2008, SHOULD PRIMARY CARE	10	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2008	336	7654					1158	+		10.1136/bmj.39581.507627.AD	http://dx.doi.org/10.1136/bmj.39581.507627.AD			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308WJ	18497410	Green Published			2022-12-28	WOS:000256420900034
J	Benhar, M; Forrester, MT; Hess, DT; Stamler, JS				Benhar, Moran; Forrester, Michael T.; Hess, Douglas T.; Stamler, Jonathan S.			Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins	SCIENCE			English	Article							NITRIC-OXIDE SYNTHASE; S-NITROSYLATION; ENDOTHELIAL-CELLS; REDUCTASE; DENITROSATION; NITROSOTHIOLS; NITROSATION; INHIBITION; APOPTOSIS; ENZYME	Nitric oxide acts substantially in cellular signal transduction through stimulus- coupled S- nitrosylation of cysteine residues. The mechanisms that might subserve protein denitrosylation in cellular signaling remain uncharacterized. Our search for denitrosylase activities focused on caspase- 3, an exemplar of stimulus- dependent denitrosylation, and identified thioredoxin and thioredoxin reductase in a biochemical screen. In resting human lymphocytes, thioredoxin- 1 actively denitrosylated cytosolic caspase- 3 and thereby maintained a low steady- state amount of S- nitrosylation. Upon stimulation of Fas, thioredoxin- 2 mediated denitrosylation of mitochondria- associated caspase- 3, a process required for caspase- 3 activation, and promoted apoptosis. Inhibition of thioredoxin- thioredoxin reductases enabled identification of additional substrates subject to endogenous S- nitrosylation. Thus, specific enzymatic mechanisms may regulate basal and stimulus- induced denitrosylation in mammalian cells.	[Benhar, Moran; Hess, Douglas T.; Stamler, Jonathan S.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Forrester, Michael T.; Stamler, Jonathan S.] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Duke University	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.	staml001@mc.duke.edu	Benhar, Moran/AAV-5764-2020	Benhar, Moran/0000-0002-7094-3456; Stamler, Jonathan/0000-0002-6866-1572	NHLBI NIH HHS [P01 HL075443-050003, R01 HL059130, R01 HL059130-11, P01 HL075443] Funding Source: Medline; NIEHS NIH HHS [U19 ES012496, U19 ES012496-05] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL075443, R01HL059130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U19ES012496] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; ARNER ESJ, 1995, J BIOL CHEM, V270, P3479, DOI 10.1074/jbc.270.8.3479; Erwin PA, 2005, J BIOL CHEM, V280, P19888, DOI 10.1074/jbc.M413058200; Forrester MT, 2007, J BIOL CHEM, V282, P13977, DOI 10.1074/jbc.M609684200; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Hoffmann J, 2001, J BIOL CHEM, V276, P41383, DOI 10.1074/jbc.M107566200; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Jeong W, 2004, J BIOL CHEM, V279, P3142, DOI 10.1074/jbc.M307932200; Kim JE, 2004, J BIOL CHEM, V279, P9758, DOI 10.1074/jbc.M312722200; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Mitchell DA, 2007, P NATL ACAD SCI USA, V104, P11609, DOI 10.1073/pnas.0704898104; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; Ravi K, 2004, P NATL ACAD SCI USA, V101, P2619, DOI 10.1073/pnas.0300464101; Rigobello MP, 2004, J INORG BIOCHEM, V98, P1634, DOI 10.1016/j.jinorgbio.2004.04.020; Sengupta R, 2007, BIOCHEMISTRY-US, V46, P8472, DOI 10.1021/bi700449x; Sliskovic I, 2005, J BIOL CHEM, V280, P8733, DOI 10.1074/jbc.M408080200; Stoyanovsky DA, 2005, J AM CHEM SOC, V127, P15815, DOI 10.1021/ja0529135; Verdoucq L, 1999, J BIOL CHEM, V274, P19714, DOI 10.1074/jbc.274.28.19714	26	430	437	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2008	320	5879					1050	1054		10.1126/science.1158265	http://dx.doi.org/10.1126/science.1158265			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18497292	Green Accepted			2022-12-28	WOS:000256059800038
J	Christakis, NA; Fowler, JH				Christakis, Nicholas A.; Fowler, James H.			The collective dynamics of smoking in a large social network	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SELF-REPORTED SMOKING; DIFFUSION; CESSATION; TRIALS	BACKGROUND The prevalence of smoking has decreased substantially in the United States over the past 30 years. We examined the extent of the person-to-person spread of smoking behavior and the extent to which groups of widely connected people quit together. METHODS We studied a densely interconnected social network of 12,067 people assessed repeatedly from 1971 to 2003 as part of the Framingham Heart Study. We used network analytic methods and longitudinal statistical models. RESULTS Discernible clusters of smokers and nonsmokers were present in the network, and the clusters extended to three degrees of separation. Despite the decrease in smoking in the overall population, the size of the clusters of smokers remained the same across time, suggesting that whole groups of people were quitting in concert. Smokers were also progressively found in the periphery of the social network. Smoking cessation by a spouse decreased a person's chances of smoking by 67% (95% confidence interval [CI], 59 to 73). Smoking cessation by a sibling decreased the chances by 25% (95% CI, 14 to 35). Smoking cessation by a friend decreased the chances by 36% (95% CI, 12 to 55). Among persons working in small firms, smoking cessation by a coworker decreased the chances by 34% (95% CI, 5 to 56). Friends with more education influenced one another more than those with less education. These effects were not seen among neighbors in the immediate geographic area. CONCLUSIONS Network phenomena appear to be relevant to smoking cessation. Smoking behavior spreads through close and distant social ties, groups of interconnected people stop smoking in concert, and smokers are increasingly marginalized socially. These findings have implications for clinical and public health interventions to reduce and prevent smoking.	[Christakis, Nicholas A.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Christakis, Nicholas A.] Mt Auburn Hosp, Dept Med, Cambridge, MA USA; [Christakis, Nicholas A.] Harvard Univ, Dept Sociol, Cambridge, MA 02138 USA; [Fowler, James H.] Univ Calif San Diego, Dept Polit Sci, San Diego, CA 92103 USA	Harvard University; Harvard Medical School; Harvard University; Mount Auburn Hospital; Harvard University; University of California System; University of California San Diego	Christakis, NA (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	christakis@hcp.med.harvard.edu	Christakis, Nicholas A/C-3205-2009; Fowler, James H/C-2750-2008; Christakis, Nicholas A/B-6690-2008	Fowler, James H/0000-0001-7795-1638; 	NHLBI NIH HHS [N01-HC-25195, N01HC25195] Funding Source: Medline; NIA NIH HHS [R01 AG024448, R-01 AG24448, P01 AG031093, R01 AG024448-01, P-01 AG031093, P01 AG031093-01] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG024448, P01AG031093] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beck N, 2001, ANNU REV POLIT SCI, V4, P271, DOI 10.1146/annurev.polisci.4.1.271; BONACICH P, 1972, J MATH SOCIOL, V2, P113, DOI 10.1080/0022250X.1972.9989806; Bruckner H, 2005, J ADOLESCENT HEALTH, V36, P271, DOI 10.1016/j.jadohealth.2005.01.005; Carrington PJ, 2005, MODELS METHODS SOCIA, V28; Centola D, 2007, PHYSICA A, V374, P449, DOI 10.1016/j.physa.2006.06.018; Chen PH, 2001, ADDICT BEHAV, V26, P517, DOI 10.1016/S0306-4603(00)00142-8; Christakis NA, 2006, NEW ENGL J MED, V354, P719, DOI 10.1056/NEJMsa050196; Christakis NA, 2004, BRIT MED J, V329, P184, DOI 10.1136/bmj.329.7459.184; Christakis NA, 2007, NEW ENGL J MED, V357, P370, DOI 10.1056/NEJMsa066082; Crane D, 1999, ANN AM ACAD POLIT SS, V566, P13, DOI 10.1177/0002716299566001002; CUTLER DM, 2007, W13477 NBER; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; *DEP HHS, 1989, DHHS PUBL CDC; FEINLEIB M, 1975, PREV MED, V4, P518, DOI 10.1016/0091-7435(75)90037-7; Fowler J. H., 2005, SOCIAL LOGIC POLITIC; KAMADA T, 1989, INFORM PROCESS LETT, V31, P7, DOI 10.1016/0020-0190(89)90102-6; King G, 2000, AM J POLIT SCI, V44, P347, DOI 10.2307/2669316; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Malchodi CS, 2003, OBSTET GYNECOL, V101, P504, DOI 10.1016/S0029-7844(02)03070-3; MCKNIGHT AJ, 1986, ACCIDENT ANAL PREV, V18, P339, DOI 10.1016/0001-4575(86)90047-3; McPherson M, 2001, ANNU REV SOCIOL, V27, P415, DOI 10.1146/annurev.soc.27.1.415; Moody J, 2005, AM J SOCIOL, V110, P1206, DOI 10.1086/421509; *NAT CTR HLTH STAT, FASTST A Z; National Center for Health Statistics, 2003, HLTH US 2003 CHARTB; Newman MEJ, 2003, SIAM REV, V45, P167, DOI 10.1137/S003614450342480; Pampel FC, 2005, SOC SCI RES, V34, P117, DOI 10.1016/j.ssresearch.2003.12.003; PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI 10.2105/AJPH.84.7.1086; Powell LM, 2005, J HEALTH ECON, V24, P950, DOI 10.1016/j.jhealeco.2005.02.002; Rogers E., 2003, DIFFUSION INNOVATION, VFifth; ROSEN M, 1989, INT J EPIDEMIOL, V18, P993, DOI 10.1093/ije/18.4.993; Schildcrout JS, 2005, BIOSTATISTICS, V6, P633, DOI 10.1093/biostatistics/kxi033; Strauss RS, 2003, ARCH PEDIAT ADOL MED, V157, P746, DOI 10.1001/archpedi.157.8.746; SZABO G, NETWORK EFFECTS SERV; Treiman D. J., 1977, OCCUPATIONAL PRESTIG; Vartiainen E, 2002, J EPIDEMIOL COMMUN H, V56, P167, DOI 10.1136/jech.56.3.167; Wing RR, 1999, J CONSULT CLIN PSYCH, V67, P132, DOI 10.1037/0022-006X.67.1.132; 2005, MMWR MORB MORTAL WKL, V55, P1121	38	1395	1410	6	278	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2008	358	21					2249	2258		10.1056/NEJMsa0706154	http://dx.doi.org/10.1056/NEJMsa0706154			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	303EK	18499567	Bronze, Green Accepted, Green Published, Green Submitted			2022-12-28	WOS:000256023600007
J	Stone, GW; Witzenbichler, B; Guagliumi, G; Peruga, JZ; Brodie, BR; Dudek, D; Kornowski, R; Hartmann, F; Gersh, BJ; Pocock, SJ; Dangas, G; Wong, SC; Kirtane, AJ; Parise, H; Mehran, R				Stone, Gregg W.; Witzenbichler, Bernhard; Guagliumi, Giulio; Peruga, Jan Z.; Brodie, Bruce R.; Dudek, Dariusz; Kornowski, Ran; Hartmann, Franz; Gersh, Bernard J.; Pocock, Stuart J.; Dangas, George; Wong, S. Chiu; Kirtane, Ajay J.; Parise, Helen; Mehran, Roxana		HORIZONS AMI Trial Investigators	Bivalirudin during primary PCI in acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE CORONARY SYNDROMES; GLYCOPROTEIN IIB/IIIA BLOCKADE; RANDOMIZED CONTROLLED-TRIAL; CLINICAL-OUTCOMES; ACUITY TRIAL; BLOOD-TRANSFUSION; INTERVENTION; ABCIXIMAB; THERAPY; IMPACT	Background Treatment with the direct thrombin inhibitor bivalirudin, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in similar suppression of ischemia while reducing hemorrhagic complications in patients with stable angina and non-ST-segment elevation acute coronary syndromes who are undergoing percutaneous coronary intervention (PCI). The safety and efficacy of bivalirudin in high-risk patients are unknown. Methods We randomly assigned 3602 patients with ST-segment elevation myocardial infarction who presented within 12 hours after the onset of symptoms and who were undergoing primary PCI to treatment with heparin plus a glycoprotein IIb/IIIa inhibitor or to treatment with bivalirudin alone. The two primary end points of the study were major bleeding and combined adverse clinical events, defined as the combination of major bleeding or major adverse cardiovascular events, including death, reinfarction, target-vessel revascularization for ischemia, and stroke (hereinafter referred to as net adverse clinical events) within 30 days. Results Anticoagulation with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, resulted in a reduced 30-day rate of net adverse clinical events (9.2% vs. 12.1%; relative risk, 0.76; 95% confidence interval [CI] 0.63 to 0.92; P = 0.005), owing to a lower rate of major bleeding (4.9% vs. 8.3%; relative risk, 0.60; 95% CI, 0.46 to 0.77; P< 0.001). There was an increased risk of acute stent thrombosis within 24 hours in the bivalirudin group, but no significant increase was present by 30 days. Treatment with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, resulted in significantly lower 30-day rates of death from cardiac causes (1.8% vs. 2.9%; relative risk, 0.62; 95% CI, 0.40 to 0.95; P = 0.03) and death from all causes (2.1% vs. 3.1%; relative risk, 0.66; 95% CI, 0.44 to 1.00; P = 0.047). Conclusions In patients with ST-segment elevation myocardial infarction who are undergoing primary PCI, anticoagulation with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in significantly reduced 30-day rates of major bleeding and net adverse clinical events.	[Stone, Gregg W.; Dangas, George; Kirtane, Ajay J.; Parise, Helen; Mehran, Roxana] Columbia Univ, Med Ctr, Cardiovasc Res Fdn, New York, NY 10022 USA; [Witzenbichler, Bernhard] Charite Univ Med Berlin, Berlin, Germany; [Guagliumi, Giulio] Osped Riuniti Bergamo, I-24100 Bergamo, Italy; [Peruga, Jan Z.] Silesian Ctr Heart Dis, Lodz, Poland; [Brodie, Bruce R.] LeBauer Cardiovasc Res Fdn, Greensboro, NC USA; [Brodie, Bruce R.] Moses Cone Hosp, Greensboro, NC USA; [Dudek, Dariusz] Jagiellonian Univ, Krakow, Poland; [Kornowski, Ran] Rabin Med Ctr, Petah Tiqwa, Israel; [Hartmann, Franz] Univ Klinikum Schleswig Holstein, D-23538 Lubeck, Germany; [Gersh, Bernard J.] Mayo Clin, Rochester, MN USA; [Pocock, Stuart J.] London Sch Hyg & Trop Med, London WC1, England; [Wong, S. Chiu] New York Presbyterian Hosp, Weill Cornell Med Ctr, New York, NY USA	Cardiovascular Research Foundation (CRF); Columbia University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ospedali Riuniti di Bergamo; Silesian Center for Heart Diseases; LeBauer-Brodie Center for Cardiovascular Research & Education; Moses Cone Memorial Hospital; Jagiellonian University; Rabin Medical Center; University of Kiel; Schleswig Holstein University Hospital; Mayo Clinic; University of London; London School of Hygiene & Tropical Medicine; Cornell University; NewYork-Presbyterian Hospital	Stone, GW (corresponding author), Columbia Univ, Med Ctr, Cardiovasc Res Fdn, 111 E 59th St,11th Fl, New York, NY 10022 USA.	gs2184@columbia.edu	Mehran, Roxana/ABF-4160-2021; Suryapranata, H./H-8095-2014; Guagliumi, Giulio/K-8006-2016; Witzenbichler, Bernhard/ABC-2525-2021	Witzenbichler, Bernhard/0000-0001-9322-1926; Banning, Adrian/0000-0002-2842-7861; Parise, Helen/0000-0001-7761-4973				Armstrong PW, 2007, JAMA-J AM MED ASSOC, V297, P43; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Cardina C, 2005, REF USER SERV Q, V45, P80; Cutlip DE, 2007, CIRCULATION, V115, P2344, DOI 10.1161/CIRCULATIONAHA.106.685313; Dauerman HL, 2007, CORONARY ARTERY DIS, V18, P141, DOI 10.1097/MCA.0b013e328010a4b2; De Luca G, 2005, JAMA-J AM MED ASSOC, V293, P1759, DOI 10.1001/jama.293.14.1759; De Luca G, 2007, INT J CARDIOL, V119, P306, DOI 10.1016/j.ijcard.2006.07.143; De Luca G, 2007, AM HEART J, V153, P343, DOI 10.1016/j.ahj.2006.11.020; Eikelboom JW, 2006, CIRCULATION, V114, P774, DOI 10.1161/CIRCULATIONAHA.106.612812; Feit F, 2007, AM J CARDIOL, V100, P1364, DOI 10.1016/j.amjcard.2007.06.026; Fox KAA, 2007, JAMA-J AM MED ASSOC, V297, P1892, DOI 10.1001/jama.297.17.1892; Greenbaum AB, 2007, AM HEART J, V154, P702, DOI 10.1016/j.ahj.2007.06.001; Gurbel PA, 2005, CIRCULATION, V111, P1153, DOI 10.1161/01.CIR.0000157138.02645.11; Hochman JS, 2007, JAMA-J AM MED ASSOC, V297, P1657; Kandzari DE, 2004, AM HEART J, V147, P457, DOI 10.1016/j.ahj.2003.08.011; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Kereiakes DJ, 2000, AM HEART J, V140, P74, DOI 10.1067/mhj.2000.106615; Kinnaird TD, 2003, AM J CARDIOL, V92, P930, DOI 10.1016/S0002-9149(03)00972-X; Lincoff AM, 2006, JAMA-J AM MED ASSOC, V296, P46; Lincoff AM, 2004, JAMA-J AM MED ASSOC, V292, P696, DOI 10.1001/jama.292.6.696; Lincoff AM, 2003, JAMA-J AM MED ASSOC, V289, P853, DOI 10.1001/jama.289.7.853; LINCOFF AM, 2003, JAMA-J AM MED ASSOC, V289, P1638; Manoukian SV, 2007, J AM COLL CARDIOL, V49, P1362, DOI 10.1016/j.jacc.2007.02.027; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; Nikolsky E, 2007, AM J CARDIOL, V99, P1055, DOI 10.1016/j.amjcard.2006.11.066; Rao SV, 2004, JAMA-J AM MED ASSOC, V292, P1555, DOI 10.1001/jama.292.13.1555; Ross AM, 2005, J AM COLL CARDIOL, V45, P1775, DOI 10.1016/j.jacc.2005.02.061; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; Stone GW, 2007, JAMA-J AM MED ASSOC, V298, P2497, DOI 10.1001/jama.298.21.2497; Stone GW, 2006, NEW ENGL J MED, V355, P2203, DOI 10.1056/NEJMoa062437; Stone GW, 2002, NEW ENGL J MED, V346, P957, DOI 10.1056/NEJMoa013404; Stone GW, 2004, AM HEART J, V148, P764, DOI 10.1016/j.ahj.2004.04.036; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482	33	1418	1477	1	56	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2008	358	21					2218	2230		10.1056/NEJMoa0708191	http://dx.doi.org/10.1056/NEJMoa0708191			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303EK	18499566	Green Accepted			2022-12-28	WOS:000256023600004
J	Ying, QL; Wray, J; Nichols, J; Batlle-Morera, L; Doble, B; Woodgett, J; Cohen, P; Smith, A				Ying, Qi-Long; Wray, Jason; Nichols, Jennifer; Batlle-Morera, Laura; Doble, Bradley; Woodgett, James; Cohen, Philip; Smith, Austin			The ground state of embryonic stem cell self-renewal	NATURE			English	Article							PLURIPOTENCY; ACTIVATION; DIFFERENTIATION; TERATOCARCINOMA; MAINTENANCE; EXPRESSION; MECHANISM; SURVIVAL; RECEPTOR; GENE	In the three decades since pluripotent mouse embryonic stem (ES) cells were first described(1,2) they have been derived and maintained by using various empirical combinations of feeder cells, conditioned media, cytokines, growth factors, hormones, fetal calf serum, and serum extracts(1-7). Consequently ES-cell self-renewal is generally considered to be dependent on multifactorial stimulation of dedicated transcriptional circuitries, pre-eminent among which is the activation of STAT3 by cytokines (ref. 8). Here we show, however, that extrinsic stimuli are dispensable for the derivation, propagation and pluripotency of ES cells. Self-renewal is enabled by the elimination of differentiation-inducing signalling from mitogen-activated protein kinase. Additional inhibition of glycogen synthase kinase 3 consolidates biosynthetic capacity and suppresses residual differentiation. Complete bypass of cytokine signalling is confirmed by isolating ES cells genetically devoid of STAT3. These findings reveal that ES cells have an innate programme for self-replication that does not require extrinsic instruction. This property may account for their latent tumorigenicity. The delineation of minimal requirements for self-renewal now provides a defined platform for the precise description and dissection of the pluripotent state.	[Ying, Qi-Long] Univ So Calif, Ctr Stem Cell & Regenerat Med, Dept Cell & Neurobiol, Keck Sch Med, Los Angeles, CA 90033 USA; [Wray, Jason; Nichols, Jennifer; Batlle-Morera, Laura; Smith, Austin] Univ Cambridge, Wellcome Trust Ctr Stem Cell Res, Cambridge CB2 1QR, England; [Doble, Bradley] McMaster Univ, Mcmaster Stem Cell & Canc Res Inst, Hamilton, ON L8N 3Z5, Canada; [Woodgett, James] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; [Cohen, Philip] Univ Dundee, Div Signal Transduct Therapy, Dundee DD1 5EH, Scotland; [Cohen, Philip] Univ Dundee, MRC Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland	University of Southern California; University of Cambridge; McMaster University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Dundee; University of Dundee	Ying, QL (corresponding author), Univ So Calif, Ctr Stem Cell & Regenerat Med, Dept Cell & Neurobiol, Keck Sch Med, 1501 San Pablo St,ZNI 529, Los Angeles, CA 90033 USA.	qying@keck.usc.edu; ags39@cscr.cam.ac.uk	Woodgett, Jim/F-1087-2010; Doble, Brad/L-7551-2016; Doble, Bradley/V-7848-2019	Woodgett, Jim/0000-0003-3731-5797; Doble, Brad/0000-0002-0260-2983; Doble, Bradley/0000-0002-0260-2983; Smith, Austin/0000-0002-3029-4682; BATLLE MORERA, LAURA/0000-0002-6924-9002; Nichols, Jennifer/0000-0002-8650-1388	Biotechnology and Biological Sciences Research Council [G15381/2] Funding Source: Medline; CIHR [12858, 12043] Funding Source: Medline; Medical Research Council [MC_U127084348, G9806702] Funding Source: Medline; MRC [MC_U127084348, G9806702] Funding Source: UKRI; Medical Research Council [G0300723B] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); CIHR(Canadian Institutes of Health Research (CIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Arias AM, 2006, NAT REV GENET, V7, P34, DOI 10.1038/nrg1750; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Buehr M, 2003, PHILOS T R SOC B, V358, P1397, DOI 10.1098/rstb.2003.1327; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chen SB, 2006, P NATL ACAD SCI USA, V103, P17266, DOI 10.1073/pnas.0608156103; Colman-Lerner A, 2005, NATURE, V437, P699, DOI 10.1038/nature03998; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Doble BW, 2007, DEV CELL, V12, P957, DOI 10.1016/j.devcel.2007.04.001; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Hao J, 2006, DEV BIOL, V290, P81, DOI 10.1016/j.ydbio.2005.11.011; Kunath T, 2007, DEVELOPMENT, V134, P2895, DOI 10.1242/dev.02880; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; Murray JT, 2004, BIOCHEM J, V384, P477, DOI 10.1042/BJ20041057; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niemann C, 2002, DEVELOPMENT, V129, P95; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Ogawa K, 2006, BIOCHEM BIOPH RES CO, V343, P159, DOI 10.1016/j.bbrc.2006.02.127; Ogawa K, 2004, GENES CELLS, V9, P471, DOI 10.1111/j.1356-9597.2004.00736.x; Rathjen J, 1999, J CELL SCI, V112, P601; Saba-El-Leil MK, 2003, EMBO REP, V4, P964, DOI 10.1038/sj.embor.embor939; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Stavridis MP, 2007, DEVELOPMENT, V134, P2889, DOI 10.1242/dev.02858; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Wilder PJ, 1997, DEV BIOL, V192, P614, DOI 10.1006/dbio.1997.8777; Ying QL, 2003, METHOD ENZYMOL, V365, P327; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; YOSHIDA K, 1994, MECH DEVELOP, V45, P163, DOI 10.1016/0925-4773(94)90030-2; Zhen Y, 2007, ONCOGENE, V26, P6372, DOI 10.1038/sj.onc.1210473	36	2405	2514	5	338	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 22	2008	453	7194					519	U5		10.1038/nature06968	http://dx.doi.org/10.1038/nature06968			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303EL	18497825	Green Accepted			2022-12-28	WOS:000256023700042
J	Bozec, A; Bakiri, L; Hoebertz, A; Eferl, R; Schilling, AF; Komnenovic, V; Scheuch, H; Priemel, M; Stewart, CL; Amling, M; Wagner, EF				Bozec, Aline; Bakiri, Latifa; Hoebertz, Astrid; Eferl, Robert; Schilling, Arndt F.; Komnenovic, Vukoslav; Scheuch, Harald; Priemel, Matthias; Stewart, Colin L.; Amling, Michael; Wagner, Erwin F.			Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia	NATURE			English	Article							LEUKEMIA INHIBITORY FACTOR; PAGETS-DISEASE; STEM-CELLS; C-FOS; MICE; EXPRESSION; GENE; GROWTH; BCL-2; DIFFERENTIATION	Osteoclasts are multinucleated haematopoietic cells that resorb bone. Increased osteoclast activity causes osteoporosis, a disorder resulting in a low bone mass and a high risk of fractures(1). Increased osteoclast size and numbers are also a hallmark of other disorders, such as Paget's disease and multiple myeloma(2). The protein c- Fos, a component of the AP- 1 transcription factor complex, is essential for osteoclast differentiation(3). Here we show that the Fos- related protein Fra- 2 controls osteoclast survival and size. The bones of Fra- 2- deficient newborn mice have giant osteoclasts, and signalling through leukaemia inhibitory factor ( LIF) and its receptor is impaired. Similarly, newborn animals lacking LIF have giant osteoclasts, and we show that LIF is a direct transcriptional target of Fra- 2 and c- Jun. Moreover, bones deficient in Fra- 2 and LIF are hypoxic and express increased levels of hypoxia- induced factor 1 alpha ( HIF1 alpha) and Bcl- 2. Overexpression of Bcl- 2 is sufficient to induce giant osteoclasts in vivo, whereas Fra- 2 and LIF affect HIF1a through transcriptional modulation of the HIF prolyl hydroxylase PHD2. This pathway is operative in the placenta, because specific inactivation of Fra- 2 in the embryo alone does not cause hypoxia or the giant osteoclast phenotype. Thus placenta- induced hypoxia during embryogenesis leads to the formation of giant osteoclasts in young pups. These findings offer potential targets for the treatment of syndromes associated with increased osteoclastogenesis.	[Bozec, Aline; Bakiri, Latifa; Hoebertz, Astrid; Eferl, Robert; Komnenovic, Vukoslav; Scheuch, Harald; Wagner, Erwin F.] Res Inst Mol Pathol, A-1030 Vienna, Austria; [Schilling, Arndt F.; Priemel, Matthias; Amling, Michael] Univ Med Ctr Hamburg Eppendorf, Dept Trauma Hand & Reconstruct Surg, Ctr Biomech & Skeletal Biol, D-20246 Hamburg, Germany; [Stewart, Colin L.] Inst Med Biol, Dev & Regenerat Biol Lab, Singapore 138648, Singapore	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Hamburg; University Medical Center Hamburg-Eppendorf; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB)	Wagner, EF (corresponding author), CNIO, C Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	wagner@imp.ac.at	Bakiri, Latifa/N-5780-2014; Bakiri, Latifa/AAP-1674-2020	Eferl, Robert/0000-0002-6074-7144; bakiri, latifa/0000-0002-6300-2420; Wagner, Erwin F/0000-0001-7872-0196				Adamopoulos IE, 2006, BIOCHEM BIOPH RES CO, V350, P478, DOI 10.1016/j.bbrc.2006.09.076; Arnett TR, 2003, J CELL PHYSIOL, V196, P2, DOI 10.1002/jcp.10321; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Bakiri L, 2007, BONE, V40, P867, DOI 10.1016/j.bone.2006.11.005; Berra E, 2006, EMBO REP, V7, P41, DOI 10.1038/sj.embor.7400598; Brandwood CP, 2003, J PATHOL, V201, P504, DOI 10.1002/path.1463; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Dagoneau N, 2004, AM J HUM GENET, V74, P298, DOI 10.1086/381715; Eferl R, 2007, GENESIS, V45, P447, DOI 10.1002/dvg.20311; Egle A, 2004, BLOOD, V103, P2276, DOI 10.1182/blood-2003-07-2469; Ehrlich LA, 2005, IMMUNOL REV, V208, P252, DOI 10.1111/j.0105-2896.2005.00323.x; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; Filgueira L, 2004, J HISTOCHEM CYTOCHEM, V52, P411, DOI 10.1177/002215540405200312; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HSU LW, 1994, BIOCHEM J, V302, P103, DOI 10.1042/bj3020103; Ivanov SV, 2007, ONCOGENE, V26, P802, DOI 10.1038/sj.onc.1209842; Jeong CH, 2007, J BIOL CHEM, V282, P13672, DOI 10.1074/jbc.M700534200; Karreth F, 2004, DEVELOPMENT, V131, P5717, DOI 10.1242/dev.01414; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kawasaki K, 1997, ENDOCRINOLOGY, V138, P4959, DOI 10.1210/en.138.11.4959; Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092-8674(00)80290-1; Martens JHA, 2005, EMBO J, V24, P800, DOI 10.1038/sj.emboj.7600545; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Sasabe E, 2005, CANCER SCI, V96, P394, DOI 10.1111/j.1349-7006.2005.00065.x; Schipani E, 2001, GENE DEV, V15, P2865; Schipani E, 2006, ANN NY ACAD SCI, V1068, P66, DOI 10.1196/annals.1346.009; Sims NA, 2004, J CLIN INVEST, V113, P379, DOI 10.1172/JCI200419872; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Takeda K, 2006, MOL CELL BIOL, V26, P8336, DOI 10.1128/MCB.00425-06; Tallquist MD, 2000, GENESIS, V26, P113, DOI 10.1002/(SICI)1526-968X(200002)26:2<113::AID-GENE3>3.0.CO;2-2; Utting JC, 2006, EXP CELL RES, V312, P1693, DOI 10.1016/j.yexcr.2006.02.007; WARE CB, 1995, DEVELOPMENT, V121, P1283	34	145	154	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 10	2008	454	7201					221	U61		10.1038/nature07019	http://dx.doi.org/10.1038/nature07019			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	323RU	18548006				2022-12-28	WOS:000257466900045
J	Jafri, NS; Hornung, CA; Howden, CW				Jafri, Nadim S.; Hornung, Carlton A.; Howden, Colin W.			Meta-analysis: Sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment	ANNALS OF INTERNAL MEDICINE			English	Review							TRIPLE THERAPY; RISK-FACTORS; ERADICATION THERAPY; RANDOMIZED-TRIAL; ANTIMICROBIAL RESISTANCE; ANTIBIOTIC-RESISTANCE; TREATMENT REGIMENS; UNITED-STATES; PEPTIC-ULCER; FAILURE	Background: Standard proton-pump inhibitor-based therapy for Helicobacter pylori infection fails in up to one quarter of patients. Sequential therapy may be more efficacious. Purpose: To compare sequential therapy with standard triple therapy for H. pylori infection. Data Sources: MEDLINE, EMBASE (1981 to October 2007), the Cochrane Central Register of Controlled Trials, and Google Scholar. PubMed and Ovid were the search engines used. Study Selection: Randomized, controlled trials (RCTs) comparing sequential and standard triple therapies in treatment-naive patients with documented H. pylori infection. Data Extraction: 3 reviewers independently assessed trial eligibility and quality and extracted data on eradication. Data Synthesis: The crude rates of H. pylori eradication in 10 RCTs involving 2747 patients were 93.4% (95% CI, 91.3% to 95.5%) for sequential therapy (n = 1363) and 76.9% (CI, 71.0% to 82.8%) for standard triple therapy (n = 1384) (relative risk reduction, 71% [CI, 64% to 77%]; absolute risk reduction, 16 percentage points [CI, 14 to 19 percentage points]). The median rates of adherence were 97.4% (range, 90.0% to 98.9%) for sequential therapy and 96.8% (range, 93.0% to 100%) for standard therapy. Sequential therapy appeared superior in prespecified sensitivity (subgroup) analyses stratified by trial quality; smoking status; diagnosis (ulcer disease or nonulcer dyspepsia); resistance to clarithromycin, imidazoles, or both; duration of triple therapy; and method of diagnosis. Both treatments had similar side effect profiles. Limitations: Only 1 study was double-blinded. Most patients were from Italy. There was clear evidence of publication bias. Conclusion: Sequential therapy appears superior to standard triple therapy for eradication of H. pylori infection. If RCTs in other countries confirm these findings, 10-day sequential therapy could become a standard treatment for H. pylori infection in treatment-naive patients.	Univ Louisville, Louisville, KY 40292 USA	University of Louisville	Howden, CW (corresponding author), Northwestern Univ, Div Gastroenterol, Feinberg Sch Med, 676 N St Clair St,Suite 1400, Chicago, IL 60611 USA.	c-howden@northwestern.edu						ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; Broutet N, 2003, ALIMENT PHARM THER, V17, P99, DOI 10.1046/j.1365-2036.2003.01396.x; Chey WD, 2007, AM J GASTROENTEROL, V102, P1808, DOI 10.1111/j.1572-0241.2007.01393.x; De Francesco V, 2006, ANN INTERN MED, V144, P94, DOI 10.7326/0003-4819-144-2-200601170-00006; De Francesco V, 2004, DIGEST LIVER DIS, V36, P322, DOI 10.1016/j.dld.2003.12.015; De Francesco V, 2004, ALIMENT PHARM THER, V19, P407, DOI 10.1046/j.1365-2036.2004.01818.x; De Francesco V, 2001, DIGEST LIVER DIS, V33, P676, DOI 10.1016/S1590-8658(01)80044-X; De Francesco V, 2006, J MICROBIOL, V44, P660; DEFRANCESCO V, 2001, GUT S11, V48, pA94; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Focareta R, 2003, DIG LIVER DIS S4, V35, pS33; Focareta R, 2002, DIGEST LIVER DIS, V34, pA17; Francavilla R, 2005, GASTROENTEROLOGY, V129, P1414, DOI 10.1053/j.gastro.2005.09.007; Fuccio L, 2007, ANN INTERN MED, V147, P553, DOI 10.7326/0003-4819-147-8-200710160-00008; Gessner BD, 2005, CLIN INFECT DIS, V41, P1261, DOI 10.1086/496925; Gisbert JP, 2001, EUR J GASTROEN HEPAT, V13, P1303, DOI 10.1097/00042737-200111000-00007; Graham DY, 2007, HELICOBACTER, V12, P275, DOI 10.1111/j.1523-5378.2007.00518.x; Graham DY, 2007, ANN INTERN MED, V147, P434, DOI 10.7326/0003-4819-147-6-200709180-00022; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HIGGINS JPT, 2005, COCHRANE LIB; Hopkins RJ, 2001, HELICOBACTER, V6, P81, DOI 10.1046/j.1523-5378.2001.00012.x; Houben MHMG, 1999, ALIMENT PHARM THER, V13, P1047; HUANG JQ, 1998, AM J GASTROENTEROL, V93, P1639; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Koletzko S, 2006, GUT, V55, P1711, DOI 10.1136/gut.2006.091272; Laheij RJF, 1999, ALIMENT PHARM THERAP, V13, P857; Laine L, 2000, AM J GASTROENTEROL, V95, P3393, DOI 10.1111/j.1572-0241.2000.03349.x; Malfertheiner P, 2007, GUT, V56, P772, DOI 10.1136/gut.2006.101634; Meyer JM, 2002, ANN INTERN MED, V136, P13, DOI 10.7326/0003-4819-136-1-200201010-00008; Moayyedi P, 2007, LANCET, V370, P1010, DOI 10.1016/S0140-6736(07)61455-X; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; SAAD RJ, 2006, GASTROENTEROL HEPATO, V1, P30; SACKETT DL, 2000, EVIDENCE BASED MED P, P133; Scaccianoce G, 2006, CAN J GASTROENTEROL, V20, P113, DOI 10.1155/2006/258768; Vaira D, 2007, ANN INTERN MED, V146, P556, DOI 10.7326/0003-4819-146-8-200704170-00006; Vakil N, 2004, ALIMENT PHARM THERAP, V20, P99, DOI 10.1111/j.1365-2036.2004.02029.x; Zullo A, 2005, ALIMENT PHARM THERAP, V21, P1419, DOI 10.1111/j.1365-2036.2005.02519.x; Zullo A, 2003, ALIMENT PHARM THER, V17, P719, DOI 10.1046/j.1365-2036.2003.01461.x; Zullo A, 2007, GUT, V56, P1353, DOI 10.1136/gut.2007.125658	41	207	217	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 17	2008	148	12					923	+		10.7326/0003-4819-148-12-200806170-00226	http://dx.doi.org/10.7326/0003-4819-148-12-200806170-00226			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	323DU	18490667				2022-12-28	WOS:000257425000004
J	Mehrotra, A; Keehl-Markowitz, L; Ayanian, JZ				Mehrotra, Ateev; Keehl-Markowitz, Lori; Ayanian, John Z.			Implementing open-access scheduling of visits in primary care practices: A cautionary tale	ANNALS OF INTERNAL MEDICINE			English	Article							WAITING-TIMES; MODEL; CONTINUITY; QUALITY; PROJECT; PATIENT; SYSTEM; GP	Background: Open-access scheduling (also known as advanced access or same-day access) is a popular tool for improving patient access to primary care appointments. Objective: To assess the effect of open-access scheduling and describe the barriers to implementing the open-access scheduling model in primary care. Design: Case series. Setting: Boston, Massachusetts, metropolitan area. Participants: 6 primary care practices studied from October 2003 through June 2006. Intervention: Implementation of open-access scheduling. Measurements: Time to third available appointments, no-show rates, and patient and staff satisfaction with appointment availability. Results: 5 of 6 practices were able to implement open-access scheduling. Within 4 months of implementation, these 5 practices substantially reduced their mean wait for third available appointments from 21 to 8 days for 15-minute visits and from 39 to 14 days for 30-minute visits. However, none of the 5 practices attained the goal of same-day access, and waits for third available appointments increased during 2 years of follow-up. No consistent changes in patient or staff satisfaction or patient no-show rates were found. Barriers to implementation included decreases in appointment supply from provider leaves of absence and departures and increases in appointment demand when practices reopened to new patients after initial implementation of open-access scheduling. Limitations: The study lacked control practices. The small number of practices and providers precluded formal statistical comparisons. Conclusion: In 5 of 6 primary care practices, implementation of open-access scheduling improved appointment access in some practices. However, none was able to achieve same-day access and patient and staff satisfaction and patient no-show rates were unchanged. Broader evaluation of open-access scheduling in primary care is needed.	RAND Hlth, Pittsburgh, PA USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Partners Community Healthcare, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	RAND Corporation; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Mehrotra, A (corresponding author), Univ Pittsburgh, Sch Med, Div Gen Internal Med, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA.	mehrotra@rand.org	Mehrotra, Ateev/AAO-8454-2021	Mehrotra, Ateev/0000-0003-2223-1582	NCATS NIH HHS [KL2 TR000146] Funding Source: Medline; NCRR NIH HHS [KL2-RR024154-01, KL2 RR024154, KL2 RR024154-01] Funding Source: Medline; PHS HHS [5 T32 HP11001-15] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000146] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024154] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		[Anonymous], 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Armstrong B, 2005, J HEALTHC MANAG, V50, P399, DOI 10.1097/00115514-200511000-00009; Atlas SJ, 2006, J GEN INTERN MED, V21, P973, DOI 10.1007/BF02743147; Auerbach AD, 2007, NEW ENGL J MED, V357, P608, DOI 10.1056/NEJMsb070738; Belardi FG, 2004, FAM MED, V36, P341; Boelke C, 2000, Med Group Manage J, V47, P58; BOELKE C, 2000, MED GROUP MANAGE J, V47, P68; BOELKE C, 2000, MED GROUP MANAGE J, V47, P64; Bundy DG, 2005, PEDIATRICS, V116, P82, DOI 10.1542/peds.2004-2573; Christakis DA, 2001, PEDIATRICS, V107, P524, DOI 10.1542/peds.107.3.524; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Dixon S, 2006, FAM PRACT, V23, P233, DOI 10.1093/fampra/cmi104; Green LV, 2007, JT COMM J QUAL PATIE, V33, P211, DOI 10.1016/S1553-7250(07)33025-0; Kennedy JG, 2003, FAM MED, V35, P666; Kilo C M, 2000, J Med Pract Manage, V16, P126; Knight AW, 2005, MED J AUSTRALIA, V183, P101, DOI 10.5694/j.1326-5377.2005.tb06941.x; Landon BE, 2004, ANN INTERN MED, V140, P887, DOI 10.7326/0003-4819-140-11-200406010-00010; Lewandowski S, 2006, AM J MANAG CARE, V12, P573; *MASS MED SOC, 2006, JUN 2006 PHYS WORKF; MCCLAIN B, 2007, WASHINGTON POST 0206, pHE1; Meyers ML, 2003, J HEALTHC MANAG, V48, P125; Murray M, 2003, JAMA-J AM MED ASSOC, V289, P1035, DOI 10.1001/jama.289.8.1035; Murray M, 2003, JAMA-J AM MED ASSOC, V289, P1042, DOI 10.1001/jama.289.8.1042; Murray M, 2000, Fam Pract Manag, V7, P45; Murray M, 1999, Manag Care Q, V7, P45; Newman ED, 2004, ARTHRIT RHEUM-ARTHR, V51, P253, DOI 10.1002/art.20239; O'Connor ME, 2006, ARCH PEDIAT ADOL MED, V160, P889, DOI 10.1001/archpedi.160.9.889; O'Hare C Dennis, 2004, Fam Pract Manag, V11, P35; Parente DH, 2005, HEALTH CARE MANAGE R, V30, P220, DOI 10.1097/00004010-200507000-00006; Pickin M, 2004, BRIT J GEN PRACT, V54, P334; Pierdon Steven, 2004, Fam Pract Manag, V11, P35; Radel S J, 2001, J Healthc Qual, V23, P11; Radel S.J., 2001, J HEALTHC QUAL, V23, P52; Radel S.J., 2001, J HEALTHC QUAL, V23, P15; Rohrer JE, 2007, HEALTH SERV MANAG RE, V20, P134, DOI 10.1258/095148407780744679; Safran DG, 2006, J GEN INTERN MED, V21, P13, DOI 10.1111/j.1525-1497.2005.00311.x; Salisbury C, 2004, BRIT J GEN PRACT, V54, P330; Salisbury C, 2007, BRIT J GEN PRACT, V57, P615; Schall Marie W, 2004, Jt Comm J Qual Saf, V30, P415; Solberg Leif I, 2004, Jt Comm J Qual Saf, V30, P15; Solberg LI, 2006, ANN FAM MED, V4, P69, DOI 10.1370/afm.426; Solberg LI, 2004, AM J MANAG CARE, V10, P717; Sperl-Hillen J. M., 2008, Preventing Chronic Disease, V5, pA16; Steinbauer Jeffrey R, 2006, Fam Pract Manag, V13, P59; Strindhall Margareta, 2007, Qual Manag Health Care, V16, P16; Valenti William M, 2004, AIDS Read, V14, P220; Witt Mary J, 2006, J Med Pract Manage, V22, P107	47	72	74	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 17	2008	148	12					915	+		10.7326/0003-4819-148-12-200806170-00004	http://dx.doi.org/10.7326/0003-4819-148-12-200806170-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	323DU	18559842	Green Accepted			2022-12-28	WOS:000257425000003
J	Hatsukami, DK; Stead, LF; Gupta, PC				Hatsukami, Dorothy K.; Stead, Lindsay F.; Gupta, Prokash C.			Tobacco addiction	LANCET			English	Review							SUSTAINED-RELEASE BUPROPION; RECEPTOR PARTIAL AGONIST; SMOKING WITHDRAWAL DYNAMICS; OVER-THE-COUNTER; NICOTINE REPLACEMENT THERAPY; CIGARETTE-SMOKING; CONTROLLED-TRIAL; TRANSDERMAL NICOTINE; CONJUGATE VACCINE; MAJOR DEPRESSION		[Hatsukami, Dorothy K.] Univ Minnesota, Ctr Comprehens Canc, Minneapolis, MN USA; [Stead, Lindsay F.] Univ Oxford, Dept Primary Hlth Care, Oxford, England; [Gupta, Prokash C.] Healis Sekhsaria Inst Publ Hlth, Bombay, Maharashtra, India	University of Minnesota System; University of Minnesota Twin Cities; University of Oxford	Hatsukami, DK (corresponding author), Univ Minnesota, Tobacco Use Res Ctr, 2701 Univ Ave SE 201, Minneapolis, MN 55414 USA.	hatsu001@umn.edu			NIDA NIH HHS [P50 DA013333] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA013333] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		*AM SOC HLTH SYST, 2004, AHFS DRUG INF; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Balfour DJK, 2004, NICOTINE TOB RES, V6, P899, DOI 10.1080/14622200412331324965; Benowitz NL, 1999, PRIMARY CARE, V26, P611, DOI 10.1016/S0095-4543(05)70120-2; Benowitz NL, 1998, J PHARMACOL EXP THER, V287, P958; Benwell MEM, 1997, EUR J PHARMACOL, V325, P13, DOI 10.1016/S0014-2999(97)00101-5; BENWELL MEM, 1995, BRIT J PHARMACOL, V114, P454, DOI 10.1111/j.1476-5381.1995.tb13248.x; Boyadjieva NI, 1997, LIFE SCI, V61, pPL59; BRANDON TH, 1990, ADDICT BEHAV, V15, P105, DOI 10.1016/0306-4603(90)90013-N; Breslau N, 2000, AM J PUBLIC HEALTH, V90, P1122, DOI 10.2105/AJPH.90.7.1122; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P1069; BRESLAU N, 1994, ADDICTION, V89, P743, DOI 10.1111/j.1360-0443.1994.tb00960.x; Caggiula AR, 2001, PHARMACOL BIOCHEM BE, V70, P515, DOI 10.1016/S0091-3057(01)00676-1; Caggiula AR, 2002, PHYSIOL BEHAV, V77, P683, DOI 10.1016/S0031-9384(02)00918-6; Caggiula AR, 2002, PSYCHOPHARMACOLOGY, V163, P230, DOI 10.1007/s00213-002-1156-5; Cahill K., 2007, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CDC006103.PUB2; Centers for Disease Control and Prevention, 2002, MMWR-MORBID MORTAL W, V51, P642; Chaudhri N, 2006, PSYCHOPHARMACOLOGY, V184, P353, DOI 10.1007/s00213-005-0178-1; CINCIRIPINI PM, 2006, 8 ANN C SOC RES NIC; Cohen C, 2002, BEHAV PHARMACOL, V13, P451, DOI 10.1097/00008877-200209000-00018; Cohen C, 2005, NEUROPSYCHOPHARMACOL, V30, P145, DOI 10.1038/sj.npp.1300541; Croghan IT, 2007, MAYO CLIN PROC, V82, P186, DOI 10.4065/82.2.186; Degenhardt L, 2001, Nicotine Tob Res, V3, P225; Donny EC, 2003, PSYCHOPHARMACOLOGY, V169, P68, DOI 10.1007/s00213-003-1473-3; Durcan MJ, 2002, AM J HEALTH BEHAV, V26, P213, DOI 10.5993/AJHB.26.3.6; EVINS AE, 2006, SOC RES NC TOB 12 AN; FAGERSTROM KO, 1989, J BEHAV MED, V12, P159, DOI 10.1007/BF00846549; FAGERSTROM KO, 1978, ADDICT BEHAV, V3, P235, DOI 10.1016/0306-4603(78)90024-2; FIORE MC, 1990, JAMA-J AM MED ASSOC, V263, P2760, DOI 10.1001/jama.263.20.2760; Fiore MC, 2002, JAMA-J AM MED ASSOC, V288, P1768, DOI 10.1001/jama.288.14.1768; Fiore MC, 2008, TREATING TOBACCO USE; Franzon M, 2002, JAMA-J AM MED ASSOC, V288, P3108, DOI 10.1001/jama.288.24.3108; Fryer JD, 1999, J PHARMACOL EXP THER, V288, P88; Fu YT, 2001, J NEUROSCI, V21, P8979, DOI 10.1523/JNEUROSCI.21-22-08979.2001; Gilbert DG, 2002, J CONSULT CLIN PSYCH, V70, P142, DOI 10.1037//0022-006X.70.1.142; GLASSMAN AH, 1990, JAMA-J AM MED ASSOC, V264, P1546, DOI 10.1001/jama.264.12.1546; Godtfredsen NS, 2003, J EPIDEMIOL COMMUN H, V57, P412, DOI 10.1136/jech.57.6.412; Godtfredsen NS, 2002, THORAX, V57, P967, DOI 10.1136/thorax.57.11.967; Godtfredsen NS, 2005, JAMA-J AM MED ASSOC, V294, P1505, DOI 10.1001/jama.294.12.1505; Gonzales D, 2006, JAMA-J AM MED ASSOC, V296, P47, DOI 10.1001/jama.296.1.47; Gonzales DH, 2001, CLIN PHARMACOL THER, V69, P438, DOI 10.1067/mcp.2001.115750; Gotti C, 2006, TRENDS PHARMACOL SCI, V27, P482, DOI 10.1016/j.tips.2006.07.004; Gourlay S G, 2004, Cochrane Database Syst Rev, pCD000058, DOI 10.1002/14651858.CD000058.pub2; GOURLAY SG, 1995, BRIT MED J, V311, P363, DOI 10.1136/bmj.311.7001.363; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P1107, DOI 10.1001/archpsyc.61.11.1107; Haggstram FM, 2006, PULM PHARMACOL THER, V19, P205, DOI 10.1016/j.pupt.2005.05.003; Hajek P, 1999, ARCH INTERN MED, V159, P2033, DOI 10.1001/archinte.159.17.2033; Hall SM, 2004, AM J PSYCHIAT, V161, P2100, DOI 10.1176/appi.ajp.161.11.2100; Hall SM, 2002, ARCH GEN PSYCHIAT, V59, P930, DOI 10.1001/archpsyc.59.10.930; Hatsukami DK, 2005, CHEST, V128, P2528, DOI 10.1378/chest.128.4.2528; Hatsukami DK, 2005, CLIN PHARMACOL THER, V78, P456, DOI 10.1016/j.clpt.2005.08.007; Haustein KO, 2003, INT J CLIN PHARM TH, V41, P56; Hays JT, 2001, ANN INTERN MED, V135, P423, DOI 10.7326/0003-4819-135-6-200109180-00011; HEATHERTON TF, 1989, BRIT J ADDICT, V84, P791; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Hecht SS, 2004, JNCI-J NATL CANCER I, V96, P107, DOI 10.1093/jnci/djh016; HENNINGFIELD JE, 1993, J CONSULT CLIN PSYCH, V61, P743, DOI 10.1037/0022-006X.61.5.743; Henningfield JE, 1998, FOOD DRUG LAW J, V53, P75; HENNINGFIELD JE, 1996, HDB EXPT PHARM, P272; Hopkins DP, 2001, AM J PREV MED, V20, P16, DOI 10.1016/S0749-3797(00)00297-X; Hughes J.R., 1992, INT J SMOKING CESSAT, V1, P21; Hughes JR, 2007, NICOTINE TOB RES, V9, P315, DOI 10.1080/14622200701188919; Hughes JR, 2006, NICOTINE TOB RES, V8, P739, DOI 10.1080/14622200600789726; Hughes JR, 2003, TOB CONTROL, V12, P21, DOI 10.1136/tc.12.1.21; Hughes JR, 2005, ADDICTION, V100, P1074, DOI 10.1111/j.1360-0443.2005.01174.x; HUGHES JR, 1990, RES ADV ALCOHOL DRUG, V10, P317; HUGHES JR, 1990, J PHARMACOL EXP THER, V252, P1175; Hughes JR, 2004, ADDICTION, V99, P29, DOI 10.1111/j.1360-0443.2004.00540.x; Hughes JR, 2007, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD000031.PUB3; Hukkanen J, 2005, PHARMACOL REV, V57, P79, DOI 10.1124/pr.57.1.3; Hurt RD, 2003, J CLIN ONCOL, V21, P914, DOI 10.1200/JCO.2003.08.160; Hyman SE, 2005, AM J PSYCHIAT, V162, P1414, DOI 10.1176/appi.ajp.162.8.1414; John U, 2004, DRUG ALCOHOL DEPEN, V76, P287, DOI 10.1016/j.drugalcdep.2004.06.004; Jorenby DE, 1999, NEW ENGL J MED, V340, P685, DOI 10.1056/NEJM199903043400903; Jorenby DE, 2006, JAMA-J AM MED ASSOC, V296, P56, DOI 10.1001/jama.296.1.56; Joseph AM, 2003, PROG CARDIOVASC DIS, V45, P429, DOI 10.1053/pcad.2003.YPCAD14; Kandel DB, 2001, DRUG ALCOHOL DEPEN, V64, P233, DOI 10.1016/S0376-8716(01)00126-0; Killen JD, 2004, J CONSULT CLIN PSYCH, V72, P729, DOI 10.1037/0022-006X.72.4.729; Killen JD, 1997, EXP CLIN PSYCHOPHARM, V5, P137, DOI 10.1037/1064-1297.5.2.137; Killen JD, 2006, J CONSULT CLIN PSYCH, V74, P286, DOI 10.1037/0022-006X.74.2.286; Lancaster T., 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000165.pub2, DOI 10.1002/14651858.CD000165.PUB2, 10.1002/14651858.CD000165.pub2.AMBIGUOUS]; Lasser K, 2000, JAMA-J AM MED ASSOC, V284, P2606, DOI 10.1001/jama.284.20.2606; Lerman C, 2002, ONCOGENE, V21, P7412, DOI 10.1038/sj.onc.1205801; Lipkus IM, 2000, AM J PREV MED, V18, P1, DOI 10.1016/S0749-3797(99)00106-3; Mackay J, 2006, TOBACCO ATLAS; Mai SK, 2007, HLTH CONS SMOK REP S, V2, P30; Mansvelder HD, 2000, NEURON, V27, P349, DOI 10.1016/S0896-6273(00)00042-8; Mansvelder HD, 2002, NEURON, V33, P905, DOI 10.1016/S0896-6273(02)00625-6; McCarthy DE, 2006, J ABNORM PSYCHOL, V115, P454, DOI 10.1037/0021-843X.115.3.454; Munafo MR, 2004, NICOTINE TOB RES, V6, P583, DOI 10.1080/14622200410001734030; Nides M, 2006, ARCH INTERN MED, V166, P1561, DOI 10.1001/archinte.166.15.1561; *OFF POP STAT CENS, 1995, OPCS SER, P29; Oncken C, 2006, ARCH INTERN MED, V166, P1571, DOI 10.1001/archinte.166.15.1571; Palmatier M, 2006, PSYCHOPHARMACOLOGY, V184, P391, DOI 10.1007/s00213-005-0183-4; Paterson D, 2000, PROG NEUROBIOL, V61, P75, DOI 10.1016/S0301-0082(99)00045-3; Piasecki TM, 1998, J ABNORM PSYCHOL, V107, P238, DOI 10.1037/0021-843X.107.2.238; Piasecki TM, 2003, J ABNORM PSYCHOL, V112, P3, DOI 10.1037/0021-843X.112.1.3; Piasecki TM, 2003, J ABNORM PSYCHOL, V112, P14, DOI 10.1037/0021-843X.112.1.14; Piasecki TM, 2002, ADDICTION, V97, P1093, DOI 10.1046/j.1360-0443.2002.00216.x; Piasecki TM, 2000, J ABNORM PSYCHOL, V109, P74, DOI 10.1037/0021-843X.109.1.74; Picciotto MR, 2002, J NEUROSCI, V22, P3338; Pidoplichko VI, 1997, NATURE, V390, P401, DOI 10.1038/37120; Pierce JP, 2002, JAMA-J AM MED ASSOC, V288, P1260, DOI 10.1001/jama.288.10.1260; Piper ME, 2006, NICOTINE TOB RES, V8, P339, DOI 10.1080/14622200600672765; Prochazka AV, 2004, ARCH INTERN MED, V164, P2229, DOI 10.1001/archinte.164.20.2229; RIMER BK, 1990, CHEST, V97, P547, DOI 10.1378/chest.97.3.547; Rose JE, 2006, PSYCHOPHARMACOLOGY, V184, P274, DOI 10.1007/s00213-005-0250-x; Royal College of Physicians of London, 2000, NIC ADD BRIT REP TOB; Saccone SF, 2007, HUM MOL GENET, V16, P36, DOI 10.1093/hmg/ddl438; Satoskar SD, 2003, INT IMMUNOPHARMACOL, V3, P957, DOI 10.1016/S1567-5769(03)00094-8; Schiffer WK, 2001, SYNAPSE, V42, P196, DOI 10.1002/syn.10000; Shiffman S, 1996, HEALTH PSYCHOL, V15, P455, DOI 10.1037/0278-6133.15.6.455; Shiffman S, 2004, ADDICTION, V99, P83, DOI 10.1111/j.1360-0443.2004.00576.x; Shiffman S, 2002, ARCH INTERN MED, V162, P1267, DOI 10.1001/archinte.162.11.1267; Simon JA, 2004, ARCH INTERN MED, V164, P1797, DOI 10.1001/archinte.164.16.1797; Stead LF, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002850.pub2; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub3; Stead LF, 2002, JAMA-J AM MED ASSOC, V288, P3109, DOI 10.1001/jama.288.24.3109-JLT1225-1-4; Sullivan F, 1999, COMPUT SCI ENG, V1, P2; SUMMERS KL, 1995, NEUROCHEM RES, V20, P753, DOI 10.1007/BF01705545; TATLEY M, 2001, BUPROPION ZYBAN 2 LI; Taylor T, 2005, SMOKING RELATED BEHA; *THOMPS HEALTHC IN, 2006, PHYS DESK REF; TONNESEN P, 1993, ADDICTION, V88, P533, DOI 10.1111/j.1360-0443.1993.tb02060.x; Tonstad S, 2006, JAMA-J AM MED ASSOC, V296, P64, DOI 10.1001/jama.296.1.64; Transdisciplinary Tobacco Use Research Center (TTURC) Tobacco Dependence, 2007, Nicotine Tob Res, V9 Suppl 4, pS555, DOI 10.1080/14622200701673480; U.S. Department of Health and Human Services, 2006, HLTH CONS INV EXP TO; *US DEP HHS, 1990, DHHS PUBL CDC; US Department of Health and Human Services, 1988, HLTH CONS SMOK NIC A; Wagena EJ, 2005, ARCH INTERN MED, V165, P2286, DOI 10.1001/archinte.165.19.2286; West R, 2000, THORAX, V55, P987, DOI 10.1136/thorax.55.12.987; West R, 2007, THORAX, V62, P998, DOI 10.1136/thx.2007.078758; Williams KE, 2007, CURR MED RES OPIN, V23, P793, DOI 10.1185/030079907X182185; Wonnacott S, 2005, CURR OPIN PHARMACOL, V5, P53, DOI 10.1016/j.coph.2004.12.002; World Health Organization, 1991, INT CLASS DIS ICD 10; Zevin S, 1998, CLIN DERMATOL, V16, P557, DOI 10.1016/S0738-081X(98)00038-8	136	159	161	1	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2008	371	9629					2027	2038		10.1016/S0140-6736(08)60871-5	http://dx.doi.org/10.1016/S0140-6736(08)60871-5			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	312YY	18555914	Green Accepted			2022-12-28	WOS:000256709500030
J	Peul, WC; van den Hout, WB; Brand, R; Thomeer, RTWM; Koes, BW				Peul, Wilco C.; van den Hout, Wilbert B.; Brand, Ronald; Thomeer, Ralph T. W. M.; Koes, Bart W.		Leiden The Hague Spine Intervent	Prolonged conservative care versus early surgery in patients with sciatica caused by lumbar disc herniation: two year results of a randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							FOLLOW-UP; PROSPECTIVE COHORT; SPINE; PAIN; DISKECTOMY; DURATION; OUTCOMES	Objectives To evaluate the effects of early lumbar disc surgery compared with prolonged conservative care for patients with sciatica over two years of follow-up. Design Randomised controlled trial. Setting Nine Dutch hospitals. Participants 283 patients with 6-12 weeks of sciatica. Interventions Early surgery or an intended six months of continued conservative treatment, with delayed surgery if needed. Main outcome measures Scores from Roland disability questionnaire for sciatica, visual analogue scale for leg pain, and Likert self rating scale of global perceived recovery. Results Of the 141 patients assigned to undergo early surgery, 125 (89%) underwent microdiscectomy. Of the 142 patients assigned to conservative treatment, 62 (44%) eventually required surgery, seven doing so in the second year of follow-up. There was no significant overall difference between treatment arms in disability scores during the first two years (P=0.25). Improvement in leg pain was faster for patients randomised to early surgery, with a significant difference between "areas under the curves" over two years (P=0.05). This short term benefit of early surgery was no longer significant by six months and continued to narrow between six months and 24 months. Patient satisfaction decreased slightly between one and two years for both groups. At two years 20% of all patients reported an unsatisfactory outcome. Conclusions Early surgery achieved more rapid relief of sciatica than conservative care, but outcomes were similar by one year and these did not change during the second year. Trial Registry ISRCT No 26872154.	[Peul, Wilco C.; Thomeer, Ralph T. W. M.] Leiden Univ, Med Ctr, Dept Neurosurg, NL-2300 RC Leiden, Netherlands; [Peul, Wilco C.] Med Ctr Haaglanden, Dept Neurosurg, The Hague, Netherlands; [van den Hout, Wilbert B.] Leiden Univ, Med Ctr, Dept Med Decis Making, NL-2300 RC Leiden, Netherlands; [Brand, Ronald] Leiden Univ, Med Ctr, Dept Med Stat, NL-2300 RC Leiden, Netherlands; [Koes, Bart W.] Erasmus MC, Res Dept Gen Practice, NL-3000 CA Rotterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Haaglanden Medical Center; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC	Peul, WC (corresponding author), Leiden Univ, Med Ctr, Dept Neurosurg, POB 9600, NL-2300 RC Leiden, Netherlands.	w.c.peul@lumc.nl	Koes, Bart w/K-4614-2016	Koes, Bart w/0000-0002-0450-9969; van den Hout, Wilbert B./0000-0002-6425-0135				Atlas SJ, 1996, SPINE, V21, P1777, DOI 10.1097/00007632-199608010-00011; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Buttermann GR, 2004, J BONE JOINT SURG AM, V86A, P670, DOI 10.2106/00004623-200404000-00002; CHERKIN DC, 1994, SPINE, V19, P1201, DOI 10.1097/00007632-199405310-00001; Collins SL, 1997, PAIN, V72, P95, DOI 10.1016/S0304-3959(97)00005-5; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; HURME M, 1987, SPINE, V12, P933, DOI 10.1097/00007632-198711000-00016; Koes BW, 2007, BMJ-BRIT MED J, V334, P1313, DOI 10.1136/bmj.39223.428495.BE; Mayer HM, 2005, Z ORTHOP GRENZGEB, V143, P287, DOI 10.1055/s-2005-836630; Ng LCL, 2004, J BONE JOINT SURG BR, V86B, P546, DOI 10.1302/0301-620X.86B4.14419; Nygaard OP, 2000, J NEUROSURG, V92, P131, DOI 10.3171/spi.2000.92.2.0131; Osterman H, 2006, SPINE, V31, P2409; PATRICK DL, 1995, SPINE, V20, P1899, DOI 10.1097/00007632-199509000-00011; Peul WC, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-8; Peul WC, 2007, NEW ENGL J MED, V356, P2245, DOI 10.1056/NEJMoa064039; PROLO DJ, 1986, SPINE, V11, P601, DOI 10.1097/00007632-198607000-00012; Rothoerl RD, 2002, NEUROSURG REV, V25, P162, DOI 10.1007/s101430100184; Stam J, 1996, Ned Tijdschr Geneeskd, V140, P2621; Vader JP, 2000, SPINE, V25, P1831, DOI 10.1097/00007632-200007150-00015; Vroomen PCAJ, 2002, BRIT J GEN PRACT, V52, P119; WEBER H, 1983, SPINE, V8, P131, DOI 10.1097/00007632-198303000-00003; Weber H, 1978, J Oslo City Hosp, V28, P33; Weinstein JN, 2006, JAMA-J AM MED ASSOC, V296, P2441, DOI 10.1001/jama.296.20.2441	23	179	188	1	21	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 14	2008	336	7657					1355	1358		10.1136/bmj.a143	http://dx.doi.org/10.1136/bmj.a143			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316YB	18502911	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000256984700041
J	Akin, O; Mullins, RD				Akin, Orkun; Mullins, R. Dyche			Capping protein increases the rate of actin-based motility by promoting filament nucleation by the Arp2/3 complex	CELL			English	Article							CELL MOTILITY; LISTERIA-MONOCYTOGENES; WASP/SCAR PROTEINS; ENA/VASP PROTEINS; ATP HYDROLYSIS; FREE SYSTEM; BARBED END; IN-VITRO; N-WASP; POLYMERIZATION	Capping protein (CP) is an integral component of Arp2/3-nucleated actin networks that drive amoeboid motility. Increasing the concentration of capping protein, which caps barbed ends of actin filaments and prevents elongation, increases the rate of actin-based motility in vivo and in vitro. We studied the synergy between CP and Arp2/3 using an in vitro actin-based motility system reconstituted from purified proteins. We find that capping protein increases the rate of motility by promoting more frequent filament nucleation by the Arp2/3 complex and not by increasing the rate of filament elongation as previously suggested. One consequence of this coupling between capping and nucleation is that, while the rate of motility depends strongly on the concentration of CP and Arp2/3, the net rate of actin assembly is insensitive to changes in either factor. By reorganizing their architecture, dendritic actin networks harness the same assembly kinetics to drive different rates of motility.	[Akin, Orkun; Mullins, R. Dyche] Univ Calif San Francisco, Sch Med, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Mullins, RD (corresponding author), Univ Calif San Francisco, Sch Med, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.	dyche@mullinslab.ucsf.edu		Akin, Orkun/0000-0003-1719-4887	NATIONAL EYE INSTITUTE [PN2EY016546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061010] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NEI NIH HHS [PN2 EY016546, PN2 EY016546-04] Funding Source: Medline; NIGMS NIH HHS [R01 GM061010-09, R01 GM061010, R01GM61010] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Applewhite DA, 2007, MOL BIOL CELL, V18, P2579, DOI 10.1091/mbc.e06-11-0990; Baum B, 2005, CURR BIOL, V15, pR305, DOI 10.1016/j.cub.2005.04.004; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; Bernheim-Groswasser A, 2002, NATURE, V417, P308, DOI 10.1038/417308a; Cameron LA, 1999, P NATL ACAD SCI USA, V96, P4908, DOI 10.1073/pnas.96.9.4908; Cameron LA, 2004, MOL BIOL CELL, V15, P2312, DOI 10.1091/mbc.E03-12-0913; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; Co C, 2007, CELL, V128, P901, DOI 10.1016/j.cell.2006.12.049; COOPER JA, 1985, BIOCHEMISTRY-US, V24, P793, DOI 10.1021/bi00324a039; DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; Dayel MJ, 2004, PLOS BIOL, V2, P476, DOI 10.1371/journal.pbio.0020091; Dayel MJ, 2001, P NATL ACAD SCI USA, V98, P14871, DOI 10.1073/pnas.261419298; Eddy RJ, 1997, J CELL BIOL, V139, P1243, DOI 10.1083/jcb.139.5.1243; Goley ED, 2004, MOL CELL, V16, P269, DOI 10.1016/j.molcel.2004.09.018; Goley ED, 2006, NAT REV MOL CELL BIO, V7, P713, DOI 10.1038/nrm2026; Haviv L, 2006, P NATL ACAD SCI USA, V103, P4906, DOI 10.1073/pnas.0508269103; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; Iwasa JH, 2007, CURR BIOL, V17, P395, DOI 10.1016/j.cub.2007.02.012; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; Kelly AE, 2006, J BIOL CHEM, V281, P10589, DOI 10.1074/jbc.M507470200; Kovar DR, 2006, CURR OPIN CELL BIOL, V18, P11, DOI 10.1016/J.CEB.2005.12.011; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Machesky LM, 1997, BIOCHEM J, V328, P105; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Martin AC, 2006, NAT CELL BIOL, V8, P826, DOI 10.1038/ncb1443; May RC, 2000, NAT CELL BIOL, V2, P246, DOI 10.1038/35008673; Mejillano MR, 2004, CELL, V118, P363, DOI 10.1016/j.cell.2004.07.019; Merrifield CJ, 2004, EUR J CELL BIOL, V83, P13, DOI 10.1078/0171-9335-00356; Miyoshi T, 2006, J CELL BIOL, V175, P947, DOI 10.1083/jcb.200604176; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Mullins RD, 1999, CURR BIOL, V9, P405, DOI 10.1016/S0960-9822(99)80187-0; Plastino J, 2004, CURR BIOL, V14, P1766, DOI 10.1016/j.cub.2004.09.054; Samarin S, 2003, J CELL BIOL, V163, P131, DOI 10.1083/jcb.200303191; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; Stevens JM, 2006, NAT REV MICROBIOL, V4, P91, DOI 10.1038/nrmicro1320; van der Gucht J, 2005, P NATL ACAD SCI USA, V102, P7847, DOI 10.1073/pnas.0502121102; Vignjevic D, 2003, J CELL BIOL, V160, P951, DOI 10.1083/jcb.200208059; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Wiesner S, 2003, J CELL BIOL, V160, P387, DOI 10.1083/jcb.200207148; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7	44	175	179	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	2008	133	5					841	851		10.1016/j.cell.2008.04.011	http://dx.doi.org/10.1016/j.cell.2008.04.011			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510928	Green Accepted, Bronze			2022-12-28	WOS:000256274500016
J	Dolan, L				Dolan, Liam			Plant evolution: TALEs of development	CELL			English	Editorial Material							KNOX GENES; LAND	TALE homeodomain proteins regulate development in many eukaryotes. Now, Lee et al. (2008) report that two TALE homeodomain proteins control zygote development of the unicellular green alga Chlamydomonas. This implicates TALE gene loss and diversification in the evolution of new diploid body plans that appeared when land plants evolved from algal ancestors over 450 million years ago.	John Innes Ctr, Dept Cell & Dev Biol, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Dolan, L (corresponding author), John Innes Ctr, Dept Cell & Dev Biol, Norwich NR4 7UH, Norfolk, England.	liam.dolan@bbsrc.ac.uk		Dolan, Liam/0000-0003-1206-7096	Biotechnology and Biological Sciences Research Council [BBS/B/04498] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BARTON MK, 1993, DEVELOPMENT, V119, P823; Byrne ME, 2003, DEVELOPMENT, V130, P3941, DOI 10.1242/dev.00620; Hake S, 2004, ANNU REV CELL DEV BI, V20, P125, DOI 10.1146/annurev.cellbio.20.031803.093824; Kenrick P, 1997, NATURE, V389, P33, DOI 10.1038/37918; Menand B, 2007, SCIENCE, V316, P1477, DOI 10.1126/science.1142618; Sano R, 2005, EVOL DEV, V7, P69, DOI 10.1111/j.1525-142X.2005.05008.x; Singer SD, 2007, PLANT CELL REP, V26, P2039, DOI 10.1007/s00299-007-0409-5; Zhao H, 2001, GENE DEV, V15, P2767, DOI 10.1101/gad.919501	8	4	4	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 30	2008	133	5					771	773		10.1016/j.cell.2008.05.016	http://dx.doi.org/10.1016/j.cell.2008.05.016			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510922	Bronze			2022-12-28	WOS:000256274500010
J	Wachter, S; Ramirez-Ruiz, E; Dwarkadas, VV; Kouveliotou, C; Granot, J; Patel, SK; Figer, D				Wachter, S.; Ramirez-Ruiz, E.; Dwarkadas, V. V.; Kouveliotou, C.; Granot, J.; Patel, S. K.; Figer, D.			An infrared ring around the magnetar SGR 1900+14	NATURE			English	Article							GAMMA-RAY BURSTS; SGR 1900+14; STARS; DISCOVERY; PULSAR; DUST; SGR-1806-20; CLUSTER	Magnetars(1,2) are a special class of slowly rotating ( period similar to 5 - 12 s) neutron stars with extremely strong magnetic fields (>10(14) G) - at least an order of magnitude larger than those of the 'normal' radio pulsars. The potential evolutionary links and differences between these two types of object are still unknown; recent studies, however, have provided circumstantial evidence connecting magnetars with very massive progenitor stars(3-5). Here we report the discovery of an infrared elliptical ring or shell surrounding the magnetar SGR 1900+14. The appearance and energetics of the ring are difficult to interpret within the framework of the progenitor's stellar mass loss or the subsequent evolution of the supernova remnant. We suggest instead that a dust- free cavity was produced in the magnetar environment by the giant flare emitted by the source in August 1998. Considering the total energy released in the flare, the theoretical dust- destruction radius matches well with the observed dimensions of the ring. We conclude that SGR 1900+14 is unambiguously associated with a cluster of massive stars, thereby solidifying the link between magnetars and massive stars.	[Wachter, S.] CALTECH, Spitzer Sci Ctr, Pasadena, CA 91125 USA; [Dwarkadas, V. V.] Univ Chicago, Dept Astron & Astrophys, Chicago, IL 60637 USA; [Kouveliotou, C.] NASA, George C Marshall Space Flight Ctr, NSSTC, Huntsville, AL 35805 USA; [Granot, J.] Univ Hertfordshire, Ctr Astrophys Res, Hatfield AL10 9AB, Herts, England; [Patel, S. K.] Opt Sci Corp, Huntsville, AL 35806 USA; [Figer, D.] Rochester Inst Technol, Chester F Carlson Ctr Imaging Sci, Rochester, NY 14623 USA	California Institute of Technology; University of Chicago; National Aeronautics & Space Administration (NASA); NASA Marshall Space Flight Center; University of Hertfordshire; Rochester Institute of Technology	Wachter, S (corresponding author), CALTECH, Spitzer Sci Ctr, Pasadena, CA 91125 USA.	wachter@ipac.caltech.edu	Dwarkadas, Vikram/AAV-8210-2021	Granot, Jonathan/0000-0001-8530-8941	STFC [PP/D000920/1] Funding Source: UKRI; Science and Technology Facilities Council [PP/D000920/1] Funding Source: researchfish	STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))		Chan KW, 2000, ASTROPHYS J, V533, pL33, DOI 10.1086/312603; COX IJ, 2000, IEEE INT C IM PROC, V3, P1; Crowther PA, 2007, ANNU REV ASTRON ASTR, V45, P177, DOI 10.1146/annurev.astro.45.051806.110615; Draine BT, 2003, ANNU REV ASTRON ASTR, V41, P241, DOI 10.1146/annurev.astro.41.011802.094840; DUNCAN RC, 1992, ASTROPHYS J, V392, pL9, DOI 10.1086/186413; Elkenberry SS, 2001, ASTROPHYS J, V563, pL133, DOI 10.1086/338360; Figer DF, 2005, ASTROPHYS J, V622, pL49, DOI 10.1086/429159; Frail DA, 1999, NATURE, V398, P127, DOI 10.1038/18163; Fruchter A, 2001, ASTROPHYS J, V563, P597, DOI 10.1086/323520; Gaensler BM, 2001, ASTROPHYS J, V559, P963, DOI 10.1086/322358; Gaensler BM, 2005, ASTROPHYS J, V620, pL95, DOI 10.1086/428725; Gruendl RA, 2000, ASTRON J, V120, P2670, DOI 10.1086/316830; Hartmann DH, 1997, NUCL PHYS A, V621, pC83; Heger A, 2003, ASTROPHYS J, V591, P288, DOI 10.1086/375341; Hurley K, 1999, ASTROPHYS J, V510, pL111, DOI 10.1086/311820; Kaplan DL, 2002, ASTROPHYS J, V566, P378, DOI 10.1086/338039; KOO DC, 1995, ASTROPHYS J, V442, pL679; Kouveliotou C, 1998, NATURE, V393, P235, DOI 10.1038/30410; Morris PW, 2006, ASTROPHYS J, V640, pL179, DOI 10.1086/503669; Muno MP, 2006, ASTROPHYS J, V636, pL41, DOI 10.1086/499776; Palmer DM, 2005, NATURE, V434, P1107, DOI 10.1038/nature03525; Smith N, 2007, ASTRON J, V134, P846, DOI 10.1086/518563; Stratta G, 2005, ASTRON ASTROPHYS, V441, P83, DOI 10.1051/0004-6361:20053302; Tanaka YT, 2007, ASTROPHYS J, V665, pL55, DOI 10.1086/521025; Vrba FJ, 2000, ASTROPHYS J, V533, pL17, DOI 10.1086/312602; Vrba FJ, 1996, ASTROPHYS J, V468, P225, DOI 10.1086/177685; Wachter S, 2007, ASTROPHYS SPACE SCI, V308, P67, DOI 10.1007/s10509-007-9304-3; Waxman E, 2000, ASTROPHYS J, V537, P796, DOI 10.1086/309053; WEIS K, 2003, ASTRON ASTROPHYS, V308, P67; WOODS PM, 2006, COMPACT STELLAR XRAY, P547, DOI DOI 10.1017/CBO9780511536281	30	17	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	2008	453	7195					626	628		10.1038/nature06987	http://dx.doi.org/10.1038/nature06987			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305NN	18509437	Green Submitted			2022-12-28	WOS:000256185200037
J	Fowler, FJ; Gallagher, PM; Anthony, DL; Larsen, K; Skinner, JS				Fowler, Floyd J., Jr.; Gallagher, Patricia M.; Anthony, Denise L.; Larsen, Kirk; Skinner, Jonathan S.			Relationship between regional per capita medicare expenditures and patient perceptions of quality of care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GEOGRAPHIC-VARIATION; HEALTH; BENEFICIARIES; SERVICES; OUTCOMES; BOSTON	Context Wide variations in Medicare expenditures exist across regions, but little is known about whether beneficiaries residing in low- expenditure regions perceive receiving lower- quality care than those in high- expenditure regions. Objective To evaluate how Medicare beneficiaries' perceptions of their health care are related to per capita expenditure in the areas where they live. Design, Setting, and Respondents A probability sample of Medicare beneficiaries living in households in the United States was surveyed by a combination of mail and telephone in 2005. Each respondent was allocated to 1 of 5 quintiles, depending on mean age-, sex-, and race- adjusted per capita Medicare expenditures based on Centers for Medicare & Medicaid Services claims data. Main Outcome Measures The survey included 3 questions about perceived un-met need for care, 4 questions about the perceived quality of ambulatory care, and 3 questions rating the perceived quality of overall care. Results Of 4000 Medicare beneficiaries sampled, 160 ( 4%) were ascertained to have died or to be living in a long- term care facility. Of the remaining 3840 potentially eligible beneficiaries, 2515 ( 65%) responded. Per capita expenditures were highly related to receiving more medical care, such as mean number of ambulatory visits to physicians in the past year ( range from lowest to highest expenditure quintile, 3.4- 3.9; P <. 001 for linear trend) and more cardiac tests ( respondents reporting receiving tests in past year, 158/ 387 [ 40.1%] to 468/ 739 [ 63.5%]; P <. 001 for linear trend). However, 7 of the 10 measures of perceived quality, including perceived unmet needs for tests and treatment ( respondents reporting unmet needs, 15/ 387 [ 3.9%] to 37/ 739 [ 5.0%]; P=. 25 for linear trend) and spending enough time with physicians ( respondents reporting adequate time, 311/ 387 [ 88.7%] to 603/ 739 [ 87.0%]; P=. 94 for linear trend), were unrelated to expenditures, while the overall rating of perceived quality of care was higher in the lower- expenditure areas ( respondents reporting overall care rating of 9 or 10, 242/ 387 [ 63.3%] to 404/ 739 [ 55.4%]; P=. 008 for linear trend). Conclusion In this representative sample of Medicare beneficiaries, no consistent association was observed between the mean per capita expenditure in a geographic area and the perceptions of the quality of medical care of the people who live in those areas.	[Fowler, Floyd J., Jr.; Gallagher, Patricia M.; Larsen, Kirk] Univ Massachusetts, Survey Res Ctr, Boston, MA 02125 USA; [Fowler, Floyd J., Jr.] Fdn Informed Med Decis Making, Boston, MA USA; [Anthony, Denise L.] Dartmouth Coll, Dept Sociol, Hanover, NH 03755 USA; [Skinner, Jonathan S.] Dartmouth Coll, Dept Econ, Hanover, NH 03755 USA	University of Massachusetts System; University of Massachusetts Boston; Dartmouth College; Dartmouth College	Fowler, FJ (corresponding author), Univ Massachusetts, Survey Res Ctr, 100 Morrissey Blvd, Boston, MA 02125 USA.	floyd.fowler@umb.edu		Anthony, Denise/0000-0001-5815-9055	NATIONAL INSTITUTE ON AGING [P01AG019783] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG19783, P01 AG019783-07, P01 AG019783] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American Association for Public Opinion Research, 2004, STAND DEF FIN DISP C; [Anonymous], ANSWERING QUESTIONS; Arday SL, 2000, HEALTH CARE FINANC R, V21, P107; Baicker K, 2004, HEALTH AFFAIR, V23, pW4184, DOI 10.1377/hlthaff.W4.184; Baicker K, 2006, HEALTH AFFAIR, V25, pW355, DOI 10.1377/hlthaff.25.w355; BAMATO AE, 2007, MED CARE, V45, P386; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; Davis K, 2007, MIRROR MIRROR WALL I; Feenberg D, 2000, NATL TAX J, V53, P713, DOI 10.17310/ntj.2000.3S.05; Fiscella K, 2000, JAMA-J AM MED ASSOC, V283, P2579, DOI 10.1001/jama.283.19.2579; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; FISHER ES, 1994, NEW ENGL J MED, V331, P989, DOI 10.1056/NEJM199410133311506; Fowler F., 2002, SURVEY RES METHOD; GATSONIS CA, 1995, MED CARE, V33, P625, DOI 10.1097/00005650-199506000-00005; Jencks SF, 2003, JAMA-J AM MED ASSOC, V289, P305, DOI 10.1001/jama.289.3.305; Landrum MB, 2008, HEALTH AFFAIR, V27, P159, DOI 10.1377/hlthaff.27.1.159; MCCLELLAN M, 1995, AM ECON REV, V85, P38; O'Connor AM, 1999, BRIT MED J, V319, P731, DOI 10.1136/bmj.319.7212.731; OCONNOR AM, 2004, HLTH AFF MILLWOOD; Schoen C, 2007, HEALTH AFFAIR, V26, pW717, DOI 10.1377/hlthaff.26.6.w717; STRAUSS MJ, 1986, JAMA-J AM MED ASSOC, V255, P1143, DOI 10.1001/jama.255.9.1143; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; Wennberg JE., DARTMOUTH ATLAS HLTH; Wennberg John E, 2002, Health Aff (Millwood), VSuppl Web Exclusives, pW96; Willis G.B, 2004, COGNITIVE INTERVIEWI	27	49	49	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2008	299	20					2406	2412		10.1001/jama.299.20.2406	http://dx.doi.org/10.1001/jama.299.20.2406			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305BD	18505950	Bronze, Green Accepted			2022-12-28	WOS:000256151900025
J	Duffy, SJ; Dart, AM				Duffy, Stephen J.; Dart, Anthony M.			Novel cardiac therapies and innocent bystanders	LANCET			English	Editorial Material							HUMAN ATHEROSCLEROSIS; HIGH-RISK; AGI-1067; HYPOTHESIS; PREVENTION; EVENTS		[Duffy, Stephen J.; Dart, Anthony M.] Alfred Hosp, Dept Cardiovasc Med, Melbourne, Vic 3004, Australia; [Duffy, Stephen J.; Dart, Anthony M.] Baker Heart Res Inst, Alfred & Baker Med Unit, Melbourne, Vic, Australia	Florey Institute of Neuroscience & Mental Health; Baker Heart and Diabetes Institute	Duffy, SJ (corresponding author), Alfred Hosp, Dept Cardiovasc Med, Melbourne, Vic 3004, Australia.	s.duffy@alfred.org.au	Dart, Anthony/E-7461-2010	Dart, Anthony/0000-0003-1360-3778				Barter PJ, 2007, NEW ENGL J MED, V357, P2109, DOI 10.1056/NEJMoa0706628; Franks AM, 2006, ANN PHARMACOTHER, V40, P66, DOI 10.1345/aph.1G142; Kris-Etherton PM, 2004, CIRCULATION, V110, P637, DOI 10.1161/01.CIR.0000137822.39831.F1; Munzel T, 2001, CIRCULATION, V104, P1571, DOI 10.1161/hc3801.095585; Schmieder RE, 2007, LANCET, V369, P1208, DOI 10.1016/S0140-6736(07)60242-6; Shah S, 2007, ANTIOXID REDOX SIGN, V9, P911, DOI 10.1089/ars.2007.1629; Steinberg D, 2002, CIRCULATION, V105, P2107, DOI 10.1161/01.CIR.0000014762.06201.06; Stocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003; Tardif JC, 2003, CIRCULATION, V107, P552, DOI 10.1161/01.CIR.0000047525.58618.3C; Tardif JC, 2008, LANCET, V371, P1761, DOI 10.1016/S0140-6736(08)60763-1; Tardif JC, 2008, ATHEROSCLEROSIS, V197, P480, DOI 10.1016/j.atherosclerosis.2006.11.039; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9; Yusuf S, 2008, NEW ENGL J MED, V358, P1547, DOI 10.1056/NEJMoa0801317	13	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 24	2008	371	9626					1726	1728		10.1016/S0140-6736(08)60737-0	http://dx.doi.org/10.1016/S0140-6736(08)60737-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304IO	18502279				2022-12-28	WOS:000256103400005
J	Lindstrom, J; Uusitupa, M				Lindstrom, Jaana; Uusitupa, Matti			Lifestyle intervention, diabetes, and cardiovascular disease	LANCET			English	Editorial Material							IMPAIRED GLUCOSE-TOLERANCE; FOLLOW-UP; PREVENTION; MELLITUS; ACARBOSE; NIDDM; RISK; DIET; IGT		[Lindstrom, Jaana] Natl Publ Hlth Inst, Diabet Unit, Dept Hlth Promot & Chron Dis Prevent, FIN-00300 Helsinki, Finland; [Lindstrom, Jaana] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; [Uusitupa, Matti] Univ Kuopio, FIN-70211 Kuopio, Finland	Finland National Institute for Health & Welfare; University of Helsinki; University of Eastern Finland	Lindstrom, J (corresponding author), Natl Publ Hlth Inst, Diabet Unit, Dept Hlth Promot & Chron Dis Prevent, FIN-00300 Helsinki, Finland.	jaana.lindstrom@ktl.fi	Uusitupa, Matti Ilmari Julius/AAX-4929-2020	Lindstrom, Jaana/0000-0001-9255-020X				Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5; Chiasson JL, 2003, JAMA-J AM MED ASSOC, V290, P486, DOI 10.1001/jama.290.4.486; Diabetes Prevention Program Research Group, 2002, NEW ENGL J MED, V346, P393, DOI [10.1056/NEJMoa012512, DOI 10.1056/NEJMOA012512]; Hjerkinn EM, 2004, J INTERN MED, V255, P68, DOI 10.1046/j.0954-6820.2003.01248.x; Howard BV, 2006, JAMA-J AM MED ASSOC, V295, P655, DOI 10.1001/jama.295.6.655; Joslin EP, 1921, J AMER MED ASSOC, V76, P79; Kosaka K, 2005, DIABETES RES CLIN PR, V67, P152, DOI 10.1016/j.diabres.2004.06.010; Li GW, 2008, LANCET, V371, P1783, DOI 10.1016/S0140-6736(08)60766-7; Lindstrom J, 2006, LANCET, V368, P1673, DOI 10.1016/S0140-6736(06)69701-8; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; Ramachandran A, 2006, DIABETOLOGIA, V49, P289, DOI 10.1007/s00125-005-0097-z; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; TURPEINEN O, 1979, INT J EPIDEMIOL, V8, P99, DOI 10.1093/ije/8.2.99	13	11	11	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	2008	371	9626					1731	1733		10.1016/S0140-6736(08)60740-0	http://dx.doi.org/10.1016/S0140-6736(08)60740-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304IO	18502282				2022-12-28	WOS:000256103400008
J	Retnakaran, R; Zinman, B				Retnakaran, Ravi; Zinman, Bernard			Type 1 diabetes, hyperglycaemia, and the heart	LANCET			English	Review							CORONARY-ARTERY-DISEASE; INTIMA-MEDIA THICKNESS; ALL-CAUSE MORTALITY; CARDIOVASCULAR-DISEASE; PITTSBURGH EPIDEMIOLOGY; GLYCEMIC CONTROL; RISK-FACTORS; INSULIN-RESISTANCE; COMPLICATIONS TRIAL/EPIDEMIOLOGY; AUTONOMIC NEUROPATHY	Type 1 diabetes is associated with a substantially increased risk of cardiovascular disease that might not always be appreciated in view of the fairly young age of patients with this condition. In fact, in type 1 diabetes, the heart is subject to a variety of pathological insults, including accelerated atherosclerosis, cardiac autonomic neuropathy, and possibly intrinsic cardiomyopathy. Although the relation between hyperglycaemia and microvascular complications has been well established, a direct effect of hyperglycaemia on cardiovascular disease in type 1 diabetes has long been debated. More recently, several studies, most notably the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications, have clarified this issue and provided conclusive evidence that hyperglycaemia is indeed a mediator of cardiovascular risk in type 1 diabetes and that intensive diabetes therapy can reduce cardiovascular disease outcomes. We review current concepts in type 1 diabetes and the heart, focusing on recent insights into the central role of hyperglycaemia.	[Retnakaran, Ravi; Zinman, Bernard] Mt Sinai Hosp, Leadership Sinai Ctr Diabet, Toronto, ON M5T 3L9, Canada; [Zinman, Bernard] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5T 3L9, Canada; [Retnakaran, Ravi; Zinman, Bernard] Univ Toronto, Div Endocrinol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Zinman, B (corresponding author), Mt Sinai Hosp, Leadership Sinai Ctr Diabet, 60 Murray St,Suite L5-025,Mailbox 17, Toronto, ON M5T 3L9, Canada.	zinman@mshri.on.ca	Zinman, Bernard/E-7266-2013; Retnakaran, Ravi/P-2002-2015	Retnakaran, Ravi/0000-0003-1989-027X				Aepfelbacher FC, 2004, INT J CARDIOL, V94, P47, DOI 10.1016/j.ijcard.2003.04.012; Avogaro A, 2004, AM J CARDIOL, V93, p13A, DOI 10.1016/j.amjcard.2003.11.003; Bax JJ, 2007, DIABETES CARE, V30, P2729, DOI 10.2337/dc07-9927; Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; Boudina S, 2007, CIRCULATION, V115, P3213, DOI 10.1161/CIRCULATIONAHA.106.679597; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Chan NN, 2003, ARTERIOSCL THROM VAS, V23, P1048, DOI 10.1161/01.ATV.0000072968.00157.6B; Cleary PA, 2006, DIABETES, V55, P3556, DOI 10.2337/db06-0653; Colhoun HM, 2002, DIABETES CARE, V25, P1813, DOI 10.2337/diacare.25.10.1813; Colhoun HM, 2000, J AM COLL CARDIOL, V36, P2160, DOI 10.1016/S0735-1097(00)00986-4; Costacou T, 2005, J DIABETES COMPLICAT, V19, P183, DOI 10.1016/j.jdiacomp.2005.01.003; Costacou T, 2005, DIABETOLOGIA, V48, P41, DOI 10.1007/s00125-004-1597-y; Costacou T, 2007, AM J CARDIOL, V100, P1543, DOI 10.1016/j.amjcard.2007.06.050; Dabelea D, 2003, DIABETES, V52, P2833, DOI 10.2337/diabetes.52.11.2833; Dahl-Jorgensen K, 2005, DIABETOLOGIA, V48, P1445, DOI 10.1007/s00125-005-1832-1; DECKERT T, 1978, DIABETOLOGIA, V14, P363, DOI 10.1007/BF01228130; Devaraj S, 2006, DIABETES, V55, P774, DOI 10.2337/diabetes.55.03.06.db05-1417; Diabet Control Complications Trial Res Grp, 1998, DIABETOLOGIA, V41, P416; DORMAN JS, 1984, DIABETES, V33, P271, DOI 10.2337/diabetes.33.3.271; Du XL, 2003, J CLIN INVEST, V112, P1049, DOI 10.1172/JCI200318127; EARLE K, 1992, NEW ENGL J MED, V326, P673, DOI 10.1056/NEJM199203053261005; Eckel RH, 2002, CIRCULATION, V105, P2923, DOI 10.1161/01.CIR.0000017823.53114.4C; Erbey JR, 1998, DIABETES CARE, V21, P610, DOI 10.2337/diacare.21.4.610; Faxon DP, 2004, CIRCULATION, V109, P2617, DOI 10.1161/01.CIR.0000128520.37674.EF; Forrest KYZ, 2000, ATHEROSCLEROSIS, V148, P159, DOI 10.1016/S0021-9150(99)00217-8; Genuth S, 1999, DIABETES CARE, V22, P99; Giannattasio C, 1999, DIABETOLOGIA, V42, P987, DOI 10.1007/s001250051257; Grandi AM, 2006, AM J CARDIOL, V97, P71, DOI 10.1016/j.amjcard.2005.07.110; Groop PH, 2007, DIABETES CARE, V30, P2706, DOI 10.2337/dc07-0030; Haller MJ, 2004, DIABETES CARE, V27, P2911, DOI 10.2337/diacare.27.12.2911; Hokanson JE, 2002, DIABETES, V51, P1208, DOI 10.2337/diabetes.51.4.1208; Holl RW, 1999, DIABETES CARE, V22, P1151, DOI 10.2337/diacare.22.7.1151; Jarvisalo MJ, 2004, CIRCULATION, V109, P2885, DOI 10.1161/01.CIR.0000129304.98566.D8; Jarvisalo MJ, 2002, DIABETES, V51, P493, DOI 10.2337/diabetes.51.2.493; Jarvisalo MJ, 2001, CIRCULATION, V104, P2943, DOI 10.1161/hc4901.100522; Jenkins AJ, 2003, DIABETES CARE, V26, P810, DOI 10.2337/diacare.26.3.810; JENSEN T, 1987, DIABETOLOGIA, V30, P144, DOI 10.1007/BF00274218; Juutilainen A, 2008, DIABETES CARE, V31, P714, DOI 10.2337/dc07-2124; Kadowaki T, 2006, J CLIN INVEST, V116, P1784, DOI 10.1172/JCI29126; KAISER N, 1993, DIABETES, V42, P80, DOI 10.2337/diabetes.42.1.80; Kilpatrick ES, 2007, DIABETES CARE, V30, P707, DOI 10.2337/dc06-1982; Klein BEK, 2004, ARCH INTERN MED, V164, P1917, DOI 10.1001/archinte.164.17.1917; Kretowski A, 2006, DIABETOLOGIA, V49, P1946, DOI 10.1007/s00125-006-0317-1; Kretowski A, 2007, DIABETES, V56, P863, DOI 10.2337/db06-1321; KROLEWSKI AS, 1987, AM J CARDIOL, V59, P750, DOI 10.1016/0002-9149(87)91086-1; Lachin JM, 2008, DIABETES, V57, P995, DOI 10.2337/db07-1618; Lacquemant C, 2000, KIDNEY INT, V57, P1437, DOI 10.1046/j.1523-1755.2000.00988.x; Laing SP, 2003, DIABETOLOGIA, V46, P760, DOI 10.1007/s00125-003-1116-6; Larsen J, 2002, DIABETES, V51, P2637, DOI 10.2337/diabetes.51.8.2637; Larsen JR, 2005, DIABETOLOGIA, V48, P776, DOI 10.1007/s00125-005-1700-z; Larsen JR, 2004, DIABETES CARE, V27, P963, DOI 10.2337/diacare.27.4.963; Lehto S, 1999, ARTERIOSCL THROM VAS, V19, P1014, DOI 10.1161/01.ATV.19.4.1014; Libby P, 2005, CIRCULATION, V111, P3489, DOI 10.1161/CIRCULATIONAHA.104.529651; Lloyd CE, 1996, ARTERIOSCL THROM VAS, V16, P720, DOI 10.1161/01.ATV.16.6.720; Maahs DM, 2007, DIABETES, V56, P2774, DOI 10.2337/db07-0539; Maahs DM, 2006, J CLIN ENDOCR METAB, V91, P3757, DOI 10.1210/jc.2006-1730; Maahs DM, 2005, CIRCULATION, V111, P747, DOI 10.1161/01.CIR.0000155251.03724.A5; Margeirsdottir HD, 2008, DIABETOLOGIA, V51, P554, DOI 10.1007/s00125-007-0921-8; Maser RE, 2003, DIABETES CARE, V26, P1895, DOI 10.2337/diacare.26.6.1895; Monnier L, 2006, JAMA-J AM MED ASSOC, V295, P1681, DOI 10.1001/jama.295.14.1681; Nathan DM, 2003, NEW ENGL J MED, V348, P761; Nathan DM, 2005, NEW ENGL J MED, V353, P2643, DOI 10.1056/nejmoa052187; Olson JC, 2000, DIABETES, V49, P1571, DOI 10.2337/diabetes.49.9.1571; Orchard TJ, 1998, INT J EPIDEMIOL, V27, P976, DOI 10.1093/ije/27.6.976; Orchard TJ, 1999, DIABETES, V48, P1454, DOI 10.2337/diabetes.48.7.1454; Orchard TJ, 2003, DIABETES CARE, V26, P1374, DOI 10.2337/diacare.26.5.1374; Orchard TJ, 1996, DIABETES RES CLIN PR, V34, pS165, DOI 10.1016/S0168-8227(96)01321-6; Orchard TJ, 2006, DIABETES CARE, V29, P2528, DOI 10.2337/dc06-1161; Pajunen P, 2000, AM J CARDIOL, V86, P1080, DOI 10.1016/S0002-9149(00)01163-2; Pambianco G, 2006, DIABETES, V55, P1463, DOI 10.2337/db05-1423; Paterson AD, 2007, DIABETES CARE, V30, P2107, DOI 10.2337/dc06-1441; Pettersson-Fernholm K, 2004, DIABETES CARE, V27, P503, DOI 10.2337/diacare.27.2.503; Pettersson-Fernholm K, 2003, DIABETES, V52, P891, DOI 10.2337/diabetes.52.3.891; Poornima IG, 2006, CIRC RES, V98, P596, DOI 10.1161/01.RES.0000207406.94146.c2; Prince CT, 2007, DIABETOLOGIA, V50, P2280, DOI 10.1007/s00125-007-0797-7; Purnell JQ, 1998, JAMA-J AM MED ASSOC, V280, P140, DOI 10.1001/jama.280.2.140; RETNAKARAN R, 2006, CLIN DIABETES, P35; Rodriguez RR, 2007, DIABETES CARE, V30, P2599, DOI 10.2337/dc07-0922; Ronnback M, 2004, CIRCULATION, V110, P1076, DOI 10.1161/01.CIR.0000139903.29522.8D; RUDDY TD, 1988, J CLIN ENDOCR METAB, V66, P113, DOI 10.1210/jcem-66-1-113; Schannwell CM, 2002, CARDIOLOGY, V98, P33, DOI 10.1159/000064682; Schram MT, 2005, DIABETOLOGIA, V48, P370, DOI 10.1007/s00125-004-1628-8; Schwab KO, 2006, DIABETES CARE, V29, P218, DOI 10.2337/diacare.29.02.06.dc05-0724; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shankar A, 2007, AM J EPIDEMIOL, V166, P393, DOI 10.1093/aje/kwm096; Shishehbor MH, 2003, AM J CARDIOL, V91, P1514, DOI 10.1016/S0002-9149(03)00414-4; Shivalkar B, 2006, AM J CARDIOL, V97, P77, DOI 10.1016/j.amjcard.2005.07.111; Sibley SD, 2003, J CLIN ENDOCR METAB, V88, P3379, DOI 10.1210/jc.2002-021693; Soedamah-Muthu SS, 2008, DIABETOLOGIA, V51, P493, DOI 10.1007/s00125-007-0905-8; Soedamah-Muthu SS, 2006, DIABETES CARE, V29, P798, DOI 10.2337/diacare.29.04.06.dc05-1433; Soedamah-Muthu SS, 2004, DIABETES CARE, V27, P530, DOI 10.2337/diacare.27.2.530; Soedamah-Muthu SS, 2006, DIABETOLOGIA, V49, P660, DOI 10.1007/s00125-005-0120-4; Steffes MW, 2003, JAMA-J AM MED ASSOC, V290, P2159, DOI 10.1001/jama.290.16.2159; Stettler C, 2006, AM HEART J, V152, P27, DOI 10.1016/j.ahj.2005.09.015; TASKINEN MR, 1992, DIABETES, V41, P12, DOI 10.2337/diab.41.2.S12; TEUPE B, 1991, LANCET, V337, P361, DOI 10.1016/0140-6736(91)90988-2; Torffvit O, 2005, DIABETIC MED, V22, P723, DOI 10.1111/j.1464-5491.2005.01476.x; Tuomilehto J, 1998, DIABETOLOGIA, V41, P784, DOI 10.1007/s001250050988; VALSANIA P, 1991, AM HEART J, V122, P695, DOI 10.1016/0002-8703(91)90513-H; Vinik AI, 2003, DIABETES CARE, V26, P1553, DOI 10.2337/diacare.26.5.1553; Wadwa RP, 2006, INT J BIOCHEM CELL B, V38, P996, DOI 10.1016/j.biocel.2005.09.015; Watts GF, 1996, METABOLISM, V45, P1101, DOI 10.1016/S0026-0495(96)90009-8; Weinrauch Larry A, 2005, J Clin Hypertens (Greenwich), V7, P159, DOI 10.1111/j.1524-6175.2005.04307.x; Wiltshire EJ, 2002, DIABETES, V51, P2282, DOI 10.2337/diabetes.51.7.2282; Witte DR, 2005, DIABETOLOGIA, V48, P164, DOI 10.1007/s00125-004-1617-y	106	81	85	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	2008	371	9626					1790	1799		10.1016/S0140-6736(08)60767-9	http://dx.doi.org/10.1016/S0140-6736(08)60767-9			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304IO	18502304				2022-12-28	WOS:000256103400034
J	Gregoryanz, E; Lundegaard, LF; McMahon, MI; Guillaume, C; Nelmes, RJ; Mezouar, M				Gregoryanz, Eugene; Lundegaard, Lars F.; McMahon, Malcolm I.; Guillaume, Christophe; Nelmes, Richard J.; Mezouar, Mohamed			Structural diversity of sodium	SCIENCE			English	Article							LIQUID METALLIC HYDROGEN; DENSE LITHIUM; SUPERCONDUCTIVITY; CONSTITUTION; PRESSURE	Sodium exhibits a pronounced minimum of the melting temperature at similar to 118 gigapascals and 300 kelvin. Using single- crystal high- pressure diffraction techniques, we found that the minimum of the sodium melting curve is associated with a concentration of seven different crystalline phases. Slight changes in pressure and/ or temperature induce transitions between numerous structural modifications, several of which are highly complex. The complexity of the phase behavior above 100 gigapascals suggests extraordinary liquid and solid states of sodium at extreme conditions and has implications for other seemingly simple metals.	[Gregoryanz, Eugene; Lundegaard, Lars F.; McMahon, Malcolm I.; Guillaume, Christophe; Nelmes, Richard J.] Univ Edinburgh, Sch Phys, Edinburgh EH9 3JZ, Midlothian, Scotland; [Gregoryanz, Eugene; Lundegaard, Lars F.; McMahon, Malcolm I.; Guillaume, Christophe; Nelmes, Richard J.] Univ Edinburgh, Ctr Sci Extreme Condit, Edinburgh EH9 3JZ, Midlothian, Scotland; [Mezouar, Mohamed] European Synchrotron Radiat Facil, F-38043 Grenoble, France	University of Edinburgh; University of Edinburgh; European Synchrotron Radiation Facility (ESRF)	Gregoryanz, E (corresponding author), Univ Edinburgh, Sch Phys, Edinburgh EH9 3JZ, Midlothian, Scotland.	e.gregoryanz@ed.ac.uk	McMahon, Malcolm I/D-9765-2012	McMahon, Malcolm I/0000-0003-4343-344X; Gregoryanz, Eugene/0000-0001-9080-8756; Lundegaard, Lars Fahl/0000-0003-1271-3182				Babaev E, 2004, NATURE, V431, P666, DOI 10.1038/nature02910; BERGARA A, 2007, 21 AIRAPT 45 EHPRG I, P103; Brovman E. G., 1972, Soviet Physics - JETP, V35, P783; BROVMAN EG, 1972, SOV PHYS JETP-USSR, V34, P1300; DAVIS KB, 1995, PHYS REV LETT, V75, P3969, DOI 10.1103/PhysRevLett.75.3969; Degtyareva O, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.205502; Gregoryanz E, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.185502; Gregoryanz E, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.175701; Hanfland M, 2000, NATURE, V408, P174, DOI 10.1038/35041515; Hanfland M, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.184109; JAFFE JE, 1981, PHYS REV B, V23, P6176, DOI 10.1103/PhysRevB.23.6176; Katsnelson MI, 2000, PHYS REV B, V61, P14420, DOI 10.1103/PhysRevB.61.14420; Lundegaard L. F., 2007, THESIS U EDINBURGH; McMahon MI, 2007, P NATL ACAD SCI USA, V104, P17297, DOI 10.1073/pnas.0709309104; McMahon MI, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.140102; McMahon MI, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.055501; McMahon MI, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.255502; Neaton JB, 1999, NATURE, V400, P141, DOI 10.1038/22067; Neaton JB, 2001, PHYS REV LETT, V86, P2830, DOI 10.1103/PhysRevLett.86.2830; Pearson W. B., 1972, CRYSTAL CHEM PHYS ME; Raty JY, 2007, NATURE, V449, P448, DOI 10.1038/nature06123; Rodriguez-Prieto A, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.172104; Shimizu K, 2002, NATURE, V419, P597, DOI 10.1038/nature01098; Smorgrav E, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.135301; STRAUS DM, 1977, PHYS REV LETT, V38, P415, DOI 10.1103/PhysRevLett.38.415; Struzhkin VV, 2002, SCIENCE, V298, P1213, DOI 10.1126/science.1078535; Syassen K., 2002, HIGH PRESSURE PHENOM, P266; Wigner E, 1933, PHYS REV, V43, P0804, DOI 10.1103/PhysRev.43.804	29	134	135	5	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2008	320	5879					1054	1057		10.1126/science.1155715	http://dx.doi.org/10.1126/science.1155715			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18497293				2022-12-28	WOS:000256059800039
J	Sanders, GD; Bayoumi, AM; Holodnly, M; Owens, DK				Sanders, Gillian D.; Bayoumi, Ahmed M.; Holodnly, Mark; Owens, Douglas K.			Cost-effectiveness of HIV screening in patients older than 55 years of age	ANNALS OF INTERNAL MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; PROTEASE INHIBITOR THERAPY; PLASMA VIRAL LOAD; CD4 CELL COUNT; LONG-TERM RESPONSE; RNA LEVELS; INFECTED PATIENTS; HETEROSEXUAL TRANSMISSION; PROGNOSTIC VALUE	Background: Although HIV infection is more prevalent in people younger than age 45 years, a substantial number of infections occur in older persons. Recent guidelines recommend HIV screening in patients age 13 to 64 years. The cost-effectiveness of HIV screening in patients age 55 to 75 years is uncertain. Objective: To examine the costs and benefits of HIV screening in patients age 55 to 75 years. Design: Markov model. Data Sources: Derived from the literature. Target Population: Patients age 55 to 75 years with unknown HIV status. Time Horizon: Lifetime. Perspective: Societal. Intervention: HIV screening program for patients age 55 to 75 years compared with current practice. Outcome Measures: Life-years, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness. Results of Base-Case Analysis: For a 65-year-old patient, HIV screening using traditional counseling costs $55 440 per QALY compared with current practice when the prevalence of HIV was 0.5% and the patient did not have a sexual partner at risk. In sexually active patients, the incremental cost-effectiveness ratio was $30 020 per QALY. At a prevalence of 0.1%, HIV screening cost less than $60 000 per QALY for patients younger than age 75 years with a partner at risk if less costly streamlined counseling is used. Results of Sensitivity Analysis: Cost-effectiveness of HIV screening depended on HIV prevalence, age of the patient, counseling costs, and whether the patient was sexually active. Sensitivity analyses with other variables did not change the results substantially. Limitations: The effects of age on the toxicity and efficacy of highly active antiretroviral therapy and death from AIDS were uncertain. Sensitivity analyses exploring these variables did not qualitatively affect the results. Conclusion: If the tested population has an HIV prevalence of 0.1% or greater, HIV screening in persons from age 55 to 75 years reaches conventional levels of cost-effectiveness when counseling is streamlined and if the screened patient has a partner at risk. Screening patients with advanced age for HIV is economically attractive in many circumstances.	Duke Univ, Duke Clin Res Inst, Durham, NC 27715 USA; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; Vet Affairs Palo Alto Hlth Care System, Palo Alto, CA USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA	Duke University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Sanders, GD (corresponding author), Duke Univ, Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA.	gillian.sanders@duke.edu		Holodniy, Mark/0000-0002-6655-7982	NIA NIH HHS [P30 AG017253, P30-AG017253] Funding Source: Medline; NIDA NIH HHS [R01 DA015612-10, R01 DA015612, R01 DA15612-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG017253] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015612, R37DA015612] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		[Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 2006, MMWR RECOMM REP; Bindman AB, 1998, JAMA-J AM MED ASSOC, V280, P1416, DOI 10.1001/jama.280.16.1416; Bonfanti P, 2000, J ACQ IMMUN DEF SYND, V23, P236; Bozzette SA, 1998, NEW ENGL J MED, V339, P1897, DOI 10.1056/NEJM199812243392606; Braithwaite RS, 2005, AM J MED, V118, P890, DOI 10.1016/j.amjmed.2004.12.034; Branson Bernard M., 2006, Morbidity and Mortality Weekly Report, V55, P1; BrunVezinet F, 1997, LANCET, V350, P983, DOI 10.1016/S0140-6736(97)03380-1; Butcher D, 2000, ARCH INTERN MED, V160, P394, DOI 10.1001/archinte.160.3.394-a; CACERES CF, 1994, AIDS, V8, P1051, DOI 10.1097/00002030-199408000-00004; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Casado JL, 1998, AIDS, V12, pF131, DOI 10.1097/00002030-199811000-00005; *CDC, 1988, MMWR-MORBID MORTAL W, V36, P845; *CDC, 1988, MMWR-MORBID MORTAL W, V36, P833; *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P538; *CDCP, 2001, HIV COUNS TEST PUBL; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P329; *CDCP, HIV AIDS SURV REP 20, V14; *CDCP, 2005, HIV AIDS SURV REP, V17; Celentano DD, 1998, SCIENCE, V280, P1889, DOI 10.1126/science.280.5371.1889; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P309; Chen RY, 2006, CLIN INFECT DIS, V42, P1003, DOI 10.1086/500453; Chene G, 1998, AIDS, V12, P2313, DOI 10.1097/00002030-199817000-00013; Cook J, 1999, AIDS RES HUM RETROV, V15, P499, DOI 10.1089/088922299311024; Coombs RW, 1996, J INFECT DIS, V174, P704, DOI 10.1093/infdis/174.4.704; Cooper D, 1999, LANCET, V353, P2061, DOI 10.1016/S0140-6736(98)10391-4; D'Amato RM, 1998, ANTIVIR THER, V3, P147; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; Deschamps MM, 1996, ANN INTERN MED, V125, P324, DOI 10.7326/0003-4819-125-4-199608150-00011; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; deWolf F, 1997, AIDS, V11, P1799, DOI 10.1097/00002030-199715000-00003; DICLEMENTE RJ, 1995, JAMA-J AM MED ASSOC, V274, P1271, DOI 10.1001/jama.274.16.1271; Drusano GL, 1998, ANTIMICROB AGENTS CH, V42, P358; Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2; Erb P, 2000, ARCH INTERN MED, V160, P1134, DOI 10.1001/archinte.160.8.1134; ERICKSON B, 1990, SEX TRANSM DIS, V17, P194, DOI 10.1097/00007435-199010000-00009; Espinoza L, 2007, AM J PUBLIC HEALTH, V97, P144, DOI 10.2105/AJPH.2005.077461; Freedberg KA, 2001, NEW ENGL J MED, V344, P824, DOI 10.1056/NEJM200103153441108; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Gable CB, 1996, J ACQ IMMUN DEF SYND, V12, P413, DOI 10.1097/00042560-199608010-00013; GalettoLacour A, 1996, J INFECT DIS, V173, P1388, DOI 10.1093/infdis/173.6.1388; Goetz MB, 2001, AIDS, V15, P1576, DOI 10.1097/00002030-200108170-00017; Grabar S, 2004, AIDS, V18, P2029, DOI 10.1097/00002030-200410210-00007; Grabar S, 2006, J ANTIMICROB CHEMOTH, V57, P4, DOI 10.1093/jac/dki411; Grimes RM, 2002, CLIN INFECT DIS, V34, P1530, DOI 10.1086/340404; Guardiola JM, 1999, ARCH INTERN MED, V159, P194, DOI 10.1001/archinte.159.2.194; Gulick RM, 2000, ANN INTERN MED, V133, P35, DOI 10.7326/0003-4819-133-1-200007040-00007; Gulick RM, 1998, JAMA-J AM MED ASSOC, V280, P35, DOI 10.1001/jama.280.1.35; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HARRIS RL, 1990, INFECT CONT HOSP EP, V11, P628; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; HENRARD DR, 1995, JAMA-J AM MED ASSOC, V274, P554, DOI 10.1001/jama.274.7.554; Hightow LB, 2003, AIDS EDUC PREV, V15, P282, DOI 10.1521/aeap.15.4.282.23826; *HITS 2000 INV, 2004, J ACQ IMMUN DEF SYND, V35, P511; *HIV COST SERV UT, 2001, NEW ENGL J MED, V344, P817; HOLMAN S, 1994, PUBLIC HEALTH REP, V109, P521; HONIDEN S, 2002, MED DECIS MAKING, V22, P560; Hughes MD, 1997, ANN INTERN MED, V126, P929, DOI 10.7326/0003-4819-126-12-199706150-00001; Ioannidis JPA, 1996, AIDS, V10, P255, DOI 10.1097/00002030-199603000-00003; Irwin K, 1996, ANN INTERN MED, V125, P471, DOI 10.7326/0003-4819-125-6-199609150-00007; Justice AC, 2004, AIDS, V18, pS49, DOI 10.1097/00002030-200401001-00008; Kamb ML, 1998, JAMA-J AM MED ASSOC, V280, P1161, DOI 10.1001/jama.280.13.1161; Karon JM, 2001, AM J PUBLIC HEALTH, V91, P1060, DOI 10.2105/AJPH.91.7.1060; Kassler WJ, 1997, AIDS, V11, P1045, DOI 10.1097/00002030-199708000-00014; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Kaufmann GR, 1998, AIDS, V12, P1625, DOI 10.1097/00002030-199813000-00009; KEET IPM, 1992, AIDS, V6, P223, DOI 10.1097/00002030-199202000-00014; Keet IPM, 1997, J INFECT DIS, V176, P665, DOI 10.1086/514088; Keiser P, 1999, J ACQ IMMUN DEF SYND, V20, P28, DOI 10.1097/00042560-199901010-00004; Keita-Perse O, 1998, AIDS, V12, pF175, DOI 10.1097/00002030-199815000-00002; Kelen GD, 1999, ANN EMERG MED, V33, P147, DOI 10.1016/S0196-0644(99)70387-2; Kelen GD, 1996, ANN EMERG MED, V27, P687, DOI 10.1016/S0196-0644(96)70184-1; Kempf DJ, 1998, AIDS, V12, pF9, DOI 10.1097/00002030-199805000-00001; King JT, 2003, MED DECIS MAKING, V23, P9, DOI 10.1177/0272989X02239652; Knobel H, 2001, AIDS, V15, P1591, DOI 10.1097/00002030-200108170-00025; Koblin BA, 1999, AM J EPIDEMIOL, V150, P1026, DOI 10.1093/oxfordjournals.aje.a009926; Kozak Lola Jean, 2004, Vital Health Stat 13, P1; LAUMAN EO, 1994, SOCIAL ORG SEXUALITY; Le Moing V, 2002, AIDS, V16, P21, DOI 10.1097/00002030-200201040-00004; LEMP GF, 1994, JAMA-J AM MED ASSOC, V272, P449, DOI 10.1001/jama.272.6.449; Lindau ST, 2007, NEW ENGL J MED, V357, P762, DOI 10.1056/NEJMoa067423; LOVEDAY C, 1995, LANCET, V345, P790, DOI 10.1016/S0140-6736(95)90668-1; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; MACDONALD KL, 1989, ANN INTERN MED, V110, P617, DOI 10.7326/0003-4819-110-8-617; Maher K, 1999, J ACQ IMMUN DEF SYND, V22, P358; Manfredi R, 2004, AGEING RES REV, V3, P31, DOI 10.1016/j.arr.2003.07.001; Marschner IC, 1998, J INFECT DIS, V177, P40, DOI 10.1086/513823; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Mocroft A, 1998, AIDS, V12, P2161, DOI 10.1097/00002030-199816000-00011; Mole L, 1999, PHARMACOECONOMICS, V16, P307, DOI 10.2165/00019053-199916030-00007; Monforte AD, 1998, AIDS, V12, P1631, DOI 10.1097/00002030-199813000-00010; Monforte AD, 2000, AIDS, V14, P499, DOI 10.1097/00002030-200003310-00005; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; Montaner JSG, 1998, AIDS, V12, pF23, DOI 10.1097/00002030-199805000-00003; MUSICCO M, 1994, ARCH INTERN MED, V154, P1971, DOI 10.1001/archinte.154.17.1971; Mylonakis E, 2000, AM J MED, V109, P568, DOI 10.1016/S0002-9343(00)00583-0; Nogueras M, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-159; O'Brien TR, 1998, J ACQ IMMUN DEF SYND, V18, P155, DOI 10.1097/00042560-199806010-00007; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002; Operskalski EA, 1997, AM J EPIDEMIOL, V146, P655, DOI 10.1093/oxfordjournals.aje.a009331; Orlando G, 2006, HIV MED, V7, P549, DOI 10.1111/j.1468-1293.2006.00420.x; Owens DK, 1996, ARCH INTERN MED, V156, P394, DOI 10.1001/archinte.156.4.394; Owens DK, 2007, AM J PUBLIC HEALTH, V97, P2173, DOI 10.2105/AJPH.2007.110700; Padian NS, 1997, AM J EPIDEMIOL, V146, P350, DOI 10.1093/oxfordjournals.aje.a009276; Paltiel AD, 2006, ANN INTERN MED, V145, P797, DOI 10.7326/0003-4819-145-11-200612050-00004; Paltiel AD, 2005, NEW ENGL J MED, V352, P586, DOI 10.1056/NEJMsa042088; *PAN ANT GUID AD A, 2008, GUID US ANT AG HIV 1; Paredes R, 2000, ARCH INTERN MED, V160, P1123, DOI 10.1001/archinte.160.8.1123; Paredes R, 1999, J ACQ IMMUN DEF SYND, V22, P132; Paris D, 1999, AIDS RES HUM RETROV, V15, P1631, DOI 10.1089/088922299309676; Pedersen C, 1997, J ACQ IMMUN DEF SYND, V16, P93, DOI 10.1097/00042560-199710010-00004; Perez JL, 2003, CLIN INFECT DIS, V36, P212, DOI 10.1086/345669; Phillips AN, 2007, LANCET, V370, P1923, DOI 10.1016/S0140-6736(07)61815-7; Pialoux G, 1998, NEW ENGL J MED, V339, P1269, DOI 10.1056/NEJM199810293391802; Powderly WG, 1999, AIDS, V13, P1873, DOI 10.1097/00002030-199910010-00009; *PRES US EX OFF, BUDG US GOV FISC YEA; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Raboud JM, 1999, J ACQ IMMUN DEF SYND, V22, P260; Raboud JM, 1998, AIDS, V12, P1619, DOI 10.1097/00002030-199813000-00008; Reijers MHE, 2000, AIDS, V14, P59, DOI 10.1097/00002030-200001070-00007; REVICKI DA, 1995, MED CARE, V33, pAS173; Rhone SA, 1998, J INFECT DIS, V178, P662, DOI 10.1086/515365; Rhone SA, 1998, AIDS, V12, P619, DOI 10.1097/00002030-199806000-00011; Roca B, 1999, J INFECTION, V39, P141, DOI 10.1016/S0163-4453(99)90006-3; Roca B, 2000, AIDS, V14, P157, DOI 10.1097/00002030-200001280-00011; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; Safrin S, 1999, AIDS, V13, P2493, DOI 10.1097/00002030-199912240-00002; Salzberger B, 1999, Eur J Med Res, V4, P449; SAMUEL MC, 1993, J ACQ IMMUN DEF SYND, V6, P303; Sanders GD, 2005, NEW ENGL J MED, V352, P570, DOI 10.1056/NEJMsa042657; SCHWARTZ JS, 1990, JAMA-J AM MED ASSOC, V264, P1704, DOI 10.1001/jama.264.13.1704; Silverberg MJ, 2007, ARCH INTERN MED, V167, P684, DOI 10.1001/archinte.167.7.684; Sinclair M, 2004, INT J STD AIDS, V15, P33, DOI 10.1258/095646204322637236; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Spijkerman IJB, 1997, AIDS, V11, P1383, DOI 10.1097/00002030-199711000-00013; STALL R, 1994, ARCH INTERN MED, V154, P57, DOI 10.1001/archinte.154.1.57; Staszewski S, 1998, AIDS, V12, P2360; Stuart JWTC, 1999, AIDS, V13, pF53, DOI 10.1097/00002030-199905070-00001; Sullivan AK, 1998, INT J STD AIDS, V9, P711, DOI 10.1258/0956462981921251; Tebas P, 1999, AIDS, V13, pF23, DOI 10.1097/00002030-199902040-00002; Tengs TO, 2002, MED DECIS MAKING, V22, P475, DOI 10.1177/0272989X02238300; Tsevat J, 1996, MED CARE, V34, P44, DOI 10.1097/00005650-199601000-00004; Tsevat J, 1999, ANN INTERN MED, V131, P194, DOI 10.7326/0003-4819-131-3-199908030-00006; Tumbarello M, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-46; TURNER BJ, 1994, ARCH INTERN MED, V154, P1561, DOI 10.1001/archinte.154.14.1561; *US GEN ACC OFF, 1998, FUND IMPL NEW COMB T; Valdez H, 1999, ARCH INTERN MED, V159, P1771, DOI 10.1001/archinte.159.15.1771; van Roon EN, 1999, J ACQ IMMUN DEF SYND, V20, P290, DOI 10.1097/00042560-199903010-00012; Viard JP, 2001, J INFECT DIS, V183, P1290, DOI 10.1086/319678; Vlahov D, 1998, JAMA-J AM MED ASSOC, V279, P35, DOI 10.1001/jama.279.1.35; Walensky R. P., 2004, Morbidity and Mortality Weekly Report, V53, P523; Walensky RP, 2006, ANN INTERN MED, V145, P459, DOI 10.7326/0003-4819-145-6-200609190-00010; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; Welch K, 2000, CLIN INFECT DIS, V30, P407, DOI 10.1086/313670; Welles SL, 1996, J INFECT DIS, V174, P696, DOI 10.1093/infdis/174.4.696; Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251; Yerly S, 1998, ARCH INTERN MED, V158, P247, DOI 10.1001/archinte.158.3.247; Zingmond DS, 2003, JAIDS-J ACQ IMM DEF, V33, pS84, DOI 10.1097/00126334-200306012-00005; 2000, MED LETT DRUGS THER, V42, P1	164	57	60	1	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 17	2008	148	12					889	+		10.7326/0003-4819-148-12-200806170-00002	http://dx.doi.org/10.7326/0003-4819-148-12-200806170-00002			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	323DU	18559840	Green Accepted			2022-12-28	WOS:000257425000001
J	Martinez-Gonzalez, MA; de la Fuente-Arrillaga, C; Nunez-Cordoba, JM; Basterra-Gortari, FJ; Beunza, JJ; Vazquez, Z; Benito, S; Tortosa, A; Bes-Rastrollo, M				Martinez-Gonzalez, M. A.; de la Fuente-Arrillaga, C.; Nunez-Cordoba, J. M.; Basterra-Gortari, F. J.; Beunza, J. J.; Vazquez, Z.; Benito, S.; Tortosa, A.; Bes-Rastrollo, M.			Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; VIRGIN OLIVE OIL; LIFE-STYLE; MYOCARDIAL-INFARCTION; ENDOTHELIAL DYSFUNCTION; PLASMA-CONCENTRATIONS; MONOUNSATURATED-FAT; METABOLIC SYNDROME; SURVIVAL; INFLAMMATION	Objective To assess the relation between adherence to a Mediterranean diet and the incidence of diabetes among initially healthy participants. Design Prospective cohort study with estimates of relative risk adjusted for sex, age, years of university education, total energy intake, body mass index, physical activity, sedentary habits, smoking, family history of diabetes, and personal history of hypertension. Setting Spanish university department. Participants 13 380 Spanish university graduates without diabetes at baseline followed up fora median of 4.4 years. Main outcome measures Dietary habits assessed at baseline with a validated 136 item food frequency questionnaire and scored on a nine point index. New cases of diabetes confirmed through medical reports and an additional detailed questionnaire posted to those who self reported a new diagnosis of diabetes by a doctor during follow-up. Confirmed cases of type 2 diabetes. Results Participants who adhered closely to a Mediterranean diet had a lower risk of diabetes. The incidence rate ratios adjusted for sex and age were 0.41 (95% confidence interval 0.19 to 0.87) for those with moderate adherence (score 3-6) and 0.17 (0.04 to 0.75) for those with the highest adherence (score 7-9) compared with those with low adherence (score <3). In the fully adjusted analyses the results were similar. A two point increase in the score was associated with a 35% relative reduction in the risk of diabetes (incidence rate ratio 0.65, 0.44 to 0.95), with a significant inverse linear trend (P=0.04) in the multivariate analysis. Conclusion Adherence to a Mediterranean diet is associated with a reduced risk of diabetes.	[Martinez-Gonzalez, M. A.; de la Fuente-Arrillaga, C.; Nunez-Cordoba, J. M.; Basterra-Gortari, F. J.; Beunza, J. J.; Vazquez, Z.; Benito, S.; Tortosa, A.; Bes-Rastrollo, M.] Univ Navarra, Sch Med, Clin Univ, Dept Prevent Med & Publ Hlth, E-31080 Pamplona, Spain; [Nunez-Cordoba, J. M.] Hosp Virgen Camino, Dept Prevent Med & Qual Management, Pamplona, Spain; [Basterra-Gortari, F. J.] Hosp Navarra, Dept Endocrinol, Pamplona, Spain	University of Navarra; Hospital Virgen del Camino; Servicio Navarro de Salud - Osasunbidea; Servicio Navarro de Salud - Osasunbidea	Martinez-Gonzalez, MA (corresponding author), Univ Navarra, Sch Med, Clin Univ, Dept Prevent Med & Publ Hlth, E-31080 Pamplona, Spain.	mamartinez@unav.es	Beunza, Juan-Jose/ABF-4650-2020; Bes-Rastrollo, Maira/A-1329-2009; Vázquez-Ruiz, Zenaida/AAB-7202-2020; Martinez-Gonzalez, Miguel A./AAE-7669-2019	Bes-Rastrollo, Maira/0000-0002-9139-4206; Vázquez-Ruiz, Zenaida/0000-0002-6828-9627; Beunza, Juan-Jose/0000-0001-8192-2952; Martinez-Gonzalez, Miguel A./0000-0002-3917-9808				Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; Alberti KGMM, 2007, DIABETIC MED, V24, P451, DOI 10.1111/j.1464-5491.2007.02157.x; Bach A, 2006, PUBLIC HEALTH NUTR, V9, P132, DOI 10.1079/PHN2005936; Bes-Rastrollo M., 2005, REV ESP OBES, V3, P352; Biesalski H. K., 2004, European Journal of Nutrition, V43, DOI 10.1007/s00394-004-0493-z; Biesalski HK, 2004, EUR J NUTR, V43, P26, DOI 10.1007/s00394-004-1106-6; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; Esposito K, 2004, JAMA-J AM MED ASSOC, V292, P1440, DOI 10.1001/jama.292.12.1440; Estruch R, 2006, ANN INTERN MED, V145, P1, DOI 10.7326/0003-4819-145-1-200607040-00004; Fito M, 2008, EUR J CLIN NUTR, V62, P570, DOI 10.1038/sj.ejcn.1602724; Fung TT, 2005, AM J CLIN NUTR, V82, P163; Garg A, 1998, AM J CLIN NUTR, V67, p577S, DOI 10.1093/ajcn/67.3.577S; Gonzalez-Clemente JM, 2007, REV ESP CARDIOL, V60, P1167, DOI 10.1157/13111789; Hossain P, 2007, NEW ENGL J MED, V356, P213, DOI 10.1056/NEJMp068177; Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492; Iestra J, 2006, EUR J CARDIOV PREV R, V13, P894, DOI 10.1097/01.hjr.0000201517.36214.ba; *INT DIAB FED, 2006, DIAB ATL; Knoops KTB, 2004, JAMA-J AM MED ASSOC, V292, P1433, DOI 10.1001/jama.292.12.1433; Lopez-Garcia E, 2004, AM J CLIN NUTR, V80, P1029, DOI 10.1093/ajcn/80.4.1029; Mantzoros CS, 2006, AM J CLIN NUTR, V84, P328; Martinez-Gonzalez MA, 2005, PUBLIC HEALTH NUTR, V8, P920, DOI 10.1079/PHN2005745; Martinez-Gonzalez MA, 2004, EUR J EPIDEMIOL, V19, P9, DOI 10.1023/B:EJEP.0000013351.60227.7b; Martinez-Gonzalez MA, 2002, EUR J NUTR, V41, P153, DOI 10.1007/s00394-002-0370-6; Martinez-Gonzalez MA, 2002, NUTR NEUROSCI, V5, P65, DOI 10.1080/10284150290007047; MARTINMORENO JM, 1993, INT J EPIDEMIOL, V22, P512, DOI 10.1093/ije/22.3.512; Meigs JB, 2004, JAMA-J AM MED ASSOC, V291, P1978, DOI 10.1001/jama.291.16.1978; Mitrou PN, 2007, ARCH INTERN MED, V167, P2461, DOI 10.1001/archinte.167.22.2461; Mozaffarian D, 2007, LANCET, V370, P667, DOI 10.1016/S0140-6736(07)61343-9; Paniagua JA, 2007, J AM COLL NUTR, V26, P434, DOI 10.1080/07315724.2007.10719633; Perez-Jimenez F, 2005, EUR J CLIN INVEST, V35, P421, DOI 10.1111/j.1365-2362.2005.01516.x; Perez-Jimenez F, 2002, ATHEROSCLEROSIS, V163, P385, DOI 10.1016/S0021-9150(02)00033-3; Perez-Martinez P, 2007, ATHEROSCLEROSIS, V194, pE141, DOI 10.1016/j.atherosclerosis.2006.11.033; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Ramachandran A, 2006, DIABETOLOGIA, V49, P289, DOI 10.1007/s00125-005-0097-z; Rocca AS, 2001, ENDOCRINOLOGY, V142, P1148, DOI 10.1210/en.142.3.1148; Ros E, 2003, AM J CLIN NUTR, V78, p617S, DOI 10.1093/ajcn/78.3.617S; SALASSALVADO J, 2007, EUR J CLIN NUTR 0418; Salmeron J, 2001, AM J CLIN NUTR, V73, P1019; Schroder H, 2007, J NUTR BIOCHEM, V18, P149, DOI 10.1016/j.jnutbio.2006.05.006; Schulze MB, 2007, ARCH INTERN MED, V167, P956, DOI 10.1001/archinte.167.9.956; Segui-Gomez M, 2006, INT J EPIDEMIOL, V35, P1417, DOI 10.1093/ije/dyl223; Tortosa A, 2007, DIABETES CARE, V30, P2957, DOI 10.2337/dc07-1231; Trichopoulou A, 2007, EUR J EPIDEMIOL, V22, P871, DOI 10.1007/s10654-007-9190-6; Trichopoulou A, 2005, ARCH INTERN MED, V165, P929, DOI 10.1001/archinte.165.8.929; TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457; Trichopoulou A, 2005, BMJ-BRIT MED J, V330, P991, DOI 10.1136/bmj.38415.644155.8F; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Willett WC, 2006, PUBLIC HEALTH NUTR, V9, P105, DOI 10.1079/PHN2005931	48	343	345	0	45	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 14	2008	336	7657					1348	1351		10.1136/bmj.39561.501007.BE	http://dx.doi.org/10.1136/bmj.39561.501007.BE			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316YB	18511765	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000256984700039
J	Dahlin, E; Neely, AS; Larsson, A; Backman, L; Nyberg, L				Dahlin, Erika; Neely, Anna Stigsdotter; Larsson, Anne; Backman, Lars; Nyberg, Lars			Transfer of learning after updating training mediated by the striatum	SCIENCE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; HEALTHY OLDER-ADULTS; EXECUTIVE FUNCTIONS; PREFRONTAL CORTEX; DOPAMINE RELEASE; WORKING-MEMORY; METAANALYSIS; DIVERSITY; UNITY	Process-specific training can improve performance on untrained tasks, but the magnitude of gain is variable and often there is no transfer at all. We demonstrate transfer to a 3-back test of working memory after 5 weeks of training in updating. The transfer effect was based on a joint training-related activity increase for the criterion (letter memory) and transfer tasks in a striatal region that also was recruited pretraining. No transfer was observed to a task that did not engage updating and striatal regions, and age-related striatal changes imposed constraints on transfer. These findings indicate that transfer can occur if the criterion and transfer tasks engage specific overlapping processing components and brain regions.	[Dahlin, Erika; Nyberg, Lars] Umea Univ, Dept Integrat Med Biol, S-90187 Umea, Sweden; [Dahlin, Erika; Larsson, Anne; Nyberg, Lars] Umea Univ, Dept Radiat Sci, S-90187 Umea, Sweden; [Neely, Anna Stigsdotter] Umea Univ, Dept Psychol, S-90187 Umea, Sweden; [Larsson, Anne; Nyberg, Lars] Umea Univ, Umea Ctr Funct Brain Imaging UFBI, S-90187 Umea, Sweden; [Backman, Lars] Karolinska Inst, Aging Res Ctr, S-11330 Stockholm, Sweden	Umea University; Umea University; Umea University; Umea University; Karolinska Institutet	Dahlin, E (corresponding author), Umea Univ, Dept Integrat Med Biol, S-90187 Umea, Sweden.	erika.dahlin@physiol.umu.se	Stigsdotter Neely, Anna/H-4140-2012; Nyberg, Lars/C-2514-2009; Nyberg, Lars/M-5986-2019	Nyberg, Lars/0000-0002-3367-1746; Nyberg, Lars/0000-0002-3367-1746; Larsson, Anne/0000-0003-3229-2346				Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; Buckner RL, 2004, NEURON, V44, P195, DOI 10.1016/j.neuron.2004.09.006; Cohen J, 2002, CURR OPIN NEUROBIOL, V12, P223, DOI 10.1016/S0959-4388(02)00314-8; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; Collette F, 2005, HUM BRAIN MAPP, V25, P409, DOI 10.1002/hbm.20118; Derwinger A, 2003, AGING NEUROPSYCHOL C, V10, P202, DOI 10.1076/anec.10.3.202.16452; Erickson KI, 2007, CEREB CORTEX, V17, P192, DOI 10.1093/cercor/bhj137; Erickson KI, 2007, NEUROBIOL AGING, V28, P272, DOI 10.1016/j.neurobiolaging.2005.12.012; Friedman NP, 2006, PSYCHOL SCI, V17, P172, DOI 10.1111/j.1467-9280.2006.01681.x; Jonides J, 2004, NAT NEUROSCI, V7, P10, DOI 10.1038/nn0104-10; Klingberg T, 2005, J AM ACAD CHILD PSY, V44, P177, DOI 10.1097/00004583-200502000-00010; LOVETT MC, 1994, J EXP PSYCHOL LEARN, V20, P366, DOI 10.1037/0278-7393.20.2.366; Mahncke HW, 2006, P NATL ACAD SCI USA, V103, P12523, DOI 10.1073/pnas.0605194103; Martinez D, 2003, J CEREBR BLOOD F MET, V23, P285, DOI 10.1097/01.WCB.0000048520.34839.1A; Mcnab F, 2008, NAT NEUROSCI, V11, P103, DOI 10.1038/nn2024; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Monchi O, 2006, NEUROIMAGE, V33, P907, DOI 10.1016/j.neuroimage.2006.06.058; Nee DE, 2007, COGN AFFECT BEHAV NE, V7, P1, DOI 10.3758/CABN.7.1.1; NEELY AS, 1993, J GERONTOL, V48, pP233, DOI 10.1093/geronj/48.5.P233; O'Reilly RC, 2006, SCIENCE, V314, P91, DOI 10.1126/science.1127242; O'Reilly RC, 2006, NEURAL COMPUT, V18, P283, DOI 10.1162/089976606775093909; Olesen PJ, 2004, NAT NEUROSCI, V7, P75, DOI 10.1038/nn1165; Peterson BS, 2002, COGNITIVE BRAIN RES, V13, P427, DOI 10.1016/S0926-6410(02)00054-X; Postuma RB, 2006, CEREB CORTEX, V16, P1508, DOI 10.1093/cercor/bhj088; Raz N, 2003, AM J NEURORADIOL, V24, P1849; Rebok GW, 2007, J GERONTOL B-PSYCHOL, V62, P53, DOI 10.1093/geronb/62.special_issue_1.53; Schott BH, 2007, BRAIN, V130, P2412, DOI 10.1093/brain/awm147; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657	28	613	634	5	157	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2008	320	5882					1510	1512		10.1126/science.1155466	http://dx.doi.org/10.1126/science.1155466			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556560				2022-12-28	WOS:000256676400049
J	Krumholz, HM; Lee, TH				Krumholz, Harlan M.; Lee, Thomas H.			Redefining quality - Implications of recent clinical trials	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CORONARY		[Krumholz, Harlan M.] Yale Univ, Sch Med, New Haven, CT 06504 USA; [Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA; [Lee, Thomas H.] Partners Healthcare Syst, Boston, MA USA	Yale University; Yale University; Partners Healthcare System	Krumholz, HM (corresponding author), Yale Univ, Sch Med, New Haven, CT 06504 USA.		, Harlan/AAI-2875-2020					Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Gillespie MJ, 2006, CIRCULATION, V113, pE805; Nissen SE, 2007, NEW ENGL J MED, V357, P100; Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761; Nissen SE, 2007, NEW ENGL J MED, V356, P1304, DOI 10.1056/NEJMoa070635; Smith SC, 2006, CIRCULATION, V113, P2363, DOI 10.1161/CIRCULATIONAHA.106.174516; Yusuf S, 2008, NEW ENGL J MED, V358, P1547, DOI 10.1056/NEJMoa0801317	7	57	61	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2008	358	24					2537	2539		10.1056/NEJMp0803740	http://dx.doi.org/10.1056/NEJMp0803740			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311IJ	18539915				2022-12-28	WOS:000256593600001
J	Kirch, DG; Vernon, DJ				Kirch, Darrell G.; Vernon, David J.			Confronting the complexity of the physician workforce equation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Kirch, Darrell G.; Vernon, David J.] Assoc Amer Med Coll, Washington, DC 20037 USA	Association of American Medical Colleges	Kirch, DG (corresponding author), Assoc Amer Med Coll, 2450 N St NW, Washington, DC 20037 USA.	dgkirch@aamc.org						*AM AC PHYS ASS, 2008, FACTS GLANC; American Academy of Nurse Practitioners, FREQ ASK QUEST WHY C; *ASS AM MED COLL, 2006, AAMC STAT PHYS WORKF; Cooper RA, 2002, HEALTH AFFAIR, V21, P140, DOI 10.1377/hlthaff.21.1.140; *CTR MED MED SERV, NAT HLTH EXP SEL EC; Goodman DC, 2008, JAMA-J AM MED ASSOC, V299, P335, DOI 10.1001/jama.299.3.335; Landrum MB, 2008, HEALTH AFFAIR, V27, P159, DOI 10.1377/hlthaff.27.1.159; Mullan F, 2005, NEW ENGL J MED, V353, P1810, DOI 10.1056/NEJMsa050004; SALSBERG E, 2007, ASS AM MED COLL ANN; U. S. Census Bureau, 2007, PROJ POP US AG SEX 2; *US CENS BUR, 2007, PEOPL HLTH INS COV S; *US DEP HHS, 2006, HLTH US	12	29	29	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2008	299	22					2680	2682		10.1001/jama.299.22.2680	http://dx.doi.org/10.1001/jama.299.22.2680			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311FN	18544728				2022-12-28	WOS:000256586200025
J	Atkin, S; Walton, C				Atkin, Stephen; Walton, Christopher			Commentary: Controversies in NICE guidance on management of type 2 diabetes	BRITISH MEDICAL JOURNAL			English	Editorial Material							THERAPY		[Atkin, Stephen] Hull York Med Sch, Michael White Diabet Ctr, Kingston Upon Hull HU3 2RW, N Humberside, England; [Walton, Christopher] Hull & E Yorkshire Hosp Trust, Michael White Diabet Ctr, Kingston Upon Hull HU3 2RW, N Humberside, England	University of Hull; University of York - UK	Atkin, S (corresponding author), Hull York Med Sch, Michael White Diabet Ctr, Kingston Upon Hull HU3 2RW, N Humberside, England.	Stephen.Atkin@hyms.ac.uk	Atkin, stephen/ABE-7047-2020; atkin, stephen/D-7400-2014	atkin, stephen/0000-0002-5887-7257				Holman RR, 2007, NEW ENGL J MED, V357, P1716, DOI 10.1056/NEJMoa075392; Home P, 2008, BMJ-BRIT MED J, V336, P458, DOI 10.1136/bmj.39499.514410.80; Horvath K, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005613.pub3; *NAT HEART LUNG BL, 2008, HNLBI CHANG INT BLOO; *NAT I HLTH CLIN E, 2008, MAN TYP 2 DIAB UPD; Nathan DM, 2006, DIABETES CARE, V29, P1963, DOI 10.2337/dc06-9912; Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761	7	0	0	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2008	336	7656					1308	1309		10.1136/bmj.39581.495069.AD	http://dx.doi.org/10.1136/bmj.39581.495069.AD			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312XO	18535075	Green Published			2022-12-28	WOS:000256705900038
J	Miyoshi, T; Kanoh, J; Saito, M; Ishikawa, F				Miyoshi, Tomoichiro; Kanoh, Junko; Saito, Motoki; Ishikawa, Fuyuki			Fission yeast Pot1-Tpp1 protects telomeres and regulates telomere length	SCIENCE			English	Article							END-BINDING-PROTEIN; SINGLE-STRANDED-DNA; SCHIZOSACCHAROMYCES-POMBE; DOMAIN PROTEIN; POT1; COMPLEX; RECOGNITION; TPP1	Telomeres are specialized chromatin structures that protect chromosomal ends. Protection of telomeres 1 ( Pot1) binds to the telomeric G- rich overhang, thereby protecting telomeres and regulating telomerase. Mammalian POT1 and TPP1 interact and constitute part of the six- protein shelterin complex. Here we report that Tpz1, the TPP1 homolog in fission yeast, forms a complex with Pot1. Tpz1 binds to Ccq1 and the previously undiscovered protein Poz1 ( Pot1- associated in Schizosaccharomyces pombe), which protect telomeres redundantly and regulate telomerase in positive and negative manners, respectively. Thus, the Pot1- Tpz1 complex accomplishes its functions by recruiting effector molecules Ccq1 and Poz1. Moreover, Poz1 bridges Pot1- Tpz1 and Taz1- Rap1, thereby connecting the single- stranded and double- stranded telomeric DNA regions. Such molecular architectures are similar to those of mammalian shelterin, indicating that the overall DNA- protein architecture is conserved across evolution.	[Miyoshi, Tomoichiro; Kanoh, Junko; Saito, Motoki; Ishikawa, Fuyuki] Kyoto Univ, Grad Sch Biostudies, Dept Gene Mech, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Ishikawa, F (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Gene Mech, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	fishikaw@lif.kyoto-u.ac.jp	Ishikawa, Fuyuki/AAU-4056-2021; Kanoh, Junko/AGM-9632-2022	Ishikawa, Fuyuki/0000-0002-5580-2305; Miyoshi, Tomoichiro/0000-0002-5319-7877				Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Chikashige Y, 2001, CURR BIOL, V11, P1618, DOI 10.1016/S0960-9822(01)00457-2; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Croy JE, 2006, J MOL BIOL, V361, P80, DOI 10.1016/j.jmb.2006.06.002; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Flory MR, 2004, MOL CELL, V16, P619, DOI 10.1016/j.molcel.2004.10.027; Haering CH, 2000, P NATL ACAD SCI USA, V97, P6367, DOI 10.1073/pnas.130187397; Hockemeyer D, 2007, NAT STRUCT MOL BIOL, V14, P754, DOI 10.1038/nsmb1270; Hockemeyer D, 2006, CELL, V126, P63, DOI 10.1016/j.cell.2006.04.044; Horvath MP, 1998, CELL, V95, P963, DOI 10.1016/S0092-8674(00)81720-1; Lei M, 2003, NATURE, V426, P198, DOI 10.1038/nature02092; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Naito T, 1998, NAT GENET, V20, P203, DOI 10.1038/2517; Nakamura TM, 1998, SCIENCE, V282, P493, DOI 10.1126/science.282.5388.493; Sugiyama T, 2007, CELL, V128, P491, DOI 10.1016/j.cell.2006.12.035; Wu L, 2006, CELL, V126, P49, DOI 10.1016/j.cell.2006.05.037; Xin HW, 2007, NATURE, V445, P559, DOI 10.1038/nature05469	17	170	174	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2008	320	5881					1341	1344		10.1126/science.1154819	http://dx.doi.org/10.1126/science.1154819			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309DO	18535244				2022-12-28	WOS:000256441100045
J	Guiso, L; Monte, F; Sapienza, P; Zingales, L				Guiso, Luigi; Monte, Ferdinando; Sapienza, Paola; Zingales, Luigi			Diversity - Culture, gender, and math	SCIENCE			English	Editorial Material							SEX-DIFFERENCES		[Sapienza, Paola] Northwestern Univ, JL Kellogg Grad Sch Management, Evanston, IL 60208 USA; [Zingales, Luigi] Univ Chicago, Grad Sch Business, Chicago, IL 60637 USA; [Guiso, Luigi] European Univ Inst, I-50133 Florence, Italy; [Monte, Ferdinando] Univ Chicago, Dept Econ, Chicago, IL 60637 USA	Northwestern University; University of Chicago; European University Institute; University of Chicago	Sapienza, P (corresponding author), Northwestern Univ, JL Kellogg Grad Sch Management, Evanston, IL 60208 USA.	Paola-Sapienza@northwestern.edu	Sapienza, Paola/CSU-7580-2022; Zingales, Luigi/AAY-8081-2020; Monte, Ferdinando/V-3968-2019; Sapienza, Paola/P-4917-2016	Sapienza, Paola/0000-0002-3663-422X; Zingales, Luigi/0000-0002-6804-1883; Sapienza, Paola/0000-0002-3663-422X				Baron -Cohen S., 2003, ESSENTIAL DIFFERENCE; BENBOW C P, 1980, Science (Washington D C), V210, P1262, DOI 10.1126/science.7434028; Cavalli-Sforza LL, 1996, HIST GEOGRAPHY HUMAN; Goldin C, 2006, J ECON PERSPECT, V20, P133, DOI 10.1257/jep.20.4.133; Halpern D. F., 2005, GENDER DIFFERENCES M, P48; Hausmann R., 2006, GLOBAL GENDER GAP RE; HEDGES LV, 1995, SCIENCE, V269, P41, DOI 10.1126/science.7604277; Inglehart R., 2000, WORLD VALUES SURVEYS; Kimura Doreen, 1999, SEX COGNITION; Ontario Student Assistance Program, 2020, PROGRAM INT STUDENT; Spelke ES, 2005, AM PSYCHOL, V60, P950, DOI 10.1037/0003-066X.60.9.950; SPOLAORE E, 2006, 5630 CEPR; 2005, EDGE            0510	13	453	458	2	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2008	320	5880					1164	1165		10.1126/science.1154094	http://dx.doi.org/10.1126/science.1154094			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306FF	18511674				2022-12-28	WOS:000256233000020
J	Carel, JC; Leger, J				Carel, Jean-Claude; Leger, Juliane			Precocious puberty	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MCCUNE-ALBRIGHT-SYNDROME; LONG-TERM TREATMENT; FINAL HEIGHT; HORMONE AGONIST; ADULT HEIGHT; BODY-COMPOSITION; STATURAL GROWTH; YOUNG GIRLS; 11.25 MG; CHILDREN		[Carel, Jean-Claude; Leger, Juliane] Hop Robert Debre, Dept Endocrinol Diabetol & Pediat, INSERM, U690, F-75935 Paris 19, France; [Carel, Jean-Claude; Leger, Juliane] Hop Robert Debre, Ctr Reference Malad Endocriniennes Croissance, F-75935 Paris 19, France; [Carel, Jean-Claude; Leger, Juliane] Univ Paris 07, F-75935 Paris 19, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Carel, JC (corresponding author), Hop Robert Debre, Dept Endocrinol Diabetol & Pediat, INSERM, U690, 48 Blvd Serurier, F-75935 Paris 19, France.	jean-claude.carel@inserm.fr	Carel, Jean-Claude/AAZ-7691-2020	Carel, Jean-Claude/0000-0002-0424-6767				BAR A, 1995, J PEDIATR-US, V126, P955, DOI 10.1016/S0022-3476(95)70221-0; Bertelloni S, 1998, EUR J PEDIATR, V157, P363, DOI 10.1007/s004310050831; Bhatia S, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e30; Boot AM, 1998, J CLIN ENDOCR METAB, V83, P370, DOI 10.1210/jc.83.2.370; Carel JC, 2006, EUR J ENDOCRINOL, V154, P119, DOI 10.1530/eje.1.02056; Carel JC, 1999, J CLIN ENDOCR METAB, V84, P1973; Carel JC, 2004, HUM REPROD UPDATE, V10, P135, DOI 10.1093/humupd/dmh012; Carel JC, 2002, J CLIN ENDOCR METAB, V87, P4111, DOI 10.1210/jc.2001-020243; Chalumeau M, 2003, J PEDIATR-US, V143, P445, DOI 10.1067/S0022-3476(03)00328-7; De Sanctis V, 2000, J PEDIATR ENDOCR MET, V13, P687; de Vries L, 2006, EUR J ENDOCRINOL, V154, P891, DOI 10.1530/eje.1.02151; DORN LD, 2007, PUBERTY PRECOCIOUS S, P309; Eugster EA, 2003, J PEDIATR-US, V143, P60, DOI 10.1016/S0022-3476(03)00128-8; Feuillan P, 2007, J CLIN ENDOCR METAB, V92, P2100, DOI 10.1210/jc.2006-2350; Heger S, 2006, MOL CELL ENDOCRINOL, V254, P217, DOI 10.1016/j.mce.2006.04.012; Herman-Giddens ME, 2004, PEDIATRICS, V113, P911, DOI 10.1542/peds.113.4.911; HermanGiddens ME, 1997, PEDIATRICS, V99, P505, DOI 10.1542/peds.99.4.505; Kaplowitz P, 2004, J CLIN ENDOCR METAB, V89, P3644, DOI 10.1210/jc.2003-031532; Kaplowitz PB, 1999, PEDIATRICS, V104, P936, DOI 10.1542/peds.104.4.936; Klein KO, 2001, J CLIN ENDOCR METAB, V86, P4711, DOI 10.1210/jc.86.10.4711; Klein KO, 1999, J CLIN ENDOCR METAB, V84, P411, DOI 10.1210/jc.84.2.411; Lahlou N, 2000, J PEDIATR ENDOCR MET, V13, P723; Leger J, 2000, J PEDIATR-US, V137, P819, DOI 10.1067/mpd.2000.109201; Leschek EW, 1999, J CLIN ENDOCR METAB, V84, P175, DOI 10.1210/jc.84.1.175; Linam LE, 2007, PEDIATR RADIOL, V37, P1013, DOI 10.1007/s00247-007-0599-6; Liu G, 1999, NEW ENGL J MED, V341, P1731, DOI 10.1056/NEJM199912023412304; MARSHALL WA, 1969, ARCH DIS CHILD, V44, P291, DOI 10.1136/adc.44.235.291; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13; MartiHenneberg C, 1997, J PEDIATR-US, V131, P618, DOI 10.1016/S0022-3476(97)70073-8; Matchock RL, 2006, AM J HUM BIOL, V18, P481, DOI 10.1002/ajhb.20508; Michaud PA, 2006, MOL CELL ENDOCRINOL, V254, P172, DOI 10.1016/j.mce.2006.04.037; Midyett LK, 2003, PEDIATRICS, V111, P47, DOI 10.1542/peds.111.1.47; Mul D, 2001, PEDIATR RES, V50, P479, DOI 10.1203/00006450-200110000-00010; Nathan BM, 2005, ENDOCRIN METAB CLIN, V34, P617, DOI 10.1016/j.ecl.2005.04.015; NEELY EK, 1995, J PEDIATR-US, V127, P47, DOI 10.1016/S0022-3476(95)70255-5; NEELY EK, 1992, J PEDIATR-US, V121, P634, DOI 10.1016/S0022-3476(05)81162-X; Palmert MR, 1999, J CLIN ENDOCR METAB, V84, P4480, DOI 10.1210/jc.84.12.4480; Palmert MR, 1999, J CLIN ENDOCR METAB, V84, P415, DOI 10.1210/jc.84.2.415; Papadimitriou A, 2006, J PEDIATR-US, V149, P43, DOI 10.1016/j.jpeds.2006.02.005; Parent AS, 2003, ENDOCR REV, V24, P668, DOI 10.1210/er.2002-0019; Pasquino AM, 1999, J CLIN ENDOCR METAB, V84, P1978; Pasquino AM, 1999, J CLIN ENDOCR METAB, V84, P449, DOI 10.1210/jc.84.2.449; PAUL D, 1995, J CLIN ENDOCR METAB, V80, P546, DOI 10.1210/jc.80.2.546; Pectasides D, 2008, CANCER TREAT REV, V34, P1, DOI 10.1016/j.ctrv.2007.08.007; Resende EAMR, 2007, J CLIN ENDOCR METAB, V92, P1424, DOI 10.1210/jc.2006-1569; Roger M, 1996, DIAGNOSTICS ENDOCRIN, P346; Rosenfield RL, 2000, PEDIATRICS, V106, P622, DOI 10.1542/peds.106.3.622; Soriano-Guillen L, 2005, J CLIN ENDOCR METAB, V90, P147, DOI 10.1210/jc.2004-1438; Stanhope R, 2003, J PEDIATR-US, V143, P426, DOI 10.1067/S0022-3476(03)00492-X; Sun SMS, 2002, PEDIATRICS, V110, P911, DOI 10.1542/peds.110.5.911; Teilmann G, 2005, PEDIATRICS, V116, P1323, DOI 10.1542/peds.2005-0012; Teilmann G, 2006, PEDIATRICS, V118, pE391, DOI 10.1542/peds.2005-2939; Tremblay L, 2005, CHILD PSYCHIAT HUM D, V36, P73, DOI 10.1007/s10578-004-3489-2; Vottero A, 2006, J CLIN ENDOCR METAB, V91, P1284, DOI 10.1210/jc.2005-1693; Wu TJ, 2002, PEDIATRICS, V110, P752, DOI 10.1542/peds.110.4.752; XhrouetHeinrichs D, 1997, ACTA PAEDIATR, V86, P808	56	339	357	2	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2008	358	22					2366	2377		10.1056/NEJMcp0800459	http://dx.doi.org/10.1056/NEJMcp0800459			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307GF	18509122				2022-12-28	WOS:000256306700007
J	Parienti, JJ; Thirion, M; Megarbane, B; Souweine, B; Ouchikhe, A; Polito, A; Forel, JM; Marque, S; Misset, B; Airapetian, N; Daurel, C; Mira, JP; Ramakers, M; du Cheyron, D; Le Coutour, X; Daubin, C; Charbonneau, P				Parienti, Jean-Jacques; Thirion, Marina; Megarbane, Bruno; Souweine, Bertrand; Ouchikhe, Abdelali; Polito, Andrea; Forel, Jean-Marie; Marque, Sophie; Misset, Benoit; Airapetian, Norair; Daurel, Claire; Mira, Jean-Paul; Ramakers, Michel; du Cheyron, Damien; Le Coutour, Xavier; Daubin, Cedric; Charbonneau, Pierre		Cathedia Study Grp	Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY-ILL PATIENTS; BLOOD-STREAM INFECTION; POVIDONE-IODINE; VASCULAR ACCESS; CARE PATIENTS; SITE; COMPLICATIONS; PREVENTION; VEIN; COLONIZATION	Context Based on concerns about the risk of infection, the jugular site is often preferred over the femoral site for short- term dialysis vascular access. Objective To determine whether jugular catheterization decreases the risk of nosocomial complications compared with femoral catheterization. Design, Setting, and Patients A concealed, randomized, multicenter, evaluator-blinded, parallel- group trial ( the Cathedia Study) of 750 patients from a network of 9 tertiary care university medical centers and 3 general hospitals in France conducted between May 2004 and May 2007. The severely ill, bed- bound adults had a body mass index ( BMI) of less than 45 and required a first catheter insertion for renal replacement therapy. Intervention Patients were randomized to receive jugular or femoral vein catheterization by operators experienced in placement at both sites. Main Outcome Measures Rates of infectious complications, defined as catheter colonization on removal ( primary end point), and catheter- related bloodstream infection. Results Patient and catheter characteristics, including duration of catheterization, were similar in both groups. More hematomas occurred in the jugular group than in the femoral group ( 13/ 366 patients [ 3.6%] vs 4/ 370 patients [ 1.1%], respectively; P=. 03). The risk of catheter colonization at removal did not differ significantly between the femoral and jugular groups ( incidence of 40.8 vs 35.7 per 1000 catheter- days; hazard ratio [ HR], 0.85; 95% confidence interval [ CI], 0.62- 1.16; P=. 31). A prespecified subgroup analysis demonstrated significant qualitative heterogeneity by BMI ( P for the interaction term < .001). Jugular catheterization significantly increased incidence of catheter colonization vs femoral catheterization ( 45.4 vs 23.7 per 1000 catheter- days; HR, 2.10; 95% CI, 1.13- 3.91; P=. 017) in the lowest tercile ( BMI < 24.2), whereas jugular catheterization significantly decreased this incidence ( 24.5 vs 50.9 per 1000 catheter- days; HR, 0.40; 95% CI, 0.23- 0.69; P <. 001) in the highest tercile ( BMI > 28.4). The rate of catheter- related bloodstream infection was similar in both groups ( 2.3 vs 1.5 per 1000 catheter- days, respectively; P=. 42). Conclusion Jugular venous catheterization access does not appear to reduce the risk of infection compared with femoral access, except among adults with a high BMI, and may have a higher risk of hematoma. Trial Registration clinicaltrials. gov Identifier: NCT00277888.	[Parienti, Jean-Jacques; Le Coutour, Xavier] Cote Nacre Univ Hosp Ctr, Dept Biostat & Clin Res, F-14033 Caen, France; [Parienti, Jean-Jacques; Ramakers, Michel; du Cheyron, Damien; Daubin, Cedric; Charbonneau, Pierre] Cote Nacre Univ Hosp Ctr, Dept Med Intens Care, F-14033 Caen, France; [Ouchikhe, Abdelali] Cote Nacre Univ Hosp Ctr, Dept Surg Intens Care, F-14033 Caen, France; [Daurel, Claire] Cote Nacre Univ Hosp Ctr, Dept Microbiol, F-14033 Caen, France; [Thirion, Marina; Marque, Sophie; Mira, Jean-Paul] Cochin Univ Hosp Ctr, Dept Med Intens Care, Paris, France; [Misset, Benoit; Mira, Jean-Paul] Univ Paris 05, Fac Med, INSERM, Cochin Inst,U567, Paris, France; [Megarbane, Bruno] Lariboisiere Univ Hosp Ctr, Dept Med Intens Care, Paris, France; [Megarbane, Bruno] Univ Paris 07, Paris, France; [Souweine, Bertrand] Univ Hosp Ctr, Dept Med Intens Care, Clermont Ferrand, France; [Souweine, Bertrand] Univ Hosp Ctr, Dept Nephrol, Clermont Ferrand, France; [Polito, Andrea] Univ Hosp Ctr, Dept Med Intens Care, Garches, France; [Forel, Jean-Marie] Univ Hosp Ctr, Dept Med Intens Care, Marseille, France; [Misset, Benoit] St Joseph Hosp, Paris, France; Univ Hosp Ctr, Dept Med Intens Care, Amiens, France; [Airapetian, Norair] Univ Hosp Ctr, Dept Nephrol, Amiens, France	CHU de Caen NORMANDIE; CHU de Caen NORMANDIE; CHU de Caen NORMANDIE; CHU de Caen NORMANDIE; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Clermont Ferrand; CHU Clermont Ferrand; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens	Parienti, JJ (corresponding author), Cote Nacre Univ Hosp Ctr, Dept Biostat & Clin Res, Ave Cote Nacre, F-14033 Caen, France.	parienti-jj@chu-caen.fr	TERZI, Nicolas/AAD-4348-2019; Philippart, Francois/AAF-2791-2019; Parienti, Jean-Jacques/AAD-1701-2021; Chiche, Jean-Daniel/P-5220-2017; souweine, bertrand/HHR-8972-2022; Misset, Benoit/P-7817-2018	TERZI, Nicolas/0000-0003-4036-6245; Philippart, Francois/0000-0002-7323-0742; Parienti, Jean-Jacques/0000-0002-4774-5590; Chiche, Jean-Daniel/0000-0002-6433-6254; Buleon, Clement/0000-0003-4550-3827; Megarbane, Bruno/0000-0002-2522-2764; Chantepie, Sylvain P/0000-0003-0457-2252; VALETTE, Xavier/0000-0001-5049-9186; ALLARDET-SERVENT, Jerome/0000-0002-6464-2382; Misset, Benoit/0000-0001-6466-0065				[Anonymous], 2001, AM J KIDNEY DIS, V37, pS137, DOI [DOI 10.1016/S0272-6386(01)70007-8, 10.1016/s0272-6386(01)70007-8]; Bearman GML, 2006, SEMIN RESP CRIT CARE, V27, P310, DOI 10.1055/s-2006-945534; Brookes S T, 2001, Health Technol Assess, V5, P1; BRUNBUISSON C, 1987, ARCH INTERN MED, V147, P873, DOI 10.1001/archinte.147.5.873; Canaud B, 2004, CONTRIB NEPHROL, V144, P291; Crnich CJ, 2002, CLIN INFECT DIS, V34, P1232, DOI 10.1086/339863; Deshpande KS, 2005, CRIT CARE MED, V33, P13, DOI 10.1097/01.CCM.0000149838.47048.60; Goetz AM, 1998, INFECT CONT HOSP EP, V19, P842; GOWARDMAN JR, 2008, INTENSIVE CARE MED; Harb A, 2005, INTENS CARE MED, V31, P812, DOI 10.1007/s00134-005-2621-5; Harden J L, 1995, Nutr Clin Pract, V10, P60, DOI 10.1177/011542659501000260; Hoste EAJ, 2004, J AM SOC NEPHROL, V15, P454, DOI 10.1097/01.ASN.0000110182.14608.0C; Karakitsos D, 2007, ANESTHESIOLOGY, V107, P181, DOI 10.1097/01.anes.0000268280.02529.88; Karakitsos D, 2006, CRIT CARE, V10, DOI 10.1186/cc5101; Lorente L, 2005, CRIT CARE, V9, pR631, DOI 10.1186/cc3824; Lorente L, 2007, CRIT CARE MED, V35, P2424, DOI 10.1097/01.CCM.0000284589.63641.B8; MAKI DG, 1991, LANCET, V338, P339, DOI 10.1016/0140-6736(91)90479-9; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; McGee DC, 2003, NEW ENGL J MED, V348, P1123, DOI 10.1056/NEJMra011883; Mermel LA, 2000, ANN INTERN MED, V132, P391, DOI 10.7326/0003-4819-132-5-200003070-00009; Merrer J, 2001, JAMA-J AM MED ASSOC, V286, P700, DOI 10.1001/jama.286.6.700; MONCRIEF JA, 1958, ANN SURG, V147, P166; MURR M M, 1991, Journal of Burn Care and Rehabilitation, V12, P576, DOI 10.1097/00004630-199111000-00014; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; O'Grady NP, 2005, CRIT CARE MED, V33, P234, DOI 10.1097/01.CCM.0000150758.10396.F3; Oliver MJ, 2000, KIDNEY INT, V58, P2543, DOI 10.1046/j.1523-1755.2000.00439.x; Parienti JJ, 2002, JAMA-J AM MED ASSOC, V288, P722, DOI 10.1001/jama.288.6.722; Parienti JJ, 2002, JAMA-J AM MED ASSOC, V288, P2688, DOI 10.1001/jama.288.21.2688-JLT1204-5-2; Parienti JJ, 2004, CRIT CARE MED, V32, P708, DOI 10.1097/01.CCM.0000115265.05604.7B; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; RICHET H, 1990, J CLIN MICROBIOL, V28, P2520, DOI 10.1128/JCM.28.11.2520-2525.1990; Rijnders BJA, 2002, CLIN INFECT DIS, V35, P1053, DOI 10.1086/342905; Rupp ME, 2005, ANN INTERN MED, V143, P570, DOI 10.7326/0003-4819-143-8-200510180-00007; Schetz M, 2007, CONTRIB NEPHROL, V156, P275; Souweine B, 1999, CRIT CARE MED, V27, P2394, DOI 10.1097/00003246-199911000-00012; Souweine B, 2006, AM J KIDNEY DIS, V47, P879, DOI 10.1053/j.ajkd.2006.01.023; Timsit JF, 2003, CRIT CARE, V7, P397, DOI 10.1186/cc2179; Timsit JF, 1998, CHEST, V114, P207, DOI 10.1378/chest.114.1.207; Trick WE, 2006, AM J INFECT CONTROL, V34, P636, DOI 10.1016/j.ajic.2006.02.008; TROTTIER SJ, 1995, CRIT CARE MED, V23, P52, DOI 10.1097/00003246-199501000-00011; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; Wester JPJ, 2002, CRIT CARE MED, V30, P1261, DOI 10.1097/00003246-200206000-00017	42	236	254	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2008	299	20					2413	2422		10.1001/jama.299.20.2413	http://dx.doi.org/10.1001/jama.299.20.2413			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305BD	18505951	Bronze			2022-12-28	WOS:000256151900026
J	Bao, HM; Lyons, JR; Zhou, CM				Bao, Huiming; Lyons, J. R.; Zhou, Chuanming			Triple oxygen isotope evidence for elevated CO(2) levels after a Neoproterozoic glaciation	NATURE			English	Article							ATMOSPHERIC CARBON-DIOXIDE; OLIGOCENE ASH BED; SULFATE; OXIDATION; OZONE; EARTH; FRACTIONATION; PRODUCTIVITY; DELTA-O-18; EXCHANGE	Understanding the composition of the atmosphere over geological time is critical to understanding the history of the Earth system, as the atmosphere is closely linked to the lithosphere, hydrosphere and biosphere. Although much of the history of the lithosphere and hydrosphere is contained in rock and mineral records, corresponding information about the atmosphere is scarce and elusive owing to the lack of direct records. Geologists have used sedimentary minerals, fossils and geochemical models to place constraints on the concentrations of carbon dioxide, oxygen or methane in the past(1-4). Here we show that the triple oxygen isotope composition of sulphate from ancient evaporites and barites shows variable negative oxygen-17 isotope anomalies over the past 750 million years. We propose that these anomalies track those of atmospheric oxygen and in turn reflect the partial pressure of carbon dioxide (p(CO2)) in the past through a photochemical reaction network linking stratospheric ozone to carbon dioxide and to oxygen(5,6). Our results suggest that p(CO2) was much higher in the early Cambrian than in younger eras, agreeing with previous modelling results(2). We also find that the (17)O isotope anomalies of barites from Marinoan (similar to 635 million years ago) cap carbonates display a distinct negative spike (around 20.70%), suggesting that by the time barite was precipitating in the immediate aftermath of a Neoproterozoic global glaciation, the p(CO2) was at its highest level in the past 750 million years. Our finding is consistent with the 'snowball Earth' hypothesis(7,8) and/or a massive methane release(9) after the Marinoan glaciation.	[Bao, Huiming] Louisiana State Univ, Dept Geol & Geophys, Baton Rouge, LA 70803 USA; [Lyons, J. R.] Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; [Zhou, Chuanming] Chinese Acad Sci, State Key Lab Palaeobiol & Stratig, Nanjing Inst Geol & Palaeontol, Nanjing 210008, Peoples R China	Louisiana State University System; Louisiana State University; University of California System; University of California Los Angeles; Chinese Academy of Sciences	Bao, HM (corresponding author), Louisiana State Univ, Dept Geol & Geophys, E235 Howe Russell Geosci Complex, Baton Rouge, LA 70803 USA.	bao@lsu.edu	Zhou, Chuanming/E-5313-2010; Bao, Huiming/C-1069-2012					Alexander B, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL014879; Balci N, 2007, GEOCHIM COSMOCHIM AC, V71, P3796, DOI 10.1016/j.gca.2007.04.017; Bao HM, 2000, ANAL CHEM, V72, P4029, DOI 10.1021/ac000086e; Bao HM, 2006, ANAL CHEM, V78, P304, DOI 10.1021/ac051568z; Bao HM, 2000, NATURE, V406, P176, DOI 10.1038/35018052; Bao HM, 2005, CHEM GEOL, V214, P127, DOI 10.1016/j.chemgeo.2004.08.052; Bao HM, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL016869; Bao HM, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006669; BENDER M, 1994, GLOBAL BIOGEOCHEM CY, V8, P363, DOI 10.1029/94GB00724; Berner RA, 2006, GEOCHIM COSMOCHIM AC, V70, P5653, DOI 10.1016/j.gca.2005.11.032; Blunier T, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001460; Ekart DD, 1999, AM J SCI, V299, P805, DOI 10.2475/ajs.299.10.805; Gamsjager H., 1983, ADV INORG BIOINORG, V2, P317; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; Howell KJ, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026518; Jiang GQ, 2006, J SEDIMENT RES, V76, P978, DOI 10.2110/jsr.2006.086; Jiang GQ, 2003, NATURE, V426, P822, DOI 10.1038/nature02201; Kasemann SA, 2005, EARTH PLANET SC LETT, V231, P73, DOI 10.1016/j.epsl.2004.12.006; Luz B, 2005, GEOCHIM COSMOCHIM AC, V69, P1099, DOI 10.1016/j.gca.2004.09.001; Luz B, 1999, NATURE, V400, P547, DOI 10.1038/22987; Mauersberger K, 2005, ADV ATOM MOL OPT PHY, V50, P1, DOI 10.1016/S1049-250X(04)50001-0; Miller MF, 2002, GEOCHIM COSMOCHIM AC, V66, P1881, DOI 10.1016/S0016-7037(02)00832-3; Pierrehumbert RT, 2004, NATURE, V429, P646, DOI 10.1038/nature02640; Royer DL, 2001, SCIENCE, V292, P2310, DOI 10.1126/science.292.5525.2310; RYE R, 1995, NATURE, V378, P603, DOI 10.1038/378603a0; Savarino J, 2000, J GEOPHYS RES-ATMOS, V105, P29079, DOI 10.1029/2000JD900456; VANSTEMPVOORT DR, 1994, ACS SYM SER, V550, P446; Young ED, 2002, GEOCHIM COSMOCHIM AC, V66, P1095, DOI 10.1016/S0016-7037(01)00832-8; YUNG YL, 1991, GEOPHYS RES LETT, V18, P13, DOI 10.1029/90GL02478; Yung YL, 1997, J GEOPHYS RES-ATMOS, V102, P10857, DOI 10.1029/97JD00528	30	171	190	6	145	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 22	2008	453	7194					504	506		10.1038/nature06959	http://dx.doi.org/10.1038/nature06959			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303EL	18497821				2022-12-28	WOS:000256023700038
J	Calonge, N; Petitti, DB; DeWitt, TG; Gordis, L; Gregory, KD; Harris, R; Isham, G; LeFevre, ML; Loveland-Cherry, C; Marion, LN; Moyer, VA; Ockene, JK; Sawaya, GF; Siu, AL; Teutsch, SM; Yawn, BP				Calonge, Ned; Petitti, Diana B.; DeWitt, Thomas G.; Gordis, Leon; Gregory, Kimberly D.; Harris, Russell; Isham, George; LeFevre, Michael L.; Loveland-Cherry, Carol; Marion, Lucy N.; Moyer, Virginia A.; Ockene, Judith K.; Sawaya, George F.; Siu, Albert L.; Teutsch, Steven M.; Yawn, Barbara P.		US Preventive Serv Task Force	Screening for gestational diabetes mellitus: US preventive services task force recommendation statement	ANNALS OF INTERNAL MEDICINE			English	Article							DIAGNOSIS	Description: Update of 2003 U. S. Preventive Services Task Force (USPSTF) recommendation about screening for gestational diabetes. Methods: The USPSTF weighed the evidence on maternal and neonatal benefits (reduction in preeclampsia, mortality, brachial plexus injury, clavicular fractures, admission to the neonatal intensive care unit for serious illnesses) and harms (physical and psychological harms) of screening for gestational diabetes identified for their 2003 recommendation and the accompanying systematic review of articles published since the 2003 review for screening after 24 weeks' gestation. Additional searches were performed for evidence published from 1966 to 1999 on screening before 24 weeks. Recommendation: Current evidence is insufficient to assess the balance of benefits and harms of screening for gestational diabetes mellitus, either before or after 24 weeks' gestation. (I statement.)	[Calonge, Ned] Colorado Dept Publ Hlth & Environm, Denver, CO USA; [Petitti, Diana B.] Univ So Calif, Keck Sch Med, Sierra Madre, CA USA; [DeWitt, Thomas G.] Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; [Gordis, Leon] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Gregory, Kimberly D.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; [Harris, Russell] Univ N Carolina, Sch Med, Chapel Hill, NC USA; [Isham, George] HealthPartners, Minneapolis, MN USA; [LeFevre, Michael L.] Univ Missouri, Sch Med, Columbia, MO USA; [Loveland-Cherry, Carol] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA; [Marion, Lucy N.] Med Coll Georgia, Sch Nursing, Augusta, GA 30912 USA; [Moyer, Virginia A.] Univ Texas Houston, Hlth Sci Ctr, Houston, TX USA; [Ockene, Judith K.] Univ Massachusetts, Sch Med, Worcester, MA USA; [Sawaya, George F.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Siu, Albert L.] Mt Sinai Sch Med, New York, NY USA; [Teutsch, Steven M.] Merck & Co Inc, West Point, PA USA; [Yawn, Barbara P.] Olmsted Med Ctr, Rochester, MN USA; US Prevent Serv Task Force, Agcy Healthcare Res & Qual, Rockville, MD USA	Colorado Department of Public Health & Environment; University of Southern California; Cincinnati Children's Hospital Medical Center; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Cedars Sinai Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Missouri System; University of Missouri Columbia; University of Michigan System; University of Michigan; University System of Georgia; Augusta University; University of Texas System; University of Texas Health Science Center Houston; University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California San Francisco; Icahn School of Medicine at Mount Sinai; Merck & Company; Olmsted Medical Center; Agency for Healthcare Research & Quality	Calonge, N (corresponding author), Colorado Dept Publ Hlth & Environm, Denver, CO USA.							*AM AC FAM PHYS PO, 2007, SUMM REC CLIN PREV S; Am Diabetes Assoc, 2006, DIABETES CARE, V29, pS4; American College of Obstetricians and Gynecologists Committee on Practice Bulletins--Obstetrics, 2001, Obstet Gynecol, V98, P525; American Diabetes Association, 2004, DIABETES CARE S1, V27, P380, DOI [10.2337/diacare.27.2007.S88, DOI 10.2337/DIACARE.27.2007.S88]; Bartha JL, 2000, AM J OBSTET GYNECOL, V182, P346, DOI 10.1016/S0002-9378(00)70222-5; Berg AO, 2003, OBSTET GYNECOL, V101, P393, DOI 10.1016/S0029-7844(02)03056-9; Brody SC, 2003, OBSTET GYNECOL, V101, P380, DOI 10.1016/S0029-7844(02)03057-0; Crowther CA, 2005, NEW ENGL J MED, V352, P2477, DOI 10.1056/NEJMoa042973; Daniells S, 2003, DIABETES CARE, V26, P385, DOI 10.2337/diacare.26.2.385; HARLASS FE, 1991, AM J OBSTET GYNECOL, V164, P564, DOI 10.1016/S0002-9378(11)80021-9; Hillier TA, 2008, ANN INTERN MED, V148, P766, DOI 10.7326/0003-4819-148-10-200805200-00009; Jovanovic L, 2001, JAMA-J AM MED ASSOC, V286, P2516, DOI 10.1001/jama.286.20.2516; LANGER N, 1994, OBSTET GYNECOL, V84, P329; LAVIN JP, 1981, AM J OBSTET GYNECOL, V141, P491, DOI 10.1016/S0002-9378(15)33266-X; Lemen PM, 1998, AM J OBSTET GYNECOL, V178, P1251, DOI 10.1016/S0002-9378(98)70330-8; Marquette G P, 1985, Am J Perinatol, V2, P7, DOI 10.1055/s-2007-999901; Moses RG, 1998, DIABETES CARE, V21, P1803, DOI 10.2337/diacare.21.11.1803; OSULLIVAN JB, 1966, OBSTET GYNECOL, V27, P683; Rumbold AR, 2002, AUST NZ J OBSTET GYN, V42, P131, DOI 10.1111/j.0004-8666.2002.00131.x; Southwick RD, 2000, J REPROD MED, V45, P31; SPIRITO A, 1989, OBSTET GYNECOL, V73, P562	21	67	69	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 20	2008	148	10					759	U67						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308EX	18490688				2022-12-28	WOS:000256372200005
J	Wang, XT; Arai, S; Song, XY; Reichart, D; Du, K; Pascual, G; Tempst, P; Rosenfeld, MG; Glass, CK; Kurokawa, R				Wang, Xiangting; Arai, Shigeki; Song, Xiaoyuan; Reichart, Donna; Du, Kun; Pascual, Gabriel; Tempst, Paul; Rosenfeld, Michael G.; Glass, Christopher K.; Kurokawa, Riki			Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription	NATURE			English	Article							PRO-ONCOPROTEIN TLS/FUS; NONCODING RNAS; GENE-EXPRESSION; COACTIVATOR; GENOME; TLS; IDENTIFICATION; CHROMATIN; COMPLEX; MICE	With the recent recognition of non- coding RNAs ( ncRNAs) flanking many genes(1-5), a central issue is to obtain a full understanding of their potential roles in regulated gene transcription programmes, possibly through different mechanisms(6-12). Here we show that an RNA- binding protein, TLS ( for translocated in liposarcoma), serves as a key transcriptional regulatory sensor of DNA damage signals that, on the basis of its allosteric modulation by RNA, specifically binds to and inhibits CREB- binding protein ( CBP) and p300 histone acetyltransferase activities on a repressed gene target, cyclin D1 ( CCND1) in human cell lines. Recruitment of TLS to the CCND1 promoter to cause gene- specific repression is directed by single- stranded, low- copy- number ncRNA transcripts tethered to the 5' regulatory regions of CCND1 that are induced in response to DNA damage signals. Our data suggest that signal-induced ncRNAs localized to regulatory regions of transcription units can act cooperatively as selective ligands, recruiting and modulating the activities of distinct classes of RNA- binding co-regulators in response to specific signals, providing an unexpected ncRNA/RNA-binding protein-based strategy to integrate transcriptional programmes.	[Arai, Shigeki; Du, Kun; Kurokawa, Riki] Saitama Med Univ, Res Ctr Genom Med, Div Gene Struct & Funct, Hidaka, Saitama 3501241, Japan; [Wang, Xiangting; Song, Xiaoyuan; Rosenfeld, Michael G.] Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; [Wang, Xiangting] Univ Calif San Diego, Sch Med, Mol Pathol Grad Program, La Jolla, CA 92093 USA; [Reichart, Donna; Pascual, Gabriel; Glass, Christopher K.] Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Pascual, Gabriel; Rosenfeld, Michael G.; Glass, Christopher K.] Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; [Tempst, Paul] Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Saitama Medical University; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Memorial Sloan Kettering Cancer Center	Kurokawa, R (corresponding author), Saitama Med Univ, Res Ctr Genom Med, Div Gene Struct & Funct, 1397-1 Yamane, Hidaka, Saitama 3501241, Japan.	mgr@ucsd.edu; ckg@ucsd.edu; rkurokaw@saitama-med.ac.jp	Glass, Christopher/AAI-3933-2021; , songxy/P-1094-2014; xiangting, wang/P-1010-2014	Glass, Christopher/0000-0003-4344-3592; , songxy/0000-0002-9011-5033; xiangting, wang/0000-0003-2106-3425; Tempst, Paul/0000-0002-6680-3987	Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [P30 CA008748, CA097134, CA52599, P30 CA08748, R01 CA052599, R01 CA052599-19] Funding Source: Medline; NHLBI NIH HHS [R01 HL059694-10, R01 HL059694, HL59694] Funding Source: Medline; NIDDK NIH HHS [R01 DK039949, DK074868, DK39949, R01 DK091183, R37 DK039949, R37 DK039949-26] Funding Source: Medline; NINDS NIH HHS [R01 NS034934, NS34934, R01 NS034934-20A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, R01CA052599, R01CA097134] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039949, P01DK074868, R01DK091183, R01DK039949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034934] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Baechtold H, 1999, J BIOL CHEM, V274, P34337, DOI 10.1074/jbc.274.48.34337; Bernstein E, 2005, GENE DEV, V19, P1635, DOI 10.1101/gad.1324305; Bertone P, 2004, SCIENCE, V306, P2242, DOI 10.1126/science.1103388; Bertrand P, 1999, ONCOGENE, V18, P4515, DOI 10.1038/sj.onc.1203048; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Feng JC, 2006, GENE DEV, V20, P1470, DOI 10.1101/gad.1416106; Hicks GG, 2000, NAT GENET, V24, P175, DOI 10.1038/72842; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; Kapranov P, 2007, NAT REV GENET, V8, P413, DOI 10.1038/nrg2083; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kuroda M, 2000, EMBO J, V19, P453, DOI 10.1093/emboj/19.3.453; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lerga A, 2001, J BIOL CHEM, V276, P6807, DOI 10.1074/jbc.M008304200; Martianov I, 2007, NATURE, V445, P666, DOI 10.1038/nature05519; Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Miyakawa Y, 2001, BIOCHEM BIOPH RES CO, V284, P71, DOI 10.1006/bbrc.2001.4950; Murata T, 2001, HUM MOL GENET, V10, P1071, DOI 10.1093/hmg/10.10.1071; O'Neill MJ, 2005, HUM MOL GENET, V14, pR113, DOI 10.1093/hmg/ddi108; Petruk S, 2006, CELL, V127, P1209, DOI 10.1016/j.cell.2006.10.039; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Ron D, 1997, CURR TOP MICROBIOL, V220, P131; Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806; Sanchez-Elsner T, 2006, SCIENCE, V311, P1118, DOI 10.1126/science.1117705; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Uranishi H, 2001, J BIOL CHEM, V276, P13395, DOI 10.1074/jbc.M011176200; Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761	29	772	841	1	114	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	2008	454	7200					126	U11		10.1038/nature06992	http://dx.doi.org/10.1038/nature06992			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	321MC	18509338	Green Accepted			2022-12-28	WOS:000257308300051
J	Lopez-Garcia, E; van Dam, RM; Li, TY; Rodriguez-Artalejo, F; Hu, FB				Lopez-Garcia, Esther; van Dam, Rob M.; Li, Tricia Y.; Rodriguez-Artalejo, Fernando; Hu, Frank B.			The relationship of coffee consumption with mortality	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; PHYSICAL-ACTIVITY; CARDIOVASCULAR-DISEASE; ALCOHOL-CONSUMPTION; RISK; DEATH; MEN; CAFFEINE; DRINKING; HEALTH	Background: Coffee consumption has been linked to various beneficial and detrimental health effects, but data on its relation with mortality are sparse. Objective: To assess the association between coffee consumption and mortality from cardiovascular disease (CVD), cancer, and all causes during 18 years of follow-up in men and 24 years of follow-up in women. Design: Sex-specific Cox proportional hazard models were used to investigate the association between coffee consumption and incidence of all-cause and disease-specific mortality in a prospective cohort study. Setting: Health Professionals Follow-up Study and Nurses' Health Study. Participants: 41 736 men and 86 214 women with no history of CVD or cancer at baseline. Measurements: Coffee consumption was assessed first in 1986 for men and in 1980 for women and then every 2 to 4 years through 2004. Investigators documented 6888 deaths (2049 due to CVD and 2491 due to cancer) among men and 11 095 deaths (2368 due to CVD and 5011 due to cancer) among women. Results: After adjustment for age, smoking, and other CVD and cancer risk factors, the relative risks for all-cause mortality in men across categories of coffee consumption (<1 cup per month, 1 cup per month to 4 cups per week, 5 to 7 cups per week, 2 to 3 cups per day, 4 to 5 cups per day, and >= 6 cups per day) were 1.0, 1.07 (95% CI, 0.99 to 1.16), 1.02 (CI, 0.95 to 1.11), 0.97 (CI, 0.89 to 1.05), 0.93 (CI, 0.81 to 1.07), and 0.80 (CI, 0.62 to 1.04), respectively (P for trend = 0.008). For women, the relative risks were 1.0, 0.98 (CI, 0.91 to 1.05), 0.93 (CI, 0.87 to 0.98), 0.82 (CI, 0.77 to 0.87), 0.74 (CI, 0.68 to 0.81), and 0.83 (CI, 0.73 to 0.95), respectively (P for trend < 0.001). This inverse association was mainly due to a moderately reduced risk for CVD mortality and was independent of caffeine intake. By contrast, coffee consumption was not statistically significantly associated with risk for cancer death after adjustment for potential confounders. Decaffeinated coffee consumption was associated with a small reduction in all-cause and CVD mortality. Limitation: Coffee consumption was estimated from self-report; thus, some measurement error is inevitable. Conclusion: Regular coffee consumption was not associated with an increased mortality rate in either men or women. The possibility of a modest benefit of coffee consumption on all-cause and CVD mortality needs to be further investigated.	Univ Autonoma Madrid, Dept Prevent Med & Publ Hlth, Sch Med, E-28049 Madrid, Spain; Harvard Univ, Sch Publ Hlth, Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; CIBERESP CIBER Epidemiol & Publ Health, Barcelona, Spain	Autonomous University of Madrid; Harvard University; Brigham & Women's Hospital; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP	Lopez-Garcia, E (corresponding author), Univ Autonoma Madrid, Dept Prevent Med & Publ Hlth, Sch Med, Avenida Arzobispo Morcillo 4, E-28049 Madrid, Spain.	esther.lopez@uam.es	Hu, Frank/C-1919-2013; Lopez-Garcia, Esther/A-8894-2019; van Dam, Rob M/F-9674-2010	van Dam, Rob M/0000-0002-7354-8734	NATIONAL CANCER INSTITUTE [P01CA087969, P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060712, R01HL034594] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnlov J, 2004, JAMA-J AM MED ASSOC, V291, P1199, DOI 10.1001/jama.291.10.1199-a; ChasanTaber S, 1996, EPIDEMIOLOGY, V7, P81, DOI 10.1097/00001648-199601000-00014; Colditz GA, 2005, NAT REV CANCER, V5, P388, DOI 10.1038/nrc1608; DAWBER TR, 1974, NEW ENGL J MED, V291, P871, DOI 10.1056/NEJM197410242911703; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; Andersen LF, 2006, AM J CLIN NUTR, V83, P1039, DOI 10.1093/ajcn/83.5.1039; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; Gomez-Ruiz JA, 2007, J AGR FOOD CHEM, V55, P6962, DOI 10.1021/jf0710985; Greenberg JA, 2007, AM J CLIN NUTR, V85, P392, DOI 10.1093/ajcn/85.2.392; Happonen P, 2004, J NUTR, V134, P2381, DOI 10.1093/jn/134.9.2381; Hart C, 1997, J EPIDEMIOL COMMUN H, V51, P461, DOI 10.1136/jech.51.4.461; Hartley TR, 2004, AM J CARDIOL, V93, P1022, DOI 10.1016/j.amjcard.2003.12.057; Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849; Huber WW, 2002, ARCH TOXICOL, V75, P685, DOI 10.1007/s00204-001-0295-5; Iwai Nobuo, 2002, J Epidemiol, V12, P191; JACOBSEN BK, 1986, J NATL CANCER I, V76, P823; Jazbec A, 2003, J HEALTH POPUL NUTR, V21, P332; Kleemola P, 2000, ARCH INTERN MED, V160, P3393, DOI 10.1001/archinte.160.22.3393; Koh-Banerjee P, 2003, AM J CLIN NUTR, V78, P719, DOI 10.1093/ajcn/78.4.719; Kurozawa Y, 2005, BRIT J CANCER, V93, P607, DOI 10.1038/sj.bjc.6602737; La Vecchia C, 2005, J HEPATOL, V42, P444, DOI 10.1016/j.jhep.2005.01.004; Larsson SC, 2007, GASTROENTEROLOGY, V132, P1740, DOI 10.1053/j.gastro.2007.03.044; LEGRADY D, 1987, AM J EPIDEMIOL, V126, P803, DOI 10.1093/oxfordjournals.aje.a114717; LINDSTED KD, 1992, J CLIN EPIDEMIOL, V45, P733, DOI 10.1016/0895-4356(92)90051-N; Lopez-Garcia E, 2006, CIRCULATION, V113, P2045, DOI 10.1161/CIRCULATIONAHA.105.598664; Lopez-Garcia E, 2006, AM J CLIN NUTR, V84, P888, DOI 10.1093/ajcn/84.4.888; Meisinger C, 2005, CIRCULATION, V112, P651, DOI 10.1161/CIRCULATIONAHA.104.529297; MURRAY SS, 1981, AM J EPIDEMIOL, V113, P661, DOI 10.1093/oxfordjournals.aje.a113145; Paganini-Hill A, 2007, PREV MED, V44, P305, DOI 10.1016/j.ypmed.2006.12.011; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; Rockhill B, 2001, AM J PUBLIC HEALTH, V91, P578, DOI 10.2105/AJPH.91.4.578; ROSENGREN A, 1991, J INTERN MED, V230, P67, DOI 10.1111/j.1365-2796.1991.tb00407.x; ROSNER B, 1989, STAT MED, V8, P1051, DOI 10.1002/sim.4780080905; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; Scharf G, 2001, ADV EXP MED BIOL, V500, P535; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Stensvold I, 1996, BRIT MED J, V312, P544, DOI 10.1136/bmj.312.7030.544; Tavani A, 2004, CANCER CAUSE CONTROL, V15, P743, DOI 10.1023/B:CACO.0000043415.28319.c1; Tavani A, 2003, ORAL ONCOL, V39, P695, DOI 10.1016/S1368-8375(03)00081-2; Thong FSL, 2002, J APPL PHYSIOL, V92, P2347, DOI 10.1152/japplphysiol.01229.2001; TVERDAL A, 1990, BRIT MED J, V300, P566, DOI 10.1136/bmj.300.6724.566; van Dam RM, 2006, NUTR METAB CARDIOVAS, V16, P69, DOI 10.1016/j.numecd.2005.10.003; van Dam RM, 2005, JAMA-J AM MED ASSOC, V294, P97, DOI 10.1001/jama.294.1.97; VANDENBROUCKE JP, 1986, AM J EPIDEMIOL, V123, P359, DOI 10.1093/oxfordjournals.aje.a114245; Verhoef P, 2002, AM J CLIN NUTR, V76, P1244, DOI 10.1093/ajcn/76.6.1244; von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; Woodward M, 1999, J EPIDEMIOL COMMUN H, V53, P481, DOI 10.1136/jech.53.8.481; Yukawa GS, 2004, BIOCHEMISTRY-MOSCOW+, V69, P70, DOI 10.1023/B:BIRY.0000016354.05438.0f	49	132	138	0	34	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 17	2008	148	12					904	+		10.7326/0003-4819-148-12-200806170-00003	http://dx.doi.org/10.7326/0003-4819-148-12-200806170-00003			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	323DU	18559841	Green Accepted			2022-12-28	WOS:000257425000002
J	Ago, T; Liu, T; Zhai, P; Chen, W; Li, H; Molkentin, JD; Vatner, SF; Sadoshima, J				Ago, Tetsuro; Liu, Tong; Zhai, Peiyong; Chen, Wei; Li, Hong; Molkentin, Jeffery D.; Vatner, Stephen F.; Sadoshima, Junichi			A redox-dependent pathway for regulating class IIHDACs and cardiac hypertrophy	CELL			English	Article							HISTONE DEACETYLASE; NUCLEAR-FACTOR; THIOREDOXIN; ACTIVATION; HEART; INHIBITION; PROTEIN-1; PHENOTYPE; APOPTOSIS; STRESS	Thioredoxin 1 (Trx1) facilitates the reduction of signaling molecules and transcription factors by cysteine thiol-disulfide exchange, thereby regulating cell growth and death. Here we studied the molecular mechanism by which Trx1 attenuates cardiac hypertrophy. Trx1 upregulates DnaJb5, a heat shock protein 40, and forms a multiple-protein complex with DnaJb5 and class II histone deacetylases (HDACs), master negative regulators of cardiac hypertrophy. Both Cys-274/Cys-276 in DnaJb5 and Cys-667/Cys-669 in HDAC4 are oxidized and form intramolecular disulfide bonds in response to reactive oxygen species (ROS)-generating hypertrophic stimuli, such as phenylephrine, whereas they are reduced by Trx1. Whereas reduction of Cys-274/Cys-276 in DnaJb5 is essential for interaction between DnaJb5 and HDAC4, reduction of Cys-667/Cys-669 in HDAC4 inhibits its nuclear export, independently of its phosphorylation status. Our study reveals a novel regulatory mechanism of cardiac hypertrophy through which the nucleocytoplasmic shuttling of class II HDACs is modulated by their redox modification in a Trx1-sensitive manner.	[Ago, Tetsuro; Zhai, Peiyong; Vatner, Stephen F.; Sadoshima, Junichi] Univ Med & Dent New Jersey, New Jersey Med Sch, Cardiovasc Res Inst, Dept Cell Biol & Mol Med, Newark, NJ 07103 USA; [Liu, Tong; Chen, Wei; Li, Hong] Univ Med & Dent New Jersey, New Jersey Med Sch, Ctr Canc, Ctr Adv Prote Res, Newark, NJ 07103 USA; [Liu, Tong; Chen, Wei; Li, Hong] Univ Med & Dent New Jersey, New Jersey Med Sch, Ctr Canc, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; [Molkentin, Jeffery D.] Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Sadoshima, J (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Cardiovasc Res Inst, Dept Cell Biol & Mol Med, Newark, NJ 07103 USA.	sadoshju@umdnj.edu	Li, Hong/K-8436-2013	Ago, Tetsuro/0000-0003-4560-6594; Molkentin, Jeffery/0000-0002-3558-6529; Li, Hong/0000-0001-5731-5335; Sadoshima, Junichi/0000-0003-3724-4132	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL069020, R01HL067727, R01HL091469, P01HL059139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023039, R01AG028787] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL059139, HL 59139, HL67727, P01 HL069020, HL69020, HL91469] Funding Source: Medline; NIA NIH HHS [R01 AG028787, AG28787, AG23039] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ago T, 2006, ANTIOXID REDOX SIGN, V8, P1635, DOI 10.1089/ars.2006.8.1635; Backs J, 2006, CIRC RES, V98, P15, DOI 10.1161/01.RES.0000197782.21444.8f; Berndt C, 2007, AM J PHYSIOL-HEART C, V292, pH1227, DOI 10.1152/ajpheart.01162.2006; Cave AC, 2006, ANTIOXID REDOX SIGN, V8, P691, DOI 10.1089/ars.2006.8.691; Choi HI, 2006, FREE RADICAL BIO MED, V40, P651, DOI 10.1016/j.freeradbiomed.2005.09.018; Dai YS, 2005, MOL CELL BIOL, V25, P9936, DOI 10.1128/MCB.25.22.9936-9948.2005; Hirotani S, 2002, CIRCULATION, V105, P509, DOI 10.1161/hc0402.102863; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kwon SH, 2003, J MOL CELL CARDIOL, V35, P615, DOI 10.1016/S0022-2828(03)00084-1; Li GQ, 1997, AM J PHYSIOL-HEART C, V273, pH1090, DOI 10.1152/ajpheart.1997.273.3.H1090; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Morisco C, 2001, J MOL CELL CARDIOL, V33, P561, DOI 10.1006/jmcc.2000.1332; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nishinaka Y, 2004, J BIOL CHEM, V279, P37559, DOI 10.1074/jbc.M405473200; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; Potthoff MJ, 2007, J CLIN INVEST, V117, P2459, DOI 10.1172/JCI31960; Qiu XB, 2006, CELL MOL LIFE SCI, V63, P2560, DOI 10.1007/s00018-006-6192-6; Rajasekaran NS, 2007, CELL, V130, P427, DOI 10.1016/j.cell.2007.06.044; Siwik DA, 1999, CIRC RES, V85, P147, DOI 10.1161/01.RES.85.2.147; Tang W, 2001, BIOCHEMISTRY-US, V40, P14985, DOI 10.1021/bi0107593; Tao L, 2004, P NATL ACAD SCI USA, V101, P11471, DOI 10.1073/pnas.0402941101; Vannini A, 2004, P NATL ACAD SCI USA, V101, P15064, DOI 10.1073/pnas.0404603101; Yamamoto M, 2003, J CLIN INVEST, V112, P1395, DOI 10.1172/JCI200317700	24	274	277	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	2008	133	6					978	993		10.1016/j.cell.2008.04.041	http://dx.doi.org/10.1016/j.cell.2008.04.041			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	312TJ	18555775	Green Submitted, Bronze			2022-12-28	WOS:000256693400014
J	Basto, R; Brunk, K; Vinadogrova, T; Peel, N; Franz, A; Khodjakov, A; Raff, JW				Basto, Renata; Brunk, Kathrin; Vinadogrova, Tatiana; Peel, Nina; Franz, Anna; Khodjakov, Alexey; Raff, Jordan W.			Centrosome amplification can initiate tumorigenesis in flies	CELL			English	Article							ASYMMETRIC CELL-DIVISION; REGULATES SPINDLE ORIENTATION; NEUROBLAST SELF-RENEWAL; NEURAL STEM-CELLS; CENTRIOLE DUPLICATION; TUMOR-SUPPRESSOR; DROSOPHILA-MELANOGASTER; CHROMOSOME INSTABILITY; CYCLE PROGRESSION; CORTICAL POLARITY	Centrosome amplification is a common feature of many cancer cells, and it has been previously proposed that centrosome amplification can drive genetic instability and so tumorigenesis. To test this hypothesis, we generated Drosophila lines that have extra centrosomes in similar to 60% of their somatic cells. Many cells with extra centrosomes initially form multipolar spindles, but these spindles ultimately become bipolar. This requires a delay in mitosis that is mediated by the spindle assembly checkpoint (SAC). As a result of this delay, there is no dramatic increase in genetic instability in flies with extra centrosomes, and these flies maintain a stable diploid genome over many generations. The asymmetric division of the larval neural stem cells, however, is compromised in the presence of extra centrosomes, and larval brain cells with extra centrosomes can generate metastatic tumors when transplanted into the abdomens of wild-type hosts. Thus, centrosome amplification can initiate tumorigenesis in flies.	[Basto, Renata; Brunk, Kathrin; Peel, Nina; Franz, Anna; Raff, Jordan W.] Gurdon Inst, Cambridge CB2 1QN, England; [Vinadogrova, Tatiana; Khodjakov, Alexey] New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; [Vinadogrova, Tatiana; Khodjakov, Alexey] SUNY Albany, Dept Biomed Sci, Albany, NY 12222 USA; [Peel, Nina] NIDDK, NIH, Lab Biochem & Genet, Bethesda, MD 20892 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Basto, R (corresponding author), Inst Curie, CNRS, UMR 144, 26 Rue Ulm, Paris 05, France.	renata.basto@curie.fr; j.raff@gurdon.cam.ac.uk		Franz, Anna/0000-0002-2070-326X; Peel, Nina/0000-0002-4277-4106	Cancer Research UK Funding Source: Medline; NIGMS NIH HHS [R01 GM059363, R01 GM059363-10] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059363] Funding Source: NIH RePORTER	Cancer Research UK(Cancer Research UK); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947; Baker JD, 2004, DEVELOPMENT, V131, P3411, DOI 10.1242/dev.01229; Basto R, 2006, CELL, V125, P1375, DOI 10.1016/j.cell.2006.05.025; Bello B, 2006, DEVELOPMENT, V133, P2639, DOI 10.1242/dev.02429; Betschinger J, 2006, CELL, V124, P1241, DOI 10.1016/j.cell.2006.01.038; Bettencourt-Dias M, 2005, CURR BIOL, V15, P2199, DOI 10.1016/j.cub.2005.11.042; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Bowman SK, 2006, DEV CELL, V10, P731, DOI 10.1016/j.devcel.2006.05.005; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Buffin E, 2007, NAT CELL BIOL, V9, P565, DOI 10.1038/ncb1570; Caussinus E, 2005, NAT GENET, V37, P1125, DOI 10.1038/ng1632; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; D'Assoro AB, 2002, BREAST CANCER RES TR, V75, P25, DOI 10.1023/A:1016550619925; Dix CI, 2007, CURR BIOL, V17, P1759, DOI 10.1016/j.cub.2007.08.065; Endow SA, 1998, J CELL SCI, V111, P2487; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Gonzalez C, 2007, NAT REV GENET, V8, P462, DOI 10.1038/nrg2103; Goshima G, 2005, J CELL BIOL, V171, P229, DOI 10.1083/jcb.200505107; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Harris H, 2008, J CELL SCI, V121, P3, DOI 10.1242/jcs.025742; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; IkeshimaKataoka H, 1997, NATURE, V390, P625, DOI 10.1038/37641; Izumi Y, 2006, NAT CELL BIOL, V8, P586, DOI 10.1038/ncb1409; Karpova N, 2006, CELL MOTIL CYTOSKEL, V63, P301, DOI 10.1002/cm.20124; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Kleylein-Sohn J, 2007, DEV CELL, V13, P190, DOI 10.1016/j.devcel.2007.07.002; Lee CY, 2006, GENE DEV, V20, P3464, DOI 10.1101/gad.1489406; Lee CY, 2006, DEV CELL, V10, P441, DOI 10.1016/j.devcel.2006.01.017; LEE HS, 1988, MOL CELL BIOL, V8, P4727, DOI 10.1128/MCB.8.11.4727; Lingle WL, 2000, CURR TOP DEV BIOL, V49, P313; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Lucas EP, 2007, J CELL BIOL, V178, P725, DOI 10.1083/jcb.200704081; Martinez-Campos M, 2004, J CELL BIOL, V165, P673, DOI 10.1083/jcb.200402130; Murphy TD, 2003, J CELL SCI, V116, P2321, DOI 10.1242/jcs.00463; Nigg EA, 2006, INT J CANCER, V119, P2717, DOI 10.1002/ijc.22245; Peel N, 2007, CURR BIOL, V17, P834, DOI 10.1016/j.cub.2007.04.036; Pihan GA, 2001, CANCER RES, V61, P2212; Pihan GA, 2003, CANCER RES, V63, P1398; Pihan GA, 1998, CANCER RES, V58, P3974; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Rebollo E, 2007, DEV CELL, V12, P467, DOI 10.1016/j.devcel.2007.01.021; RING D, 1982, J CELL BIOL, V94, P549, DOI 10.1083/jcb.94.3.549; Rusan NM, 2007, J CELL BIOL, V177, P13, DOI 10.1083/jcb.200612140; Saunders W, 2005, SEMIN CANCER BIOL, V15, P25, DOI 10.1016/j.semcancer.2004.09.003; Siegrist SE, 2005, CELL, V123, P1323, DOI 10.1016/j.cell.2005.09.043; Siller KH, 2006, NAT CELL BIOL, V8, P594, DOI 10.1038/ncb1412; Skold HN, 2005, J CELL SCI, V118, P1745, DOI 10.1242/jcs.02304; Sluder G, 1997, J CELL SCI, V110, P421; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Stevens NR, 2007, CURR BIOL, V17, P1498, DOI 10.1016/j.cub.2007.07.060; Swallow CJ, 2005, ONCOGENE, V24, P306, DOI 10.1038/sj.onc.1208275; Uetake Y, 2007, J CELL BIOL, V176, P173, DOI 10.1083/jcb.200607073; Varmark H, 2007, CURR BIOL, V17, P1735, DOI 10.1016/j.cub.2007.09.031; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; Wunderlich V, 2002, J MOL MED, V80, P545, DOI 10.1007/s00109-002-0374-y; Yu FW, 2006, NEURON, V51, P13, DOI 10.1016/j.neuron.2006.06.016	61	402	409	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	2008	133	6					1032	1042		10.1016/j.cell.2008.05.039	http://dx.doi.org/10.1016/j.cell.2008.05.039			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	312TJ	18555779	Green Accepted, Bronze, Green Submitted			2022-12-28	WOS:000256693400018
J	Harder, JL; Margolis, B				Harder, Jennifer L.; Margolis, Ben			SnapShot: Tight and adherens junction signaling	CELL			English	Editorial Material							CELL-ADHESION; CYTOSKELETON		[Harder, Jennifer L.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Harder, JL (corresponding author), Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069605] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; Kohler K, 2005, BIOL CELL, V97, P659; Martin-Belmonte F, 2008, CURR OPIN CELL BIOL, V20, P227, DOI 10.1016/j.ceb.2008.01.001; Mege RM, 2006, CURR OPIN CELL BIOL, V18, P541, DOI 10.1016/j.ceb.2006.08.004; Perez-Moreno M, 2006, DEV CELL, V11, P601, DOI 10.1016/j.devcel.2006.10.010; Sakisaka T, 2007, CURR OPIN CELL BIOL, V19, P593, DOI 10.1016/j.ceb.2007.09.007; Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219; Yap AS, 2007, CURR OPIN CELL BIOL, V19, P508, DOI 10.1016/j.ceb.2007.09.008	9	13	13	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 13	2008	133	6							e2	10.1016/j.cell.2008.06.002	http://dx.doi.org/10.1016/j.cell.2008.06.002			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	312TJ	18555786	Bronze			2022-12-28	WOS:000256693400025
J	Lange, OF; Lakomek, NA; Fares, C; Schroder, GF; Walter, KFA; Becker, S; Meiler, J; Grubmuller, H; Griesinger, C; de Groot, BL				Lange, Oliver F.; Lakomek, Nils-Alexander; Fares, Christophe; Schroeder, Gunnar F.; Walter, Korvin F. A.; Becker, Stefan; Meiler, Jens; Grubmueller, Helmut; Griesinger, Christian; de Groot, Bert L.			Recognition dynamics up to microseconds revealed from an RDC-derived ubiquitin ensemble in solution	SCIENCE			English	Article							RESIDUAL DIPOLAR COUPLINGS; PROTEIN BACKBONE MOTION; N-15 NMR RELAXATION; MODEL-FREE APPROACH; ORDER PARAMETERS; BINDING DOMAINS; SPECTROSCOPY; CATALYSIS; INFORMATION; ENTROPY	Protein dynamics are essential for protein function, and yet it has been challenging to access the underlying atomic motions in solution on nanosecond-to-microsecond time scales. We present a structural ensemble of ubiquitin, refined against residual dipolar couplings (RDCs), comprising solution dynamics up to microseconds. The ensemble covers the complete structural heterogeneity observed in 46 ubiquitin crystal structures, most of which are complexes with other proteins. Conformational selection, rather than induced-fit motion, thus suffices to explain the molecular recognition dynamics of ubiquitin. Marked correlations are seen between the flexibility of the ensemble and contacts formed in ubiquitin complexes. A large part of the solution dynamics is concentrated in one concerted mode, which accounts for most of ubiquitin's molecular recognition heterogeneity and ensures a low entropic complex formation cost.	[Lakomek, Nils-Alexander; Fares, Christophe; Walter, Korvin F. A.; Becker, Stefan; Griesinger, Christian] Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, D-37077 Gottingen, Germany; [Lange, Oliver F.; Schroeder, Gunnar F.; Grubmueller, Helmut; de Groot, Bert L.] Max Planck Inst Biophys Chem, Dept Theoret & Computat Biophys, D-37077 Gottingen, Germany; [Meiler, Jens] Vanderbilt Univ, Struct Biol Ctr, Nashville, TN 37212 USA	Max Planck Society; Max Planck Society; Vanderbilt University	Griesinger, C (corresponding author), Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, Fassberg 11, D-37077 Gottingen, Germany.	cigr@nmr.mpibpc.mpg.de; bgroot@gwdg.de	Lakomek, Nils A/K-6568-2016; Fares, Christophe/G-2481-2011; Schröder, Gunnar F/H-5261-2013; Lange, Oliver/B-2861-2009; Lange, Oliver/G-1366-2010; Lange, Oliver/K-5749-2012	Lakomek, Nils A/0000-0002-4285-6339; Schröder, Gunnar F/0000-0003-1803-5431; Lange, Oliver/0000-0002-4018-7020; Meiler, Jens/0000-0001-8945-193X				AKKE M, 1993, J AM CHEM SOC, V115, P9832, DOI 10.1021/ja00074a073; Akke M, 1996, J AM CHEM SOC, V118, P911, DOI 10.1021/ja953503r; Bertoncini CW, 2005, P NATL ACAD SCI USA, V102, P1430, DOI 10.1073/pnas.0407146102; Best RB, 2006, P NATL ACAD SCI USA, V103, P10901, DOI 10.1073/pnas.0511156103; Boehr DD, 2006, SCIENCE, V313, P1638, DOI 10.1126/science.1130258; Bouvignies G, 2005, P NATL ACAD SCI USA, V102, P13885, DOI 10.1073/pnas.0505129102; Bouvignies G, 2006, J AM CHEM SOC, V128, P15100, DOI 10.1021/ja066704b; Briggman KB, 2003, J AM CHEM SOC, V125, P10164, DOI 10.1021/ja035904+; Brzovic PS, 2006, CELL CYCLE, V5, P2867, DOI 10.4161/cc.5.24.3592; Chang SL, 2005, J MAGN RESON, V174, P43, DOI 10.1016/j.jmr.2005.01.008; CLARKSON T, 1995, SCIENCE, V267, P383; Eisenmesser EZ, 2005, NATURE, V438, P117, DOI 10.1038/nature04105; FRAUENFELDER H, 1985, SCIENCE, V229, P337, DOI 10.1126/science.4012322; Frederick KK, 2007, NATURE, V448, P325, DOI 10.1038/nature05959; Goh CS, 2004, CURR OPIN STRUC BIOL, V14, P104, DOI 10.1016/j.sbi.2004.01.005; Grunberg R, 2004, STRUCTURE, V12, P2125, DOI 10.1016/j.str.2004.09.014; Harper JW, 2006, CELL, V124, P1133, DOI 10.1016/j.cell.2006.03.009; Henzler-Wildman KA, 2007, NATURE, V450, P913, DOI 10.1038/nature06407; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kiel C, 2006, J MOL BIOL, V355, P821, DOI 10.1016/j.jmb.2005.10.010; Kolano C, 2006, NATURE, V444, P469, DOI 10.1038/nature05352; Lakomek NA, 2006, J BIOMOL NMR, V34, P101, DOI 10.1007/s10858-005-5686-0; Lakomek NA, 2005, ANGEW CHEM INT EDIT, V44, P7776, DOI 10.1002/anie.200502573; Lindorff-Larsen K, 2005, NATURE, V433, P128, DOI 10.1038/nature03199; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Markwick PRL, 2007, J AM CHEM SOC, V129, P4724, DOI 10.1021/ja0687668; Massi F, 2005, PROTEIN SCI, V14, P735, DOI 10.1110/ps.041139505; Meiler J, 2001, J AM CHEM SOC, V123, P6098, DOI 10.1021/ja010002z; Mittermaier A, 2006, SCIENCE, V312, P224, DOI 10.1126/science.1124964; Ottiger M, 1998, J AM CHEM SOC, V120, P12334, DOI 10.1021/ja9826791; Penengo L, 2006, CELL, V124, P1183, DOI 10.1016/j.cell.2006.02.020; Peti W, 2002, J AM CHEM SOC, V124, P5822, DOI 10.1021/ja011883c; Richter B, 2007, J BIOMOL NMR, V37, P117, DOI 10.1007/s10858-006-9117-7; Ruan K, 2005, J AM CHEM SOC, V127, P15032, DOI 10.1021/ja055520e; Sugase K, 2007, NATURE, V447, P1021, DOI 10.1038/nature05858; Tang C, 2007, NATURE, V449, P1078, DOI 10.1038/nature06232; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; TOLMAN JR, 1995, P NATL ACAD SCI USA, V92, P9279, DOI 10.1073/pnas.92.20.9279; Tolman JR, 2002, J AM CHEM SOC, V124, P12020, DOI 10.1021/ja0261123; Wang LC, 2001, P NATL ACAD SCI USA, V98, P7684, DOI 10.1073/pnas.121069998; Yang DW, 1997, J MOL BIOL, V272, P790, DOI 10.1006/jmbi.1997.1285	44	806	816	2	190	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2008	320	5882					1471	1475		10.1126/science.1157092	http://dx.doi.org/10.1126/science.1157092			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556554	Green Published			2022-12-28	WOS:000256676400038
J	Winograd, IJ; Roseboom, EH				Winograd, Isaac J.; Roseboom, Eugene H., Jr.			Yucca Mountain revisited	SCIENCE			English	Editorial Material									[Winograd, Isaac J.; Roseboom, Eugene H., Jr.] US Geol Survey, Reston, VA 20192 USA	United States Department of the Interior; United States Geological Survey	Winograd, IJ (corresponding author), US Geol Survey, Reston, VA 20192 USA.	ijwinogr@usgs.gov						Bodvarsson G. S., 2003, YUCCA MOUNTAIN PROJE; DAPPOLONIA E, 1990, J GEOTECH ENG-ASCE, V116, P4, DOI 10.1061/(ASCE)0733-9410(1990)116:1(4); KAFKA AL, 2007, EOS, V88, P8; KAFKA AL, 2007, EOS, V88, P1; KONIKOW LF, 1992, ADV WATER RESOUR, V15, P75, DOI 10.1016/0309-1708(92)90033-X; MacFarlane Allison, 2006, UNCERTAINTY UNDERGRO; MAYR E, 1961, SCIENCE, V134, P1501, DOI 10.1126/science.134.3489.1501; National Research Council, 1995, TECHN BAS YUCC MOUNT; National Research Council (NRC), 1957, DISP RAD WAST LAND; National Research Council (NRC), 2001, DISP HIGH LEV WAST S; *NRC, 2003, 1 STEP TIM STAG DEV; Oreskes Naomi, 2000, PREDICTION SCI DECIS, P23; Raymo ME, 2008, NATURE, V451, P284, DOI 10.1038/nature06589; Rosa Eugene A., 1993, PUBLIC REACTIONS NUC, P291; ROSENBOOM EH, 1983, 903 US GEOL SURV; SCRIVEN M, 1959, SCIENCE, V130, P477, DOI 10.1126/science.130.3374.477; *US NUCL REG COMM, 1985, FED REGISTER, V50, P29641; WEINBERG AM, 1985, ISSUES SCI TECHNOL, V2, P59; Winograd I. J., 1986, 990 US GEOL SURV; WINOGRAD IJ, 1981, SCIENCE, V212, P1457, DOI 10.1126/science.212.4502.1457; WINOGRAD IJ, 1974, EOS T AM GEOPHYS UN, V55, P884, DOI 10.1029/EO055i010p00884; WOLLENBERG HA, 1983, LBL15010 U CAL BERK	22	6	6	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2008	320	5882					1426	1427		10.1126/science.1156399	http://dx.doi.org/10.1126/science.1156399			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556535				2022-12-28	WOS:000256676400019
J	Riemersma-van Der Lek, RF; Swaab, DF; Twisk, J; Hol, EM; Hoogendijk, WJG; Van Someren, EJW				Riemersma-van der Lek, Rixt F.; Swaab, Dick F.; Twisk, Jos; Hol, Elly M.; Hoogendijk, Witte J. G.; Van Someren, Eus J. W.			Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLACEBO-CONTROLLED TRIAL; LONG-TERM-CARE; ALZHEIMERS-DISEASE; NURSING-HOME; SUPRACHIASMATIC NUCLEUS; STATISTICAL ISSUES; CORNELL SCALE; WORK GROUP; DEMENTIA; SLEEP	Context Cognitive decline, mood, behavioral and sleep disturbances, and limitations of activities of daily living commonly burden elderly patients with dementia and their caregivers. Circadian rhythm disturbances have been associated with these symptoms. Objective To determine whether the progression of cognitive and noncognitive symptoms may be ameliorated by individual or combined long- term application of the 2 major synchronizers of the circadian timing system: bright light and melatonin. Design, Setting, and Participants A long- term, double- blind, placebo-controlled, 2 x 2 factorial randomized trial performed from 1999 to 2004 with 189 residents of 12 group care facilities in the Netherlands; mean ( SD) age, 85.8 ( 5.5) years; 90% were female and 87% had dementia. Interventions Random assignment by facility to long- term daily treatment with whole-day bright ( +/- 1000 lux) or dim ( +/- 300 lux) light and by participant to evening melatonin ( 2.5 mg) or placebo for a mean ( SD) of 15 ( 12) months ( maximum period of 3.5 years). Main Outcome Measures Standardized scales for cognitive and noncognitive symptoms, limitations of activities of daily living, and adverse effects assessed every 6 months. Results Light attenuated cognitive deterioration by a mean of 0.9 points ( 95% confidence interval [ CI], 0.04- 1.71) on the Mini- Mental State Examination or a relative 5%. Light also ameliorated depressive symptoms by 1.5 points ( 95% CI, 0.24- 2.70) on the Cornell Scale for Depression in Dementia or a relative 19%, and attenuated the increase in functional limitations over time by 1.8 points per year( 95% CI, 0.61- 2.92) on the nurse-informant activities of daily living scale or a relative 53% difference. Melatonin shortened sleep onset latency by 8.2 minutes( 95% CI, 1.08- 15.38) or 19% and increased sleep duration by 27 minutes( 95% CI, 9- 46) or6%. However, melatonin adversely affected scores on the Philadelphia Geriatric Centre Affect Rating Scale, both for positive affect (- 0.5 points; 95% CI, - 0.10 to - 1.00) and negative affect ( 0.8 points; 95% CI, 0.20- 1.44). Melatonin also increased withdrawn behavior by 1.02 points ( 95% CI, 0.18- 1.86) on the Multi Observational Scale for Elderly Subjects scale, although this effect was not seen if given in combination with light. Combined treatment also attenuated aggressive behavior by 3.9 points ( 95% CI, 0.88- 6.92) on the Cohen- Mansfield Agitation Index or 9%, increased sleep efficiency by 3.5% ( 95% CI, 0.8%- 6.1%), and improved nocturnal restlessness by 1.00 minute per hour each year ( 95% CI, 0.26- 1.78) or 9% ( treatment x time effect). Conclusions Light has a modest benefit in improving some cognitive and noncognitive symptoms of dementia. To counteract the adverse effect of melatonin on mood, it is recommended only in combination with light. Trial Registration controlled- trials. com/isrctn Identifier: ISRCTN93133646.	[Riemersma-van der Lek, Rixt F.; Swaab, Dick F.; Hol, Elly M.; Van Someren, Eus J. W.] Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, NL-1105 BA Amsterdam, Netherlands; [Twisk, Jos] Vrije Univ Amsterdam Med Ctr, Dept Clin Epidemiol & Biostat, Amsterdam, Netherlands; [Hoogendijk, Witte J. G.] Vrije Univ Amsterdam Med Ctr, Dept Psychiat, Amsterdam, Netherlands; [Van Someren, Eus J. W.] Vrije Univ Amsterdam Med Ctr, Dept Neurol, Amsterdam, Netherlands; [Van Someren, Eus J. W.] Vrije Univ Amsterdam Med Ctr, Dept Clin Neurophysiol, Amsterdam, Netherlands; [Van Someren, Eus J. W.] Vrije Univ Amsterdam Med Ctr, Dept Med Psychol, Amsterdam, Netherlands; [Hoogendijk, Witte J. G.] Vrije Univ Amsterdam Med Ctr, Res Inst Neurosci CNCR, Amsterdam, Netherlands; [Van Someren, Eus J. W.] Vrije Univ Amsterdam Med Ctr, Alzheimer Ctr, Amsterdam, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Van Someren, EJW (corresponding author), Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.	e.van.someren@nin.knaw.nl	Hol, Elly/J-2025-2019; Van Someren, Eus/AAA-6789-2020; Hol, Elly M/F-1891-2013	Hol, Elly/0000-0001-5604-2603; Hol, Elly M/0000-0001-5604-2603; Swaab, Dick/0000-0002-9665-7845				ALEXOPOULOS GS, 1988, BIOL PSYCHIAT, V23, P271, DOI 10.1016/0006-3223(88)90038-8; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; AncoliIsrael S, 1997, SLEEP, V20, P24, DOI 10.1093/sleep/20.1.24; Banerjee S, 2003, J NEUROL NEUROSUR PS, V74, P1315, DOI 10.1136/jnnp.74.9.1315; Bentham P, 2004, LANCET, V363, P2105; Burback D, 1999, DEMENT GERIATR COGN, V10, P534, DOI 10.1159/000017201; CARMAN JS, 1976, AM J PSYCHIAT, V133, P1181; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Cho KW, 2001, NAT NEUROSCI, V4, P567, DOI 10.1038/88384; COHENMANSFIELD J, 1989, J GERONTOL, V44, pM77, DOI 10.1093/geronj/44.3.M77; de Jonghe J F M, 2003, Tijdschr Gerontol Geriatr, V34, P74; deJonghe JFM, 1996, J AM GERIATR SOC, V44, P888, DOI 10.1111/j.1532-5415.1996.tb03762.x; Devanand DP, 1997, ARCH GEN PSYCHIAT, V54, P257; Donaldson C, 1998, INT J GERIATR PSYCH, V13, P248; Dorenlot P, 2005, INT J GERIATR PSYCH, V20, P471, DOI 10.1002/gps.1238; Edinger JD, 2004, SLEEP, V27, P1567, DOI 10.1093/sleep/27.8.1567; FEKETE M, 1985, PHYSIOL BEHAV, V34, P883, DOI 10.1016/0031-9384(85)90008-3; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GIBBONS RD, 1993, ARCH GEN PSYCHIAT, V50, P739; Gimeno V, 1998, NEUROPSYCHOBIOLOGY, V38, P108, DOI 10.1159/000026525; Gonzalez-Salvador T, 2000, INT J GERIATR PSYCH, V15, P181, DOI 10.1002/(SICI)1099-1166(200002)15:2<181::AID-GPS96>3.0.CO;2-I; Harwood DG, 1998, AM J GERIAT PSYCHIAT, V6, P212; HELMES E, 1987, J GERONTOL, V42, P395, DOI 10.1093/geronj/42.4.395; HOLMES D, 1990, GERONTOLOGIST, V30, P178, DOI 10.1093/geront/30.2.178; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kaufer DI, 2000, J NEUROPSYCH CLIN N, V12, P233, DOI 10.1176/appi.neuropsych.12.2.233; Kavirajan H, 2007, LANCET NEUROL, V6, P782, DOI 10.1016/S1474-4422(07)70195-3; Kushida CA, 2001, SLEEP MED, V2, P389, DOI 10.1016/S1389-9457(00)00098-8; Lawton MP, 1996, J GERONTOL B-PSYCHOL, V51, pP3, DOI 10.1093/geronb/51B.1.P3; LAWTON MP, 1975, J GERONTOL, V30, P85, DOI 10.1093/geronj/30.1.85; Lee HCB, 2003, BIOL PSYCHIAT, V54, P353, DOI 10.1016/S0006-3223(03)00543-2; Liu RY, 2000, J NEUROPATH EXP NEUR, V59, P314, DOI 10.1093/jnen/59.4.314; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Middleton B, 2002, NEUROSCI LETT, V329, P41, DOI 10.1016/S0304-3940(02)00574-8; MISHIMA K, 1994, ACTA PSYCHIAT SCAND, V89, P1, DOI 10.1111/j.1600-0447.1994.tb01477.x; MOE KE, 1995, J SLEEP RES, V4, P15, DOI 10.1111/j.1365-2869.1995.tb00145.x; Moore RY, 1996, PROG BRAIN RES, V111, P103, DOI 10.1016/S0079-6123(08)60403-3; Petkova E, 2002, PSYCHOSOM MED, V64, P531, DOI 10.1097/00006842-200205000-00018; Purandare N, 2001, INT J GERIATR PSYCH, V16, P960, DOI 10.1002/gps.449; RIEMERSMA RF, 2004, NEUROENDOCRINE IMMUN, V4, P195; Ryden M B, 1989, J Gerontol Nurs, V15, P27; Salzman C, 2002, BIOL PSYCHIAT, V52, P265, DOI 10.1016/S0006-3223(02)01337-9; Serfaty M, 2002, INT J GERIATR PSYCH, V17, P1120, DOI 10.1002/gps.760; Siddiqui O, 1998, J Biopharm Stat, V8, P545; Singer C, 2003, SLEEP, V26, P893, DOI 10.1093/sleep/26.7.893; Sink KM, 2005, JAMA-J AM MED ASSOC, V293, P596, DOI 10.1001/jama.293.5.596; Slaughter S, 2006, J AM GERIATR SOC, V54, P1436, DOI 10.1111/j.1532-5415.2006.00851.x; Sloane P., 1990, AM J ALZHEIMER CARE, P22, DOI DOI 10.1177/153331759000500606; SWAAB DF, 1985, BRAIN RES, V342, P37, DOI 10.1016/0006-8993(85)91350-2; TOZAWA T, 1998, NEUROBIOL AGING, V19, pS182; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; TWISK JWR, 2003, APPL LONGITUDINAL DA, P280; Van Someren EJW, 2000, EXP GERONTOL, V35, P1229, DOI 10.1016/S0531-5565(00)00191-1; Van Someren EJW, 1999, CHRONOBIOL INT, V16, P505, DOI 10.3109/07420529908998724; Van Someren EJW, 2002, PROG BRAIN RES, V138, P205, DOI 10.1016/S0079-6123(02)38080-4; Van Someren EJW, 2007, SLEEP MED REV, V11, P465, DOI 10.1016/j.smrv.2007.07.003; Van Someren EJW, 2007, J SLEEP RES, V16, P269, DOI 10.1111/j.1365-2869.2007.00592.x; VanSomeren EJW, 1997, BIOL PSYCHIAT, V41, P955, DOI 10.1016/S0006-3223(97)89928-3; Walker MP, 2004, NEURON, V44, P121, DOI 10.1016/j.neuron.2004.08.031; Zhdanova IV, 2001, J CLIN ENDOCR METAB, V86, P4727, DOI 10.1210/jc.86.10.4727; Zhdanova IV, 1997, SLEEP, V20, P899; Zhou JN, 2001, ARCH GEN PSYCHIAT, V58, P655, DOI 10.1001/archpsyc.58.7.655	62	455	462	3	103	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2008	299	22					2642	2655		10.1001/jama.299.22.2642	http://dx.doi.org/10.1001/jama.299.22.2642			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311FN	18544724	Bronze			2022-12-28	WOS:000256586200021
J	Soyke, JM				Soyke, Jennifer M.			Genug syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												jmsoykemd@comcast.net							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2008	299	22					2606	2606		10.1001/jama.299.22.2606	http://dx.doi.org/10.1001/jama.299.22.2606			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311FN	18544714				2022-12-28	WOS:000256586200001
J	Kaplan, NM				Kaplan, Norman M.			De'ja' vu for primary aldosteronism	LANCET			English	Editorial Material							PRIMARY HYPERALDOSTERONISM; DIAGNOSIS		Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Kaplan, NM (corresponding author), Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.	Norman.kaplan@utsouthwestern.edu						Calhoun DA, 2002, HYPERTENSION, V40, P892, DOI 10.1161/01.HYP.0000040261.30455.B6; CONN JW, 1965, J AMER MED ASSOC, V193, P200, DOI 10.1001/jama.1965.03090030022005; Douma S, 2001, J HYPERTENS S2, V19, pS12; Douma S, 2008, LANCET, V371, P1921, DOI 10.1016/S0140-6736(08)60834-X; Giacchetti G, 2006, J HYPERTENS, V24, P737, DOI 10.1097/01.hjh.0000217857.20241.0f; GORDON RD, 1993, J HYPERTENS, V11, pS310; Kaplan NM, 2007, HYPERTENSION, V50, P454, DOI 10.1161/HYPERTENSIONAHA.106.086124; Nwariaku FE, 2006, ARCH SURG-CHICAGO, V141, P497, DOI 10.1001/archsurg.141.5.497; Rayner BL, 2000, S AFR MED J, V90, P394; Rossi GP, 2008, J HYPERTENS, V26, P613, DOI 10.1097/HJH.0b013e3282f4b3e6; Strauch B, 2003, J HUM HYPERTENS, V17, P349, DOI 10.1038/sj.jhh.1001554; SWALES JD, 1983, BRIT MED J, V287, P702, DOI 10.1136/bmj.287.6394.702	12	9	9	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	2008	371	9628					1890	1891		10.1016/S0140-6736(08)60809-0	http://dx.doi.org/10.1016/S0140-6736(08)60809-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310OI	18539206				2022-12-28	WOS:000256538500005
J	Syassen, N; Bauer, DM; Lettner, M; Volz, T; Dietze, D; Garcia-Ripoll, JJ; Cirac, JI; Rempe, G; Durr, S				Syassen, N.; Bauer, D. M.; Lettner, M.; Volz, T.; Dietze, D.; Garcia-Ripoll, J. J.; Cirac, J. I.; Rempe, G.; Duerr, S.			Strong dissipation inhibits losses and induces correlations in cold molecular gases	SCIENCE			English	Article							TONKS-GIRARDEAU GAS; IMPENETRABLE BOSONS; OPTICAL LATTICE; ULTRACOLD ATOMS; STATE; SCATTERING; COLLISIONS	Atomic quantum gases in the strong- correlation regime offer unique possibilities to explore a variety of many- body quantum phenomena. Reaching this regime has usually required both strong elastic and weak inelastic interactions because the latter produce losses. We show that strong inelastic collisions can actually inhibit particle losses and drive a system into a strongly correlated regime. Studying the dynamics of ultracold molecules in an optical lattice confined to one dimension, we show that the particle loss rate is reduced by a factor of 10. Adding a lattice along the one dimension increases the reduction to a factor of 2000. Our results open the possibility to observe exotic quantum many- body phenomena with systems that suffer from strong inelastic collisions.	[Syassen, N.; Bauer, D. M.; Lettner, M.; Volz, T.; Dietze, D.; Garcia-Ripoll, J. J.; Cirac, J. I.; Rempe, G.; Duerr, S.] Max Planck Inst Quantum Opt, D-85748 Garching, Germany; [Garcia-Ripoll, J. J.] Univ Complutense, Fac Fis, E-28040 Madrid, Spain	Max Planck Society; Complutense University of Madrid	Durr, S (corresponding author), Max Planck Inst Quantum Opt, Hans Kopfermann Str 1, D-85748 Garching, Germany.	stephan.duerr@mpq.mpg.de	Cirac, J. Ignacio/A-9105-2017; Dietze, Daniel R/E-2375-2012; Volz, Thomas/I-3114-2013; Volz, Thomas/AAL-5405-2021; Dürr, Stephan/C-3760-2017; Garcia-Ripoll, Juan Jose/B-8302-2008	Cirac, J. Ignacio/0000-0003-3359-1743; Dietze, Daniel R/0000-0002-8021-6818; Volz, Thomas/0000-0001-9850-4992; Volz, Thomas/0000-0001-9850-4992; Dürr, Stephan/0000-0003-0811-6211; Garcia-Ripoll, Juan Jose/0000-0001-8993-4624				ANDERSON PW, 1987, SCIENCE, V235, P1196, DOI 10.1126/science.235.4793.1196; Auerbach A., 1994, INTERACTING ELECT QU; Bohn JL, 1997, PHYS REV A, V56, P1486, DOI 10.1103/PhysRevA.56.1486; Burt EA, 1997, PHYS REV LETT, V79, P337, DOI 10.1103/PhysRevLett.79.337; COHENTANNOUDJI C, 1992, ATOM PHOTON INTERACT, P49; Durr S, 2006, AIP CONF PROC, V869, P278; Durr S, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.020406; Gangardt DM, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.010401; GIRARDEAU M, 1960, J MATH PHYS, V1, P516, DOI 10.1063/1.1703687; KAGAN Y, 1985, JETP LETT+, V42, P209; Kinoshita T, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.190406; Kinoshita T, 2004, SCIENCE, V305, P1125, DOI 10.1126/science.1100700; Kitaev AY, 2003, ANN PHYS-NEW YORK, V303, P2, DOI 10.1016/S0003-4916(02)00018-0; LIEB EH, 1963, PHYS REV, V130, P1605, DOI 10.1103/PhysRev.130.1605; Marte A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.283202; MISRA B, 1977, J MATH PHYS, V18, P756, DOI 10.1063/1.523304; Olshanii M, 1998, PHYS REV LETT, V81, P938, DOI 10.1103/PhysRevLett.81.938; Paredes B, 2004, NATURE, V429, P277, DOI 10.1038/nature02530; Stoferle T, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.130403; Stormer HL, 1999, REV MOD PHYS, V71, pS298, DOI 10.1103/RevModPhys.71.S298; Syassen N, 2006, PHYS REV A, V74, DOI 10.1103/PhysRevA.74.062706; Tolra BL, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.190401; Tonks L, 1936, PHYS REV, V50, P955, DOI 10.1103/PhysRev.50.955; VERHAAR BJ, 1994, LASER PHYS, V4, P1050; Verstraete F, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.207204; Volz T, 2006, NAT PHYS, V2, P692, DOI 10.1038/nphys415; WILCZEK F, 1982, PHYS REV LETT, V48, P1144, DOI 10.1103/PhysRevLett.48.1144	28	259	261	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2008	320	5881					1329	1331		10.1126/science.1155309	http://dx.doi.org/10.1126/science.1155309			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309DO	18535241	Green Submitted			2022-12-28	WOS:000256441100042
J	Parving, HH; Persson, F; Lewis, JB; Lewis, EJ; Hollenberg, NK				Parving, Hans-Henrik; Persson, Frederik; Lewis, Julia B.; Lewis, Edmund J.; Hollenberg, Norman K.		AVOID Study Investigators	Aliskiren combined with losartan in type 2 diabetes and nephropathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RENIN-ANGIOTENSIN-SYSTEM; GLOMERULAR HEMODYNAMICS; SERUM CREATININE; ALBUMINURIA; BLOCKADE; MICROALBUMINURIA; HYPERTENSION; IRBESARTAN; INHIBITOR; EFFICACY	Background: Diabetic nephropathy is the leading cause of end-stage renal disease in developed countries. We evaluated the renoprotective effects of dual blockade of the renin-angiotensin-aldosterone system by adding treatment with aliskiren, an oral direct renin inhibitor, to treatment with the maximal recommended dose of losartan (100 mg daily) and optimal antihypertensive therapy in patients who had hypertension and type 2 diabetes with nephropathy. Methods: We enrolled 599 patients in this multinational, randomized, double-blind study. After a 3-month, open-label, run-in period during which patients received 100 mg of losartan daily, patients were randomly assigned to receive 6 months of treatment with aliskiren (150 mg daily for 3 months, followed by an increase in dosage to 300 mg daily for another 3 months) or placebo, in addition to losartan. The primary outcome was a reduction in the ratio of albumin to creatinine, as measured in an early-morning urine sample, at 6 months. Results: The baseline characteristics of the two groups were similar. Treatment with 300 mg of aliskiren daily, as compared with placebo, reduced the mean urinary albumin-to-creatinine ratio by 20% (95% confidence interval, 9 to 30; P<0.001), with a reduction of 50% or more in 24.7% of the patients who received aliskiren as compared with 12.5% of those who received placebo (P<0.001). A small difference in blood pressure was seen between the treatment groups by the end of the study period (systolic, 2 mm Hg lower [P=0.07] and diastolic, 1 mm Hg lower [P=0.08] in the aliskiren group). The total numbers of adverse and serious adverse events were similar in the groups. Conclusions: Aliskiren may have renoprotective effects that are independent of its blood-pressure-lowering effect in patients with hypertension, type 2 diabetes, and nephropathy who are receiving the recommended renoprotective treatment. (ClinicalTrials.gov number, NCT00097955.).	[Parving, Hans-Henrik] Univ Copenhagen Hosp, Rigshosp, Dept Med Endocrinol, DK-2100 Copenhagen O, Denmark; [Parving, Hans-Henrik] Aarhus Univ, Fac Hlth Sci, Aarhus, Denmark; [Persson, Frederik] Steno Diabet Ctr, DK-2820 Gentofte, Denmark; [Lewis, Julia B.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Lewis, Edmund J.] Rush Univ, Med Ctr, Chicago, IL 60612 USA; [Hollenberg, Norman K.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Hollenberg, Norman K.] Harvard Univ, Sch Med, Boston, MA USA	Rigshospitalet; University of Copenhagen; Aarhus University; Steno Diabetes Center; Vanderbilt University; Rush University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Parving, HH (corresponding author), Univ Copenhagen Hosp, Rigshosp, Dept Med Endocrinol, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark.	hhparving@dadlnet.dk	Adasheva, Tatiana/J-5713-2013; House, Andrew/G-3304-2011; Persson, Frederik/AAE-6572-2020; Zoccali, Carmine/B-9445-2009; Kos, Katarina/G-6772-2014; Mihaila, Romeo-Gabriel/A-1387-2011; Zadionchenko, Vladimir/A-7445-2016; kos, katarina/F-3085-2013; Rutten, Joost/L-4618-2015; Persson, Frederik/E-6973-2015; Oliveras, Anna/I-2269-2019; Aldigier, Jean/O-8551-2016; Mihaila, Romeo Gabriel/G-1084-2016; Remuzzi, Giuseppe/V-9766-2017	Adasheva, Tatiana/0000-0002-3763-8994; Persson, Frederik/0000-0001-6242-6638; Mihaila, Romeo-Gabriel/0000-0001-9198-353X; Zadionchenko, Vladimir/0000-0003-2377-5266; Rutten, Joost/0000-0002-5259-9794; Persson, Frederik/0000-0001-6242-6638; Oliveras, Anna/0000-0002-5503-545X; Aldigier, Jean/0000-0002-1804-981X; Kos, Katarina/0000-0003-3761-2249; Ruilope, Luis M/0000-0001-6278-7951; Svendsen, Ole Lander/0000-0003-2846-9532; Carvalho, Davide/0000-0002-3156-3741; Remuzzi, Giuseppe/0000-0002-6194-3446				Andersen S, 2000, KIDNEY INT, V58, P2129; Bakris GL, 2007, KIDNEY INT, V72, P879, DOI 10.1038/sj.ki.5002455; BARTELS H, 1972, CLIN CHIM ACTA, V37, P193, DOI 10.1016/0009-8981(72)90432-9; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; BURGESS E, 2007, J AM SOC NEPHROL, V18, pA57; de Zeeuw D, 2004, CIRCULATION, V110, P921, DOI 10.1161/01.CIR.0000139860.33974.28; de Zeeuw D, 2004, KIDNEY INT, V65, P2309, DOI 10.1111/j.1523-1755.2004.00653.x; Epstein M, 2006, CLIN J AM SOC NEPHRO, V1, P940, DOI 10.2215/CJN.00240106; Feldman G, 2007, J AM SOC NEPHROL, V18, P1662, DOI 10.1681/ASN.2006050527; Fisher ND, 2007, CIRCULATION, V116, P556; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; Gradman AH, 2005, CIRCULATION, V111, P1012, DOI 10.1161/01.CIR.0000156466.02908.ED; Hollenberg NK, 2005, KIDNEY INT, V68, P2901, DOI 10.1111/j.1523-1755.2005.00773.x; Hollenberg NK, 2003, KIDNEY INT, V63, P172, DOI 10.1046/j.1523-1755.2003.00701.x; Hollenberg NK, 2007, J HYPERTENS, V25, P1921, DOI 10.1097/HJH.0b013e328277596e; HOSTETTER TH, 1981, KIDNEY INT, V19, P410, DOI 10.1038/ki.1981.33; Ibsen H, 2005, HYPERTENSION, V45, P198, DOI 10.1161/01.HYP.0000154082.72286.2a; Imanishi M, 1999, DIABETOLOGIA, V42, P999, DOI 10.1007/s001250051259; Kelly DJ, 2007, DIABETOLOGIA, V50, P2398, DOI 10.1007/s00125-007-0795-9; Langham RG, 2002, DIABETOLOGIA, V45, P1572, DOI 10.1007/s00125-002-0946-y; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LEWIS EJ, 1994, NEW ENGL J MED, V330, P152; LUETSCHER JA, 1985, NEW ENGL J MED, V312, P1412, DOI 10.1056/NEJM198505303122202; Mogensen CE, 2000, BRIT MED J, V321, P1440, DOI 10.1136/bmj.321.7274.1440; Nguyen G, 2002, J CLIN INVEST, V109, P1417, DOI 10.1172/JCI200214276; Nguyen G, 2007, J AM SOC NEPHROL, V18, p60A; Oparil S, 2007, LANCET, V370, P1542; Oparil S, 2007, LANCET, V370, P221, DOI 10.1016/S0140-6736(07)61124-6; Palmer BF, 2002, NEW ENGL J MED, V347, P1256, DOI 10.1056/NEJMra020676; PARVING HH, 1983, LANCET, V1, P1175; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; PARVING HH, 2008, BRENNER RECTORS KIDN, V2, P1265; Phillip L, 2007, J AM SOC NEPHROL, V18, p169A; REMUZZI A, 1993, J NEPHROL, V6, P36; Rohlfing CL, 2000, DIABETES CARE, V23, P187, DOI 10.2337/diacare.23.2.187; Rohlfing CL, 2000, DIABETES CARE, V23, P876; Rossing K, 2005, KIDNEY INT, V68, P1190, DOI 10.1111/j.1523-1755.2005.00511.x; Rossing K, 2007, DAN MED BULL, V54, P79; ROSSING P, 1994, DIABETOLOGIA, V37, P511, DOI 10.1007/s001250050140; Schjoedt KJ, 2005, KIDNEY INT, V68, P2829, DOI 10.1111/j.1523-1755.2005.00756.x; Staessen JA, 2006, LANCET, V368, P2124; TREVISAN R, 1995, AM J HYPERTENS, V8, P876, DOI 10.1016/0895-7061(95)00162-I; Uresin Y, 2007, J RENIN-ANGIO-ALDO S, V8, P190, DOI 10.3317/jraas.2007.028; 1991, WIEN KLIN WOCHENS S, V189, P1	46	805	863	4	61	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2008	358	23					2433	2446		10.1056/NEJMoa0708379	http://dx.doi.org/10.1056/NEJMoa0708379			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308HY	18525041				2022-12-28	WOS:000256380700003
J	Thomas, SJ; Hughes, C; Atkinson, C; Ness, AR; Revington, P				Thomas, Steven J.; Hughes, Ceri; Atkinson, Charlotte; Ness, Andrew R.; Revington, Peter			Is there an epidemic of admissions for surgical treatment of dental abscesses in the UK?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							GREAT-BRITAIN; EXPERIENCE; CHILDREN		[Thomas, Steven J.; Hughes, Ceri] Univ Bristol, Div Oral & Maxillofacial Surg, Bristol BS1 2LY, Avon, England; [Atkinson, Charlotte; Ness, Andrew R.] Univ Bristol, Dept Oral & Dent Sci, Bristol BS1 2LY, Avon, England; [Revington, Peter] N Bristol NHS Trust, Bristol BS16 1LE, Avon, England	University of Bristol; University of Bristol; North Bristol NHS Trust	Thomas, SJ (corresponding author), Univ Bristol, Div Oral & Maxillofacial Surg, Bristol BS1 2LY, Avon, England.	Steve.Thomas@bristol.ac.uk	Berryman, Katie/J-4236-2014; Atkinson, Charlotte/AGA-4037-2022; Ness, Andy R/M-7612-2013	Ness, Andy R/0000-0003-3548-9523				Bulut M, 2004, EMERG MED J, V21, P122, DOI 10.1136/emj.2003.002865; Carter L, 2006, BRIT DENT J, V200, P243, DOI 10.1038/sj.bdj.4813368; Green AW, 2001, BRIT DENT J, V190, P529, DOI 10.1038/sj.bdj.4801024a; Morris G, 2006, BRIT DENT J, V200, P601, DOI 10.1038/sj.bdj.4813695; *NAT AUD OFF, 2004, REF NHS DENT ENS EFF; *NAT COMM PAT PUBL, 2007, DENT WATCH REP; *NAT I HLTH CLIN E, 2004, DENT REC REC INT ROU; *OFF NAT STAT, 2000, AD DENT HLTH SURV OR; Pitts NB, 2007, COMMUNITY DENT HLTH, V24, P59; Pitts NB, 2006, COMMUNITY DENT HLTH, V23, P44; Steele JG, 2000, BRIT DENT J, V189, P598, DOI 10.1038/sj.bdj.4800840a	11	40	40	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	2008	336	7655					1219	1220		10.1136/bmj.39549.605602.BE	http://dx.doi.org/10.1136/bmj.39549.605602.BE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311PS	18511797	Green Published			2022-12-28	WOS:000256612700027
J	Chahrour, M; Jung, SY; Shaw, C; Zhou, XB; Wong, STC; Qin, J; Zoghbi, HY				Chahrour, Maria; Jung, Sung Yun; Shaw, Chad; Zhou, Xiaobo; Wong, Stephen T. C.; Qin, Jun; Zoghbi, Huda Y.			MeCP2, a key contributor to neurological disease, activates and represses transcription	SCIENCE			English	Article							RETT-SYNDROME; METHYLTRANSFERASE DEFICIENCY; HISTONE DEACETYLASE; BDNF TRANSCRIPTION; MENTAL-RETARDATION; GENE; EXPRESSION; PHOSPHORYLATION; DISORDERS; BRAIN	Mutations in the gene encoding the transcriptional repressor methyl- CpG binding protein 2 ( MeCP2) cause the neurodevelopmental disorder Rett syndrome. Loss of function as well as increased dosage of the MECP2 gene cause a host of neuropsychiatric disorders. To explore the molecular mechanism( s) underlying these disorders, we examined gene expression patterns in the hypothalamus of mice that either lack or overexpress MeCP2. In both models, MeCP2 dysfunction induced changes in the expression levels of thousands of genes, but unexpectedly the majority of genes (similar to 85%) appeared to be activated by MeCP2. We selected six genes and confirmed that MeCP2 binds to their promoters. Furthermore, we showed that MeCP2 associates with the transcriptional activator CREB1 at the promoter of an activated target but not a repressed target. These studies suggest that MeCP2 regulates the expression of a wide range of genes in the hypothalamus and that it can function as both an activator and a repressor of transcription.	[Chahrour, Maria; Shaw, Chad; Zoghbi, Huda Y.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Jung, Sung Yun; Qin, Jun] Baylor Coll Med, Ctr Mol Discovery, Dept Biochem, Houston, TX 77030 USA; [Jung, Sung Yun; Qin, Jun] Baylor Coll Med, Ctr Mol Discovery, Dept Mol Biol, Houston, TX 77030 USA; [Zhou, Xiaobo; Wong, Stephen T. C.] Methodist Hosp, Res Inst, Ctr Bioinformat, Houston, TX 77030 USA; [Zhou, Xiaobo; Wong, Stephen T. C.] Weill Cornell Coll Med, Houston, TX 77030 USA; [Qin, Jun] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Zoghbi, Huda Y.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; [Zoghbi, Huda Y.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Zoghbi, Huda Y.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Zoghbi, Huda Y.] Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA; [Zoghbi, Huda Y.] Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; [Zoghbi, Huda Y.] Texas Childrens Hosp, Howard Hughes Med Inst, Baylor Coll Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Cornell University; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	Zoghbi, HY (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.	hzoghbi@bcm.edu		Zoghbi, Huda/0000-0002-0700-3349; Shaw, Chad/0000-0001-7267-5398; Chahrour, Maria/0000-0002-3174-1480	Howard Hughes Medical Institute Funding Source: Medline; NICHD NIH HHS [HD024064, P30 HD024064, P30 HD024064-19] Funding Source: Medline; NINDS NIH HHS [R01 NS057819, R01 NS057819-02, NS057819] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS057819] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Araujo HC, 2005, AM J MED GENET A, V133A, P122, DOI 10.1002/ajmg.a.30226; Axelrod FB, 2006, PEDIATRICS, V118, P309, DOI 10.1542/peds.2005-3032; Bhalla K, 2004, J HUM GENET, V49, P308, DOI 10.1007/s10038-004-0145-4; Chang QA, 2006, NEURON, V49, P341, DOI 10.1016/j.neuron.2005.12.027; Chao HT, 2007, NEURON, V56, P58, DOI 10.1016/j.neuron.2007.08.018; Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446; Collins AL, 2004, HUM MOL GENET, V13, P2679, DOI 10.1093/hmg/ddh282; Gardina PJ, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-325; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Klein ME, 2007, NAT NEUROSCI, V10, P1513, DOI 10.1038/nn2010; Martin CL, 2007, AM J MED GENET B, V144B, P869, DOI 10.1002/ajmg.b.30530; Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842; Moretti P, 2006, CURR OPIN GENET DEV, V16, P276, DOI 10.1016/j.gde.2006.04.009; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Srinivasan K, 2005, METHODS, V37, P345, DOI 10.1016/j.ymeth.2005.09.007; Sykut-Cegielska J, 2004, ACTA BIOCHIM POL, V51, P875; Tudor M, 2002, P NATL ACAD SCI USA, V99, P15536, DOI 10.1073/pnas.242566899; Verbruggen KT, 2007, EUR J PEDIATR, V166, P921, DOI 10.1007/s00431-006-0340-8; Yasui DH, 2007, P NATL ACAD SCI USA, V104, P19416, DOI 10.1073/pnas.0707442104; Zhou ZL, 2006, NEURON, V52, P255, DOI 10.1016/j.neuron.2006.09.037	22	1272	1317	4	143	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2008	320	5880					1224	1229		10.1126/science.1153252	http://dx.doi.org/10.1126/science.1153252			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306FF	18511691	Green Accepted			2022-12-28	WOS:000256233000041
J	Cohen, S; Zhou, ZL; Greenberg, ME				Cohen, Sonia; Zhou, Zhaolan; Greenberg, Michael E.			Medicine - Activating a repressor	SCIENCE			English	Editorial Material							RETT-SYNDROME; DNA METHYLATION; MECP2; PHOSPHORYLATION; TRANSCRIPTION; PROMOTER; SYNAPSE; BRAIN		[Cohen, Sonia; Zhou, Zhaolan; Greenberg, Michael E.] Childrens Hosp, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA; [Cohen, Sonia; Zhou, Zhaolan; Greenberg, Michael E.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Cohen, Sonia; Zhou, Zhaolan; Greenberg, Michael E.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Cohen, S (corresponding author), Childrens Hosp, FM Kirby Neurobiol Ctr, 300 Longwood Ave, Boston, MA 02115 USA.	michael.greenberg@childrens.harvard.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K99NS058391, R00NS058391, R01NS048276] Funding Source: NIH RePORTER; NICHD NIH HHS [P30 HD018655-27, P30 HD018655-26, P30 HD018655, P30 HD018655-25] Funding Source: Medline; NIGMS NIH HHS [T32 GM007753] Funding Source: Medline; NINDS NIH HHS [K99 NS058391, R01 NS048276-02, R01 NS048276-03, R01 NS048276, R00 NS058391-03, R01 NS048276-05, R00 NS058391, R01 NS048276-04, K99 NS058391-02, K99 NS058391-01, R00 NS058391-04, R01 NS048276-01, R00 NS058391-05] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chahrour M, 2008, SCIENCE, V320, P1224, DOI 10.1126/science.1153252; Chahrour M, 2007, NEURON, V56, P422, DOI 10.1016/j.neuron.2007.10.001; Chao HT, 2007, NEURON, V56, P58, DOI 10.1016/j.neuron.2007.08.018; Flavell SW, 2008, ANNU REV NEUROSCI, V31, P563, DOI 10.1146/annurev.neuro.31.060407.125631; Georgel PT, 2003, J BIOL CHEM, V278, P32181, DOI 10.1074/jbc.M305308200; Horike S, 2005, NAT GENET, V37, P31, DOI 10.1038/ng1491; Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Metivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544; Sebat J, 2007, SCIENCE, V316, P445, DOI 10.1126/science.1138659; Tudor M, 2002, P NATL ACAD SCI USA, V99, P15536, DOI 10.1073/pnas.242566899; Zhou ZL, 2006, NEURON, V52, P255, DOI 10.1016/j.neuron.2006.09.037; Zoghbi HY, 2003, SCIENCE, V302, P826, DOI 10.1126/science.1089071	14	32	32	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2008	320	5880					1172	1173		10.1126/science.1159146	http://dx.doi.org/10.1126/science.1159146			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306FF	18511680	Green Accepted			2022-12-28	WOS:000256233000026
J	Grott, M				Grott, Matthias			Planetary science - Is Mars geodynamically dead?	SCIENCE			English	Editorial Material									[Grott, Matthias] German Aerosp Ctr, DLR, Inst Planetary Res, D-12489 Berlin, Germany	Helmholtz Association; German Aerospace Centre (DLR)	Grott, M (corresponding author), German Aerosp Ctr, DLR, Inst Planetary Res, Rutherfordstr 2, D-12489 Berlin, Germany.	matthias.grott@dlr.de						Grott M, 2008, ICARUS, V193, P503, DOI 10.1016/j.icarus.2007.08.015; Hauck SA, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001801; LANGSETH MG, 1976, P LUNAR PLANET SCI C, V7, P3143; Neukum G, 2004, NATURE, V432, P971, DOI 10.1038/nature03231; Phillips RJ, 2008, SCIENCE, V320, P1182, DOI 10.1126/science.1157546; Schumacher S, 2006, J GEOPHYS RES-PLANET, V111, DOI 10.1029/2005JE002429.2006; Taylor GJ, 2006, J GEOPHYS RES-PLANET, V111, DOI 10.1029/2005JE002645; WANKE H, 1994, PHILOS T R SOC A, V349, P285, DOI 10.1098/rsta.1994.0132; Wieczorek MA, 2008, ICARUS, V196, P506, DOI 10.1016/j.icarus.2007.10.026	9	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2008	320	5880					1171	1172		10.1126/science.1159365	http://dx.doi.org/10.1126/science.1159365			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306FF	18511679				2022-12-28	WOS:000256233000025
J	Robock, A				Robock, Alan			Atmospheric science - Whither geoengineering?	SCIENCE			English	Editorial Material							ALBEDO-ENHANCEMENT; OZONE DEPLETION		[Robock, Alan] Rutgers State Univ, Dept Environm Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Robock, A (corresponding author), Rutgers State Univ, Dept Environm Sci, New Brunswick, NJ 08901 USA.	robock@envsci.rutgers.edu	Robock, Alan/B-6385-2016	Robock, Alan/0000-0002-6319-5656				Angel R, 2006, P NATL ACAD SCI USA, V103, P17184, DOI 10.1073/pnas.0608163103; Bower K, 2006, ATMOS RES, V82, P328, DOI 10.1016/j.atmosres.2005.11.013; Buesseler KO, 2008, SCIENCE, V319, P162, DOI 10.1126/science.1154305; Crutzen PJ, 2006, CLIMATIC CHANGE, V77, P211, DOI 10.1007/s10584-006-9101-y; Fleming JR, 2007, WILSON Q         SPR, P46; KHAN E, 2001, RESPONSE OPTIONS LIM; LANE L, 2007, WORKSHOP REPORT MANA; Metz ORDB, 2007, CLIMATE CHANGE 2007; Robock A, 2008, B ATOM SCI, V64, P14, DOI 10.1080/00963402.2008.11461140; Solomon S, 1999, REV GEOPHYS, V37, P275, DOI 10.1029/1999RG900008; Solomon S., 2007, PHYS SCI BASIS WORKI; Tilmes S, 2008, SCIENCE, V320, P1201, DOI 10.1126/science.1153966; Trenberth KE, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL030524; Wigley TML, 2006, SCIENCE, V314, P452, DOI 10.1126/science.1131728	14	39	40	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	2008	320	5880					1166	1167		10.1126/science.1159280	http://dx.doi.org/10.1126/science.1159280			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306FF	18511675				2022-12-28	WOS:000256233000021
J	Hull, RP; Goldsmith, DJA				Hull, Richard P.; Goldsmith, David J. A.			Nephrotic syndrome in adults	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RENAL-VEIN THROMBOSIS; GLOMERULAR-FILTRATION-RATE; PROTEIN EXCRETION RATE; THROMBOEMBOLIC COMPLICATIONS; MEMBRANOUS NEPHROPATHY; CONTROLLED TRIAL; BLOOD-PRESSURE; DISEASE; FAILURE; RISK		[Hull, Richard P.; Goldsmith, David J. A.] Guys Hosp, Renal Unit, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust	Goldsmith, DJA (corresponding author), Guys Hosp, Renal Unit, London SE1 9RT, England.	david.goldsmith@gstt.nhs.uk	Goldsmith, David J.A./H-8500-2013					BELLOMO R, 1993, NEPHRON, V63, P249, DOI 10.1159/000187205; BUERKERT J, 1991, KIDNEY INT, V39, P850, DOI 10.1038/ki.1991.107; Burden R, 2005, CLIN MED, V5, P635, DOI 10.7861/clinmedicine.5-6-635; Cameron JS, 2002, AM J NEPHROL, V22, P240, DOI 10.1159/000063768; Charlesworth JA, 2008, NEPHROLOGY, V13, P45, DOI 10.1111/j.1440-1797.2007.00890.x; Crew RJ, 2004, CLIN NEPHROL, V62, P245; Davison AMA, 2005, OXFORD TXB CLIN NEPH; Fried LF, 2001, KIDNEY INT, V59, P260, DOI 10.1046/j.1523-1755.2001.00487.x; GANSEVOORT RT, 1995, NEPHROL DIAL TRANSPL, V10, P1963; Glassock RJ, 2007, J AM SOC NEPHROL, V18, P2221, DOI 10.1681/ASN.2006111300; GOLDSMITH DJ, 2007, ABC KIDNEY DIS; GUARNIERI GF, 1989, KIDNEY INT, V36, pS195; Haas M, 1997, AM J KIDNEY DIS, V30, P621, DOI 10.1016/S0272-6386(97)90485-6; ICHIKAWA I, 1983, J CLIN INVEST, V71, P91, DOI 10.1172/JCI110756; Jayawardene SA, 2002, INT J CLIN PRACT, V56, P129; Kayali F, 2008, AM J MED, V121, P226, DOI 10.1016/j.amjmed.2007.08.042; Koomans HA, 2001, NEPHROL DIAL TRANSPL, V16, P221, DOI 10.1093/ndt/16.2.221; Korbet SM, 1996, AM J KIDNEY DIS, V27, P647, DOI 10.1016/S0272-6386(96)90098-0; KULSHRESTHA S, 2006, COCHRANE DB SYST REV; Li YJ, 1996, CHINESE J NEPHROLOGY, V12, P76; LLACH F, 1980, AM J MED, V69, P819, DOI 10.1016/S0002-9343(80)80006-4; LLACH F, 1984, POSTGRAD MED, V76, P111, DOI 10.1080/00325481.1984.11698782; Locatelli F, 1996, NEPHROL DIAL TRANSPL, V11, P461; Mahmoodi BK, 2008, CIRCULATION, V117, P224, DOI 10.1161/CIRCULATIONAHA.107.716951; Mees EJD, 1996, NEPHROL DIAL TRANSPL, V11, P1224; Nakao N, 2003, LANCET, V361, P117, DOI 10.1016/S0140-6736(03)12229-5; *NAT KIDN FED UK, COLL DIS RES MED INF; National Collaborating Centre for Chronic Conditions, 2008, CHRON KIDN DIS EARL; OGI M, 1994, AM J KIDNEY DIS, V24, P427, DOI 10.1016/S0272-6386(12)80899-7; ORDONEZ JD, 1993, KIDNEY INT, V44, P638, DOI 10.1038/ki.1993.292; Orth SR, 1998, NEW ENGL J MED, V338, P1202, DOI 10.1056/NEJM199804233381707; PARAG KB, 1990, AM J KIDNEY DIS, V15, P176, DOI 10.1016/S0272-6386(12)80516-6; *REN UN ROYAL INF, EXC SOURC INF REN DI; Ruggenenti P, 1997, LANCET, V349, P1857; Ruggenenti P, 1998, BRIT MED J, V316, P504, DOI 10.1136/bmj.316.7130.504; Ruggenenti P, 1998, KIDNEY INT, V53, P1209, DOI 10.1046/j.1523-1755.1998.00874.x; SARASIN FP, 1994, KIDNEY INT, V45, P578, DOI 10.1038/ki.1994.75; Singhal R, 2006, THROMB RES, V118, P397, DOI 10.1016/j.thromres.2005.03.030; Tonelli M, 2003, J AM SOC NEPHROL, V14, P1605, DOI 10.1097/01.ASN.0000068461.45784.2F; Tsouli SG, 2006, J CARDIOVASC PHARM T, V11, P1, DOI 10.1177/107424840601100101; WAGONER RD, 1983, KIDNEY INT, V23, P368, DOI 10.1038/ki.1983.28; WHEELER DC, 1994, AM J KIDNEY DIS, V23, P331, DOI 10.1016/S0272-6386(12)80994-2; WU HM, 2004, COCHRANE DB SYST REV	43	145	164	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 24	2008	336	7654					1185	1189		10.1136/bmj.39576.709711.80	http://dx.doi.org/10.1136/bmj.39576.709711.80			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308WJ	18497417	Green Published			2022-12-28	WOS:000256420900043
J	Demay, MB; Rosenthal, DI; Deshpande, V; Harris, NL; Stephen, A; Barbesino, G; Deshpande, V				Demay, Marie B.; Rosenthal, Daniel I.; Deshpande, Vikram; Harris, Nancy Lee; Stephen, Antonia; Barbesino, Giuseppe; Deshpande, Vikram			Case 16-2008: A 46-year-old woman with bone pain - Brown tumor associated with osteitis fibrosa cystica in a patient with celiac disease, malabsorption, vitamin D deficiency, hypocalcemia, and secondary hyperparathyroidism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PARATHYROID CARCINOMA		[Demay, Marie B.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; [Rosenthal, Daniel I.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Deshpande, Vikram] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Demay, Marie B.] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; [Rosenthal, Daniel I.] Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; [Deshpande, Vikram] Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University	Demay, MB (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.							Anderson LA, 2007, WORLD J GASTROENTERO, V13, P146, DOI 10.3748/wjg.v13.i1.146; Arabi A, 2006, J CLIN ENDOCR METAB, V91, P2480, DOI 10.1210/jc.2005-2518; Boyle NH, 1999, EUR J SURG ONCOL, V25, P100; Broadus AE, 2002, NEW ENGL J MED, V346, P694, DOI 10.1056/NEJMcpc020007; BUCHANAN WW, 1981, CAN MED ASSOC J, V124, P812; Lotinun S, 2005, ENDOCRINOLOGY, V146, P4074, DOI 10.1210/en.2005-0480; Rao DS, 2002, J BONE MINER RES, V17, pN75; Silano M, 2007, BMC GASTROENTEROL, V7, DOI 10.1186/1471-230X-7-8; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	9	12	12	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2008	358	21					2266	2274		10.1056/NEJMcpc0802020	http://dx.doi.org/10.1056/NEJMcpc0802020			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303EK	18499570				2022-12-28	WOS:000256023600011
J	Dougherty, D; Conway, PH				Dougherty, Denise; Conway, Patrick H.			The "3T's" road map to transform US health care - The "how" of high-quality care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CLINICAL-RESEARCH		[Dougherty, Denise; Conway, Patrick H.] Agcy Healthcare Res & Qual, Off Extramural Res Educ & Prior Populat, Rockville, MD 20850 USA; [Conway, Patrick H.] Childrens Hosp, Med Ctr, Ctr Hlth Care Qual, Div Hlth Policy & Clin Effectiveness, Cincinnati, OH 45229 USA; [Conway, Patrick H.] Childrens Hosp, Med Ctr, Div Gen Pediat, Cincinnati, OH 45229 USA	Agency for Healthcare Research & Quality; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Dougherty, D (corresponding author), Agcy Healthcare Res & Qual, Off Extramural Res Educ & Prior Populat, 540 Gaither Rd, Rockville, MD 20850 USA.	denise.dougherty@ahrq.hhs.gov						*AG HEALTHC RES QU, MEAS HEALTHC QUAL NA; *AG HEALTHC RES QU, CONS PROV POL GUID E; Berwick DM, 2008, JAMA-J AM MED ASSOC, V299, P1182, DOI 10.1001/jama.299.10.1182; Congressional Budget Office, 2022, PRESCR DRUGS SPEND U; Leatherman S, 2007, INT J QUAL HEALTH C, V19, P334, DOI 10.1093/intqhc/mzm049; Lee TH, 2007, NEW ENGL J MED, V357, P1175, DOI 10.1056/NEJMp078102; Mangione-Smith R, 2007, NEW ENGL J MED, V357, P1515, DOI 10.1056/NEJMsa064637; Moses H, 2005, JAMA-J AM MED ASSOC, V294, P1333, DOI 10.1001/jama.294.11.1333; Rosenthal MB, 2007, HEALTH AFFAIR, V26, P1674, DOI 10.1377/hlthaff.26.6.1674; *RW JOHNS FDN, AL FORC QUAL REG MAR; Slutsky JR, 2007, HEALTH AFFAIR, V26, pW122, DOI 10.1377/hlthaff.26.2.w122; Sung NS, 2003, JAMA-J AM MED ASSOC, V289, P1278, DOI 10.1001/jama.289.10.1278; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Woolf SH, 2008, JAMA-J AM MED ASSOC, V299, P211, DOI 10.1001/jama.2007.26	14	245	261	2	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2008	299	19					2319	2321		10.1001/jama.299.19.2319	http://dx.doi.org/10.1001/jama.299.19.2319			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302QN	18492974				2022-12-28	WOS:000255984500028
J	Bone, A; Ncube, F; Nichols, T; Noah, ND				Bone, Angie; Ncube, Fortune; Nichols, Tom; Noah, Norman D.			Body piercing in England: a survey of piercing at sites other than earlobe	BRITISH MEDICAL JOURNAL			English	Article							COMPLICATIONS; ADOLESCENTS; PREVALENCE; TATTOOS	Objectives To estimate the prevalence of body piercing, other than of earlobes, in the general adult population in England, and to describe the distribution of body piercing by age group, sex, social class, anatomical site, and who performed the piercings. To estimate the proportion of piercings that resulted in complications and the proportion of piercings that resulted in professional help being sought after the piercing. Design Cross sectional household survey. Setting All regions of England 2005. Participants 10 503 adults aged 16 and over identified with a two stage selection process: random selection of geographical areas and filling predefined quotas of individuals. Results weighted to reflect the national demographic profile of adults aged 16 and over. Main outcome measures Estimates of the prevalence of body piercing overall and by age group, sex, and anatomical site. Estimates, in those aged 16-24, of the proportion of piercings associated with complications and the seeking of professional help. Results The prevalence of body piercing was 1049/10 503 (10%, 95% confidence interval 9.4% to 10.6%). Body piercing was more common in women than in men and in younger age groups. Nearly half the women aged 16-24 reported having had a piercing (305/659, 46.2%, 42.0% to 50.5%). Of the 754 piercings in those aged 16-24, complications were reported with 233 (31.0%, 26.8% to 35.5%); professional help was sought with 115 (15.2%, 11.8% to 19.5%); and hospital admission was required with seven (0.9%, 0.3% to 3.2%). Conclusions Body piercing is common in adults in England, particularly in young women. Problems are common and the assistance of health services is often required. Though serious complications requiring admission to hospital seem uncommon, the popularity of the practice might place a substantial burden on health services.	[Bone, Angie; Ncube, Fortune; Nichols, Tom] Hlth Protect Agcy, Ctr Infect, London NW9 5EQ, England; [Noah, Norman D.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	Health Protection Agency; University of London; London School of Hygiene & Tropical Medicine	Bone, A (corresponding author), Springfield Hosp, SW London Hlth Protect Unit, Lupin Ward, Jasmine Tower, London SW17 7DJ, England.	abone@nhs.net			Department of Health Funding Source: Medline	Department of Health		Armstrong ML, 2004, J ADOLESCENT HEALTH, V35, P58, DOI 10.1016/j.jadohealth.2003.08.012; BENON L, 1999, ENV HLTH J       OCT, P316; Brooks TL, 2003, J ADOLESCENT HEALTH, V32, P44, DOI 10.1016/S1054-139X(02)00446-9; Caliendo C, 2005, J ADV NURS, V49, P474, DOI 10.1111/j.1365-2648.2004.03320.x; Carroll ST, 2002, PEDIATRICS, V109, P1021, DOI 10.1542/peds.109.6.1021; GOULD M, 2003, OBSERVER        0914; Greif J, 1999, Clin Nurs Res, V8, P368, DOI 10.1177/10547739922158368; Hanif J, 2001, BRIT MED J, V322, P906, DOI 10.1136/bmj.322.7291.906; Hayes MO, 2001, AM J INFECT CONTROL, V29, P271, DOI 10.1067/mic.2001.114402; Laumann AE, 2006, J AM ACAD DERMATOL, V55, P413, DOI 10.1016/j.jaad.2006.03.026; Makkai T, 2001, Commun Dis Intell Q Rep, V25, P67; Mayers LB, 2002, MAYO CLIN PROC, V77, P29, DOI 10.4065/77.1.29; Roberts TA, 2004, J ADOLESCENT HEALTH, V34, P224, DOI 10.1016/j.jadohealth.2003.06.005; Simplot TC, 1998, AM J OTOLARYNG, V19, P305, DOI 10.1016/S0196-0709(98)90003-5; STIM A, 2003, LANCET, V361, P1205; Stirn A, 2006, J PSYCHOSOM RES, V60, P531, DOI 10.1016/j.jpsychores.2005.09.002; The Market Research Society, 2006, OCC GROUP JOB DICT; Theodossy T, 2003, BRIT DENT J, V194, P551, DOI 10.1038/sj.bdj.4810199; Whittle J Gary, 2004, Prim Dent Care, V11, P92, DOI 10.1308/1355761041208494; Williams RL, 2000, BIOMETRICS, V56, P645, DOI 10.1111/j.0006-341X.2000.00645.x; Willmott FE, 2001, INT J STD AIDS, V12, P358, DOI 10.1258/0956462011923282; Wooldridge J., 2002, ECONOMETRIC ANAL CRO	22	69	71	1	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 21	2008	336	7658					1426	1428		10.1136/bmj.39580.497176.25	http://dx.doi.org/10.1136/bmj.39580.497176.25			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	318WJ	18556275	Green Submitted, Green Accepted, Bronze, Green Published			2022-12-28	WOS:000257123200035
J	Julu, POO; Engerstrom, IW; Hansen, S; Apartopoulos, F; Engerstrom, B; Pini, G; Delamont, RS; Smeets, EEJ				Julu, Peter O. O.; Engerstrom, Ingegerd Witt; Hansen, Stig; Apartopoulos, Flora; Engerstrom, Bengt; Pini, Giorgio; Delamont, Robert S.; Smeets, Eric E. J.			Cardiorespiratory challenges in Rett's syndrome	LANCET			English	Editorial Material							DISORDER		[Julu, Peter O. O.] Barts & London Queen Marys Sch Med & Dent, Wingate Inst Neurogastroenterol, London E1 2AJ, England; [Julu, Peter O. O.; Engerstrom, Ingegerd Witt; Engerstrom, Bengt] Ostersund Hosp, Rett Ctr, Froson, Sweden; [Hansen, Stig; Apartopoulos, Flora] S Glasgow Univ Hosp, Inst Neurol Sci, Glasgow, Lanark, Scotland; [Pini, Giorgio] Area Vasta Toscana, Child Neuropsychiat, Nord Occidentale, Italy; [Pini, Giorgio] Area Vasta Toscana, Ctr Rett Versilia, Nord Occidentale, Italy; [Delamont, Robert S.] Kings Coll Hosp NHS Fdn Trust & Kings Coll, Reg Neurosci Ctr, London, England; [Smeets, Eric E. J.] Univ Hosp Maastricht, Dept Clin Genet, Maastricht, Netherlands	University of London; Queen Mary University London; University of Glasgow; University of London; King's College London; Maastricht University; Maastricht University Medical Centre (MUMC)	Julu, POO (corresponding author), Barts & London Queen Marys Sch Med & Dent, Wingate Inst Neurogastroenterol, London E1 2AJ, England.	p.julu@imperial.ac.uk		Julu, Peter/0000-0001-7903-1990				Armstrong DD, 2002, MENT RETARD DEV D R, V8, P72, DOI 10.1002/mrdd.10027; Glaze DG, 2002, MENT RETARD DEV D R, V8, P66, DOI 10.1002/mrdd.10024; Julu POO, 2001, ARCH DIS CHILD, V85, P29, DOI 10.1136/adc.85.1.29; Julu POO, 2005, BRAIN DEV-JPN, V27, pS43, DOI 10.1016/j.braindev.2005.02.012; Julu POO, 1997, ARCH DIS CHILD, V77, P464; JULU POO, 2001, RETT DISORDER DEV BR, P131; Kerr A, 1998, NEW DEVELOPMENTS IN CHILD NEUROLOGY, P191; NOMURA Y, 1992, BRAIN DEV-JPN, V14, pS21; NOMURA Y, 1985, BRAIN DEV-JPN, V7, P334, DOI 10.1016/S0387-7604(85)80040-1; Smeets EEJ, 2006, BRAIN DEV-JPN, V28, P625, DOI 10.1016/j.braindev.2006.04.010	10	45	45	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2008	371	9629					1981	1983		10.1016/S0140-6736(08)60849-1	http://dx.doi.org/10.1016/S0140-6736(08)60849-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312YY	18555901				2022-12-28	WOS:000256709500009
J	Chazdon, RL				Chazdon, Robin L.			Beyond deforestation: Restoring forests and ecosystem services on degraded lands	SCIENCE			English	Editorial Material							BIODIVERSITY; CONSERVATION; RESTORATION	Despite continued forest conversion and degradation, forest cover is increasing in countries across the globe. New forests are regenerating on former agricultural land, and forest plantations are being established for commercial and restoration purposes. Plantations and restored forests can improve ecosystem services and enhance biodiversity conservation, but will not match the composition and structure of the original forest cover. Approaches to restoring forest ecosystems depend strongly on levels of forest and soil degradation, residual vegetation, and desired restoration outcomes. Opportunities abound to combine ambitious forest restoration and regeneration goals with sustainable rural livelihoods and community participation. New forests will require adaptive management as dynamic, resilient systems that can withstand stresses of climate change, habitat fragmentation, and other anthropogenic effects.	[Chazdon, Robin L.] Univ Connecticut, Dept Ecol & Evolut Biol, Storrs, CT 06269 USA	University of Connecticut	Chazdon, RL (corresponding author), Univ Connecticut, Dept Ecol & Evolut Biol, Storrs, CT 06269 USA.	chazdon@uconn.edu	Chazdon, Robin/O-9766-2018	Chazdon, Robin/0000-0002-7349-5687				Barlow J, 2007, P NATL ACAD SCI USA, V104, P18555, DOI 10.1073/pnas.0703333104; Chazdon RL, 2003, PERSPECT PLANT ECOL, V6, P51, DOI 10.1078/1433-8319-00042; Chokkalingam Unna, 2005, P405, DOI 10.1007/0-387-29112-1_58; Ciccarese L, 2005, IN ST WA MA, V3, P111; Cote SD, 2004, ANNU REV ECOL EVOL S, V35, P113, DOI 10.1146/annurev.ecolsys.35.021103.105725; Cramer VA, 2008, TRENDS ECOL EVOL, V23, P104, DOI 10.1016/j.tree.2007.10.005; Diaz S, 2004, J VEG SCI, V15, P295, DOI 10.1111/j.1654-1103.2004.tb02266.x; FAO, 2006, 147 FAO; Grainger A, 2008, P NATL ACAD SCI USA, V105, P818, DOI 10.1073/pnas.0703015105; Harvey CA, 2008, CONSERV BIOL, V22, P8, DOI 10.1111/j.1523-1739.2007.00863.x; Hobbs RJ, 2006, GLOBAL ECOL BIOGEOGR, V15, P1, DOI 10.1111/j.1466-822x.2006.00212.x; ITTO-International Tropical Timber Organization, 2002, POLICY DEV SERIES, V13; Jordan William R., 2003, SUNFLOWER FOREST ECO; Kauppi PE, 2006, P NATL ACAD SCI USA, V103, P17574, DOI 10.1073/pnas.0608343103; Lamb D, 2005, SCIENCE, V310, P1628, DOI 10.1126/science.1111773; Laurance William F, 2006, Ecology, V87, P469, DOI 10.1890/05-0064; Lindenmayer DB, 2004, BIOL CONSERV, V119, P151, DOI 10.1016/j.biocon.2003.10.028; Monela G. C., 2004, STUDY SOCIAL EC ENV; Poffenberger M, 2006, INT J ENVIRON SUSTAI, V5, P57, DOI 10.1504/IJESD.2006.008683; Prach K, 2007, LINKING RESTORATION, P121, DOI DOI 10.1007/978-0-387-35303-6; Sabogal Cesar, 2005, P361, DOI 10.1007/0-387-29112-1_52; Sampaio AB, 2007, RESTOR ECOL, V15, P462, DOI 10.1111/j.1526-100X.2007.00242.x; *STAT FOR ADM, 2005, CHIN FOR DEV REP; Walker Lawrence R., 2007, P1, DOI 10.1007/978-0-387-35303-6_1; Wuethrich B, 2007, SCIENCE, V315, P1070, DOI 10.1126/science.315.5815.1070; Zimmerman J. K., 2007, OLD FIELDS DYNAMICS, P51	26	987	1042	40	852	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2008	320	5882					1458	1460		10.1126/science.1155365	http://dx.doi.org/10.1126/science.1155365			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556551				2022-12-28	WOS:000256676400034
J	Choi, SH; Kim, B; Frisbie, CD				Choi, Seong Ho; Kim, BongSoo; Frisbie, C. Daniel			Electrical resistance of long conjugated molecular wires	SCIENCE			English	Article							CHARGE-LIMITED CURRENTS; N-BENZYLIDENEANILINES; ACTIVATED CONDUCTION; TRANSPORT; JUNCTIONS; DNA; MECHANISM; OLIGOMERS; BEHAVIOR; LENGTH	The charge transport mechanism of a wire can be revealed by how its electrical resistance varies with length. We have measured the resistance and current-voltage characteristics of conjugated molecular wires ranging in length from 1 to 7 nanometers, connected between metal electrodes. We observe the theoretically predicted change in direct-current transport from tunneling to hopping as a function of systematically controlled wire length. We also demonstrate that site-specific disruption of conjugation in the wires greatly increases resistance in the hopping regime but has only a small effect in the tunneling regime. These nanoscale transport measurements elucidate the role of molecular length and bond architecture on molecular conductivity and open opportunities for greater understanding of electrical transport in conjugated polymer films.	[Choi, Seong Ho; Kim, BongSoo; Frisbie, C. Daniel] Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA; [Choi, Seong Ho; Kim, BongSoo; Frisbie, C. Daniel] Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Frisbie, CD (corresponding author), Univ Minnesota, Dept Chem, 207 Pleasant St SE, Minneapolis, MN 55455 USA.	frisbie@cems.umn.edu	Kim, BongSoo/AFT-7846-2022; Frisbie, C Daniel/F-3995-2011	Kim, BongSoo/0000-0002-4982-6343; 				AKABA R, 1980, B CHEM SOC JPN, V53, P1993, DOI 10.1246/bcsj.53.1993; Beebe JM, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.026801; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; Berlin YA, 2003, J PHYS CHEM A, V107, P3970, DOI 10.1021/jp034225i; Berlin YA, 2005, RADIAT PHYS CHEM, V74, P124, DOI 10.1016/j.radphyschem.2005.04.004; Berlin YA, 2002, CHEM PHYS, V275, P61, DOI 10.1016/S0301-0104(01)00536-5; Carroll RL, 2002, ANGEW CHEM INT EDIT, V41, P4379, DOI 10.1002/1521-3773(20021202)41:23<4378::AID-ANIE4378>3.0.CO;2-A; Conwell EM, 2005, P NATL ACAD SCI USA, V102, P8795, DOI 10.1073/pnas.0501406102; Cui XD, 2001, SCIENCE, V294, P571, DOI 10.1126/science.1064354; Davis WB, 1998, NATURE, V396, P60, DOI 10.1038/23912; Engelkes VB, 2004, J AM CHEM SOC, V126, P14287, DOI 10.1021/ja046274u; Giese B, 2001, NATURE, V412, P318, DOI 10.1038/35085542; Giese B, 2000, ACCOUNTS CHEM RES, V33, P631, DOI 10.1021/ar990040b; Gray HB, 2005, P NATL ACAD SCI USA, V102, P3534, DOI 10.1073/pnas.0408029102; Grozema FC, 2000, J AM CHEM SOC, V122, P10903, DOI 10.1021/ja001497f; Grozema FC, 2002, ADV MATER, V14, P228, DOI 10.1002/1521-4095(20020205)14:3<228::AID-ADMA228>3.0.CO;2-3; Grozema FC, 2002, J PHYS CHEM B, V106, P7791, DOI 10.1021/jp021114v; Harada J, 2004, ACTA CRYSTALLOGR B, V60, P578, DOI 10.1107/S0108768104016532; He J, 2005, J AM CHEM SOC, V127, P1384, DOI 10.1021/ja043279i; Hu WP, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.027801; Kubatkin S, 2003, NATURE, V425, P698, DOI 10.1038/nature02010; Kwok K.S., 2002, MATER TODAY, V5, P28, DOI [DOI 10.1016/S1369-7021(02)05227-6, 10.1016/S1369-7021(02)05227-6]; LAMPERT MA, 1956, PHYS REV, V103, P1648, DOI 10.1103/PhysRev.103.1648; NEWTON MD, 1991, CHEM REV, V91, P767, DOI 10.1021/cr00005a007; Nitzan A, 2003, SCIENCE, V300, P1384, DOI 10.1126/science.1081572; Prins P, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.146601; ROSE A, 1955, PHYS REV, V97, P1538, DOI 10.1103/PhysRev.97.1538; Rosink JJWM, 2000, LANGMUIR, V16, P4547, DOI 10.1021/1a9916861; Salomon A, 2003, ADV MATER, V15, P1881, DOI 10.1002/adma.200306091; Segal D, 2000, J PHYS CHEM B, V104, P2790, DOI 10.1021/jp994296a; Segal D, 2000, J PHYS CHEM B, V104, P3817, DOI 10.1021/jp993260f; Selzer Y, 2005, NANO LETT, V5, P61, DOI 10.1021/nl048372j; Selzer Y, 2004, J AM CHEM SOC, V126, P4052, DOI 10.1021/ja039015y; Shen YL, 2004, CHEMPHYSCHEM, V5, P16, DOI 10.1002/cphc.200300942; Sikes HD, 2001, SCIENCE, V291, P1519, DOI 10.1126/science.1055745; SZE SM, 1981, PHYS SEMICONDUCTOR; TOUR JM, 1995, J AM CHEM SOC, V117, P9529, DOI 10.1021/ja00142a021; Tsuji T, 2001, J AM CHEM SOC, V123, P6381, DOI 10.1021/ja010192d; Wold DJ, 2001, J AM CHEM SOC, V123, P5549, DOI 10.1021/ja0101532; Zhu XY, 2004, SURF SCI REP, V56, P1, DOI 10.1016/j.surfrep.2004.09.002	40	585	586	12	299	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2008	320	5882					1482	1486		10.1126/science.1156538	http://dx.doi.org/10.1126/science.1156538			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556556				2022-12-28	WOS:000256676400041
J	Montoya, D; Zavala, MA; Rodriguez, MA; Purves, DW				Montoya, Daniel; Zavala, Miguel A.; Rodriguez, Miguel A.; Purves, Drew W.			Animal versus wind dispersal and the robustness of tree species to deforestation	SCIENCE			English	Article							LONG-DISTANCE DISPERSAL; SEED DISPERSAL; HABITAT; CORRIDORS; NETWORKS	Studies suggest that populations of different species do not decline equally after habitat loss. However, empirical tests have been confined to fine spatiotemporal scales and have rarely included plants. Using data from 89,365 forest survey plots covering peninsular Spain, we explored, for each of 34 common tree species, the relationship between probability of occurrence and the local cover of remaining forest. Twenty-four species showed a significant negative response to forest loss, so that decreased forest cover had a negative effect on tree diversity, but the responses of individual species were highly variable. Animal-dispersed species were less vulnerable to forest loss, with six showing positive responses to decreased forest cover. The results imply that plant-animal interactions help prevent the collapse of forest communities that suffer habitat destruction.	[Montoya, Daniel; Zavala, Miguel A.; Rodriguez, Miguel A.] Univ Alcala de Henares, Dept Ecol, Alcala De Henares 28871, Spain; [Zavala, Miguel A.] Inst Nacl Invest & Tecnol Agr & Alimentaria, Ctr Invest Forestal, Madrid 28040, Spain; [Purves, Drew W.] Microsoft Res Cambridge, Cambridge CB3 0FB, England	Universidad de Alcala; Instituto Nacional Investigacion Tecnologia Agraria Alimentaria (INIA); Microsoft	Montoya, D (corresponding author), Univ Alcala de Henares, Dept Ecol, Alcala De Henares 28871, Spain.	daniel.montoya@alu.uah.es	Montoya, Daniel/L-2266-2019; Rodriguez, Miguel A/A-3409-2011; Zavala, Miguel A./H-3603-2015	Montoya, Daniel/0000-0002-5521-5282; Rodriguez, Miguel A/0000-0002-4082-2995; Zavala, Miguel A./0000-0003-1456-0132				Bascompte J, 2001, ECOL LETT, V4, P417, DOI 10.1046/j.1461-0248.2001.00242.x; Bascompte J, 2007, ANNU REV ECOL EVOL S, V38, P567, DOI 10.1146/annurev.ecolsys.38.091206.095818; Chetkiewicz CLB, 2006, ANNU REV ECOL EVOL S, V37, P317, DOI 10.1146/annurev.ecolsys.37.091305.110050; Conradt L, 2001, OIKOS, V95, P416, DOI 10.1034/j.1600-0706.2001.950306.x; Damschen EI, 2006, SCIENCE, V313, P1284, DOI 10.1126/science.1130098; Fahrig L, 2001, BIOL CONSERV, V100, P65, DOI 10.1016/S0006-3207(00)00208-1; Fahrig L, 2003, ANNU REV ECOL EVOL S, V34, P487, DOI 10.1146/annurev.ecolsys.34.011802.132419; Ferraz G, 2007, SCIENCE, V315, P238, DOI 10.1126/science.1133097; Gomez JM, 2003, ECOGRAPHY, V26, P573, DOI 10.1034/j.1600-0587.2003.03586.x; HANSKI I, 1994, ECOLOGY, V75, P747, DOI 10.2307/1941732; Hanski I, 1998, NATURE, V396, P41, DOI 10.1038/23876; Hanski I, 1999, METAPOPULATION ECOLO; Higgins SI, 2003, ECOLOGY, V84, P1945, DOI 10.1890/01-0616; Johst K, 2002, OIKOS, V98, P263, DOI 10.1034/j.1600-0706.2002.980208.x; Jordano P, 2007, P NATL ACAD SCI USA, V104, P3278, DOI 10.1073/pnas.0606793104; MANZANEQUE FG, 2005, BOSQUES IBERICOS INT; McEuen AB, 2004, ECOLOGY, V85, P507, DOI 10.1890/03-4006; *MIN AGR PESC AL, 1995, SEG INV FOR NAC; Montoya JM, 2006, NATURE, V442, P259, DOI 10.1038/nature04927; Purves DW, 2007, ECOL MONOGR, V77, P77, DOI 10.1890/05-1923; Purves DW, 2005, J ECOL, V93, P658, DOI 10.1111/j.1365-2745.2005.00988.x; Purvis A, 2000, SCIENCE, V288, P328, DOI 10.1126/science.288.5464.328; Rees M, 2001, SCIENCE, V293, P650, DOI 10.1126/science.1062586; Restrepo C, 1999, ECOLOGY, V80, P668, DOI 10.1890/0012-9658(1999)080[0668:AETGAF]2.0.CO;2; Sanchez-Gomez D, 2006, NEW PHYTOL, V170, P795, DOI 10.1111/j.1469-8137.2006.01711.x; SMITH CC, 1974, AM NAT, V108, P499, DOI 10.1086/282929; Sole R. V., 2007, SELF ORG COMPLEX ECO	27	104	109	3	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2008	320	5882					1502	1504		10.1126/science.1158404	http://dx.doi.org/10.1126/science.1158404			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18535208	Green Submitted			2022-12-28	WOS:000256676400046
J	Howie, J; Metcalfe, D; Walker, J				Howie, John; Metcalfe, David; Walker, John			The state of general practice - not all for the better	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Howie, John] Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland; [Metcalfe, David] Univ Manchester, Manchester M13 9PL, Lancs, England; [Walker, John] Univ Newcastle Upon Tyne, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of Edinburgh; University of Manchester; Newcastle University - UK	Howie, J (corresponding author), Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland.	john.howie00@btinternet.com							0	8	8	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2008	336	7656					1310	1310		10.1136/bmj.a172	http://dx.doi.org/10.1136/bmj.a172			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312XO	18535076	Green Published			2022-12-28	WOS:000256705900039
J	DeLuca, TH; Zackrisson, O; Gundale, MJ; Nilsson, MC				DeLuca, Thomas H.; Zackrisson, Olle; Gundale, Michael J.; Nilsson, Marie-Charlotte			Ecosystem feedbacks and nitrogen fixation in boreal forests	SCIENCE			English	Article									[DeLuca, Thomas H.] Wilderness Soc, Ecol & Econ Res Dept, Bozeman, MT 59715 USA; [DeLuca, Thomas H.; Zackrisson, Olle; Gundale, Michael J.; Nilsson, Marie-Charlotte] Swedish Univ Agr Sci, Dept Forest Ecol & Management, S-90183 Umea, Sweden	Swedish University of Agricultural Sciences	DeLuca, TH (corresponding author), Wilderness Soc, Ecol & Econ Res Dept, 503 W Mendenhall, Bozeman, MT 59715 USA.	tom_deluca@tws.org	DeLuca, Thomas Henry/B-4547-2012; Gundale, Michael J/O-1265-2013; Hegethorn, Marie-Charlotte Nilsson/B-1802-2017; DeLuca, Thomas/GYU-3468-2022	DeLuca, Thomas Henry/0000-0003-1561-9597; Gundale, Michael J/0000-0003-2447-609X; Hegethorn, Marie-Charlotte Nilsson/0000-0002-9254-2223; 				Bever JD, 2003, NEW PHYTOL, V157, P465, DOI 10.1046/j.1469-8137.2003.00714.x; DeLuca TH, 2002, NATURE, V419, P917, DOI 10.1038/nature01051; Reich PB, 2006, NATURE, V440, P922, DOI 10.1038/nature04486; Vitousek PM, 2002, BIOGEOCHEMISTRY, V57, P1, DOI 10.1023/A:1015798428743; Wardle DA, 2003, SCIENCE, V300, P972, DOI 10.1126/science.1082709; Zackrisson O, 2004, ECOLOGY, V85, P3327, DOI 10.1890/04-0461	6	129	135	6	170	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2008	320	5880					1181	1181		10.1126/science.1154836	http://dx.doi.org/10.1126/science.1154836			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306FF	18511682				2022-12-28	WOS:000256233000028
J	Peri, F; Nusslein-Volhard, C				Peri, Francesca; Nuesslein-Volhard, Christiane			Live imaging of neuronal degradation by microglia reveals a role for v0-ATPase a1 in phagosomal fusion in vivo	CELL			English	Article							APOPTOTIC CELLS; V-ATPASES; P53-DEPENDENT APOPTOSIS; CAENORHABDITIS-ELEGANS; EARLY MACROPHAGES; DEVELOPING BRAIN; LYSOSOME FUSION; ZEBRAFISH; PHAGOCYTOSIS; ACIDIFICATION	A significant proportion of neurons in the brain undergo programmed cell death. In order to prevent the diffusion of damaging degradation products, dying neurons are quickly digested by microglia. Despite the importance of microglia in several neuronal pathologies, the mechanism underlying their degradation of neurons remains elusive. Here, we exploit a microglial population in the zebrafish to study this process in intact living brains. In vivo imaging reveals that digestion of neurons occurs in compartments arising from the progressive fusion of vesicles. We demonstrate that this fusion is mediated by the v0-ATPase a1 subunit. By applying live pH indicators, we show that the a1 subunit mediates fusion between phagosomes and lysosomes during phagocytosis, a function that is independent of its proton pump activity. As a real-time description of microglial phagocytosis in vivo, this work advances our understanding of microglial-mediated neuronal degeneration, a hallmark of many neuronal diseases.	[Peri, Francesca; Nuesslein-Volhard, Christiane] Max Planck Inst Dev Biol, D-72076 Tubingen, Germany	Max Planck Society	Peri, F (corresponding author), EMBL Heidlberg, Meyerhofstr 1, D-69117 Heidelberg, Germany.	peri@embl.de		Peri, Francesca/0000-0001-7068-4952				Barron KD, 1995, J NEUROL SCI, V134, P57, DOI 10.1016/0022-510X(95)00209-K; Bayer MJ, 2003, J CELL BIOL, V162, P211, DOI 10.1083/jcb.200212004; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Blott EJ, 2001, J CELL SCI, V114, P2405; BOUVIER G, 1994, J LEUKOCYTE BIOL, V55, P729, DOI 10.1002/jlb.55.6.729; Bowman EJ, 2004, J BIOL CHEM, V279, P33131, DOI 10.1074/jbc.M404638200; Campbell WA, 2006, J NEUROCHEM, V96, P1423, DOI 10.1111/j.1471-4159.2006.03648.x; de Saint-Vis B, 1998, IMMUNITY, V9, P325, DOI 10.1016/S1074-7613(00)80615-9; Desjardins M, 2003, CURR OPIN CELL BIOL, V15, P498, DOI 10.1016/S0955-0674(03)00083-8; Duhon D, 2002, J MUSCLE RES CELL M, V23, P803, DOI 10.1023/A:1024435913949; GEISOW MJ, 1981, J CELL BIOL, V89, P645, DOI 10.1083/jcb.89.3.645; GRINSTEIN S, 1992, J EXP BIOL, V172, P179; Harris E, 2002, J CELL SCI, V115, P3703, DOI 10.1242/jcs.00050; Herbomel P, 1999, DEVELOPMENT, V126, P3735; Herbomel P, 2001, DEV BIOL, V238, P274, DOI 10.1006/dbio.2001.0393; Hiesinger PR, 2005, CELL, V121, P607, DOI 10.1016/j.cell.2005.03.012; Kawasaki-Nishi S, 2003, FEBS LETT, V545, P76, DOI 10.1016/S0014-5793(03)00396-X; Kettenmann H, 2007, NATURE, V446, P987, DOI 10.1038/nature05713; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Koster RW, 2001, DEV BIOL, V233, P329, DOI 10.1006/dbio.2001.0242; Kuan CY, 2000, TRENDS NEUROSCI, V23, P291, DOI 10.1016/S0166-2236(00)01581-2; Kurant E, 2008, CELL, V133, P498, DOI 10.1016/j.cell.2008.02.052; Lauber K, 2004, MOL CELL, V14, P277, DOI 10.1016/S1097-2765(04)00237-0; Liegeois S, 2006, J CELL BIOL, V173, P949, DOI 10.1083/jcb.200511072; Liu TX, 2003, DEV CELL, V5, P903, DOI 10.1016/S1534-5807(03)00339-3; MCNEIL PL, 1983, J CELL BIOL, V97, P692, DOI 10.1083/jcb.97.3.692; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Muller O, 2002, EMBO J, V21, P259, DOI 10.1093/emboj/21.3.259; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Nijhawan D, 2000, ANNU REV NEUROSCI, V23, P73, DOI 10.1146/annurev.neuro.23.1.73; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Ober EA, 1999, DEV BIOL, V215, P167, DOI 10.1006/dbio.1999.9455; Parnaik R, 2000, CURR BIOL, V10, P857, DOI 10.1016/S0960-9822(00)00598-4; Perzov N, 2002, J EXP BIOL, V205, P1209; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Pujol N, 2001, J BIOL CHEM, V276, P11913, DOI 10.1074/jbc.M009451200; Rhodes J, 2005, DEV CELL, V8, P97, DOI 10.1016/j.devcel.2004.11.014; Schneider VA, 2006, NEURON, V50, P683, DOI 10.1016/j.neuron.2006.04.024; Streit W. J., 1995, SCI AM, V273, P58; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Westerfield M., 1993, ZEBRAFISH BOOK GUIDE	42	394	403	0	31	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 30	2008	133	5					916	927		10.1016/j.cell.2008.04.037	http://dx.doi.org/10.1016/j.cell.2008.04.037			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510934	Green Accepted, Bronze			2022-12-28	WOS:000256274500022
J	Bellary, S; O'Hare, JP; Raymond, NT; Gumber, A; Mughal, S; Szczepura, A; Kumar, S; Barnett, AH				Bellary, S.; O'Hare, J. P.; Raymond, N. T.; Gumber, A.; Mughal, S.; Szczepura, A.; Kumar, S.; Barnett, A. H.		UKADS Study Grp	Enhanced diabetes care to patients of south Asian ethnic origin (the United Kingdom Asian Diabetes Study): a cluster randomised controlled trial	LANCET			English	Article							ANTIHYPERTENSIVE DRUG-TREATMENT; QUALITY-OF-CARE; SELF-MANAGEMENT; BLOOD-PRESSURE; UK; EDUCATION; OUTCOMES; PEOPLE; INTERVENTIONS; HYPERTENSION	Background Delivery of high-quality, evidence-based health care to deprived sectors of the community is a major goal for society. We investigated the effectiveness of a culturally sensitive, enhanced care package in UK general practices for improvement of cardiovasular risk factors in patients of south Asian origin with type 2 diabetes. Methods In this cluster randomised controlled trial, 21 inner-city practices in the UK were assigned by simple randomisation to intervention (enhanced care including additional time with practice nurse and support from a link worker and diabetes-specialist nurse [nine practices; n=8681) or control (standard care [12 practices; n=618]) groups. All adult patients of south Asian origin with type 2 diabetes were eligible. Prescribing algorithms with clearly defined targets were provided for all practices. Primary outcomes were changes in blood pressure, total cholesterol, and glycaemic control (haemoglobin A(1c)) after 2 years. Analysis was by intention to treat. This trial is registered, number ISRCTN 38297969. Findings We recorded significant differences between treatment groups in diastolic blood pressure (1-91 [95% CI -2.88 to -0 . 94] Turn Hg, p=0. 0001) and mean arterial pressure (1 . 36 [-2.49 to -0 . 23] mm Hg, p=0.0180), after adjustment for confounders and clustering. We noted no significant differences between groups for total cholesterol (0.03 [-0.04 to 0.11] mmol/L), systolic blood pressure (-0.33 [-2.41 to 1.75] mm Hg), or HbA(1c) (-0.15% [-0.33 to 0.03]). Economic analysis suggests that the nurse-led intervention was not cost effective (incremental cost-effectiveness ratio 28 pound 933 per QALY gained). Across the whole study population over the 2 years of the trial, systolic blood pressure, diastolic blood pressure, and cholesterol decreased significantly by 4.9 (95% CI 4.0-5.9) mm Hg, 3.8 (3.2-4.4) mm Hg, and 0.45 (0.40-0.51) mmol/L, respectively, and we recorded a small and non-significant increase for haernoglobin A(1c) (0 - 04% [-0.04 to 0. 131), p=0. 290). Interpretation We recorded additional, although small, benefits from our culturally tailored care package that were greater than the secular changes achieved in the UK in recent years. Stricter targets in general practice and further measures to motivate patients are needed to achieve best possible health-care outcomes in south Asian patients with diabetes. Funding Pfizer, Sanofi-Aventis, Servier Laboratories UK, Merck Sharp & Dohme/ Schering-Plough, Takeda UK, Roche, Merck Pharma, Daiichi-Sankyo UK, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Bristol-Myers Squibb, Solvay Health Care, and Assurance Medical Society UK.	[Bellary, S.; Mughal, S.; Barnett, A. H.] Heart England NHS Fdn Trust, Undergrad Ctr, Birmingham B9 5SS, W Midlands, England; [O'Hare, J. P.; Raymond, N. T.; Gumber, A.; Szczepura, A.; Kumar, S.] Warwick Med Sch, Coventry, W Midlands, England; [Bellary, S.; Barnett, A. H.] Univ Birmingham, Birmingham, W Midlands, England	Heart of England NHS Foundation Trust; University of Warwick; University of Birmingham	Barnett, AH (corresponding author), Heart England NHS Fdn Trust, Undergrad Ctr, Bordesley Green E, Birmingham B9 5SS, W Midlands, England.	anthony.barnett@heartofengland.nhs.uk	Bellary, Srikanth/ABA-1977-2020; Gumber, Anil/H-3007-2019; kumar, sudhesh/D-6945-2013	Bellary, Srikanth/0000-0002-5924-5278; Gumber, Anil/0000-0002-8621-6966; Szczepura, Ala/0000-0001-6244-9872; kumar, sudhesh/0000-0003-4326-5941				ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; [Anonymous], 2007, DIABETES CARE, V30, pS4, DOI [10.2337/dc07-S004, DOI 10.2337/DC07-S004]; Barnett AH, 2006, DIABETOLOGIA, V49, P2234, DOI 10.1007/s00125-006-0325-1; Brown SA, 2002, DIABETES CARE, V25, P259, DOI 10.2337/diacare.25.2.259; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Chaturvedi N, 1996, J EPIDEMIOL COMMUN H, V50, P137, DOI 10.1136/jech.50.2.137; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; COLLINS R, 1994, BRIT MED BULL, V50, P272, DOI 10.1093/oxfordjournals.bmb.a072892; Davies MJ, 2008, BMJ-BRIT MED J, V336, P491, DOI 10.1136/bmj.39474.922025.BE; Dolan P., 1995, SOCIAL TARIFF EUROQO; Gammon BD, 2008, BRIT MED J, V336, DOI 10.1136/bmj.39416.697778.94; Gerstein HC, 2000, LANCET, V355, P253; Greenhalgh PM, 1997, DIABETIC MED, V14, P10; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Gueyffier F, 1997, ANN INTERN MED, V126, P761, DOI 10.7326/0003-4819-126-10-199705150-00002; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Hunt S, 2003, BRIT MED J, V327, P352, DOI 10.1136/bmj.327.7411.352; Hussain-Gambles M, 2004, HEALTH TECHNOL ASSES, V8, P1; Khunti K, 2007, DIABETIC MED, V24, P1436, DOI 10.1111/j.1464-5491.2007.02276.x; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; MATHER HM, 1985, BRIT MED J, V291, P1081, DOI 10.1136/bmj.291.6502.1081; Millett C, 2007, PLOS MED, V4, P1087, DOI 10.1371/journal.pmed.0040191; O'Hare JP, 2004, DIABETIC MED, V21, P1357, DOI 10.1111/j.1464-5491.2004.01373.x; Raftery J, 2001, BRIT MED J, V323, P1300, DOI 10.1136/bmj.323.7324.1300; Saxena S, 2007, J AMBUL CARE MANAG, V30, P218, DOI 10.1097/01.JAC.0000278982.65063.5c; Shekelle P, 2003, BRIT MED J, V326, P457, DOI 10.1136/bmj.326.7387.457; Singer JD, 1998, J EDUC BEHAV STAT, V23, P323; Smeeth L, 2002, CONTROL CLIN TRIALS, V23, P409, DOI 10.1016/S0197-2456(02)00208-8; Stone M, 2005, FAM PRACT, V22, P647, DOI 10.1093/fampra/cmi069; Sullivan LM, 1999, STAT MED, V18, P855, DOI 10.1002/(SICI)1097-0258(19990415)18:7<855::AID-SIM117>3.0.CO;2-7; Underwood M, 1998, BRIT J GEN PRACT, V48, P1089; Williams B, 2004, J HUM HYPERTENS, V18, P139, DOI 10.1038/sj.jhh.1001683; Wright A, 2002, DIABETES CARE, V25, P330, DOI 10.2337/diacare.25.2.330	33	93	93	0	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	2008	371	9626					1769	1776		10.1016/S0140-6736(08)60764-3	http://dx.doi.org/10.1016/S0140-6736(08)60764-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304IO	18502301	Green Submitted			2022-12-28	WOS:000256103400031
J	Guyatt, GH; Oxman, AD; Kunz, R; Jaeschke, R; Helfand, M; Liberati, A; Vist, GE; Schunemann, HJ				Guyatt, Gordon H.; Oxman, Andrew D.; Kunz, Regina; Jaeschke, Roman; Helfand, Mark; Liberati, Alessandro; Vist, Gunn E.; Schunemann, Holger J.		GRADE Working Grp	GRADE: Incorporating considerations of resources use into grading recommendations	BRITISH MEDICAL JOURNAL			English	Editorial Material							COST-EFFECTIVENESS; MAGNESIUM-SULFATE; MAGPIE TRIAL; PREECLAMPSIA; WOMEN		[Guyatt, Gordon H.] McMaster Univ, Dept Clin Epidemiol & Biostat, CLARITY Res Grp, Hamilton, ON L8N 3Z5, Canada; [Oxman, Andrew D.; Vist, Gunn E.] Norwegian Knowledge Ctr Hlth Serv, N-0130 Oslo, Norway; [Kunz, Regina] Univ Basel Hosp, Basel Inst Clin Epidemiol, CH-4031 Basel, Switzerland; [Jaeschke, Roman] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; [Helfand, Mark] Portland VA Med Ctr, Portland, OR 97201 USA; [Helfand, Mark] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; [Liberati, Alessandro] Univ Modena & Reggio Emilia, I-40127 Bologna, Italy; [Liberati, Alessandro] Agenzia Sanit Reg, I-40127 Bologna, Italy; [Schunemann, Holger J.] Italian Natl Canc Inst Regina Elena, Dept Epidemiol, Rome, Italy	McMaster University; Norwegian Knowledge Centre for Health Services; University of Basel; McMaster University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; Oregon Health & Science University; Universita di Modena e Reggio Emilia	Guyatt, GH (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, CLARITY Res Grp, Hamilton, ON L8N 3Z5, Canada.	guyatt@mcmaster.ca	Whittington, Craig/B-1380-2008; Djulbegovic, Benjamin/I-3661-2012; Oxman, Andrew/Y-3004-2019; Fervers, Béatrice/AAD-1847-2022	Whittington, Craig/0000-0002-1950-0334; Djulbegovic, Benjamin/0000-0003-0671-1447; Oxman, Andrew/0000-0002-5608-5061; Fervers, Béatrice/0000-0003-3498-6499; Flottorp, Signe/0000-0003-2961-7461; Schunemann, Holger/0000-0003-3211-8479; Tuut, Mariska/0000-0002-0880-6215				Duley L, 2002, LANCET, V359, P1877, DOI 10.1016/s0140-6736(02)08778-0; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2493, DOI 10.1001/jama.263.18.2493; Friedberg M, 1999, JAMA-J AM MED ASSOC, V282, P1453, DOI 10.1001/jama.282.15.1453; Garber AM, 1997, J HEALTH ECON, V16, P1, DOI 10.1016/S0167-6296(96)00506-1; Gold MR, 1996, COST EFFECTIVENESS H; Guyatt G, 2006, CHEST, V129, P182, DOI 10.1378/chest.129.1.182; Luce BR, 1996, COST EFFECTIVENESS H, P176; Montori VM, 2004, BMJ-BRIT MED J, V329, P1093, DOI 10.1136/bmj.329.7474.1093; OBRIEN B, 2002, USERS GUIDES MED LIT, P621; Owens DK, 1998, J GEN INTERN MED, V13, P716, DOI 10.1046/j.1525-1497.1998.00211.x; Simon J, 2006, BJOG-INT J OBSTET GY, V113, P144, DOI 10.1111/j.1471-0528.2005.00785.x	11	300	322	0	23	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2008	336	7654					1170	1173		10.1136/bmj.39504.506319.80	http://dx.doi.org/10.1136/bmj.39504.506319.80			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308WJ	18497416	Green Published			2022-12-28	WOS:000256420900039
J	Montgomery, B				Montgomery, Brett			Evidence based case report - Does paracetamol cause hypertension?	BRITISH MEDICAL JOURNAL			English	Editorial Material							ANALGESIC USE; RISK; ACETAMINOPHEN; FREQUENCY; WOMEN; MEN		[Montgomery, Brett] Univ Western Australia, Discipline Gen Practice, Sch Primary Aboriginal & Rural Hlth Care, Claremont, WA 6010, Australia	University of Western Australia	Montgomery, B (corresponding author), Univ Western Australia, Discipline Gen Practice, Sch Primary Aboriginal & Rural Hlth Care, 328 Stirling Highway, Claremont, WA 6010, Australia.	brett@multiline.com.au						Brotman DJ, 2003, ARCH INTERN MED, V163, P1113, DOI 10.1001/archinte.163.9.1113-b; CHALMERS JP, 1984, CLIN EXP HYPERTENS A, V6, P1077, DOI 10.3109/10641968409039582; Curhan GC, 2002, ARCH INTERN MED, V162, P2204, DOI 10.1001/archinte.162.19.2204; Dedier J, 2002, HYPERTENSION, V40, P604, DOI 10.1161/01.HYP.0000035856.77718.DA; Forman JP, 2007, ARCH INTERN MED, V167, P394, DOI 10.1001/archinte.167.4.394; Kurth T, 2005, ARCH INTERN MED, V165, P1903, DOI 10.1001/archinte.165.16.1903; McGettigan P, 2006, JAMA-J AM MED ASSOC, V296, P1633, DOI 10.1001/jama.296.13.jrv60011; OLEARY C, 2007, W AUSTR         0228, P15; RADACK KL, 1987, ANN INTERN MED, V107, P628, DOI 10.7326/0003-4819-107-5-628	9	12	14	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2008	336	7654					1190	1191		10.1136/bmj.39526.654016.AD	http://dx.doi.org/10.1136/bmj.39526.654016.AD			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308WJ	18497418	Green Published			2022-12-28	WOS:000256420900044
J	Holmgren, A				Holmgren, Arne			Biochemistry - SNO removal	SCIENCE			English	Editorial Material							THIOREDOXIN SYSTEM		Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden	Karolinska Institutet	Holmgren, A (corresponding author), Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden.	arne.holmgren@ki.se						Arner ESJ, 2006, SEMIN CANCER BIOL, V16, P420, DOI 10.1016/j.semcancer.2006.10.009; Benhar M, 2008, SCIENCE, V320, P1050, DOI 10.1126/science.1158265; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; HERS DT, 2005, NAT REV MOL CELL BIO, V6, P150; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Landino LM, 2008, METHOD ENZYMOL, V440, P95, DOI 10.1016/S0076-6879(07)00805-1; Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Mitchell DA, 2007, P NATL ACAD SCI USA, V104, P11609, DOI 10.1073/pnas.0704898104; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; Sengupta R, 2007, BIOCHEMISTRY-US, V46, P8472, DOI 10.1021/bi700449x	11	21	22	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2008	320	5879					1019	1020		10.1126/science.1159246	http://dx.doi.org/10.1126/science.1159246			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18497281				2022-12-28	WOS:000256059800025
J	Benn, CS; Diness, BR; Roth, A; Nante, E; Fisker, AB; Lisse, IM; Yazdanbakhsh, M; Whittle, H; Rodrigues, A; Aaby, P				Benn, Christine Stabell; Diness, Birgitte Rode; Roth, Adam; Nante, Ernesto; Fisker, Ane Baerent; Lisse, Ida Maria; Yazdanbakhsh, Maria; Whittle, Hilton; Rodrigues, Amabelia; Aaby, Peter			Effect of 50 000 IU vitamin A given with BCG vaccine on mortality in infants in Guinea-Bissau: randomised placebo controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD MORTALITY; SUPPLEMENTATION; IMPACT; MORBIDITY; RESPONSES; CHILDREN; GROWTH; BIRTH	Objective To investigate the effect of high dose vitamin A supplementation given with BCG vaccine at birth in an African setting with high infant mortality. Design Randomised placebo controlled trial. Setting Bandim Health Project's demographic surveillance system in Guinea-Bissau, covering approximately 90 000 inhabitants. Participants 4345 infants due to receive BCG. Intervention Infants were randomised to 50 000 IU vitamin A or placebo and followed until age 12 months. Main outcome measure Mortality rate ratios. Results 174 children died during follow-up (mortality=47/ 1000 person-years). Vitamin A supplementation was not significantly associated with mortality; the mortality rate ratio was 1.07 (95% confidence interval 0.79 to 1.44). The effect was 1.00 (0.65 to 1.56) during the first four months and 1.13 (0.75 to 1.68) from 4 to 12 months of age. The mortality rate ratio in boys was 0.84 (0.55 to 1.27) compared with 1.39 (0.90 to 2.14) in girls (P for interaction=0.10). An explorative analysis revealed a strong interaction between vitamin A and season of administration. Conclusions Vitamin A supplementation given with BCG vaccine at birth had no significant benefit in this African setting. Although little doubt exists that vitamin A supplementation reduces mortality in older children, a global recommendation of supplementation for all newborn infants may not contribute to better survival. Registration Clinical trials NCT00168597.	[Benn, Christine Stabell; Diness, Birgitte Rode; Roth, Adam] Statens Serum Inst, Bandim Hlth Project, DK-2300 Copenhagen, Denmark; [Roth, Adam] Lund Univ, Dept Med Microbiol, S-20502 Malmo, Sweden; [Nante, Ernesto; Fisker, Ane Baerent; Rodrigues, Amabelia; Aaby, Peter] Indepth Network, Bandim Hlth Project, Bissau, Guinea Bissau; [Lisse, Ida Maria] Herlev Univ Hosp, Dept Pathol, DK-2730 Herlev, Denmark; [Yazdanbakhsh, Maria] Leiden Univ, Med Ctr, Dept Immunoparasitol, NL-2333 AZ Leiden, Netherlands; [Whittle, Hilton] MRC Labs, Fajara, Gambia	Statens Serum Institut; Lund University; University of Copenhagen; Herlev & Gentofte Hospital; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; MRC Laboratory Molecular Biology	Benn, CS (corresponding author), Statens Serum Inst, Bandim Hlth Project, Artillerivej 5, DK-2300 Copenhagen, Denmark.	cb@ssi.dk	Yazdanbakhsh, Maria/AAI-3996-2020; Fisker, Ane B/E-9283-2019	Yazdanbakhsh, Maria/0000-0002-7666-1441; Fisker, Ane B/0000-0002-8521-0992; Aaby, Peter/0000-0001-8331-1389				ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462; Aguayo Victor M., 2005, Food and Nutrition Bulletin, V26, P348; ANKER M, 1999, STANDARD VERBAL AUTO; Bahl R, 1997, EUR J CLIN NUTR, V51, P26, DOI 10.1038/sj.ejcn.1600352; Benn CS, 2007, VACCINE, V25, P777, DOI 10.1016/j.vaccine.2006.09.044; Benn CS, 2005, BMJ-BRIT MED J, V331, P1428, DOI 10.1136/bmj.38670.639340.55; Benn CS, 1997, LANCET, V350, P101, DOI 10.1016/S0140-6736(96)12019-5; Benn CS, 2003, INT J EPIDEMIOL, V32, P822, DOI 10.1093/ije/dyg208; Bhutta ZA, 2008, LANCET, V371, P417, DOI 10.1016/S0140-6736(07)61693-6; Coutsoudis A, 1996, S Afr Med J, V86, P1337; Cox D. R., 1984, ANAL SURVIVAL DATA; Diness BR, 2007, AM J CLIN NUTR, V86, P1152, DOI 10.1093/ajcn/86.4.1152; FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898; Fisker AB, 2007, AM J CLIN NUTR, V86, P1032, DOI 10.1093/ajcn/86.4.1032; Hadi H, 2004, EUR J CLIN NUTR, V58, P990, DOI 10.1038/sj.ejcn.1601920; Humphrey Jean H, 2006, J Infect Dis, V193, P860, DOI 10.1086/500366; Humphrey JH, 1996, J PEDIATR-US, V128, P489, DOI 10.1016/S0022-3476(96)70359-1; *IND NETW, 2003, STAND VERB AUT QUEST; KJOLHEDE CL, 1995, INT J EPIDEMIOL, V24, P399, DOI 10.1093/ije/24.2.399; KLEMM R, 2008, 1 MICR FOR M IST TUR; Malaba LC, 2005, AM J CLIN NUTR, V81, P454, DOI 10.1093/ajcn.81.2.454; Moore SE, 2006, TROP MED INT HEALTH, V11, P1529, DOI 10.1111/j.1365-3156.2006.01700.x; Nante JE, 2008, EUR J CLIN NUTR, V62, P842, DOI 10.1038/sj.ejcn.1602796; Rahmathullah L, 2003, BMJ-BRIT MED J, V327, P254, DOI 10.1136/bmj.327.7409.254; Rondo PHC, 2001, J TROP PEDIATRICS, V47, P307, DOI 10.1093/tropej/47.5.307; ROSS DA, 1995, AM J PUBLIC HEALTH, V85, P1246, DOI 10.2105/AJPH.85.9.1246; SOMMER A, 1986, LANCET, V1, P1169; Benn CS, 2006, J INFECT DIS, V194, P719, DOI 10.1086/506457; Tolba AM, 1998, J TROP PEDIATRICS, V44, P174, DOI 10.1093/tropej/44.3.174; *UNICEF, 2004, VIT MIN DEF; Villamor E, 2005, CLIN MICROBIOL REV, V18, P446, DOI 10.1128/CMR.18.3.446-464.2005; West Jr K, 2007, 1 MICR FOR M IST TUR; West KP, 1997, J NUTR, V127, P1957, DOI 10.1093/jn/127.10.1957; *WHO UNICEF IVACG, 1997, VIT A SUPPL GUID THE; YASSAI MB, 1989, J TROP PEDIATRICS, V35, P247, DOI 10.1093/tropej/35.5.247	35	93	95	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 21	2008	336	7658					1416	+		10.1136/bmj.39542.509444.AE	http://dx.doi.org/10.1136/bmj.39542.509444.AE			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318WJ	18558641	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000257123200032
J	Russell, K; Broadbridge, C; Murray, S; Waghorn, D; Mahoney, A				Russell, Katherine; Broadbridge, Carl; Murray, Sebastian; Waghorn, David; Mahoney, Allan			Gardening can seriously damage your health	LANCET			English	Editorial Material							PULMONARY ASPERGILLOSIS		[Russell, Katherine; Waghorn, David] Wycombe Gen Hosp, Dept Microbiol, High Wycombe HP11 2TT, Bucks, England; [Broadbridge, Carl; Murray, Sebastian; Mahoney, Allan] Wycombe Gen Hosp, Dept Anaesthet, High Wycombe HP11 2TT, Bucks, England		Waghorn, D (corresponding author), Wycombe Gen Hosp, Dept Microbiol, Queen Alexandra Rd, High Wycombe HP11 2TT, Bucks, England.	David.Waghorn@buckshosp.nhs.uk						Arendrup MC, 2006, SCAND J INFECT DIS, V38, P945, DOI 10.1080/00365540600606580; Balkissoon Ron, 2006, COPD, V3, P63, DOI 10.1080/15412550500513878; Batard E, 2003, EUR J CLIN MICROBIOL, V22, P357, DOI 10.1007/s10096-003-0939-x; Siddiqui S, 2007, CLIN INFECT DIS, V45, P673, DOI 10.1086/520985; Walsh TJ, 2008, CLIN INFECT DIS, V46, P327, DOI 10.1086/525258	5	16	17	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2008	371	9629					2056	2056		10.1016/S0140-6736(08)60877-6	http://dx.doi.org/10.1016/S0140-6736(08)60877-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312YY	18555920				2022-12-28	WOS:000256709500036
J	Lee, AH; Scapa, EF; Cohen, DE; Glimcher, LH				Lee, Ann-Hwee; Scapa, Erez F.; Cohen, David E.; Glimcher, Laurie H.			Regulation of hepatic lipogenesis by the transcription factor XBP1	SCIENCE			English	Article							UNFOLDED PROTEIN RESPONSE; STEAROYL-COA DESATURASE-1; PLASMA-CELL DIFFERENTIATION; ENDOPLASMIC-RETICULUM; MICE; EXPRESSION; GENES; CARBOHYDRATE; BIOGENESIS	Dietary carbohydrates regulate hepatic lipogenesis by controlling the expression of critical enzymes in glycolytic and lipogenic pathways. We found that the transcription factor XBP1, a key regulator of the unfolded protein response, is required for the unrelated function of normal fatty acid synthesis in the liver. XBP1 protein expression in mice was elevated after feeding carbohydrates and corresponded with the induction of critical genes involved in fatty acid synthesis. Inducible, selective deletion of XBP1 in the liver resulted in marked hypocholesterolemia and hypotriglyceridemia, secondary to a decreased production of lipids from the liver. This phenotype was not accompanied by hepatic steatosis or compromise in protein secretory function. The identification of XBP1 as a regulator of lipogenesis has important implications for human dyslipidemias.	[Lee, Ann-Hwee; Glimcher, Laurie H.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; [Scapa, Erez F.; Cohen, David E.; Glimcher, Laurie H.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Scapa, Erez F.; Cohen, David E.] Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Lee, AH (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA.	ahlee@hsph.harvard.edu; lglimche@hsph.harvard.edu	Longo, Kenneth A/A-5631-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI056296, R01AI032412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK048873, R29DK048873, R01DK056626, R01DK048873] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32412, P01 AI56296, R01 AI032412, P01 AI056296] Funding Source: Medline; NIDDK NIH HHS [R01 DK048873, DK48873, R37 DK048873, DK56626, R29 DK048873, R01 DK056626] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Elheiga L, 2003, P NATL ACAD SCI USA, V100, P10207, DOI 10.1073/pnas.1733877100; Acosta-Alvear D, 2007, MOL CELL, V27, P53, DOI 10.1016/j.molcel.2007.06.011; Basciano Heather, 2005, Nutr Metab (Lond), V2, P5, DOI 10.1186/1743-7075-2-5; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; Foufelle F, 2002, BIOCHEM J, V366, P377, DOI 10.1042/BJ20020430; Ginsberg HN, 2006, OBESITY, V14, p41S, DOI 10.1038/oby.2006.281; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hussain MM, 2003, FRONT BIOSCI, V8, pS500, DOI 10.2741/1071; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee AH, 2005, EMBO J, V24, P4368, DOI 10.1038/sj.emboj.7600903; Miyazaki M, 2004, J BIOL CHEM, V279, P25164, DOI 10.1074/jbc.M402781200; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; SCHOTZ MC, 1957, AM J PHYSIOL, V188, P399, DOI 10.1152/ajplegacy.1957.188.2.399; Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010; Sriburi R, 2004, J CELL BIOL, V167, P35, DOI 10.1083/jcb.200406136; Stone SJ, 2004, J BIOL CHEM, V279, P11767, DOI 10.1074/jbc.M311000200; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; Yu XX, 2005, HEPATOLOGY, V42, P362, DOI 10.1002/hep.20783	21	708	748	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2008	320	5882					1492	1496		10.1126/science.1158042	http://dx.doi.org/10.1126/science.1158042			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556558	Green Accepted			2022-12-28	WOS:000256676400044
J	de la Cruz, C; Huang, Q; Lynn, JW; Li, JY; Ratcliff, W; Zarestky, JL; Mook, HA; Chen, GF; Luo, JL; Wang, NL; Dai, PC				de la Cruz, Clarina; Huang, Q.; Lynn, J. W.; Li, Jiying; Ratcliff, W., II; Zarestky, J. L.; Mook, H. A.; Chen, G. F.; Luo, J. L.; Wang, N. L.; Dai, Pengcheng			Magnetic order close to superconductivity in the iron-based layered LaO(1-x)F(x)FeAs systems	NATURE			English	Article								Following the discovery of long- range antiferromagnetic order in the parent compounds of high- transition- temperature ( high- T(c)) copper oxides(1,2), there have been efforts to understand the role of magnetism in the superconductivity that occurs when mobile 'electrons' or 'holes' are doped into the antiferromagnetic parent compounds. Superconductivity in the newly discovered rare- earth iron- based oxide systems ROFeAs ( R, rare- earth metal) also arises from either electron(3-7) or hole(8) doping of their non- superconducting parent compounds. The parent material LaOFeAs is metallic but shows anomalies near 150 K in both resistivity and d. c. magnetic susceptibility(3). Although optical conductivity and theoretical calculations suggest that LaOFeAs exhibits a spin- density- wave ( SDW) instability that is suppressed by doping with electrons to induce superconductivity(9), there has been no direct evidence of SDW order. Here we report neutron- scattering experiments that demonstrate that LaOFeAs undergoes an abrupt structural distortion below 155 K, changing the symmetry from tetragonal ( space group P4/ nmm) to monoclinic ( space group P112/ n) at low temperatures, and then, at similar to 137 K, develops long- range SDW- type antiferromagnetic order with a small moment but simple magnetic structure(9). Doping the system with fluorine suppresses both the magnetic order and the structural distortion in favour of superconductivity. Therefore, like high- T(c) copper oxides, the superconducting regime in these iron- based materials occurs in close proximity to a long- range- ordered antiferromagnetic ground state.	[de la Cruz, Clarina; Dai, Pengcheng] Univ Tennessee, Dept Phys & Astron, Knoxville, TN 37996 USA; [de la Cruz, Clarina; Mook, H. A.; Dai, Pengcheng] Oak Ridge Natl Lab, Oak Ridge, TN 37831 USA; [Huang, Q.; Lynn, J. W.; Li, Jiying; Ratcliff, W., II] Natl Inst Stand & Technol, NIST Ctr Neutron Res, Gaithersburg, MD 20899 USA; [Li, Jiying] Univ Maryland, Dept Mat Sci & Engn, College Pk, MD 20742 USA; [Zarestky, J. L.] Iowa State Univ, Ames Lab, Ames, IA 50011 USA; [Zarestky, J. L.] Iowa State Univ, Dept Phys & Astron, Ames, IA 50011 USA; [Chen, G. F.; Luo, J. L.; Wang, N. L.] Chinese Acad Sci, Beijing Natl Lab Condensed Matter Phys, Inst Phys, Beijing 100080, Peoples R China	University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory; National Institute of Standards & Technology (NIST) - USA; University System of Maryland; University of Maryland College Park; Iowa State University; United States Department of Energy (DOE); Ames National Laboratory; Iowa State University; Chinese Academy of Sciences; Institute of Physics, CAS	Dai, PC (corresponding author), Univ Tennessee, Dept Phys & Astron, Knoxville, TN 37996 USA.	daip@ornl.gov	Wang, Nan/GRY-3150-2022; Lynn, Jeffrey/AAI-2588-2021; dela Cruz, Clarina R/C-2747-2013; Lynn, Jeffrey/R-4030-2019; Dai, Pengcheng/C-9171-2012	dela Cruz, Clarina R/0000-0003-4233-2145; Lynn, Jeffrey/0000-0003-3626-4932; Dai, Pengcheng/0000-0002-6088-3170; Ratcliff, William/0000-0001-8956-3851				CAO C, 2008, IN PRESS PHYS REV B; CHEN GF, 2008, SUPERCONDUCTING PROP; CHEN GF, 2008, IN PRESS PHYS REV LE; CHEN XH, 2008, NATURE          0525; DONG J, 2008, COMPETING ORDERS SPI; Han Q, 2008, EPL-EUROPHYS LETT, V82, DOI 10.1209/0295-5075/82/37007; HAULE K, 2008, IN PRESS PHYS REV LE; Kamihara Y, 2008, J AM CHEM SOC, V130, P3296, DOI 10.1021/ja800073m; MA FJ, 2008, IRON BASED LAYERED S; REN ZA, 2008, IN PRESS MAT RES INN; SI Q, 2008, STRONG CORRELATIONS; SINGH DJ, 2008, LOW CARRIER DENSITY; TRANQUADA JM, 1988, PHYS REV LETT, V60, P156, DOI 10.1103/PhysRevLett.60.156; TRANQUADA JM, 1995, NATURE, V375, P561, DOI 10.1038/375561a0; VAKNIN D, 1987, PHYS REV LETT, V58, P2802, DOI 10.1103/PhysRevLett.58.2802; Wen HH, 2008, EPL-EUROPHYS LETT, V82, DOI 10.1209/0295-5075/82/17009; XU G, 2008, IN PRESS EUROPHYS LE	17	1643	1645	17	526	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2008	453	7197					899	902		10.1038/nature07057	http://dx.doi.org/10.1038/nature07057			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311WV	18509333	Green Submitted			2022-12-28	WOS:000256632000038
J	Seton, M; Pless, M; Fishman, JA; Caruso, PA; Hedley-Whyte, ET; Steere, AC				Seton, Margaret; Pless, Misha; Fishman, Jay A.; Caruso, Paul A.; Hedley-Whyte, E. Tessa; Steere, Allen C.			A man with headache and visual changes after liver transplantation - Ruptured mycotic aneurysm of the basilar artery due to invasive aspergillosis of the ethmoid and sphenoid sinuses, resulting from infection with Aspergillus fumigatus. - Infarction of the right optic nerve and pons.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GIANT-CELL ARTERITIS; PLACEBO-CONTROLLED TRIAL; FUNGAL-INFECTIONS; POLYMYALGIA-RHEUMATICA; MEDICAL PROGRESS; RANDOMIZED-TRIAL; DOUBLE-BLIND; RECIPIENTS; VASCULITIS; METHOTREXATE		[Seton, Margaret] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Seton, Margaret] Massachusetts Gen Hosp, Rheumatol Unit, Boston, MA 02114 USA; [Pless, Misha] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Fishman, Jay A.] Massachusetts Gen Hosp, Dept Infect Dis, Boston, MA 02114 USA; [Caruso, Paul A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Hedley-Whyte, E. Tessa] Massachusetts Gen Hosp, Div Neuropathol, Dept Pathol, Boston, MA 02114 USA; [Seton, Margaret; Fishman, Jay A.] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; [Pless, Misha] Harvard Univ, Sch Med, Dept Neurol, Cambridge, MA 02138 USA; [Hedley-Whyte, E. Tessa] Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA; [Caruso, Paul A.] Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; [Caruso, Paul A.] Massachusetts Eye & Ear Infirm, Dept Radiol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University; Harvard University; Harvard University; Massachusetts Eye & Ear Infirmary	Seton, M (corresponding author), Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA.		Hedley-Whyte, E Tessa/AAJ-9975-2021	Hedley-Whyte, E Tessa/0000-0002-1687-8905				AIELLO PD, 1993, OPHTHALMOLOGY, V100, P550; Atkison PR, 1997, TRANSPLANTATION, V64, P773, DOI 10.1097/00007890-199709150-00020; Chan CCK, 2001, BRIT J OPHTHALMOL, V85, P1061, DOI 10.1136/bjo.85.9.1061; Cornblath WT, 1997, OPHTHALMOLOGY, V104, P854, DOI 10.1016/S0161-6420(97)30222-X; Danesh-Meyer H, 2005, OPHTHALMOLOGY, V112, P1098, DOI 10.1016/j.ophtha.2005.01.036; Dummer JS, 2004, J HEART LUNG TRANSPL, V23, P1376, DOI 10.1016/j.healun.2003.09.028; Fishman J A, 2002, Transpl Infect Dis, V4 Suppl 3, P3, DOI 10.1034/j.1399-3062.4.s3.1.x; Fishman JA, 2008, NEW ENGL J MED, V358, P1604, DOI 10.1056/NEJMcpc0801192; Fishman JA, 2007, NEW ENGL J MED, V357, P2601, DOI 10.1056/NEJMra064928; Genereau T, 1998, J RHEUMATOL, V25, P183; GUNJI Y, 1993, TRANSPLANT P, V25, P752; Hayreh SS, 2003, OPHTHALMOLOGY, V110, P1204, DOI 10.1016/S0161-6420(03)00228-8; Hoffman GS, 2007, ANN INTERN MED, V146, P621, DOI 10.7326/0003-4819-146-9-200705010-00004; Hoffman GS, 2002, CLEV CLIN J MED, V69, P117; Hoffman GS, 2002, ARTHRITIS RHEUM, V46, P1309, DOI 10.1002/art.10262; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1065; Husain S, 2003, CLIN INFECT DIS, V37, P221, DOI 10.1086/375822; Jover JA, 2001, ANN INTERN MED, V134, P106, DOI 10.7326/0003-4819-134-2-200101160-00010; KARCHMER AW, 1995, T AM CLIN CLIMAT ASS, V106, P38; LIU GT, 1994, OPHTHALMOLOGY, V101, P1779; Pappas PG, 2006, AM J TRANSPLANT, V6, P386, DOI 10.1111/j.1600-6143.2005.01176.x; Patel R, 1996, TRANSPLANTATION, V62, P926, DOI 10.1097/00007890-199610150-00010; Pizzolato GP, 1998, NEUROLOGY, V50, P1154, DOI 10.1212/WNL.50.4.1154; RUBIN RH, 1981, AM J MED, V70, P405, DOI 10.1016/0002-9343(81)90780-4; Salvarani C, 2002, NEW ENGL J MED, V347, P261, DOI 10.1056/NEJMra011913; Salvarani C, 2001, ARTHRIT RHEUM-ARTHR, V45, P140, DOI 10.1002/1529-0131(200104)45:2<140::AID-ANR166>3.0.CO;2-2; Salvarani C, 2007, ANN INTERN MED, V146, P631, DOI 10.7326/0003-4819-146-9-200705010-00005; Seton M, 2004, J RHEUMATOL, V31, P1467; Singh N, 2003, INFECT DIS CLIN N AM, V17, P113, DOI 10.1016/S0891-5520(02)00067-3; Singh N, 1997, TRANSPLANTATION, V64, P716, DOI 10.1097/00007890-199709150-00009; Tsamandas AC, 1997, TRANSPLANTATION, V64, P252, DOI 10.1097/00007890-199707270-00013; Weyand CM, 2003, ANN INTERN MED, V139, P505, DOI 10.7326/0003-4819-139-6-200309160-00015	32	16	17	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2008	358	24					2619	2628		10.1056/NEJMcpc0802849	http://dx.doi.org/10.1056/NEJMcpc0802849			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311IJ	18550878				2022-12-28	WOS:000256593600011
J	Stipanovich, A; Valjent, E; Matamales, M; Nishi, A; Ahn, JH; Maroteaux, M; Bertran-Gonzalez, J; Brami-Cherrier, K; Enslen, H; Corbille, AG; Filhol, O; Nairn, AC; Greengard, P; Herve, D; Girault, JA				Stipanovich, Alexandre; Valjent, Emmanuel; Matamales, Miriam; Nishi, Akinori; Ahn, Jung-Hyuck; Maroteaux, Matthieu; Bertran-Gonzalez, Jesus; Brami-Cherrier, Karen; Enslen, Herve; Corbille, Anne-Gaelle; Filhol, Odile; Nairn, Angus C.; Greengard, Paul; Herve, Denis; Girault, Jean-Antoine			A phosphatase cascade by which rewarding stimuli control nucleosomal response	NATURE			English	Article							HISTONE H3 PHOSPHORYLATION; INNERVATED BRAIN-REGIONS; NUCLEAR EXPORT; DOPAMINERGIC NEUROTRANSMISSION; REGULATED PHOSPHOPROTEIN; PROTEIN PHOSPHATASE-1; GENE-EXPRESSION; DRUG-ADDICTION; KINASE; DARPP-32	Dopamine orchestrates motor behaviour and reward- driven learning. Perturbations of dopamine signalling have been implicated in several neurological and psychiatric disorders, and in drug addiction. The actions of dopamine are mediated in part by the regulation of gene expression in the striatum, through mechanisms that are not fully understood. Here we show that drugs of abuse, as well as food reinforcement learning, promote the nuclear accumulation of 32- kDa dopamine- regulated and cyclic- AMP- regulated phosphoprotein ( DARPP- 32). This accumulation is mediated through a signalling cascade involving dopamine D1 receptors, cAMP- dependent activation of protein phosphatase- 2A, dephosphorylation of DARPP- 32 at Ser 97 and inhibition of its nuclear export. The nuclear accumulation of DARPP- 32, a potent inhibitor of protein phosphatase- 1, increases the phosphorylation of histone H3, an important component of nucleosomal response. Mutation of Ser 97 profoundly alters behavioural effects of drugs of abuse and decreases motivation for food, underlining the functional importance of this signalling cascade.	[Stipanovich, Alexandre; Valjent, Emmanuel; Matamales, Miriam; Maroteaux, Matthieu; Bertran-Gonzalez, Jesus; Brami-Cherrier, Karen; Enslen, Herve; Corbille, Anne-Gaelle; Herve, Denis; Girault, Jean-Antoine] INSERM, UMR S 839, F-75005 Paris, France; [Stipanovich, Alexandre; Valjent, Emmanuel; Matamales, Miriam; Maroteaux, Matthieu; Bertran-Gonzalez, Jesus; Brami-Cherrier, Karen; Enslen, Herve; Corbille, Anne-Gaelle; Herve, Denis; Girault, Jean-Antoine] Univ Paris 06, F-75005 Paris, France; [Stipanovich, Alexandre; Valjent, Emmanuel; Matamales, Miriam; Maroteaux, Matthieu; Bertran-Gonzalez, Jesus; Brami-Cherrier, Karen; Enslen, Herve; Corbille, Anne-Gaelle; Herve, Denis; Girault, Jean-Antoine] Inst Fer Moulin, F-75005 Paris, France; [Nishi, Akinori] Kurume Univ, Sch Med, Dept Pharmacol, Fukuoka 8300011, Japan; [Nishi, Akinori; Ahn, Jung-Hyuck; Nairn, Angus C.; Greengard, Paul] Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; [Filhol, Odile] CEA, INSERM, U873, F-38054 Grenoble, France; [Nairn, Angus C.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06508 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Kurume University; Rockefeller University; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Yale University	Girault, JA (corresponding author), INSERM, UMR S 839, F-75005 Paris, France.	girault@fer-a-moulin.inserm.fr	Girault, Jean-Antoine/F-7518-2013; Filhol-Cochet, Odile/I-3962-2016; Bertran-Gonzalez, J/L-1410-2017; Enslen, Hervé/M-3400-2017; Enslen, Hervé/AAH-4492-2021; HERVE, Denis/E-2929-2017; Matamales, Miriam/J-5189-2014; brami-cherrier, karen/I-9263-2014	Girault, Jean-Antoine/0000-0002-7900-1705; Bertran-Gonzalez, J/0000-0002-3794-1782; Enslen, Hervé/0000-0001-9741-5293; Enslen, Hervé/0000-0001-9741-5293; HERVE, Denis/0000-0003-1376-1522; Matamales, Miriam/0000-0001-9978-0091; brami-cherrier, karen/0000-0002-3009-3821; Ahn, Jung-Hyuck/0000-0001-9589-3881; Nairn, Angus/0000-0002-7075-0195; Valjent, Emmanuel/0000-0002-1034-606X; Filhol, Odile/0000-0003-1964-7958; Greengard, Paul/0000-0002-4437-0893	NIDA NIH HHS [P01 DA010044-11, P01 DA010044-090002, P01 DA010044-14S1, P01 DA010044-050002, P01 DA010044-14, P01 DA010044-120005, P01 DA010044-030002, P01 DA010044-110005, P01 DA010044-080002, P01 DA010044-04, P01 DA010044-13, P01 DA010044, P01 DA010044-10, P01 DA010044-140005, P01 DA010044-060002, P01 DA010044-130005, P01 DA010044-139002, P01 DA010044-05, DA10044, P01 DA010044-08, P01 DA010044-129002, P01 DA010044-09, P01 DA010044-100002, P01 DA010044-020002, P01 DA010044-07, P01 DA010044-040002, P01 DA010044-070002, P01 DA010044-06, P01 DA010044-12, P01 DA010044-149002] Funding Source: Medline; NIMH NIH HHS [P50 MH074866-040001, P50 MH074866-010001, P50 MH074866, P50 MH074866-050001, P50 MH074866-020001, P50 MH074866-029001, P50 MH074866-049001, P50 MH074866-030001, P50 MH074866-019001, MH74866, P50 MH074866-039001, P50 MH074866-059001] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH074866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA010044] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ahn JH, 2007, P NATL ACAD SCI USA, V104, P2979, DOI 10.1073/pnas.0611532104; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Beaulieu JM, 2005, CELL, V122, P261, DOI 10.1016/j.cell.2005.05.012; Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; BODE AM, 2005, SCI STKE, V281, P1; Brami-Cherrier K, 2005, J NEUROSCI, V25, P11444, DOI 10.1523/JNEUROSCI.1711-05.2005; Di Chiara G, 1999, EUR J PHARMACOL, V375, P13, DOI 10.1016/S0014-2999(99)00372-6; DRAGO J, 1994, P NATL ACAD SCI USA, V91, P12564, DOI 10.1073/pnas.91.26.12564; Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; Gong SC, 2003, NATURE, V425, P917, DOI 10.1038/nature02033; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009; Kumar A, 2005, NEURON, V48, P303, DOI 10.1016/j.neuron.2005.09.023; Levenson JM, 2006, CELL MOL LIFE SCI, V63, P1009, DOI 10.1007/s00018-006-6026-6; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Nicola SM, 2000, ANNU REV NEUROSCI, V23, P185, DOI 10.1146/annurev.neuro.23.1.185; Nishi A, 2000, P NATL ACAD SCI USA, V97, P12840, DOI 10.1073/pnas.220410397; Nishi A, 1999, J NEUROCHEM, V72, P2015, DOI 10.1046/j.1471-4159.1999.0722015.x; NISHI K, 1994, J BIOL CHEM, V269, P6320; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; OUIMET CC, 1984, J NEUROSCI, V4, P111; OUIMET CC, 1990, J NEUROCYTOL, V19, P39, DOI 10.1007/BF01188438; Panasyuk G, 2006, J BIOL CHEM, V281, P31188, DOI 10.1074/jbc.M602618200; Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304; Poon IKH, 2005, TRAFFIC, V6, P173, DOI 10.1111/j.1600-0854.2005.00268.x; Rastogi S, 2006, J BIOL CHEM, V281, P2951, DOI 10.1074/jbc.M508669200; Reynolds JNJ, 2002, NEURAL NETWORKS, V15, P507, DOI 10.1016/S0893-6080(02)00045-X; Salvador LM, 2001, J BIOL CHEM, V276, P40146, DOI 10.1074/jbc.M106710200; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; Schultz W, 2000, ANNU REV NEUROSCI, V23, P473, DOI 10.1146/annurev.neuro.23.1.473; Stedman DR, 2004, FEBS LETT, V566, P275, DOI 10.1016/j.febslet.2004.04.042; Svenningsson P, 2004, ANNU REV PHARMACOL, V44, P269, DOI 10.1146/annurev.pharmtox.44.101802.121415; Svenningsson P, 2003, SCIENCE, V302, P1412, DOI 10.1126/science.1089681; Usui H, 1998, FEBS LETT, V430, P312, DOI 10.1016/S0014-5793(98)00684-X; Valjent E, 2000, J NEUROSCI, V20, P8701; Valjent E, 2005, P NATL ACAD SCI USA, V102, P491, DOI 10.1073/pnas.0408305102; Vanderschuren LJMJ, 1999, J NEUROSCI, V19, P9579, DOI 10.1523/jneurosci.19-21-09579.1999; WALAAS SI, 1983, NATURE, V301, P69; Zhang Y, 2006, J NEUROSCI, V26, P2645, DOI 10.1523/JNEUROSCI.3923-05.2006	44	172	177	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2008	453	7197					879	U23		10.1038/nature06994	http://dx.doi.org/10.1038/nature06994			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311WV	18496528	Green Accepted, Green Published			2022-12-28	WOS:000256632000034
J	Delamothe, T				Delamothe, Tony			Universality, equity, and quality of care	BRITISH MEDICAL JOURNAL			English	Editorial Material							HEART-DISEASE; SEX		BMJ, London WC1H 9JR, England		Delamothe, T (corresponding author), BMJ, London WC1H 9JR, England.	tdelamothe@bmj.com						[Anonymous], 1982, STRATEGY EQUALITY RE; *DEP HLTH, 2008, FAIL AS SEEK ORD RES; *DEP HLTH, 2003, TACKL IN PROGR ACT; *DEP HLTH, 2008, TACKL HLTH IN 2007 S; *DEP HLTH, 2007, OUR NHS OUR FUT NHS; *DEP HLTH SCOTL, 1944, CMN6502; DIXON A, 2003, 1 LOND SCH EC; Doyal L, 2001, BRIT MED J, V323, P1061, DOI 10.1136/bmj.323.7320.1061; EATON L, 2002, BRIT MED J, V324, P564; GILL PS, BLACK MINORITY ETHNI; GUBB J, 2008, CIVITAS REV, V5, P1; Hippisley-Cox J, 2001, BMJ-BRIT MED J, V322, P832, DOI 10.1136/bmj.322.7290.832; HITCHEN L, 2008, BRIT MED J, V336, P1039; Klein R., 2006, NEW POLITICS NHS CRE, V5st edition; Kmietowicz Z, 2001, BRIT MED J, V322, P751, DOI 10.1136/bmj.322.7289.751; Lawson N., 2008, MACHINES MARKETS MOR; LEATHERMAN S, 2003, QUEST QUALITY MIDTER; Leatherman S, 2008, QUEST QUALITY REFINI; *PARL OFF SCI TECH, 2007, POSTNOTE, V276, P1; Pell JP, 2000, BRIT MED J, V320, P15, DOI 10.1136/bmj.320.7226.15; SEIKHRI N, 2008, BRIT MED J, V336, P1058; Young J, 2006, BMJ-BRIT MED J, V333, P508, DOI 10.1136/bmj.38961.641400.BE	22	17	17	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 7	2008	336	7656					1278	1281		10.1136/bmj.a169	http://dx.doi.org/10.1136/bmj.a169			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312XO	18535070	Green Published			2022-12-28	WOS:000256705900029
J	Mackenbach, JP; Stirbu, I; Roskam, AJR; Schaap, MM; Menvielle, G; Leinsalu, M; Kunst, AE				Mackenbach, Johan P.; Stirbu, Irina; Roskam, Albert-Jan R.; Schaap, Maartje M.; Menvielle, Gwenn; Leinsalu, Mall; Kunst, Anton E.		European Union Working Grp Socioec	Socioeconomic inequalities in health in 22 European countries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OCCUPATIONAL CLASS; EASTERN-EUROPE; SOCIAL-CLASS; EDUCATIONAL INEQUALITIES; CARDIOVASCULAR-DISEASE; MEDICAL INTERVENTION; LIFE EXPECTANCY; RISK-FACTORS; MORTALITY; MEN	Background: Comparisons among countries can help to identify opportunities for the reduction of inequalities in health. We compared the magnitude of inequalities in mortality and self-assessed health among 22 countries in all parts of Europe. Methods: We obtained data on mortality according to education level and occupational class from census-based mortality studies. Deaths were classified according to cause, including common causes, such as cardiovascular disease and cancer; causes related to smoking; causes related to alcohol use; and causes amenable to medical intervention, such as tuberculosis and hypertension. Data on self-assessed health, smoking, and obesity according to education and income were obtained from health or multipurpose surveys. For each country, the association between socioeconomic status and health outcomes was measured with the use of regression-based inequality indexes. Results: In almost all countries, the rates of death and poorer self-assessments of health were substantially higher in groups of lower socioeconomic status, but the magnitude of the inequalities between groups of higher and lower socioeconomic status was much larger in some countries than in others. Inequalities in mortality were small in some southern European countries and very large in most countries in the eastern and Baltic regions. These variations among countries appeared to be attributable in part to causes of death related to smoking or alcohol use or amenable to medical intervention. The magnitude of inequalities in self-assessed health also varied substantially among countries, but in a different pattern. Conclusions: We observed variation across Europe in the magnitude of inequalities in health associated with socioeconomic status. These inequalities might be reduced by improving educational opportunities, income distribution, health-related behavior, or access to health care.	[Mackenbach, Johan P.; Stirbu, Irina; Roskam, Albert-Jan R.; Schaap, Maartje M.; Menvielle, Gwenn; Kunst, Anton E.] Erasmus Univ, Med Ctr, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands; [Menvielle, Gwenn] INSERM, Unite 687, St Maurice, France; [Leinsalu, Mall] Sodertorn Univ Coll, Stockholm Ctr Hlth Soc Transit, Sodertorn, Sweden; [Leinsalu, Mall] Natl Inst Hlth Dev, Dept Epidemiol & Biostat, Tallinn, Estonia	Erasmus University Rotterdam; Erasmus MC; Institut National de la Sante et de la Recherche Medicale (Inserm); Sodertorn University; National Institute for Health Development - Estonia	Mackenbach, JP (corresponding author), Erasmus Univ, Med Ctr, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands.	j.mackenbach@erasmusmc.nl	Chang, Shulan/H-2270-2011; Geckova, Andrea Madarasova/AAF-2993-2019; Dzurova, Dagmar/D-4412-2009; Rychtarikova, Jitka/R-1828-2017; Rodrigues, Ana Paula Santana/V-9161-2017; Leinsalu, Mall/I-3768-2018	Geckova, Andrea Madarasova/0000-0003-2993-3798; Dzurova, Dagmar/0000-0003-0530-4997; Rychtarikova, Jitka/0000-0002-6417-1920; Strand, Bjorn Heine/0000-0003-4385-8886; COSTA, Giuseppe/0000-0003-3187-4889; Rodrigues, Ana Paula Santana/0000-0002-7658-8475; Burstrom, Bo/0000-0001-5770-9422; Kunst, Anton/0000-0002-3313-5273; Glickman, Myer/0000-0001-6067-3811; Fritzell, Johan/0000-0003-0496-3085; Regidor, Enrique/0000-0002-2374-9861; Martikainen, Pekka/0000-0001-9374-1438; Demarest, Stefaan/0000-0003-2823-1372; Van Oyen, Herman/0000-0003-2119-4433; Bopp, Matthias/0000-0003-0766-3723; Leinsalu, Mall/0000-0003-4453-4760; Wojtyniak, Bogdan/0000-0002-2135-8226				[Anonymous], 3 WORLDS WELFARE CAP; Bobak M, 1996, BRIT MED J, V312, P421; BOS V, 2002, TIJDSCHRIFT GEZONDHE, V80, P158; Britton A, 2000, J EPIDEMIOL COMMUN H, V54, P328, DOI 10.1136/jech.54.5.328; Cavelaars AEJM, 1998, INT J EPIDEMIOL, V27, P222, DOI 10.1093/ije/27.2.222; Cavelaars AEJM, 1998, J EPIDEMIOL COMMUN H, V52, P219, DOI 10.1136/jech.52.4.219; CHARLTON JRH, 1983, LANCET, V1, P691; DAHL E, 2006, HLTH INEQUALITIES EU, P193; Ezzati M, 2005, LANCET, V365, P28; Ezzati M, 2003, LANCET, V362, P271, DOI 10.1016/S0140-6736(03)13968-2; Ferrera M., 1996, J EUR SOC POLICY, V6, P17, DOI [10.1177/095892879600600102, DOI 10.1177/09582879600600102]; Fritzell J., 2001, NORDIC WELFARE STATE, P18; Huisman M, 2005, TOB CONTROL, V14, P106, DOI 10.1136/tc.2004.008573; Knoops KTB, 2004, JAMA-J AM MED ASSOC, V292, P1433, DOI 10.1001/jama.292.12.1433; KUBIK AK, 1995, CANCER, V75, P2452, DOI 10.1002/1097-0142(19950515)75:10<2452::AID-CNCR2820751010>3.0.CO;2-E; Kunst AE, 1998, BMJ-BRIT MED J, V316, P1636, DOI 10.1136/bmj.316.7145.1636; Kunst AE, 1998, SOC SCI MED, V46, P1459, DOI 10.1016/S0277-9536(98)00041-0; Kunst AE, 2001, GUIDELINES MONITORIN; KUNST AE, 1997, THESIS ERASMUS U ROT; KUNST AE, 2007, COMP ED INEQUALITIES; Leinsalu M, 2003, INT J EPIDEMIOL, V32, P1081, DOI 10.1093/ije/dyg192; Leon DA, 1997, LANCET, V350, P383, DOI 10.1016/S0140-6736(97)03360-6; Lopez AD, 1994, TOB CONTROL, V3, P242, DOI [DOI 10.1136/TC.3.3.242, 10.1136/tc.3.3.242]; Mackenbach JP, 2003, LANCET, V362, P1409, DOI 10.1016/S0140-6736(03)14639-9; Mackenbach JP, 1997, LANCET, V349, P1655, DOI 10.1016/S0140-6736(96)07226-1; Mackenbach JP, 2000, EUR HEART J, V21, P1141, DOI 10.1053/euhj.1999.1990; Mackenbach JP, 1997, SOC SCI MED, V44, P757, DOI 10.1016/S0277-9536(96)00073-1; Marmot M, 2005, LANCET, V365, P1099, DOI 10.1016/S0140-6736(05)74234-3; McKee M, 2001, BRIT MED J, V323, P1051, DOI 10.1136/bmj.323.7320.1051; Murphy M, 2006, AM J PUBLIC HEALTH, V96, P1293, DOI 10.2105/AJPH.2004.056929; Nolte E, 2004, BRIT MED J, V328, P494; NOLTE E, 2004, WORLD HOSP HLTH SERV, V40, P40; NOLTE E, 2004, WORLD HOSP HLTH SERV, V40, P42; Nolte Ellen, 2004, World Hosp Health Serv, V40, P12; PAMUK ER, 1985, POP STUD-J DEMOG, V39, P17, DOI 10.1080/0032472031000141256; PEKKANEN J, 1995, BRIT MED J, V311, P589, DOI 10.1136/bmj.311.7005.589; Powles JW, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-116; Pudule I, 1999, J EPIDEMIOL COMMUN H, V53, P277, DOI 10.1136/jech.53.5.277; Shkolnikov VM, 2007, SOC SCI MED, V64, P1392, DOI 10.1016/j.socscimed.2006.11.014; Shkolnikov VM, 2006, J EPIDEMIOL COMMUN H, V60, P875, DOI 10.1136/jech.2005.044719; Smith GD, 1994, EUROPEAN J PUBLIC HL, V4, P131, DOI DOI 10.1093/EURPUB/4.2.131; van Oort FVA, 2005, J EPIDEMIOL COMMUN H, V59, P214, DOI 10.1136/jech.2003.016493; Velkova A, 1997, INT J EPIDEMIOL, V26, P75, DOI 10.1093/ije/26.1.75	43	1987	2022	8	378	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2008	358	23					2468	2481		10.1056/NEJMsa0707519	http://dx.doi.org/10.1056/NEJMsa0707519			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	308HY	18525043				2022-12-28	WOS:000256380700006
J	Heath, I				Heath, Iona			Let's not widen the gulf in children's health care	BRITISH MEDICAL JOURNAL			English	Editorial Material												iona.heath@dsl.pipex.com							0	1	1	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 31	2008	336	7655					1215	1215		10.1136/bmj.a170	http://dx.doi.org/10.1136/bmj.a170			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311PS	18511795	Green Published			2022-12-28	WOS:000256612700025
J	Kassiotis, G; O'Garra, A				Kassiotis, George; O'Garra, Anne			Immunology - Immunity benefits from a little suppression	SCIENCE			English	Editorial Material							REGULATORY T-CELLS; FOXP3; ENTEROPATHY; MECHANISM; SCURFIN; MOUSE; SELF		[Kassiotis, George; O'Garra, Anne] Natl Inst Med Res, MRC, Div Immunoregulat, Ridgeway, London NW7 1AA, England		Kassiotis, G (corresponding author), Natl Inst Med Res, MRC, Div Immunoregulat, Ridgeway, London NW7 1AA, England.	gkassio@nimr.mrc.ac.uk; aogarra@nimr.mrc.ac.uk		Kassiotis, George/0000-0002-8457-2633; O'Garra, Anne/0000-0001-9845-6134	MRC [MC_U117565642, MC_U117581330] Funding Source: UKRI; Medical Research Council [MC_U117565642, MC_U117581330] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Almeida ARM, 2006, J IMMUNOL, V177, P192, DOI 10.4049/jimmunol.177.1.192; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Haribhai D, 2007, J IMMUNOL, V178, P2961, DOI 10.4049/jimmunol.178.5.2961; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hsieh CS, 2004, IMMUNITY, V21, P267, DOI 10.1016/j.immuni.2004.07.009; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; Lund JM, 2008, SCIENCE, V320, P1220, DOI 10.1126/science.1155209; Pacholczyk R, 2006, IMMUNITY, V25, P249, DOI 10.1016/j.immuni.2006.05.016; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707	13	10	11	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	2008	320	5880					1168	1169		10.1126/science.1159090	http://dx.doi.org/10.1126/science.1159090			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306FF	18511677				2022-12-28	WOS:000256233000023
J	Green, JL; Bohannan, BJM; Whitaker, RJ				Green, Jessica L.; Bohannan, Brendan J. M.; Whitaker, Rachel J.			Microbial biogeography: From taxonomy to traits	SCIENCE			English	Review							SOIL BACTERIA; COMMUNITY ECOLOGY; FUNCTIONAL TRAITS; COPY NUMBER; BIODIVERSITY; ORGANISMS; SPECTRA; GROWTH; SIZE	The biogeographic variation of life has predominantly been studied using taxonomy, but this focus is changing. There is a resurging interest in understanding patterns in the distribution not only of taxa but also of the traits those taxa possess. Patterns of trait variation shed light on fundamental questions in biology, including why organisms live where they do and how they will respond to environmental change. Technological advances such as environmental genomics place microbial ecology in a unique position to move trait- based biogeography forward. We anticipate that as trait- based biogeography continues to evolve, micro- and macroorganisms will be studied in concert, establishing a science that is informed by and relevant to all domains of life.	[Green, Jessica L.; Bohannan, Brendan J. M.] Univ Oregon, Dept Biol, Ctr Ecol & Evolut Biol, Eugene, OR 97403 USA; [Whitaker, Rachel J.] Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	University of Oregon; University of Illinois System; University of Illinois Urbana-Champaign	Green, JL (corresponding author), Univ Oregon, Dept Biol, Ctr Ecol & Evolut Biol, Eugene, OR 97403 USA.	jlgreen@uoregon.edu	Bohannan, Brendan J. M./R-1582-2017; Green, Jessica/C-4828-2009	Bohannan, Brendan J. M./0000-0003-2907-1016; 	Division Of Environmental Biology [0816885] Funding Source: National Science Foundation	Division Of Environmental Biology(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))		Baas-Becking L.G.M., 1934, GEOBIOLOGIE INLEIDIN, P263; Beja O, 2000, SCIENCE, V289, P1902, DOI 10.1126/science.289.5486.1902; Binnerup SJ, 2001, FEMS MICROBIOL ECOL, V37, P231, DOI 10.1111/j.1574-6941.2001.tb00870.x; DeLong EF, 2006, SCIENCE, V311, P496, DOI 10.1126/science.1120250; Dethlefsen L, 2006, TRENDS ECOL EVOL, V21, P517, DOI 10.1016/j.tree.2006.06.013; Enquist BJ, 2007, NATURE, V449, P218, DOI 10.1038/nature06061; Fierer N, 2007, ECOLOGY, V88, P1354, DOI 10.1890/05-1839; Giraud A, 2001, SCIENCE, V291, P2606, DOI 10.1126/science.1056421; Horner-Devine MC, 2006, ECOLOGY, V87, pS100, DOI 10.1890/0012-9658(2006)87[100:PCAOIB]2.0.CO;2; Hubbell SP, 2005, FUNCT ECOL, V19, P166, DOI 10.1111/j.0269-8463.2005.00965.x; Johnson ZI, 2006, SCIENCE, V311, P1737, DOI 10.1126/science.1118052; Konstantinidis KT, 2004, P NATL ACAD SCI USA, V101, P3160, DOI 10.1073/pnas.0308653100; Linnaeus C., 1781, AMOENITATES ACAD, V2, P17; Lomolino M. V., 2006, BIOGEOGRAPHY; Martiny JBH, 2006, NAT REV MICROBIOL, V4, P102, DOI 10.1038/nrmicro1341; McGill BJ, 2006, TRENDS ECOL EVOL, V21, P178, DOI 10.1016/j.tree.2006.02.002; Ram RJ, 2005, SCIENCE, V308, P1915, DOI 10.1126/science. 1109070; Rinaldo A, 2002, P ROY SOC B-BIOL SCI, V269, P2051, DOI 10.1098/rspb.2002.2102; Rossello-Mora R, 2008, ISME J, V2, P242, DOI 10.1038/ismej.2007.93; Sabehi G, 2007, ISME J, V1, P48, DOI 10.1038/ismej.2007.10; Savage VM, 2007, J THEOR BIOL, V247, P213, DOI 10.1016/j.jtbi.2007.03.007; Schimper AFW., 1903, PLANT GEOGRAPHY PHYS; Shipley B, 2006, SCIENCE, V314, P812, DOI 10.1126/science.1131344; Shrestha PM, 2007, ENVIRON MICROBIOL, V9, P2464, DOI 10.1111/j.1462-2920.2007.01364.x; Singer RS, 2006, NAT REV MICROBIOL, V4, P943, DOI 10.1038/nrmicro1553; Stevenson BS, 2004, APPL ENVIRON MICROB, V70, P6670, DOI 10.1128/AEM.70.11.6670-6677.2004; Swenson NG, 2007, AM J BOT, V94, P451, DOI 10.3732/ajb.94.3.451; Weider LJ, 2005, ANNU REV ECOL EVOL S, V36, P219, DOI 10.1146/annurev.ecolsys.36.102003.152620; Westoby M, 2006, TRENDS ECOL EVOL, V21, P261, DOI 10.1016/j.tree.2006.02.004; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Wright IJ, 2004, NATURE, V428, P821, DOI 10.1038/nature02403	31	406	419	8	374	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2008	320	5879					1039	1043		10.1126/science.1153475	http://dx.doi.org/10.1126/science.1153475			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18497288				2022-12-28	WOS:000256059800034
J	Morrow, R				Morrow, Robert			Engineering - Wi-Fi-Fo-Fum	SCIENCE			English	Editorial Material									[Morrow, Robert] Morrow Tech Serv, Centerville, IN 47330 USA		Morrow, R (corresponding author), Morrow Tech Serv, 6976 Kempton Rd, Centerville, IN 47330 USA.	rkmorrow@ieee.org						ANDREWS J, 2007, FUNDAMENTALS WIMAX; LAROCCA J, 2002, 802 11 DEMYSTIFIED; LINKS C, 1994, BYTE             MAY, P99; Rappaport T. S., 1996, WIRELESS COMMUNICATI	4	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2008	320	5879					1018	1019		10.1126/science.1153827	http://dx.doi.org/10.1126/science.1153827			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18497280				2022-12-28	WOS:000256059800024
J	Vento, S; Nobili, V				Vento, Sandro; Nobili, Valerio			Aminotransferases as predictors of mortality	LANCET			English	Editorial Material							FATTY LIVER-DISEASE; RISK		[Vento, Sandro] Annunziata Hosp, Infect Dis Unit, I-87100 Cosenza, Italy; [Nobili, Valerio] Bambino Gesu Pediat Hosp, Liver Unit, Rome, Italy	IRCCS Bambino Gesu	Vento, S (corresponding author), Annunziata Hosp, Infect Dis Unit, I-87100 Cosenza, Italy.	ventosandro@yahoo.it	Nobili, Valerio/K-8670-2018; Vento, Sandro/I-1662-2017	Vento, Sandro/0000-0003-0084-4062; nobili, valerio/0000-0002-4570-3979				Adams LA, 2007, ANN EPIDEMIOL, V17, P863, DOI 10.1016/j.annepidem.2007.05.013; Arndt V, 1998, INT ARCH OCC ENV HEA, V71, P405, DOI 10.1007/s004200050299; DE RITIS F, 1955, Boll Soc Ital Biol Sper, V31, P394; Elinav E, 2006, J AM GERIATR SOC, V54, P1719, DOI 10.1111/j.1532-5415.2006.00921.x; FRIEDMAN LS, 1987, ANN INTERN MED, V107, P137, DOI 10.7326/0003-4819-107-2-137; Kagansky N, 2004, LIVER INT, V24, P588, DOI 10.1111/j.1478-3231.2004.0969.x; Kim HC, 2005, STROKE, V36, P1642, DOI 10.1161/01.STR.0000173404.37692.9b; Kim HC, 2004, BMJ-BRIT MED J, V328, P983, DOI 10.1136/bmj.38050.593634.63; Lee TH, 2008, HEPATOLOGY, V47, P880, DOI 10.1002/hep.22090; Targher G, 2007, ATHEROSCLEROSIS, V191, P235, DOI 10.1016/j.atherosclerosis.2006.08.021	10	11	11	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY-JUN	2008	371	9627					1822	1823		10.1016/S0140-6736(08)60778-3	http://dx.doi.org/10.1016/S0140-6736(08)60778-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307NL	18514716				2022-12-28	WOS:000256325500009
J	Jouvenet, N; Bieniasz, PD; Simon, SM				Jouvenet, Nolwenn; Bieniasz, Paul D.; Simon, Sanford M.			Imaging the biogenesis of individual HIV-1 virions in live cells	NATURE			English	Article							PLASMA-MEMBRANE; FLUORESCENT PROTEINS; LIVING CELLS; VIRUS; MICROSCOPY; RELEASE; VISUALIZATION; REPLICATION; MACROPHAGES; CLATHRIN	Observations of individual virions in live cells have led to the characterization of their attachment, entry and intracellular transport(1). However, the assembly of individual virions has never been observed in real time. Insights into this process have come primarily from biochemical analyses of populations of virions or from microscopic studies of fixed infected cells. Thus, some assembly properties, such as kinetics and location, are either unknown or controversial(2-5). Here we describe quantitatively the genesis of individual virions in real time, from initiation of assembly to budding and release. We studied fluorescently tagged derivatives of Gag, the major structural component of HIV-1-which is sufficient to drive the assembly of virus- like particles(6) - with the use of fluorescence resonance energy transfer, fluorescence recovery after photobleaching and total- internal- reflection fluorescent microscopy in living cells. Virions appeared individually at the plasma membrane, their assembly rate accelerated as Gag protein accumulated in cells, and typically 5 - 6 min was required to complete the assembly of a single virion. These approaches allow a previously unobserved view of the genesis of individual virions and the determination of parameters of viral assembly that are inaccessible with conventional techniques.	[Jouvenet, Nolwenn; Bieniasz, Paul D.] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10065 USA; [Jouvenet, Nolwenn; Bieniasz, Paul D.] Rockefeller Univ, Lab Retrovirol, New York, NY 10065 USA; [Simon, Sanford M.] Rockefeller Univ, Lab Cellular Biophys, New York, NY 10065 USA	Rockefeller University; Rockefeller University; Rockefeller University	Bieniasz, PD (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10065 USA.	pbienias@adarc.org; simon@rockefeller.edu	jouvenet, nolwenn/K-2067-2019	jouvenet, nolwenn/0000-0001-6103-6048; Simon, Sanford/0000-0002-8615-4224	NIAID NIH HHS [R01 AI089844] Funding Source: Medline; NIGMS NIH HHS [P20 GM072015-04, R01 GM087977, P20 GM072015-01, P20 GM072015, P20 GM072015-02S1, P20 GM072015-02, P20 GM072015-04S1, P20 GM072015-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI089844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM072015, R01GM087977] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bieniasz PD, 2006, VIROLOGY, V344, P55, DOI 10.1016/j.virol.2005.09.044; Brandenburg B, 2007, NAT REV MICROBIOL, V5, P197, DOI 10.1038/nrmicro1615; Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785; Derdowski A, 2004, J VIROL, V78, P1230, DOI 10.1128/JVI.78.3.1230-1242.2004; Finzi A, 2007, J VIROL, V81, P7476, DOI 10.1128/JVI.00308-07; Gottlinger HG, 2001, AIDS, V15, pS13; Hubner W, 2007, J VIROL, V81, P12596, DOI 10.1128/JVI.01088-07; Jaiswal JK, 2002, J CELL BIOL, V159, P625, DOI 10.1083/jcb.200208154; Jaiswal JK, 2007, NAT CHEM BIOL, V3, P92, DOI 10.1038/nchembio855; Jouvenet N, 2006, PLOS BIOL, V4, P2296, DOI 10.1371/journal.pbio.0040435; Keyel PA, 2004, J BIOL CHEM, V279, P13190, DOI 10.1074/jbc.M312717200; Larson DR, 2005, P NATL ACAD SCI USA, V102, P15453, DOI 10.1073/pnas.0504812102; Larson DR, 2003, J CELL BIOL, V162, P1233, DOI 10.1083/jcb.200303200; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Neil SJD, 2008, NATURE, V451, P425, DOI 10.1038/nature06553; Neil SJD, 2007, CELL HOST MICROBE, V2, P193, DOI 10.1016/j.chom.2007.08.001; Neil Stuart J. D., 2006, PLoS Pathogens, V2, DOI 10.1371/jounral.ppat.0020039; Pedelacq JD, 2006, NAT BIOTECHNOL, V24, P79, DOI 10.1038/nbt1172; Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008; Perez-Caballero D, 2004, J VIROL, V78, P9560, DOI 10.1128/JVI.78.17.9560-9563.2004; Pornillos O, 2002, TRENDS CELL BIOL, V12, P569, DOI 10.1016/S0962-8924(02)02402-9; Rappoport JZ, 2003, TRAFFIC, V4, P460, DOI 10.1034/j.1600-0854.2003.00100.x; Shaner NC, 2005, NAT METHODS, V2, P905, DOI 10.1038/NMETH819; Sherer NM, 2003, TRAFFIC, V4, P785, DOI 10.1034/j.1600-0854.2003.00135.x; SIMON S, 1994, P NATL ACAD SCI USA, V91, P1128, DOI 10.1073/pnas.91.3.1128; Tramier M, 2006, MICROSC RES TECHNIQ, V69, P933, DOI 10.1002/jemt.20370; Welsch S, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030036	27	247	250	2	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 10	2008	454	7201					236	240		10.1038/nature06998	http://dx.doi.org/10.1038/nature06998			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	323RU	18500329	Green Accepted			2022-12-28	WOS:000257466900048
J	Schieppati, A; Henter, JI; Daina, E; Aperia, A				Schieppati, Arrigo; Henter, Jan-Inge; Daina, Erica; Aperia, Anita			Why rare diseases are an important medical and social issue	LANCET			English	Article							ORPHAN DRUGS		[Schieppati, Arrigo; Daina, Erica] Ist Ric Farmacol Mario Negri, Clin Res Ctr Rare Dis Aldo & Cele Dacco, I-24020 Bergamo, Italy; [Henter, Jan-Inge; Aperia, Anita] Astrid Lindgren Childrens Hosp, Dept Women & Child Hlth, Karolinska Inst, Stockholm, Sweden	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Karolinska Institutet	Schieppati, A (corresponding author), Ist Ric Farmacol Mario Negri, Clin Res Ctr Rare Dis Aldo & Cele Dacco, Via GB Camozzi 3, I-24020 Bergamo, Italy.	raredis@marionegri.it	Daina, Erica/AAA-6433-2020; Daina, Erica/ABA-3117-2020	Daina, Erica/0000-0002-2419-5493; Henter, Jan-Inge/0000-0002-0629-2126				Dionisi-Vici C, 2002, J PEDIATR-US, V140, P321, DOI 10.1067/mpd.2002.122394; Eurordis, EURORDISCARE2 SURV D; Haffner ME, 2006, NEW ENGL J MED, V354, P445, DOI 10.1056/NEJMp058317; *IND EXP GROUP, 2004, ETH LEG SOC ASP GEN; *ORPH, RAR DIS NUMB PREL RE; *ORPHANXCHANGE, ORPH DRUGS; *US DEP HHS, 1989, REP NAT COMM ORPH DI; VANWEELY S, PRIORITY MED EUROPE; Wastfelt M, 2006, J INTERN MED, V260, P1, DOI 10.1111/j.1365-2796.2006.01666.x; WEINER DL, PEDIAT INBORN ERRORS; World Health Organization, INT CLASS DIS; 2005, OVERVIEW CURRENT CTR	12	333	351	2	59	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2008	371	9629					2039	2041		10.1016/S0140-6736(08)60872-7	http://dx.doi.org/10.1016/S0140-6736(08)60872-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312YY	18555915				2022-12-28	WOS:000256709500031
J	Kohanski, MA; Collins, JJ				Kohanski, Michael A.; Collins, James J.			Rewiring bacteria, two components at a time	CELL			English	Editorial Material							ESCHERICHIA-COLI; GENE-EXPRESSION; RIBOREGULATORS	In this issue, Skerker et al. (2008) present a rational method for rewiring the protein-protein interactions and output responses of prokaryotic two-component signal transduction systems. This work has important implications for understanding the specificity of protein interactions and for designing protein-based synthetic signaling cascades.	[Kohanski, Michael A.; Collins, James J.] Boston Univ, Ctr BioDynam, Dept Biomed Engn, Boston, MA 02215 USA; [Kohanski, Michael A.; Collins, James J.] Boston Univ, Ctr Adv Biotechnol, Boston, MA 02215 USA; [Kohanski, Michael A.] Boston Univ, Sch Med, Boston, MA 02118 USA	Boston University; Boston University; Boston University	Collins, JJ (corresponding author), Boston Univ, Ctr BioDynam, Dept Biomed Engn, 44 Cummington St, Boston, MA 02215 USA.	jcollins@bu.edu						Bayer TS, 2005, NAT BIOTECHNOL, V23, P337, DOI 10.1038/nbt1069; Becskei A, 2000, NATURE, V405, P590, DOI 10.1038/35014651; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; Hoch JA, 2000, CURR OPIN MICROBIOL, V3, P165, DOI 10.1016/S1369-5274(00)00070-9; Isaacs FJ, 2004, NAT BIOTECHNOL, V22, P841, DOI 10.1038/nbt986; Levskaya A, 2005, NATURE, V438, P441, DOI 10.1038/nature04405	7	11	12	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 13	2008	133	6					947	948		10.1016/j.cell.2008.05.035	http://dx.doi.org/10.1016/j.cell.2008.05.035			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	312TJ	18555769	Bronze			2022-12-28	WOS:000256693400008
J	Kording, E; Rupen, M; Knigge, C; Fender, R; Dhawan, V; Templeton, M; Muxlow, T				Kording, Elmar; Rupen, Michael; Knigge, Christian; Fender, Rob; Dhawan, Vivek; Templeton, Matthew; Muxlow, Tom			A transient radio jet in an erupting dwarf nova	SCIENCE			English	Article							X-RAY BINARIES; SS-CYGNI; ACCRETION RATE; STATES; EVOLUTION; OUTBURST; STARS; EMISSION; MODEL	Astrophysical jets seem to occur in nearly all types of accreting objects, from supermassive black holes to young stellar objects. On the basis of x- ray binaries, a unified scenario describing the disc/ jet coupling has evolved and been extended to many accreting objects. The only major exceptions are thought to be cataclysmic variables: Dwarf novae, weakly accreting white dwarfs, show similar outburst behavior to x- ray binaries, but no jet has yet been detected. Here we present radio observations of a dwarf nova in outburst showing variable flat- spectrum radio emission that is best explained as synchrotron emission originating in a transient jet. Both the inferred jet power and the relation to the outburst cycle are analogous to those seen in x- ray binaries, suggesting that the disc/ jet coupling mechanism is ubiquitous.	[Kording, Elmar; Knigge, Christian; Fender, Rob] Univ Southampton, Sch Phys & Astron, Southampton SO17 1BJ, Hants, England; [Rupen, Michael; Dhawan, Vivek] Natl Radio Astron Observ, Socorro, NM 87801 USA; [Templeton, Matthew] Amer Assoc Variable Star Observers, Cambridge, MA 02138 USA; [Muxlow, Tom] Univ Manchester, Jodrell Bank Observ, Macclesfield SK11 9DL, Cheshire, England	University of Southampton; National Radio Astronomy Observatory (NRAO); University of Manchester; Jodrell Bank Centre for Astrophysics	Kording, E (corresponding author), Univ Southampton, Sch Phys & Astron, Southampton SO17 1BJ, Hants, England.	elmar@phys.soton.ac.uk		Muxlow, Thomas/0000-0001-5797-8796; Templeton, Matthew/0000-0003-1918-0622; Knigge, Christian/0000-0002-1116-2553	Science and Technology Facilities Council [PP/D001013/1] Funding Source: researchfish; STFC [PP/D001013/1] Funding Source: UKRI	Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))		Belloni T, 2005, ASTRON ASTROPHYS, V440, P207, DOI 10.1051/0004-6361:20042457; Benz AO, 1996, ASTR SOC P, V93, P188; BENZ AO, 1983, NATURE, V302, P45, DOI 10.1038/302045a0; BENZ AO, 1989, ASTRON ASTROPHYS, V218, P137; Fender RP, 2004, MON NOT R ASTRON SOC, V355, P1105, DOI 10.1111/j.1365-2966.2004.08384.x; Fender RP, 2001, MON NOT R ASTRON SOC, V322, P31, DOI 10.1046/j.1365-8711.2001.04080.x; Fuerst E., 1986, ASTRON ASTROPHYS, V154, P377; Gudel M, 1996, ASTR SOC P, V93, P303; Harrison TE, 1999, ASTROPHYS J, V515, pL93, DOI 10.1086/311982; Iijima T, 2003, ASTRON ASTROPHYS, V404, P997, DOI 10.1051/0004-6361:20030528; Klein-Wolt M, 2008, ASTROPHYS J, V675, P1407, DOI 10.1086/525843; Kording EG, 2008, MON NOT R ASTRON SOC, V383, P277, DOI 10.1111/j.1365-2966.2007.12529.x; Kording EG, 2006, MON NOT R ASTRON SOC, V369, P1451, DOI 10.1111/j.1365-2966.2006.10383.x; Kording EG, 2006, MON NOT R ASTRON SOC, V372, P1366, DOI 10.1111/j.1365-2966.2006.10954.x; Lasota JP, 2001, NEW ASTRON REV, V45, P449, DOI 10.1016/S1387-6473(01)00112-9; Livio M, 1999, PHYS REP, V311, P225, DOI 10.1016/S0370-1573(98)00102-1; MacFadyen AI, 2001, ASTROPHYS J, V550, P410, DOI 10.1086/319698; Maitra D, 2004, ASTROPHYS J, V608, P444, DOI 10.1086/382746; Migliari S, 2004, MON NOT R ASTRON SOC, V351, P186, DOI 10.1111/j.1365-2966.2004.07768.x; Mioduszewski AJ, 2004, ASTROPHYS J, V615, P432, DOI 10.1086/424376; Schreiber MR, 2007, ASTRON ASTROPHYS, V473, P897, DOI 10.1051/0004-6361:20078146; Soker N, 2004, ASTRON ASTROPHYS, V422, P1039, DOI 10.1051/0004-6361:20040402; TAYLOR AR, 1986, NATURE, V319, P38, DOI 10.1038/319038a0; Tomov T, 1998, ASTRON ASTROPHYS, V333, pL67; Warner B, 2002, MON NOT R ASTRON SOC, V335, P84, DOI 10.1046/j.1365-8711.2002.05596.x; Wheatley PJ, 2003, MON NOT R ASTRON SOC, V345, P49, DOI 10.1046/j.1365-8711.2003.06936.x; White RJ, 2004, ASTROPHYS J, V616, P998, DOI 10.1086/425115; WRIGHT AE, 1975, MON NOT R ASTRON SOC, V170, P41, DOI 10.1093/mnras/170.1.41	29	113	114	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2008	320	5881					1318	1320		10.1126/science.1155492	http://dx.doi.org/10.1126/science.1155492			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309DO	18535237	Green Submitted			2022-12-28	WOS:000256441100038
J	Gonzalez, MC; Hidalgo, CA; Barabasi, AL				Gonzalez, Marta C.; Hidalgo, Cesar A.; Barabasi, Albert-Laszlo			Understanding individual human mobility patterns	NATURE			English	Article							FLIGHT SEARCH PATTERNS; SCALING LAWS	Despite their importance for urban planning(1), traffic forecasting(2) and the spread of biological(3-5) and mobile viruses(6), our understanding of the basic laws governing human motion remains limited owing to the lack of tools to monitor the time- resolved location of individuals. Here we study the trajectory of 100,000 anonymized mobile phone users whose position is tracked for a six- month period. We find that, in contrast with the random trajectories predicted by the prevailing Levy flight and random walk models(7), human trajectories show a high degree of temporal and spatial regularity, each individual being characterized by a time-independent characteristic travel distance and a significant probability to return to a few highly frequented locations. After correcting for differences in travel distances and the inherent anisotropy of each trajectory, the individual travel patterns collapse into a single spatial probability distribution, indicating that, despite the diversity of their travel history, humans follow simple reproducible patterns. This inherent similarity in travel patterns could impact all phenomena driven by human mobility, from epidemic prevention to emergency response, urban planning and agent- based modelling.	[Gonzalez, Marta C.; Hidalgo, Cesar A.; Barabasi, Albert-Laszlo] Northeastern Univ, Ctr Complex Network Res, Boston, MA 02115 USA; [Gonzalez, Marta C.; Hidalgo, Cesar A.; Barabasi, Albert-Laszlo] Northeastern Univ, Dept Phys Biol & Comp Sci, Boston, MA 02115 USA; [Hidalgo, Cesar A.; Barabasi, Albert-Laszlo] Univ Notre Dame, Ctr Complex Network Res, Notre Dame, IN 46556 USA; [Hidalgo, Cesar A.; Barabasi, Albert-Laszlo] Univ Notre Dame, Dept Phys & Comp Sci, Notre Dame, IN 46556 USA; [Barabasi, Albert-Laszlo] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA	Northeastern University; Northeastern University; University of Notre Dame; University of Notre Dame; Harvard University; Dana-Farber Cancer Institute	Barabasi, AL (corresponding author), Northeastern Univ, Ctr Complex Network Res, Boston, MA 02115 USA.	alb@neu.edu	Barabasi, Albert-Laszlo/S-6474-2017; Gonzalez, Marta C./E-9456-2011; Hidalgo, Cesar A./B-5155-2009	Gonzalez, Marta C./0000-0002-8482-0318; Hidalgo, Cesar A./0000-0002-6977-9492; Barabasi, Albert/0000-0002-4028-3522; /0000-0002-6031-5982				Barabasi AL, 2005, NATURE, V435, P207, DOI 10.1038/nature03459; Caldarelli G., 2007, SCALE FREE NETWORKS; Cecconi F, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.088102; Colizza V, 2007, PLOS MED, V4, P95, DOI 10.1371/journal.pmed.0040013; Condamin S, 2007, NATURE, V450, P77, DOI 10.1038/nature06201; Dorogovtsev SN, 2003, EVOLUTION NETWORKS B; EAGLE N, IN PRESS BEHAV ECOL; Edwards AM, 2007, NATURE, V449, P1044, DOI 10.1038/nature06199; Eubank S, 2004, NATURE, V429, P180, DOI 10.1038/nature02541; Gonzalez MC, 2007, NAT PHYS, V3, P224, DOI 10.1038/nphys581; Gonzalez MC, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.088702; Havlin S, 2002, ADV PHYS, V51, P187, DOI 10.1080/00018730110116353; Hidalgo CA, 2008, PHYSICA A, V387, P3017, DOI 10.1016/j.physa.2008.01.073; Horner MW., 2001, J TRANSP GEOGR, V9, P255, DOI DOI 10.1016/S0966-6923(01)00019-9; Hufnagel L, 2004, P NATL ACAD SCI USA, V101, P15124, DOI 10.1073/pnas.0308344101; Kitamura R, 2000, TRANSPORTATION, V27, P25, DOI 10.1023/A:1005259324588; Klafter J, 1996, PHYS TODAY, V49, P33, DOI 10.1063/1.881487; Kleinberg J, 2007, NATURE, V449, P287, DOI 10.1038/449287a; MANTEGNA RN, 1994, PHYS REV LETT, V73, P2946, DOI 10.1103/PhysRevLett.73.2946; Onnela JP, 2007, P NATL ACAD SCI USA, V104, P7332, DOI 10.1073/pnas.0610245104; Palla G, 2007, NATURE, V446, P664, DOI 10.1038/nature05670; RAMOSFERNANDEZ G, 2004, BEHAV ECOL SOCIOBIOL, V273, P1743; Redner S, 2001, GUIDE 1 PASSAGE PROC; Schlich R, 2003, TRANSPORTATION, V30, P13, DOI 10.1023/A:1021230507071; Sims DW, 2008, NATURE, V451, P1098, DOI 10.1038/nature06518; Sohn T, 2006, LECT NOTES COMPUT SC, V4206, P212; Song CM, 2005, NATURE, V433, P392, DOI 10.1038/nature03248; Viswanathan GM, 1996, NATURE, V381, P413, DOI 10.1038/381413a0; Yook SH, 2002, P NATL ACAD SCI USA, V99, P13382, DOI 10.1073/pnas.172501399	30	3606	3779	45	1051	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 5	2008	453	7196					779	782		10.1038/nature06958	http://dx.doi.org/10.1038/nature06958			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308UK	18528393				2022-12-28	WOS:000256415300043
J	Ash, C; Foley, J; Pennisi, E				Ash, Caroline; Foley, John; Pennisi, Elizabeth			Lost in microbial space - Introduction	SCIENCE			English	Editorial Material																			0	3	3	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2008	320	5879					1027	1027		10.1126/science.320.5879.1027	http://dx.doi.org/10.1126/science.320.5879.1027			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18497284				2022-12-28	WOS:000256059800030
J	Lamb, MP; Dietrich, WE; Aciego, SM; DePaolo, DJ; Manga, M				Lamb, Michael P.; Dietrich, William E.; Aciego, Sarah M.; DePaolo, Donald J.; Manga, Michael			Formation of Box Canyon, Idaho, by megaflood: Implications for seepage erosion on Earth and Mars	SCIENCE			English	Article							SNAKE-RIVER-PLAIN; BIG-LOST-RIVER; MARTIAN VALLEYS; AGE; PLATEAU; HAWAII; HE-3	Amphitheater- headed canyons have been used as diagnostic indicators of erosion by groundwater seepage, which has important implications for landscape evolution on Earth and astrobiology on Mars. Of perhaps any canyon studied, Box Canyon, Idaho, most strongly meets the proposed morphologic criteria for groundwater sapping because it is incised into a basaltic plain with no drainage network upstream, and approximately 10 cubic meters per second of seepage emanates from its vertical headwall. However, sediment transport constraints, He-4 and C-14 dates, plunge pools, and scoured rock indicate that a megaflood ( greater than 220 cubic meters per second) carved the canyon about 45,000 years ago. These results add to a growing recognition of Quaternary catastrophic flooding in the American northwest, and may imply that similar features on Mars also formed by floods rather than seepage erosion.	[Lamb, Michael P.; Dietrich, William E.; Aciego, Sarah M.; DePaolo, Donald J.; Manga, Michael] Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Lamb, MP (corresponding author), Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA.	mpl@berkeley.edu	Manga, Michael/D-3847-2013	Manga, Michael/0000-0003-3286-4682				Aciego SM, 2007, EARTH PLANET SC LETT, V254, P288, DOI 10.1016/j.epsl.2006.11.039; Bathurst JC, 2002, J HYDROL, V269, P11, DOI 10.1016/S0022-1694(02)00191-9; Bretz JH, 1923, J GEOL, V31, P617, DOI 10.1086/623053; CERLING TE, 1994, GEOLOGY, V22, P227, DOI 10.1130/0091-7613(1994)022<0227:CHANAO>2.3.CO;2; Christensen PR, 2004, SPACE SCI REV, V110, P85, DOI 10.1023/B:SPAC.0000021008.16305.94; Dunne T., 1980, PROG PHYS GEOG, V4, P211, DOI [10.1177/030913338000400204, DOI 10.1177/030913338000400204, DOI 10.1016/S1546-5098(08)60146-6]; FORMAN SL, 1993, QUATERNARY RES, V40, P30, DOI 10.1006/qres.1993.1053; HARRISON KP, 2005, J GEOPHYS RES; HOWARD AD, 1988, WATER RESOUR RES, V24, P1659, DOI 10.1029/WR024i010p01659; HOWARD AD, 1994, J GEOPHYS RES-SOL EA, V99, P13971, DOI 10.1029/94JB00744; Kauffman JD, 2005, GEOLOGIC MAP TWIN FA; KOCHEL RC, 1986, J GEOPHYS RES-SOLID, V91, pE175, DOI 10.1029/JB091iB13p0E175; LAITY JE, 1985, GEOL SOC AM BULL, V96, P203, DOI 10.1130/0016-7606(1985)96<203:SPATDO>2.0.CO;2; Lamb M. P., 2006, J GEOPHYS RES, V111; Lamb MP, 2007, GEOL SOC AM BULL, V119, P805, DOI 10.1130/B25986.1; LAMB MP, 2008, J GEOPHYS RES; Luque R. F., 1976, J HYDRAUL RES, V14, P127, DOI DOI 10.1080/00221687609499677; Madsen DB, 2001, PALAEOGEOGR PALAEOCL, V167, P243, DOI 10.1016/S0031-0182(00)00240-6; MALDE HE, 1991, QUATERNARY NONGLACI, V2; MALDE HE, 1971, US GEOL SURV PROF PA, V20, P20; Malin MC, 1999, NATURE, V397, P589, DOI 10.1038/17551; OCONNOR JE, 1993, 274 GSA, P90; RATHBURN SL, 1993, GEOMORPHOLOGY, V8, P305, DOI 10.1016/0169-555X(93)90026-X; Reimer PJ, 2004, RADIOCARBON, V46, P1029, DOI 10.1017/S0033822200032999; RUSSEL IC, 2002, US GEOL SURV B, V199, P192; SCHUMM SA, 1995, GEOMORPHOLOGY, V12, P281; Stearns HT, 1936, J GEOL, V44, P429, DOI 10.1086/624441; Tauxe L., 2004, GEOCHEM GEOPHYS GEOS, V5; TOMASKO MG, 2005, NATURE, V438; TOMASSON H, 1973, NATTURUFRAEDINGURINN, V43, P12	30	92	93	3	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2008	320	5879					1067	1070		10.1126/science.1156630	http://dx.doi.org/10.1126/science.1156630			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18497296				2022-12-28	WOS:000256059800043
J	Squyres, SW; Arvidson, RE; Ruff, S; Gellert, R; Morris, RV; Ming, DW; Crumpler, L; Farmer, JD; Des Marais, DJ; Yen, A; McLennan, SM; Calvin, W; Bell, JF; Clark, BC; Wang, A; Mccoy, TJ; Schmidt, ME; de Souza, PA				Squyres, S. W.; Arvidson, R. E.; Ruff, S.; Gellert, R.; Morris, R. V.; Ming, D. W.; Crumpler, L.; Farmer, J. D.; Des Marais, D. J.; Yen, A.; McLennan, S. M.; Calvin, W.; Bell, J. F., III; Clark, B. C.; Wang, A.; McCoy, T. J.; Schmidt, M. E.; de Souza, P. A., Jr.			Detection of silica-rich deposits on Mars	SCIENCE			English	Article							GEOTHERMAL FIELDS; GUSEV CRATER; HOT-SPRINGS; NEW-ZEALAND; PRECIPITATION; SPECTROSCOPY; MINERALOGY; POWDERS; TES	Mineral deposits on the martian surface can elucidate ancient environmental conditions on the planet. Opaline silica deposits ( as much as 91 weight percent SiO2) have been found in association with volcanic materials by the Mars rover Spirit. The deposits are present both as light- toned soils and as bedrock. We interpret these materials to have formed under hydrothermal conditions and therefore to be strong indicators of a former aqueous environment. This discovery is important for understanding the past habitability of Mars because hydrothermal environments on Earth support thriving microbial ecosystems.	[Squyres, S. W.; Bell, J. F., III] Cornell Univ, Dept Astron, Ithaca, NY 14853 USA; [Arvidson, R. E.; Wang, A.] Washington Univ, Dept Earth & Planetary Sci, St Louis, MO 63130 USA; [Ruff, S.; Farmer, J. D.] Arizona State Univ, Sch Earth & Space Explorat, Tempe, AZ 85287 USA; [Gellert, R.] Univ Guelph, Dept Phys, Guelph, ON N1G 2W1, Canada; [Morris, R. V.; Ming, D. W.] NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA; [Crumpler, L.] New Mexico Museum Nat Hist & Sci, Albuquerque, NM 87104 USA; [Des Marais, D. J.] NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; [Yen, A.] CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; [McLennan, S. M.] SUNY Stony Brook, Dept Geosci, Stony Brook, NY 11794 USA; [Calvin, W.] Univ Nevada, Dept Geol Sci, Reno, NV 89557 USA; [Clark, B. C.] Lockheed Martin Corp, Littleton, CO 80127 USA; [McCoy, T. J.; Schmidt, M. E.] Smithsonian Inst, Natl Museum Nat Hist, Dept Mineral Sci, Washington, DC 20560 USA; [de Souza, P. A., Jr.] CSIRO, Tasmanian Informat & Commun Technol Ctr, Hobart, Tas 7000, Australia	Cornell University; Washington University (WUSTL); Arizona State University; Arizona State University-Tempe; University of Guelph; National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Nevada System of Higher Education (NSHE); University of Nevada Reno; Lockheed Martin; Smithsonian Institution; Smithsonian National Museum of Natural History; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Squyres, SW (corresponding author), Cornell Univ, Dept Astron, Space Sci Bldg, Ithaca, NY 14853 USA.	squyres@astro.cornell.edu	de Souza, Paulo/W-2993-2019; de Souza, Paulo A/B-8961-2008; de Souza, Paulo/P-7294-2019; Farmer, Jack D/B-9343-2019	de Souza, Paulo/0000-0002-0091-8925; de Souza, Paulo A/0000-0002-0091-8925; McLennan, Scott/0000-0003-4259-7178; McCoy, Timothy/0000-0002-4573-3553				ALMEIDA RM, 1992, PHYS REV B, V45, P161, DOI 10.1103/PhysRevB.45.161; Bandfield JL, 2000, SCIENCE, V287, P1626, DOI 10.1126/science.287.5458.1626; Bell JF, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002070; Cady SL, 1996, CIBA F SYMP, V202, P150; Christensen PR, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002117; DOEMEL WN, 1977, APPL ENVIRON MICROB, V34, P433, DOI 10.1128/AEM.34.4.433-452.1977; DOVE PM, 1994, REV MINERAL, V29, P259; Glotch TD, 2006, J GEOPHYS RES-PLANET, V111, DOI 10.1029/2005JE002671; Herkenhoff KE, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002076; INSKEEP WP, 2003, GEOTHERMAL BIOL GEOC; Johnson JR, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL029894; Kim SJ, 1999, J AM CERAM SOC, V82, P927, DOI 10.1111/j.1151-2916.1999.tb01855.x; Klingelhofer G, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002138; Kraft MD, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018848; Marion GM, 2008, GEOCHIM COSMOCHIM AC, V72, P242, DOI 10.1016/j.gca.2007.10.012; Michalski JR, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018354; Michalski JR, 2005, ICARUS, V174, P161, DOI 10.1016/j.icarus.2004.10.022; MILLIKEN RE, 2007, AM GEOPH UN FALL M S; Morris R.V., 2000, LUNAR PLANET SCI C, VXXXI; Murchie S, 2007, J GEOPHYS RES-PLANET, V112, DOI 10.1029/2006JE002682; Nam HD, 1998, JPN J APPL PHYS 1, V37, P4603, DOI 10.1143/JJAP.37.4603; RICE MS, 2008, 39 ANN LUN PLAN SCI; Rieder R., 2003, Journal of Geophysical Research, V108, pROV7, DOI 10.1029/2003JE002150; Rodgers KA, 2004, EARTH-SCI REV, V66, P1, DOI 10.1016/j.earscirev.2003.10.001; Rodgers KA, 2002, CLAY MINER, V37, P299, DOI 10.1180/0009855023720035; Salisbury J.W., 1991, INFRARED 2 1 25 MUM; SALISBURY JW, 1987, J GEOPHYS RES-SOLID, V92, P702, DOI 10.1029/JB092iB01p00702; Siering PL, 2006, GEOMICROBIOL J, V23, P129, DOI 10.1080/01490450500533916; Squyres SW, 2007, SCIENCE, V316, P738, DOI 10.1126/science.1139045; Tosca NJ, 2007, GEOCHIM COSMOCHIM AC, V71, P2680, DOI 10.1016/j.gca.2007.03.020; Tosca NJ, 2008, J GEOPHYS RES-PLANET, V113, DOI 10.1029/2007JE003019; WALTER MR, 1993, ICARUS, V101, P129, DOI 10.1006/icar.1993.1011; Yen AS, 2008, J GEOPHYS RES-PLANET, V113, DOI 10.1029/2007JE002978	34	324	327	0	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2008	320	5879					1063	1067		10.1126/science.1155429	http://dx.doi.org/10.1126/science.1155429			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18497295				2022-12-28	WOS:000256059800042
J	Ellis, SG; Tendera, M; de Belder, MA; van Boven, AJ; Widimsky, P; Janssens, L; Andersen, HR; Betriu, A; Savonitto, S; Adamus, J; Peruga, JZ; Kosmider, M; Katz, O; Neunteufl, T; Jorgova, J; Dorobantu, M; Grinfeld, L; Armstrong, P; Brodie, BR; Herrmann, HC; Montalescot, G; Neumann, FJ; Effron, MB; Barnathan, ES; Topol, EJ				Ellis, Stephen G.; Tendera, Michal; de Belder, Mark A.; van Boven, Ad J.; Widimsky, Petr; Janssens, Luc; Andersen, H. R.; Betriu, Amadeo; Savonitto, Stefano; Adamus, Jerzy; Peruga, Jan Z.; Kosmider, Maciej; Katz, Olivier; Neunteufl, Thomas; Jorgova, Julia; Dorobantu, Maria; Grinfeld, Liliana; Armstrong, Paul; Brodie, Bruce R.; Herrmann, Howard C.; Montalescot, Gilles; Neumann, Franz-Josef; Effron, Mark B.; Barnathan, Elliot S.; Topol, Eric J.		FINESSE Investigators	Facilitated PCI in patients with ST-elevation myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERCUTANEOUS CORONARY INTERVENTION; INTRAVENOUS THROMBOLYTIC THERAPY; TO-BALLOON TIME; PRIMARY ANGIOPLASTY; IMMEDIATE ANGIOPLASTY; FIBRINOLYTIC THERAPY; REPERFUSION THERAPY; 30-DAY MORTALITY; SYMPTOM-ONSET; RISK PATIENTS	Background We hypothesized that percutaneous coronary intervention (PCI) preceded by early treatment with abciximab plus half-dose reteplase (combination-facilitated PCI) or with abciximab alone (abciximab-facilitated PCI) would improve outcomes in patients with acute ST-segment elevation myocardial infarction, as compared with abciximab administered immediately before the procedure (primary PCI). Methods In this international, double-blind, placebo-controlled study, we randomly assigned patients with ST-segment elevation myocardial infarction who presented 6 hours or less after the onset of symptoms to receive combination-facilitated PCI, abciximab-facilitated PCI, or primary PCI. All patients received unfractionated heparin or enoxaparin before PCI and a 12-hour infusion of abciximab after PCI. The primary end point was the composite of death from all causes, ventricular fibrillation occurring more than 48 hours after randomization, cardiogenic shock, and congestive heart failure during the first 90 days after randomization. Results A total of 2452 patients were randomly assigned to a treatment group. Significantly more patients had early ST-segment resolution with combination-facilitated PCI (43.9%) than with abciximab-facilitated PCI (33.1%) or primary PCI (31.0%; P = 0.01 and P = 0.003, respectively). The primary end point occurred in 9.8%, 10.5%, and 10.7% of the patients in the combination-facilitated PCI group, abciximab-facilitated PCI group, and primary-PCI group, respectively (P = 0.55); 90-day mortality rates were 5.2%, 5.5%, and 4.5%, respectively (P = 0.49). Conclusions Neither facilitation of PCI with reteplase plus abciximab nor facilitation with abciximab alone significantly improved the clinical outcomes, as compared with abciximab given at the time of PCI, in patients with ST-segment elevation myocardial infarction.	[Ellis, Stephen G.] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44195 USA; [Tendera, Michal] Med Univ Silesia, Katowice, Poland; [de Belder, Mark A.] James Cook Univ Hosp, Middlesbrough, Cleveland, England; [van Boven, Ad J.] Med Centrum Leeuwarden, Leeuwarden, Netherlands; [Widimsky, Petr] Charles Univ Prague, Prague, Czech Republic; [Widimsky, Petr] Univ Hosp Kralovske Vinohrady, Prague, Czech Republic; [Janssens, Luc] AZ Imelda Ziekenhuis, Bonheiden, Belgium; [Andersen, H. R.] Skejby Univ Hosp, Aarhus N, Denmark; [Betriu, Amadeo] Hosp Clin Barcelona, Barcelona, Spain; [Savonitto, Stefano] Osped Niguarda Ca Granda, Milan, Italy; [Adamus, Jerzy] Centralny Szpital Klin WAM, Warsaw, Poland; [Peruga, Jan Z.] Uniwersytet Medycznego, Katedra 2, Klin Kardiol 1, Lodz, Poland; [Kosmider, Maciej] SP ZOZ Szpital Klin 3, Lodz, Poland; [Katz, Olivier] Clin St Joseph, Colmar, France; [Neunteufl, Thomas] Allgemeines Krankenhaus Wien, Vienna, Austria; [Jorgova, Julia] UMHAT St George, Plovdiv, Bulgaria; [Dorobantu, Maria] Emergency Hosp Floreasca, Bucharest, Romania; [Grinfeld, Liliana] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina; [Armstrong, Paul] Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada; [Brodie, Bruce R.] LeBauer Cardiovasc Res, Greensboro, NC USA; [Herrmann, Howard C.] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA; [Montalescot, Gilles] Hop La Pitie Salpetriere, Paris, France; [Neumann, Franz-Josef] Herz Zentrum Bad Krozingen, Bad Krozingen, Germany; [Effron, Mark B.] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Barnathan, Elliot S.] Centocor Inc, Res & Dev, Malvern, PA 19355 USA; [Topol, Eric J.] Scripps Res Inst, La Jolla, CA USA; [Topol, Eric J.] Scripps Clin, La Jolla, CA USA	Cleveland Clinic Foundation; Medical University Silesia; James Cook University Hospital; Medical Center Leeuwarden; Charles University Prague; University Hospital Vinohrady; Imeldaziekenhuis; Aarhus University; University of Barcelona; Hospital Clinic de Barcelona; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Hospital Italiano de Buenos Aires; University of Buenos Aires; University of Alberta; LeBauer-Brodie Center for Cardiovascular Research & Education; University of Pennsylvania; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Eli Lilly; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; Scripps Research Institute; Scripps Research Institute	Ellis, SG (corresponding author), Cleveland Clin, Dept Cardiovasc Med, F25,9500 Euclid Ave, Cleveland, OH 44195 USA.	elliss@ccf.org	DOROBANTU, MARIA/AAS-2934-2020; Widimsky, Petr/P-8088-2016; Georgescu, Catalina Arsenescu/R-5709-2017; Munzel, Thomas/A-2912-2014; Tendera, Michal/AAA-1875-2022; Ponikowski, Piotr/O-6454-2015; Benedek, Theodora/F-6353-2016; Effron, Mark B./P-9300-2015; Benedek, Imre/E-7052-2017	Widimsky, Petr/0000-0001-5686-7752; Georgescu, Catalina Arsenescu/0000-0001-5142-7598; Munzel, Thomas/0000-0001-5503-4150; Ponikowski, Piotr/0000-0002-3391-7064; Benedek, Theodora/0000-0001-8326-1537; Effron, Mark B./0000-0003-4050-5030; Benedek, Imre/0000-0003-0051-4047; Tendera, Michal/0000-0002-0812-6113; Moscucci, Mauro/0000-0002-9123-4472; Armstrong, Paul/0000-0002-0460-3445; CASELLA, Gianni/0000-0002-0701-7329; Topol, Eric/0000-0002-1478-4729; Botto, Fernando/0000-0002-0572-8493				Andersen HR, 2003, NEW ENGL J MED, V349, P733, DOI 10.1056/NEJMoa025142; [Anonymous], 2008, J AM COLL CARDIOL, V51, P210; Antman EM, 1999, CIRCULATION, V99, P2720, DOI 10.1161/01.CIR.99.21.2720; Antoniucci D, 2002, AM J CARDIOL, V89, P1248, DOI 10.1016/S0002-9149(02)02320-2; Betriu A, 1997, NEW ENGL J MED, V336, P1621; Betriu A, 1997, NEW ENGL J MED, V337, P287; Brodie BR, 2006, J AM COLL CARDIOL, V47, P289, DOI 10.1016/j.jacc.2005.08.065; Brodie BR, 2007, AM J CARDIOL, V99, P1680, DOI 10.1016/j.amjcard.2007.01.047; Cannon CP, 2000, JAMA-J AM MED ASSOC, V283, P2941, DOI 10.1001/jama.283.22.2941; Christian TF, 1998, AM HEART J, V135, P310, DOI 10.1016/S0002-8703(98)70098-5; Clemmensen P, 2005, J ELECTROCARDIOL, V38, P194, DOI 10.1016/j.jelectrocard.2005.06.035; Cura FA, 2004, AM J CARDIOL, V94, P859, DOI 10.1016/j.amjcard.2004.06.018; de Lemos JA, 2000, CIRCULATION, V101, P239, DOI 10.1161/01.CIR.101.3.239; De Luca G, 2004, CIRCULATION, V109, P1223, DOI 10.1161/01.CIR.0000121424.76486.20; Ellis SG, 2004, AM HEART J, V147, DOI 10.1016/j.ahj.2003.07.025; Gersh BJ, 2005, JAMA-J AM MED ASSOC, V293, P979, DOI 10.1001/jama.293.8.979; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Kastrati A, 2004, JAMA-J AM MED ASSOC, V291, P947, DOI 10.1001/jama.291.8.947; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Keeley EC, 2006, LANCET, V367, P579, DOI 10.1016/S0140-6736(06)68148-8; Keeley EC, 2006, LANCET, V367, P1656; Liem AL, 1998, J AM COLL CARDIOL, V32, P629, DOI 10.1016/S0735-1097(98)00280-0; Luepker RV, 2000, JAMA-J AM MED ASSOC, V284, P60, DOI 10.1001/jama.284.1.60; Maioli M, 2007, J AM COLL CARDIOL, V49, P1517, DOI 10.1016/j.jacc.2006.12.036; Manoukian SV, 2007, J AM COLL CARDIOL, V49, P1362, DOI 10.1016/j.jacc.2007.02.027; Montalescot G, 2004, JAMA-J AM MED ASSOC, V292, P362, DOI 10.1001/jama.292.3.362; Nallamothu BK, 2007, HEART, V93, P1552, DOI 10.1136/hrt.2006.112847; Pinto DS, 2006, CIRCULATION, V114, P2019, DOI 10.1161/CIRCULATIONAHA.106.638353; Ross AM, 1998, CIRCULATION, V97, P1549, DOI 10.1161/01.CIR.97.16.1549; Schomig A, 2005, JAMA-J AM MED ASSOC, V293, P2865, DOI 10.1001/jama.293.23.2865; Schomig A, 2003, CIRCULATION, V108, P1084, DOI 10.1161/01.CIR.0000086346.32856.9C; SIMES RJ, 1995, CIRCULATION, V91, P1923, DOI 10.1161/01.CIR.91.7.1923; Stenestrand U, 2006, JAMA-J AM MED ASSOC, V296, P1749, DOI 10.1001/jama.296.14.1749; Stone GW, 1997, NEW ENGL J MED, V337, P1168; Topol EJ, 2000, CIRCULATION, V101, P2788; Topol EJ, 2001, LANCET, V357, P1905; Van de Werf F, 2006, LANCET, V367, P569, DOI 10.1016/S0140-6736(06)68147-6; Waters RE, 2004, J AM COLL CARDIOL, V43, P2153, DOI 10.1016/j.jacc.2003.12.057; Weaver WD, 1997, JAMA-J AM MED ASSOC, V278, P2093, DOI 10.1001/jama.278.23.2093; Weaver WD, 1998, JAMA-J AM MED ASSOC, V279, P1876; Widimsky P, 2003, EUR HEART J, V24, P94, DOI 10.1016/S0195-668X(02)00468-2; Zahn R, 2005, HEART, V91, P1041, DOI 10.1136/hrt.2004.045336; Zijlstra F, 1997, J AM COLL CARDIOL, V29, P908, DOI 10.1016/S0735-1097(97)00018-1; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	45	473	505	0	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2008	358	21					2205	2217		10.1056/NEJMoa0706816	http://dx.doi.org/10.1056/NEJMoa0706816			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303EK	18499565				2022-12-28	WOS:000256023600003
J	Kauffmann, F; Cambon-Thomsen, A				Kauffmann, Francine; Cambon-Thomsen, Anne			Tracing biological collections - Between books and clinical trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Kauffmann, Francine] INSERM, U780, F-94807 Villejuif, France; [Cambon-Thomsen, Anne] INSERM, U558, Toulouse, France; [Cambon-Thomsen, Anne] Univ Toulouse 3, F-31062 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Kauffmann, F (corresponding author), INSERM, U780, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.	kauffmann@vjf.inserm.fr						Cambon-Thomsen A, 2003, NAT GENET, V34, P25, DOI 10.1038/ng0503-25b; Chadwick Ruth, 2004, Res Publica, V10, P123, DOI 10.1023/B:RESP.0000034637.15364.11; De Angelis CD, 2005, JAMA-J AM MED ASSOC, V293, P2927, DOI 10.1001/jama.293.23.jed50037; Ginsburg GS, 2008, JAMA-J AM MED ASSOC, V299, P1359, DOI 10.1001/jama.299.11.1359; Ioannidis JPA, 2006, NAT GENET, V38, P3, DOI 10.1038/ng0106-3; Manolio TA, 2007, NAT GENET, V39, P1045, DOI 10.1038/ng2127; Milanovic F., 2007, GENOMICS SOC POLICY, V23, P17, DOI DOI 10.1186/1746-5354-3-1-17; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Topol EJ, 2007, JAMA-J AM MED ASSOC, V298, P218, DOI 10.1001/jama.298.2.218; Yuille M, 2008, BRIEF BIOINFORM, V9, P14, DOI 10.1093/bib/bbm050; 2007, FED REG, V72, P49290; PUBLIC POPULATION PR	12	42	45	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 21	2008	299	19					2316	2318		10.1001/jama.299.19.2316	http://dx.doi.org/10.1001/jama.299.19.2316			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302QN	18492973				2022-12-28	WOS:000255984500027
J	Carlson, ME; Hsu, M; Conboy, IM				Carlson, Morgan E.; Hsu, Michael; Conboy, Irina M.			Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells	NATURE			English	Article							SKELETAL-MUSCLE; PROLIFERATION; P16(INK4A); ARREST; MICE	Adult skeletal muscle robustly regenerates throughout an organism's life, but as the muscle ages, its ability to repair diminishes and eventually fails(1,2). Previous work suggests that the regenerative potential of muscle stem cells (satellite cells) is not triggered in the old muscle because of a decline in Notch activation, and that it can be rejuvenated by forced local activation of Notch(3). Here we report that, in addition to the loss of Notch activation, old muscle produces excessive transforming growth factor (TGF)-beta (but not myostatin), which induces unusually high levels of TGF-beta pSmad3 in resident satellite cells and interferes with their regenerative capacity. Importantly, endogenous Notch and pSmad3 antagonize each other in the control of satellite-cell proliferation, such that activation of Notch blocks the TGF-beta-dependent upregulation of the cyclin-dependent kinase (CDK) inhibitors p15, p16, p21 and p27, whereas inhibition of Notch induces them. Furthermore, in muscle stem cells, Notch activity determines the binding of pSmad3 to the promoters of these negative regulators of cell-cycle progression. Attenuation of TGF-beta/pSmad3 in old, injured muscle restores regeneration to satellite cells in vivo. Thus a balance between endogenous pSmad3 and active Notch controls the regenerative competence of muscle stem cells, and deregulation of this balance in the old muscle microniche interferes with regeneration.	[Carlson, Morgan E.; Hsu, Michael; Conboy, Irina M.] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Conboy, IM (corresponding author), Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA.	iconboy@berkeley.edu		Hsu, Mike/0000-0001-7086-1808	NIA NIH HHS [R21 AG27892, R21 AG027892, R01 AG027252] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG027252, R21AG027892] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barcellos-Hoff MH, 1996, J MAMMARY GLAND BIOL, V1, P353, DOI 10.1007/BF02017391; Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090; CARLSON ME, 2007, AGING CELL; Collins CA, 2005, CELL CYCLE, V4, P1338, DOI 10.4161/cc.4.10.2114; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Conboy IM, 2003, SCIENCE, V302, P1575, DOI 10.1126/science.1087573; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Grounds MD, 1998, ANN NY ACAD SCI, V854, P78, DOI 10.1111/j.1749-6632.1998.tb09894.x; Husmann Irene, 1996, Cytokine and Growth Factor Reviews, V7, P249, DOI 10.1016/S1359-6101(96)00029-9; Ito T, 2007, BIOCHEM BIOPH RES CO, V359, P108, DOI 10.1016/j.bbrc.2007.05.067; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; Joulia D, 2003, EXP CELL RES, V286, P263, DOI 10.1016/S0014-4827(03)00074-0; Krishnamurthy J, 2006, NATURE, V443, P453, DOI 10.1038/nature05092; Li LH, 2005, ANNU REV CELL DEV BI, V21, P605, DOI 10.1146/annurev.cellbio.21.012704.131525; Lin J, 2003, BIOCHEM BIOPH RES CO, V300, P938, DOI 10.1016/S0006-291X(02)02949-2; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091; Morgan JE, 2002, J CELL BIOL, V157, P693, DOI 10.1083/jcb.200108047; Natarajan E, 2006, AM J PATHOL, V168, P1821, DOI 10.2353/ajpath.2006.051027; Olson NE, 2000, J BIOL CHEM, V275, P11270, DOI 10.1074/jbc.275.15.11270; Rao P, 2003, MOL CELL BIOL, V23, P6694, DOI 10.1128/MCB.23.18.6694-6701.2003; Renault V, 2002, AGING CELL, V1, P132, DOI 10.1046/j.1474-9728.2002.00017.x; SCHULTZ E, 1982, MECH AGEING DEV, V20, P377, DOI 10.1016/0047-6374(82)90105-1; Stepanova L, 2005, BLOOD, V106, P827, DOI 10.1182/blood-2004-06-2242; Svoboda P, 2007, CURR OPIN MOL THER, V9, P248; Untergasser G, 2005, MECH AGEING DEV, V126, P59, DOI 10.1016/j.mad.2004.09.023; Wagers AJ, 2005, CELL, V122, P659, DOI 10.1016/j.cell.2005.08.021	30	345	353	2	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 24	2008	454	7203					528	U9		10.1038/nature07034	http://dx.doi.org/10.1038/nature07034			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	329IC	18552838	Green Accepted, Green Submitted			2022-12-28	WOS:000257860300054
J	Bainbridge, KE; Hoffman, HJ; Cowie, CC				Bainbridge, Kathleen E.; Hoffman, Howard J.; Cowie, Catherine C.			Diabetes and hearing impairment in the United States: Audiometric evidence from the National Health and Nutrition Examination Survey, 1999 to 2004	ANNALS OF INTERNAL MEDICINE			English	Article							PRIMARY-CARE; INNER-EAR; EPIDEMIOLOGY; ADULTS; NOISE; ASSOCIATION; POPULATION; PREVALENCE; MANAGEMENT; THRESHOLD	Background: Diabetes might affect the vasculature and neural system of the inner ear, leading to hearing impairment. Objective: To determine whether hearing impairment is more prevalent among U. S. adults with diabetes. Design: Cross-sectional analysis of nationally representative data. Setting: National Health and Nutrition Examination Survey, 1999 to 2004. Participants: 5140 noninstitutionalized adults age 20 to 69 years who had audiometric testing. Measurements: Hearing impairment was assessed from the pure tone average of thresholds over low or mid-frequencies (500, 1000, and 2000 Hz) and high frequencies (3000, 4000, 6000, and 8000 Hz) and was defined as mild or greater severity (pure tone average > 25 decibels hearing level [dB HL]) and moderate or greater severity (pure tone average > 40 dB HL). Results: Hearing impairment was more prevalent among adults with diabetes. Age-adjusted prevalence of low-or mid-frequency hearing impairment of mild or greater severity in the worse ear was 21.3% (95% CI, 15.0% to 27.5%) among 399 adults with diabetes compared with 9.4% (CI, 8.2% to 10.5%) among 4741 adults without diabetes. Similarly, age-adjusted prevalence of high-frequency hearing impairment of mild or greater severity in the worse ear was 54.1% (CI, 45.9% to 62.3%) among those with diabetes compared with 32.0% (CI, 30.5% to 33.5%) among those without diabetes. The association between diabetes and hearing impairment was independent of known risk factors for hearing impairment, such as noise exposure, ototoxic medication use, and smoking (adjusted odds ratios for low- or mid-frequency and high-frequency hearing impairment were 1.82 [CI, 1.27 to 2.60] and 2.16 [CI, 1.47 to 3.18], respectively). Limitations: The diagnosis of diabetes was based on self-report. The investigators could not distinguish between type 1 and type 2 diabetes. Noise exposure was based on participant recall. Conclusion: Hearing impairment is common in adults with diabetes, and diabetes seems to be an independent risk factor for the condition.	[Bainbridge, Kathleen E.] Social & Sci Syst, Silver Spring, MD 20910 USA; Natl Inst Deafness & Other Commun Disorders, Bethesda, MD USA; NIDDK, Bethesda, MD USA	Social & Scientific Systems; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Bainbridge, KE (corresponding author), Social & Sci Syst, 8757 Georgia Ave,12th Floor, Silver Spring, MD 20910 USA.	kbainbridge@s-3.com		Hoffman, Howard/0000-0003-4105-0808	NIAAA NIH HHS [HHSN267200700001C] Funding Source: Medline; NIDDK NIH HHS [GS1-0F-00381L, N001 DK12478] Funding Source: Medline; NLM NIH HHS [HHSN267200700001G] Funding Source: Medline; PHS HHS [HHSN 26720070000 1G] Funding Source: Medline	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Axelsson A, 1978, Acta Otolaryngol Suppl, V356, P1; AXELSSON A, 1995, EAR HEARING, V16, P245, DOI 10.1097/00003446-199506000-00001; Bagai A, 2006, JAMA-J AM MED ASSOC, V295, P416, DOI 10.1001/jama.295.4.416; Bogardus ST, 2003, JAMA-J AM MED ASSOC, V289, P1986, DOI 10.1001/jama.289.15.1986; Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653; Cowie CC, 2006, DIABETES CARE, V29, P1263, DOI 10.2337/dc06-0062; Cruickshanks KJ, 2003, ARCH OTOLARYNGOL, V129, P1041, DOI 10.1001/archotol.129.10.1041; Cruickshanks KJ, 1998, JAMA-J AM MED ASSOC, V279, P1715, DOI 10.1001/jama.279.21.1715; Dalton DS, 2003, GERONTOLOGIST, V43, P661, DOI 10.1093/geront/43.5.661; Dalton DS, 1998, DIABETES CARE, V21, P1540, DOI 10.2337/diacare.21.9.1540; Dalton DS, 2001, AUDIOLOGY, V40, P1; Erdem T, 2003, EUR ARCH OTO-RHINO-L, V260, P62, DOI 10.1007/s00405-002-0519-1; FRIEDMAN SA, 1975, ARCH INTERN MED, V135, P573, DOI 10.1001/archinte.135.4.573; Fukushima H, 2005, OTOLARYNG HEAD NECK, V133, P100, DOI 10.1016/j.otohns.2005.02.004; GATES GA, 1993, ARCH OTOLARYNGOL, V119, P156; Gates GA, 2000, HEARING RES, V141, P220, DOI 10.1016/S0378-5955(99)00223-3; GELFAND S, 2001, ESSENTIALS AUDIOLOGY; Helzner EP, 2005, J AM GERIATR SOC, V53, P2119, DOI 10.1111/j.1532-5415.2005.00525.x; ISHII EK, 1992, SCI TOTAL ENVIRON, V127, P155, DOI 10.1016/0048-9697(92)90474-7; JORGENSEN MB, 1961, ARCHIV OTOLARYNGOL, V74, P373; Kasemsuwan Lalida, 2001, Journal of the Medical Association of Thailand, V84, P1389; KURIEN M, 1989, J LARYNGOL OTOL, V103, P164, DOI 10.1017/S0022215100108345; Ma FC, 1998, J LARYNGOL OTOL, V112, P835, DOI 10.1017/S0022215100141842; Maassen JA, 2004, DIABETES, V53, pS103, DOI 10.2337/diabetes.53.2007.S103; MAKISHIMA K, 1971, ANN OTO RHINOL LARYN, V80, P218, DOI 10.1177/000348947108000208; Makishima K, 1978, OTOLARYNGOLOGY, V86; Marshall JD, 2007, EUR J HUM GENET, V15, P1193, DOI 10.1038/sj.ejhg.5201933; Minton JAL, 2003, REV ENDOCR METAB DIS, V4, P53, DOI 10.1023/A:1021875403463; Muhr P, 2006, INT J AUDIOL, V45, P247, DOI 10.1080/14992020500190052; *NAT DIAB DAT GROU, 1995, NIH PUBL NAT I DIAB; National Institute of Diabetes and Digestive and Kidney Diseases, 2005, NAT DIAB STAT FACT S; PLEIS JR, 2007, VITAL HLTH STAT, V10, P1; Sakuta H, 2007, DIABETES RES CLIN PR, V75, P229, DOI 10.1016/j.diabres.2006.06.029; Sasso FC, 1999, METABOLISM, V48, P1346, DOI 10.1016/S0026-0495(99)90141-5; Strawbridge WJ, 1996, AM J EPIDEMIOL, V144, P135, DOI 10.1093/oxfordjournals.aje.a008900; Tambs K, 2003, INT J AUDIOL, V42, P89, DOI 10.3109/14992020309078340; TAYLOR IG, 1978, J LARYNGOL OTOL, V92, P99, DOI 10.1017/S0022215100085108; VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625; Yueh B, 2003, JAMA-J AM MED ASSOC, V289, P1976, DOI 10.1001/jama.289.15.1976	39	252	270	0	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	2008	149	1					1	+		10.7326/0003-4819-149-1-200807010-00231	http://dx.doi.org/10.7326/0003-4819-149-1-200807010-00231			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	323EZ	18559825	Green Accepted			2022-12-28	WOS:000257428200001
J	Ley, RE; Hamady, M; Lozupone, C; Turnbaugh, PJ; Ramey, RR; Bircher, JS; Schlegel, ML; Tucker, TA; Schrenzel, MD; Knight, R; Gordon, JI				Ley, Ruth E.; Hamady, Micah; Lozupone, Catherine; Turnbaugh, Peter J.; Ramey, Rob Roy; Bircher, J. Stephen; Schlegel, Michael L.; Tucker, Tammy A.; Schrenzel, Mark D.; Knight, Rob; Gordon, Jeffrey I.			Evolution of mammals and their gut microbes	SCIENCE			English	Article							PHYLOGENETIC ANALYSIS; MOLECULAR ANALYSIS; FECAL MICROBIOTA; DIVERSITY; ECOLOGY; SEQUENCES; UNIFRAC; OBESITY; FLORA	Mammals are metagenomic in that they are composed of not only their own gene complements but also those of all of their associated microbes. To understand the coevolution of the mammals and their indigenous microbial communities, we conducted a network- based analysis of bacterial 16S ribosomal RNA gene sequences from the fecal microbiota of humans and 59 other mammalian species living in two zoos and in the wild. The results indicate that host diet and phylogeny both influence bacterial diversity, which increases from carnivory to omnivory to herbivory; that bacterial communities codiversified with their hosts; and that the gut microbiota of humans living a modern life- style is typical of omnivorous primates.	[Ley, Ruth E.; Lozupone, Catherine; Turnbaugh, Peter J.; Gordon, Jeffrey I.] Washington Univ, Sch Med, Ctr Genome Sci, St Louis, MO 63108 USA; [Hamady, Micah] Univ Colorado, Dept Comp Sci, Boulder, CO 80309 USA; [Lozupone, Catherine; Knight, Rob] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; [Ramey, Rob Roy] Wildlife Sci Int Inc, Nederland, CO 80466 USA; [Bircher, J. Stephen] St Louis Zoo, St Louis, MO 63110 USA; [Schlegel, Michael L.; Tucker, Tammy A.; Schrenzel, Mark D.] Zool Soc San Diego, San Diego, CA 92112 USA	Washington University (WUSTL); University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; Zoological Society of San Diego	Gordon, JI (corresponding author), Washington Univ, Sch Med, Ctr Genome Sci, St Louis, MO 63108 USA.	jgordon@wustl.edu	Lozupone, Catherine/AAD-9317-2020; Knight, Rob/D-1299-2010; Ley, Ruth E/M-8542-2014; Vazquez-Dominguez, Guillermo GVD/L-7818-2014	Ley, Ruth E/0000-0002-9087-1672; Turnbaugh, Peter/0000-0002-0888-2875; Knight, Rob/0000-0002-0975-9019	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070977, P01DK078669, R01DK030292, R37DK030292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008759, T32GM065103] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK078669-02, P01 DK078669, R01 DK030292, DK70977, DK78669, R01 DK070977-04, R01 DK070977, R01 DK030292-24, DK30292] Funding Source: Medline; NIGMS NIH HHS [T32 GM142607, T32 GM065103, T32 GM008759, T32 GM065103-07, T32GM065103] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnason U, 2002, P NATL ACAD SCI USA, V99, P8151, DOI 10.1073/pnas.102164299; Brooks SPJ, 2003, CAN J MICROBIOL, V49, P589, DOI 10.1139/W03-075; Cerling TE, 1998, PHILOS T R SOC B, V353, P159, DOI 10.1098/rstb.1998.0198; Cerling TE, 1997, NATURE, V389, P153, DOI 10.1038/38229; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Dethlefsen L, 2007, NATURE, V449, P811, DOI 10.1038/nature06245; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Frey JC, 2006, APPL ENVIRON MICROB, V72, P3788, DOI 10.1128/AEM.72.5.3788-3792.2006; Hayashi H, 2003, MICROBIOL IMMUNOL, V47, P557, DOI 10.1111/j.1348-0421.2003.tb03418.x; Hayashi H, 2002, MICROBIOL IMMUNOL, V46, P819, DOI 10.1111/j.1348-0421.2002.tb02769.x; Hayashi H, 2002, MICROBIOL IMMUNOL, V46, P535, DOI 10.1111/j.1348-0421.2002.tb02731.x; Huang Y, 2001, SCIENCE, V293, P1647, DOI 10.1126/science.1060143; Huber T, 2004, BIOINFORMATICS, V20, P2317, DOI 10.1093/bioinformatics/bth226; Koch P.L., 1994, STABLE ISOTOPES ECOL; Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Lister AM, 2004, PHILOS T R SOC B, V359, P221, DOI 10.1098/rstb.2003.1436; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Lozupone C, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-371; MacFadden BJ, 2005, TRENDS ECOL EVOL, V20, P355, DOI 10.1016/j.tree.2005.05.003; Moran NA, 2006, CURR BIOL, V16, pR866, DOI 10.1016/j.cub.2006.09.019; Ozutsumi Y, 2005, BIOSCI BIOTECH BIOCH, V69, P1793, DOI 10.1271/bbb.69.1793; Pagani M, 2005, SCIENCE, V309, P600, DOI 10.1126/science.1110063; Rawls JF, 2006, CELL, V127, P423, DOI 10.1016/j.cell.2006.08.043; Russell JB, 2001, SCIENCE, V292, P1119, DOI 10.1126/science.1058830; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Stevens C. E., 2004, COMP PHYSL VERTEBRAT; Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07	30	2295	2433	35	1110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 20	2008	320	5883					1647	1651		10.1126/science.1155725	http://dx.doi.org/10.1126/science.1155725			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	315NM	18497261	Green Accepted			2022-12-28	WOS:000256886700051
J	Kamerow, D				Kamerow, Douglas			Placebo pills for children	BRITISH MEDICAL JOURNAL			English	Editorial Material									RTI Int, Res Triangle Pk, NC 27709 USA	Research Triangle Institute	Kamerow, D (corresponding author), RTI Int, Res Triangle Pk, NC 27709 USA.	dkamerow@rti.org		Kamerow, Douglas/0000-0001-7000-9957					0	0	0	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 14	2008	336	7657					1339	1339		10.1136/bmj.39603.698889.59	http://dx.doi.org/10.1136/bmj.39603.698889.59			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316YB	18556311	Green Published			2022-12-28	WOS:000256984700034
J	Lalloo, DG; Hill, DR				Lalloo, David G.; Hill, David R.			Preventing malaria intravellers	BMJ-BRITISH MEDICAL JOURNAL			English	Review							DOUBLE-BLIND; NONIMMUNE TRAVELERS; RISK-FACTORS; PROPHYLAXIS; CHEMOPROPHYLAXIS; MEFLOQUINE; SURVEILLANCE; COMMUNITY; EFFICACY		[Lalloo, David G.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; [Hill, David R.] Natl Travel Hlth Network & Ctr, London WC1E 6AU, England; [Hill, David R.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	Liverpool School of Tropical Medicine; University of Liverpool; University of London; London School of Hygiene & Tropical Medicine	Lalloo, DG (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.	dlalloo@liverpool.ac.uk		Lalloo, David/0000-0001-7680-2200				Angell SY, 2005, INFECT DIS CLIN N AM, V19, P49, DOI 10.1016/j.idc.2004.11.001; [Anonymous], 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000363.PUB2; Baird JK, 2005, NEW ENGL J MED, V352, P1565, DOI 10.1056/NEJMra043207; *CDCP, 2008, CDC HLTH INF INT TRA, pCH4; Checkley AM, 2007, TRENDS PARASITOL, V23, P462, DOI 10.1016/j.pt.2007.08.010; Chen LH, 2007, JAMA-J AM MED ASSOC, V297, P2251, DOI 10.1001/jama.297.20.2251; Chiodini P, 2007, GUIDELINES MALARIA P; CROFT AM, 2007, CLIN EVID; Fontanet AL, 2005, T ROY SOC TROP MED H, V99, P91, DOI 10.1016/j.trstmh.2004.01.006; Fradin MS, 2002, NEW ENGL J MED, V347, P13, DOI 10.1056/NEJMoa011699; Hale BR, 2003, CLIN INFECT DIS, V36, P541, DOI 10.1086/367542; Health Protection Agency, 2008, HLTH PROT REP, P2; Hill DR, 2006, AM J TROP MED HYG, V75, P402, DOI 10.4269/ajtmh.2006.75.402; *HTLH CAN, 2004, CAN COMMUN DIS RE S1, V30, P1; Jelinek T, 1999, LANCET, V354, P1609, DOI 10.1016/S0140-6736(99)01969-8; Kimani EW, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-63; Lalloo DG, 2007, J INFECTION, V54, P111, DOI 10.1016/j.jinf.2006.12.003; Leder K, 2004, CLIN INFECT DIS, V39, P1104, DOI 10.1086/424510; Legros F, 2007, EMERG INFECT DIS, V13, P883, DOI 10.3201/eid1305.060955; McGready R, 2001, AM J TROP MED HYG, V65, P285, DOI 10.4269/ajtmh.2001.65.285; Moore DAJ, 2004, T ROY SOC TROP MED H, V98, P55, DOI 10.1016/S0035-9203(03)00007-5; Morgan M, 2005, ETHNIC HEALTH, V10, P355, DOI 10.1080/13557850500242035; NOSTEN F, 1994, J INFECT DIS, V169, P595, DOI 10.1093/infdis/169.3.595; Ohrt C, 1997, ANN INTERN MED, V126, P963, DOI 10.7326/0003-4819-126-12-199706150-00006; Overbosch D, 2001, CLIN INFECT DIS, V33, P1015, DOI 10.1086/322694; Schlagenhauf P, 2003, BMJ-BRIT MED J, V327, P1078, DOI 10.1136/bmj.327.7423.1078; SCHLAGENHAUF P, 1995, B WORLD HEALTH ORGAN, V73, P215; Thwing Julie, 2007, Morbidity and Mortality Weekly Report, V56, P23; Williams Christopher J, 2007, Travel Med Infect Dis, V5, P295, DOI 10.1016/j.tmaid.2007.05.001; World Health Organization, 2007, INT TRAV HLTH	30	24	24	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 14	2008	336	7657					1362	1366		10.1136/bmj.a153	http://dx.doi.org/10.1136/bmj.a153			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316YB	18556317	Green Accepted, Green Published			2022-12-28	WOS:000256984700043
J	Subedi, R; Shneor, R; Monaghan, P; Anderson, BD; Aniol, K; Annand, J; Arrington, J; Benaoum, H; Benmokhtar, F; Boeglin, W; Chen, JP; Choi, S; Cisbani, E; Craver, B; Frullani, S; Garibaldi, F; Gilad, S; Gilman, R; Glamazdin, O; Hansen, JO; Higinbotham, DW; Holmstrom, T; Ibrahim, H; Igarashi, R; de Jager, CW; Jans, E; Jiang, X; Kaufman, LJ; Kelleher, A; Kolarkar, A; Kumbartzki, G; LeRose, JJ; Lindgren, R; Liyanage, N; Margaziotis, DJ; Markowitz, P; Marrone, S; Mazouz, M; Meekins, D; Michaels, R; Moffit, B; Perdrisat, CF; Piasetzky, E; Potokar, M; Punjabi, V; Qiang, Y; Reinhold, J; Ron, G; Rosner, G; Saha, A; Sawatzky, B; Shahinyan, A; Sirca, S; Slifer, K; Solvignon, P; Sulkosky, V; Urciuoli, GM; Voutier, E; Watson, JW; Weinstein, LB; Wojtsekhowski, B; Wood, S; Zheng, XC; Zhu, L				Subedi, R.; Shneor, R.; Monaghan, P.; Anderson, B. D.; Aniol, K.; Annand, J.; Arrington, J.; Benaoum, H.; Benmokhtar, F.; Boeglin, W.; Chen, J. -P.; Choi, Seonho; Cisbani, E.; Craver, B.; Frullani, S.; Garibaldi, F.; Gilad, S.; Gilman, R.; Glamazdin, O.; Hansen, J. -O.; Higinbotham, D. W.; Holmstrom, T.; Ibrahim, H.; Igarashi, R.; de Jager, C. W.; Jans, E.; Jiang, X.; Kaufman, L. J.; Kelleher, A.; Kolarkar, A.; Kumbartzki, G.; LeRose, J. J.; Lindgren, R.; Liyanage, N.; Margaziotis, D. J.; Markowitz, P.; Marrone, S.; Mazouz, M.; Meekins, D.; Michaels, R.; Moffit, B.; Perdrisat, C. F.; Piasetzky, E.; Potokar, M.; Punjabi, V.; Qiang, Y.; Reinhold, J.; Ron, G.; Rosner, G.; Saha, A.; Sawatzky, B.; Shahinyan, A.; Sirca, S.; Slifer, K.; Solvignon, P.; Sulkosky, V.; Urciuoli, G. M.; Voutier, E.; Watson, J. W.; Weinstein, L. B.; Wojtsekhowski, B.; Wood, S.; Zheng, X. -C.; Zhu, L.			Probing cold dense nuclear matter	SCIENCE			English	Article							SHORT-RANGE CORRELATIONS	The protons and neutrons in a nucleus can form strongly correlated nucleon pairs. Scattering experiments, in which a proton is knocked out of the nucleus with high-momentum transfer and high missing momentum, show that in carbon-12 the neutron-proton pairs are nearly 20 times as prevalent as proton-proton pairs and, by inference, neutron-neutron pairs. This difference between the types of pairs is due to the nature of the strong force and has implications for understanding cold dense nuclear systems such as neutron stars.	[Chen, J. -P.; Gilman, R.; Hansen, J. -O.; Higinbotham, D. W.; de Jager, C. W.; LeRose, J. J.; Meekins, D.; Michaels, R.; Saha, A.; Wojtsekhowski, B.; Wood, S.] Thomas Jefferson Natl Accelerator Facil, Newport News, VA 23606 USA; [Subedi, R.; Anderson, B. D.; Watson, J. W.] Kent State Univ, Kent, OH 44242 USA; [Shneor, R.; Piasetzky, E.; Ron, G.] Tel Aviv Univ, IL-69978 Tel Aviv, Israel; [Monaghan, P.; Gilad, S.; Qiang, Y.; Zheng, X. -C.] MIT, Cambridge, MA 02139 USA; [Aniol, K.; Margaziotis, D. J.] Calif State Univ Los Angeles, Los Angeles, CA 90032 USA; [Annand, J.; Rosner, G.] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland; [Arrington, J.; Zheng, X. -C.] Argonne Natl Lab, Argonne, IL 60439 USA; [Benaoum, H.] Syracuse Univ, Syracuse, NY 13244 USA; [Benaoum, H.] Prince Mohammad Univ, Al Khobar 31952, Saudi Arabia; [Benmokhtar, F.; Kaufman, L. J.] Univ Maryland, College Pk, MD 20742 USA; [Boeglin, W.; Markowitz, P.; Reinhold, J.] Florida Int Univ, Miami, FL 33199 USA; [Choi, Seonho] Seoul Natl Univ, Seoul 151747, South Korea; [Cisbani, E.; Frullani, S.; Garibaldi, F.; Urciuoli, G. M.] Ist Nazl Fis Nucl, Sez Roma, I-00185 Rome, Italy; [Craver, B.; Lindgren, R.; Liyanage, N.; Sawatzky, B.; Slifer, K.; Zheng, X. -C.] Univ Virginia, Charlottesville, VA 22904 USA; [Gilman, R.; Jiang, X.; Kumbartzki, G.] Rutgers State Univ, Piscataway, NJ 08855 USA; [Glamazdin, O.] Kharkov Phys & Technol Inst, UA-310108 Kharkov, Ukraine; [Holmstrom, T.; Kelleher, A.; Moffit, B.; Perdrisat, C. F.; Sulkosky, V.] Coll William & Mary, Williamsburg, VA 23187 USA; [Ibrahim, H.; Weinstein, L. B.] Old Dominion Univ, Norfolk, VA 23508 USA; [Igarashi, R.] Univ Saskatchewan, Saskatoon, SK S7N 5E2, Canada; [Jans, E.] Natl Inst Subatomaire Fys, Amsterdam, Netherlands; [Kaufman, L. J.] Univ Massachusetts, Amherst, MA 01003 USA; [Kolarkar, A.] Univ Kentucky, Lexington, KY 40506 USA; [Marrone, S.] Dipartimento Fis, Bari, Italy; [Marrone, S.] Ist Nazl Fis Nucl, Sez Bari, I-70126 Bari, Italy; [Mazouz, M.; Voutier, E.] Lab Phys Subatom & Cosmol, F-38026 Grenoble, France; [Potokar, M.; Sirca, S.] Jozef Stefan Inst, Ljubljana 1000, Slovenia; [Punjabi, V.] Norfolk State Univ, Norfolk, VA 23504 USA; [Sawatzky, B.; Solvignon, P.] Temple Univ, Philadelphia, PA 19122 USA; [Shahinyan, A.] Yerevan Phys Inst, Yerevan 375036, Armenia; [Sirca, S.] Univ Ljubljana, Dept Phys, Ljubljana 1000, Slovenia; [Zhu, L.] Univ Illinois, Urbana, IL 61801 USA	United States Department of Energy (DOE); Jefferson National Accelerator; University System of Ohio; Kent State University; Kent State University Kent; Kent State University Salem; Tel Aviv University; Massachusetts Institute of Technology (MIT); California State University System; California State University Los Angeles; University of Glasgow; United States Department of Energy (DOE); Argonne National Laboratory; Syracuse University; University System of Maryland; University of Maryland College Park; State University System of Florida; Florida International University; Seoul National University (SNU); Istituto Nazionale di Fisica Nucleare (INFN); University of Virginia; Rutgers State University New Brunswick; Kharkov Institute of Physics & Technology; William & Mary; Old Dominion University; University of Saskatchewan; University of Massachusetts System; University of Massachusetts Amherst; University of Kentucky; Istituto Nazionale di Fisica Nucleare (INFN); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Institut National Polytechnique de Grenoble; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute; Norfolk State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Yerevan Physics Institute; University of Ljubljana; University of Illinois System; University of Illinois Urbana-Champaign	Higinbotham, DW (corresponding author), Thomas Jefferson Natl Accelerator Facil, Newport News, VA 23606 USA.	doug@jlab.org	Higinbotham, Douglas W./J-9394-2014; Cisbani, Evaristo/C-9249-2011; Ibrahim, Hassan/W-7713-2019; Markowitz, Pete/AAC-3382-2020; Rosner, Guenther/ABB-5516-2021; Arrington, John R/D-1116-2012; Benaoum, Hachemi/C-9101-2011	Higinbotham, Douglas W./0000-0003-2758-6526; Cisbani, Evaristo/0000-0002-6774-8473; Ibrahim, Hassan/0000-0002-4177-7209; Arrington, John R/0000-0002-0702-1328; Benaoum, Hachemi/0000-0003-4749-6675; Hachemi, Benaoum/0000-0002-5581-4314; Reinhold, Joerg/0000-0001-5876-9654; Kolarkar, Ameya/0000-0002-2068-2876; Gilman, Ronald/0000-0002-7106-2845; Mazouz, Malek/0000-0003-2375-4676; Qiang, Yi/0000-0001-7026-7841; Markowitz, Pete/0000-0002-5661-586X; Benmokhtar, Fatiha/0000-0003-3670-4045; Glamazdin, Alexander/0000-0002-4172-7324; Kumbartzki, Gerfried/0000-0003-4537-9280; Voutier, Eric/0000-0003-4990-3369				Aclander J, 1999, PHYS LETT B, V453, P211, DOI 10.1016/S0370-2693(99)00336-6; Alcorn J, 2004, NUCL INSTRUM METH A, V522, P294, DOI 10.1016/j.nima.2003.11.415; Baym G, 2002, NUCL PHYS A, V702, p3C, DOI 10.1016/S0375-9474(02)00684-X; BAYM G, 1995, NUCL PHYS A, V590, pC233, DOI 10.1016/0375-9474(95)00238-V; Benmokhtar F, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.082305; Dickhoff WH, 2004, PROG PART NUCL PHYS, V52, P377, DOI 10.1016/j.ppnp.2004.02.038; Egiyan KS, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.082501; Egiyan KS, 2003, PHYS REV C, V68, DOI 10.1103/PhysRevC.68.014313; FRANKFURT LL, 1981, PHYS REP, V76, P216, DOI 10.1016/0370-1573(81)90129-0; FRANKFURT LL, 1993, PHYS REV C, V48, P2451, DOI 10.1103/PhysRevC.48.2451; Frick T, 2005, PHYS REV C, V71, DOI 10.1103/PhysRevC.71.014313; Kelly JJ, 1996, ADV NUCL PHYS, V23, P75; LAPIKAS L, 1993, NUCL PHYS A, V553, pC297, DOI 10.1016/0375-9474(93)90630-G; Lattimer JM, 2004, SCIENCE, V304, P536, DOI 10.1126/science.1090720; Malki A, 2002, PHYS REV C, V65, DOI 10.1103/PhysRevC.65.015207; MARDOR I, 1992, PHYS REV C, V46, P761, DOI 10.1103/PhysRevC.46.761; Niyazov RA, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.052303; Piasetzky E, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.162504; Sargsian MM, 2005, PHYS REV C, V71, DOI 10.1103/PhysRevC.71.044615; Schiavilla R, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.132501; Shneor R, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.072501; Tang A, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.042301	22	315	322	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2008	320	5882					1476	1478		10.1126/science.1156675	http://dx.doi.org/10.1126/science.1156675			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18511658	Green Submitted			2022-12-28	WOS:000256676400039
J	Goldston, D				Goldston, David			A delicate balance	NATURE			English	Editorial Material											Goldston, D (corresponding author), Harvard Univ, Ctr Environm, Cambridge, MA 02138 USA.	partyofonecolumn@gmail.com							0	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 12	2008	453	7197					838	838		10.1038/453838a	http://dx.doi.org/10.1038/453838a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311WV	18548041	Bronze			2022-12-28	WOS:000256632000012
J	Roati, G; D'Errico, C; Fallani, L; Fattori, M; Fort, C; Zaccanti, M; Modugno, G; Modugno, M; Inguscio, M				Roati, Giacomo; D'Errico, Chiara; Fallani, Leonardo; Fattori, Marco; Fort, Chiara; Zaccanti, Matteo; Modugno, Giovanni; Modugno, Michele; Inguscio, Massimo			Anderson localization of a non-interacting Bose-Einstein condensate	NATURE			English	Article							QUANTUM DIFFUSION; LATTICES; LIGHT; ABSENCE	Anderson localization of waves in disordered media was originally predicted(1) fifty years ago, in the context of transport of electrons in crystals(2). The phenomenon is much more general(3) and has been observed in a variety of systems, including light waves(4,5). However, Anderson localization has not been observed directly for matter waves. Owing to the high degree of control over most of the system parameters ( in particular the interaction strength), ultracold atoms offer opportunities for the study of disorder- induced localization(6). Here we use a non- interacting Bose - Einstein condensate to study Anderson localization. The experiment is performed with a one- dimensional quasi- periodic lattice - a system that features a crossover between extended and exponentially localized states, as in the case of purely random disorder in higher dimensions. Localization is clearly demonstrated through investigations of the transport properties and spatial and momentum distributions. We characterize the crossover, finding that the critical disorder strength scales with the tunnelling energy of the atoms in the lattice. This controllable system may be used to investigate the interplay of disorder and interaction ( ref. 7 and references therein), and to explore exotic quantum phases(8,9).	[Roati, Giacomo; D'Errico, Chiara; Fallani, Leonardo; Fattori, Marco; Fort, Chiara; Zaccanti, Matteo; Modugno, Giovanni; Modugno, Michele; Inguscio, Massimo] Univ Florence, LENS, I-50019 Sesto Fiorentino, Italy; [Roati, Giacomo; D'Errico, Chiara; Fallani, Leonardo; Fattori, Marco; Fort, Chiara; Zaccanti, Matteo; Modugno, Giovanni; Modugno, Michele; Inguscio, Massimo] Univ Florence, Dept Fis, I-50019 Sesto Fiorentino, Italy; [Roati, Giacomo; D'Errico, Chiara; Fallani, Leonardo; Fattori, Marco; Fort, Chiara; Zaccanti, Matteo; Modugno, Giovanni; Inguscio, Massimo] INFM CNR, I-50019 Sesto Fiorentino, Italy; [Fattori, Marco] Ctr Studi Ric E Fermi, Museo Storico Fis, I-00184 Rome, Italy; [Modugno, Michele] Univ Florence, Dipartimento Matemat Applicata, I-50139 Florence, Italy; [Modugno, Michele] Univ Trent, BEC INFM Ctr, I-38050 Trento, Italy	University of Florence; University of Florence; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Florence; University of Trento	Inguscio, M (corresponding author), Univ Florence, LENS, I-50019 Sesto Fiorentino, Italy.	inguscio@lens.unifi.it	Fallani, Leonardo/C-5347-2008; Zaccanti, Matteo/D-2474-2014; D'Errico, Chiara/AAV-6574-2020; Fort, Chiara/B-9142-2018; roati, giacomo/C-5459-2009; Modugno, Michele/A-6218-2009; Modugno, Giovanni/AAT-9718-2021; Modugno, Giovanni/C-3179-2009; Fallani, Leonardo/GXN-0557-2022	Fallani, Leonardo/0000-0001-5327-3254; Zaccanti, Matteo/0000-0001-6214-4921; D'Errico, Chiara/0000-0003-0546-9900; Fort, Chiara/0000-0001-8817-3077; Modugno, Michele/0000-0002-0532-1423; Modugno, Giovanni/0000-0002-4394-8593; Modugno, Giovanni/0000-0002-4394-8593; Fallani, Leonardo/0000-0001-5327-3254; Inguscio, Massimo/0000-0001-8152-8103				ANDERSON PW, 1958, PHYS REV, V109, P1492, DOI 10.1103/PhysRev.109.1492; Aubry S., 1980, Annals of the Israel Physical Society, V3, P133; Aulbach C, 2004, NEW J PHYS, V6, DOI 10.1088/1367-2630/6/1/070; Burger S, 2002, EUROPHYS LETT, V57, P1, DOI 10.1209/epl/i2002-00532-1; Clement D, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.170409; D'Errico C, 2007, NEW J PHYS, V9, DOI 10.1088/1367-2630/9/7/223; Damski B, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.080403; Dubi Y, 2007, NATURE, V449, P876, DOI 10.1038/nature06180; Fallani L, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.130404; Fattori M, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.080405; Fort C, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.170410; Gerbier F, 2005, PHYS REV A, V72, DOI 10.1103/PhysRevA.72.053606; GREMPEL DR, 1982, PHYS REV LETT, V49, P833, DOI 10.1103/PhysRevLett.49.833; Hadzibabic Z, 2006, NATURE, V441, P1118, DOI 10.1038/nature04851; HARPER PG, 1955, P PHYS SOC LOND A, V68, P874, DOI 10.1088/0370-1298/68/10/304; KRAMER B, 1993, REP PROG PHYS, V56, P1469, DOI 10.1088/0034-4885/56/12/001; Lahini Y, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.013906; LEE PA, 1985, REV MOD PHYS, V57, P287, DOI 10.1103/RevModPhys.57.287; Lewenstein M, 2007, ADV PHYS, V56, P243, DOI 10.1080/00018730701223200; Lugan P, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.170403; Lye JE, 2007, PHYS REV A, V75, DOI 10.1103/PhysRevA.75.061603; Lye JE, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.070401; Ovchinnikov YB, 1999, PHYS REV LETT, V83, P284, DOI 10.1103/PhysRevLett.83.284; Pedri P, 2001, PHYS REV LETT, V87, part. no., DOI 10.1103/PhysRevLett.87.220401; Roati G, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.010403; ROUX G, 2008, QUASIPERIODIC BOSEHU; Schulte T, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.170411; Schwartz T, 2007, NATURE, V446, P52, DOI 10.1038/nature05623; VANALBADA MP, 1985, PHYS REV LETT, V55, P2692, DOI 10.1103/PhysRevLett.55.2692; Wiersma DS, 1997, NATURE, V390, P671, DOI 10.1038/37757; Zhong JX, 2001, PHYS REV LETT, V86, P2485, DOI 10.1103/PhysRevLett.86.2485	32	1244	1255	2	123	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2008	453	7197					895	U36		10.1038/nature07071	http://dx.doi.org/10.1038/nature07071			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311WV	18548066	Green Submitted			2022-12-28	WOS:000256632000037
J	Westaby, S				Westaby, Stephen			Advanced heart failure - an "off-the-shelf" solution?	LANCET			English	Editorial Material									Oxford Heart Ctr, Oxford OX3 9DU, England		Westaby, S (corresponding author), Oxford Heart Ctr, Oxford OX3 9DU, England.	swestaby@AHF.org.uk						BOYLE AJ, 2008, J AM COLL CARDIO SA, V51, pA69; Cadeiras Martin, 2007, Heart Fail Clin, V3, P321, DOI 10.1016/j.hfc.2007.04.004; DANDEL M, 2008, J AM COLL CARDIOL  S, V51, pA68; Lietz K, 2007, J AM COLL CARDIOL, V50, P1282, DOI 10.1016/j.jacc.2007.04.099; MCALISTER FA, 2007, JAMA-J AM MED ASSOC, V297, P2505; MOORE SA, 2008, J AM COLL CARDIOL  S, V51, pA68; Redfield MM, 2002, NEW ENGL J MED, V347, P1442, DOI 10.1056/NEJMe020115; Rose EA, 2001, NEW ENGL J MED, V345, P1435, DOI 10.1056/NEJMoa012175; ROSE EA, 2007, CIRCULATION, V116; Thekkudan J, 2008, J HEART LUNG TRANSPL, V27, pS122, DOI 10.1016/j.healun.2007.11.179; Vaidya V, 2008, J AM COLL CARDIOL, V51, pA258; Westaby S, 2000, LANCET, V356, P900, DOI 10.1016/S0140-6736(00)02680-5; 2008, HANSARD, V699, P265	13	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	2008	371	9628					1898	1900		10.1016/S0140-6736(08)60813-2	http://dx.doi.org/10.1016/S0140-6736(08)60813-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310OI	18539210				2022-12-28	WOS:000256538500010
J	Porto, JV				Porto, J. V.			Physics - Improving correlations despite particle loss	SCIENCE			English	Editorial Material									Univ Maryland, Natl Inst Stand & Technol, Joint Quantum Inst, Gaithersburg, MD 20899 USA	National Institute of Standards & Technology (NIST) - USA; University System of Maryland; University of Maryland College Park	Porto, JV (corresponding author), Univ Maryland, Natl Inst Stand & Technol, Joint Quantum Inst, Gaithersburg, MD 20899 USA.	trey@nist.gov	Porto, Trey/AAH-2101-2021	Porto, James/0000-0002-6290-7535				Brennen GK, 2005, J PHYS B-AT MOL OPT, V38, P1687, DOI 10.1088/0953-4075/38/11/010; Kinoshita T, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.190406; Syassen N, 2008, SCIENCE, V320, P1329, DOI 10.1126/science.1155309; WILCZEK F, 1982, PHYS REV LETT, V48, P1144, DOI 10.1103/PhysRevLett.48.1144	6	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	2008	320	5881					1300	1301		10.1126/science.1159748	http://dx.doi.org/10.1126/science.1159748			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309DO	18535233				2022-12-28	WOS:000256441100031
J	Kang, HK; Luff, AJ				Kang, Hyong Kwon; Luff, A. J.			Management of retinal detachment: a guide for non-ophthalmologists	BMJ-BRITISH MEDICAL JOURNAL			English	Review							LATTICE DEGENERATION; RISK; BREAKS; EYES; PREVALENCE; PATHOLOGY; FLOATERS; FLASHES; TEARS		[Kang, Hyong Kwon; Luff, A. J.] Southampton Univ Hosp NHS Trust, Eye Unit, Southampton SO16 6YD, Hants, England	University of Southampton; University Hospital Southampton NHS Foundation Trust	Kang, HK (corresponding author), 3 Colleen Close, Cherrybrook, NSW 2126, Australia.	kwonkang@ozemail.com.au						Abouzeid H, 2006, ACTA OPHTHALMOL SCAN, V84, P597, DOI 10.1111/j.1600-0420.2006.00676.x; AKIBA J, 1993, OPHTHALMOLOGY, V100, P1384; Boberg-Ans G, 2006, ACTA OPHTHALMOL SCAN, V84, P613, DOI 10.1111/j.1600-0420.2006.00719.x; BROD RD, 1991, OPHTHALMOLOGY, V98, P1366; Byer NE, 1998, OPHTHALMOLOGY, V105, P1045, DOI 10.1016/S0161-6420(98)96006-7; CELORIO JM, 1991, AM J OPHTHALMOL, V111, P20, DOI 10.1016/S0002-9394(14)76891-6; Classe J G, 1992, Optom Clin, V2, P113; Dayan MR, 1996, EYE, V10, P456, DOI 10.1038/eye.1996.100; Ghazi NG, 2002, EYE, V16, P411, DOI 10.1038/sj.eye.6700197; Go SL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1237, DOI 10.1001/archopht.123.9.1237; Gonzales CR, 2004, OPHTHALMOLOGY, V111, P518, DOI 10.1016/j.ophtha.2003.06.011; Green WR, 2006, RETINA-J RET VIT DIS, V3, P1921; Hikichi T, 1997, JPN J OPHTHALMOL, V41, P154, DOI 10.1016/S0021-5155(97)00033-6; HIKICHI T, 1994, AM J OPHTHALMOL, V117, P593, DOI 10.1016/S0002-9394(14)70065-0; Lee RWJ, 2008, EYE, V22, P636, DOI 10.1038/sj.eye.6702724; MARMOR MF, 2006, RETINA, P1891; Mastropasqua L, 1999, BRIT J OPHTHALMOL, V83, P1046, DOI 10.1136/bjo.83.9.1046; MURAKAMI F, 1982, OPHTHALMOLOGICA, V185, P136, DOI 10.1159/000309235; PETERS AL, 1995, S AFR MED J, V85, P158; Polkinghorne PJ, 2004, CLIN EXP OPHTHALMOL, V32, P159, DOI 10.1111/j.1442-9071.2004.00003.x; POLLAK A, 1981, BRIT J OPHTHALMOL, V65, P469, DOI 10.1136/bjo.65.7.469; Ripandelli G, 2003, OPHTHALMOLOGY, V110, P2355, DOI 10.1016/S0161-6420(03)00819-4; Sarrafizadeh R, 2001, OPHTHALMOLOGY, V108, P2273, DOI 10.1016/S0161-6420(01)00822-3; Saw SM, 2006, ACTA OPHTHALMOL SCAN, V84, P606, DOI 10.1111/j.1600-0420.2006.00715.x; Sharma S, 1999, ARCH OPHTHALMOL-CHIC, V117, P343, DOI 10.1001/archopht.117.3.343; TILLERY WV, 1976, T AM ACAD OPHTHALMOL, V81, pP509; Tuft SJ, 2006, OPHTHALMOLOGY, V113, P650, DOI 10.1016/j.ophtha.2006.01.001; Wang NK, 2005, OPHTHALMOLOGY, V112, P1891, DOI 10.1016/j.ophtha.2005.06.019; Wilkinson C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.Cd003170.pub2; Wong TY, 1999, ARCH OPHTHALMOL-CHIC, V117, P379, DOI 10.1001/archopht.117.3.379	30	35	35	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	2008	336	7655					1235	1240		10.1136/bmj.39581.525532.47	http://dx.doi.org/10.1136/bmj.39581.525532.47			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311PS	18511798	Green Published			2022-12-28	WOS:000256612700032
J	Santelli, CM; Orcutt, BN; Banning, E; Bach, W; Moyer, CL; Sogin, ML; Staudigel, H; Edwards, KJ				Santelli, Cara M.; Orcutt, Beth N.; Banning, Erin; Bach, Wolfgang; Moyer, Craig L.; Sogin, Mitchell L.; Staudigel, Hubert; Edwards, Katrina J.			Abundance and diversity of microbial life in ocean crust	NATURE			English	Article							DISSOLVED ORGANIC-CARBON; BACTERIAL; COMMUNITY; GEOMICROBIOLOGY; QUANTIFICATION; HYBRIDIZATION; PROGRAM	Oceanic lithosphere exposed at the sea floor undergoes seawater rock alteration reactions involving the oxidation and hydration of glassy basalt. Basalt alteration reactions are theoretically capable of supplying sufficient energy for chemolithoautotrophic growth(1). Such reactions have been shown to generate microbial biomass in the laboratory(2), but field- based support for the existence of microbes that are supported by basalt alteration is lacking. Here, using quantitative polymerase chain reaction, in situ hybridization and microscopy, we demonstrate that prokaryotic cell abundances on seafloor- exposed basalts are 3 - 4 orders of magnitude greater than in overlying deep sea water. Phylogenetic analyses of basaltic lavas from the East Pacific Rise ( 9 degrees N) and around Hawaii reveal that the basalt- hosted biosphere harbours high bacterial community richness and that community membership is shared between these sites. We hypothesize that alteration reactions fuel chemolithoautotrophic microorganisms, which constitute a trophic base of the basalt habitat, with important implications for deep- sea carbon cycling and chemical exchange between basalt and sea water.	[Santelli, Cara M.; Bach, Wolfgang; Edwards, Katrina J.] Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA; [Santelli, Cara M.; Banning, Erin] Woods Hole Oceanog Inst, MIT WHOI Joint Program Oceanog & Ocean Engn, Woods Hole, MA 02543 USA; [Orcutt, Beth N.; Edwards, Katrina J.] Univ So Calif, Geomicrobiol Grp, Dept Biol Sci, Los Angeles, CA 90089 USA; [Bach, Wolfgang] Univ Bremen, Fachbereich Geowissensch, D-28334 Bremen, Germany; [Moyer, Craig L.] Western Washington Univ, Dept Biol, Bellingham, WA 98225 USA; [Sogin, Mitchell L.] Marine Biol Lab, Josephine Bay Paul Ctr, Woods Hole, MA 02543 USA; [Staudigel, Hubert] Univ Calif San Diego, Scripps Inst Oceanog, Inst Geophys & Planetary Phys, La Jolla, CA 92037 USA	Woods Hole Oceanographic Institution; Massachusetts Institute of Technology (MIT); Woods Hole Oceanographic Institution; University of Southern California; University of Bremen; Western Washington University; Marine Biological Laboratory - Woods Hole; University of California System; University of California San Diego; Scripps Institution of Oceanography	Edwards, KJ (corresponding author), Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA.	kje@usc.edu	Orcutt, Beth N/A-4051-2011; Bach, Wolfgang/D-3713-2017; Santelli, Cara/AAG-2453-2019; Sogin, Mitchell/AAE-7186-2019	Orcutt, Beth N/0000-0002-6233-3578; Bach, Wolfgang/0000-0002-3099-7142; Santelli, Cara/0000-0001-8617-0008; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ashelford KE, 2006, APPL ENVIRON MICROB, V72, P5734, DOI 10.1128/AEM.00556-06; Bach W, 2003, GEOCHIM COSMOCHIM AC, V67, P3871, DOI 10.1016/S0016-7037(03)00304-1; BARBER RT, 1968, NATURE, V220, P274, DOI 10.1038/220274a0; Biddle JF, 2006, P NATL ACAD SCI USA, V103, P3846, DOI 10.1073/pnas.0600035103; Cole JR, 2003, NUCLEIC ACIDS RES, V31, P442, DOI 10.1093/nar/gkg039; Cowen JP, 2003, SCIENCE, V299, P120, DOI 10.1126/science.1075653; Daims H, 1999, SYST APPL MICROBIOL, V22, P434, DOI 10.1016/S0723-2020(99)80053-8; DAVIS RE, 2005, EOS T AGU S, V86; Edwards KJ, 2005, TRENDS MICROBIOL, V13, P449, DOI 10.1016/j.tim.2005.07.005; Edwards KJ, 2003, APPL ENVIRON MICROB, V69, P2906, DOI 10.1128/AEM.69.5.2906-2913.2003; Hong SH, 2006, P NATL ACAD SCI USA, V103, P117, DOI 10.1073/pnas.0507245102; Huber JA, 2006, ENVIRON MICROBIOL, V8, P88, DOI 10.1111/j.1462-2920.2005.00872.x; Huber JA, 2003, FEMS MICROBIOL ECOL, V43, P393, DOI 10.1111/j.1574-6941.2003.tb01080.x; Huber JA, 2007, SCIENCE, V318, P97, DOI 10.1126/science.1146689; Huber T, 2004, BIOINFORMATICS, V20, P2317, DOI 10.1093/bioinformatics/bth226; Hughes JB, 2005, METHOD ENZYMOL, V397, P292, DOI 10.1016/S0076-6879(05)97017-1; Hughes JB, 2001, APPL ENVIRON MICROB, V67, P4399, DOI 10.1128/AEM.67.10.4399-4406.2001; Karner MB, 2001, NATURE, V409, P507, DOI 10.1038/35054051; Klappenbach JA, 2001, NUCLEIC ACIDS RES, V29, P181, DOI 10.1093/nar/29.1.181; Kormas KA, 2006, ENVIRON MICROBIOL, V8, P909, DOI 10.1111/j.1462-2920.2005.00978.x; Kormas KA, 2003, FEMS MICROBIOL ECOL, V45, P115, DOI 10.1016/S0168-6496(03)00128-4; Lang SQ, 2006, GEOCHIM COSMOCHIM AC, V70, P3830, DOI 10.1016/j.gca.2006.04.031; Ley RE, 2006, APPL ENVIRON MICROB, V72, P3685, DOI 10.1128/AEM.72.5.3685-3695.2006; Nadkarni MA, 2002, MICROBIOL-SGM, V148, P257, DOI 10.1099/00221287-148-1-257; Pernthaler A, 2002, APPL ENVIRON MICROB, V68, P3094, DOI 10.1128/AEM.68.6.3094-3101.2002; RASKIN L, 1994, APPL ENVIRON MICROB, V60, P1232, DOI 10.1128/AEM.60.4.1232-1240.1994; Reysenbach AL, 2000, APPL ENVIRON MICROB, V66, P3798, DOI 10.1128/AEM.66.9.3798-3806.2000; Rogers DR, 2003, GEOBIOLOGY, V1, P109, DOI 10.1046/j.1472-4669.2003.00009.x; Schloss PD, 2006, APPL ENVIRON MICROB, V72, P6773, DOI 10.1128/AEM.00474-06; Schloss PD, 2005, APPL ENVIRON MICROB, V71, P1501, DOI 10.1128/AEM.71.3.1501-1506.2005; Sekar R, 2003, APPL ENVIRON MICROB, V69, P2928, DOI 10.1128/AEm.69.5.2928-2935.2003; Takai K, 2000, APPL ENVIRON MICROB, V66, P5066, DOI 10.1128/AEM.66.11.5066-5072.2000; Tringe SG, 2005, SCIENCE, V308, P554, DOI 10.1126/science.1107851; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Webster G, 2003, J MICROBIOL METH, V55, P155, DOI 10.1016/S0167-7012(03)00140-4; Whitman WB, 1998, P NATL ACAD SCI USA, V95, P6578, DOI 10.1073/pnas.95.12.6578	37	281	291	2	177	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	2008	453	7195					653	U7		10.1038/nature06899	http://dx.doi.org/10.1038/nature06899			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305NN	18509444				2022-12-28	WOS:000256185200044
J	Thompson, DWJ; Kennedy, JJ; Wallace, JM; Jones, PD				Thompson, David W. J.; Kennedy, John J.; Wallace, John M.; Jones, Phil D.			A large discontinuity in the mid-twentieth century in observed global-mean surface temperature	NATURE			English	Article								Data sets used to monitor the Earth's climate indicate that the surface of the Earth warmed from 1910 to 1940, cooled slightly from 1940 to 1970, and then warmed markedly from 1970 onward(1). The weak cooling apparent in the middle part of the century has been interpreted in the context of a variety of physical factors, such as atmosphere - ocean interactions and anthropogenic emissions of sulphate aerosols(2). Here we call attention to a previously overlooked discontinuity in the record at 1945, which is a prominent feature of the cooling trend in the midtwentieth century. The discontinuity is evident in published versions of the global- mean temperature time series(1), but stands out more clearly after the data are filtered for the effects of internal climate variability. We argue that the abrupt temperature drop of similar to 0.3 degrees C in 1945 is the apparent result of uncorrected instrumental biases in the sea surface temperature record. Corrections for the discontinuity are expected to alter the character of mid- twentieth century temperature variability but not estimates of the century-long trend in global- mean temperatures.	[Thompson, David W. J.] Colorado State Univ, Dept Atmospher Sci, Ft Collins, CO 80523 USA; [Kennedy, John J.] Met Off Hadley Ctr, Exeter EX1 3PB, Devon, England; [Wallace, John M.] Univ Washington, Dept Atmospher Sci, Seattle, WA 98195 USA; [Jones, Phil D.] Univ E Anglia, Climat Res Unit, Sch Environm Sci, Norwich NR4 7TJ, Norfolk, England	Colorado State University; Met Office - UK; Hadley Centre; University of Washington; University of Washington Seattle; University of East Anglia	Thompson, DWJ (corresponding author), Colorado State Univ, Dept Atmospher Sci, Ft Collins, CO 80523 USA.	davet@atmos.colostate.edu	Thompson, David W J/F-9627-2012; Jones, Philip Douglas/C-8718-2009	Thompson, David W J/0000-0002-5413-4376; Jones, Philip Douglas/0000-0001-5032-5493				Brohan P, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006548; FOLLAND CK, 1995, Q J ROY METEOR SOC, V121, P319, DOI 10.1002/qj.49712152206; Hegerl GC, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P663; Kent EC, 2006, J ATMOS OCEAN TECH, V23, P464, DOI 10.1175/JTECH1843.1; Kent EC, 2007, J ATMOS OCEAN TECH, V24, P214, DOI 10.1175/JTECH1949.1; Rayner NA, 2006, J CLIMATE, V19, P446, DOI 10.1175/JCLI3637.1; Robock A, 2007, ATMOS CHEM PHYS, V7, P2003, DOI 10.5194/acp-7-2003-2007; Smith TM, 2002, J CLIMATE, V15, P73, DOI 10.1175/1520-0442(2002)015<0073:BCFHSS>2.0.CO;2; Trenberth KE, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P235; WALLACE JM, 1995, SCIENCE, V270, P780, DOI 10.1126/science.270.5237.780; Worley SJ, 2005, INT J CLIMATOL, V25, P823, DOI 10.1002/joc.1166; YULAEVA E, 1994, J CLIMATE, V7, P1719, DOI 10.1175/1520-0442(1994)007<1719:TSOEIG>2.0.CO;2; 1963, MARINE OBSERVERS HDB	13	207	217	5	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	2008	453	7195					646	U5		10.1038/nature06982	http://dx.doi.org/10.1038/nature06982			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305NN	18509442				2022-12-28	WOS:000256185200042
J	Qureshi, AC; Lindsay, AC; Mensah, K; Jackson, JE; Farrimond, JG; Mittal, TK; Kelion, A; Khaghani, A; Mitchell, AG				Qureshi, Ayesha C.; Lindsay, Alistair C.; Mensah, Kwabena; Jackson, James E.; Farrimond, John G.; Mittal, Tarun K.; Kelion, Andrew; Khaghani, Asghar; Mitchell, Andrew G.			Tamponade and the rule of tens	LANCET			English	Editorial Material									[Qureshi, Ayesha C.; Lindsay, Alistair C.; Mensah, Kwabena; Kelion, Andrew; Khaghani, Asghar; Mitchell, Andrew G.] Harefield Hosp, Dept Cardiol & Cardiothorac Surg, Harefield UB9 6JH, Middx, England; [Farrimond, John G.] Harefield Hosp, Dept Anaesthet & Crit Care, Harefield UB9 6JH, Middx, England; [Mittal, Tarun K.] Harefield Hosp, Dept Radiol, Harefield UB9 6JH, Middx, England; [Jackson, James E.] Hammersmith Hosp, Dept Intervent Radiol, London, England	Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Imperial College London	Qureshi, AC (corresponding author), Harefield Hosp, Dept Cardiol & Cardiothorac Surg, Harefield UB9 6JH, Middx, England.	drkatiequreshi@yahoo.co.uk	Lindsay, Alistair/AAH-7128-2020					Beck CS, 1935, J AMER MED ASSOC, V104, P714, DOI 10.1001/jama.1935.02760090018005; Bilchick KC, 2002, LANCET, V359, P1940, DOI 10.1016/S0140-6736(02)08763-9; SHAPIRO B, 1984, J THORAC CARDIOV SUR, V87, P814; Spodick DH, 2003, NEW ENGL J MED, V349, P684, DOI 10.1056/NEJMra022643	4	0	0	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	2008	371	9626					1810	1810		10.1016/S0140-6736(08)60769-2	http://dx.doi.org/10.1016/S0140-6736(08)60769-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304IO	18502306				2022-12-28	WOS:000256103400036
J	Tardif, JC; McMurray, JJV; Klug, E; Small, R; Schumi, J; Choi, J; Cooper, J; Scott, R; Lewis, EF; L'Allier, PL; Pfeffer, MA				Tardif, Jean-Claude; McMurray, John J. V.; Klug, Eric; Small, Robert; Schumi, Jennifer; Choi, Jasmine; Cooper, Jim; Scott, Robert; Lewis, Eldrin F.; L'Allier, Philippe L.; Pfeffer, Marc A.		ARISE Trial Investigators	Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial	LANCET			English	Article							B TYPE-I; FEMORAL ATHEROSCLEROSIS; SELECTIVE-INHIBITION; OXIDATIVE STRESS; PROBUCOL; ANTIOXIDANT; EXPRESSION; PREVENTION; HYPERCHOLESTEROLEMIA; ROSIGLITAZONE	Background Oxidative stress and inflammation are involved in the pathophysiology of atherosclerosis. Our aim was to assess the effects of the antioxidant succinobucol (AGI-1067) on cardiovascular outcomes in patients with recent acute coronary syndromes already managed with conventional treatments. Methods After an acute coronary syndrome occurring 14-365 days before recruitment, 6144 patients were randomly assigned with a computer-generated randomisation list, stratified by study site, to receive succinobucol (n=3078) or placebo (n=3066) in addition to standard of care. Enrolment began in July, 2003; this event-driven trial was stopped in August, 2006, after the prespecified number of primary outcome events had occurred. The composite primary endpoint was time to first occurrence of cardiovascular death, resuscitated cardiac arrest, myocardial infarction, stroke, unstable angina, or coronary revascularisation. Efficacy analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00066898. Findings All randomised patients were included in the efficacy analyses. Succinobucol had no effect on the primary endpoint (530 events in succinobucol group vs 529 in placebo group; hazard ratio 1. 00, 95% Cl 0 . 89-1.13, p=0.96), The composite secondary endpoint of cardiovascular death, cardiac arrest, myocardial infarction, or stroke occurred in fewer patients in the succinobucol group than in the placebo group (207 vs 252 events; 0 . 81, 0.68-0.98, p=0.029). The tertiary endpoint of new-onset diabetes developed in fewer patients without diabetes at baseline in the succinobucol group than in such patients in the placebo group (30 of 1923 vs 82 of 1950 patients; 0 . 37, 0.24-0.56, p<0.0001). New-onset atrial fibrillation occurred more often in the succinobucol group than in the placebo group (107 of 2818 vs 55 of 2787 patients; 1 . 87, 1.67-2.09, p=0.0002). Although the number of patients who reported any treatment emergent adverse event was much the same in the two groups, more patients in the succinobucol group than in the placebo group reported bleeding episodes or anaemia (32 vs 18 and 37 vs ten, respectively) as serious adverse events. Relative to treatment with placebo, succinobucol increased LDL cholesterol and systolic blood pressure, and decreased HDL cholesterol and glycated haemoglobin (p<0 . 0001 for all). Interpretation Although succinobucol had no effect on the primary endpoint, changes in the rates of other clinical outcomes-both beneficial and harmful-will need to be further assessed before succinobucol. is used in patients with atherosclerosis or as an antidiabetic agent.	[Tardif, Jean-Claude; L'Allier, Philippe L.] Univ Montreal, Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; [McMurray, John J. V.] Univ Glasgow, British Heart Fdn, Cardiovasc Res Ctr, Glasgow, Lanark, Scotland; [Klug, Eric] Sunninghill Hosp, Johannesburg, South Africa; [Small, Robert; Choi, Jasmine; Cooper, Jim; Scott, Robert] AtheroGen Inc, Alpharetta, GA USA; [Schumi, Jennifer] Stat Collaborat Inc, Washington, DC USA; [Lewis, Eldrin F.; Pfeffer, Marc A.] Brigham & Womens Hosp, Boston, MA 02115 USA	Universite de Montreal; University of Glasgow; Harvard University; Brigham & Women's Hospital	Tardif, JC (corresponding author), Univ Montreal, Montreal Heart Inst, 5000 Belanger St, Montreal, PQ H1T 1C8, Canada.	jean-claude.tardif@icm-mhi.org	Arnold, Malcolm/G-2869-2011; Petrella, Robert J/G-6557-2018; mcmurray, John/B-2467-2013	mcmurray, John/0000-0002-6317-3975; Scott, Robert/0000-0001-8266-1061				American Diabetes Association, 2004, Diabetes Care, V27 Suppl 1, pS5, DOI 10.2337/diacare.27.2007.S5; Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5; Crow RS, 1997, AM J CARDIOL, V80, P138, DOI 10.1016/S0002-9149(97)00307-X; Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9; Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039; FUKUDA M, 1995, BIOCHEM BIOPH RES CO, V209, P953, DOI 10.1006/bbrc.1995.1590; Gerstein HC, 2006, LANCET, V368, P1096, DOI 10.1016/S0140-6736(06)69420-8; Gorogawa S, 2002, DIABETES RES CLIN PR, V57, P1, DOI 10.1016/S0168-8227(02)00005-0; Hirano K, 2005, ARTERIOSCL THROM VAS, V25, P2422, DOI 10.1161/01.ATV.0000185834.98941.3d; Home PD, 2007, NEW ENGL J MED, V357, P28, DOI 10.1056/NEJMoa073394; JOHANSSON J, 1995, ARTERIOSCL THROM VAS, V15, P1049, DOI 10.1161/01.ATV.15.8.1049; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kunsch C, 2004, J PHARMACOL EXP THER, V308, P820, DOI 10.1124/jpet.103.059733; Luyendyk JP, 2007, ARTERIOSCL THROM VAS, V27, P1857, DOI 10.1161/ATVBAHA.107.143552; Meng CQ, 2002, BIOORG MED CHEM LETT, V12, P2545, DOI 10.1016/S0960-894X(02)00516-4; Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761; Rinninger F, 1999, ARTERIOSCL THROM VAS, V19, P1325, DOI 10.1161/01.ATV.19.5.1325; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sawayama Y, 2002, J AM COLL CARDIOL, V39, P610, DOI 10.1016/S0735-1097(01)01783-1; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Sundell CL, 2003, J PHARMACOL EXP THER, V305, P1116, DOI 10.1124/jpet.102.048132; Tardif JC, 2003, CIRCULATION, V107, P552, DOI 10.1161/01.CIR.0000047525.58618.3C; Tardif JC, 1997, NEW ENGL J MED, V337, P365, DOI 10.1056/NEJM199708073370601; Tardif JC, 2008, ATHEROSCLEROSIS, V197, P480, DOI 10.1016/j.atherosclerosis.2006.11.039; Temple R, 2006, PHARMACOEPIDEM DR S, V15, P241, DOI 10.1002/pds.1211; UEHARA Y, 1991, DIABETES RES CLIN EX, V17, P131; WALLDIUS G, 1994, AM J CARDIOL, V74, P875, DOI 10.1016/0002-9149(94)90579-7; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; YAMAMOTO A, 1986, AM J CARDIOL, V57, pH29, DOI 10.1016/0002-9149(86)90434-0; Zhang YZ, 2005, J CLIN INVEST, V115, P2870, DOI 10.1172/JCI25327	31	148	154	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	2008	371	9626					1761	1768		10.1016/S0140-6736(08)60763-1	http://dx.doi.org/10.1016/S0140-6736(08)60763-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304IO	18502300				2022-12-28	WOS:000256103400030
J	Strom, SL				Strom, Suzanne L.			Microbial ecology of ocean biogeochemistry: A community perspective	SCIENCE			English	Review							EMILIANIA-HUXLEYI; CHEMICAL DEFENSE; HETEROTROPHIC PROTISTS; PHYTOPLANKTON BLOOM; GROWTH-RATES; MARINE; TRAITS; SPECIFICITY; INHIBITION; ECOSYSTEM	The oceans harbor a tremendous diversity of marine microbes. Different functional groups of bacteria, archaea, and protists arise from this diversity to dominate various habitats and drive globally important biogeochemical cycles. Explanations for the distribution of microbial taxa and their associated activity often focus on resource availability and abiotic conditions. However, the continual reshaping of communities by mortality, allelopathy, symbiosis, and other processes shows that community interactions exert strong selective pressure on marine microbes. Deeper exploration of microbial interactions is now possible via molecular prospecting and taxon- specific experimental approaches. A holistic outlook that encompasses the full array of selective pressures on individuals will help elucidate the maintenance of microbial diversity and the regulation of biogeochemical reactions by planktonic communities.	[Strom, Suzanne L.] Western Washington Univ, Shannon Point Marine Ctr, Anacortes, WA 98221 USA	Western Washington University	Strom, SL (corresponding author), Western Washington Univ, Shannon Point Marine Ctr, Anacortes, WA 98221 USA.	Suzanne.Strom@wwu.edu						Assmy P, 2007, DEEP-SEA RES PT I, V54, P340, DOI 10.1016/j.dsr.2006.12.005; Bidle KD, 2004, NAT REV MICROBIOL, V2, P643, DOI 10.1038/nrmicro956; Calbet A, 2004, LIMNOL OCEANOGR, V49, P51, DOI 10.4319/lo.2004.49.1.0051; DeLong EF, 2006, SCIENCE, V311, P496, DOI 10.1126/science.1120250; Falkowski PG, 2008, SCIENCE, V320, P1034, DOI 10.1126/science.1153213; FENCHEL T, 1995, OPHELIA, V43, P45, DOI 10.1080/00785326.1995.10430576; FROST BW, 1980, PHYSL ECOLOGY PHYTOP, V7, P465; Green JL, 2008, SCIENCE, V320, P1039, DOI 10.1126/science.1153475; Hamm CE, 2003, NATURE, V421, P841, DOI 10.1038/nature01416; Henneke P, 2004, J EXP MED, V199, P1, DOI 10.1084/jem.20031256; Hutchins DA, 1999, NATURE, V400, P858, DOI 10.1038/23680; Johnson ZI, 2006, SCIENCE, V311, P1737, DOI 10.1126/science.1118052; Legrand C, 2003, PHYCOLOGIA, V42, P406, DOI 10.2216/i0031-8884-42-4-406.1; Litchman E, 2007, ECOL LETT, V10, P1170, DOI 10.1111/j.1461-0248.2007.01117.x; Long RA, 2001, APPL ENVIRON MICROB, V67, P4975, DOI 10.1128/AEM.67.11.4975-4983.2001; Longhurst, 2006, ECOLOGICAL GEOGRAPHY; Marshall JA, 2005, MAR BIOL, V147, P533, DOI 10.1007/s00227-005-1596-7; MATRAI PA, 1993, CONT SHELF RES, V13, P831, DOI 10.1016/0278-4343(93)90012-M; Matz C, 2002, AQUAT MICROB ECOL, V27, P137, DOI 10.3354/ame027137; Mills Eric., 1989, BIOL OCEANOGRAPHY EA; Mizumoto H, 2007, J VIROL, V81, P1372, DOI 10.1128/JVI.01082-06; Palenik B, 2003, NATURE, V424, P1037, DOI 10.1038/nature01943; Palenik B, 2006, P NATL ACAD SCI USA, V103, P13555, DOI 10.1073/pnas.0602963103; Pinhassi J, 2005, APPL ENVIRON MICROB, V71, P7650, DOI 10.1128/AEM.71.12.7650-7660.2005; Pohnert G, 2005, CHEMBIOCHEM, V6, P946, DOI 10.1002/cbic.200400348; Rose JM, 2007, LIMNOL OCEANOGR, V52, P886, DOI 10.4319/lo.2007.52.2.0886; Smayda Theodore J., 2002, Harmful Algae, V1, P95, DOI 10.1016/S1568-9883(02)00010-0; Steinke M, 1996, BIOLOGICAL AND ENVIRONMENTAL CHEMISTRY OF DMSP AND RELATED SULFONIUM COMPOUNDS, P317; Strom S, 2003, LIMNOL OCEANOGR, V48, P217, DOI 10.4319/lo.2003.48.1.0217; Strom S, 2003, LIMNOL OCEANOGR, V48, P230, DOI 10.4319/lo.2003.48.1.0230; Strom SL, 2000, MICROBIAL ECOLOGY OC, P351; Strom SL, 2007, AQUAT MICROB ECOL, V47, P107, DOI 10.3354/ame047107; Strom SL, 2007, LIMNOL OCEANOGR, V52, P1480, DOI 10.4319/lo.2007.52.4.1480; Suttle CA, 2007, NAT REV MICROBIOL, V5, P801, DOI 10.1038/nrmicro1750; Tillmann U, 2003, AQUAT MICROB ECOL, V32, P73, DOI 10.3354/ame032073; Vardi A, 2006, PLOS BIOL, V4, P411, DOI 10.1371/journal.pbio.0040060; Wilson WH, 2002, J MAR BIOL ASSOC UK, V82, P369, DOI 10.1017/S002531540200560X; Wolfe GV, 1996, LIMNOL OCEANOGR, V41, P1151, DOI 10.4319/lo.1996.41.6.1151; Wootton EC, 2007, ENVIRON MICROBIOL, V9, P216, DOI 10.1111/j.1462-2920.2006.01130.x; ZUBKOV MV, 1992, FEMS MICROBIOL ECOL, V101, P245	40	176	190	16	202	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2008	320	5879					1043	1045		10.1126/science.1153527	http://dx.doi.org/10.1126/science.1153527			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18497289				2022-12-28	WOS:000256059800035
J	Keren, K; Pincus, Z; Allen, GM; Barnhart, EL; Marriott, G; Mogilner, A; Theriot, JA				Keren, Kinneret; Pincus, Zachary; Allen, Greg M.; Barnhart, Erin L.; Marriott, Gerard; Mogilner, Alex; Theriot, Julie A.			Mechanism of shape determination in motile cells	NATURE			English	Article							FISH KERATOCYTES; RETROGRADE FLOW; LEADING-EDGE; ACTIN; DYNAMICS; LAMELLIPODIA; CYTOSKELETON; LOCOMOTION; FRAGMENTS; MIGRATION	The shape of motile cells is determined by many dynamic processes spanning several orders of magnitude in space and time, from local polymerization of actin monomers at subsecond timescales to global, cell-scale geometry that may persist for hours. Understanding the mechanism of shape determination in cells has proved to be extremely challenging due to the numerous components involved and the complexity of their interactions. Here we harness the natural phenotypic variability in a large population of motile epithelial keratocytes from fish (Hypsophrys nicaraguensis) to reveal mechanisms of shape determination. We find that the cells inhabit a low-dimensional, highly correlated spectrum of possible functional states. We further show that a model of actin network treadmilling in an inextensible membrane bag can quantitatively recapitulate this spectrum and predict both cell shape and speed. Our model provides a simple biochemical and biophysical basis for the observed morphology and behaviour of motile cells.	[Keren, Kinneret; Pincus, Zachary; Allen, Greg M.; Barnhart, Erin L.; Theriot, Julie A.] Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; [Theriot, Julie A.] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Keren, Kinneret] Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel; [Pincus, Zachary] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; [Marriott, Gerard] Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; [Mogilner, Alex] Univ Calif Davis, Dept Neurobiol Physiol & Behav, Davis, CA 95616 USA; [Mogilner, Alex] Univ Calif Davis, Dept Math, Davis, CA 95616 USA	Stanford University; Stanford University; Technion Israel Institute of Technology; Yale University; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Davis; University of California System; University of California Davis	Theriot, JA (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.	theriot@stanford.edu	Mogilner, Alex/A-3135-2008; Theriot, Julie/HHN-2034-2022	Keren, Kinneret/0000-0002-2962-6977; Pincus, Zachary/0000-0001-9785-5977; Marriott, Gerard/0000-0003-3197-4839; Theriot, Julie/0000-0002-2334-2535	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM064346] Funding Source: NIH RePORTER; NIGMS NIH HHS [U54 GM064346-099040, U54 GM64346, U54 GM064346] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson KI, 2000, CURR BIOL, V10, P253, DOI 10.1016/S0960-9822(00)00357-2; Bakal C, 2007, SCIENCE, V316, P1753, DOI 10.1126/science.1140324; Carlier MF, 2007, J BIOL CHEM, V282, P23005, DOI 10.1074/jbc.R700020200; COOTES TF, 1995, COMPUT VIS IMAGE UND, V61, P38, DOI 10.1006/cviu.1995.1004; EUTENEUER U, 1984, NATURE, V310, P58, DOI 10.1038/310058a0; Footer MJ, 2007, P NATL ACAD SCI USA, V104, P2181, DOI 10.1073/pnas.0607052104; GANDER W, 1994, BIT, V34, P558, DOI 10.1007/BF01934268; Goodrich HB, 1924, BIOL BULL-US, V46, P252, DOI 10.2307/1536726; Grimm HP, 2003, EUR BIOPHYS J BIOPHY, V32, P563, DOI 10.1007/s00249-003-0300-4; Jurado C, 2005, MOL BIOL CELL, V16, P507, DOI 10.1091/mbc.E04-10-0860; Kovar DR, 2004, P NATL ACAD SCI USA, V101, P14725, DOI 10.1073/pnas.0405902101; Kozlov MM, 2007, BIOPHYS J, V93, P3811, DOI 10.1529/biophysj.107.110411; KUCIK DF, 1990, J CELL BIOL, V111, P1617, DOI 10.1083/jcb.111.4.1617; Lacayo CI, 2007, PLOS BIOL, V5, P2035, DOI 10.1371/journal.pbio.0050233; LEE J, 1993, NATURE, V362, P167, DOI 10.1038/362167a0; Lee J, 1997, J CELL SCI, V110, P2833; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Parekh SH, 2005, NAT CELL BIOL, V7, P1219, DOI 10.1038/ncb1336; Petchprayoon C, 2005, BIOCONJUGATE CHEM, V16, P1382, DOI 10.1021/bc050006j; Pincus Z, 2007, J MICROSC-OXFORD, V227, P140, DOI 10.1111/j.1365-2818.2007.01799.x; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Prass M, 2006, J CELL BIOL, V174, P767, DOI 10.1083/jcb.200601159; Raucher D, 2000, J CELL BIOL, V148, P127, DOI 10.1083/jcb.148.1.127; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; SANGER JW, 1980, J EXP ZOOL, V213, P227, DOI 10.1002/jez.1402130210; SCHAUS TE, IN PRESS BIOPHYS J; Sheetz MP, 2006, ANNU REV BIOPH BIOM, V35, P417, DOI 10.1146/annurev.biophys.35.040405.102017; Svitkina TM, 1997, J CELL BIOL, V139, P397, DOI 10.1083/jcb.139.2.397; Tanaka J, 2003, P NATL ACAD SCI USA, V100, P13851, DOI 10.1073/pnas.2233339100; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; Vallotton P, 2005, MOL BIOL CELL, V16, P1223, DOI 10.1091/mbc.E04-07-0615; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; Watanabe N, 2002, SCIENCE, V295, P1083, DOI 10.1126/science.1067470; Wilson CA, 2006, IEEE T IMAGE PROCESS, V15, P1939, DOI 10.1109/TIP.2006.873434; Zaidel-Bar R, 2004, BIOCHEM SOC T, V32, P416, DOI 10.1042/BST0320416	36	511	516	2	84	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 22	2008	453	7194					475	U1		10.1038/nature06952	http://dx.doi.org/10.1038/nature06952			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303EL	18497816	Green Accepted, Bronze			2022-12-28	WOS:000256023700033
J	Rousseau, P				Rousseau, Paul			Wanting	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												palliativedoctor@aol.com							0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	2008	299	23					2722	2722		10.1001/jama.299.23.2722	http://dx.doi.org/10.1001/jama.299.23.2722			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314JH	18559992				2022-12-28	WOS:000256805200001
J	Isaacs, D				Isaacs, David			Commentary: Controversies in SIGN guidance on management of invasive meningococcal disease in children and young people	BRITISH MEDICAL JOURNAL			English	Editorial Material							HEALTH-CARE-DELIVERY		[Isaacs, David] Childrens Hosp Westmead, Dept Infect Dis & Microbiol, Westmead, NSW 2145, Australia; [Isaacs, David] Univ Sydney, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney	Isaacs, D (corresponding author), Childrens Hosp Westmead, Dept Infect Dis & Microbiol, Westmead, NSW 2145, Australia.	davidi@chw.edu.au						Booy R, 2001, ARCH DIS CHILD, V85, P386, DOI 10.1136/adc.85.5.386; Gray SJ, 2006, J MED MICROBIOL, V55, P887, DOI 10.1099/jmm.0.46288-0; HAMDEN A, 2007, BRIT MED J, V335, P409; Heyderman RS, 2004, ARCH DIS CHILD, V89, P1064, DOI 10.1136/adc.2003.036004; Ninis N, 2005, BRIT MED J, V330, P1475, DOI 10.1136/bmj.330.7506.1475; Thompson MJ, 2006, LANCET, V367, P397, DOI 10.1016/S0140-6736(06)67932-4	6	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 14	2008	336	7657					1370	1371		10.1136/bmj.a240	http://dx.doi.org/10.1136/bmj.a240			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316YB	18556319	Green Published			2022-12-28	WOS:000256984700045
J	Noorani, MA				Noorani, M. A.			Commercial transplantation in Pakistan	BRITISH MEDICAL JOURNAL			English	Editorial Material												maqsoodnoorani@yahoo.co.uk							0	7	7	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 14	2008	336	7657					1378	1378		10.1136/bmj.39559.489051.94	http://dx.doi.org/10.1136/bmj.39559.489051.94			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316YB	18556323	Green Published			2022-12-28	WOS:000256984700049
J	Billy, J; Josse, V; Zuo, ZC; Bernard, A; Hambrecht, B; Lugan, P; Clement, D; Sanchez-Palencia, L; Bouyer, P; Aspect, A				Billy, Juliette; Josse, Vincent; Zuo, Zhanchun; Bernard, Alain; Hambrecht, Ben; Lugan, Pierre; Clement, David; Sanchez-Palencia, Laurent; Bouyer, Philippe; Aspect, Alain			Direct observation of Anderson localization of matter waves in a controlled disorder	NATURE			English	Article							LATTICES; DIFFUSION; TRANSPORT; LIGHT	In 1958, Anderson predicted the localization(1) of electronic wave-functions in disordered crystals and the resulting absence of diffusion. It is now recognized that Anderson localization is ubiquitous in wave physics(2) because it originates from the interference between multiple scattering paths. Experimentally, localization has been reported for light waves(3-7), microwaves(8,9), sound waves(10) and electron gases(11). However, there has been no direct observation of exponential spatial localization of matter waves of any type. Here we observe exponential localization of a Bose Einstein condensate released into a one- dimensional waveguide in the presence of a controlled disorder created by laser speckle(12). We operate in a regime of pure Anderson localization, that is, with weak disorder - such that localization results from many quantum reflections of low amplitude - and an atomic density low enough to render interactions negligible. We directly image the atomic density profiles as a function of time, and find that weak disorder can stop the expansion and lead to the formation of a stationary, exponentially localized wavefunction - a direct signature of Anderson localization. We extract the localization length by fitting the exponential wings of the profiles, and compare it to theoretical calculations. The power spectrum of the one- dimensional speckle potentials has a high spatial frequency cutoff, causing exponential localization to occur only when the de Broglie wavelengths of the atoms in the expanding condensate are greater than an effective mobility edge corresponding to that cutoff. In the opposite case, we find that the density profiles decay algebraically, as predicted in ref. 13. The method presented here can be extended to localization of atomic quantum gases in higher dimensions, and with controlled interactions.	[Billy, Juliette; Josse, Vincent; Zuo, Zhanchun; Bernard, Alain; Hambrecht, Ben; Lugan, Pierre; Clement, David; Sanchez-Palencia, Laurent; Bouyer, Philippe; Aspect, Alain] Ecole Polytech, CNRS, Lab Charles Fabry, Inst Opt, F-91127 Palaiseau, France; [Billy, Juliette; Josse, Vincent; Zuo, Zhanchun; Bernard, Alain; Hambrecht, Ben; Lugan, Pierre; Clement, David; Sanchez-Palencia, Laurent; Bouyer, Philippe; Aspect, Alain] Univ Paris Sud, F-91127 Palaiseau, France	Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Bouyer, P (corresponding author), Ecole Polytech, CNRS, Lab Charles Fabry, Inst Opt, Campus Polytech,RD 128, F-91127 Palaiseau, France.	philippe.bouyer@institutoptique.fr	Josse, Vincent/M-5199-2017; Bernard, Alain/B-6142-2012; Billy, Juliette/H-5765-2013; BOUYER, Philippe/A-9823-2009; Sanchez-Palencia, Laurent/C-5586-2012; CLEMENT, David/A-1915-2009	Josse, Vincent/0000-0003-1461-9747; BOUYER, Philippe/0000-0003-4458-0089; Sanchez-Palencia, Laurent/0000-0003-1839-6173; CLEMENT, David/0000-0003-1451-0610				Akkermans E., 2006, MESOSCOPIC PHYS ELEC; ANDERSON PW, 1958, PHYS REV, V109, P1492, DOI 10.1103/PhysRev.109.1492; Bilas N, 2006, EUR PHYS J D, V40, P387, DOI 10.1140/epjd/e2006-00166-3; BLOCH I, 2007, IN PRESS REV MOD PHY; Chabanov AA, 2000, NATURE, V404, P850, DOI 10.1038/35009055; CHABE J, 2007, EXPT OBSERVATION AND; Clement D, 2006, NEW J PHYS, V8, DOI 10.1088/1367-2630/8/8/165; Clement D, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.170409; DALICHAOUCH R, 1991, NATURE, V354, P53, DOI 10.1038/354053a0; Damski B, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.080403; Fallani L, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.130404; FISHER MPA, 1989, PHYS REV B, V40, P546, DOI 10.1063/1.38820; Fort C, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.170410; GIAMARCHI T, 1988, PHYS REV B, V37, P325, DOI 10.1103/PhysRevB.37.325; Goodman JW., 2020, SPECKLE PHENOMENA OP; Guerin W, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.200402; Kuhn RC, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.250403; Lahini Y, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.013906; Lewenstein M, 2007, ADV PHYS, V56, P243, DOI 10.1080/00018730701223200; Lugan P, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.180402; Lugan P, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.170403; MOORE FL, 1994, PHYS REV LETT, V73, P2974, DOI 10.1103/PhysRevLett.73.2974; Sanchez-Palencia L, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.210401; Sanpera A, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.040401; Scheffold F, 1999, NATURE, V398, P206, DOI 10.1038/18347; Schulte T, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.170411; Schwartz T, 2007, NATURE, V446, P52, DOI 10.1038/nature05623; Skipetrov SE, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.165301; Storzer M, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.063904; van Tiggelen B., 1999, WAVE DIFFUSION COMPL, P1; WEAVER RL, 1990, WAVE MOTION, V12, P129, DOI 10.1016/0165-2125(90)90034-2; Wiersma DS, 1997, NATURE, V390, P671, DOI 10.1038/37757	32	1175	1191	10	210	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2008	453	7197					891	894		10.1038/nature07000	http://dx.doi.org/10.1038/nature07000			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311WV	18548065	Green Submitted			2022-12-28	WOS:000256632000036
J	Greene, B; Nurse, P				Greene, Brian; Nurse, Paul			Science on the streets of the big apple	CELL			English	Editorial Material								A five-day festival of science takes place this week at venues across New York City. The festival features not only leading researchers from New York and beyond but also actors, writers, musicians, and choreographers in a series of multimedia programs designed to reveal science to the general public in exciting new ways.	[Greene, Brian] Columbia Univ, Dept Phys, New York, NY 10027 USA; [Nurse, Paul] Rockefeller Univ, New York, NY 10021 USA	Columbia University; Rockefeller University	Greene, B (corresponding author), Columbia Univ, Dept Phys, 538 W 120th St, New York, NY 10027 USA.	greene@physics.columbia.edu; nurse@mail.rockefeller.edu							0	0	0	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 30	2008	133	5					757	758		10.1016/j.cell.2008.05.017	http://dx.doi.org/10.1016/j.cell.2008.05.017			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510916	Bronze			2022-12-28	WOS:000256274500004
J	Li, D; Kaner, RB				Li, Dan; Kaner, Richard B.			Materials science - Graphene-based materials	SCIENCE			English	Editorial Material							FUNCTIONALIZED GRAPHENE; AQUEOUS DISPERSIONS; OXIDE; GRAPHITE; FILMS; TRANSPARENT; REDUCTION		[Li, Dan] Univ Wollongong, ARC Ctr Excellence Electromat Sci, Intelligent Polymer Res Inst, Wollongong, NSW 2522, Australia; [Kaner, Richard B.] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; [Kaner, Richard B.] Univ Calif Los Angeles, Dept Mat Sci & Engn, Los Angeles, CA 90095 USA; [Kaner, Richard B.] Univ Calif Los Angeles, Calif Nanosyst Inst, Los Angeles, CA 90095 USA	University of Wollongong; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Li, D (corresponding author), Univ Wollongong, ARC Ctr Excellence Electromat Sci, Intelligent Polymer Res Inst, Wollongong, NSW 2522, Australia.	danli@uow.edu.au; kaner@chem.ucla.edu	Wang, Huanting/G-8399-2011; Kaner, Richard B./K-1594-2019; Li, Dan/B-9316-2008	Wang, Huanting/0000-0002-9887-5555; Kaner, Richard B./0000-0003-0345-4924; Li, Dan/0000-0003-3461-5751				Becerril HA, 2008, ACS NANO, V2, P463, DOI 10.1021/nn700375n; Berger C, 2006, SCIENCE, V312, P1191, DOI 10.1126/science.1125925; Bunch JS, 2007, SCIENCE, V315, P490, DOI 10.1126/science.1136836; Dikin DA, 2007, NATURE, V448, P457, DOI 10.1038/nature06016; Eda G, 2008, NAT NANOTECHNOL, V3, P270, DOI 10.1038/nnano.2008.83; Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849; Gilje S, 2007, NANO LETT, V7, P3394, DOI 10.1021/nl0717715; Gomez-Navarro C, 2007, NANO LETT, V7, P3499, DOI 10.1021/nl072090c; Li D, 2008, NAT NANOTECHNOL, V3, P101, DOI 10.1038/nnano.2007.451; Li XL, 2008, SCIENCE, V319, P1229, DOI 10.1126/science.1150878; McAllister MJ, 2007, CHEM MATER, V19, P4396, DOI 10.1021/cm0630800; Niyogi S, 2006, J AM CHEM SOC, V128, P7720, DOI 10.1021/ja060680r; Stankovich S, 2006, J MATER CHEM, V16, P155, DOI 10.1039/b512799h; Stankovich S, 2007, CARBON, V45, P1558, DOI 10.1016/j.carbon.2007.02.034; Stankovich S, 2006, NATURE, V442, P282, DOI 10.1038/nature04969; Wang X, 2008, NANO LETT, V8, P323, DOI 10.1021/nl072838r; Wu JS, 2007, CHEM REV, V107, P718, DOI 10.1021/cr068010r; Xu YX, 2008, J AM CHEM SOC, V130, P5856, DOI 10.1021/ja800745y	18	1299	1364	4	772	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	2008	320	5880					1170	1171		10.1126/science.1158180	http://dx.doi.org/10.1126/science.1158180			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306FF	18511678				2022-12-28	WOS:000256233000024
J	Pronin, E				Pronin, Emily			How we see ourselves and how we see others	SCIENCE			English	Review							BIAS BLIND SPOT; INTROSPECTION ILLUSION; PLURALISTIC IGNORANCE; PERSPECTIVE-TAKING; SOCIAL-INTERACTION; SELF; PERCEPTIONS; FUTURE; TRANSPARENCY; PROJECTION	People see themselves differently from how they see others. They are immersed in their own sensations, emotions, and cognitions at the same time that their experience of others is dominated by what can be observed externally. This basic asymmetry has broad consequences. It leads people to judge themselves and their own behavior differently from how they judge others and those others' behavior. Often, those differences produce disagreement and conflict. Understanding the psychological basis of those differences may help mitigate some of their negative effects.	[Pronin, Emily] Princeton Univ, Dept Psychol, Princeton, NJ 08540 USA; [Pronin, Emily] Princeton Univ, Woodrow Wilson Sch Publ & Int Affairs, Princeton, NJ 08540 USA	Princeton University; Princeton University	Pronin, E (corresponding author), Princeton Univ, Dept Psychol, Princeton, NJ 08540 USA.	epronin@princeton.edu						Ames DR, 2004, J PERS SOC PSYCHOL, V87, P340, DOI 10.1037/0022-3514.87.3.340; ANDERSEN SM, 1984, J PERS SOC PSYCHOL, V46, P280, DOI 10.1037/0022-3514.46.2.280; Bargh JA, 2006, CURR DIR PSYCHOL SCI, V15, P1, DOI 10.1111/j.0963-7214.2006.00395.x; Bargh JA, 2008, PERSPECT PSYCHOL SCI, V3, P73, DOI 10.1111/j.1745-6916.2008.00064.x; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; BUEHLER R, 1994, J PERS SOC PSYCHOL, V67, P366, DOI 10.1037/0022-3514.67.3.366; Chartrand TL, 1999, J PERS SOC PSYCHOL, V76, P893, DOI 10.1037/0022-3514.76.6.893; Dawkins Richard, 1976, SELFISH GENE; Dinstein I, 2008, CURR BIOL, V18, pR13, DOI 10.1016/j.cub.2007.11.004; Douglas KM, 2004, BRIT J SOC PSYCHOL, V43, P585, DOI 10.1348/0144666042565416; Epley N, 2004, J PERS SOC PSYCHOL, V87, P327, DOI 10.1037/0022-3514.87.3.327; Epley N, 2000, J PERS SOC PSYCHOL, V79, P861, DOI 10.1037//0022-3514.79.6.861; Epley N, 2006, J PERS SOC PSYCHOL, V91, P872, DOI 10.1037/0022-3514.91.5.872; Fang X, 2007, J CONSUM RES, V34, P97, DOI 10.1086/513050; Frantz CM, 2006, BASIC APPL SOC PSYCH, V28, P157, DOI 10.1207/s15324834basp2802_5; FREDERICK S, 2003, TIME DECISION, P89; Gilbert DT, 2007, SCIENCE, V317, P1351, DOI 10.1126/science.1144161; GILBERT DT, 1995, PSYCHOL BULL, V117, P21, DOI 10.1037/0033-2909.117.1.21; HASTORF AH, 1954, J ABNORM SOC PSYCH, V49, P129, DOI 10.1037/h0057880; ICHHEISER G, 1949, AM J SOCIOL S, V55; Jones E. E., 1972, ATTRIBUTION PERCEIV; KENNY DA, 1987, PSYCHOL BULL, V102, P390, DOI 10.1037/0033-2909.102.3.390; Keysar B, 2002, PSYCHOL SCI, V13, P207, DOI 10.1111/1467-9280.00439; Kruger J, 2004, PERS SOC PSYCHOL B, V30, P328, DOI 10.1177/0146167203259932; Leakey R., 1992, ORIGINS RECONSIDERED; Libby LK, 2002, J PERS SOC PSYCHOL, V82, P167, DOI 10.1037//0022-3514.82.2.167; Liberman N., 2007, SOCIAL PSYCHOL HDB B, P353; Malle B. F., 2005, NEW UNCONSCIOUS, P225; Malloy TE, 2007, INT J BEHAV DEV, V31, P603, DOI 10.1177/0165025407080590; McClure SM, 2004, SCIENCE, V306, P503, DOI 10.1126/science.1100907; McIsaac HK, 2004, PSYCHOL SCI, V15, P248, DOI 10.1111/j.0956-7976.2004.00660.x; Miller DT, 1998, J PERS SOC PSYCHOL, V74, P53, DOI 10.1037/0022-3514.74.1.53; Mitchell JP, 2005, J COGNITIVE NEUROSCI, V17, P1306, DOI 10.1162/0898929055002418; NIGRO G, 1983, COGNITIVE PSYCHOL, V15, P467, DOI 10.1016/0010-0285(83)90016-6; Ochsner KN, 2004, J COGNITIVE NEUROSCI, V16, P1746, DOI 10.1162/0898929042947829; PARFIT D, 1971, PHILOS REV, V80, P3, DOI 10.2307/2184309; Piaget Jean, 1929, CHILDS CONCEPTION WO; Pinker S., 1997, MIND WORKS; PRENTICE DA, 1990, J PERS SOC PSYCHOL, V59, P369, DOI 10.1037/0022-3514.59.3.369; Prentice DA, 1996, ADV EXP SOC PSYCHOL, V28, P161, DOI 10.1016/S0065-2601(08)60238-5; Pronin E, 2006, J PERS SOC PSYCHOL, V90, P197, DOI 10.1037/0022-3514.90.2.197; Pronin E, 2004, PSYCHOL REV, V111, P781, DOI 10.1037/0033-295X.111.3.781; Pronin E, 2001, J PERS SOC PSYCHOL, V81, P639, DOI 10.1037//0022-3514.81.4.639; Pronin E, 2008, PERS SOC PSYCHOL B, V34, P224, DOI 10.1177/0146167207310023; Pronin E, 2007, J PERS SOC PSYCHOL, V92, P585, DOI 10.1037/0022-3514.92.4.585; Pronin E, 2007, J EXP SOC PSYCHOL, V43, P565, DOI 10.1016/j.jesp.2006.05.011; Pronin E, 2006, BASIC APPL SOC PSYCH, V28, P385, DOI 10.1207/s15324834basp2804_12; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; Robbins JM, 2005, PERS SOC PSYCHOL REV, V9, P32, DOI 10.1207/s15327957pspr0901_3; Ross L., 1991, PERSON SITUATION; Saxe R, 2005, TRENDS COGN SCI, V9, P174, DOI 10.1016/j.tics.2005.01.012; Shelton JN, 2005, J PERS SOC PSYCHOL, V88, P91, DOI 10.1037/0022-3514.88.1.91; Taylor SE, 2003, J PERS SOC PSYCHOL, V85, P605, DOI 10.1037/0022-3514.85.4.605; TAYLOR SE, 1988, PSYCHOL BULL, V103, P193, DOI 10.1037/0033-2909.103.2.193; Todorov A, 2004, J PERS SOC PSYCHOL, V87, P482, DOI 10.1037/0022-3514.87.4.482; Uhlmann EL, 2005, PSYCHOL SCI, V16, P474; VALLONE RP, 1985, J PERS SOC PSYCHOL, V49, P577, DOI 10.1037/0022-3514.49.3.577; Van Boven L, 2003, J PERS SOC PSYCHOL, V85, P249, DOI 10.1037/0022-3514.85.2.249; Van Boven L, 2003, NEGOTIATION J, V19, P117, DOI 10.1023/A:1023693700484; Vorauer JD, 1998, PERS SOC PSYCHOL B, V24, P371, DOI 10.1177/0146167298244004; WEINSTEIN ND, 1980, J PERS SOC PSYCHOL, V39, P806, DOI 10.1037/0022-3514.39.5.806; Wellman H.M., 2002, HDB CHILDHOOD COGNIT, P167, DOI DOI 10.1002/9780470996652.CH8; Wilson T., 2002, HEURISTICS BIASES PS, P185, DOI [https://doi.org/10.1017/CBO9780511808098.012, DOI 10.1017/CBO9780511808098.012]	63	187	194	3	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2008	320	5880					1177	1180		10.1126/science.1154199	http://dx.doi.org/10.1126/science.1154199			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	306FF	18511681				2022-12-28	WOS:000256233000027
J	Ogden, CL; Carroll, MD; Flegal, KM				Ogden, Cynthia L.; Carroll, Margaret D.; Flegal, Katherine M.			High body mass index for age among US children and adolescents, 2003-2006	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OVERWEIGHT; OBESITY; RECOMMENDATIONS; PREVALENCE	Context The prevalence of overweight among US children and adolescents increased between 1980 and 2004. Objectives To estimate the prevalence of 3 measures of high body mass index ( BMI) for age ( calculated as weight in kilograms divided by height in meters squared) and to examine recent trends for US children and adolescents using national data with measured heights and weights. Design, Setting, and Participants Height and weight measurements were obtained from 8165 children and adolescents as part of the 2003- 2004 and 2005- 2006 National Health and Nutrition Examination Survey ( NHANES), nationally representative surveys of the US civilian, noninstitutionalized population. Main Outcome Measures Prevalence of BMI for age at or above the 97th percentile, at or above the 95th percentile, and at or above the 85th percentile of the 2000 sex- specific Centers for Disease Control and Prevention ( CDC) BMI- for- age growth charts among US children by age, sex, and racial/ ethnic group. Results Because no statistically significant differences in the prevalence of high BMI for age were found between estimates for 2003- 2004 and 2005- 2006, data for the 4 years were combined to provide more stable estimates for the most recent time period. Overall, in 2003- 2006, 11.3% ( 95% confidence interval [ CI], 9.7%- 12.9%) of children and adolescents aged 2 through 19 years were at or above the 97th percentile of the 2000 BMI- for- age growth charts, 16.3% ( 95% CI, 14.5%- 18.1%) were at or above the 95th percentile, and 31.9% ( 95% CI, 29.4%- 34.4%) were at or above the 85th percentile. Prevalence estimates varied by age and by racial/ ethnic group. Analyses of the trends in high BMI for age showed no statistically significant trend over the 4 time periods ( 1999- 2000, 2001- 2002, 2003- 2004, and 2005- 2006) for either boys or girls ( P values between .07 and .41). Conclusion The prevalence of high BMI for age among children and adolescents showed no significant changes between 2003- 2004 and 2005- 2006 and no significant trends between 1999 and 2006.	[Ogden, Cynthia L.; Carroll, Margaret D.; Flegal, Katherine M.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Ogden, CL (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4414, Hyattsville, MD 20782 USA.	cogden@cdc.gov	Flegal, Katherine M/A-4608-2013	Flegal, Katherine/0000-0002-0838-469X				Barlow SE, 2007, PEDIATRICS, V120, pS164, DOI 10.1542/peds.2007-2329C; Barlow SE, 2002, PEDIATRICS, V110, P236; COLE TJ, 1990, EUR J CLIN NUTR, V44, P45; Flegal KM, 2006, HEALTH EDUC RES, V21, P755, DOI 10.1093/her/cyl128; Freedman DS, 2008, OBESITY, V16, P1105, DOI 10.1038/oby.2008.30; Guo, 2002, VITAL HLTH STAT, V11, DOI DOI 10.1016/J.BBRC.2015.06.114; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; HIMES JH, 1994, AM J CLIN NUTR, V59, P307, DOI 10.1093/ajcn/59.2.307; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Ogden CL, 2007, GASTROENTEROLOGY, V132, P2087, DOI 10.1053/j.gastro.2007.03.052; ROCHE AF, 1981, AM J CLIN NUTR, V34, P2831, DOI 10.1093/ajcn/34.12.2831	12	1292	1312	1	46	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2008	299	20					2401	2405		10.1001/jama.299.20.2401	http://dx.doi.org/10.1001/jama.299.20.2401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305BD	18505949				2022-12-28	WOS:000256151900024
J	Frew, AJ				Frew, Anthony J.			Sublingual immunotherapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GRASS ALLERGEN TABLETS; DOUBLE-BLIND; EFFICACY; POLLEN; ANAPHYLAXIS; RHINITIS; BURDEN; RHINOCONJUNCTIVITIS; EXTRACT; SAFETY		Brighton Gen Hosp, Dept Resp Med, Brighton BN2 3EW, E Sussex, England	Brighton and Sussex University Hospitals NHS Trust; Brighton General Hospital	Frew, AJ (corresponding author), Brighton Gen Hosp, Dept Resp Med, Brighton BN2 3EW, E Sussex, England.	anthony.frew@bsuh.nhs.uk						Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Alvarez-Cuesta E, 2007, ALLERGY, V62, P1100, DOI 10.1111/j.1398-9995.2007.01520.x; Alvarez-Cuesta E, 2007, ALLERGY, V62, P810, DOI 10.1111/j.1398-9995.2007.01365.x; Antico A, 2006, ALLERGY, V61, P1236, DOI 10.1111/j.1398-9995.2006.01155.x; Bachert C, 2007, CLIN EXP ALLERGY, V37, P772, DOI 10.1111/j.1365-2222.2007.02706.x; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Blaiss MS, 2007, ALLERGY ASTHMA PROC, V28, P393, DOI 10.2500/aap.2007.28.3013; BMJ Group, 2008, Drug Ther Bull, V46, P9, DOI 10.1136/dtb.2008.01.0001; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Calderon MA, 2007, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001936.PUB2; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, pS25, DOI 10.1016/j.jaci.2007.06.019; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Dunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Eifan AO, 2007, ALLERGY, V62, P567, DOI 10.1111/j.1398-9995.2006.01301.x; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Frew AJ, 2001, J ALLERGY CLIN IMMUN, V107, P441, DOI 10.1067/mai.2001.113525; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Mauro M, 2007, Eur Ann Allergy Clin Immunol, V39, P119; Meltzer EO, 2007, CLIN THER, V29, P1428, DOI 10.1016/j.clinthera.2007.07.013; Nathan RA, 2007, ALLERGY ASTHMA PROC, V28, P3, DOI 10.2500/aap.2007.28.2934; Nelson HS, 2007, J ALLERGY CLIN IMMUN, V119, P769, DOI 10.1016/j.jaci.2007.01.036; Reed SD, 2004, PHARMACOECONOMICS, V22, P345, DOI 10.2165/00019053-200422060-00002; Roder E, 2007, J ALLERGY CLIN IMMUN, V119, P892, DOI 10.1016/j.jaci.2006.12.651; Scadding GK, 2008, CLIN EXP ALLERGY, V38, P19, DOI 10.1111/j.1365-2222.2007.02888.x; Van Ree R, 2008, ALLERGY, V63, P310, DOI 10.1111/j.1398-9995.2007.01612.x; VARNEY V, 1992, CLIN EXP ALLERGY, V22, P43, DOI 10.1111/j.1365-2222.1992.tb00113.x; White P, 1998, CLIN EXP ALLERGY, V28, P266; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x	30	60	64	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2008	358	21					2259	2264		10.1056/NEJMct0708337	http://dx.doi.org/10.1056/NEJMct0708337			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303EK	18499568				2022-12-28	WOS:000256023600008
J	Boyer, V; Marino, AM; Pooser, RC; Lett, PD				Boyer, Vincent; Marino, Alberto M.; Pooser, Raphael C.; Lett, Paul D.			Entangled images from four-wave mixing	SCIENCE			English	Article							PODOLSKY-ROSEN PARADOX; CRITERION; PHASE	Two beams of light can be quantum mechanically entangled through correlations of their phase and intensity fluctuations. For a pair of spatially extended image- carrying light fields, the concept of entanglement can be applied not only to the entire images but also to their smaller details. We used a spatially multimode amplifier based on four- wave mixing in a hot vapor to produce twin images that exhibit localized entanglement. The images can be bright fields that display position- dependent quantum noise reduction in their intensity difference or vacuum twin beams that are strongly entangled when projected onto a large range of different spatial modes. The high degree of spatial entanglement demonstrates that the system is an ideal source for parallel continuous- variable quantum information protocols.	[Boyer, Vincent; Marino, Alberto M.; Pooser, Raphael C.; Lett, Paul D.] Univ Maryland, Joint Quantum Inst, Natl Inst Stand & Technol, Gaithersburg, MD 20899 USA	National Institute of Standards & Technology (NIST) - USA; University System of Maryland; University of Maryland College Park	Boyer, V (corresponding author), Univ Maryland, Joint Quantum Inst, Natl Inst Stand & Technol, Gaithersburg, MD 20899 USA.	vincent.boyer@nist.gov; paul.lett@nist.gov	Marino, Alberto/C-7193-2013	Boyer, Vincent/0000-0002-6900-8786; Pooser, Raphael/0000-0002-2922-453X; Marino, Alberto/0000-0001-5377-1122				Boyer V, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.143601; Braunstein SL, 2005, REV MOD PHYS, V77, P513, DOI 10.1103/RevModPhys.77.513; Delaubert V, 2006, PHYS REV A, V74, DOI 10.1103/PhysRevA.74.053823; Duan LM, 2000, PHYS REV LETT, V84, P2722, DOI 10.1103/PhysRevLett.84.2722; Howell JC, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.210403; Hsu MTL, 2005, PHYS REV A, V72, DOI 10.1103/PhysRevA.72.013802; Jedrkiewicz O, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.243601; Jing JT, 2006, PHYS REV A, V74, DOI 10.1103/PhysRevA.74.041804; KIM CH, 1994, PHYS REV LETT, V73, P1605, DOI 10.1103/PhysRevLett.73.1605; Kolobov M. I., 2007, QUANTUM IMAGING; Kolobov MI, 2000, PHYS REV LETT, V85, P3789, DOI 10.1103/PhysRevLett.85.3789; Kolobov MI, 1999, REV MOD PHYS, V71, P1539, DOI 10.1103/RevModPhys.71.1539; KUMAR P, 1994, OPT COMMUN, V104, P374, DOI 10.1016/0030-4018(94)90573-8; Lassen M, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.083602; Laurat J, 2004, PHYS REV A, V70, DOI 10.1103/PhysRevA.70.042315; Law CK, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.127903; Lopez L, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.013604; Lukin MD, 2000, ADV ATOM MOL OPT PHY, V42, P347, DOI 10.1016/S1049-250X(08)60190-1; Mair A, 2001, NATURE, V412, P313, DOI 10.1038/35085529; McCormick CF, 2007, OPT LETT, V32, P178, DOI 10.1364/OL.32.000178; Mosset A, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.223603; Navez P, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.032307; OU ZY, 1992, PHYS REV LETT, V68, P3663, DOI 10.1103/PhysRevLett.68.3663; REID MD, 1989, PHYS REV A, V40, P913, DOI 10.1103/PhysRevA.40.913; REID MD, 1988, PHYS REV LETT, V60, P2731, DOI 10.1103/PhysRevLett.60.2731; Silberhorn C, 2001, PHYS REV LETT, V86, P4267, DOI 10.1103/PhysRevLett.86.4267; Simon R, 2000, PHYS REV LETT, V84, P2726, DOI 10.1103/PhysRevLett.84.2726; Treps N, 2003, SCIENCE, V301, P940, DOI 10.1126/science.1086489; Villar AS, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.243603; Yonezawa H, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.110503	30	456	463	3	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 25	2008	321	5888					544	547		10.1126/science.1158275	http://dx.doi.org/10.1126/science.1158275			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	329RS	18556517				2022-12-28	WOS:000257888900042
J	Neuser, K; Triphan, T; Mronz, M; Poeck, B; Strauss, R				Neuser, Kirsa; Triphan, Tilman; Mronz, Markus; Poeck, Burkhard; Strauss, Roland			Analysis of a spatial orientation memory in Drosophila	NATURE			English	Article							WORKING-MEMORY; EXPRESSION; GENE; MELANOGASTER; MUTANTS; OPERANT; DUNCE; FLY; RSK	Flexible goal- driven orientation requires that the position of a target be stored, especially in case the target moves out of sight. The capability to retain, recall and integrate such positional information into guiding behaviour has been summarized under the term spatial working memory(1). This kind of memory contains specific details of the presence that are not necessarily part of a long- term memory. Neurophysiological studies in primates(2) indicate that sustained activity of neurons encodes the sensory information even though the object is no longer present. Furthermore they suggest that dopamine transmits the respective input to the prefrontal cortex, and simultaneous suppression by GABA spatially restricts this neuronal activity(3). Here we show that Drosophila melanogaster possesses a similar spatial memory during locomotion. Using a new detour setup, we show that flies can remember the position of an object for several seconds after it has been removed from their environment. In this setup, flies are temporarily lured away from the direction towards their hidden target, yet they are thereafter able to aim for their former target. Furthermore, we find that the GABAergic ( stainable with antibodies against GABA) ring neurons(4) of the ellipsoid body in the central brain are necessary and their plasticity is sufficient for a functional spatial orientation memory in flies. We also find that the protein kinase S6KII ( ignorant)(5) is required in a distinct subset of ring neurons to display this memory. Conditional expression of S6KII in these neurons only in adults can restore the loss of the orientation memory of the ignorant mutant. The S6KII signalling pathway therefore seems to be acutely required in the ring neurons for spatial orientation memory in flies.	[Neuser, Kirsa; Triphan, Tilman; Mronz, Markus; Poeck, Burkhard; Strauss, Roland] Univ Wurzburg, Lehrstuhl Genet & Neurobiol, Biozentrum, D-97074 Wurzburg, Germany	University of Wurzburg	Strauss, R (corresponding author), Johannes Gutenberg Univ Mainz, Inst Zool Neurobiol 3, Col Kleinmann Weg 2, D-55099 Mainz, Germany.	rstrauss@uni-mainz.de						Botella JA, 2003, MOL BIOL CELL, V14, P241, DOI 10.1091/mbc.E02-05-0297; BRAND AH, 1993, DEVELOPMENT, V118, P401; BULTHOFF H, 1982, J COMP PHYSIOL, V148, P471; Chafee MV, 1998, J NEUROPHYSIOL, V79, P2919, DOI 10.1152/jn.1998.79.6.2919; Collett TS, 2002, NAT REV NEUROSCI, V3, P542, DOI 10.1038/nrn872; DAVIS RL, 1981, J CELL BIOL, V90, P101, DOI 10.1083/jcb.90.1.101; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; Dietzl G, 2007, NATURE, V448, P151, DOI 10.1038/nature05954; DUDAI Y, 1976, P NATL ACAD SCI USA, V73, P1684, DOI 10.1073/pnas.73.5.1684; Funahashi S, 2006, NEUROSCIENCE, V139, P251, DOI 10.1016/j.neuroscience.2005.07.003; HANESCH U, 1989, CELL TISSUE RES, V257, P343, DOI 10.1007/BF00261838; HEISENBERG M, 1979, Z NATURFORSCH C, V34, P143; Kim MJ, 2006, EMBO J, V25, P3056, DOI 10.1038/sj.emboj.7601180; Kim YC, 2003, GENE EXPR PATTERNS, V3, P237, DOI 10.1016/S1567-133X(02)00098-4; Liu G, 2006, NATURE, V439, P551, DOI 10.1038/nature04381; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; McGuire SE, 2003, SCIENCE, V302, P1765, DOI 10.1126/science.1089035; McGuire SE, 2005, PROG NEUROBIOL, V76, P328, DOI 10.1016/j.pneurobio.2005.09.003; MRONZ M, 2004, THESIS U WURZBURG; Myers AP, 2004, MOL CELL BIOL, V24, P4255, DOI 10.1128/MCB.24.10.4255-4266.2004; Postle BR, 2006, NEUROSCIENCE, V139, P23, DOI 10.1016/j.neuroscience.2005.06.005; Putz G, 2004, J NEUROSCI, V24, P9745, DOI 10.1523/JNEUROSCI.3211-04.2004; Renn SCP, 1999, J NEUROBIOL, V41, P189; STRAUSS R, 1993, J NEUROSCI, V13, P1852, DOI 10.1523/jneurosci.13-05-01852.1993; Strauss R, 2002, CURR OPIN NEUROBIOL, V12, P633, DOI 10.1016/S0959-4388(02)00385-9; Strauss R, 1997, J EXP BIOL, V200, P1281; Strauss R, 1998, J COMP PHYSIOL A, V182, P411, DOI 10.1007/s003590050190; SWEENEY ST, 1995, NEURON, V14, P341, DOI 10.1016/0896-6273(95)90290-2; Torroja L, 1999, CURR BIOL, V9, P489, DOI 10.1016/S0960-9822(99)80215-2; Wustmann G, 1996, J COMP PHYSIOL A, V179, P429, DOI 10.1007/BF00194996	30	256	259	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 26	2008	453	7199					1244	U44		10.1038/nature07003	http://dx.doi.org/10.1038/nature07003			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	318FA	18509336				2022-12-28	WOS:000257075800044
J	Bayram, O; Krappmann, S; Ni, M; Bok, JW; Helmstaedt, K; Valerius, O; Braus-Stromeyer, S; Kwon, NJ; Keller, NP; Yu, JH; Braus, GH				Bayram, Oezguer; Krappmann, Sven; Ni, Min; Bok, Jin Woo; Helmstaedt, Kerstin; Valerius, Oliver; Braus-Stromeyer, Susanna; Kwon, Nak-Jung; Keller, Nancy P.; Yu, Jae-Hyuk; Braus, Gerhard H.			VelB/VeA/LaeA complex coordinates light signal with fungal development and secondary metabolism	SCIENCE			English	Article							TANDEM AFFINITY PURIFICATION; ASPERGILLUS-NIDULANS; COP9 SIGNALOSOME; REGULATOR; VEA; BIOSYNTHESIS; LOCUS	Differentiation and secondary metabolism are correlated processes in fungi that respond to light. In Aspergillus nidulans, light inhibits sexual reproduction as well as secondary metabolism. We identified the heterotrimeric velvet complex VelB/VeA/LaeA connecting light-responding developmental regulation and control of secondary metabolism. VeA, which is primarily expressed in the dark, physically interacts with VelB, which is expressed during sexual development. VeA bridges VelB to the nuclear master regulator of secondary metabolism, LaeA. Deletion of either velB or veA results in defects in both sexual fruiting-body formation and the production of secondary metabolites.	[Bayram, Oezguer; Krappmann, Sven; Helmstaedt, Kerstin; Valerius, Oliver; Braus-Stromeyer, Susanna; Braus, Gerhard H.] Univ Gottingen, Inst Microbiol & Genet, D-37077 Gottingen, Germany; [Ni, Min; Kwon, Nak-Jung; Yu, Jae-Hyuk] Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; [Ni, Min; Kwon, Nak-Jung; Yu, Jae-Hyuk] Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; [Bok, Jin Woo; Keller, Nancy P.] Univ Wisconsin, Dept Plant Pathol, Madison, WI 53706 USA; [Bok, Jin Woo; Keller, Nancy P.] Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI 53706 USA; [Helmstaedt, Kerstin] Res Ctr Mol Physiol Brain CMPB, Deutsch Forschungsgemeinschaft DFG, D-37077 Gottingen, Germany	University of Gottingen; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; German Research Foundation (DFG)	Braus, GH (corresponding author), Univ Gottingen, Inst Microbiol & Genet, D-37077 Gottingen, Germany.	gbraus@gwdg.de	Bayram, Özgür/P-6326-2019; Braus, Gerhard/ABC-6293-2021; Yu, Jae-Hyuk/A-2343-2008; Bok, Jin Woo/F-7140-2010; Krappmann, Sven/K-2615-2012; Keller, Nancy P./ABC-5911-2021; Braus, Gerhard H/G-3999-2012	Bayram, Özgür/0000-0002-0283-5322; Braus, Gerhard/0000-0002-3117-5626; Braus, Gerhard H/0000-0002-3117-5626; Yu, Jae-Hyuk/0000-0002-6530-8407; Krappmann, Sven/0000-0002-8299-7777; Braus-Stromeyer, Susanna A./0000-0003-0830-3949				Adams TH, 1998, MICROBIOL MOL BIOL R, V62, P35, DOI 10.1128/MMBR.62.1.35-54.1998; Bok JW, 2006, MOL MICROBIOL, V61, P1636, DOI 10.1111/j.1365-2958.2006.05330.x; Bok JW, 2004, EUKARYOT CELL, V3, P527, DOI 10.1128/EC.3.2.527-535.2004; Brakhage AA, 1997, FEMS MICROBIOL LETT, V148, P1; Braus GH, 2002, MYCOLOGY S, V15, P215; Busch S, 2003, MOL MICROBIOL, V49, P717, DOI 10.1046/j.1365-2958.2003.03612.x; Busch S, 2007, P NATL ACAD SCI USA, V104, P8089, DOI 10.1073/pnas.0702108104; Calvo AM, 2002, MICROBIOL MOL BIOL R, V66, P447, DOI 10.1128/MMBR.66.3.447-459.2002; Dreyer J, 2007, APPL ENVIRON MICROB, V73, P3412, DOI 10.1128/AEM.00129-07; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hicks JK, 2002, MYCOTA, V11, P55; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Kato N, 2003, EUKARYOT CELL, V2, P1178, DOI 10.1128/EC.2.6.1178-1186.2003; Keller NP, 2005, NAT REV MICROBIOL, V3, P937, DOI 10.1038/nrmicro1286; Kim HS, 2002, FUNGAL GENET BIOL, V37, P72, DOI 10.1016/S1087-1845(02)00029-4; Krappmann S, 2005, EUKARYOT CELL, V4, P1298, DOI 10.1128/EC.4.7.1298-1307.2005; Li SJ, 2006, MOL MICROBIOL, V62, P1418, DOI 10.1111/j.1365-2958.2006.05447.x; MOONEY JL, 1990, GENE DEV, V4, P1473, DOI 10.1101/gad.4.9.1473; Ni M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000970; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Purschwitz J, 2008, CURR BIOL, V18, P255, DOI 10.1016/j.cub.2008.01.061; Rohila JS, 2004, PLANT J, V38, P172, DOI 10.1111/j.1365-313X.2004.02031.x; Shwab EK, 2007, EUKARYOT CELL, V6, P1656, DOI 10.1128/EC.00186-07; Sprote P, 2007, ARCH MICROBIOL, V188, P69, DOI 10.1007/s00203-007-0224-y; Stinnett SM, 2007, MOL MICROBIOL, V63, P242, DOI 10.1111/j.1365-2958.2006.05506.x; WOLOSHUK CP, 1994, APPL ENVIRON MICROB, V60, P2408, DOI 10.1128/AEM.60.7.2408-2414.1994	26	607	661	16	189	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2008	320	5882					1504	1506		10.1126/science.1155888	http://dx.doi.org/10.1126/science.1155888			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556559	Green Accepted			2022-12-28	WOS:000256676400047
J	Purves, D; Pacala, S				Purves, Drew; Pacala, Stephen			Predictive models of forest dynamics	SCIENCE			English	Editorial Material							LAND-USE HISTORY; ECOSYSTEMS; RANGE	Dynamic global vegetation models (DGVMs) have shown that forest dynamics could dramatically alter the response of the global climate system to increased atmospheric carbon dioxide over the next century. But there is little agreement between different DGVMs, making forest dynamics one of the greatest sources of uncertainty in predicting future climate. DGVM predictions could be strengthened by integrating the ecological realities of biodiversity and height-structured competition for light, facilitated by recent advances in the mathematics of forest modeling, ecological understanding of diverse forest communities, and the availability of forest inventory data.	[Purves, Drew] Microsoft Res, Computat Ecol & Environm Sci Grp, Cambridge, England; [Pacala, Stephen] Princeton Univ, Dept Ecol & Evolut Biol, Princeton, NJ 08544 USA	Microsoft; Princeton University	Purves, D (corresponding author), Microsoft Res, Computat Ecol & Environm Sci Grp, Cambridge, England.							Baker TR, 2004, GLOBAL CHANGE BIOL, V10, P545, DOI 10.1111/j.1365-2486.2004.00751.x; Baker TR, 2004, PHILOS T R SOC B, V359, P353, DOI 10.1098/rstb.2003.1422; Bond WJ, 2005, NEW PHYTOL, V165, P525, DOI 10.1111/j.1469-8137.2004.01252.x; Caspersen JP, 2000, SCIENCE, V290, P1148, DOI 10.1126/science.290.5494.1148; Condit R, 2006, SCIENCE, V313, P98, DOI 10.1126/science.1124712; Cramer W, 2001, GLOBAL CHANGE BIOL, V7, P357, DOI 10.1046/j.1365-2486.2001.00383.x; Davis AJ, 1998, NATURE, V391, P783, DOI 10.1038/35842; Friedlingstein P, 2006, J CLIMATE, V19, P3337, DOI 10.1175/JCLI3800.1; Gilbert B, 2006, ECOLOGY, V87, P1281, DOI 10.1890/0012-9658(2006)87[1281:LHTITT]2.0.CO;2; Hurtt GC, 2006, GLOBAL CHANGE BIOL, V12, P1208, DOI 10.1111/j.1365-2486.2006.01150.x; Keeling HC, 2007, GLOBAL ECOL BIOGEOGR, V16, P618, DOI 10.1111/j.1466-8238.2007.00314.x; Landsberg J, 2003, CAN J FOREST RES, V33, P385, DOI 10.1139/X02-129; Loehle C, 1998, J BIOGEOGR, V25, P735, DOI 10.1046/j.1365-2699.1998.2540735.x; Millennium Ecosystem Assessment, 2005, EC HUM WELL BEING BI; Moorcroft PR, 2003, P ROY SOC B-BIOL SCI, V270, P1215, DOI 10.1098/rspb.2002.2251; Moorcroft PR, 2001, ECOL MONOGR, V71, P557, DOI 10.1890/0012-9615(2001)071[0557:AMFSVD]2.0.CO;2; Okino MS, 1998, CHEM REV, V98, P391, DOI 10.1021/cr950223l; Oldfield S., 1998, WORLD LIST THREATENE; Pacala SW, 1996, ECOL MONOGR, V66, P1, DOI 10.2307/2963479; Raupach MR, 2005, GLOBAL CHANGE BIOL, V11, P378, DOI 10.1111/j.1365-2486.2005.00917.x; Tilman D, 2006, NATURE, V441, P629, DOI 10.1038/nature04742	21	249	255	5	124	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	2008	320	5882					1452	1453		10.1126/science.1155359	http://dx.doi.org/10.1126/science.1155359			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556548				2022-12-28	WOS:000256676400031
J	Barron, M				Barron, Michael			Science & music: Raising the roof	NATURE			English	Editorial Material									[Barron, Michael] Univ Bath, Dept Architecture & Civil Engn, Bath BA2 7AY, Avon, England	University of Bath	Barron, M (corresponding author), Univ Bath, Dept Architecture & Civil Engn, Bath BA2 7AY, Avon, England.								0	0	1	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 12	2008	453	7197					859	860		10.1038/453859a	http://dx.doi.org/10.1038/453859a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311WV	18548056				2022-12-28	WOS:000256632000025
J	Hunte, F; Jaroszynski, J; Gurevich, A; Larbalestier, DC; Jin, R; Sefat, AS; McGuire, MA; Sales, BC; Christen, DK; Mandrus, D				Hunte, F.; Jaroszynski, J.; Gurevich, A.; Larbalestier, D. C.; Jin, R.; Sefat, A. S.; McGuire, M. A.; Sales, B. C.; Christen, D. K.; Mandrus, D.			Two-band superconductivity in LaFeAsO0.89F0.11 at very high magnetic fields	NATURE			English	Article								The recent synthesis of the superconductor LaFeAsO0.89F0.11 with transition temperature T-c approximate to 26 K ( refs 1 - 4) has been quickly followed by reports of even higher transition temperatures in related compounds: 41 K in CeFeAsO0.84F0.16 ( ref. 5), 43 K in SmFeAsO0.9F0.1 ( ref. 6), and 52 K in NdFeAsO0.89F0.11 and PrFeAsO0.89F0.11 ( refs 7, 8). These discoveries have generated much interest(9,10) in the mechanisms and manifestations of unconventional superconductivity in the family of doped quaternary layered oxypnictides LnOTMPn ( Ln: La, Pr, Ce, Sm; TM: Mn, Fe, Co, Ni; Pn: P, As), because many features of these materials set them apart from other known superconductors. Here we report resistance measurements of LaFeAsO0.89F0.11 at high magnetic fields, up to 45 T, that show a remarkable enhancement of the upper critical field B-c2 compared to values expected from the slopes dB(c2)/ dT approximate to 2 T K-1 near Tc, particularly at low temperatures where the deduced B-c2(0) approximate to 63 - 65 T exceeds the paramagnetic limit. We argue that oxypnictides represent a new class of high-field superconductors with B-c2 values surpassing those of Nb3Sn, MgB2 and the Chevrel phases, and perhaps exceeding the 100 T magnetic field benchmark of the high- T-c copper oxides.	[Hunte, F.; Jaroszynski, J.; Gurevich, A.; Larbalestier, D. C.] Florida State Univ, Natl High Magnet Field Lab, Tallahassee, FL 32310 USA; [Jin, R.; Sefat, A. S.; McGuire, M. A.; Sales, B. C.; Christen, D. K.; Mandrus, D.] Oak Ridge Natl Lab, Mat Sci & Technol Div, Oak Ridge, TN 37831 USA	State University System of Florida; Florida State University; United States Department of Energy (DOE); Oak Ridge National Laboratory	Hunte, F (corresponding author), Florida State Univ, Natl High Magnet Field Lab, Tallahassee, FL 32310 USA.	hunte@asc.magnet.fsu.edu	Christen, David/A-9709-2008; Sefat, Athena/R-5457-2016; Mandrus, David/H-3090-2014; Gurevich, Alex/A-4327-2008; Larbalestier, David/B-2277-2008; McGuire, Michael/B-5453-2009	Sefat, Athena/0000-0002-5596-3504; Gurevich, Alex/0000-0003-0759-8941; Larbalestier, David/0000-0001-7098-7208; McGuire, Michael/0000-0003-1762-9406; Sales, Brian/0000-0002-6335-5912				AHILAN K, 2008, 19F NMR INVESTIGATIO; BLATTER G, 2003, PHYS SUPERCONDUCTORS, V1, P800; CAO C, 2008, COEXISTENCE ANTIFERR; CHEN GF, 2008, SUPERCONDUCTING PROP; CHEN GF, 2008, SUPERCONDUCTIVITY 41; CHEN XH, 2008, SUPERCONDUCTIVITY 43; DAI X, 2008, EVEN PARITY ORBITAL; DONG J, 2008, COMPETING ORDERS SPI; Glazman L. I., 1988, Soviet Physics - JETP, V67, P1235; Gurevich A, 2007, PHYSICA C, V456, P160, DOI 10.1016/j.physc.2007.01.008; Kamihara Y, 2008, J AM CHEM SOC, V130, P3296, DOI 10.1021/ja800073m; KUROKI K, 2008, UNCONVENTIONAL SUPER; Lebegue S, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.035110; MA F, 2008, IRON BASED SUPERCOND; MAZIN II, 2008, UNCONVENTIONAL SIGN; MCGUIRE MA, 2008, EVIDENCE SPIN DENSIT; Nagamatsu J, 2001, NATURE, V410, P63, DOI 10.1038/35065039; Quebe P, 2000, J ALLOY COMPD, V302, P70, DOI 10.1016/S0925-8388(99)00802-6; REN ZA, 2008, SUPERCONDUCTIVITY 52; REN ZA, 2008, SUPERCONDUCTIVITY IR; Sefat AS, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.174503; SINGH DJ, 2008, LOW CARRIER DENSITY; WERTHAME.NR, 1966, PHYS REV, V147, P295, DOI 10.1103/PhysRev.147.295; ZHU X, 2008, UPPER CRITICAL FIELD; ZIMMER BI, 1995, J ALLOY COMPD, V229, P238, DOI 10.1016/0925-8388(95)01672-4	26	454	462	2	152	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 12	2008	453	7197					903	905		10.1038/nature07058	http://dx.doi.org/10.1038/nature07058			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311WV	18509332	Green Submitted			2022-12-28	WOS:000256632000039
J	Baqui, AH; El-Arifeen, S; Darmstadt, GL; Ahmed, S; Williams, EK; Seraji, HR; Mannan, I; Rahman, SM; Shah, R; Saha, SK; Syed, U; Winch, PJ; Lefevre, A; Santosham, M; Black, RE				Baqui, Abdullah H.; El-Arifeen, Shams; Darmstadt, Gary L.; Ahmed, Saifuddin; Williams, Emma K.; Seraji, Habibur R.; Mannan, Ishtiaq; Rahman, Syed M.; Shah, Rasheduzzaman; Saha, Samir K.; Syed, Uzma; Winch, Peter J.; Lefevre, Amnesty; Santosham, Mathuram; Black, Robert E.		Projahnmo Study Grp	Effect of community-based newborn-care intervention package implemented through two service-delivery strategies in Sylhet district, Bangladesh: a cluster-randomised controlled trial	LANCET			English	Article							NEONATAL HEALTH; MORTALITY; OUTCOMES; SEPSIS	Background Neonatal mortality accounts for a high proportion of deaths in children under the age of 5 years in Bangladesh. Therefore the project for advancing the health of newborns and mothers (Projahnmo) implemented a community-based intervention package through government and non-government organisation infrastructures to reduce neonatal mortality. Methods In Sylhet district, 24 clusters (with a population of about 20000 each) were randomly assigned in equal numbers to one of two intervention arms or to the comparison arm. Because of the study design, masking was not feasible. All married women of reproductive age (15-49 years) were eligible to participate. In the home-care arm, female community health workers (one per 4000 population) identified pregnant women, made two antenatal home visits to promote birth and newborn-care preparedness, made postnatal home visits to assess newborns on the first, third, and seventh days of birth, and referred or treated sick neonates. In the community-care arm, birth and newborn-care preparedness and careseeking from qualified providers were promoted solely through group sessions held by female and male community mobilisers. The primary outcome was reduction in neonatal mortality. Analysis was by intention to treat. The study is registered with ClinicalTrials.gov, number 00198705. Findings The number of clusters per arm was eight. The number of participants was 36059, 40159, and 37598 in the home-care, community-care, and comparison arms, respectively, with 14769,16325, and 15350 livebirths, respectively. In the last 6 months of the 30-month intervention, neonatal mortality rates were 29.2 per 1000, 45.2 per 1000, and 43.5 per 1000 in the home-care, community-care, and comparison arms, respectively. Neonatal mortality was reduced in the home-care arm by 34% (adjusted relative risk 0 . 66; 95% CI 0.47-0.93) during the last 6 months versus that in the comparison arm. No mortality reduction was noted in the community-care arm (0 . 95; 0 . 69-1.31). Interpretation A home-care strategy to promote an integrated package of preventive and curative newborn care is effective in reducing neonatal mortality in communities with a weak health system, low health-care use, and high neonatal mortality. Funding United States Agency for International Development and saving newborn lives programme by Save the Children (US) with a grant from Bill and Melinda Gates Foundation.	[Baqui, Abdullah H.; Darmstadt, Gary L.; Williams, Emma K.; Seraji, Habibur R.; Mannan, Ishtiaq; Shah, Rasheduzzaman; Winch, Peter J.; Lefevre, Amnesty; Santosham, Mathuram; Black, Robert E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; [Baqui, Abdullah H.; El-Arifeen, Shams; Seraji, Habibur R.; Mannan, Ishtiaq; Rahman, Syed M.; Shah, Rasheduzzaman] Int Ctr Diarrhoeal Dis Res, Child Hlth Unit, Dhaka 1000, Bangladesh; [Ahmed, Saifuddin] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD USA; [Saha, Samir K.] Dhaka Shishu Hosp, Dhaka, Bangladesh; [Syed, Uzma] Save Children, Dhaka, Bangladesh	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; International Centre for Diarrhoeal Disease Research (ICDDR); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Save the Children	Baqui, AH (corresponding author), Suite E-8138,615 N Wolfe St, Baltimore, MD 21205 USA.	abaqui@jhsph.edu	Darmstadt, Gary/AAU-7488-2020; Shah, Rashed/Q-4965-2019; Shah, Mohammad/K-9146-2013; Rahman, Syed Moshfiqur/AAH-9000-2019; Shah, Rashed Z/D-4688-2015; LeFevre, Amnesty E/A-3162-2019	Shah, Rashed/0000-0001-9488-5134; Rahman, Syed Moshfiqur/0000-0002-9441-0590; Shah, Rashed Z/0000-0001-9488-5134; LeFevre, Amnesty E/0000-0001-8437-7240; Black, Robert/0000-0001-9926-7984; Williams, Emma/0000-0003-0547-0194; Arifeen, Shams/0000-0002-5372-5932; Darmstadt, Gary/0000-0002-7522-5824; Alam, Neeloy Ashraful/0000-0001-7034-1095				Ahmad OB, 2000, B WORLD HEALTH ORGAN, V78, P1175; Armitage P., 2001, STAT METHODS MED RES; Awasthi S, 2006, B WORLD HEALTH ORGAN, V84, P819, DOI 10.2471/BLT.05.029207; Bang Abhay T, 2005, J Perinatol, V25 Suppl 1, pS92, DOI 10.1038/sj.jp.7211277; Bang AT, 2005, PEDIATR INFECT DIS J, V24, P335, DOI 10.1097/01.inf.0000157094.43609.17; Bang AT, 1999, LANCET, V354, P1955, DOI 10.1016/S0140-6736(99)03046-9; Bhutta ZA, 2005, PEDIATRICS, V115, P519, DOI 10.1542/peds.2004-1441; Borghi J, 2005, LANCET, V366, P1882, DOI 10.1016/S0140-6736(05)67758-6; Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8; Campbell MK, 2004, COMPUT BIOL MED, V34, P113, DOI 10.1016/S0010-4825(03)00039-8; Carlin JB, 2008, LANCET, V371, P135, DOI 10.1016/S0140-6736(08)60106-3; Daga S. R., 1993, Indian Journal of Pediatrics, V60, P627, DOI 10.1007/BF02821721; Darmstadt GL, 2007, PEDIATR INFECT DIS J, V26, P501, DOI 10.1097/INF.0b013e318059c25b; De Zoysa I, 1998, SOC SCI MED, V47, P2101, DOI 10.1016/S0277-9536(98)00275-5; DONNER A, 1993, J CLIN EPIDEMIOL, V46, P123, DOI 10.1016/0895-4356(93)90050-B; DONNER A, 1994, AM J EPIDEMIOL, V140, P279, DOI 10.1093/oxfordjournals.aje.a117247; Feiveson AH, 2002, STATA J, V2, P107, DOI 10.1177/1536867X0200200201; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; Haines A, 2007, LANCET, V369, P2121, DOI 10.1016/S0140-6736(07)60325-0; Haws RA, 2007, HEALTH POLICY PLANN, V22, P193, DOI 10.1093/heapol/czm009; HILL Z, 2001, FAMILY COMMUNITY PRA; Jokhio AH, 2005, NEW ENGL J MED, V352, P2091, DOI 10.1056/NEJMsa042830; Lawn JE, 2006, LANCET, V367, P1541, DOI 10.1016/S0140-6736(06)68587-5; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Lewin SA, 2005, COCHRANE DB SYST REV, V1, P1, DOI DOI 10.1002/14651858.CD004015.PUB2; Manandhar DS, 2004, LANCET, V364, P970, DOI 10.1016/S0140-6736(04)17021-9; *NIPORT MA ORC MAC, 2001, BANGL DEM HLTH SURV; PRATINIDHI A, 1986, B WORLD HEALTH ORGAN, V64, P291; Sachs J, 2002, MACROECONOMICS HLTH; Winch PJ, 2005, LANCET, V366, P478, DOI 10.1016/S0140-6736(05)66836-5	30	413	414	0	34	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	2008	371	9628					1936	1944		10.1016/S0140-6736(08)60835-1	http://dx.doi.org/10.1016/S0140-6736(08)60835-1			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310OI	18539225				2022-12-28	WOS:000256538500030
J	Shiell, A; Hawe, P; Gold, L				Shiell, Alan; Hawe, Penelope; Gold, Lisa			Complex interventions or complex systems? Implications for health economic evaluation	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PUBLIC-HEALTH; PREVENTION; DELIVERY		[Shiell, Alan; Hawe, Penelope] Univ Calgary, Populat Hlth Intervent Res Ctr, Calgary, AB T2N 4N1, Canada; [Gold, Lisa] Deakin Univ, Hlth Econ Unit, Sch Hlth & Social Dev, Melbourne, Vic, Australia	University of Calgary; Deakin University	Shiell, A (corresponding author), Univ Calgary, Populat Hlth Intervent Res Ctr, Calgary, AB T2N 4N1, Canada.	ashiell@ucalgary.ca	Shiell, Alan/AAL-4146-2020	Shiell, Alan/0000-0001-5914-1084; Gold, Lisa/0000-0002-2733-900X				Begun J, 2003, ADV HLTH CARE ORGAN, V253, P253; Byford S, 2003, NATL I ECON REV, V186, P98, DOI DOI 10.1177/002795010300100114; Byrne M, 2006, AM J MANAG CARE, V12, P261; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Campbell NC, 2007, BMJ-BRIT MED J, V334, P455, DOI 10.1136/bmj.39108.379965.BE; Chapman S, 2001, INT J EPIDEMIOL, V30, P1226, DOI 10.1093/ije/30.6.1226; Goodwin MA, 2001, AM J PREV MED, V21, P20, DOI 10.1016/S0749-3797(01)00310-5; HALLEY JD, 2008, COMPLEXITY      0227, DOI DOI 10.1002/CPLX.20216; Hawe P, 2004, J EPIDEMIOL COMMUN H, V58, P788, DOI 10.1136/jech.2003.014415; Hawe P, 2004, BMJ-BRIT MED J, V328, P1561, DOI 10.1136/bmj.328.7455.1561; Hawe P, 2008, HEALTH EDUC RES, V23, P62, DOI 10.1093/her/cyl162; Leischow SJ, 2006, AM J PUBLIC HEALTH, V96, P403, DOI 10.2105/AJPH.2005.082842; Litaker D, 2006, J GEN INTERN MED, V21, pS30, DOI 10.1111/j.1525-1497.2006.00360.x; Medical Research Council, 2000, FRAM DEV EV RAND CON; Miller WL, 2001, J FAM PRACTICE, V50, P872; Oakley A, 2006, BRIT MED J, V332, P413, DOI 10.1136/bmj.332.7538.413; Pawson Ray, 2005, J Health Serv Res Policy, V10 Suppl 1, P21, DOI 10.1258/1355819054308530; Plsek PE, 2001, BRIT MED J, V323, P625, DOI 10.1136/bmj.323.7313.625; RICKLES D, IN PRESS MED HLTH CA; Rickles D, 2007, J EPIDEMIOL COMMUN H, V61, P933, DOI 10.1136/jech.2006.054254; SAGOFF M, 1998, DEMOCRACY SOCIAL VAL, P91; Siahpush M, 2001, AUST NZ J PUBL HEAL, V25, P473, DOI 10.1111/j.1467-842X.2001.tb00665.x; Wolff N, 2001, J Health Serv Res Policy, V6, P123, DOI 10.1258/1355819011927224; Zimmerman B., 1998, EDGEWARE INSIGHTS CO; ZIMMERMAN MA, 1990, AM J COMMUN PSYCHOL, V18, P169, DOI 10.1007/BF00922695	25	356	359	0	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 7	2008	336	7656					1281	1283		10.1136/bmj.39569.510521.AD	http://dx.doi.org/10.1136/bmj.39569.510521.AD			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	312XO	18535071	Green Published			2022-12-28	WOS:000256705900030
J	Delamothe, T				Delamothe, Tony			NHS at 60 - Founding principles	BRITISH MEDICAL JOURNAL			English	Editorial Material												tdelamothe@bmj.com						Calder Angus, 1971, PEOPLES WAR BRITAIN; Jacobs Lawrence R., 1993, HLTH NATIONS PUBLIC; Klein R., 2006, NEW POLITICS NHS CRE, V5st edition; Marwick A, 1996, BRIT SOC 1945; Ministry of Health, 1944, CMD6502; Pater J., 1981, MAKING NATL HLTH SER; TIMMINS N, 1995, 5 GIANTS BIOGRAPHY W; Webster C., 2002, NATL HLTH SERVICE PO	8	24	24	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 31	2008	336	7655					1216	1218		10.1136/bmj.39582.501192.94	http://dx.doi.org/10.1136/bmj.39582.501192.94			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311PS	18511796	Green Published			2022-12-28	WOS:000256612700026
J	Bonetta, L				Bonetta, Laura			Getting up close and personal with your genome	CELL			English	Editorial Material								A new type of company is offering to scan a person's genome and reveal the information it holds for as little as $1000. Are these services fun novelty items or do they provide valuable information that will help people take better care of their health?											0	16	16	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 30	2008	133	5					753	756		10.1016/j.cell.2008.05.008	http://dx.doi.org/10.1016/j.cell.2008.05.008			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510915	Bronze			2022-12-28	WOS:000256274500003
J	Sasai, N; Yakura, R; Kamiya, D; Nakazawa, Y; Sasai, Y				Sasai, Noriaki; Yakura, Rieko; Kamiya, Daisuke; Nakazawa, Yoko; Sasai, Yoshiki			Ectodermal factor restricts mesoderm differentiation by inhibiting p53	CELL			English	Article							GERM-LAYER SPECIFICATION; ZINC-FINGER PROTEINS; EMBRYONIC STEM-CELLS; EARLY XENOPUS EMBRYO; TGF-BETA; TRANSCRIPTIONAL REGULATION; MOLECULAR MECHANISMS; UBIQUITIN LIGASE; DNA-BINDING; COMPETENCE	During gastrulation of the amphibian embryo, specification of the three germ layers, endo-, ecto-, and mesoderm, is regulated by maternal and zygotic mechanisms. Although it is known that mesoderm specification requires the cooperation between TGF-beta signaling and p53 activity and requires maternal factors, essential zygotic factors have been elusive. Here, we report that the Zn-finger protein XFDL156 is an ectodermal, zygotic factor that suppresses mesodermal differentiation. XFDL156 overexpression suppresses mesodermal markers, and its depletion induces aberrant mesodermal differentiation in the presumptive ectoderm. Furthermore, we find that XFDL156 and its mammalian homologs interact with the C-terminal regulatory region of p53, thereby inhibiting p53 target gene induction and mesodermal differentiation. Thus, XFDL156 actively restricts mesodermal differentiation in the presumptive ectoderm by controlling the spatiotemporal responsiveness to p53.	[Sasai, Noriaki; Yakura, Rieko; Kamiya, Daisuke; Nakazawa, Yoko; Sasai, Yoshiki] RIKEN, Ctr Dev Biol, Organogenesis & Neurogenesis Grp, Kobe, Hyogo 6500047, Japan	RIKEN	Sasai, N (corresponding author), RIKEN, Ctr Dev Biol, Organogenesis & Neurogenesis Grp, Kobe, Hyogo 6500047, Japan.	norisa@cdb.riken.jp; yoshikisasai@cdb.riken.jp		Sasai, Noriaki/0000-0003-0360-1138				Bell E, 2003, DEVELOPMENT, V130, P1381, DOI 10.1242/dev.00344; Bellefroid E, 1997, MECH DEVELOP, V63, P99, DOI 10.1016/S0925-4773(97)00034-8; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Cordenonsi M, 2007, SCIENCE, V315, P840, DOI 10.1126/science.1135961; Dupont S, 2005, CELL, V121, P87, DOI 10.1016/j.cell.2005.01.033; Eimon PM, 2002, DEVELOPMENT, V129, P3089; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; Germain S, 2000, GENE DEV, V14, P435; Grimm OH, 2002, NAT CELL BIOL, V4, P519, DOI 10.1038/ncb812; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Heasman J, 2006, DEVELOPMENT, V133, P1205, DOI 10.1242/dev.02304; HOEVER M, 1994, ONCOGENE, V9, P109; KINOSHITA M, 1994, FEBS LETT, V352, P191, DOI 10.1016/0014-5793(94)00909-0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Liu KJ, 2005, DEVELOPMENT, V132, P1511, DOI 10.1242/dev.01703; Looman C, 2002, MOL BIOL EVOL, V19, P2118, DOI 10.1093/oxfordjournals.molbev.a004037; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Marechal V, 1997, ONCOGENE, V14, P1427, DOI 10.1038/sj.onc.1200967; Matsuo-Takasaki M, 2005, DEVELOPMENT, V132, P3885, DOI 10.1242/dev.01959; Mir A, 2007, DEVELOPMENT, V134, P779, DOI 10.1242/dev.02768; Mizuseki K, 1998, DEVELOPMENT, V125, P579; Nakatani J, 2000, MECH DEVELOP, V91, P81, DOI 10.1016/S0925-4773(99)00274-9; Nakayama T, 2001, MECH DEVELOP, V100, P251, DOI 10.1016/S0925-4773(00)00533-5; Onai T, 2004, DEV CELL, V7, P95, DOI 10.1016/j.devcel.2004.06.004; Onai T, 2007, EMBO J, V26, P2350, DOI 10.1038/sj.emboj.7601684; Sasai N, 2004, NAT CELL BIOL, V6, P741, DOI 10.1038/ncb1158; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Smith J, 1997, CURR OPIN GENET DEV, V7, P474, DOI 10.1016/S0959-437X(97)80073-1; SMITH WC, 1995, CELL, V82, P37, DOI 10.1016/0092-8674(95)90050-0; Snir M, 2006, EMBO J, V25, P3664, DOI 10.1038/sj.emboj.7601238; Steinbach OC, 1997, NATURE, V389, P395, DOI 10.1038/38755; Stewart David, 2006, V322, P165; Sun BI, 1999, DEVELOPMENT, V126, P1467; Takebayashi-Suzuki K, 2003, DEVELOPMENT, V130, P3929, DOI 10.1242/dev.00615; Tosoni D, 2005, CELL, V123, P875, DOI 10.1016/j.cell.2005.10.021; Trindade M, 2003, DEVELOPMENT, V130, P4611, DOI 10.1242/dev.00489; TSAI RYL, 1999, ROAZ MOL CELL BIOL, V18, P6447; Wardle FC, 2006, SEMIN CELL DEV BIOL, V17, P99, DOI 10.1016/j.semcdb.2005.11.008; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; Watanabe K, 2005, NAT NEUROSCI, V8, P288, DOI 10.1038/nn1402; Watanabe M, 1999, DEVELOPMENT, V126, P5621; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; Zhang C, 2007, DIFFERENTIATION, V75, P536, DOI 10.1111/j.1432-0436.2007.00190.x; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974	52	36	36	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 30	2008	133	5					878	890		10.1016/j.cell.2008.03.035	http://dx.doi.org/10.1016/j.cell.2008.03.035			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510931	Bronze			2022-12-28	WOS:000256274500019
J	Roch, N; Florens, S; Bouchiat, V; Wernsdorfer, W; Balestro, F				Roch, Nicolas; Florens, Serge; Bouchiat, Vincent; Wernsdorfer, Wolfgang; Balestro, Franck			Quantum phase transition in a single-molecule quantum dot	NATURE			English	Article							KONDO; FABRICATION; FIELD	Quantum criticality is the intriguing possibility offered by the laws of quantum mechanics when the wave function of a many- particle physical system is forced to evolve continuously between two distinct, competing ground states(1). This phenomenon, often related to a zero- temperature magnetic phase transition, is believed to govern many of the fascinating properties of strongly correlated systems such as heavy- fermion compounds or high- temperature superconductors(1). In contrast to bulk materials with very complex electronic structures, artificial nanoscale devices could offer a new and simpler means of understanding quantum phase transitions(2,3). Here we demonstrate this possibility in a single- molecule quantum dot, where a gate voltage induces a crossing of two different types of electron spin state ( singlet and triplet) at zero magnetic field. The quantum dot is operated in the Kondo regime, where the electron spin on the quantum dot is partially screened by metallic electrodes. This strong electronic coupling between the quantum dot and the metallic contacts provides the strong electron correlations necessary to observe quantum critical behaviour. The quantum magnetic phase transition between two different Kondo regimes is achieved by tuning gate voltages and is fundamentally different from previously observed Kondo transitions in semiconductor and nanotube quantum dots(4,5). Our work may offer new directions in terms of control and tunability for molecular spintronics(6).	[Roch, Nicolas; Florens, Serge; Bouchiat, Vincent; Wernsdorfer, Wolfgang; Balestro, Franck] CNRS, Inst Neel, F-38042 Grenoble 9, France; [Roch, Nicolas; Florens, Serge; Bouchiat, Vincent; Wernsdorfer, Wolfgang; Balestro, Franck] Univ Grenoble 1, F-38042 Grenoble 9, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Balestro, F (corresponding author), CNRS, Inst Neel, BP 166, F-38042 Grenoble 9, France.	franck.balestro@grenoble.cnrs.fr	BOUCHIAT, Vincent L/R-4327-2017; roch, nicolas/F-9351-2011; nicolas, roch/B-1072-2014; Wernsdorfer, Wolfgang/M-2280-2016	BOUCHIAT, Vincent L/0000-0002-9818-8181; roch, nicolas/0000-0001-8177-9738; Wernsdorfer, Wolfgang/0000-0003-4602-5257				AFFLECK I, 1995, PHYS REV B, V52, P9528, DOI 10.1103/PhysRevB.52.9528; Bogani L, 2008, NAT MATER, V7, P179, DOI 10.1038/nmat2133; Costi TA, 2000, PHYS REV LETT, V85, P1504, DOI 10.1103/PhysRevLett.85.1504; Craig NJ, 2004, SCIENCE, V304, P565, DOI 10.1126/science.1095452; Cronenwett SM, 1998, SCIENCE, V281, P540, DOI 10.1126/science.281.5376.540; Esen G, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2149174; Georges A, 1999, PHYS REV LETT, V82, P3508, DOI 10.1103/PhysRevLett.82.3508; GLAZMAN LI, 1988, JETP LETT+, V47, P452; Goldhaber-Gordon D, 1998, NATURE, V391, P156, DOI 10.1038/34373; GROBIS M, 2007, HDB MAGNETISM MAGNE, V1; Hewson A C, 1993, KONDO PROBLEM HEAVY; Hofstetter W, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.235301; Hofstetter W, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.016803; HOLM JV, 2007, GATE DEPENDENT TUNNE; Houck AA, 2005, NANO LETT, V5, P1685, DOI 10.1021/nl050799i; JONES BA, 1988, PHYS REV LETT, V61, P125, DOI 10.1103/PhysRevLett.61.125; Kogan A, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.113309; Liang WJ, 2002, NATURE, V417, P725, DOI 10.1038/nature00790; NOZIERES P, 1980, J PHYS-PARIS, V41, P193, DOI 10.1051/jphys:01980004103019300; Nygard J, 2000, NATURE, V408, P342, DOI 10.1038/35042545; O'Neill K, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2716989; Paaske J, 2006, NAT PHYS, V2, P460, DOI 10.1038/nphys340; Park H, 1999, APPL PHYS LETT, V75, P301, DOI 10.1063/1.124354; Park H, 2000, NATURE, V407, P57, DOI 10.1038/35024031; Parks JJ, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.026601; Pasupathy AN, 2004, SCIENCE, V306, P86, DOI 10.1126/science.1102068; Pustilnik M, 2000, PHYS REV LETT, V84, P1756, DOI 10.1103/PhysRevLett.84.1756; Pustilnik M, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.045328; Quay CHL, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.245311; Sachdev S, 2008, NAT PHYS, V4, P173, DOI 10.1038/nphys894; Sasaki S, 2000, NATURE, V405, P764, DOI 10.1038/35015509; Strachan DR, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1857095; Trouwborst ML, 2006, J APPL PHYS, V99, DOI 10.1063/1.2203410; van der Zant HSJ, 2006, FARADAY DISCUSS, V131, P347, DOI 10.1039/b506240n; Vojta M, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.140405; Wu ZM, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2760150; Yu LH, 2004, NANO LETT, V4, P79, DOI 10.1021/nl034893f; Zarand G, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.166802	39	229	231	1	121	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	2008	453	7195					633	U3		10.1038/nature06930	http://dx.doi.org/10.1038/nature06930			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305NN	18509439	Green Submitted			2022-12-28	WOS:000256185200039
J	Chang, HH; Hemberg, M; Barahona, M; Ingber, DE; Huang, S				Chang, Hannah H.; Hemberg, Martin; Barahona, Mauricio; Ingber, Donald E.; Huang, Sui			Transcriptome-wide noise controls lineage choice in mammalian progenitor cells	NATURE			English	Article							EUKARYOTIC GENE-EXPRESSION; SINGLE-CELL; STEM-CELLS; DYNAMICS; HEMATOPOIESIS; STOCHASTICITY	Phenotypic cell-to-cell variability within clonal populations may be a manifestation of 'gene expression noise'(1-6), or it may reflect stable phenotypic variants(7). Such 'non-genetic cell individuality'(7) can arise from the slow fluctuations of protein levels(8) in mammalian cells. These fluctuations produce persistent cell individuality, thereby rendering a clonal population heterogeneous. However, it remains unknown whether this heterogeneity may account for the stochasticity of cell fate decisions in stem cells. Here we show that in clonal populations of mouse haematopoietic progenitor cells, spontaneous 'outlier' cells with either extremely high or low expression levels of the stem cell marker Sca-1 (also known as Ly6a; ref. 9) reconstitute the parental distribution of Sca-1 but do so only after more than one week. This slow relaxation is described by a gaussian mixture model that incorporates noise- driven transitions between discrete subpopulations, suggesting hidden multi-stability within one cell type. Despite clonality, the Sca-1 outliers had distinct transcriptomes. Although their unique gene expression profiles eventually reverted to that of the median cells, revealing an attractor state, they lasted long enough to confer a greatly different proclivity for choosing either the erythroid or the myeloid lineage. Preference in lineage choice was associated with increased expression of lineage-specific transcription factors, such as a > 200-fold increase in Gata1 (ref. 10) among the erythroid-prone cells, or a > 15-fold increased PU.1 (Sfpi1) (ref. 11) expression among myeloid-prone cells. Thus, clonal heterogeneity of gene expression level is not due to independent noise in the expression of individual genes, but reflects metastable states of a slowly fluctuating transcriptome that is distinct in individual cells and may govern the reversible, stochastic priming of multipotent progenitor cells in cell fate decision.	[Chang, Hannah H.; Ingber, Donald E.; Huang, Sui] Childrens Hosp, Vasc Biol Programme, Dept Pathol & Surg, Boston, MA 02115 USA; [Chang, Hannah H.; Ingber, Donald E.; Huang, Sui] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Chang, Hannah H.] Harvard Univ, Sch Med, Program Biophys, Boston, MA 02115 USA; [Chang, Hannah H.] Harvard Univ, Sch Med, MD PhD Programme, Boston, MA 02115 USA; [Hemberg, Martin; Barahona, Mauricio] Univ London Imperial Coll Sci Technol & Med, Dept Bioengn, London SW7 2AZ, England; [Hemberg, Martin; Barahona, Mauricio] Univ London Imperial Coll Sci Technol & Med, Inst Math Sci, London SW7 2AZ, England; [Ingber, Donald E.] Harvard Inst Biol Inspired Engn, Cambridge, MA 02139 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Imperial College London; Imperial College London; Harvard University	Huang, S (corresponding author), Univ Calgary, Inst Biocomplex & Informat, Calgary, AB T2N 1N4, Canada.	sui.huang@ucalgary.ca	Barahona, Mauricio/C-3638-2008; Ingber, Donald E/AAC-5894-2019; Barahona, Mauricio/M-9747-2019	Barahona, Mauricio/0000-0002-1089-5675; Barahona, Mauricio/0000-0002-1089-5675	NATIONAL CANCER INSTITUTE [P01CA045548, R21CA123284] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA045548, P01 CA045548-210002, R21 CA123284] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blake WJ, 2003, NATURE, V422, P633, DOI 10.1038/nature01546; Cantor AB, 2002, MOL CELL BIOL, V22, P4268, DOI 10.1128/MCB.22.12.4268-4279.2002; Chang HH, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-11; Eichler GS, 2003, BIOINFORMATICS, V19, P2321, DOI 10.1093/bioinformatics/btg307; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Enver T, 1998, BLOOD, V92, P348, DOI 10.1182/blood.V92.2.348.Con3_348_351; Guido NJ, 2006, NATURE, V439, P856, DOI 10.1038/nature04473; Holmes C, 2007, STEM CELLS, V25, P1339, DOI 10.1634/stemcells.2006-0644; Huang S, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.128701; Huang S, 2007, DEV BIOL, V305, P695, DOI 10.1016/j.ydbio.2007.02.036; Kaern M, 2005, NAT REV GENET, V6, P451, DOI 10.1038/nrg1615; Koschmieder S, 2005, INT J HEMATOL, V81, P368, DOI 10.1532/IJH97.05051; Kurchan J, 1996, J PHYS A-MATH GEN, V29, P1929, DOI 10.1088/0305-4470/29/9/009; Orkin SH, 2002, NAT IMMUNOL, V3, P323, DOI 10.1038/ni0402-323; Pedraza JM, 2005, SCIENCE, V307, P1965, DOI 10.1126/science.1109090; Raser JM, 2004, SCIENCE, V304, P1811, DOI 10.1126/science.1098641; Rosenfeld N, 2005, SCIENCE, V307, P1962, DOI 10.1126/science.1106914; Sigal A, 2006, NATURE, V444, P643, DOI 10.1038/nature05316; SPUDICH JL, 1976, NATURE, V262, P467, DOI 10.1038/262467a0; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Uhlenbeck GE, 1930, PHYS REV, V36, P0823, DOI 10.1103/PhysRev.36.823; VANDERIJN M, 1989, P NATL ACAD SCI USA, V86, P4634; WANG R, 1992, DEVELOPMENT, V114, P303; Zenger VE, 1998, CYTOMETRY, V33, P138, DOI 10.1002/(SICI)1097-0320(19981001)33:2<138::AID-CYTO8>3.0.CO;2-F	25	783	792	4	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 22	2008	453	7194					544	U10		10.1038/nature06965	http://dx.doi.org/10.1038/nature06965			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303EL	18497826	Green Accepted			2022-12-28	WOS:000256023700047
J	Hart, JT				Hart, Julian Tudor			Worlds of difference	LANCET			English	Editorial Material							HEALTH-CARE; DEMAND; NHS		[Hart, Julian Tudor] Univ Coll Swansea, Swansea Med Sch, Swansea SA2 8PP, W Glam, Wales	Swansea University	Hart, JT (corresponding author), Univ Coll Swansea, Swansea Med Sch, Singleton Park, Swansea SA2 8PP, W Glam, Wales.	julian@tudorhart.freeserve.co.uk						CHECKLAND EOA, 1974, POOR LAW REPORT 1834, P338; CHING P, 1995, SOC SCI MED, V41, P37, DOI 10.1016/0277-9536(94)00306-E; Coulter A, 2005, BMJ-BRIT MED J, V331, P1199, DOI 10.1136/bmj.331.7526.1199; Craig D., 2006, PLUNDERING PUBLIC SE; ENTHOVEN A, 1990, INT COMP HLTH CARE S, P57; FOOT M, 1962, ANEURIN BEVAN BIOGRA, V1, P464; Frankel S, 2000, BMJ-BRIT MED J, V321, P40, DOI 10.1136/bmj.321.7252.40; Frankel S, 1999, LANCET, V353, P1304, DOI 10.1016/S0140-6736(98)06451-4; HART JT, 1992, LANCET, V340, P772, DOI 10.1016/0140-6736(92)92304-X; Hart JT, 2006, POLITICAL EC HLTH CA; Heath I, 2007, BRIT MED J, V335, P183, DOI 10.1136/bmj.39286.704722.59; Mocan HN, 2004, WORLD DEV, V32, P289, DOI 10.1016/j.worlddev.2003.07.006; *NAT AUD OFF, 2005, REF NORF NORW PFJ HO; NUNNS A, 2007, GUARDIAN LONDON 0327, P31; Pollock AM, 2007, PUBLIC MONEY MANAGE, V27, P127, DOI 10.1111/j.1467-9302.2007.00568.x; POTTER B, 2000, LIFE TIMES SIDNEY B, P145; SMITH A, 1993, ENQUIRY NATURE CAUSE, P429; Starfield B, 2007, BRIT J GEN PRACT, V57, P527; Sutherland Kathryn, 1776, INTRO COMMENTARY A S, p[ix, 465]; Townsend P., 1962, LAST REFUGE; WEBSTER C, 1988, HLTH SERVICES WAR, V1, P253	21	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY-JUN	2008	371	9627					1883	1885		10.1016/S0140-6736(08)60802-8	http://dx.doi.org/10.1016/S0140-6736(08)60802-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307NL	18514732				2022-12-28	WOS:000256325500032
J	Schawinski, K; Justham, S; Wolf, C; Podsiadlowski, P; Sullivan, M; Steenbrugge, KC; Bell, T; Roser, HJ; Walker, ES; Astier, P; Balam, D; Balland, C; Carlberg, R; Conley, A; Fouchez, D; Guy, J; Hardin, D; Hook, I; Howell, DA; Pain, R; Perrett, K; Pritchet, C; Regnault, N; Yi, SK				Schawinski, Kevin; Justham, Stephen; Wolf, Christian; Podsiadlowski, Philipp; Sullivan, Mark; Steenbrugge, Katrien C.; Bell, Tony; Roeser, Hermann-Josef; Walker, Emma S.; Astier, Pierre; Balam, Dave; Balland, Christophe; Carlberg, Ray; Conley, Alex; Fouchez, Dominique; Guy, Julien; Hardin, Delphine; Hook, Isobel; Howell, D. Andrew; Pain, Reynald; Perrett, Kathy; Pritchet, Chris; Regnault, Nicolas; Yi, Sukyoung K.			Supernova shock breakout from a red supergiant	SCIENCE			English	Article							EVOLUTION; STAR; PROGENITOR; GRB-060218; MECHANISM; GALAXIES; SN-1987A; 2006AJ; COSMOS; GALEX	Massive stars undergo a violent death when the supply of nuclear fuel in their cores is exhausted, resulting in a catastrophic "core-collapse" supernova. Such events are usually only detected at least a few days after the star has exploded. Observations of the supernova SNLS-04D2dc with the Galaxy Evolution Explorer space telescope reveal a radiative precursor from the supernova shock before the shock reached the surface of the star and show the initial expansion of the star at the beginning of the explosion. Theoretical models of the ultraviolet light curve confirm that the progenitor was a red supergiant, as expected for this type of supernova. These observations provide a way to probe the physics of core- collapse supernovae and the internal structures of their progenitor stars.	[Schawinski, Kevin; Justham, Stephen; Wolf, Christian; Podsiadlowski, Philipp; Sullivan, Mark; Bell, Tony; Walker, Emma S.; Hook, Isobel] Univ Oxford, Dept Phys, Oxford OX1 3RH, England; [Steenbrugge, Katrien C.] Univ Oxford St Johns Coll, Res Ctr, Oxford OX1 3JP, England; [Roeser, Hermann-Josef] Max Planck Inst Astron, D-69117 Heidelberg, Germany; [Astier, Pierre; Balland, Christophe; Guy, Julien; Hardin, Delphine; Pain, Reynald; Regnault, Nicolas] CNRS, Lab Phys Nucl & Hautes Energies, IN2P3, F-75252 Paris 05, France; [Astier, Pierre; Balland, Christophe; Guy, Julien; Hardin, Delphine; Pain, Reynald; Regnault, Nicolas] Univ Paris 06, F-75252 Paris 05, France; [Astier, Pierre; Balland, Christophe; Guy, Julien; Hardin, Delphine; Pain, Reynald; Regnault, Nicolas] Univ Paris 07, F-75252 Paris 05, France; [Balam, Dave; Pritchet, Chris] Univ Victoria, Dept Phys & Astron, Victoria, BC V8T 3P6, Canada; [Carlberg, Ray; Conley, Alex; Howell, D. Andrew; Perrett, Kathy] Univ Toronto, Dept Phys & Astron, Toronto, ON M5S 3H4, Canada; [Fouchez, Dominique] CNRS, Ctr Phys Particules Marseille, IN2P3, F-13288 Marseille 9, France; [Fouchez, Dominique] Univ Aix Marseille 2, Case 907, F-13288 Marseille 9, France; [Yi, Sukyoung K.] Yonsei Univ, Dept Astron, Seoul 120749, South Korea	University of Oxford; University of Oxford; Max Planck Society; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; University of Victoria; University of Toronto; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Yonsei University	Schawinski, K (corresponding author), Univ Oxford, Dept Phys, Oxford OX1 3RH, England.	kevins@astro.ox.ac.uk; sjustham@astro.ox.ac.uk; cwolf@astro.ox.ac.uk	Carlberg, Raymond G/I-6947-2012; Schawinski, Kevin/N-7057-2016; Howell, Andy/ABE-6446-2020; Yi, Sukyoung/AAO-7826-2020; Hook, Isobel M/S-8590-2017	Carlberg, Raymond G/0000-0002-7667-0081; Schawinski, Kevin/0000-0001-5464-0888; Hook, Isobel M/0000-0002-2960-978X; Wolf, Christian/0000-0002-4569-016X; Sullivan, Mark/0000-0001-9053-4820				Arnett D., 1996, PRINCETON SERIES AST; Astier P, 2006, ASTRON ASTROPHYS, V447, P31, DOI 10.1051/0004-6361:20054185; Buras R, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.241101; Burrows A, 2006, ASTROPHYS J, V640, P878, DOI 10.1086/500174; Calzavara AJ, 2004, MON NOT R ASTRON SOC, V351, P694, DOI 10.1111/j.1365-2966.2004.07818.x; Campana S, 2006, NATURE, V442, P1008, DOI 10.1038/natureO4892; ENSMAN L, 1992, ASTROPHYS J, V393, P742, DOI 10.1086/171542; FALK SW, 1973, ASTROPHYS J, V180, pL65, DOI 10.1086/181154; FRANSSON C, 1989, ASTROPHYS J, V341, pL59, DOI 10.1086/185457; Fryer CL, 2007, PUBL ASTRON SOC PAC, V119, P1211, DOI 10.1086/523768; Ghisellini G, 2007, MON NOT R ASTRON SOC, V382, pL77, DOI 10.1111/j.1745-3933.2007.00396.x; Li LX, 2007, MON NOT R ASTRON SOC, V375, P240, DOI 10.1111/j.1365-2966.2006.11286.x; Lundqvist P, 1999, ASTROPHYS J, V511, P389, DOI 10.1086/306654; Mazzali PA, 2006, NATURE, V442, P1018, DOI 10.1038/nature05081; Mezzacappa A, 2005, ANNU REV NUCL PART S, V55, P467, DOI 10.1146/annurev.nucl.55.090704.151608; Morrissey P, 2007, ASTROPHYS J SUPPL S, V173, P682, DOI 10.1086/520512; Nomoto K, 2006, NUCL PHYS A, V777, P424, DOI 10.1016/j.nuclphysa.2006.05.008; Quimby RM, 2007, ASTROPHYS J, V666, P1093, DOI 10.1086/520532; Scoville N, 2007, ASTROPHYS J SUPPL S, V172, P1, DOI 10.1086/516585; Smartt SJ, 2004, SCIENCE, V303, P499, DOI 10.1126/science.1092967; Soderberg AM, 2008, NATURE, V453, P469, DOI 10.1038/nature06997; Stritzinger M, 2002, ASTRON J, V124, P2100, DOI 10.1086/342544; Zamojski MA, 2007, ASTROPHYS J SUPPL S, V172, P468, DOI 10.1086/516593	25	102	103	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	2008	321	5886					223	226		10.1126/science.1160456	http://dx.doi.org/10.1126/science.1160456			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324IS	18556514	Green Submitted			2022-12-28	WOS:000257512900032
J	Davis, BN; Hilyard, AC; Lagna, G; Hata, A				Davis, Brandi N.; Hilyard, Aaron C.; Lagna, Giorgio; Hata, Akiko			SMAD proteins control DROSHA-mediated microRNA maturation	NATURE			English	Article							TGF-BETA; POSTTRANSCRIPTIONAL REGULATION; EXPRESSION SIGNATURE; BINDING-PROTEIN; CANCER; TARGETS; GENES; RNA; DIFFERENTIATION; INHIBITION	MicroRNAs ( miRNAs) are small non- coding RNAs that participate in the spatiotemporal regulation of messenger RNA and protein synthesis. Aberrant miRNA expression leads to developmental abnormalities and diseases, such as cardiovascular disorders and cancer; however, the stimuli and processes regulating miRNA biogenesis are largely unknown. The transforming growth factor beta ( TGF-beta) and bone morphogenetic protein ( BMP) family of growth factors orchestrates fundamental biological processes in development and in the homeostasis of adult tissues, including the vasculature. Here we show that induction of a contractile phenotype in human vascular smooth muscle cells by TGF-beta and BMPs is mediated by miR- 21. miR- 21 downregulates PDCD4 ( programmed cell death 4), which in turn acts as a negative regulator of smooth muscle contractile genes. Surprisingly, TGF-beta and BMP signalling promotes a rapid increase in expression of mature miR- 21 through a post- transcriptional step, promoting the processing of primary transcripts of miR- 21 ( pri- miR- 21) into precursor miR- 21 ( pre- miR- 21) by the DROSHA ( also known as RNASEN) complex. TGF-beta- and BMP- specific SMAD signal transducers are recruited to pri- miR- 21 in a complex with the RNA helicase p68 ( also known as DDX5), a component of the DROSHA microprocessor complex. The shared cofactor SMAD4 is not required for this process. Thus, regulation of miRNA biogenesis by ligand- specific SMAD proteins is critical for control of the vascular smooth muscle cell phenotype and potentially for SMAD4- independent responses mediated by the TGF-beta and BMP signalling pathways.	[Davis, Brandi N.; Hata, Akiko] Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; [Davis, Brandi N.; Hilyard, Aaron C.; Lagna, Giorgio; Hata, Akiko] Tufts Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA	Tufts University; Tufts Medical Center	Hata, A (corresponding author), Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA.	akiko.hata@tufts.edu	Davis-Dusenbery, Brandi/N-2798-2013	Davis-Dusenbery, Brandi/0000-0001-7811-8613	NHLBI NIH HHS [R01 HL082854, R21 HL086572, HL086572, R21 HL086572-02, R01 HL082854-03, HL082854] Funding Source: Medline; NICHD NIH HHS [R01 HD042149, HD042149, R01 HD042149-05] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD042149] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082854, R21HL086572] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arteaga CL, 2006, CURR OPIN GENET DEV, V16, P30, DOI 10.1016/j.gde.2005.12.009; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bachman KE, 2005, CURR OPIN ONCOL, V17, P49, DOI 10.1097/01.cco.0000143682.45316.ae; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Chan MC, 2007, MOL CELL BIOL, V27, P5776, DOI 10.1128/MCB.00218-07; Diederichs S, 2006, CANCER RES, V66, P6097, DOI 10.1158/0008-5472.CAN-06-0537; Esau CC, 2008, METHODS, V44, P55, DOI 10.1016/j.ymeth.2007.11.001; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Fukuda T, 2007, NAT CELL BIOL, V9, P604, DOI 10.1038/ncb1577; Giehl K, 2007, CELLS TISSUES ORGANS, V185, P123, DOI 10.1159/000101313; Glick AB, 2004, CANCER BIOL THER, V3, P276, DOI 10.4161/cbt.3.3.849; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; Guil S, 2007, NAT STRUCT MOL BIOL, V14, P591, DOI 10.1038/nsmb1250; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Ijichi H, 2004, ONCOGENE, V23, P1043, DOI 10.1038/sj.onc.1207222; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Ji RR, 2007, CIRC RES, V100, P1579, DOI 10.1161/CIRCRESAHA.106.141986; Kim VN, 2006, TRENDS GENET, V22, P165, DOI 10.1016/j.tig.2006.01.003; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 2007, J BIOL CHEM, V282, P37244, DOI 10.1074/jbc.M708137200; Landthaler M, 2004, CURR BIOL, V14, P2162, DOI 10.1016/j.cub.2004.11.001; Lee EJ, 2008, RNA, V14, P35, DOI 10.1261/rna.804508; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Morrell Nicholas W, 2006, Proc Am Thorac Soc, V3, P680, DOI 10.1513/pats.200605-118SF; Obernosterer G, 2006, RNA, V12, P1161, DOI 10.1261/rna.2322506; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; OWENS GK, 1995, PHYSIOL REV, V75, P487; Rensen SSM, 2007, NETH HEART J, V15, P100, DOI 10.1007/BF03085963; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Schmittgen TD, 2008, METHODS, V44, P31, DOI 10.1016/j.ymeth.2007.09.006; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; ten Dijke P, 2007, NAT REV MOL CELL BIO, V8, P857, DOI 10.1038/nrm2262; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; van Rooij E, 2006, P NATL ACAD SCI USA, V103, P18255, DOI 10.1073/pnas.0608791103; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Warner DR, 2004, BIOCHEM BIOPH RES CO, V324, P70, DOI 10.1016/j.bbrc.2004.09.017; Wiemer EAC, 2007, EUR J CANCER, V43, P1529, DOI 10.1016/j.ejca.2007.04.002; Wulczyn FG, 2007, FASEB J, V21, P415, DOI 10.1096/fj.06-6130com; Zhao Y, 2007, TRENDS BIOCHEM SCI, V32, P189, DOI 10.1016/j.tibs.2007.02.006; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	50	1048	1106	3	100	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 3	2008	454	7200					56	U2		10.1038/nature07086	http://dx.doi.org/10.1038/nature07086			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	321MC	18548003	Green Accepted			2022-12-28	WOS:000257308300034
J	Mozaffarian, D				Mozaffarian, Dariush			Promise of improving metabolic and lifestyle risk in practice	LANCET			English	Editorial Material							PREVENTION; DISEASE; GUIDELINES		[Mozaffarian, Dariush] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, Boston, MA 02115 USA; [Mozaffarian, Dariush] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; [Mozaffarian, Dariush] Harvard Univ, Sch Med, Dept Epidemiol, Boston, MA USA; [Mozaffarian, Dariush] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Mozaffarian, D (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA.	dmozaffa@hsph.harvard.edu	Mozaffarian, Dariush/B-2276-2008					Brunner E, 2001, PUBLIC HEALTH NUTR, V4, P1297, DOI 10.1079/PHN2001272; Chowdhury Pranesh P., 2007, Morbidity and Mortality Weekly Report, V56, P1; Graham I, 2007, EUR HEART J, V28, P2375, DOI 10.1093/eurheartj/ehm316; Kotseva K, 2001, LANCET, V357, P995, DOI 10.1016/S0140-6736(00)04235-5; Lutfiyya MN, 2008, J GEN INTERN MED, V23, P821, DOI 10.1007/s11606-008-0581-5; MOZAFFARIAN D, IN PRESS CIRCULATION; Newby LK, 2006, CIRCULATION, V113, P203, DOI 10.1161/CIRCULATIONAHA.105.505636; Thorndike AN, 2007, AM J PUBLIC HEALTH, V97, P1878, DOI 10.2105/AJPH.2006.092577; Wofford TS, 2007, PREV MED, V45, P295, DOI 10.1016/j.ypmed.2007.06.013; Wood DA, 2008, LANCET, V371, P1999, DOI 10.1016/S0140-6736(08)60868-5	10	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2008	371	9629					1973	1974		10.1016/S0140-6736(08)60844-2	http://dx.doi.org/10.1016/S0140-6736(08)60844-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312YY	18555896				2022-12-28	WOS:000256709500004
J	Warner, KE; Mackay, JL				Warner, Kenneth E.; Mackay, Judith Longstaff			Smoking cessation treatment in a public-health context	LANCET			English	Editorial Material									[Warner, Kenneth E.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA; [Mackay, Judith Longstaff] Bloomberg Initiat Reduce Tobacco Use, Hong Kong, Hong Kong, Peoples R China	University of Michigan System; University of Michigan	Warner, KE (corresponding author), Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA.	kwarner@umich.edu		Warner, Kenneth/0000-0002-8214-1776				[Anonymous], 2006, TOBACCO CONTROL POLI; Chaloupka FJ, 2000, TOBACCO CONTROL DEVE, P237; CHAPMAN S, 1985, LANCET, V1, P918; Cromwell J, 1997, JAMA-J AM MED ASSOC, V278, P1759, DOI 10.1001/jama.278.21.1759; Fichtenberg CM, 2002, BMJ-BRIT MED J, V325, P188, DOI 10.1136/bmj.325.7357.188; Hatsukami DK, 2008, LANCET, V371, P2027, DOI 10.1016/S0140-6736(08)60871-5; Lantz PM, 2000, TOB CONTROL, V9, P47, DOI 10.1136/tc.9.1.47; Saffer H, 2000, J HEALTH ECON, V19, P1117, DOI 10.1016/S0167-6296(00)00054-0; World Health Organization, WHO FRAM CONV TOB CO	9	13	13	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 14	2008	371	9629					1976	1978		10.1016/S0140-6736(08)60846-6	http://dx.doi.org/10.1016/S0140-6736(08)60846-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	312YY	18555898				2022-12-28	WOS:000256709500006
J	Zheng, JP; Kang, J; Huang, SG; Chen, P; Yao, WZ; Yang, L; Bai, CX; Wang, CZ; Wang, C; Chen, BY; Shi, Y; Liu, CT; Chen, P; Li, Q; Wang, ZS; Huang, YJ; Luo, ZY; Chen, FP; Yuan, JZ; Yuan, BT; Qian, HP; Zhi, RC; Zhong, NS				Zheng, Jin-Ping; Kang, Jian; Huang, Shao-Guang; Chen, Ping; Yao, Wan-Zen; Yang, Lan; Bai, Chun-Xue; Wang, Chang-Zheng; Wang, Chen; Chen, Bao-Yuan; Shi, Yi; Liu, Chun-Tao; Chen, Ping; Li, Qiang; Wang, Zhen-Shan; Huang, Yi-Jiang; Luo, Zhi-Yang; Chen, Fei-Peng; Yuan, Jian-Zhang; Yuan, Ben-Tong; Qian, Hui-Ping; Zhi, Rong-Chang; Zhong, Nan-Shan			Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study	LANCET			English	Article							LYSINE SALT MONOHYDRATE; CARBOCYSTEINE-LYSINE; DOUBLE-BLIND; BRONCHITIS; CLEARANCE; THERAPY	Background Chronic obstructive pulmonary disease (COPD) is characterised by airflow limitation, and has many components including mucus hypersecretion, oxidative stress, and airway inflammation. We aimed to assess whether carbocisteine, a mucolytic agent with anti-inflammatory and antioxidation activities, could reduce the yearly exacerbation rate in patients with COPD. Methods We did a randomised, double-blind, placebo-controlled study of 709 patients from 22 centres in China. Participants were eligible if they were diagnosed as having COPD with a postbronchodilator forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) ratio (FEV1/FVC) of less than 0.7 and an FEV1 between 25% and 79% of the predicted value, were aged between 40 and 80 years, had a history of at least two COPD exacerbations within the previous 2 years, and had remained clinically stable for over 4 weeks before the study. Patients were randomly assigned to receive 1500 mg carbocisteine or placebo per day for a year. The primary endpoint was exacerbation rate over 1 year, and analysis was by intention to treat. This trial is registered with the Japan Clinical Trials Registry (http://umin. ac.jp/ctr/index/htm) number UMIN-CRT C000000233. Findings 354 patients were assigned to the carbocisteine group and 355 to the placebo group. Numbers of exacerbations per patient per year declined significantly in the carbocisteine group compared with the placebo group (1.01 [SE 0.06] vs 1.35 [SE 0.06]), risk ratio 0.75 (95% CI 0.62-0.92, p=0.004). Non-significant interactions were found between the preventive effects and COPD severity, smoking, as well as concomitant use of inhaled corticosteroids. Carbocisteine was well tolerated. Interpretation Mucolytics, such as carbocisteine, should be recognised as a worthwhile treatment for prevention of exacerbations in Chinese patients with COPD.	[Zheng, Jin-Ping; Zhong, Nan-Shan] First Affiliated Hosp, Guangzhou Med Coll, State Key Lab Resp Dis, Guangzhou Inst Resp Dis, Guangzhou 510120, Peoples R China; [Kang, Jian] China Med Univ, Affiliated Hosp 1, Shenyang, Peoples R China; [Huang, Shao-Guang] Shanghai Jiao Tong Univ, Sch Med, Ruijing Hosp, Shanghai 200030, Peoples R China; [Chen, Ping] Shenyang PLA Gen Hosp, Shenyang, Peoples R China; [Yao, Wan-Zen] Peking Univ, Hosp 3, Beijing 100871, Peoples R China; [Yang, Lan] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian 710049, Peoples R China; [Bai, Chun-Xue] Fudan Univ, Zhongshan Hosp, Shanghai 200433, Peoples R China; [Wang, Chang-Zheng] Xin Qiao Hosp, Chongqing, Peoples R China; [Wang, Chen] Chao Yang Hosp, Beijing, Peoples R China; [Chen, Bao-Yuan] Tianjin Gen Hosp, Tianjin, Peoples R China; [Shi, Yi] Nanjing PLA Gen Hosp, Nanjing, Peoples R China; [Liu, Chun-Tao] Huaxi Hosp, Chengdu, Peoples R China; [Chen, Ping] Second Xiangya Hosp, Changsha, Peoples R China; [Li, Qiang] Changhai Hosp, Shanghai, Peoples R China; [Wang, Zhen-Shan] Dalian Med Univ, Affiliated Hosp 2, Dalian, Peoples R China; [Huang, Yi-Jiang] Hainan Prov Hosp, Haikou, Peoples R China; [Luo, Zhi-Yang] First Municipal Hosp, Foshan, Peoples R China; [Chen, Fei-Peng] Second Affiliated Hosp, Guangzhou Med Coll, Guangzhou, Peoples R China; [Yuan, Jian-Zhang] Red Cross Hosp, Guangzhou, Peoples R China; [Yuan, Ben-Tong] Second Municipal Hosp, Shenzhen, Peoples R China; [Qian, Hui-Ping] Xinhai Hosp, Guangzhou, Peoples R China; [Zhi, Rong-Chang] Panyu Hosp, Guangzhou, Peoples R China	Guangzhou Medical University; State Key Laboratory of Respiratory Disease; China Medical University; Shanghai Jiao Tong University; Peking University; Xi'an Jiaotong University; Fudan University; Army Medical University; Sichuan University; Naval Medical University; Dalian Medical University; Guangzhou Medical University	Zhong, NS (corresponding author), First Affiliated Hosp, Guangzhou Med Coll, State Key Lab Resp Dis, Guangzhou Inst Resp Dis, Guangzhou 510120, Peoples R China.	nanshan@vip.163.com						Allegra L, 1996, RESPIRATION, V63, P174; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196; Boonyapiwat B, 2004, ANAL BIOCHEM, V335, P91, DOI 10.1016/j.ab.2004.08.003; BRAGA PC, 1990, RESPIRATION, V57, P353; Brandolini L, 2003, EUR CYTOKINE NETW, V14, P20; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Carpagnano GE, 2004, EUR J PHARMACOL, V505, P169, DOI 10.1016/j.ejphar.2004.10.007; Casaburi R, 2002, EUR RESPIR J, V19, P217, DOI 10.1183/09031936.02.00269802; Chen Ping, 2005, Zhonghua Jiehe He Huxi Zazhi, V28, P458; Decramer M, 2005, LANCET, V365, P1552, DOI 10.1016/S0140-6736(05)66456-2; Guizzardi F, 2006, J MOL MED, V84, P97, DOI 10.1007/s00109-005-0720-y; Ishii Y, 2002, EUR J PHARMACOL, V449, P183, DOI 10.1016/S0014-2999(02)01981-7; Jones PW, 2001, THORAX, V56, P880, DOI 10.1136/thorax.56.11.880; LIU S, 2000, THORAX, P1; Mitchell SC, 2006, J AM GERIATR SOC, V54, P1792, DOI 10.1111/j.1532-5415.2006.00926.x; Poole PJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001287.pub2; Poole P. J., 2001, BRIT MED J, V322, P1; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; SAKAKURA Y, 1985, CLIN OTOLARYNGOL, V10, P79, DOI 10.1111/j.1365-2273.1985.tb01171.x; Steventon GB, 2006, EUR RESPIR J, V27, P865, DOI 10.1183/09031936.06.00144905; Tatsumi K, 2007, J AM GERIATR SOC, V55, P1884, DOI 10.1111/j.1532-5415.2007.01373.x; Yasuda H, 2006, EUR RESPIR J, V28, P51, DOI 10.1183/09031936.06.00058505; Yasuda H, 2006, J AM GERIATR SOC, V54, P378, DOI 10.1111/j.1532-5415.2005.00592_9.x; Zheng JP, 2007, CHEST, V132, P1756, DOI 10.1378/chest.06-3009; Zheng JP, 2002, CHINESE MED J-PEKING, V115, P50; ZHONG NS, 1997, ASTHMA, P1869; Zhou YM, 2006, RESPIROLOGY, V11, P603, DOI 10.1111/j.1440-1843.2006.00897.x	28	244	289	2	211	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2008	371	9629					2013	2018		10.1016/S0140-6736(08)60869-7	http://dx.doi.org/10.1016/S0140-6736(08)60869-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312YY	18555912				2022-12-28	WOS:000256709500027
J	Polier, S; Dragovic, Z; Hartl, FU; Bracher, A				Polier, Sigrun; Dragovic, Zdravko; Hartl, F. Ulrich; Bracher, Andreas			Structural basis for the cooperation of Hsp70 and Hsp110 chaperones in protein folding	CELL			English	Article							NUCLEOTIDE EXCHANGE FACTOR; MARINESCO-SJOGREN-SYNDROME; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONES; ALLOSTERIC REGULATION; INTERDOMAIN LINKER; CRYSTAL-STRUCTURE; YEAST; GRPE; DNAK	Protein folding by Hsp70 is tightly controlled by cochaperones, including J-domain proteins that trigger ATP hydrolysis and nucleotide exchange factors (NEFs) that remove ADP from Hsp70. Here we present the crystal structure of the yeast NEF Sse1p (Hsp110) in complex with the nucleotide-binding domain (NBD) of Hsp70. Hsp110 proteins are homologous to Hsp70s and consist of an NBD, a beta sandwich domain, and a three helix bundle domain (3HBD). In the complex, the NBD of Sse1p is ATP bound, and together with the 3HBD it embraces the NBD of Hsp70, inducing opening and the release of bound ADP from Hsp70. Mutations that abolish NEF activity are lethal, thus defining nucleotide exchange on Hsp70 as an essential function of Sse1p. Our data suggest that Sse1p does not employ the nucleotide-dependent allostery and peptide-binding mode of canonical Hsp70s, and that direct interactions of substrate with Sse1p may support Hsp70-assisted protein folding in a cooperative process.	[Polier, Sigrun; Dragovic, Zdravko; Hartl, F. Ulrich; Bracher, Andreas] Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany	Max Planck Society	Hartl, FU (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, Am Klopferspitz 18, D-82152 Martinsried, Germany.	uhartl@biochem.mpg.de; bracher@biochem.mpg.de	Hartl, F. Ulrich/Y-8206-2019					Andreasson C, 2008, J BIOL CHEM, V283, P8877, DOI 10.1074/jbc.M710063200; Anttonen AK, 2005, NAT GENET, V37, P1309, DOI 10.1038/ng1677; Bukau B, 2006, CELL, V125, P443, DOI 10.1016/j.cell.2006.04.014; Chang YW, 2008, J BIOL CHEM, V283, P15502, DOI 10.1074/jbc.M708992200; Dragovic Z, 2006, EMBO J, V25, P2519, DOI 10.1038/sj.emboj.7601138; Easton DP, 2000, CELL STRESS CHAPERON, V5, P276, DOI 10.1379/1466-1268(2000)005<0276:THAGSP>2.0.CO;2; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Goeckeler JL, 2002, MOL BIOL CELL, V13, P2760, DOI 10.1091/mbc.02-04-0051; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Kabani M, 2002, FEBS LETT, V531, P339, DOI 10.1016/S0014-5793(02)03570-6; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Liu QL, 2007, CELL, V131, P106, DOI 10.1016/j.cell.2007.08.039; Liu XD, 1999, J BIOL CHEM, V274, P26654, DOI 10.1074/jbc.274.38.26654; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; Oh HJ, 1999, J BIOL CHEM, V274, P15712, DOI 10.1074/jbc.274.22.15712; Oh HJ, 1997, J BIOL CHEM, V272, P31636, DOI 10.1074/jbc.272.50.31636; Raviol H, 2006, FEBS LETT, V580, P168, DOI 10.1016/j.febslet.2005.11.069; Raviol H, 2006, EMBO J, V25, P2510, DOI 10.1038/sj.emboj.7601139; Rist W, 2006, J BIOL CHEM, V281, P16493, DOI 10.1074/jbc.M600847200; Senderek J, 2005, NAT GENET, V37, P1312, DOI 10.1038/ng1678; Shaner L, 2004, J BIOL CHEM, V279, P21992, DOI 10.1074/jbc.M313739200; Shaner L, 2006, BIOCHEMISTRY-US, V45, P15075, DOI 10.1021/bi061279k; Shomura Y, 2005, MOL CELL, V17, P367, DOI 10.1016/j.molcel.2004.12.023; Sondermann H, 2001, SCIENCE, V291, P1553, DOI 10.1126/science.1057268; Steel GJ, 2004, SCIENCE, V303, P98, DOI 10.1126/science.1092287; Swain JF, 2007, MOL CELL, V26, P27, DOI 10.1016/j.molcel.2007.02.020; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Vogel M, 2006, J BIOL CHEM, V281, P38705, DOI 10.1074/jbc.M609020200; WILBANKS SM, 1995, J BIOL CHEM, V270, P2251, DOI 10.1074/jbc.270.5.2251; Young JC, 2003, TRENDS BIOCHEM SCI, V28, P541, DOI 10.1016/j.tibs.2003.08.009; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	34	188	194	1	32	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 13	2008	133	6					1068	1079		10.1016/j.cell.2008.05.022	http://dx.doi.org/10.1016/j.cell.2008.05.022			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	312TJ	18555782	Bronze, Green Accepted			2022-12-28	WOS:000256693400021
J	Wang, B; Heath-Engel, H; Zhang, DL; Nguyen, N; Thomas, DY; Hanrahan, JW; Shore, GC				Wang, Bing; Heath-Engel, Hannah; Zhang, Donglei; Nguyen, Nhi; Thomas, David Y.; Hanrahan, John W.; Shore, Gordon C.			BAP31 interacts with Sec61 translocons and promotes retrotranslocation of CFTR Delta F508 via the Derlin-1 complex	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; ENDOPLASMIC-RETICULUM MEMBRANE; ER-ASSOCIATED DEGRADATION; CLASS-I MOLECULES; PROTEIN TRANSLOCATION; UBIQUITIN-LIGASE; QUALITY-CONTROL; CYTOCHROME-C; CFTR; ASSOCIATION	BAP31 is an endoplasmic reticulum protein-sorting factor that associates with newly synthesized integral membrane proteins and controls their fate (i.e., egress, retention, survival, or degradation). BAP31 is itself an integral membrane protein and a constituent of several large protein complexes. Here, we show that a part of the BAP31 population interacts with two components of the Sec61 preprotein translocon, Sec61 beta and TRAM. BAP31 associates with the N terminus of one of its newly synthesized client proteins, the Delta F508 mutant of CFTR, and promotes its retrotranslocation from the ER and degradation by the cytoplasmic 26S proteasome system. Depletion of BAP31 reduces the proteasomal degradation of Delta F508 and permits a significant fraction of the surviving protein to reach the cell surface. Of note, BAP31 also associates physically and functionally with the Derlin-1 protein disclocation complex in the Delta F508 degradation pathway. Thus, BAP31 operates at early steps to deliver newly synthesized CFTR Delta F508 to its degradation pathway.	[Wang, Bing; Heath-Engel, Hannah; Zhang, Donglei; Nguyen, Nhi; Thomas, David Y.; Shore, Gordon C.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; [Shore, Gordon C.] McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; [Hanrahan, John W.] McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University	Shore, GC (corresponding author), McGill Univ, Dept Biochem, Mclntyre Med Sci Bldg, Montreal, PQ H3G 1Y6, Canada.	gordon.shore@mcgill.ca	Hanrahan, John/AGG-1926-2022; Thomas, David/M-7661-2017	Hanrahan, John/0000-0001-9080-2039; wang, bing/0000-0002-6549-8837; Thomas, David/0000-0002-8854-762X				Adachi T, 1996, EMBO J, V15, P1534, DOI 10.1002/j.1460-2075.1996.tb00497.x; Annaert WG, 1997, J CELL BIOL, V139, P1397, DOI 10.1083/jcb.139.6.1397; Cao K, 2003, CELL, V115, P355, DOI 10.1016/S0092-8674(03)00815-8; Carlson EJ, 2006, EMBO J, V25, P4557, DOI 10.1038/sj.emboj.7601307; Carvalho P, 2006, CELL, V126, P361, DOI 10.1016/j.cell.2006.05.043; Chen EY, 2004, J BIOL CHEM, V279, P39620, DOI 10.1074/jbc.M407887200; Denic V, 2006, CELL, V126, P349, DOI 10.1016/j.cell.2006.05.045; Ducret A, 2003, EUR J BIOCHEM, V270, P342, DOI 10.1046/j.1432-1033.2003.03395.x; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Greenfield JJA, 1999, J CELL SCI, V112, P1477; Hu D, 2006, J BIOCHEM MOL BIOL, V39, P677; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; KIM KM, 1994, EMBO J, V13, P3793, DOI 10.1002/j.1460-2075.1994.tb06690.x; Kleizen B, 2005, MOL CELL, V20, P277, DOI 10.1016/j.molcel.2005.09.007; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; Lambert G, 2001, J BIOL CHEM, V276, P20340, DOI 10.1074/jbc.M011209200; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Neuber O, 2005, NAT CELL BIOL, V7, P993, DOI 10.1038/ncb1298; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; Paquet ME, 2004, J IMMUNOL, V172, P7548, DOI 10.4049/jimmunol.172.12.7548; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Schamel WWA, 2003, P NATL ACAD SCI USA, V100, P9861, DOI 10.1073/pnas.1633363100; Spiliotis ET, 2000, IMMUNITY, V13, P841, DOI 10.1016/S1074-7613(00)00081-9; Stojanovic M, 2005, J BIOL CHEM, V280, P30018, DOI 10.1074/jbc.M501306200; Sun F, 2006, J BIOL CHEM, V281, P36856, DOI 10.1074/jbc.M607085200; Szczesna-Skorupa E, 2006, J BIOL CHEM, V281, P4142, DOI 10.1074/jbc.M509522200; Taxis C, 2002, MOL BIOL CELL, V13, P1806, DOI 10.1091/mbc.01-08-0399; Tsai M, 2002, J CELL BIOL, V159, P207, DOI 10.1083/jcb.200207120; Wahlman J, 2007, CELL, V129, P943, DOI 10.1016/j.cell.2007.03.046; WALTER P, 1983, METHOD ENZYMOL, V96, P84; Wang B, 2004, MOL CELL BIOL, V24, P2767, DOI 10.1128/MCB.24.7.2767-2778.2004; Wang B, 2003, J BIOL CHEM, V278, P14461, DOI 10.1074/jbc.M209684200; WARD CL, 1994, J BIOL CHEM, V269, P25710; Ye YH, 2005, P NATL ACAD SCI USA, V102, P14132, DOI 10.1073/pnas.0505006102; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656; Younger JM, 2006, CELL, V126, P571, DOI 10.1016/j.cell.2006.06.041; Younger JM, 2004, J CELL BIOL, V167, P1075, DOI 10.1083/jcb.200410065; Zen K, 2004, J BIOL CHEM, V279, P44924, DOI 10.1074/jbc.M402115200	43	118	123	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	2008	133	6					1080	1092		10.1016/j.cell.2008.04.042	http://dx.doi.org/10.1016/j.cell.2008.04.042			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	312TJ	18555783	Bronze			2022-12-28	WOS:000256693400022
J	Gandhi, GY; Murad, MH; Fujiyoshi, A; Mullan, RJ; Flynn, DN; Elamin, MB; Swiglo, BA; Isley, WL; Guyatt, GH; Montori, VM				Gandhi, Gunjan Y.; Murad, M. Hassan; Fujiyoshi, Akira; Mullan, Rebecca J.; Flynn, David N.; Elamin, Mohamed B.; Swiglo, Brian A.; Isley, William L.; Guyatt, Gordon H.; Montori, Victor M.			Patient-important outcomes in registered diabetes trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED-TRIALS; CARDIOVASCULAR EVENTS; ROSIGLITAZONE; REGISTRATION; RISK; TESTOSTERONE; METAANALYSIS; STATEMENT; DEATH; MEN	Context Concerns about the safety and efficacy of diabetes interventions persist, in part because randomized clinical trials ( RCTs) have not measured their effect on patient-important outcomes, ie, death and quality of life ( morbidity, pain, function). Objective To systematically determine the extent to which ongoing and future RCTs in diabetes will ascertain patient- important outcomes. Data Sources On November 10, 2007, we searched primary RCT registries ClinicalTrials. gov ( http:// www. clinicaltrials. gov), International Standard Randomized Controlled Trial Number Register ( http:// isrctn. org), and Australian New Zealand Clinical Trials Registry ( http:// www. anzctr. org. au). Study Selection We identified phase 2 through 4 RCTs enrolling patients with diabetes. Of 2019 RCTs, 1054 proved eligible. We randomly sampled 50% of the eligible RCTs ( 527 of 1054) and selected 436 registered since registration became mandatory ( 2004). Data Extraction Pairs of reviewers working independently collected study characteristics and determined the outcomes measured and their type ( physiological outcomes, surrogate outcomes thought to reflect an increased risk for patient- important outcomes, and patient- important outcomes). Results Of the 436 registered RCTs included in this analysis, 24 ( 6%) had not started enrollment, 109 ( 25%) were actively enrolling, and 303 ( 69%) had completed enrollment. Primary outcomes were patient- important outcomes in only 78 of 436 RCTs ( 18%; 95% confidence interval [ CI], 14%- 22%), physiological and laboratory outcomes in 69 of 436 ( 16%; 95% CI, 13%- 20%), and surrogate outcomes in 268 of 436 ( 61%; 95% CI, 57%- 66%). Patient- important outcomes were reported as primary or secondary outcomes in 201 of 436 ( 46%; 95% CI, 41%- 51%). In multivariate analysis, large trials ( odds ratio [ OR], 1.10; 95% CI, 1.02- 1.19 for every additional 100 patients) and trials of longer duration ( OR, 1.03; 95% CI, 1.01- 1.06 for every additional 30 days) were more likely while parallel design RCTs ( OR, 0.15; 95% CI, 0.05- 0.44) and type 2 diabetes trials ( OR, 0.23; 95% CI, 0.09- 0.61) were less likely to assess patient- important outcomes as a primary outcome. Conclusion In this sample of registered ongoing RCTs in diabetes, only 18% included patient- important outcomes as primary outcomes.	[Gandhi, Gunjan Y.; Murad, M. Hassan; Fujiyoshi, Akira; Mullan, Rebecca J.; Flynn, David N.; Elamin, Mohamed B.; Swiglo, Brian A.; Isley, William L.; Montori, Victor M.] Mayo Clin, Coll Med, Knowledge & Encounter Res Unit, Rochester, MN 55905 USA; [Gandhi, Gunjan Y.; Swiglo, Brian A.; Isley, William L.; Montori, Victor M.] Mayo Clin, Coll Med, Div Endocrinol Diabet Metab & Nutr, Rochester, MN 55905 USA; [Murad, M. Hassan] Mayo Clin, Coll Med, Div Prevent Occupat & Aerosp Med, Rochester, MN 55905 USA; [Guyatt, Gordon H.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada	Mayo Clinic; Mayo Clinic; Mayo Clinic; McMaster University	Montori, VM (corresponding author), Mayo Clin, Coll Med, Knowledge & Encounter Res Unit, 200 1st St SW, Rochester, MN 55905 USA.	montori.victor@mayo.edu	Murad, M. Hassan/AAW-4367-2020	Fujiyoshi, Akira/0000-0002-5790-7119; Montori, Victor/0000-0003-0595-2898; Murad, Mohammad Hassan/0000-0001-5502-5975				Boers M, 2005, CLIN EXP RHEUMATOL, V23, pS10; Bucher HC, 1999, JAMA-J AM MED ASSOC, V282, P771, DOI 10.1001/jama.282.8.771; Chan AW, 2005, LANCET, V365, P1159, DOI 10.1016/S0140-6736(05)71879-1; Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; Cleland JGF, 2007, LANCET, V370, P1103, DOI 10.1016/S0140-6736(07)61488-3; DeAngelis CD, 2004, JAMA-J AM MED ASSOC, V292, P1363, DOI 10.1001/jama.292.11.1363; Ferreira-Gonzalez I, 2007, BRIT MED J, V334, P786, DOI 10.1136/bmj.39136.682083.AE; Guyatt Gordon, 2004, ACP J Club, V140, pA11; Guyatt GH, 2008, PLOS MED, V5, P3, DOI 10.1371/journal.pmed.0050004; Haddad RM, 2007, MAYO CLIN PROC, V82, P29; Home PD, 2007, NEW ENGL J MED, V357, P28, DOI 10.1056/NEJMoa073394; Kastelein JJP, 2008, NEW ENGL J MED, V358, P1431, DOI 10.1056/NEJMoa0800742; Laine C, 2007, JAMA-J AM MED ASSOC, V298, P93, DOI 10.1001/jama.298.1.jed70037; McIver B, 1996, DIABETOLOGIA, V39, P731; Montori VM, 2006, DIABETES CARE, V29, P1833, DOI 10.2337/dc06-0077; Mulrow CD, 2007, ANN INTERN MED, V147, P585, DOI 10.7326/0003-4819-147-8-200710160-00013; Nathan DM, 2007, NEW ENGL J MED, V357, P64, DOI 10.1056/NEJMe078117; Nathan DM, 2006, DIABETES CARE, V29, P1963, DOI 10.2337/dc06-9912; Nissen SE, 2005, JAMA-J AM MED ASSOC, V294, P2581, DOI 10.1001/JAMA.294.20.JOC50147; Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761; Richter B, 2000, DIABETOLOGIA, V43, P254, DOI 10.1007/s001250050039; Riis P, 2000, DIABETOLOGIA, V43, P526; Rosen CJ, 2007, NEW ENGL J MED, V357, P844, DOI 10.1056/NEJMp078167; Sim I, 2006, LANCET, V367, P1631, DOI 10.1016/S0140-6736(06)68708-4; Singh S, 2007, JAMA-J AM MED ASSOC, V298, P1189, DOI 10.1001/jama.298.10.1189; Tracz MJ, 2006, J CLIN ENDOCR METAB, V91, P2011, DOI 10.1210/jc.2006-0036; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Vijan S, 2000, DIABETOLOGIA, V43, P125, DOI 10.1007/s001250050017; WHO, INT CLIN TRIALS REG; Zarin DA, 2007, JAMA-J AM MED ASSOC, V297, P2112, DOI 10.1001/jama.297.19.2112	30	173	180	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	2008	299	21					2543	2549		10.1001/jama.299.21.2543	http://dx.doi.org/10.1001/jama.299.21.2543			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308AR	18523223				2022-12-28	WOS:000256361200026
J	Tanaka, H; Imai, Y; Hiramatsu, N; Ito, Y; Imanaka, K; Oshita, M; Hijioka, T; Katayama, K; Yabuuchi, I; Yoshihara, H; Inoue, A; Kato, M; Takehara, T; Tamura, S; Kasahara, A; Hayashi, N; Tsukuma, H				Tanaka, Hideo; Imai, Yasuharu; Hiramatsu, Naoki; Ito, Yuri; Imanaka, Kazuho; Oshita, Masahide; Hijioka, Taizo; Katayama, Kazuhiro; Yabuuchi, Iwao; Yoshihara, Harumasa; Inoue, Atsuo; Kato, Michio; Takehara, Tetsuo; Tamura, Shinji; Kasahara, Akinori; Hayashi, Norio; Tsukuma, Hideaki			Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003	ANNALS OF INTERNAL MEDICINE			English	Article							PRIMARY LIVER-CANCER; HEPATITIS-C VIRUS; INTERFERON THERAPY; UNITED-STATES; MORTALITY; TRENDS; INFECTION; PATTERNS; INCREASE; RATES	Background: Japan has the highest incidence rate of primary liver cancer attributed to chronic hepatitis C virus (HCV) infection among developed countries. Molecular clock analysis of HCV sequences revealed that the spread of HCV took place earlier in Japan than in other countries. This might influence recent temporal trends in hepatocellular carcinoma (HCC) incidence. Objective: To characterize the contribution of HCV-related hepatocellular carcinoma (HCC) to recent changes in HCC incidence in Osaka, Japan. Design: Population-based survey. Setting: Osaka Cancer Registry and 10 hospitals in Osaka. Participants: 63 862 patients with HCC that was diagnosed between 1981 and 2003 in Osaka Prefecture, including 5253 HCV-seropositive patients with HCC that was diagnosed between 1990 and 2003 at 10 hospitals. Measurements: Incidence of HCC and estimated incidence rate of HCV-related HCC, measured by multiplying the prevalence of anti-HCV by the corresponding HCC incidence rate. Results: Between 1981 and 2003, peak incidence of HCC among men age 50 to 59 years, 60 to 69 years, and 70 to 79 years occurred in 1986, 1995, and 2000, respectively, with marked downward trends thereafter (average annual change, -7.9, -22.3, and -12.4 per 100 000 persons, respectively). Similar trends were observed in women. Estimated sex- and age-specific incidence of HCV-related HCC (per 100 000 persons) decreased from 255 to 92 cases at the maximum in men age 60 to 69 years and from 61 to 34 cases in women age 60 to 69 years, whereas estimated incidence of non-HCV-related HCC did not change between 1990 and 2003. Limitation: Infection was determined only by HCV seropositivity. Conclusion: The incidence of HCC in Osaka started to decrease by 2000, mainly because of decreased HCV-related HCC.	Osaka Med Ctr Canc & Cardiovasc Dis, Osaka, Japan; Ikeda Municipal Hosp, Osaka, Japan; Osaka Univ, Grad Sch Med, Osaka, Japan; Osaka Police Hosp, Osaka, Japan; Natl Hosp Org Osaka Minami Med Ctr, Osaka, Japan; Osaka Koseinenkin Hosp, Osaka, Japan; Otemae Hosp, Osaka, Japan; Ossaka Rousai Hosp, Osaka, Japan; Osaka Gen Med Ctr, Osaka, Japan; Natl Hosp Org Osaka Natl Hosp, Osaka, Japan	Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka University; Osaka Police Hospital; Osaka National Hospital	Tanaka, H (corresponding author), 1-1 Kanokoden,Chikusa Ku, Nagoya, Aichi 4648681, Japan.	hitanaka@aichi-cc.jp	Ito, Yuri/AAA-2742-2021; Tanaka, Hideo/A-8145-2016					Ajiki W, 2000, JPN J CLIN ONCOL, V30, P318; Davila JA, 2004, GASTROENTEROLOGY, V127, P1372, DOI 10.1053/j.gastro.2004.07.020; El-Serag H, 2003, ANN INTERN MED, V139, P817, DOI 10.7326/0003-4819-139-10-200311180-00009; El-Serag HB, 2000, ARCH INTERN MED, V160, P3227, DOI 10.1001/archinte.160.21.3227; Ferlay J, 2001, GLOBOCAN 2000 CANC I; Fritz APC., 2013, INT CLASSIFICATION D; Iida F, 1999, B WORLD HEALTH ORGAN, V77, P573; Imai Y, 1998, ANN INTERN MED, V129, P94, DOI 10.7326/0003-4819-129-2-199807150-00005; Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z; La Vecchia C, 2000, EUR J CANCER, V36, P909, DOI 10.1016/S0959-8049(00)00052-6; McGlynn KA, 2001, INT J CANCER, V94, P290, DOI 10.1002/ijc.1456; Parkin D M, 1992, IARC Sci Publ, P45; PARKIN DM, 2002, IARC SCI PUBL, V143, P719; PARKIN DM, 1997, IARC SCI PUBL, V143, P1146; PARKIN DM, 2002, IARC SCI PUBL, V155, P264; Sasaki F, 1996, J Epidemiol, V6, P198; TANAKA H, 1994, CANCER CAUSE CONTROL, V5, P409, DOI 10.1007/BF01694754; Tanaka H, 2000, INT J CANCER, V87, P741, DOI 10.1002/1097-0215(20000901)87:5&lt;741::AID-IJC18&gt;3.0.CO;2-B; Tanaka H, 2002, HEPATOL RES, V24, pS11; Tanaka H, 1999, CANCER SURV, V33, P213; Tanaka H, 1998, J Epidemiol, V8, P292; Tanaka H, 2007, JPN J CLIN ONCOL, V37, P193, DOI 10.1093/jjco/hyl148; Tanaka Y, 2006, GASTROENTEROLOGY, V130, P703, DOI 10.1053/j.gastro.2006.01.032; TaylorRobinson SD, 1997, LANCET, V350, P1142, DOI 10.1016/S0140-6736(05)63789-0; Tsukuma Hideaki, 2005, Asian Pac J Cancer Prev, V6, P244; Yoshizawa H, 2002, HEPATOL RES, V24, pS28; Yoshizawa H, 2002, ONCOLOGY-BASEL, V62, P8, DOI 10.1159/000048270	27	97	98	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2008	148	11					820	U29		10.7326/0003-4819-148-11-200806030-00004	http://dx.doi.org/10.7326/0003-4819-148-11-200806030-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308CG	18519928				2022-12-28	WOS:000256365300003
J	Benjamin, A				Benjamin, Andrea			The competent novice - Audit: How to do it in practice	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							QUALITY IMPROVEMENT		[Benjamin, Andrea] BMJ Learning, London WC1H 9JR, England		Benjamin, A (corresponding author), BMJ Learning, BMA House, London WC1H 9JR, England.	ABenjamin@bmjgroup.com						ANDERSON DG, ABC AUDIT; Balogh R, 1995, INT J QUAL HEALTH C, V7, P343, DOI 10.1093/intqhc/7.4.343; Department of Health, 2000, NHS CANC PLAN PLAN I; Dixon N, 1996, GOOD PRACTICE CLIN A; FRASER RC, 1997, AUDIT TRENDS, V5, P131; GRIMSHAW JM, 2001, MED CARE S, V39, P112; Irvine D, 1991, MAKING SENSE AUDIT; Jamtvedt G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000259.pub2; KELSON M, 1998, PROMOTING PATIENT IN; Kendall JM, 1996, J ACCID EMERG MED, V13, P49; Morrell C, 1997, QUAL HEALTH CARE, V6, P29, DOI 10.1136/qshc.6.1.29; National Institute for Health and Clinical Excellence, 2002, PRINC BEST PRACT CLI; *NHS CLIN GOV SUPP, PRACT HDB CLIN AUD 2; *ROYAL COLL PHYS, 2007, NAT SENT STROK AUD 2; Scally G, 1998, BRIT MED J, V317, P61, DOI 10.1136/bmj.317.7150.61; SMITH R, 1992, BRIT MED J, V305, P905, DOI 10.1136/bmj.305.6859.905	16	75	80	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	2008	336	7655					1241	1245		10.1136/bmj.39527.628322.AD	http://dx.doi.org/10.1136/bmj.39527.628322.AD			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311PS	18511799	Green Published			2022-12-28	WOS:000256612700033
J	Krause, O; Birkmann, SM; Usuda, T; Hattori, T; Goto, M; Rieke, GH; Misselt, KA				Krause, Oliver; Birkmann, Stephan M.; Usuda, Tomonori; Hattori, Takashi; Goto, Miwa; Rieke, George H.; Misselt, Karl A.			The Cassiopeia A supernova was of type IIb	SCIENCE			English	Article							SN 1993J; IB SUPERNOVAE; PROGENITOR; REMNANT; SN-1993J; SPECTROSCOPY; EXPLOSION; SPECTRA; REGIONS; EJECTA	Cassiopeia A is the youngest supernova remnant known in the Milky Way and a unique laboratory for supernova physics. We present an optical spectrum of the Cassiopeia A supernova near maximum brightness, obtained from observations of a scattered light echo more than three centuries after the direct light of the explosion swept past Earth. The spectrum shows that Cassiopeia A was a type IIb supernova and originated from the collapse of the helium core of a red supergiant that had lost most of its hydrogen envelope before exploding. Our finding concludes a long- standing debate on the Cassiopeia A progenitor and provides new insight into supernova physics by linking the properties of the explosion to the wealth of knowledge about its remnant.	[Krause, Oliver; Birkmann, Stephan M.; Goto, Miwa] Max Planck Inst Astron, D-69117 Heidelberg, Germany; [Usuda, Tomonori; Hattori, Takashi] Natl Inst Nat Sci, Natl Astron Observ Japan, Hilo, HI 96720 USA; [Rieke, George H.; Misselt, Karl A.] Univ Arizona, Steward Observ, Tucson, AZ 85721 USA	Max Planck Society; National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); University of Arizona	Krause, O (corresponding author), Max Planck Inst Astron, Konigstuhl 17, D-69117 Heidelberg, Germany.	krause@mpia.de						ALDERING G, 1994, ASTRON J, V107, P662, DOI 10.1086/116886; Chevalier RA, 2003, ASTROPHYS J, V593, pL23, DOI 10.1086/377572; CHEVALIER RA, 1978, ASTROPHYS J, V219, P931, DOI 10.1086/155855; CLOCCHIATTI A, 1995, ASTROPHYS J, V446, P167, DOI 10.1086/175776; Fesen RA, 2006, ASTROPHYS J, V636, P848, DOI 10.1086/498087; Fesen RA, 2001, ASTROPHYS J SUPPL S, V133, P161, DOI 10.1086/319181; FESEN RA, 1991, ASTROPHYS J, V371, P621, DOI 10.1086/169926; Fesen RA, 2006, ASTROPHYS J, V645, P283, DOI 10.1086/504254; FILIPPENKO AV, 1993, ASTROPHYS J, V415, pL103, DOI 10.1086/187043; FILIPPENKO AV, 1988, ASTRON J, V96, P1941, DOI 10.1086/114940; Fransson C, 2005, ASTROPHYS J, V622, P991, DOI 10.1086/426495; Fransson C, 1996, ASTROPHYS J, V461, P993, DOI 10.1086/177119; Hollenbach DJ, 1997, ANNU REV ASTRON ASTR, V35, P179, DOI 10.1146/annurev.astro.35.1.179; HUGHES DW, 1980, NATURE, V285, P132, DOI 10.1038/285132a0; KIM J, IN PRESS ASTROPHYS J; Krause O, 2005, SCIENCE, V308, P1604, DOI 10.1126/science.1112035; LAWRENCE SS, 1995, ASTRON J, V109, P2635, DOI 10.1086/117477; Matheson T, 2000, ASTRON J, V120, P1487, DOI 10.1086/301518; Maund JR, 2004, NATURE, V427, P129, DOI 10.1038/nature02161; PODSIADLOWSKI P, 1992, ASTROPHYS J, V391, P246, DOI 10.1086/171341; REED JE, 1995, ASTROPHYS J, V440, P706, DOI 10.1086/175308; Renaud M, 2006, ASTROPHYS J, V647, pL41, DOI 10.1086/507300; REST A, IN PRESS ASTROPHYS J; RICHMOND MW, 1994, ASTRON J, V107, P1022, DOI 10.1086/116915; SPAANS M, 1994, ASTROPHYS J, V437, P270, DOI 10.1086/174994; SWARTZ DA, 1993, NATURE, V365, P232, DOI 10.1038/365232a0; Thielemann FK, 1996, ASTROPHYS J, V460, P408, DOI 10.1086/176980; Tominaga N, 2005, ASTROPHYS J, V633, pL97, DOI 10.1086/498570; WOOSLEY SE, 1986, ANNU REV ASTRON ASTR, V24, P205, DOI 10.1146/annurev.aa.24.090186.001225; WOOSLEY SE, 1994, ASTROPHYS J, V429, P300, DOI 10.1086/174319; Young PA, 2006, ASTROPHYS J, V640, P891, DOI 10.1086/500108	31	177	179	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	2008	320	5880					1195	1197		10.1126/science.1155788	http://dx.doi.org/10.1126/science.1155788			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306FF	18511684	Green Submitted			2022-12-28	WOS:000256233000032
J	Kimura, Y; Inoue, T; Yin, FX; Tsuzaki, K				Kimura, Yuuji; Inoue, Tadanobu; Yin, Fuxing; Tsuzaki, Kaneaki			Inverse temperature dependence of toughness in an ultrafine grain-structure steel	SCIENCE			English	Article							MECHANICAL-PROPERTIES; FRACTURE-TOUGHNESS; BEHAVIOR; CARBON; IMPROVEMENT; STRENGTH	Materials are typically ductile at higher temperatures and become brittle at lower temperatures. In contrast to the typical ductile- to- brittle transition behavior of body- centered cubic (bcc) steels, we observed an inverse temperature dependence of toughness in an ultrahigh- strength bcc steel with an ultrafine elongated ferrite grain structure that was processed by a thermomechanical treatment without the addition of a large amount of an alloying element. The enhanced toughness is attributed to a delamination that was a result of crack branching on the aligned {100} cleavage planes in the bundles of the ultrafine elongated ferrite grains strengthened by nanometer- sized carbides. In the temperature range from 60 degrees to -60 degrees C, the yield strength was greater, leading to the enhancement of the toughness.	[Kimura, Yuuji; Inoue, Tadanobu; Yin, Fuxing; Tsuzaki, Kaneaki] Natl Inst Mat Sci, Tsukuba, Ibaraki 3050047, Japan	National Institute for Materials Science	Kimura, Y (corresponding author), Natl Inst Mat Sci, 1-2-1 Sengen, Tsukuba, Ibaraki 3050047, Japan.	kimura.yuuji@nims.go.jp	Inoue, Tadanobu/U-8874-2019; KIMURA, Yuuji/H-2918-2011; Yin, Fuxing/AAE-4626-2020	INOUE, Tadanobu/0000-0002-7366-7688; Yin, Fuxing/0000-0002-5260-9091; Kimura, Yuuji/0000-0002-8907-0704				[Anonymous], 1990, PROPERTIES SELECTION; Becker W. T., 2002, ASM HDB, V11, P557; Belyakov A, 2004, MATER TRANS, V45, P2812, DOI 10.2320/matertrans.45.2812; Bush R. H., 1962, T ASM, V55, P654; Iorio LE, 2006, METALL MATER TRANS A, V37A, P1165, DOI 10.1007/s11661-006-1094-7; Karimpoor AA, 2007, SCRIPTA MATER, V56, P201, DOI 10.1016/j.scriptamat.2006.10.018; Kimura Y, 2007, SCRIPTA MATER, V57, P465, DOI 10.1016/j.scriptamat.2007.05.039; Krauss G., 1990, STEELS HEAT TREATMEN, P205; KUM DW, 1983, J MECH PHYS SOLIDS, V31, P173, DOI 10.1016/0022-5096(83)90049-2; Maloney JL, 2005, ACTA MATER, V53, P533, DOI 10.1016/j.actamat.2004.09.041; Mintz B, 2007, MATER SCI TECH-LOND, V23, P1346, DOI 10.1179/174328407X168801; Morito S, 2003, ACTA MATER, V51, P1789, DOI 10.1016/S1359-6454(02)00577-3; Morris JW, 2003, ISIJ INT, V43, P410, DOI 10.2355/isijinternational.43.410; NISHIJIMA S, 1989, 5 NAT RES I MET; Ohmori A, 2004, ISIJ INT, V44, P1063, DOI 10.2355/isijinternational.44.1063; Philip TV, 1990, ASM HDB, V1, P430; RAO KTV, 1989, METALL TRANS A, V20, P485, DOI 10.1007/BF02653929; Sakai Y, 2000, ULTRAFINE GRAINED MATERIALS, P361; Shanmugam P, 1996, ENG FRACT MECH, V53, P991, DOI 10.1016/0013-7944(95)00159-X; Song R, 2005, ACTA MATER, V53, P4881, DOI 10.1016/j.actamat.2005.07.009; SPAEDER GJ, 1970, METALL TRANS, V1, P2011, DOI 10.1007/BF02642806; Stolyarov VV, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2167800; Takaki S, 2001, J MATER PROCESS TECH, V117, P359, DOI 10.1016/S0924-0136(01)00797-X; TOMITA Y, 1991, METALL TRANS A, V22, P1093, DOI 10.1007/BF02661103; Tomita Y, 2000, INT MATER REV, V45, P27, DOI 10.1179/095066000771048791; Tsuji N, 2004, MATER TRANS, V45, P2272, DOI 10.2320/matertrans.45.2272; TUFFNELL GW, 1968, T ASM, V61, P798; YEN CM, 1970, METALL TRANS, V1, P3037; Zhou W, 1996, SCRIPTA MATER, V34, P633, DOI 10.1016/1359-6462(95)00564-1	29	276	288	17	244	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2008	320	5879					1057	1060		10.1126/science.1156084	http://dx.doi.org/10.1126/science.1156084			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18497294				2022-12-28	WOS:000256059800040
J	Barthelemy, P; Bertolotti, J; Wiersma, DS				Barthelemy, Pierre; Bertolotti, Jacopo; Wiersma, Diederik S.			A Levy flight for light	NATURE			English	Article							ANOMALOUS DIFFUSION; FLUCTUATIONS	A random walk is a stochastic process in which particles or waves travel along random trajectories. The first application of a random walk was in the description of particle motion in a fluid (brownian motion); now it is a central concept in statistical physics, describing transport phenomena such as heat, sound and light diffusion(1). Levy flights are a particular class of generalized random walk in which the step lengths during the walk are described by a 'heavy-tailed' probability distribution. They can describe all stochastic processes that are scale invariant(2,3). Levy flights have accordingly turned out to be applicable to a diverse range of fields, describing animal foraging patterns(4), the distribution of human travel(5) and even some aspects of earthquake behaviour(6). Transport based on Levy flights has been extensively studied numerically(7-9), but experimental work has been limited(10,11) and, to date, it has not seemed possible to observe and study Levy transport in actual materials. For example, experimental work on heat, sound, and light diffusion is generally limited to normal, brownian, diffusion. Here we show that it is possible to engineer an optical material in which light waves perform a Levy flight. The key parameters that determine the transport behaviour can be easily tuned, making this an ideal experimental system in which to study Levy flights in a controlled way. The development of a material in which the diffusive transport of light is governed by Levy statistics might even permit the development of new optical functionalities that go beyond normal light diffusion.	[Barthelemy, Pierre; Bertolotti, Jacopo; Wiersma, Diederik S.] European Lab Nonlinear Spect, I-50019 Florence, Italy; [Barthelemy, Pierre; Bertolotti, Jacopo; Wiersma, Diederik S.] INFM BEC, I-50019 Florence, Italy		Wiersma, DS (corresponding author), European Lab Nonlinear Spect, Via Nello Carrara 1, I-50019 Florence, Italy.	wiersma@lens.unifi.it	wiersma, diederik/ABG-6454-2021; Bertolotti, Jacopo/Z-4359-2019; Bertolotti, Jacopo/A-4314-2009; Barthelemy, Pierre/A-4316-2009; Barthelemy, Pierre/D-2266-2010	wiersma, diederik/0000-0001-8150-7425; Bertolotti, Jacopo/0000-0002-7163-6343; Bertolotti, Jacopo/0000-0002-7163-6343; 				BARDOU F, 1994, PHYS REV LETT, V72, P203, DOI 10.1103/PhysRevLett.72.203; Bartumeus F, 2005, ECOLOGY, V86, P3078, DOI 10.1890/04-1806; Buldyrev SV, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.041108; Cao H, 1999, PHYS REV LETT, V82, P2278, DOI 10.1103/PhysRevLett.82.2278; Corral A, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.178501; Drysdale PM, 1998, PHYS REV E, V58, P5382, DOI 10.1103/PhysRevE.58.5382; FRENKEL D, 1992, EUROPHYS LETT, V20, P7, DOI 10.1209/0295-5075/20/1/002; GEISEL T, 1985, PHYS REV LETT, V54, P616, DOI 10.1103/PhysRevLett.54.616; Kubo R., 1991, STAT PHYS; Lepri S, 2007, PHYS REV A, V75, DOI 10.1103/PhysRevA.75.063820; Levy P., 1954, THEORIE ADDITION VAR, V1; MANDELBROT B, 1963, J BUS, V36, P394, DOI 10.1086/294632; Mandelbrot B. B., 1977, FRACTAL GEOMETRY NAT; MANTEGNA RN, 1994, PHYS REV LETT, V73, P2946, DOI 10.1103/PhysRevLett.73.2946; MANTEGNA RN, 1995, NATURE, V376, P46, DOI 10.1038/376046a0; Metzler R, 2007, CHAOS SOLITON FRACT, V34, P129, DOI 10.1016/j.chaos.2007.01.055; Nolan JP, 2002, STABLE DISTRIBUTIONS; OTT A, 1990, PHYS REV LETT, V65, P2201, DOI 10.1103/PhysRevLett.65.2201; Rikken GLJA, 1996, NATURE, V381, P54, DOI 10.1038/381054a0; Ripoll J, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.173903; Sapienza R, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.263902; Scheffold F, 1998, PHYS REV LETT, V81, P5800, DOI 10.1103/PhysRevLett.81.5800; Sharma D, 2006, FLUCT NOISE LETT, V6, pL95, DOI 10.1142/S0219477506003185; Sheng P., 1995, INTRO WAVE SCATTERIN, Vsecond; Shlesinger MF, 2001, NATURE, V411, P641, DOI 10.1038/35079702; SHLESINGER MF, 1993, NATURE, V363, P31, DOI 10.1038/363031a0; SOLOMON TH, 1993, PHYS REV LETT, V71, P3975, DOI 10.1103/PhysRevLett.71.3975; YODH AG, 1999, Patent No. 5917190	29	527	532	7	109	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 22	2008	453	7194					495	498		10.1038/nature06948	http://dx.doi.org/10.1038/nature06948			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303EL	18497819				2022-12-28	WOS:000256023700036
J	O'Neill, JS; Maywood, ES; Chesham, JE; Takahashi, JS; Hastings, MH				O'Neill, John S.; Maywood, Elizabeth S.; Chesham, Johanna E.; Takahashi, Joseph S.; Hastings, Michael H.			cAMP-dependent signaling as a core component of the mammalian circadian pacemaker	SCIENCE			English	Article							CLOCK FUNCTION; FEEDBACK LOOP; CYCLIC-AMP; NEURONS; OSCILLATION; PHASE; CELLS; EPAC	The mammalian circadian clockwork is modeled as transcriptional and posttranslational feedback loops, whereby circadian genes are periodically suppressed by their protein products. We show that adenosine 3 ', 5 '-monophosphate (cAMP) signaling constitutes an additional, bona fide component of the oscillatory network. cAMP signaling is rhythmic and sustains the transcriptional loop of the suprachiasmatic nucleus, determining canonical pacemaker properties of amplitude, phase, and period. This role is general and is evident in peripheral mammalian tissues and cell lines, which reveals an unanticipated point of circadian regulation in mammals qualitatively different from the existing transcriptional feedback model. We propose that daily activation of cAMP signaling, driven by the transcriptional oscillator, in turn sustains progression of transcriptional rhythms. In this way, clock output constitutes an input to subsequent cycles.	[O'Neill, John S.; Maywood, Elizabeth S.; Chesham, Johanna E.; Hastings, Michael H.] MRC, Mol Biol Lab, Cambridge CB2 0QH, England; [Takahashi, Joseph S.] Northwestern Univ, Howard Hughes Med Inst, Dept Neurobiol & Physiol, Evanston, IL 60208 USA	MRC Laboratory Molecular Biology; Howard Hughes Medical Institute; Northwestern University	Hastings, MH (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 0QH, England.	mha@mrc-lmb.cam.ac.uk	Takahashi, Joseph S/E-8482-2012; Takahashi, Joseph S./Y-2781-2019	Takahashi, Joseph S/0000-0003-0384-8878; Takahashi, Joseph S./0000-0003-0384-8878; O'Neill, John Stuart/0000-0003-2204-6096; Hastings, Michael Harvey/0000-0001-8576-6651	MRC [MC_U105170643] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council Funding Source: Medline; Howard Hughes Medical Institute Funding Source: Medline; Medical Research Council [MC_U105170643, U.1051.02.004(78799)] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Aton SJ, 2006, P NATL ACAD SCI USA, V103, P19188, DOI 10.1073/pnas.0607466103; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dodd AN, 2007, SCIENCE, V318, P1789, DOI 10.1126/science.1146757; ESKIN A, 1983, SCIENCE, V220, P82, DOI 10.1126/science.6298939; Fan YZ, 2007, CURR BIOL, V17, P1091, DOI 10.1016/j.cub.2007.05.048; Harrisingh MC, 2007, J NEUROSCI, V27, P12489, DOI 10.1523/JNEUROSCI.3680-07.2007; Hastings MH, 2003, NAT REV NEUROSCI, V4, P649, DOI 10.1038/nrn1177; Hirata H, 2002, SCIENCE, V298, P840, DOI 10.1126/science.1074560; Huang CC, 2006, MOL PHARMACOL, V69, P846, DOI 10.1124/mol.105.018093; Lakin-Thomas PL, 2006, J BIOL RHYTHM, V21, P83, DOI 10.1177/0748730405286102; LIPPE C, 1991, COMP BIOCHEM PHYS C, V99, P209, DOI 10.1016/0742-8413(91)90101-X; Lundkvist GB, 2005, J NEUROSCI, V25, P7682, DOI 10.1523/JNEUROSCI.2211-05.2005; Maywood ES, 2006, CURR BIOL, V16, P599, DOI 10.1016/j.cub.2006.02.023; Nakajima M, 2005, SCIENCE, V308, P414, DOI 10.1126/science.1108451; NIKAIDO SS, 1989, NEURON, V3, P609, DOI 10.1016/0896-6273(89)90271-7; Nitabach MN, 2002, CELL, V109, P485, DOI 10.1016/S0092-8674(02)00737-7; PROSSER RA, 1989, J NEUROSCI, V9, P1073; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Rosenbaum T, 2004, NEURON, V42, P193, DOI 10.1016/S0896-6273(04)00199-0; Sato TK, 2006, NAT GENET, V38, P312, DOI 10.1038/ng1745; Shi GX, 2006, MOL CELL BIOL, V26, P9136, DOI 10.1128/MCB.00332-06; TAKAHASHI JS, 1982, SCIENCE, V217, P1104, DOI 10.1126/science.6287576; Ueda HR, 2005, NAT GENET, V37, P187, DOI 10.1038/ng1504; Xu Y, 2005, NATURE, V434, P640, DOI 10.1038/nature03453	25	303	311	2	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 16	2008	320	5878					949	953		10.1126/science.1152506	http://dx.doi.org/10.1126/science.1152506			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301AH	18487196	Green Accepted			2022-12-28	WOS:000255868300047
J	Xiao, H; Murakami, H; Suga, H; Ferre-D'Amare, AR				Xiao, Hong; Murakami, Hiroshi; Suga, Hiroaki; Ferre-D'Amare, Adrian R.			Structural basis of specific tRNA aminoacylation by a small in vitro selected ribozyme	NATURE			English	Article							PROTEIN-SYNTHESIS; CRYSTAL-STRUCTURE; ACTIVE-SITE; SYNTHETASE; ORIGIN; REVEALS; COMPLEX	In modern organisms, protein enzymes are solely responsible for the aminoacylation of transfer RNA. However, the evolution of protein synthesis in the RNA world required RNAs capable of catalysing this reaction. Ribozymes that aminoacylate RNA by using activated amino acids have been discovered through selection in vitro(1-5). Flexizyme is a 45- nucleotide ribozyme capable of charging tRNA in trans with various activated L- phenylalanine derivatives. In addition to a more than 10(5) rate enhancement and more than 10(4)-fold discrimination against some non- cognate amino acids, this ribozyme achieves good regioselectivity: of all the hydroxyl groups of a tRNA, it exclusively aminoacylates the terminal 3'-OH5-7. Here we report the 2.8-angstrom resolution structure of flexizyme fused to a substrate RNA. Together with randomization of ribozyme core residues and reselection, this structure shows that very few nucleotides are needed for the aminoacylation of specific tRNAs. Although it primarily recognizes tRNA through base- pairing with the CCA terminus of the tRNA molecule, flexizyme makes numerous local interactions to position the acceptor end of tRNA precisely. A comparison of two crystallographically independent flexizyme conformations, only one of which appears capable of binding activated phenylalanine, suggests that this ribozyme may achieve enhanced specificity by coupling active- site folding to tRNA docking. Such a mechanism would be reminiscent of the mutually induced fit of tRNA and protein employed by some aminoacyl- tRNA synthetases(8,9) to increase specificity.	[Xiao, Hong; Ferre-D'Amare, Adrian R.] Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; [Murakami, Hiroshi; Suga, Hiroaki] Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo 1538904, Japan; [Suga, Hiroaki] Univ Tokyo, Dept Chem & Biotechnol, Grad Sch Engn, Tokyo 1138656, Japan	Fred Hutchinson Cancer Center; University of Tokyo; University of Tokyo	Ferre-D'Amare, AR (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA.	aferre@fhcrc.org						BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cusack S, 1996, EMBO J, V15, P2834, DOI 10.1002/j.1460-2075.1996.tb00644.x; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Ferre-D'Amare AR, 2000, J MOL BIOL, V295, P541, DOI 10.1006/jmbi.1999.3398; FerreDAmare AR, 1996, NUCLEIC ACIDS RES, V24, P977, DOI 10.1093/nar/24.5.977; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; Golden BL, 1998, SCIENCE, V282, P259, DOI 10.1126/science.282.5387.259; Illangasekare M, 1999, RNA, V5, P1482, DOI 10.1017/S1355838299991264; ILLANGASEKARE M, 1995, SCIENCE, V267, P643, DOI 10.1126/science.7530860; Illangasekare M, 1999, P NATL ACAD SCI USA, V96, P5470, DOI 10.1073/pnas.96.10.5470; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIRSEBOM LA, 1994, EMBO J, V13, P4870, DOI 10.1002/j.1460-2075.1994.tb06814.x; Klein DJ, 2006, SCIENCE, V313, P1752, DOI 10.1126/science.1129666; Lee N, 2000, NAT STRUCT BIOL, V7, P28; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Moulinier L, 2001, EMBO J, V20, P5290, DOI 10.1093/emboj/20.18.5290; Murakami H, 2003, CHEM BIOL, V10, P655, DOI 10.1016/S1074-5521(03)00145-5; Murakami H, 2006, NAT METHODS, V3, P357, DOI 10.1038/NMETH877; Nissen P, 2001, P NATL ACAD SCI USA, V98, P4899, DOI 10.1073/pnas.081082398; ORGEL LE, 1989, J MOL EVOL, V29, P465, DOI 10.1007/BF02602917; Perona JJ, 2007, BIOCHEMISTRY-US, V46, P10419, DOI 10.1021/bi7014647; Ramaswamy K, 2004, J AM CHEM SOC, V126, P11454, DOI 10.1021/ja046843y; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Rupert Peter B, 2004, Methods Mol Biol, V252, P303; Saenger W., 1984, PRINCIPLES NUCL ACID; Saito H, 2001, EMBO J, V20, P1797, DOI 10.1093/emboj/20.7.1797; Saito H, 2002, NUCLEIC ACIDS RES, V30, P5151, DOI 10.1093/nar/gkf641; Saito H, 2001, RNA, V7, P1867; Saito H, 2001, J AM CHEM SOC, V123, P7178, DOI 10.1021/ja015756s; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; Selmer M, 2006, SCIENCE, V313, P1935, DOI 10.1126/science.1131127; Serganov A, 2005, NAT STRUCT MOL BIOL, V12, P218, DOI 10.1038/nsmb906; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; WONG JTF, 1991, ORIGINS LIFE EVOL B, V21, P165, DOI 10.1007/BF01809445	36	102	105	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 17	2008	454	7202					358	U60		10.1038/nature07033	http://dx.doi.org/10.1038/nature07033			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326ND	18548004				2022-12-28	WOS:000257665300044
J	Snape, MD; Kelly, DF; Lewis, S; Banner, C; Kibwana, L; Moore, CE; Diggle, L; John, T; Yu, LM; Borrow, R; Borkowski, A; Nau, C; Pollard, AJ				Snape, M. D.; Kelly, D. F.; Lewis, S.; Banner, C.; Kibwana, L.; Moore, C. E.; Diggle, L.; John, T.; Yu, L. M.; Borrow, R.; Borkowski, A.; Nau, C.; Pollard, A. J.			Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study	BRITISH MEDICAL JOURNAL			English	Article							CONJUGATE VACCINE; NEISSERIA-MENINGITIDIS; ANTIBODY PERSISTENCE; BACTERICIDAL ANTIBODY; IMMUNIZATION CAMPAIGN; IMMUNOLOGICAL MEMORY; CHILDREN; IMMUNOGENICITY; CARRIAGE; MECHANISMS	Objective To determine the persistence of bactericidal antibody titres following immunisation with serogroup C meningococcal glycoconjugate vaccine at age 6-15 years in,order to examine changes in persistence of antibodies with age. Design Observational study. Setting Secondary and tertiary educationat institutions in the United Kingdom. Participants Healthy adolescents aged 11-20 years previously immunised between 6 and 15 years of age with one of the three serogroup C meningococcal vaccines. Intervention Serum obtained by venepuncture. Main outcome measures Percentage of participants with (rabbit complement) serum bactericidal antibody titres of at teast 1:8; geometric mean titres of serogroup C meningococcal serum bactericidal antibody. Results Five years after immunisation, 84.1% (95% confidence interval 81.6% to 86.3%) of 987 participants had a bactericidal antibody titre of at least 1:8. Geometric mean tithes of bactericidal antibody were significantly lower in 11-13 year olds (147, 95% confidence interval 115 to 188) than in 14-16 year olds (300, 237 to 380) and 17-20 year olds (360, 252 to 515) (P<0.0001 for both comparisons). Within these age bands, no significant difference in geometric mean titres of bactericidal antibody between recipients of the different serogroup C meningococcal vaccines was seen. More than 70% of participants had received a vaccine from one manufacturer; in this cohort, geometric mean titres were higher in those immunised at aged 10 years or above than in those immunised before the age of 10. Conclusions Higher concentrations of bactericidal antibody are seen five years after immunisation with serogroup C meningococcal-vaccine at age 10 years or above than in younger age groups, possibly owing to immunological maturation. This provides support for adolescent immunisation programmes to generate sustained protection against serogroup C meningococcal disease not only for the vaccine recipients but also, through the maintenance of herd immunity, for younger children.	[Snape, M. D.; Kelly, D. F.; Lewis, S.; Banner, C.; Kibwana, L.; Moore, C. E.; Diggle, L.; John, T.; Pollard, A. J.] Univ Oxford, Churchill Hosp, Oxford Vaccine Grp, Dept Paediatr,Ctr Clin Vaccinol & Trop Med, Oxford OX3 7LJ, England; [Yu, L. M.] Univ Oxford, Ctr Stat Med, Oxford OX3 7LJ, England; [Borrow, R.] Hlth Protect Agcy, Vaccine Evaluat Unit, Manchester, Lancs, England; [Borkowski, A.; Nau, C.] Novartis Vaccines, Marburg, Germany	University of Oxford; University of Oxford; Health Protection Agency; Novartis	Snape, MD (corresponding author), Univ Oxford, Churchill Hosp, Oxford Vaccine Grp, Dept Paediatr,Ctr Clin Vaccinol & Trop Med, S Parks Rd, Oxford OX3 7LJ, England.	matthew.snape@paediatrics.ox.ac.uk	Yu, LM/J-4284-2012; Kelly, Dominic F/C-5498-2011; Moore, Catrin/K-1980-2017	Moore, Catrin/0000-0002-8639-9846; Yu, Ly-Mee/0000-0003-0331-7364; Kelly, Dominic/0000-0002-6063-8896; Snape, Matthew/0000-0003-0531-5426				Auckland C, 2006, J INFECT DIS, V194, P1745, DOI 10.1086/509619; Borrow R, 2002, J INFECT DIS, V186, P1353, DOI 10.1086/344324; Burrage M, 2002, INFECT IMMUN, V70, P4946, DOI 10.1128/IAI.70.9.4946-4954.2002; CARTWRIGHT KAV, 1987, EPIDEMIOL INFECT, V99, P591, DOI 10.1017/S0950268800066449; CAUGANT DA, 1994, J CLIN MICROBIOL, V32, P323, DOI 10.1128/JCM.32.2.323-330.1994; de Febres OC, 1999, VACCINE, V18, P656, DOI 10.1016/S0264-410X(99)00272-8; De Wals P, 2001, JAMA-J AM MED ASSOC, V285, P177, DOI 10.1001/jama.285.2.177; GHEESLING LL, 1994, J CLIN MICROBIOL, V32, P1475, DOI 10.1128/JCM.32.6.1475-1482.1994; GLODE MP, 1977, J INFECT DIS, V135, P94, DOI 10.1093/infdis/135.1.94; Hambleton S, 2005, CLIN MICROBIOL REV, V18, P70, DOI 10.1128/CMR.18.1.70-80.2005; Johnson CE, 1996, PEDIATR INFECT DIS J, V15, P687, DOI 10.1097/00006454-199608000-00010; Maiden MCJ, 2002, LANCET, V359, P1829, DOI 10.1016/S0140-6736(02)08679-8; McVernon J, 2003, PEDIATR INFECT DIS J, V22, P659, DOI 10.1097/00006454-200307000-00019; McVernon J, 2002, PEDIATR INFECT DIS J, V21, P747, DOI 10.1097/00006454-200208000-00010; Miller E, 2001, VACCINE, V20, pS58, DOI 10.1016/S0264-410X(01)00299-7; PATON JC, 1986, AM J DIS CHILD, V140, P135, DOI 10.1001/archpedi.1986.02140160053031; Pihlgren M, 2006, J IMMUNOL, V176, P165, DOI 10.4049/jimmunol.176.1.165; Pihlgren M, 2003, J IMMUNOL, V170, P2824, DOI 10.4049/jimmunol.170.6.2824; Siegrist CA, 2003, VACCINE, V21, P3406, DOI 10.1016/S0264-410X(03)00342-6; Snape MD, 2006, CLIN INFECT DIS, V43, P1387, DOI 10.1086/508776; Snape MD, 2005, PEDIATR INFECT DIS J, V24, P128, DOI 10.1097/01.inf.0000151029.58752.27; Sorensen RU, 1998, J ALLERGY CLIN IMMUN, V102, P215, DOI 10.1016/S0091-6749(98)70089-2; Traggiai E, 2003, VACCINE, V21, pS35, DOI 10.1016/S0264-410X(03)00198-1; Trotter C, 2003, VACCINE, V21, P1094, DOI 10.1016/S0264-410X(02)00630-8; Trotter CL, 2004, LANCET, V364, P365, DOI 10.1016/S0140-6736(04)16725-1	25	88	91	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 28	2008	336	7659					1487	+		10.1136/bmj.39563.545255.AE	http://dx.doi.org/10.1136/bmj.39563.545255.AE			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	324GN	18535032	Green Accepted, Green Published, Green Submitted, Bronze			2022-12-28	WOS:000257505900037
J	Colman, I; Friedman, BW; Brown, MD; Innes, GD; Grafstein, E; Roberts, TE; Rowe, BH				Colman, Ian; Friedman, Benjamin W.; Brown, Michael D.; Innes, Grant D.; Grafstein, Eric; Roberts, Ted E.; Rowe, Brian H.			Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTRAVENOUS DEXAMETHASONE; MANAGEMENT; GUIDELINES; QUALITY; THERAPY; PLACEBO	Objective To examine the effectiveness of parenteral corticosteroids for the relief of acute severe migraine headache and prevention of recurrent headaches. Design Meta-analysis. Data sources Electronic databases (Cochrane Central Register of Controlled Trials, Medline, Embase, LILACS, and CINAHL), conference proceedings, clinical practice guidelines, contacts with industry, and correspondence with authors. Selection criteria Randomised controlled trials in which corticosteroids (alone or combined with standard abortive therapy) were compared with placebo or any other standard treatment for acute migraine in adults. Review methods Two reviewers independently assessed relevance, inclusion, and study quality. Weighted mean differences and relative risks were calculated and are reported with 95% confidence intervals. Results From 666 potentially relevant abstracts, seven studies met the inclusion criteria. All included trials used standard abortive, therapy and subsequently compared single dose parenteral dexamethasone with placebo, examining pain relief and recurrence of headache within 72 hours. Dexamethasone and placebo provided similar pain reduction (weighted mean difference 0.37, 95% confidence interval -0.20 to 0.94). Dexamethasone was, however, more effective than placebo in reducing recurrence rates (relative risk 0.74, 95% confidence interval 0.60 to 0.90). Side effect profiles between dexamethasone and placebo groups were similar. Conclusion When added to standard abortive therapy for migraine headache, single dose parenteral dexamethasone is associated with a 26% relative reduction in headache recurrence (number needed to treat=9) within 72 hours.	[Colman, Ian; Rowe, Brian H.] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada; [Friedman, Benjamin W.] Albert Einstein Coll Med, Dept Emergency Med, Bronx, NY 10467 USA; [Brown, Michael D.] Michigan State Univ, Dept Epidemiol, Grand Rapids, MI USA; [Brown, Michael D.] Michigan State Univ, Program Emergency Med, Grand Rapids, MI USA; [Innes, Grant D.] Univ Calgary, Div Emergency Med, Calgary, AB T2N 1N4, Canada; [Grafstein, Eric] Providence Hlth Care, Dept Emergency Med, Vancouver, BC, Canada; [Grafstein, Eric] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; [Roberts, Ted E.] Univ Alberta, Dept Med, Div Neurol, Edmonton, AB, Canada; [Rowe, Brian H.] Univ Alberta, Dept Emergency Med, Walter C Mackenzie Ctr 1G1 42, Edmonton, AB T6G 2B7, Canada	University of Alberta; Yeshiva University; Albert Einstein College of Medicine; Michigan State University; Michigan State University; University of Calgary; St. Paul's Hospital; University of Saskatchewan; University of Alberta; University of Alberta	Rowe, BH (corresponding author), Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada.	brian.rowe@ualberta.ca	Brown, Michael Donald/GRJ-1945-2022	Colman, Ian/0000-0001-5924-0277; Brown, Michael/0000-0001-6893-350X				Ausejo M, 1999, BRIT MED J, V319, P595, DOI 10.1136/bmj.319.7210.595; Baden Eric Y, 2006, CJEM, V8, P393; Bond Kenneth, 2007, Healthc Q, V10, P32; Brandes JL, 2007, JAMA-J AM MED ASSOC, V297, P1443, DOI 10.1001/jama.297.13.1443; Colman I, 2004, NEUROLOGY, V62, P1695, DOI 10.1212/01.WNL.0000127304.91605.BA; COLMAN I, 2003, COCHRANE LIB; Donaldson D, 2008, AM J EMERG MED, V26, P124, DOI 10.1016/j.ajem.2007.03.029; Ducharme J, 1998, ACAD EMERG MED, V5, P899; FIESSELER FW, 2006, ACAD EMERGY MED, V13, pS137; FIESSLER F, 2007, ACAD EMERG MED S1, V14, pS71; Friedman BW, 2007, NEUROLOGY, V69, P2038, DOI 10.1212/01.WNL.0000281105.78936.1d; Goadsby PJ, 1997, NEUROL CLIN, V15, P27, DOI 10.1016/S0733-8619(05)70293-0; Hamel E, 1999, Can J Clin Pharmacol, V6 Suppl A, p9A; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Innes G D, 1999, CJEM, V1, P26; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jones AE, 2003, ACAD EMERG MED, V10, P1054, DOI 10.1197/S1069-6563(03)00346-4; Kelly AM, 2008, EMERG MED J, V25, DOI 10.1136/emj.2007.052068; Lenert LA, 2003, MED CARE, V41, P299, DOI 10.1097/00005650-200302000-00011; Lipton RB, 2002, HEADACHE, V42, pS3, DOI 10.1046/j.1526-4610.2002.0420s1003.x; Lipton RB, 1999, HEADACHE, V39, pS9, DOI 10.1111/j.1526-4610.1999.00003.x; Moore KL, 1997, AM FAM PHYSICIAN, V56, P2039; Ospina MB, 2006, ACAD EMERG MED, V13, P102, DOI 10.1197/j.aem.2005.07.039; Osterhaus J T, 1992, Pharmacoeconomics, V2, P67, DOI 10.2165/00019053-199202010-00008; PrysePhillips WEM, 1997, CAN MED ASSOC J, V156, P1273; RASKIN NH, 1993, NEUROLOGY, V43, P39; Rowe BH, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002178; Rowe BH, 2008, HEADACHE, V48, P333, DOI 10.1111/j.1526-4610.2007.00959.x; Silberstein SD, 2000, NEUROLOGY, V55, P754, DOI 10.1212/WNL.55.6.754; Snow V, 2002, ANN INTERN MED, V137, P840, DOI 10.7326/0003-4819-137-10-200211190-00014; STEWART W, 1994, NEUROLOGY, V44, P23; van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108; Vinson DR, 2002, ANN EMERG MED, V39, P215, DOI 10.1067/mem.2002.121400; Welch KMA, 2003, NEUROLOGY, V61, pS2, DOI 10.1212/WNL.61.8_suppl_4.S2	34	86	89	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 14	2008	336	7657					1359	1361		10.1136/bmj.39566.806725.BE	http://dx.doi.org/10.1136/bmj.39566.806725.BE			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316YB	18541610	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000256984700042
J	Kieffer, SW; Jakosky, BM				Kieffer, Susan W.; Jakosky, Bruce M.			Enceladus - Oasis or ice ball?	SCIENCE			English	Editorial Material							PLUME; ORIGIN		[Kieffer, Susan W.] Univ Illinois, Dept Geol, Urbana, IL 61802 USA; [Jakosky, Bruce M.] Univ Colorado, Atmospher & Space Phys Lab, Boulder, CO 80309 USA; [Jakosky, Bruce M.] Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	Kieffer, SW (corresponding author), Univ Illinois, Dept Geol, Urbana, IL 61802 USA.	skieffer@uiuc.edu; bruce.jakosky@lasp.colorado.edu						Brown RH, 2006, SCIENCE, V311, P1425, DOI 10.1126/science.1121031; Gioia G, 2007, P NATL ACAD SCI USA, V104, P13578, DOI 10.1073/pnas.0706018104; Hansen CJ, 2006, SCIENCE, V311, P1422, DOI 10.1126/science.1121254; Jakosky BM, 1998, J GEOPHYS RES-PLANET, V103, P19359, DOI 10.1029/98JE01892; Kieffer SW, 2006, SCIENCE, V314, P1764, DOI 10.1126/science.1133519; Nimmo F, 2007, NATURE, V447, P289, DOI 10.1038/nature05783; Porco CC, 2006, SCIENCE, V311, P1393, DOI 10.1126/science.1123013; SHOCK EL, 1990, ORIGINS LIFE EVOL B, V20, P331, DOI 10.1007/BF01808115; Spencer JR, 2006, SCIENCE, V311, P1401, DOI 10.1126/science.1121661; Spitale JN, 2007, NATURE, V449, P695, DOI 10.1038/nature06217; SULLIVAN W, 2007, PLANETS LIFE EMERGIN, P357; Waite JH, 2006, SCIENCE, V311, P1419, DOI 10.1126/science.1121290	12	12	12	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	2008	320	5882					1432	1433		10.1126/science.1159702	http://dx.doi.org/10.1126/science.1159702			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556539				2022-12-28	WOS:000256676400023
J	Pain, E				Pain, Elisabeth			Sustaining forests in a changing world	SCIENCE			English	Editorial Material																			0	1	1	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	2008	320	5882					1514	1517		10.1126/science.320.5882.1514	http://dx.doi.org/10.1126/science.320.5882.1514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	312MV	18556562				2022-12-28	WOS:000256676400050
J	Ehrlich, HJ; Muller, M; Oh, HML; Tambyah, PA; Joukhadar, C; Montomoli, E; Fisher, D; Berezuk, G; Fritsch, S; Low-Baselli, A; Vartian, N; Bobrovsky, R; Pavlova, BG; Pollabauer, EM; Kistner, O; Barrett, PN				Ehrlich, Hartmut J.; Mueller, Markus; Oh, Helen M. L.; Tambyah, Paul A.; Joukhadar, Christian; Montomoli, Emanuele; Fisher, Dale; Berezuk, Greg; Fritsch, Sandor; Loew-Baselli, Alexandra; Vartian, Nina; Bobrovsky, Roman; Pavlova, Borislava G.; Poellabauer, Eva Maria; Kistner, Otfried; Barrett, P. Noel		Baxter H5N1 Pandem Influenza Vacci	A clinical trial of a whole-virus H5N1 vaccine derived from cell culture	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							I RANDOMIZED-TRIAL; MF59-ADJUVANTED INFLUENZA; PANDEMIC INFLUENZA; RESPONSES; SAFETY; IMMUNOGENICITY; ANTIGENICITY; ANTIBODY	Background: Widespread infections of avian species with avian influenza H5N1 virus and its limited spread to humans suggest that the virus has the potential to cause a human influenza pandemic. An urgent need exists for an H5N1 vaccine that is effective against divergent strains of H5N1 virus. Methods: In a randomized, dose-escalation, phase 1 and 2 study involving six subgroups, we investigated the safety of an H5N1 whole-virus vaccine produced on Vero cell cultures and determined its ability to induce antibodies capable of neutralizing various H5N1 strains. In two visits 21 days apart, 275 volunteers between the ages of 18 and 45 years received two doses of vaccine that each contained 3.75 mu g, 7.5 mu g, 15 mu g, or 30 mu g of hemagglutinin antigen with alum adjuvant or 7.5 mu g or 15 mu g of hemagglutinin antigen without adjuvant. Serologic analysis was performed at baseline and on days 21 and 42. Results: The vaccine induced a neutralizing immune response not only against the clade 1 (A/Vietnam/1203/2004) virus strain but also against the clade 2 and 3 strains. The use of adjuvants did not improve the antibody response. Maximum responses to the vaccine strain were obtained with formulations containing 7.5 mu g and 15 mu g of hemagglutinin antigen without adjuvant. Mild pain at the injection site (in 9 to 27% of subjects) and headache (in 6 to 31% of subjects) were the most common adverse events identified for all vaccine formulations. Conclusions: A two-dose vaccine regimen of either 7.5 mu g or 15 mu g of hemagglutinin antigen without adjuvant induced neutralizing antibodies against diverse H5N1 virus strains in a high percentage of subjects, suggesting that this may be a useful H5N1 vaccine. (ClinicalTrials.gov number, NCT00349141.).	[Mueller, Markus; Joukhadar, Christian] Med Univ Vienna, Vienna Gen Hosp AKH, Dept Clin Pharmacol, A-1090 Vienna, Austria; [Ehrlich, Hartmut J.; Berezuk, Greg; Fritsch, Sandor; Loew-Baselli, Alexandra; Vartian, Nina; Bobrovsky, Roman; Pavlova, Borislava G.; Poellabauer, Eva Maria; Kistner, Otfried; Barrett, P. Noel] Baxter BioSci, Dept Global Res & Dev, Vienna, Austria; [Oh, Helen M. L.] Changi Gen Hosp, Singapore, Singapore; [Tambyah, Paul A.; Fisher, Dale] Natl Univ Singapore, Singapore 117548, Singapore; [Tambyah, Paul A.; Fisher, Dale] Natl Univ Singapore Hosp, Singapore 117548, Singapore; [Montomoli, Emanuele] Univ Siena, I-53100 Siena, Italy	Medical University of Vienna; Changi General Hospital; National University of Singapore; National University of Singapore; University of Siena	Muller, M (corresponding author), Med Univ Vienna, Vienna Gen Hosp AKH, Dept Clin Pharmacol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	markus.mueller@meduniwien.ac.at	Bauer, Martin/AFU-1231-2022; MONTOMOLI, EMANUELE/Q-2122-2015; Bauer, Martin/F-5837-2019; pavlova, borislava/G-3226-2010; Zeitlinger, Markus/GSN-3508-2022	Bauer, Martin/0000-0003-4818-1560; MONTOMOLI, EMANUELE/0000-0001-7595-4974; Bauer, Martin/0000-0003-4818-1560; Zeitlinger, Markus/0000-0002-1873-3953; Griss, Johannes/0000-0003-2206-9511; Hsu, Li Yang/0000-0002-0396-066X				Bresson JL, 2006, LANCET, V367, P1657, DOI 10.1016/S0140-6736(06)68656-X; COLLETT D, 1991, MODELING BINARY DATA, P202; Committee for Proprietary Medicinal Products, 1997, NOT GUID HARM REQ IN; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; Hehme N, 2004, VIRUS RES, V103, P163, DOI 10.1016/j.virusres.2004.02.029; Kistner O, 1998, VACCINE, V16, P960, DOI 10.1016/S0264-410X(97)00301-0; Kistner O, 2007, VACCINE, V25, P6028, DOI 10.1016/j.vaccine.2007.05.013; Leroux-Roels I, 2007, LANCET, V370, P580, DOI 10.1016/S0140-6736(07)61297-5; Lin JT, 2006, LANCET, V368, P991, DOI 10.1016/S0140-6736(06)69294-5; LU BL, 1982, INFECT IMMUN, V38, P530, DOI 10.1128/IAI.38.2.530-535.1982; Nicholson KG, 2001, LANCET, V357, P1937, DOI 10.1016/S0140-6736(00)05066-2; NICHOLSON KG, 1979, J BIOL STAND, V7, P123, DOI 10.1016/S0092-1157(79)80044-X; Nicolson C, 2005, VACCINE, V23, P2943, DOI 10.1016/j.vaccine.2004.08.054; REED L. J., 1938, AMER JOUR HYG, V27, P493; Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999; SCHILD GC, 1975, B WORLD HEALTH ORGAN, V52, P43; Stephenson I, 2005, J INFECT DIS, V191, P1210, DOI 10.1086/428948; Stephenson I, 2004, VIRUS RES, V103, P91, DOI 10.1016/j.virusres.2004.02.019; Stephenson I, 2003, LANCET, V362, P1959, DOI 10.1016/S0140-6736(03)15014-3; Treanor JJ, 2006, NEW ENGL J MED, V354, P1343, DOI 10.1056/NEJMoa055778; WOOD JM, 1994, VACCINE, V12, P167, DOI 10.1016/0264-410X(94)90056-6; Wood JM, 2002, VACCINE, V20, pB40, DOI 10.1016/S0264-410X(02)00509-1; Wood JM, 2001, PHILOS T R SOC B, V356, P1953, DOI 10.1098/rstb.2001.0981	23	204	221	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2008	358	24					2573	2584		10.1056/NEJMoa073121	http://dx.doi.org/10.1056/NEJMoa073121			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311IJ	18550874				2022-12-28	WOS:000256593600005
J	Jager, RD; Mieler, WF; Miller, JW				Jager, Rama D.; Mieler, William F.; Miller, Joan W.			Medical progress: Age-related macular degeneration	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							COMPLEMENT FACTOR-H; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; TISSUE-PLASMINOGEN ACTIVATOR; THICK SUBMACULAR HEMORRHAGE; 5-YEAR INCIDENCE; VISUAL IMPAIRMENT; CIGARETTE-SMOKING; VITAMIN-E; JAPANESE POPULATION; GEOGRAPHIC ATROPHY		[Jager, Rama D.; Mieler, William F.] Univ Chicago, Sect Ophthalmol & Visual Sci, Dept Surg, Chicago, IL 60637 USA; [Miller, Joan W.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA	University of Chicago; Harvard University; Harvard Medical School	Jager, RD (corresponding author), Univ Retina & Macula Assoc, 6320 W 159th St,Suite A, Oak Forest, IL 60452 USA.	rjager@uretina.com		Miller, Joan/0000-0003-2046-3996				ALGVERE PV, IN PRESS ACTA OPHTHA; Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; Anand R, 2000, OPHTHALMOLOGY, V107, P2224; Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0; [Anonymous], 2006, AGE RELATED MACULAR; Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529; Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058; Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7; Bidwell G, 2005, EYE, V19, P945, DOI 10.1038/sj.eye.6701955; BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X; Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008; Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488; Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621; BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032; Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329; Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53; Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167; Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f; Chen LJ, 2006, MOL VIS, V12, P1536; Chew EY, 2005, ARCH OPHTHALMOL-CHIC, V123, P395, DOI 10.1001/archopht.123.3.395; Colenbrander August, 2007, International Ophthalmology Clinics, V47, P139, DOI 10.1097/IIO.0b013e31802bd939; Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477; de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326; DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49; Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613; Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001; Dowling J, 2005, EXPERT REV MED DEVIC, V2, P73, DOI 10.1586/17434440.2.1.73; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7; Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726; FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640; FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513; Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5; Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564; Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598; GASS JD, 1967, AM J OPHTHALMOL, V63; Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750; Gragoudas E S, 2004, PHOTODYNAMIC THERAPY; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042; Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1; Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0; Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021; Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010; Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002; Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9; Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643; Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185; Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612; Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013; Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506; Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069; Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6; KLEIN R, 1995, OPHTHALMOLOGY, V102, P371; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128; KLEIN R, 1995, OPHTHALMOLOGY, V102, P1126, DOI 10.1016/S0161-6420(13)30905-1; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Lonn E, 2005, JAMA-J AM MED ASSOC, V293, P1338, DOI 10.1001/jama.293.11.1338; Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741; MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480; Marneros AG, 2007, FASEB J, V21, P3809, DOI 10.1096/fj.07-8422com; Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110; Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047; Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2; Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923; Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022; Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042; National Eye Institute, AG REL EYE DIS STUD; Okamoto H, 2006, MOL VIS, V12, P156; Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020; Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158; Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004; Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671; Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259; Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822; Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321; Seddon JM, 2004, ARCH OPHTHALMOL-CHIC, V122, P426; Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728; Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0; Singh RP, 2006, BRIT J OPHTHALMOL, V90, P429, DOI 10.1136/bjo.2005.085001; Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007; Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401; Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001; Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7; Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978; van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101; van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509; VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625; VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5; Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z; Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598	99	1103	1157	4	116	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	2008	358	24					2606	2617		10.1056/NEJMra0801537	http://dx.doi.org/10.1056/NEJMra0801537			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311IJ	18550876				2022-12-28	WOS:000256593600008
J	Tanriverdi, F; Unluhizarci, K; Kocyigit, I; Tuna, IS; Karaca, Z; Durak, AC; Selcuklu, A; Casanueva, FF; Kelestimur, F				Tanriverdi, Fatih; Unluhizarci, Kursad; Kocyigit, Ismail; Tuna, Ibrahim S.; Karaca, Zuleyha; Durak, Ahmet C.; Selcuklu, Ahmet; Casanueva, Felipe F.; Kelestimur, Fahrettin			Brief communication: Pituitary volume and function in competing and retired male boxers	ANNALS OF INTERNAL MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; HYPOPITUITARISM; SPORT	Background: Pituitary consequences of chronic head trauma in boxing have not been investigated in detail. Objective: To investigate the pituitary function in retired or active amateur boxers. Design: Cross-sectional, observational study. Setting: Turkey. Participants: 61 actively competing (n = 44) or retired (n = 17) male boxers of the Turkish National Boxing Team. Measurements: Body composition variables, pituitary volume (in 38 of 61 boxers), and pituitary function. Results: 9 of 61 boxers (15%) had growth hormone (GH) deficiency and 5 of 61 boxers (8%) had adrenocorticotropic hormone deficiency. All boxers with GH deficiency except 1 were retired from boxing. Of 17 retired boxers, 8 (47%) had GH deficiency. Retired boxers with GH deficiency had significantly lower pituitary volume than retired boxers with normal GH. Limitation: Pituitary volume was measured in only 38 of 61 boxers, and the study had no comparison group. Conclusion: This study suggests that retired boxers have a high rate of pituitary dysfunction. Therefore, investigation of pituitary function in boxers, particularly retired ones, is recommended.	Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; Inst Salud Carlos III, Santiago De Compostela, Spain	Erciyes University; Instituto de Salud Carlos III	Tanriverdi, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fatihtan@erciyes.edu.tr	Karaca, Züleyha/ABB-7891-2021; kelestimur, f/ABE-9873-2021; selcuklu, selcuklu/GON-9516-2022	Tuna, Ibrahim/0000-0003-4170-6483; KOCYIGIT, ISMAIL/0000-0002-6654-4727				Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BURKE CW, 1992, CLIN ENDOCRINOL, V36, P133, DOI 10.1111/j.1365-2265.1992.tb00946.x; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelestimur Fahrettin, 2005, Pituitary, V8, P259, DOI 10.1007/s11102-006-6051-3; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lamberts SWJ, 1998, LANCET, V352, P127; Melmed S, 2003, J CLIN INVEST, V112, P1603, DOI 10.1172/JCI200320401; Orme SM, 1996, CLIN ENDOCRINOL, V45, P135, DOI 10.1046/j.1365-2265.1996.d01-1562.x; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Regal M, 2001, CLIN ENDOCRINOL, V55, P735, DOI 10.1046/j.1365-2265.2001.01406.x; Takano K, 1999, AM J NEURORADIOL, V20, P312; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Zazryn TR, 2003, BRIT J SPORT MED, V37, P448, DOI 10.1136/bjsm.37.5.448; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	17	71	71	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2008	148	11					827	U35		10.7326/0003-4819-148-11-200806030-00005	http://dx.doi.org/10.7326/0003-4819-148-11-200806030-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308CG	18519929				2022-12-28	WOS:000256365300004
J	Teoh, NC; Bowden, FJ				Teoh, Narci C.; Bowden, Francis J.			The case for resurrecting the long case	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Teoh, Narci C.; Bowden, Francis J.] Australian Natl Univ, Sch Med, Canberra Hosp, Canberra, ACT, Australia	Australian National University; Canberra Hospital	Teoh, NC (corresponding author), Australian Natl Univ, Sch Med, Canberra Hosp, Canberra, ACT, Australia.	frank.bowden@act.gov.au							0	3	3	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 31	2008	336	7655					1250	1250		10.1136/bmj.39583.596111.94	http://dx.doi.org/10.1136/bmj.39583.596111.94			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311PS	18511802	Green Submitted, Green Published			2022-12-28	WOS:000256612700036
J	Hillaire-Marcel, C; de Vernal, A				Hillaire-Marcel, Claude; de Vernal, Anne			Comment on "mixed-layer deepening during Heinrich events: A multi-planktonic foraminiferal delta O-18 approach"	SCIENCE			English	Editorial Material							NORTHWEST NORTH-ATLANTIC; LABRADOR SEA; WATER		[Hillaire-Marcel, Claude; de Vernal, Anne] Univ Quebec, Geochem & Geodynam Res Ctr, Montreal, PQ H3C 3P8, Canada	University of Quebec; University of Quebec Montreal	Hillaire-Marcel, C (corresponding author), Univ Quebec, Geochem & Geodynam Res Ctr, CP 8888, Montreal, PQ H3C 3P8, Canada.	chm@uqam.ca	de Vernal, Anne/D-5602-2013; Hillaire-Marcel, Claude/C-9153-2013; Hillaire-Marcel, Claude/H-1441-2012	de Vernal, Anne/0000-0001-5656-724X; Hillaire-Marcel, Claude/0000-0002-3733-4632; 				Darling KF, 2006, PALEOCEANOGRAPHY, V21, DOI 10.1029/2005PA001189; de Vernal A, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2001PA000665; de Vernal A, 2006, GLOBAL PLANET CHANGE, V54, P263, DOI 10.1016/j.gloplacha.2006.06.023; DUPLESSY JC, 1986, NATURE, V320, P350, DOI 10.1038/320350a0; Gherardi JM, 2005, EARTH PLANET SC LETT, V240, P710, DOI 10.1016/j.epsl.2005.09.061; Hillaire-Marcel C, 2004, QUATERNARY SCI REV, V23, P245, DOI 10.1016/j.quascirev.2003.08.006; Hillaire-Marcel C, 2001, NATURE, V410, P1073, DOI 10.1038/35074059; Hillaire-Marcel C, 2000, CAN J EARTH SCI, V37, P795, DOI [10.1139/cjes-37-5-795, 10.1139/e99-108]; Hillaire-Marcel C, 2008, EARTH PLANET SC LETT, V268, P143, DOI 10.1016/j.epsl.2008.01.012; HILRECHT H, 1996, EXTANT PLANKTIC FORA; Lototskaya A, 1998, MAR MICROPALEONTOL, V34, P47, DOI 10.1016/S0377-8398(98)00005-X; LUCOTTE M, 1994, CAN J EARTH SCI, V31, P5, DOI 10.1139/e94-002; Rashid H, 2007, SCIENCE, V318, P439, DOI 10.1126/science.1146138; Stanford JD, 2006, PALEOCEANOGRAPHY, V21, DOI 10.1029/2006PA001340; TOLDERLUND D S, 1971, Micropaleontology (New York), V17, P297, DOI 10.2307/1485143	15	7	7	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 30	2008	320	5880								10.1126/science.1153316	http://dx.doi.org/10.1126/science.1153316			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306FF	18511673				2022-12-28	WOS:000256233000015
J	Kanwar, R; Fortini, ME				Kanwar, Ritu; Fortini, Mark E.			RETRACTED: The big brain aquaporin is required for endosome maturation and notch receptor trafficking (Retracted article. See vol. 142, pg. 170, 2010)	CELL			English	Article; Retracted Publication							AMYLOID PRECURSOR PROTEIN; MOSAIC ANALYSIS; DROSOPHILA; GENE; HRS; ENDOCYTOSIS; COMPARTMENT; ACTIVATION; VACUOLAR; ENCODES	Activity of the big brain (bib) gene influences Notch signaling during Drosophila nervous system development. We demonstrate that Bib, which belongs to the aquaporin family of channel proteins, is required for endosome maturation in Drosophila epithelial cells. In the absence of Bib, early endosomes arrest and form abnormal clusters, and cells exhibit reduced acidification of endocytic trafficking organelles. Bib acts downstream of Hrs in early endosome morphogenesis and regulates biogenesis of endocytic compartments prior to the formation of Rab7-containing late endosomes. Abnormal endosome morphology caused by loss of Bib is accompanied by overaccumulation of Notch, Delta, and other signaling molecules as well as reduced intracellular trafficking of Notch to nuclei. Analysis of several endosomal trafficking mutants reveals a correlation between endosomal acidification and levels of Notch signaling. Our findings reveal an unprecedented role for an aquaporin in endosome maturation, trafficking, and acidification.	[Kanwar, Ritu; Fortini, Mark E.] NCI, Canc & Dev Biol Lab, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Fortini, ME (corresponding author), NCI, Canc & Dev Biol Lab, 1050 Boyles St,Bldg 560,Room 22-12, Frederick, MD 21701 USA.	fortini@ncifcrf.gov			Intramural NIH HHS [NIH0011405438] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC010912, Z01BC010912] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Childress JL, 2006, CURR BIOL, V16, P2228, DOI 10.1016/j.cub.2006.09.031; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; Doherty D, 1997, DEVELOPMENT, V124, P3881; Faundez Victor, 2004, Sci STKE, V2004, pre8, DOI 10.1126/stke.2332004re8; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Gallagher CM, 2006, DEV CELL, V11, P641, DOI 10.1016/j.devcel.2006.09.014; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Hoepfner S, 2005, CELL, V121, P437, DOI 10.1016/j.cell.2005.02.017; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; Hurtado-Lorenzo A, 2006, NAT CELL BIOL, V8, P124, DOI 10.1038/ncb1348; Jaekel R, 2006, DEV CELL, V11, P655, DOI 10.1016/j.devcel.2006.09.019; Jekely G, 2003, EMBO REP, V4, P1163, DOI 10.1038/sj.embor.7400019; King LS, 2004, NAT REV MOL CELL BIO, V5, P687, DOI 10.1038/nrm1469; KOENIG JH, 1990, CELL TISSUE RES, V262, P233, DOI 10.1007/BF00309878; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Kopan R, 2000, GENE DEV, V14, P2799, DOI 10.1101/gad.836900; Le Borgne R, 2005, DEVELOPMENT, V132, P1751, DOI 10.1242/dev.01789; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Lloyd TE, 2002, CELL, V108, P261, DOI 10.1016/S0092-8674(02)00611-6; Matsuo H, 2004, SCIENCE, V303, P531, DOI 10.1126/science.1092425; MELLMAN I, 1992, J EXP BIOL, V172, P39; Moberg KH, 2005, DEV CELL, V9, P699, DOI 10.1016/j.devcel.2005.09.018; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Piwon N, 2000, NATURE, V408, P369, DOI 10.1038/35042597; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; RAO Y, 1992, DEVELOPMENT, V116, P31; RAO Y, 1990, NATURE, V345, P163, DOI 10.1038/345163a0; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; Rink J, 2005, CELL, V122, P735, DOI 10.1016/j.cell.2005.06.043; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Seto ES, 2006, J CELL BIOL, V173, P95, DOI 10.1083/jcb.200510123; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Thompson BJ, 2005, DEV CELL, V9, P711, DOI 10.1016/j.devcel.2005.09.020; Vaccari T, 2005, DEV CELL, V9, P687, DOI 10.1016/j.devcel.2005.09.019; Vaccari T, 2008, J CELL BIOL, V180, P755, DOI 10.1083/jcb.200708127; Verkman AS, 2005, J CELL SCI, V118, P3225, DOI 10.1242/jcs.02519; Weber U, 2003, DEV CELL, V5, P559, DOI 10.1016/S1534-5807(03)00273-9; XU T, 1994, METHOD CELL BIOL, V44, P655, DOI 10.1016/S0091-679X(08)60937-1; Yanochko GM, 2002, J NEUROSCI, V22, P2530, DOI 10.1523/JNEUROSCI.22-07-02530.2002	47	31	31	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	2008	133	5					852	863		10.1016/j.cell.2008.04.038	http://dx.doi.org/10.1016/j.cell.2008.04.038			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510929	Bronze, Green Accepted			2022-12-28	WOS:000256274500017
J	Sakaguchi, S; Yamaguchi, T; Nomura, T; Ono, M				Sakaguchi, Shimon; Yamaguchi, Tomoyuki; Nomura, Takashi; Ono, Masahiro			Regulatory T cells and immune tolerance	CELL			English	Review							IMMUNOLOGICAL SELF-TOLERANCE; TRANSCRIPTION FACTOR FOXP3; THYMIC EPITHELIAL-CELLS; DENDRITIC CELLS; IN-VIVO; AUTOIMMUNE-DISEASE; RETINOIC-ACID; TGF-BETA; INTESTINAL INFLAMMATION; FOREIGN ANTIGEN	Regulatory T cells (Tregs) play an indispensable role in maintaining immunological unresponsiveness to self-antigens and in suppressing excessive immune responses deleterious to the host. Tregs are produced in the thymus as a functionally mature subpopulation of T cells and can also be induced from naive T cells in the periphery. Recent research reveals the cellular and molecular basis of Treg development and function and implicates dysregulation of Tregs in immunological disease.	[Sakaguchi, Shimon; Yamaguchi, Tomoyuki; Nomura, Takashi; Ono, Masahiro] Kyoto Univ, Inst Frontier Med Sci, Dept Expt Pathol, Kyoto 6068507, Japan; [Sakaguchi, Shimon] Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan; [Sakaguchi, Shimon] Osaka Univ, Expt Immunol Lab, WPI Frontier Immunol Res Ctr, Suita, Osaka 5650871, Japan	Kyoto University; Japan Science & Technology Agency (JST); Osaka University	Sakaguchi, S (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Dept Expt Pathol, Kyoto 6068507, Japan.	shimon@frontier.kyoto-u.ac.jp	Sakaguchi, Shimon/C-9535-2009; Ono, Masahiro/H-2378-2011; Jin, Zhi/O-3281-2015	Ono, Masahiro/0000-0002-9284-7326; Yamaguchi, Tomoyuki/0000-0002-4159-5448				Akiyama T, 2005, SCIENCE, V308, P248, DOI 10.1126/science.1105677; Antony PA, 2006, J IMMUNOL, V176, P5255, DOI 10.4049/jimmunol.176.9.5255; Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; Aschenbrenner K, 2007, NAT IMMUNOL, V8, P351, DOI 10.1038/ni1444; Baecher-Allan C, 2004, SEMIN IMMUNOL, V16, P89, DOI 10.1016/j.smim.2003.12.005; Belkaid Y, 2005, NAT IMMUNOL, V6, P353, DOI 10.1038/ni1181; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Benson MJ, 2007, J EXP MED, V204, P1765, DOI 10.1084/jem.20070719; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Brode S, 2006, J IMMUNOL, V177, P6603, DOI 10.4049/jimmunol.177.10.6603; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Burchill MA, 2007, J IMMUNOL, V178, P280, DOI 10.4049/jimmunol.178.1.280; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; CANTOR H, 1976, J EXP MED, V143, P1391, DOI 10.1084/jem.143.6.1391; Caudy AA, 2007, J ALLERGY CLIN IMMUN, V119, P482, DOI 10.1016/j.jaci.2006.10.007; Celli S, 2007, IMMUNITY, V27, P625, DOI 10.1016/j.immuni.2007.08.018; Chen CX, 2006, J BIOL CHEM, V281, P36828, DOI 10.1074/jbc.M608848200; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Cobb BS, 2006, J EXP MED, V203, P2519, DOI 10.1084/jem.20061692; Collison LW, 2007, NATURE, V450, P566, DOI 10.1038/nature06306; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Danke NA, 2004, J IMMUNOL, V172, P5967, DOI 10.4049/jimmunol.172.10.5967; Fehervari Z, 2004, INT IMMUNOL, V16, P1769, DOI 10.1093/intimm/dxh178; Fisson S, 2003, J EXP MED, V198, P737, DOI 10.1084/jem.20030686; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; FOWELL D, 1993, J EXP MED, V177, P627, DOI 10.1084/jem.177.3.627; Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Haribhai D, 2007, J IMMUNOL, V178, P2961, DOI 10.4049/jimmunol.178.5.2961; Hill JA, 2007, IMMUNITY, V27, P786, DOI 10.1016/j.immuni.2007.09.010; Hirota K, 2007, J EXP MED, V204, P2803, DOI 10.1084/jem.20071397; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hsieh CS, 2006, NAT IMMUNOL, V7, P401, DOI 10.1038/ni1318; Huehn J, 2005, TRENDS IMMUNOL, V26, P632, DOI 10.1016/j.it.2005.10.001; Itoh M, 1999, J IMMUNOL, V162, P5317; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; Kajiura F, 2004, J IMMUNOL, V172, P2067, DOI 10.4049/jimmunol.172.4.2067; Kallikourdis M, 2007, P NATL ACAD SCI USA, V104, P594, DOI 10.1073/pnas.0604268104; Kawahata K, 2002, J IMMUNOL, V168, P4399, DOI 10.4049/jimmunol.168.9.4399; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; Klein L, 2003, P NATL ACAD SCI USA, V100, P8886, DOI 10.1073/pnas.1533365100; Koonpaew S, 2006, J EXP MED, V203, P119, DOI 10.1084/jem.20050903; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852; Laurence A, 2007, IMMUNITY, V26, P371, DOI 10.1016/j.immuni.2007.02.009; Lee I, 2005, J EXP MED, V201, P1037, DOI 10.1084/jem.20041709; Li B, 2007, CELL CYCLE, V6, P1432; Lin W, 2007, NAT IMMUNOL, V8, P359, DOI 10.1038/ni1445; Malek TR, 2004, NAT REV IMMUNOL, V4, P665, DOI 10.1038/nri1435; Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478; Mathis D, 2007, NAT REV IMMUNOL, V7, P645, DOI 10.1038/nri2136; Maynard CL, 2007, NAT IMMUNOL, V8, P931, DOI 10.1038/ni1504; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; Miyara M, 2007, TRENDS MOL MED, V13, P108, DOI 10.1016/j.molmed.2007.01.003; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; Nishikawa H, 2005, BLOOD, V106, P1008, DOI 10.1182/blood-2005-02-0607; Ochs HD, 2005, IMMUNOL REV, V203, P156, DOI 10.1111/j.0105-2896.2005.00231.x; Ono M, 2007, NATURE, V446, P685, DOI 10.1038/nature05673; Pacholczyk R, 2007, IMMUNITY, V27, P493, DOI 10.1016/j.immuni.2007.07.019; Pandiyan P, 2007, NAT IMMUNOL, V8, P1353, DOI 10.1038/ni1536; POWRIE F, 1990, J EXP MED, V172, P1701, DOI 10.1084/jem.172.6.1701; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; SAKAGUCHI S, 1982, J EXP MED, V156, P1577, DOI 10.1084/jem.156.6.1577; SAKAGUCHI S, 1985, J EXP MED, V161, P72, DOI 10.1084/jem.161.1.72; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sakaguchi S, 2000, CURR OPIN IMMUNOL, V12, P684, DOI 10.1016/S0952-7915(00)00163-1; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Samy ET, 2005, J EXP MED, V202, P771, DOI 10.1084/jem.20041033; Sather BD, 2007, J EXP MED, V204, P1335, DOI 10.1084/jem.20070081; Scheinecker C, 2002, J EXP MED, V196, P1079, DOI 10.1084/jem.20020991; Schneider MA, 2007, J EXP MED, V204, P735, DOI 10.1084/jem.20061405; Setoguchi R, 2005, J EXP MED, V201, P723, DOI 10.1084/jem.20041982; Shevach EM, 2006, IMMUNITY, V25, P195, DOI 10.1016/j.immuni.2006.08.003; Shevach EM, 2006, IMMUNOL REV, V212, P60, DOI 10.1111/j.0105-2896.2006.00415.x; Shimizu J, 1999, J IMMUNOL, V163, P5211; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Singh B, 2001, IMMUNOL REV, V182, P190, DOI 10.1034/j.1600-065X.2001.1820115.x; Stephens LA, 2005, P NATL ACAD SCI USA, V102, P17418, DOI 10.1073/pnas.0507454102; Sugimoto N, 2006, INT IMMUNOL, V18, P1197, DOI 10.1093/intimm/dxl060; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Sutmuller RPM, 2006, TRENDS IMMUNOL, V27, P387, DOI 10.1016/j.it.2006.06.005; Szanya V, 2002, J IMMUNOL, V169, P2461, DOI 10.4049/jimmunol.169.5.2461; Tadokoro CE, 2006, J EXP MED, V203, P505, DOI 10.1084/jem.20050783; Takahashi T, 1998, INT IMMUNOL, V10, P1969, DOI 10.1093/intimm/10.12.1969; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Tang QZ, 2008, NAT IMMUNOL, V9, P239, DOI 10.1038/ni1572; Tang QZ, 2006, NAT IMMUNOL, V7, P83, DOI 10.1038/ni1289; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Uhlig HH, 2006, J IMMUNOL, V177, P5852, DOI 10.4049/jimmunol.177.9.5852; van Santen HM, 2004, J EXP MED, V200, P1221, DOI 10.1084/jem.20041022; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Vieira PL, 2004, J IMMUNOL, V172, P5986, DOI 10.4049/jimmunol.172.10.5986; von Boehmer H, 2005, NAT IMMUNOL, V6, P338, DOI 10.1038/ni1180; Waldmann H, 2006, IMMUNOL REV, V212, P301, DOI 10.1111/j.0105-2896.2006.00406.x; Wan YSY, 2007, NATURE, V445, P766, DOI 10.1038/nature05479; Wang HY, 2007, CURR OPIN IMMUNOL, V19, P217, DOI 10.1016/j.coi.2007.02.004; Watanabe N, 2005, NATURE, V436, P1181, DOI 10.1038/nature03886; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Yagi H, 2004, INT IMMUNOL, V16, P1643, DOI 10.1093/intimm/dxh165; Yamaguchi T, 2007, IMMUNITY, V27, P145, DOI 10.1016/j.immuni.2007.04.017; Yamanouchi J, 2007, NAT GENET, V39, P329, DOI 10.1038/ng1958; Yamazaki S, 2003, J EXP MED, V198, P235, DOI 10.1084/jem.20030422; Yao Z, 2007, BLOOD, V109, P4368, DOI 10.1182/blood-2006-11-055756; Yurchenko E, 2006, J EXP MED, V203, P2451, DOI 10.1084/jem.20060956; Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563	114	3469	3734	8	431	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 30	2008	133	5					775	787		10.1016/j.cell.2008.05.009	http://dx.doi.org/10.1016/j.cell.2008.05.009			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	306UY	18510923	Bronze			2022-12-28	WOS:000256274500011
J	Camilleri, M; Kerstens, R; Rykx, A; Vandeplassche, L				Camilleri, Michael; Kerstens, Rene; Rykx, An; Vandeplassche, Lieve			A placebo-controlled trial of prucalopride for severe chronic constipation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; COLONIC TRANSIT; DOUBLE-BLIND; K+ CHANNEL; LAXATIVES; ADULTS; QUESTIONNAIRE; EPIDEMIOLOGY; VALIDATION; MOTILITY	Background: In this 12-week trial, we aimed to determine the efficacy of prucalopride, a selective, high-affinity 5-hydroxytryptamine(sub 4) receptor agonist, in patients with severe chronic constipation. Methods: In our multicenter, randomized, placebo-controlled, parallel-group, phase 3 trial, patients with severe chronic constipation ( <= 2 spontaneous, complete bowel movements per week) received placebo or 2 or 4 mg of prucalopride, once daily, for 12 weeks. The primary efficacy end point was the proportion of patients having three or more spontaneous, complete bowel movements per week, averaged over 12 weeks. Secondary efficacy end points were derived from daily diaries and validated questionnaires completed by patients. Adverse events, clinical laboratory values, and cardiovascular effects were monitored. Results: Efficacy was analyzed in 620 patients. The proportion of patients with three or more spontaneous, complete bowel movements per week was 30.9% of those receiving 2 mg of prucalopride and 28.4% of those receiving 4 mg of prucalopride, as compared with 12.0% in the placebo group (P<0.001 for both comparisons). Over 12 weeks, 47.3% of patients receiving 2 mg of prucalopride and 46.6% of those receiving 4 mg of prucalopride had an increase in the number of spontaneous, complete bowel movements of one or more per week, on average, as compared with 25.8% in the placebo group (P<0.001 for both comparisons). All other secondary efficacy end points, including patients' satisfaction with their bowel function and treatment and their perception of the severity of their constipation symptoms, were significantly improved with the use of 2 or 4 mg of prucalopride as compared with placebo, at week 12. The most frequent treatment-related adverse events were headache and abdominal pain. There were no significant cardiovascular effects of treatment. Conclusion: Over 12 weeks, prucalopride significantly improved bowel function and reduced the severity of symptoms in patients with severe chronic constipation. Larger and longer trials are required to further assess the risks and benefits of the use of prucalopride for chronic constipation. (ClinicalTrials.gov number, NCT00483886.).	[Camilleri, Michael] Mayo Clin, Coll Med, Rochester, MN 55905 USA; [Kerstens, Rene; Rykx, An; Vandeplassche, Lieve] Movetis, Turnhout, Belgium	Mayo Clinic; Shire Pharmaceuticals Limited	Camilleri, M (corresponding author), Mayo Clin, Coll Med, Charlton 8-110,200 1st St SW, Rochester, MN 55905 USA.	camilleri.michael@mayo.edu	Kerstens, Rene/ABA-1196-2020					Bosshard W, 2004, DRUG AGING, V21, P911, DOI 10.2165/00002512-200421140-00002; Bouras EP, 1999, GUT, V44, P682, DOI 10.1136/gut.44.5.682; Bouras EP, 2001, GASTROENTEROLOGY, V120, P354, DOI 10.1053/gast.2001.21166; Briejer MR, 2001, NEUROGASTROENT MOTIL, V13, P465, DOI 10.1046/j.1365-2982.2001.00280.x; Briejer MR, 2001, EUR J PHARMACOL, V423, P71, DOI 10.1016/S0014-2999(01)01087-1; Camilleri M, 2007, NEUROGASTROENT MOTIL, V19, P30, DOI 10.1111/j.1365-2982.2006.00865.x; Chapman H, 2007, EUR J PHARMACOL, V554, P98, DOI 10.1016/j.ejphar.2006.10.019; Coremans G, 2003, DIGESTION, V67, P82, DOI 10.1159/000070202; *CTR DRUG EV RES, QUEST ANS ZELN TEG M; De Maeyer JH, 2008, NEUROGASTROENT MOTIL, V20, P99, DOI 10.1111/j.1365-2982.2007.01059.x; Dennison C, 2005, PHARMACOECONOMICS, V23, P461, DOI 10.2165/00019053-200523050-00006; Emmanuel AV, 2002, ALIMENT PHARM THER, V16, P1347, DOI 10.1046/j.1365-2036.2002.01272.x; Frank L, 1999, SCAND J GASTROENTERO, V34, P870, DOI 10.1080/003655299750025327; Galligan JJ, 2005, NEUROGASTROENT MOTIL, V17, P643, DOI 10.1111/j.1365-2982.2005.00675.x; Higgins PDR, 2004, AM J GASTROENTEROL, V99, P750, DOI 10.1111/j.1572-0241.2004.04114.x; Irvine EJ, 2002, AM J GASTROENTEROL, V97, P1986; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Johanson JF, 2007, ALIMENT PHARM THER, V25, P599, DOI 10.1111/j.1365-2036.2006.03238.x; Johanson JF, 2008, AM J GASTROENTEROL, V103, P170, DOI 10.1111/j.1572-0241.2007.01524.x; Johanson JF, 2004, CLIN GASTROENTEROL H, V2, P796, DOI 10.1016/S1542-3565(04)00356-8; Jones MP, 2002, DIGEST DIS SCI, V47, P2222, DOI 10.1023/A:1020131126397; Krogh K, 2002, SCAND J GASTROENTERO, V37, P431, DOI 10.1080/003655202317316060; Lembo A, 2003, NEW ENGL J MED, V349, P1360, DOI 10.1056/NEJMra020995; Loening-Baucke V, 2007, ARCH DIS CHILD, V92, P486, DOI 10.1136/adc.2006.098335; Marquis P, 2005, SCAND J GASTROENTERO, V40, P540, DOI 10.1080/00365520510012208; Petticrew M, 2001, QUAL HEALTH CARE, V10, P268, DOI 10.1136/qhc.0100268..; Potet F, 2001, J PHARMACOL EXP THER, V299, P1007; Schiller Lawrence R, 2004, Rev Gastroenterol Disord, V4 Suppl 2, pS43; Sloots CEJ, 2002, ALIMENT PHARM THER, V16, P759, DOI 10.1046/j.1365-2036.2002.01210.x; Stewart WF, 1999, AM J GASTROENTEROL, V94, P3530, DOI 10.1111/j.1572-0241.1999.01642.x; STIVLAND T, 1991, GASTROENTEROLOGY, V101, P107, DOI 10.1016/0016-5085(91)90466-X; Straus SMJM, 2006, J AM COLL CARDIOL, V47, P362, DOI 10.1016/j.jacc.2005.08.067; Tramonte SM, 1997, J GEN INTERN MED, V12, P15, DOI 10.1046/j.1525-1497.1997.12103.x; Ware J., 2001, SF 36 PHYS MENTAL HL, P1994	34	362	383	2	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2008	358	22					2344	2354		10.1056/NEJMoa0800670	http://dx.doi.org/10.1056/NEJMoa0800670			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307GF	18509121				2022-12-28	WOS:000256306700005
J	Woolf, SH				Woolf, Steven H.			The power of prevention and what it requires	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARE		[Woolf, Steven H.] Virginia Commonwealth Univ, Dept Family Med, Richmond, VA 23298 USA; [Woolf, Steven H.] Virginia Commonwealth Univ, Dept Epidemiol, Richmond, VA 23298 USA; [Woolf, Steven H.] Virginia Commonwealth Univ, Dept Community Med, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Woolf, SH (corresponding author), Virginia Commonwealth Univ, Dept Family Med, 1200 E Broad St, Richmond, VA 23298 USA.	swoolf@vcu.edu						*AG HEALTHC RES QU, 2007, GUID CLIN PREV SERV; Cohen JT, 2008, NEW ENGL J MED, V358, P661, DOI 10.1056/NEJMp0708558; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; LAKDAWALLA DN, 2005, HLTH AFF MILLWOOD S2, V24; Maciosek MV, 2006, AM J PREV MED, V31, P52, DOI 10.1016/j.amepre.2006.03.012; Mongan JJ, 2008, NEW ENGL J MED, V358, P1509, DOI 10.1056/NEJMsb0707912; *NAT BUS GROUP HLT, PREV CHRON DIS US ST; *NAT BUS GROUP HLT, RED BURD SMOK EMPL H; *PARTN PREV, 2007, WHY INV REC IMPR YOU; *REUT, 2006, USA TODAY       0610; Russell LB., 2007, PREVENTIONS POTENTIA; *US C, 2007, LONG TERM OUTL HLTH; Woolf SH, 2006, HARVARD HLTH POLICY, V7, P5; Woolf SH, 2006, JOINING HANDS PARTNE	15	54	54	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2008	299	20					2437	2439		10.1001/jama.299.20.2437	http://dx.doi.org/10.1001/jama.299.20.2437			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305BD	18505953				2022-12-28	WOS:000256151900028
J	Sokol, DK				Sokol, Daniel K.			The essence of medicine	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ London St Georges Hosp, London, England	St Georges University London	Sokol, DK (corresponding author), Univ London St Georges Hosp, London, England.	daniel.sokol@talk21.com							0	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	2008	336	7654					1163	1163		10.1136/bmj.39583.748727.94	http://dx.doi.org/10.1136/bmj.39583.748727.94			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308WJ	18497412	Green Published			2022-12-28	WOS:000256420900036
J	Andersson, AF; Banfield, JF				Andersson, Anders F.; Banfield, Jillian F.			Virus population dynamics and acquired virus resistance in natural microbial communities	SCIENCE			English	Article							DNA; RECOMBINATION; SEQUENCES; ELEMENTS; REPEATS; GENOMES; PHAGE; BACTERIOPHAGES; MECHANISMS; EVOLUTION	Viruses shape microbial community structure and function by altering the fitness of their hosts and by promoting genetic exchange. The complexity of most natural ecosystems has precluded detailed studies of virus- host interactions. We reconstructed virus and host bacterial and archaeal genome sequences from community genomic data from two natural acidophilic biofilms. Viruses were matched to their hosts by analyzing spacer sequences that occur among clustered regularly interspaced short palindromic repeats (CRISPRs) that are a hallmark of virus resistance. Virus population genomic analyses provided evidence that extensive recombination shuffles sequence motifs sufficiently to evade CRISPR spacers. Only the most recently acquired spacers match coexisting viruses, which suggests that community stability is achieved by rapid but compensatory shifts in host resistance levels and virus population structure.	[Andersson, Anders F.; Banfield, Jillian F.] Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA; [Andersson, Anders F.; Banfield, Jillian F.] Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Banfield, JF (corresponding author), Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA.	jbanfield@berkeley.edu	Andersson, Anders/J-9310-2019	Andersson, Anders/0000-0002-3627-6899; Banfield, Jill/0000-0001-8203-8771				Barrangou R, 2007, SCIENCE, V315, P1709, DOI 10.1126/science.1138140; Bolotin A, 2005, MICROBIOL-SGM, V151, P2551, DOI 10.1099/mic.0.28048-0; Botstein D, 1980, Ann N Y Acad Sci, V354, P484, DOI 10.1111/j.1749-6632.1980.tb27987.x; BRATBAK G, 1990, APPL ENVIRON MICROB, V56, P1400, DOI 10.1128/AEM.56.5.1400-1405.1990; Breitbart M, 2005, TRENDS MICROBIOL, V13, P278, DOI 10.1016/j.tim.2005.04.003; Brussow H, 2001, MOL MICROBIOL, V39, P213, DOI 10.1046/j.1365-2958.2001.02228.x; Canchaya C, 2003, CURR OPIN MICROBIOL, V6, P417, DOI 10.1016/S1369-5274(03)00086-9; Chen YG, 2006, BMC GENET, V7, DOI 10.1186/1471-2156-7-54; Deveau H, 2008, J BACTERIOL, V190, P1390, DOI 10.1128/JB.01412-07; Druschel GK, 2004, GEOCHEM T, V5, P13, DOI 10.1186/1467-4866-5-13; Fuhrman JA, 1999, NATURE, V399, P541, DOI 10.1038/21119; Godde JS, 2006, J MOL EVOL, V62, P718, DOI 10.1007/s00239-005-0223-z; Haft DH, 2005, PLOS COMPUT BIOL, V1, P474, DOI 10.1371/journal.pcbi.0010060; Juhala RJ, 2000, J MOL BIOL, V299, P27, DOI 10.1006/jmbi.2000.3729; Lillestol Reidun K., 2006, Archaea, V2, P59, DOI 10.1155/2006/542818; Lo I, 2007, NATURE, V446, P537, DOI 10.1038/nature05624; Makarova KS, 2006, BIOL DIRECT, V1, DOI 10.1186/1745-6150-1-7; Mojica FJM, 2005, J MOL EVOL, V60, P174, DOI 10.1007/s00239-004-0046-3; Nilsson AS, 2001, MOL PHYLOGENET EVOL, V21, P259, DOI 10.1006/mpev.2001.1020; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; Pedulla ML, 2003, CELL, V113, P171, DOI 10.1016/S0092-8674(03)00233-2; Peng X, 2004, MOL MICROBIOL, V54, P366, DOI 10.1111/j.1365-2958.2004.04287.x; Peng X, 2001, VIROLOGY, V291, P226, DOI 10.1006/viro.2001.1190; Pourcel C, 2005, MICROBIOL-SGM, V151, P653, DOI 10.1099/mic.0.27437-0; Pride DT, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-8; Prust C, 2005, NAT BIOTECHNOL, V23, P195, DOI 10.1038/nbt1062; Rossler N, 2004, MOL MICROBIOL, V52, P413, DOI 10.1111/j.1365-2958.2003.03983.x; Snyder JC, 2007, P NATL ACAD SCI USA, V104, P19102, DOI 10.1073/pnas.0709445104; Tang SL, 2004, J BACTERIOL, V186, P2810, DOI 10.1128/JB.186.9.2810-2817.2004; Tetart F, 1998, J MOL BIOL, V282, P543, DOI 10.1006/jmbi.1998.2047; Thingstad TF, 2000, LIMNOL OCEANOGR, V45, P1320, DOI 10.4319/lo.2000.45.6.1320; Tyson GW, 2008, ENVIRON MICROBIOL, V10, P200, DOI 10.1111/j.1462-2920.2007.01444.x; Tyson GW, 2004, NATURE, V428, P37, DOI 10.1038/nature02340; Vestergaard G, 2008, J VIROL, V82, P371, DOI 10.1128/JVI.01410-07; Wiedenheft B, 2004, J VIROL, V78, P1954, DOI 10.1128/JVI.78.4.1954-1961.2004	35	357	378	2	109	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 23	2008	320	5879					1047	1050		10.1126/science.1157358	http://dx.doi.org/10.1126/science.1157358			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18497291				2022-12-28	WOS:000256059800037
J	Emanuel, K				Emanuel, Kerry			Retrospective - Edward N. Lorenz (1917-2008)	SCIENCE			English	Biographical-Item									[Emanuel, Kerry] MIT, Program Atmospheres Oceans & Climate, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Emanuel, K (corresponding author), MIT, Program Atmospheres Oceans & Climate, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	emanuel@texmex.mit.edu							0	2	2	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2008	320	5879					1025	1025		10.1126/science.1159438	http://dx.doi.org/10.1126/science.1159438			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18497283				2022-12-28	WOS:000256059800029
J	Selman, C; Lingard, S; Gems, D; Partridge, L; Withers, DJ				Selman, Colin; Lingard, Steven; Gems, David; Partridge, Linda; Withers, Dominic J.			Comment on brain IRS2 signaling coordinates life span and nutrient homeostasis	SCIENCE			English	Editorial Material							SURVIVAL CHARACTERISTICS; DIETARY RESTRICTION; CALORIC RESTRICTION; MICE; BIOMARKERS; EXTENSION; INSULIN		[Selman, Colin; Lingard, Steven; Withers, Dominic J.] UCL, Rayne Inst, Ctr Diabet & Endocrinol, Dept Med, London WC1E 6JJ, England; [Gems, David; Partridge, Linda] UCL, Ctr Res Ageing, Dept Biol, London WC1E 6BT, England	University of London; King's College London; University College London; University of London; University College London	Withers, DJ (corresponding author), UCL, Rayne Inst, Ctr Diabet & Endocrinol, Dept Med, 5 Univ St, London WC1E 6JJ, England.	d.withers@ucl.ac.uk	Withers, Dominic J/D-7671-2014; Partridge, Linda/A-5501-2010; Partridge, Linda/E-7342-2015	Withers, Dominic J/0000-0002-8009-7521; Selman, Colin/0000-0002-8727-0593; Gems, David/0000-0002-6653-4676; Partridge, Linda/0000-0001-9615-0094				Barger JL, 2003, EXP GERONTOL, V38, P1343, DOI 10.1016/j.exger.2003.10.017; Bartke A, 2007, CELL METAB, V6, P153, DOI 10.1016/j.cmet.2007.08.007; Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898; Liang HY, 2003, EXP GERONTOL, V38, P1353, DOI 10.1016/j.exger.2003.10.019; Selman C, 2008, FASEB J, V22, P807, DOI 10.1096/fj.07-9261com; Selman C, 2006, PHYSIOL GENOMICS, V27, P187, DOI 10.1152/physiolgenomics.00084.2006; Taguchi A, 2007, SCIENCE, V317, P369, DOI 10.1126/science.1142179; Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492; Turturro A, 2002, J GERONTOL A-BIOL, V57, pB379, DOI 10.1093/gerona/57.11.B379; Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116	14	39	39	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 23	2008	320	5879								10.1126/science.1152366	http://dx.doi.org/10.1126/science.1152366			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303RY	18497277				2022-12-28	WOS:000256059800018
J	Albert, P; Calverley, P				Albert, Paul; Calverley, Peter			A PEACE-ful solution to COPD exacerbations?	LANCET			English	Editorial Material							OBSTRUCTIVE PULMONARY-DISEASE; CONTROLLED-TRIAL; PREVENTION; FLUTICASONE; PREVALENCE; PROPIONATE; SALMETEROL; TIOTROPIUM		[Albert, Paul; Calverley, Peter] Univ Liverpool, Sch Clin Sci, Liverpool L9 7AL, Merseyside, England	University of Liverpool	Calverley, P (corresponding author), Univ Liverpool, Sch Clin Sci, Liverpool L9 7AL, Merseyside, England.	pmacal@liverpool.ac.uk						Buist AS, 2007, LANCET, V370, P741, DOI 10.1016/S0140-6736(07)61377-4; Calverley P, 2003, LANCET, V361, P449, DOI 10.1016/S0140-6736(03)12459-2; Calverley Peter M A, 2005, COPD, V2, P143; Calverley PMA, 2007, LANCET, V370, P774, DOI 10.1016/S0140-6736(07)61381-6; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Decramer M, 2005, LANCET, V365, P1552, DOI 10.1016/S0140-6736(05)66456-2; Niewoehner DE, 2005, ANN INTERN MED, V143, P317, DOI 10.7326/0003-4819-143-5-200509060-00007; Poole PJ, 2001, BMJ-BRIT MED J, V322, P1271, DOI 10.1136/bmj.322.7297.1271; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Soler-Cataluna JJ, 2005, THORAX, V60, P925, DOI 10.1136/thx.2005.040527; Wedzicha JA, 2008, AM J RESP CRIT CARE, V177, P19, DOI 10.1164/rccm.200707-973OC; Zheng JP, 2008, LANCET, V371, P2013, DOI 10.1016/S0140-6736(08)60869-7; Zhong N, 2007, AM J RESP CRIT CARE, V176, P753, DOI 10.1164/rccm.200612-1749OC; Zhou YM, 2006, RESPIROLOGY, V11, P603, DOI 10.1111/j.1440-1843.2006.00897.x	14	8	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2008	371	9629					1975	1976		10.1016/S0140-6736(08)60845-4	http://dx.doi.org/10.1016/S0140-6736(08)60845-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312YY	18555897				2022-12-28	WOS:000256709500005
J	Delamothe, T				Delamothe, Tony			NHS at 60 - A comprehensive service	BRITISH MEDICAL JOURNAL			English	Editorial Material									BMJ, London WC1H 9JR, England		Delamothe, T (corresponding author), BMJ, London WC1H 9JR, England.	tdelamothe@bmj.com						*BMA, 2007, RAT WAY NHS ENGL DIS; Colquhoun D, 2007, BRIT MED J, V335, P736, DOI 10.1136/bmj.39360.446528.BE; *DEP HLTH, 2007, OUR NHS OUR FUT NHS; *DEP HLTH, 1997, CMND3807; Hawe E, 2008, OHE COMPENDIUM HLTH; Jefford M, 2005, BMJ-BRIT MED J, V331, P1075, DOI 10.1136/bmj.331.7524.1075; KLEIN R, 1993, HLTH CARE UK 1992 93; Klein R., 2006, NEW POLITICS NHS CRE, V5st edition; Klein R, 2007, BRIT MED BULL, V81-82, P39, DOI 10.1093/bmb/ldm013; Leatherman S, 2008, QUEST QUALITY REFINI; Leatherman Sheila, 2004, BMJ, V328, pE288, DOI 10.1136/bmj.328.7445.E288; Marcus R, 2007, BRIT MED J, V334, P826, DOI 10.1136/bmj.39171.426690.AD; Ministry of Health, 1944, CMD6502; *SECR STAT HLTH, 2002, CMND5503; *SECR STAT HLTH, 2004, CMND6268; Seddon N., 2007, QUITE LIKE HEAVEN OP; Wanless, 2002, SECURING OUR FUTURE; Wanless D, 2001, SECURING OUR FUTURE	18	6	6	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 14	2008	336	7657					1344	1345		10.1136/bmj.a253	http://dx.doi.org/10.1136/bmj.a253			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316YB	18556315	Green Published			2022-12-28	WOS:000256984700037
J	Frech, SA; DuPont, HL; Bourgeois, AL; McKenzie, R; Belkind-Gerson, J; Figueroa, JF; Okhuysen, PC; Guerrero, NH; Martinez-Sandoval, FG; Melendez-Romero, JHM; Jiang, ZD; Asturias, EJ; Halpern, J; Torres, OR; Hoffman, AS; Villar, CP; Kassem, RN; Flyer, DC; Andersen, BH; Kazempour, K; Breisch, SA; Glenn, GM				Frech, Sarah A.; DuPont, Herbert L.; Bourgeois, A. Louis; McKenzie, Robin; Belkind-Gerson, Jaime; Figueroa, Jose F.; Okhuysen, Pablo C.; Guerrero, Norma H.; Martinez-Sandoval, Francisco G.; Melendez-Romero, Juan H. M.; Jiang, Zhi-Dong; Asturias, Edwin J.; Halpern, Jane; Torres, Olga R.; Hoffman, Ana S.; Villar, Christina P.; Kassem, Raniya N.; Flyer, David C.; Andersen, Bo H.; Kazempour, Kazem; Breisch, Sally A.; Glenn, Gregory M.			Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial	LANCET			English	Article							TRANSCUTANEOUS IMMUNIZATION; RELATIVE IMPORTANCE; VACCINE; ENTEROTOXIN; EFFICACY; PROTECTION; SAFETY; MEXICO; ETEC	Background Enterotoxigenic Escherichia coli (ETEC) is a major cause of travellers' diarrhoea. We investigated the rate of diarrhoea attacks, safety, and feasibility of a vaccine containing heat-labile enterotoxin (LT) from ETEC delivered to the skin by patch in travellers to Mexico and Guatemala. Methods In this phase 11 study, healthy adults (aged 18-64 years) who planned to travel to Mexico or Guatemala and had access to a US regional vaccination centre were eligible. A centralised randomisation code was used for allocation, which was masked to participants and site staff. Primary endpoints were to investigate the field rate of ETEC diarrhoea, and to assess the safety of heat-labile toxins from E coli (LT) delivered via patch. Secondary endpoints included vaccine efficacy against travellers' diarrhoea and ETEC. Participants were vaccinated before travel, with two patches given 2-3 weeks apart. Patches contained either 37.5 mu g of LT or placebo. Participants tracked stool output on diary cards in country and provided samples for pathogen identification if diarrhoea occurred. Diarrhoea was graded by the number of loose stools in 24 h: mild (three), moderate (four or five), and severe (at least six). Analysis was per protocol. The trial is registered with ClinicalTrials.gov, number NCT00516659. Findings Recruitment closed after 201 participants were assigned patches. 178 individuals received two vaccinations and travelled and 170 were analysed. 24 (22%) of 111 placebo recipients had diarrhoea, of whom 11 (10%) had ETEC diarrhoea. The vaccine was safe and immunogenic. The 59 LT-patch h recipients were protected against moderate-to-severe diarrhoea (protective efficacy [PE] 75%, p=0.0070) and severe diarrhoea (PE 84%, p=0.0332). LT-patch recipients who became ill had shorter episodes of diarrhoea (0.5 days vs 2. 1 days, p=0.0006) with fewer loose stools (3.7 vs 10.5, p<0.0001) than placebo. Interpretation Travellers' diarrhoea is a common ailment, with ETEC diarrhoea illness occurring in 10% of cases. The vaccine patch is safe and feasible, with benefits to the rate and severity of travellers' diarrhoea.	[Frech, Sarah A.; Villar, Christina P.; Kassem, Raniya N.; Flyer, David C.; Andersen, Bo H.; Glenn, Gregory M.] IOMAI Corp, Gaithersburg, MD 20878 USA; [DuPont, Herbert L.; Jiang, Zhi-Dong] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA; [Bourgeois, A. Louis; McKenzie, Robin; Asturias, Edwin J.; Halpern, Jane; Torres, Olga R.; Hoffman, Ana S.; Glenn, Gregory M.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Belkind-Gerson, Jaime] Inst Nacl Salud Publ, Cuernavaca, Morelos, Mexico; [Figueroa, Jose F.; Okhuysen, Pablo C.] Univ Texas Houston, Sch Med, Houston, TX USA; [Guerrero, Norma H.] Hosp Jardines Guadalupe, Guadalajara, Jalisco, Mexico; [Martinez-Sandoval, Francisco G.; Melendez-Romero, Juan H. M.] Univ Autonoma Guadalajara, Guadalajara, Jalisco, Mexico; [Kazempour, Kazem; Breisch, Sally A.] Amarex Clin Res, Germantown, MD USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Instituto Nacional de Salud Publica; University of Texas System; University of Texas Health Science Center Houston; Universidad Autonoma de Guadalajara	Glenn, GM (corresponding author), IOMAI Corp, Gaithersburg, MD 20878 USA.	gglenn@iomai.com	DuPont, Herbert/AAH-6776-2021; Asturias, Edwin/D-9842-2016	Asturias, Edwin/0000-0002-1275-0787; Okhuysen, Pablo/0000-0002-1596-3411				Adachi JA, 2001, CLIN INFECT DIS, V32, P1706, DOI 10.1086/320756; Allen KP, 2006, INFECT IMMUN, V74, P869, DOI 10.1128/IAI.74.2.869-875.2006; Berberov EM, 2004, INFECT IMMUN, V72, P3914, DOI 10.1128/IAI.72.7.3914-3924.2004; BLACK RE, 1990, REV INFECT DIS, V12, pS73; BLACK RE, 1981, B WORLD HEALTH ORGAN, V59, P263; Bouckenooghe AR, 2002, J TRAVEL MED, V9, P137, DOI 10.2310/7060.2002.23206; Bourgeois AL, 2007, 4 INT C VACC ENT DIS; CLEMENS JD, 1988, J INFECT DIS, V158, P372, DOI 10.1093/infdis/158.2.372; Crane JK, 2006, INFECT IMMUN, V74, P1505, DOI 10.1128/IAI.74.3.1505-1515.2006; DUPONT HL, 1977, AM J EPIDEMIOL, V105, P37, DOI 10.1093/oxfordjournals.aje.a112353; Freytag LC, 1999, CURR TOP MICROBIOL, V236, P215; Glenn GM, 2007, EXPERT REV VACCINES, V6, P809, DOI 10.1586/14760584.6.5.809; Glenn GM, 2007, INFECT IMMUN, V75, P2163, DOI 10.1128/IAI.01740-06; Jiang ZD, 2000, J INFECT DIS, V181, P779, DOI 10.1086/315272; Jiang ZD, 2002, J INFECT DIS, V185, P497, DOI 10.1086/338834; McKenzie R, 2007, VACCINE, V25, P3684, DOI 10.1016/j.vaccine.2007.01.043; PELTOLA H, 1991, LANCET, V338, P1285, DOI 10.1016/0140-6736(91)92590-X; Qadri F, 2006, VACCINE, V24, P1726, DOI 10.1016/j.vaccine.2005.08.110; Sack DA, 2007, VACCINE, V25, P4392, DOI 10.1016/j.vaccine.2007.03.034; Scerpella, 1995, J Travel Med, V2, P22, DOI 10.1111/j.1708-8305.1995.tb00615.x; Steffen R, 2005, J TRAVEL MED, V12, P102; Steinsland H, 2003, LANCET, V362, P286, DOI 10.1016/S0140-6736(03)13971-2; Taylor DN, 2006, AM J TROP MED HYG, V74, P1060, DOI 10.4269/ajtmh.2006.74.1060; Wiedermann G, 2000, J TRAVEL MED, V7, P27; World health organization, 1999, WEEKLY EPIDEMIOL REC, V13, P98; Zhang JF, 2006, INFECT IMMUN, V74, P3607, DOI 10.1128/IAI.01836-05	26	142	145	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	2008	371	9629					2019	2025		10.1016/S0140-6736(08)60839-9	http://dx.doi.org/10.1016/S0140-6736(08)60839-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312YY	18554712				2022-12-28	WOS:000256709500028
J	Cichowski, K; Hahn, WC				Cichowski, Karen; Hahn, William C.			Unexpected pieces to the senescence puzzle	CELL			English	Review							ONCOGENE-INDUCED SENESCENCE; BREAST-CANCER CELLS; CELLULAR SENESCENCE; TUMORIGENESIS; FIBROBLASTS; BARRIER; GROWTH	Although initially described as the end state of cells after extended rounds of division in culture, it is now clear that cellular senescence induced by different stimuli plays an important role in tumor suppression in vivo. Three recent studies in Cell report that secreted proteins play an important role in enforcing the senescence response (Acosta et al., 2008; Kuilman et al., 2008; Wajapeyee et al., 2008). These new studies identify unanticipated contributors to this tumor-suppressing cell state.	[Cichowski, Karen] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA; [Hahn, William C.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Cichowski, Karen; Hahn, William C.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Hahn, William C.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Hahn, William C.] Broad Inst Harvard, Cambridge, MA 02142 USA; [Hahn, William C.] MIT, Cambridge, MA 02142 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT)	Cichowski, K (corresponding author), Brigham & Womens Hosp, Div Genet, 75 Francis St, Boston, MA 02115 USA.	kcichowski@rics.bwh.harvard.edu; william_hahn@dfci.harvard.edu			NIA NIH HHS [R01 AG023145, R01 AG023145-05] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG023145] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams PD, 2007, AGING CELL, V6, P425, DOI 10.1111/j.1474-9726.2007.00313.x; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Burger AM, 2005, EUR J CANCER, V41, P1515, DOI 10.1016/j.ejca.2005.04.023; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Wilson HMP, 2002, CELL GROWTH DIFFER, V13, P205; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yang G, 2006, P NATL ACAD SCI USA, V103, P16472, DOI 10.1073/pnas.0605752103	18	61	64	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 13	2008	133	6					958	961		10.1016/j.cell.2008.05.027	http://dx.doi.org/10.1016/j.cell.2008.05.027			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	312TJ	18555773	Bronze, Green Accepted			2022-12-28	WOS:000256693400012
J	O'Brien, SJ				O'Brien, Stephen J.			The platypus genome unraveled	CELL			English	Editorial Material							EVOLUTION	The genome of the platypus has been sequenced, assembled, and annotated by an international genomics team. Like the animal itself the platypus genome contains an amalgam of mammal, reptile, and bird-like features.	NCI, Lab Gen Divers, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	O'Brien, SJ (corresponding author), NCI, Lab Gen Divers, Frederick, MD 21702 USA.	obrien@ncifcrf.gov	OBRIEN, STEPHEN/ABD-1346-2020	OBRIEN, STEPHEN/0000-0001-7857-0757				[Anonymous], 1999, WALKERS MAMMALS WORL; Green P, 2007, GENOME RES, V17, P1547, DOI 10.1101/gr.7050807; JACOB K. T., 1940, BOT GAZ, V102, P143, DOI 10.1086/334941; Murphy WJ, 2005, SCIENCE, V309, P613, DOI 10.1126/science.1111387; O'Brien SJ, 2001, SCIENCE, V292, P2264, DOI 10.1126/science.1059393; OBRIEN SJ, 1993, NAT GENET, V3, P103, DOI 10.1038/ng0293-103; Pontius JU, 2007, GENOME RES, V17, P1675, DOI 10.1101/gr.6380007; VEYRUNES F, 2008, GENOME RES; Warren WC, 2008, NATURE, V453, P175, DOI 10.1038/nature06936; Wilson D. E., 2005, MAMMAL SPECIES WORLD	10	8	8	2	8	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 13	2008	133	6					953	955		10.1016/j.cell.2008.05.038	http://dx.doi.org/10.1016/j.cell.2008.05.038			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	312TJ	18555772	Bronze			2022-12-28	WOS:000256693400011
J	Boasso, A; Shearer, GM; Clerici, M				Boasso, Adriano; Shearer, Gene M.; Clerici, Mario			The hunt for an HIV vaccine: time to rethink recent failures	LANCET			English	Editorial Material							INFECTION		[Clerici, Mario] Univ Milan, Dept Biomed Sci & Technol, I-20100 Milan, Italy; [Clerici, Mario] Fdn Don C Gnocchi, I-20100 Milan, Italy; [Boasso, Adriano] Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Dept Immunol, London, England; [Shearer, Gene M.] NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA	University of Milan; IRCCS Fondazione Don Carlo Gnocchi Onlus; Imperial College London; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Clerici, M (corresponding author), Univ Milan, Dept Biomed Sci & Technol, I-20100 Milan, Italy.	mario.clerici@unimi.it		Boasso, Adriano/0000-0001-9673-6319; Clerici, Mario/0000-0001-5920-6191	NATIONAL CANCER INSTITUTE [ZIABC009267, Z01BC009267] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 2007, Nature, V449, P390; Boasso A, 2008, CLIN IMMUNOL, V126, P235, DOI 10.1016/j.clim.2007.08.015; Boasso A, 2007, CURR DRUG METAB, V8, P217, DOI 10.2174/138920007780362527; Brenchley JM, 2006, NAT IMMUNOL, V7, P235, DOI 10.1038/ni1316; Chirmule N, 1996, MICROBIOL REV, V60, P386, DOI 10.1128/MMBR.60.2.386-406.1996; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; Franchini G, 2002, VACCINE, V20, pA52, DOI 10.1016/S0264-410X(02)00388-2; Herbeuval JP, 2006, AIDS REV, V8, P3; Munier ML, 2007, IMMUNOL CELL BIOL, V85, P6, DOI 10.1038/sj.icb.7100015	10	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 7	2008	371	9628					1897	1898		10.1016/S0140-6736(08)60812-0	http://dx.doi.org/10.1016/S0140-6736(08)60812-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310OI	18539209				2022-12-28	WOS:000256538500009
J	Kong, MF; Lawden, M; Howlett, T				Kong, Marie-France; Lawden, Mark; Howlett, Trevor			The Addison's disease dilemma-autoimmune or ALD?	LANCET			English	Editorial Material							X-LINKED ADRENOLEUKODYSTROPHY		[Kong, Marie-France; Howlett, Trevor] Univ Hosp Leicester NHS Trust, Dept Diabet & Endocrinol, Leicester LE5 4PW, Leics, England; [Lawden, Mark] Univ Hosp Leicester NHS Trust, Dept Neurol, Leicester LE5 4PW, Leics, England	University Hospitals of Leicester NHS Trust; University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester	Kong, MF (corresponding author), Univ Hosp Leicester NHS Trust, Dept Diabet & Endocrinol, Gwendolen Rd, Leicester LE5 4PW, Leics, England.	marie-france.kong@uhl-tr.nhs.uk						Baumann M, 2003, EUR J PEDIATR, V162, P6, DOI 10.1007/s00431-002-1097-3; Irvine W. J., 1972, CLINICS ENDOCRINOLOG, V1, P549; KONG MF, 1994, CLIN ENDOCRINOL, V41, P757, DOI 10.1111/j.1365-2265.1994.tb02790.x; Moser HW, 2007, NAT CLIN PRACT NEURO, V3, P140, DOI 10.1038/ncpneuro0421; Moser HW, 2005, ARCH NEUROL-CHICAGO, V62, P1073, DOI 10.1001/archneur.62.7.1073	5	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 7	2008	371	9628					1970	1970		10.1016/S0140-6736(08)60838-7	http://dx.doi.org/10.1016/S0140-6736(08)60838-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310OI	18539228				2022-12-28	WOS:000256538500033
J	Baliga, NS				Baliga, Nitin S.			Systems biology - The scale of prediction	SCIENCE			English	Editorial Material							SURVIVAL		Inst Syst Biol, Seattle, WA 98103 USA	Institute for Systems Biology (ISB)	Baliga, NS (corresponding author), Inst Syst Biol, 1441 N 34th St, Seattle, WA 98103 USA.	nbaliga@systemsbiology.org						Barrett CL, 2005, P NATL ACAD SCI USA, V102, P19103, DOI 10.1073/pnas.0505231102; Bonneau R, 2007, CELL, V131, P1354, DOI 10.1016/j.cell.2007.10.053; Dodd AN, 2005, SCIENCE, V309, P630, DOI 10.1126/science.1115581; Dufresne A, 2003, P NATL ACAD SCI USA, V100, P10020, DOI 10.1073/pnas.1733211100; Kirschner MW, 2005, CELL, V121, P503, DOI 10.1016/j.cell.2005.05.005; Mascher T, 2006, MICROBIOL MOL BIOL R, V70, P910, DOI 10.1128/MMBR.00020-06; Nikaido SS, 2000, PHOTOCHEM PHOTOBIOL, V71, P758, DOI 10.1562/0031-8655(2000)071<0758:DACVIS>2.0.CO;2; Tagkopoulos I, 2008, SCIENCE, V320, P1313, DOI 10.1126/science.1154456	8	13	14	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	2008	320	5881					1297	1298		10.1126/science.1159485	http://dx.doi.org/10.1126/science.1159485			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309DO	18535232				2022-12-28	WOS:000256441100029
J	Christiaen, L; Davidson, B; Kawashima, T; Powell, W; Nolla, H; Vranizan, K; Levine, M				Christiaen, Lionel; Davidson, Brad; Kawashima, Takeshi; Powell, Weston; Nolla, Hector; Vranizan, Karen; Levine, Michael			The transcription/migration interface in heart precursors of Ciona intestinalis	SCIENCE			English	Article							SIMPLE CHORDATE; ACTIN; MIGRATION; RHO; LAMELLIPODIA; NETWORKS	Gene regulatory networks direct the progressive determination of cell fate during embryogenesis, but how they control cell behavior during morphogenesis remains largely elusive. Cell sorting, microarrays, and targeted molecular manipulations were used to analyze cardiac cell migration in the ascidian Ciona intestinalis. The heart network regulates genes involved in most cellular activities required for migration, including adhesion, cell polarity, and membrane protrusions. We demonstrated that fibroblast growth factor signaling and the forkhead transcription factor FoxF directly upregulate the small guanosine triphosphatase RhoDF, which synergizes with Cdc42 to contribute to the protrusive activity of migrating cells. Moreover, RhoDF induces membrane protrusions independently of other cellular activities required for migration. We propose that transcription regulation of specific effector genes determines the coordinated deployment of discrete cellular modules underlying migration.	[Christiaen, Lionel; Davidson, Brad; Powell, Weston; Levine, Michael] Univ Calif Berkeley, Ctr Integrat Genom, Div Genet Genom & Dev, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; [Kawashima, Takeshi] Dept Energy, Joint Genome Inst, Walnut Creek, CA 94598 USA; [Nolla, Hector] Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA; [Vranizan, Karen] Univ Calif Berkeley, Funct Genom Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Joint BioEnergy Institute - JBEI; Joint Genome Institute - JGI; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Christiaen, L (corresponding author), Univ Calif Berkeley, Ctr Integrat Genom, Div Genet Genom & Dev, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.	lionelchristiaen@berkeley.edu; mlevine@berkeley.edu	Kawashima, Takeshi/M-4510-2015; Powell, Weston/I-6961-2019	Christiaen, Lionel/0000-0001-5930-5667; Davidson, Brad/0000-0001-5082-7872; Levine, Michael/0000-0001-7629-0081; Powell, Weston/0000-0002-1555-1425	PHS HHS [18B-106681] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bakal C, 2007, SCIENCE, V316, P1753, DOI 10.1126/science.1140324; Beh J, 2007, DEVELOPMENT, V134, P3297, DOI 10.1242/dev.010140; Borghese L, 2006, DEV CELL, V10, P497, DOI 10.1016/j.devcel.2006.02.004; Corbo JC, 1997, DEVELOPMENT, V124, P589; Davidson B, 2005, DEVELOPMENT, V132, P4811, DOI 10.1242/dev.02051; Davidson B, 2006, GENE DEV, V20, P2728, DOI 10.1101/gad.1467706; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; Edwards KA, 1997, DEV BIOL, V191, P103, DOI 10.1006/dbio.1997.8707; Ellis S, 2000, CURR BIOL, V10, P1387, DOI 10.1016/S0960-9822(00)00777-6; Imai KS, 2006, SCIENCE, V312, P1183, DOI 10.1126/science.1123404; Koestler SA, 2008, NAT CELL BIOL, V10, P306, DOI 10.1038/ncb1692; Ma L, 1998, P NATL ACAD SCI USA, V95, P15362, DOI 10.1073/pnas.95.26.15362; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Pellegrin S, 2005, CURR BIOL, V15, P129, DOI 10.1016/j.cub.2005.01.011; Randazzo PA, 2003, DEV CELL, V4, P287, DOI 10.1016/S1534-5807(03)00067-4; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Satou Y, 2004, DEVELOPMENT, V131, P2533, DOI 10.1242/dev.01145; Stathopoulos A, 2005, DEV CELL, V9, P449, DOI 10.1016/j.devcel.2005.09.005; Veeman MT, 2008, DEVELOPMENT, V135, P33, DOI 10.1242/dev.010892; Wang H, 2006, DEV CELL, V10, P117, DOI 10.1016/j.devcel.2005.11.004; Yang C, 2007, PLOS BIOL, V5, P2624, DOI 10.1371/journal.pbio.0050317; Zaidel-Bar R, 2007, NAT CELL BIOL, V9, P858, DOI 10.1038/ncb0807-858	22	99	100	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	2008	320	5881					1349	1352		10.1126/science.1158170	http://dx.doi.org/10.1126/science.1158170			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309DO	18535245				2022-12-28	WOS:000256441100047
J	Korenaga, J				Korenaga, Jun			Comment on "intermittent plate tectonics?"	SCIENCE			English	Editorial Material							CONVECTION; MANTLE		Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA	Yale University	Korenaga, J (corresponding author), Yale Univ, Dept Geol & Geophys, POB 208109, New Haven, CT 06520 USA.	jun.korenaga@yale.edu	Korenaga, Jun/B-2279-2008	Korenaga, Jun/0000-0002-4785-2273				ALGEO TJ, 1995, AM J SCI, V295, P787, DOI 10.2475/ajs.295.7.787; Carlson RW, 2005, REV GEOPHYS, V43, DOI 10.1029/2004RG000156; GURNIS M, 1993, NATURE, V364, P589, DOI 10.1038/364589a0; KARATO S, 1993, SCIENCE, V260, P771, DOI 10.1126/science.260.5109.771; Korenaga J, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001760; Korenaga J, 2008, J GEOPHYS RES-SOL EA, V113, DOI 10.1029/2007JB005100; Korenaga J, 2007, EARTH PLANET SC LETT, V257, P350, DOI 10.1016/j.epsl.2007.03.007; Korenaga J, 2006, GEOPHYS MONOGR SER, V164, P7, DOI 10.1029/164GM03; Lyubetskaya T, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2005JB004223; Miller KG, 2005, SCIENCE, V310, P1293, DOI 10.1126/science.1116412; POLLACK HN, 1993, REV GEOPHYS, V31, P267, DOI 10.1029/93RG01249; Silver PG, 2008, SCIENCE, V319, P85, DOI 10.1126/science.1148397; SOLOMATOV VS, 1995, PHYS FLUIDS, V7, P266, DOI 10.1063/1.868624; Solomatov VS, 2000, J GEOPHYS RES-SOL EA, V105, P21795, DOI 10.1029/2000JB900197; Turcotte D. L., 1982, GEODYNAMICS APPL CON, DOI 10.1017/CBO9780511843877	15	10	10	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	2008	320	5881								10.1126/science.1155214	http://dx.doi.org/10.1126/science.1155214			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309DO	18535229				2022-12-28	WOS:000256441100023
J	Nickolas, TL; O'Rourke, MJ; Yang, J; Sise, ME; Canetta, PA; Barasch, N; Buchen, C; Khan, F; Mori, K; Gigllo, J; Devarajan, P; Barasch, J				Nickolas, Thomas L.; O'Rourke, Matthew J.; Yang, Jun; Sise, Meghan E.; Canetta, Pietro A.; Barasch, Nicholas; Buchen, Charles; Khan, Faris; Mori, Kiyoshi; Gigllo, James; Devarajan, Prasad; Barasch, Jonathan			Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE-RENAL-FAILURE; CRITICALLY-ILL PATIENTS; SERUM CREATININE; MORTALITY; NGAL; BIOMARKER; IRON; PROGNOSIS; MARKER; IL-18	Background: A single serum creatinine measurement cannot distinguish acute kidney injury from chronic kidney disease or prerenal azotemia. Objective: To test the sensitivity and specificity of a single measurement of urinary neutrophil gelatinase-associated lipocalin (NGAL) and other urinary proteins to detect acute kidney injury in a spectrum of patients. Design: Prospective cohort study. Setting: Emergency department of Columbia University Medical Center, New York, New York. Participants: 635 patients admitted to the hospital with acute kidney injury, prerenal azotemia, chronic kidney disease, or normal kidney function. Measurements: Diagnosis of acute kidney injury was based on the RIFLE (risk, injury, failure, loss, and end-stage) criteria and assigned by researchers who were blinded to experimental measurements. Urinary NGAL was measured by immunoblot, N-acetyl-beta-D-glucosaminidase (NAG) by enzyme measurement, alpha(1)-microglobulin and alpha(1)-acid glycoprotein by immunonephelometry, and serum creatinine by Jaffe kinetic reaction. Experimental measurements were not available to treating physicians. Results: Patients with acute kidney injury had a significantly elevated mean urinary NGAL level compared with the other kidney function groups (416 mu g/g creatinine [SD, 387]; P = 0.001). At a cutoff value of 130 mu g/g creatinine, sensitivity and specificity of NGAL for detecting acute injury were 0.900 (95% CI, 0.73 to 0.98) and 0.995 (CI, 0.990 to 1.00), respectively, and positive and negative likelihood ratios were 181.5 (CI, 58.33 to 564.71) and 0.10 (CI, 0.03 to 0.29); these values were superior to those for NAG, alpha(1)-microglobulin, alpha(1)-acid glycoprotein, fractional excretion of sodium, and serum creatinine. In multiple logistic regression, urinary NGAL level was highly predictive of clinical outcomes, including nephrology consultation, dialysis, and admission to the intensive care unit (odds ratio, 24.71 [CI, 7.69 to 79.42]). Limitations: All patients came from a single center. Few kidney biopsies were performed. Conclusion: A single measurement of urinary NGAL helps to distinguish acute injury from normal function, prerenal azotemia, and chronic kidney disease and predicts poor inpatient outcomes.			Nickolas, TL (corresponding author), Columbia Univ, PH 4 Stem,Room 124,622 W 168th St, New York, NY 10032 USA.	tln2001@columbia.edu	Mori, Kiyoshi/N-1267-2014; Canetta, Pietro/I-3823-2019	Mori, Kiyoshi/0000-0002-7285-8351; Canetta, Pietro/0000-0003-1130-5486; Devarajan, Prasad/0000-0002-7847-8552	NCRR NIH HHS [UL1 RR024156] Funding Source: Medline; NIDDK NIH HHS [R01 DK073462, R01 DK073462-03, P01 DK055388, R01 DK058872] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058872, R01DK073462, P01DK055388] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agresti A, 2003, CATEGORICAL DATA ANA; Ahlstrom A, 2004, CLIN NEPHROL, V62, P344; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Berger T, 2006, P NATL ACAD SCI USA, V103, P1834, DOI 10.1073/pnas.0510847103; Bonventre JV, 2003, J AM SOC NEPHROL, V14, P2199, DOI 10.1097/01.ASN.0000079785.13922.F6; Brivet FG, 1996, CRIT CARE MED, V24, P192, DOI 10.1097/00003246-199602000-00003; BUNDGAARD JR, 1994, BIOCHEM BIOPH RES CO, V202, P1468, DOI 10.1006/bbrc.1994.2096; Chertow GM, 2005, J AM SOC NEPHROL, V16, P3365, DOI 10.1681/ASN.2004090740; CHERTOW GM, 1995, ARCH INTERN MED, V155, P1505, DOI 10.1001/archinte.155.14.1505; de Vries B, 2004, TRANSPLANTATION, V78, P1116, DOI 10.1097/01.TP.0000138096.14126.CA; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Fischer MJ, 2005, AM J KIDNEY DIS, V46, P1049, DOI 10.1053/j.ajkd.2005.09.006; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; Gottlieb SS, 2002, J CARD FAIL, V8, P136, DOI 10.1054/jcaf.2002.125289; Han WK, 2008, KIDNEY INT, V73, P863, DOI 10.1038/sj.ki.5002715; Han WK, 2002, KIDNEY INT, V62, P237, DOI 10.1046/j.1523-1755.2002.00433.x; Herget-Rosenthal S, 2004, KIDNEY INT, V66, P1115, DOI 10.1111/j.1523-1755.2004.00861.x; Herget-Rosenthal S, 2004, CLIN CHEM, V50, P552, DOI 10.1373/clinchem.2003.027763; KAUFMAN J, 1991, AM J KIDNEY DIS, V17, P191, DOI 10.1016/S0272-6386(12)81128-0; Lameire Norbert, 2004, Curr Opin Crit Care, V10, P468, DOI 10.1097/01.ccx.0000144939.24897.71; Lassnigg A, 2004, J AM SOC NEPHROL, V15, P1597, DOI 10.1097/01.ASN.0000130340.93930.DD; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Liangos O, 2007, J AM SOC NEPHROL, V18, P904, DOI 10.1681/ASN.2006030221; Liano F, 1996, KIDNEY INT, V50, P811, DOI 10.1038/ki.1996.380; MAHER ER, 1989, Q J MED, V72, P857; Mishra J, 2003, J AM SOC NEPHROL, V14, P2534, DOI 10.1097/01.ASN.0000088027.54400.C6; Mishra J, 2006, PEDIATR NEPHROL, V21, P856, DOI 10.1007/s00467-006-0055-0; Mishra Jaya, 2005, Lancet, V365, P1231, DOI 10.1016/S0140-6736(05)74811-X; Mori K, 2007, KIDNEY INT, V71, P967, DOI 10.1038/sj.ki.5002165; Mori K, 2005, J CLIN INVEST, V115, P610, DOI 10.1172/JCI200523056; NGUYEN MT, 2006, J AM SOC NEPHROL, V17, pA49; NOVIS BK, 1994, ANESTH ANALG, V78, P143; PALLER MS, 1988, KIDNEY INT, V34, P474, DOI 10.1038/ki.1988.205; Parikh CR, 2006, KIDNEY INT, V70, P199, DOI 10.1038/sj.ki.5001527; Parikh CR, 2006, AM J TRANSPLANT, V6, P1639, DOI 10.1111/j.1600-6143.2006.01352.x; Parikh CR, 2005, J AM SOC NEPHROL, V16, P3046, DOI 10.1681/ASN.2005030236; Parikh CR, 2004, AM J KIDNEY DIS, V43, P405, DOI 10.1053/j.ajkd.2003.10.040; PASCUAL J, 1990, J AM GERIATR SOC, V38, P25, DOI 10.1111/j.1532-5415.1990.tb01592.x; Schmidt-Ott KM, 2007, J AM SOC NEPHROL, V18, P407, DOI 10.1681/ASN.2006080882; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; Smith GL, 2003, J CARD FAIL, V9, P13, DOI 10.1054/jcaf.2003.3; Star RA, 1998, KIDNEY INT, V54, P1817, DOI 10.1046/j.1523-1755.1998.00210.x; Stone DH, 2005, SURGERY, V138, P368, DOI 10.1016/j.surg.2005.06.004; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; Vera T, 2005, J AM SOC NEPHROL, V16, P950, DOI 10.1681/ASN.2004090736; Wagener G, 2006, ANESTHESIOLOGY, V105, P485, DOI 10.1097/00000542-200609000-00011; Xue JL, 2006, J AM SOC NEPHROL, V17, P1135, DOI 10.1681/ASN.2005060668; Yang J, 2002, MOL CELL, V10, P1045, DOI 10.1016/S1097-2765(02)00710-4; ZANARDO G, 1994, J THORAC CARDIOV SUR, V107, P1489, DOI 10.1016/S0022-5223(94)70429-5; Zappitelli M, 2007, CRIT CARE, V11, DOI 10.1186/cc6089	52	506	537	0	41	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2008	148	11					810	U21		10.7326/0003-4819-148-11-200806030-00003	http://dx.doi.org/10.7326/0003-4819-148-11-200806030-00003			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308CG	18519927	Green Accepted			2022-12-28	WOS:000256365300002
J	Conde, CA; Cubeddu, RJ				Conde, Cesar A.; Cubeddu, Roberto J.			The aorta in osteoporosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Conde, Cesar A.; Cubeddu, Roberto J.] Mt Sinai Med Ctr, Miami Beach, FL 33140 USA	Mount Sinai Medical Center	Conde, CA (corresponding author), Mt Sinai Med Ctr, Miami Beach, FL 33140 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2008	358	22					2388	2388		10.1056/NEJMicm070575	http://dx.doi.org/10.1056/NEJMicm070575			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307GF	18509124				2022-12-28	WOS:000256306700009
J	Reece, SE; Drew, DR; Gardner, A				Reece, Sarah E.; Drew, Damien R.; Gardner, Andy			Sex ratio adjustment and kin discrimination in malaria parasites	NATURE			English	Article							LOCAL MATE COMPETITION; PLASMODIUM-FALCIPARUM; POPULATION-STRUCTURE; TOXOPLASMA-GONDII; BLOOD PARASITES; PREMATURE REJECTION; FERTILITY INSURANCE; EVOLUTION; VIRULENCE; TRANSMISSION	Malaria parasites and related Apicomplexans are the causative agents of the some of the most serious infectious diseases of humans, companion animals, livestock and wildlife. These parasites must undergo sexual reproduction to transmit from vertebrate hosts to vectors, and their sex ratios are consistently female- biased. Sex allocation theory, a cornerstone of evolutionary biology, is remarkably successful at explaining female- biased sex ratios in multicellular taxa, but has proved controversial when applied to malaria parasites. Here we show that, as predicted by theory, sex ratio is an important fitness- determining trait and Plasmodium chabaudi parasites adjust their sex allocation in response to the presence of unrelated conspecifics. This suggests that P. chabaudi parasites use kin discrimination to evaluate the genetic diversity of their infections, and they adjust their behaviour in response to environmental cues. Malaria parasites provide a novel way to test evolutionary theory, and support the generality and power of a darwinian approach.	[Reece, Sarah E.; Gardner, Andy] Univ Edinburgh, Inst Evolut Biol, Ashworth Labs, Sch Biol Sci, Edinburgh EH9 3JT, Midlothian, Scotland; [Reece, Sarah E.; Drew, Damien R.] Univ Edinburgh, Inst Immunol & Infect Res, Ashworth Labs, Sch Biol Sci, Edinburgh EH9 3JT, Midlothian, Scotland; [Drew, Damien R.] Walter & Eliza Hall Inst Med Res, Ctr Biotechnol, Bundoora, Vic 3086, Australia	University of Edinburgh; University of Edinburgh; Walter & Eliza Hall Institute	Reece, SE (corresponding author), Univ Edinburgh, Inst Evolut Biol, Ashworth Labs, Sch Biol Sci, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.	sarah.reece@ed.ac.uk	Reece, Sarah E/C-9447-2009; Reece, Sarah/AAA-6426-2020; Gardner, Andy/K-5353-2013	Reece, Sarah E/0000-0001-6716-6732; Reece, Sarah/0000-0001-6716-6732; Gardner, Andy/0000-0002-1304-3734	Biotechnology and Biological Sciences Research Council Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Al-Olayan EM, 2002, INT J PARASITOL, V32, P1133, DOI 10.1016/S0020-7519(02)00087-5; CHARNOV E L, 1982; Conway DJ, 1999, P NATL ACAD SCI USA, V96, P4506, DOI 10.1073/pnas.96.8.4506; CROZIER RH, 1986, EVOLUTION, V40, P1100, DOI 10.1111/j.1558-5646.1986.tb00578.x; Drew DR, 2007, MOL BIOCHEM PARASIT, V156, P199, DOI 10.1016/j.molbiopara.2007.08.004; DYE C, 1993, J THEOR BIOL, V161, P131, DOI 10.1006/jtbi.1993.1045; Ferguson DJP, 2003, TRENDS PARASITOL, V19, P157, DOI 10.1016/S1471-4922(03)00032-1; Ferguson DJP, 2002, TRENDS PARASITOL, V18, P355, DOI 10.1016/S1471-4922(02)02330-9; Fisher R.A., 1930, GENETICAL THEORY NAT; FRANK S. A., 2002, EVOLUTION, V56, P2561; FRANK SA, 1990, ANNU REV ECOL SYST, V21, P13, DOI 10.1146/annurev.es.21.110190.000305; FRANK SA, 1992, P ROY SOC B-BIOL SCI, V250, P195, DOI 10.1098/rspb.1992.0149; FRANK SA, 1994, P ROY SOC B-BIOL SCI, V258, P153, DOI 10.1098/rspb.1994.0156; Gardner A, 2003, J THEOR BIOL, V223, P515, DOI 10.1016/S0022-5193(03)00142-5; HAMILTON WD, 1967, SCIENCE, V156, P477, DOI 10.1126/science.156.3774.477; Hardy I.C.W, 2002, SEX RATIOS CONCEPTS; HERRE EA, 1993, SCIENCE, V259, P1442, DOI 10.1126/science.259.5100.1442; JANSE CJ, 1985, PARASITOLOGY, V91, P19, DOI 10.1017/S0031182000056481; Khan SM, 2005, CELL, V121, P675, DOI 10.1016/j.cell.2005.03.027; Mackinnon MJ, 1999, EVOLUTION, V53, P689, DOI [10.2307/2640710, 10.1111/j.1558-5646.1999.tb05364.x]; Mehdiabadi NJ, 2006, NATURE, V442, P881, DOI 10.1038/442881a; Nee S, 2002, P ROY SOC B-BIOL SCI, V269, P755, DOI 10.1098/rspb.2001.1938; Nesse RM, 1995, WHY WE GET SICK NEW; Osgood SM, 2002, J PARASITOL, V88, P494, DOI 10.1645/0022-3395(2002)088[0494:GSROAM]2.0.CO;2; Paul REL, 2003, ECOL LETT, V6, P866, DOI 10.1046/j.1461-0248.2003.00509.x; Paul REL, 2000, SCIENCE, V287, P128, DOI 10.1126/science.287.5450.128; PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897; Paul REL, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P153; Pickering J, 2000, EVOL ECOL RES, V2, P171; Razakandrainibe FG, 2005, P NATL ACAD SCI USA, V102, P17388, DOI 10.1073/pnas.0508871102; Read AF, 2002, SEX RATIOS: CONCEPTS AND RESEARCH METHODS, P314, DOI 10.1017/CBO9780511542053.016; READ AF, 1992, PARASITOLOGY, V104, P387, DOI 10.1017/S0031182000063630; READ AF, 1995, P ROY SOC B-BIOL SCI, V260, P359, DOI 10.1098/rspb.1995.0105; Reece SE, 2000, TRENDS ECOL EVOL, V15, P259, DOI 10.1016/S0169-5347(00)01893-0; Reece SE, 2005, P ROY SOC B-BIOL SCI, V272, P511, DOI 10.1098/rspb.2004.2972; Robert V, 2003, PARASITOLOGY, V127, P1, DOI 10.1017/S0031182003003299; Robert V, 1996, T ROY SOC TROP MED H, V90, P621, DOI 10.1016/S0035-9203(96)90408-3; Robert V, 2003, AM J TROP MED HYG, V68, P169, DOI 10.4269/ajtmh.2003.68.169; Rousset F, 2007, EVOLUTION, V61, P2320, DOI 10.1111/j.1558-5646.2007.00191.x; Schall JJ, 2000, PARASITOLOGY, V121, P575, DOI 10.1017/S0031182000006818; SHUTLER D, 1995, P NATL ACAD SCI USA, V92, P6748, DOI 10.1073/pnas.92.15.6748; van Dijk MR, 2001, CELL, V104, P153, DOI 10.1016/S0092-8674(01)00199-4; Walliker David, 1998, P235; WERREN JH, 1980, SCIENCE, V208, P1157, DOI 10.1126/science.208.4448.1157; West SA, 2005, EVOLUTION, V59, P1211; West SA, 2000, P ROY SOC B-BIOL SCI, V267, P257, DOI 10.1098/rspb.2000.0995; West SA, 2003, TRENDS PARASITOL, V19, P155, DOI 10.1016/S1471-4922(03)00033-3; West SA, 2002, J PARASITOL, V88, P258, DOI 10.1645/0022-3395(2002)088[0258:FIATSR]2.0.CO;2; West SA, 2001, TRENDS PARASITOL, V17, P525, DOI 10.1016/S1471-4922(01)02058-X; West SA, 2006, NAT REV MICROBIOL, V4, P597, DOI 10.1038/nrmicro1461	50	159	164	2	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	2008	453	7195					609	U1		10.1038/nature06954	http://dx.doi.org/10.1038/nature06954			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305NN	18509435	Green Accepted			2022-12-28	WOS:000256185200034
J	Berridge, V				Berridge, Virginia			POLYCLINICS: haven't we been there before?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									London Sch Hyg & Trop Med, Ctr Hist Publ Hlth, London WC1, England	University of London; London School of Hygiene & Tropical Medicine	Berridge, V (corresponding author), London Sch Hyg & Trop Med, Ctr Hist Publ Hlth, London WC1, England.	Virginia.Berridge@lshtm.ac.uk		berridge, virginia/0000-0001-8011-8348				Armstrong D, 1983, POLITICAL ANATOMY BO; Bosanquet Chris, 1998, GEN PRACTICE NATL HL, P53; CARVEL J, 2007, GUARDIAN        0711, P3; Digby Anne, 1999, EVOLUTION BRIT GEN P; Godber G, 1983, Soc Soc Hist Med Bull (Lond), V32, P4; Honigsbaum F, 1989, HLTH HAPPINESS SECUR, P106; JONES E, 2007, LONDONS INTERWAR HLT; LEWIS J, 1983, MED HIST, V27, P151, DOI 10.1017/S0025727300042617	8	5	5	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 24	2008	336	7654					1161	1162		10.1136/bmj.39583.414572.AD	http://dx.doi.org/10.1136/bmj.39583.414572.AD			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308WJ	18497411	Green Published, Green Accepted			2022-12-28	WOS:000256420900035
J	Li, GW; Zhang, P; Wang, JP; Gregg, EW; Yang, WY; Gong, QH; Li, H; Li, HL; Jiang, YY; An, YL; Shuai, Y; Zhang, B; Zhang, JL; Thompson, TJ; Gerzoff, RB; Roglic, G; Hu, YH; Bennett, PH				Li, Guangwei; Zhang, Ping; Wang, Jinping; Gregg, Edward W.; Yang, Wenying; Gong, Qiuhong; Li, Hui; Li, Hongliang; Jiang, Yayun; An, Yali; Shuai, Ying; Zhang, Bo; Zhang, Jingling; Thompson, Theodore J.; Gerzoff, Robert B.; Roglic, Gojka; Hu, Yinghua; Bennett, Peter H.			The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study	LANCET			English	Article							IMPAIRED GLUCOSE-TOLERANCE; MORTALITY; RISK; REDUCTION; EXERCISE; PROGRAM; PEOPLE; NIDDM; IGT	Background Intensive lifestyle interventions can reduce the incidence of type 2 diabetes in people with impaired glucose tolerance, but how long these benefits extend beyond the period of active intervention, and whether such interventions reduce the risk of cardiovascular disease (CVD) and mortality, is unclear. We aimed to assess whether intensive lifestyle interventions have a long-term effect on the risk of diabetes, diabetes-related macrovascular and microvascular complications, and mortality. Methods In 1986, 577 adults with impaired glucose tolerance from 33 clinics in China were randomly assigned to either the control group or to one of three lifestyle intervention groups (diet, exercise, or diet plus exercise). Active intervention took place over 6 years until 1992. In 2006, study participants were followed-up to assess the long-term effect of the interventions. The primary outcomes were diabetes incidence, CVD incidence and mortality, and all-cause mortality. Findings Compared with control participants, those in the combined lifestyle intervention groups had a 51% lower incidence of diabetes (hazard rate ratio [HRR] 0 . 49; 95% CI 0 . 33-0-73) during the active intervention period and a 43% lower incidence (0 . 57; 0 . 41-0 . 81) over the 20 year period, controlled for age and clustering by clinic. The average annual incidence of diabetes was 7% for intervention participants versus 11% in control participants, with 20-year cumulative incidence of 80% in the intervention groups and 93% in the control group. Participants in the intervention group spent an average of 3.6 fewer years with diabetes than those in the control group. There was no significant difference between the intervention and control groups in the rate of first CVD events (HRR 0 . 98; 95% CI 0 . 71-1.37), CVD mortality (0 . 83; 0.48-1.40), and all-cause mortality (0 - 96; 0 . 65-1.41), but our study had limited statistical power to detect differences for these outcomes. Interpretation Group-based lifestyle interventions over 6 years can prevent or delay diabetes for up to 14 years after the active intervention. However, whether lifestyle intervention also leads to reduced CVD and mortality remains unclear. Funding Centers for Disease Control and Prevention, WHO, the China-Japan Friendship Hospital, and Da Qing First Hospital.	[Zhang, Ping; Gregg, Edward W.; Thompson, Theodore J.; Gerzoff, Robert B.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA 30341 USA; [Li, Guangwei; Yang, Wenying; Gong, Qiuhong; Li, Hongliang; An, Yali; Shuai, Ying; Zhang, Bo] China Japan Friendship Hosp, Dept Endocrinol, Beijing 100029, Peoples R China; [Wang, Jinping; Li, Hui; Jiang, Yayun; Zhang, Jingling; Hu, Yinghua] Da Qing First Hosp, Dept Cardiol, Da Qing, Peoples R China; [Roglic, Gojka] WHO, Dept Chron Dis & Hlth Promot, CH-1211 Geneva, Switzerland; [Bennett, Peter H.] NIDDKD, Phoenix Epidemiol & Clin Res Branch, NIH, Phoenix, AZ USA	Centers for Disease Control & Prevention - USA; China-Japan Friendship Hospital; World Health Organization; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Zhang, P (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA 30341 USA.	guangwei_li@medmail.com.cn; pzhang@cdc.gov	Bennett, Peter/AAH-9605-2021; Northe, Hilda/I-1916-2012; wang, jinping/AAE-4392-2020; Li, Hongliang/AAV-1697-2020	Northe, Hilda/0000-0002-8873-5014; Roglic, Gojka/0000-0003-0872-0689; Gregg, Edward/0000-0003-2381-6822	PHS HHS [U58/CCU424123-01-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Chiasson Jean-Louis, 2006, Endocr Pract, V12 Suppl 1, P25; Chiasson JL, 2003, JAMA-J AM MED ASSOC, V290, P486, DOI 10.1001/jama.290.4.486; EFRON B, 1988, J AM STAT ASSOC, V83, P414, DOI 10.2307/2288857; Gelman A., 2007, DATA ANAL USING REGR; Gerstein HC, 2007, DIABETES RES CLIN PR, V78, P305, DOI 10.1016/j.diabres.2007.05.004; Hamman RF, 2006, DIABETES CARE, V29, P2102, DOI 10.2337/dc06-0560; He J, 2005, NEW ENGL J MED, V353, P1124, DOI 10.1056/NEJMsa050467; Holloszy JO, 2005, J APPL PHYSIOL, V99, P338, DOI 10.1152/japplphysiol.00123.2005; *INT DIAB FED, 2006, DIAB ATL; Knowler WC, 1997, DIABETOLOGIA, V40, P680, DOI 10.1007/s001250050734; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kosaka K, 2005, DIABETES RES CLIN PR, V67, P152, DOI 10.1016/j.diabres.2004.06.010; Lindstrom J, 2006, LANCET, V368, P1673, DOI 10.1016/S0140-6736(06)69701-8; Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; Ramachandran A, 2006, DIABETOLOGIA, V49, P289, DOI 10.1007/s00125-005-0097-z; Roglic G, 2005, DIABETES CARE, V28, P2130, DOI 10.2337/diacare.28.9.2130; Rubin RR, 2002, CONTROL CLIN TRIALS, V23, P157; SAAD MF, 1988, NEW ENGL J MED, V319, P1500, DOI 10.1056/NEJM198812083192302; Steffes MW, 2003, JAMA-J AM MED ASSOC, V290, P2159, DOI 10.1001/jama.290.16.2159; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; *WHO, 1985, TECHN REP SER GHO, V727; Wu YF, 2006, BMJ-BRIT MED J, V333, P362, DOI 10.1136/bmj.333.7564.362; Wu ZS, 2001, CIRCULATION, V103, P462	24	1034	1161	4	162	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	2008	371	9626					1783	1789		10.1016/S0140-6736(08)60766-7	http://dx.doi.org/10.1016/S0140-6736(08)60766-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	304IO	18502303				2022-12-28	WOS:000256103400033
J	Raj, A; Gomez, C; Silverman, JG				Raj, Anita; Gomez, Charlemagne; Silverman, Jay G.			Human rights - Driven to a fiery death - The tragedy of self-immolation in Afghanistan	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Raj, Anita] Boston Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02215 USA; [Gomez, Charlemagne] Med Mondial, Cologne, Germany; [Silverman, Jay G.] Harvard Univ, Sch Publ Hlth, Dep Soc Human Dev & Hlth, Boston, MA 02115 USA	Boston University; Harvard University; Harvard T.H. Chan School of Public Health	Raj, A (corresponding author), Boston Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02215 USA.							*CENTR INT AG, WORLD FACTB AFGH; *UN DEV PROGR, HUM DEV REP AFGH 200; *UNIFEM, AFGH UNIFEM FACT SHE	3	18	18	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 22	2008	358	21					2201	2203		10.1056/NEJMp0801340	http://dx.doi.org/10.1056/NEJMp0801340			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	303EK	18499564				2022-12-28	WOS:000256023600002
J	Schreiner, P; Chen, X; Husnjak, K; Randles, L; Zhang, NX; Elsasser, S; Finley, D; Dikic, I; Walters, KJ; Groll, M				Schreiner, Patrick; Chen, Xiang; Husnjak, Koraljka; Randles, Leah; Zhang, Naixia; Elsasser, Suzanne; Finley, Daniel; Dikic, Ivan; Walters, Kylie J.; Groll, Michael			Ubiquitin docking at the proteasome through a novel pleckstrin-homology domain interaction	NATURE			English	Article							DEUBIQUITINATING ENZYME; STRUCTURAL BASIS; MULTIUBIQUITIN CHAIN; PROTEIN INTERACTOME; EAP45-GLUE DOMAIN; RECOGNITION; DEGRADATION; COMPLEX; BINDING; SUBUNIT	Targeted protein degradation is largely performed by the ubiquitin-proteasome pathway, in which substrate proteins are marked by covalently attached ubiquitin chains that mediate recognition by the proteasome. It is currently unclear how the proteasome recognizes its substrates, as the only established ubiquitin receptor intrinsic to the proteasome is Rpn10/S5a (ref. 1), which is not essential for ubiquitin- mediated protein degradation in budding yeast(2). In the accompanying manuscript we report that Rpn13 (refs 3-7), a component of the nine-subunit proteasome base, functions as a ubiquitin receptor(8), complementing its known role in docking de-ubiquitinating enzyme Uch37/UCHL5 (refs 4-6) to the proteasome. Here we merge crystallography and NMRdata to describe the ubiquitin-binding mechanism of Rpn13. We determine the structure of Rpn13 alone and complexed with ubiquitin. The co-complex reveals a novel ubiquitin-binding mode in which loops rather than secondary structural elements are used to capture ubiquitin. Further support for the role of Rpn13 as a proteasomal ubiquitin receptor is demonstrated by its ability to bind ubiquitin and proteasome subunit Rpn2/S1 simultaneously. Finally, we provide a model structure of Rpn13 complexed to diubiquitin, which provides insights into how Rpn13 as a ubiquitin receptor is coupled to substrate deubiquitination by Uch37.	[Schreiner, Patrick; Groll, Michael] Tech Univ Munich, Ctr Integrated Prot Sci, Dept Chem, Lehrstuhl Biochem, D-85747 Garching, Germany; [Chen, Xiang; Randles, Leah; Zhang, Naixia; Walters, Kylie J.] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; [Husnjak, Koraljka; Dikic, Ivan] Univ Frankfurt, Inst Biochem 2, D-60590 Frankfurt, Germany; [Husnjak, Koraljka; Dikic, Ivan] Mediterranean Inst Life Sci, Tumor Biol Program, Split 21000, Croatia; [Elsasser, Suzanne; Finley, Daniel] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Dikic, Ivan] Univ Split, Sch Med, Dept Immunol, Split 21000, Croatia; [Groll, Michael] Charite Univ Med Berlin CCM, Inst Biochem, D-10117 Berlin, Germany	Technical University of Munich; University of Minnesota System; University of Minnesota Twin Cities; Goethe University Frankfurt; Harvard University; Harvard Medical School; University of Split; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Groll, M (corresponding author), Tech Univ Munich, Ctr Integrated Prot Sci, Dept Chem, Lehrstuhl Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	ivan.dikic@biochem2.de; walte048@umn.edu; michael.groll@ch.tum.de	Dikic, Ivan/O-4650-2015; Groll, Michael/F-5572-2015; Groll, Michael/C-1174-2010; Husnjak, Koraljka/C-3717-2015; Chen, Xiang/E-2840-2010	Dikic, Ivan/0000-0001-8156-9511; Husnjak, Koraljka/0000-0003-0573-6239; Schreiner, Patrick/0000-0002-3141-9133	NCI NIH HHS [R01 CA097004-05, R01 CA097004, CA097004, R01 CA097004-06A1] Funding Source: Medline; NIGMS NIH HHS [R37 GM043601-17, T32 GM008700-09, R37 GM043601, R01 GM043601, T32 GM008700, GM43601, GM008700] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043601, T32GM008700, R37GM043601] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam SL, 2006, NAT STRUCT MOL BIOL, V13, P1029, DOI 10.1038/nsmb1160; BORNAR MG, 2007, EMBO REP, V8, P247; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Crosas B, 2006, CELL, V127, P1401, DOI 10.1016/j.cell.2006.09.051; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; Gandhi TKB, 2006, NAT GENET, V38, P285, DOI 10.1038/ng1747; Hamazaki J, 2006, EMBO J, V25, P4524, DOI 10.1038/sj.emboj.7601338; Hanna J, 2006, CELL, V127, P99, DOI 10.1016/j.cell.2006.07.038; Hirano S, 2006, NAT STRUCT MOL BIOL, V13, P1031, DOI 10.1038/nsmb1163; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jorgensen JP, 2006, J MOL BIOL, V360, P1043, DOI 10.1016/j.jmb.2006.06.011; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Lam YA, 1997, J BIOL CHEM, V272, P28438, DOI 10.1074/jbc.272.45.28438; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Lee S, 2006, NAT STRUCT MOL BIOL, V13, P264, DOI 10.1038/nsmb1064; Lemmon MA, 2004, BIOCHEM SOC T, V32, P707, DOI 10.1042/BST0320707; Ohno A, 2005, STRUCTURE, V13, P521, DOI 10.1016/j.str.2005.01.011; Penengo L, 2006, CELL, V124, P1183, DOI 10.1016/j.cell.2006.02.020; Qiu XB, 2006, EMBO J, V25, P5742, DOI 10.1038/sj.emboj.7601450; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Wang QH, 2005, J MOL BIOL, V348, P727, DOI 10.1016/j.jmb.2005.03.007; Yao TT, 2006, NAT CELL BIOL, V8, P994, DOI 10.1038/ncb1460; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071	28	249	256	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 22	2008	453	7194					548	552		10.1038/nature06924	http://dx.doi.org/10.1038/nature06924			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303EL	18497827	Green Accepted			2022-12-28	WOS:000256023700048
